DRAVPe01811,IFKAIWSGIKSLF,13,Hp1090,Heterometrus petersii,"P0DJ02,T1DEJ9",None,HCV,Flaviviridae,In vitro HCV RNA inhibitory assay,[Ref.20950663]Hepatitis C virus (HCV): inhibition of viral infection in Huh7.5.1 cells(IC50 = 7.62 μg/ml (5.0 μM)).,No hemolysis information or data found in the reference(s) presented in this entry,"[Ref.20950663]the peptide concentration was less than 20 μg/ml, the viability of the peptide-treated cells was greater than 90%.",Unnamed: 13,DRAVPe01811.cif,Linear,Free,Amidation,None.1,L,membrane,Has the ability to prevent the initiation step of HCV infection by direct interaction with HCV virus and readily disrupting their phospholipid membrane.,1509.85,C76H116N16O16,CDEHMNPQRTVY,I,10,2,0,2.1,3,8,107.69,1282,20 hour,30 min,>10 hour,127.69,5500,458.33,20950663,Peptides. 2011 Jan;32(1):11-9.,"Yan R, Zhao Z, He Y, Wu L, Cai D, Hong W, Wu Y, Cao Z, Zheng C, Li W. ",A new natural α-helical peptide from the venom of the scorpion Heterometrus petersii kills HCV.,10.1016/j.peptides.2010.10.008,Unnamed: 45,Anti-HCV
DRAVPe01810,GFGCPFNQGKCHRHCRSIRRRGGYCDGFLKQRCVCYRK,38,BmKDfsin3,Mesobuthus martensii Karsch,A0A384E0Y8,,HCV,Flaviviridae,qPCR,[Ref.31963532]Hepatitis C virus (HCV): inhibition of viral replication in Huh7.5.1 cells(IC50=3.35±1.1 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.31963532]Human hepatocellular carcinoma Huh-7.5.1 cells:	CC50=60.63±1.36 µM.,,DRAVPe01810.cif,Cyclic,Free,Free,"Disulfide bonds between Cys4 and Cys25, Cys11 and Cys33, Cys15 and Cys35.",L,Not found,"BmKDfsin3 is revealed to enter into cells. Using an upstream MyD88 dimerization inhibitor ST2345 or kinase IRAK-1/4 inhibitor I, the inhibition of p38 activation represses HCV replication in vitro.",4494.26,C190H299N69O47S6,AEMTW,R,10.0,12,1,11,16,6,-92.37,-12439,30 hour,>20 hour,>10 hour,28.16,3355,90.68,31963532,Antibiotics (Basel). 2020 Jan 17;9(1):33.,"Cheng Y, Sun F, Li S, Gao M, Wang L, Sarhan M, Abdel-Rahman MA, Li W, Kwok HF, Wu Y, Cao Z. ",Inhibitory Activity of a Scorpion Defensin BmKDfsin3 against Hepatitis C Virus.,10.3390/antibiotics9010033,,Anti-HCV
DRAVPe01809,FIKRIARLLRKIF,13,Kn2-7,Synthetic construct(derived from BmKn2),No entry found,,HIV,Retroviridae,Luciferase Assay ,[Ref.22536342]human Immunodeficiency viruses-1(HIV-1): inhibition of viral particle(EC50= 2.76 μg/ml (1.65 μM)).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22536342]TZM-bl cells: CC50 = 38.46 µg/ml.,,DRAVPe01809.cif,Linear,Free,Free,,L,Not found,"Kn2-7 aggregates and inserts into viral envelope so that the hydrophobic peptide region aligns with the lipid core region and the hydrophilic peptide regions form the interior region of the pore, with the help of positive charge of peptide somehow",1674.15,C81H140N24O14,CDEGHMNPQSTVWY,IR,12.31,5,0,5,0,8,55.38,-2349,1.1 hour,3 min,2 min,157.69,0,0.0,22536342,PLoS One. 2012;7(4):e34947.,"Chen Y, Cao L, Zhong M, Zhang Y, Han C, Li Q, Yang J, Zhou D, Shi W, He B, Liu F, Yu J, Sun Y, Cao Y, Li Y, Li W, Guo D, Cao Z, Yan H.",Anti-HIV-1 activity of a new scorpion venom peptide derivative Kn2-7. ,10.1371/journal.pone.0034947,,Anti-HIV
DRAVPe01808,MITHGCYTRTRHKHKLKKTL,20,SA-35,Synthetic construct,No entry found,,RSV,Paramyxoviridae,Antiviral assay,[Ref.32124885]Respiratory syncytial virus (RSV):SA-35 caused a significant decrease of the RSV infectivity by 33 times at concentrations 1 mg/ml.,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.32124885]MA-104 cells:CC50= 2.1 ± 0.1 mg/ml.,,DRAVPe01808.cif,Linear,Free,Free,,L,Not found,It is likely that these peptides exert anti-RSV activity through a combination of two mechanisms: destabilization of the viral envelope and competitive inhibition of attachment/fusion of the virus with the target cell.,2452.97,C107H182N36O26S2,ADEFNPQSVW,KT,10.58,9,0,9,7,3,-111.0,-5711,30 hour,>20 hour,>10 hour,58.5,1490,78.42,32124885,J Mater Chem B. 2020 Apr 1;8(13):2607-2617,"Kozhikhova KV, Shilovskiy IP, Shatilov AA, Timofeeva AV, Turetskiy EA, Vishniakova LI, Nikolskii AA, Barvinskaya ED, Karthikeyan S, Smirnov VV, Kudlay DA, Andreev SM, Khaitov MR","Linear and dendrimeric antiviral peptides: design, chemical synthesis and activity against human respiratory syncytial virus.",10.1039/c9tb02485a,,Anti-RSV
DRAVPe01807,KRRGGGKLLKLLLKLLLKLLKC,22,NC-783,Synthetic construct,No entry found,,RSV,Paramyxoviridae,Antiviral assay,[Ref.32124885]Respiratory syncytial virus (RSV):inhibition of viral infection in the MA-104 cell(IC50=0.04mg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.32124885]MA-104 cells:CC50= 0.04 ± 0.01 mg/ml.,,DRAVPe01807.cif,Linear,Free,Free,,L,Not found,It is likely that these peptides exert anti-RSV activity through a combination of two mechanisms: destabilization of the viral envelope and competitive inhibition of attachment/fusion of the virus with the target cell.,2505.32,C117H222N34O23S,ADEFHIMNPQSTVWY,L,11.27,8,0,8,4,10,31.36,-984,1.3 hour,3 min,2 min,177.27,0,0.0,32124885,J Mater Chem B. 2020 Apr 1;8(13):2607-2617,"Kozhikhova KV, Shilovskiy IP, Shatilov AA, Timofeeva AV, Turetskiy EA, Vishniakova LI, Nikolskii AA, Barvinskaya ED, Karthikeyan S, Smirnov VV, Kudlay DA, Andreev SM, Khaitov MR","Linear and dendrimeric antiviral peptides: design, chemical synthesis and activity against human respiratory syncytial virus.",10.1039/c9tb02485a,,Anti-RSV
DRAVPe01806,gikefkrivqrikdflrnlv,20,GI-20D,Synthetic construct(derived from LL-37),No entry found,,EBOV,Filoviridae,Plaque assay,[Ref.32252021]Ebola Virus(EBOV):inhibition of viral infection in Hela cells(IC50=0.99 µM);inhibition of viral infection in primary macrophages(IC50=2.2 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01806.cif,Linear,Free,Amidation,,D,Not found,"Act as CatB inhibitors to block the endosomal processing of EBOV GP, thus preventing virus entry.",2473.01,H-38O-19,ACDEFGHIKLMNPQRSTVWY,ACDEFGHIKLMNPQRSTVWY,11.0,0,0,0,0,0,0.0,0,,,,0.0,0,0.0,32252021,iScience. 2020 Apr 24;23(4):100999.,"Yu Y, Cooper CL, Wang G, Morwitzer MJ, Kota K, Tran JP, Bradfute SB, Liu Y, Shao J, Zhang AK, Luo LG, Reid SP, Hinrichs SH, Su K.",Engineered Human Cathelicidin Antimicrobial Peptides Inhibit Ebola Virus Infection.,10.1016/j.isci.2020.100999,,Anti-EBOV
DRAVPe01805,GXKRlVQRlKDXlRNLV,17,17BIPHE2,Synthetic construct(derived from LL-37),No entry found,,EBOV,Filoviridae,Plaque assay,[Ref.32252021]Ebola Virus(EBOV):inhibition of viral infection in Hela cells(IC50=0.71 µM);inhibition of viral infection in primary macrophages(IC50=5.6 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01805.cif,Linear,Free,Amidation,The 'X' at position 2 and 12 indicates biphenylalanine.,"Mixed(D-Leu5, 9, 13)",Not found,"Act as CatB inhibitors to block the endosomal processing of EBOV GP, thus preventing virus entry.",2030.86,C61H103N25O12,ACEFHIMPSTWY,R,11.72,5,1,4,2,3,-117.65,-6282,30 hour,>20 hour,>10 hour,57.06,0,0.0,32252021,iScience. 2020 Apr 24;23(4):100999.,"Yu Y, Cooper CL, Wang G, Morwitzer MJ, Kota K, Tran JP, Bradfute SB, Liu Y, Shao J, Zhang AK, Luo LG, Reid SP, Hinrichs SH, Su K.",Engineered Human Cathelicidin Antimicrobial Peptides Inhibit Ebola Virus Infection.,10.1016/j.isci.2020.100999,,Anti-EBOV
DRAVPe01803,RGAHINGRWDSRCHRF,16,FBP1,Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Plaque reduction assay,[Ref.35259078]influenza A virus(H1N1): inhibition of viral multicycle growth in MDCK cells(>50% inhibition at 100 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01803.cif,Linear,Free,Free,,L,HA,FBP could have dual functions: blocked HA-mediated fusion by binding and inhibited endosomal acidification from interfering viral entry by the endocytic pathway.,1968.19,C83H126N34O21S,EKLMPQTVY,R,11.52,6,1,5,5,4,-139.38,-7256,1 hour,2 min,2 min,30.63,5500,366.67,35259078,Emerg Microbes Infect. 2022 Dec;11(1):926-937.,"Zhao H, Meng X, Peng Z, Lam H, Zhang C, Zhou X, Chan JF, Kao RYT, To KK, Yuen KY.","Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants. ",10.1080/22221751.2022.2051753,,Anti-Anti-Influenza A virus
DRAVPe01804,RGAHIKGRWDSRCHRF,16,FBP2,Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Plaque reduction assay,[Ref.35259078]influenza A virus(H1N1): inhibition of viral multicycle growth in MDCK cells(>50% inhibition at 50 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01804.cif,Linear,Free,Free,,L,HA,FBP could have dual functions: blocked HA-mediated fusion by binding and inhibited endosomal acidification from interfering viral entry by the endocytic pathway.,1982.26,C85H132N34O20S,ELMNPQTVY,R,11.54,7,1,6,4,4,-141.88,-7147,1 hour,2 min,2 min,30.63,5500,366.67,35259078,Emerg Microbes Infect. 2022 Dec;11(1):926-937.,"Zhao H, Meng X, Peng Z, Lam H, Zhang C, Zhou X, Chan JF, Kao RYT, To KK, Yuen KY.","Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants. ",10.1080/22221751.2022.2051753,,Anti-Anti-Influenza A virus
DRAVPe01802,RGAHIKGRWKSRCHRF,16,FBP,Synthetic construct,No entry found,,"Influenza A virus, Influenza B virus, SARS-CoV-2","Orthomyxoviridae, Coronaviridae",Plaque reduction assay,[Ref.35259078]influenza A virus(H1N1): inhibition of viral multicycle growth in MDCK cells(IC50=3.9 μg/ml);##influenza A virus(H3N2): inhibition of viral replication in MDCK cells(IC50=1.6 μg/ml);##influenza B virus: inhibition of viral replication in MDCK cells(IC50=7.1 μg/ml);##SARS-CoV-2 HKU001a: inhibition of viral replication in Vero E6 cells(IC50=2.9 μg/ml);##SARS-CoV-2 B.1.1.63: inhibition of viral replication in Vero E6 cells(IC50=3.0 μg/ml);##SARS-CoV-2 Delta: inhibition of viral replication in Vero E6 cells(IC50=3.9 μg/ml).,[Ref.35259078]No significant haemolysis was observed when Turkey red blood cells (RBC) were treated with FBP.,[Ref.35259078]no significant cytotoxicity was detected in MDCK cells treated with 1 mg/ml of FBP.,,DRAVPe01802.cif,Linear,Free,Free,,L,HA,FBP could have dual functions: blocked HA-mediated fusion by binding and inhibited endosomal acidification from interfering viral entry by the endocytic pathway.the notable antiviral activity and fusion inhibition activity of FBP on SARS-CoV-2 could be attributed to the inhibition of FBP on endosomal acidification,1995.34,C87H139N35O18S,DELMNPQTVY,R,12.01,8,0,8,4,4,-144.38,-6830,1 hour,2 min,2 min,30.63,5500,366.67,35259078,Emerg Microbes Infect. 2022 Dec;11(1):926-937.,"Zhao H, Meng X, Peng Z, Lam H, Zhang C, Zhou X, Chan JF, Kao RYT, To KK, Yuen KY.","Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants. ",10.1080/22221751.2022.2051753,,"Anti-Anti-Influenza A virus, Anti-Influenza B virus, Anti-SARS-CoV-2"
DRAVPe01801,IPLRGAFINGRWDSQCHRFS,20,U5,Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Plaque reduction assay,[Ref.35259078]influenza A virus(H1N1): inhibition of viral replication in MDCK cells(IC50=12.9 μg/ml);,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01801.cif,Linear,Free,Free,,L,HA,Bind to the HA stem of group 1 influenza A virus.,2360.68,C105H158N34O27S,EKMTVY,R,10.26,4,1,3,6,7,-47.0,-4910,20 hour,30 min,>10 hour,63.5,5500,289.47,35259078,Emerg Microbes Infect. 2022 Dec;11(1):926-937.,"Zhao H, Meng X, Peng Z, Lam H, Zhang C, Zhou X, Chan JF, Kao RYT, To KK, Yuen KY.","Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants. ",10.1080/22221751.2022.2051753,,Anti-Anti-Influenza A virus
DRAVPe01800,FINGRWDSQCHRFSNGAIACA,21,U4,Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Plaque reduction assay,[Ref.35259078]influenza A virus(H1N1): inhibition of viral replication in MDCK cells(IC50=6.6 μg/ml);,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01800.cif,Linear,Free,Free,,L,HA,Bind to the HA stem of group 1 influenza A virus.,2353.62,C101H149N33O29S2,EKLMPTVY,A,8.08,3,1,2,8,8,-21.43,-4084,1.1 hour,3 min,2 min,51.43,5625,281.25,35259078,Emerg Microbes Infect. 2022 Dec;11(1):926-937.,"Zhao H, Meng X, Peng Z, Lam H, Zhang C, Zhou X, Chan JF, Kao RYT, To KK, Yuen KY.","Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants. ",10.1080/22221751.2022.2051753,,Anti-Anti-Influenza A virus
DRAVPe01799,WEDWVR,6,C6b,Synthetic construct(derived from gp36 membrane proximal external region of FIV),No entry found,,FIV,Retroviridae,,[Ref.30240422]Feline immunodeficiency virus (FIV): inhibition of virus replication in lymphoid cells(IC50>50 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01799.cif,Linear,Free,Free,,L,membrane,Elicit antiviral activity by inhibiting the fusion of the FIV and host cell membrane. ,889.97,C42H55N11O11,ACFGHIKLMNPQSTY,W,4.37,1,2,-1,0,3,-151.67,-2175,2.8 hour,3 min,2 min,48.33,11000,2200.0,30240422,PLoS One. 2018 Sep 21;13(9):e0204042,"Grimaldi M, Stillitano I, Amodio G, Santoro A, Buonocore M, Moltedo O, Remondelli P, D'Ursi AM.",Structural basis of antiviral activity of peptides from MPER of FIV gp36,10.1371/journal.pone.0204042,,Anti-FIV
DRAVPe01798,DWVRWI,6,C6a,Synthetic construct(derived from gp36 membrane proximal external region of FIV),No entry found,,FIV,Retroviridae,,[Ref.30240422]Feline immunodeficiency virus (FIV): inhibition of virus replication in lymphoid cells(IC50=0.06-0.15 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01798.cif,Linear,Free,Free,,L,membrane,Elicit antiviral activity by inhibiting the fusion of the FIV and host cell membrane. ,874.01,C43H59N11O9,ACEFGHKLMNPQSTY,W,5.84,1,1,0,0,4,-18.33,-1002,1.1 hour,3 min,>10 hour,113.33,11000,2200.0,30240422,PLoS One. 2018 Sep 21;13(9):e0204042,"Grimaldi M, Stillitano I, Amodio G, Santoro A, Buonocore M, Moltedo O, Remondelli P, D'Ursi AM.",Structural basis of antiviral activity of peptides from MPER of FIV gp36,10.1371/journal.pone.0204042,,Anti-FIV
DRAVPe01797,WEDWVRWI,8,C8,Synthetic construct(derived from gp36 membrane proximal external region of FIV),No entry found,,FIV,Retroviridae,,[Ref.30240422]Feline immunodeficiency virus (FIV): inhibition of virus replication in lymphoid cells(IC50=0.05-0.06 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01797.cif,Linear,Free,Free,,L,membrane,Elicit antiviral activity by inhibiting the fusion of the FIV and host cell membrane. ,1189.34,C59H76N14O13,ACFGHKLMNPQSTY,W,4.37,1,2,-1,0,5,-68.75,-1450,2.8 hour,3 min,2 min,85.0,16500,2357.14,30240422,PLoS One. 2018 Sep 21;13(9):e0204042,"Grimaldi M, Stillitano I, Amodio G, Santoro A, Buonocore M, Moltedo O, Remondelli P, D'Ursi AM.",Structural basis of antiviral activity of peptides from MPER of FIV gp36,10.1371/journal.pone.0204042,,Anti-FIV
DRAVPe01796,XGSGSGVALDPIDIAnti-SIVLNKAKSDLEESKEWIRRSNGKLDSI,42,Chol-PEG4-VG,Synthetic construct,No entry found,,HPIV 3,Paramyxoviridae,Plaque reduction assay,"[Ref.28344321]Human parainfluenza viruse 3(HPIV 3): inhibition of virus infection in Vero cells(IC90=0.1 ± 0.0001 nM,IC50<0.0007 nM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.28344321]Vero cells: CC50>10000 nM.,,DRAVPe01796.cif,Linear,Acetylation,Amidation,The 'X' at position 1 indicates cholesterol-PEG4 conjugated cysteine.,L,membrane,"Peptides derived from the HRC of paramyxovirus F proteins interfere with formation of the six-helix bundle in a dominant-negative manner by binding to the transiently exposed HRN coiled coil in the transient fusion intermediate, thereby inhibiting membrane fusion.",4510.27,C190H316N54O64,CFHMQTY,S,5.05,6,7,-1,13,14,-38.33,-8236,,,,102.14,5500,134.15,28344321,Sci Rep. 2017 Mar 8;7:43610.,"Mathieu C, Augusto MT, Niewiesk S, Horvat B, Palermo LM, Sanna G, Madeddu S, Huey D, Castanho MA, Porotto M, Santos NC, Moscona A",Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides,10.1038/srep43610,,Anti-HPIV 3
DRAVPe01795,XGSGSGVALDPIDIAnti-SIVLNKAKSDLEESKEWIRRSNGKLDSI,42,Chol-VG,Synthetic construct,No entry found,,HPIV 3,Paramyxoviridae,Plaque reduction assay,"[Ref.28344321]Human parainfluenza viruse 3(HPIV 3): inhibition of virus infection in Vero cells(IC90=1.7 ± 0.42 nM,IC50=0.06 ± 0.035 nM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.28344321]Vero cells: CC50=9000 nM.,,DRAVPe01795.cif,Linear,Acetylation,Amidation,The 'X' at position 1 indicates cholesterol-conjugated cysteine.,L,membrane,"Peptides derived from the HRC of paramyxovirus F proteins interfere with formation of the six-helix bundle in a dominant-negative manner by binding to the transiently exposed HRN coiled coil in the transient fusion intermediate, thereby inhibiting membrane fusion.",4510.27,C190H316N54O64,CFHMQTY,S,5.05,6,7,-1,13,14,-38.33,-8236,,,,102.14,5500,134.15,28344321,Sci Rep. 2017 Mar 8;7:43610.,"Mathieu C, Augusto MT, Niewiesk S, Horvat B, Palermo LM, Sanna G, Madeddu S, Huey D, Castanho MA, Porotto M, Santos NC, Moscona A",Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides,10.1038/srep43610,,Anti-HPIV 3
DRAVPe01794,VALDPIDIAnti-SIVLNKAKSDLEESKEWIRRSNGKLDSIGSGSGX,42,VG-PEG24-Chol,Synthetic construct,No entry found,,HPIV 3,Paramyxoviridae,Plaque reduction assay,"[Ref.28344321]Human parainfluenza viruse 3(HPIV 3): inhibition of virus infection in Vero cells(IC90=0.1 ± 0.0003 nM,IC50=0.007 ± 0.007 nM);##Nipah virus(NiV):inhibition of virus infection in Vero cells(IC90~2 nM.",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.28344321]Vero cells: CC50=1300 nM.,,DRAVPe01794.cif,Linear,Acetylation,Amidation,The 'X' at position 42 indicates cholesterol-PEG24 conjugated cysteine.,L,membrane,"Peptides derived from the HRC of paramyxovirus F proteins interfere with formation of the six-helix bundle in a dominant-negative manner by binding to the transiently exposed HRN coiled coil in the transient fusion intermediate, thereby inhibiting membrane fusion.",4510.27,C190H316N54O64,CFHMQTY,S,5.05,6,7,-1,13,14,-38.33,-8236,100 hour,>20 hour,>10 hour,102.14,5500,134.15,28344321,Sci Rep. 2017 Mar 8;7:43610.,"Mathieu C, Augusto MT, Niewiesk S, Horvat B, Palermo LM, Sanna G, Madeddu S, Huey D, Castanho MA, Porotto M, Santos NC, Moscona A",Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides,10.1038/srep43610,,Anti-HPIV 3
DRAVPe01792,VALDPIDIAnti-SIVLNKAKSDLEESKEWIRRSNGKLDSIGSGSGX,42,VG-Chol,Synthetic construct,No entry found,,HPIV 3,Paramyxoviridae,Plaque reduction assay,"[Ref.28344321]Human parainfluenza viruse 3(HPIV 3): inhibition of virus infection in Vero cells(IC90=0.7 ± 0.26 nM,IC50=0.015 ± 0.07 nM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.28344321]Vero cells: CC50+10000 nM.,,DRAVPe01792.cif,Linear,Acetylation,Amidation,The 'X' at position 42 indicates cholesterol-conjugated cysteine.,L,membrane,"Peptides derived from the HRC of paramyxovirus F proteins interfere with formation of the six-helix bundle in a dominant-negative manner by binding to the transiently exposed HRN coiled coil in the transient fusion intermediate, thereby inhibiting membrane fusion.",4510.27,C190H316N54O64,CFHMQTY,S,5.05,6,7,-1,13,14,-38.33,-8236,100 hour,>20 hour,>10 hour,102.14,5500,134.15,28344321,Sci Rep. 2017 Mar 8;7:43610.,"Mathieu C, Augusto MT, Niewiesk S, Horvat B, Palermo LM, Sanna G, Madeddu S, Huey D, Castanho MA, Porotto M, Santos NC, Moscona A",Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides,10.1038/srep43610,,Anti-HPIV 3
DRAVPe01793,VALDPIDIAnti-SIVLNKAKSDLEESKEWIRRSNGKLDSIGSGSGX,42,VG-PEG4-Chol,Synthetic construct,No entry found,,HPIV 3,Paramyxoviridae,Plaque reduction assay,"[Ref.28344321]Human parainfluenza viruse 3(HPIV 3): inhibition of virus infection in Vero cells(IC90=0.7 ± 0.007 nM,IC50=0.03 ± 0.04 nM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.28344321]Vero cells: CC50=4500 nM.,,DRAVPe01793.cif,Linear,Acetylation,Amidation,The 'X' at position 42 indicates cholesterol-PEG4 conjugated cysteine.,L,membrane,"Peptides derived from the HRC of paramyxovirus F proteins interfere with formation of the six-helix bundle in a dominant-negative manner by binding to the transiently exposed HRN coiled coil in the transient fusion intermediate, thereby inhibiting membrane fusion.",4510.27,C190H316N54O64,CFHMQTY,S,5.05,6,7,-1,13,14,-38.33,-8236,100 hour,>20 hour,>10 hour,102.14,5500,134.15,28344321,Sci Rep. 2017 Mar 8;7:43610.,"Mathieu C, Augusto MT, Niewiesk S, Horvat B, Palermo LM, Sanna G, Madeddu S, Huey D, Castanho MA, Porotto M, Santos NC, Moscona A",Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides,10.1038/srep43610,,Anti-HPIV 3
DRAVPe01791,VALDPIDIAnti-SIVLNKAKSDLEESKEWIRRSNGKLDSIGSGSGC,42,VG,Synthetic construct,No entry found,,HPIV 3,Paramyxoviridae,Plaque reduction assay,"[Ref.28344321]Human parainfluenza viruse 3(HPIV 3): inhibition of virus infection in Vero cells(IC90=280 ± 247 nM,IC50=1 nM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.28344321]Vero cells: CC50>10000 nM.,,DRAVPe01791.cif,Linear,Acetylation,Amidation,,L,membrane,"Peptides derived from the HRC of paramyxovirus F proteins interfere with formation of the six-helix bundle in a dominant-negative manner by binding to the transiently exposed HRN coiled coil in the transient fusion intermediate, thereby inhibiting membrane fusion.",4502.08,C193H323N55O66S,FHMQTY,S,5.05,6,7,-1,14,14,-32.38,-8108,100 hour,>20 hour,>10 hour,102.14,5500,134.15,28344321,Sci Rep. 2017 Mar 8;7:43610.,"Mathieu C, Augusto MT, Niewiesk S, Horvat B, Palermo LM, Sanna G, Madeddu S, Huey D, Castanho MA, Porotto M, Santos NC, Moscona A",Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides,10.1038/srep43610,,Anti-HPIV 3
DRAVPe01790,SKVNGQSGRMEFFWTIAK,18,m15 /Leu17,Synthetic construct(derived from influenza viral HA),No entry found,,Influenza A virus,Orthomyxoviridae,Infection assay,[Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>60% inhibition at 30 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01790.cif,Linear,Free,Free,,L,HA receptor binding domain (RBD),Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry.,2086.4,C94H144N26O26S,CDHLPY,FGKS,9.99,3,1,2,6,6,-48.89,-3109,1.9 hour,>20 hour,>10 hour,43.33,5500,323.53,27623031,ACS Infect Dis. 2016 Mar 11;2(3):187-93,"Chen Q, Guo Y",Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor,10.1021/acsinfecdis.5b00139,,Anti-Anti-Influenza A virus
DRAVPe01789,SKVNGQSGRMEFFWTALK,18,m14 /lle16,Synthetic construct(derived from influenza viral HA),No entry found,,Influenza A virus,Orthomyxoviridae,Infection assay,[Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>10% inhibition at 30 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01789.cif,Linear,Free,Free,,L,HA receptor binding domain (RBD),Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry.,2086.4,C94H144N26O26S,CDHIPY,FGKS,9.99,3,1,2,6,6,-52.78,-3109,1.9 hour,>20 hour,>10 hour,43.33,5500,323.53,27623031,ACS Infect Dis. 2016 Mar 11;2(3):187-93,"Chen Q, Guo Y",Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor,10.1021/acsinfecdis.5b00139,,Anti-Anti-Influenza A virus
DRAVPe01787,SKVNGQSGRMAFFWTILK,18,m9 /Glu11,Synthetic construct(derived from influenza viral HA),No entry found,,Influenza A virus,Orthomyxoviridae,Infection assay,[Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>50% inhibition at 30 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01787.cif,Linear,Free,Free,,L,HA receptor binding domain (RBD),Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry.,2070.44,C95H148N26O24S,CDEHPY,FGKS,11.17,3,0,3,6,7,-8.33,-1936,1.9 hour,>20 hour,>10 hour,65.0,5500,323.53,27623031,ACS Infect Dis. 2016 Mar 11;2(3):187-93,"Chen Q, Guo Y",Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor,10.1021/acsinfecdis.5b00139,,Anti-Anti-Influenza A virus
DRAVPe01788,SKVNGQSGRMEFAWTILK,18,m11 /Phe13,Synthetic construct(derived from influenza viral HA),No entry found,,Influenza A virus,Orthomyxoviridae,Infection assay,[Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>80% inhibition at 30 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01788.cif,Linear,Free,Free,,L,HA receptor binding domain (RBD),Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry.,2052.38,C91H146N26O26S,CDHPY,GKS,9.99,3,1,2,6,6,-43.33,-2915,1.9 hour,>20 hour,>10 hour,65.0,5500,323.53,27623031,ACS Infect Dis. 2016 Mar 11;2(3):187-93,"Chen Q, Guo Y",Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor,10.1021/acsinfecdis.5b00139,,Anti-Anti-Influenza A virus
DRAVPe01786,SKVNGQSGRAEFFWTILK,18,m8 /Met10,Synthetic construct(derived from influenza viral HA),No entry found,,Influenza A virus,Orthomyxoviridae,Infection assay,[Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>80% inhibition at 30 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01786.cif,Linear,Free,Free,,L,HA receptor binding domain (RBD),Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry.,2068.36,C95H146N26O26,CDHMPY,FGKS,9.99,3,1,2,6,7,-38.33,-2852,1.9 hour,>20 hour,>10 hour,65.0,5500,323.53,27623031,ACS Infect Dis. 2016 Mar 11;2(3):187-93,"Chen Q, Guo Y",Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor,10.1021/acsinfecdis.5b00139,,Anti-Anti-Influenza A virus
DRAVPe01785,SKVNGQAGRMEFFWTILK,18,m6 /Ser7,Synthetic construct(derived from influenza viral HA),No entry found,,Influenza A virus,Orthomyxoviridae,Infection assay,[Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(~60% inhibition at 30 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01785.cif,Linear,Free,Free,,L,HA receptor binding domain (RBD),Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry.,2112.48,C97H150N26O25S,CDHPY,FGK,9.99,3,1,2,5,7,-23.33,-2277,1.9 hour,>20 hour,>10 hour,65.0,5500,323.53,27623031,ACS Infect Dis. 2016 Mar 11;2(3):187-93,"Chen Q, Guo Y",Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor,10.1021/acsinfecdis.5b00139,,Anti-Anti-Influenza A virus
DRAVPe01784,SKVNGASGRMEFFWTILK,18,m5 /GIn6,Synthetic construct(derived from influenza viral HA),No entry found,,Influenza A virus,Orthomyxoviridae,Infection assay,[Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>60% inhibition at 30 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01784.cif,Linear,Free,Free,,L,HA receptor binding domain (RBD),Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry.,2071.42,C95H147N25O25S,CDHPQY,FGKS,9.99,3,1,2,6,7,-8.33,-2063,1.9 hour,>20 hour,>10 hour,65.0,5500,323.53,27623031,ACS Infect Dis. 2016 Mar 11;2(3):187-93,"Chen Q, Guo Y",Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor,10.1021/acsinfecdis.5b00139,,Anti-Anti-Influenza A virus
DRAVPe01783,SKVAGQSGRMEFFWTILK,18,m4 /Asn4,Synthetic construct(derived from influenza viral HA),No entry found,,Influenza A virus,Orthomyxoviridae,Infection assay,[Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>70% inhibition at 30 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01783.cif,Linear,Free,Free,,L,HA receptor binding domain (RBD),Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry.,2085.45,C96H149N25O25S,CDHNPY,FGKS,9.99,3,1,2,5,7,-8.33,-1953,1.9 hour,>20 hour,>10 hour,65.0,5500,323.53,27623031,ACS Infect Dis. 2016 Mar 11;2(3):187-93,"Chen Q, Guo Y",Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor,10.1021/acsinfecdis.5b00139,,Anti-Anti-Influenza A virus
DRAVPe01782,SKANGQSGRMEFFWTILK,18,m3 /Val3,Synthetic construct(derived from influenza viral HA),No entry found,,Influenza A virus,Orthomyxoviridae,Infection assay,[Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>50% inhibition at 30 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01782.cif,Linear,Free,Free,,L,HA receptor binding domain (RBD),Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry.,2100.42,C95H146N26O26S,CDHPVY,FGKS,9.99,3,1,2,6,6,-51.11,-3021,1.9 hour,>20 hour,>10 hour,48.89,5500,323.53,27623031,ACS Infect Dis. 2016 Mar 11;2(3):187-93,"Chen Q, Guo Y",Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor,10.1021/acsinfecdis.5b00139,,Anti-Anti-Influenza A virus
DRAVPe01781,SAVNGQSGRMEFFWTILK,18,m2 /Arg2 ,Synthetic construct(derived from influenza viral HA),No entry found,,Influenza A virus,Orthomyxoviridae,Infection assay,[Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(~20% inhibition at 30 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01781.cif,Linear,Free,Free,,L,HA receptor binding domain (RBD),Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry.,2071.38,C94H143N25O26S,CDHPY,FGS,8.46,2,1,1,6,7,-6.11,-2062,1.9 hour,>20 hour,>10 hour,65.0,5500,323.53,27623031,ACS Infect Dis. 2016 Mar 11;2(3):187-93,"Chen Q, Guo Y",Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor,10.1021/acsinfecdis.5b00139,,Anti-Anti-Influenza A virus
DRAVPe01780,AKVNGQSGRMEFFWTILK,18,m1 /Ser1,Synthetic construct(derived from influenza viral HA),No entry found,,Influenza A virus,Orthomyxoviridae,Infection assay,[Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>20% inhibition at 30 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01780.cif,Linear,Free,Free,,L,HA receptor binding domain (RBD),Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry.,2112.48,C97H150N26O25S,CDHPY,FGK,9.99,3,1,2,5,7,-23.33,-2277,4.4 hour,>20 hour,>10 hour,65.0,5500,323.53,27623031,ACS Infect Dis. 2016 Mar 11;2(3):187-93,"Chen Q, Guo Y",Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor,10.1021/acsinfecdis.5b00139,,Anti-Anti-Influenza A virus
DRAVPe01779,PxTXXLPX,8,"Plitidepsin, Aplidine",Synthetic construct,No entry found,,SARS-CoV-2,Coronaviridae,antiviral assay,"[Ref.33495306]SARS-CoV-2:inhibition of replication In Vero E6 cells(IC50=0.70 nM,IC90=1.76 nM);inhibition of replication In hACE2-HEK293T cells(IC50=0.73 nM,IC90=0.88 nM);inhibition of replication In pneumocyte-like cells(IC50=1.62 nM,IC90=3.14 nM).##[Ref.35231500]SARS-CoV-2 D614G:inhibition of replication in Vero E6 cells(IC50=5.2 nM);##SARS-CoV-2 Delta:inhibition of replication in Vero E6 cells(IC50=3.9 nM);##SARS-CoV-2 Omicron:inhibition of replication in Vero E6 cells(IC50=4.3 nM).",No hemolysis information or data found in the reference(s) presented in this entry,"[Ref.33495306]Vero E6 cells:CC10=0.36 nM,CC50=1.99 nM;hACE2-293T cells:CC10=2.00 nM,CC50>200 nM;pneumocyte-like cells:CC10=20.88 nM,CC50=65.43 nM.",,DRAVPe01779.cif,Linear,Pyruvoyl,Free,"The 'X' at position 2 is N-methylleucine,position 4 is 4-amino-3-hydroxy-5-methyl-Heptanoic acid, position 5 is Hydroxyisovalerylpropionyl, and position 8 is N-methyl-4-methyl-tyrosine.There is a Sidechain-Mainchain Bond between position 3 and 8.",Mixed(D-meth-Leu2),Not found,The antiviral activity of plitidepsin against SARS-CoV-2 is mediated through inhibition of the known target eEF1A (eukaryotic translation elongation factor 1A).,871.84,C20H26N4O2,ACDEFGHIKMNQRSVWY,X,5.96,0,0,0,1,1,-1.25,235,>20 hour,>20 hour,?,48.75,0,0.0,35231500##33495306,Antiviral Res. 2022 Apr;200:105270.##Science. 2021 Feb 26;371(6532):926-931. ,"Sachse M, Tenorio R, Fernández de Castro I, Muñoz-Basagoiti J, Perez-Zsolt D, Raïch-Regué D, Rodon J, Losada A, Avilés P, Cuevas C, Paredes R, Segalés J, Clotet B, Vergara-Alert J, Izquierdo-Useros N, Risco C.##White KM, Rosales R, Yildiz S, Kehrer T, Miorin L, Moreno E, Jangra S, Uccellini MB, Rathnasinghe R, Coughlan L, Martinez-Romero C, Batra J, Rojc A, Bouhaddou M, Fabius JM, Obernier K, Dejosez M, Guillén MJ, Losada A, Avilés P, Schotsaert M, Zwaka T, Vignuzzi M, Shokat KM, Krogan NJ, Garc",Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis.##Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. ,10.1016/j.antiviral.2022.105270##10.1126/science.abf4058,,Anti-SARS-CoV-2
DRAVPe01778,XxXVXAaXXXX,11,"Alisporivir, Debio-025",Synthetic construct,No entry found,,SARS-CoV-2,Coronaviridae,plaque assay,"[Ref.32376613]SARS-CoV-2:Inhibition of infection in Vero E6 cells(EC50=0.46±0.04 µM,E90=3.10±1.40 μM).##[Ref.32568027]SARS-CoV-2:Inhibition of infection in Vero E6 cells(EC50=4.9±1.3 µM);##SARS-CoV:Inhibition of infection in Vero E6 cells(EC50=4.3±1.0 µM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.32376613]Vero E6 cells:CC50>20µM.,,DRAVPe01778.cif,Cyclic,No specific N-terminal,No specific C-terminal,"The 'X' at position 1 is alpha-aminobutyric acid,position 2 is N-methylalanine,the 'V' at position 3 is N-methylalanine,the 'X' at position 5,8,9 are N-methylleucine,the 'X' at position 10 is N-methylvaline and position 11 is N-methyl-(4R)-4-[(E)-but-2-enyl]-4-methyl-L-threonyl","Mixed(D-Ala7,D-meth-Ala2)",Not found,Comment: No comments found on DRAMP database,0.0,C8H-2N2O-6,CDEFGHIKLMNPQRSTWY,X,0.0,0,0,0,0,2,54.55,585,,,,35.45,0,0.0,32376613##32568027,Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00876-20. ##J Gen Virol. 2020 Sep;101(9):925-940.,"Softic L, Brillet R, Berry F, Ahnou N, Nevers Q, Morin-Dewaele M, Hamadat S, Bruscella P, Fourati S, Pawlotsky JM, Ahmed-Belkacem A.##Ogando NS, Dalebout TJ, Zevenhoven-Dobbe JC, Limpens RWAL, van der Meer Y, Caly L, Druce J, de Vries JJC, Kikkert M, Bárcena M, Sidorov I, Snijder EJ.","Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025).##SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology.",10.1128/AAC.00876-20##10.1099/jgv.0.001453,,Anti-SARS-CoV-2
DRAVPe01777,ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL,35,P3,Synthetic construct,No entry found,,SARS-CoV-2,Coronaviridae,Neutralizing assay,[Ref.32482145]HCoV-19:inhibition of HCoV-19 S mediated cell–cell fusion(EC50=0.72 μM);neutralizing activities against pseudotype HCoV-19 virus(EC50=0.32 μM);inhibition of authentic HCoV-19 virus infection in Vero E6 cells(EC50=0.58 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01777.cif,Linear,Free,Free,,L,Not found,Comment: No comments found on DRAMP database,3893.41,C168H287N47O58,CFHMPTWY,ILN,4.36,3,6,-3,9,15,-8.29,-5930,20 hour,30 min,>10 hour,142.0,0,0.0,32482145,Emerg Microbes Infect. 2020 Dec;9(1):1238-1241.,"Sun H, Li Y, Liu P, Qiao C, Wang X, Wu L, Liu K, Hu Y, Su C, Tan S, Zou S, Wu G, Yan J, Gao GF, Qi J, Wang Q. ",Structural basis of HCoV-19 fusion core and an effective inhibition peptide against virus entry.,10.1080/22221751.2020.1770631,,Anti-SARS-CoV-2
DRAVPe01776,RGAHIKGRWKSRCHRF,16,FBP,Synthetic construct,No entry found,,SARS-CoV-2,Coronaviridae,Plaque reduction assay,"[Ref.35259078]A(H1N1)(IC50 = 3.9 μg/ml);A(H3N2)(IC50 = 1.6 μg/ml);FluB (IC50 = 7.1 μg/ml);##SARS-CoV-2 (HKU001a):inhibition of infection in Vero-E6 cells(IC50=2.9 μg/ml);##SARS-CoV-2 (B.1.1.63, D614G):inhibition of infection in Vero-E6 cells(IC50=3.0 μg/ml);##SARS-CoV-2(Delta):inhibition of infection in Vera-E6 cells(IC50=3.9 μg/ml).",[Ref.35259078]No significant hemolysis against Turkey red blood cells (RBC).,[Ref.35259078]No significant cytotoxicity was detected in MDCK(Madin Darby canine kidney) cells at 1 mg/ml(TC50 > 1 mg/ml).,,DRAVPe01776.cif,Linear,Free,Free,,L,membrane,The fusion-inhibition peptide FBP could broadly inhibit influenza virus and SARS-CoV-2 by interfering the viral fusion by the endocytic pathway and showed potently antiviral activity against the influenza virus in mice and SARS-CoV-2 variants in hamsters.,1995.34,C87H139N35O18S,DELMNPQTVY,R,12.01,8,0,8,4,4,-144.38,-6830,1 hour,2 min,2 min,30.63,5500,366.67,35259078,Emerg Microbes Infect. 2022 Dec;11(1):926-937.,"Zhao H, Meng X, Peng Z, Lam H, Zhang C, Zhou X, Chan JF, Kao RYT, To KK, Yuen KY.","Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants.",10.1080/22221751.2022.2051753,,Anti-SARS-CoV-2
DRAVPe01775,SALEEQYKTFLDKFMHELEDLLYQLAL,27,P10,Synthetic construct,No entry found,,SARS-CoV-2,Coronaviridae,plaque assay ,[Ref.33580154]SARS-CoV-2:95% inhibition of replication in Vero-E6 cells at 10 μM;inhibition of replication in Calu-3 cells(IC50=42 nM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.33580154]The peptide proved to be devoid of cell toxicity on Vero-E6 and Calu-3 cells.,,DRAVPe01775.cif,Linear,Free,Amidation,,L,Not found,"The peptide was designed mimicking the N-terminal helix of hACE2 protein,which could prevent the SARS-CoV-2 from infecting human cells, blocking the interaction between hACE2 and the virus spike protein.",3288.76,C152H231N33O46S,CGINPRVW,L,4.35,3,6,-3,4,11,-20.0,-3140,1.9 hour,>20 hour,>10 hour,108.52,2980,114.62,33580154,Commun Biol. 2021 Feb 12;4(1):197.,"Karoyan P, Vieillard V, Gómez-Morales L, Odile E, Guihot A, Luyt CE, Denis A, Grondin P, Lequin O.",Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection.,10.1038/s42003-021-01736-8,,Anti-SARS-CoV-2
DRAVPe01774,SALEEQYKTFLDKFMHELEDLLYQLSL,27,P9,Synthetic construct,No entry found,,SARS-CoV-2,Coronaviridae,plaque assay ,[Ref.33580154]SARS-CoV-2:93% inhibition of replication in Vero-E6 cells at 10 μM;inhibition of replication in Calu-3 cells(IC50=53 nM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.33580154]The peptide proved to be devoid of cell toxicity on Vero-E6 and Calu-3 cells.,,DRAVPe01774.cif,Linear,Free,Amidation,,L,Not found,"The peptide was designed mimicking the N-terminal helix of hACE2 protein,which could prevent the SARS-CoV-2 from infecting human cells, blocking the interaction between hACE2 and the virus spike protein.",3304.76,C152H231N33O47S,CGINPRVW,L,4.35,3,6,-3,5,10,-29.63,-3661,1.9 hour,>20 hour,>10 hour,104.81,2980,114.62,33580154,Commun Biol. 2021 Feb 12;4(1):197.,"Karoyan P, Vieillard V, Gómez-Morales L, Odile E, Guihot A, Luyt CE, Denis A, Grondin P, Lequin O.",Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection.,10.1038/s42003-021-01736-8,,Anti-SARS-CoV-2
DRAVPe01773,SALEEQLKTFLDKFMHELEDLLYQLAL,27,P8,Synthetic construct,No entry found,,SARS-CoV-2,Coronaviridae,plaque assay ,[Ref.33580154]SARS-CoV-2:91% inhibition of replication in Vero-E6 cells at 10 μM;inhibition of replication in Calu-3 cells(IC50=46 nM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.33580154]The peptide proved to be devoid of cell toxicity on Vero-E6 and Calu-3 cells.,,DRAVPe01773.cif,Linear,Free,Amidation,,L,Not found,"The peptide was designed mimicking the N-terminal helix of hACE2 protein,which could prevent the SARS-CoV-2 from infecting human cells, blocking the interaction between hACE2 and the virus spike protein.",3238.74,C149H233N33O45S,CGINPRVW,L,4.35,3,6,-3,3,12,-1.11,-2634,1.9 hour,>20 hour,>10 hour,122.96,1490,57.31,33580154,Commun Biol. 2021 Feb 12;4(1):197.,"Karoyan P, Vieillard V, Gómez-Morales L, Odile E, Guihot A, Luyt CE, Denis A, Grondin P, Lequin O.",Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection.,10.1038/s42003-021-01736-8,,Anti-SARS-CoV-2
DRAVPe01772,SALEEQYKTFLDKFLHELEDLLYQLALAL,29,P7,Synthetic construct,No entry found,,SARS-CoV-2,Coronaviridae,plaque assay ,[Ref.33580154]SARS-CoV-2:54% inhibition of replication in Vero-E6 cells at 10 μM;inhibition of replication in Calu-3 cells(IC50>1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01772.cif,Linear,Free,Amidation,,L,Not found,"The peptide was designed mimicking the N-terminal helix of hACE2 protein,which could prevent the SARS-CoV-2 from infecting human cells, blocking the interaction between hACE2 and the virus spike protein.",3454.96,C162H249N35O48,CGIMNPRVW,L,4.35,3,6,-3,4,14,7.24,-2210,1.9 hour,>20 hour,>10 hour,131.38,2980,106.43,33580154,Commun Biol. 2021 Feb 12;4(1):197.,"Karoyan P, Vieillard V, Gómez-Morales L, Odile E, Guihot A, Luyt CE, Denis A, Grondin P, Lequin O.",Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection.,10.1038/s42003-021-01736-8,,Anti-SARS-CoV-2
DRAVPe01771,RFDGKGLGIYQYMEEIEHAASRFAYFFYQHLA,32,Covid_extented_1,Synthetic construct,No entry found,,SARS-CoV-2,Coronaviridae,virus neutralization assay,[Ref.34624194]SARS-CoV-2:inhibition of infection in Vero cells(IC50=5.76 ± 1.65 μM);##SARS-CoV-2 variants B.1.1.7:inhibition of infection in Vero cells(IC50=5.57 ± 4.04 μM);##SARS-CoV-2 variants B.1.351:inhibition of infection in Vero cells(IC50=7.37 ± 1.80 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01771.cif,Linear,Acylation,Amidation,,D,Not found,The peptide acts as an inhibitor of the RBD–ACE2 interaction,3859.33,C181H253N45O48S,CNPTVW,AFY,6.03,5,4,1,8,12,-33.13,-4489,1 hour,2 min,2 min,61.25,5960,192.26,34624194,J Med Chem. 2021 Oct 28;64(20):14955-14967.,"Valiente PA, Wen H, Nim S, Lee J, Kim HJ, Kim J, Perez-Riba A, Paudel YP, Hwang I, Kim KD, Kim S, Kim PM. ",Computational Design of Potent D-Peptide Inhibitors of SARS-CoV-2.,10.1021/acs.jmedchem.1c00655,,Anti-SARS-CoV-2
DRAVPe01770,LQTALYALMEEIHIAALEKTWTALRHQYT,29,Covid3,Synthetic construct,No entry found,,SARS-CoV-2,Coronaviridae,virus neutralization assay,[Ref.34624194]SARS-CoV-2:inhibition of infection in Vero cells(IC50=6.56 ± 2.14 μM);##SARS-CoV-2 variants B.1.1.7:inhibition of infection in Vero cells(IC50=33.40 ± 10.75 μM);##SARS-CoV-2 variants B.1.351:inhibition of infection in Vero cells(IC50=11.13 ± 3.82 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01770.cif,Linear,Acylation,Amidation,,D,Not found,The peptide acts as an inhibitor of the RBD–ACE2 interaction ,3415.95,C156H244N40O44S,CDFGNPSV,AL,6.02,4,3,1,6,13,1.03,-2369,5.5 hour,3 min,2 min,111.38,8480,302.86,34624194,J Med Chem. 2021 Oct 28;64(20):14955-14967.,"Valiente PA, Wen H, Nim S, Lee J, Kim HJ, Kim J, Perez-Riba A, Paudel YP, Hwang I, Kim KD, Kim S, Kim PM. ",Computational Design of Potent D-Peptide Inhibitors of SARS-CoV-2.,10.1021/acs.jmedchem.1c00655,,Anti-SARS-CoV-2
DRAVPe01769,RVKR,4,CMK,Synthetic construct,No entry found,,SARS-CoV-2,Coronaviridae,Plaque assay,"[Ref.33007239]SARS-CoV-2:inhibition of virus production in Vero E6 cells(IC50=0.057 µM).##[Ref.31683742]Virus:Zika virus (ZIKV):inhibition of virus release in Vero cells(IC50=18.59 µM);Japanese encephalitis virus (JEV):inhibition of virus release in BHK-21 cells(IC50=19.91 µM).##[Ref.23617302]Hepatitis B virus (HBV):Inhibition of HBeAg secretion in HepG2.2.15 cells(26±11% inhibition at 20 µM,21±13% Inhibition at 100 µM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.31683742]Vero cells:CC50=712.9 µM.##[Ref.33007239]Vero E6 cells:IC50=318.2 µM.,,DRAVPe01769.cif,Linear,Decanoyl(C10),chloromethylketone(CMK),,L,Not found,"CMK blocks virus entry, but it further suppresses cleavage of spikes and the syncytium.",557.7,C23H47N11O5,ACDEFGHILMNPQSTWY,R,12.01,3,0,3,0,1,-217.5,-3135,1 hour,2 min,2 min,72.5,0,0.0,23617302##31683742##33007239,Liver Int. 2013 Sep;33(8):1230-8. ##Viruses. 2019 Oct 31;11(11):1011.##Cell Rep. 2020 Oct 13;33(2):108254.,"Pang YJ, Tan XJ, Li DM, Zheng ZH, Lei RX, Peng XM.##Imran M, Saleemi MK, Chen Z, Wang X, Zhou D, Li Y, Zhao Z, Zheng B, Li Q, Cao S, Ye J.##Cheng YW, Chao TL, Li CL, Chiu MF, Kao HC, Wang SH, Pang YH, Lin CH, Tsai YM, Lee WH, Tao MH, Ho TC, Wu PY, Jang LT, Chen PJ, Chang SY, Yeh SH.",Therapeutic potential of furin inhibitors for the chronic infection of hepatitis B virus.##Decanoyl-Arg-Val-Lys-Arg-Chloromethylketone: An Antiviral Compound That Acts against Flaviviruses through the Inhibition of Furin-Mediated prM Cleavage.##Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects. ,10.1111/liv.12185##10.3390/v11111011##10.1016/j.celrep.2020.108254,,Anti-SARS-CoV-2
DRAVPe01768,PHSCN,5,ATN-161,Synthetic construct,No entry found,,SARS-CoV-2,Coronaviridae,ELISA,[Ref.33102950]SARS-CoV-2:inhibition of virus replication In VeroE6 cells(IC50=3.16 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01768.cif,Linear,Acylation,Amidation,,L,Not found,The peptide inhibits the spike protein interaction with α5β1 integrin and the interaction between α5β1 integrin and ACE2.,556.59,C21H32N8O8S,ADEFGIKLMQRTVWY,CHNPS,7.12,1,0,1,3,0,-132.0,-1342,>20 hour,>20 hour,?,0.0,0,0.0,33102950,JACC Basic Transl Sci. 2021 Jan;6(1):1-8.,"Beddingfield BJ, Iwanaga N, Chapagain PP, Zheng W, Roy CJ, Hu TY, Kolls JK, Bix GJ.","The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection.",10.1016/j.jacbts.2020.10.003,,Anti-SARS-CoV-2
DRAVPe01767,ANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQ,42,SARS-CoV-2 HR1P,Synthetic construct,P0DTC2,,SARS-CoV-2,Coronaviridae,Cell-cell fusion assay,"[Ref.32047258]SARS-CoV-2(No inhibition of cell-cell fusion up to 40 µM in Huh-7 cells,No inhibition of infection up to 40 µM in 293T/ACE2 cells)",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01767.cif,Linear,Free,Free,,L,Not found,The peptide acted as a fusion inhibitor which against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection.,4386.89,C187H314N56O65,CEHMPRWY,AQ,8.54,3,2,1,14,17,-21.9,-6039,4.4 hour,>20 hour,>10 hour,100.0,0,0.0,32047258,Cell Mol Immunol. 2020 Jul;17(7):765-767.,"Xia S, Zhu Y, Liu M, Lan Q, Xu W, Wu Y, Ying T, Liu S, Shi Z, Jiang S, Lu L.",Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein.,10.1038/s41423-020-0374-2,,Anti-SARS-CoV-2
DRAVPe01766,SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSGC,42,EK1-GSGSGC,Synthetic construct,Q8BB25,,SARS-CoV-2,Coronaviridae,"Cell-cell fusion assay,infectivity assay","[Ref.33082259]SARS-CoV-2:ihibition of cell-cell fusion in 293T cells(IC50=293±60 nM,IC90>900 nM),inhibition of infection in Vero E6 cells(IC50~ 41 nM);##SARS-CoV-2_D614G:ihibition of cell-cell fusion in 293T cells(IC50=261±136 nM,IC90=892±100 nM);##SARS-CoV-2_S943P:ihibition of cell-cell fusion in 293T cells(IC50=286±104 nM,IC90>1000 nM);##SARS-CoV-2_S247R:ihibition of cell-cell fusion in 293T cells(IC50=194±107 nM,IC90=893±77 nM);##MERS-CoV:ihibition of cell-cell fusion in 293T cells(IC50>1000 nM,IC90>1000 nM),inhibition of infection in Vero E6 cells(IC50~ 2 nM);##SARS-CoV-1:ihibition of cell-cell fusion in 293T cells(IC50=36±5 nM,IC90>1000 nM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.33082259]Human embryonic kidney HEK293T cells:<5% Cytotoxicity at 10 µM;Vero E6 cells:18% Cytotoxicity at 10 µM.,,DRAVPe01766.cif,Linear,Free,Free,,L,membrane,The lipopeptide is derived from the C-terminal heptad repeat (HRC) domain of SARS-CoV-2 S that potently inhibits infection by SARS-CoV-2. ,4780.43,C211H341N49O72S2,HPRW,EL,4.36,5,10,-5,12,13,-37.86,-6573,1.9 hour,>20 hour,>10 hour,102.14,2980,72.68,33082259,mBio. 2020 Oct 20;11(5):e01935-20.,"Outlaw VK, Bovier FT, Mears MC, Cajimat MN, Zhu Y, Lin MJ, Addetia A, Lieberman NAP, Peddu V, Xie X, Shi PY, Greninger AL, Gellman SH, Bente DA, Moscona A, Porotto M.",Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain.,10.1128/mBio.01935-20,,Anti-SARS-CoV-2
DRAVPe01765,SLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKELGSGSGC,42,MERS-CoV-HR2P-GSGSGC,Synthetic construct,"R9UQ53,K9N5Q8",,SARS-CoV-2,Coronaviridae,"Cell-cell fusion assay,infectivity assay","[Ref.33082259]SARS-CoV-2:ihibition of cell-cell fusion in 293T cells(IC50>650 nM,IC90>1000 nM),inhibition of infection in Vero E6 cells(IC50~ 36 nM);##SARS-CoV-2_D614G:ihibition of cell-cell fusion in 293T cells(IC50=1000 nM,IC90>1000 nM);##SARS-CoV-2_S943P:ihibition of cell-cell fusion in 293T cells(IC50>1000,IC90>1000 nM);##SARS-CoV-2_S247R:ihibition of cell-cell fusion in 293T cells(IC50>700 nM,IC90>1000 nM);##MERS-CoV:ihibition of cell-cell fusion in 293T cells(IC50=417±180 nM,IC90>1000 nM),inhibition of infection in Vero E6 cells(IC50~ 4 nM);##SARS-CoV-1:ihibition of cell-cell fusion in 293T cells(IC50=40±34 nM,IC90>700 nM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.33082259]Human embryonic kidney HEK293T cells:<10% Cytotoxicity at 10 µM;Vero E6 cells:12% Cytotoxicity at 10 µM.,,DRAVPe01765.cif,Linear,Free,Free,,L,membrane,The lipopeptide is derived from the C-terminal heptad repeat (HRC) domain of SARS-CoV-2 S that potently inhibits infection by SARS-CoV-2. ,4590.23,C200H331N49O69S2,FHPRW,L,4.18,2,5,-3,17,14,10.48,-3597,1.9 hour,>20 hour,>10 hour,118.33,2980,72.68,33082259,mBio. 2020 Oct 20;11(5):e01935-20.,"Outlaw VK, Bovier FT, Mears MC, Cajimat MN, Zhu Y, Lin MJ, Addetia A, Lieberman NAP, Peddu V, Xie X, Shi PY, Greninger AL, Gellman SH, Bente DA, Moscona A, Porotto M.",Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain.,10.1128/mBio.01935-20,,Anti-SARS-CoV-2
DRAVPe01764,DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGSGSGC,42,SARS-CoV-2-S(1168–1203)-GSGSGC,Synthetic construct,P0DTC2,,SARS-CoV-2,Coronaviridae,"Cell-cell fusion assay,infectivity assay","[Ref.33082259]SARS-CoV-2:ihibition of cell-cell fusion in 293T cells(IC50=10±8 nM,IC90=98±57 nM),inhibition of infection in Vero E6 cells(IC50~ 6 nM);##SARS-CoV-2_D614G:ihibition of cell-cell fusion in 293T cells(IC50=8±4 nM,IC90=96±50 nM);##SARS-CoV-2_S943P:ihibition of cell-cell fusion in 293T cells(IC50=6±4 nM,IC90=75±42 nM);##SARS-CoV-2_S247R:ihibition of cell-cell fusion in 293T cells(IC50=9±7 nM,IC90=78±59 nM);##MERS-CoV:ihibition of cell-cell fusion in 293T cells(IC50=35±10 nM,IC90>1000 nM),inhibition of infection in Vero E6 cells(IC50~ 3 nM);##SARS-CoV-1:ihibition of cell-cell fusion in 293T cells(IC50=7±5 nM,IC90=43±6 nM).",No hemolysis information or data found in the reference(s) presented in this entry,"[Ref.33082259]Human embryonic kidney HEK293T cells:18% Cytotoxicity at 10 µM;Vero E6 cells:12% Cytotoxicity at 1 µM,30% Cytotoxicity at 10 µM;Human airway epithelial cells:25% Cytotoxicity at 1 µM.",,DRAVPe01764.cif,Linear,Free,Free,,L,membrane,The lipopeptide is derived from the C-terminal heptad repeat (HRC) domain of SARS-CoV-2 S that potently inhibits infection by SARS-CoV-2. ,4456.95,C187H316N54O69S,FHMPTWY,ILNS,4.2,3,7,-4,15,15,-15.95,-7072,1.1 hour,3 min,>10 hour,118.33,0,0.0,33082259##33597220,mBio. 2020 Oct 20;11(5):e01935-20.##Science. 2021 Mar 26;371(6536):1379-1382.,"Outlaw VK, Bovier FT, Mears MC, Cajimat MN, Zhu Y, Lin MJ, Addetia A, Lieberman NAP, Peddu V, Xie X, Shi PY, Greninger AL, Gellman SH, Bente DA, Moscona A, Porotto M.##de Vries RD, Schmitz KS, Bovier FT, Predella C, Khao J, Noack D, Haagmans BL, Herfst S, Stearns KN, Drew-Bear J, Biswas S, Rockx B, McGill G, Dorrello NV, Gellman SH, Alabi CA, de Swart RL, Moscona A, Porotto M.",Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain.##Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets.,10.1128/mBio.01935-20##10.1126/science.abf4896,,Anti-SARS-CoV-2
DRAVPe01763,NGAICWGPCPTAFRQIGNCGRFRVRCCRIR,30,8P9R(branched P9R),Synthetic construct,No entry found,,SARS-CoV-2,Coronaviridae,Plaque reduction assay,[Ref.33750821]SARS-CoV-2:inhibition of replication in high salt condition(IC50 = 0.3 μg/ml),[Ref.33750821]No obvious hemolysis was observed when turkey red blood cells were treated at 200 μg/ml.,[Ref.33750821]Vero-E6 cells:the cytotoxicity indicated that TC50 of 8P9R was higher than 200 μg/ml.,,DRAVPe01763.cif,Branched,Free,Free,,L,Not found,Have dual-antiviral mechanisms of cross-linking viruses to stop viral entry (mediated by TMPRSS2 for SARS-CoV-2) and of reducing endosomal acidification to inhibit viral entry through endocytic pathway.,3412.05,C144H232N52O35S5,DEHKLMSY,R,10.46,6,0,6,12,9,-15.0,-7004,1.4 hour,3 min,>10 hour,55.33,5750,198.28,33750821,Nat Commun. 2021 Mar 9;12(1):1517. ,"Zhao H, To KKW, Lam H, Zhou X, Chan JF, Peng Z, Lee ACY, Cai J, Chan WM, Ip JD, Chan CC, Yeung ML, Zhang AJ, Chu AWH, Jiang S, Yuen KY.",Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2.,10.1038/s41467-021-21825-w,,Anti-SARS-CoV-2
DRAVPe01762,NGAICWGPCPTAFRQIGNCGRFRVRCCRIR,30,"MBD-4 (11-40) (P9 [H21R,K23R,K28R], P9R)",Synthetic construct,P82019,6M56,SARS-CoV-2,Coronaviridae,Plaque reduction assay,[Ref.32843628]SARS-CoV-2:Inhibition of infection in Vero E6 cells(IC50=0.9 µg/ml);##SARS-CoV:Inhibition of infection in Vero E6 cells(IC50=4.2 µg/ml);##MERS-CoV:Inhibition of infection in Vero E6 cells(IC50=22 µg/ml);##Human rhinovirus (HRV):inhibition of infection in RD cells(IC50=5.7 µg/ml);##Human parainﬂuenza virus 3:Inhibition of infection in LLC-MK2 cells(IC50>25 µg/ml);##Human Influenza A Virus H1N1:Inhibition of infection In MDCK cells(IC50=0.6 µg/ml);##Human Influenza A Virus H7N9:Inhibition of infection In MDCK cells(IC50=0.9 µg/ml).,[Ref.32843628]P9R did not cause the hemolysis of Chicken red blood cells.,"[Ref.32843628]The CC50 of P9R was >300 μg/ml for MDCK, VeroE6 and A549 cells.",,DRAVPe01762.cif,Linear,Free,Free,,L,Not found,Mechanistic studies show that positively charged P9R broadly inhibits viral replication by binding to different viruses and then inhibits virus–host endosomal acidification to prevent the endosomal release of pH-dependent viruses. ,3412.05,C144H232N52O35S5,DEHKLMSY,R,10.46,6,0,6,12,9,-15.0,-7004,1.4 hour,3 min,>10 hour,55.33,5750,198.28,32843628,Nat Commun. 2020 Aug 25;11(1):4252.,"Zhao H, To KKW, Sze KH, Yung TT, Bian M, Lam H, Yeung ML, Li C, Chu H, Yuen KY.",A broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2.,10.1038/s41467-020-17986-9,,Anti-SARS-CoV-2
DRAVPe01761,NGAICWGPCPTAFRQIGNCGHFKVRCCKIR,30,MBD-4 (11-40)(P9),Synthetic construct,P82019,6M56,SARS-CoV-2,Coronaviridae,Plaque reduction assay,[Ref.32843628]SARS-CoV-2:Inhibition of infection in Vero E6 cells(IC50=2.4 µg/ml);##SARS-CoV:Inhibition of infection in Vero E6 cells(IC50=6.2 µg/ml);##MERS-CoV:Inhibition of infection in Vero E6 cells(IC50=8.8 µg/ml);##Human rhinovirus (HRV):inhibition of infection in RD cells(IC50=34 µg/ml);##Human parainﬂuenza virus 3:Inhibition of infection in LLC-MK2 cells(IC50>25 µg/ml);##Human Influenza A Virus H1N1:Inhibition of infection In MDCK cells(IC50=1.6 µg/ml);##Human Influenza A Virus H7N9:Inhibition of infection In MDCK cells(IC50=3.3 µg/ml).##[Ref.26911565]Human Influenza A Virus H1N1(IC50=1.2 µg/ml);Human Influenza A Virus H3N2(IC50=1.2 µg/ml);Human Influenza A Virus H5N1(IC50=2.4 µg/ml);Human Influenza A Virus H7N7(IC50=0.8 µg/ml);Human Influenza A Virus H7N9(IC50=4.6 µg/ml);MERS-CoV(IC50=4.8 µg/ml);SARS-CoV(IC50=4.8 µg/ml),No hemolysis information or data found in the reference(s) presented in this entry,[Ref.26911565]Cytotoxicity against Madin-Darby canine kidney cells(TC50=380 μg/ml).,,DRAVPe01761.cif,Linear,Free,Free,,L,Not found,Mechanistic studies show that positively charged P9 broadly inhibits viral replication by binding to different viruses and then inhibits virus–host endosomal acidification to prevent the endosomal release of pH-dependent viruses. ,3336.98,C144H227N47O35S5,DELMSY,C,9.41,6,0,6,12,9,-6.67,-4104,1.4 hour,3 min,>10 hour,55.33,5750,198.28,26911565##32843628,Sci Rep. 2016 Feb 25;6:22008. ##Nat Commun. 2020 Aug 25;11(1):4252.,"Zhao H, Zhou J, Zhang K, Chu H, Liu D, Poon VK, Chan CC, Leung HC, Fai N, Lin YP, Zhang AJ, Jin DY, Yuen KY, Zheng BJ.##Zhao H, To KKW, Sze KH, Yung TT, Bian M, Lam H, Yeung ML, Li C, Chu H, Yuen KY.",A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses. ##A broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2.,10.1038/srep22008##10.1038/s41467-020-17986-9,,Anti-SARS-CoV-2
DRAVPe01760,DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL,36,"2019-nCoV-HR2P(SARS-CoV-2-S(1168-1203),SARS-HR2P)",Synthetic construct,Q5DIC5,,SARS-CoV-2,Coronaviridae,Cell-cell fusion assay,"[Ref.32047258]SARS-CoV-2:ihibition of cell-cell fusion in Huh-7 cells(IC50=0.18 µM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=0.98 µM).##[Ref.30989115]SARS-CoV:ihibition of cell-cell fusion in Huh-7 cells(IC50=0.52±0.11 µM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=2.81 µM);##MERS-CoV:ihibition of cell-cell fusion in Huh-7 cells(IC50>5 µM);##HCoV-OC43:ihibition of cell-cell fusion in Huh-7 cells(IC50>5 µM);##HCoV-229E:ihibition of cell-cell fusion in Huh-7 cells(IC50>5 µM);##HCoV-NL63:ihibition of cell-cell fusion in Huh-7 cells(IC50>5 µM);##CoV-WIV1:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=2.73 µM);##CoV-Rs3367:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=3.05 µM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01760.cif,Linear,Free,Free,,L,membrane,2019-nCoV HR1 and HR2 regions are able to interact with each other to form 6-HB and suggest that 2019-nCoV-HR2P may inhibit 2019-nCoV fusion with and entry into the target cell.,4008.5,C172H292N48O61,CFHMPTWY,ILN,4.2,3,7,-4,9,15,-17.78,-6802,1.1 hour,3 min,>10 hour,138.06,0,0.0,30989115##32047258,Sci Adv. 2019 Apr 10;5(4):eaav4580.##Cell Mol Immunol. 2020 Jul;17(7):765-767.,"Xia S, Yan L, Xu W, Agrawal AS, Algaissi A, Tseng CK, Wang Q, Du L, Tan W, Wilson IA, Jiang S, Yang B, Lu L.##Xia S, Zhu Y, Liu M, Lan Q, Xu W, Wu Y, Ying T, Liu S, Shi Z, Jiang S, Lu L.",A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike.##Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein.,10.1126/sciadv.aav4580##10.1038/s41423-020-0374-2,,Anti-SARS-CoV-2
DRAVPe01758,AWDFGSLGGVFTSIGKALHQVFGAIYGAA,29,DENV2 Ep (419-447),Synthetic construct,Q9WDA6,,DENV-2,Flaviviridae,Plaque assay,[Ref.20881042]DENV2(dengue virus type 2): Inhibition of DENV-2 infection in BHK-21 cells (IC90~250µM),No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01758.cif,Linear,Free,Free,,L,low-pH endosome,"an initial, nonspecific interaction of the hydrophobicC terminus of the peptide inhibitor with the viral membranecarries it with the virion into the endosome, allowing aspecific interaction of the peptide with domain II as theprotein reconfigures, inhibiting the final zipping of thestem",2941.34,C139H202N34O37,CEMNPR,G,6.79,2,1,1,10,15,73.79,1974,4.4 hour,>20 hour,>10 hour,91.03,6990,249.64,20881042,J Virol. 2010 Dec;84(24):12549-54.,"Schmidt AG, Yang PL, Harrison SC.",Peptide inhibitors of flavivirus entry derived from the E protein stem.,10.1128/JVI.01440-10,,Anti-Anti-DENV-2
DRAVPe01759,GDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELG,38,SARS-CoV-S (1149–1186),Synthetic construct,P59594,,SARS-CoV,Coronaviridae,Fusion inhibition assay,"[Ref.15158473]SARS-CoV: inhibition of SARS-CoV cytopathic effect in Vero E6 cells ( synthetic HR2-38 IC50=0.5-5nM, GST-HR2-38 IC50=66.2nM)",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01759.cif,Linear,Free,Free,,L,GST,as GST-fusion polypeptide,4122.6,C176H298N50O63,CFHMPTWY,ILN,4.2,3,7,-4,11,15,-18.95,-6614,30 hour,>20 hour,>10 hour,130.79,0,0.0,15158473,Biochem Biophys Res Commun. 2004 Jun 18;319(1):283-8.,"Zhu J, Xiao G, Xu Y, Yuan F, Zheng C, Liu Y, Yan H, Cole DK, Bell JI, Rao Z, Tien P, Gao GF.",Following the rule: formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors.,10.1016/j.bbrc.2004.04.141,,Anti-SARS-CoV
DRAVPe01757,AWDFGSLGGVFTSIGKALHQVFGGAFGAA,29,"DENV2 Ep (419-447)[A24G,I25A,Y26F]",Synthetic construct,Q9WDA6,,DENV-2,Flaviviridae,Plaque assay,[Ref.20881042]DENV2(dengue virus type 2): Inhibition of DENV-2 infection in BHK-21 cells (IC90~2µM),No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01757.cif,Linear,Free,Free,,L,low-pH endosome,"an initial, nonspecific interaction of the hydrophobicC terminus of the peptide inhibitor with the viral membranecarries it with the virion into the endosome, allowing aspecific interaction of the peptide with domain II as theprotein reconfigures, inhibiting the final zipping of thestem",2869.23,C135H194N34O36,CEMNPRY,G,6.79,2,1,1,10,15,71.03,1888,4.4 hour,>20 hour,>10 hour,77.59,5500,196.43,20881042,J Virol. 2010 Dec;84(24):12549-54.,"Schmidt AG, Yang PL, Harrison SC.",Peptide inhibitors of flavivirus entry derived from the E protein stem.,10.1128/JVI.01440-10,,Anti-Anti-DENV-2
DRAVPe01756,ALNCYWPLNDYGFYTTTGIGYQPYRVVVLSFEL,33,SARS-CoV Sgp (471-503),Synthetic construct,P59594,,SARS-CoV,Coronaviridae,Plaque reduction assay,[Ref.16153058]SARS-CoV(Severe acute respiratory syndrome): inhibition of SARS-CoV infction in Vero cells (EC50=41.6µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01756.cif,Linear,Free,Free,,L,not found,"block the binding between the RBD and angiotensin-convertingenzyme 2, resulting in the inhibition of SARS-CoV entrance into host cells in vitro",3864.39,C184H260N40O50S,HKM,Y,4.37,1,2,-1,15,12,16.67,-1016,4.4 hour,>20 hour,>10 hour,88.48,12950,404.69,16153058,J Comb Chem. 2005 Sep-Oct;7(5):648-56.,"Hu H, Li L, Kao RY, Kou B, Wang Z, Zhang L, Zhang H, Hao Z, Tsui WH, Ni A, Cui L, Fan B, Guo F, Rao S, Jiang C, Li Q, Sun M, He W, Liu G.",Screening and identification of linear B-cell epitopes and entry-blocking peptide of severe acute respiratory syndrome (SARS)-associated coronavirus using synthetic overlapping peptide library.,10.1021/cc0500607,,Anti-SARS-CoV
DRAVPe01755,SLTQINTTLLDLEYEMRSLQQVVKALNESYIDLKEL,36,"MERS-CoV-HR2P [T1263E,L1267R]",Synthetic construct,K9N5Q8,,MERS-CoV,Coronaviridae,Cell–cell fusion,[Ref.24473083]MERS-COV(Middle East respiratory syndrome coronavirus): inhibition of cell–cell fusion infection in Huh-7 and 293T/MERS/EGFP cells (IC50=0.93±0.15µM); inhibition of MERS-CoV infection in Vero cells (IC50=0.6µM); inhibition of MERS-CoV infection in Calu-3 cells (IC50=0.6µM); inhibition of MERS-CoV infection in HFL cells (IC50=13.9µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.24473083]HR2P has low or no in vitro toxic effect.,,DRAVPe01755.cif,Linear,Free,Free,,L,HR1 domain,"interact with the viral HR1 domain to form heterologous 6-HB and block viral fusion coreformation, resulting in inhibition of MERS-CoV S protein-mediated membrane fusion.",4212.82,C186H308N46O62S,CFGHPW,L,4.36,3,6,-3,10,13,-17.78,-5735,1.9 hour,>20 hour,>10 hour,127.22,2980,85.14,24473083,Nat Commun. 2014;5:3067.,"Lu L, Liu Q, Zhu Y, Chan KH, Qin L, Li Y, Wang Q, Chan JF, Du L, Yu F, Ma C, Ye S, Yuen KY, Zhang R, Jiang S.",Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor.,10.1038/ncomms4067,,Anti-MERS-CoV
DRAVPe01754,LTQINTTLLDLTYEMLSLQQVVKALNESYIDLKEL,35,MERS-S (1252-1286),Synthetic construct,K9N5Q8##R9UQ53,,MERS-CoV PsV,Coronaviridae,pseudovirus entry inhibition assay,[Ref.24067982]MERS-COV(Middle East respiratory syndrome coronavirus): inhibition of MERS-CoV PsV infection in 293T/Huh7 cells (EC50~3.013µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01754.cif,Linear,Free,Free,,L,membrane,inhibit MERS-CoV fusion and entry by using a pseudotyped-virus system,4054.71,C182H302N42O59S,CFGHPRW,L,4.18,2,5,-3,10,14,15.71,-2987,5.5 hour,3 min,2 min,142.0,2980,87.65,24067982,J Virol. 2013 Dec;87(24):13134-40.,"Gao J, Lu G, Qi J, Li Y, Wu Y, Deng Y, Geng H, Li H, Wang Q, Xiao H, Tan W, Yan J, Gao GF.",Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus.,10.1128/JVI.02433-13,,Anti-MERS-CoV
DRAVPe01753,RIQQIEQKIHHIEQRIQQIEQRISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL,59,T21N36,Synthetic construct,A1YNW7,,HIV-1,Retroviridae,Cell-cell fusion assay,[Ref.31932193]HIV-1(human immunodeficiency virus 1): inhiition of cell-cell fusion between TZM-bl cells and HL2/3 cells(IC50=81.8±5.69nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01753.cif,Linear,Acetylation,Free,,L,gp41,function as potent inhibitors of viral infection by forming a coiled-coil structure covalently stabilized by interchain disulfide bonds,7070.23,C312H526N100O87,CDFMPY,Q,10.78,10,4,6,6,24,-45.25,-12299,1 hour,2 min,2 min,133.9,5500,94.83,31932193,Bioorg Med Chem. 2020 Feb 15;28(4):115214.,"Lai W, Wang C, Yan J, Liu H, Zhang W, Lin B, Xi Z.",Suitable fusion of N-terminal heptad repeats to achieve covalently stabilized potent N-peptide inhibitors of HIV-1 infection.,10.1016/j.bmc.2019.115214,,Anti-HIV-1
DRAVPe01752,RIQQIEQKIHHIEQRIQQIEQRAIEAQQHLLQLTVWGIKQLQARIL,46,T21N23,Synthetic construct,,,HIV-1,Retroviridae,Cell-cell fusion assay,[Ref.31932193]HIV-1(human immunodeficiency virus 1): inhiition of cell-cell fusion between TZM-bl cells and HL2/3 cells(IC50=38.9±35.8nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01752.cif,Linear,Acetylation,Free,,L,gp41,function as potent inhibitors of viral infection by forming a coiled-coil structure covalently stabilized by interchain disulfide bonds,5605.54,C249H417N79O68,CDFMNPSY,Q,9.97,9,4,5,2,19,-52.83,-9943,1 hour,2 min,2 min,131.52,5500,122.22,31932193,Bioorg Med Chem. 2020 Feb 15;28(4):115214.,"Lai W, Wang C, Yan J, Liu H, Zhang W, Lin B, Xi Z.",Suitable fusion of N-terminal heptad repeats to achieve covalently stabilized potent N-peptide inhibitors of HIV-1 infection.,10.1016/j.bmc.2019.115214,,Anti-HIV-1
DRAVPe01751,RIQQIEQKIHHIEQRIQQIEQLLQLTVWGIKQLQARIL,38,T21N17,Synthetic construct,,,HIV-1,Retroviridae,Cell-cell fusion assay,[Ref.31932193]HIV-1(human immunodeficiency virus 1): inhiition of cell-cell fusion between TZM-bl cells and HL2/3 cells(IC50=251±41.1nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01751.cif,Linear,Acetylation,Free,,L,gp41,function as potent inhibitors of viral infection by forming a coiled-coil structure covalently stabilized by interchain disulfide bonds,4671.52,C210H354N64O56,CDFMNPSY,Q,9.98,7,3,4,2,16,-37.37,-7050,1 hour,2 min,2 min,143.68,5500,148.65,31932193,Bioorg Med Chem. 2020 Feb 15;28(4):115214.,"Lai W, Wang C, Yan J, Liu H, Zhang W, Lin B, Xi Z.",Suitable fusion of N-terminal heptad repeats to achieve covalently stabilized potent N-peptide inhibitors of HIV-1 infection.,10.1016/j.bmc.2019.115214,,Anti-HIV-1
DRAVPe01750,LHQNIVDVQYMYGLS,15,"HCV gp (696–710), E2-79",Synthetic construct,Q99IB8,,HCV,Flaviviridae,HCV infection assay,[Ref.28638089]HCV(Hepatitis C virus): inhibition of HCVcc infection in Huh7.5/CD81 cells (IC50=1~5nM),No hemolysis information or data found in the reference(s) presented in this entry,[Ref.28638089]have no effect on the viability of Huh7.5-CD81 cells at concentrations of 10 nM,,DRAVPe01750.cif,Linear,Free,Free,,L,Envelope protein,"Inhibits HCV entry at the post-attachment step and block cell-to-cell transmission, inhibit the late steps of HCV life cycle, such as HCV package and release.",1780.03,C80H122N20O24S,ACEFKPRTW,LQVY,5.08,1,1,0,5,5,9.33,-865,5.5 hour,3 min,2 min,116.67,2980,212.86,28638089,A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2.,"Yin P, Zhang L, Ye F, Deng Y, Lu S, Li YP, Zhang L, Tan W.",A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2.,10.1038/s41598-017-04274-8,,Anti-HCV
DRAVPe01749,GLLHLHQNIVDVQYM,15,"HCV gp (692–706), E2-78",Synthetic construct,Q99IB8,,HCV,Flaviviridae,HCV infection assay,[Ref.28638089]HCV(Hepatitis C virus): inhibition of HCVcc infection in Huh7.5/CD81 cells (IC50=1~5nM),No hemolysis information or data found in the reference(s) presented in this entry,[Ref.28638089]have no effect on the viability of Huh7.5-CD81 cells at concentrations of 10 nM,,DRAVPe01749.cif,Linear,Free,Free,,L,Envelope protein,"Inhibits HCV entry at the post-attachment step and block cell-to-cell transmission, inhibit the late steps of HCV life cycle, such as HCV package and release.",1780.07,C80H126N22O22S,ACEFKPRSTW,L,5.97,2,1,1,3,6,27.33,-485,30 hour,>20 hour,>10 hour,142.67,1490,106.43,28638089,A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2.,"Yin P, Zhang L, Ye F, Deng Y, Lu S, Li YP, Zhang L, Tan W.",A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2.,10.1038/s41598-017-04274-8,,Anti-HCV
DRAVPe01748,FGCTWMNSTGFTKTC,15,"HCV gp (552–566), E2-43",Synthetic construct,Q99IB8,,HCV,Flaviviridae,HCV infection assay,[Ref.28638089]HCV(Hepatitis C virus): inhibition of HCVcc infection in Huh7.5/CD81 cells (IC50=1~5nM),No hemolysis information or data found in the reference(s) presented in this entry,[Ref.28638089]have no effect on the viability of Huh7.5-CD81 cells at concentrations of 10 nM,,DRAVPe01748.cif,Linear,Free,Free,,L,Envelope protein,"Inhibits HCV entry at the post-attachment step and block cell-to-cell transmission, inhibit the late steps of HCV life cycle, such as HCV package and release.",1683.93,C73H106N18O22S3,ADEHILPQRVY,T,8.06,1,0,1,10,3,-1.33,-1079,1.1 hour,3 min,2 min,0.0,5625,401.79,28638089,A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2.,"Yin P, Zhang L, Ye F, Deng Y, Lu S, Li YP, Zhang L, Tan W.",A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2.,10.1038/s41598-017-04274-8,,Anti-HCV
DRAVPe01747,QGSWFGCTWMNSTGF,18,"HCV gp (548–562), E2-42",Synthetic construct,Q99IB8,,HCV,Flaviviridae,HCV infection assay,[Ref.28638089]HCV(Hepatitis C virus): inhibition of HCVcc infection in Huh7.5/CD81 cells (IC50=1~5nM),No hemolysis information or data found in the reference(s) presented in this entry,[Ref.28638089]have no effect on the viability of Huh7.5-CD81 cells at concentrations of 10 nM,,DRAVPe01747.cif,Linear,Free,Free,,L,Envelope protein,"Inhibits HCV entry at the post-attachment step and block cell-to-cell transmission, inhibit the late steps of HCV life cycle, such as HCV package and release.",1708.88,C77H101N19O22S2,ADEHIKLPRVY,G,5.52,0,0,0,9,4,-20.0,-705,0.8 hour,10 min,>10 hour,0.0,11000,785.71,28638089,A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2.,"Yin P, Zhang L, Ye F, Deng Y, Lu S, Li YP, Zhang L, Tan W.",A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2.,10.1038/s41598-017-04274-8,,Anti-HCV
DRAVPe01746,VEPGQLKLNWFKK,13,P7(DENV-2 gp (662-674)),Synthetic construct,P14340,,"DENV-1, DENV-2",Flaviviridae,Plaque assay,"[Ref.29709564]DENV-2(dengue virus serotype 2): inhibition of virus entry in HUVECs(human umbilical vein endothelial cells)(65 ± 6% inhibition at 40 μM,55± 12% inhibition at 20 μM,41± 13% inhibition at 10 μM,IC50=12.86±5.96µM);##DENV-1(dengue virus serotype 1): inhibition of virus entry in HUVECs(human umbilical vein endothelial cells)(65 ± 12% inhibition at 40 μM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.29709564]No toxic effect on HUVEC(Human umbilical vein endothelial cells) at concentrations up to 100 µM,,DRAVPe01746.cif,Linear,Free,Free,,L,β3 integrin,might be involved in blocking viral entry via occupying the binding site in the receptor on the host cell(β3 integrin).,1586.9,C76H119N19O18,ACDHIMRSTY,K,9.7,3,1,2,2,5,-80.77,-1551,100 hour,>20 hour,>10 hour,82.31,5500,458.33,29709564,Antiviral Res. 2018 Jul;155:20-27.,"Cui X, Wu Y, Fan D, Gao N, Ming Y, Wang P, An J.",Peptides P4 and P7 derived from E protein inhibit entry of dengue virus serotype 2 via interacting with β3 integrin.,10.1016/j.antiviral.2018.04.018,,"Anti-Anti-DENV-1, Anti-Anti-DENV-2"
DRAVPe01745,CKIPFEIMDLEKRHV,15,P4(DENV-2 gp (613-627)),Synthetic construct,P14340,,DENV-2,Flaviviridae,Plaque assay,"[Ref.29709564]DENV-2(dengue virus serotype 2): inhibition of virus entry in HUVECs(human umbilical vein endothelial cells)(70 ± 9% inhibition at 40 μM,44 ± 10% inhibition at 20 μM,40± 6% inhibition at 10 μM,IC50=19.08±2.52µM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.29709564]No toxic effect on HUVEC(Human umbilical vein endothelial cells) at concentrations up to 100 µM,,DRAVPe01745.cif,Linear,Free,Free,,L,β3 integrin,might be involved in blocking viral entry via occupying the binding site in the receptor on the host cell(β3 integrin).,1858.25,C83H136N22O22S2,AGNQSTWY,EIK,6.75,4,3,1,1,5,-22.67,-2761,1.2 hour,>20 hour,>10 hour,97.33,0,0.0,29709564,Antiviral Res. 2018 Jul;155:20-27.,"Cui X, Wu Y, Fan D, Gao N, Ming Y, Wang P, An J.",Peptides P4 and P7 derived from E protein inhibit entry of dengue virus serotype 2 via interacting with β3 integrin.,10.1016/j.antiviral.2018.04.018,,Anti-Anti-DENV-2
DRAVPe01733,GNHILSLVQNAPYGLYFIHFSW,22,MHV (1096–1117)[Y1117W],Synthetic construct,P11224,,MHV,,Plaque reduction assay,[Ref.16616792]MHV(murine hepatitis virus): inhibition of virus infection in L2 cells(22% inhibition at 30 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.16616792]No cytotoxic at a concentration of 30 μM on L2 cells,,DRAVPe01733.cif,Linear,Free,Free,,L,cell membrane,inhibits viral entry through coiled coil interactions.,2576.94,C125H174N30O30,CDEKMRT,L,6.92,2,0,2,8,10,34.55,540,30 hour,>20 hour,>10 hour,106.36,8480,403.81,16616792,Virus Res. 2006 Sep;120(1-2):146-55.,"Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF.",Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein.,10.1016/j.virusres.2006.03.001,,Anti-MHV
DRAVPe01734,GYFVQDDGEWKFTGSSYYY,19,MHV (1144–1162),Synthetic construct,P11224,,MHV,,Plaque reduction assay,"[Ref.16616792]MHV(murine hepatitis virus): inhibition of virus infection in L2 cells(98% inhibition at 30 Μm, IC50=4 μM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.16616792]No cytotoxic at a concentration of 30 μM on L2cells,,DRAVPe01734.cif,Linear,Free,Free,,L,cell membrane,inhibits viral entry through coiled coil interactions.,2312.43,C110H138N22O34,ACHILMNPR,Y,4.03,1,3,-2,10,4,-93.16,-3012,30 hour,>20 hour,>10 hour,15.26,11460,636.67,16616792,Virus Res. 2006 Sep;120(1-2):146-55.,"Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF.",Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein.,10.1016/j.virusres.2006.03.001,,Anti-MHV
DRAVPe01732,AACEVAKNLNESLIDLQELGKYEQYIKW,28,AAC-SARS-CoV (1170–1194),Synthetic construct,Q19QX0,,SARS-CoV,Coronaviridae,Plaque reduction assay,[Ref.16616792]SARS-CoV: inhibition of  virus infection in Vero-E6 cells(42% inhibition at 30 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.16616792]No cytotoxic at a concentration of 30 μM on Vero-E6 cells,,DRAVPe01732.cif,Linear,Free,Free,,L,cell membrane,inhibits viral entry through coiled coil interactions.,3269.72,C147H230N36O46S,FHMPRT,EL,4.59,3,5,-2,7,11,-41.43,-3711,4.4 hour,>20 hour,>10 hour,104.64,8480,314.07,16616792,Virus Res. 2006 Sep;120(1-2):146-55.,"Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF.",Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein.,10.1016/j.virusres.2006.03.001,,Anti-SARS-CoV
DRAVPe01731,GVFVFNGTSWFITQRNFFS,19,SARS-CoV (1075–1093),Synthetic construct,Q19QX0,,SARS-CoV,Coronaviridae,Plaque reduction assay,"[Ref.16616792]SARS-CoV: inhibition of  virus infection in Vero-E6 cells(83% inhibition at 30 μM,IC50~2 μM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.16616792]No cytotoxic at a concentration of 30 μM on Vero-E6 cells,,DRAVPe01731.cif,Linear,Free,Free,,L,cell membrane,inhibits viral entry through coiled coil interactions.,2254.53,C109H148N26O27,ACDEHKLMPY,F,9.75,1,0,1,8,9,37.89,-1357,30 hour,>20 hour,>10 hour,51.05,5500,305.56,16616792,Virus Res. 2006 Sep;120(1-2):146-55.,"Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF.",Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein.,10.1016/j.virusres.2006.03.001,,Anti-SARS-CoV
DRAVPe01730,GYHLMSFPQAAP-HGVVFLHVTW,22,SARS-CoV (1028–1049)[Y1049W],Synthetic construct,Q19QX0,,SARS-CoV,Coronaviridae,Plaque reduction assay,"[Ref.16616792]SARS-CoV: inhibition of  virus infection in Vero-E6 cells(90% inhibition at 30 μM,IC50~2 μM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.16616792]No cytotoxic at a concentration of 30 μM on Vero-E6 cells,,DRAVPe01730.cif,Linear,Free,Free,,L,cell membrane,inhibits viral entry through coiled coil interactions.,2607.98,C120H166N30O26S,CDEIKNR,HV,7.02,3,0,3,5,10,45.65,1247,30 hour,>20 hour,>10 hour,80.43,6990,317.73,16616792,Virus Res. 2006 Sep;120(1-2):146-55.,"Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF.",Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein.,10.1016/j.virusres.2006.03.001,,Anti-SARS-CoV
DRAVPe01729,ATAGWTFGAGAALQIPFAMQMAY,23,SARS-CoV (864-886),Synthetic construct,Q19QX0,,SARS-CoV,Coronaviridae,Plaque reduction assay,[Ref.16616792]SARS-CoV: inhibition of  virus infection in Vero-E6 cells(39% inhibition at 30 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.16616792]No cytotoxic at a concentration of 30 μM on Vero-E6 cells,,DRAVPe01729.cif,Linear,Free,Free,,L,cell membrane,inhibits viral entry through coiled coil interactions.,2374.76,C110H160N26O29S2,CDEHKNRSV,A,5.57,0,0,0,6,12,73.48,2196,4.4 hour,>20 hour,>10 hour,64.35,6990,317.73,16616792,Virus Res. 2006 Sep;120(1-2):146-55.,"Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF.",Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein.,10.1016/j.virusres.2006.03.001,,Anti-SARS-CoV
DRAVPe01727,TLKPIFKLPLGINITNFR,18,"SARS-CoV-S (215-232), peptide 9626",Synthetic construct,P59594,,SARS-CoV PsV,Coronaviridae,western blot,[Ref.19853613]SARS-COV: inhibition of SARS-CoV/HIV PsV virus infection in 293T/ACE2 cells (IC50=11µM); inhibition of SARS-CoV/HIV PsV virus entry in 293T/ACE2 cells(80% at 50µM) ,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01727.cif,Linear,Free,Free,,L,not found,"Presumably inhibit virus entry by binding to Spike protein, hACE2, or an unknown co-receptor.",2085.56,C100H165N25O23,ACDEHMQSVWY,IL,11.17,3,0,3,5,8,34.44,-802,7.2 hour,>20 hour,>10 hour,130.0,0,0.0,19853613,J Mol Biol. 2009 Dec 11;394(4):600-5.,"Guo Y, Tisoncik J, McReynolds S, Farzan M, Prabhakar BS, Gallagher T, Rong L, Caffrey M.",Identification of a new region of SARS-CoV S protein critical for viral entry.,10.1016/j.jmb.2009.10.032,,Anti-SARS-CoV PsV
DRAVPe01728,MWKTPTLKYFGGFNFSQIL,19,SARS-CoV (770-788)[Y771W],Synthetic construct,Q19QX0,,SARS-CoV,Coronaviridae,Plaque reduction assay,[Ref.16616792]SARS-CoV: inhibition of  virus infection in Vero-E6 cells(58% inhibition at 30 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.16616792]No cytotoxic at a concentration of 30 μM on Vero-E6 cells,,DRAVPe01728.cif,Linear,Free,Free,,L,cell membrane,inhibits viral entry through coiled coil interactions.,2278.7,C111H160N24O26S,ACDEHRV,F,9.7,2,0,2,7,7,4.21,-170,30 hour,>20 hour,>10 hour,61.58,6990,388.33,16616792,Virus Res. 2006 Sep;120(1-2):146-55.,"Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF.",Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein.,10.1016/j.virusres.2006.03.001,,Anti-SARS-CoV
DRAVPe01726,QNQSANQFQKEISQINEVLTTTNTSLGKLQDDVNQNNQSLNTLQKE,46,"N46eg(SARS-CoV (902-947)[K2N,I4S,N9Q,A11E,Q16N,S18V,S23N,A25S,V32D,A37N,A39S,V44Q,Q46E])",Synthetic construct,P59594,,SARS-CoV,Coronaviridae,cell fusion inhibition assay,[Ref.18983873]SARS-CoV:inhibition of cell fusion in Hela cells (IC50=5.07 ± 0.17 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18983873]No discernable cytotoxicity on HeLa or VeroE6 cells at the concentrations of 25 μM.,,DRAVPe01726.cif,Linear,Free,Free,,L,membrane,"Binding to the HR2 region and blocking the formation of  a 6-helix bundle during the fusion step of virus entry, thus inhibiting virus entry.",5205.59,C216H356N66O83,CHMPRWY,Q,4.51,3,5,-2,18,11,-119.13,-13570,0.8 hour,10 min,>10 hour,74.13,0,0.0,18983873,Antiviral Res. 2009 Jan;81(1):82-7.,"Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, Wang WK.",Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors.,10.1016/j.antiviral.2008.10.001,,Anti-SARS-CoV
DRAVPe01725,QKQIANQFNKAISQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQ,46,N46(SARS-CoV (902-947)),Synthetic construct,P59594,,SARS-CoV,Coronaviridae,cell fusion inhibition assay,[Ref.18983873]SARS-CoV:inhibition of cell fusion in Hela cells (IC50=3.97 ± 1.40 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18983873]No discernable cytotoxicity on HeLa or VeroE6 cells at the concentrations of 25 μM.,,DRAVPe01725.cif,Linear,Free,Free,,L,membrane,"Binding to the HR2 region and blocking the formation of  a 6-helix bundle during the fusion step of virus entry, thus inhibiting virus entry.",5027.67,C216H366N64O73,CHMPRWY,Q,9.53,4,2,2,14,17,-45.65,-7939,0.8 hour,10 min,>10 hour,97.61,0,0.0,18983873,Antiviral Res. 2009 Jan;81(1):82-7.,"Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, Wang WK.",Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors.,10.1016/j.antiviral.2008.10.001,,Anti-SARS-CoV
DRAVPe01723,GINASVVNIQKEIDRLNEVAKNLNESLIDL,30,P4(SARS-CoV (1153–1182)),Synthetic construct,P59594,,SARS-CoV,Coronaviridae,cell fusion inhibition assay,[Ref.18983873]SARS-CoV:inhibition of cell fusion in Hela cells (IC50=0.80 ± 0.21 μM);inhibition of SARS-CoV infection in Vero-E6 cells (IC50=3.17 ± 0.24 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18983873]No discernable cytotoxicity on HeLa or VeroE6 cells at the concentrations of 25 μM.,,DRAVPe01723.cif,Linear,Free,Free,,L,membrane,"Binding to the HR1 region and blocking the formation of  a 6-helix bundle during the fusion step of virus entry, thus inhibiting virus entry.",3322.76,C143H245N41O49,CFHMPTWY,N,4.51,3,5,-2,8,13,-11.33,-5339,30 hour,>20 hour,>10 hour,139.67,0,0.0,18983873,Antiviral Res. 2009 Jan;81(1):82-7.,"Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, Wang WK.",Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors.,10.1016/j.antiviral.2008.10.001,,Anti-SARS-CoV
DRAVPe01724,GINASVVNIQKEIDRLNEVAKNL,23,P6(SARS-CoV (1153–1175)),Synthetic construct,P59594,,SARS-CoV,Coronaviridae,cell fusion inhibition assay,[Ref.18983873]SARS-CoV:inhibition of cell fusion in Hela cells (IC50=1.04 ± 0.22 μM); inhibition of SARS-CoV infection in Vero-E6 cells (IC50=2.28 ± 0.81 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18983873]No discernable cytotoxicity on HeLa or VeroE6 cells at the concentrations of 25 μM.,,DRAVPe01724.cif,Linear,Free,Free,,L,membrane,"Binding to the HR1 region and blocking the formation of  a 6-helix bundle during the fusion step of virus entry, thus inhibiting virus entry.",2537.9,C109H189N33O36,CFHMPTWY,N,6.18,3,3,0,6,10,-18.26,-4258,30 hour,>20 hour,>10 hour,131.3,0,0.0,18983873,Antiviral Res. 2009 Jan;81(1):82-7.,"Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, Wang WK.",Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors.,10.1016/j.antiviral.2008.10.001,,Anti-SARS-CoV
DRAVPe01722,GINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE,37,P1(SARS-CoV (1153-1189)),Synthetic construct,P59594,,SARS-CoV,Coronaviridae,cell fusion inhibition assay,[Ref.18983873]SARS-CoV:inhibition of cell fusion in Hela cells (IC50=0.62 ± 0.20 μM);inhibition of SARS-CoV infection in Vero-E6 cells (IC50=3.04 ± 0.06 μM).##[Ref.15043961]SARS-CoV:inhibition of the cytopathic effect in Vero E6 cells(IC50~19 μM/L).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18983873]No discernable cytotoxicity on HeLa or VeroE6 cells at the concentrations of 25 μM.,,DRAVPe01722.cif,Linear,Free,Free,,L,membrane,"Binding to the HR1 region and blocking the formation of  a 6-helix bundle during the fusion step of virus entry, thus inhibiting virus entry.",4170.69,C181H302N50O62,CFHMPTW,ELN,4.49,4,7,-3,10,14,-42.43,-7238,30 hour,>20 hour,>10 hour,123.78,1490,41.39,18983873##15043961,Antiviral Res. 2009 Jan;81(1):82-7.##Lancet. 2004 Mar 20;363(9413):938-47.,"Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, Wang WK.##Liu S, Xiao G, Chen Y, He Y, Niu J, Escalante CR, Xiong H, Farmar J, Debnath AK, Tien P, Jiang S.",Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors.##Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors.,10.1093/infdis/jiv325.##10.1016/j.antiviral.2008.10.001.##10.1016/S0140-6736(04)15788-7.,,Anti-SARS-CoV
DRAVPe01721,AWDFGSVGGVFNSLGKGIHQIFGAAFKSL,29,ZIKV Ep (424-452),Synthetic construct,Q32ZE1,,ZIKV,Flaviviridae,"qRT-PCR, western blotting, the plaque assay",[Ref.28232248]Zika virus (ZIKV):inhibition of Zika virus (ZIKV) infection in Vero cells (IC50=1.32μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01721.cif,Linear,Free,Free,,L,membrane,Peptide derived from protein E stem may inhibit virus infection by blocking virus entry.,3011.43,C142H208N36O37,CEMPRTY,G,8.64,3,1,2,10,14,49.66,622,4.4 hour,>20 hour,>10 hour,84.14,5500,196.43,28232248,Antiviral Res. 2017 May;141:140-149.,"Chen L, Liu Y, Wang S, Sun J, Wang P, Xin Q, Zhang L, Xiao G, Wang W.",Antiviral activity of peptide inhibitors derived from the protein E stem against Japanese encephalitis and Zika viruses.,10.1016/j.antiviral.2017.02.009,,Anti-ZIKV
DRAVPe01719,AWDFGSIGGVFNSIGRAVHQVFGGAFRTL,29,JEV Ep (424–452),Synthetic construct,P0DOH7,,JEV,Flaviviridae,"qRT-PCR, western blotting, the plaque assay",[Ref.28232248]Japanese encephalitis virus (JEV):inhibition of JEV infection in BHK-21 (baby hamster kidney) cells (IC50=7.66 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01719.cif,Linear,Free,Free,,L,membrane,Peptide derived from protein E stem may inhibit virus infection by blocking virus entry.,3067.46,C142H208N40O37,CEKMPY,G,9.65,3,1,2,10,14,47.24,-1257,4.4 hour,>20 hour,>10 hour,80.69,5500,196.43,28232248,Antiviral Res. 2017 May;141:140-149.,"Chen L, Liu Y, Wang S, Sun J, Wang P, Xin Q, Zhang L, Xiao G, Wang W.",Antiviral activity of peptide inhibitors derived from the protein E stem against Japanese encephalitis and Zika viruses.,10.1016/j.antiviral.2017.02.009,,Anti-JEV
DRAVPe01720,AWDFGSIGGVFNSIGRAVHQVF,22,JEV Ep (424–445),Synthetic construct,P0DOH7,,"JEV, ZIKV",Flaviviridae,"qRT-PCR, western blotting, the plaque assay",[Ref.28232248]Japanese encephalitis virus (JEV):inhibition of JEV infection in BHK-21 (baby hamster kidney) cells (IC50=3.93 nM);##Zika virus (ZIKV):inhibition of Zika virus (ZIKV) infection in Vero cells (IC50=3.27μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01720.cif,Linear,Free,Free,,L,membrane,"The peptide prevented JEV infection in mice by reducing viral load and the inflammatory response in the brain, thereby improving the survival rate.",2364.65,C110H158N30O29,CEKLMPTY,G,6.79,2,1,1,7,11,51.36,-667,4.4 hour,>20 hour,>10 hour,84.09,5500,261.9,28232248,Antiviral Res. 2017 May;141:140-149.,"Chen L, Liu Y, Wang S, Sun J, Wang P, Xin Q, Zhang L, Xiao G, Wang W.",Antiviral activity of peptide inhibitors derived from the protein E stem against Japanese encephalitis and Zika viruses.,10.1016/j.antiviral.2017.02.009,,"Anti-JEV, Anti-ZIKV"
DRAVPe01718,AALGDTAWDFGSIGGVFNSIGRAVHQVFGGAFRTL,35,JEV Ep (418–452),Synthetic construct,P0DOH7,,JEV,Flaviviridae,"qRT-PCR, western blotting, the plaque assay",[Ref.28232248]Japanese encephalitis virus (JEV):inhibition of JEV infection in BHK-21 (baby hamster kidney) cells (IC50=58.07 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01718.cif,Linear,Free,Free,,L,membrane,Peptide derived from protein E stem may inhibit virus infection by blocking virus entry.,3596.02,C164H244N46O46,CEKMPY,G,6.79,3,2,1,12,17,47.14,-1438,4.4 hour,>20 hour,>10 hour,83.71,5500,161.76,28232248,Antiviral Res. 2017 May;141:140-149.,"Chen L, Liu Y, Wang S, Sun J, Wang P, Xin Q, Zhang L, Xiao G, Wang W.",Antiviral activity of peptide inhibitors derived from the protein E stem against Japanese encephalitis and Zika viruses.,10.1016/j.antiviral.2017.02.009,,Anti-JEV
DRAVPe01717,SIGGVFNSIGRAVHQVFGGAFRTL,24,JEV Ep (428–452),Synthetic construct,P0DOH7,,JEV,Flaviviridae,"qRT-PCR, western blotting, the plaque assay",[Ref.28232248]Japanese encephalitis virus (JEV):inhibition of JEV infection in BHK-21 (baby hamster kidney) cells (IC50=94.10 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01717.cif,Linear,Free,Free,,L,membrane,Peptide derived from protein E stem may inhibit virus infection by blocking virus entry.,2490.85,C113H176N34O30,CDEKMPWY,G,12.0,3,0,3,9,11,57.92,-1191,1.9 hour,>20 hour,>10 hour,93.33,0,0.0,28232248,Antiviral Res. 2017 May;141:140-149.,"Chen L, Liu Y, Wang S, Sun J, Wang P, Xin Q, Zhang L, Xiao G, Wang W.",Antiviral activity of peptide inhibitors derived from the protein E stem against Japanese encephalitis and Zika viruses.,10.1016/j.antiviral.2017.02.009,,Anti-JEV
DRAVPe01716,STLGKAFSTTLKGAQRLAALGDTAWDFG,28,JEV Ep (401–428),Synthetic construct,P0DOH7,,JEV,Flaviviridae,"qRT-PCR, western blotting, the plaque assay, immunofluorescence analysis",[Ref.28232248]Japanese encephalitis virus (JEV):inhibition of JEV infection in BHK-21 (baby hamster kidney) cells (IC50=3790.71 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01716.cif,Linear,Free,Free,,L,membrane,Peptide derived from protein E stem may inhibit virus infection by blocking virus entry.,2884.24,C129H203N35O40,CEHIMNPVY,A,8.31,3,2,1,10,12,0.36,-2530,1.9 hour,>20 hour,>10 hour,73.57,5500,203.7,28232248,Antiviral Res. 2017 May;141:140-149.,"Chen L, Liu Y, Wang S, Sun J, Wang P, Xin Q, Zhang L, Xiao G, Wang W.",Antiviral activity of peptide inhibitors derived from the protein E stem against Japanese encephalitis and Zika viruses.,10.1016/j.antiviral.2017.02.009,,Anti-JEV
DRAVPe01714,LDLSDEMAMLLQEVVKQLNDSYIDLKELGNYTYYNKW,37,HKU4-HR2P3,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,Cell–Cell Fusion Assay,[Ref.30646495]MERS-CoV:inhibition of cell-cell fusion between 293T cells and Huh-7 cells(IC50=0.55 μM);##MERS-CoV Q1020:inhibition of Pseudovirus Infection in Huh-7 cells(IC50=0.48 μM);##MERS-CoV Q1020H:inhibition of Pseudovirus Infection in Huh-7 cells(IC50=0.52 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30646495]No cytotoxicity against Huh-7 cells up to 100 μM.,,DRAVPe01714.cif,Linear,Free,Free,,L,membrane,The peptide bind with HR1 of MERS-CoV and thus disrupting the process of MERS-6HB formation can inhibit virus–cell membrane fusion and abolish viral infection.,4457.05,C201H308N46O64S2,CFHPR,L,4.14,3,7,-4,11,12,-47.03,-5567,5.5 hour,3 min,2 min,102.7,11460,318.33,30646495,Viruses. 2019 Jan 14;11(1):56. doi: 10.3390/v11010056,"Xia S, Lan Q, Pu J, Wang C, Liu Z, Xu W, Wang Q, Liu H, Jiang S, Lu L.",Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4.,10.3390/v11010056,,Anti-MERS-CoV
DRAVPe01715,GGGSLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKEL,39,MERS-HR2P,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,Cell–Cell Fusion Assay,[Ref.30646495]MERS-CoV:inhibition of cell-cell fusion between 293T cells and Huh-7 cells(IC50=1.07 μM);##MERS-CoV Q1020:inhibition of Pseudovirus Infection in Huh-7 cells(IC50=1.14 μM);##MERS-CoV Q1020H:inhibition of Pseudovirus Infection in Huh-7 cells(IC50=1.71 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30646495]No cytotoxicity against Huh-7 cells up to 100 μM.,,DRAVPe01715.cif,Linear,Free,Free,,L,membrane,The peptide bind with HR1 of MERS-CoV and thus disrupting the process of MERS-6HB formation can inhibit virus–cell membrane fusion and abolish viral infection.,4312.94,C191H316N46O64S,CFHPRW,L,4.18,2,5,-3,14,14,8.97,-3045,30 hour,>20 hour,>10 hour,127.44,2980,78.42,30646495,Viruses. 2019 Jan 14;11(1):56. doi: 10.3390/v11010056,"Xia S, Lan Q, Pu J, Wang C, Liu Z, Xu W, Wang Q, Liu H, Jiang S, Lu L.",Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4.,10.3390/v11010056,,Anti-MERS-CoV
DRAVPe01713,EISKINTTLLDLSDEMAMLLQEVVKQLNDSYIDLKEL,37,HKU4-HR2P2,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,Cell–Cell Fusion Assay,[Ref.30646495]MERS-CoV:inhibition of cell-cell fusion between 293T cells and Huh-7 cells(IC50=0.38 μM);##MERS-CoV Q1020:inhibition of Pseudovirus Infection in Huh-7 cells(IC50=0.34 μM);##MERS-CoV Q1020H:inhibition of Pseudovirus Infection in Huh-7 cells(IC50=0.44 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30646495]No cytotoxicity against Huh-7 cells up to 100 μM.,,DRAVPe01713.cif,Linear,Free,Free,,L,membrane,The peptide bind with HR1 of MERS-CoV and thus disrupting the process of MERS-6HB formation can inhibit virus–cell membrane fusion and abolish viral infection.,4266.93,C187H314N44O64S2,CFGHPRW,L,4.07,3,8,-5,8,14,-2.43,-4990,1 hour,30 min,>10 hour,134.32,1490,41.39,30646495,Viruses. 2019 Jan 14;11(1):56. doi: 10.3390/v11010056,"Xia S, Lan Q, Pu J, Wang C, Liu Z, Xu W, Wang Q, Liu H, Jiang S, Lu L.",Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4.,10.3390/v11010056,,Anti-MERS-CoV
DRAVPe01712,GPNFAEISKINTTLLDLSDEMAMLLQEVVKQLNDSYI,37,HKU4-HR2P1,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,Cell–Cell Fusion Assay,[Ref.30646495]MERS-CoV:inhibition of cell-cell fusion between 293T cells and Huh-7 cells(IC50=1.09 μM);##MERS-CoV Q1020:inhibition of Pseudovirus Infection in Huh-7 cells(IC50=2.15 μM);##MERS-CoV Q1020H:inhibition of Pseudovirus Infection in Huh-7 cells(IC50=2.72 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30646495]No cytotoxicity against Huh-7 cells up to 100 μM.,,DRAVPe01712.cif,Linear,Free,Free,,L,membrane,The peptide bind with HR1 of MERS-CoV and thus disrupting the process of MERS-6HB formation can inhibit virus–cell membrane fusion and abolish viral infection.,4154.76,C183H298N44O61S2,CHRW,L,4.02,2,6,-4,10,14,4.05,-3957,30 hour,>20 hour,>10 hour,115.95,1490,41.39,30646495,Viruses. 2019 Jan 14;11(1):56. doi: 10.3390/v11010056,"Xia S, Lan Q, Pu J, Wang C, Liu Z, Xu W, Wang Q, Liu H, Jiang S, Lu L.",Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4.,10.3390/v11010056,,Anti-MERS-CoV
DRAVPe01711,ISLTPLLVCVAALLLLEQ,18,E1P52-2,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01711.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,1909.4,C89H157N19O24S,DFGHKMNRWY,L,4.0,0,1,-1,3,12,197.22,3402,20 hour,30 min,>10 hour,216.67,0,0.0,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01709,GVISLTPLLVCVAALLLL,18,E1P52,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=55.7± 5.7 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01709.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,1808.34,C86H154N18O21S,DEFHKMNQRWY,L,5.52,0,0,0,4,13,257.22,5135,30 hour,>20 hour,>10 hour,232.78,0,0.0,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01710,VISLTPLLVCVAALLLLE,18,E1P52-1,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01710.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,1880.4,C89H158N18O23S,DFGHKMNQRWY,L,4.0,0,1,-1,3,13,240.0,4360,100 hour,>20 hour,>10 hour,232.78,0,0.0,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01708,RGVISLTPLLVCVAALLL,18,E1P51-2,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01708.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,1851.36,C86H155N21O21S,DEFHKMNQWY,L,8.25,1,0,1,4,12,211.11,3151,1 hour,2 min,2 min,211.11,0,0.0,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01707,WRGVISLTPLLVCVAALL,18,E1P51-1,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01707.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,1924.42,C91H154N22O21S,DEFHKMNQY,L,8.25,1,0,1,4,12,185.0,2892,2.8 hour,3 min,2 min,189.44,5500,323.53,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01705,DFWRGVISLTPLLVCVAA,18,E1P50-2,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01705.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,1960.36,C92H146N22O23S,EHKMNQY,LV,5.83,1,1,0,4,11,138.89,1334,1.1 hour,3 min,>10 hour,146.11,5500,323.53,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01706,FWRGVISLTPLLVCVAAL,18,E1P51,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01706.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,1958.44,C94H152N22O21S,DEHKMNQY,L,8.25,1,0,1,4,12,179.44,2698,1.1 hour,3 min,2 min,167.78,5500,323.53,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01704,FDFWRGVISLTPLLVCVA,18,E1P50-1,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01704.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2036.46,C98H150N22O23S,EHKMNQY,LV,5.83,1,1,0,4,11,144.44,1451,1.1 hour,3 min,2 min,140.56,5500,323.53,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01703,PFDFWRGVISLTPLLVCV,18,E1P50,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01703.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2062.5,C100H152N22O23S,AEHKMNQY,LV,6.22,1,1,0,4,10,125.56,1270,>20 hour,>20 hour,?,135.0,5500,323.53,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01702,VPFDFWRGVISLTPLLVC,18,E1P49-2,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01702.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2062.5,C100H152N22O23S,AEHKMNQY,LV,5.8,1,1,0,4,10,125.56,1270,100 hour,>20 hour,>10 hour,135.0,5500,323.53,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01701,KVPFDFWRGVISLTPLLV,18,E1P49-1,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=63.3 ± 5.8 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01701.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2087.54,C103H159N23O23,ACEHMNQY,LV,8.75,2,1,1,3,10,90.0,587,1.3 hour,3 min,2 min,135.0,5500,323.53,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01699,LWKVPFDFWRGVISLTPL,18,E1P48-2,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=14.7 ± 0.6 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01699.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2174.62,C109H160N24O23,ACEHMNQY,L,8.75,2,1,1,3,10,61.67,416,5.5 hour,3 min,2 min,118.89,11000,647.06,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01700,WKVPFDFWRGVISLTPLL,18,E1P49,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=17.3 ± 3.2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01700.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2174.62,C109H160N24O23,ACEHMNQY,L,8.75,2,1,1,3,10,61.67,416,2.8 hour,3 min,2 min,118.89,11000,647.06,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01697,EYLWKVPFDFWRGVISLT,18,E1P48,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=44.7 ± 3.2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01697.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2256.63,C112H158N24O26,ACHMNQ,FLVW,6.17,2,2,0,4,9,22.78,-771,1 hour,30 min,>10 hour,97.22,12490,734.71,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01698,YLWKVPFDFWRGVISLTP,18,E1P48-1,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=70.7 ±9.5 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01698.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2224.63,C112H158N24O24,ACEHMNQ,FLPVW,8.59,2,1,1,4,9,33.33,-90,2.8 hour,10 min,2 min,97.22,12490,734.71,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01695,ILEYLWKVPFDFWRGVIS,18,E1P47-1,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=5.4 ± 0.0 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01695.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2268.69,C114H162N24O25,ACHMNQT,FILVW,6.07,2,2,0,3,10,51.67,-22,20 hour,30 min,>10 hour,118.89,12490,734.71,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01696,LEYLWKVPFDFWRGVISL,18,E1P47-2,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=6.6± 0.6 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01696.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2268.69,C114H162N24O25,ACHMNQT,L,6.07,2,2,0,3,10,47.78,-22,5.5 hour,3 min,2 min,118.89,12490,734.71,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01694,WILEYLWKVPFDFWRGVI,18,E1P47,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=2.7 ± 0.3 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01694.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2367.82,C122H167N25O24,ACHMNQST,W,6.07,2,2,0,2,11,51.11,551,2.8 hour,3 min,2 min,118.89,17990,1058.24,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01692,NYWILEYLWKVPFDFWRG,18,E1P46-1,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=12.3 ± 0.6 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01692.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2432.81,C124H162N26O26,ACHMQST,W,6.07,2,2,0,4,9,-23.89,-1023,1.4 hour,3 min,>10 hour,81.11,19480,1145.88,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01693,YWILEYLWKVPFDFWRGV,18,E1P46-2,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=32.3 ± 11.0 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01693.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2417.84,C125H165N25O25,ACHMNQST,W,6.07,2,2,0,3,10,18.89,45,2.8 hour,10 min,2 min,97.22,19480,1145.88,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01691,SNYWILEYLWKVPFDFWR,18,E1P46,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=19.7 ± 8.1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01691.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2462.84,C125H164N26O27,ACGHMQT,W,5.79,2,2,0,4,9,-26.11,-1457,1.9 hour,>20 hour,>10 hour,81.11,19480,1145.88,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01690,ASNYWILEYLWKVPFDFW,18,E1P45-2,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=11.3 ± 3.8 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01690.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2377.73,C122H157N23O27,CGHMQRT,W,4.37,1,2,-1,4,10,8.89,216,4.4 hour,>20 hour,>10 hour,86.67,19480,1145.88,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01689,LASNYWILEYLWKVPFDF,18,E1P45-1,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=12.7 ±1.2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01689.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2304.67,C117H158N22O27,CGHMQRT,L,4.37,1,2,-1,4,10,35.0,475,5.5 hour,3 min,2 min,108.33,13980,822.35,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01688,QLASNYWILEYLWKVPFD,18,E1P45,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=27.7 ±5.8 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01688.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2285.63,C113H157N23O28,CGHMRT,L,4.37,1,2,-1,4,9,0.0,-377,0.8 hour,10 min,>10 hour,108.33,13980,822.35,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01686,TEQLASNYWILEYLWKVP,18,E1P44-1,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01686.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2253.58,C109H157N23O29,CDFGHMR,L,4.53,1,2,-1,5,8,-19.44,-741,7.2 hour,>20 hour,>10 hour,108.33,13980,822.35,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01687,EQLASNYWILEYLWKVPF,18,E1P44-2,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=90.3 ± 15.3 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01687.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2299.65,C114H159N23O28,CDGHMRT,L,4.53,1,2,-1,4,9,0.0,-186,1 hour,30 min,>10 hour,108.33,13980,822.35,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01685,WTEQLASNYWILEYLWKV,18,E1P44,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01685.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2342.68,C115H160N24O29,CDFGHMPR,LW,4.53,1,2,-1,5,9,-15.56,-508,2.8 hour,3 min,2 min,108.33,19480,1145.88,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01684,RWTEQLASNYWILEYLWK,18,E1P43-2,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=19.7 ± 9.1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01684.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2399.73,C116H163N27O29,CDFGHMPV,LW,6.14,2,2,0,5,8,-63.89,-2404,1 hour,2 min,2 min,92.22,19480,1145.88,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01683,WRWTEQLASNYWILEYLW,18,E1P43-1,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=6.8 ± 0.3 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01683.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2457.77,C121H161N27O29,CDFGHKMPV,W,4.53,1,2,-1,5,9,-47.22,-1616,2.8 hour,3 min,2 min,92.22,24980,1469.41,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01682,FWRWTEQLASNYWILEYL,18,E1P43,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=43.0 ± 10.8 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01682.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2418.74,C119H160N26O29,CDGHKMPV,LW,4.53,1,2,-1,5,9,-26.67,-1551,1.1 hour,3 min,2 min,92.22,19480,1145.88,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01680,SEFWRWTEQLASNYWILE,18,E1P42-1,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=31.0 ± 3.5 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01680.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2358.59,C112H152N26O31,CDGHKMPV,EW,4.25,1,3,-2,5,8,-64.44,-3050,1.9 hour,>20 hour,>10 hour,70.56,17990,1058.24,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01681,EFWRWTEQLASNYWILEY,18,E1P42-2,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01681.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2434.69,C118H156N26O31,CDGHKMPV,EW,4.25,1,3,-2,5,8,-67.22,-2724,1 hour,30 min,>10 hour,70.56,19480,1145.88,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01679,ESEFWRWTEQLASNYWIL,18,E1P42,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=50.0 ± 8.7 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01679.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2358.59,C112H152N26O31,CDGHKMPV,EW,4.25,1,3,-2,5,8,-64.44,-3050,1 hour,30 min,>10 hour,70.56,17990,1058.24,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01677,KWESEFWRWTEQLASNYW,18,E1P41-1,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=66.7 ± 20.2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01677.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2446.66,C117H152N28O31,CDGHIMPV,W,4.79,2,3,-1,5,7,-137.22,-4356,1.3 hour,3 min,2 min,27.22,23490,1381.76,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01678,WESEFWRWTEQLASNYWI,18,E1P41-2,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=22.0 ± 0.0 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01678.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2431.65,C117H151N27O31,CDGHKMPV,W,4.25,1,3,-2,5,8,-90.56,-3309,2.8 hour,3 min,2 min,48.89,23490,1381.76,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01676,LKWESEFWRWTEQLASNY,18,E1P41,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01676.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2373.61,C112H153N27O31,CDGHIMPV,EW,4.79,2,3,-1,5,7,-111.11,-4097,5.5 hour,3 min,2 min,48.89,17990,1058.24,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01675,ELKWESEFWRWTEQLASN,18,E1P40-2,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01675.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2339.55,C108H151N27O32,CDGHIMPVY,E,4.49,2,4,-2,4,7,-123.33,-4764,1 hour,30 min,>10 hour,48.89,16500,970.59,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01674,CELKWESEFWRWTEQLAS,18,E1P40-1,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=34.0 ± 15.4 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01674.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2328.58,C107H150N26O31S,DGHIMNPVY,E,4.49,2,4,-2,4,7,-90.0,-3972,1.2 hour,>20 hour,>10 hour,48.89,16500,970.59,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01673,ACELKWESEFWRWTEQLA,18,E1P40,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01673.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2312.58,C107H150N26O30S,DGHIMNPVY,E,4.49,2,4,-2,3,8,-75.56,-3451,4.4 hour,>20 hour,>10 hour,54.44,16500,970.59,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01671,AVACELKWESEFWRWTEQ,18,E1P39-1,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=44.0 ± 13.9 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01671.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2298.56,C106H148N26O30S,DGHIMNPY,E,4.49,2,4,-2,3,8,-73.33,-3539,4.4 hour,>20 hour,>10 hour,48.89,16500,970.59,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01672,VACELKWESEFWRWTEQL,18,E1P39-2,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=37.7 ± 7.0 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01672.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2340.64,C109H154N26O30S,DGHIMNPY,E,4.49,2,4,-2,3,8,-62.22,-3228,100 hour,>20 hour,>10 hour,65.0,16500,970.59,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01670,CAVACELKWESEFWRWTE,18,E1P39,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=11.3 ± 1.5 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01670.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2273.57,C104H145N25O29S2,DGHIMNPQY,E,4.49,2,4,-2,4,8,-40.0,-2857,1.2 hour,>20 hour,>10 hour,48.89,16625,977.94,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01668,LTCAVACELKWESEFWRW,18,E1P38-1,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01668.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2257.61,C105H149N25O27S2,DGHIMNPQY,EW,4.79,2,3,-1,4,9,0.56,-1684,5.5 hour,3 min,2 min,70.56,16625,977.94,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01669,TCAVACELKWESEFWRWT,18,E1P38-2,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01669.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2245.56,C103H145N25O28S2,DGHIMNPQY,EW,4.78,2,3,-1,5,8,-24.44,-2433,7.2 hour,>20 hour,>10 hour,48.89,16625,977.94,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01667,NLTCAVACELKWESEFWR,18,E1P38,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01667.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2185.5,C98H145N25O28S2,DGHIMPQY,E,4.79,2,3,-1,5,8,-13.89,-2581,1.4 hour,3 min,>10 hour,70.56,11125,654.41,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. ,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01665,VPNLTCAVACELKWESEF,18,E1P37-1,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=80.0 ± 62.4 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01665.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2039.35,C91H139N21O28S2,DGHIMQRY,E,4.25,1,3,-2,5,8,30.56,-918,100 hour,>20 hour,>10 hour,86.67,5625,330.88,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. ,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01666,PNLTCAVACELKWESEFR,18,E1P37-2,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=99.0 ± 22.5 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01666.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,2096.4,C92H142N24O28S2,DGHIMQY,E,4.79,2,3,-1,5,7,-17.78,-2814,>20 hour,>20 hour,?,70.56,5625,330.88,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. ,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01664,PVPNLTCAVACELKWESE,18,E1P37,Synthetic construct,No entry found,,HIV,Retroviridae,Fluorescence resonance energy transfer (FRET) assay,[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=41.0 ± 8.7 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01664.cif,Linear,Free,Free,,L,gp41,The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection.,1989.29,C87H137N21O28S2,DFGHIMQRY,E,4.25,1,3,-2,5,7,6.11,-1216,>20 hour,>20 hour,?,86.67,5625,330.88,26905802,Biochim Biophys Acta. 2016 Jun;1860(6):1139-48.,"Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.",Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. ,10.1016/j.bbagen.2016.02.008,,Anti-HIV
DRAVPe01663,yAIIXYNKYXNC,12,compound 6,Synthetic construct,No entry found,,"ZIKV,DENV,WNV",Flaviviridae,protease enzymatic inhibition assay,[Ref.30783498]Zika Virus(ZIKV):inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50=3.2 ± 0.4 μM);##Dengue virus serotype 2:inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50>20 μM);##West Nile virus:inhibition of flaviviral Protease(West Nile virus NS2B-NS3 protease) activity in Huh-7 cells(IC50>20 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01663.cif,Linear,Thioether-acyl moiety (−S-Ac−)(forms a macrocycle through the side chain of the underlined cysteine residue),Amidation,"The 'X' at position 5 indicates N-methyl-4-O-methyl-tyrosine, position 10 indicates N-methyl-leucine.",Mixed(D-Tyr1),NS2B-NS3 protease,No machanism information found in the reference(s) presented in this entry,1487.12,C50H70N12O11S,DEFGHLMPQRSTVW,INYX,8.15,1,0,1,5,3,-1.67,-618,,,,73.33,2980,270.91,30783498,ACS Med Chem Lett. 2019 Jan 4;10(2):168-174.,"Nitsche C, Passioura T, Varava P, Mahawaththa MC, Leuthold MM, Klein CD, Suga H, Otting G. ",De Novo Discovery of Nonstandard Macrocyclic Peptides as Noncompetitive Inhibitors of the Zika Virus NS2B-NS3 Protease. ,10.1021/acsmedchemlett.8b00535,,"Anti-ZIKV,Anti-DENV,Anti-WNV"
DRAVPe01662,YTLPFHNXTFFC,12,compound 5,Synthetic construct,No entry found,,"ZIKV,DENV,WNV",Flaviviridae,protease enzymatic inhibition assay,[Ref.30783498]Zika Virus(ZIKV):inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50≥50 μM);##Dengue virus serotype 2:inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50>10 μM);##West Nile virus:inhibition of flaviviral Protease(West Nile virus NS2B-NS3 protease) activity in Huh-7 cells(IC50>10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01662.cif,Linear,Thioether-acyl moiety (−S-Ac−)(forms a macrocycle through the side chain of the underlined cysteine residue),Amidation,The 'X' at position 8 indicates N-methyl-glycine.,L,NS2B-NS3 protease,No machanism information found in the reference(s) presented in this entry,1500.92,C68H86N14O15S,ADEGIKMQRSVW,F,6.73,1,0,1,5,4,30.83,-144,2.8 hour,10 min,2 min,32.5,1490,135.45,30783498,ACS Med Chem Lett. 2019 Jan 4;10(2):168-174.,"Nitsche C, Passioura T, Varava P, Mahawaththa MC, Leuthold MM, Klein CD, Suga H, Otting G. ",De Novo Discovery of Nonstandard Macrocyclic Peptides as Noncompetitive Inhibitors of the Zika Virus NS2B-NS3 Protease. ,10.1021/acsmedchemlett.8b00535,,"Anti-ZIKV,Anti-DENV,Anti-WNV"
DRAVPe01661,YXIAKYNXXIPC,12,compound 4,Synthetic construct,No entry found,,"ZIKV,DENV,WNV",Flaviviridae,protease enzymatic inhibition assay,[Ref.30783498]Zika Virus(ZIKV):inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50=4.6 ± 0.3 μM);##Dengue virus serotype 2:inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50≥20 μM);##West Nile virus:inhibition of flaviviral Protease(West Nile virus NS2B-NS3 protease) activity in Huh-7 cells(IC50≥20 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01661.cif,Linear,Thioether-acyl moiety (−S-Ac−)(forms a macrocycle through the side chain of the underlined cysteine residue),Amidation,"The 'X' at position 2 indicates N-methyl-glycine, position 8 and 9 indicates N-methyl-4-O-methyl-tyrosine.",L,NS2B-NS3 protease,No machanism information found in the reference(s) presented in this entry,1418.29,C51H71N11O10S,DEFGHLMQRSTVW,X,8.18,1,0,1,4,3,14.17,46,2.8 hour,10 min,2 min,73.33,2980,270.91,30783498,ACS Med Chem Lett. 2019 Jan 4;10(2):168-174.,"Nitsche C, Passioura T, Varava P, Mahawaththa MC, Leuthold MM, Klein CD, Suga H, Otting G. ",De Novo Discovery of Nonstandard Macrocyclic Peptides as Noncompetitive Inhibitors of the Zika Virus NS2B-NS3 Protease. ,10.1021/acsmedchemlett.8b00535,,"Anti-ZIKV,Anti-DENV,Anti-WNV"
DRAVPe01660,YTNFYLYPYXFC,12,compound 3,Synthetic construct,No entry found,,"ZIKV,DENV,WNV",Flaviviridae,protease enzymatic inhibition assay,[Ref.30783498]Zika Virus(ZIKV):inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50=2.2 ± 0.1 μM);##Dengue virus serotype 2:inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50>20 μM);##West Nile virus:inhibition of flaviviral Protease(West Nile virus NS2B-NS3 protease) activity in Huh-7 cells(IC50>20 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01660.cif,Linear,Thioether-acyl moiety (−S-Ac−)(forms a macrocycle through the side chain of the underlined cysteine residue),Amidation,The 'X' at position 10 indicates MeYMe(N-methyl-4-O-methyl-tyrosine).,L,NS2B-NS3 protease,No machanism information found in the reference(s) presented in this entry,1605.03,C76H90N12O17S,ADEGHIKMQRSVW,Y,5.52,0,0,0,7,3,7.5,239,2.8 hour,10 min,2 min,32.5,5960,541.82,30783498,ACS Med Chem Lett. 2019 Jan 4;10(2):168-174.,"Nitsche C, Passioura T, Varava P, Mahawaththa MC, Leuthold MM, Klein CD, Suga H, Otting G. ",De Novo Discovery of Nonstandard Macrocyclic Peptides as Noncompetitive Inhibitors of the Zika Virus NS2B-NS3 Protease. ,10.1021/acsmedchemlett.8b00535,,"Anti-ZIKV,Anti-DENV,Anti-WNV"
DRAVPe01659,YXKXKXXKXXKC,12,compound 2,Synthetic construct,No entry found,,"ZIKV,DENV,WNV",Flaviviridae,protease enzymatic inhibition assay,[Ref.30783498]Zika Virus(ZIKV):inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50=0.25 ± 0.01 μM);##Dengue virus serotype 2:inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50=1.7 ± 0.1 μM);##West Nile virus:inhibition of flaviviral Protease(West Nile virus NS2B-NS3 protease) activity in Huh-7 cells(IC50=3.9 ± 0.4 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01659.cif,Linear,Thioether-acyl moiety (−S-Ac−)(forms a macrocycle through the side chain of the underlined cysteine residue),Amidation,"The 'X' at position 2,7,9 and 10 indicates MeYMe(N-methyl-4-O-methyl-tyrosine), position 4 indicates MeF(N-methyl-phenylalanine), position 6 indicates MeS(N-methyl-serine).",L,NS2B-NS3 protease,No machanism information found in the reference(s) presented in this entry,1465.01,C36H52N10O2S,ADEFGHILMNPQRSTVW,X,9.87,4,0,4,2,0,-120.0,-2106,2.8 hour,10 min,2 min,0.0,1490,135.45,30783498,ACS Med Chem Lett. 2019 Jan 4;10(2):168-174.,"Nitsche C, Passioura T, Varava P, Mahawaththa MC, Leuthold MM, Klein CD, Suga H, Otting G. ",De Novo Discovery of Nonstandard Macrocyclic Peptides as Noncompetitive Inhibitors of the Zika Virus NS2B-NS3 Protease. ,10.1021/acsmedchemlett.8b00535,,"Anti-ZIKV,Anti-DENV,Anti-WNV"
DRAVPe01658,YWKIXNTLVNIC,12,compound 1,Synthetic construct,No entry found,,"ZIKV,DENV,WNV",Flaviviridae,protease enzymatic inhibition assay,[Ref.30783498]Zika Virus(ZIKV):inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50=1.5 ± 0.1 μM);##Dengue virus serotype 2:inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50>10 μM);##West Nile virus: inhibition of flaviviral Protease(West Nile virus NS2B-NS3 protease) activity in Huh-7 cells(IC50>10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01658.cif,Linear,Thioether-acyl moiety (−S-Ac−)(forms a macrocycle through the side chain of the underlined cysteine residue),Amidation,The 'X' at position 4 indicates MeYMe(N-methyl-4-O-methyl-tyrosine).,L,NS2B-NS3 protease,No machanism information found in the reference(s) presented in this entry,1477.97,C64H97N15O15S,ADEFGHMPQRS,IN,8.2,1,0,1,5,5,47.5,87,2.8 hour,10 min,2 min,121.67,6990,635.45,30783498,ACS Med Chem Lett. 2019 Jan 4;10(2):168-174.,"Nitsche C, Passioura T, Varava P, Mahawaththa MC, Leuthold MM, Klein CD, Suga H, Otting G. ",De Novo Discovery of Nonstandard Macrocyclic Peptides as Noncompetitive Inhibitors of the Zika Virus NS2B-NS3 Protease. ,10.1021/acsmedchemlett.8b00535,,"Anti-ZIKV,Anti-DENV,Anti-WNV"
DRAVPe01657,GVLV,4,Peptide 6,Synthetic construct,No entry found,,"SARS-CoV-2,HCMV,VZV","Coronaviridae, Herpesviridae",Cytopathic effect assay,[Ref.34502335]SARS-CoV-2 UC-1074:inhibition of virus activity in Vero cells(EC50≥20 μM);##SARS-CoV-2 UC-1075:inhibition of virus activity in Vero cells(EC50>20 μM);##cytomegalovirus (HCMV) AD-169 Strain:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>4 µM);##cytomegalovirus (HCMV) Davis strain:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>20 µM);##varicella-zoster virus (VZV) TK+ VZV Strain OKA:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>20 µM);##varicella-zoster virus (VZV) TK-VZV Strain 07–1:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>20 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.34502335]Vero cell:CC50=77.4 ±0.7 µM.,,DRAVPe01657.cif,Linear,Acylation,Methyl amidation,,L,Main protease,No machanism information found in the reference(s) presented in this entry,386.49,C18H34N4O5,ACDEFHIKMNPQRSTWY,V,5.52,0,0,0,1,3,295.0,1394,30 hour,>20 hour,>10 hour,242.5,0,0.0,34502335,Int J Mol Sci. 2021 Aug 30;22(17):9427.,"Di Micco S, Musella S, Sala M, Scala MC, Andrei G, Snoeck R, Bifulco G, Campiglia P, Fasano A.","Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation.",10.3390/ijms22179427,,"Anti-SARS-CoV-2,Anti-HCMV,Anti-VZV"
DRAVPe01656,GVLVQ,5,Peptide 5,Synthetic construct,No entry found,,"SARS-CoV-2,HCMV,VZV","Coronaviridae, Herpesviridae",Cytopathic effect assay,[Ref.34502335]SARS-CoV-2 UC-1074:inhibition of virus activity in Vero cells(EC50≥20 μM);##SARS-CoV-2 UC-1075:inhibition of virus activity in Vero cells(EC50>20 μM);##cytomegalovirus (HCMV) AD-169 Strain:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>20 µM);##cytomegalovirus (HCMV) Davis strain:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>100 µM);##varicella-zoster virus (VZV) TK+ VZV Strain OKA:inhibition of virus activity in human embryonic lung (HEL) cells(EC50=59.80 µM);##varicella-zoster virus (VZV) TK-VZV Strain 07–1:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>100 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.34502335]Vero cell:CC50=75.0 ±2.2 µM.,,DRAVPe01656.cif,Linear,Acylation,Methyl amidation,,L,Main protease,No machanism information found in the reference(s) presented in this entry,514.62,C23H42N6O7,ACDEFHIKMNPRSTWY,V,5.52,0,0,0,1,3,166.0,840,30 hour,>20 hour,>10 hour,194.0,0,0.0,34502335,Int J Mol Sci. 2021 Aug 30;22(17):9427.,"Di Micco S, Musella S, Sala M, Scala MC, Andrei G, Snoeck R, Bifulco G, Campiglia P, Fasano A.","Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation.",10.3390/ijms22179427,,"Anti-SARS-CoV-2,Anti-HCMV,Anti-VZV"
DRAVPe01655,GGVLVQPG,8,Peptide 4,Synthetic construct,No entry found,,"SARS-CoV-2,HCMV,VZV","Coronaviridae, Herpesviridae",Cytopathic effect assay,[Ref.34502335]SARS-CoV-2 UC-1074:inhibition of virus activity in Vero cells(EC50≥20 μM);##SARS-CoV-2 UC-1075:inhibition of virus activity in Vero cells(EC50>20 μM);##cytomegalovirus (HCMV) AD-169 Strain:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>20 µM);##cytomegalovirus (HCMV) Davis strain:inhibition of virus activity in human embryonic lung (HEL) cells(EC50=100 µM);##varicella-zoster virus (VZV) TK+ VZV Strain OKA:inhibition of virus activity in human embryonic lung (HEL) cells(EC50=78.20 µM);##varicella-zoster virus (VZV) TK-VZV Strain 07–1:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>100 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.34502335]Vero cell:CC50=74.9 ± 4.9 µM.,,DRAVPe01655.cif,Linear,Pivaloylation,Methyl amidation,,L,Main protease,No machanism information found in the reference(s) presented in this entry,725.84,C32H55N9O10,ACDEFHIKMNRSTWY,G,5.52,0,0,0,3,3,73.75,1028,30 hour,>20 hour,>10 hour,121.25,0,0.0,34502335,Int J Mol Sci. 2021 Aug 30;22(17):9427.,"Di Micco S, Musella S, Sala M, Scala MC, Andrei G, Snoeck R, Bifulco G, Campiglia P, Fasano A.","Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation.",10.3390/ijms22179427,,"Anti-SARS-CoV-2,Anti-HCMV,Anti-VZV"
DRAVPe01653,GGVLVQPG,8,Peptide 2,Synthetic construct,No entry found,,"SARS-CoV-2,HCMV,VZV","Coronaviridae, Herpesviridae",Cytopathic effect assay,[Ref.34502335]SARS-CoV-2 UC-1074:inhibition of virus activity in Vero cells(EC50≥17.6 ± 2.4 μM);##SARS-CoV-2 UC-1075:inhibition of virus activity in Vero cells(EC50>20 μM);##cytomegalovirus (HCMV) AD-169 Strain:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>20 µM);##cytomegalovirus (HCMV) Davis strain:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>20 µM);##varicella-zoster virus (VZV) TK+ VZV Strain OKA:inhibition of virus activity in human embryonic lung (HEL) cells(EC50=50.05 µM);##varicella-zoster virus (VZV) TK-VZV Strain 07–1:inhibition of virus activity in human embryonic lung (HEL) cells(EC50=48.42 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.34502335]Vero cell:CC50=83.0 ± 17.0 µM.,,DRAVPe01653.cif,Linear,Acylation,Amidation,,L,Main protease,No machanism information found in the reference(s) presented in this entry,725.84,C32H55N9O10,ACDEFHIKMNRSTWY,G,5.52,0,0,0,3,3,73.75,1028,30 hour,>20 hour,>10 hour,121.25,0,0.0,34502335,Int J Mol Sci. 2021 Aug 30;22(17):9427.,"Di Micco S, Musella S, Sala M, Scala MC, Andrei G, Snoeck R, Bifulco G, Campiglia P, Fasano A.","Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation.",10.3390/ijms22179427,,"Anti-SARS-CoV-2,Anti-HCMV,Anti-VZV"
DRAVPe01654,GGVLVQPG,8,Peptide 3,Synthetic construct,No entry found,,"SARS-CoV-2,HCMV,VZV","Coronaviridae, Herpesviridae",Cytopathic effect assay,[Ref.34502335]SARS-CoV-2 UC-1074:inhibition of virus activity in Vero cells(EC50>20 μM);##SARS-CoV-2 UC-1075:inhibition of virus activity in Vero cells(EC50>20 μM);##cytomegalovirus (HCMV) AD-169 Strain:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>20 µM);##cytomegalovirus (HCMV) Davis strain:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>100 µM);##varicella-zoster virus (VZV) TK+ VZV Strain OKA:inhibition of virus activity in human embryonic lung (HEL) cells(EC50=58.09 µM);##varicella-zoster virus (VZV) TK-VZV Strain 07–1:inhibition of virus activity in human embryonic lung (HEL) cells(EC50=81.09 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.34502335]Vero cell:CC50=81.8 ± 2.1 µM.,,DRAVPe01654.cif,Linear,Acylation,Methyl amidation,,L,Main protease,No machanism information found in the reference(s) presented in this entry,725.84,C32H55N9O10,ACDEFHIKMNRSTWY,G,5.52,0,0,0,3,3,73.75,1028,30 hour,>20 hour,>10 hour,121.25,0,0.0,34502335,Int J Mol Sci. 2021 Aug 30;22(17):9427.,"Di Micco S, Musella S, Sala M, Scala MC, Andrei G, Snoeck R, Bifulco G, Campiglia P, Fasano A.","Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation.",10.3390/ijms22179427,,"Anti-SARS-CoV-2,Anti-HCMV,Anti-VZV"
DRAVPe01652,SAHS,4,Ac-SAHS-NH2,Synthetic construct,No entry found,,Influenza virus,Orthomyxoviridae,Neutralization assay,[Ref.34681184]A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells(EC50=5.77 ± 0.01 × 10−7 μM);##A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells(EC50=4.3 ± 0.3 × 10−10 μM);##A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells(EC50=9.36 ± 0.1 × 10−7 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01652.cif,Linear,Acylation,Amidation,,L,hemagglutinin (HA),"Hemagglutinin is the major glycoprotein component of the viral envelope along with neuraminidase (NA), peptide derived from Lactoferrin binds Influenza A virus hemagglutinin (HA) inhibiting the hemagglutination and infection of major virus subtypes.",400.39,C15H24N6O7,CDEFGIKLMNPQRTVWY,S,6.46,1,0,1,2,1,-75.0,-965,1.9 hour,>20 hour,>10 hour,25.0,0,0.0,34681184,Pharmaceuticals (Basel). 2021 Sep 23;14(10):959. ,"Scala MC, Agamennone M, Pietrantoni A, Di Sarno V, Bertamino A, Superti F, Campiglia P, Sala M.","Discovery of a Novel Tetrapeptide against Influenza A Virus: Rational Design, Synthesis, Bioactivity Evaluation and Computational Studies.",10.3390/ph14100959,,Anti-Influenza virus
DRAVPe01651,SKHS,4,Peptide 17(lactoferrin 418–421),Synthetic construct,P24627,,Influenza virus,Orthomyxoviridae,Neutralization assay,[Ref.28878220]A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells(EC50=3 ± 0.61 pM);##A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells(EC50=0.048 ± 0.0012 pM);##A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells(EC50=5.0 ± 0.02 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01651.cif,Linear,Acylation,Amidation,,L,hemagglutinin (HA),"Hemagglutinin is the major glycoprotein component of the viral envelope along with neuraminidase (NA), peptide derived from Lactoferrin binds Influenza A virus hemagglutinin (HA) inhibiting the hemagglutination and infection of major virus subtypes.",457.49,C18H31N7O7,ACDEFGILMNPQRTVWY,S,8.49,2,0,2,2,0,-217.5,-1701,1.9 hour,>20 hour,>10 hour,0.0,0,0.0,28878220##34681184,Sci Rep. 2017 Sep 6;7(1):10593.##Pharmaceuticals (Basel). 2021 Sep 23;14(10):959. ,"Scala MC, Sala M, Pietrantoni A, Spensiero A, Di Micco S, Agamennone M, Bertamino A, Novellino E, Bifulco G, Gomez-Monterrey IM, Superti F, Campiglia P.##Scala MC, Agamennone M, Pietrantoni A, Di Sarno V, Bertamino A, Superti F, Campiglia P, Sala M.","Lactoferrin-derived Peptides Active towards Influenza: Identification of Three Potent Tetrapeptide Inhibitors.##Discovery of a Novel Tetrapeptide against Influenza A Virus: Rational Design, Synthesis, Bioactivity Evaluation and Computational Studies.",10.1038/s41598-017-10492-x##10.3390/ph14100959,,Anti-Influenza virus
DRAVPe01650,SLDC,4,Peptide 15(lactoferrin 422-425),Synthetic construct,P24627,,Influenza virus,Orthomyxoviridae,Neutralization assay,[Ref.28878220]A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells(EC50=0.5 ± 0.001 pM);##A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells(EC50=4.6 ± 0.05 pM);##A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells(EC50=4.3 ± 0.03 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01650.cif,Linear,Acylation,Amidation,,L,hemagglutinin (HA),"Hemagglutinin is the major glycoprotein component of the viral envelope along with neuraminidase (NA), peptide derived from Lactoferrin binds Influenza A virus hemagglutinin (HA) inhibiting the hemagglutination and infection of major virus subtypes.",436.48,C16H28N4O8S,AEFGHIKMNPQRTVWY,CDLS,3.8,0,1,-1,2,1,50.0,-592,1.9 hour,>20 hour,>10 hour,97.5,0,0.0,28878220##34681184,Sci Rep. 2017 Sep 6;7(1):10593.##Pharmaceuticals (Basel). 2021 Sep 23;14(10):959. ,"Scala MC, Sala M, Pietrantoni A, Spensiero A, Di Micco S, Agamennone M, Bertamino A, Novellino E, Bifulco G, Gomez-Monterrey IM, Superti F, Campiglia P.##Scala MC, Agamennone M, Pietrantoni A, Di Sarno V, Bertamino A, Superti F, Campiglia P, Sala M.","Lactoferrin-derived Peptides Active towards Influenza: Identification of Three Potent Tetrapeptide Inhibitors.##Discovery of a Novel Tetrapeptide against Influenza A Virus: Rational Design, Synthesis, Bioactivity Evaluation and Computational Studies.",10.1038/s41598-017-10492-x##10.3390/ph14100959,,Anti-Influenza virus
DRAVPe01649,SKHSSLDC,8,Peptide 16(lactoferrin 418-425),Synthetic construct,P24627,,Influenza virus,Orthomyxoviridae,Neutralization assay,[Ref.28878220]A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells(EC50=80 ± 0.19 pM);##A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells(EC50=0.1 ± 0.001 pM);##A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells(EC50=5.0 ± 0.45 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01649.cif,Linear,Free,Free,,L,hemagglutinin (HA),"Hemagglutinin is the major glycoprotein component of the viral envelope along with neuraminidase (NA), peptide derived from Lactoferrin binds Influenza A virus hemagglutinin (HA) inhibiting the hemagglutination and infection of major virus subtypes.",875.95,C34H57N11O14S,AEFGIMNPQRTVWY,S,6.46,2,1,1,4,1,-83.75,-2293,1.9 hour,>20 hour,>10 hour,48.75,0,0.0,28878220,Sci Rep. 2017 Sep 6;7(1):10593.,"Scala MC, Sala M, Pietrantoni A, Spensiero A, Di Micco S, Agamennone M, Bertamino A, Novellino E, Bifulco G, Gomez-Monterrey IM, Superti F, Campiglia P.",Lactoferrin-derived Peptides Active towards Influenza: Identification of Three Potent Tetrapeptide Inhibitors.,10.1038/s41598-017-10492-x,,Anti-Influenza virus
DRAVPe01648,VLRP,4,Peptide 14(lactoferrin 426–429),Synthetic construct,P24627,3IB0,Influenza virus,Orthomyxoviridae,Neutralization assay,[Ref.28878220]A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells(EC50=0.45 ± 0.1 pM);##A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells(EC50=1 ± 0.05 pM);##A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells(EC50=250 ± 0.42 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01648.cif,Linear,Free,Free,,L,hemagglutinin (HA),"Hemagglutinin is the major glycoprotein component of the viral envelope along with neuraminidase (NA), peptide derived from Lactoferrin binds Influenza A virus hemagglutinin (HA) inhibiting the hemagglutination and infection of major virus subtypes.",483.61,C22H41N7O5,ACDEFGHIKMNQSTWY,LPRV,9.72,1,0,1,0,2,47.5,-596,100 hour,>20 hour,>10 hour,170.0,0,0.0,28878220,Sci Rep. 2017 Sep 6;7(1):10593.,"Scala MC, Sala M, Pietrantoni A, Spensiero A, Di Micco S, Agamennone M, Bertamino A, Novellino E, Bifulco G, Gomez-Monterrey IM, Superti F, Campiglia P.",Lactoferrin-derived Peptides Active towards Influenza: Identification of Three Potent Tetrapeptide Inhibitors.,10.1038/s41598-017-10492-x,,Anti-Influenza virus
DRAVPe01647,SLDCVLRP,8,Peptide 13(lactoferrin 422–429),Synthetic construct,P24627,3IB0,Influenza virus,Orthomyxoviridae,Neutralization assay,[Ref.28878220]A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells(EC50=0.3 ± 0.5 pM);##A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells(EC50=2.5± 0.37 pM);##A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells(EC50=300± 0.2 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01647.cif,Linear,Free,Free,,L,hemagglutinin (HA),"Hemagglutinin is the major glycoprotein component of the viral envelope along with neuraminidase (NA), peptide derived from Lactoferrin binds Influenza A virus hemagglutinin (HA) inhibiting the hemagglutination and infection of major virus subtypes.",902.08,C38H67N11O12S,AEFGHIKMNQTWY,L,5.55,1,1,0,2,3,48.75,-1188,1.9 hour,>20 hour,>10 hour,133.75,0,0.0,28878220,Sci Rep. 2017 Sep 6;7(1):10593.,"Scala MC, Sala M, Pietrantoni A, Spensiero A, Di Micco S, Agamennone M, Bertamino A, Novellino E, Bifulco G, Gomez-Monterrey IM, Superti F, Campiglia P.",Lactoferrin-derived Peptides Active towards Influenza: Identification of Three Potent Tetrapeptide Inhibitors.,10.1038/s41598-017-10492-x,,Anti-Influenza virus
DRAVPe01646,KSETKN,6,Peptide 8(lactoferrin 633-638),Synthetic construct,P24627,3IB0,Influenza virus,Orthomyxoviridae,Neutralization assay,[Ref.28878220]A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells(EC50=0.5 ± 0.01 pM);##A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells(EC50=500 ± 0.46 pM);##A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells(EC50=400.000 ± 210 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01646.cif,Linear,Free,Free,,L,hemagglutinin (HA),"Hemagglutinin is the major glycoprotein component of the viral envelope along with neuraminidase (NA), peptide derived from Lactoferrin binds Influenza A virus hemagglutinin (HA) inhibiting the hemagglutination and infection of major virus subtypes.",705.77,C28H51N9O12,ACDFGHILMPQRVWY,K,8.59,2,1,1,3,0,-271.67,-3052,1.3 hour,3 min,2 min,0.0,0,0.0,28878220,Sci Rep. 2017 Sep 6;7(1):10593.,"Scala MC, Sala M, Pietrantoni A, Spensiero A, Di Micco S, Agamennone M, Bertamino A, Novellino E, Bifulco G, Gomez-Monterrey IM, Superti F, Campiglia P.",Lactoferrin-derived Peptides Active towards Influenza: Identification of Three Potent Tetrapeptide Inhibitors.,10.1038/s41598-017-10492-x,,Anti-Influenza virus
DRAVPe01645,TNGESTADWAKN,12,Peptide 6(lactoferrin 552-563),Synthetic construct,P24627,3IB0,Influenza virus,Orthomyxoviridae,Neutralization assay,[Ref.28878220]A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells(EC50=400 ±0.02 pM);##A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells(EC50=50.000 ± 230 pM);##A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells(EC50=10.000± 120 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01645.cif,Linear,Free,Free,,L,hemagglutinin (HA),"Hemagglutinin is the major glycoprotein component of the viral envelope along with neuraminidase (NA), peptide derived from Lactoferrin binds Influenza A virus hemagglutinin (HA) inhibiting the hemagglutination and infection of major virus subtypes.",1293.31,C53H80N16O22,CFHILMPQRVY,ANT,4.37,1,2,-1,6,3,-148.33,-3601,7.2 hour,>20 hour,>10 hour,16.67,5500,500.0,28878220,Sci Rep. 2017 Sep 6;7(1):10593.,"Scala MC, Sala M, Pietrantoni A, Spensiero A, Di Micco S, Agamennone M, Bertamino A, Novellino E, Bifulco G, Gomez-Monterrey IM, Superti F, Campiglia P.",Lactoferrin-derived Peptides Active towards Influenza: Identification of Three Potent Tetrapeptide Inhibitors.,10.1038/s41598-017-10492-x,,Anti-Influenza virus
DRAVPe01644,KANEGLTWNSLKDK,14,Peptide 4(lactoferrin 441–454),Synthetic construct,P24627,3IB0,Influenza virus,Orthomyxoviridae,Neutralization assay,[Ref.28878220]A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells(EC50=1± 0.15 pM);##A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells(EC50=50.000 ± 250 pM);##A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells(EC50=1.000 ± 360 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01644.cif,Linear,Free,Free,,L,hemagglutinin (HA),"Hemagglutinin is the major glycoprotein component of the viral envelope along with neuraminidase (NA), peptide derived from Lactoferrin binds Influenza A virus hemagglutinin (HA) inhibiting the hemagglutination and infection of major virus subtypes.",1603.8,C70H114N20O23,CFHIMPQRVY,K,8.5,3,2,1,5,4,-136.43,-3651,1.3 hour,3 min,2 min,62.86,5500,423.08,28878220,Sci Rep. 2017 Sep 6;7(1):10593.,"Scala MC, Sala M, Pietrantoni A, Spensiero A, Di Micco S, Agamennone M, Bertamino A, Novellino E, Bifulco G, Gomez-Monterrey IM, Superti F, Campiglia P.",Lactoferrin-derived Peptides Active towards Influenza: Identification of Three Potent Tetrapeptide Inhibitors.,10.1038/s41598-017-10492-x,,Anti-Influenza virus
DRAVPe01643,SKHSSLDCVLRP,12,Peptide 1(lactoferrin 418–429),Synthetic construct,P24627,3IB0,Influenza virus,Orthomyxoviridae,Neutralization assay,[Ref.28878220]A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells(EC50=4 ± 0.37 pM);##A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells(EC50=3.1 ± 0.12 pM);##A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells(EC50=5.8 ± 0.7 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01643.cif,Linear,Free,Free,,L,hemagglutinin (HA),"Hemagglutinin is the major glycoprotein component of the viral envelope along with neuraminidase (NA), peptide derived from Lactoferrin binds Influenza A virus hemagglutinin (HA) inhibiting the hemagglutination and infection of major virus subtypes.",1341.55,C56H96N18O18S,AEFGIMNQTWY,S,7.97,3,1,2,4,3,-40.0,-2889,1.9 hour,>20 hour,>10 hour,89.17,0,0.0,28878220,Sci Rep. 2017 Sep 6;7(1):10593.,"Scala MC, Sala M, Pietrantoni A, Spensiero A, Di Micco S, Agamennone M, Bertamino A, Novellino E, Bifulco G, Gomez-Monterrey IM, Superti F, Campiglia P.",Lactoferrin-derived Peptides Active towards Influenza: Identification of Three Potent Tetrapeptide Inhibitors.,10.1038/s41598-017-10492-x,,Anti-Influenza virus
DRAVPe01642,AGVSGHGQHGVHG,13,Alloferon-1 [H1A],Synthetic construct,P83412,,"HHV,CBV2","Herpesviridae, Picornaviridae",Antiviral assay(cytopathic effect),[Ref.21766388]Coxsackie virus 971 PT(971 PT CVB2):inhibition of virus replication in LLC-MK2 cells(IC50=358.00 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,"[Ref.21766388]No cytotoxicity against Vero cells,LLC-MK2 cells and Hep-2 cells up to 187.50 µg/ml.",,DRAVPe01642.cif,Linear,Free,Free,,L,Not found,The peptide may inhibit the replication of DNA and RNA viruses.,1199.25,C49H74N20O16,CDEFIKLMNPRTWY,G,7.06,3,0,3,6,3,-43.85,-833,4.4 hour,>20 hour,>10 hour,52.31,0,0.0,21766388,J Pept Sci. 2011 Nov;17(11):715-9.,"Kuczer M, Midak-Siewirska A, Zahorska R, Luczak M, Konopińska D.",Further studies on the antiviral activity of alloferon and its analogues.,10.1002/psc.1388,,"Anti-HHV,Anti-CBV2"
DRAVPe01641,RGVSGHGQHGVHG,13,Alloferon-1 [H1R],Synthetic construct,P83412,,"HHV,CBV2","Herpesviridae, Picornaviridae",Antiviral assay(cytopathic effect),[Ref.21766388]HHV-1 McIntyre strain:inhibition of virus replication in Vero cells(IC50=321.10 µg/ml);##HHV-1:inhibition of virus replication in Vero cells(IC50=277.50 µg/ml);inhibition of virus replication in HEp-2 cells(IC50=602.18 µg/ml);##Coxsackie virus 971 PT(971 PT CVB2):inhibition of virus replication in LLC-MK2 cells(IC50=577.73 µg/ml);inhibition of virus replication in Hep-2 cells(IC50=167.71 µg/ml);##CVB2:inhibition of virus replication in LLC-MK2 cells(IC50=355.18 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,"[Ref.21766388]No cytotoxicity against Vero cells,LLC-MK2 cells and Hep-2 cells up to 143.75 µg/ml.",,DRAVPe01641.cif,Linear,Free,Free,,L,Not found,The peptide may inhibit the replication of DNA and RNA viruses.,1284.36,C52H81N23O16,ACDEFIKLMNPTWY,G,9.77,4,0,4,6,2,-92.31,-2506,1 hour,2 min,2 min,44.62,0,0.0,21766388,J Pept Sci. 2011 Nov;17(11):715-9.,"Kuczer M, Midak-Siewirska A, Zahorska R, Luczak M, Konopińska D.",Further studies on the antiviral activity of alloferon and its analogues.,10.1002/psc.1388,,"Anti-HHV,Anti-CBV2"
DRAVPe01640,KGVSGHGQHGVHG,13,Alloferon-1 [H1K],Synthetic construct,P83412,,"HHV,CBV2","Herpesviridae, Picornaviridae",Antiviral assay(cytopathic effect),[Ref.21766388]HHV-1 McIntyre strain:inhibition of virus replication in Vero cells(IC50=147.09 µg/ml);inhibition of virus replication in Hep-2 cells(IC50=241.90 µg/ml);##HHV-1:inhibition of virus replication in Vero cells(IC50=9.19 µg/ml);inhibition of virus replication in HEp-2 cells(IC50=12.98 µg/ml);##Coxsackie virus 971 PT(971 PT CVB2):inhibition of virus replication in LLC-MK2 cells(IC50=157.73 µg/ml);inhibition of virus replication in Hep-2 cells(IC50=107.04 µg/ml);##CVB2:inhibition of virus replication in LLC-MK2 cells(IC50=190.67 µg/ml);inhibition of virus replication in Hep-2 cells(IC50=74.00 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,"[Ref.21766388]No cytotoxicity against Vero cells,LLC-MK2 cells and Hep-2 cells up to 218.75 µg/ml.",,DRAVPe01640.cif,Linear,Free,Free,,L,Not found,The peptide may inhibit the replication of DNA and RNA viruses.,1256.35,C52H81N21O16,ACDEFILMNPRTWY,G,8.77,4,0,4,6,2,-87.69,-1569,1.3 hour,3 min,2 min,44.62,0,0.0,21766388,J Pept Sci. 2011 Nov;17(11):715-9.,"Kuczer M, Midak-Siewirska A, Zahorska R, Luczak M, Konopińska D.",Further studies on the antiviral activity of alloferon and its analogues.,10.1002/psc.1388,,"Anti-HHV,Anti-CBV2"
DRAVPe01639,GQGKAHNGRLITANP,15,DENV Envelope glycoprotein (340 – 354),Synthetic construct(derived from DENV Envelope glycoprotein),Q5UB51##P17763,,DENV,Flaviviridae,Focus-forming assay (FFA),"[Ref.30508603]DENV-1:inhibition of virus infection in Vero cells(83%±3.72% inhibition at 50 μM,IC50=33 μM);##DENV-2:inhibition of virus infection in Vero cells(IC50=10 μM);##DENV-3:inhibition of virus infection in Vero cells(60% inhibition at 20μM);##DENV-4:inhibition of virus infection in Vero cells(55% inhibition at 20μM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30508603]<20% cytotoxicity against Vero and C6/36 cells at 200 μM.,,DRAVPe01639.cif,Linear,Free,Free,,L,E protein,"The peptide acts as inhibitors by binding to the E protein, suppressing its conformational changes, and preventing its binding to the cellular receptor, thereby inhibiting viral entry.",1533.71,C64H108N24O20,CDEFMSVWY,G,11.0,3,0,3,6,4,-91.33,-3024,30 hour,>20 hour,>10 hour,65.33,0,0.0,30508603,Virus Res. 2019 Jan 15;260:142-150.,"John AM, Jittmittraphap A, Chattanadee S, Alwin Prem Anand A, Shenbagarathai R, Leaungwutiwong P.",In vitro analysis of synthetic peptides in blocking the entry of dengue virus.,10.1016/j.virusres.2018.11.016,,Anti-DENV
DRAVPe01638,DRGWGNGCGLFG,12,DENV Envelope glycoprotein (98-109),Synthetic construct(derived from DENV Envelope glycoprotein),Q5UB51##P17763,,DENV,Flaviviridae,Focus-forming assay (FFA),"[Ref.30508603]DENV-1:inhibition of virus infection in Vero cells(88%±3.89% inhibition at 50 μM,IC50=10 μM);##DENV-2:inhibition of virus infection in Vero cells(IC50=10 μM);##DENV-3:inhibition of virus infection in Vero cells(60% inhibition at 20μM);##DENV-4:inhibition of virus infection in Vero cells(55% inhibition at 20μM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30508603]<20% cytotoxicity against Vero and C6/36 cells at 200 μM.,,DRAVPe01638.cif,Linear,Free,Free,,L,E protein,"The peptide acts as inhibitors by binding to the E protein, suppressing its conformational changes, and preventing its binding to the cellular receptor, thereby inhibiting viral entry.",1238.34,C53H75N17O16S,AEHIKMPQSTVY,G,5.83,1,1,0,7,3,-44.17,-1407,1.1 hour,3 min,>10 hour,32.5,5500,500.0,30508603,Virus Res. 2019 Jan 15;260:142-150.,"John AM, Jittmittraphap A, Chattanadee S, Alwin Prem Anand A, Shenbagarathai R, Leaungwutiwong P.",In vitro analysis of synthetic peptides in blocking the entry of dengue virus.,10.1016/j.virusres.2018.11.016,,Anti-DENV
DRAVPe01637,LEHGSCVTTMAKDKPTL,17,DENV Envelope glycoprotein (25-41),Synthetic construct(derived from DENV Envelope glycoprotein),Q5UB51##P17763,,DENV,Flaviviridae,Focus-forming assay (FFA),"[Ref.30508603]DENV-1:inhibition of virus infection in Vero cells(58%±2.55% inhibition at 50 μM,IC50=10 μM);##DENV-2:inhibition of virus infection in Vero cells(IC50=10 μM);##DENV-3:inhibition of virus infection in Vero cells(60% inhibition at 20μM);##DENV-4:inhibition of virus infection in Vero cells(55% inhibition at 20μM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30508603]<20% cytotoxicity against Vero and C6/36 cells at 200 μM.,,DRAVPe01637.cif,Linear,Free,Free,,L,E protein,"The peptide acts as inhibitors by binding to the E protein, suppressing its conformational changes, and preventing its binding to the cellular receptor, thereby inhibiting viral entry.",1831.13,C77H131N21O26S2,FINQRWY,T,6.74,3,2,1,6,4,-28.82,-2214,5.5 hour,3 min,2 min,68.82,0,0.0,30508603,Virus Res. 2019 Jan 15;260:142-150.,"John AM, Jittmittraphap A, Chattanadee S, Alwin Prem Anand A, Shenbagarathai R, Leaungwutiwong P.",In vitro analysis of synthetic peptides in blocking the entry of dengue virus.,10.1016/j.virusres.2018.11.016,,Anti-DENV
DRAVPe01636,RRRRRRRXPLSPPLRNTHPQAMQWNSTTF,29,7R-Ahx-HBV Large envelope protein (96-116),Synthetic construct,P03138,,HBV,Hepadnaviridae,FQ-PCR,[Ref.21144865]HBV:inhibition of cell proliferation in HepG2.2.15 cells(EC50=6.5 ± 1.5 μM;EC90=41.4 ±8.7 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.21144865]HepG2.2.15:LC50=515.9± 43.8 μM.,,DRAVPe01636.cif,Linear,Free,Free,The 'X' at position 8 is 6-aminocaproic acid.,L,DNA,The peptide can efficiently enter cells and inhibit the envelopment of HBV nucleocapsids and subsequent secretion of viral particles.,3628.37,C150H245N59O37S,CDEGIKVY,R,12.85,9,0,9,7,5,-172.76,-14358,1 hour,2 min,2 min,30.34,5500,196.43,21144865,Antiviral Res. 2011 Jan;89(1):109-14.,"Pan XB, Wei L, Han JC, Ma H, Deng K, Cong X.",Artificial recombinant cell-penetrating peptides interfere with envelopment of hepatitis B virus nucleocapsid and viral production.,10.1016/j.antiviral.2010.12.001,,Anti-HBV
DRAVPe01635,RRRRRRRXLDPAFR,14,7R-Ahx-HBV Large envelope protein (19-24),Synthetic construct,P03138,,HBV,Hepadnaviridae,FQ-PCR,[Ref.21144865]HBV:inhibition of cell proliferation in HepG2.2.15 cells(EC50=3.0 ± 1.0 μM;EC90=10.9 ± 3.4 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.21144865]No cytotoxicity was observed at 1mM of peptide concentration against HepG2.2.15.,,DRAVPe01635.cif,Linear,Free,Free,The 'X' at position 8 is 6-aminocaproic acid.,L,DNA,The peptide can efficiently enter cells and inhibit the envelopment of HBV nucleocapsids and subsequent secretion of viral particles.,1922.47,C75H133N37O15,CEGHIKMNQSTVWY,R,12.48,8,1,7,0,3,-233.57,-11837,1 hour,2 min,2 min,35.0,0,0.0,21144865,Antiviral Res. 2011 Jan;89(1):109-14.,"Pan XB, Wei L, Han JC, Ma H, Deng K, Cong X.",Artificial recombinant cell-penetrating peptides interfere with envelopment of hepatitis B virus nucleocapsid and viral production.,10.1016/j.antiviral.2010.12.001,,Anti-HBV
DRAVPe01633,RRRRRRRXPTSNHSPTSCPPTCPGYRWMCLRRF,33,7R-Ahx-HBV Large envelope protein (219-243),Synthetic construct,P03138,,HBV,Hepadnaviridae,FQ-PCR,[Ref.21144865]HBV:inhibition of cell proliferation in HepG2.2.15 cells(EC50=12.8 ± 2.0 μM;EC90=85.6 ± 9.5 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.21144865]HepG2.2.15:LC50=457.9 ± 41.0 μM.,,DRAVPe01633.cif,Linear,Free,Free,The 'X' at position 8 is 6-aminocaproic acid.,L,DNA,The peptide can efficiently enter cells and inhibit the envelopment of HBV nucleocapsids and subsequent secretion of viral particles.,4099.99,C167H270N66O40S4,ADEIKQV,R,12.0,11,0,11,12,3,-153.94,-16119,1 hour,2 min,2 min,11.82,7115,222.34,21144865,Antiviral Res. 2011 Jan;89(1):109-14.,"Pan XB, Wei L, Han JC, Ma H, Deng K, Cong X.",Artificial recombinant cell-penetrating peptides interfere with envelopment of hepatitis B virus nucleocapsid and viral production.,10.1016/j.antiviral.2010.12.001,,Anti-HBV
DRAVPe01634,RRRRRRRXGSLLGRMKGA,18,7R-Ahx-P3,Synthetic construct,,,HBV,Hepadnaviridae,FQ-PCR,[Ref.21144865]HBV:inhibition of cell proliferation in HepG2.2.15 cells(EC50=2.5 ±1.0 μM;EC90=8.6± 3.2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.21144865]HepG2.2.15:LC50=828.7 ± 50.3 μM.,,DRAVPe01634.cif,Linear,Free,Free,The 'X' at position 8 is 6-aminocaproic acid.,L,DNA,The peptide can efficiently enter cells and inhibit the envelopment of HBV nucleocapsids and subsequent secretion of viral particles.,2193.84,C83H158N42O18S,CDEFHINPQTVWY,R,12.85,9,0,9,4,3,-170.0,-11149,1 hour,2 min,2 min,48.89,0,0.0,21144865,Antiviral Res. 2011 Jan;89(1):109-14.,"Pan XB, Wei L, Han JC, Ma H, Deng K, Cong X.",Artificial recombinant cell-penetrating peptides interfere with envelopment of hepatitis B virus nucleocapsid and viral production.,10.1016/j.antiviral.2010.12.001,,Anti-HBV
DRAVPe01632,EEQAKTFLDKFNHEAEDLFYQSSGLGKGDFR,31,P6(ACE2 (4-26)-G-ACE2 (333-339)),Synthetic construct(derived from angiotensin-converting enzyme 2),Q9BYF1,,SARS-CoV,Coronaviridae,Pseudovirus infection assay,[Ref.16510163]SARS-CoV:inhibition of pseudovirus infection in HeLa cells(IC50=0.1 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01632.cif,Linear,Free,Free,,L,spike glycoprotein,"Virus entry into cells is mediated through interactions between spike (S) glycoprotein and angiotensin-converting enzyme 2 (ACE2), peptide derived from ACE2 could bind with spike glycoprotein and inhibits virus entry.",3607.89,C161H236N42O53,CIMPVW,EF,4.7,5,7,-2,8,9,-106.45,-8374,1 hour,30 min,>10 hour,44.19,1490,49.67,16510163,Virology. 2006 Jun 20;350(1):15-25.,"Han DP, Penn-Nicholson A, Cho MW.",Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor.,10.1016/j.virol.2006.01.029,,Anti-SARS-CoV
DRAVPe01631,EEQAKTFLDKFNHEAEDLFYQSSLASWNYNTNITEE,36,P5(ACE2 (4-39)),Synthetic construct(derived from angiotensin-converting enzyme 2),Q9BYF1,,SARS-CoV,Coronaviridae,Pseudovirus infection assay,[Ref.16510163]SARS-CoV:inhibition of pseudovirus infection in HeLa cells(IC50=6 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01631.cif,Linear,Free,Free,,L,spike glycoprotein,"Virus entry into cells is mediated through interactions between spike (S) glycoprotein and angiotensin-converting enzyme 2 (ACE2), peptide derived from ACE2 could bind with spike glycoprotein and inhibits virus entry.",4313.57,C192H275N47O67,CGMPRV,E,4.16,3,8,-5,12,11,-106.39,-9351,1 hour,30 min,>10 hour,51.67,8480,242.29,16510163,Virology. 2006 Jun 20;350(1):15-25.,"Han DP, Penn-Nicholson A, Cho MW.",Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor.,10.1016/j.virol.2006.01.029,,Anti-SARS-CoV
DRAVPe01630,EEQAKTFLDKFNHEAEDLFYQSS,23,P4(ACE2 (4-26)),Synthetic construct(derived from angiotensin-converting enzyme 2),Q9BYF1,,SARS-CoV,Coronaviridae,Pseudovirus infection assay,[Ref.16510163]SARS-CoV:inhibition of pseudovirus infection in HeLa cells(IC50=50 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01630.cif,Linear,Free,Free,,L,spike glycoprotein,"Virus entry into cells is mediated through interactions between spike (S) glycoprotein and angiotensin-converting enzyme 2 (ACE2), peptide derived from ACE2 could bind with spike glycoprotein and inhibits virus entry.",2776.95,C124H178N30O43,CGIMPRVW,E,4.35,3,6,-3,5,7,-115.22,-6527,1 hour,30 min,>10 hour,42.61,1490,67.73,16510163,Virology. 2006 Jun 20;350(1):15-25.,"Han DP, Penn-Nicholson A, Cho MW.",Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor.,10.1016/j.virol.2006.01.029,,Anti-SARS-CoV
DRAVPe01629,NHEAEDLFY,9,P3(ACE2 (15-23)),Synthetic construct(derived from angiotensin-converting enzyme 2),Q9BYF1,,SARS-CoV,Coronaviridae,Pseudovirus infection assay,[Ref.16510163]SARS-CoV:inhibition of pseudovirus infection in HeLa cells(30% inhibition at 100 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01629.cif,Linear,Free,Free,,L,spike glycoprotein,"Virus entry into cells is mediated through interactions between spike (S) glycoprotein and angiotensin-converting enzyme 2 (ACE2), peptide derived from ACE2 could bind with spike glycoprotein and inhibits virus entry.",1137.17,C51H68N12O18,CGIKMPQRSTVW,E,4.13,1,3,-2,2,3,-112.22,-2407,1.4 hour,3 min,>10 hour,54.44,1490,186.25,16510163,Virology. 2006 Jun 20;350(1):15-25.,"Han DP, Penn-Nicholson A, Cho MW.",Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor.,10.1016/j.virol.2006.01.029,,Anti-SARS-CoV
DRAVPe01628,DKFNHEAED,9,P2(ACE2 (12-20)),Synthetic construct(derived from angiotensin-converting enzyme 2),Q9BYF1,,SARS-CoV,Coronaviridae,Pseudovirus infection assay,[Ref.16510163]SARS-CoV:inhibition of pseudovirus infection in HeLa cells(40% inhibition at 100 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01628.cif,Linear,Free,Free,,L,spike glycoprotein,"Virus entry into cells is mediated through interactions between spike (S) glycoprotein and angiotensin-converting enzyme 2 (ACE2), peptide derived from ACE2 could bind with spike glycoprotein and inhibits virus entry.",1104.1,C46H65N13O19,CGILMPQRSTVWY,DE,4.31,2,4,-2,1,2,-222.22,-4312,1.1 hour,3 min,>10 hour,11.11,0,0.0,16510163,Virology. 2006 Jun 20;350(1):15-25.,"Han DP, Penn-Nicholson A, Cho MW.",Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor.,10.1016/j.virol.2006.01.029,,Anti-SARS-CoV
DRAVPe01627,EEQAKTFLDK,10,P1(ACE2 (4-13)),Synthetic construct(derived from angiotensin-converting enzyme 2),Q9BYF1,,SARS-CoV,Coronaviridae,Pseudovirus infection assay,[Ref.16510163]SARS-CoV:inhibition of pseudovirus infection in HeLa cells(25% inhibition at 100 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01627.cif,Linear,Free,Free,,L,spike glycoprotein,"Virus entry into cells is mediated through interactions between spike (S) glycoprotein and angiotensin-converting enzyme 2 (ACE2), peptide derived from ACE2 could bind with spike glycoprotein and inhibits virus entry.",1208.33,C53H85N13O19,CGHIMNPRSVWY,EK,4.68,2,3,-1,1,3,-141.0,-3184,1 hour,30 min,>10 hour,49.0,0,0.0,16510163,Virology. 2006 Jun 20;350(1):15-25.,"Han DP, Penn-Nicholson A, Cho MW.",Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor.,10.1016/j.virol.2006.01.029,,Anti-SARS-CoV
DRAVPe01625,HAKFWW,6,,Synthetic construct,No entry found,,HIV,Retroviridae,integrase assay,[Ref.8524782]HIV-1:inhibition of integrase-mediated 3'-processing and integration(IC50=30 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01625.cif,Linear,Free,Amidation,,L,integrase,"The peptide may inhibit integrase-mediated 3'-processing and integration, which is useful for inhibiting virus replication.",874.01,C46H55N11O7,CDEGILMNPQRSTVY,W,8.76,2,0,2,0,4,-71.67,-76,3.5 hour,10 min,>10 hour,16.67,11000,2200.0,8524782,Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60.,"Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH.",Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.,10.1073/pnas.92.25.11456,,Anti-HIV
DRAVPe01626,HCAFWW,6,,Synthetic construct,No entry found,,HIV,Retroviridae,integrase assay,[Ref.8524782]HIV-1:inhibition of integrase-mediated 3'-processing and integration(IC50=49 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01626.cif,Linear,Free,Amidation,,L,integrase,"The peptide may inhibit integrase-mediated 3'-processing and integration, which is useful for inhibiting virus replication.",848.98,C43H48N10O7S,DEGIKLMNPQRSTVY,W,6.73,1,0,1,1,4,35.0,607,3.5 hour,10 min,>10 hour,16.67,11000,2200.0,8524782,Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60.,"Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH.",Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.,10.1073/pnas.92.25.11456,,Anti-HIV
DRAVPe00001,EEHEKYHSNW,10,NL1,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>2000 µM);inhibition of strand transfer catalyzed by integrase(IC50>2000 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00001,DRAVPe00001.cif,Linear,Free,Amidation,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1358.39,C60H79N17O20,ACDFGILMPQRTV,E,5.33,3,3,0,3,1,-273.0,-4315,1 hour,30 min,>10 hour,0.0,6990,776.67,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00002,ASCDKCQLKG,10,NL2,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>2000 µM);inhibition of strand transfer catalyzed by integrase(IC50>2000 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00002,DRAVPe00002.cif,Linear,Free,Amidation,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1052.23,C41H73N13O15S2,EFHIMNPRTVWY,CK,8.09,2,1,1,4,2,-54.0,-1853,4.4 hour,>20 hour,>10 hour,49.0,125,13.89,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00003,HGQVDCSPGIWQLDCTH,17,NL3 ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=1000 µM);inhibition of strand transfer catalyzed by integrase(IC50=1000 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00003,DRAVPe00003.cif,Linear,Free,Amidation,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1896.08,C80H118N24O26S2,AEFKMNRY,CDGHQ,5.05,2,2,0,6,4,-45.29,-2316,3.5 hour,10 min,>10 hour,62.94,5625,351.56,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00004,VHVASGY,7,NL4,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>2000 µM);inhibition of strand transfer catalyzed by integrase(IC50>2000 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00004,DRAVPe00004.cif,Linear,Free,Amidation,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",731.81,C33H49N9O10,CDEFIKLMNPQRTW,V,6.71,1,0,1,3,3,64.29,263,100 hour,>20 hour,>10 hour,97.14,1490,248.33,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00005,PAETGQET,8,NL5,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>2000 µM);inhibition of strand transfer catalyzed by integrase(IC50>2000 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00005,DRAVPe00005.cif,Linear,Free,Amidation,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",831.83,C33H53N9O16,CDFHIKLMNRSVWY,ET,3.8,0,2,-2,3,1,-151.25,-2155,>20 hour,>20 hour,?,12.5,0,0.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00006,TAYFLLKLAGRW,12,NL-6 ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=21±7 µM);inhibition of strand transfer catalyzed by integrase(IC50=2.7±1  µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00006,DRAVPe00006.cif,Linear,Free,Amidation,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1438.74,C71H107N17O15,CDEHIMNPQSV,L,9.99,2,0,2,3,7,50.83,145,7.2 hour,>20 hour,>10 hour,114.17,6990,635.45,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00007,GRWPVKT,7,NL7,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>2000 µM);inhibition of strand transfer catalyzed by integrase(IC50>2000 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00007,DRAVPe00007.cif,Linear,Free,Amidation,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",843.0,C39H62N12O9,ACDEFHILMNQSY,GKPRTVW,11.0,2,0,2,2,2,-111.43,-1573,30 hour,>20 hour,>10 hour,41.43,5500,916.67,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00008,HTDNGSNF,8,NL8,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>2000 µM);inhibition of strand transfer catalyzed by integrase(IC50>2000 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00008,DRAVPe00008.cif,Linear,Free,Amidation,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",890.86,C36H50N12O15,ACEIKLMPQRVWY,N,5.08,1,1,0,5,1,-160.0,-2871,3.5 hour,10 min,>10 hour,0.0,0,0.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00009,ACWWAGIKQEF,11,NL-9 ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=95±9 µM);inhibition of strand transfer catalyzed by integrase(IC50=56±5  µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00009,DRAVPe00009.cif,Linear,Free,Amidation,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1338.55,C64H87N15O15S,DHLMNPRSTVY,AW,6.04,1,1,0,2,6,2.73,50,4.4 hour,>20 hour,>10 hour,53.64,11000,1100.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00010,FGIPYNPQSQ,10,NL10,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>1000 µM);inhibition of strand transfer catalyzed by integrase(IC50>1000 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00010,DRAVPe00010.cif,Linear,Free,Amidation,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1150.26,C53H75N13O16,ACDEHKLMRTVW,PQ,5.52,0,0,0,4,2,-89.0,-1242,1.1 hour,3 min,2 min,39.0,1490,165.56,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00011,ESMNKELKKI,10,NL11,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>2000 µM);inhibition of strand transfer catalyzed by integrase(IC50>2000 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00011,DRAVPe00011.cif,Linear,Free,Amidation,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1219.46,C52H94N14O17S,ACDFGHPQRTVWY,K,8.59,3,2,1,2,2,-128.0,-2812,1 hour,30 min,>10 hour,78.0,0,0.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00012,VRDQAEHLKT,10,NL12,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>2000 µM);inhibition of strand transfer catalyzed by integrase(IC50>2000 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00012,DRAVPe00012.cif,Linear,Free,Amidation,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1196.33,C50H85N17O17,CFGIMNPSWY,ADEHKLQRTV,6.72,3,2,1,1,3,-130.0,-3800,100 hour,>20 hour,>10 hour,78.0,0,0.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00013,FIHNFKRK,8,NL13,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>2000 µM);inhibition of strand transfer catalyzed by integrase(IC50>2000 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00013,DRAVPe00013.cif,Linear,Free,Amidation,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1089.31,C52H80N16O10,ACDEGLMPQSTVWY,FK,11.17,4,0,4,1,3,-111.25,-2644,1.1 hour,3 min,2 min,48.75,0,0.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00014,GYSAGERIVD,10,NL14,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>2000 µM);inhibition of strand transfer catalyzed by integrase(IC50>2000 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00014,DRAVPe00014.cif,Linear,Free,Amidation,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1066.14,C45H71N13O17,CFHKLMNPQTW,G,4.37,1,2,-1,4,3,-39.0,-2134,30 hour,>20 hour,>10 hour,78.0,1490,165.56,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00015,WKGPAKLLWK,10,NL15,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>1000 µM);inhibition of strand transfer catalyzed by integrase(IC50>1000 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00015,DRAVPe00015.cif,Linear,Free,Amidation,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1226.53,C62H95N15O11,CDEFHIMNQRSTVY,K,10.3,3,0,3,1,5,-61.0,60,2.8 hour,3 min,2 min,88.0,11000,1222.22,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00016,VPRRKAKI,8,NL16,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>1000 µM);inhibition of strand transfer catalyzed by integrase(IC50>1000 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00016,DRAVPe00016.cif,Linear,Free,Amidation,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",967.23,C43H82N16O9,CDEFGHLMNQSTWY,KR,12.02,4,0,4,0,3,-98.75,-3017,100 hour,>20 hour,>10 hour,97.5,0,0.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00017,AAYFLLKLAGRW,12,NL6-T1A ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=100±10 µM);inhibition of strand transfer catalyzed by integrase(IC50=47±7  µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00017,DRAVPe00017.cif,Linear,Free,Free,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1408.71,C70H105N17O14,CDEHIMNPQSTV,AL,9.99,2,0,2,2,8,71.67,583,4.4 hour,>20 hour,>10 hour,122.5,6990,635.45,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00018,TAAFLLKLAGRW,12,NL6-Y3A ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=193±10 µM);inhibition of strand transfer catalyzed by integrase(IC50=119±11  µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00018,DRAVPe00018.cif,Linear,Free,Free,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1346.64,C65H103N17O14,CDEHIMNPQSVY,AL,11.0,2,0,2,2,8,76.67,340,7.2 hour,>20 hour,>10 hour,122.5,5500,500.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00019,TAYALLKLAGRW,12,NL6-F4A ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50>333  µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00019,DRAVPe00019.cif,Linear,Free,Free,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1362.64,C65H103N17O15,CDEFHIMNPQSV,AL,9.99,2,0,2,3,7,42.5,28,7.2 hour,>20 hour,>10 hour,122.5,6990,635.45,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00020,TAYFALKLAGRW,12,NL6-L5A ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=115±21 µM);inhibition of strand transfer catalyzed by integrase(IC50=51±7  µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00020,DRAVPe00020.cif,Linear,Free,Free,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1396.65,C68H101N17O15,CDEHIMNPQSV,A,9.99,2,0,2,3,7,34.17,-166,7.2 hour,>20 hour,>10 hour,90.0,6990,635.45,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00021,TAYFLAKLAGRW,12,NL6-L6A ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50>333  µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00021,DRAVPe00021.cif,Linear,Free,Free,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1396.65,C68H101N17O15,CDEHIMNPQSV,A,9.99,2,0,2,3,7,34.17,-166,7.2 hour,>20 hour,>10 hour,90.0,6990,635.45,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00022,TAYFLLALAGRW,12,NL6-K7A ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=113±15 µM);inhibition of strand transfer catalyzed by integrase(IC50=56±7  µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00022,DRAVPe00022.cif,Linear,Free,Free,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1381.64,C68H100N16O15,CDEHIKMNPQSV,AL,8.41,1,0,1,3,8,98.33,881,7.2 hour,>20 hour,>10 hour,122.5,6990,635.45,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00023,TAYFLLKAAGRW,12,NL6-L8A ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50=106±7  µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00023,DRAVPe00023.cif,Linear,Free,Free,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1396.65,C68H101N17O15,CDEHIMNPQSV,A,9.99,2,0,2,3,7,34.17,-166,7.2 hour,>20 hour,>10 hour,90.0,6990,635.45,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00024,TAYFLLKLAARW,12,NL6-G10A ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=118±10 µM);inhibition of strand transfer catalyzed by integrase(IC50=19±6  µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00024,DRAVPe00024.cif,Linear,Free,Free,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1452.76,C72H109N17O15,CDEGHIMNPQSV,AL,9.99,2,0,2,2,8,69.17,232,7.2 hour,>20 hour,>10 hour,122.5,6990,635.45,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00025,TAYFLLKLAGAW,12,NL6-R11A ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=83±15 µM);inhibition of strand transfer catalyzed by integrase(IC50=80±8  µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00025,DRAVPe00025.cif,Linear,Free,Free,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1353.63,C68H100N14O15,CDEHIMNPQRSV,AL,8.26,1,0,1,3,8,103.33,1818,7.2 hour,>20 hour,>10 hour,122.5,6990,635.45,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00026,TAYFLLKLAGRA,12,NL6-W12A ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50>333 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00026,DRAVPe00026.cif,Linear,Free,Free,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1323.6,C63H102N16O15,CDEHIMNPQSVW,AL,9.99,2,0,2,3,7,73.33,93,7.2 hour,>20 hour,>10 hour,122.5,1490,135.45,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00027,AAWWAGIKQEF,11,NL9-C2A ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=277±47 µM);inhibition of strand transfer catalyzed by integrase(IC50=311±19  µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00027,DRAVPe00027.cif,Linear,Free,Free,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1306.49,C64H87N15O15,CDHLMNPRSTVY,A,6.05,1,1,0,1,7,-3.64,103,4.4 hour,>20 hour,>10 hour,62.73,11000,1100.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00028,ACAWAGIKQEF,11,NL9-W3A ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=33±6 µM);inhibition of strand transfer catalyzed by integrase(IC50=34±8  µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00028,DRAVPe00028.cif,Linear,Free,Free,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1223.41,C56H82N14O15S,DHLMNPRSTVY,A,6.04,1,1,0,2,6,27.27,-2,4.4 hour,>20 hour,>10 hour,62.73,5500,550.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00029,ACWAAGIKQEF,11,NL9-W4A ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50>333 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00029,DRAVPe00029.cif,Linear,Free,Free,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1223.41,C56H82N14O15S,DHLMNPRSTVY,A,6.04,1,1,0,2,6,27.27,-2,4.4 hour,>20 hour,>10 hour,62.73,5500,550.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00030,ACWWAAIKQEF,11,NL9-G6A ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=90±10 µM);inhibition of strand transfer catalyzed by integrase(IC50=43±7  µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00030,DRAVPe00030.cif,Linear,Free,Free,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1352.57,C65H89N15O15S,DGHLMNPRSTVY,A,6.04,1,1,0,1,7,22.73,137,4.4 hour,>20 hour,>10 hour,62.73,11000,1100.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00031,ACWWAGAKQEF,11,NL9-I7A ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50>333 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00031,DRAVPe00031.cif,Linear,Free,Free,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1296.47,C61H81N15O15S,DHILMNPRSTVY,A,6.04,1,1,0,2,6,-21.82,-261,4.4 hour,>20 hour,>10 hour,27.27,11000,1100.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00032,ACWWAGIAQEF,11,NL9-K8A ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=62±13 µM);inhibition of strand transfer catalyzed by integrase(IC50=55±7  µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00032,DRAVPe00032.cif,Linear,Free,Free,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1281.45,C61H80N14O15S,DHKLMNPRSTVY,A,4.0,0,1,-1,2,7,54.55,786,4.4 hour,>20 hour,>10 hour,62.73,11000,1100.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00033,ACWWAGIKAEF,11,NL9-Q9A ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50>333 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00033,DRAVPe00033.cif,Linear,Free,Free,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1281.49,C62H84N14O14S,DHLMNPQRSTVY,A,6.04,1,1,0,2,7,50.91,785,4.4 hour,>20 hour,>10 hour,62.73,11000,1100.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00034,ACWWAGIKQAF,11,NL9-E10A ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50>333 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00034,DRAVPe00034.cif,Linear,Free,Free,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1280.51,C62H85N15O13S,DEHLMNPRSTVY,A,8.27,1,0,1,2,7,50.91,912,4.4 hour,>20 hour,>10 hour,62.73,11000,1100.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00035,ACWWAGIKQEA,11,NL9-F11A ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=245±13 µM);inhibition of strand transfer catalyzed by integrase(IC50=206±12  µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00035,DRAVPe00035.cif,Linear,Free,Free,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1262.45,C58H83N15O15S,DFHLMNPRSTVY,A,6.04,1,1,0,2,6,-6.36,-67,4.4 hour,>20 hour,>10 hour,62.73,11000,1100.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00036,TASFLLKLAGRW,12,NL6-1 ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=186±23 µM);inhibition of strand transfer catalyzed by integrase(IC50=11±2  µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00036,DRAVPe00036.cif,Linear,Free,Amidation,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1362.64,C65H103N17O15,CDEHIMNPQVY,L,11.0,2,0,2,3,7,55.0,-181,7.2 hour,>20 hour,>10 hour,114.17,5500,500.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00037,TAYFLLILAGRW,12,NL6-2 ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=4.1±0.7 µM);inhibition of strand transfer catalyzed by integrase(IC50=3.0±1.0  µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00037,DRAVPe00037.cif,Linear,Free,Amidation,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1423.72,C71H106N16O15,CDEHKMNPQSV,L,8.41,1,0,1,3,8,120.83,1192,7.2 hour,>20 hour,>10 hour,146.67,6990,635.45,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00038,TAYFLLKLAGRL,12,NL6-3 ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=315±30 µM);inhibition of strand transfer catalyzed by integrase(IC50=38±2  µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00038,DRAVPe00038.cif,Linear,Free,Amidation,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1365.68,C66H108N16O15,CDEHIMNPQSVW,L,9.99,2,0,2,3,7,90.0,404,7.2 hour,>20 hour,>10 hour,146.67,1490,135.45,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00039,ASWWAGIKQEF,11,NL9-1 ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=294±41 µM);inhibition of strand transfer catalyzed by integrase(IC50=163±15  µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00039,DRAVPe00039.cif,Linear,Free,Amidation,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1322.49,C64H87N15O16,CDHLMNPRTVY,AW,6.05,1,1,0,2,6,-27.27,-418,4.4 hour,>20 hour,>10 hour,53.64,11000,1100.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00040,ACGWAGIKQEF,11,NL9-2 ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=46±5 µM);inhibition of strand transfer catalyzed by integrase(IC50=16±2  µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00040,DRAVPe00040.cif,Linear,Free,Amidation,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1209.38,C55H80N14O15S,DHLMNPRSTVY,AG,6.04,1,1,0,3,5,7.27,-89,4.4 hour,>20 hour,>10 hour,53.64,5500,550.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00041,ACWGAGIKQEF,11,NL9-3 ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50>333 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00041,DRAVPe00041.cif,Linear,Free,Amidation,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1209.38,C55H80N14O15S,DHLMNPRSTVY,AG,6.04,1,1,0,3,5,7.27,-89,4.4 hour,>20 hour,>10 hour,53.64,5500,550.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00042,ACWWAGIRQEF,11,NL9-4 ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50>333 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00042,DRAVPe00042.cif,Linear,Free,Amidation,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1366.56,C64H87N17O15S,DHKLMNPSTVY,AW,6.04,1,1,0,2,6,-2.73,-887,4.4 hour,>20 hour,>10 hour,53.64,11000,1100.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00043,TAYFLL,6,NL6-4,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=500 µM);inhibition of strand transfer catalyzed by integrase(IC50=500 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00043,DRAVPe00043.cif,Linear,Free,Amidation,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",726.87,C37H54N6O9,CDEGHIKMNPQRSVW,L,5.18,0,0,0,2,4,170.0,1192,7.2 hour,>20 hour,>10 hour,146.67,1490,298.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00044,YFLLKL,6,NL6-5 ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=20 µM);inhibition of strand transfer catalyzed by integrase(IC50=20 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00044,DRAVPe00044.cif,Linear,Free,Amidation,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",796.02,C42H65N7O8,ACDEGHIMNPQRSTVW,L,8.59,1,0,1,1,4,150.0,1205,2.8 hour,10 min,2 min,195.0,1490,298.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00045,KLAGRW,6,NL6-6,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>100 µM);inhibition of strand transfer catalyzed by integrase(IC50>100 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00045,DRAVPe00045.cif,Linear,Free,Amidation,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",729.88,C34H55N11O7,CDEFHIMNPQSTVY,AGKLRW,11.0,2,0,2,1,3,-68.33,-1047,1.3 hour,3 min,2 min,81.67,5500,1100.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00046,ACWWAG,6,NL9-5 ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>100 µM);inhibition of strand transfer catalyzed by integrase(IC50>100 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00046,DRAVPe00046.cif,Linear,Free,Amidation,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",692.79,C33H40N8O7S,DEFHIKLMNPQRSTVY,AW,5.56,0,0,0,2,4,65.0,1050,4.4 hour,>20 hour,>10 hour,33.33,11000,2200.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00047,WAGIKQ,6,NL9-6 ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>100 µM);inhibition of strand transfer catalyzed by integrase(IC50>100 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00047,DRAVPe00047.cif,Linear,Free,Amidation,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",701.82,C33H51N9O8,CDEFHLMNPRSTVY,AGIKQW,8.75,1,0,1,1,3,-40.0,-109,2.8 hour,3 min,2 min,81.67,5500,1100.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00048,IKQEF,5,NL9-7 ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>100 µM);inhibition of strand transfer catalyzed by integrase(IC50>100 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00048,DRAVPe00048.cif,Linear,Free,Amidation,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",663.77,C31H49N7O9,ACDGHLMNPRSTVWY,EFIKQ,6.0,1,1,0,0,2,-72.0,-1000,20 hour,30 min,>10 hour,78.0,0,0.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00049,tayfllklagrw,12,DNL-6,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=65±8 µM);inhibition of strand transfer catalyzed by integrase(IC50=13±1  µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00049,DRAVPe00049.cif,Linear,Free,Free,,D,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1438.74,H-22O-11,ACDEFGHIKLMNPQRSTVWY,ACDEFGHIKLMNPQRSTVWY,9.99,0,0,0,0,0,0.0,0,,,,0.0,0,0.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00050,WRGALKLLFYAT,12,RNL-6,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=96±2 µM);inhibition of strand transfer catalyzed by integrase(IC50=16±4  µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00050,DRAVPe00050.cif,Linear,Free,Free,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1438.74,C71H107N17O15,CDEHIMNPQSV,L,9.99,2,0,2,3,7,50.83,145,2.8 hour,3 min,2 min,114.17,6990,635.45,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00051,wrgalkllfyat,12,RDNL-6,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=3.5±1 µM);inhibition of strand transfer catalyzed by integrase(IC50=4.0±1  µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00051,DRAVPe00051.cif,Linear,Free,Free,,D,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1438.74,H-22O-11,ACDEFGHIKLMNPQRSTVWY,ACDEFGHIKLMNPQRSTVWY,9.99,0,0,0,0,0,0.0,0,,,,0.0,0,0.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00052,acwwagikqef,11,DNL-9 ,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>1000 µM);inhibition of strand transfer catalyzed by integrase(IC50>1000 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00052,DRAVPe00052.cif,Linear,Free,Free,,D,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1338.55,H-20O-10,ACDEFGHIKLMNPQRSTVWY,ACDEFGHIKLMNPQRSTVWY,6.04,0,0,0,0,0,0.0,0,,,,0.0,0,0.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00053,FEQKIGAWWCA,11,RNL-9,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>1000 µM);inhibition of strand transfer catalyzed by integrase(IC50>1000 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00053,DRAVPe00053.cif,Linear,Free,Free,,L,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1338.55,C64H87N15O15S,DHLMNPRSTVY,AW,5.99,1,1,0,2,6,2.73,50,1.1 hour,3 min,2 min,53.64,11000,1100.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00054,feqkigawwca,11,RDNL-9,Synthetic construct(derived from HIV-1 integrase),No entry found,,HIV,Retroviridae,Integrase Assay,[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>1000 µM);inhibition of strand transfer catalyzed by integrase(IC50>1000 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00054,DRAVPe00054.cif,Linear,Free,Free,,D,Integrase,"HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer).",1338.55,H-20O-10,ACDEFGHIKLMNPQRSTVWY,ACDEFGHIKLMNPQRSTVWY,5.99,0,0,0,0,0,0.0,0,,,,0.0,0,0.0,16854053,J Med Chem. 2006 Jul 27;49(15):4477-86.,"Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.",Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,10.1021/jm060307u,,Anti-HIV
DRAVPe00055,DFRELNKRTQDFWEVQLGIP,20,4277(derived from DNA-polymerase domain of HIV-1 RT (20-mers)),Synthetic construct(derived from HIV-1 Reverse Transcriptase),No entry found,,HIV,Retroviridae,Dot-blot assay,[Ref.15790559]HIV-1:the level of peptide binding to HIV integrase is very low.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00055,DRAVPe00055.cif,Linear,Free,Free,,L,Integrase,"Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RT DNA polymerase domain inhibits all three integrase-associated activities (3′-end processing, strand transfer, and disintegration) and inhibit virus replication.",2491.79,C113H171N31O33,ACHMSY,DEFLQR,4.78,3,4,-1,3,7,-95.5,-5871,1.1 hour,3 min,>10 hour,73.0,5500,289.47,15790559,J Biol Chem. 2005 Jun 10;280(23):21987-96.,"Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.",Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,10.1074/jbc.M414679200,,Anti-HIV
DRAVPe00056,SPAIFQSSMTKILEPFRKQN,20,4285(derived from DNA-polymerase domain of HIV-1 RT (20-mers)),Synthetic construct(derived from HIV-1 Reverse Transcriptase),No entry found,,HIV,Retroviridae,Dot-blot assay,[Ref.15790559]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=35 µM);inhibition of strand transfer catalyzed by integrase(IC50=270 µM);inhibition of disintegration catalyzed by integrase(IC50>100 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00056,DRAVPe00056.cif,Linear,Free,Free,,L,Integrase,"Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RT DNA polymerase domain inhibits all three integrase-associated activities (3′-end processing, strand transfer, and disintegration) and inhibit virus replication.",2322.71,C104H168N28O30S,CDGHVWY,S,9.99,3,1,2,5,6,-52.5,-3844,1.9 hour,>20 hour,>10 hour,63.5,0,0.0,15790559,J Biol Chem. 2005 Jun 10;280(23):21987-96.,"Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.",Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,10.1074/jbc.M414679200,,Anti-HIV
DRAVPe00057,FRKQNPDIVIYQYMD,15,4286’-1(derived from the DNA-polymerase domain of HIV-1 RT (14-mer) ),Synthetic construct(derived from HIV-1 Reverse Transcriptase),No entry found,,HIV,Retroviridae,Dot-blot assay,[Ref.15790559]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=119 µM);inhibition of strand transfer catalyzed by integrase(IC50=97 µM);inhibition of disintegration catalyzed by integrase(IC50>270 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00057,DRAVPe00057.cif,Linear,Free,Free,,L,Integrase,"Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RT DNA polymerase domain inhibits all three integrase-associated activities (3′-end processing, strand transfer, and disintegration) and inhibit virus replication.",1930.21,C88H132N22O25S,ACEGHLSTW,DIQY,5.96,2,2,0,3,4,-81.33,-3670,1.1 hour,3 min,2 min,71.33,2980,212.86,15790559,J Biol Chem. 2005 Jun 10;280(23):21987-96.,"Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.",Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,10.1074/jbc.M414679200,,Anti-HIV
DRAVPe00058,KILEPFRKQNPDIVIYQYMD,20,4286(derived from DNA-polymerase domain of HIV-1 RT (20-mers)),Synthetic construct(derived from HIV-1 Reverse Transcriptase),No entry found,,HIV,Retroviridae,Dot-blot assay,[Ref.15790559]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=4.8 µM);inhibition of strand transfer catalyzed by integrase(IC50=4.5 µM);inhibition of disintegration catalyzed by integrase(IC50=9.4 µM);##HIV-1:the level of peptide binding to HIV integrase is high.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00058,DRAVPe00058.cif,Linear,Free,Free,,L,Integrase,"Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RT DNA polymerase domain inhibits all three integrase-associated activities (3′-end processing, strand transfer, and disintegration) and inhibit virus replication.",2510.93,C116H180N28O32S,ACGHSTW,I,6.12,3,3,0,3,6,-64.5,-3922,1.3 hour,3 min,2 min,92.5,2980,156.84,15790559,J Biol Chem. 2005 Jun 10;280(23):21987-96.,"Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.",Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,10.1074/jbc.M414679200,,Anti-HIV
DRAVPe00059,PDIVIYQYMDDLYVGSDLEI,20,"4287(derived from DNA-polymerase domain of HIV-1 RT (20-mers)),34(derived from the HIV-1 HXB2 Pol region of the viral genome)",Synthetic construct(derived from HIV-1 Reverse Transcriptase),No entry found,,HIV,Retroviridae,Dot-blot assay,"[Ref.15790559]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=22 µM);inhibition of strand transfer catalyzed by integrase(IC50=54 µM);inhibition of disintegration catalyzed by integrase(IC50>120 µM);##HIV-1:the level of peptide binding to HIV integrase is high.##[Ref.16879966]HIV:inhibition of 3′-processing catalyzed by wild-type integrase(IC50=6±1 µM);inhibition of strand transfer catalyzed by wild-type integrase(IC50=10±1 µM);inhibition of 3′-processing catalyzed by soluble mutant integrase(IC50=28±2 µM);inhibition of strand transfer catalyzed by soluble mutant integrase(IC50=23±2 µM);inhibition of 3′-processing catalyzed by C130S integrase(IC50=41±2 µM);inhibition of strand transfer catalyzed by C130S integrase(IC50=2±1 µM);inhibition of 3′-processing catalyzed by C130S integrase(IC50=20 µM);inhibition of strand transfer catalyzed by C130A integrase(IC50=5 µM).##NOTE:soluble mutant,C130S,C130S integrase are mutant IN.",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00059,DRAVPe00059.cif,Linear,Free,Free,,L,Integrase,"Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RT DNA polymerase domain inhibits all three integrase-associated activities (3′-end processing, strand transfer, and disintegration) and inhibit virus replication.",2361.65,C108H161N21O36S,ACFHKNRTW,D,3.28,0,5,-5,5,7,18.5,-1508,>20 hour,>20 hour,?,126.5,4470,235.26,15790559##16879966,J Biol Chem. 2005 Jun 10;280(23):21987-96.##Bioorg Med Chem Lett. 2006 Oct 1;16(19):5199-202.,"Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.##Zawahir Z, Neamati N.",Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.##Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genome. ,10.1074/jbc.M414679200##10.1016/j.bmcl.2006.07.022,,Anti-HIV
DRAVPe00060,DIQKLVGKLNWASQIYPGIK,20,4295(derived from DNA-polymerase domain of HIV-1 RT (20-mers)),Synthetic construct(derived from HIV-1 Reverse Transcriptase),No entry found,,HIV,Retroviridae,Dot-blot assay,[Ref.15790559]HIV-1:the level of peptide binding to HIV integrase is low.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00060,DRAVPe00060.cif,Linear,Free,Free,,L,Integrase,"Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RT DNA polymerase domain inhibits all three integrase-associated activities (3′-end processing, strand transfer, and disintegration) and inhibit virus replication.",2271.69,C106H171N27O28,CEFHMRT,IK,9.53,3,1,2,5,8,-20.0,-1197,1.1 hour,3 min,>10 hour,117.0,6990,367.89,15790559,J Biol Chem. 2005 Jun 10;280(23):21987-96.,"Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.",Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,10.1074/jbc.M414679200,,Anti-HIV
DRAVPe00061,IAEIQKQGQGQWTYQIYQEP,20,4302(derived from DNA-polymerase domain of HIV-1 RT (20-mers)),Synthetic construct(derived from HIV-1 Reverse Transcriptase),No entry found,,HIV,Retroviridae,Dot-blot assay,[Ref.15790559]HIV-1:the level of peptide binding to HIV integrase is high.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00061,DRAVPe00061.cif,Linear,Free,Free,,L,Integrase,"Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RT DNA polymerase domain inhibits all three integrase-associated activities (3′-end processing, strand transfer, and disintegration) and inhibit virus replication.",2408.65,C109H162N28O34,CDFHLMNRSV,Q,4.53,1,2,-1,5,5,-116.0,-3448,20 hour,30 min,>10 hour,63.5,8480,446.32,15790559,J Biol Chem. 2005 Jun 10;280(23):21987-96.,"Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.",Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,10.1074/jbc.M414679200,,Anti-HIV
DRAVPe00062,KQLTEAVQKITTEAnti-SIVIWGK,20,"4306(derived from DNA-polymerase domain of HIV-1 RT (20-mers)),53(derived from the HIV-1 HXB2 Pol region of the viral genome)",Synthetic construct(derived from HIV-1 Reverse Transcriptase),No entry found,,HIV,Retroviridae,Dot-blot assay,"[Ref.15790559]HIV-1:the level of peptide binding to HIV integrase is high.##[Ref.16879966]HIV:inhibition of 3′-processing catalyzed by wild-type integrase(IC50=7±1 µM);inhibition of strand transfer catalyzed by wild-type integrase(IC50=4±1 µM);inhibition of 3′-processing catalyzed by soluble mutant integrase(IC50=51±7 µM);inhibition of strand transfer catalyzed by soluble mutant integrase(IC50=31±7 µM);inhibition of 3′-processing catalyzed by C130S integrase(IC50=29±1 µM);inhibition of strand transfer catalyzed by C130S integrase(IC50=2±1 µM);inhibition of 3′-processing catalyzed by C130S integrase(IC50=15 µM);inhibition of strand transfer catalyzed by C130A integrase(IC50=10 µM).##NOTE:soluble mutant,C130S,C130S integrase are mutant IN.",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00062,DRAVPe00062.cif,Linear,Free,Free,,L,Integrase,"Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RT DNA polymerase domain inhibits all three integrase-associated activities (3′-end processing, strand transfer, and disintegration) and inhibit virus replication.",2272.67,C103H174N26O31,CDFHMNPRY,IKT,8.5,3,2,1,5,8,-12.0,-1962,1.3 hour,3 min,2 min,112.0,5500,289.47,15790559##16879966,J Biol Chem. 2005 Jun 10;280(23):21987-96.##Bioorg Med Chem Lett. 2006 Oct 1;16(19):5199-202.,"Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.##Zawahir Z, Neamati N.",Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.##Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genome. ,10.1074/jbc.M414679200##10.1016/j.bmcl.2006.07.022,,Anti-HIV
DRAVPe00063,TPKFKLPIQKETWETWWTEY,20,4308(derived from DNA-polymerase domain of HIV-1 RT (20-mers)),Synthetic construct(derived from HIV-1 Reverse Transcriptase),No entry found,,HIV,Retroviridae,Dot-blot assay,[Ref.15790559]HIV-1:the level of peptide binding to HIV integrase is high.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00063,DRAVPe00063.cif,Linear,Free,Free,,L,Integrase,"Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RT DNA polymerase domain inhibits all three integrase-associated activities (3′-end processing, strand transfer, and disintegration) and inhibit virus replication.",2611.98,C127H179N27O33,ACDGHMNRSV,T,5.9,3,3,0,5,6,-123.0,-3323,7.2 hour,>20 hour,>10 hour,39.0,17990,946.84,15790559,J Biol Chem. 2005 Jun 10;280(23):21987-96.,"Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.",Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,10.1074/jbc.M414679200,,Anti-HIV
DRAVPe00064,ETWETWWTEYWQATWIPEWE,20,"4309(derived from DNA-polymerase domain of HIV-1 RT (20-mers)),56(derived from the HIV-1 HXB2 Pol region of the viral genome)",Synthetic construct(derived from HIV-1 Reverse Transcriptase),No entry found,,HIV,Retroviridae,Dot-blot assay,"[Ref.16879966]HIV:inhibition of 3′-processing catalyzed by wild-type integrase(IC50=6±1 µM);inhibition of strand transfer catalyzed by wild-type integrase(IC50=2±1 µM);inhibition of 3′-processing catalyzed by soluble mutant integrase(IC50=13±2 µM);inhibition of strand transfer catalyzed by soluble mutant integrase(IC50=9±2 µM);inhibition of 3′-processing catalyzed by C130S integrase(IC50=126±3 µM);inhibition of strand transfer catalyzed by C130S integrase(IC50=27±1 µM);inhibition of 3′-processing catalyzed by C130S integrase(IC50=25 µM);inhibition of strand transfer catalyzed by C130A integrase(IC50=5 µM).##NOTE:soluble mutant,C130S,C130S integrase are mutant IN.",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00064,DRAVPe00064.cif,Linear,Free,Free,,L,Integrase,"Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RT DNA polymerase domain inhibits all three integrase-associated activities (3′-end processing, strand transfer, and disintegration) and inhibit virus replication.",2757.95,C135H165N27O37,CDFGHKLMNRSV,W,3.51,0,5,-5,5,8,-129.0,-2930,1 hour,30 min,>10 hour,24.5,34490,1815.26,15790559##16879966,J Biol Chem. 2005 Jun 10;280(23):21987-96.##Bioorg Med Chem Lett. 2006 Oct 1;16(19):5199-202.,"Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.##Zawahir Z, Neamati N.",Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.##Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genome. ,10.1074/jbc.M414679200##10.1016/j.bmcl.2006.07.022,,Anti-HIV
DRAVPe00065,GYVTNRGRQKVVTLTDTTNQ,20,4315(derived from the RNase H domain of HIV-1 RT (20-mes)),Synthetic construct(derived from HIV-1 Reverse Transcriptase),No entry found,,HIV,Retroviridae,Dot-blot assay,[Ref.15790559]HIV-1:the level of peptide binding to HIV integrase is very low,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00065,DRAVPe00065.cif,Linear,Free,Free,,L,Integrase,Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication.,2251.48,C94H159N31O33,ACEFHIMPSW,T,9.99,3,1,2,10,4,-98.0,-6254,30 hour,>20 hour,>10 hour,63.0,1490,78.42,15790559,J Biol Chem. 2005 Jun 10;280(23):21987-96.,"Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.",Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,10.1074/jbc.M414679200,,Anti-HIV
DRAVPe00066,VVTLTDTTNQKTELQAIYLA,20,4316(derived from the RNase H domain of HIV-1 RT (20-mes)),Synthetic construct(derived from HIV-1 Reverse Transcriptase),No entry found,,HIV,Retroviridae,Dot-blot assay,[Ref.15790559]HIV-1:the level of peptide binding to HIV integrase is high.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00066,DRAVPe00066.cif,Linear,Free,Free,,L,Integrase,Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication.,2222.52,C98H164N24O34,CFGHMPRSW,T,4.37,1,2,-1,7,8,8.5,-2041,100 hour,>20 hour,>10 hour,117.0,1490,78.42,15790559,J Biol Chem. 2005 Jun 10;280(23):21987-96.,"Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.",Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,10.1074/jbc.M414679200,,Anti-HIV
DRAVPe00067,KTELQAIYLALQDSGLEVNI,20,4317(derived from the RNase H domain of HIV-1 RT (20-mes)),Synthetic construct(derived from HIV-1 Reverse Transcriptase),No entry found,,HIV,Retroviridae,Dot-blot assay,[Ref.15790559]HIV-1:the level of peptide binding to HIV integrase is low,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00067,DRAVPe00067.cif,Linear,Free,Free,,L,Integrase,Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication.,2218.53,C99H164N24O33,CFHMPRW,L,4.14,1,3,-2,5,9,19.5,-1360,1.3 hour,3 min,2 min,141.5,1490,78.42,15790559,J Biol Chem. 2005 Jun 10;280(23):21987-96.,"Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.",Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,10.1074/jbc.M414679200,,Anti-HIV
DRAVPe00068,LQDSGLEVNIVTDSQYALGI,20,"4318(derived from the RNase H domain of HIV-1 RT (20-mes)),65(derived from the HIV-1 HXB2 Pol region of the viral genome)",Synthetic construct(derived from HIV-1 Reverse Transcriptase),No entry found,,HIV,Retroviridae,Dot-blot assay,"[Ref.16879966]HIV:inhibition of 3′-processing catalyzed by wild-type integrase(IC50=11±1 µM);inhibition of strand transfer catalyzed by wild-type integrase(IC50=2±1 µM);inhibition of 3′-processing catalyzed by soluble mutant integrase(IC50>167 µM);inhibition of strand transfer catalyzed by soluble mutant integrase(IC50=36±14 µM);inhibition of 3′-processing catalyzed by C130S integrase(IC50=18±3 µM);inhibition of strand transfer catalyzed by C130S integrase(IC50=4±1 µM);inhibition of 3′-processing catalyzed by C130S integrase(IC50>167 µM);inhibition of strand transfer catalyzed by C130A integrase(IC50=20 µM).##NOTE:soluble mutant,C130S,C130S integrase are mutant IN.",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00068,DRAVPe00068.cif,Linear,Free,Free,,L,Integrase,Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication.,2135.36,C93H151N23O34,CFHKMPRW,L,3.49,0,3,-3,7,8,26.0,-1511,5.5 hour,3 min,2 min,131.5,1490,78.42,15790559##16879966,J Biol Chem. 2005 Jun 10;280(23):21987-96.##Bioorg Med Chem Lett. 2006 Oct 1;16(19):5199-202.,"Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.##Zawahir Z, Neamati N.",Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.##Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genome. ,10.1074/jbc.M414679200##10.1016/j.bmcl.2006.07.022,,Anti-HIV
DRAVPe00069,VTDSQYALGIIQAQPDQSES,20,4319(derived from the RNase H domain of HIV-1 RT (20-mes)),Synthetic construct(derived from HIV-1 Reverse Transcriptase),No entry found,,HIV,Retroviridae,Dot-blot assay,[Ref.15790559]HIV-1:the level of peptide binding to HIV integrase is low.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00069,DRAVPe00069.cif,Linear,Free,Free,,L,Integrase,Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication.,2150.28,C91H144N24O36,CFHKMNRW,Q,3.49,0,3,-3,6,6,-51.5,-3596,100 hour,>20 hour,>10 hour,83.0,1490,78.42,15790559,J Biol Chem. 2005 Jun 10;280(23):21987-96.,"Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.",Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,10.1074/jbc.M414679200,,Anti-HIV
DRAVPe00070,IQAQPDQSESELVNQIIEQL,20,4320(derived from the RNase H domain of HIV-1 RT (20-mes)),Synthetic construct(derived from HIV-1 Reverse Transcriptase),No entry found,,HIV,Retroviridae,Dot-blot assay,[Ref.15790559]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>120 µM);inhibition of strand transfer catalyzed by integrase(IC50>120 µM);inhibition of disintegration catalyzed by integrase(IC50>120 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00070,DRAVPe00070.cif,Linear,Free,Free,,L,Integrase,Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication.,2282.49,C97H160N26O37,CFGHKMRTWY,Q,3.5,0,4,-4,3,7,-55.5,-3984,20 hour,30 min,>10 hour,117.0,0,0.0,15790559,J Biol Chem. 2005 Jun 10;280(23):21987-96.,"Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.",Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,10.1074/jbc.M414679200,,Anti-HIV
DRAVPe00071,ELVNQIIEQLIKKEKVYLAW,20,"4321(derived from the RNase H domain of HIV-1 RT (20-mes)),64(derived from the HIV-1 HXB2 Pol region of the viral genome)",Synthetic construct(derived from HIV-1 Reverse Transcriptase),No entry found,,HIV,Retroviridae,Dot-blot assay,"[Ref.15790559]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=6.9 µM);inhibition of strand transfer catalyzed by integrase(IC50=5 µM);inhibition of disintegration catalyzed by integrase(IC50>100 µM);##HIV-1:the level of peptide binding to HIV integrase is high.##[Ref.16879966]HIV:inhibition of 3′-processing catalyzed by wild-type integrase(IC50=15±2 µM);inhibition of strand transfer catalyzed by wild-type integrase(IC50=14±4 µM);inhibition of 3′-processing catalyzed by soluble mutant integrase(IC50=113±11 µM);inhibition of strand transfer catalyzed by soluble mutant integrase(IC50=83±5 µM);inhibition of 3′-processing catalyzed by C130S integrase(IC50=136±5 µM);inhibition of strand transfer catalyzed by C130S integrase(IC50=7±1 µM);inhibition of 3′-processing catalyzed by C130S integrase(IC50=45 µM);inhibition of strand transfer catalyzed by C130A integrase(IC50=15 µM).##NOTE:soluble mutant,C130S,C130S integrase are mutant IN.",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00071,DRAVPe00071.cif,Linear,Free,Free,,L,Integrase,Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication.,2457.94,C116H189N27O31,CDFGHMPRST,EIKL,6.32,3,3,0,2,10,1.0,-1320,1 hour,30 min,>10 hour,151.0,6990,367.89,15790559##16879966,J Biol Chem. 2005 Jun 10;280(23):21987-96.##Bioorg Med Chem Lett. 2006 Oct 1;16(19):5199-202.,"Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.##Zawahir Z, Neamati N.",Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.##Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genome. ,10.1074/jbc.M414679200##10.1016/j.bmcl.2006.07.022,,Anti-HIV
DRAVPe00072,NQIIEQLIKKEKVY,14,4321’-1( derived from the RNase H domain of HIV-1 RT (15-mer)),Synthetic construct(derived from HIV-1 Reverse Transcriptase),No entry found,,HIV,Retroviridae,Dot-blot assay,[Ref.15790559]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>240 µM);inhibition of strand transfer catalyzed by integrase(IC50>240 µM);inhibition of disintegration catalyzed by integrase(IC50>120 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00072,DRAVPe00072.cif,Linear,Free,Free,,L,Integrase,Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication.,1746.08,C80H136N20O23,ACDFGHMPRSTW,IK,8.43,3,2,1,2,5,-64.29,-2441,1.4 hour,3 min,>10 hour,132.14,1490,114.62,15790559,J Biol Chem. 2005 Jun 10;280(23):21987-96.,"Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.",Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,10.1074/jbc.M414679200,,Anti-HIV
DRAVPe00073,IKKEKVYLAWVPAHKGIGN,19,4322(derived from the RNase H domain of HIV-1 RT (20-mes)),Synthetic construct(derived from HIV-1 Reverse Transcriptase),No entry found,,HIV,Retroviridae,Dot-blot assay,[Ref.15790559]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>120 µM);inhibition of strand transfer catalyzed by integrase(IC50>120 µM);inhibition of disintegration catalyzed by integrase(IC50>120 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00073,DRAVPe00073.cif,Linear,Free,Free,,L,Integrase,Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication.,2151.58,C102H163N27O24,CDFMQRST,K,9.83,5,1,4,4,8,-29.47,-978,20 hour,30 min,>10 hour,102.63,6990,388.33,15790559,J Biol Chem. 2005 Jun 10;280(23):21987-96.,"Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.",Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,10.1074/jbc.M414679200,,Anti-HIV
DRAVPe00074,EQVDKLVSAGIRKVLFLDGI,20,4324(derived from the RNase H domain of HIV-1 RT (20-mes)),Synthetic construct(derived from HIV-1 Reverse Transcriptase),No entry found,,HIV,Retroviridae,Dot-blot assay,[Ref.15790559]HIV-1:the level of peptide binding to HIV integrase is high.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00074,DRAVPe00074.cif,Linear,Free,Free,,L,Integrase,Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication.,2200.61,C100H170N26O29,CHMNPTWY,LV,6.22,3,3,0,3,10,48.5,-1582,1 hour,30 min,>10 hour,146.0,0,0.0,15790559,J Biol Chem. 2005 Jun 10;280(23):21987-96.,"Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.",Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,10.1074/jbc.M414679200,,Anti-HIV
DRAVPe00075,ESELVSQIIEQLIKK,15,5628(derived from  RNase H domain of HIV-1 RT (15-mers)),Synthetic construct(derived from HIV-1 Reverse Transcriptase),No entry found,,HIV,Retroviridae,Dot-blot assay,[Ref.15790559]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>120 µM);inhibition of strand transfer catalyzed by integrase(IC50=60 µM);inhibition of disintegration catalyzed by integrase(IC50>120 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00075,DRAVPe00075.cif,Linear,Free,Free,,L,Integrase,Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication.,1757.06,C78H137N19O26,ACDFGHMNPRTWY,EI,4.79,2,3,-1,2,6,-10.67,-2077,1 hour,30 min,>10 hour,149.33,0,0.0,15790559,J Biol Chem. 2005 Jun 10;280(23):21987-96.,"Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.",Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,10.1074/jbc.M414679200,,Anti-HIV
DRAVPe00076,LQQLLFIHFRIGCQH,15,Vpr 15,Synthetic construct(HIV-1 gene product),No entry found,,HIV,Retroviridae,Luciferase assay,[Ref.20586421]HIV-1:inhibition of strand transfer catalyzed by integrase(IC50=5.5 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00076,DRAVPe00076.cif,Linear,Free,Free,,L,Integrase,"IN is an essential enzyme for the stable infection of host cells because it catalyzes the insertion of viral DNA inside the pre-integration complex (PIC) into the genome of host cells in two successive reactions, designated as strand transfer and 3′-end-processing. The peptide could inhibit the activity of integrase and thus inhibit virus replication.",1853.22,C86H133N25O19S,ADEKMNPSTVWY,LQ,8.27,3,0,3,2,7,44.67,-808,5.5 hour,3 min,2 min,130.0,0,0.0,20586421,J Med Chem. 2010 Jul 22;53(14):5356-60.,"Suzuki S, Urano E, Hashimoto C, Tsutsumi H, Nakahara T, Tanaka T, Nakanishi Y, Maddali K, Han Y, Hamatake M, Miyauchi K, Pommier Y, Beutler JA, Sugiura W, Fuji H, Hoshino T, Itotani K, Nomura W, Narumi T, Yamamoto N, Komano JA, Tamamura H. ",Peptide HIV-1 integrase inhibitors from HIV-1 gene products.,10.1021/jm1003528,,Anti-HIV
DRAVPe00077,TNWLWYIKIFIMIV,14,Env4-4,Synthetic construct,No entry found,,HIV,Retroviridae,Luciferase assay,[Ref.20586421]HIV-1:inhibition of strand transfer catalyzed by integrase(IC50=1.9 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00077,DRAVPe00077.cif,Linear,Free,Free,,L,Integrase,"IN is an essential enzyme for the stable infection of host cells because it catalyzes the insertion of viral DNA inside the pre-integration complex (PIC) into the genome of host cells in two successive reactions, designated as strand transfer and 3′-end-processing. The peptide could inhibit the activity of integrase and thus inhibit virus replication.",1840.3,C94H138N18O18S,ACDEGHPQRS,I,8.26,1,0,1,3,9,139.29,2373,7.2 hour,>20 hour,>10 hour,160.0,12490,960.77,20586421,J Med Chem. 2010 Jul 22;53(14):5356-60.,"Suzuki S, Urano E, Hashimoto C, Tsutsumi H, Nakahara T, Tanaka T, Nakanishi Y, Maddali K, Han Y, Hamatake M, Miyauchi K, Pommier Y, Beutler JA, Sugiura W, Fuji H, Hoshino T, Itotani K, Nomura W, Narumi T, Yamamoto N, Komano JA, Tamamura H. ",Peptide HIV-1 integrase inhibitors from HIV-1 gene products.,10.1021/jm1003528,,Anti-HIV
DRAVPe00078,LQQLLF,6,Vpr-1,Synthetic construct(derived from HIV-1 gene products(Vpr)),No entry found,,HIV,Retroviridae,Luciferase assay,[Ref.20586421]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50>11 µM);inhibition of strand transfer catalyzed by integrase(IC50=68±1.0 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00078,DRAVPe00078.cif,Linear,Acetylation,Amidation,,L,Integrase,"IN is an essential enzyme for the stable infection of host cells because it catalyzes the insertion of viral DNA inside the pre-integration complex (PIC) into the genome of host cells in two successive reactions, designated as strand transfer and 3′-end-processing. The peptide could inhibit the activity of integrase and thus inhibit virus replication.",760.93,C37H60N8O9,ACDEGHIKMNPRSTVWY,L,5.52,0,0,0,0,4,120.0,666,5.5 hour,3 min,2 min,195.0,0,0.0,20586421,J Med Chem. 2010 Jul 22;53(14):5356-60.,"Suzuki S, Urano E, Hashimoto C, Tsutsumi H, Nakahara T, Tanaka T, Nakanishi Y, Maddali K, Han Y, Hamatake M, Miyauchi K, Pommier Y, Beutler JA, Sugiura W, Fuji H, Hoshino T, Itotani K, Nomura W, Narumi T, Yamamoto N, Komano JA, Tamamura H. ",Peptide HIV-1 integrase inhibitors from HIV-1 gene products.,10.1021/jm1003528,,Anti-HIV
DRAVPe00079,LQQLLFRRRRRRRR,14,Vpr-1 R8,Synthetic construct(derived from HIV-1 gene products(Vpr)),No entry found,,HIV,Retroviridae,Luciferase assay,[Ref.20586421]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=6.1±1.1 µM);inhibition of strand transfer catalyzed by integrase(IC50>11 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00079,DRAVPe00079.cif,Linear,Acetylation,Amidation,,L,Integrase,"IN is an essential enzyme for the stable infection of host cells because it catalyzes the insertion of viral DNA inside the pre-integration complex (PIC) into the genome of host cells in two successive reactions, designated as strand transfer and 3′-end-processing. The peptide could inhibit the activity of integrase and thus inhibit virus replication.",2010.43,C85H156N40O17,ACDEGHIKMNPSTVWY,R,12.85,8,0,8,0,4,-205.71,-11270,5.5 hour,3 min,2 min,83.57,0,0.0,20586421,J Med Chem. 2010 Jul 22;53(14):5356-60.,"Suzuki S, Urano E, Hashimoto C, Tsutsumi H, Nakahara T, Tanaka T, Nakanishi Y, Maddali K, Han Y, Hamatake M, Miyauchi K, Pommier Y, Beutler JA, Sugiura W, Fuji H, Hoshino T, Itotani K, Nomura W, Narumi T, Yamamoto N, Komano JA, Tamamura H. ",Peptide HIV-1 integrase inhibitors from HIV-1 gene products.,10.1021/jm1003528,,Anti-HIV
DRAVPe00080,IHFRIGRRRRRRRR,14,Vpr-2 R8,Synthetic construct(derived from HIV-1 gene products(Vpr)),No entry found,,HIV,Retroviridae,Luciferase assay,[Ref.20586421]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=0.70±0.06 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.83±0.07 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00080,DRAVPe00080.cif,Linear,Acetylation,Amidation,,L,Integrase,"IN is an essential enzyme for the stable infection of host cells because it catalyzes the insertion of viral DNA inside the pre-integration complex (PIC) into the genome of host cells in two successive reactions, designated as strand transfer and 3′-end-processing. The peptide could inhibit the activity of integrase and thus inhibit virus replication.",1991.39,C83H151N43O15,ACDEKLMNPQSTVWY,R,12.9,10,0,10,1,3,-230.71,-12518,20 hour,30 min,>10 hour,55.71,0,0.0,20586421,J Med Chem. 2010 Jul 22;53(14):5356-60.,"Suzuki S, Urano E, Hashimoto C, Tsutsumi H, Nakahara T, Tanaka T, Nakanishi Y, Maddali K, Han Y, Hamatake M, Miyauchi K, Pommier Y, Beutler JA, Sugiura W, Fuji H, Hoshino T, Itotani K, Nomura W, Narumi T, Yamamoto N, Komano JA, Tamamura H. ",Peptide HIV-1 integrase inhibitors from HIV-1 gene products.,10.1021/jm1003528,,Anti-HIV
DRAVPe00081,LQQLLFIHFRIGRRRRRRRR,20,Vpr-3 R8,Synthetic construct(derived from HIV-1 gene products(Vpr)),No entry found,,HIV,Retroviridae,Integrase assay,[Ref.20586421]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=0.004±0.0001 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.008±0.001 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00081,DRAVPe00081.cif,Linear,Acetylation,Amidation,,L,Integrase,"IN is an essential enzyme for the stable infection of host cells because it catalyzes the insertion of viral DNA inside the pre-integration complex (PIC) into the genome of host cells in two successive reactions, designated as strand transfer and 3′-end-processing. The peptide could inhibit the activity of integrase and thus inhibit virus replication.",2734.31,C120H209N51O23,ACDEKMNPSTVWY,R,12.9,10,0,10,1,7,-125.5,-11852,5.5 hour,3 min,2 min,97.5,0,0.0,20586421,J Med Chem. 2010 Jul 22;53(14):5356-60.,"Suzuki S, Urano E, Hashimoto C, Tsutsumi H, Nakahara T, Tanaka T, Nakanishi Y, Maddali K, Han Y, Hamatake M, Miyauchi K, Pommier Y, Beutler JA, Sugiura W, Fuji H, Hoshino T, Itotani K, Nomura W, Narumi T, Yamamoto N, Komano JA, Tamamura H. ",Peptide HIV-1 integrase inhibitors from HIV-1 gene products.,10.1021/jm1003528,,Anti-HIV
DRAVPe00082,EAIIRILQQLLFIHFRIGRRRRRRRR,26,Vpr-4 R8,Synthetic construct(derived from HIV-1 gene products(Vpr)),No entry found,,HIV,Retroviridae,Integrase assay,[Ref.20586421]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=0.005±0.002 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.006±0.006 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00082,DRAVPe00082.cif,Linear,Acetylation,Amidation,,L,Integrase,"IN is an essential enzyme for the stable infection of host cells because it catalyzes the insertion of viral DNA inside the pre-integration complex (PIC) into the genome of host cells in two successive reactions, designated as strand transfer and 3′-end-processing. The peptide could inhibit the activity of integrase and thus inhibit virus replication.",3430.17,C152H266N60O31,CDKMNPSTVWY,R,12.6,11,1,10,1,11,-68.46,-12368,1 hour,30 min,>10 hour,123.85,0,0.0,20586421,J Med Chem. 2010 Jul 22;53(14):5356-60.,"Suzuki S, Urano E, Hashimoto C, Tsutsumi H, Nakahara T, Tanaka T, Nakanishi Y, Maddali K, Han Y, Hamatake M, Miyauchi K, Pommier Y, Beutler JA, Sugiura W, Fuji H, Hoshino T, Itotani K, Nomura W, Narumi T, Yamamoto N, Komano JA, Tamamura H. ",Peptide HIV-1 integrase inhibitors from HIV-1 gene products.,10.1021/jm1003528,,Anti-HIV
DRAVPe00083,TYGDTWAGVEAIIRI,15,Vpr 49-63 ,Synthetic construct(derived from HIV-1 viral protein R (Vpr)),No entry found,,HIV,Retroviridae,Dot-blot binding assay,[Ref.17490682]HIV-1:inhibit the activity of  RNA-dependent DNA polymerase(IC50>>150 µM);inhibit the activity of DNA-dependent DNA polymerase(IC50>>150 µM);inhibit the activity of Rnase H(IC50>>200 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00083,DRAVPe00083.cif,Linear,Free,Free,,L,Reverse Transcriptase,The viral enzymes RT and IN have cardinal roles in the early stages of the replication of retroviruses and retrotransposons. The peptide derived from viral protein R (Vpr) could inhibit  Reverse Transcriptase(RT) and thus inhibit the replication of HIV-1.,1664.88,C76H117N19O23,CFHKLMNPQS,I,4.37,1,2,-1,5,7,36.0,-910,7.2 hour,>20 hour,>10 hour,110.67,6990,499.29,17490682,J Mol Biol. 2007 Jun 22;369(5):1230-43.,"Gleenberg IO, Herschhorn A, Hizi A.",Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,10.1016/j.jmb.2007.03.073,,Anti-HIV
DRAVPe00084,TWAGVEAIIRILQQL,15,Vpr 53-67,Synthetic construct(derived from HIV-1 viral protein R (Vpr)),No entry found,,HIV,Retroviridae,Dot-blot binding assay,[Ref.17490682]HIV-1:inhibit the activity of  RNA-dependent DNA polymerase(IC50=0.88 µM);inhibit the activity of DNA-dependent DNA polymerase(IC50=0.88 µM);inhibit the activity of Rnase H(IC50=6.9 µM);##Inhibition of 3′-end processing catalyzed by integrase(IC50>200 µM);inhibition of strand transfer catalyzed by integrase(IC50=144 µM);inhibition of disintegration catalyzed by integrase(IC50=27 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00084,DRAVPe00084.cif,Linear,Free,Free,,L,"Integrase,Reverse Transcriptase",The viral enzymes RT and IN have cardinal roles in the early stages of the replication of retroviruses and retrotransposons. The peptide derived from viral protein R (Vpr) could inhibit integrase(IN) and Reverse Transcriptase(RT) and thus inhibit the replication of HIV-1.,1711.04,C79H131N21O21,CDFHKMNPSY,I,5.66,1,1,0,2,9,79.33,15,7.2 hour,>20 hour,>10 hour,162.67,5500,392.86,17490682,J Mol Biol. 2007 Jun 22;369(5):1230-43.,"Gleenberg IO, Herschhorn A, Hizi A.",Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,10.1016/j.jmb.2007.03.073,,Anti-HIV
DRAVPe00085,VEAIIRILQQLLFIH,15,Vpr 57-71,Synthetic construct(derived from HIV-1 viral protein R (Vpr)),No entry found,,HIV,Retroviridae,Dot-blot binding assay,[Ref.17490682]HIV-1:inhibit the activity of  RNA-dependent DNA polymerase(IC50=0.22 µM);inhibit the activity of DNA-dependent DNA polymerase(IC50=0.22 µM);inhibit the activity of Rnase H(IC50=2 µM);##Inhibition of 3′-end processing catalyzed by integrase(IC50=7.8 µM);inhibition of strand transfer catalyzed by integrase(IC50=16 µM);inhibition of disintegration catalyzed by integrase(IC50=3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00085,DRAVPe00085.cif,Linear,Free,Free,,L,"Integrase,Reverse Transcriptase",The viral enzymes RT and IN have cardinal roles in the early stages of the replication of retroviruses and retrotransposons. The peptide derived from viral protein R (Vpr) could inhibit integrase(IN) and Reverse Transcriptase(RT) and thus inhibit the replication of HIV-1.,1806.22,C86H144N22O20,CDGKMNPSTWY,I,6.72,2,1,1,0,10,133.33,580,100 hour,>20 hour,>10 hour,208.0,0,0.0,17490682,J Mol Biol. 2007 Jun 22;369(5):1230-43.,"Gleenberg IO, Herschhorn A, Hizi A.",Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,10.1016/j.jmb.2007.03.073,,Anti-HIV
DRAVPe00086,IRILQQLLFIHFRIG,15,Vpr 61-75,Synthetic construct(derived from HIV-1 viral protein R (Vpr)),No entry found,,HIV,Retroviridae,Dot-blot binding assay,[Ref.17490682]HIV-1:inhibit the activity of  RNA-dependent DNA polymerase(IC50=0.7 µM);inhibit the activity of DNA-dependent DNA polymerase(IC50=1.3 µM);inhibit the activity of Rnase H(IC50=5.25 µM);##Inhibition of 3′-end processing catalyzed by integrase(IC50=1.3 µM);inhibition of strand transfer catalyzed by integrase(IC50=1 µM);inhibition of disintegration catalyzed by integrase(IC50=10 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00086,DRAVPe00086.cif,Linear,Free,Free,,L,"Integrase,Reverse Transcriptase",The viral enzymes RT and IN have cardinal roles in the early stages of the replication of retroviruses and retrotransposons. The peptide derived from viral protein R (Vpr) could inhibit integrase(IN) and Reverse Transcriptase(RT) and thus inhibit the replication of HIV-1.,1867.31,C90H147N25O18,ACDEKMNPSTVWY,I,12.0,3,0,3,1,9,102.67,-424,20 hour,30 min,>10 hour,182.0,0,0.0,17490682,J Mol Biol. 2007 Jun 22;369(5):1230-43.,"Gleenberg IO, Herschhorn A, Hizi A.",Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,10.1016/j.jmb.2007.03.073,,Anti-HIV
DRAVPe00087,QQLLFIHFRIGCQHS,15,Vpr 65-79 ,Synthetic construct(derived from HIV-1 viral protein R (Vpr)),No entry found,,HIV,Retroviridae,Dot-blot binding assay,[Ref.17490682]HIV-1:inhibit the activity of  RNA-dependent DNA polymerase(IC50=33 µM);inhibit the activity of DNA-dependent DNA polymerase(IC50=43 µM);inhibit the activity of Rnase H(IC50=16.5 µM);##Inhibition of 3′-end processing catalyzed by integrase(IC50=76 µM);inhibition of strand transfer catalyzed by integrase(IC50=14 µM);inhibition of disintegration catalyzed by integrase(IC50=10 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00087,DRAVPe00087.cif,Linear,Free,Free,,L,"Integrase,Reverse Transcriptase",The viral enzymes RT and IN have cardinal roles in the early stages of the replication of retroviruses and retrotransposons. The peptide derived from viral protein R (Vpr) could inhibit integrase(IN) and Reverse Transcriptase(RT) and thus inhibit the replication of HIV-1.,1827.14,C83H127N25O20S,ADEKMNPTVWY,Q,8.27,3,0,3,3,6,14.0,-1640,0.8 hour,10 min,>10 hour,104.0,0,0.0,17490682,J Mol Biol. 2007 Jun 22;369(5):1230-43.,"Gleenberg IO, Herschhorn A, Hizi A.",Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,10.1016/j.jmb.2007.03.073,,Anti-HIV
DRAVPe00088,FIHFRIGCQHSRIGI,15,Vpr 69-83,Synthetic construct(derived from HIV-1 viral protein R (Vpr)),No entry found,,HIV,Retroviridae,Dot-blot binding assay,[Ref.17490682]HIV-1:inhibit the activity of  RNA-dependent DNA polymerase(IC50>>200 µM);inhibit the activity of DNA-dependent DNA polymerase(IC50>>200 µM);inhibit the activity of Rnase H(IC50>>200 µM);##Inhibition of 3′-end processing catalyzed by integrase(IC50>>200 µM);inhibition of strand transfer catalyzed by integrase(IC50>>200 µM);inhibition of disintegration catalyzed by integrase(IC50>>200 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00088,DRAVPe00088.cif,Linear,Free,Free,,L,"Integrase,Reverse Transcriptase",The viral enzymes RT and IN have cardinal roles in the early stages of the replication of retroviruses and retrotransposons. The peptide derived from viral protein R (Vpr) could inhibit integrase(IN) and Reverse Transcriptase(RT) and thus inhibit the replication of HIV-1.,1784.11,C81H126N26O18S,ADEKLMNPTVWY,I,10.35,4,0,4,4,6,37.33,-1930,1.1 hour,3 min,2 min,104.0,0,0.0,17490682,J Mol Biol. 2007 Jun 22;369(5):1230-43.,"Gleenberg IO, Herschhorn A, Hizi A.",Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,10.1016/j.jmb.2007.03.073,,Anti-HIV
DRAVPe00089,HFPRIWLHSLGQHIY,15,Vpr 33-47 ,Synthetic construct(derived from HIV-1 viral protein R (Vpr)),No entry found,,HIV,Retroviridae,Dot-blot binding assay,[Ref.17490682]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=187 µM);inhibition of strand transfer catalyzed by integrase(IC50=41 µM);inhibition of disintegration catalyzed by integrase(IC50=73 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00089,DRAVPe00089.cif,Linear,Free,Free,,L,Integrase,The viral enzymes RT and IN have cardinal roles in the early stages of the replication of retroviruses and retrotransposons. The peptide derived from viral protein R (Vpr) could inhibit integrase(IN) and thus inhibit the replication of HIV-1.,1904.21,C92H130N26O19,ACDEKMNTV,H,8.77,4,0,4,3,6,-21.33,-1205,3.5 hour,10 min,>10 hour,104.0,6990,499.29,17490682,J Mol Biol. 2007 Jun 22;369(5):1230-43.,"Gleenberg IO, Herschhorn A, Hizi A.",Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,10.1016/j.jmb.2007.03.073,,Anti-HIV
DRAVPe00090,QLLIRMIYKNILFYLVPGPGHGAEPERRNIKYL,33,I33,Synthetic construct,No entry found,,HIV,Retroviridae,Disintegration assay,[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=9 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM.,DRAVPe00090,DRAVPe00090.cif,Linear,Free,Free,,L,Integrase,"The peptide bound tightly to the integrase(IN) and inhibited both in vitro IN activities, containing 3′ end processing and strand transfer.",3913.69,C183H291N49O44S,CDSTW,L,9.82,6,2,4,8,12,-12.73,-3510,0.8 hour,10 min,>10 hour,118.18,4470,139.69,12054767,J Mol Biol. 2002 Apr 19;318(1):45-58.,"de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. ",A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,10.1016/S0022-2836(02)00033-5,,Anti-HIV
DRAVPe00091,RMIYKNILFYLVPGPGHGAEPERRNIKYL,29,I29,Synthetic construct,No entry found,,HIV,Retroviridae,Disintegration assay,[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=85 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM.,DRAVPe00091,DRAVPe00091.cif,Linear,Free,Free,,L,Integrase,Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus.,3446.08,C160H250N44O39S,CDQSTW,GILPRY,9.82,6,2,4,8,9,-44.14,-4432,1 hour,2 min,2 min,94.14,4470,159.64,12054767,J Mol Biol. 2002 Apr 19;318(1):45-58.,"de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. ",A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,10.1016/S0022-2836(02)00033-5,,Anti-HIV
DRAVPe00092,QLLIRMI,7,LCD278B,Synthetic construct,No entry found,,HIV,Retroviridae,Disintegration assay,[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50>200 µM);no inhibition of HIV-1 infection up to 100 μM.,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM.,DRAVPe00092,DRAVPe00092.cif,Linear,Free,Free,,L,Integrase,Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus.,886.16,C40H75N11O9S,ACDEFGHKNPSTVWY,IL,9.75,1,0,1,0,4,150.0,157,0.8 hour,10 min,>10 hour,222.86,0,0.0,12054767,J Mol Biol. 2002 Apr 19;318(1):45-58.,"de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. ",A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,10.1016/S0022-2836(02)00033-5,,Anti-HIV
DRAVPe00093,AEPERRNIKYL,11,EBR24,Synthetic construct,No entry found,,HIV,Retroviridae,Disintegration assay,[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=50 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM.,DRAVPe00093,DRAVPe00093.cif,Linear,Free,Free,,L,Integrase,Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus.,1388.59,C61H101N19O18,CDFGHMQSTVW,ER,8.63,3,2,1,2,3,-147.27,-4414,4.4 hour,>20 hour,>10 hour,80.0,1490,149.0,12054767,J Mol Biol. 2002 Apr 19;318(1):45-58.,"de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. ",A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,10.1016/S0022-2836(02)00033-5,,Anti-HIV
DRAVPe00094,LFYLVPGPGH,10,EBR26,Synthetic construct,No entry found,,HIV,Retroviridae,Disintegration assay,[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50>200 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM.,DRAVPe00094,DRAVPe00094.cif,Linear,Free,Free,,L,Integrase,Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus.,1099.3,C55H78N12O12,ACDEIKMNQRSTW,GLP,6.74,1,0,1,3,4,61.0,1394,5.5 hour,3 min,2 min,107.0,1490,165.56,12054767,J Mol Biol. 2002 Apr 19;318(1):45-58.,"de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. ",A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,10.1016/S0022-2836(02)00033-5,,Anti-HIV
DRAVPe00095,YQLLIRMIYKNI,12,EBR28,Synthetic construct,No entry found,,HIV,Retroviridae,Disintegration assay,[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=5 µM);inhibition of HIV-1 infection in HeLa CD4-β-Gal cells(IC50=40 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM.,DRAVPe00095,DRAVPe00095.cif,Linear,Free,Free,,L,Integrase,Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus.,1567.95,C74H122N18O17S,ACDEFGHPSTVW,I,9.7,2,0,2,3,5,41.67,-598,2.8 hour,10 min,2 min,162.5,2980,270.91,12054767,J Mol Biol. 2002 Apr 19;318(1):45-58.,"de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. ",A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,10.1016/S0022-2836(02)00033-5,,Anti-HIV
DRAVPe00096,YALLIRMIYKNI,12,EBR28[Q2A],Synthetic construct,No entry found,,HIV,Retroviridae,Disintegration assay,[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=8 µM);inhibition of HIV-1 infection in HeLa CD4-β-Gal cells(IC50~100 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM.,DRAVPe00096,DRAVPe00096.cif,Linear,Free,Free,,L,Integrase,Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus.,1510.9,C72H119N17O16S,CDEFGHPQSTVW,I,9.7,2,0,2,3,6,85.83,137,2.8 hour,10 min,2 min,170.83,2980,270.91,12054767,J Mol Biol. 2002 Apr 19;318(1):45-58.,"de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. ",A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,10.1016/S0022-2836(02)00033-5,,Anti-HIV
DRAVPe00097,YQALIRMIYKNI,12,EBR28[L3A],Synthetic construct,No entry found,,HIV,Retroviridae,Disintegration assay,[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=165 µM);no inhibition of HIV-1 infection up to 100 μM.,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM.,DRAVPe00097,DRAVPe00097.cif,Linear,Free,Free,,L,Integrase,Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus.,1525.87,C71H116N18O17S,CDEFGHPSTVW,I,9.7,2,0,2,3,5,25.0,-909,2.8 hour,10 min,2 min,138.33,2980,270.91,12054767,J Mol Biol. 2002 Apr 19;318(1):45-58.,"de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. ",A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,10.1016/S0022-2836(02)00033-5,,Anti-HIV
DRAVPe00098,YQLAIRMIYKNI,12,EBR28[L4A],Synthetic construct,No entry found,,HIV,Retroviridae,Disintegration assay,[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=14 µM);no inhibition of HIV-1 infection up to 100 μM.,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM.,DRAVPe00098,DRAVPe00098.cif,Linear,Free,Free,,L,Integrase,Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus.,1525.87,C71H116N18O17S,CDEFGHPSTVW,I,9.7,2,0,2,3,5,25.0,-909,2.8 hour,10 min,2 min,138.33,2980,270.91,12054767,J Mol Biol. 2002 Apr 19;318(1):45-58.,"de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. ",A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,10.1016/S0022-2836(02)00033-5,,Anti-HIV
DRAVPe00099,YQLLARMIYKNI,12,EBR28[I5A],Synthetic construct,No entry found,,HIV,Retroviridae,Disintegration assay,[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=45 µM);no inhibition of HIV-1 infection up to 100 μM.,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM.,DRAVPe00099,DRAVPe00099.cif,Linear,Free,Free,,L,Integrase,Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus.,1525.87,C71H116N18O17S,CDEFGHPSTVW,ILY,9.7,2,0,2,3,5,19.17,-909,2.8 hour,10 min,2 min,138.33,2980,270.91,12054767,J Mol Biol. 2002 Apr 19;318(1):45-58.,"de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. ",A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,10.1016/S0022-2836(02)00033-5,,Anti-HIV
DRAVPe00100,YQLLIAMIYKNI,12,EBR28[R6A],Synthetic construct,No entry found,,HIV,Retroviridae,Disintegration assay,[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=34 µM);no inhibition of HIV-1 infection up to 100 μM.,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM.,DRAVPe00100,DRAVPe00100.cif,Linear,Free,Free,,L,Integrase,Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus.,1482.84,C71H115N15O17S,CDEFGHPRSTVW,I,8.5,1,0,1,3,6,94.17,1075,2.8 hour,10 min,2 min,170.83,2980,270.91,12054767,J Mol Biol. 2002 Apr 19;318(1):45-58.,"de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. ",A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,10.1016/S0022-2836(02)00033-5,,Anti-HIV
DRAVPe00101,YQLLIRAIYKNI,12,EBR28[M7A],Synthetic construct,No entry found,,HIV,Retroviridae,Disintegration assay,[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=70 µM);inhibition of HIV-1 infection in HeLa CD4-β-Gal cells(IC50~100 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM.,DRAVPe00101,DRAVPe00101.cif,Linear,Free,Free,,L,Integrase,Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus.,1507.84,C72H118N18O17,CDEFGHMPSTVW,I,9.7,2,0,2,3,6,40.83,-652,2.8 hour,10 min,2 min,170.83,2980,270.91,12054767,J Mol Biol. 2002 Apr 19;318(1):45-58.,"de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. ",A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,10.1016/S0022-2836(02)00033-5,,Anti-HIV
DRAVPe00102,YQLLIRMAYKNI,12,EBR28[I8A],Synthetic construct,No entry found,,HIV,Retroviridae,Disintegration assay,[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=35 µM);no inhibition of HIV-1 infection up to 100 μM.,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM.,DRAVPe00102,DRAVPe00102.cif,Linear,Free,Free,,L,Integrase,Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus.,1525.87,C71H116N18O17S,CDEFGHPSTVW,ILY,9.7,2,0,2,3,5,19.17,-909,2.8 hour,10 min,2 min,138.33,2980,270.91,12054767,J Mol Biol. 2002 Apr 19;318(1):45-58.,"de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. ",A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,10.1016/S0022-2836(02)00033-5,,Anti-HIV
DRAVPe00103,YQLLIRMIAKNI,12,EBR28[Y9A],Synthetic construct,No entry found,,HIV,Retroviridae,Disintegration assay,[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=40 µM);inhibition of HIV-1 infection in HeLa CD4-β-Gal cells(IC50~100 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM.,DRAVPe00103,DRAVPe00103.cif,Linear,Free,Free,,L,Integrase,Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus.,1475.86,C68H118N18O16S,CDEFGHPSTVW,I,9.99,2,0,2,2,6,67.5,-403,2.8 hour,10 min,2 min,170.83,1490,135.45,12054767,J Mol Biol. 2002 Apr 19;318(1):45-58.,"de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. ",A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,10.1016/S0022-2836(02)00033-5,,Anti-HIV
DRAVPe00104,YQLLIRMIYANI,12,EBR28[K10A],Synthetic construct,No entry found,,HIV,Retroviridae,Disintegration assay,[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=11 µM);no inhibition of HIV-1 infection up to 100 μM.,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM.,DRAVPe00104,DRAVPe00104.cif,Linear,Free,Free,,L,Integrase,Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus.,1510.86,C71H115N17O17S,CDEFGHKPSTVW,I,8.59,1,0,1,3,6,89.17,138,2.8 hour,10 min,2 min,170.83,2980,270.91,12054767,J Mol Biol. 2002 Apr 19;318(1):45-58.,"de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. ",A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,10.1016/S0022-2836(02)00033-5,,Anti-HIV
DRAVPe00105,YQLLIRMIYKAI,12,EBR28[N11A],Synthetic construct,No entry found,,HIV,Retroviridae,Disintegration assay,[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=7 µM);inhibition of HIV-1 infection in HeLa CD4-β-Gal cells(IC50~100 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM.,DRAVPe00105,DRAVPe00105.cif,Linear,Free,Free,,L,Integrase,Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus.,1524.93,C73H121N17O16S,CDEFGHNPSTVW,I,9.7,2,0,2,2,6,85.83,247,2.8 hour,10 min,2 min,170.83,2980,270.91,12054767,J Mol Biol. 2002 Apr 19;318(1):45-58.,"de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. ",A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,10.1016/S0022-2836(02)00033-5,,Anti-HIV
DRAVPe00106,YQLLIRMIYKNA,12,EBR28[I12A],Synthetic construct,No entry found,,HIV,Retroviridae,Disintegration assay,[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=11 µM);inhibition of HIV-1 infection in HeLa CD4-β-Gal cells(IC50~100 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM.,DRAVPe00106,DRAVPe00106.cif,Linear,Free,Free,,L,Integrase,Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus.,1525.87,C71H116N18O17S,CDEFGHPSTVW,ILY,9.7,2,0,2,3,5,19.17,-909,2.8 hour,10 min,2 min,138.33,2980,270.91,12054767,J Mol Biol. 2002 Apr 19;318(1):45-58.,"de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. ",A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,10.1016/S0022-2836(02)00033-5,,Anti-HIV
DRAVPe00107,YQLLIRMIY,9,LCE41,Synthetic construct,No entry found,,HIV,Retroviridae,Disintegration assay,[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=5 µM);inhibition of HIV-1 infection in HeLa CD4-β-Gal cells(IC50=55 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM.,DRAVPe00107,DRAVPe00107.cif,Linear,Free,Free,,L,Integrase,Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus.,1212.52,C58H93N13O13S,ACDEFGHKNPSTVW,ILY,8.59,1,0,1,2,4,87.78,129,2.8 hour,10 min,2 min,173.33,2980,372.5,12054767,J Mol Biol. 2002 Apr 19;318(1):45-58.,"de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. ",A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,10.1016/S0022-2836(02)00033-5,,Anti-HIV
DRAVPe00108,YQLLIRMI,8,LCE40,Synthetic construct,No entry found,,HIV,Retroviridae,Disintegration assay,[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=120 µM);no inhibition of HIV-1 infection up to 100 μM.,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM.,DRAVPe00108,DRAVPe00108.cif,Linear,Free,Free,,L,Integrase,Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus.,1049.34,C49H84N12O11S,ACDEFGHKNPSTVW,IL,8.75,1,0,1,1,4,115.0,143,2.8 hour,10 min,2 min,195.0,1490,212.86,12054767,J Mol Biol. 2002 Apr 19;318(1):45-58.,"de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. ",A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,10.1016/S0022-2836(02)00033-5,,Anti-HIV
DRAVPe00109,QLLIRMIYKNI,11,LCD278C,Synthetic construct,No entry found,,HIV,Retroviridae,Disintegration assay,[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=21 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM.,DRAVPe00109,DRAVPe00109.cif,Linear,Free,Free,,L,Integrase,Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus.,1404.78,C65H113N17O15S,ACDEFGHPSTVW,I,9.99,2,0,2,2,5,57.27,-584,0.8 hour,10 min,>10 hour,177.27,1490,149.0,12054767,J Mol Biol. 2002 Apr 19;318(1):45-58.,"de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. ",A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,10.1016/S0022-2836(02)00033-5,,Anti-HIV
DRAVPe00110,YQLLIRPIYKNI,12,ProEBR28,Synthetic construct,No entry found,,HIV,Retroviridae,Disintegration assay,[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50>200 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM.,DRAVPe00110,DRAVPe00110.cif,Linear,Free,Free,,L,Integrase,Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus.,1533.88,C74H120N18O17,ACDEFGHMSTVW,I,9.7,2,0,2,3,5,12.5,-833,2.8 hour,10 min,2 min,162.5,2980,270.91,12054767,J Mol Biol. 2002 Apr 19;318(1):45-58.,"de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. ",A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,10.1016/S0022-2836(02)00033-5,,Anti-HIV
DRAVPe00111,LSELDDRADALQAGASQFETSAAKLKRKYWWKN,33,C35,Synthetic construct,No entry found,,HIV,Retroviridae,Disintegration assay,[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50>200 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM.,DRAVPe00111,DRAVPe00111.cif,Linear,Free,Free,,L,Integrase,Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus.,3798.23,C169H262N48O52,CHIMPV,A,8.38,6,5,1,7,13,-92.12,-8333,5.5 hour,3 min,2 min,65.45,12490,390.31,12054767,J Mol Biol. 2002 Apr 19;318(1):45-58.,"de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. ",A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,10.1016/S0022-2836(02)00033-5,,Anti-HIV
DRAVPe00112,TGEKVWDRGNVTLLCDCP,18,P11(derived from E2 envelope protein of GB virus C),Synthetic construct(derived from E2 envelope protein of GB virus C),No entry found,,HIV,Retroviridae,Gp41-Mediated Cell-Cell Fusion Assay,[Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=439.7 μM);inhibition of HIV(HXB2) infection in TZM-bl Cells(IC50=162.1 μM);inhibition of HIV(BAL) infection in TZM-bl Cells(IC50=484.5 μM);inhibition of HIV(69-7) infection in TZM-bl Cells(IC50=208.8 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00112,DRAVPe00112.cif,Linear,Free,Free,,L,membrane,"E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner.",2006.28,C85H136N24O28S2,AFHIMQSY,CDGLTV,4.56,2,3,-1,7,5,-33.89,-3181,7.2 hour,>20 hour,>10 hour,75.56,5625,330.88,20718496,J Med Chem. 2010 Aug 26;53(16):6054-63. ,"Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. ",Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,10.1021/jm100452c,,Anti-HIV
DRAVPe00113,LPAFCQAIGWGDPITHWS,18,P19(derived from E2 envelope protein of GB virus C),Synthetic construct(derived from E2 envelope protein of GB virus C),No entry found,,HIV,Retroviridae,Gp41-Mediated Cell-Cell Fusion Assay,[Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=369.5 μM);inhibition of HIV(HXB2) infection in TZM-bl Cells(IC50=46.0 μM);inhibition of HIV(BAL) infection in TZM-bl Cells(IC50=194.3 μM);inhibition of HIV(69-7) infection in TZM-bl Cells(IC50=71.4 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00113,DRAVPe00113.cif,Linear,Free,Free,,L,membrane,"E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner.",1999.27,C94H131N23O24S,EKMNRVY,AGIPW,5.08,1,1,0,5,8,23.33,429,5.5 hour,3 min,2 min,76.11,11000,647.06,20718496,J Med Chem. 2010 Aug 26;53(16):6054-63. ,"Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. ",Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,10.1021/jm100452c,,Anti-HIV
DRAVPe00114,FCQAIGWGDPITHWSHGQ,18,P20(derived from E2 envelope protein of GB virus C),Synthetic construct(derived from E2 envelope protein of GB virus C),No entry found,,HIV,Retroviridae,Gp41-Mediated Cell-Cell Fusion Assay,[Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=347.6 μM);inhibition of HIV(HXB2) infection in TZM-bl Cells(IC50=70.1 μM);inhibition of HIV(BAL) infection in TZM-bl Cells(IC50=125.5 μM);inhibition of HIV(69-7) infection in TZM-bl Cells(IC50=111.1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00114,DRAVPe00114.cif,Linear,Free,Free,,L,membrane,"E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner.",2040.24,C93H126N26O25S,EKLMNRVY,G,5.97,2,1,1,6,6,-38.33,-1170,1.1 hour,3 min,2 min,48.89,11000,647.06,20718496,J Med Chem. 2010 Aug 26;53(16):6054-63. ,"Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. ",Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,10.1021/jm100452c,,Anti-HIV
DRAVPe00115,AIGWGDPITHWSHGQNRW,18,P21(derived from E2 envelope protein of GB virus C),Synthetic construct(derived from E2 envelope protein of GB virus C),No entry found,,HIV,Retroviridae,Gp41-Mediated Cell-Cell Fusion Assay,[Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=832.9 μM);inhibition of HIV(HXB2) infection in TZM-bl Cells(IC50=44.9 μM);inhibition of HIV(BAL) infection in TZM-bl Cells(IC50=529.1 μM);inhibition of HIV(69-7) infection in TZM-bl Cells(IC50=371.1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00115,DRAVPe00115.cif,Linear,Free,Free,,L,membrane,"E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner.",2118.3,C97H132N30O25,CEFKLMVY,GW,6.96,3,1,2,6,6,-97.78,-2965,4.4 hour,>20 hour,>10 hour,48.89,16500,970.59,20718496,J Med Chem. 2010 Aug 26;53(16):6054-63. ,"Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. ",Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,10.1021/jm100452c,,Anti-HIV
DRAVPe00116,PITHWSHGQNRWPLSCPQ,18,P23(derived from E2 envelope protein of GB virus C),Synthetic construct(derived from E2 envelope protein of GB virus C),No entry found,,HIV,Retroviridae,Gp41-Mediated Cell-Cell Fusion Assay,[Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=508.8 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00116,DRAVPe00116.cif,Linear,Free,Free,,L,membrane,"E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner.",2144.4,C96H138N30O25S,ADEFKMVY,P,8.68,3,0,3,6,4,-110.56,-3461,>20 hour,>20 hour,?,43.33,11000,647.06,20718496,J Med Chem. 2010 Aug 26;53(16):6054-63. ,"Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. ",Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,10.1021/jm100452c,,Anti-HIV
DRAVPe00117,HGQNRWPLSCPQYVYGSV,18,P25(derived from E2 envelope protein of GB virus C),Synthetic construct(derived from E2 envelope protein of GB virus C),No entry found,,HIV,Retroviridae,Gp41-Mediated Cell-Cell Fusion Assay,[Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=304.4 μM),No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00117,DRAVPe00117.cif,Linear,Free,Free,,L,membrane,"E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner.",2091.33,C94H135N27O26S,ADEFIKMT,GPQSVY,8.21,2,0,2,8,4,-70.0,-2589,3.5 hour,10 min,>10 hour,53.89,8480,498.82,20718496,J Med Chem. 2010 Aug 26;53(16):6054-63. ,"Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. ",Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,10.1021/jm100452c,,Anti-HIV
DRAVPe00118,SWFASTGGRDSKIDVWSL,18,P34(derived from E2 envelope protein of GB virus C),Synthetic construct(derived from E2 envelope protein of GB virus C),No entry found,,HIV,Retroviridae,Gp41-Mediated Cell-Cell Fusion Assay,[Ref.20718496]HIV-1:inhibition of HIV(HXB2) infection in TZM-bl Cells(IC50=237.4 μM);inhibition of HIV(BAL) infection in TZM-bl Cells(IC50=411.2 μM);inhibition of HIV(69-7) infection in TZM-bl Cells(IC50=118.6 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00118,DRAVPe00118.cif,Linear,Free,Free,,L,membrane,"E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner.",2012.21,C91H134N24O28,CEHMNPQY,S,5.68,2,2,0,7,7,-26.67,-2887,1.9 hour,>20 hour,>10 hour,65.0,11000,647.06,20718496,J Med Chem. 2010 Aug 26;53(16):6054-63. ,"Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. ",Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,10.1021/jm100452c,,Anti-HIV
DRAVPe00119,SDRDTVVELSEWGVPCAT,18,P45(derived from E2 envelope protein of GB virus C),Synthetic construct(derived from E2 envelope protein of GB virus C),No entry found,,HIV,Retroviridae,Gp41-Mediated Cell-Cell Fusion Assay,[Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=141.2 μM);inhibition of HIV(HXB2) infection in TZM-bl Cells(IC50=48.8 μM);inhibition of HIV(BAL) infection in TZM-bl Cells(IC50=505.5 μM);inhibition of HIV(69-7) infection in TZM-bl Cells(IC50=43.7 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00119,DRAVPe00119.cif,Linear,Free,Free,,L,membrane,"E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner.",1964.13,C83H130N22O31S,FHIKMNQY,V,3.92,1,4,-3,6,6,-20.56,-3452,1.9 hour,>20 hour,>10 hour,75.56,5500,323.53,20718496,J Med Chem. 2010 Aug 26;53(16):6054-63. ,"Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. ",Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,10.1021/jm100452c,,Anti-HIV
DRAVPe00120,DTVVELSEWGVPCATCIL,18,P46(derived from E2 envelope protein of GB virus C),Synthetic construct(derived from E2 envelope protein of GB virus C),No entry found,,HIV,Retroviridae,Gp41-Mediated Cell-Cell Fusion Assay,[Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=428.8 μM);inhibition of HIV(HXB2) infection in TZM-bl Cells(IC50=39.9 μM);inhibition of HIV(BAL) infection in TZM-bl Cells(IC50=462.8 μM);inhibition of HIV(69-7) infection in TZM-bl Cells(IC50=24.1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00120,DRAVPe00120.cif,Linear,Free,Free,,L,membrane,"E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner.",1935.24,C85H135N19O28S2,FHKMNQRY,V,3.57,0,3,-3,6,8,88.33,364,1.1 hour,3 min,>10 hour,118.89,5625,330.88,20718496,J Med Chem. 2010 Aug 26;53(16):6054-63. ,"Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. ",Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,10.1021/jm100452c,,Anti-HIV
DRAVPe00121,VELSEWGVPCATCILDRR,18,P47(derived from E2 envelope protein of GB virus C),Synthetic construct(derived from E2 envelope protein of GB virus C),No entry found,,HIV,Retroviridae,Gp41-Mediated Cell-Cell Fusion Assay,[Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=330.8 μM);inhibition of HIV(HXB2) infection in TZM-bl Cells(IC50=58.6 μM);inhibition of HIV(BAL) infection in TZM-bl Cells(IC50=140.3 μM);inhibition of HIV(69-7) infection in TZM-bl Cells(IC50=20.1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00121,DRAVPe00121.cif,Linear,Free,Free,,L,membrane,"E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner.",2047.37,C88H143N25O27S2,FHKMNQY,CELRV,4.68,2,3,-1,5,7,18.89,-2767,100 hour,>20 hour,>10 hour,102.78,5625,330.88,20718496,J Med Chem. 2010 Aug 26;53(16):6054-63. ,"Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. ",Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,10.1021/jm100452c,,Anti-HIV
DRAVPe00122,RFPFHRCGAGPKLTKDLE,18,P59(derived from E2 envelope protein of GB virus C),Synthetic construct(derived from E2 envelope protein of GB virus C),No entry found,,HIV,Retroviridae,Gp41-Mediated Cell-Cell Fusion Assay,[Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=529.6 μM),No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00122,DRAVPe00122.cif,Linear,Free,Free,,L,membrane,"E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner.",2072.42,C93H146N28O24S,IMNQSVWY,FGKLPR,9.31,5,2,3,4,5,-78.89,-4293,1 hour,2 min,2 min,48.89,0,0.0,20718496,J Med Chem. 2010 Aug 26;53(16):6054-63. ,"Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. ",Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,10.1021/jm100452c,,Anti-HIV
DRAVPe00123,LVRRRSELMGRRNPVCPG,18,P97(derived from E2 envelope protein of GB virus C),Synthetic construct(derived from E2 envelope protein of GB virus C),No entry found,,HIV,Retroviridae,Gp41-Mediated Cell-Cell Fusion Assay,[Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=537.6 μM),No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00123,DRAVPe00123.cif,Linear,Free,Free,,L,membrane,"E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner.",2096.5,C86H154N34O23S2,ADFHIKQTWY,R,11.82,5,1,4,5,4,-77.22,-6802,5.5 hour,3 min,2 min,75.56,0,0.0,20718496,J Med Chem. 2010 Aug 26;53(16):6054-63. ,"Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. ",Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,10.1021/jm100452c,,Anti-HIV
DRAVPe00124,LQEVDAGNFIPPPRWLLL,18,P109(derived from E2 envelope protein of GB virus C),Synthetic construct(derived from E2 envelope protein of GB virus C),No entry found,,HIV,Retroviridae,Gp41-Mediated Cell-Cell Fusion Assay,[Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=687.1 μM);inhibition of HIV(HXB2) infection in TZM-bl Cells(IC50=37.5 μM);inhibition of HIV(BAL) infection in TZM-bl Cells(IC50=294.8 μM);inhibition of HIV(69-7) infection in TZM-bl Cells(IC50=60.8 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00124,DRAVPe00124.cif,Linear,Free,Free,,L,membrane,"E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner.",2078.44,C99H152N24O25,CHKMSTY,L,4.37,1,2,-1,2,9,21.67,-593,5.5 hour,3 min,2 min,130.0,5500,323.53,20718496,J Med Chem. 2010 Aug 26;53(16):6054-63. ,"Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. ",Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,10.1021/jm100452c,,Anti-HIV
DRAVPe00125,WVNQLAVLGLPAVDAAVA,18,P124(derived from E2 envelope protein of GB virus C),Synthetic construct(derived from E2 envelope protein of GB virus C),No entry found,,HIV,Retroviridae,Gp41-Mediated Cell-Cell Fusion Assay,[Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=332.7 μM);inhibition of HIV(BAL) infection in TZM-bl Cells(IC50=94.7 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00125,DRAVPe00125.cif,Linear,Free,Free,,L,membrane,"E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner.",1807.12,C84H135N21O23,CEFHIKMRSTY,A,3.8,0,1,-1,2,13,132.22,2234,2.8 hour,3 min,2 min,157.22,5500,323.53,20718496,J Med Chem. 2010 Aug 26;53(16):6054-63. ,"Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. ",Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,10.1021/jm100452c,,Anti-HIV
DRAVPe00126,SAnti-VSVGMKPSPRP,12,VMI5,Synthetic construct(phage display),No entry found,,HIV,Retroviridae,Affinity binding assay,[Ref.12480936]HIV-1:binding with vif proteins.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00126,DRAVPe00126.cif,Linear,Free,Free,,L,Vif proteins,"Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication.",1241.47,C53H92N16O16S,ACDEFHILNQTWY,PS,11.0,2,0,2,4,2,-47.5,-1930,1.9 hour,>20 hour,>10 hour,48.33,0,0.0,12480936,J Biol Chem. 2003 Feb 21;278(8):6596-602.,"Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.",Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,10.1074/jbc.M210164200,,Anti-HIV
DRAVPe00127,SNQGGSPLPRSV,12,VMI7,Synthetic construct(phage display),No entry found,,HIV,Retroviridae,Affinity binding assay,[Ref.12480936]HIV-1:inhibition of Vif-Vif bingding(IC50=7.43 μM);##The peptide is able to effectively inhibit HIV-1 replication At the concentration of 50 μM.,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12480936]No significant cytotoxicity on H9 cells up to 50 μM.,DRAVPe00127,DRAVPe00127.cif,Linear,Free,Free,,L,Vif proteins,"Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication.",1198.3,C49H83N17O18,ACDEFHIKMTWY,S,9.47,1,0,1,6,2,-82.5,-2646,1.9 hour,>20 hour,>10 hour,56.67,0,0.0,12480936,J Biol Chem. 2003 Feb 21;278(8):6596-602.,"Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.",Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,10.1074/jbc.M210164200,,Anti-HIV
DRAVPe00128,LPLPAPSFHRTT,12,VMI9,Synthetic construct(phage display),No entry found,,HIV,Retroviridae,Affinity binding assay,[Ref.12480936]HIV-1:inhibition of Vif-Vif bingding(IC50=4.84 μM);####The peptide is able to effectively inhibit HIV-1 replication At the concentration of 50 μM.,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12480936]No significant cytotoxicity on H9 cells up to 50 μM.,DRAVPe00128,DRAVPe00128.cif,Linear,Free,Free,,L,Vif proteins,"Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication.",1336.56,C62H97N17O16,CDEGIKMNQVWY,P,9.76,2,0,2,3,4,-20.83,-1349,5.5 hour,3 min,2 min,73.33,0,0.0,12480936,J Biol Chem. 2003 Feb 21;278(8):6596-602.,"Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.",Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,10.1074/jbc.M210164200,,Anti-HIV
DRAVPe00129,SPYPSWSTPAGR,12,VMI16,Synthetic construct(phage display),No entry found,,HIV,Retroviridae,Affinity binding assay,[Ref.12480936]HIV-1:binding with vif proteins.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00129,DRAVPe00129.cif,Linear,Free,Free,,L,Vif proteins,"Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication.",1305.41,C59H84N16O18,CDEFHIKLMNQV,PS,8.46,1,0,1,6,2,-110.0,-2275,1.9 hour,>20 hour,>10 hour,8.33,6990,635.45,12480936,J Biol Chem. 2003 Feb 21;278(8):6596-602.,"Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.",Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,10.1074/jbc.M210164200,,Anti-HIV
DRAVPe00130,KPKQIKPPLPSV,12,vif 155-166,Synthetic construct(derived from the proline-enriched C terminus of Vif),No entry found,,HIV,Retroviridae,ELISA,[Ref.12480936]HIV-1:inhibition of Vif-Vif bingding(IC50=17.39 μM);####The peptide is able to effectively inhibit HIV-1 replication At the concentration of 50 μM.,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12480936]No significant cytotoxicity on H9 cells up to 50 μM.,DRAVPe00130,DRAVPe00130.cif,Linear,Free,Free,,L,Vif proteins,"Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication.",1331.66,C63H110N16O15,ACDEFGHMNRTWY,P,10.3,3,0,3,1,3,-82.5,-1171,1.3 hour,3 min,2 min,89.17,0,0.0,12480936,J Biol Chem. 2003 Feb 21;278(8):6596-602.,"Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.",Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,10.1074/jbc.M210164200,,Anti-HIV
DRAVPe00131,WQVMIVWQVDRMRIR,15,vif 5-19,Synthetic construct(derived from HIV-1 Vif protein),No entry found,,HIV,Retroviridae,ELISA,[Ref.12480936]HIV-1:inhibit vif-vif binding.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00131,DRAVPe00131.cif,Linear,Free,Free,,L,Vif proteins,"Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication.",2016.46,C91H146N28O20S2,ACEFGHKLNPSTY,RV,11.7,3,1,2,0,7,-2.67,-3324,2.8 hour,3 min,2 min,110.0,11000,785.71,12480936,J Biol Chem. 2003 Feb 21;278(8):6596-602.,"Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.",Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,10.1074/jbc.M210164200,,Anti-HIV
DRAVPe00132,RHHYESTHPRISSEV,15,vif 41-55,Synthetic construct(derived from HIV-1 Vif protein),No entry found,,HIV,Retroviridae,ELISA,[Ref.12480936]HIV-1:inhibit vif-vif binding.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00132,DRAVPe00132.cif,Linear,Free,Free,,L,Vif proteins,"Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication.",1834.97,C78H119N27O25,ACDFGKLMNQW,HS,7.03,5,2,3,5,2,-152.67,-6139,1 hour,2 min,2 min,45.33,1490,106.43,12480936,J Biol Chem. 2003 Feb 21;278(8):6596-602.,"Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.",Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,10.1074/jbc.M210164200,,Anti-HIV
DRAVPe00133,ESTHPRISSEVHIPL,15,vif 45-59,Synthetic construct(derived from HIV-1 Vif protein),No entry found,,HIV,Retroviridae,ELISA,[Ref.12480936]HIV-1:inhibit vif-vif binding.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00133,DRAVPe00133.cif,Linear,Free,Free,,L,Vif proteins,"Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication.",1701.9,C74H120N22O24,ACDFGKMNQWY,S,6.01,3,2,1,4,4,-48.0,-3183,1 hour,30 min,>10 hour,97.33,0,0.0,12480936,J Biol Chem. 2003 Feb 21;278(8):6596-602.,"Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.",Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,10.1074/jbc.M210164200,,Anti-HIV
DRAVPe00134,HTGERDWHLGQGVSI,15,vif 73-87,Synthetic construct(derived from HIV-1 Vif protein),No entry found,,HIV,Retroviridae,ELISA,[Ref.12480936]HIV-1:inhibit vif-vif binding.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00134,DRAVPe00134.cif,Linear,Free,Free,,L,Vif proteins,"Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication.",1691.82,C73H110N24O23,ACFKMNPY,G,5.99,3,2,1,5,4,-83.33,-3225,3.5 hour,10 min,>10 hour,71.33,5500,392.86,12480936,J Biol Chem. 2003 Feb 21;278(8):6596-602.,"Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.",Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,10.1074/jbc.M210164200,,Anti-HIV
DRAVPe00135,RDWHLGQGVSIEWRK,15,vif 77-91,Synthetic construct(derived from HIV-1 Vif protein),No entry found,,HIV,Retroviridae,ELISA,[Ref.12480936]HIV-1:inhibit vif-vif binding.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00135,DRAVPe00135.cif,Linear,Free,Free,,L,Vif proteins,"Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication.",1867.1,C84H127N27O22,ACFMNPTY,GRW,8.75,4,2,2,3,5,-116.67,-4410,1 hour,2 min,2 min,71.33,11000,785.71,12480936,J Biol Chem. 2003 Feb 21;278(8):6596-602.,"Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.",Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,10.1074/jbc.M210164200,,Anti-HIV
DRAVPe00136,LGQGVSIEWRKKRYS,15,vif 81-95,Synthetic construct(derived from HIV-1 Vif protein),No entry found,,HIV,Retroviridae,ELISA,[Ref.12480936]HIV-1:inhibit vif-vif binding.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00136,DRAVPe00136.cif,Linear,Free,Free,,L,Vif proteins,"Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication.",1807.09,C81H131N25O22,ACDFHMNPT,GKRS,10.28,4,1,3,5,4,-106.0,-4214,5.5 hour,3 min,2 min,71.33,6990,499.29,12480936,J Biol Chem. 2003 Feb 21;278(8):6596-602.,"Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.",Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,10.1074/jbc.M210164200,,Anti-HIV
DRAVPe00137,RYSTQVDPDLADQLI,15,vif 93-107,Synthetic construct(derived from HIV-1 Vif protein),No entry found,,HIV,Retroviridae,ELISA,[Ref.12480936]HIV-1:inhibit vif-vif binding.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00137,DRAVPe00137.cif,Linear,Free,Free,,L,Vif proteins,"Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication.",1733.9,C75H120N20O27,CEFGHKMNW,D,3.93,1,3,-2,3,5,-55.33,-3766,1 hour,2 min,2 min,104.0,1490,106.43,12480936,J Biol Chem. 2003 Feb 21;278(8):6596-602.,"Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.",Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,10.1074/jbc.M210164200,,Anti-HIV
DRAVPe00138,QVDPDLADQLIHLYY,15,vif 97-111,Synthetic construct(derived from HIV-1 Vif protein),No entry found,,HIV,Retroviridae,ELISA,[Ref.12480936]HIV-1:inhibit vif-vif binding.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00138,DRAVPe00138.cif,Linear,Free,Free,,L,Vif proteins,"Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication.",1803.0,C83H123N19O26,CEFGKMNRSTW,DL,3.93,1,3,-2,2,6,-20.0,-1665,0.8 hour,10 min,>10 hour,130.0,2980,212.86,12480936,J Biol Chem. 2003 Feb 21;278(8):6596-602.,"Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.",Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,10.1074/jbc.M210164200,,Anti-HIV
DRAVPe00139,DLADQLIHLYYFDCF,15,vif 101-115,Synthetic construct(derived from HIV-1 Vif protein),No entry found,,HIV,Retroviridae,ELISA,[Ref.12480936]HIV-1:inhibit vif-vif binding.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00139,DRAVPe00139.cif,Linear,Free,Free,,L,Vif proteins,"Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication.",1876.11,C89H122N18O25S,EGKMNPRSTVW,DL,3.93,1,3,-2,3,7,40.0,-791,1.1 hour,3 min,>10 hour,110.67,2980,212.86,12480936,J Biol Chem. 2003 Feb 21;278(8):6596-602.,"Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.",Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,10.1074/jbc.M210164200,,Anti-HIV
DRAVPe00140,QLIHLYYFDCFSESA,15,vif 105-119,Synthetic construct(derived from HIV-1 Vif protein),No entry found,,HIV,Retroviridae,ELISA,[Ref.12480936]HIV-1:inhibit vif-vif binding.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00140,DRAVPe00140.cif,Linear,Free,Free,,L,Vif proteins,"Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication.",1836.05,C86H118N18O25S,GKMNPRTVW,FLSY,4.35,1,2,-1,5,6,27.33,-900,0.8 hour,10 min,>10 hour,84.67,2980,212.86,12480936,J Biol Chem. 2003 Feb 21;278(8):6596-602.,"Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.",Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,10.1074/jbc.M210164200,,Anti-HIV
DRAVPe00141,LYYFDCFSESAIRKA,15,vif 109-123,Synthetic construct(derived from HIV-1 Vif protein),No entry found,,HIV,Retroviridae,ELISA,[Ref.12480936]HIV-1:inhibit vif-vif binding.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00141,DRAVPe00141.cif,Linear,Free,Free,,L,Vif proteins,"Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication.",1813.06,C84H121N19O24S,GHMNPQTVW,AFSY,6.06,2,2,0,5,6,2.67,-2238,5.5 hour,3 min,2 min,65.33,2980,212.86,12480936,J Biol Chem. 2003 Feb 21;278(8):6596-602.,"Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.",Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,10.1074/jbc.M210164200,,Anti-HIV
DRAVPe00142,ESAIRKAILGHIVSP,15,vif 117-131,Synthetic construct(derived from HIV-1 Vif protein),No entry found,,HIV,Retroviridae,ELISA,[Ref.12480936]HIV-1:inhibit vif-vif binding.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00142,DRAVPe00142.cif,Linear,Free,Free,,L,Vif proteins,"Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication.",1590.89,C71H123N21O20,CDFMNQTWY,I,8.85,3,1,2,3,7,42.67,-1046,1 hour,30 min,>10 hour,136.67,0,0.0,12480936,J Biol Chem. 2003 Feb 21;278(8):6596-602.,"Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.",Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,10.1074/jbc.M210164200,,Anti-HIV
DRAVPe00143,RKAILGHIVSPRCEY,15,vif 121-135,Synthetic construct(derived from HIV-1 Vif protein),No entry found,,HIV,Retroviridae,ELISA,[Ref.12480936]HIV-1:inhibit vif-vif binding.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00143,DRAVPe00143.cif,Linear,Free,Free,,L,Vif proteins,"Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication.",1742.07,C77H128N24O20S,DFMNQTW,IR,9.31,4,1,3,4,5,-16.0,-2757,1 hour,2 min,2 min,104.0,1490,106.43,12480936,J Biol Chem. 2003 Feb 21;278(8):6596-602.,"Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.",Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,10.1074/jbc.M210164200,,Anti-HIV
DRAVPe00144,VSPRCEYQAGHNKVG,15,vif 129-143,Synthetic construct(derived from HIV-1 Vif protein),No entry found,,HIV,Retroviridae,ELISA,[Ref.12480936]HIV-1:inhibit vif-vif binding.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00144,DRAVPe00144.cif,Linear,Free,Free,,L,Vif proteins,"Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication.",1644.83,C69H109N23O22S,DFILMTW,GV,8.18,3,1,2,6,3,-92.67,-3461,100 hour,>20 hour,>10 hour,45.33,1490,106.43,12480936,J Biol Chem. 2003 Feb 21;278(8):6596-602.,"Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.",Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,10.1074/jbc.M210164200,,Anti-HIV
DRAVPe00145,CEYQAGHNKVGSLQY,15,vif 133-147,Synthetic construct(derived from HIV-1 Vif protein),No entry found,,HIV,Retroviridae,ELISA,[Ref.12480936]HIV-1:inhibit vif-vif binding.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00145,DRAVPe00145.cif,Linear,Free,Free,,L,Vif proteins,"Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication.",1696.85,C73H109N21O24S,DFIMPRTW,GQY,6.74,2,1,1,7,3,-86.67,-2449,1.2 hour,>20 hour,>10 hour,52.0,2980,212.86,12480936,J Biol Chem. 2003 Feb 21;278(8):6596-602.,"Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.",Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,10.1074/jbc.M210164200,,Anti-HIV
DRAVPe00146,AGHNKVGSLQYLALA,15,vif 137-151,Synthetic construct(derived from HIV-1 Vif protein),No entry found,,HIV,Retroviridae,ELISA,[Ref.12480936]HIV-1:inhibit vif-vif binding.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00146,DRAVPe00146.cif,Linear,Free,Free,,L,Vif proteins,"Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication.",1541.77,C69H112N20O20,CDEFIMPRTW,AL,8.64,2,0,2,5,7,26.67,18,4.4 hour,>20 hour,>10 hour,117.33,1490,106.43,12480936,J Biol Chem. 2003 Feb 21;278(8):6596-602.,"Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.",Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,10.1074/jbc.M210164200,,Anti-HIV
DRAVPe00147,KVGSLQYLALAALIT,15,vif 141-155,Synthetic construct(derived from HIV-1 Vif protein),No entry found,,HIV,Retroviridae,ELISA,[Ref.12480936]HIV-1:inhibit vif-vif binding.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00147,DRAVPe00147.cif,Linear,Free,Free,,L,Vif proteins,"Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication.",1560.9,C73H125N17O20,CDEFHMNPRW,L,8.59,1,0,1,4,9,124.67,1781,1.3 hour,3 min,2 min,169.33,1490,106.43,12480936,J Biol Chem. 2003 Feb 21;278(8):6596-602.,"Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.",Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,10.1074/jbc.M210164200,,Anti-HIV
DRAVPe00148,LQYLALAALITPKKI,15,vif 145-159,Synthetic construct(derived from HIV-1 Vif protein),No entry found,,HIV,Retroviridae,ELISA,[Ref.12480936]HIV-1:inhibit vif-vif binding.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00148,DRAVPe00148.cif,Linear,Free,Free,,L,Vif proteins,"Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication.",1656.08,C80H138N18O19,CDEFGHMNRSVW,L,9.7,2,0,2,2,9,98.0,1560,5.5 hour,3 min,2 min,176.0,1490,106.43,12480936,J Biol Chem. 2003 Feb 21;278(8):6596-602.,"Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.",Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,10.1074/jbc.M210164200,,Anti-HIV
DRAVPe00149,ALAALITPKKIKPPL,15,vif 149-163,Synthetic construct(derived from HIV-1 Vif protein),No entry found,,HIV,Retroviridae,ELISA,[Ref.12480936]HIV-1:inhibit vif-vif binding.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00149,DRAVPe00149.cif,Linear,Free,Free,,L,Vif proteins,"Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication.",1574.03,C76H136N18O17,CDEFGHMNQRSVWY,AKLP,10.3,3,0,3,1,8,57.33,1081,4.4 hour,>20 hour,>10 hour,150.0,0,0.0,12480936,J Biol Chem. 2003 Feb 21;278(8):6596-602.,"Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.",Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,10.1074/jbc.M210164200,,Anti-HIV
DRAVPe00150,LITPKKIKPPLPSVT,15,vif 153-167,Synthetic construct(derived from HIV-1 Vif protein),No entry found,,HIV,Retroviridae,ELISA,[Ref.12480936]HIV-1:inhibit vif-vif binding.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00150,DRAVPe00150.cif,Linear,Free,Free,,L,Vif proteins,"Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication.",1632.06,C78H138N18O19,ACDEFGHMNQRWY,P,10.3,3,0,3,3,5,3.33,-147,5.5 hour,3 min,2 min,123.33,0,0.0,12480936,J Biol Chem. 2003 Feb 21;278(8):6596-602.,"Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.",Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,10.1074/jbc.M210164200,,Anti-HIV
DRAVPe00151,KKIKPPLPSVTKLTE,15,vif 157-171,Synthetic construct(derived from HIV-1 Vif protein),No entry found,,HIV,Retroviridae,ELISA,[Ref.12480936]HIV-1:inhibit vif-vif binding.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00151,DRAVPe00151.cif,Linear,Free,Free,,L,Vif proteins,"Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication.",1679.08,C78H139N19O21,ACDFGHMNQRWY,K,10.0,4,1,3,3,4,-65.33,-1875,1.3 hour,3 min,2 min,97.33,0,0.0,12480936,J Biol Chem. 2003 Feb 21;278(8):6596-602.,"Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.",Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,10.1074/jbc.M210164200,,Anti-HIV
DRAVPe00152,PPLPSVTKLTEDRWN,15,vif 161-175,Synthetic construct(derived from HIV-1 Vif protein),No entry found,,HIV,Retroviridae,ELISA,[Ref.12480936]HIV-1:inhibit vif-vif binding.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00152,DRAVPe00152.cif,Linear,Free,Free,,L,Vif proteins,"Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication.",1752.99,C79H125N21O24,ACFGHIMQY,P,6.49,2,2,0,4,4,-100.0,-3497,>20 hour,>20 hour,?,71.33,5500,392.86,12480936,J Biol Chem. 2003 Feb 21;278(8):6596-602.,"Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.",Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,10.1074/jbc.M210164200,,Anti-HIV
DRAVPe00153,SVTKLTEDRWNKPQK,15,vif 165-179,Synthetic construct(derived from HIV-1 Vif protein),No entry found,,HIV,Retroviridae,ELISA,[Ref.12480936]HIV-1:inhibit vif-vif binding.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00153,DRAVPe00153.cif,Linear,Free,Free,,L,Vif proteins,"Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication.",1830.07,C80H132N24O25,ACFGHIMY,K,9.7,4,2,2,4,3,-179.33,-5653,1.9 hour,>20 hour,>10 hour,45.33,5500,392.86,12480936,J Biol Chem. 2003 Feb 21;278(8):6596-602.,"Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.",Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,10.1074/jbc.M210164200,,Anti-HIV
DRAVPe00154,LTEDRWNKPQKTKGH,15,vif 169-183,Synthetic construct(derived from HIV-1 Vif protein),No entry found,,HIV,Retroviridae,ELISA,[Ref.12480936]HIV-1:inhibit vif-vif binding.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00154,DRAVPe00154.cif,Linear,Free,Free,,L,Vif proteins,"Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication.",1838.06,C80H128N26O24,ACFIMSVY,K,9.7,5,2,3,4,2,-226.0,-6089,5.5 hour,3 min,2 min,26.0,5500,392.86,12480936,J Biol Chem. 2003 Feb 21;278(8):6596-602.,"Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.",Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,10.1074/jbc.M210164200,,Anti-HIV
DRAVPe00155,RWNKPQKTKGHRGSH,15,vif 173-187,Synthetic construct(derived from HIV-1 Vif protein),No entry found,,HIV,Retroviridae,ELISA,[Ref.12480936]HIV-1:inhibit vif-vif binding.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00155,DRAVPe00155.cif,Linear,Free,Free,,L,Vif proteins,"Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication.",1817.05,C78H125N31O20,ACDEFILMVY,K,12.02,7,0,7,5,1,-259.33,-6975,1 hour,2 min,2 min,0.0,5500,392.86,12480936,J Biol Chem. 2003 Feb 21;278(8):6596-602.,"Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.",Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,10.1074/jbc.M210164200,,Anti-HIV
DRAVPe00156,PTGERVWDRGNVTLLCDCPN,20,P4,Synthetic construct(derived from region of GB virus C glycoprotein E2),No entry found,,HIV,Retroviridae,Luciferase assay,[Ref.21543477]HIV-1(92UG024):inhibition of HIV replication in TZM-bl cells(IC50=15.07 μM);##HIV-1(RU570):inhibition of HIV replication in TZM-bl cells(IC50=18.28 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00156,DRAVPe00156.cif,Linear,Free,Free,,L,membrane,The possible mechanism of action is that the peptide could inhibit  membrane fusion and inhibit HIV-1 replication in cells.,2245.51,C94H149N29O31S2,AFHIKMQSY,CDGLNPRTV,4.56,2,3,-1,8,5,-59.0,-4782,>20 hour,>20 hour,?,68.0,5625,296.05,21543477,J Virol. 2011 Jul;85(14):7037-47.,"Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. ",Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,10.1128/JVI.02366-10,,Anti-HIV
DRAVPe00157,WDRGNVTLLCDCPNGPWVWV,20,P4-7,Synthetic construct(derived from region of GB virus C glycoprotein E2),No entry found,,HIV,Retroviridae,Luciferase assay,[Ref.21543477]HIV-1(92UG024):inhibition of HIV replication in TZM-bl cells(IC50=2.59 μM);##HIV-1(RU570):inhibition of HIV replication in TZM-bl cells(IC50=2.66 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00157,DRAVPe00157.cif,Linear,Free,Free,,L,membrane,The possible mechanism of action is that the peptide could inhibit  membrane fusion and inhibit HIV-1 replication in cells.,2330.66,C106H152N28O28S2,AEFHIKMQSY,VW,4.21,1,2,-1,7,8,-3.5,-1482,2.8 hour,3 min,2 min,82.5,16625,875.0,21543477,J Virol. 2011 Jul;85(14):7037-47.,"Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. ",Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,10.1128/JVI.02366-10,,Anti-HIV
DRAVPe00158,WDRGNVTLLCDCPNGPWVWV,20,P4-7,Synthetic construct(derived from region of GB virus C glycoprotein E2),No entry found,,HIV,Retroviridae,Luciferase assay,[Ref.21543477]HIV-1(NL4-3):inhibition of HIV replication(IC50=3.0 μM);##HIV-1(YU-2):inhibition of HIV replication(IC50=5.2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00158,DRAVPe00158.cif,Linear,Acetylation,Free,,L,membrane,The possible mechanism of action is that the peptide could inhibit  membrane fusion and inhibit HIV-1 replication in cells.,2330.66,C106H152N28O28S2,AEFHIKMQSY,VW,4.21,1,2,-1,7,8,-3.5,-1482,2.8 hour,3 min,2 min,82.5,16625,875.0,21543477,J Virol. 2011 Jul;85(14):7037-47.,"Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. ",Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,10.1128/JVI.02366-10,,Anti-HIV
DRAVPe00159,GPWVWVPAFCQAVGWGDPIT,20,P6,Synthetic construct(derived from region of GB virus C glycoprotein E2),No entry found,,HIV,Retroviridae,Luciferase assay,[Ref.21543477]HIV-1(92UG024):inhibition of HIV replication in TZM-bl cells(IC50=16.80 μM);##HIV-1(RU570):inhibition of HIV replication in TZM-bl cells(IC50=3.57 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00159,DRAVPe00159.cif,Linear,Free,Free,,L,membrane,The possible mechanism of action is that the peptide could inhibit  membrane fusion and inhibit HIV-1 replication in cells.,2186.52,C106H144N24O25S,EHKLMNRSY,GPVW,3.8,0,1,-1,5,10,48.0,1790,30 hour,>20 hour,>10 hour,73.0,16500,868.42,21543477,J Virol. 2011 Jul;85(14):7037-47.,"Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. ",Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,10.1128/JVI.02366-10,,Anti-HIV
DRAVPe00160,TLLCDCPNGPWVWVPAFCQA,20,P6-1,Synthetic construct(derived from region of GB virus C glycoprotein E2),No entry found,,HIV,Retroviridae,Luciferase assay,[Ref.21543477]HIV-1(92UG024):inhibition of HIV replication in TZM-bl cells(IC50=2.36 μM);##HIV-1(RU570):inhibition of HIV replication in TZM-bl cells(IC50=1.29 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00160,DRAVPe00160.cif,Linear,Free,Free,,L,membrane,The possible mechanism of action is that the peptide could inhibit  membrane fusion and inhibit HIV-1 replication in cells.,2220.61,C102H146N24O26S3,EHIKMRSY,CP,3.8,0,1,-1,6,9,58.5,1049,7.2 hour,>20 hour,>10 hour,78.0,11125,585.53,21543477,J Virol. 2011 Jul;85(14):7037-47.,"Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. ",Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,10.1128/JVI.02366-10,,Anti-HIV
DRAVPe00161,LCDCPNGPWVWVPAFCQAVG,20,P6-2,Synthetic construct(derived from region of GB virus C glycoprotein E2),No entry found,,HIV,Retroviridae,Luciferase assay,[Ref.21543477]HIV-1(92UG024):inhibition of HIV replication in TZM-bl cells(IC50=3.33 μM);##HIV-1(RU570):inhibition of HIV replication in TZM-bl cells(IC50=1.32 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00161,DRAVPe00161.cif,Linear,Free,Free,,L,membrane,The possible mechanism of action is that the peptide could inhibit  membrane fusion and inhibit HIV-1 replication in cells.,2162.53,C99H140N24O25S3,EHIKMRSTY,CPV,3.8,0,1,-1,6,9,62.0,1312,5.5 hour,3 min,2 min,73.0,11125,585.53,21543477,J Virol. 2011 Jul;85(14):7037-47.,"Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. ",Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,10.1128/JVI.02366-10,,Anti-HIV
DRAVPe00162,LCDCPNGPWVWVPAFCQAVG,20,P6-2,Synthetic construct(derived from region of GB virus C glycoprotein E2),No entry found,,HIV,Retroviridae,Luciferase assay,[Ref.21543477]HIV-1(NL4-3):inhibition of HIV replication(IC50=2.3 μM);##HIV-1(YU-2):inhibition of HIV replication(IC50=2.4 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00162,DRAVPe00162.cif,Linear,Acetylation,Free,,L,membrane,The possible mechanism of action is that the peptide could inhibit  membrane fusion and inhibit HIV-1 replication in cells.,2162.53,C99H140N24O25S3,EHIKMRSTY,CPV,3.8,0,1,-1,6,9,62.0,1312,5.5 hour,3 min,2 min,73.0,11125,585.53,21543477,J Virol. 2011 Jul;85(14):7037-47.,"Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. ",Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,10.1128/JVI.02366-10,,Anti-HIV
DRAVPe00163,DCPNGPWVWVPAFCQAVGWG,20,P6-3,Synthetic construct(derived from region of GB virus C glycoprotein E2),No entry found,,HIV,Retroviridae,Luciferase assay,[Ref.21543477]HIV-1(92UG024):inhibition of HIV replication in TZM-bl cells(IC50=4.00 μM);##HIV-1(RU570):inhibition of HIV replication in TZM-bl cells(IC50=2.00 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00163,DRAVPe00163.cif,Linear,Free,Free,,L,membrane,The possible mechanism of action is that the peptide could inhibit  membrane fusion and inhibit HIV-1 replication in cells.,2189.49,C103H137N25O25S2,EHIKLMRSTY,GPVW,3.8,0,1,-1,6,9,24.0,1019,1.1 hour,3 min,>10 hour,53.5,16625,875.0,21543477,J Virol. 2011 Jul;85(14):7037-47.,"Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. ",Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,10.1128/JVI.02366-10,,Anti-HIV
DRAVPe00164,PNGPWVWVPAFCQAVGWGDP,20,P6-4,Synthetic construct(derived from region of GB virus C glycoprotein E2),No entry found,,HIV,Retroviridae,Luciferase assay,[Ref.21543477]HIV-1(92UG024):inhibition of HIV replication in TZM-bl cells(IC50=11.88 μM);##HIV-1(RU570):inhibition of HIV replication in TZM-bl cells(IC50=8.04 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00164,DRAVPe00164.cif,Linear,Free,Free,,L,membrane,The possible mechanism of action is that the peptide could inhibit  membrane fusion and inhibit HIV-1 replication in cells.,2183.47,C105H139N25O25S,EHIKLMRSTY,P,3.8,0,1,-1,5,9,3.5,891,>20 hour,>20 hour,?,53.5,16500,868.42,21543477,J Virol. 2011 Jul;85(14):7037-47.,"Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. ",Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,10.1128/JVI.02366-10,,Anti-HIV
DRAVPe00165,RGTKALTEVIPLTEEAEC,18,PepA,Synthetic construct,No entry found,,HIV,Retroviridae,RT-Polymerase Assay,[Ref.18952602]HIV-1: inhibition of polymerase activity of HIV-1 RT(Ki =35 ± 5 μM).##NOTE:Ki: inhibition constants ,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00165,DRAVPe00165.cif,Linear,Free,Free,,L,Reverse Transcriptase,"HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase.",1960.23,C83H142N22O30S,DFHMNQSWY,E,4.49,2,4,-2,5,6,-22.78,-3078,1 hour,2 min,2 min,92.22,0,0.0,18952602,J Biol Chem. 2009 Jan 2;284(1):254-264.,"Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.",A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,10.1074/jbc.M802199200,,Anti-HIV
DRAVPe00166,GTKALTEVIPLTEEAEC,17,P1,Synthetic construct(derived from Pep-A),No entry found,,HIV,Retroviridae,RT-Polymerase Assay,"[Ref.18952602]HIV-1: inhibition of polymerase activity of HIV-1 RT(Ki =7.5±2.3 μM);inhibition of PHA-P-activated PBMCs infected with HIV-1-LAI(EC50=78.2 nM,associated with Pep-1).##NOTE:Ki: inhibition constants ",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00166,DRAVPe00166.cif,Linear,Free,Free,,L,Reverse Transcriptase,"HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase.",1804.04,C77H130N18O29S,DFHMNQRSWY,E,4.09,1,4,-3,5,6,2.35,-1586,30 hour,>20 hour,>10 hour,97.65,0,0.0,18952602,J Biol Chem. 2009 Jan 2;284(1):254-264.,"Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.",A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,10.1074/jbc.M802199200,,Anti-HIV
DRAVPe00167,ATKALTEVIPLTEEAEC,17,P2,Synthetic construct(derived from Pep-A),No entry found,,HIV,Retroviridae,RT-Polymerase Assay,[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =28 ±11 μM).##NOTE:Ki: inhibition constants ,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00167,DRAVPe00167.cif,Linear,Free,Free,,L,Reverse Transcriptase,"HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase.",1818.07,C78H132N18O29S,DFGHMNQRSWY,E,4.09,1,4,-3,4,7,15.29,-1499,4.4 hour,>20 hour,>10 hour,103.53,0,0.0,18952602,J Biol Chem. 2009 Jan 2;284(1):254-264.,"Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.",A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,10.1074/jbc.M802199200,,Anti-HIV
DRAVPe00168,GAKALTEVIPLTEEAEC,17,P3,Synthetic construct(derived from Pep-A),No entry found,,HIV,Retroviridae,RT-Polymerase Assay,[Ref.18952602]HIV-1: inhibition of polymerase activity of HIV-1 RT(Ki =10.3 ± 2.1 μM).##NOTE:Ki: inhibition constants ,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00168,DRAVPe00168.cif,Linear,Free,Free,,L,Reverse Transcriptase,"HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase.",1774.02,C76H128N18O28S,DFHMNQRSWY,E,4.09,1,4,-3,4,7,17.06,-1148,30 hour,>20 hour,>10 hour,103.53,0,0.0,18952602,J Biol Chem. 2009 Jan 2;284(1):254-264.,"Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.",A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,10.1074/jbc.M802199200,,Anti-HIV
DRAVPe00169,GTAALTEVIPLTEEAEC,17,P4,Synthetic construct(derived from Pep-A),No entry found,,HIV,Retroviridae,RT-Polymerase Assay,[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =15 ± 2.9 μM).##NOTE:Ki: inhibition constants ,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00169,DRAVPe00169.cif,Linear,Free,Free,,L,Reverse Transcriptase,"HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase.",1746.95,C74H123N17O29S,DFHKMNQRSWY,E,3.58,0,4,-4,5,7,35.88,-850,30 hour,>20 hour,>10 hour,103.53,0,0.0,18952602,J Biol Chem. 2009 Jan 2;284(1):254-264.,"Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.",A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,10.1074/jbc.M802199200,,Anti-HIV
DRAVPe00170,GTKGLTEVIPLTEEAEC,17,P5,Synthetic construct(derived from Pep-A),No entry found,,HIV,Retroviridae,RT-Polymerase Assay,[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =20 ± 3.7 μM).##NOTE:Ki: inhibition constants ,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00170,DRAVPe00170.cif,Linear,Free,Free,,L,Reverse Transcriptase,"HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase.",1790.02,C76H128N18O29S,DFHMNQRSWY,E,4.09,1,4,-3,6,5,-10.59,-1673,30 hour,>20 hour,>10 hour,91.76,0,0.0,18952602,J Biol Chem. 2009 Jan 2;284(1):254-264.,"Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.",A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,10.1074/jbc.M802199200,,Anti-HIV
DRAVPe00171,GTKAATEVIPLTEEAEC,17,P6,Synthetic construct(derived from Pep-A),No entry found,,HIV,Retroviridae,RT-Polymerase Assay,"[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =5.7 ± 2.3 μM);inhibition of PHA-P-activated PBMCs infected with HIV-1-LAI(EC50=170 nM,associated with Pep-1).##NOTE:Ki: inhibition constants ",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00171,DRAVPe00171.cif,Linear,Free,Free,,L,Reverse Transcriptase,"HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase.",1761.96,C74H124N18O29S,DFHMNQRSWY,E,4.09,1,4,-3,5,6,-9.41,-1897,30 hour,>20 hour,>10 hour,80.59,0,0.0,18952602,J Biol Chem. 2009 Jan 2;284(1):254-264.,"Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.",A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,10.1074/jbc.M802199200,,Anti-HIV
DRAVPe00172,GTKALAEVIPLTEEAEC,17,P7,Synthetic construct(derived from Pep-A),No entry found,,HIV,Retroviridae,RT-Polymerase Assay,[Ref.18952602]HIV-1: inhibition of polymerase activity of HIV-1 RT(Ki =13.5 ± 2.1 μM).##NOTE:Ki: inhibition constants ,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00172,DRAVPe00172.cif,Linear,Free,Free,,L,Reverse Transcriptase,"HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase.",1774.02,C76H128N18O28S,DFHMNQRSWY,E,4.09,1,4,-3,4,7,17.06,-1148,30 hour,>20 hour,>10 hour,103.53,0,0.0,18952602,J Biol Chem. 2009 Jan 2;284(1):254-264.,"Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.",A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,10.1074/jbc.M802199200,,Anti-HIV
DRAVPe00173,GTKALTAVIPLTEEAEC,17,P8,Synthetic construct(derived from Pep-A),No entry found,,HIV,Retroviridae,RT-Polymerase Assay,"[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =57 ± 19 μM);inhibition of PHA-P-activated PBMCs infected with HIV-1-LAI(EC50=290 nM,associated with Pep-1).##NOTE:Ki: inhibition constants ",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00173,DRAVPe00173.cif,Linear,Free,Free,,L,Reverse Transcriptase,"HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase.",1746.01,C75H128N18O27S,DFHMNQRSWY,AET,4.25,1,3,-2,5,7,33.53,-724,30 hour,>20 hour,>10 hour,103.53,0,0.0,18952602,J Biol Chem. 2009 Jan 2;284(1):254-264.,"Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.",A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,10.1074/jbc.M802199200,,Anti-HIV
DRAVPe00174,GTKALTEAIPLTEEAEC,17,P9,Synthetic construct(derived from Pep-A),No entry found,,HIV,Retroviridae,RT-Polymerase Assay,[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =15 ±7.3 μM).##NOTE:Ki: inhibition constants ,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00174,DRAVPe00174.cif,Linear,Free,Free,,L,Reverse Transcriptase,"HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase.",1775.99,C75H126N18O29S,DFHMNQRSVWY,E,4.09,1,4,-3,5,6,-11.76,-1809,30 hour,>20 hour,>10 hour,86.47,0,0.0,18952602,J Biol Chem. 2009 Jan 2;284(1):254-264.,"Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.",A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,10.1074/jbc.M802199200,,Anti-HIV
DRAVPe00175,GTKALTEVAPLTEEAEC,17,P10,Synthetic construct(derived from Pep-A),No entry found,,HIV,Retroviridae,RT-Polymerase Assay,"[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =7.3 ± 2.9 μM);inhibition of PHA-P-activated PBMCs infected with HIV-1-LAI(EC50=140 nM,associated with Pep-1).##NOTE:Ki: inhibition constants ",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00175,DRAVPe00175.cif,Linear,Free,Free,,L,Reverse Transcriptase,"HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase.",1761.96,C74H124N18O29S,DFHIMNQRSWY,E,4.09,1,4,-3,5,6,-13.53,-1897,30 hour,>20 hour,>10 hour,80.59,0,0.0,18952602,J Biol Chem. 2009 Jan 2;284(1):254-264.,"Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.",A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,10.1074/jbc.M802199200,,Anti-HIV
DRAVPe00176,GTKALTEVIALTEEAEC,17,P11,Synthetic construct(derived from Pep-A),No entry found,,HIV,Retroviridae,RT-Polymerase Assay,[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =7 ± 1.4 μM).##NOTE:Ki: inhibition constants ,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00176,DRAVPe00176.cif,Linear,Free,Free,,L,Reverse Transcriptase,"HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase.",1778.0,C75H128N18O29S,DFHMNPQRSWY,E,4.09,1,4,-3,5,7,22.35,-1405,30 hour,>20 hour,>10 hour,103.53,0,0.0,18952602,J Biol Chem. 2009 Jan 2;284(1):254-264.,"Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.",A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,10.1074/jbc.M802199200,,Anti-HIV
DRAVPe00177,GTKALTEVIPATEEAEC,17,P12,Synthetic construct(derived from Pep-A),No entry found,,HIV,Retroviridae,RT-Polymerase Assay,[Ref.18952602]HIV-1: inhibition of polymerase activity of HIV-1 RT(Ki =22 ± 3 μM).##NOTE:Ki: inhibition constants ,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00177,DRAVPe00177.cif,Linear,Free,Free,,L,Reverse Transcriptase,"HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase.",1761.96,C74H124N18O29S,DFHMNQRSWY,E,4.09,1,4,-3,5,6,-9.41,-1897,30 hour,>20 hour,>10 hour,80.59,0,0.0,18952602,J Biol Chem. 2009 Jan 2;284(1):254-264.,"Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.",A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,10.1074/jbc.M802199200,,Anti-HIV
DRAVPe00178,GTKALTEVIPLAEEAEC,17,P13,Synthetic construct(derived from Pep-A),No entry found,,HIV,Retroviridae,RT-Polymerase Assay,[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =10.2 ± 2.5 μM).##NOTE:Ki: inhibition constants ,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00178,DRAVPe00178.cif,Linear,Free,Free,,L,Reverse Transcriptase,"HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase.",1774.02,C76H128N18O28S,DFHMNQRSWY,E,4.09,1,4,-3,4,7,17.06,-1148,30 hour,>20 hour,>10 hour,103.53,0,0.0,18952602,J Biol Chem. 2009 Jan 2;284(1):254-264.,"Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.",A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,10.1074/jbc.M802199200,,Anti-HIV
DRAVPe00179,GTKALTEVIPLTAEAEC,17,P14,Synthetic construct(derived from Pep-A),No entry found,,HIV,Retroviridae,RT-Polymerase Assay,[Ref.18952602]HIV-1: inhibition of polymerase activity of HIV-1 RT(Ki =14 ± 3 μM).##NOTE:Ki: inhibition constants ,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00179,DRAVPe00179.cif,Linear,Free,Free,,L,Reverse Transcriptase,"HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase.",1746.01,C75H128N18O27S,DFHMNQRSWY,AET,4.25,1,3,-2,5,7,33.53,-724,30 hour,>20 hour,>10 hour,103.53,0,0.0,18952602,J Biol Chem. 2009 Jan 2;284(1):254-264.,"Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.",A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,10.1074/jbc.M802199200,,Anti-HIV
DRAVPe00180,GTKALTEVIPLTEAAEC,17,P15,Synthetic construct(derived from Pep-A),No entry found,,HIV,Retroviridae,RT-Polymerase Assay,[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =14 ± 2.2 μM).##NOTE:Ki: inhibition constants ,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00180,DRAVPe00180.cif,Linear,Free,Free,,L,Reverse Transcriptase,"HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase.",1746.01,C75H128N18O27S,DFHMNQRSWY,AET,4.25,1,3,-2,5,7,33.53,-724,30 hour,>20 hour,>10 hour,103.53,0,0.0,18952602,J Biol Chem. 2009 Jan 2;284(1):254-264.,"Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.",A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,10.1074/jbc.M802199200,,Anti-HIV
DRAVPe00181,GTKWLTEVWPLC,12,P16,Synthetic construct(derived from Pep-A),No entry found,,HIV,Retroviridae,RT-Polymerase Assay,[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =14 ± 4 μM).##NOTE:Ki: inhibition constants ,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00181,DRAVPe00181.cif,Linear,Free,Free,,L,Reverse Transcriptase,"HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase.",1432.7,C68H101N15O17S,ADFHIMNQRSY,LTW,5.99,1,1,0,4,5,14.17,326,30 hour,>20 hour,>10 hour,89.17,11000,1000.0,18952602,J Biol Chem. 2009 Jan 2;284(1):254-264.,"Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.",A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,10.1074/jbc.M802199200,,Anti-HIV
DRAVPe00182,GTKAWTEVWPLC,12,P17,Synthetic construct(derived from Pep-A),No entry found,,HIV,Retroviridae,RT-Polymerase Assay,[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =35 ± 11 μM).##NOTE:Ki: inhibition constants ,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00182,DRAVPe00182.cif,Linear,Free,Free,,L,Reverse Transcriptase,"HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase.",1390.62,C65H95N15O17S,DFHIMNQRSY,TW,5.99,1,1,0,4,5,-2.5,15,30 hour,>20 hour,>10 hour,65.0,11000,1000.0,18952602,J Biol Chem. 2009 Jan 2;284(1):254-264.,"Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.",A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,10.1074/jbc.M802199200,,Anti-HIV
DRAVPe00183,GTKALTEVIPLTC,13,P18,Synthetic construct(derived from Pep-A),No entry found,,HIV,Retroviridae,RT-Polymerase Assay,"[Ref.18952602]HIV-1:inhibition of PHA-P-activated PBMCs infected with HIV-1-LAI(EC50>1000 nM,associated with Pep-1);inhibition of polymerase activity of HIV-1 RT(Ki =53± 12 μM).##NOTE:Ki: inhibition constants ",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00183,DRAVPe00183.cif,Linear,Free,Free,,L,Reverse Transcriptase,"HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase.",1345.62,C59H104N14O19S,DFHMNQRSWY,T,5.99,1,1,0,5,5,70.0,276,30 hour,>20 hour,>10 hour,120.0,0,0.0,18952602,J Biol Chem. 2009 Jan 2;284(1):254-264.,"Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.",A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,10.1074/jbc.M802199200,,Anti-HIV
DRAVPe00184,GTKAATEVIPLTC,13,P19,Synthetic construct(derived from Pep-A),No entry found,,HIV,Retroviridae,RT-Polymerase Assay,[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =49 ± 9 μM).##NOTE:Ki: inhibition constants ,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00184,DRAVPe00184.cif,Linear,Free,Free,,L,Reverse Transcriptase,"HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase.",1303.54,C56H98N14O19S,DFHMNQRSWY,T,5.99,1,1,0,5,5,54.62,-35,30 hour,>20 hour,>10 hour,97.69,0,0.0,18952602,J Biol Chem. 2009 Jan 2;284(1):254-264.,"Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.",A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,10.1074/jbc.M802199200,,Anti-HIV
DRAVPe00185,GTKWLTEWIPLC,12,P24,Synthetic construct(derived from Pep-A),No entry found,,HIV,Retroviridae,RT-Polymerase Assay,"[Ref.18952602]HIV-1:inhibition of PHA-P-activated PBMCs infected with HIV-1-LAI(EC50=2.3 nM,associated with Pep-1); inhibition of polymerase activity of HIV-1 RT(Ki =0.7 ± 0.05 μM).##NOTE:Ki: inhibition constants ",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00185,DRAVPe00185.cif,Linear,Free,Free,,L,Reverse Transcriptase,"HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase.",1446.73,C69H103N15O17S,ADFHMNQRSVY,LTW,5.99,1,1,0,4,5,16.67,414,30 hour,>20 hour,>10 hour,97.5,11000,1000.0,18952602,J Biol Chem. 2009 Jan 2;284(1):254-264.,"Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.",A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,10.1074/jbc.M802199200,,Anti-HIV
DRAVPe00186,KWLTEWIPLTAEAEC,15,P26,Synthetic construct(derived from Pep-A),No entry found,,HIV,Retroviridae,RT-Polymerase Assay,"[Ref.18952602]HIV-1:inhibition of PHA-P-activated PBMCs infected with HIV-1-LAI(EC50>1000 nM,associated with Pep-1); inhibition of polymerase activity of HIV-1 RT(Ki =1.8± 0.7 μM).##NOTE:Ki: inhibition constants ",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00186,DRAVPe00186.cif,Linear,Free,Free,,L,Reverse Transcriptase,"HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase.",1790.06,C83H124N18O24S,DFGHMNQRSVY,E,4.25,1,3,-2,3,7,-6.67,-680,1.3 hour,3 min,2 min,91.33,11000,785.71,18952602,J Biol Chem. 2009 Jan 2;284(1):254-264.,"Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.",A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,10.1074/jbc.M802199200,,Anti-HIV
DRAVPe00187,GTKWLTEWIPLTAEC,15,P27,Synthetic construct(derived from Pep-A),No entry found,,HIV,Retroviridae,RT-Polymerase Assay,"[Ref.18952602]HIV-1:inhibition of PHA-P-activated PBMCs infected with HIV-1-LAI(EC50<0.32 nM,associated with Pep-1); inhibition of polymerase activity of HIV-1 RT(Ki =0.05 ± 0.01 μM).##NOTE:Ki: inhibition constants ",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00187,DRAVPe00187.cif,Linear,Free,Free,,L,Reverse Transcriptase,"HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase.",1748.03,C81H122N18O23S,DFHMNQRSVY,T,4.53,1,2,-1,5,6,-2.67,-343,30 hour,>20 hour,>10 hour,84.67,11000,785.71,18952602,J Biol Chem. 2009 Jan 2;284(1):254-264.,"Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.",A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,10.1074/jbc.M802199200,,Anti-HIV
DRAVPe00188,GTKWATEWAPLTAEAEC,17,P28,Synthetic construct(derived from Pep-A),No entry found,,HIV,Retroviridae,RT-Polymerase Assay,[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =2 ± 0.6 μM).##NOTE:Ki: inhibition constants ,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00188,DRAVPe00188.cif,Linear,Free,Free,,L,Reverse Transcriptase,"HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase.",1864.06,C83H122N20O27S,DFHIMNQRSVY,A,4.25,1,3,-2,5,7,-40.0,-1465,30 hour,>20 hour,>10 hour,46.47,11000,687.5,18952602,J Biol Chem. 2009 Jan 2;284(1):254-264.,"Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.",A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,10.1074/jbc.M802199200,,Anti-HIV
DRAVPe00189,KWLTEWIPLTAEC,13,P29,Synthetic construct(derived from Pep-A),No entry found,,HIV,Retroviridae,RT-Polymerase Assay,[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =1 ± 0.4 μM).##NOTE:Ki: inhibition constants ,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00189,DRAVPe00189.cif,Linear,Free,Free,,L,Reverse Transcriptase,"HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase.",1589.87,C75H112N16O20S,DFGHMNQRSVY,ELTW,4.53,1,2,-1,3,6,5.38,-180,1.3 hour,3 min,2 min,97.69,11000,916.67,18952602,J Biol Chem. 2009 Jan 2;284(1):254-264.,"Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.",A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,10.1074/jbc.M802199200,,Anti-HIV
DRAVPe00190,GTKWLTEWIPLTAEAEC,17,PAW,Synthetic construct(derived from Pep-A),No entry found,,HIV,Retroviridae,RT-Polymerase Assay,"[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =0.7 ± 0.2 μM);inhibition of PHA-P-activated PBMCs infected with HIV-1-LAI(EC50=1.8 nM,associated with Pep-1).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00190,DRAVPe00190.cif,Linear,Free,Free,,L,Reverse Transcriptase,"HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase.",1948.22,C89H134N20O27S,DFHMNQRSVY,ET,4.25,1,3,-2,5,7,-12.35,-843,30 hour,>20 hour,>10 hour,80.59,11000,687.5,18952602,J Biol Chem. 2009 Jan 2;284(1):254-264.,"Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.",A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,10.1074/jbc.M802199200,,Anti-HIV
DRAVPe00191,GAKTETLVIPETELEAC,17,Pscr,Synthetic construct(derived from Pep-A),No entry found,,HIV,Retroviridae,RT-Polymerase Assay,[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =61 ± 12 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00191,DRAVPe00191.cif,Linear,Free,Free,,L,Reverse Transcriptase,"HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase.",1804.04,C77H130N18O29S,DFHMNQRSWY,E,4.09,1,4,-3,5,6,2.35,-1586,30 hour,>20 hour,>10 hour,97.65,0,0.0,18952602,J Biol Chem. 2009 Jan 2;284(1):254-264.,"Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.",A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,10.1074/jbc.M802199200,,Anti-HIV
DRAVPe00192,LEAIPMSIPPEVKFNKPFVF,20,VIRIP,Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=14.79±2.56 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.17448989]No cytotoxicity against P4-CCR5 cells up tp 1000 µM.,DRAVPe00192,DRAVPe00192.cif,Linear,Free,Free,,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2303.79,C112H171N23O27S,CDGHQRTWY,P,6.14,2,2,0,2,9,39.0,118,5.5 hour,3 min,2 min,92.5,0,0.0,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00193,AEAIPMSIPPEVKFNKPFVF,20,VIRIP[A1],Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50>100 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00193,DRAVPe00193.cif,Linear,Free,Free,,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2261.71,C109H165N23O27S,CDGHLQRTWY,P,6.19,2,2,0,2,9,29.0,-193,4.4 hour,>20 hour,>10 hour,78.0,0,0.0,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00194,LAAIPMSIPPEVKFNKPFVF,20,VIRIP[A2],Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50>100 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00194,DRAVPe00194.cif,Linear,Free,Free,,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2245.75,C110H169N23O25S,CDGHQRTWY,P,8.59,2,1,1,2,10,65.5,980,5.5 hour,3 min,2 min,97.5,0,0.0,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00195,LEAAPMSIPPEVKFNKPFVF,20,VIRIP[A4],Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50>100 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00195,DRAVPe00195.cif,Linear,Free,Free,,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2261.71,C109H165N23O27S,CDGHQRTWY,P,6.14,2,2,0,2,9,25.5,-193,5.5 hour,3 min,2 min,78.0,0,0.0,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00196,LEAIAMSIPPEVKFNKPFVF,20,VIRIP[A5],Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=23.50±5.19 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00196,DRAVPe00196.cif,Linear,Free,Free,,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2277.75,C110H169N23O27S,CDGHQRTWY,FP,6.14,2,2,0,2,10,56.0,299,5.5 hour,3 min,2 min,97.5,0,0.0,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00197,LEAIPASIPPEVKFNKPFVF,20,VIRIP[A6],Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=13.00±1.04 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00197,DRAVPe00197.cif,Linear,Free,Free,,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2243.67,C110H167N23O27,CDGHMQRTWY,P,6.14,2,2,0,2,10,38.5,64,5.5 hour,3 min,2 min,97.5,0,0.0,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00198,LEAIPMSAPPEVKFNKPFVF,20,VIRIP[A8],Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=23.46±0.28 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00198,DRAVPe00198.cif,Linear,Free,Free,,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2261.71,C109H165N23O27S,CDGHQRTWY,P,6.14,2,2,0,2,9,25.5,-193,5.5 hour,3 min,2 min,78.0,0,0.0,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00199,LEAIPMSIAPEVKFNKPFVF,20,VIRIP[A9],Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=16.33±4.34 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00199,DRAVPe00199.cif,Linear,Free,Free,,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2277.75,C110H169N23O27S,CDGHQRTWY,FP,6.14,2,2,0,2,10,56.0,299,5.5 hour,3 min,2 min,97.5,0,0.0,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00200,LEAIPMSIPAEVKFNKPFVF,20,VIRIP[A10],Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=9.72±1.66 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00200,DRAVPe00200.cif,Linear,Free,Free,,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2277.75,C110H169N23O27S,CDGHQRTWY,FP,6.14,2,2,0,2,10,56.0,299,5.5 hour,3 min,2 min,97.5,0,0.0,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00201,LEAIPMSIPPAVKFNKPFVF,20,VIRIP[A11],Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=11.00±4.75 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00201,DRAVPe00201.cif,Linear,Free,Free,,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2245.75,C110H169N23O25S,CDGHQRTWY,P,8.59,2,1,1,2,10,65.5,980,5.5 hour,3 min,2 min,97.5,0,0.0,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00202,LEAIPMSIPPEAKFNKPFVF,20,VIRIP[A12],Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=10.64±2.23 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00202,DRAVPe00202.cif,Linear,Free,Free,,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2275.73,C110H167N23O27S,CDGHQRTWY,P,6.14,2,2,0,2,9,27.0,-105,5.5 hour,3 min,2 min,83.0,0,0.0,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00203,LEAIPMSIPPEVAFNKPFVF,20,VIRIP[A13],Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=4.73±0.61 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00203,DRAVPe00203.cif,Linear,Free,Free,,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2246.69,C109H164N22O27S,CDGHQRTWY,P,4.53,1,2,-1,2,10,67.5,854,5.5 hour,3 min,2 min,97.5,0,0.0,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00204,LEAIPMSIPPEVKANKPFVF,20,VIRIP[A14],Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=4.62±1.32 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00204,DRAVPe00204.cif,Linear,Free,Free,,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2227.69,C106H167N23O27S,CDGHQRTWY,P,6.14,2,2,0,2,9,34.0,1,5.5 hour,3 min,2 min,97.5,0,0.0,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00205,LEAIPMSIPPEVKFAKPFVF,20,VIRIP[A15],Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=17.41±3.66 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00205,DRAVPe00205.cif,Linear,Free,Free,,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2260.76,C111H170N22O26S,CDGHNQRTWY,P,6.14,2,2,0,1,10,65.5,963,5.5 hour,3 min,2 min,97.5,0,0.0,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00206,LEAIPMSIPPEVKFNAPFVF,20,VIRIP[A16],Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=10.81±0.68 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00206,DRAVPe00206.cif,Linear,Free,Free,,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2246.69,C109H164N22O27S,CDGHQRTWY,P,4.53,1,2,-1,2,10,67.5,854,5.5 hour,3 min,2 min,97.5,0,0.0,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00207,LEAIPMSIPPEVKFNKAFVF,20,VIRIP[A17],Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=12.72±10.17 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00207,DRAVPe00207.cif,Linear,Free,Free,,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2277.75,C110H169N23O27S,CDGHQRTWY,FP,6.14,2,2,0,2,10,56.0,299,5.5 hour,3 min,2 min,97.5,0,0.0,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00208,LEAIPMSIPPEVKFNKPAVF,20,VIRIP[A18],Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50>100 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00208,DRAVPe00208.cif,Linear,Free,Free,,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2227.69,C106H167N23O27S,CDGHQRTWY,P,6.14,2,2,0,2,9,34.0,1,5.5 hour,3 min,2 min,97.5,0,0.0,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00209,LEAIPMSIPPEVKFNKPFAF,20,VIRIP[A19],Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50>100 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00209,DRAVPe00209.cif,Linear,Free,Free,,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2275.73,C110H167N23O27S,CDGHQRTWY,P,6.14,2,2,0,2,9,27.0,-105,5.5 hour,3 min,2 min,83.0,0,0.0,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00210,LEAIPMSIPPEVKFNKPFVA,20,VIRIP[A20],Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50>100 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00210,DRAVPe00210.cif,Linear,Free,Free,,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2227.69,C106H167N23O27S,CDGHQRTWY,P,6.14,2,2,0,2,9,34.0,1,5.5 hour,3 min,2 min,97.5,0,0.0,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00211,LEAIPMSIPPEVKFNKPFVF,20,N-Ac-VIRIP,Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50>100 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00211,DRAVPe00211.cif,Linear,Acetylation,Free,,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2303.79,C112H171N23O27S,CDGHQRTWY,P,6.14,2,2,0,2,9,39.0,118,5.5 hour,3 min,2 min,92.5,0,0.0,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00212,LEAIPMSIPPEVKFNKPFVF,20,VIRIP-amide,Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50>100 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00212,DRAVPe00212.cif,Linear,Free,Amidation,,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2303.79,C112H171N23O27S,CDGHQRTWY,P,6.14,2,2,0,2,9,39.0,118,5.5 hour,3 min,2 min,92.5,0,0.0,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00213,LEAIPMSIPPEVKFNKPFVF,20,N-Ac-VIRIP-amide,Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50>100 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00213,DRAVPe00213.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2303.79,C112H171N23O27S,CDGHQRTWY,P,6.14,2,2,0,2,9,39.0,118,5.5 hour,3 min,2 min,92.5,0,0.0,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00214,LEAIPMSIPPEVAFAKPFVF,20,"VIRIP[A13,A15]",Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=3.45±0.44 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00214,DRAVPe00214.cif,Linear,Free,Free,,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2203.67,C108H163N21O26S,CDGHNQRTWY,P,4.53,1,2,-1,1,11,94.0,1699,5.5 hour,3 min,2 min,102.5,0,0.0,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00215,LEAIPMSIPPEVFFNKPFVF,20,VIRIP[F13],Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.66±0.06 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00215,DRAVPe00215.cif,Linear,Free,Free,,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2322.79,C115H168N22O27S,CDGHQRTWY,FP,4.53,1,2,-1,2,10,72.5,971,5.5 hour,3 min,2 min,92.5,0,0.0,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00216,LEAIPMCIPPECAFNKPFVF,20,"VIRIP[A13,C7,C12]",Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=1.00±0.21 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00216,DRAVPe00216.cif,Cyclic,Free,Free,Disulfide bond between Cys7 and Cys12,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2266.76,C107H160N22O26S3,DGHQRSTWY,P,4.53,1,2,-1,3,9,75.5,1046,5.5 hour,3 min,2 min,83.0,125,6.58,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00217,LEAIPCSIPPCVAFNKPFVF,20,"VIRIP[A13,C6,C11]",Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.18±0.08 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00217,DRAVPe00217.cif,Cyclic,Free,Free,Disulfide bond between Cys6 and Cys11,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2192.66,C105H158N22O25S2,DGHMQRTWY,P,5.99,1,1,0,4,10,100.5,1556,5.5 hour,3 min,2 min,97.5,125,6.58,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00218,LEAIPCSIPpCVAFNKPFVF,20,"VIRIP[A13,C6,C11,p10]",Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.94±0.54 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00218,DRAVPe00218.cif,Cyclic,Free,Free,Disulfide bond between Cys6 and Cys11,Mixed(D-Pro10),membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2192.66,C100H149N21O23S2,DGHMQRTWY,FP,5.99,1,1,0,4,10,108.5,1556,5.5 hour,3 min,2 min,97.5,125,6.58,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00219,LEAIPCSIPPCVGFGKPFVF,20,"VIRIP[C6,C11,G13,G15]",Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.73±0.13 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00219,DRAVPe00219.cif,Cyclic,Free,Free,Disulfide bond between Cys6 and Cys11,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2121.58,C102H153N21O24S2,DHMNQRTWY,P,5.99,1,1,0,5,9,105.0,2227,5.5 hour,3 min,2 min,92.5,125,6.58,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00220,LEAIPCSIPPCVLFNKPFVF,20,"VIRIP[C6,C11,L13]",Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.84±0.08 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00220,DRAVPe00220.cif,Cyclic,Free,Free,Disulfide bond between Cys6 and Cys11,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2234.74,C108H164N22O25S2,DGHMQRTWY,P,5.99,1,1,0,4,10,110.5,1867,5.5 hour,3 min,2 min,112.0,125,6.58,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00221,LEAIPCSIPPCVFFNKPFVF,20,"VIRIP[C6,C11,F13]",Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.93±0.05 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.17448989]No cytotoxicity against P4-CCR5 cells up tp 1000 µM.,DRAVPe00221,DRAVPe00221.cif,Cyclic,Free,Free,Disulfide bond between Cys6 and Cys11,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2268.76,C111H162N22O25S2,DGHMQRTWY,FP,5.99,1,1,0,4,10,105.5,1673,5.5 hour,3 min,2 min,92.5,125,6.58,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00222,LEAIPCSIPPCFAFNKPFVF,20,"VIRIP[A13,C6,C11,F12]",Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.27±0.04 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.17448989]No cytotoxicity against P4-CCR5 cells up tp 1000 µM.,DRAVPe00222,DRAVPe00222.cif,Cyclic,Free,Free,Disulfide bond between Cys6 and Cys11,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2240.71,C109H158N22O25S2,DGHMQRTWY,FP,5.99,1,1,0,4,10,93.5,1450,5.5 hour,3 min,2 min,83.0,125,6.58,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00223,LEAIPMSIPPEFLFGKPFVF,20,"VIRIP[F12,L13,G15]",Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=1.34±0.42 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.17448989]No cytotoxicity against P4-CCR5 cells up tp 1000 µM.,DRAVPe00223,DRAVPe00223.cif,Linear,Free,Free,,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2279.77,C114H167N21O26S,CDHNQRTWY,FP,4.53,1,2,-1,2,10,86.0,1817,5.5 hour,3 min,2 min,97.5,0,0.0,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00224,LEAIPCSIPPCVFFGKPFVF,20,"VIRIP[C6,C11,F13,G15]",Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.28±0.02 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00224,DRAVPe00224.cif,Cyclic,Free,Free,Disulfide bond between Cys6 and Cys11,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2211.71,C109H159N21O24S2,DHMNQRTWY,FP,5.99,1,1,0,4,10,121.0,2431,5.5 hour,3 min,2 min,92.5,125,6.58,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00225,LEAIPCSIPPCFLFGKPFVF,20,"VIRIP[C6,C11,F12,L13,G15]",Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.39±0.13 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00225,DRAVPe00225.cif,Cyclic,Free,Free,Disulfide bond between Cys6 and Cys11,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2225.73,C110H161N21O24S2,DHMNQRTWY,FP,5.99,1,1,0,4,10,119.0,2519,5.5 hour,3 min,2 min,97.5,125,6.58,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00226,LEAIPCSIPpCVFFNKPFVF,20,"VIRIP[C6,C11,p10,F13]",Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.33±0.07 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00226,DRAVPe00226.cif,Cyclic,Free,Free,Disulfide bond between Cys6 and Cys11,Mixed(D-Pro10),membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2268.76,C106H153N21O23S2,DGHMQRTWY,F,5.99,1,1,0,4,10,113.5,1673,5.5 hour,3 min,2 min,92.5,125,6.58,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00227,LEAIPCSIPpCFLFNKPFVF,20,"VIRIP[C6,C11,p10,F12,L13]",Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.20±0.04 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.17448989]No cytotoxicity against P4-CCR5 cells up tp 1000 µM.,DRAVPe00227,DRAVPe00227.cif,Cyclic,Free,Free,Disulfide bond between Cys6 and Cys11,Mixed(D-Pro10),membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2282.79,C107H155N21O23S2,DGHMQRTWY,F,5.99,1,1,0,4,10,111.5,1761,5.5 hour,3 min,2 min,97.5,125,6.58,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00228,LEAIPMGIPpEVXFNKPFVF,20,"VIRIP[G7,p10,L-Tic13]",Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.28±0.08 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.17448989]No cytotoxicity against P4-CCR5 cells up tp 1000 µM.,DRAVPe00228,DRAVPe00228.cif,Linear,Free,Free,The 'X' at position 13 is L-tetrahydro-isoquinoline-3-carboxylic acid(Tic).,Mixed(D-Pro10),membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2256.92,C100H146N20O22S,CDHQRSTWY,FP,4.53,1,2,-1,2,9,68.5,1107,5.5 hour,3 min,2 min,92.5,0,0.0,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00229,LEKIPMSIPpEVXFNKPFVF,20,"VIRIP[K3,p10,L-Tic13]",Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.41±0.13 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00229,DRAVPe00229.cif,Linear,Free,Free,The 'X' at position 13 is L-tetrahydro-isoquinoline-3-carboxylic acid(Tic).,Mixed(D-Pro10),membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2344.04,C104H155N21O23S,ACDGHQRTWY,FP,6.14,2,2,0,2,8,38.0,-63,5.5 hour,3 min,2 min,87.5,0,0.0,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00230,KVINPEPIVEPFMSKPFALF,20,scrambled VIRIP,Synthetic construct(derived from α1-antitrypsin),No entry found,,HIV,Retroviridae,ELISA,[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50>100 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.17448989]No cytotoxicity against P4-CCR5 cells up tp 1000 µM.,DRAVPe00230,DRAVPe00230.cif,Linear,Free,Free,,L,membrane,The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane.,2303.79,C112H171N23O27S,CDGHQRTWY,P,6.14,2,2,0,2,9,39.0,118,1.3 hour,3 min,2 min,92.5,0,0.0,17448989,Cell. 2007 Apr 20;129(2):263-75.,"Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.",Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,10.1016/j.cell.2007.02.042,,Anti-HIV
DRAVPe00231,YTSLIHSLIEEGQNQQEKNEQELLELDKWASLWNWF,36,T-20S[138G],Synthetic construct(derived from Enfuvirtide),No entry found,,HIV,Retroviridae,MAGI assay,[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=1.3± 0.5 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50=65± 8.8 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50=141±26 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50=185±68 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00231,DRAVPe00231.cif,Linear,Free,Free,,L,membrane,"The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion.",4420.86,C201H296N50O63,CMPRV,EL,4.3,3,7,-4,9,13,-86.39,-6825,2.8 hour,10 min,2 min,89.44,17990,514.0,19073606,J Biol Chem. 2009 Feb 20;284(8):4914-20.,"Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.",Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,10.1074/jbc.M807169200,,Anti-HIV
DRAVPe00232,YTSLIHSLIEEAQNQQEKNEQELLELDKWASLWNWF,36,T-20S[138A],Synthetic construct(derived from Enfuvirtide),No entry found,,HIV,Retroviridae,MAGI assay,[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=0.6 ± 0.1 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50=3.6± 1.7 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50=3.5 ±0.9 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50=3.2 ± 1.0 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00232,DRAVPe00232.cif,Linear,Free,Free,,L,membrane,"The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion.",4434.89,C202H298N50O63,CGMPRV,EL,4.3,3,7,-4,8,14,-80.28,-6738,2.8 hour,10 min,2 min,92.22,17990,514.0,19073606,J Biol Chem. 2009 Feb 20;284(8):4914-20.,"Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.",Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,10.1074/jbc.M807169200,,Anti-HIV
DRAVPe00233,YTSLIHSLIEEVQNQQEKNEQELLELDKWASLWNWF,36,T-20S[138V],Synthetic construct(derived from Enfuvirtide),No entry found,,HIV,Retroviridae,MAGI assay,[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=0.4 ± 0.2 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50=31 ± 14 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50=22 ± 3.5 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50=23 ± 5.7 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00233,DRAVPe00233.cif,Linear,Free,Free,,L,membrane,"The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion.",4462.94,C204H302N50O63,CGMPR,EL,4.3,3,7,-4,8,14,-73.61,-6515,2.8 hour,10 min,2 min,97.5,17990,514.0,19073606,J Biol Chem. 2009 Feb 20;284(8):4914-20.,"Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.",Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,10.1074/jbc.M807169200,,Anti-HIV
DRAVPe00234,YTSLIHSLIEELQNQQEKNEQELLELDKWASLWNWF,36,T-20S[138L],Synthetic construct(derived from Enfuvirtide),No entry found,,HIV,Retroviridae,MAGI assay,[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=0.7± 0.1 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50=13± 6 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50=2.9 ±0.7 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50=2.2± 0.4 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00234,DRAVPe00234.cif,Linear,Free,Free,,L,membrane,"The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion.",4476.97,C205H304N50O63,CGMPRV,L,4.3,3,7,-4,8,14,-74.72,-6427,2.8 hour,10 min,2 min,100.28,17990,514.0,19073606,J Biol Chem. 2009 Feb 20;284(8):4914-20.,"Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.",Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,10.1074/jbc.M807169200,,Anti-HIV
DRAVPe00235,YTSLIHSLIEEIQNQQEKNEQELLELDKWASLWNWF,36,T-20S[138I],Synthetic construct(derived from Enfuvirtide),No entry found,,HIV,Retroviridae,MAGI assay,[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=0.5 ± 0.1 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50=4.9± 2 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50=2.9 ±0.8 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50=2.4 ± 0.6 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00235,DRAVPe00235.cif,Linear,Free,Free,,L,membrane,"The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion.",4476.97,C205H304N50O63,CGMPRV,EL,4.3,3,7,-4,8,14,-72.78,-6427,2.8 hour,10 min,2 min,100.28,17990,514.0,19073606,J Biol Chem. 2009 Feb 20;284(8):4914-20.,"Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.",Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,10.1074/jbc.M807169200,,Anti-HIV
DRAVPe00236,YTSLIHSLIEEMQNQQEKNEQELLELDKWASLWNWF,36,T-20S[138M],Synthetic construct(derived from Enfuvirtide),No entry found,,HIV,Retroviridae,MAGI assay,[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=0.7± 0.2 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50=4.4± 0.1 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50=1.7±0.5 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50=1.2± 0.4 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00236,DRAVPe00236.cif,Linear,Free,Free,,L,membrane,"The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion.",4495.0,C204H302N50O63S,CGPRV,EL,4.3,3,7,-4,8,13,-80.0,-6684,2.8 hour,10 min,2 min,89.44,17990,514.0,19073606,J Biol Chem. 2009 Feb 20;284(8):4914-20.,"Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.",Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,10.1074/jbc.M807169200,,Anti-HIV
DRAVPe00237,YTSLIHSLIEEPQNQQEKNEQELLELDKWASLWNWF,36,T-20S[138P],Synthetic construct(derived from Enfuvirtide),No entry found,,HIV,Retroviridae,MAGI assay,[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=446± 167 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50>1000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00237,DRAVPe00237.cif,Linear,Free,Free,,L,membrane,"The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion.",4460.92,C204H300N50O63,CGMRV,EL,4.3,3,7,-4,8,13,-89.72,-6919,2.8 hour,10 min,2 min,89.44,17990,514.0,19073606,J Biol Chem. 2009 Feb 20;284(8):4914-20.,"Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.",Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,10.1074/jbc.M807169200,,Anti-HIV
DRAVPe00238,YTSLIHSLIEETQNQQEKNEQELLELDKWASLWNWF,36,T-20S[138T],Synthetic construct(derived from Enfuvirtide),No entry found,,HIV,Retroviridae,MAGI assay,[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=0.9± 0.2 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50=39± 8.5 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50=161±35 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50=124±43nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00238,DRAVPe00238.cif,Linear,Free,Free,,L,membrane,"The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion.",4464.91,C203H300N50O64,CGMPRV,EL,4.3,3,7,-4,9,13,-87.22,-7176,2.8 hour,10 min,2 min,89.44,17990,514.0,19073606,J Biol Chem. 2009 Feb 20;284(8):4914-20.,"Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.",Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,10.1074/jbc.M807169200,,Anti-HIV
DRAVPe00239,YTSLIHSLIEEFQNQQEKNEQELLELDKWASLWNWF,36,T-20S[138F],Synthetic construct(derived from Enfuvirtide),No entry found,,HIV,Retroviridae,MAGI assay,[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=9.4± 2.6 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50=203± 89 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50=393 ± 119 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50=478 ± 116 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00239,DRAVPe00239.cif,Linear,Free,Free,,L,membrane,"The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion.",4510.98,C208H302N50O63,CGMPRV,EL,4.3,3,7,-4,8,14,-77.5,-6621,2.8 hour,10 min,2 min,89.44,17990,514.0,19073606,J Biol Chem. 2009 Feb 20;284(8):4914-20.,"Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.",Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,10.1074/jbc.M807169200,,Anti-HIV
DRAVPe00240,YTSLIHSLIEEYQNQQEKNEQELLELDKWASLWNWF,36,T-20S[138Y],Synthetic construct(derived from Enfuvirtide),No entry found,,HIV,Retroviridae,MAGI assay,[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=25 ±9nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50=516 ±223 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50>1000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00240,DRAVPe00240.cif,Linear,Free,Free,,L,membrane,"The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion.",4526.98,C208H302N50O64,CGMPRV,EL,4.3,3,7,-4,9,13,-88.89,-6933,2.8 hour,10 min,2 min,89.44,19480,556.57,19073606,J Biol Chem. 2009 Feb 20;284(8):4914-20.,"Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.",Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,10.1074/jbc.M807169200,,Anti-HIV
DRAVPe00241,YTSLIHSLIEEWQNQQEKNEQELLELDKWASLWNWF,36,T-20S[138W],Synthetic construct(derived from Enfuvirtide),No entry found,,HIV,Retroviridae,MAGI assay,[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=29± 14 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50>1000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00241,DRAVPe00241.cif,Linear,Free,Free,,L,membrane,"The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion.",4550.02,C210H303N51O63,CGMPRV,EL,4.3,3,7,-4,8,14,-87.78,-6686,2.8 hour,10 min,2 min,89.44,23490,671.14,19073606,J Biol Chem. 2009 Feb 20;284(8):4914-20.,"Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.",Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,10.1074/jbc.M807169200,,Anti-HIV
DRAVPe00242,YTSLIHSLIEENQNQQEKNEQELLELDKWASLWNWF,36,T-20S[138N],Synthetic construct(derived from Enfuvirtide),No entry found,,HIV,Retroviridae,MAGI assay,[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=19± 4 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50>1000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00242,DRAVPe00242.cif,Linear,Free,Free,,L,membrane,"The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion.",4477.91,C203H299N51O64,CGMPRV,EL,4.3,3,7,-4,9,13,-95.0,-7583,2.8 hour,10 min,2 min,89.44,17990,514.0,19073606,J Biol Chem. 2009 Feb 20;284(8):4914-20.,"Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.",Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,10.1074/jbc.M807169200,,Anti-HIV
DRAVPe00243,YTSLIHSLIEEQQNQQEKNEQELLELDKWASLWNWF,36,T-20S[138Q],Synthetic construct(derived from Enfuvirtide),No entry found,,HIV,Retroviridae,MAGI assay,[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=34± 11 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50>1000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00243,DRAVPe00243.cif,Linear,Free,Free,,L,membrane,"The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion.",4491.94,C204H301N51O64,CGMPRV,EL,4.3,3,7,-4,8,13,-95.0,-7473,2.8 hour,10 min,2 min,89.44,17990,514.0,19073606,J Biol Chem. 2009 Feb 20;284(8):4914-20.,"Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.",Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,10.1074/jbc.M807169200,,Anti-HIV
DRAVPe00244,YTSLIHSLIEEDQNQQEKNEQELLELDKWASLWNWF,36,T-20S[138D],Synthetic construct(derived from Enfuvirtide),No entry found,,HIV,Retroviridae,MAGI assay,[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=210± 94 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50>1000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00244,DRAVPe00244.cif,Linear,Free,Free,,L,membrane,"The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion.",4478.89,C203H298N50O65,CGMPRV,EL,4.16,3,8,-5,8,13,-95.0,-7791,2.8 hour,10 min,2 min,89.44,17990,514.0,19073606,J Biol Chem. 2009 Feb 20;284(8):4914-20.,"Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.",Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,10.1074/jbc.M807169200,,Anti-HIV
DRAVPe00245,YTSLIHSLIEEEQNQQEKNEQELLELDKWASLWNWF,36,T-20S[138E],Synthetic construct(derived from Enfuvirtide),No entry found,,HIV,Retroviridae,MAGI assay,[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=283± 80 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50>1000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00245,DRAVPe00245.cif,Linear,Free,Free,,L,membrane,"The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion.",4492.92,C204H300N50O65,CGMPRV,E,4.21,3,8,-5,8,13,-95.0,-7600,2.8 hour,10 min,2 min,89.44,17990,514.0,19073606,J Biol Chem. 2009 Feb 20;284(8):4914-20.,"Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.",Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,10.1074/jbc.M807169200,,Anti-HIV
DRAVPe00246,YTSLIHSLIEEHQNQQEKNEQELLELDKWASLWNWF,36,T-20S[138H],Synthetic construct(derived from Enfuvirtide),No entry found,,HIV,Retroviridae,MAGI assay,[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=210± 85 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50>1000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00246,DRAVPe00246.cif,Linear,Free,Free,,L,membrane,"The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion.",4500.95,C205H300N52O63,CGMPRV,EL,4.53,4,7,-3,8,13,-94.17,-7385,2.8 hour,10 min,2 min,89.44,17990,514.0,19073606,J Biol Chem. 2009 Feb 20;284(8):4914-20.,"Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.",Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,10.1074/jbc.M807169200,,Anti-HIV
DRAVPe00247,YTSLIHSLIEEKQNQQEKNEQELLELDKWASLWNWF,36,T-20S[138K],Synthetic construct(derived from Enfuvirtide),No entry found,,HIV,Retroviridae,MAGI assay,[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=708±145 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50>1000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00247,DRAVPe00247.cif,Linear,Free,Free,,L,membrane,"The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion.",4491.98,C205H305N51O63,CGMPRV,EL,4.54,4,7,-3,8,13,-96.11,-7474,2.8 hour,10 min,2 min,89.44,17990,514.0,19073606,J Biol Chem. 2009 Feb 20;284(8):4914-20.,"Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.",Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,10.1074/jbc.M807169200,,Anti-HIV
DRAVPe00248,YTSLIHSLIEERQNQQEKNEQELLELDKWASLWNWF,36,T-20S[138R],Synthetic construct(derived from Enfuvirtide),No entry found,,HIV,Retroviridae,MAGI assay,[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=362± 114 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50>1000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00248,DRAVPe00248.cif,Linear,Free,Free,,L,membrane,"The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion.",4519.99,C205H305N53O63,CGMPV,EL,4.54,4,7,-3,8,13,-97.78,-8411,2.8 hour,10 min,2 min,89.44,17990,514.0,19073606,J Biol Chem. 2009 Feb 20;284(8):4914-20.,"Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.",Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,10.1074/jbc.M807169200,,Anti-HIV
DRAVPe00249,WMEWDREINNYTSLIHSLIEEAQNQQEKNEQELL,34,C34S[138A],Synthetic construct(derived from C34),No entry found,,HIV,Retroviridae,MAGI assay,[Ref.19073606]HIV-1 NL4-3:inhibition of virus replication in HeLa cells(EC50=2.0± 0.4 nM);##HIV-1(NL4-3V38A):inhibition of virus replication in HeLa cells(EC50=1.7± 0.3 nM);##HIV-1(NL4-3N43D):inhibition of virus replication in HeLa cells(EC50=2.0 ±0.6 nM);##HIV-1(NL4-3N43D/S138A):inhibition of virus replication in HeLa cells(EC50=1.3 ±0.6 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00249,DRAVPe00249.cif,Linear,Free,Free,,L,membrane,"The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion.",4232.6,C184H280N50O63S,CFGPV,E,4.21,3,8,-5,8,10,-119.41,-9649,2.8 hour,3 min,2 min,83.24,12490,378.48,19073606,J Biol Chem. 2009 Feb 20;284(8):4914-20.,"Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.",Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,10.1074/jbc.M807169200,,Anti-HIV
DRAVPe00250,WMEWDREINNYTSLIHSLIEELQNQQEKNEQELL,34,C34S[138L],Synthetic construct(derived from C34),No entry found,,HIV,Retroviridae,MAGI assay,[Ref.19073606]HIV-1 NL4-3:inhibition of virus replication in HeLa cells(EC50=1.5± 0.4 nM);##HIV-1(NL4-3V38A):inhibition of virus replication in HeLa cells(EC50=1.2± 0.6 nM);##HIV-1(NL4-3N43D):inhibition of virus replication in HeLa cells(EC50=0.5 ±0.2 nM);##HIV-1(NL4-3N43D/S138A):inhibition of virus replication in HeLa cells(EC50=0.4±0.2 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00250,DRAVPe00250.cif,Linear,Free,Free,,L,membrane,"The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion.",4274.68,C187H286N50O63S,ACFGPV,E,4.21,3,8,-5,8,10,-113.53,-9338,2.8 hour,3 min,2 min,91.76,12490,378.48,19073606,J Biol Chem. 2009 Feb 20;284(8):4914-20.,"Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.",Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,10.1074/jbc.M807169200,,Anti-HIV
DRAVPe00251,WMEWDREINNYTSLIHSLIEETQNQQEKNEQELL,34,C34S[138T],Synthetic construct(derived from C34),No entry found,,HIV,Retroviridae,MAGI assay,[Ref.19073606]HIV-1 NL4-3:inhibition of virus replication in HeLa cells(EC50=2.6± 0.2 nM);##HIV-1(NL4-3V38A):inhibition of virus replication in HeLa cells(EC50=4.8± 1.3 nM);##HIV-1(NL4-3N43D):inhibition of virus replication in HeLa cells(EC50=32 ± 5.5 nM);##HIV-1(NL4-3N43D/S138A):inhibition of virus replication in HeLa cells(EC50=24 ±6.6nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00251,DRAVPe00251.cif,Linear,Free,Free,,L,membrane,"The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion.",4262.63,C185H282N50O64S,ACFGPV,E,4.21,3,8,-5,9,9,-126.76,-10087,2.8 hour,3 min,2 min,80.29,12490,378.48,19073606,J Biol Chem. 2009 Feb 20;284(8):4914-20.,"Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.",Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,10.1074/jbc.M807169200,,Anti-HIV
DRAVPe00252,WMEWDREINNYTSLIHSLIEEWQNQQEKNEQELL,34,C34S[138W],Synthetic construct(derived from C34),No entry found,,HIV,Retroviridae,MAGI assay,[Ref.19073606]HIV-1 NL4-3:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1(NL4-3V38A):inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1(NL4-3N43D):inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1(NL4-3N43D/S138A):inhibition of virus replication in HeLa cells(EC50>1000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00252,DRAVPe00252.cif,Linear,Free,Free,,L,membrane,"The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion.",4347.74,C192H285N51O63S,ACFGPV,E,4.21,3,8,-5,8,10,-127.35,-9597,2.8 hour,3 min,2 min,80.29,17990,545.15,19073606,J Biol Chem. 2009 Feb 20;284(8):4914-20.,"Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.",Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,10.1074/jbc.M807169200,,Anti-HIV
DRAVPe00253,WMEWDREINNYTSLIHSLIEEPQNQQEKNEQELL,34,C34S[138P],Synthetic construct(derived from C34),No entry found,,HIV,Retroviridae,MAGI assay,[Ref.19073606]HIV-1 NL4-3:inhibition of virus replication in HeLa cells(EC50=46±11 nM);##HIV-1(NL4-3V38A):inhibition of virus replication in HeLa cells(EC50=436± 125 nM);##HIV-1(NL4-3N43D):inhibition of virus replication in HeLa cells(EC50=250 ± 80 nM);##HIV-1(NL4-3N43D/S138A):inhibition of virus replication in HeLa cells(EC50=176±50 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00253,DRAVPe00253.cif,Linear,Free,Free,,L,membrane,"The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion.",4258.64,C186H282N50O63S,ACFGV,E,4.21,3,8,-5,8,9,-129.41,-9830,2.8 hour,3 min,2 min,80.29,12490,378.48,19073606,J Biol Chem. 2009 Feb 20;284(8):4914-20.,"Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.",Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,10.1074/jbc.M807169200,,Anti-HIV
DRAVPe00254,WQEWEQKITALLEQAQIQQEKNEYELQKLDKWASLWEWF,39,1249,Synthetic construct,No entry found,,HIV,Retroviridae,MAGI/cMAGI infectivity assay,[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.003 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.013 μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.022 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.363 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=8.140 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00254,DRAVPe00254.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.",4995.58,C233H338N56O67,CGHMPRV,EQ,4.43,4,8,-4,4,16,-109.49,-7562,2.8 hour,3 min,2 min,77.69,28990,762.89,17640899,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. ,"Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.","Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.",10.1073/pnas.0701478104,DRAVPa0873,Anti-HIV
DRAVPe00255,MTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELL,36,651,Synthetic construct,No entry found,,HIV,Retroviridae,MAGI/cMAGI infectivity assay,[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.008 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.033μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.060 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.151 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=7.599 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00255,DRAVPe00255.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.",4480.9,C193H296N52O67S2,ACFGPV,E,4.21,3,8,-5,10,9,-116.67,-10192,30 hour,>20 hour,>10 hour,75.83,12490,356.86,17640899,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. ,"Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.","Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.",10.1073/pnas.0701478104,DRAVPa0971,Anti-HIV
DRAVPe00256,MTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLEL,38,2410,Synthetic construct,No entry found,,HIV,Retroviridae,MAGI/cMAGI infectivity assay,[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.008 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.032μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.039 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.137 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=4.975 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00256,DRAVPe00256.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.",4723.18,C204H314N54O71S2,ACFGPV,E,4.14,3,9,-6,10,10,-109.74,-10381,30 hour,>20 hour,>10 hour,82.11,12490,337.57,17640899,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. ,"Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.","Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.",10.1073/pnas.0701478104,,Anti-HIV
DRAVPe00257,TTWEEWDREINEYTSRIESLIRESQEQQEKNEQELREL,38,2429,Synthetic construct,No entry found,,HIV,Retroviridae,MAGI/cMAGI infectivity assay,[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.012 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.021μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.056 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.037 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.167 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00257,DRAVPe00257.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.",4826.14,C205H319N59O76,ACFGHMPV,E,4.29,5,12,-7,9,8,-177.89,-16817,7.2 hour,>20 hour,>10 hour,61.58,12490,337.57,17640899,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. ,"Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.","Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.",10.1073/pnas.0701478104,,Anti-HIV
DRAVPe00258,MTWMAWDRAIANYAALIHALIEAAQNQQEKNEAALLEL,38,2638,Synthetic construct,No entry found,,HIV,Retroviridae,MAGI/cMAGI infectivity assay,[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.061 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.079μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.079 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.120 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.250 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00258,DRAVPe00258.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.",4312.93,C192H300N52O57S2,CFGPSV,A,4.57,3,5,-2,5,20,1.05,-3352,30 hour,>20 hour,>10 hour,108.42,12490,337.57,17640899,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. ,"Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.","Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.",10.1073/pnas.0701478104,,Anti-HIV
DRAVPe00259,TTWEAWDRAIAEYAARIEALIRASQEQQEKNEAELREL,38,290676,Synthetic construct,No entry found,,HIV,Retroviridae,MAGI/cMAGI infectivity assay,[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.006 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.013μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.022 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.072 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=1.314 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00259,DRAVPe00259.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.",4489.93,C195H307N57O65,CFGHMPV,AE,4.52,5,9,-4,5,16,-87.89,-11171,7.2 hour,>20 hour,>10 hour,82.63,12490,337.57,17640899,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. ,"Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.","Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.",10.1073/pnas.0701478104,,Anti-HIV
DRAVPe00260,MTWEAWDRAIAEYAARIEALIRAAQEQQEKNEAALREL,38,2544,Synthetic construct,No entry found,,HIV,Retroviridae,MAGI/cMAGI infectivity assay,[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.007 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.026μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.033 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.014 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.021 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00260,DRAVPe00260.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.",4445.98,C194H307N57O61S,CFGHPSV,A,4.64,5,8,-3,3,18,-60.26,-9296,30 hour,>20 hour,>10 hour,87.89,12490,337.57,17640899,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. ,"Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.","Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.",10.1073/pnas.0701478104,,Anti-HIV
DRAVPe00261,TTWEAWDRAIAEYAARIEALIRAAQEQQEKNEAILREL,38,267209,Synthetic construct,No entry found,,HIV,Retroviridae,MAGI/cMAGI infectivity assay,[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.007 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.021μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.034 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.024 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.039 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00261,DRAVPe00261.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.",4457.97,C196H311N57O62,CFGHMPSV,A,4.64,5,8,-3,4,18,-60.0,-9477,7.2 hour,>20 hour,>10 hour,95.53,12490,337.57,17640899,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. ,"Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.","Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.",10.1073/pnas.0701478104,,Anti-HIV
DRAVPe00262,TTWEAWDRAIAEYAARIEALIRALQEQQEKNEAALREL,38,267221,Synthetic construct,No entry found,,HIV,Retroviridae,MAGI/cMAGI infectivity assay,[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.011 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.035μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.028 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.035 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.050 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00262,DRAVPe00262.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.",4457.97,C196H311N57O62,CFGHMPSV,A,4.64,5,8,-3,4,18,-61.84,-9477,7.2 hour,>20 hour,>10 hour,95.53,12490,337.57,17640899,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. ,"Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.","Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.",10.1073/pnas.0701478104,DRAVPa1316,Anti-HIV
DRAVPe00263,TTWEAWDRAIAEYAARIEALIRAAQELQEKNEAALREL,38,267226,Synthetic construct,No entry found,,HIV,Retroviridae,MAGI/cMAGI infectivity assay,[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.007 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.021μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.035 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.030 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.020 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00263,DRAVPe00263.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.",4400.92,C194H308N56O61,CFGHMPSV,A,4.64,5,8,-3,4,19,-47.89,-8742,7.2 hour,>20 hour,>10 hour,98.16,12490,337.57,17640899,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. ,"Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.","Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.",10.1073/pnas.0701478104,,Anti-HIV
DRAVPe00264,TTWEAWDRAIAEYAARIEALIRALQEQQEKNEAILREL,38,267225,Synthetic construct,No entry found,,HIV,Retroviridae,MAGI/cMAGI infectivity assay,[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.019 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.043μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.079 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.038 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.196 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00264,DRAVPe00264.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.",4500.05,C199H317N57O62,CFGHMPSV,A,4.64,5,8,-3,4,18,-54.74,-9166,7.2 hour,>20 hour,>10 hour,103.16,12490,337.57,17640899,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. ,"Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.","Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.",10.1073/pnas.0701478104,,Anti-HIV
DRAVPe00265,TTWEAWDRAIAEYAARIEALIRAAQEQQEKLEAALREL,38,267227,Synthetic construct,No entry found,,HIV,Retroviridae,MAGI/cMAGI infectivity assay,[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.012 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.045μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.028 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.025 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.044 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00265,DRAVPe00265.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.",4414.94,C195H310N56O61,CFGHMNPSV,A,4.64,5,8,-3,3,19,-47.89,-8632,7.2 hour,>20 hour,>10 hour,98.16,12490,337.57,17640899,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. ,"Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.","Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.",10.1073/pnas.0701478104,DRAVPa1317,Anti-HIV
DRAVPe00266,TTWEAWDRAIAEYAARIEALIRAAQEQQEKLEAVLREL,38,291022,Synthetic construct,No entry found,,HIV,Retroviridae,MAGI/cMAGI infectivity assay,[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.022 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.049μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.093 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.046 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.242 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00266,DRAVPe00266.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.",4443.0,C197H314N56O61,CFGHMNPS,A,4.64,5,8,-3,3,19,-41.58,-8409,7.2 hour,>20 hour,>10 hour,103.16,12490,337.57,17640899,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. ,"Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.","Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.",10.1073/pnas.0701478104,,Anti-HIV
DRAVPe00267,TTWEAWDRAIAEYAARIEALIRALQELQEKNEAALREL,38,290822,Synthetic construct,No entry found,,HIV,Retroviridae,MAGI/cMAGI infectivity assay,[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.030 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.054μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.084 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.147 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.242 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00267,DRAVPe00267.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.",4443.0,C197H314N56O61,CFGHMPSV,A,4.64,5,8,-3,4,19,-42.63,-8431,7.2 hour,>20 hour,>10 hour,105.79,12490,337.57,17640899,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. ,"Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.","Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.",10.1073/pnas.0701478104,,Anti-HIV
DRAVPe00268,TTWEAWDRAIAEYAARIEALIRALQELQEKNEAILREL,38,290821,Synthetic construct,No entry found,,HIV,Retroviridae,MAGI/cMAGI infectivity assay,[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.065 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.118μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.154 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.192 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50>20 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00268,DRAVPe00268.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.",4485.08,C200H320N56O61,CFGHMPSV,A,4.64,5,8,-3,4,19,-35.53,-8120,7.2 hour,>20 hour,>10 hour,113.42,12490,337.57,17640899,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. ,"Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.","Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.",10.1073/pnas.0701478104,,Anti-HIV
DRAVPe00269,TTWEAWDRAIAEYAARIEALIRAAQELQEKLEAALREL,38,267228,Synthetic construct,No entry found,,HIV,Retroviridae,MAGI/cMAGI infectivity assay,[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.172 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.600μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.416 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.555 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.987 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00269,DRAVPe00269.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.",4399.97,C196H313N55O60,CFGHMNPSV,A,4.64,5,8,-3,3,20,-28.68,-7586,7.2 hour,>20 hour,>10 hour,108.42,12490,337.57,17640899,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. ,"Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.","Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.",10.1073/pnas.0701478104,,Anti-HIV
DRAVPe00270,TTWEAWDRAIAEYAARIEALIRALQELQEKLEAILREL,38,267229,Synthetic construct,No entry found,,HIV,Retroviridae,MAGI/cMAGI infectivity assay,[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=3.162 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50>20μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50>20 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50>20 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50>20 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00270,DRAVPe00270.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.",4484.13,C202H325N55O60,CFGHMNPSV,A,4.64,5,8,-3,3,20,-16.32,-6964,7.2 hour,>20 hour,>10 hour,123.68,12490,337.57,17640899,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. ,"Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.","Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.",10.1073/pnas.0701478104,,Anti-HIV
DRAVPe00271,AEAMSQVTN,9,p2(gag) peptide[Δ10-14],Synthetic construct,No entry found,,HIV,Retroviridae,Protease inhibition assay,[Ref.15113844]HIV:inhibition of protease activity in CEM/LAV-1 cells(IC50=5 μM).,,,DRAVPe00271,DRAVPe00271.cif,Linear,Free,Free,,L,autolysis,The peptide blocks the autolysis of HIV-1 virions for the conservation of viral species.,950.03,C37H63N11O16S,CDFGHIKLPRWY,A,4.0,0,1,-1,3,3,-25.56,-1495,4.4 hour,>20 hour,>10 hour,54.44,0,0.0,15113844,J Biochem. 2004 Mar;135(3):447-53. ,"Misumi S, Morikawa Y, Tomonaga M, Ohkuma K, Takamune N, Shoji S.",Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide. ,10.1093/jb/mvh052,,Anti-HIV
DRAVPe00272,AAAMSQVTN,9,"p2(gag) peptide[Δ10-14,E2A]",Synthetic construct,No entry found,,HIV,Retroviridae,Protease inhibition assay,[Ref.15113844]HIV:inhibition of protease activity in CEM/LAV-1 cells(IC50=100 μM).,,,DRAVPe00272,DRAVPe00272.cif,Linear,Free,Free,,L,autolysis,The peptide blocks the autolysis of HIV-1 virions for the conservation of viral species.,891.99,C35H61N11O14S,CDEFGHIKLPRWY,A,5.57,0,0,0,3,4,33.33,-633,4.4 hour,>20 hour,>10 hour,65.56,0,0.0,15113844,J Biochem. 2004 Mar;135(3):447-53. ,"Misumi S, Morikawa Y, Tomonaga M, Ohkuma K, Takamune N, Shoji S.",Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide. ,10.1093/jb/mvh052,,Anti-HIV
DRAVPe00273,AEAMAQVTN,9,"p2(gag) peptide[Δ10-14,S5A]",Synthetic construct,No entry found,,HIV,Retroviridae,Protease inhibition assay,[Ref.15113844]HIV:inhibition of protease activity in CEM/LAV-1 cells(IC50=124 μM).,,,DRAVPe00273,DRAVPe00273.cif,Linear,Free,Free,,L,autolysis,The peptide blocks the autolysis of HIV-1 virions for the conservation of viral species.,934.03,C37H63N11O15S,CDFGHIKLPRSWY,A,4.0,0,1,-1,2,4,3.33,-974,4.4 hour,>20 hour,>10 hour,65.56,0,0.0,15113844,J Biochem. 2004 Mar;135(3):447-53. ,"Misumi S, Morikawa Y, Tomonaga M, Ohkuma K, Takamune N, Shoji S.",Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide. ,10.1093/jb/mvh052,,Anti-HIV
DRAVPe00274,AEAMSQVTNTATIM,14,p2(gag) peptide,Synthetic construct,No entry found,,HIV,Retroviridae,Protease inhibition assay,[Ref.15113844]HIV:inhibition of protease activity in CEM/LAV-1 cells(IC50=10 μM).,,,DRAVPe00274,DRAVPe00274.cif,Linear,Free,Free,,L,autolysis,The peptide blocks the autolysis of HIV-1 virions for the conservation of viral species.,1467.67,C59H102N16O23S2,CDFGHKLPRWY,AT,4.0,0,1,-1,5,5,32.14,-1101,4.4 hour,>20 hour,>10 hour,70.0,0,0.0,15113844,J Biochem. 2004 Mar;135(3):447-53. ,"Misumi S, Morikawa Y, Tomonaga M, Ohkuma K, Takamune N, Shoji S.",Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide. ,10.1093/jb/mvh052,,Anti-HIV
DRAVPe00275,AEAASQVTNTATIM,14,p2(gag) peptide[M4A],Synthetic construct,No entry found,,HIV,Retroviridae,Protease inhibition assay,[Ref.15113844]HIV:inhibition of protease activity in CEM/LAV-1 cells(IC50=142 μM).,,,DRAVPe00275,DRAVPe00275.cif,Linear,Free,Free,,L,autolysis,The peptide blocks the autolysis of HIV-1 virions for the conservation of viral species.,1407.56,C57H98N16O23S,CDFGHKLPRWY,A,4.0,0,1,-1,5,6,31.43,-1155,4.4 hour,>20 hour,>10 hour,77.14,0,0.0,15113844,J Biochem. 2004 Mar;135(3):447-53. ,"Misumi S, Morikawa Y, Tomonaga M, Ohkuma K, Takamune N, Shoji S.",Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide. ,10.1093/jb/mvh052,,Anti-HIV
DRAVPe00276,AEASQVTNTATIM,13,p2(gag) peptide[ΔM4],Synthetic construct,No entry found,,HIV,Retroviridae,Protease inhibition assay,[Ref.15113844]HIV:inhibition of protease activity in CEM/LAV-1 cells(IC50=126 μM).,,,DRAVPe00276,DRAVPe00276.cif,Linear,Free,Free,,L,autolysis,The peptide blocks the autolysis of HIV-1 virions for the conservation of viral species.,1336.48,C54H93N15O22S,CDFGHKLPRWY,AT,4.0,0,1,-1,5,5,20.0,-1336,4.4 hour,>20 hour,>10 hour,75.38,0,0.0,15113844,J Biochem. 2004 Mar;135(3):447-53. ,"Misumi S, Morikawa Y, Tomonaga M, Ohkuma K, Takamune N, Shoji S.",Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide. ,10.1093/jb/mvh052,,Anti-HIV
DRAVPe00277,AEAMSQVANTATIM,14,p2(gag) peptide[T8A],Synthetic construct,No entry found,,HIV,Retroviridae,Protease inhibition assay,[Ref.15113844]HIV:inhibition of protease activity in CEM/LAV-1 cells(IC50=110 μM).,,,DRAVPe00277,DRAVPe00277.cif,Linear,Free,Free,,L,autolysis,The peptide blocks the autolysis of HIV-1 virions for the conservation of viral species.,1437.65,C58H100N16O22S2,CDFGHKLPRWY,A,4.0,0,1,-1,4,6,50.0,-663,4.4 hour,>20 hour,>10 hour,77.14,0,0.0,15113844,J Biochem. 2004 Mar;135(3):447-53. ,"Misumi S, Morikawa Y, Tomonaga M, Ohkuma K, Takamune N, Shoji S.",Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide. ,10.1093/jb/mvh052,,Anti-HIV
DRAVPe00278,GIPCGESCVWIPCISAALGCSCKNKVCYRN,30,Circulin-A (CIRA; Plant defensin),Chassalia parviflora ,P56871,1BH4,HIV,Retroviridae,,[Ref.18008336]HIV-1:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=40-260 nM).,[Ref.10430870] EC50 = 1020 μM against blood type A human erythrocytes.,[Ref.18008336]CEM-SS cells:IC50=500 nM.,DRAVPe00278,DRAVPe00278.cif,Cyclic,Cyclization (N termini to C termini),Cyclization (C termini to N termini),"Disulfide bonds between Cys4 and Cys20, Cys8 and Cys22, Cys13 and Cys27.",L,Not found,No machanism information found in the reference(s) presented in this entry,3175.78,C134H216N38O39S6,DFHMQT,C,8.33,3,1,2,15,9,41.67,-1224,30 hour,>20 hour,>10 hour,78.0,7365,253.97,18008336##10430870,Biopolymers. 2008;90(1):51-60.##Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):8913-8. ,"Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.##Tam JP, Lu YA, Yang JL, Chiu KW.",Cyclotides as natural anti-HIV agents.##An unusual structural motif of antimicrobial peptides containing end-to-end macrocycle and cystine-knot disulfides.,10.1002/bip.20886##10.1073/pnas.96.16.8913,,Anti-HIV
DRAVPe00279,GVIPCGESCVFIPCISTLLGCSCKNKVCYRN,31,Circulin-B (CIRB; Plant defensin),Chassalia parviflora ,P56879,2ERI,HIV,Retroviridae,,[Ref.18008336]HIV-1:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=40-260 nM).,[Ref.10430870] EC50 = 550 μM against blood type A human erythrocytes.,[Ref.10430870] It caused 50% cell growth inhibition of mouse fibroblasts at 820 μM.##[Ref.18008336]CEM-SS cells:IC50=500 nM.,DRAVPe00279,DRAVPe00279.cif,Cyclic,Cyclization (N termini to C termini),Cyclization (C termini to N termini),"Disulfide bonds between Cys5 and Cys19, Cys9 and Cys21, Cys14 and Cys27.",L,Not found,No machanism information found in the reference(s) presented in this entry,3307.98,C141H232N38O41S6,ADHMQW,C,8.33,3,1,2,16,9,64.19,-882,30 hour,>20 hour,>10 hour,90.97,1865,62.17,18008336##10430870,Biopolymers. 2008;90(1):51-60.##Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):8913-8. ,"Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.##Tam JP, Lu YA, Yang JL, Chiu KW.",Cyclotides as natural anti-HIV agents.##An unusual structural motif of antimicrobial peptides containing end-to-end macrocycle and cystine-knot disulfides.,10.1002/bip.20886##10.1073/pnas.96.16.8913,,Anti-HIV
DRAVPe00280,GIPCGESCVFIPCITSVAGCSCKSKVCYRN,30,Circulin-C (CIRC; Plant defensin),Chassalia parviflora ,P84641,,HIV,Retroviridae,,[Ref.18008336]HIV-1:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=50-275 nM).##[Ref.10691702]HIV-1(HIV-1 IIIB):inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=73 nM);##HIV-1(HIV-1 RF):inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=165 nM);##HIV-1(HIV-1 214):inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=213 nM);##HIV-1(HIV-1 205):inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=155 nM);##HIV-1(HIV-1 G):inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=111 nM);##HIV-1(HIV-1 SK1):inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=51 nM);##HIV-1(HIV-1 N119):inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=241 nM);##HIV-1(HIV-1 A17):inhibition the cytopathic effects of HIV-1 infection in MT-2 cells(EC50=247 nM);##HIV-1(HIV-1G9106):inhibition the cytopathic effects of HIV-1 infection in MT-2 cells(EC50=67 nM);##HIV-1(HIV-1 H1122):inhibition the cytopathic effects of HIV-1 infection in MT-2 cells(EC50=48 nM);##HIV-1(HIV-1 IIIB):inhibition the cytopathic effects of HIV-1 infection in MT-2 cells(EC50=200 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00280,DRAVPe00280.cif,Cyclic,Cyclization (N termini to C termini),Cyclization (N termini to C termini),"Disulfide bonds between Cys4 and Cys20, Cys8 and Cys22,Cys13 and Cys27.",L,Not found,No machanism information found in the reference(s) presented in this entry,3125.72,C131H214N36O40S6,DHLMQW,C,8.33,3,1,2,16,8,56.0,-1361,30 hour,>20 hour,>10 hour,71.33,1865,64.31,18008336##10691702,Biopolymers. 2008;90(1):51-60.##J Nat Prod. 2000 Feb;63(2):176-8.,"Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.##Gustafson KR, Walton LK, Sowder RC Jr, Johnson DG, Pannell LK, Cardellina JH Jr, Boyd MR.",Cyclotides as natural anti-HIV agents.##New circulin macrocyclic polypeptides from Chassalia parvifolia.,10.1002/bip.20886##10.1021/np990432r,,Anti-HIV
DRAVPe00281,KIPCGESCVWIPCVTSIFNCKCENKVCYHD,30,Circulin-D (CIRD; Plant defensin),Chassalia parviflora ,P84642,,HIV,Retroviridae,"XTT [2,3-bis-(2-methoxy-4-nitro-5-sulphophenyl)-2H-tetrazolium-5-carboxanilide]",[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=50-275 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00281,DRAVPe00281.cif,Cyclic,Cyclization (N termini to C termini),Cyclization (N termini to C termini),"Disulfide bonds between Cys4 and Cys20, Cys8 and Cys22,Cys13 and Cys27.",L,Not found,No machanism information found in the reference(s) presented in this entry,3420.03,C148H228N38O43S6,ALMQR,C,6.71,4,3,1,13,8,11.33,-2563,1.3 hour,3 min,2 min,68.0,7365,253.97,18008336,Biopolymers. 2008;90(1):51-60.,"Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.",Cyclotides as natural anti-HIV agents.,10.1002/bip.20886,,Anti-HIV
DRAVPe00282,KIPCGESCVWIPCLTSVFNCKCENKVCYHD,30,Circulin-E (CIRE; Plant defensin),Chassalia parviflora ,P84643,,HIV,Retroviridae,,[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=50-275 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00282,DRAVPe00282.cif,Cyclic,Cyclization (N termini to C termini),Cyclization (N termini to C termini),"Disulfide bonds between Cys4 and Cys20, Cys8 and Cys22,Cys13 and Cys27.",L,Not found,No machanism information found in the reference(s) presented in this entry,3420.03,C148H228N38O43S6,AMQR,C,6.71,4,3,1,13,8,9.0,-2563,1.3 hour,3 min,2 min,68.0,7365,253.97,18008336,Biopolymers. 2008;90(1):51-60.,"Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.",Cyclotides as natural anti-HIV agents.,10.1002/bip.20886,,Anti-HIV
DRAVPe00283,AIPCGESCVWIPCISAAIGCSCKNKVCYR,29,Circulin-F (CIRF; Plant defensin),Chassalia parviflora,P84644,,HIV,Retroviridae,,[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=50-275 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00283,DRAVPe00283.cif,Cyclic,Cyclization (N termini to C termini),Cyclization (N termini to C termini),"Disulfide bonds between Cys4 and Cys20, Cys8 and Cys22,Cys13 and Cys27.",L,Not found,No machanism information found in the reference(s) presented in this entry,3075.7,C131H212N36O37S6,DFHLMQT,C,8.34,3,1,2,13,10,65.17,-473,4.4 hour,>20 hour,>10 hour,84.14,7365,263.04,18008336,Biopolymers. 2008;90(1):51-60.,"Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.",Cyclotides as natural anti-HIV agents.,10.1002/bip.20886,,Anti-HIV
DRAVPe00284,GVIPCGESCVFIPCISAAIGCSCKNKVCYRN,31,Cycloviolin-A (Plant defensin),Leonia cymosa (Sacha uba),P84637,,HIV,Retroviridae,,[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=130 nM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18008336]CEM-SS cells:IC50=560 nM.,DRAVPe00284,DRAVPe00284.cif,Cyclic,Cyclization (N termini to C termini),Cyclization (N termini to C termini),"Disulfide bonds between Cys5 and Cys21, Cys9 and Cys23,Cys14 and Cys28.",L,Not found,No machanism information found in the reference(s) presented in this entry,3235.88,C137H224N38O40S6,DHLMQTW,C,8.33,3,1,2,15,10,68.06,-755,30 hour,>20 hour,>10 hour,84.84,1865,62.17,18008336,Biopolymers. 2008;90(1):51-60.,"Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.",Cyclotides as natural anti-HIV agents.,10.1002/bip.20886,,Anti-HIV
DRAVPe00285,GTACGESCYVLPCFTVGCTCTSSQCFKN,28,Cycloviolin-B (Plant defensin),Leonia cymosa (Sacha uba),P84638,,HIV,Retroviridae,,[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=130 nM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18008336]CEM-SS cells:IC50=560 nM.,DRAVPe00285,DRAVPe00285.cif,Cyclic,Cyclization (N termini to C termini),Cyclization (N termini to C termini),"Disulfide bonds between Cys4 and Cys18, Cys8 and Cys20,Cys13 and Cys25.",L,Not found,No machanism information found in the reference(s) presented in this entry,2910.33,C120H185N31O41S6,DHIMRW,C,5.96,1,1,0,18,6,38.93,-1389,30 hour,>20 hour,>10 hour,38.21,1865,69.07,18008336,Biopolymers. 2008;90(1):51-60.,"Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.",Cyclotides as natural anti-HIV agents.,10.1002/bip.20886,,Anti-HIV
DRAVPe00286,GIPCGESCVFIPCLTTVAGCSCKNKVCYRN,30,Cycloviolin-C (Plant defensin),Leonia cymosa (Sacha uba),P84639,,HIV,Retroviridae,,[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=130 nM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18008336]CEM-SS cells:IC50=560 nM.,DRAVPe00286,DRAVPe00286.cif,Cyclic,Cyclization (N termini to C termini),Cyclization (N termini to C termini),"Disulfide bonds between Cys4 and Cys20, Cys8 and Cys22,Cys13 and Cys27.",L,Not found,No machanism information found in the reference(s) presented in this entry,3166.77,C133H217N37O40S6,DHMQW,C,8.33,3,1,2,16,8,45.0,-1602,30 hour,>20 hour,>10 hour,71.33,1865,64.31,18008336,Biopolymers. 2008;90(1):51-60.,"Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.",Cyclotides as natural anti-HIV agents.,10.1002/bip.20886,,Anti-HIV
DRAVPe00287,GFPCGESCVFIPCISAAIGCSCKNKVCYRN,30,Cycloviolin-D (Plant defensin),Leonia cymosa (Sacha uba),P84640,,HIV,Retroviridae,,[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=130 nM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18008336]CEM-SS cells:IC50=560 nM.,DRAVPe00287,DRAVPe00287.cif,Cyclic,Cyclization (N termini to C termini),Cyclization (N termini to C termini),"Disulfide bonds between Cys4 and Cys20, Cys8 and Cys22,Cys13 and Cys27.",L,Not found,No machanism information found in the reference(s) presented in this entry,3170.76,C135H213N37O39S6,DHLMQTW,C,8.33,3,1,2,15,9,50.67,-1353,30 hour,>20 hour,>10 hour,65.0,1865,64.31,18008336,Biopolymers. 2008;90(1):51-60.,"Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.",Cyclotides as natural anti-HIV agents.,10.1002/bip.20886,,Anti-HIV
DRAVPe00288,GIPCGESCVWIPCISAAIGCSCKSKVCYRN,30,Cycloviolacin-O13 (Cyclotide c3; Plant defensin),Viola odorata (Sweet violet),Q5USN8,,HIV,Retroviridae,,[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=320 nM).,[Ref.16872274] It has 50% hemolytic activity at 1.0 μM and 75% hemolytic activity at 1.5 μM against human type A red blood cells,[Ref.18008336]CEM-SS cells:IC50=6400 nM.,DRAVPe00288,DRAVPe00288.cif,Cyclic,Cyclization (N termini to C termini),Cyclization (N termini to C termini),Disulfide bonds between Cys4 and Cys20; Cys8 and Cys22; Cys13 and Cys27.,L,Not found,No machanism information found in the reference(s) presented in this entry,3148.75,C133H215N37O39S6,DFHLMQT,C,8.33,3,1,2,15,9,53.0,-900,30 hour,>20 hour,>10 hour,78.0,7365,253.97,18008336##16872274,Biopolymers. 2008;90(1):51-60.##Biochem J. 2006 Nov 15;400(1):1-12.,"Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.##Ireland DC, Colgrave ML, Craik DJ.","Cyclotides as natural anti-HIV agents.##A novel suite of cyclotides from Viola odorata: sequence variation and the implications for structure, function and stability.",10.1002/bip.20886##10.1042/BJ20060627,,Anti-HIV
DRAVPe00289,GSIPACGESCFKGKCYTPGCSCSKYPLCAKN,31,Cycloviolacin-O14 (Plant defensin),Viola odorata (Sweet violet),P85177,2GJ0,HIV,Retroviridae,,[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=440 nM).,[Ref:16872274] It has 3% hemolytic activity at 1.0 μM and 13% hemolytic activity at 1.5 μM against human type A red blood cells,[Ref.18008336]CEM-SS cells:IC50=4800 nM.,DRAVPe00289,DRAVPe00289.cif,Cyclic,Cyclization (N termini to C termini),Cyclization (N termini to C termini),Disulfide bonds between Cys6 and Cys20; Cys10 and Cys22; Cys15 and Cys27.,L,Not found,No machanism information found in the reference(s) presented in this entry,3203.74,C135H212N36O42S6,DHMQRVW,C,8.64,4,1,3,18,5,-18.71,-2422,30 hour,>20 hour,>10 hour,31.61,3355,111.83,18008336##16872274,Biopolymers. 2008;90(1):51-60.##Biochem J. 2006 Nov 15;400(1):1-12.,"Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.##Ireland DC, Colgrave ML, Craik DJ.","Cyclotides as natural anti-HIV agents.##A novel suite of cyclotides from Viola odorata: sequence variation and the implications for structure, function and stability.",10.1002/bip.20886##10.1042/BJ20060627,,Anti-HIV
DRAVPe00290,GLPTCGETCFGGTCNTPGCTCDPWPVCTHN,30,Cycloviolacin-O24 (Plant defensin),Viola odorata (Sweet violet),P84637,,HIV,Retroviridae,,[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=308 nM).,[Ref:16872274] It has 75% hemolytic activity at 25.0 μM against human type A red blood cells.,[Ref.18008336]CEM-SS cells:IC50=6170 nM.,DRAVPe00290,DRAVPe00290.cif,Cyclic,Cyclization (N termini to C termini),Cyclization (N termini to C termini),Disulfide bonds between Cys5 and Cys19; Cys9 and Cys21; Cys14 and Cys27.,L,Not found,No machanism information found in the reference(s) presented in this entry,3072.44,C126H187N35O43S6,AIKMQRSY,CT,4.35,1,2,-1,19,4,-16.33,-2224,30 hour,>20 hour,>10 hour,22.67,5875,202.59,18008336##16872274,Biopolymers. 2008;90(1):51-60.##Biochem J. 2006 Nov 15;400(1):1-12.,"Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.##Ireland DC, Colgrave ML, Craik DJ.","Cyclotides as natural anti-HIV agents.##A novel suite of cyclotides from Viola odorata: sequence variation and the implications for structure, function and stability.",10.1002/bip.20886##10.1042/BJ20060627,,Anti-HIV
DRAVPe00291,GGTIFDCGETCFLGTCYTPGCSCGNYGFCYGTN,33,Cycloviolacin-Y1 (Plants),Viola yedoensis (Chinese herb),No entry found,,HIV,Retroviridae,,"[Ref.18081258] Anti-HIV activity:EC50=1.2μM, IC50>4.5μM. ##NOTE:EC50 refers to the values for HIV-infected cell cultures, IC50 refers to the values for uninfected cell cultures.##[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=1210 nM).",[Ref.18081258] It has hemolytic activity.,[Ref.18008336]CEM-SS cells:IC50>4470 nM.,DRAVPe00291,DRAVPe00291.cif,Cyclic,Cyclization (N termini to C termini),Cyclization (N termini to C termini),Disulfide bonds between Cys7 and Cys21; Cys11 and Cys23; Cys16 and Cys29.,L,Not found,No machanism information found in the reference(s) presented in this entry,3412.77,C145H203N35O49S6,AHKMQRVW,G,3.67,0,2,-2,25,5,14.24,-1150,30 hour,>20 hour,>10 hour,23.64,4845,151.41,18008336##18081258,Biopolymers. 2008;90(1):51-60.## J Nat Prod. 2008 Jan;71(1):47-52.,"Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.##Wang CK, Colgrave ML, Gustafson KR, Ireland DC, Goransson U, Craik DJ.",Cyclotides as natural anti-HIV agents.##Anti-HIV cyclotides from the Chinese medicinal herb Viola yedoensis.,10.1002/bip.20886##10.1021/np070393g,,Anti-HIV
DRAVPe00292,GDPTFCGETCRVIPVCTYSAALGCTCDDRSDGLCKRN,37,Palicourein (Cyclotides; Plants),Palicourea condensata (Cappel),P84645,1R1F,HIV,Retroviridae,,[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=100 nM).,No hemolysis information or data found in the reference(s) presented in this entry,"[Ref.11430013] Cytotoxicity: human T-lymphoblastoid cell line (CEM-SS)(EC50=0.10 Μm, IC50=1.5 μM) . ##[Ref.18008336]CEM-SS cells:IC50=1500 nM.",DRAVPe00292,DRAVPe00292.cif,Cyclic,Cyclization (N termini to C termini),Cyclization (N termini to C termini),"Disulfide bonds between Cys1 and Cys19; Cys5 and Cys21; Cys11 and Cys28;hydrogen bonds between the oxygen atoms of the Glu3 carboxyl group and the backbone amides of residues Thr12, Thr13, and Ser14, and the side chain of Ser14. ",L,Not found,No machanism information found in the reference(s) presented in this entry,3928.43,C159H256N48O56S6,HMQW,C,4.78,4,5,-1,18,8,-18.92,-7498,30 hour,>20 hour,>10 hour,52.7,1865,51.81,18008336,Biopolymers. 2008;90(1):51-60.,"Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.",Cyclotides as natural anti-HIV agents.,10.1002/bip.20886,,Anti-HIV
DRAVPe00293,GVPCGESCVFIPCITGVIGCSCSSNVCYLN,30,Cycloviolacin-Y4 (Plants),Viola yedoensis (Chinese herb),No entry found,,HIV,Retroviridae,,"[Ref.18618891]Effects: H. contortus( IC50=2.01μM, IC99=6.73μM) and T. colubriformis(IC50=2.27μM, IC99=5.26μM).##[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=120 nM).",[Ref:18081258] HD50=9.3 μM against human type A red blood cells.,[Ref.18008336]CEM-SS cells:IC50=1720 nM.,DRAVPe00293,DRAVPe00293.cif,Cyclic,Cyclization (N termini to C termini),Cyclization (N termini to C termini),Disulfide bonds between Cys4 and Cys20; Cys8 and Cys22; Cys13 and Cys27.,L,Not found,No machanism information found in the reference(s) presented in this entry,3025.55,C127H202N32O41S6,ADHKMQRW,C,4.0,0,1,-1,18,9,104.67,1386,30 hour,>20 hour,>10 hour,90.67,1865,64.31,18008336##18081258,Biopolymers. 2008;90(1):51-60.## J Nat Prod. 2008 Jan;71(1):47-52.,"Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.##Wang CK, Colgrave ML, Gustafson KR, Ireland DC, Goransson U, Craik DJ.",Cyclotides as natural anti-HIV agents.##Anti-HIV cyclotides from the Chinese medicinal herb Viola yedoensis.,10.1002/bip.20886##10.1021/np070393g,,Anti-HIV
DRAVPe00294,GIPCAESCVWIPCTVTALVGCSCSDKVCYN,30,Cycloviolacin-Y5 (Plants),Viola yedoensis (Chinese herb),No entry found,,HIV,Retroviridae,,"[Ref.18618891]Effects: H. contortus( IC50=2.28μM, IC99=22.24μM) and T. colubriformis(IC50=2.40μM, IC99=10.97μM).##[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=40 nM).",[Ref:18081258] HD50=8.7 μM against human type A red blood cells.,[Ref.18008336]CEM-SS cells:IC50=1760 nM.,DRAVPe00294,DRAVPe00294.cif,Cyclic,Cyclization (N termini to C termini),Cyclization (N termini to C termini),Disulfide bonds between Cys4 and Cys21; Cys8 and Cys23; Cys13 and Cys28.,L,Not found,No machanism information found in the reference(s) presented in this entry,3122.67,C132H209N33O42S6,FHMQR,C,4.37,1,2,-1,15,10,79.33,323,30 hour,>20 hour,>10 hour,84.33,7365,253.97,18008336##18081258,Biopolymers. 2008;90(1):51-60.## J Nat Prod. 2008 Jan;71(1):47-52.,"Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.##Wang CK, Colgrave ML, Gustafson KR, Ireland DC, Goransson U, Craik DJ.",Cyclotides as natural anti-HIV agents.##Anti-HIV cyclotides from the Chinese medicinal herb Viola yedoensis.,10.1002/bip.20886##10.1021/np070393g,,Anti-HIV
DRAVPe00295,SISCGESCAMISFCFTEVIGCSCKNKVCYLN,31,Leaf cyclotide 1 (Vhl-1; Plant defensin),Viola hederacea (Australian violet),P84522,1ZA8,HIV,Retroviridae,,[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=870 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00295,DRAVPe00295.cif,Cyclic,Cyclization (N termini to C termini),Cyclization (N termini to C termini),Disulfide bonds between Cys4 and Cys21; Cys8 and Cys23; Cys13 and Cys28.,L,Not found,No machanism information found in the reference(s) presented in this entry,3340.94,C140H223N35O45S7,DHPQRW,C,5.85,2,2,0,17,9,69.03,-1027,1.9 hour,>20 hour,>10 hour,72.26,1865,62.17,18008336,Biopolymers. 2008;90(1):51-60.,"Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.",Cyclotides as natural anti-HIV agents.,10.1002/bip.20886,,Anti-HIV
DRAVPe01960,CGESCAXISFCFTEVIGCSCKNKVCYLNSIS,31,"Leaf cyclotide, Vhl-1",Viola hederacea,P84522,1ZA8,HIV,Retroviridae,cytopathic effect assay,[Ref.15824119]HIV-1:inhibition of cytopathic effect(EC50=0.87 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Cyclic,No specific N-terminal,No specific C-terminal,"The 'X' at position 7 indicates Methionine sulfoxide. The N-terminal and C-terminal cyclized by a amide bond. Disulfide bonds between Cys1 and Cys18, Cys5 and Cys20, Cys11 and Cys25.",L,Not found,No mechanism information found in the reference(s).,3321.08,C135H212N34O43S6,DHMPQRW,C,6.1,2,2,0,17,9,62.9,-1262,1.2 hour,>20 hour,>10 hour,72.26,1865,62.17,15824119,J Biol Chem. 2005 Jun 10;280(23):22395-405.,"Chen B, Colgrave ML, Daly NL, Rosengren KJ, Gustafson KR, Craik DJ. ","Isolation and characterization of novel cyclotides from Viola hederaceae: solution structure and anti-HIV activity of vhl-1, a leaf-specific expressed cyclotide.",10.1074/jbc.M501737200,,Anti-HIV
DRAVPe00296,GLPVCGETCVGGTCNTPGCTCSWPVCTRN,29,Kalata-B1 (Plant defensin),Oldenlandia affinis ,P56254,2KHB##1NB1,HIV,Retroviridae,,[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=140 nM).,[Ref.12779323] HD50 = 300 μM against Human type A red blood cells.,[Ref.18008336]CEM-SS cells:IC50=3500 nM.,DRAVPe00296,DRAVPe00296.cif,Cyclic,Cyclization (N termini to C termini),Cyclization (C termini to N termini),"Disulfide bonds between Cys5 and Cys19, Cys9 and Cys21, Cys14 and Cys26.",L,Not found,No machanism information found in the reference(s) presented in this entry,2916.34,C117H187N35O40S6,ADFHIKMQY,C,5.96,1,1,0,19,5,15.17,-1951,30 hour,>20 hour,>10 hour,43.45,5875,209.82,18008336##12779323,Biopolymers. 2008;90(1):51-60.##Biochemistry. 2003 Jun 10;42(22):6688-95.,"Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.##Barry DG, Daly NL, Clark RJ, Sando L, Craik DJ.",Cyclotides as natural anti-HIV agents.##Linearization of a naturally occurring circular protein maintains structure but eliminates hemolytic activity. ,10.1002/bip.20886##10.1021/bi027323n,,Anti-HIV
DRAVPe00297,GSVLNCGETCLLGTCYTTGCTCNKYRVCTKD,31,Kalata-B8 (Plant defensin),Oldenlandia affinis,P85175,2B38,HIV,Retroviridae,,[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=2500 nM).,[Ref.20564013] It produced 7% hemolysis at the 62μM.,[Ref.18008336]CEM-SS cells:IC50>11000 nM.,DRAVPe00297,DRAVPe00297.cif,Cyclic,Cyclization (N termini to C termini),Cyclization (C termini to N termini),Disulfide bonds between Cys6 and Cys20; Cys10 and Cys22; Cys15 and Cys28.,L,Not found,No machanism information found in the reference(s) presented in this entry,3307.81,C134H220N38O47S6,AFHIMPQW,CT,7.76,3,2,1,21,5,-2.26,-3965,30 hour,>20 hour,>10 hour,56.45,3355,111.83,18008336##20564013,Biopolymers. 2008;90(1):51-60.##Biopolymers. 2010;94(5):647-58.,"Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.##Plan MR, Rosengren KJ, Sando L, Daly NL, Craik DJ.",Cyclotides as natural anti-HIV agents.##Structural and biochemical characteristics of the cyclotide kalata B5 from Oldenlandia affinis.,10.1002/bip.20886##10.1002/bip.21409,,Anti-HIV
DRAVPe00298,GLPICGETCVGGTCNTPGCSCSWPVCTRN,29,Varv peptide E (Varv E; Plant defensin),Viola arvensis (European field pansy) (Field violet),P83835,,HIV,Retroviridae,,[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=350 nM).,[Ref.20580652] HD50=6.96 µM against human type O red blood cells.,"[Ref.20580652] Cytotoxicity: U251(IC50=38.84μg/mL), MDA-MB-231(IC50>10μg/mL), A549(IC50>10μg/mL), DU145(IC50>10μg/mL), BEL-7402(IC50>10μg/mL).##[Ref.14987049] Cytotoxicity: U-937 GTB (lymphoma)(IC50 =",DRAVPe00298,DRAVPe00298.cif,Cyclic,Cyclization (N termini to C termini),Cyclization (C termini to N termini),Disulfide bonds between Cys5 and Cys19; Cys9 and Cys21; Cys14 and Cys26.,L,Not found,No machanism information found in the reference(s) presented in this entry,2916.34,C117H187N35O40S6,ADFHKMQY,C,5.96,1,1,0,19,5,15.86,-1946,30 hour,>20 hour,>10 hour,46.9,5875,209.82,18008336##20580652,Biopolymers. 2008;90(1):51-60.##Peptides. 2010 Aug;31(8):1434-40.,"Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.##Tang J, Wang CK, Pan X, Yan H, Zeng G, Xu W, He W, Daly NL, Craik DJ, Tan N.",Cyclotides as natural anti-HIV agents.##Isolation and characterization of cytotoxic cyclotides from Viola tricolor.,10.1002/bip.20886##10.1016/j.peptides.2010.05.004,,Anti-HIV
DRAVPe00299,ACYCRIPACIAGERRYGTCIYQGRLWAFCC,30,"Neutrophil defensin 1 (Defensin, alpha 1; HNP-1, HP-1; Human, mammals, animals)",Homo sapiens (Human),P59665##P11479##Q14125##Q6EZF6,2KHT,SARS-CoV-2,Coronaviridae,,[Ref.34206990]SARS-CoV-2:inhibition of infection in HEK293T-hACE2 cells(approximately 50% inbibition at 1 μg/mL (290 nM));##SARS-CoV-2 variant P.1:inhibition of infection in HeLa-hACE2 cells(67% inbibition at 50 μg/mL);##SARS-CoV-2 variant B.1.1.7:inhibition of infection in HeLa-hACE2 cells(58% inbibition at 50 μg/mL).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.34206990]No cytotoxicity on HEK293T cells up to 50 μg/mL.,DRAVPe00299,DRAVPe00299.cif,Cyclic,Free,Cyclization(Cys2 and Cys30).,"Disulfide bonds between Cys2 and Cys30,Cys4 and Cys19,Cys9 and Cys29.",L,Not found,No machanism information found in the reference(s) presented in this entry,3448.09,C150H228N44O38S6,DHKMNSV,C,8.68,4,1,3,13,10,30.0,-3229,4.4 hour,>20 hour,>10 hour,65.33,10345,356.72,34206990,Viruses. 2021 Jun 26;13(7):1246.,"Xu C, Wang A, Marin M, Honnen W, Ramasamy S, Porter E, Subbian S, Pinter A, Melikyan GB, Lu W, Chang TL.",Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry.,10.3390/v13071246,DRAVPa1304,Anti-SARS-CoV-2
DRAVPe00300,CYCRIPACIAGERRYGTCIYQGRLWAFCC,29,"Neutrophil defensin 2 (HNP-2, HP-2, HP2; Human, mammals, animals)",Homo sapiens (Human),P59665##P11479##Q14125##Q6EZF6##P59666##P11479##Q14125,1ZMH##1ZMI##1ZMK,SARS-CoV-2,Coronaviridae,,[Ref.34206990]SARS-CoV-2:inhibition of infection in HEK293T-hACE2 cells(approximately 50% inbibition at 1 μg/mL (290 nM)).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00300,DRAVPe00300.cif,Cyclic,Cyclization (N termini to C termini),Cyclization (N termini to C termini),"Disulfide bonds between Cys1 and Cys29,Cys3 and Cys18,Cys8 and Cys28.",L,Not found,No machanism information found in the reference(s) presented in this entry,3377.01,C147H223N43O37S6,DHKMNSV,C,8.67,4,1,3,13,9,24.83,-3410,1.2 hour,>20 hour,>10 hour,64.14,10345,369.46,34206990,Viruses. 2021 Jun 26;13(7):1246.,"Xu C, Wang A, Marin M, Honnen W, Ramasamy S, Porter E, Subbian S, Pinter A, Melikyan GB, Lu W, Chang TL.",Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry.,10.3390/v13071246,,Anti-SARS-CoV-2
DRAVPe00301,DCYCRIPACIAGERRYGTCIYQGRLWAFCC,30,"Neutrophil defensin 3 (Defensin, alpha 3; HNP-3, HP-3, HP3; Human, mammals, animals)",Homo sapiens (Human),P59666##P11479##Q14125,1DFN##2PM4##2PM5,SARS-CoV-2,Coronaviridae,,[Ref.34206990]SARS-CoV-2:inhibition of infection in HEK293T-hACE2 cells(approximately 50% inbibition at 1 μg/mL (290 nM)).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00301,DRAVPe00301.cif,Cyclic,Free,Cyclization of a C-terminal Cys residue (forming a disulfide bond),"Disulfide bonds between Cys2 and Cys30,Cys4 and Cys19,Cys9 and Cys29.",L,Not found,No machanism information found in the reference(s) presented in this entry,3492.1,C151H228N44O40S6,HKMNSV,C,8.33,4,2,2,13,9,12.33,-4282,1.1 hour,3 min,>10 hour,62.0,10345,356.72,34206990,Viruses. 2021 Jun 26;13(7):1246.,"Xu C, Wang A, Marin M, Honnen W, Ramasamy S, Porter E, Subbian S, Pinter A, Melikyan GB, Lu W, Chang TL.",Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry.,10.3390/v13071246,,Anti-SARS-CoV-2
DRAVPe00302,VCSCRLVFCRRTELRVGNCLIGGVSFTYCCTRV,33,"Neutrophil defensin 4 (Defensin, alpha 4; HNP-4, HP-4; Human, mammals, animals)",Homo sapiens (Human),P12838,1ZMM,SARS-CoV-2,Coronaviridae,,[Ref.34206990]SARS-CoV-2: showed inhibition against SARS-CoV-2.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00302,DRAVPe00302.cif,Cyclic,Free,Free,"Disulfide bonds between Cys2 and Cys30,Cys4 and Cys19,Cys9 and Cys29.",L,Not found,No machanism information found in the reference(s) presented in this entry,3715.46,C157H261N49O43S6,ADHKMPQW,C,8.98,5,1,4,16,11,66.06,-4636,100 hour,>20 hour,>10 hour,91.21,1865,58.28,34206990,Viruses. 2021 Jun 26;13(7):1246.,"Xu C, Wang A, Marin M, Honnen W, Ramasamy S, Porter E, Subbian S, Pinter A, Melikyan GB, Lu W, Chang TL.",Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry.,10.3390/v13071246,,Anti-SARS-CoV-2
DRAVPe00303,AFTCHCRRSCYSTEYSYGTCTVMGINHRFCCL,32,"Human defensin-6 (HD-6; Defensin, alpha 6; Human, mammals, animals)",Homo sapiens (Human),Q01524,1ZMQ##3QTE,SARS-CoV-2,Coronaviridae,,"[Ref.34206990]SARS-CoV-2:inhibition of infection in HEK293T-hACE2 cells(HD6 only blocked SARS-CoV-2 infection at the highest concentration tested (50 μg/mL, 13 μM)).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.34206990]No cytotoxicity on HEK293T cells up to 50 μg/mL.,DRAVPe00303,DRAVPe00303.cif,Cyclic,Free,Free,"Disulfide bonds between Cys4 and Cys31,Cys6 and Cys20,Cys10 and Cys30.",L,Not found,No machanism information found in the reference(s) presented in this entry,3714.27,C156H234N46O46S7,DKPQW,C,8.35,5,1,4,19,6,0.0,-5487,4.4 hour,>20 hour,>10 hour,36.56,4845,156.29,34206990,Viruses. 2021 Jun 26;13(7):1246.,"Xu C, Wang A, Marin M, Honnen W, Ramasamy S, Porter E, Subbian S, Pinter A, Melikyan GB, Lu W, Chang TL.",Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry.,10.3390/v13071246,,Anti-SARS-CoV-2
DRAVPe00304,GWFDVVKHIAKRF,13,D70(Derived from Uperin 7.1),Synthetic construct,No entry found,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=2.99 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:50% Cell death at 10.6 µM.,DRAVPe00304,DRAVPe00304.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,1602.9,C78H115N21O16,CELMNPQSTY,FKV,9.99,4,1,3,1,7,0.0,-1536,30 hour,>20 hour,>10 hour,82.31,5500,458.33,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00305,VDKPDYRPRPRPPNM,15,"Metalnikowin-1 (Metalnikowin I; Insects, animals)",Palomena prasina (Green shield bug) (Cimex prasinus),P80408,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>54.4 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >54.4 µM.,DRAVPe00305,DRAVPe00305.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1838.12,C80H128N26O22S,ACEFGHILQSTW,P,9.98,4,2,2,2,1,-207.33,-6814,100 hour,>20 hour,>10 hour,19.33,1490,106.43,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00306,FLFPLITSFLSKVL,14,"Ranatuerin-9 (Frogs, amphibians, animals)",Lithobates catesbeiana (American bullfrog) (Rana catesbeiana),P82824,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=16.7 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:50% Cell death at 34.6 µM.,DRAVPe00306,DRAVPe00306.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1625.03,C83H129N15O18,ACDEGHMNQRWY,L,8.75,1,0,1,3,9,175.0,2266,1.1 hour,3 min,2 min,160.0,0,0.0,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00307,INLKAIAALAKKLL,14,Mastoparan M,Hornet Vespa mandarinia,P04205,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>67.6 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >67.6 µM.,DRAVPe00307,DRAVPe00307.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1479.91,C70H130N18O16,CDEFGHMPQRSTVWY,AL,10.3,3,0,3,1,10,115.71,1347,20 hour,30 min,>10 hour,195.71,0,0.0,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00308,IKWKKLLRAAKRIL,14,"DASamP2(D74,derived from polybia-MPI)",Synthetic construct,No entry found,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>57.6 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:50% Cell death at 1.3 µM.,DRAVPe00308,DRAVPe00308.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,1737.25,C83H149N25O15,CDEFGHMNPQSTVY,K,12.03,6,0,6,0,8,-10.71,-2149,20 hour,30 min,>10 hour,153.57,5500,423.08,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00309,FRPALIVRTKGTRL,14,Hyposin-5 (frog),Phyllomedusa hypochondrialis,No entry found,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>61.4 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >61.4 µM.,DRAVPe00309,DRAVPe00309.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1628.0,C74H130N24O17,CDEHMNQSWY,R,12.3,4,0,4,3,6,0.71,-3092,1.1 hour,3 min,2 min,111.43,0,0.0,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00310,FFGKVLKLIRKIF,13,"DASamP1(D76,derived from temporin-PTa)",Synthetic construct,No entry found,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=0.63 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:50% Cell death at 6.78 µM.,DRAVPe00310,DRAVPe00310.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,1609.08,C82H133N19O14,ACDEHMNPQSTWY,FK,11.26,4,0,4,1,8,96.92,203,1.1 hour,3 min,2 min,142.31,0,0.0,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00311,GNNRPVYIPQPRPPHPRI,18,Apidaecin IA (insect),Apis mellifera L,P35581,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>47.7 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >47.4 µM.,DRAVPe00311,DRAVPe00311.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2108.44,C95H150N32O23,ACDEFKLMSTW,P,11.71,4,0,4,4,3,-140.56,-5356,30 hour,>20 hour,>10 hour,59.44,1490,87.65,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00312,GKPRPYSPRPTSHPRPIRV,19,Drosocin (insect),Drosophila melanogaster,No entry found,4EZR,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>45.5 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >45.5 µM.,DRAVPe00312,DRAVPe00312.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2198.56,C98H160N34O24,ACDEFLMNQW,P,12.01,6,0,6,5,2,-157.89,-6950,30 hour,>20 hour,>10 hour,35.79,1490,82.78,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00313,VFQFLGRIIAnti-HHVGNFVHGFSHVF,23,"Clavanin-B (His-rich; chordates, animals)",Styela clava (Sea squirt),P80711,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=7.1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:50% Cell death at 37.1 µM.,DRAVPe00313,DRAVPe00313.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2695.13,C131H184N36O27,ACDEKMPTWY,F,9.75,5,0,5,5,12,75.22,-50,100 hour,>20 hour,>10 hour,101.3,0,0.0,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00314,TRSSRAGLQFPVGRVHRLLRK,21,Buforin II (toad),Synthetic construct(derived from buforin I after treatment with endoproteinase),P55897,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>41.1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >41.1 µM.,DRAVPe00314,DRAVPe00314.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2434.88,C106H184N40O26,CDEIMNWY,R,12.6,7,0,7,5,7,-63.81,-7021,7.2 hour,>20 hour,>10 hour,88.1,0,0.0,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00315,GFGKAFHSVSNFAKKHKTA,19,Styelin A (tunicate),Styela clava,P81469,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>48.8 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >48.5 µM.,DRAVPe00315,DRAVPe00315.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,2062.36,C95H144N28O24,CDEILMPQRWY,K,10.48,6,0,6,6,7,-55.79,-2724,30 hour,>20 hour,>10 hour,31.05,0,0.0,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00316,LLKELWTKIKGAGKAVLGKIKGLL,24,"Ponericin-L2 (ants, insects, animals)",Pachycondyla goeldii (Ponerine ant),P82422,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=1.4 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:50% Cell death at 24.7 µM.,DRAVPe00316,DRAVPe00316.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2578.27,C123H217N31O28,CDFHMNPQRSY,KL,10.3,6,1,5,5,12,39.58,1043,5.5 hour,3 min,2 min,150.42,5500,239.13,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00317,HVDKKVADKVLLLKQLRIMRLLTRL,25,"Spinigerin (Insects, animals)",Pseudacanthotermes spiniger (Termite),P82357,1ZRW##1ZRV,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=3.05 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >33.3 µM.,DRAVPe00317,DRAVPe00317.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,3000.77,C136H247N41O32S,CEFGNPSWY,L,11.07,8,2,6,1,12,15.6,-4153,3.5 hour,10 min,>10 hour,163.6,0,0.0,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00318,GLNTLKKVFQGLHEAIKLINNHVQ,24,Pseudin 1 (frog),Pseudis paradoxa,P83188,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=35.7 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >36.8 µM.,DRAVPe00318,DRAVPe00318.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2715.19,C123H204N36O33,CDMPRSWY,L,9.7,5,1,4,6,10,-14.17,-2208,30 hour,>20 hour,>10 hour,125.83,0,0.0,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00319,RQRVEELSKFSKKGAAARRRK,21,Misgurin (fish),Misgurnus anguillicaudatus,P81474,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>40.0 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >40.0 µM.,DRAVPe00319,DRAVPe00319.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2501.92,C106H189N41O29,CDHIMNPTWY,R,11.84,9,2,7,3,6,-163.81,-10445,1 hour,2 min,2 min,46.67,0,0.0,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00320,NLVSGLIEARKYLEQLHRKLKNRKV,25,D88 (frog),Synthetic construct(derived from chain A of distinctin),No entry found,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>33.3 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >33.3 µM.,DRAVPe00320,DRAVPe00320.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,3006.59,C134H233N43O35,CDFMPTW,L,10.55,8,2,6,5,9,-74.4,-6725,1.4 hour,3 min,>10 hour,120.8,1490,62.08,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00321,IWLTALKFLGKHAAKHLAKQQLSKL,25,Lycotoxin I (spider),Lycosa carolinensis,No entry found,7MMM,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>35.2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:50% Cell death at 2.4 µM.,DRAVPe00321,DRAVPe00321.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2844.49,C135H223N37O30,CDEMNPRVY,L,10.6,7,0,7,3,13,6.4,-619,20 hour,30 min,>10 hour,125.2,5500,229.17,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00322,GLFDIIKKIAESW,13,B1(derived from Aurein 1.2),Synthetic construct(derived from Aurein 1.2),No entry found,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=11.7 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:50% Cell death at 37.0 µM.,DRAVPe00322,DRAVPe00322.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,1519.8,C73H114N16O19,CHMNPQRTVY,I,6.07,2,2,0,2,7,38.46,-229,30 hour,>20 hour,>10 hour,127.69,5500,458.33,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00323,GLWEKIDKFASII,13,B2(derived from Caerin 3.2),Synthetic construct(derived from Caerin 3.2),No entry found,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>65.8 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >65.8 µM.,DRAVPe00323,DRAVPe00323.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,1519.8,C73H114N16O19,CHMNPQRTVY,I,6.07,2,2,0,2,7,38.46,-229,30 hour,>20 hour,>10 hour,127.69,5500,458.33,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00324,GIIDIAKKLFESW,13,B3(derived from Uperin 2.7),Synthetic construct(derived from Uperin 2.7),No entry found,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=20.1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >65.8 µM.,DRAVPe00324,DRAVPe00324.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,1519.8,C73H114N16O19,CHMNPQRTVY,I,6.07,2,2,0,2,7,38.46,-229,30 hour,>20 hour,>10 hour,127.69,5500,458.33,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00325,GWFDIIKKIASEL,13,B4(derived from Uperin 7.1),Synthetic construct(derived from Uperin 7.1),No entry found,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=10.7 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:50% Cell death at 38.9 µM.,DRAVPe00325,DRAVPe00325.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,1519.8,C73H114N16O19,CHMNPQRTVY,I,6.07,2,2,0,2,7,38.46,-229,30 hour,>20 hour,>10 hour,127.69,5500,458.33,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00326,GIFDKLAKEISIW,13,B5(derived from Brevinin-2DYd),Synthetic construct(derived from Brevinin-2DYd),No entry found,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>65.8 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >65.8 µM.,DRAVPe00326,DRAVPe00326.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,1519.8,C73H114N16O19,CHMNPQRTVY,I,6.07,2,2,0,2,7,38.46,-229,30 hour,>20 hour,>10 hour,127.69,5500,458.33,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00327,GIWSDLAEIIKKF,13,B6(derived from Ponericin W3),Synthetic construct(derived from Ponericin W3),No entry found,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=11.4 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >65.8 µM.,DRAVPe00327,DRAVPe00327.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,1519.8,C73H114N16O19,CHMNPQRTVY,I,6.07,2,2,0,2,7,38.46,-229,30 hour,>20 hour,>10 hour,127.69,5500,458.33,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00328,GFLDIIEKIAKSW,13,B7(derived from Ranatuerin 3),Synthetic construct(derived from Ranatuerin 3),No entry found,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=10.5 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >65.8 µM.,DRAVPe00328,DRAVPe00328.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,1519.8,C73H114N16O19,CHMNPQRTVY,I,6.07,2,2,0,2,7,38.46,-229,30 hour,>20 hour,>10 hour,127.69,5500,458.33,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00329,GWLKKIESIIDAF,13,B8(derived from Cecropin),Synthetic construct(derived from Cecropin),No entry found,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=29.5 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >65.8 µM.,DRAVPe00329,DRAVPe00329.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,1519.8,C73H114N16O19,CHMNPQRTVY,I,6.07,2,2,0,2,7,38.46,-229,30 hour,>20 hour,>10 hour,127.69,5500,458.33,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00330,ILGPVLGLVSDTLDDVLGIL,20,Maximin H5,Bombina maxima,No entry found,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>49.4 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >49.7 µM.,DRAVPe00330,DRAVPe00330.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2022.41,C93H160N20O29,ACEFHKMNQRWY,L,3.42,0,3,-3,5,11,148.0,2217,20 hour,30 min,>10 hour,199.5,0,0.0,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00331,ILGPVLGLVSRTLRRVLGIL,20,Maximin H5r3,Synthetic construct(derived from Maximin H5),No entry found,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=2.2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:50% Cell death at 8.7 µM.,DRAVPe00331,DRAVPe00331.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2145.71,C99H181N29O23,ACDEFHKMNQWY,L,12.3,3,0,3,5,11,133.0,357,20 hour,30 min,>10 hour,199.5,0,0.0,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00332,GFKRIVQRIKDFLRNLV,17,GF-17,Synthetic construct(derived from LL-37),No entry found,,"HIV, EBOV","Retroviridae, Filoviridae",Plaque assay,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=0.76 μM);##[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50=0.98 μM).(EC50:50% effective concentration for inhibition of virus replication);##[Ref.32252021]Ebola Virus(EBOV):inhibition of viral infection in Hela cells(IC50=10.1 µM);inhibition of viral infection in primary macrophages(IC50>20 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:50% Cell death at 10.8 µM.##[Ref.18591279]CEM-SS cells:TC50=8.9 μM.(TC50:the concentration that reduced cell viability by 50%),DRAVPe00332,DRAVPe00332.cif,Linear,Free,Amidation,,L,Not found,"Act as CatB inhibitors to block the endosomal processing of EBOV GP, thus preventing virus entry.",2102.56,C97H164N30O22,ACEHMPSTWY,R,11.72,5,1,4,2,8,-9.41,-4210,30 hour,>20 hour,>10 hour,125.88,0,0.0,20086159##18591279##32252021,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.##Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. ##iScience. 2020 Apr 24;23(4):100999.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.##Wang G, Watson KM, Buckheit RW Jr. ##Yu Y, Cooper CL, Wang G, Morwitzer MJ, Kota K, Tran JP, Bradfute SB, Liu Y, Shao J, Zhang AK, Luo LG, Reid SP, Hinrichs SH, Su K.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.##Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.##Engineered Human Cathelicidin Antimicrobial Peptides Inhibit Ebola Virus Infection.,10.1128/AAC.01448-09##10.1128/AAC.00452-08##10.1016/j.isci.2020.100999,,"Anti-HIV, Anti-EBOV"
DRAVPe00333,GFNEIVQDIEDFLQNLV,17,GF-17−,Synthetic construct(derived from LL-37),No entry found,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>25.1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >25.1 µM.,DRAVPe00333,DRAVPe00333.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1993.2,C90H137N21O30,ACHKMPRSTWY,DEFILNQV,3.43,0,4,-4,3,8,12.94,-2076,30 hour,>20 hour,>10 hour,125.88,0,0.0,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00334,GLRSKIWLWVLLMIWQESNKFKKM,24,DRS S9,Synthetic construct(derived from Dermaseptin S9),No entry found,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=31.6 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >32.9 µM.,DRAVPe00334,DRAVPe00334.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,3035.75,C145H228N36O31S2,ACDHPTY,KL,10.46,5,1,4,4,11,-1.25,-1374,30 hour,>20 hour,>10 hour,109.58,16500,717.39,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00335,GLRSRIWLWVLLMIWQESNRFKRM,24,DRS S9r3,Synthetic construct(derived from Dermaseptin S9),No entry found,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=1.25 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >32.1 µM.,DRAVPe00335,DRAVPe00335.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,3119.79,C145H228N42O31S2,ACDHPTY,LR,12.0,5,1,4,4,11,-8.75,-4185,30 hour,>20 hour,>10 hour,109.58,16500,717.39,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00336,GLKKLLGKLLKKLGKLLLK,19,GLK-19,Synthetic construct,No entry found,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>47.5 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:50% Cell death at 25.1 µM.,DRAVPe00336,DRAVPe00336.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2104.82,C102H194N26O20,ACDEFHIMNPQRSTVWY,L,10.78,7,0,7,3,9,30.0,825,30 hour,>20 hour,>10 hour,184.74,0,0.0,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00337,GLRRLLGRLLRRLGRLLLR,19,GLR-19,Synthetic construct,No entry found,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=4.4 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:50% Cell death at 25.7 µM.,DRAVPe00337,DRAVPe00337.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2300.92,C102H194N40O20,ACDEFHIKMNPQSTVWY,L,12.78,7,0,7,3,9,7.89,-5734,30 hour,>20 hour,>10 hour,184.74,0,0.0,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00338,KGRGKQGGKVRAKAKTRSS,19,Parasin I (fish),Parasilurus asotus,No entry found,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>50.0 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >50.0 µM.,DRAVPe00338,DRAVPe00338.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2000.34,C82H154N34O24,CDEFHILMNPWY,K,12.32,8,0,8,7,3,-171.58,-7600,1.3 hour,3 min,2 min,25.79,0,0.0,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00339,GIWDTIKSMGKVFAGKILQNL,21,"Brevinin-2-related peptide (Frogs, amphibians, animals)",Rana septentrionalis (mink frog),No entry found,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=1.65 μM).,[Ref.15556063]HC50=70 µM against human erythrocytes,[Ref.20086159]CEM-SS cells:50% Cell death at 7.42 µM.,DRAVPe00339,DRAVPe00339.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,2319.79,C107H175N27O28S,CEHPRY,GIK,9.7,3,1,2,6,9,28.57,-259,30 hour,>20 hour,>10 hour,111.43,5500,275.0,20086159##15556063,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.##Comp Biochem Physiol C Toxicol Pharmacol. 2004 Oct;139(1-3):31-38.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.##Bevier CR, Sonnevend A, Kolodziejek J, Nowotny N, Nielsen PF, Conlon JM.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.##Purification and characterization of antimicrobial peptides from the skin secretions of the mink frog (Rana septentrionalis).,10.1128/AAC.01448-09##10.1016/j.cca.2004.08.019,,Anti-HIV
DRAVPe00340,GLLGLLGSVVSHVVPAIVGHF,21,"Maculatin-1.3 (frog, amphibia, animals)",Litoria eucnemis (Australian anurans),No entry found,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=4.0 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:50% Cell death at 8.02 µM.,DRAVPe00340,DRAVPe00340.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,2071.49,C98H159N25O24,CDEKMNQRTWY,V,6.92,2,0,2,6,12,162.38,3723,30 hour,>20 hour,>10 hour,166.67,0,0.0,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00341,SWKSMAKKLKEYMEKLKQRA,20,"M-zodatoxin-Lt3a (M-ZDTX-Lt3a; Latarcin-3a, Ltc-3a; spiders, Arthropods, animals)",Lachesana tarabaevi (Spider),Q1ELU3,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=32.7 μM).,[Ref.16735513]20% hemolytic activity at >120 μM against rabbit erythrocytes ,[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >40.3 µM.,DRAVPe00341,DRAVPe00341.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2484.02,C111H187N31O29S2,CDFGHINPTV,K,10.12,7,2,5,3,5,-136.0,-5383,1.9 hour,>20 hour,>10 hour,49.0,6990,367.89,20086159##16735513,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.##J Biol Chem. 2006 Jul 28;281(30):20983-209892.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.##Kozlov SA, Vassilevski AA, Feofanov AV, Surovoy AY, Karpunin DV, Grishin EV.","Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.##Latarcins, antimicrobial and cytolytic peptides from the venom of the spider Lachesana tarabaevi (Zodariidae) that exemplify biomolecular diversity.",10.1128/AAC.01448-09##10.1074/jbc.M602168200,,Anti-HIV
DRAVPe00342,GAWKNFWSSLRKGFYDGEAGRAIRR,25,D94 (bacteria),Synthetic construct(derived from chain A of plantaricin JK),No entry found,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>34.1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >34.1 µM.,DRAVPe00342,DRAVPe00342.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2929.3,C133H198N42O34,CHMPQTV,GR,10.93,6,2,4,8,9,-93.2,-7024,30 hour,>20 hour,>10 hour,43.2,12490,520.42,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00343,GFKDLLKGAAKALVKTVLF,19,"Ascaphin-8 (Frogs, amphibians, animals)",Ascaphus truei (Coastal tailed frog),P0CJ32,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=1.2 μM).,[Ref.15207717]HC50=50 μM against human erythrocytes,[Ref.20086159]CEM-SS cells:50% Cell death at 2.9 µM.,DRAVPe00343,DRAVPe00343.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,2019.5,C97H163N23O23,CEHIMNPQRSWY,KL,10.0,4,1,3,3,11,73.68,754,30 hour,>20 hour,>10 hour,128.42,0,0.0,20086159##15207717,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.##Biochem Biophys Res Commun. 2004 Jul 16;320(1):170-175.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.##Conlon JM, Sonnevend A, Davidson C, Smith DD, Nielsen PF.","Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.##The ascaphins: a family of antimicrobial peptides from the skin secretions of the most primitive extant frog, Ascaphus truei.",10.1128/AAC.01448-09##10.1016/j.bbrc.2004.05.141,,Anti-HIV
DRAVPe00344,GLADFLNKAVGKVVDFVKS,19,Desertcolin 1 (frog),Crinia deserticola,No entry found,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>49.9 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >49.9 µM.,DRAVPe00344,DRAVPe00344.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,2007.36,C93H151N23O26,CEHIMPQRTWY,V,8.5,3,2,1,4,10,51.58,-667,30 hour,>20 hour,>10 hour,112.63,0,0.0,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00345,GFLSILKKVLPKVMAHMK,18,"Melectin (MEP; Insects, animals)",Melecta albifrons (Cuckoo bee) (Melecta punctata),P86170,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=4.34 μM).,[Ref.18942691]LC50>100 μM against rat red blood cells,[Ref.20086159]CEM-SS cells:50% Cell death at 7.75 µM.,DRAVPe00345,DRAVPe00345.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,2040.64,C96H166N24O20S2,CDENQRTWY,K,10.48,5,0,5,2,8,61.67,793,30 hour,>20 hour,>10 hour,124.44,0,0.0,20086159##18942691,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.##Chembiochem. 2008 Nov 24;9(17):2815-2821.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.##Cerovský V, Hovorka O, Cvacka J, Voburka Z, Bednárová L, Borovicková L, Slaninová J, Fucík V.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.##Melectin: a novel antimicrobial peptide from the venom of the cleptoparasitic bee Melecta albifrons.,10.1128/AAC.01448-09##10.1002/cbic.200800476,,Anti-HIV
DRAVPe00346,SLSRFLRFLKIVYRRAF,17,"D98 (frog,derived from temporin-LTc)",Synthetic construct(derived from temporin-LTc),No entry found,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=0.83 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:50% Cell death at 8.6 µM.,DRAVPe00346,DRAVPe00346.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,2172.65,C104H166N30O21,CDEGHMNPQTW,R,12.01,5,0,5,3,9,32.35,-3770,1.9 hour,>20 hour,>10 hour,114.71,1490,93.13,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00347,RPKHPIKHQGLPQEVLNENLLRF,23,Isracidin (cow),bovine colostrum,No entry found,,HIV,Retroviridae,,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>36.2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >36.2 µM.,DRAVPe00347,DRAVPe00347.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2764.23,C125H203N39O32,ACDMSTWY,L,9.99,6,2,4,3,7,-98.7,-5568,1 hour,2 min,2 min,97.39,0,0.0,20086159,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,10.1128/AAC.01448-09,,Anti-HIV
DRAVPe00348,GIGTKILGGVKTALKGALKELASTYAN,27,"Maximin-1 (Toads, amphibians, animals)",Bombina maxima (Giant fire-bellied toad) (Chinese red belly toad),P83080##Q58T87,,HIV,Retroviridae,,"[Ref.11835991]HIV-1:inhibition the cytopathic effects of HIV-1 (IC50=15.5 µg/ml, EC50=21.4 µg/ml).##NOTE: IC50 means the concentration that can inhibit 50% growth of cells. EC50 was defined as the concentration of antiviral agent reducing HIV-1 replication by 50%.",[Ref:11835991]Little hemolytic activity at 50 μg/ml against red blood cells,No cytotoxicity information found in the reference(s) presented,DRAVPe00348,DRAVPe00348.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,2675.16,C120H208N32O36,CDFHMPQRW,G,9.83,4,1,3,11,11,25.19,-140,30 hour,>20 hour,>10 hour,112.22,1490,57.31,11835991,Peptides. 2002 Mar;23(3):427-435.,"Lai R, Zheng YT, Shen JH, Liu GJ, Liu H, Lee WH, Tang SZ, Zhang Y.",Antimicrobial peptides from skin secretions of Chinese red belly toad Bombina maxima.,,,Anti-HIV
DRAVPe00349,GIGGKILSGLKTALKGAAKELASTYLH,27,"Maximin-3 (Toads, amphibians, animals)",Bombina maxima (Giant fire-bellied toad) (Chinese red belly toad),P83082##Q58T40##Q58T43##Q58T46##Q58T48##Q58T64##Q58T65##Q58T68##Q58T69,,HIV,Retroviridae,,"[Ref.11835991]HIV-1:inhibition the cytopathic effects of HIV-1 (IC50=11.4 µg/ml, EC50=1.5 µg/ml).##NOTE: IC50 means the concentration that can inhibit 50% growth of cells. EC50 was defined as the concentration of antiviral agent reducing HIV-1 replication by 50%.",[Ref:11835991]Little hemolytic activity at 50 μg/ml against red blood cells,No cytotoxicity information found in the reference(s) presented,DRAVPe00349,DRAVPe00349.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2698.2,C122H209N33O35,CDFMNPQRVW,GL,9.83,5,1,4,10,11,24.44,63,30 hour,>20 hour,>10 hour,115.93,1490,57.31,11835991,Peptides. 2002 Mar;23(3):427-435.,"Lai R, Zheng YT, Shen JH, Liu GJ, Liu H, Lee WH, Tang SZ, Zhang Y.",Antimicrobial peptides from skin secretions of Chinese red belly toad Bombina maxima.,,,Anti-HIV
DRAVPe00350,GIGGVLLSAGKAALKGLAKVLAEKYAN,27,"Maximin-4 (Toads, amphibians, animals)",Bombina maxima (Giant fire-bellied toad) (Chinese red belly toad),P83083##Q58T42##Q58T44##Q58T52##Q58T62##Q58T77##Q58T79,2MHW,HIV,Retroviridae,,"[Ref.11835991]HIV-1:inhibition the cytopathic effects of HIV-1 (IC50=24.2 µg/ml, EC50=21.9 µg/ml).##NOTE: IC50 means the concentration that can inhibit 50% growth of cells. EC50 was defined as the concentration of antiviral agent reducing HIV-1 replication by 50%.",[Ref:11835991]Little hemolytic activity at 50 μg/ml against red blood cells,No cytotoxicity information found in the reference(s) presented,DRAVPe00350,DRAVPe00350.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,2613.14,C119H206N32O33,CDFHMPQRTW,A,9.83,4,1,3,8,14,59.26,1397,30 hour,>20 hour,>10 hour,130.37,1490,57.31,11835991,Peptides. 2002 Mar;23(3):427-435.,"Lai R, Zheng YT, Shen JH, Liu GJ, Liu H, Lee WH, Tang SZ, Zhang Y.",Antimicrobial peptides from skin secretions of Chinese red belly toad Bombina maxima.,,,Anti-HIV
DRAVPe00351,SIGAKILGGVKTFFKGALKELASTYLQ,27,"Maximin-5 (Toads, amphibians, animals)",Bombina maxima (Giant fire-bellied toad) (Chinese red belly toad),P83084##Q58T60##Q58T61,,HIV,Retroviridae,,"[Ref.11835991]HIV-1:inhibition the cytopathic effects of HIV-1 (IC50=34.4 µg/ml, EC50=39.8 µg/ml).##NOTE: IC50 means the concentration that can inhibit 50% growth of cells. EC50 was defined as the concentration of antiviral agent reducing HIV-1 replication by 50%.",[Ref:11835991]Little hemolytic activity at 50 μg/ml against red blood cells,No cytotoxicity information found in the reference(s) presented,DRAVPe00351,DRAVPe00351.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2841.39,C133H218N32O36,CDHMNPRW,GKL,9.82,4,1,3,9,12,40.37,208,1.9 hour,>20 hour,>10 hour,108.52,1490,57.31,11835991,Peptides. 2002 Mar;23(3):427-435.,"Lai R, Zheng YT, Shen JH, Liu GJ, Liu H, Lee WH, Tang SZ, Zhang Y.",Antimicrobial peptides from skin secretions of Chinese red belly toad Bombina maxima.,,,Anti-HIV
DRAVPe00352,GLFGVLAKVAAHVVPAIAEHF,21,Maculatin-1.1,Litoria genimaculata (Green-eyed tree frog),P82066,,HIV,Retroviridae,,[Ref.16140737]HIV:inhibit 50% of PBS-treated HIV infection of T cells(IC50=11.3 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00352,DRAVPe00352.cif,Linear,Free,Amidation,,L,membrane,"The peptide could prevent HIV infection by disrupting the integrity of the virion membrane, and inhibit the transfer of HIV from DCs to T cells.",2146.56,C103H160N26O24,CDMNQRSTWY,A,6.92,3,1,2,2,14,130.0,2613,30 hour,>20 hour,>10 hour,134.76,0,0.0,16140737,J Virol. 2005 Sep;79(18):11598-606.,"VanCompernolle SE, Taylor RJ, Oswald-Richter K, Jiang J, Youree BE, Bowie JH, Tyler MJ, Conlon JM, Wade D, Aiken C, Dermody TS, KewalRamani VN, Rollins-Smith LA, Unutmaz D.",Antimicrobial peptides from amphibian skin potently inhibit human immunodeficiency virus infection and transfer of virus from dendritic cells to T cells.,10.1128/JVI.79.18.11598-11606.2005,,Anti-HIV
DRAVPe00353,GLLSVLGSVAKHVLPHVVPVIAEHL,25,Caerin-1.1,Litoria splendida (Magnificent tree frog) (Litoria gilleni) (Litoria caerulea),P62568##P62569##Q800R2##P56226,,HIV,Retroviridae,,[Ref.16140737]HIV:inhibit 50% of PBS-treated HIV infection of T cells(IC50=7.8 μM);inhibition of HIV transfer by dendritic cells to T cells(IC50=12.6 μM),No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00353,DRAVPe00353.cif,Linear,Free,Amidation,,L,membrane,"The peptide could prevent HIV infection by disrupting the integrity of the virion membrane, and inhibit the transfer of HIV from DCs to T cells.",2585.13,C121H202N32O30,CDFMNQRTWY,V,7.02,4,1,3,4,14,118.8,2612,30 hour,>20 hour,>10 hour,171.2,0,0.0,16140737,J Virol. 2005 Sep;79(18):11598-606.,"VanCompernolle SE, Taylor RJ, Oswald-Richter K, Jiang J, Youree BE, Bowie JH, Tyler MJ, Conlon JM, Wade D, Aiken C, Dermody TS, KewalRamani VN, Rollins-Smith LA, Unutmaz D.",Antimicrobial peptides from amphibian skin potently inhibit human immunodeficiency virus infection and transfer of virus from dendritic cells to T cells.,10.1128/JVI.79.18.11598-11606.2005,,Anti-HIV
DRAVPe00354,GLFGVLGSIAKHVLPHVVPVIAEKL,25,Caerin 1.9,Litoria chloris,P81252,,HIV,Retroviridae,,[Ref.26026377]Human immunodeficiency virus (HIV): inhibition of HIV Pseudovirus (PsV) infection in CD4+ T cells(IC50=4 µM).##[Ref.16140737]Human immunodeficiency virus (HIV):inhibit 50% of PBS-treated HIV infection of T cells(IC50=1.2 μM);inhibition of HIV transfer by dendritic cells to T cells(IC50=1.6 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.26026377]CD4+ T Lymphocytes:50% cell death at 20	µM.,DRAVPe00354,DRAVPe00354.cif,Linear,Free,Amidation,,L,virion envelope,"Prevent HIV infection by disrupting the integrity of the virion membrane at concentrations that are not toxic to target cells, the peptide also inhibit the transfer of HIV from DCs to T cells.",2594.18,C124H205N31O29,CDMNQRTWY,V,8.61,4,1,3,4,14,114.8,2851,30 hour,>20 hour,>10 hour,159.6,0,0.0,26026377##16140737##33008028,Peptides. 2015 Sep;71:296-303.##J Virol. 2005 Sep;79(18):11598-606.##Antibiotics (Basel). 2020 Sep 30;9(10):661.,Inhibition of HIV infection by caerin 1 antimicrobial peptides.##Antimicrobial peptides from amphibian skin potently inhibit human immunodeficiency virus infection and transfer of virus from dendritic cells to T cells.##Caerin 1 Antimicrobial Peptides That Inhibit HIV and Neisseria May Spare Protective Lactobacilli.,"VanCompernolle S, Smith PB, Bowie JH, Tyler MJ, Unutmaz D, Rollins-Smith LA.##VanCompernolle SE, Taylor RJ, Oswald-Richter K, Jiang J, Youree BE, Bowie JH, Tyler MJ, Conlon JM, Wade D, Aiken C, Dermody TS, KewalRamani VN, Rollins-Smith LA, Unutmaz D.##Rollins-Smith LA, Smith PB, Ledeczi AM, Rowe JM, Reinert LK.",10.1016/j.peptides.2015.05.004##10.1128/JVI.79.18.11598-11606.2005##10.3390/antibiotics9100661,,Anti-HIV
DRAVPe00355,GLFSVLGAVAKHVLPHVVPVIAEKL,25,Caerin-1.6,Litoria xanthomera (Orange-thighed frog) (Litoria chloris),P62546##P56231##P81249##P62547,,HIV,Retroviridae,,[Ref.26026377]HIV: inhibition of HIV Pseudovirus (PsV) infection in CD4+ T cells(IC50=2 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.26026377]Human endocervical cells End1/E6E7:50% cell death at 10	µM.,DRAVPe00355,DRAVPe00355.cif,Linear,Free,Amidation,,L,membrane,"The peptide could disrupt the viral envelope and release p24 protein.And the more effective they were at disruption of the viral envelope, the better they were at inhibiting infection.",2594.18,C124H205N31O29,CDMNQRTWY,V,8.61,4,1,3,3,15,122.4,2850,30 hour,>20 hour,>10 hour,159.6,0,0.0,26026377,Peptides. 2015 Sep;71:296-303.,"VanCompernolle S, Smith PB, Bowie JH, Tyler MJ, Unutmaz D, Rollins-Smith LA.",Inhibition of HIV infection by caerin 1 antimicrobial peptides.,10.1016/j.peptides.2015.05.004,,Anti-HIV
DRAVPe00356,GLFKVLGSVAKHLLPHVAPVIAEKL,25,Caerin-1.7,Litoria xanthomera (Orange-thighed frog) (Litoria chloris),P62548##P62549##P56232##P81250,,HIV,Retroviridae,,[Ref.26026377]HIV: inhibition of HIV Pseudovirus (PsV) infection in CD4+ T cells(IC50=2.5 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.26026377]Human endocervical cells End1/E6E7:50% cell death at 12.5 µM.,DRAVPe00356,DRAVPe00356.cif,Linear,Free,Amidation,,L,membrane,"The peptide could disrupt the viral envelope and release p24 protein.And the more effective they were at disruption of the viral envelope, the better they were at inhibiting infection.",2637.25,C126H210N32O29,CDMNQRTWY,L,9.7,5,1,4,3,14,88.4,1979,30 hour,>20 hour,>10 hour,152.0,0,0.0,26026377,Peptides. 2015 Sep;71:296-303.,"VanCompernolle S, Smith PB, Bowie JH, Tyler MJ, Unutmaz D, Rollins-Smith LA.",Inhibition of HIV infection by caerin 1 antimicrobial peptides.,10.1016/j.peptides.2015.05.004,,Anti-HIV
DRAVPe00357,GLFKVLGSVAKHLLPHVAPIIAEKL,25,Caerin-1.19,Litoria gracilenta (Dainty green tree frog),P0C2A8,,HIV,Retroviridae,,[Ref.26026377]HIV: inhibition of HIV Pseudovirus (PsV) infection in CD4+ T cells(IC50=2.5 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00357,DRAVPe00357.cif,Linear,Free,Amidation,,L,membrane,"The peptide could disrupt the viral envelope and release p24 protein.And the more effective they were at disruption of the viral envelope, the better they were at inhibiting infection.",2651.28,C127H212N32O29,CDMNQRTWY,L,9.7,5,1,4,3,14,89.6,2067,30 hour,>20 hour,>10 hour,156.0,0,0.0,26026377,Peptides. 2015 Sep;71:296-303.,"VanCompernolle S, Smith PB, Bowie JH, Tyler MJ, Unutmaz D, Rollins-Smith LA.",Inhibition of HIV infection by caerin 1 antimicrobial peptides.,10.1016/j.peptides.2015.05.004,,Anti-HIV
DRAVPe00358,GLLSVLGSVAKHVLPHVVPVIAEKL,25,Caerin 1.10,Litoria splendida,P86502##P82104,,HIV,Retroviridae,,[Ref.26026377]Human immunodeficiency virus (HIV): inhibition of HIV Pseudovirus (PsV) infection in CD4+ T cells(IC50=2.5 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.26026377]CD4+ T Lymphocytes:50% cell death at 22	µM.,DRAVPe00358,DRAVPe00358.cif,Linear,Free,Amidation,,L,virion envelope,Inhibit the infection of HIV by disrupting the HIV envelope and release viral core protein (p24).,2576.16,C121H207N31O30,CDFMNQRTWY,V,8.61,4,1,3,4,14,116.0,2523,30 hour,>20 hour,>10 hour,171.2,0,0.0,26026377##33008028,Peptides. 2015 Sep;71:296-303.##Antibiotics (Basel). 2020 Sep 30;9(10):661.,Inhibition of HIV infection by caerin 1 antimicrobial peptides.##Caerin 1 Antimicrobial Peptides That Inhibit HIV and Neisseria May Spare Protective Lactobacilli.,"VanCompernolle S, Smith PB, Bowie JH, Tyler MJ, Unutmaz D, Rollins-Smith LA.##Rollins-Smith LA, Smith PB, Ledeczi AM, Rowe JM, Reinert LK.",10.1016/j.peptides.2015.05.004##10.3390/antibiotics9100661,,Anti-HIV
DRAVPe00359,GLLGVLGSVAKHVLPHVVPVIAEHL,25,Caerin 1.2,Litoria caerulea ,P56227,,HIV,Retroviridae,,[Ref.26026377]Human immunodeficiency virus (HIV): inhibition of HIV Pseudovirus (PsV) infection in CD4+ T cells(IC50=5 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.26026377]CD4+ T Lymphocytes:50% cell death at 22	µM.,DRAVPe00359,DRAVPe00359.cif,Linear,Free,Amidation,,L,virion envelope,Inhibit the infection of HIV by disrupting the HIV envelope and release viral core protein (p24).,2555.11,C120H200N32O29,CDFMNQRTWY,V,7.02,4,1,3,4,14,120.4,3046,30 hour,>20 hour,>10 hour,171.2,0,0.0,26026377##33008028,Peptides. 2015 Sep;71:296-303.##Antibiotics (Basel). 2020 Sep 30;9(10):661.,Inhibition of HIV infection by caerin 1 antimicrobial peptides.##Caerin 1 Antimicrobial Peptides That Inhibit HIV and Neisseria May Spare Protective Lactobacilli.,"VanCompernolle S, Smith PB, Bowie JH, Tyler MJ, Unutmaz D, Rollins-Smith LA.##Rollins-Smith LA, Smith PB, Ledeczi AM, Rowe JM, Reinert LK.",10.1016/j.peptides.2015.05.004##10.3390/antibiotics9100661,,Anti-HIV
DRAVPe00360,GLLSVLGSVVKHVIPHVVPVIAEHL,25,Caerin-1.5,Litoria caerulea (Green tree frog),P56230,,HIV,Retroviridae,,[Ref.26026377]HIV: inhibition of HIV Pseudovirus (PsV) infection in CD4+ T cells(IC50=3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.26026377]Human endocervical cells End1/E6E7:50% cell death at 12.5 µM.,DRAVPe00360,DRAVPe00360.cif,Linear,Free,Amidation,,L,membrane,"The peptide could disrupt the viral envelope and release p24 protein.And the more effective they were at disruption of the viral envelope, the better they were at inhibiting infection.",2613.19,C123H206N32O30,CDFMNQRTWY,V,7.02,4,1,3,4,14,131.2,2835,30 hour,>20 hour,>10 hour,178.8,0,0.0,26026377,Peptides. 2015 Sep;71:296-303.,"VanCompernolle S, Smith PB, Bowie JH, Tyler MJ, Unutmaz D, Rollins-Smith LA.",Inhibition of HIV infection by caerin 1 antimicrobial peptides.,10.1016/j.peptides.2015.05.004,,Anti-HIV
DRAVPe00361,GLLSVLGSVAKHVLPHVVPVIAAAL,25,"Caerin 1.1 mod 7(Caerin 1.1 [E23A,H24A])",Sythetic construct(derived from Caerin 1.1),No entry found,,HIV,Retroviridae,,[Ref.26026377]Human immunodeficiency virus (HIV): inhibition of HIV Pseudovirus (PsV) infection in CD4+ T cells(IC50=2.5 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00361,DRAVPe00361.cif,Linear,Free,Amidation,,L,virion envelope,[Ref.26026377]Inhibit the infection of HIV by disrupting the HIV envelope and release viral core protein (p24).,2461.03,C116H198N30O28,CDEFMNQRTWY,V,8.76,3,0,3,4,16,160.0,4121,30 hour,>20 hour,>10 hour,179.2,0,0.0,26026377##33008028,Peptides. 2015 Sep;71:296-303. ##Antibiotics (Basel). 2020 Sep 30;9(10):661.,Inhibition of HIV infection by caerin 1 antimicrobial peptides.##Caerin 1 Antimicrobial Peptides That Inhibit HIV and Neisseria May Spare Protective Lactobacilli.,"VanCompernolle S, Smith PB, Bowie JH, Tyler MJ, Unutmaz D, Rollins-Smith LA.##Rollins-Smith LA, Smith PB, Ledeczi AM, Rowe JM, Reinert LK.",10.1016/j.peptides.2015.05.004##10.3390/antibiotics9100661,,Anti-HIV
DRAVPe00362,GLLSVLGSVAKHVLPHVVPVIAKLH,25,"Caerin 1.1 mod 9(Caerin 1.1 [E23K,H24L,L25H])",Sythetic construct(derived from Caerin 1.1),No entry found,,HIV,Retroviridae,,[Ref.26026377]Human immunodeficiency virus (HIV): inhibition of HIV Pseudovirus (PsV) infection in CD4+ T cells(IC50=2.5 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.26026377]CD4+ T Lymphocytes:50% cell death at 17	µM.,DRAVPe00362,DRAVPe00362.cif,Linear,Free,Amidation,,L,virion envelope,[Ref.26026377]Inhibit the infection of HIV by disrupting the HIV envelope and release viral core protein (p24).,2584.19,C122H207N33O28,CDEFMNQRTWY,V,10.0,5,0,5,4,14,117.2,2738,30 hour,>20 hour,>10 hour,171.2,0,0.0,26026377,Peptides. 2015 Sep;71:296-303. ,Inhibition of HIV infection by caerin 1 antimicrobial peptides.,"VanCompernolle S, Smith PB, Bowie JH, Tyler MJ, Unutmaz D, Rollins-Smith LA.",10.1016/j.peptides.2015.05.004,,Anti-HIV
DRAVPe00363,GLLKVLGSVAKKVLPKVVPVIAEKL,25,"Caerin 1.1 mod 10(Caerin 1.1 [S4K;H12K,H16K,H24K])",Sythetic construct(derived from Caerin 1.1),No entry found,,HIV,Retroviridae,,[Ref.26026377]Human immunodeficiency virus (HIV): inhibition of HIV Pseudovirus (PsV) infection in CD4+ T cells(IC50=4 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00363,DRAVPe00363.cif,Linear,Free,Amidation,,L,virion envelope,[Ref.26026377]Inhibit the infection of HIV by disrupting the HIV envelope and release viral core protein (p24).,2599.33,C124H224N30O29,CDFHMNQRTWY,V,10.18,5,1,4,3,14,98.0,2130,30 hour,>20 hour,>10 hour,171.2,0,0.0,26026377,Peptides. 2015 Sep;71:296-303. ,Inhibition of HIV infection by caerin 1 antimicrobial peptides.,"VanCompernolle S, Smith PB, Bowie JH, Tyler MJ, Unutmaz D, Rollins-Smith LA.",10.1016/j.peptides.2015.05.004,,Anti-HIV
DRAVPe00364,GLFGVLGSIAKHLLPHVVPVIAEKL,25,Caerin 1.9 sm(Caerin 1.9 [V13L]),Sythetic construct(derived from Caerin 1.9),No entry found,,HIV,Retroviridae,,[Ref.26026377]Human immunodeficiency virus (HIV): inhibition of HIV Pseudovirus (PsV) infection in CD4+ T cells(IC50=3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.26026377]CD4+ T Lymphocytes:50% cell death at 17.5 µM.,DRAVPe00364,DRAVPe00364.cif,Linear,Free,Amidation,,L,virion envelope,[Ref.26026377]Inhibit the infection of HIV by disrupting the HIV envelope and release viral core protein (p24).,2608.21,C125H207N31O29,CDMNQRTWY,L,8.61,4,1,3,4,14,113.2,2939,30 hour,>20 hour,>10 hour,163.6,0,0.0,26026377##33008028,Peptides. 2015 Sep;71:296-303. ##Antibiotics (Basel). 2020 Sep 30;9(10):661.,Inhibition of HIV infection by caerin 1 antimicrobial peptides.##Caerin 1 Antimicrobial Peptides That Inhibit HIV and Neisseria May Spare Protective Lactobacilli.,"VanCompernolle S, Smith PB, Bowie JH, Tyler MJ, Unutmaz D, Rollins-Smith LA.##Rollins-Smith LA, Smith PB, Ledeczi AM, Rowe JM, Reinert LK.",10.1016/j.peptides.2015.05.004##10.3390/antibiotics9100661,,Anti-HIV
DRAVPe00365,GLFGILGSVAKHVLPHVIPVVAEHL,25,Caerin 1.20,Litoria caerulea/Litoria splendida,No entry found,,HIV,Retroviridae,,[Ref.26026377]Human immunodeficiency virus (HIV): inhibition of HIV Pseudovirus (PsV) infection in CD4+ T cells(IC50=7 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.26026377]CD4+ T Lymphocytes:50% cell death at 25	µM;Human endocervical cells End1/E6E7:50% cell death at 22 µM.,DRAVPe00365,DRAVPe00365.cif,Linear,Free,Amidation,,L,virion envelope,[Ref.26026377]Inhibit the infection of HIV by disrupting the HIV envelope and release viral core protein (p24).,2603.15,C124H200N32O29,CDMNQRTWY,V,7.02,4,1,3,4,14,117.6,2940,30 hour,>20 hour,>10 hour,159.6,0,0.0,26026377##33008028,Peptides. 2015 Sep;71:296-303.##Antibiotics (Basel). 2020 Sep 30;9(10):661.,Inhibition of HIV infection by caerin 1 antimicrobial peptides.##Caerin 1 Antimicrobial Peptides That Inhibit HIV and Neisseria May Spare Protective Lactobacilli.,"VanCompernolle S, Smith PB, Bowie JH, Tyler MJ, Unutmaz D, Rollins-Smith LA.##Rollins-Smith LA, Smith PB, Ledeczi AM, Rowe JM, Reinert LK.",10.1016/j.peptides.2015.05.004##10.3390/antibiotics9100661,,Anti-HIV
DRAVPe00366,FLGFLKNLF,9,"Ctry2459-WT (Ctry2459, scorpions,animals)",Chaerilus tryznai (Scorpion),P0DMF3,,HCV,Flaviviridae,,[Ref.23415044]Hepatitis C virus:inhibition of infection with HCV in Huh 7.5.1 cells (EC50=1.84 μg/ml).,[Ref.23415044] HC50 = 137.9 μg/ml  against human red blood cells.,[Ref.23415044] CC50=79.8 μg/ml against Huh7.5.1 cells.,DRAVPe00366,DRAVPe00366.cif,Linear,Free,Free,,L,Not found,"The peptide potently destabilizes the viral structural integrity, thus reducing the initiation of HCV infection",1098.35,C57H83N11O11,ACDEHIMPQRSTVWY,FL,8.75,1,0,1,2,6,133.33,1245,1.1 hour,3 min,2 min,130.0,0,0.0,23415044,Biomaterials. 2013 Apr;34(13):3511-22.,"Hong W, Zhang R, Di Z, He Y, Zhao Z, Hu J, Wu Y, Li W, Cao Z.",Design of histidine-rich peptides with enhanced bioavailability and inhibitory activity against hepatitis C virus.,10.1016/j.biomaterials.2013.01.075,,Anti-HCV
DRAVPe00367,FLGFLHHLF,9,"Ctry2459-H2 (Ctry2459 peptide derivative, His-rich)",Synthetic construct( from a scorpion venom peptide library),No entry found,,HCV,Flaviviridae,,[Ref.23415044]Hepatitis C virus:inhibition of infection with HCV in Huh 7.5.1 cells (EC50=1.08 μg/ml).,[Ref.23415044] HC50 = 203.3 μg/ml against human red blood cells.,[Ref.23415044] CC50>500 μg/ml against Huh7.5.1 cells ,DRAVPe00367,DRAVPe00367.cif,Linear,Free,Amidation,,L,Not found,"The peptide effectively enter the cells, break through the endosomes, interact with the mature viral particles, and exhibit significant antiviral activities.",1130.36,C59H79N13O10,ACDEIKMNPQRSTVWY,FL,6.92,2,0,2,1,6,144.44,1532,1.1 hour,3 min,2 min,130.0,0,0.0,23415044,Biomaterials. 2013 Apr;34(13):3511-22.,"Hong W, Zhang R, Di Z, He Y, Zhao Z, Hu J, Wu Y, Li W, Cao Z.",Design of histidine-rich peptides with enhanced bioavailability and inhibitory activity against hepatitis C virus.,10.1016/j.biomaterials.2013.01.075,,Anti-HCV
DRAVPe00368,FLHFLHHLF,9,"Ctry2459-H3 (Ctry2459 peptide derivative, His-rich)",Synthetic construct(from a scorpion venom peptide library),No entry found,,HCV,Flaviviridae,,[Ref.23415044]Hepatitis C virus:inhibition of infection with HCV in Huh 7.5.1 cells (EC50=0.85 μg/ml).,[Ref.23415044] HC50 = 416.4 μg/ml against human red blood cells.,[Ref.23415044] CC50>500 μg/ml against Huh7.5.1 cells ,DRAVPe00368,DRAVPe00368.cif,Linear,Free,Amidation,,L,Not found,"The peptide effectively enter the cells, break through the endosomes, interact with the mature viral particles, and exhibit significant antiviral activities.",1210.45,C63H83N15O10,ACDEGIKMNPQRSTVWY,FHL,7.02,3,0,3,0,6,113.33,972,1.1 hour,3 min,2 min,130.0,0,0.0,23415044,Biomaterials. 2013 Apr;34(13):3511-22.,"Hong W, Zhang R, Di Z, He Y, Zhao Z, Hu J, Wu Y, Li W, Cao Z.",Design of histidine-rich peptides with enhanced bioavailability and inhibitory activity against hepatitis C virus.,10.1016/j.biomaterials.2013.01.075,,Anti-HCV
DRAVPe00369,FLPLIGRVLSGIL,13,Temporin A,Rana temporaria (European common frog),P56917,2MAA,"CCV,FV3","Herpesviridae, Iridoviridae",,[Ref.15193922]Channel Catfish virus(CCV): inhibition of CCV infection in catfish ovary(CCO) cells(reduce viral infectivity by 50% at 15 μM);##Frog Virus 3(FV3): inhibition of FV3 infection in fathead minnow(FHM) cells(reduce viral infectivity by 50% at 58 μM).,No hemolysis information or data found in the reference(s) presented in this entry,,DRAVPe00369,DRAVPe00369.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,1397.77,C68H116N16O15,ACDEHKMNQTWY,L,9.75,1,0,1,3,8,180.77,2010,1.1 hour,3 min,2 min,202.31,0,0.0,15193922,Virology. 2004 Jun 1;323(2):268-75.,"Chinchar VG, Bryan L, Silphadaung U, Noga E, Wade D, Rollins-Smith L.",Inactivation of viruses infecting ectothermic animals by amphibian and piscine antimicrobial peptides.,10.1016/j.virol.2004.02.029,,"Anti-CCV,Anti-FV3"
DRAVPe00370,GMASKAGAIAGKIAKVALKAL,21,PGLa (frog),Xenopus laevis,Q99134,,"HIV,CCV","Retroviridae, Herpesviridae",,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>50.8 μM).##[Ref.15193922]Channel Catfish virus(CCV): inhibition of CCV infection in catfish ovary(CCO) cells(reduce viral infectivity by 50% at 100 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >50.8 µM.,DRAVPe00370,DRAVPe00370.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,1969.46,C88H161N25O23S,CDEFHNPQRTWY,A,10.48,4,0,4,4,12,84.29,1596,30 hour,>20 hour,>10 hour,121.43,0,0.0,20086159##15193922,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.##Virology. 2004 Jun 1;323(2):268-75.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.##Chinchar VG, Bryan L, Silphadaung U, Noga E, Wade D, Rollins-Smith L.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.##Inactivation of viruses infecting ectothermic animals by amphibian and piscine antimicrobial peptides.,10.1128/AAC.01448-09##10.1016/j.virol.2004.02.029,,"Anti-HIV,Anti-CCV"
DRAVPe00371,FFHHIFRGIVHVGKTIHRLVTG,22,Piscidin-1,Morone saxatilis (Striped bass),Q8UUG0,2JOS##2OJM,"CCV,FV3","Herpesviridae, Iridoviridae",,[Ref.15193922]Channel Catfish virus(CCV): inhibition of CCV infection in catfish ovary(CCO) cells(reduce viral infectivity by 50% at 4 μM);##Frog Virus 3(FV3): inhibition of FV3 infection in fathead minnow(FHM) cells(reduce viral infectivity by 50% at 13 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.11601906]No cytotoxicity against catfish ovary(CCO) cells at 0.25-25μg/ ml.,DRAVPe00371,DRAVPe00371.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2572.06,C122H187N37O25,ACDEMNPQSWY,H,12.01,7,0,7,5,10,45.45,-1561,1.1 hour,3 min,2 min,110.45,0,0.0,15193922,Virology. 2004 Jun 1;323(2):268-75.,"Chinchar VG, Bryan L, Silphadaung U, Noga E, Wade D, Rollins-Smith L.",Inactivation of viruses infecting ectothermic animals by amphibian and piscine antimicrobial peptides.,10.1016/j.virol.2004.02.029,,"Anti-CCV,Anti-FV3"
DRAVPe00372,FFHHIFRGIVHVGKTIHKLVTG,22,Piscidin-2,Morone chrysops (White bass),Q8UUG2,,"CCV,FV3","Herpesviridae, Iridoviridae",,[Ref.15193922]Channel Catfish virus(CCV): inhibition of CCV infection in catfish ovary(CCO) cells(reduce viral infectivity by 50% at 4 μM);##Frog Virus 3(FV3): inhibition of FV3 infection in fathead minnow(FHM) cells(reduce viral infectivity by 50% at 13 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00372,DRAVPe00372.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2544.05,C122H187N35O25,ACDEMNPQSWY,H,11.17,7,0,7,5,10,48.18,-624,1.1 hour,3 min,2 min,110.45,0,0.0,15193922,Virology. 2004 Jun 1;323(2):268-75.,"Chinchar VG, Bryan L, Silphadaung U, Noga E, Wade D, Rollins-Smith L.",Inactivation of viruses infecting ectothermic animals by amphibian and piscine antimicrobial peptides.,10.1016/j.virol.2004.02.029,,"Anti-CCV,Anti-FV3"
DRAVPe00373,FIHHIFRGIVHAGRSIGRFLTG,22,Piscidin 3 (fish),Morone saxatilis,No entry found,2jos,"HIV,CCV,FV3","Retroviridae, Herpesviridae, Iridoviridae",,[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=2.1 μM).##[Ref.15193922]Channel Catfish virus(CCV): inhibition of CCV infection in catfish ovary(CCO) cells(reduce viral infectivity by 50% at 11 μM);##Frog Virus 3(FV3): inhibition of FV3 infection in fathead minnow(FHM) cells(reduce viral infectivity by 50% at 16 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20086159]CEM-SS cells:50% Cell death at 6.9 µM.,DRAVPe00373,DRAVPe00373.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2491.93,C116H179N37O25,CDEKMNPQWY,GI,12.3,6,0,6,6,10,45.45,-2156,1.1 hour,3 min,2 min,106.36,0,0.0,20086159##15193922,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.##Virology. 2004 Jun 1;323(2):268-75.,"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.##Chinchar VG, Bryan L, Silphadaung U, Noga E, Wade D, Rollins-Smith L.",Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.##Inactivation of viruses infecting ectothermic animals by amphibian and piscine antimicrobial peptides.,10.1128/AAC.01448-09##10.1016/j.virol.2004.02.029,,"Anti-HIV,Anti-CCV,Anti-FV3"
DRAVPe00374,GLMDTVKNVAKNLAGHMLDKLKCKITGC,28,"Ranatuerin-2P (Ranatuerin 2P; Frogs, amphibians, animals)",Rana pipiens (Northern leopard frog),Q8QFQ4##P82847,2K10,"FV3,CCV","Iridoviridae, Herpesviridae",,[Ref.11601906]Frog Virus 3(FV3):  inhibition of FV3 infection in fathead minnow(FHM) cells(90% inhibition at 500 µM);##Channel Catfish virus(CCV):  inhibition of CCV infection in catfish ovary(CCO) cells(99% inhibition at 50 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00374,DRAVPe00374.cif,Cyclic,Free,Cyclization of a C-terminal Cys residue (forming a disulfide bond),There is a disulfide bond between Cys22 and Cys27.,L,Not found,No machanism information found in the reference(s) presented in this entry,3002.66,C128H225N37O37S4,EFPQRSWY,K,9.24,6,2,4,9,9,4.29,-2189,30 hour,>20 hour,>10 hour,97.5,125,4.63,11601906,Virology. 2001 Sep 30;288(2):351-7.,"Chinchar VG, Wang J, Murti G, Carey C, Rollins-Smith L.","Inactivation of frog virus 3 and channel catfish virus by esculentin-2P and ranatuerin-2P, two antimicrobial peptides isolated from frog skin.",10.1006/viro.2001.1080,,"Anti-FV3,Anti-CCV"
DRAVPe00375,GFLSIFRGVAKFASKGLGKDLARLGVNLVACKISKQC,37,"Esculentin-2P (Frogs, amphibians, animals)",Rana pipiens (northern leopard frog),P82846,,"FV3,CCV","Iridoviridae, Herpesviridae",,[Ref.11601906]##Frog Virus 3:  inhibition of FV3 infection in fathead minnow(FHM) cells(90% inhibition at 500 µM);##Channel Catfish virus(CCV): inhibition of CCV infection in catfish ovary(CCO) cells( 90% inhibition at 50 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00375,DRAVPe00375.cif,Cyclic,Free,Cyclization of a C-terminal Cys residue (forming a disulfide bond),There is a disulfide bond between Cys31 and Cys37.,L,Not found,No machanism information found in the reference(s) presented in this entry,3896.71,C176H296N50O45S2,EHMPTWY,GKL,10.21,7,1,6,11,17,48.11,-1869,30 hour,>20 hour,>10 hour,108.11,125,3.47,11601906,Virology. 2001 Sep 30;288(2):351-7.##Eur J Biochem. 2000 Feb;267(3):894-900.,"Chinchar VG, Wang J, Murti G, Carey C, Rollins-Smith L.","Inactivation of frog virus 3 and channel catfish virus by esculentin-2P and ranatuerin-2P, two antimicrobial peptides isolated from frog skin.",10.1006/viro.2001.1080,,"Anti-FV3,Anti-CCV"
DRAVPe00376,FVQWFSKFLGRIL,13,Temporin L(TL),Rana temporaria (European common frog),P57104,6GS5,HSV,Herpesviridae,,"[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=8.55 μM,IC90=15.66 μM);##HSV-2:inhibition of HSV-2 replication in Vero cells(IC50=8.28 μM μM,IC90=16.04 μM).",[Ref.35216177]showing residual hemolytic activity against human erythrocytes only at concentrations equal or above 50 μM.,[Ref.35216177]Vero cells:CC50= 19.61 μM,DRAVPe00376,DRAVPe00376.cif,Linear,Free,Amidation,,L,membrane,"TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction.",1640.99,C83H121N19O16,ACDEHMNPTY,F,11.0,2,0,2,2,8,82.31,160,1.1 hour,3 min,2 min,112.31,5500,458.33,35216177,Int J Mol Sci. 2022 Feb 13;23(4):2060.,"Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. ",Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs.,10.3390/ijms23042060,,Anti-HSV
DRAVPe00377,FVPWFSKFlGRIL,13,"Temporin L[Pro3,DLeu9](TL1)",Synthetic construct(derived from Temporin-L),No entry found,,"SARS-CoV-2,HSV,HCoV-OC43,HPIV-3,HCoV-229E","Coronaviridae, Herpesviridae, Paramyxoviridae",,"[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=9.99 μM,IC90=18.69 μM);##HSV-2:inhibition of HSV-2 replication in Vero cells(IC50=8.86 μM μM,IC90=16.71 μM);##SARS-CoV-2:inhibition of  replication in Vero cells(IC50=4.62 μM μM,IC90=12.14 μM);##HPIV-3:inhibition of replication in Vero cells(IC50>50.00 μM,IC90>50.00 μM);##HCoV-229E:inhibition of replication in Vero cells(IC50=7.76 μM,IC90=30.07 μM);##HCoV-OC43:inhibition of replication in Vero cells(IC50=7.33 μM,IC90=14.98 μM).",[Ref.35216177]showing residual hemolytic activity against human erythrocytes only at concentrations equal or above 50 μM.,[Ref.35216177]Vero cells:CC50= 42.18 μM,DRAVPe00377,DRAVPe00377.cif,Linear,Free,Amidation,,Mixed(D-Leu9),membrane,"TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction.",1609.98,C77H107N17O13,ACDEHMNQTY,F,11.0,2,0,2,2,7,67.69,222,1.1 hour,3 min,2 min,82.31,5500,458.33,35216177,Int J Mol Sci. 2022 Feb 13;23(4):2060.,"Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. ",Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs.,10.3390/ijms23042060,,"Anti-SARS-CoV-2,Anti-HSV,HCoV-OC43,Anti-HPIV-3,HCoV-229E"
DRAVPe00378,FVPWFSKFlPRIL,13,"Temporin L[Pro3,DLeu9,Pro10](TL2)",Synthetic construct(derived from Temporin-L),No entry found,,"SARS-CoV-2,HSV,HCoV-OC43,HPIV-3,HCoV-229E","Coronaviridae, Herpesviridae, Paramyxoviridae",,"[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=7.70 μM,IC90=18.76 μM);##HSV-2:inhibition of HSV-2 replication in Vero cells(IC50=9.83 μM μM,IC90=19.20 μM);##SARS-CoV-2:inhibition of  replication in Vero cells(IC50=4.82 μM μM,IC90=13.98 μM);##HPIV-3:inhibition of replication in Vero cells(IC50>50.00 μM,IC90>50.00 μM);##HCoV-229E:inhibition of replication in Vero cells(IC50=10.56 μM,IC90=50.00 μM);##HCoV-OC43:inhibition of replication in Vero cells(IC50=11.31 μM,IC90=24.13 μM).",[Ref.35216177]<20% hemolysis against human erythrocytes at concentrations equal or above 25 μM.,[Ref.35216177]Vero cells:CC50= 56.52 μM,DRAVPe00378,DRAVPe00378.cif,Linear,Free,Amidation,,Mixed(D-Leu9),membrane,"TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction.",1650.04,C80H111N17O13,ACDEGHMNQTY,F,11.0,2,0,2,1,7,58.46,128,1.1 hour,3 min,2 min,82.31,5500,458.33,35216177,Int J Mol Sci. 2022 Feb 13;23(4):2060.,"Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. ",Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs.,10.3390/ijms23042060,,"Anti-SARS-CoV-2,Anti-HSV,HCoV-OC43,Anti-HPIV-3,HCoV-229E"
DRAVPe00379,FVPWFSKFlpRIL,13,"Temporin L[Pro3,DLeu9,DPro10](TL3)",Synthetic construct(derived from Temporin-L),No entry found,,"SARS-CoV-2,HSV,HCoV-OC43,HPIV-3,HCoV-229E","Coronaviridae, Herpesviridae, Paramyxoviridae",,"[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50>50.00 μM,IC90>50.00 μM);##HSV-2:inhibition of HSV-2 replication in Vero cells(IC50>50.00 μM μM,IC90>50.00 μM);##SARS-CoV-2:inhibition of  replication in Vero cells(IC50>50.00 μM μM,IC90>50.00 μM);##HPIV-3:inhibition of replication in Vero cells(IC50>50.00 μM,IC90>50.00 μM);##HCoV-229E:inhibition of replication in Vero cells(IC50>50.00 μM,IC90>50.00 μM);##HCoV-OC43:inhibition of replication in Vero cells(IC50>50.00 μM,IC90>50.00 μM).",[Ref.35216177]<20% hemolysis against human erythrocytes at concentrations equal or above 25 μM.,[Ref.35216177]Vero cells:CC50>100 μM,DRAVPe00379,DRAVPe00379.cif,Linear,Free,Amidation,,"Mixed(D-Leu9,D-Pro10)",membrane,"TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction.",1650.04,C75H102N16O11,ACDEGHMNQTY,F,11.0,2,0,2,1,7,70.77,128,1.1 hour,3 min,2 min,82.31,5500,458.33,35216177,Int J Mol Sci. 2022 Feb 13;23(4):2060.,"Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. ",Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs.,10.3390/ijms23042060,,"Anti-SARS-CoV-2,Anti-HSV,HCoV-OC43,Anti-HPIV-3,HCoV-229E"
DRAVPe00380,FVPWFSKFlXRIL,13,"Temporin L[Pro3,DLeu9,Hyp10](TL4)",Synthetic construct(derived from Temporin-L),No entry found,,"SARS-CoV-2,HSV,HCoV-OC43,HPIV-3,HCoV-229E","Coronaviridae, Herpesviridae, Paramyxoviridae",,"[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=7.73 μM,IC90=15.89 μM);##HSV-2:inhibition of HSV-2 replication in Vero cells(IC50=9.61 μM μM,IC90=19.02 μM);##SARS-CoV-2:inhibition of  replication in Vero cells(IC50=6.72 μM μM,IC90=25.00 μM);##HPIV-3:inhibition of replication in Vero cells(IC50>50.00 μM,IC90>50.00 μM);##HCoV-229E:inhibition of replication in Vero cells(IC50=11.74 μM,IC90>50.00 μM);##HCoV-OC43:inhibition of replication in Vero cells(IC50=11.33 μM,IC90=27.65 μM).",[Ref.35216177]<20% hemolysis against human erythrocytes at concentrations equal or above 25 μM.,[Ref.35216177]Vero cells:CC50=60.90 μM,DRAVPe00380,DRAVPe00380.cif,Linear,Free,Amidation,The 'X' at position 10 is hydroxyproline (Hyp).,Mixed(D-Leu9),membrane,"TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction.",1664.26,C75H102N16O11,ACDEGHMNQTY,F,11.0,2,0,2,1,7,70.77,128,1.1 hour,3 min,2 min,82.31,5500,458.33,35216177,Int J Mol Sci. 2022 Feb 13;23(4):2060.,"Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. ",Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs.,10.3390/ijms23042060,,"Anti-SARS-CoV-2,Anti-HSV,HCoV-OC43,Anti-HPIV-3,HCoV-229E"
DRAVPe00381,FVPWFSKFlxRIL,13,"Temporin L[Pro3,DLeu9,DHyp10](TL5)",Synthetic construct(derived from Temporin-L),No entry found,,"SARS-CoV-2,HSV,HCoV-OC43,HPIV-3,HCoV-229E","Coronaviridae, Herpesviridae, Paramyxoviridae",,"[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50>50.00 μM,IC90>50.00 μM);##HSV-2:inhibition of HSV-2 replication in Vero cells(IC50>50.00 μM μM,IC90>50.00 μM);##SARS-CoV-2:inhibition of  replication in Vero cells(IC50>50.00 μM μM,IC90>50.00 μM);##HPIV-3:inhibition of replication in Vero cells(IC50>50.00 μM,IC90>50.00 μM);##HCoV-229E:inhibition of replication in Vero cells(IC50>50.00 μM,IC90>50.00 μM);##HCoV-OC43:inhibition of replication in Vero cells(IC50>50.00 μM,IC90>50.00 μM).",[Ref.35216177]<20% hemolysis against human erythrocytes at concentrations equal or above 25 μM.,[Ref.35216177]Vero cells:CC50>100.00 μM,DRAVPe00381,DRAVPe00381.cif,Linear,Free,Amidation,The 'x' at position 10 is D-hydroxyproline (Hyp).,"Mixed(D-Leu9,D-Hyp10)",membrane,"TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction.",1664.26,C75H102N16O11,ACDEGHMNQTY,F,11.0,2,0,2,1,7,70.77,128,1.1 hour,3 min,2 min,82.31,5500,458.33,35216177,Int J Mol Sci. 2022 Feb 13;23(4):2060.,"Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. ",Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs.,10.3390/ijms23042060,,"Anti-SARS-CoV-2,Anti-HSV,HCoV-OC43,Anti-HPIV-3,HCoV-229E"
DRAVPe00382,FVPWFSKFlxRIL,13,"Temporin L[Pro3,DLeu9,DNle10](TL7)",Synthetic construct(derived from Temporin-L),No entry found,,"SARS-CoV-2,HSV,HCoV-OC43,HPIV-3,HCoV-229E","Coronaviridae, Herpesviridae, Paramyxoviridae",,"[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=3.65 μM,IC90=12.83 μM);##HSV-2:inhibition of HSV-2 replication in Vero cells(IC50=3.13 μM μM,IC90=11.92 μM);##SARS-CoV-2:inhibition of  replication in Vero cells(IC50=1.00 μM μM,IC90=17.41 μM);##HPIV-3:inhibition of replication in Vero cells(IC50>50.00 μM,IC90>50.00 μM);##HCoV-229E:inhibition of replication in Vero cells(IC50=6.21 μM,IC90>50.00 μM);##HCoV-OC43:inhibition of replication in Vero cells(IC50=8.55 μM,IC90=24.74 μM).",[Ref.35216177]<20% hemolysis against human erythrocytes at concentrations equal or above 25 μM.,[Ref.35216177]Vero cells:CC50= 32.16 μM,DRAVPe00382,DRAVPe00382.cif,Linear,Free,Amidation,The 'x' at position 10 is D-norleucine.,"Mixed(D-Leu9,D-Nle10)",membrane,"TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction.",1664.26,C75H102N16O11,ACDEGHMNQTY,F,11.0,2,0,2,1,7,70.77,128,1.1 hour,3 min,2 min,82.31,5500,458.33,35216177,Int J Mol Sci. 2022 Feb 13;23(4):2060.,"Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. ",Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs.,10.3390/ijms23042060,,"Anti-SARS-CoV-2,Anti-HSV,HCoV-OC43,Anti-HPIV-3,HCoV-229E"
DRAVPe00383,FVPWFSKFlKRIL,13,"Temporin L[Pro3,DLeu9,Lys10](TL8)",Synthetic construct(derived from Temporin-L),No entry found,,"SARS-CoV-2,HSV,HCoV-OC43,HPIV-3,HCoV-229E","Coronaviridae, Herpesviridae, Paramyxoviridae",,"[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=2.49 μM,IC90=10.48 μM);##HSV-2:inhibition of HSV-2 replication in Vero cells(IC50=1.00 μM μM,IC90=7.99 μM);##SARS-CoV-2:inhibition of  replication in Vero cells(IC50=0.88 μM μM,IC90=12.93 μM);##HPIV-3:inhibition of replication in Vero cells(IC50=40.69 μM,IC90>50.00 μM);##HCoV-229E:inhibition of replication in Vero cells(IC50=4.39 μM,IC90=50.00 μM);##HCoV-OC43:inhibition of replication in Vero cells(IC50=2.90 μM,IC90=16.30 μM).",[Ref.35216177]About 20% hemolysis against human erythrocytes at concentrations equal or above 25 μM.,[Ref.35216177]Vero cells:CC50=22.32 μM,DRAVPe00383,DRAVPe00383.cif,Linear,Free,Amidation,,Mixed(D-Leu9),membrane,"TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction.",1681.1,C81H116N18O13,ACDEGHMNQTY,F,11.17,3,0,3,1,7,40.77,-427,1.1 hour,3 min,2 min,82.31,5500,458.33,35216177,Int J Mol Sci. 2022 Feb 13;23(4):2060.,"Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. ",Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs.,10.3390/ijms23042060,,"Anti-SARS-CoV-2,Anti-HSV,HCoV-OC43,Anti-HPIV-3,HCoV-229E"
DRAVPe00384,FVPWFSKFlkRIL,13,"Temporin L[Pro3,DLeu9,DLys10](TL9)",Synthetic construct(derived from Temporin-L),No entry found,,"SARS-CoV-2,HSV,HCoV-OC43,HPIV-3,HCoV-229E","Coronaviridae, Herpesviridae, Paramyxoviridae",,"[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=3.53 μM,IC90=12.71 μM);##HSV-2:inhibition of HSV-2 replication in Vero cells(IC50=2.80 μM μM,IC90=12.50 μM);##SARS-CoV-2:inhibition of  replication in Vero cells(IC50=4.63 μM μM,IC90=25.33 μM);##HPIV-3:inhibition of replication in Vero cells(IC50=40.64 μM,IC90>50.00 μM);##HCoV-229E:inhibition of replication in Vero cells(IC50=5.39 μM,IC90=50.00 μM);##HCoV-OC43:inhibition of replication in Vero cells(IC50=8.29 μM,IC90=29.17 μM).",[Ref.35216177]<20% hemolysis against human erythrocytes at concentrations equal or above 25 μM.,[Ref.35216177]Vero cells:CC50= 45.92 μM,DRAVPe00384,DRAVPe00384.cif,Linear,Free,Amidation,,"Mixed(D-Leu9,D-Lys10)",membrane,"TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction.",1681.1,C75H102N16O11,ACDEGHMNQTY,F,11.17,2,0,2,1,7,70.77,128,1.1 hour,3 min,2 min,82.31,5500,458.33,35216177,Int J Mol Sci. 2022 Feb 13;23(4):2060.,"Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. ",Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs.,10.3390/ijms23042060,,"Anti-SARS-CoV-2,Anti-HSV,HCoV-OC43,Anti-HPIV-3,HCoV-229E"
DRAVPe00385,FVPWFSKFlWRIL,13,"Temporin L[Pro3,DLeu9,Trp10](TL10)",Synthetic construct(derived from Temporin-L),No entry found,,"SARS-CoV-2,HSV,HCoV-OC43,HPIV-3,HCoV-229E","Coronaviridae, Herpesviridae, Paramyxoviridae",,"[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=3.01 μM,IC90=8.25 μM);##HSV-2:inhibition of HSV-2 replication in Vero cells(IC50=0.77 μM μM,IC90=12.50 μM);##SARS-CoV-2:inhibition of  replication in Vero cells(IC50=0.88 μM μM,IC90=27.71 μM);##HPIV-3:inhibition of replication in Vero cells(IC50>50.00 μM,IC90>50.00 μM);##HCoV-229E:inhibition of replication in Vero cells(IC50=0.91 μM,IC90=50.00 μM);##HCoV-OC43:inhibition of replication in Vero cells(IC50=0.96 μM,IC90=24.17 μM).",[Ref.35216177]<20% hemolysis against human erythrocytes at concentrations equal or above 25 μM.,[Ref.35216177]Vero cells:CC50= 35.47 μM,DRAVPe00385,DRAVPe00385.cif,Linear,Free,Amidation,,Mixed(D-Leu9),membrane,"TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction.",1739.14,C86H114N18O13,ACDEGHMNQTY,F,11.0,2,0,2,1,8,63.85,361,1.1 hour,3 min,2 min,82.31,11000,916.67,35216177,Int J Mol Sci. 2022 Feb 13;23(4):2060.,"Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. ",Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs.,10.3390/ijms23042060,,"Anti-SARS-CoV-2,Anti-HSV,HCoV-OC43,Anti-HPIV-3,HCoV-229E"
DRAVPe00386,FVPWFSKFlwRIL,13,"Temporin L[Pro3,DLeu9,DTrp10](TL11)",Synthetic construct(derived from Temporin-L),No entry found,,"SARS-CoV-2,HSV,HCoV-OC43,HPIV-3,HCoV-229E","Coronaviridae, Herpesviridae, Paramyxoviridae",,"[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=1.86 μM,IC90=7.89 μM);##HSV-2:inhibition of HSV-2 replication in Vero cells(IC50=0.58 μM μM,IC90=9.76 μM);##SARS-CoV-2:inhibition of  replication in Vero cells(IC50=4.07 μM μM,IC90=14.85 μM);##HPIV-3:inhibition of replication in Vero cells(IC50=41.18 μM,IC90>50.00 μM);##HCoV-229E:inhibition of replication in Vero cells(IC50=0.92 μM,IC90=50.00 μM);##HCoV-OC43:inhibition of replication in Vero cells(IC50=5.10 μM,IC90=17.41 μM).",[Ref.35216177]<40% hemolysis against human erythrocytes at concentrations equal or above 25 μM.,[Ref.35216177]Vero cells:CC50=24.12 μM,DRAVPe00386,DRAVPe00386.cif,Linear,Free,Amidation,,"Mixed(D-Leu9,D-Trp10)",membrane,"TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction.",1739.14,C75H102N16O11,ACDEGHMNQTY,F,11.0,2,0,2,1,7,70.77,128,1.1 hour,3 min,2 min,82.31,5500,458.33,35216177,Int J Mol Sci. 2022 Feb 13;23(4):2060.,"Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. ",Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs.,10.3390/ijms23042060,,"Anti-SARS-CoV-2,Anti-HSV,HCoV-OC43,Anti-HPIV-3,HCoV-229E"
DRAVPe00387,FVPWFSKFlXRIL,13,"Temporin L[Pro3,DLeu9,Aic10](TL12)",Synthetic construct(derived from Temporin-L),No entry found,,"SARS-CoV-2,HSV,HCoV-OC43,HPIV-3,HCoV-229E","Coronaviridae, Herpesviridae, Paramyxoviridae",,"[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=0.68 μM,IC90=1.58 μM);##HSV-2:inhibition of HSV-2 replication in Vero cells(IC50=0.54 μM μM,IC90=11.86 μM);##SARS-CoV-2:inhibition of  replication in Vero cells(IC50=0.65 μM μM,IC90=13.85 μM);##HPIV-3:inhibition of replication in Vero cells(IC50=33.83 μM,IC90>50.00 μM);##HCoV-229E:inhibition of replication in Vero cells(IC50=0.74 μM,IC90=20.90 μM);##HCoV-OC43:inhibition of replication in Vero cells(IC50=0.62 μM,IC90=13.18 μM).",[Ref.35216177]<20% hemolysis against human erythrocytes at concentrations equal or above 12.5 μM.,[Ref.35216177]Vero cells:CC50=8.28 μM,DRAVPe00387,DRAVPe00387.cif,Linear,Free,Amidation,The 'X' at position 10 is 2-aminoindane-2-carboxylic acid.,Mixed(D-Leu9),membrane,"TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction.",1664.26,C75H102N16O11,ACDEGHMNQTY,F,11.0,2,0,2,1,7,70.77,128,1.1 hour,3 min,2 min,82.31,5500,458.33,35216177,Int J Mol Sci. 2022 Feb 13;23(4):2060.,"Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. ",Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs.,10.3390/ijms23042060,,"Anti-SARS-CoV-2,Anti-HSV,HCoV-OC43,Anti-HPIV-3,HCoV-229E"
DRAVPe00388,FVPWFSKFlXRIL,13,"Temporin L[Pro3,DLeu9,Nle10](TL6)",Synthetic construct(derived from Temporin-L),No entry found,,"SARS-CoV-2,HSV,HCoV-OC43,HPIV-3,HCoV-229E,MeV,H1N1","Coronaviridae, Herpesviridae, Paramyxoviridae, Orthomyxoviridae",,"[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=2.66 μM,IC90=9.12 μM);##HSV-2:inhibition of HSV-2 replication in Vero cells(IC50=0.92 μM μM,IC90=6.28 μM);##SARS-CoV-2:inhibition of  replication in Vero cells(IC50=0.53 μM μM,IC90=12.15 μM);##HPIV-3:inhibition of replication in Vero cells(IC50=32.35 μM,IC90>50.00 μM);##HCoV-229E:inhibition of replication in Vero cells(IC50=2.08 μM,IC90=13.06 μM);##HCoV-OC43:inhibition of replication in Vero cells(IC50=0.97 μM,IC90=10.04 μM);##Measles virus(MeV):inhibition of MeV replication in VERO/hSLAM cells(IC50=34.58 μM μM,IC90>50.00 μM);##influenza virus(H1N1,VR-1894):inhibition of replication in MDKC cells(IC50=2.66 μM,IC90=9.12 μM).",[Ref.35216177]<20% hemolysis against human erythrocytes at concentrations equal or above 25 μM.,[Ref.35216177]Vero cells:CC50=64.52 μM,DRAVPe00388,DRAVPe00388.cif,Linear,Free,Amidation,The 'X' at position 10 is norleucine.,Mixed(D-Leu9),membrane,"TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction.",1664.26,C75H102N16O11,ACDEGHMNQTY,F,11.0,2,0,2,1,7,70.77,128,1.1 hour,3 min,2 min,82.31,5500,458.33,35216177,Int J Mol Sci. 2022 Feb 13;23(4):2060.,"Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. ",Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs.,10.3390/ijms23042060,,"Anti-SARS-CoV-2,Anti-HSV,HCoV-OC43,Anti-HPIV-3,HCoV-229E,Anti-MeV,Anti-H1N1"
DRAVPe00389,FVPWFSKFlXRILC,14,"Temporin L[Pro3,DLeu9,Nle10]-C-CHOL(TL6.1)",Synthetic construct(derived from Temporin-L),No entry found,,"SARS-CoV-2,HSV, MeV,H1N1","Coronaviridae, Herpesviridae, Paramyxoviridae, Orthomyxoviridae",,"[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=6.4 μM,IC90=11.13 μM);##SARS-CoV-2:inhibition of  replication in Vero cells(IC50=3.18 μM μM,IC90=12.03 μM);##Measles virus(MeV):inhibition of MeV replication in VERO/hSLAM cells(IC50=39.1 μM μM,IC90>50.00 μM);##influenza virus(H1N1,VR-1894):inhibition of replication in MDKC cells(IC50=5.55 μM,IC90=10.02 μM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.35216177]Vero cells:CC50>100.00 μM,DRAVPe00389,DRAVPe00389.cif,Linear,Free,PEG4-Cholesterol-NH2,The 'X' at position 10 is norleucine.,Mixed(D-Leu9),membrane,"TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction.",1767.39,C78H107N17O12S,ADEGHMNQTY,F,9.51,2,0,2,2,7,83.57,256,1.1 hour,3 min,2 min,76.43,5500,423.08,35216177,Int J Mol Sci. 2022 Feb 13;23(4):2060.,"Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. ",Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs.,10.3390/ijms23042060,,"Anti-SARS-CoV-2,Anti-HSV, Anti-MeV,Anti-H1N1"
DRAVPe00390,FVPWFSKFlXRILGGC,16,"Temporin L[Pro3,DLeu9,Nle10]-GGC-CHOL(TL6.2)",Synthetic construct(derived from Temporin-L),No entry found,,"SARS-CoV-2,HSV, MeV,H1N1","Coronaviridae, Herpesviridae, Paramyxoviridae, Orthomyxoviridae",,"[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=9.54 μM,IC90=47.95 μM);##SARS-CoV-2:inhibition of  replication in Vero cells(IC50=12.12 μM μM,IC90=49.95 μM);##Measles virus(MeV):inhibition of MeV replication in VERO/hSLAM cells(IC50=40.89 μM μM,IC90>50.00 μM);##influenza virus(H1N1,VR-1894):inhibition of replication in MDKC cells(IC50=21.12 μM,IC90=49.90 μM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.35216177]Vero cells:CC50>100.00 μM,DRAVPe00390,DRAVPe00390.cif,Linear,Free,PEG4-Cholesterol-NH2,The 'X' at position 10 is norleucine.,Mixed(D-Leu9),membrane,"TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction.",1881.5,C82H113N19O14S,ADEHMNQTY,F,9.51,2,0,2,4,7,68.13,444,1.1 hour,3 min,2 min,66.88,5500,366.67,35216177,Int J Mol Sci. 2022 Feb 13;23(4):2060.,"Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. ",Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs.,10.3390/ijms23042060,,"Anti-SARS-CoV-2,Anti-HSV, Anti-MeV,Anti-H1N1"
DRAVPe00391,CFVPWFSKFlXRIL,14,"CHOL-C-Temporin L[Pro3,DLeu9,Nle10](TL6.3)",Synthetic construct(derived from Temporin-L),No entry found,,"SARS-CoV-2,HSV, MeV,H1N1","Coronaviridae, Herpesviridae, Paramyxoviridae, Orthomyxoviridae",,"[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=0.89 μM,IC90=2.19 μM);##SARS-CoV-2:inhibition of  replication in Vero cells(IC50=0.76 μM μM,IC90=1.89 μM);##Measles virus(MeV):inhibition of MeV replication in VERO/hSLAM cells(IC50=22.3 μM μM,IC90=31.10 μM);##influenza virus(H1N1,VR-1894):inhibition of replication in MDKC cells(IC50=2.55 μM,IC90=5.89 μM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.35216177]Vero cells:CC50>100.00 μM,DRAVPe00391,DRAVPe00391.cif,Linear,Cholesterol-PEG4,Amidation,The 'X' at position 10 is norleucine.,Mixed(D-Leu9),membrane,"TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction.",1767.39,C78H107N17O12S,ADEGHMNQTY,F,9.51,2,0,2,2,7,83.57,256,1.2 hour,>20 hour,>10 hour,76.43,5500,423.08,35216177,Int J Mol Sci. 2022 Feb 13;23(4):2060.,"Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. ",Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs.,10.3390/ijms23042060,,"Anti-SARS-CoV-2,Anti-HSV, Anti-MeV,Anti-H1N1"
DRAVPe00392,CGGFVPWFSKFlXRIL,16,"CHOL-CGG-Temporin L[Pro3,DLeu9,Nle10](TL6.4)",Synthetic construct(derived from Temporin-L),No entry found,,"SARS-CoV-2,HSV, MeV,H1N1","Coronaviridae, Herpesviridae, Paramyxoviridae, Orthomyxoviridae",,"[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=2.32 μM,IC90=8.21 μM);##SARS-CoV-2:inhibition of  replication in Vero cells(IC50=1.02 μM μM,IC90=10.21 μM);##Measles virus(MeV):inhibition of MeV replication in VERO/hSLAM cells(IC50=28.88 μM μM,IC90=49.90 μM);##influenza virus(H1N1,VR-1894):inhibition of replication in MDKC cells(IC50=6.02 μM,IC90=9.90 μM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.35216177]Vero cells:CC50>100.00 μM,DRAVPe00392,DRAVPe00392.cif,Linear,Cholesterol-PEG4,Amidation,The 'X' at position 10 is norleucine.,Mixed(D-Leu9),membrane,"TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction.",1881.5,C82H113N19O14S,ADEHMNQTY,F,9.51,2,0,2,4,7,68.13,444,1.2 hour,>20 hour,>10 hour,66.88,5500,366.67,35216177,Int J Mol Sci. 2022 Feb 13;23(4):2060.,"Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. ",Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs.,10.3390/ijms23042060,,"Anti-SARS-CoV-2,Anti-HSV, Anti-MeV,Anti-H1N1"
DRAVPe00393,FVPWFSKFlXRIL,13,"Undecanoic-Temporin L[Pro3,DLeu9,Nle10](TL6.5)",Synthetic construct(derived from Temporin-L),No entry found,,"SARS-CoV-2,HSV, MeV,H1N1","Coronaviridae, Herpesviridae, Paramyxoviridae, Orthomyxoviridae",,"[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50<0.10 μM,IC90<0.10 μM);##SARS-CoV-2:inhibition of  replication in Vero cells(IC50<0.10 μM μM,IC90<0.10 μM);##Measles virus(MeV):inhibition of MeV replication in VERO/hSLAM cells(IC50=10.01 μM μM,IC90=29.18 μM);##influenza virus(H1N1,VR-1894):inhibition of replication in MDKC cells(IC50<0.10 μM,IC90<0.10 μM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.35216177]Vero cells:CC50>100.00 μM,DRAVPe00393,DRAVPe00393.cif,Linear,Undecanoic acid,Amidation,The 'X' at position 10 is norleucine.,Mixed(D-Leu9),membrane,"TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction.",1664.26,C75H102N16O11,ACDEGHMNQTY,F,11.0,2,0,2,1,7,70.77,128,1.1 hour,3 min,2 min,82.31,5500,458.33,35216177,Int J Mol Sci. 2022 Feb 13;23(4):2060.,"Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. ",Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs.,10.3390/ijms23042060,,"Anti-SARS-CoV-2,Anti-HSV, Anti-MeV,Anti-H1N1"
DRAVPe00394,FVPWFSKFlXRIL,13,"Tridecanoic-Temporin L[Pro3,DLeu9,Nle10](TL6.6)",Synthetic construct(derived from Temporin-L),No entry found,,"SARS-CoV-2,HSV, MeV,H1N1","Coronaviridae, Herpesviridae, Paramyxoviridae, Orthomyxoviridae",,"[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=1.39 μM,IC90=2.86 μM);##SARS-CoV-2:inhibition of  replication in Vero cells(IC50=0.39 μM μM,IC90=5.86 μM);##Measles virus(MeV):inhibition of MeV replication in VERO/hSLAM cells(IC50=33.36 μM μM,IC90>50.00 μM);##influenza virus(H1N1,VR-1894):inhibition of replication in MDKC cells(IC50=3.39 μM,IC90=6.66 μM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.35216177]Vero cells:CC50>100.00 μM,DRAVPe00394,DRAVPe00394.cif,Linear,Tridecanoic acid,Amidation,The 'X' at position 10 is norleucine.,Mixed(D-Leu9),membrane,"TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction.",1664.26,C75H102N16O11,ACDEGHMNQTY,F,11.0,2,0,2,1,7,70.77,128,1.1 hour,3 min,2 min,82.31,5500,458.33,35216177,Int J Mol Sci. 2022 Feb 13;23(4):2060.,"Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. ",Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs.,10.3390/ijms23042060,,"Anti-SARS-CoV-2,Anti-HSV, Anti-MeV,Anti-H1N1"
DRAVPe00395,FVPWFSKFlXRIL,13,"Pentadecanoic-Temporin L[Pro3,DLeu9,Nle10](TL6.7)",Synthetic construct(derived from Temporin-L),No entry found,,"SARS-CoV-2,HSV, MeV,H1N1","Coronaviridae, Herpesviridae, Paramyxoviridae, Orthomyxoviridae",,"[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=2.48 μM,IC90=4.86 μM);##SARS-CoV-2:inhibition of  replication in Vero cells(IC50=0.48 μM μM,IC90=7.86 μM);##Measles virus(MeV):inhibition of MeV replication in VERO/hSLAM cells(IC50=37.77 μM μM,IC90>50.00 μM);##influenza virus(H1N1,VR-1894):inhibition of replication in MDKC cells(IC50=3.48 μM,IC90=7.10 μM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.35216177]Vero cells:CC50>100.00 μM,DRAVPe00395,DRAVPe00395.cif,Linear,Pentadecanoic acid,Amidation,The 'X' at position 10 is norleucine.,Mixed(D-Leu9),membrane,"TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction.",1664.26,C75H102N16O11,ACDEGHMNQTY,F,11.0,2,0,2,1,7,70.77,128,1.1 hour,3 min,2 min,82.31,5500,458.33,35216177,Int J Mol Sci. 2022 Feb 13;23(4):2060.,"Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. ",Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs.,10.3390/ijms23042060,,"Anti-SARS-CoV-2,Anti-HSV, Anti-MeV,Anti-H1N1"
DRAVPe00396,FVPWFSKFlXRIL,13,"Hexadecenoic-Temporin L[Pro3,DLeu9,Nle10](TL6.8)",Synthetic construct(derived from Temporin-L),No entry found,,"SARS-CoV-2,HSV, MeV,H1N1","Coronaviridae, Herpesviridae, Paramyxoviridae, Orthomyxoviridae",,"[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=3.13 μM,IC90=4.96 μM);##SARS-CoV-2:inhibition of  replication in Vero cells(IC50=0.77 μM μM,IC90=6.96 μM);##Measles virus(MeV):inhibition of MeV replication in VERO/hSLAM cells(IC50=39.4 μM μM,IC90>50.00 μM);##influenza virus(H1N1,VR-1894):inhibition of replication in MDKC cells(IC50=4.77 μM,IC90=7.11 μM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.35216177]Vero cells:CC50>100.00 μM,DRAVPe00396,DRAVPe00396.cif,Linear,Palmitic acid,Amidation,The 'X' at position 10 is norleucine.,Mixed(D-Leu9),membrane,"TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction.",1664.26,C75H102N16O11,ACDEGHMNQTY,F,11.0,2,0,2,1,7,70.77,128,1.1 hour,3 min,2 min,82.31,5500,458.33,35216177,Int J Mol Sci. 2022 Feb 13;23(4):2060.,"Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. ",Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs.,10.3390/ijms23042060,,"Anti-SARS-CoV-2,Anti-HSV, Anti-MeV,Anti-H1N1"
DRAVPe00397,TLLKKVLKAAAKAALNAVLVGANA,24,Dermaseptin S4 (5-28),Synthetic construct(derived from Dermaseptin S4),No entry found,,HSV,Herpesviridae,,[Ref.23161023]HSV-2 acyclovir-sensitive strain(911411):inhibition the cytopathic effect(CPE) of HSV-2 in Vero cells(EC50=27.07 μM);##HSV-2 acyclovir-resistant strain(ROI2):inhibition of cytopathic effet(CPE) of HSV-2 in Vero cells(EC50=25.27 μM). ,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.23161023]Vero cells:CC50=34 μM.,DRAVPe00397,DRAVPe00397.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2348.9,C107H194N30O28,CDEFHIMPQRSWY,A,10.48,4,0,4,4,16,92.92,1409,7.2 hour,>20 hour,>10 hour,150.83,0,0.0,23161023,J Med Virol. 2013 Feb;85(2):272-81.,"Bergaoui I, Zairi A, Tangy F, Aouni M, Selmi B, Hani K. ", In vitro antiviral activity of dermaseptin S(4) and derivatives from amphibian skin against herpes simplex virus type 2.,10.1002/jmv.23450,,Anti-HSV
DRAVPe00398,ALWKTLLKKVLKAAAKAALNAVLVGANA,28,Dermaseptin K4S4 ,Synthetic construct(derived from Dermaseptin S4),No entry found,,HSV,Herpesviridae,,[Ref.23161023]HSV-2 acyclovir-sensitive strain(911411):inhibition the cytopathic effect(CPE) of HSV-2 in Vero cells(EC50=2.7 μM);##HSV-2 acyclovir-resistant strain(ROI2):inhibition of cytopathic effet(CPE) of HSV-2 in Vero cells(EC50=5.1 μM). ,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.23161023]Vero cells:CC50=12 μM.,DRAVPe00398,DRAVPe00398.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2847.53,C133H232N36O32,CDEFHIMPQRSY,A,10.6,5,0,5,4,19,82.5,1760,4.4 hour,>20 hour,>10 hour,146.79,5500,203.7,23161023,J Med Virol. 2013 Feb;85(2):272-81.,"Bergaoui I, Zairi A, Tangy F, Aouni M, Selmi B, Hani K. ", In vitro antiviral activity of dermaseptin S(4) and derivatives from amphibian skin against herpes simplex virus type 2.,10.1002/jmv.23450,,Anti-HSV
DRAVPe00399,ALWKTLLKKVLKAAAKAALKAVLVGANA,28,Dermaseptin K4K20S4 ,Synthetic construct(derived from Dermaseptin S4),No entry found,,HSV,Herpesviridae,,[Ref.23161023]HSV-2 acyclovir-sensitive strain(911411):inhibition the cytopathic effect(CPE) of HSV-2 in Vero cells(EC50=2.1 μM);##HSV-2 acyclovir-resistant strain(ROI2):inhibition of cytopathic effet(CPE) of HSV-2 in Vero cells(EC50=5.4 μM). ,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.23161023]Vero cells:CC50=25 μM.,DRAVPe00399,DRAVPe00399.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2861.6,C135H238N36O31,CDEFHIMPQRSY,A,10.7,6,0,6,3,19,81.07,1869,4.4 hour,>20 hour,>10 hour,146.79,5500,203.7,23161023,J Med Virol. 2013 Feb;85(2):272-81.,"Bergaoui I, Zairi A, Tangy F, Aouni M, Selmi B, Hani K. ", In vitro antiviral activity of dermaseptin S(4) and derivatives from amphibian skin against herpes simplex virus type 2.,10.1002/jmv.23450,,Anti-HSV
DRAVPe00400,ALWDTLLKKVLKAAAKAALDAVLVGANA,28,Dermaseptin D4D20S4 ,Synthetic construct(derived from Dermaseptin S4),No entry found,,HSV,Herpesviridae,,[Ref.23161023]HSV-2 acyclovir-sensitive strain(911411):inhibition the cytopathic effect(CPE) of HSV-2 in Vero cells(EC50=5.41 μM);##HSV-2 acyclovir-resistant strain(ROI2):inhibition of cytopathic effet(CPE) of HSV-2 in Vero cells(EC50=9.63 μM). ,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.23161023]Vero cells:CC50=17.75 μM.,DRAVPe00400,DRAVPe00400.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2835.43,C131H224N34O35,CEFHIMPQRSY,A,9.53,4,2,2,3,19,83.93,1235,4.4 hour,>20 hour,>10 hour,146.79,5500,203.7,23161023,J Med Virol. 2013 Feb;85(2):272-81.,"Bergaoui I, Zairi A, Tangy F, Aouni M, Selmi B, Hani K. ", In vitro antiviral activity of dermaseptin S(4) and derivatives from amphibian skin against herpes simplex virus type 2.,10.1002/jmv.23450,,Anti-HSV
DRAVPe00401,SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL,36,EK1,Synthetic construct(derived from OC43-HR2P),Q8BB25,,"SARS-CoV-2,MERS-CoV,HCoV-229E,HCoV-NL63,CoV-WIV1",Coronaviridae,Cell fusion assay,"[Ref.35087243]SARS-CoV-2 Omicron:inhibition of cell-cell fusion in Calu-3 cells(IC50=119.68 nM);inhibition of cell-cell infusion in Caco2 cells(IC50=74.99 nM);inhibition of infection(Pseudovirus)(IC50=309.4 nM);inhibition of infection(Authentic)(IC50=1138 nM);##SARS-CoV-2 Delta:inhibition of cell-cell fusion(IC50=131.8 nM);inhibition of infection(Pseudovirus)(IC50=427.55 nM);##SARS-CoV-2 D614G:inhibition of cell-cell fusion(IC50=314.6 nM);inhibition of infection(Pseudovirus)(IC50=414.85 nM).##[Ref.32231345]SARS-CoV:ihibition of cell-cell fusion in Huh-7 cells(IC50=409.3 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=3237 nM);##MERS-CoV:ihibition of cell-cell fusion in Huh-7 cells(IC50=239.5 nM),inhibition of Pseudovirus (PsV) infection in Huh-7 cells(IC50=631.8 nM),inhibit the replication of MERS-CoV in VERO-E6 cells(IC50=802.1 nM);##HCoV-OC43:ihibition of cell-cell fusion in Huh-7 cells(IC50=787.6 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=1398 nM),inhibit the replication of HCoV-OC43 in RD cells(IC50=1554 nM);##HCoV-229E:ihibition of cell-cell fusion in Huh-7 cells(IC50=207.4 nM),inhibition of Pseudovirus (PsV) infection in Huh-7 cells(IC50=3963 nM),inhibit the replication of HCoV-229E in Huh-7 cells(IC50=4375 nM);##HCoV-NL63:ihibition of cell-cell fusion in Huh-7 cells(IC50=751.0 nM),inhibition of Pseudovirus (PsV) infection in Huh-7 cells(IC50=7666 nM),inhibit the replication of HCoV-NL63 in LLC-MK2 cells(IC50=3693 nM);##CoV-WIV1:ihibition of cell-cell fusion in Huh-7 cells(IC50=265.7 nM),inhibition of Pseudovirus (PsV) infection in Huh-7 cells(IC50=5425 nM);##CoV-Rs3367:ihibition of cell-cell fusion in Huh-7 cells(IC50=237.0 nM),inhibition of Pseudovirus (PsV) infection in Huh-7 cells(IC50=6014 nM);##CoV-SHC014:ihibition of cell-cell fusion in Huh-7 cells(IC50=279.6 nM);##SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=286.7-315.0 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=2375.0 nM),inhibit the replication of MERS-CoV in VERO-E6 cells(IC50=2468 nM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00401,DRAVPe00401.cif,Linear,Free,Free,,L,membrane,"The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions  can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells.",4331.98,C196H317N43O64S,CGHPRW,EL,4.36,5,10,-5,6,13,-43.33,-6303,1.9 hour,>20 hour,>10 hour,119.17,2980,85.14,35087243##32231345,Cell Res. 2022 Apr;32(4):404-406.##Cell Res. 2020 Apr;30(4):343-355.,"Xia S, Chan JF, Wang L, Jiao F, Chik KK, Chu H, Lan Q, Xu W, Wang Q, Wang C, Yuen KY, Lu L, Jiang S.##Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L.",Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant.##Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.,10.1038/s41422-022-00617-x##10.1038/s41422-020-0305-x,,"Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-HCoV-229E,Anti-Anti-HCoV-NL63,Anti-CoV-WIV1"
DRAVPe00402,SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL,36,EK1P,Synthetic construct(derived from EK1),Q8BB25,,SARS-CoV-2,Coronaviridae,,[Ref.32231345]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=69.2 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00402,DRAVPe00402.cif,Linear,Free,PEG4-C(Palm),,L,membrane,"The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions  can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells.",4331.98,C196H317N43O64S,CGHPRW,EL,4.36,5,10,-5,6,13,-43.33,-6303,1.9 hour,>20 hour,>10 hour,119.17,2980,85.14,32231345,Cell Res. 2020 Apr;30(4):343-355.,"Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L.",Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.,10.1038/s41422-020-0305-x,,Anti-SARS-CoV-2
DRAVPe00403,SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL,36,EK1C,Synthetic construct(derived from EK1),Q8BB25,,SARS-CoV-2,Coronaviridae,,"[Ref.32231345]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=37.3-48.1 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=139.4 nM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00403,DRAVPe00403.cif,Linear,Free,PEG4-C(Chol),,L,membrane,"The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions  can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells.",4331.98,C196H317N43O64S,CGHPRW,EL,4.36,5,10,-5,6,13,-43.33,-6303,1.9 hour,>20 hour,>10 hour,119.17,2980,85.14,32231345,Cell Res. 2020 Apr;30(4):343-355.,"Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L.",Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.,10.1038/s41422-020-0305-x,,Anti-SARS-CoV-2
DRAVPe00404,SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL,36,EK1C1,Synthetic construct(derived from EK1),No entry found,,SARS-CoV-2,Coronaviridae,,"[Ref.32231345]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=56.8 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=480.3 nM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00404,DRAVPe00404.cif,Linear,Free,Chol,,L,membrane,"The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions  can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells.",4331.98,C196H317N43O64S,CGHPRW,EL,4.36,5,10,-5,6,13,-43.33,-6303,1.9 hour,>20 hour,>10 hour,119.17,2980,85.14,32231345,Cell Res. 2020 Apr;30(4):343-355.,"Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L.",Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.,10.1038/s41422-020-0305-x,,Anti-SARS-CoV-2
DRAVPe00405,SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSG,39,EK1C2,Synthetic construct(derived from EK1),No entry found,,SARS-CoV-2,Coronaviridae,,"[Ref.32231345]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=48.2 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=418.6 nM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00405,DRAVPe00405.cif,Linear,Free,Chol,,L,membrane,"The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions  can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells.",4533.16,C203H328N46O68S,CHPRW,EL,4.36,5,10,-5,9,13,-44.1,-6455,1.9 hour,>20 hour,>10 hour,110.0,2980,78.42,32231345,Cell Res. 2020 Apr;30(4):343-355.,"Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L.",Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.,10.1038/s41422-020-0305-x,,Anti-SARS-CoV-2
DRAVPe00406,SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSG,39,EK1C3,Synthetic construct(derived from EK1),No entry found,,SARS-CoV-2,Coronaviridae,,"[Ref.32231345]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=10.6 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=86.4 nM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00406,DRAVPe00406.cif,Linear,Free,PEG4-Chol,,L,membrane,"The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions  can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells.",4533.16,C203H328N46O68S,CHPRW,EL,4.36,5,10,-5,9,13,-44.1,-6455,1.9 hour,>20 hour,>10 hour,110.0,2980,78.42,32231345,Cell Res. 2020 Apr;30(4):343-355.,"Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L.",Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.,10.1038/s41422-020-0305-x,,Anti-SARS-CoV-2
DRAVPe00407,SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG,41,EK1C4,Synthetic construct(derived from EK1),No entry found,,"SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-OC43,HCoV-229E",Coronaviridae,pseudovirus inhibition assay,"[Ref.35087243]SARS-CoV-2 Omicron:inhibition of cell-cell fusion in Calu-3 cells(IC50=3.32 nM);inhibition of cell-cell infusion in Caco2 cells(IC50=0.88 nM);inhibition of infection(Pseudovirus)(IC50=8.63 nM);inhibition of infection(Authentic)(IC50=85.38 nM);##SARS-CoV-2 Delta:inhibition of cell-cell fusion(IC50=4.04 nM);inhibition of infection(Pseudovirus)(IC50=9.83 nM);##SARS-CoV-2 D614G:inhibition of cell-cell fusion(IC50=2.57 nM);inhibition of infection(Pseudovirus)(IC50=5.58 nM).##[Ref.32231345]SARS-CoV:ihibition of cell-cell fusion in Huh-7 cells(IC50=4.3 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=11.7 nM);##MERS-CoV:ihibition of cell-cell fusion in Huh-7 cells(IC50=2.5 nM),inhibition of Pseudovirus (PsV) infection in Huh-7 cells(IC50=11.1 nM),inhibit the replication of MERS-CoV in VERO-E6 cells(IC50=4.2 nM);##HCoV-OC43:ihibition of cell-cell fusion in Huh-7 cells(IC50=7.7 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=37.7 nM),inhibit the replication of HCoV-OC43 in RD cells(IC50=24.8 nM);##HCoV-229E:ihibition of cell-cell fusion in Huh-7 cells(IC50=5.2 nM),inhibition of Pseudovirus (PsV) infection in Huh-7 cells(IC50=12.4 nM),inhibit the replication of HCoV-229E in Huh-7 cells(IC50=101.5 nM);##HCoV-NL63:ihibition of cell-cell fusion in Huh-7 cells(IC50=21.4 nM),inhibition of Pseudovirus (PsV) infection in Huh-7 cells(IC50=76.6 nM),inhibit the replication of HCoV-NL63 in LLC-MK2 cells(IC50=187.6 nM);##CoV-WIV1:ihibition of cell-cell fusion in Huh-7 cells(IC50=4.5 nM),inhibition of Pseudovirus (PsV) infection in Huh-7 cells(IC50=30.8 nM);##CoV-Rs3367:ihibition of cell-cell fusion in Huh-7 cells(IC50=8.1 nM),inhibition of Pseudovirus (PsV) infection in Huh-7 cells(IC50=66.9 nM);##CoV-SHC014:ihibition of cell-cell fusion in Huh-7 cells(IC50=4.3 nM);##SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=1.3 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=15.8 nM),inhibit the replication of MERS-CoV in VERO-E6 cells(IC50=2468 nM).",No hemolysis information or data found in the reference(s) presented in this entry,"[Ref.32231345]<10% cytotoxicity against VERO-E6 cells, RD cells, LLC-MK2 cells, Huh-7 cells up to 10000 nM.",DRAVPe00407,DRAVPe00407.cif,Linear,Free,PEG4-Chol,,L,membrane,"The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions  can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells.",4677.29,C208H336N48O71S,CHPRW,EL,4.36,5,10,-5,11,13,-44.88,-6701,1.9 hour,>20 hour,>10 hour,104.63,2980,74.5,35087243##32231345,Cell Res. 2022 Apr;32(4):404-406.##Cell Res. 2020 Apr;30(4):343-355.,"Xia S, Chan JF, Wang L, Jiao F, Chik KK, Chu H, Lan Q, Xu W, Wang Q, Wang C, Yuen KY, Lu L, Jiang S.##Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L.",Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant.##Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.,10.1038/s41422-022-00617-x##10.1038/s41422-020-0305-x,,"Anti-SARS-CoV-2,Anti-SARS-CoV,Anti-MERS-CoV,Anti-HCoV-OC43,Anti-HCoV-229E"
DRAVPe00408,SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG,41,EK1C5,Synthetic construct(derived from EK1),No entry found,,SARS-CoV-2,Coronaviridae,pseudovirus inhibition assay,"[Ref.32231345]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=3.1 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=31.3 nM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00408,DRAVPe00408.cif,Linear,Free,PEG8-Chol,,L,membrane,"The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions  can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells.",4677.29,C208H336N48O71S,CHPRW,EL,4.36,5,10,-5,11,13,-44.88,-6701,1.9 hour,>20 hour,>10 hour,104.63,2980,74.5,32231345,Cell Res. 2020 Apr;30(4):343-355.,"Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L.",Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.,10.1038/s41422-020-0305-x,,Anti-SARS-CoV-2
DRAVPe00409,SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG,41,EK1C6,Synthetic construct(derived from EK1),No entry found,,SARS-CoV-2,Coronaviridae,pseudovirus inhibition assay,"[Ref.32231345]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=3.9 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=77.4 nM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00409,DRAVPe00409.cif,Linear,Free,PEG12-Chol,,L,membrane,"The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions  can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells.",4677.29,C208H336N48O71S,CHPRW,EL,4.36,5,10,-5,11,13,-44.88,-6701,1.9 hour,>20 hour,>10 hour,104.63,2980,74.5,32231345,Cell Res. 2020 Apr;30(4):343-355.,"Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L.",Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.,10.1038/s41422-020-0305-x,,Anti-SARS-CoV-2
DRAVPe00410,SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG,41,EK1C7,Synthetic construct(derived from EK1),No entry found,,SARS-CoV-2,Coronaviridae,pseudovirus inhibition assay,"[Ref.32231345]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=3.9 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=84.4 nM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00410,DRAVPe00410.cif,Linear,Free,PEG24-Chol,,L,membrane,"The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions  can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells.",4677.29,C208H336N48O71S,CHPRW,EL,4.36,5,10,-5,11,13,-44.88,-6701,1.9 hour,>20 hour,>10 hour,104.63,2980,74.5,32231345,Cell Res. 2020 Apr;30(4):343-355.,"Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L.",Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.,10.1038/s41422-020-0305-x,,Anti-SARS-CoV-2
DRAVPe00411,LKVLLYEEFKLLESLIMEILEYQKDSDIKENAEDTK,36,EK1-scrambled,Synthetic construct(derived from EK1),No entry found,,SARS-CoV-2,Coronaviridae,,"[Ref.32231345]SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-OC43,HCoV-229E,HCoV-NL63,CoV-WIV1,CoV-Rs3367,CoV-SHC014(No inhibition on the concentration up to 10 µM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00411,DRAVPe00411.cif,Linear,Free,Free,,L,membrane,"The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions  can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells.",4331.98,C196H317N43O64S,CGHPRW,EL,4.36,5,10,-5,6,13,-43.33,-6303,5.5 hour,3 min,2 min,119.17,2980,85.14,32231345,Cell Res. 2020 Apr;30(4):343-355.,"Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L.",Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.,10.1038/s41422-020-0305-x,,Anti-SARS-CoV-2
DRAVPe00412,ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL,35,IBP02V1,Synthetic construct(derived from HR2 region of SARS-CoV),No entry found,,"SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-NL63",Coronaviridae,,[Ref.34344868]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=1.1±0.1 nM);inhibition of SARS-CoV-2 pseudovirus infection in 293T/ACE2 cells(IC50=17.8 nM);inhibition of SARS-CoV-2 pseudovirus infection in Huh-7 cells(IC50=14.3 nM);##SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion(IC50=0.6±0.1 nM);inhibition of pseudovirus infection in 293T/ACE2 cells(IC50=50 nM);inhibition of pseudovirus infection in Huh-7 cells(IC50=21.5 nM);##SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=33.6±3.5 nM);##MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=66.9±7.6 nM);##HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells(IC50=62.5±17.2 nM);##HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells(IC50=203.9±8.8 nM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.34344868]No significant cytotoxicity in both 293T/ACE2 and Huh-7 cells at a concentration of 10 μM.,DRAVPe00412,DRAVPe00412.cif,Linear,Free,PEG8-K(Chol),,L,membrane,"A six-helical bundle structure is formed by two heptad repeat domains (HR1 and HR2) in S2, juxtaposing the viral and cellular membranes for fusion.The peptide derived from the HR2 sequence can competitively bind to the viral HR1 domain thus exerting antiviral activity.",3893.41,C168H287N47O58,CFHMPTWY,ILN,4.36,3,6,-3,9,15,-8.29,-5930,20 hour,30 min,>10 hour,142.0,0,0.0,34344868,Signal Transduct Target Ther. 2021 Aug 3;6(1):294. ,"Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y.",SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses.,10.1038/s41392-021-00698-x,,"Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-Anti-HCoV-NL63"
DRAVPe00413,ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL,35,HR2(1151-1185),Synthetic construct(derived from SARS-CoV spike protein),P59594,,HIV,Retroviridae,,[Ref.18442051]HIV‐luc/SARS Pseudotyped Virus:inhibition of viral-entry in Vero E3 cells(EC50=0.34 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00413,DRAVPe00413.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,3893.41,C168H287N47O58,CFHMPTWY,ILN,4.36,3,6,-3,9,15,-8.29,-5930,20 hour,30 min,>10 hour,142.0,0,0.0,18442051,J Cell Biochem. 2008 Aug 15;104(6):2335-47.,"Chu LH, Chan SH, Tsai SN, Wang Y, Cheng CH, Wong KB, Waye MM, Ngai SM.",Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors. ,10.1002/jcb.21790,,Anti-HIV
DRAVPe00414,DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL,36,IBP02V2,Synthetic construct(derived from HR2 region of SARS-CoV),No entry found,,"SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-NL63",Coronaviridae,,[Ref.34344868]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=0.6±0.03 nM);inhibition of SARS-CoV-2 pseudovirus infection in 293T/ACE2 cells(IC50=20.1 nM);inhibition of SARS-CoV-2 pseudovirus infection in Huh-7 cells(IC50=18.1 nM);##SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion(IC50=0.4±0.04 nM);inhibition of pseudovirus infection in 293T/ACE2 cells(IC50=19.3 nM);inhibition of pseudovirus infection in Huh-7 cells(IC50=20.8 nM);##SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=56.5±9.4nM);##MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=55.3±2.8 nM);##HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells(IC50=67.5±8 nM);##HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells(IC50=535.7±44.6 nM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.34344868]No significant cytotoxicity in both 293T/ACE2 and Huh-7 cells at a concentration of 10 μM.,DRAVPe00414,DRAVPe00414.cif,Linear,Free,PEG8-K(Chol),,L,membrane,"A six-helical bundle structure is formed by two heptad repeat domains (HR1 and HR2) in S2, juxtaposing the viral and cellular membranes for fusion.The peptide derived from the HR2 sequence can competitively bind to the viral HR1 domain thus exerting antiviral activity.",4008.5,C172H292N48O61,CFHMPTWY,ILN,4.2,3,7,-4,9,15,-17.78,-6802,1.1 hour,3 min,>10 hour,138.06,0,0.0,34344868,Signal Transduct Target Ther. 2021 Aug 3;6(1):294. ,"Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y.",SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses.,10.1038/s41392-021-00698-x,,"Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-HCoV-NL63"
DRAVPe00415,EISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL,36,IBP02V3,Synthetic construct(derived from HR2 region of SARS-CoV),No entry found,,"SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-NL63",Coronaviridae,,[Ref.34344868]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=0.4±0.02 nM);inhibition of SARS-CoV-2 pseudovirus infection in 293T/ACE2 cells(IC50=14.1 nM);inhibition of SARS-CoV-2 pseudovirus infection in Huh-7 cells(IC50=17.5 nM);##SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion(IC50=0.2±0.02 nM);inhibition of pseudovirus infection in 293T/ACE2 cells(IC50=40.2 nM);inhibition of pseudovirus infection in Huh-7 cells(IC50=14.4 nM);##SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=48±5.8 nM);##MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=38.5±6.2 nM);##HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells(IC50=75.8±9.9 nM);##HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells(IC50=545.7±0.9 nM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.34344868]No significant cytotoxicity in both 293T/ACE2 and Huh-7 cells at a concentration of 10 μM.,DRAVPe00415,DRAVPe00415.cif,Linear,Free,PEG8-K(Chol),,L,membrane,"A six-helical bundle structure is formed by two heptad repeat domains (HR1 and HR2) in S2, juxtaposing the viral and cellular membranes for fusion.The peptide derived from the HR2 sequence can competitively bind to the viral HR1 domain thus exerting antiviral activity.",4022.52,C173H294N48O61,CFHMPTWY,EILN,4.25,3,7,-4,9,15,-17.78,-6611,1 hour,30 min,>10 hour,138.06,0,0.0,34344868,Signal Transduct Target Ther. 2021 Aug 3;6(1):294. ,"Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y.",SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses.,10.1038/s41392-021-00698-x,,"Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-HCoV-NL63"
DRAVPe00416,ELSGINASVVNLQKEIDRLNEVAKNLNESLIDLQEL,36,IBP02V4,Synthetic construct(derived from HR2 region of SARS-CoV),No entry found,,"SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-NL63",Coronaviridae,,[Ref.34344868]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=0.3±0.02 nM);inhibition of SARS-CoV-2 pseudovirus infection in 293T/ACE2 cells(IC50=18.6 nM);inhibition of SARS-CoV-2 pseudovirus infection in Huh-7 cells(IC50=15.2 nM);##SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion(IC50=0.1±0.02 nM);inhibition of pseudovirus infection in 293T/ACE2 cells(IC50=29.2 nM);inhibition of pseudovirus infection in Huh-7 cells(IC50=26.3 nM);##SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=63±1.7 nM);##MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=22.4±2.2 nM);##HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells(IC50=66.3±3.1 nM);##HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells(IC50=502±24.2 nM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.34344868]No significant cytotoxicity in both 293T/ACE2 and Huh-7 cells at a concentration of 10 μM.,DRAVPe00416,DRAVPe00416.cif,Linear,Free,PEG8-K(Chol),,L,membrane,"A six-helical bundle structure is formed by two heptad repeat domains (HR1 and HR2) in S2, juxtaposing the viral and cellular membranes for fusion.The peptide derived from the HR2 sequence can competitively bind to the viral HR1 domain thus exerting antiviral activity.",4022.52,C173H294N48O61,CFHMPTWY,L,4.25,3,7,-4,9,15,-21.67,-6611,1 hour,30 min,>10 hour,138.06,0,0.0,34344868,Signal Transduct Target Ther. 2021 Aug 3;6(1):294. ,"Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y.",SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses.,10.1038/s41392-021-00698-x,,"Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-HCoV-NL63"
DRAVPe00417,SLTQINASVVNIQKEIDRLNEVAKNLNESLIDLQEL,36,IBP02V5,Synthetic construct(derived from HR2 region of SARS-CoV),No entry found,,"SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-NL63",Coronaviridae,Cell fusion assay,[Ref.34344868]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=2.1±0.5 nM);inhibition of SARS-CoV-2 pseudovirus infection in 293T/ACE2 cells(IC50=21 nM);inhibition of SARS-CoV-2 pseudovirus infection in Huh-7 cells(IC50=23.5 nM);##SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion(IC50=1.3±0.1 nM);inhibition of pseudovirus infection in 293T/ACE2 cells(IC50=98.8 nM);inhibition of pseudovirus infection in Huh-7 cells(IC50=27.5 nM);##SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=65.9±13.2 nM);##MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=68.4±9.7 nM);##HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells(IC50=70.8±8.7 nM);##HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells(IC50=1128.4±148.6 nM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.34344868]No significant cytotoxicity in both 293T/ACE2 and Huh-7 cells at a concentration of 10 μM.,DRAVPe00417,DRAVPe00417.cif,Linear,Free,PEG8-K(Chol),,L,membrane,"A six-helical bundle structure is formed by two heptad repeat domains (HR1 and HR2) in S2, juxtaposing the viral and cellular membranes for fusion.The peptide derived from the HR2 sequence can competitively bind to the viral HR1 domain thus exerting antiviral activity.",4065.59,C175H299N49O61,CFGHMPWY,L,4.36,3,6,-3,9,15,-20.56,-6835,1.9 hour,>20 hour,>10 hour,138.06,0,0.0,34344868,Signal Transduct Target Ther. 2021 Aug 3;6(1):294. ,"Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y.",SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses.,10.1038/s41392-021-00698-x,,"Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-HCoV-NL63"
DRAVPe00418,SLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKEL,36,MERS-LP,Synthetic construct(derived from HR2 region of MERS-CoV),No entry found,,"SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-NL63",Coronaviridae,,[Ref.34344868]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=102.9±7.2 nM);inhibition of SARS-CoV-2 pseudovirus infection in Huh-7 cells(IC50=5046±905.2 nM);##SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion(IC50=79.1±9.8 nM);inhibition of pseudovirus infection in Huh-7 cells(IC50>25000 nM);##SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50>25000 nM);##MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=82.9±8.6 nM);##HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells(IC50>25000 nM);##HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells(IC50>25000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00418,DRAVPe00418.cif,Linear,Free,PEG8-K(Chol),,L,membrane,"A six-helical bundle structure is formed by two heptad repeat domains (HR1 and HR2) in S2, juxtaposing the viral and cellular membranes for fusion.The peptide derived from the HR2 sequence can competitively bind to the viral HR1 domain thus exerting antiviral activity.",4141.78,C185H307N43O61S,CFGHPRW,L,4.18,2,5,-3,11,14,13.06,-3327,1.9 hour,>20 hour,>10 hour,138.06,2980,85.14,34344868,Signal Transduct Target Ther. 2021 Aug 3;6(1):294. ,"Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y.",SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses.,10.1038/s41392-021-00698-x,,"Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-HCoV-NL63"
DRAVPe00419,SLDYINVTFLDLQDEMNRLQEAIKVLNQSYINLKDI,36,OC43-LP,Synthetic construct(derived from HR2 region of OC43-LP),No entry found,,"SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-NL63",Coronaviridae,,[Ref.34344868]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=4.1±1 nM);inhibition of SARS-CoV-2 pseudovirus infection in Huh-7 cells(IC50=82.8±22.1 nM);##SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion(IC50=2.4±0.2 nM);inhibition of pseudovirus infection in Huh-7 cells(IC50=97.5±5.9 nM);##SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=250.4±39.7 nM);##MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=5.2±0.5 nM);##HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells(IC50=416.5±227.5 nM);##HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells(IC50=2008.8±697.9 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00419,DRAVPe00419.cif,Linear,Free,PEG8-K(Chol),,L,membrane,"A six-helical bundle structure is formed by two heptad repeat domains (HR1 and HR2) in S2, juxtaposing the viral and cellular membranes for fusion.The peptide derived from the HR2 sequence can competitively bind to the viral HR1 domain thus exerting antiviral activity.",4270.86,C190H306N48O61S,CGHPW,L,4.23,3,6,-3,9,14,-19.44,-6293,1.9 hour,>20 hour,>10 hour,127.22,2980,85.14,34344868,Signal Transduct Target Ther. 2021 Aug 3;6(1):294. ,"Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y.",SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses.,10.1038/s41392-021-00698-x,,"Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-HCoV-NL63"
DRAVPe00420,SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELK,37,EK1V1,Synthetic construct(derived from EK1),No entry found,,"SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-NL63",Coronaviridae,,[Ref.34344868]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=273.5±4.1 nM);inhibition of SARS-CoV-2 pseudovirus infection in Huh-7 cells(IC50=2672.1±384.5 nM);##SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion(IC50=214.5±20.2 nM);inhibition of pseudovirus infection in Huh-7 cells(IC50=1790.8±363.2 nM);##SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=4370.3±719.7 nM);##MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=499.8±163.3 nM);##HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells(IC50=487.2±41.3 nM);##HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells(IC50=1255.6±453.3 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00420,DRAVPe00420.cif,Linear,Free,Chol,,L,membrane,"A six-helical bundle structure is formed by two heptad repeat domains (HR1 and HR2) in S2, juxtaposing the viral and cellular membranes for fusion.The peptide derived from the HR2 sequence can competitively bind to the viral HR1 domain thus exerting antiviral activity.",4460.16,C202H329N45O65S,CGHPRW,EL,4.53,6,10,-4,6,13,-52.7,-6858,1.9 hour,>20 hour,>10 hour,115.95,2980,82.78,34344868,Signal Transduct Target Ther. 2021 Aug 3;6(1):294. ,"Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y.",SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses.,10.1038/s41392-021-00698-x,,"Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-HCoV-NL63"
DRAVPe00421,SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL,36,EK1V2,Synthetic construct(derived from EK1),No entry found,,"SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-NL63",Coronaviridae,,[Ref.34344868]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=0.9±0.2 nM);inhibition of SARS-CoV-2 pseudovirus infection in Huh-7 cells(IC50=87.2±8.3 nM);##SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion(IC50=0.5±0.2 nM);inhibition of pseudovirus infection in Huh-7 cells(IC50=106.5±5.4 nM);##SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=252±5.6 nM);##MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=1.1±0.3 nM);##HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells(IC50=59.4±13.1 nM);##HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells(IC50=503.3±20.9 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe00421.cif,Linear,Free,PEG8-K(Chol),,L,membrane,"A six-helical bundle structure is formed by two heptad repeat domains (HR1 and HR2) in S2, juxtaposing the viral and cellular membranes for fusion.The peptide derived from the HR2 sequence can competitively bind to the viral HR1 domain thus exerting antiviral activity.",4331.98,C196H317N43O64S,CGHPRW,EL,4.36,5,10,-5,6,13,-43.33,-6303,1.9 hour,>20 hour,>10 hour,119.17,2980,85.14,34344868,Signal Transduct Target Ther. 2021 Aug 3;6(1):294. ,"Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y.",SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses.,10.1038/s41392-021-00698-x,,"Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-HCoV-NL63"
DRAVPe00422,SVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK,37,IBP20,Synthetic construct(derived from HR2 region of SARS-CoV-2),No entry found,,"SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-NL63",Coronaviridae,,[Ref.34057039]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=1.36 nM);inhibition of pseudovirus infections in 293T/ACE2 cells(IC50=50.52 nM);inhibition of pseudovirus infections in Huh-7 cells(IC50=33.85 nM);##SARS-CoV-2 D614G:inhibition of pseudovirus infections in Huh-7 cells(IC50=103.17 nM);##SARS-CoV-2 N501Y:inhibition of pseudovirus infections in Huh-7 cells(IC50=128.87 nM);##SARS-CoV-2 ΔH69-V70:inhibition of pseudovirus infections in Huh-7 cells(IC50=111.41 nM);##SARS-CoV-2 E484K:inhibition of pseudovirus infections in Huh-7 cells(IC50=79.09 nM);##SARS-CoV-2 B.1.1.7:inhibition of pseudovirus infections in Huh-7 cells(IC50=88.49 nM);##SARS-CoV-2 B.1.351:inhibition of pseudovirus infections in Huh-7 cells(IC50=92.16 nM);##SARS-CoV:inhibition of pseudovirus infections in Huh-7 cells(IC50=73.86 nM);##MERS-CoV:inhibition of pseudovirus infections in Huh-7 cells(IC50=228.4 nM);##HCoV-NL63:inhibition of pseudovirus infections in Huh-7 cells(IC50=817.21 nM);##HCoV-229E:inhibition of pseudovirus infections in Huh-7 cells(IC50=471.54 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00422,DRAVPe00422.cif,Linear,Free,Chol(cholesterol),,L,membrane,"Peptides derived from HR2 sequences of viral fusion proteins, including the S protein of emerging CoVs, can competitively bind to the HR1 domain and block the formation of the viral 6-HB core, thereby inhibiting infection of the virus from which they were derived.",4347.93,C192H317N51O63,CFHMPTW,EL,4.77,5,7,-2,9,13,-60.27,-7972,1.9 hour,>20 hour,>10 hour,121.08,2980,82.78,34057039,Emerg Microbes Infect. 2021 Dec;10(1):1227-1240.,"Yu D, Zhu Y, Jiao T, Wu T, Xiao X, Qin B, Chong H, Lei X, Ren L, Cui S, Wang J, He Y.",Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants.,10.1080/22221751.2021.1937329,,"Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-HCoV-NL63"
DRAVPe00423,SVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK,37,IBP21,Synthetic construct(derived from HR2 region of SARS-CoV-2),No entry found,,SARS-CoV-2,Coronaviridae,,[Ref.34057039]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=7.5 nM);inhibition of pseudovirus infections in 293T/ACE2 cells(IC50=191.4 nM);inhibition of pseudovirus infections in Huh-7 cells(IC50=126.65 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe00423.cif,Linear,Free,C16(palmitic acid),,L,membrane,"Peptides derived from HR2 sequences of viral fusion proteins, including the S protein of emerging CoVs, can competitively bind to the HR1 domain and block the formation of the viral 6-HB core, thereby inhibiting infection of the virus from which they were derived.",4347.93,C192H317N51O63,CFHMPTW,EL,4.77,5,7,-2,9,13,-60.27,-7972,1.9 hour,>20 hour,>10 hour,121.08,2980,82.78,34057039,Emerg Microbes Infect. 2021 Dec;10(1):1227-1240.,"Yu D, Zhu Y, Jiao T, Wu T, Xiao X, Qin B, Chong H, Lei X, Ren L, Cui S, Wang J, He Y.",Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants.,10.1080/22221751.2021.1937329,,Anti-SARS-CoV-2
DRAVPe00424,SVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK,37,IBP22,Synthetic construct(derived from HR2 region of SARS-CoV-2),No entry found,,SARS-CoV-2,Coronaviridae,,[Ref.34057039]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=6.23 nM);inhibition of pseudovirus infections in 293T/ACE2 cells(IC50=179.95 nM);inhibition of pseudovirus infections in Huh-7 cells(IC50=86.33 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe00424.cif,Linear,Free,C18(stearic acid),,L,membrane,"Peptides derived from HR2 sequences of viral fusion proteins, including the S protein of emerging CoVs, can competitively bind to the HR1 domain and block the formation of the viral 6-HB core, thereby inhibiting infection of the virus from which they were derived.",4347.93,C192H317N51O63,CFHMPTW,EL,4.77,5,7,-2,9,13,-60.27,-7972,1.9 hour,>20 hour,>10 hour,121.08,2980,82.78,34057039,Emerg Microbes Infect. 2021 Dec;10(1):1227-1240.,"Yu D, Zhu Y, Jiao T, Wu T, Xiao X, Qin B, Chong H, Lei X, Ren L, Cui S, Wang J, He Y.",Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants.,10.1080/22221751.2021.1937329,,Anti-SARS-CoV-2
DRAVPe00425,SVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK,37,IBP23,Synthetic construct(derived from HR2 region of SARS-CoV-2),No entry found,,SARS-CoV-2,Coronaviridae,,[Ref.34057039]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=39.07 nM);inhibition of pseudovirus infections in 293T/ACE2 cells(IC50=1236.38 nM);inhibition of pseudovirus infections in Huh-7 cells(IC50=507.32 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe00425.cif,Linear,Free,Toc(tocophenol),,L,membrane,"Peptides derived from HR2 sequences of viral fusion proteins, including the S protein of emerging CoVs, can competitively bind to the HR1 domain and block the formation of the viral 6-HB core, thereby inhibiting infection of the virus from which they were derived.",4347.93,C192H317N51O63,CFHMPTW,EL,4.77,5,7,-2,9,13,-60.27,-7972,1.9 hour,>20 hour,>10 hour,121.08,2980,82.78,34057039,Emerg Microbes Infect. 2021 Dec;10(1):1227-1240.,"Yu D, Zhu Y, Jiao T, Wu T, Xiao X, Qin B, Chong H, Lei X, Ren L, Cui S, Wang J, He Y.",Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants.,10.1080/22221751.2021.1937329,,Anti-SARS-CoV-2
DRAVPe00426,SVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK,37,IBP24,Synthetic construct(derived from HR2 region of SARS-CoV-2),No entry found,,"SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-NL63",Coronaviridae,,[Ref.34057039]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=0.33 nM);inhibition of pseudovirus infections in 293T/ACE2 cells(IC50=3.77 nM);inhibition of pseudovirus infections in Huh-7 cells(IC50=2.89 nM);inhibition of live SARS-CoV-2 infection in Vero cells(IC50=8.97 nM);##SARS-CoV-2 D614G:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.29 nM);##SARS-CoV-2 N501Y:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.5 nM);##SARS-CoV-2 ΔH69-V70:inhibition of pseudovirus infections in Huh-7 cells(IC50=7.42 nM);##SARS-CoV-2 E484K:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.97 nM);##SARS-CoV-2 B.1.1.7:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.22 nM);##SARS-CoV-2 B.1.351:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.06 nM);##SARS-CoV:inhibition of pseudovirus infections in Huh-7 cells(IC50=21.64 nM);##MERS-CoV:inhibition of pseudovirus infections in Huh-7 cells(IC50=69.9 nM);##HCoV-NL63:inhibition of pseudovirus infections in Huh-7 cells(IC50=375.56 nM);##HCoV-229E:inhibition of pseudovirus infections in Huh-7 cells(IC50=421.48 nM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.34057039]Huh-7 cells:CC50=6.6 μM;Vero-E6 cells:CC50=13.67 μM.,,DRAVPe00426.cif,Linear,Free,PEG4-K(Chol),,L,membrane,"Peptides derived from HR2 sequences of viral fusion proteins, including the S protein of emerging CoVs, can competitively bind to the HR1 domain and block the formation of the viral 6-HB core, thereby inhibiting infection of the virus from which they were derived.",4347.93,C192H317N51O63,CFHMPTW,EL,4.77,5,7,-2,9,13,-60.27,-7972,1.9 hour,>20 hour,>10 hour,121.08,2980,82.78,34057039,Emerg Microbes Infect. 2021 Dec;10(1):1227-1240.,"Yu D, Zhu Y, Jiao T, Wu T, Xiao X, Qin B, Chong H, Lei X, Ren L, Cui S, Wang J, He Y.",Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants.,10.1080/22221751.2021.1937329,,"Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-HCoV-NL63"
DRAVPe00427,SVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK,37,IBP25,Synthetic construct(derived from HR2 region of SARS-CoV-2),No entry found,,"SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-NL63",Coronaviridae,,"[Ref.34057039]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=0.29 nM);inhibition of pseudovirus infections in 293T/ACE2 cells(IC50=2.13 nM);inhibition of pseudovirus infections in Huh-7 cells(IC50=1.43 nM),inhibition of live SARS-CoV-2 infection in Vero cells(IC50=25.71 nM);##SARS-CoV-2 D614G:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.8 nM);##SARS-CoV-2 N501Y:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.52 nM);##SARS-CoV-2 ΔH69-V70:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.56 nM);##SARS-CoV-2 E484K:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.71 nM);##SARS-CoV-2 B.1.1.7:inhibition of pseudovirus infections in Huh-7 cells(IC50=5.87 nM);##SARS-CoV-2 B.1.351:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.76 nM);##SARS-CoV:inhibition of pseudovirus infections in Huh-7 cells(IC50=17.69 nM);##MERS-CoV:inhibition of pseudovirus infections in Huh-7 cells(IC50=48.5 nM);##HCoV-NL63:inhibition of pseudovirus infections in Huh-7 cells(IC50=353.22 nM);##HCoV-229E:inhibition of pseudovirus infections in Huh-7 cells(IC50=336.14 nM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.34057039]Huh-7 cells:CC50=3.54 μM;Vero-E6 cells:CC50=6.95 μM.,,DRAVPe00427.cif,Linear,Free,PEG5-K(Chol),,L,membrane,"Peptides derived from HR2 sequences of viral fusion proteins, including the S protein of emerging CoVs, can competitively bind to the HR1 domain and block the formation of the viral 6-HB core, thereby inhibiting infection of the virus from which they were derived.",4347.93,C192H317N51O63,CFHMPTW,EL,4.77,5,7,-2,9,13,-60.27,-7972,1.9 hour,>20 hour,>10 hour,121.08,2980,82.78,34057039,Emerg Microbes Infect. 2021 Dec;10(1):1227-1240.,"Yu D, Zhu Y, Jiao T, Wu T, Xiao X, Qin B, Chong H, Lei X, Ren L, Cui S, Wang J, He Y.",Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants.,10.1080/22221751.2021.1937329,,"Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-HCoV-NL63"
DRAVPe00428,SVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK,37,IBP26,Synthetic construct(derived from HR2 region of SARS-CoV-2),No entry found,,SARS-CoV-2,Coronaviridae,,[Ref.34057039]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=0.26 nM);inhibition of pseudovirus infections in 293T/ACE2 cells(IC50=3.05 nM);inhibition of pseudovirus infections in Huh-7 cells(IC50=1.82 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00428,DRAVPe00428.cif,Linear,Free,PEG6-K(Chol),,L,membrane,"Peptides derived from HR2 sequences of viral fusion proteins, including the S protein of emerging CoVs, can competitively bind to the HR1 domain and block the formation of the viral 6-HB core, thereby inhibiting infection of the virus from which they were derived.",4347.93,C192H317N51O63,CFHMPTW,EL,4.77,5,7,-2,9,13,-60.27,-7972,1.9 hour,>20 hour,>10 hour,121.08,2980,82.78,34057039,Emerg Microbes Infect. 2021 Dec;10(1):1227-1240.,"Yu D, Zhu Y, Jiao T, Wu T, Xiao X, Qin B, Chong H, Lei X, Ren L, Cui S, Wang J, He Y.",Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants.,10.1080/22221751.2021.1937329,,Anti-SARS-CoV-2
DRAVPe00429,SVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK,37,IBP27,Synthetic construct(derived from HR2 region of SARS-CoV-2),No entry found,,"SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-NL63",Coronaviridae,,"[Ref.34057039]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=0.32 nM);inhibition of pseudovirus infections in 293T/ACE2 cells(IC50=2.77 nM);inhibition of pseudovirus infections in Huh-7 cells(IC50=1.54 nM),inhibition of live SARS-CoV-2 infection in Vero cells(IC50=29.85 nM);##SARS-CoV-2 D614G:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.75 nM);##SARS-CoV-2 N501Y:inhibition of pseudovirus infections in Huh-7 cells(IC50=7.87 nM);##SARS-CoV-2 ΔH69-V70:inhibition of pseudovirus infections in Huh-7 cells(IC50=7.56 nM);##SARS-CoV-2 E484K:inhibition of pseudovirus infections in Huh-7 cells(IC50=7.55 nM);##SARS-CoV-2 B.1.1.7:inhibition of pseudovirus infections in Huh-7 cells(IC50=7.18 nM);##SARS-CoV-2 B.1.351:inhibition of pseudovirus infections in Huh-7 cells(IC50=8.25 nM);##SARS-CoV:inhibition of pseudovirus infections in Huh-7 cells(IC50=24.95 nM);##MERS-CoV:inhibition of pseudovirus infections in Huh-7 cells(IC50=60.08 nM);##HCoV-NL63:inhibition of pseudovirus infections in Huh-7 cells(IC50=179.53 nM);##HCoV-229E:inhibition of pseudovirus infections in Huh-7 cells(IC50=231.18 nM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.34057039]Huh-7 cells:CC50=4.04 μM;Vero-E6 cells:CC50=5.05 μM.,DRAVPe00429,DRAVPe00429.cif,Linear,Free,PEG8-K(Chol),,L,membrane,"Peptides derived from HR2 sequences of viral fusion proteins, including the S protein of emerging CoVs, can competitively bind to the HR1 domain and block the formation of the viral 6-HB core, thereby inhibiting infection of the virus from which they were derived.",4347.93,C192H317N51O63,CFHMPTW,EL,4.77,5,7,-2,9,13,-60.27,-7972,1.9 hour,>20 hour,>10 hour,121.08,2980,82.78,34057039,Emerg Microbes Infect. 2021 Dec;10(1):1227-1240.,"Yu D, Zhu Y, Jiao T, Wu T, Xiao X, Qin B, Chong H, Lei X, Ren L, Cui S, Wang J, He Y.",Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants.,10.1080/22221751.2021.1937329,,"Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-HCoV-NL63"
DRAVPe00430,SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVKW,45,EKL0,Synthetic construct(derived from EK1),No entry found,,SARS-CoV-2,Coronaviridae,,"[Ref.34367893]SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=0.583±0.073 μmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50>5 μmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=0.442±0.037 μmol/L),inhibition of cell-cell fusion(IC50=0.277±0.029 μmol/L).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00430,DRAVPe00430.cif,Linear,Free,Free,,L,membrane,"The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions  can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells.",5522.3,C256H392N54O79S,CHPR,E,4.44,6,11,-5,11,15,-54.89,-7107,1.9 hour,>20 hour,>10 hour,101.78,12950,294.32,34367893,Acta Pharm Sin B. 2021 Aug 2.,"Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q.",A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases.,10.1016/j.apsb.2021.07.026,,Anti-SARS-CoV-2
DRAVPe00431,NVTFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEY,36,EKL1,Synthetic construct(derived from EK1),No entry found,,"SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-NL63",Coronaviridae,,"[Ref.34367893]SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=0.622±0.089 μmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50>5 μmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=0.746±0.152 μmol/L),inhibition of cell-cell fusion(IC50=0.220±0.034 μmol/L);inhibited authentic SARS-CoV-2 infection in Vero E6 cells(IC50=1.407±0.189 μmol/L);##inhibition of multiple HCoV Pseudovirus:SARS-CoV (IC50=6.716±5.937 μmol/L), MERS-CoV(IC50=4.086±0.345 μmol/L), HCoV-OC43(IC50=10.530±3.778 μmol/L), HCoV-NL63(IC50=3.700±0.222 μmol/L), SARSr-CoV-WIV1(IC50=30.270±4.713 μmol/L), and HCoV-Rs3367 (IC50=88.300±24.600 μmol/L),inhibition of authentic HCoV-OC43 infection in RD cells (IC50=20.290±1.092 μmol/L).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00431,DRAVPe00431.cif,Linear,Free,Free,,L,membrane,"The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions  can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells.",4388.99,C201H312N42O65S,CHPQRW,E,4.39,5,10,-5,9,11,-64.72,-6393,1.4 hour,3 min,>10 hour,97.5,5960,170.29,34367893,Acta Pharm Sin B. 2021 Aug 2.,"Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q.",A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases.,10.1016/j.apsb.2021.07.026,,"Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-HCoV-NL63"
DRAVPe00432,TFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYV,36,EKL2,Synthetic construct(derived from EK1),No entry found,,SARS-CoV-2,Coronaviridae,,"[Ref.34367893]SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=0.526±0.049 μmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50>5 μmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=4.714±1.173 μmol/L),inhibition of cell-cell fusion(IC50=1.240±0.246 μmol/L).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00432,DRAVPe00432.cif,Linear,Free,Free,,L,membrane,"The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions  can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells.",4438.06,C206H315N41O65S,CHNPQRW,E,4.39,5,10,-5,9,11,-58.61,-5743,7.2 hour,>20 hour,>10 hour,97.5,7450,212.86,34367893,Acta Pharm Sin B. 2021 Aug 2.,"Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q.",A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases.,10.1016/j.apsb.2021.07.026,,Anti-SARS-CoV-2
DRAVPe00433,LDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVKW,36,EKL3,Synthetic construct(derived from EK1),No entry found,,SARS-CoV-2,Coronaviridae,,"[Ref.34367893]SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50>10 μmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50>5 μmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50>5 μmol/L),inhibition of cell-cell fusion(IC50=2.167±0.270 μmol/L).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00433,DRAVPe00433.cif,Linear,Free,Free,,L,membrane,"The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions  can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells.",4504.17,C210H321N43O64S,CFHNPQR,E,4.57,6,10,-4,8,11,-77.78,-6106,5.5 hour,3 min,2 min,97.5,12950,370.0,34367893,Acta Pharm Sin B. 2021 Aug 2.,"Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q.",A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases.,10.1016/j.apsb.2021.07.026,,Anti-SARS-CoV-2
DRAVPe00434,SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVKWGSGC,49,EKL0C,Synthetic construct(derived from EK1),No entry found,,SARS-CoV-2,Coronaviridae,,"[Ref.34367893]SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=0.122±0.012 μmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50=0.147±0.055 μmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=0.162±0.022 μmol/L),inhibition of cell-cell fusion(IC50=0.021±0.003 μmol/L).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00434,DRAVPe00434.cif,Linear,Free,Chol,,L,membrane,"The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions  can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells.",5826.62,C266H408N58O84S2,HPR,E,4.44,6,11,-5,15,15,-48.57,-7131,1.9 hour,>20 hour,>10 hour,93.47,12950,269.79,34367893,Acta Pharm Sin B. 2021 Aug 2.,"Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q.",A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases.,10.1016/j.apsb.2021.07.026,,Anti-SARS-CoV-2
DRAVPe00435,TFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVGSGC,40,EKL2C,Synthetic construct(derived from EK1),No entry found,,SARS-CoV-2,Coronaviridae,,"[Ref.34367893]SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=0.115±0.019 μmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50=0.054±0.014 μmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=0.200±0.020 μmol/L),inhibition of cell-cell fusion(IC50=0.022±0.001 μmol/L).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00435,DRAVPe00435.cif,Linear,Free,Chol,,L,membrane,"The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions  can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells.",4742.38,C216H331N45O70S2,HNPQRW,E,4.39,5,10,-5,13,11,-50.5,-5767,7.2 hour,>20 hour,>10 hour,87.75,7450,191.03,34367893,Acta Pharm Sin B. 2021 Aug 2.,"Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q.",A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases.,10.1016/j.apsb.2021.07.026,,Anti-SARS-CoV-2
DRAVPe00436,LDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVKWGSGC,40,EKL3C,Synthetic construct(derived from EK1),No entry found,,SARS-CoV-2,Coronaviridae,,"[Ref.34367893]SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=0.127±0.293 μmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50=1.176±1.230 μmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=0.892±0.069 μmol/L),inhibition of cell-cell fusion(IC50=0.045±0.004 μmol/L).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00436,DRAVPe00436.cif,Linear,Free,Chol,,L,membrane,"The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions  can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells.",4808.49,C220H337N47O69S2,FHNPQR,E,4.57,6,10,-4,12,11,-67.75,-6130,5.5 hour,3 min,2 min,87.75,12950,332.05,34367893,Acta Pharm Sin B. 2021 Aug 2.,"Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q.",A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases.,10.1016/j.apsb.2021.07.026,,Anti-SARS-CoV-2
DRAVPe00437,SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVKWGSGK,49,EKL0P,Synthetic construct(derived from EK1),No entry found,,SARS-CoV-2,Coronaviridae,,"[Ref.34367893]SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=0.093±0.012 μmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50=0.619±0.341 μmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=0.176±0.019 μmol/L),inhibition of cell-cell fusion(IC50=0.083±0.009 μmol/L).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00437,DRAVPe00437.cif,Linear,Free,Palm,,L,membrane,"The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions  can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells.",5851.66,C269H415N59O84S,CHPR,E,4.61,7,11,-4,14,15,-61.63,-7814,1.9 hour,>20 hour,>10 hour,93.47,12950,269.79,34367893,Acta Pharm Sin B. 2021 Aug 2.,"Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q.",A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases.,10.1016/j.apsb.2021.07.026,,Anti-SARS-CoV-2
DRAVPe00438,NVTFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYGSGK,40,EKL1P,Synthetic construct(derived from EK1),No entry found,,SARS-CoV-2,Coronaviridae,,"[Ref.34367893]SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=0.182±0.034 μmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50=0.812±0.182 μmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=0.231±0.022 μmol/L),inhibition of cell-cell fusion(IC50=0.064±0.004 μmol/L).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00438,DRAVPe00438.cif,Linear,Free,Palm,,L,membrane,"The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions  can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells.",4718.35,C214H335N47O70S,CHPQRW,E,4.57,6,10,-4,12,11,-72.0,-7100,1.4 hour,3 min,>10 hour,87.75,5960,152.82,34367893,Acta Pharm Sin B. 2021 Aug 2.,"Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q.",A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases.,10.1016/j.apsb.2021.07.026,,Anti-SARS-CoV-2
DRAVPe00439,TFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVGSGK,40,EKL2P,Synthetic construct(derived from EK1),No entry found,,SARS-CoV-2,Coronaviridae,,"[Ref.34367893]SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=1.129±0.166 μmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50=0.973±0.254 μmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=0.304±0.051 μmol/L),inhibition of cell-cell fusion(IC50=0.183±0.028 μmol/L).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00439,DRAVPe00439.cif,Linear,Free,Palm,,L,membrane,"The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions  can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells.",4767.42,C219H338N46O70S,CHNPQRW,E,4.57,6,10,-4,12,11,-66.5,-6450,7.2 hour,>20 hour,>10 hour,87.75,7450,191.03,34367893,Acta Pharm Sin B. 2021 Aug 2.,"Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q.",A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases.,10.1016/j.apsb.2021.07.026,,Anti-SARS-CoV-2
DRAVPe00440,LDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVKWGSGK,40,EKL3P,Synthetic construct(derived from EK1),No entry found,,SARS-CoV-2,Coronaviridae,,"[Ref.34367893]SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=3.987±0.682 μmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50>5 μmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=2.214±0.371 μmol/L),inhibition of cell-cell fusion(IC50=0.193±0.021 μmol/L).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00440,DRAVPe00440.cif,Linear,Free,Palm,,L,membrane,"The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions  can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells.",4833.52,C223H344N48O69S,CFHNPQR,E,4.76,7,10,-3,11,11,-83.75,-6813,5.5 hour,3 min,2 min,87.75,12950,332.05,34367893,Acta Pharm Sin B. 2021 Aug 2.,"Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q.",A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases.,10.1016/j.apsb.2021.07.026,,Anti-SARS-CoV-2
DRAVPe00441,NVTFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYGSGC,40,EKL1C,Synthetic construct(derived from EK1),No entry found,,"SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-NL63,HCoV-OC43",Coronaviridae,Cell fusion assay,"[Ref.35087243]SARS-CoV-2 Omicron:inhibition of cell-cell fusion in Calu-3 cells(IC50=12.18 nM);inhibition of cell-cell infusion in Caco2 cells(IC50=5.52 nM);inhibition of infection(Pseudovirus)(IC50=26.14 nM);inhibition of infection(Authentic)(IC50=182.2 nM);##SARS-CoV-2 Delta:inhibition of cell-cell fusion(IC50=14.42 nM);inhibition of infection(Pseudovirus)(IC50=31.99 nM);##SARS-CoV-2 D614G:inhibition of cell-cell fusion(IC50=11.77 nM);inhibition of infection(Pseudovirus)(IC50=23.6 nM).##[Ref.34367893]SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=0.045±0.006 μmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50=0.037±0.009 μmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=0.040±0.005 μmol/L),inhibition of cell-cell fusion(IC50=0.008±0.001 μmol/L);inhibited authentic SARS-CoV-2 infection in Vero E6 cells(IC50=0.003±0.001 μmol/L);##SARS-CoV-2 variants(inhibition of Pseudovirus(PsV) infection):V341L(IC50=0.047±0.013 μmol/L);F342L(IC50=0.026±0.007 μmol/L);V367F(IC50=0.066±0.012 μmol/L);R408I(IC50=0.148±0.012 μmol/L);N435D(IC50=0.135±0.013 μmol/L);G476S(IC50=0.065±0.008 μmol/L);V483A(IC50=0.078±0.011 μmol/L);N501Y(IC50=0.069±0.006 μmol/L);D614G(IC50=0.104±0.010 μmol/L);12 mutations(P.1)(IC50=0.046±0.006 μmol/L);K417N-E484K-N501Y(IC50=0.113±0.013 μmol/L);8 mutations(B.1.1.7)(IC50=0.120±0.009 μmol/L);wide type(IC50=0.049±0.007 μmol/L);##inhibition of multiple HCoV Pseudovirus:SARS-CoV (IC50=0.076±0.014 μmol/L), MERS-CoV(IC50=0.048±0.006 μmol/L), HCoV-OC43(IC50=0.668±0.081 μmol/L), HCoV-NL63(IC50=0.035±0.003 μmol/L), SARSr-CoV-WIV1(IC50=0.218±0.013 μmol/L), and HCoV-Rs3367 (IC50=0.046±0.003 μmol/L),inhibition of authentic HCoV-OC43 infection in RD cells (IC50=0.281±0.018 μmol/L).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.34367893]Huh-7 cells:CC50=10 μmol/L;Caco-2 cells:CC50=13.81 μmol/L;293T/ACE2 cells:CC50=8.49 μmol/L.,DRAVPe00441,DRAVPe00441.cif,Linear,Free,Chol,,L,membrane,"The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions  can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells.",4693.31,C211H328N46O70S2,HPQRW,E,4.39,5,10,-5,13,11,-56.0,-6417,1.4 hour,3 min,>10 hour,87.75,5960,152.82,35087243##34367893,Cell Res. 2022 Apr;32(4):404-406.##Acta Pharm Sin B. 2021 Aug 2.,"Xia S, Chan JF, Wang L, Jiao F, Chik KK, Chu H, Lan Q, Xu W, Wang Q, Wang C, Yuen KY, Lu L, Jiang S.##Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q.",Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant.##A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases.,10.1038/s41422-022-00617-x##10.1016/j.apsb.2021.07.026,,"Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-HCoV-NL63,HCoV-OC43"
DRAVPe00442,SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG,41,EK1-C16,Synthetic construct(derived from EK1),No entry found,,"SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-OC43",Coronaviridae,pseudovirus inhibition assay,[Ref.35336956]SARS-CoV-2 WT:inhibition of pseudovirus (PsV) infection in Caco2 cells(IC50=0.48 μM);##SARS-CoV-2 Alpha:inhibition of pseudovirus (PsV) infection(IC50=0.19 μM);##SARS-CoV-2 Beta:inhibition of pseudovirus (PsV) infection(IC50=0.43 μM);##SARS-CoV-2 Gamma:inhibition of pseudovirus (PsV) infection(IC50=0.26 μM);##SARS-CoV-2 Delta:inhibition of pseudovirus (PsV) infection(IC50=0.11 μM);##SARS-CoV-2 Omicron:inhibition of pseudovirus (PsV) infection(IC50=0.23 μM);inhibition of authentic infection in Vero-E6-TMPRSS-2 cells(IC50=0.75 μM);##SARS-CoV:inhibition of pseudovirus (PsV) infection(IC50=0.17 μM);##SARSr-CoV WIV1:inhibition of pseudovirus (PsV) infection(IC50=0.15 μM);##SARSr-CoV Rs3367:inhibition of pseudovirus (PsV) infection(IC50=0.3 μM);##MERS-CoV:inhibition of pseudovirus (PsV) infection in Caco2 cells(IC50=0.10 μM);inhibition of cell-cell fusion(IC50=0.012 μM);##HCoV-OC43:inhibition of authentic infection in RD cells(IC50=0.07 μM);inhibition of cell-cell fusion(IC50=0.01 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.35336956]showed  no significant cytotoxicity against RD cells at the concentration of 5 μM.,DRAVPe00442,DRAVPe00442.cif,Linear,Free,PEG4-C16(palmitic acid),,L,membrane,"The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions  can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells.",4677.29,C208H336N48O71S,CHPRW,EL,4.36,5,10,-5,11,13,-44.88,-6701,1.9 hour,>20 hour,>10 hour,104.63,2980,74.5,35336956,Viruses. 2022 Mar 6;14(3):549.,"Lan Q, Chan JF, Xu W, Wang L, Jiao F, Zhang G, Pu J, Zhou J, Xia S, Lu L, Yuen KY, Jiang S, Wang Q. ","A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern.",10.3390/v14030549,,"Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-HCoV-OC43"
DRAVPe00443,ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL,35,"IPB01(SARS-CoV-S (1151-1185),SR9, SARS-CoV-2-S (1169-1203))",Synthetic construct(derived from SARS-CoV-2 S protein),P59594##P0DTC2,,"SARS-CoV-2,SARS-CoV,VSV","Coronaviridae, Rhabdoviridae","cell fusion assay, single-cycle infection assay","[Ref.32376627]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=0.022±0.005 µM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=33.74±11.827 µM);##SARS-CoV:inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 µM);##Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 µM).##[Ref.17942557]SARS-CoV:Inhibition of virus entry in VERO-E6 cells(EC50=0.005 µM).##[Ref.18442051]SARS-CoV: inhibition of PsV entry in Vero-E6 cells(EC50=0.34 µM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe00443.cif,Linear,Free,Free,,L,membrane,"The peptide was designed based on HR2 sequence lipopeptide fusion inhibitor,which showed highly potent activities in inhibiting SARS-CoV-2 S protein-mediated cell-cell fusion and pseudovirus transduction. It can  also inhibit the SARS-CoV pseudovirus efficiently.",3893.41,C168H287N47O58,CFHMPTWY,ILN,4.36,3,6,-3,9,15,-8.29,-5930,20 hour,30 min,>10 hour,142.0,0,0.0,17942557##18442051##32376627,J Virol. 2008 Jan;82(1):588-92.##J Cell Biochem. 2008 Aug 15;104(6):2335-47.##J Virol. 2020 Jul 1;94(14):e00635-20.,"Ujike M, Nishikawa H, Otaka A, Yamamoto N, Yamamoto N, Matsuoka M, Kodama E, Fujii N, Taguchi F. ##Chu LH, Chan SH, Tsai SN, Wang Y, Cheng CH, Wong KB, Waye MM, Ngai SM. ##Zhu Y, Yu D, Yan H, Chong H, He Y.","Heptad repeat-derived peptides block protease-mediated direct entry from the cell surface of severe acute respiratory syndrome coronavirus but not entry via the endosomal pathway.##Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors.##Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.",10.1128/JVI.01697-07##10.1002/jcb.21790##10.1128/JVI.00635-20,,"Anti-Anti-SARS-CoV-2,Anti-SARS-CoV,Anti-VSV"
DRAVPe00444,ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELK,36,IPB02(SARS-CoV-2-S (1169-1203)-K),Synthetic construct(derived from SARS-CoV-2 S protein),P59594##P0DTC2,,"SARS-CoV-2,SARS-CoV,VSV","Coronaviridae, Rhabdoviridae","cell fusion assay, single-cycle infection assay","[Ref.32376627]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=0.025 ± 0.002 µM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=0.08±0.017 µM);##SARS-CoV:inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC=0.251 ± 0.118 µM);##Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 µM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00444,DRAVPe00444.cif,Linear,Free,Chol,,L,membrane,"The peptide was designed based on HR2 sequence lipopeptide fusion inhibitor,which showed highly potent activities in inhibiting SARS-CoV-2 S protein-mediated cell-cell fusion and pseudovirus transduction. It can  also inhibit the SARS-CoV pseudovirus efficiently.",4021.58,C174H299N49O59,CFHMPTWY,ILN,4.66,4,6,-2,9,15,-18.89,-6485,20 hour,30 min,>10 hour,138.06,0,0.0,32376627,J Virol. 2020 Jul 1;94(14):e00635-20.,"Zhu Y, Yu D, Yan H, Chong H, He Y.","Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.",10.1128/JVI.00635-20,,"Anti-Anti-SARS-CoV-2,Anti-SARS-CoV,Anti-VSV"
DRAVPe00445,INASVVNIQKEIDRLNEVAKNLNESLIDLQELGK,34,IPB03(SARS-CoV-2-S (1172-1205)),Synthetic construct(derived from SARS-CoV-2 S protein),P59594##P0DTC2,,"SARS-CoV-2,SARS-CoV,VSV","Coronaviridae, Rhabdoviridae","cell fusion assay, single-cycle infection assay","[Ref.32376627]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=0.015 ± 0.002 µM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=0.947 ± 0.179 µM);##SARS-CoV:inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC=1.315 ± 0.463 µM);##Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 µM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00445,DRAVPe00445.cif,Linear,Free,Chol,,L,membrane,"The peptide was designed based on HR2 sequence lipopeptide fusion inhibitor,which showed highly potent activities in inhibiting SARS-CoV-2 S protein-mediated cell-cell fusion and pseudovirus transduction. It can  also inhibit the SARS-CoV pseudovirus efficiently.",3821.34,C165H283N47O56,CFHMPTWY,LN,4.66,4,6,-2,8,14,-30.88,-6637,20 hour,30 min,>10 hour,134.71,0,0.0,32376627,J Virol. 2020 Jul 1;94(14):e00635-20.,"Zhu Y, Yu D, Yan H, Chong H, He Y.","Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.",10.1128/JVI.00635-20,,"Anti-Anti-SARS-CoV-2,Anti-SARS-CoV,Anti-VSV"
DRAVPe00446,SVVNIQKEIDRLNEVAKNLNESLIDLQELGK,31,IPB04(SARS-CoV-2-S (1175-1205)),Synthetic construct(derived from SARS-CoV-2 S protein),P59594##P0DTC2,,"SARS-CoV-2,SARS-CoV,VSV","Coronaviridae, Rhabdoviridae","cell fusion assay, single-cycle infection assay","[Ref.32376627]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=0.033 ± 0.013 µM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=0.218 ± 0.063 µM);##SARS-CoV:inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC=1.053 ± 0.444 µM);##Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 µM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00446,DRAVPe00446.cif,Linear,Free,Chol,,L,membrane,"The peptide was designed based on HR2 sequence lipopeptide fusion inhibitor,which showed highly potent activities in inhibiting SARS-CoV-2 S protein-mediated cell-cell fusion and pseudovirus transduction. It can  also inhibit the SARS-CoV pseudovirus efficiently.",3523.0,C152H261N43O52,CFHMPTWY,L,4.66,4,6,-2,7,12,-42.9,-6646,1.9 hour,>20 hour,>10 hour,131.94,0,0.0,32376627,J Virol. 2020 Jul 1;94(14):e00635-20.,"Zhu Y, Yu D, Yan H, Chong H, He Y.","Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.",10.1128/JVI.00635-20,,"Anti-Anti-SARS-CoV-2,Anti-SARS-CoV,Anti-VSV"
DRAVPe00447,IQKEIDRLNEVAKNLNESLIDLQELGK,27,IPB05(SARS-CoV-2-S (1179-1205)),Synthetic construct(derived from SARS-CoV-2 S protein),P59594##P0DTC2,,"SARS-CoV-2,SARS-CoV,VSV","Coronaviridae, Rhabdoviridae","cell fusion assay, single-cycle infection assay.","[Ref.32376627]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50>5 µM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>25 µM);##SARS-CoV:inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC>25 µM);##Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 µM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00447,DRAVPe00447.cif,Linear,Free,Chol,,L,membrane,"The peptide was designed based on HR2 sequence lipopeptide fusion inhibitor,which showed highly potent activities in inhibiting SARS-CoV-2 S protein-mediated cell-cell fusion and pseudovirus transduction. It can  also inhibit the SARS-CoV pseudovirus efficiently.",3123.55,C135H232N38O46,CFHMPTWY,L,4.66,4,6,-2,5,10,-64.44,-6450,20 hour,30 min,>10 hour,130.0,0,0.0,32376627,J Virol. 2020 Jul 1;94(14):e00635-20.,"Zhu Y, Yu D, Yan H, Chong H, He Y.","Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.",10.1128/JVI.00635-20,,"Anti-Anti-SARS-CoV-2,Anti-SARS-CoV,Anti-VSV"
DRAVPe00448,IDRLNEVAKNLNESLIDLQELGK,23,IPB06(SARS-CoV-2-S (1183-1205)),Synthetic construct(derived from SARS-CoV-2 S protein),P59594##P0DTC2,,"SARS-CoV-2,SARS-CoV,VSV","Coronaviridae, Rhabdoviridae","cell fusion assay, single-cycle infection assay","[Ref.32376627]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50>5 µM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>25 µM);##SARS-CoV:inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC>25 µM);##Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 µM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00448,DRAVPe00448.cif,Linear,Free,Chol,,L,membrane,"The peptide was designed based on HR2 sequence lipopeptide fusion inhibitor,which showed highly potent activities in inhibiting SARS-CoV-2 S protein-mediated cell-cell fusion and pseudovirus transduction. It can  also inhibit the SARS-CoV pseudovirus efficiently.",2624.97,C113H194N32O39,CFHMPTWY,L,4.51,3,5,-2,5,9,-47.83,-5152,20 hour,30 min,>10 hour,135.65,0,0.0,32376627,J Virol. 2020 Jul 1;94(14):e00635-20.,"Zhu Y, Yu D, Yan H, Chong H, He Y.","Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.",10.1128/JVI.00635-20,,"Anti-Anti-SARS-CoV-2,Anti-SARS-CoV,Anti-VSV"
DRAVPe00449,IQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK,33,IPB07(SARS-CoV-2-S (1179-1211)),Synthetic construct(derived from SARS-CoV-2 S protein),P59594##P0DTC2,,"SARS-CoV-2,SARS-CoV,VSV","Coronaviridae, Rhabdoviridae","cell fusion assay, single-cycle infection assay","[Ref.32376627]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=0.017 ± 0.001 µM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=0.993 ± 0.08 µM);##SARS-CoV:inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC=1.037 ± 0.836 µM);##Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 µM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00449,DRAVPe00449.cif,Linear,Free,Chol,,L,membrane,"The peptide was designed based on HR2 sequence lipopeptide fusion inhibitor,which showed highly potent activities in inhibiting SARS-CoV-2 S protein-mediated cell-cell fusion and pseudovirus transduction. It can  also inhibit the SARS-CoV pseudovirus efficiently.",3948.49,C175H288N46O57,CFHMPTW,EL,4.77,5,7,-2,7,11,-80.0,-7776,20 hour,30 min,>10 hour,118.18,2980,93.13,32376627,J Virol. 2020 Jul 1;94(14):e00635-20.,"Zhu Y, Yu D, Yan H, Chong H, He Y.","Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.",10.1128/JVI.00635-20,,"Anti-Anti-SARS-CoV-2,Anti-SARS-CoV,Anti-VSV"
DRAVPe00450,ISGINASVVNIQKEIDRLNEVAKNLNESLIK,31,IPB08(SARS-CoV-2-S (1169-1198)-K),Synthetic construct(derived from SARS-CoV-2 S protein),P59594##P0DTC2,,"SARS-CoV-2,SARS-CoV,VSV","Coronaviridae, Rhabdoviridae","cell fusion assay, single-cycle infection assay","[Ref.32376627]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=4.66 ± 1.565 µM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=1.738 ± 0.898 µM);##SARS-CoV:inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC=1.13 ± 0.472 µM);##Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 µM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00450,DRAVPe00450.cif,Linear,Free,Chol,,L,membrane,"The peptide was designed based on HR2 sequence lipopeptide fusion inhibitor,which showed highly potent activities in inhibiting SARS-CoV-2 S protein-mediated cell-cell fusion and pseudovirus transduction. It can  also inhibit the SARS-CoV pseudovirus efficiently.",3422.93,C148H257N43O49,CFHMPTWY,IN,6.26,4,4,0,9,13,-12.58,-5362,20 hour,30 min,>10 hour,135.16,0,0.0,32376627,J Virol. 2020 Jul 1;94(14):e00635-20.,"Zhu Y, Yu D, Yan H, Chong H, He Y.","Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.",10.1128/JVI.00635-20,,"Anti-Anti-SARS-CoV-2,Anti-SARS-CoV,Anti-VSV"
DRAVPe00451,SVVNIQKEIDRLNEVAKNLNESLIK,25,IPB09(SARS-CoV-2-S (1175-1198)-K),Synthetic construct(derived from SARS-CoV-2 S protein),P59594##P0DTC2,,"SARS-CoV-2,SARS-CoV,VSV","Coronaviridae, Rhabdoviridae","cell fusion assay, single-cycle infection assay","[Ref.32376627]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50>5 µM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>25 µM);##SARS-CoV:inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC>25 µM);##Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 µM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00451,DRAVPe00451.cif,Linear,Free,Chol,,L,membrane,"The peptide was designed based on HR2 sequence lipopeptide fusion inhibitor,which showed highly potent activities in inhibiting SARS-CoV-2 S protein-mediated cell-cell fusion and pseudovirus transduction. It can  also inhibit the SARS-CoV pseudovirus efficiently.",2867.3,C124H216N36O41,CFGHMPTWY,N,5.98,4,4,0,6,10,-40.0,-5617,1.9 hour,>20 hour,>10 hour,132.4,0,0.0,32376627,J Virol. 2020 Jul 1;94(14):e00635-20.,"Zhu Y, Yu D, Yan H, Chong H, He Y.","Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.",10.1128/JVI.00635-20,,"Anti-Anti-SARS-CoV-2,Anti-SARS-CoV,Anti-VSV"
DRAVPe00452,RLFFKCIYRFFEHGLKRG,18,M2 AH,Synthetic construct(derived from influenza virus M2 protein),No entry found,,H1N1,Orthomyxoviridae,,[Ref.31375212]H1N1(A/Puerto Rico/8/34):inhibition of infection in Madin-Darby canine kidney epithelial(MDCK) cells(IC50=870 nM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.31375212]Madin-Darby canine kidney epithelial(MDCK) cells:CC50=70.3 μM,DRAVPe00452,DRAVPe00452.cif,Linear,Free,Free,,L,membrane,"M2 AH is an α-helical amphipathic peptide with basic amino acids positioned at the polar-nonpolar interface. The peptide inserts deeply into the hydrophobic core of the membrane bilayer, resulting in alteration of membrane order and curvature . This ability to alter membrane curvature enables M2 AH to induce membrane budding in vitro and in vivo. It localizes to the neck of the budding virion and plays an important role in membrane scission.",2317.79,C111H165N31O22S,ADMNPQSTVW,F,10.3,6,1,5,4,7,-23.89,-3763,1 hour,2 min,2 min,65.0,1490,87.65,31375212,Biochem Biophys Res Commun. 2019 Sep 24;517(3):507-512.,"Jung Y, Kong B, Moon S, Yu SH, Chung J, Ban C, Chung WJ, Kim SG, Kweon DH. ",Envelope-deforming antiviral peptide derived from influenza virus M2 protein.,10.1016/j.bbrc.2019.07.088,,Anti-H1N1
DRAVPe00453,RKFFKKIYRFFRKLLKRL,18,M2 MH,Synthetic construct(derived from influenza virus M2 protein),No entry found,,Influenza virus,Orthomyxoviridae,,[Ref.31375212]H1N1(A/Puerto Rico/8/34):inhibition of infection in Madin-Darby canine kidney epithelial(MDCK) cells(IC50=53 nM);##H3N2(A/Sydney/5/97):inhibition of infection in Madin-Darby canine kidney epithelial(MDCK) cells(IC50=0.058 μM);##H3N2(A/X31):inhibition of infection in Madin-Darby canine kidney epithelial(MDCK) cells(IC50=0.016 μM);##H5N2(A/aquatic bird/Korea/w81/2005 ):inhibition of infection in Madin-Darby canine kidney epithelial(MDCK) cells(IC50=0.066 μM);##H1N1(A/Swine/Iowa/15/30):inhibition of infection in Madin-Darby canine kidney epithelial(MDCK) cells(IC50=0.053 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.31375212]Madin-Darby canine kidney epithelial(MDCK) cells:CC50=19.2 μM,DRAVPe00453,DRAVPe00453.cif,Linear,Free,Free,,L,membrane,"M2 MH is an α-helical amphipathic peptide with basic amino acids positioned at the polar-nonpolar interface. The peptide inserts deeply into the hydrophobic core of the membrane bilayer, resulting in alteration of membrane order and curvature . This ability to alter membrane curvature enables M2 MH to induce membrane budding in vitro and in vivo. It localizes to the neck of the budding virion and plays an important role in membrane scission.",2488.16,C123H199N35O20,ACDEGHMNPQSTVW,K,12.02,9,0,9,1,8,-65.0,-5597,1 hour,2 min,2 min,86.67,1490,87.65,31375212,Biochem Biophys Res Commun. 2019 Sep 24;517(3):507-512.,"Jung Y, Kong B, Moon S, Yu SH, Chung J, Ban C, Chung WJ, Kim SG, Kweon DH. ",Envelope-deforming antiviral peptide derived from influenza virus M2 protein.,10.1016/j.bbrc.2019.07.088,,Anti-Influenza virus
DRAVPe00454,RLAAKCAARFAEHGLKRG,18,M2 NH,Synthetic construct(derived from influenza virus M2 protein),No entry found,,H1N1,Orthomyxoviridae,,[Ref.31375212]H1N1:did not exhibit any inhibitory effect.,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.31375212]did not show apparent cytotoxicity against Madin-Darby canine kidney epithelial(MDCK) cells up to a concentration of 100 μM.,DRAVPe00454,DRAVPe00454.cif,Linear,Free,Free,,L,membrane,"M2 NH is an α-helical amphipathic peptide with basic amino acids positioned at the polar-nonpolar interface. The peptide inserts deeply into the hydrophobic core of the membrane bilayer, resulting in alteration of membrane order and curvature . This ability to alter membrane curvature enables M2 NH to induce membrane budding in vitro and in vivo. It localizes to the neck of the budding virion and plays an important role in membrane scission.",1955.31,C84H143N31O21S,DIMNPQSTVWY,A,10.92,6,1,5,3,8,-38.33,-4230,1 hour,2 min,2 min,71.11,0,0.0,31375212,Biochem Biophys Res Commun. 2019 Sep 24;517(3):507-512.,"Jung Y, Kong B, Moon S, Yu SH, Chung J, Ban C, Chung WJ, Kim SG, Kweon DH. ",Envelope-deforming antiviral peptide derived from influenza virus M2 protein.,10.1016/j.bbrc.2019.07.088,,Anti-H1N1
DRAVPe00455,GFSSLFKAGAKYLLKQVGKAGAQQLACKAANNC,33,Brevinin-2GHk(BR2GK),Fejervarya limnocharis,A0A6G6CZ26,,Zika Virus,Flaviviridae,,[Ref.34960651]Zika Virus: inhibition of infection of Zika virus in Vero cells(IC50=3.408 ± 0.738 μM).,No hemolysis information or data found in the reference(s) presented in this entry,"[Ref.34960651]exhibited no significant toxicity to Vero, Hela, and Huh7 cells in the concentration range 0-20 µM.",DRAVPe00455,DRAVPe00455.cif,Linear,Free,Free,,L,membrane,BR2GK directly inactivated ZIKV by disrupting the integrity of the envelope and may also penetrate the host cell membrane to inhibit the middle stage of ZIKV infection. ,3386.98,C150H245N43O42S2,DEHIMPRTW,A,9.79,5,0,5,11,14,3.33,-1592,30 hour,>20 hour,>10 hour,77.27,1615,50.47,34960651,Viruses. 2021 Nov 28;13(12):2382. ,"Xiong W, Li J, Feng Y, Chai J, Wu J, Hu Y, Tian M, Lu W, Xu X, Zou M.","Brevinin-2GHk, a Peptide Derived from the Skin of Fejervarya limnocharis, Inhibits Zika Virus Infection by Disrupting Viral Integrity.",10.3390/v13122382,,Anti-ZIKV
DRAVPe00456,FLPLILPAnti-SIVTALSSFLKQG,20,Hs-1,Hypsiboas semilineatus,No entry found,,DENV,Flaviviridae,,[Ref.29153860]DENV2:reduced the number of lysis plaques by 100% at 125 µg/mL; by 60% at 7.81 μg/mL;##DENV3:reduced the number of lysis plaques by 100% at 125 µg/mL; by 50% at 7.81 μg/mL,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.29153860]No significant cytotoxicity agaisnt Vero cells up to 125μg/ mL.,DRAVPe00456,DRAVPe00456.cif,Linear,Free,Free,,L,envelope,It was possible to observe that the viral particle lost its ability to infect because of the breakdown on the envelope as the peptide acted directly on the virus. ,2144.63,C104H170N22O26,CDEHMNRWY,L,8.75,1,0,1,5,11,127.5,2333,1.1 hour,3 min,2 min,156.0,0,0.0,29153860,Virology. 2018 Jan 15;514:79-87.,"Monteiro JMC, Oliveira MD, Dias RS, Nacif-Marçal L, Feio RN, Ferreira SO, Oliveira LL, Silva CC, Paula SO.",The antimicrobial peptide HS-1 inhibits dengue virus infection.,10.1016/j.virol.2017.11.009,,Anti-DENV
DRAVPe00457,GGARDAGKAEWW,12,gg-ww,Synthetic construct,No entry found,,DENV,Flaviviridae,,[Ref.26248692]dengue virus serotype 2(DENV-2):inhibition the cytopathic effect(CPE) and plaque formation in Vero cells(IC50=77-91 μmol/L).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.26248692]It was not toxic to Vero cells up to 400 μmol/L.,DRAVPe00457,DRAVPe00457.cif,Linear,Free,Free,,L,membrane,The peptide gg-ww could exert its inhibition during the viral entry step of DENV-2 infection by interfering with viral attachment or internalization.,1303.4,C58H82N18O17,CFHILMNPQSTVY,AG,6.07,2,2,0,3,5,-108.33,-2309,30 hour,>20 hour,>10 hour,25.0,11000,1000.0,26248692,J Appl Microbiol. 2015 Oct;119(4):1170-80. ,"Chew MF, Tham HW, Rajik M, Sharifah SH. ",Anti-dengue virus serotype 2 activity and mode of action of a novel peptide.,10.1111/jam.12921,,Anti-DENV
DRAVPe00458,CNDFRSKTC,9,P1,Synthetic construct,No entry found,,Influenza viruse,Orthomyxoviridae,,[Ref.19680476]Avian influenza viruses (AIV) H9N2: inhibition of viral attachment on MDCK cells(>50% inhibition at the concentration of 50 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00458,DRAVPe00458.cif,Linear,Free,Free,,L,membrane,"Avian influenza viruses possess two important surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA) against which neutralizing antibodies are produced. This peptide inhibits the replication of the virus in ovo and in vitro by its binding to the HA glycoprotein. ",1073.21,C42H68N14O15S2,AEGHILMPQVWY,C,8.06,2,1,1,5,1,-101.11,-3626,1.2 hour,>20 hour,>10 hour,0.0,125,15.63,19680476,Int J Biol Sci. 2009 Aug 8;5(6):543-8.,"Rajik M, Omar AR, Ideris A, Hassan SS, Yusoff K.",A novel peptide inhibits the influenza virus replication by preventing the viral attachment to the host cells. ,10.7150/ijbs.5.543,,Anti-Influenza viruse
DRAVPe00459,QEGISRFKICPYHWYKQHMSLLFRRYYHKLDSII,34,CPXV012,Synthetic construct(derived from the cowpox virus protein),No entry found,,"HSV,HBV,HIV,RVFV","Herpesviridae, Hepadnaviridae, Retroviridae, Phenuiviridae",,[Ref.32872420]Herpes simplex virus-1(HSV-1):inhibition of HSV-1 infection in MelJuSo(MJS) cells(75.9 ± 5.7%  inhibition at 150 µg/mL);##Hepatitis B virus(HBV): decrease of HBeAg and viral DNA infected with HBV-1 in HepRG cells(84.0 ± 3.0% of HBeAg and 73.6 ± 2.3% of viral DNA at 100 µg/mL);##HIV-1:inhibition of virus infection in LC5-RIC reporter cells(82.7 ± 4.9% inhibition at 100 µg/mL);inhibition of virus replication in LC5-RIC reporter cells(62.2 ± 2.4% inhibition at 100 µg/mL);##Rift Valley fever virus(RVFV): inhibition of virus infection in MJS cells(65.5 ± 2.3% inhibition at 160 µg/mL).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.32872420]Did not observe any decrease in live cells against Vero and Huh7.5 cells up to 200 µg/mL.,DRAVPe00459,DRAVPe00459.cif,Linear,Free,Free,,L,envelope(phosphatidylserine),"Within virus-infected cells, this protein helps to evade the immune system by inhibiting the transporter associated with antigen processing (TAP), thereby interfering with MHC I-dependent antigen presentation. And the peptide is the segment of the CPXV012 protein responsible for blocking TAP.",4358.11,C204H303N55O48S2,ANTV,IY,9.65,9,2,7,9,10,-58.53,-6546,0.8 hour,10 min,>10 hour,80.29,11460,347.27,32872420,Cells. 2020 Aug 29;9(9):1989.,"Luteijn RD, Praest P, Thiele F, Sadasivam SM, Singethan K, Drijfhout JW, Bach C, de Boer SM, Lebbink RJ, Tao S, Helfer M, Bach NC, Protzer U, Costa AI, Killian JA, Drexler I, Wiertz EJHJ.",A Broad-Spectrum Antiviral Peptide Blocks Infection of Viruses by Binding to Phosphatidylserine in the Viral Envelope. ,10.3390/cells9091989,,"Anti-HSV,Anti-HBV,Anti-HIV,RVFV"
DRAVPe00460,TEPSTRGSWKFW,12,P1,Synthetic construct(phage display),No entry found,,JEV,Flaviviridae,,[Ref.24468276]Japanese encephalitis virus (JEV): inhibition of JEV infection in BHK-21 cells(IC50~100 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00460,DRAVPe00460.cif,Linear,Free,Free,,L,envelope protein,"E glycoprotein has been identified as the major antigenic determinant on flavivirus particles and mediates binding and fusion during viral entry,DIII has been proposed to act as the binding region for the cellular receptor. And the peptide could bingding with DIII domain and inhibit the initial step of JEV infection.",1481.63,C69H96N18O19,ACDHILMNQVY,STW,8.41,2,1,1,5,3,-132.5,-3064,7.2 hour,>20 hour,>10 hour,0.0,11000,1000.0,24468276,Antiviral Res. 2014 Apr;104:7-14.,"Zu X, Liu Y, Wang S, Jin R, Zhou Z, Liu H, Gong R, Xiao G, Wang W.",Peptide inhibitor of Japanese encephalitis virus infection targeting envelope protein domain III.,10.1016/j.antiviral.2014.01.011,,Anti-JEV
DRAVPe00461,SENRKVPFYSHS,12,P3,Synthetic construct(phage display),No entry found,,JEV,Flaviviridae,,"[Ref.24468276]Japanese encephalitis virus (JEV): inhibition of JEV infection in BHK-21 cells(IC50=1.42 ± 0.41 μM determined by plaque assay,IC50=1.12 ± 0.38 μM determined by qRT-PCR,IC90~100 μM determined by plaque assay and qRT-PCR).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00461,DRAVPe00461.cif,Linear,Free,Free,,L,envelope protein,"E glycoprotein has been identified as the major antigenic determinant on flavivirus particles and mediates binding and fusion during viral entry,DIII has been proposed to act as the binding region for the cellular receptor. And the peptide could bingding with DIII domain and inhibit the initial step of JEV infection.",1450.57,C64H95N19O20,ACDGILMQTW,S,8.33,3,1,2,5,2,-140.83,-4190,1.9 hour,>20 hour,>10 hour,24.17,1490,135.45,24468276,Antiviral Res. 2014 Apr;104:7-14.,"Zu X, Liu Y, Wang S, Jin R, Zhou Z, Liu H, Gong R, Xiao G, Wang W.",Peptide inhibitor of Japanese encephalitis virus infection targeting envelope protein domain III.,10.1016/j.antiviral.2014.01.011,,Anti-JEV
DRAVPe00462,MVDRGWGNHAGLFGKGAnti-SIV,19,DN80,Synthetic construct(derived from the E polyprotein of DENV),No entry found,,DENV,Flaviviridae,,[Ref.31351847]Dengue virus(DENV): inhibition of DENV infection in LLCKM-2 monkey kidney epithelial cells(17±10% inhibition at 49.9 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00462,DRAVPe00462.cif,Linear,Free,Free,,L,envelope,The peptide may play roles in protein-protein rearrangements or bilayer membrane interactions during the entry and fusion process and thus inhibit infection of DENV or WNV.,2001.29,C89H137N27O24S,CEPQTY,G,8.52,3,1,2,7,7,4.74,-1180,30 hour,>20 hour,>10 hour,76.84,5500,305.56,31351847,Bioorg Med Chem. 2019 Sep 15;27(18):3963-3978. ,"da Silva-Júnior EF, de Araújo-Júnior JX. ","Peptide derivatives as inhibitors of NS2B-NS3 protease from Dengue, West Nile, and Zika flaviviruses.",10.1016/j.bmc.2019.07.038,,Anti-DENV
DRAVPe00463,AWLVHTQWFLDLPLPWLPGADTQGSNWI,28,DN57,Synthetic construct(derived from the E polyprotein of DENV),No entry found,,DENV,Flaviviridae,,[Ref.31351847]Dengue virus(DENV): inhibition of DENV infection in LLCKM-2 monkey kidney epithelial cells(7±4% inhibition at 30.6 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00463,DRAVPe00463.cif,Linear,Free,Free,,L,envelope,The peptide may play roles in protein-protein rearrangements or bilayer membrane interactions during the entry and fusion process and thus inhibit infection of DENV or WNV.,3262.72,C158H221N37O39,CEKMRY,L,4.2,1,2,-1,6,14,7.14,300,4.4 hour,>20 hour,>10 hour,101.07,22000,814.81,31351847,Bioorg Med Chem. 2019 Sep 15;27(18):3963-3978. ,"da Silva-Júnior EF, de Araújo-Júnior JX. ","Peptide derivatives as inhibitors of NS2B-NS3 protease from Dengue, West Nile, and Zika flaviviruses.",10.1016/j.bmc.2019.07.038,,Anti-DENV
DRAVPe00464,AWLVHRQWFLDLPLPWLPG,19,DN81,Synthetic construct(derived from the E polyprotein of DENV),No entry found,,DENV,Flaviviridae,,[Ref.31351847]Dengue virus(DENV): inhibition of DENV infection in LLCKM-2 monkey kidney epithelial cells(25±8% inhibition at 42.6 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00464,DRAVPe00464.cif,Linear,Free,Free,,L,envelope,The peptide may play roles in protein-protein rearrangements or bilayer membrane interactions during the entry and fusion process and thus inhibit infection of DENV or WNV.,2344.79,C118H166N28O23,CEIKMNSTY,L,6.79,2,1,1,1,11,27.37,752,4.4 hour,>20 hour,>10 hour,123.16,16500,916.67,31351847,Bioorg Med Chem. 2019 Sep 15;27(18):3963-3978. ,"da Silva-Júnior EF, de Araújo-Júnior JX. ","Peptide derivatives as inhibitors of NS2B-NS3 protease from Dengue, West Nile, and Zika flaviviruses.",10.1016/j.bmc.2019.07.038,,Anti-DENV
DRAVPe00465,MAILGDTAWDFGSLGGVFTSIGKALHQVFGAIY,33,DN59,Synthetic construct(derived from the E polyprotein of DENV),No entry found,,"DENV,MNV",Flaviviridae,,"[Ref.31351847]Dengue virus(DENV): inhibition of DENV infection in LLCKM-2 monkey kidney epithelial cells(IC50~10μM,100.0±0.5% inhibition at 20 μM);##West Nile virus(WNV): inhibition of WNV infection in LLCKM-2 monkey kidney epithelial cells(>99% inhibition at <25μM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.31351847]No cytotoxicity against LLCMK-2 monkey kidney epithelial cells at 100 mg/ml.,DRAVPe00465,DRAVPe00465.cif,Linear,Free,Free,,L,envelope,The peptide may play roles in protein-protein rearrangements or bilayer membrane interactions during the entry and fusion process and thus inhibit infection of DENV or WNV.,3443.96,C161H240N38O44S,CENPR,G,5.19,2,2,0,11,16,77.58,1883,30 hour,>20 hour,>10 hour,100.61,6990,218.44,31351847,Bioorg Med Chem. 2019 Sep 15;27(18):3963-3978. ,"da Silva-Júnior EF, de Araújo-Júnior JX. ","Peptide derivatives as inhibitors of NS2B-NS3 protease from Dengue, West Nile, and Zika flaviviruses.",10.1016/j.bmc.2019.07.038,,"Anti-DENV,MNV"
DRAVPe00466,VVDRGWGNGAGLFGKGSID,19,WN82,Synthetic construct(derived from the E polyprotein of WNV),No entry found,,WNV,Flaviviridae,,[Ref.31351847]West Nile virus(WNV): inhibition of WNV infection in LLCKM-2 monkey kidney epithelial cells(4±13% inhibition at 52.5μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00466,DRAVPe00466.cif,Linear,Free,Free,,L,envelope,The peptide may play roles in protein-protein rearrangements or bilayer membrane interactions during the entry and fusion process and thus inhibit infection of DENV or WNV.,1905.1,C84H129N25O26,CEHMPQTY,G,5.93,2,2,0,8,7,-8.95,-1727,100 hour,>20 hour,>10 hour,76.84,5500,305.56,31351847,Bioorg Med Chem. 2019 Sep 15;27(18):3963-3978. ,"da Silva-Júnior EF, de Araújo-Júnior JX. ","Peptide derivatives as inhibitors of NS2B-NS3 protease from Dengue, West Nile, and Zika flaviviruses.",10.1016/j.bmc.2019.07.038,,Anti-WNV
DRAVPe00467,TFLVHREWFMDLNLPWSSAGSTVWR,25,WN53,Synthetic construct(derived from the E polyprotein of WNV),No entry found,,WNV,Flaviviridae,,"[Ref.31351847]West Nile virus(WNV): inhibition of WNV infection in LLCKM-2 monkey kidney epithelial cells(IC50~10μM,56.0±3.0% inhibition at 99μM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.31351847]No cytotoxicity against LLCMK-2 monkey kidney epithelial cells at 100 mg/ml.,DRAVPe00467,DRAVPe00467.cif,Linear,Free,Free,,L,envelope,The peptide may play roles in protein-protein rearrangements or bilayer membrane interactions during the entry and fusion process and thus inhibit infection of DENV or WNV.,3036.46,C142H203N37O36S,CIKQY,LSW,6.42,3,2,1,7,11,-8.4,-3112,7.2 hour,>20 hour,>10 hour,74.0,16500,687.5,31351847,Bioorg Med Chem. 2019 Sep 15;27(18):3963-3978. ,"da Silva-Júnior EF, de Araújo-Júnior JX. ","Peptide derivatives as inhibitors of NS2B-NS3 protease from Dengue, West Nile, and Zika flaviviruses.",10.1016/j.bmc.2019.07.038,,Anti-WNV
DRAVPe00468,TFLVHREWFMDLNLPWSSA,19,WN83,Synthetic construct(derived from the E polyprotein of WNV),No entry found,,WNV,Flaviviridae,,"[Ref.31351847]West Nile virus(WNV): inhibition of WNV infection in LLCKM-2 monkey kidney epithelial cells(IC50~10μM, 70.0±3.0% inhibition at 128 μM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.31351847]No cytotoxicity against LLCMK-2 monkey kidney epithelial cells at 100 mg/ml.,DRAVPe00468,DRAVPe00468.cif,Linear,Free,Free,,L,envelope,The peptide may play roles in protein-protein rearrangements or bilayer membrane interactions during the entry and fusion process and thus inhibit infection of DENV or WNV.,2349.69,C111H157N27O28S,CGIKQY,L,5.29,2,2,0,4,9,5.26,-1754,7.2 hour,>20 hour,>10 hour,82.11,11000,611.11,31351847,Bioorg Med Chem. 2019 Sep 15;27(18):3963-3978. ,"da Silva-Júnior EF, de Araújo-Júnior JX. ","Peptide derivatives as inhibitors of NS2B-NS3 protease from Dengue, West Nile, and Zika flaviviruses.",10.1016/j.bmc.2019.07.038,,Anti-WNV
DRAVPe00469,AIGSILGALAKGLPTLISWIKNR,23,AR-23,Rana tagoi (Tago frog),A7BJK6,6dst,"HSV,MeV,HPIV,HCoV-229E","Herpesviridae, Paramyxoviridae, Coronaviridae",,[Ref.35055066]HSV-1: Co-treatment:simultaneous addition of AR-23 and virus to the cells(IC50=0.78 μM);Virus pre-treatment: virus incubated with the peptide(IC50=0.39 μM);Cell pre-treatment: AR-23 incubated with the cells before the viral infection and  Post-treatment: AR-23 added to the infected cells(AR-23 had a slight inhibitory effect);inhibition the entry of virus(IC50=3.125μM);inhibition of viral attachment on the host cell membrane(IC50=6.25 μM);##Measles virus (MeV):Co-treatment: simultaneous addition of AR-23 and virus to the cells(IC50=6.25 μM);Virus pre-treatment: virus incubated with the peptide(IC50=3.125 μM);##Human parainfluenza virus type-2 (HPIV2):Co-treatment: simultaneous addition of AR-23 and virus to the cells(IC50=6.25 μM);Virus pre-treatment: virus incubated with the peptide(IC50=3.125 μM);##HCoV-229E:Virus pre-treatment: virus incubated with the peptide(IC50=3.125 μM);##SARS-CoV-2:Co-treatment:simultaneous addition of AR-23 and virus to the cells(60% of inhibition at 25 μM);Virus pre-treatment: virus incubated with the peptide(IC50=12.5 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.35055066]Vero cells:CC50=25 μM; >80% cytotoxic against Vero cells at 100 and 50 µM.,DRAVPe00469,DRAVPe00469.cif,Linear,Free,Amidation,,L,envelope glycoprotein,No machanism information found in the reference(s) presented in this entry,2392.91,C111H190N30O28,CDEFHMQVY,IL,11.17,3,0,3,7,12,73.04,791,4.4 hour,>20 hour,>10 hour,148.7,5500,250.0,35055066, Int J Mol Sci. 2022 Jan 14;23(2):883. ,"Chianese A, Zannella C, Monti A, De Filippis A, Doti N, Franci G, Galdiero M.",The Broad-Spectrum Antiviral Potential of the Amphibian Peptide AR-23. ,10.3390/ijms23020883,,"Anti-HSV,Anti-MeV,Anti-HPIV,Anti-HCoV-229E"
DRAVPe00470,SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG,41,EK1P4HC,Synthetic construct,No entry found,,"SARS-CoV-2,SARS-CoV,HCoV-229E,HCoV-OC43,MERS-CoV",Coronaviridae,pseudovirus inhibition assay,[Ref.34769299]SARS-CoV-2:inhibition of Pseudoviruse infection in Caco2 cells(IC50=0.8 μM);##SARS-CoV-2 B.1.1.7 (Alpha):inhibition of Pseudoviruse infection in Caco2 cells(IC50=2.28 μM);##SARS-CoV-2 B.1.351 (Beta):inhibition of Pseudoviruse infection in Caco2 cells(IC50=0.62 μM);##SARS-CoV-2 P.1 (Gamma):inhibition of Pseudoviruse infection in Caco2 cells(IC50=0.48 μM);##SARS-CoV-2 B.1.617.2 (Delta):inhibition of Pseudoviruse infection in Caco2 cells(IC50=0.11 μM);##HCoV-229E(Authentic):inhibition of infection in Caco2 cells(IC50=0.48 μM);##HCoV-OC43(Authentic):inhibition of infection in Caco2 cells(IC50=0.41 μM);##SARS-CoV:inhibition of Pseudoviruse infection in Caco2 cells(IC50=0.35 μM);##MERS-CoV:inhibition of Pseudoviruse infection in Caco2 cells(IC50=0.10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.34769299]no apparent cytotoxicity against Caco-2 cells at concentrations of up to 20 μM.,DRAVPe00470,DRAVPe00470.cif,Linear,Free,PEG4-25-HC,,L,mambrane,"The peptide targets two different sites when mediating virus–cell fusion,which are blocking viral 6-HB formation and reducing the membrane cholesterol level.",4677.29,C208H336N48O71S,CHPRW,EL,4.36,5,10,-5,11,13,-44.88,-6701,1.9 hour,>20 hour,>10 hour,104.63,2980,74.5,34769299,Int J Mol Sci. 2021 Nov 1;22(21):11869. ,"Lan Q, Wang C, Zhou J, Wang L, Jiao F, Zhang Y, Cai Y, Lu L, Xia S, Jiang S. ","25-Hydroxycholesterol-Conjugated EK1 Peptide with Potent and Broad-Spectrum Inhibitory Activity against SARS-CoV-2, Its Variants of Concern, and Other Human Coronaviruses.",10.3390/ijms222111869,,"Anti-SARS-CoV-2,SARS-CoV,Anti-HCoV-229E,Anti-HCoV-OC43,Anti-MERS-CoV"
DRAVPe00471,SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG,41,EK1P8HC,Synthetic construct,No entry found,,SARS-CoV-2,Coronaviridae,pseudovirus inhibition assay,[Ref.34769299]SARS-CoV-2:inhibition of Pseudoviruse infection in Caco2 cells(IC50=3.7 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.34769299]no apparent cytotoxicity against Caco-2 cells at concentrations of up to 20 μM.,DRAVPe00471,DRAVPe00471.cif,Linear,Free,PEG8-25-HC,,L,membrane,"The peptide targets two different sites when mediating virus–cell fusion,which are blocking viral 6-HB formation and reducing the membrane cholesterol level.",4677.29,C208H336N48O71S,CHPRW,EL,4.36,5,10,-5,11,13,-44.88,-6701,1.9 hour,>20 hour,>10 hour,104.63,2980,74.5,34769299,Int J Mol Sci. 2021 Nov 1;22(21):11869. ,"Lan Q, Wang C, Zhou J, Wang L, Jiao F, Zhang Y, Cai Y, Lu L, Xia S, Jiang S. ","25-Hydroxycholesterol-Conjugated EK1 Peptide with Potent and Broad-Spectrum Inhibitory Activity against SARS-CoV-2, Its Variants of Concern, and Other Human Coronaviruses.",10.3390/ijms222111869,,Anti-SARS-CoV-2
DRAVPe00472,SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG,41,EK1P12HC,Synthetic construct,No entry found,,SARS-CoV-2,Coronaviridae,pseudovirus inhibition assay,[Ref.34769299]SARS-CoV-2:inhibition of Pseudoviruse infection in Caco2 cells(IC50=5.2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.34769299]no apparent cytotoxicity against Caco-2 cells at concentrations of up to 20 μM.,DRAVPe00472,DRAVPe00472.cif,Linear,Free,PEG12-25-HC,,L,membrane`,"The peptide targets two different sites when mediating virus–cell fusion,which are blocking viral 6-HB formation and reducing the membrane cholesterol level.",4677.29,C208H336N48O71S,CHPRW,EL,4.36,5,10,-5,11,13,-44.88,-6701,1.9 hour,>20 hour,>10 hour,104.63,2980,74.5,34769299,Int J Mol Sci. 2021 Nov 1;22(21):11869. ,"Lan Q, Wang C, Zhou J, Wang L, Jiao F, Zhang Y, Cai Y, Lu L, Xia S, Jiang S. ","25-Hydroxycholesterol-Conjugated EK1 Peptide with Potent and Broad-Spectrum Inhibitory Activity against SARS-CoV-2, Its Variants of Concern, and Other Human Coronaviruses.",10.3390/ijms222111869,,Anti-SARS-CoV-2
DRAVPe00473,SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG,41,EK1P24HC,Synthetic construct,No entry found,,SARS-CoV-2,Coronaviridae,pseudovirus inhibition assay,[Ref.34769299]SARS-CoV-2:inhibition of Pseudoviruse infection in Caco2 cells(IC50=10.3 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.34769299]no apparent cytotoxicity against Caco-2 cells at concentrations of up to 20 μM.,DRAVPe00473,DRAVPe00473.cif,Linear,Free,PEG24-25-HC,,L,membrane,"The peptide targets two different sites when mediating virus–cell fusion,which are blocking viral 6-HB formation and reducing the membrane cholesterol level.",4677.29,C208H336N48O71S,CHPRW,EL,4.36,5,10,-5,11,13,-44.88,-6701,1.9 hour,>20 hour,>10 hour,104.63,2980,74.5,34769299,Int J Mol Sci. 2021 Nov 1;22(21):11869. ,"Lan Q, Wang C, Zhou J, Wang L, Jiao F, Zhang Y, Cai Y, Lu L, Xia S, Jiang S. ","25-Hydroxycholesterol-Conjugated EK1 Peptide with Potent and Broad-Spectrum Inhibitory Activity against SARS-CoV-2, Its Variants of Concern, and Other Human Coronaviruses.",10.3390/ijms222111869,,Anti-SARS-CoV-2
DRAVPe00474,TFLDKFNHEAEDLFYQ,16,ACE2 (27-42)(SAP1),Synthetic construct,Q9BYF1,,"SARS-CoV-2,SARS-CoV,HCoV-OC43,VSV","Coronaviridae, Rhabdoviridae",pseudovirus inhibition assay,[Ref.33356169]SARS-CoV-2:Inhibition of infection in 293T/ACE2 cells(IC50=2.39±0.20 mM);Inhibition of infection in 293T/ACE2/GFP cells(IC50=3 mM);##SARS-CoV:Inhibition of infection in 293T/ACE2 cells(80% inhibition at 3 mM);##Vesicular Stomatitis Virus (VSV):No nhibition of infection in 293T/ACE2 cells up to 3 mM;##HCoV-NL63:Inhibition of cytopathic effect in LLC-MK2 cells(30% Inhibition at 3 mM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00474,DRAVPe00474.cif,Linear,Free,Free,,L,Not found,Inhibiting SARS-CoV-2 infection by disrupting the Spike-ACE2 interaction interface with peptide-based inhibitors.,2017.18,C94H129N21O29,CGIMPRSVW,F,4.31,2,4,-2,3,6,-76.88,-3557,7.2 hour,>20 hour,>10 hour,55.0,1490,99.33,33356169,Bioconjug Chem. 2021 Jan 20;32(1):215-223.,"Larue RC, Xing E, Kenney AD, Zhang Y, Tuazon JA, Li J, Yount JS, Li PK, Sharma A.",Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2.,10.1021/acs.bioconjchem.0c00664,,"Anti-SARS-CoV-2,Anti-SARS-CoV,Anti-HCoV-OC43,Anti-VSV"
DRAVPe00475,EDLFYQSSL,9,ACE2 (37-45)(SAP2),Synthetic construct,Q9BYF1,,SARS-CoV-2,Coronaviridae,pseudovirus inhibition assay,[Ref.33356169]SARS-CoV-2:Inhibition of infection in 293T/ACE2 cells(IC50=3.72±0.37 mM),No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00475,DRAVPe00475.cif,Linear,Free,Free,,L,Not found,Inhibiting SARS-CoV-2 infection by disrupting the Spike-ACE2 interaction interface with peptide-based inhibitors.,1101.18,C50H72N10O18,ACGHIKMNPRTVW,LS,3.67,0,2,-2,3,3,-33.33,-1519,1 hour,30 min,>10 hour,86.67,1490,186.25,33356169,Bioconjug Chem. 2021 Jan 20;32(1):215-223.,"Larue RC, Xing E, Kenney AD, Zhang Y, Tuazon JA, Li J, Yount JS, Li PK, Sharma A.",Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2.,10.1021/acs.bioconjchem.0c00664,,Anti-SARS-CoV-2
DRAVPe00476,LAQMYPL,7,ACE2 (79-85)(SAP3),Synthetic construct,Q9BYF1,,SARS-CoV-2,Coronaviridae,pseudovirus inhibition assay,[Ref.33356169]SARS-CoV-2:Inhibition of infection in 293T/ACE2 cells(IC50>7.5 mM),No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00476,DRAVPe00476.cif,Linear,Free,Free,,L,Not found,Inhibiting SARS-CoV-2 infection by disrupting the Spike-ACE2 interaction interface with peptide-based inhibitors.,835.03,C39H62N8O10S,CDEFGHIKNRSTVW,L,5.52,0,0,0,1,3,70.0,832,5.5 hour,3 min,2 min,125.71,1490,248.33,33356169,Bioconjug Chem. 2021 Jan 20;32(1):215-223.,"Larue RC, Xing E, Kenney AD, Zhang Y, Tuazon JA, Li J, Yount JS, Li PK, Sharma A.",Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2.,10.1021/acs.bioconjchem.0c00664,,Anti-SARS-CoV-2
DRAVPe00477,GKGDFRIL,8,ACE2 (352-359)(SAP4),Synthetic construct,Q9BYF1,,SARS-CoV-2,Coronaviridae,pseudovirus inhibition assay,[Ref.33356169]SARS-CoV-2:Inhibition of infection in 293T/ACE2 cells(IC50>7.5 mM),No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00477,DRAVPe00477.cif,Linear,Free,Free,,L,Not found,Inhibiting SARS-CoV-2 infection by disrupting the Spike-ACE2 interaction interface with peptide-based inhibitors.,905.06,C41H68N12O11,ACEHMNPQSTVWY,G,8.75,2,1,1,2,3,-20.0,-1449,30 hour,>20 hour,>10 hour,97.5,0,0.0,33356169,Bioconjug Chem. 2021 Jan 20;32(1):215-223.,"Larue RC, Xing E, Kenney AD, Zhang Y, Tuazon JA, Li J, Yount JS, Li PK, Sharma A.",Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2.,10.1021/acs.bioconjchem.0c00664,,Anti-SARS-CoV-2
DRAVPe00478,QAKTFLDKFNHEA,13,ACE2 (24-36)(SAP5),Synthetic construct,Q9BYF1,,"SARS-CoV-2,SARS-CoV,VSV","Coronaviridae, Rhabdoviridae",pseudovirus inhibition assay,[Ref.33356169]SARS-CoV-2:Inhibition of infection in 293T/ACE2 cells(IC50>7.5 mM);No nhibition of infection in 293T/ACE2/GFP cells up to 3 mM;##SARS-CoV:Inhibition of infection in 293T/ACE2 cells(30% inhibition at 3 mM);##Vesicular Stomatitis Virus (VSV):No nhibition of infection in 293T/ACE2 cells up to 3 mM.,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00478,DRAVPe00478.cif,Linear,Free,Free,,L,Not found,Inhibiting SARS-CoV-2 infection by disrupting the Spike-ACE2 interaction interface with peptide-based inhibitors.,1548.72,C70H105N19O21,CGIMPRSVWY,AFK,6.75,3,2,1,2,5,-97.69,-3154,0.8 hour,10 min,>10 hour,45.38,0,0.0,33356169,Bioconjug Chem. 2021 Jan 20;32(1):215-223.,"Larue RC, Xing E, Kenney AD, Zhang Y, Tuazon JA, Li J, Yount JS, Li PK, Sharma A.",Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2.,10.1021/acs.bioconjchem.0c00664,,"Anti-SARS-CoV-2,SARS-CoV,Anti-VSV"
DRAVPe00479,EDLFYQ,6,ACE2 (37-42)(SAP6),Synthetic construct,Q9BYF1,,"SARS-CoV-2,SARS-CoV,VSV","Coronaviridae, Rhabdoviridae",pseudovirus inhibition assay,[Ref.33356169]SARS-CoV-2:Inhibition of infection in 293T/ACE2 cells(IC50=1.9±0.14 mM);Inhibition of infection in 293T/ACE2/GFP cells(IC50=3 mM);##SARS-CoV:Inhibition of infection in 293T/ACE2 cells(85% inhibition at 3 mM);##Vesicular Stomatitis Virus (VSV):No nhibition of infection in 293T/ACE2 cells up to 3 mM;##HCoV-NL63:Inhibition of cytopathic effect in LLC-MK2 cells(30% Inhibition at 3 mM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00479,DRAVPe00479.cif,Linear,Free,Free,,L,Not found,Inhibiting SARS-CoV-2 infection by disrupting the Spike-ACE2 interaction interface with peptide-based inhibitors.,813.86,C38H51N7O13,ACGHIKMNPRSTVW,DEFLQY,3.67,0,2,-2,1,2,-86.67,-1331,1 hour,30 min,>10 hour,65.0,1490,298.0,33356169,Bioconjug Chem. 2021 Jan 20;32(1):215-223.,"Larue RC, Xing E, Kenney AD, Zhang Y, Tuazon JA, Li J, Yount JS, Li PK, Sharma A.",Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2.,10.1021/acs.bioconjchem.0c00664,,"Anti-SARS-CoV-2,SARS-CoV,Anti-VSV"
DRAVPe00480,DEDLEELERLYRKAEEVAKEAKDASRRGDDERAKEQMERAMRLFDQVFELAQELQEKQTDGNRQKATHLDKAVKEAADELYQRVR,85,AHB1,Synthetic construct,No entry found,,SARS-CoV-2,Coronaviridae,neutralization assay,[Ref.32907861]SARS-CoV-2:Inhibition of infection in Vero E6 cells(IC50=35 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00480,DRAVPe00480.cif,Linear,Free,Free,,L,spike protein,The peptide is a high-affinity protein minibinder to the SARS-CoV-2 spike receptor binding domain (RBD) that compete with ACE2 binding. ,10096.13,C426H695N133O147S2,CIPW,E,4.9,19,24,-5,8,25,-141.88,-34516,1.1 hour,3 min,>10 hour,63.29,2980,35.48,32907861,Science. 2020 Oct 23;370(6515):426-431.,"Cao L, Goreshnik I, Coventry B, Case JB, Miller L, Kozodoy L, Chen RE, Carter L, Walls AC, Park YJ, Strauch EM, Stewart L, Diamond MS, Veesler D, Baker D. ",De novo design of picomolar SARS-CoV-2 miniprotein inhibitors.,10.1126/science.abd9909,,Anti-SARS-CoV-2
DRAVPe00481,ELEEQVMHVLDQVSELAHELLHKLTGEELERAAYFNWWATEMMLELIKSDDEREIREIEEEARRILEHLEELARK,75,AHB2,Synthetic construct,No entry found,,SARS-CoV-2,Coronaviridae,neutralization assay,[Ref.32907861]SARS-CoV-2:Inhibition of infection in Vero E6 cells(IC50=15.5 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00481,DRAVPe00481.cif,Linear,Free,Free,,L,spike protein,The peptide is a high-affinity protein minibinder to the SARS-CoV-2 spike receptor binding domain (RBD) that compete with ACE2 binding. ,9101.25,C399H633N109O128S3,CP,E,4.56,13,22,-9,7,28,-66.67,-19283,1 hour,30 min,>10 hour,102.8,12490,168.78,32907861,Science. 2020 Oct 23;370(6515):426-431.,"Cao L, Goreshnik I, Coventry B, Case JB, Miller L, Kozodoy L, Chen RE, Carter L, Walls AC, Park YJ, Strauch EM, Stewart L, Diamond MS, Veesler D, Baker D. ",De novo design of picomolar SARS-CoV-2 miniprotein inhibitors.,10.1126/science.abd9909,,Anti-SARS-CoV-2
DRAVPe00482,DKEWILQKIYEIMRLLDELGHAEASMRVSDLIYEFMKKGDERLLEEAERLLEEVER,56,LCB1,Synthetic construct,No entry found,,SARS-CoV-2,Coronaviridae,neutralization assay,[Ref.32907861]SARS-CoV-2:Inhibition of infection in Vero E6 cells(IC50=23.54 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00482,DRAVPe00482.cif,Linear,Free,Free,,L,spike protein,The peptide is a high-affinity protein minibinder to the SARS-CoV-2 spike receptor binding domain (RBD) that compete with ACE2 binding. ,6810.81,C301H485N79O94S3,CNPT,E,4.59,10,16,-6,6,20,-57.5,-13897,1.1 hour,3 min,>10 hour,106.25,8480,154.18,32907861,Science. 2020 Oct 23;370(6515):426-431.,"Cao L, Goreshnik I, Coventry B, Case JB, Miller L, Kozodoy L, Chen RE, Carter L, Walls AC, Park YJ, Strauch EM, Stewart L, Diamond MS, Veesler D, Baker D. ",De novo design of picomolar SARS-CoV-2 miniprotein inhibitors.,10.1126/science.abd9909,,Anti-SARS-CoV-2
DRAVPe00483,NDDELHMLMTDLVYEALHFAKDEEIKKRVFQLFELADKAYKNNDRQKLEKVVEELKELLERLLS,64,LCB3,Synthetic construct,No entry found,,SARS-CoV-2,Coronaviridae,neutralization assay,[Ref.32907861]SARS-CoV-2:Inhibition of infection in Vero E6 cells(IC50=48.1 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00483,DRAVPe00483.cif,Linear,Free,Free,,L,spike protein,The peptide is a high-affinity protein minibinder to the SARS-CoV-2 spike receptor binding domain (RBD) that compete with ACE2 binding. ,7736.88,C346H556N90O106S2,CGPW,L,4.94,13,16,-3,7,24,-66.25,-15515,1.4 hour,3 min,>10 hour,103.59,2980,47.3,32907861,Science. 2020 Oct 23;370(6515):426-431.,"Cao L, Goreshnik I, Coventry B, Case JB, Miller L, Kozodoy L, Chen RE, Carter L, Walls AC, Park YJ, Strauch EM, Stewart L, Diamond MS, Veesler D, Baker D. ",De novo design of picomolar SARS-CoV-2 miniprotein inhibitors.,10.1126/science.abd9909,,Anti-SARS-CoV-2
DRAVPe00484,GYIEAEVI,8,HIV-1 integrase(82-89),Synthetic construct(derived from HIV-1 integrase),P04587,,HIV,Retroviridae,HIV-1 Integrase 30 -DNA Processing Assay,[Ref.12643937]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>1 mM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00484,DRAVPe00484.cif,Linear,Free,Amidation,,L,Integrase,The peptide can inhibit the activity of integrase and thus inhibit virus repliaction.,893.0,C41H64N8O14,CDFHKLMNPQRSTW,EI,3.79,0,2,-2,2,4,78.75,287,30 hour,>20 hour,>10 hour,146.25,1490,212.86,12643937,Bioorg Med Chem Lett. 2003 Mar 24;13(6):1175-7.,"Zhao L, O'Reilly MK, Shultz MD, Chmielewski J.",Interfacial peptide inhibitors of HIV-1 integrase activity and dimerization. ,10.1016/s0960-894x(03)00040-4,,Anti-HIV
DRAVPe00485,QETAYFLLKLAGRWP,15,HIV-1 integrase(95-109),Synthetic construct(derived from HIV-1 integrase),P04587,,HIV,Retroviridae,HIV-1 Integrase 30 -DNA Processing Assay,[Ref.12643937]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=3.5 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00485,DRAVPe00485.cif,Linear,Free,Amidation,,L,Integrase,The peptide can inhibit the activity of integrase and thus inhibit virus repliaction.,1793.1,C86H129N21O21,CDHIMNSV,L,8.59,2,1,1,3,7,-16.67,-1090,0.8 hour,10 min,>10 hour,91.33,6990,499.29,12643937,Bioorg Med Chem Lett. 2003 Mar 24;13(6):1175-7.,"Zhao L, O'Reilly MK, Shultz MD, Chmielewski J.",Interfacial peptide inhibitors of HIV-1 integrase activity and dimerization. ,10.1016/s0960-894x(03)00040-4,,Anti-HIV
DRAVPe00486,STTVKAASWWA,11,HIV-1 integrase(123-133),Synthetic construct(derived from HIV-1 integrase),P04587,,HIV,Retroviridae,HIV-1 Integrase 30 -DNA Processing Assay,[Ref.12643937]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>1 mM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00486,DRAVPe00486.cif,Linear,Free,Amidation,,L,Integrase,The peptide can inhibit the activity of integrase and thus inhibit virus repliaction.,1207.35,C56H82N14O16,CDEFGHILMNPQRY,A,8.47,1,0,1,4,6,8.18,-336,1.9 hour,>20 hour,>10 hour,53.64,11000,1100.0,12643937,Bioorg Med Chem Lett. 2003 Mar 24;13(6):1175-7.,"Zhao L, O'Reilly MK, Shultz MD, Chmielewski J.",Interfacial peptide inhibitors of HIV-1 integrase activity and dimerization. ,10.1016/s0960-894x(03)00040-4,,Anti-HIV
DRAVPe00487,HLKTAVQMAVFIHNFKR,17,HIV-1 integrase(171-187),Synthetic construct(derived from HIV-1 integrase),P04587,,HIV,Retroviridae,HIV-1 Integrase 30 -DNA Processing Assay,[Ref.12643937]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=3.0 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00487,DRAVPe00487.cif,Linear,Free,Amidation,,L,Integrase,The peptide can inhibit the activity of integrase and thus inhibit virus repliaction.,2040.46,C94H150N28O21S,CDEGPSWY,AFHKV,11.17,5,0,5,2,8,8.24,-2024,3.5 hour,10 min,>10 hour,91.76,0,0.0,12643937,Bioorg Med Chem Lett. 2003 Mar 24;13(6):1175-7.,"Zhao L, O'Reilly MK, Shultz MD, Chmielewski J.",Interfacial peptide inhibitors of HIV-1 integrase activity and dimerization. ,10.1016/s0960-894x(03)00040-4,,Anti-HIV
DRAVPe00488,AGERIVDIIATDIQ,14,HIV-1 integrase(196-210),Synthetic construct(derived from HIV-1 integrase),P04587,,HIV,Retroviridae,HIV-1 Integrase 30 -DNA Processing Assay,[Ref.12643937]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=2.0 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00488,DRAVPe00488.cif,Linear,Free,Amidation,,L,Integrase,The peptide can inhibit the activity of integrase and thus inhibit virus repliaction.,1513.71,C65H112N18O23,CFHKLMNPSWY,I,4.03,1,3,-2,2,7,44.29,-1900,4.4 hour,>20 hour,>10 hour,146.43,0,0.0,12643937,Bioorg Med Chem Lett. 2003 Mar 24;13(6):1175-7.,"Zhao L, O'Reilly MK, Shultz MD, Chmielewski J.",Interfacial peptide inhibitors of HIV-1 integrase activity and dimerization. ,10.1016/s0960-894x(03)00040-4,,Anti-HIV
DRAVPe00489,QETAYFLLKLAGR,13,HIV-1 integrase(95-107),Synthetic construct(derived from HIV-1 integrase),P04587,,HIV,Retroviridae,HIV-1 Integrase 30 -DNA Processing Assay,[Ref.12643937]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=150 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00489,DRAVPe00489.cif,Linear,Free,Amidation,,L,Integrase,The peptide can inhibit the activity of integrase and thus inhibit virus repliaction.,1509.77,C70H112N18O19,CDHIMNPSVW,L,8.59,2,1,1,3,6,0.0,-1323,0.8 hour,10 min,>10 hour,105.38,1490,124.17,12643937,Bioorg Med Chem Lett. 2003 Mar 24;13(6):1175-7.,"Zhao L, O'Reilly MK, Shultz MD, Chmielewski J.",Interfacial peptide inhibitors of HIV-1 integrase activity and dimerization. ,10.1016/s0960-894x(03)00040-4,,Anti-HIV
DRAVPe00490,AGERIVDIIA,10,HIV-1 integrase(196-206),Synthetic construct(derived from HIV-1 integrase),P04587,,HIV,Retroviridae,HIV-1 Integrase 30 -DNA Processing Assay,[Ref.12643937]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=30 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00490,DRAVPe00490.cif,Linear,Free,Amidation,,L,Integrase,The peptide can inhibit the activity of integrase and thus inhibit virus repliaction.,1056.23,C46H81N13O15,CFHKLMNPQSTWY,I,4.37,1,2,-1,1,6,94.0,-709,4.4 hour,>20 hour,>10 hour,166.0,0,0.0,12643937,Bioorg Med Chem Lett. 2003 Mar 24;13(6):1175-7.,"Zhao L, O'Reilly MK, Shultz MD, Chmielewski J.",Interfacial peptide inhibitors of HIV-1 integrase activity and dimerization. ,10.1016/s0960-894x(03)00040-4,,Anti-HIV
DRAVPe00491,WNSLKIDNLDV,11,LEDGF 361–370,Synthetic construct,O75475,,HIV,Retroviridae,quantitative assay(IN enzymatic activity),[Ref.20171172]HIV-1:inhibition of integrase catalytic activity(81% inhibition at 100nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00491,DRAVPe00491.cif,Linear,Free,Free,,L,Integrase,The peptide inhibits the catalytic activity of integrase and thus inhibits integration of viral cDNA.,1316.48,C59H93N15O19,ACEFGHMPQRTY,DLN,4.21,1,2,-1,3,5,-30.0,-1854,2.8 hour,3 min,2 min,132.73,5500,550.0,20171172,Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. ,"Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A.",Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370.,10.1016/j.bbrc.2010.02.100,,Anti-HIV
DRAVPe00492,WASLKIDNLDV,11,LEDGF 361–370[N361A],Synthetic construct,O75475,,HIV,Retroviridae,quantitative assay(IN enzymatic activity),[Ref.20171172]HIV-1:inhibition of integrase catalytic activity(76% inhibition at 100nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00492,DRAVPe00492.cif,Linear,Free,Free,,L,Integrase,The peptide inhibits the catalytic activity of integrase and thus inhibits integration of viral cDNA.,1273.45,C58H92N14O18,CEFGHMPQRTY,DL,4.21,1,2,-1,2,6,18.18,-1009,2.8 hour,3 min,2 min,141.82,5500,550.0,20171172,Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. ,"Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A.",Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370.,10.1016/j.bbrc.2010.02.100,,Anti-HIV
DRAVPe00493,WNALKIDNLDV,11,LEDGF 361–370[S362A],Synthetic construct,O75475,,HIV,Retroviridae,quantitative assay(IN enzymatic activity),[Ref.20171172]HIV-1:inhibition of integrase catalytic activity(79% inhibition at 100nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00493,DRAVPe00493.cif,Linear,Free,Free,,L,Integrase,The peptide inhibits the catalytic activity of integrase and thus inhibits integration of viral cDNA.,1300.48,C59H93N15O18,CEFGHMPQRSTY,DLN,4.21,1,2,-1,2,6,-6.36,-1333,2.8 hour,3 min,2 min,141.82,5500,550.0,20171172,Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. ,"Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A.",Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370.,10.1016/j.bbrc.2010.02.100,,Anti-HIV
DRAVPe00494,WNSAKIDNLDV,11,LEDGF 361–370[L363A],Synthetic construct,O75475,,HIV,Retroviridae,quantitative assay(IN enzymatic activity),[Ref.20171172]HIV-1:inhibition of integrase catalytic activity(71% inhibition at 100nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00494,DRAVPe00494.cif,Linear,Free,Free,,L,Integrase,The peptide inhibits the catalytic activity of integrase and thus inhibits integration of viral cDNA.,1274.4,C56H87N15O19,CEFGHMPQRTY,DN,4.21,1,2,-1,3,5,-48.18,-2165,2.8 hour,3 min,2 min,106.36,5500,550.0,20171172,Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. ,"Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A.",Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370.,10.1016/j.bbrc.2010.02.100,,Anti-HIV
DRAVPe00495,WNSLAIDNLDV,11,LEDGF 361–370[K364A],Synthetic construct,O75475,,HIV,Retroviridae,quantitative assay(IN enzymatic activity),[Ref.20171172]HIV-1:inhibition of integrase catalytic activity(68% inhibition at 100nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00495,DRAVPe00495.cif,Linear,Free,Free,,L,Integrase,The peptide inhibits the catalytic activity of integrase and thus inhibits integration of viral cDNA.,1259.38,C56H86N14O19,CEFGHKMPQRTY,DLN,3.56,0,2,-2,3,6,21.82,-1118,2.8 hour,3 min,2 min,141.82,5500,550.0,20171172,Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. ,"Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A.",Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370.,10.1016/j.bbrc.2010.02.100,,Anti-HIV
DRAVPe00496,WNSLKADNLDV,11,LEDGF 361–370[I365A],Synthetic construct,O75475,,HIV,Retroviridae,quantitative assay(IN enzymatic activity),[Ref.20171172]HIV-1:inhibition of integrase catalytic activity(65% inhibition at 100nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00496,DRAVPe00496.cif,Linear,Free,Free,,L,Integrase,The peptide inhibits the catalytic activity of integrase and thus inhibits integration of viral cDNA.,1274.4,C56H87N15O19,CEFGHIMPQRTY,DLN,4.21,1,2,-1,3,5,-54.55,-2165,2.8 hour,3 min,2 min,106.36,5500,550.0,20171172,Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. ,"Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A.",Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370.,10.1016/j.bbrc.2010.02.100,,Anti-HIV
DRAVPe00497,WNSLKIANLDV,11,LEDGF 361–370[D366A],Synthetic construct,O75475,,HIV,Retroviridae,quantitative assay(IN enzymatic activity),[Ref.20171172]HIV-1:inhibition of integrase catalytic activity(58% inhibition at 100nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00497,DRAVPe00497.cif,Linear,Free,Free,,L,Integrase,The peptide inhibits the catalytic activity of integrase and thus inhibits integration of viral cDNA.,1272.47,C58H93N15O17,CEFGHMPQRTY,LN,5.84,1,1,0,3,6,18.18,-801,2.8 hour,3 min,2 min,141.82,5500,550.0,20171172,Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. ,"Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A.",Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370.,10.1016/j.bbrc.2010.02.100,,Anti-HIV
DRAVPe00498,WNSLKIDALDV,11,LEDGF 361–370[N367A],Synthetic construct,O75475,,HIV,Retroviridae,quantitative assay(IN enzymatic activity),[Ref.20171172]HIV-1:inhibition of integrase catalytic activity(75% inhibition at 100nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00498,DRAVPe00498.cif,Linear,Free,Free,,L,Integrase,The peptide inhibits the catalytic activity of integrase and thus inhibits integration of viral cDNA.,1273.45,C58H92N14O18,CEFGHMPQRTY,DL,4.21,1,2,-1,2,6,18.18,-1009,2.8 hour,3 min,2 min,141.82,5500,550.0,20171172,Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. ,"Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A.",Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370.,10.1016/j.bbrc.2010.02.100,,Anti-HIV
DRAVPe00499,WNSLKIDNADV,11,LEDGF 361–370[L368A],Synthetic construct,O75475,,HIV,Retroviridae,quantitative assay(IN enzymatic activity),[Ref.20171172]HIV-1:inhibition of integrase catalytic activity(75% inhibition at 100nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00499,DRAVPe00499.cif,Linear,Free,Free,,L,Integrase,The peptide inhibits the catalytic activity of integrase and thus inhibits integration of viral cDNA.,1274.4,C56H87N15O19,CEFGHMPQRTY,DN,4.21,1,2,-1,3,5,-48.18,-2165,2.8 hour,3 min,2 min,106.36,5500,550.0,20171172,Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. ,"Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A.",Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370.,10.1016/j.bbrc.2010.02.100,,Anti-HIV
DRAVPe00500,WNSLKIDNLAV,11,LEDGF 361–370[D369A],Synthetic construct,O75475,,HIV,Retroviridae,quantitative assay(IN enzymatic activity),[Ref.20171172]HIV-1:inhibition of integrase catalytic activity(73% inhibition at 100nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00500,DRAVPe00500.cif,Linear,Free,Free,,L,Integrase,The peptide inhibits the catalytic activity of integrase and thus inhibits integration of viral cDNA.,1272.47,C58H93N15O17,CEFGHMPQRTY,LN,5.84,1,1,0,3,6,18.18,-801,2.8 hour,3 min,2 min,141.82,5500,550.0,20171172,Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. ,"Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A.",Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370.,10.1016/j.bbrc.2010.02.100,,Anti-HIV
DRAVPe00501,WNSLKIDNLDA,11,LEDGF 361–370[V370A],Synthetic construct,O75475,,HIV,Retroviridae,quantitative assay(IN enzymatic activity),[Ref.20171172]HIV-1:inhibition of integrase catalytic activity(68% inhibition at 100nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00501,DRAVPe00501.cif,Linear,Free,Free,,L,Integrase,The peptide inhibits the catalytic activity of integrase and thus inhibits integration of viral cDNA.,1288.42,C57H89N15O19,CEFGHMPQRTVY,DLN,4.21,1,2,-1,3,5,-51.82,-2077,2.8 hour,3 min,2 min,115.45,5500,550.0,20171172,Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. ,"Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A.",Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370.,10.1016/j.bbrc.2010.02.100,,Anti-HIV
DRAVPe00502,WNSLKIANLAV,11,"LEDGF 361–370[D366A,D369A]",Synthetic construct,O75475,,HIV,Retroviridae,quantitative assay(IN enzymatic activity),[Ref.20171172]HIV-1:inhibition of integrase catalytic activity(43% inhibition at 100nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00502,DRAVPe00502.cif,Linear,Free,Free,,L,Integrase,The peptide inhibits the catalytic activity of integrase and thus inhibits integration of viral cDNA.,1228.46,C57H93N15O15,CDEFGHMPQRTY,ALN,8.75,1,0,1,3,7,66.36,252,2.8 hour,3 min,2 min,150.91,5500,550.0,20171172,Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. ,"Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A.",Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370.,10.1016/j.bbrc.2010.02.100,,Anti-HIV
DRAVPe00503,WIDNLD,6,LEDGF 365–369,Synthetic construct,O75475,,HIV,Retroviridae,quantitative assay(IN enzymatic activity),[Ref.20171172]HIV-1:inhibition of integrase catalytic activity(30% inhibition at 100nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00503,DRAVPe00503.cif,Linear,Free,Free,,L,Integrase,The peptide inhibits the catalytic activity of integrase and thus inhibits integration of viral cDNA.,774.83,C35H50N8O12,ACEFGHKMPQRSTVY,D,3.56,0,2,-2,1,3,-51.67,-1191,2.8 hour,3 min,2 min,130.0,5500,1100.0,20171172,Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. ,"Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A.",Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370.,10.1016/j.bbrc.2010.02.100,,Anti-HIV
DRAVPe00504,WKFALKVDSPDV,12,HRP2 483–493,Synthetic construct,Q7Z4V5,,HIV,Retroviridae,quantitative assay(IN enzymatic activity),[Ref.20171172]HIV-1:inhibition of integrase catalytic activity(25% inhibition at 100nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00504,DRAVPe00504.cif,Linear,Free,Free,,L,Integrase,The peptide inhibits the catalytic activity of integrase and thus inhibits integration of viral cDNA.,1404.63,C67H101N15O18,CEGHIMNQRTY,DKV,5.96,2,2,0,1,6,-10.83,-1182,2.8 hour,3 min,2 min,89.17,5500,500.0,20171172,Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. ,"Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A.",Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370.,10.1016/j.bbrc.2010.02.100,,Anti-HIV
DRAVPe00505,WEEWDKKIEEYTKKIEELIKKSQNQQ,26,WQ(628-653),Synthetic construct,P04578,,HIV,Retroviridae,ELISA,[Ref.27795416]HIV-1 IIIB:inhibition of virus infection in MT-2 cells(IC50=123.4 ±6.5 nM); inhibition of peptide against cell-cell fusion between H9/HIV-1 IIIB cells and MT-2 cells(IC50=159.5 ± 9.5 nM);##HIV-1 Bal:inhibition of virus infection in MT-2 cells(IC50=126.2 ± 9.2 nM);##HIV-1 clinical isolates(8 clinical isolates):inhibition of virus infection in MT-2 cells(IC50=81.2-383.3 nM);##HIV-1 pseudoviruses(7 pseudoviruses):inhibition of pseudoviruses infection in MT-2 cells(IC50=13.5-686.2 nM);##HIV-1 T20-resistant strains(5 strains):inhibition of virus infection in MT-2 cells(IC50=34.8-433.1 nM);##HIV-1 T2635-resistant strain(6 strains):inhibition of virus infection in MT-2 cells(IC50=195.1-1128.4 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00505,DRAVPe00505.cif,Linear,Free,Free,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3351.76,C151H236N38O48,ACFGHMPRV,EK,5.19,6,7,-1,4,6,-189.23,-8791,2.8 hour,3 min,2 min,60.0,12490,499.6,27795416,J Virol. 2016 Dec 16;91(1):e01445-16.,"Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. ",Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.,10.1128/JVI.01445-16,,Anti-HIV
DRAVPe00506,MTWEEWDKKIEEYTKKIEELIKKSQNQQ,28,MT-WQ(626-653),Synthetic construct,P04578,,HIV,Retroviridae,ELISA,[Ref.27795416]HIV-1 IIIB:inhibition of virus infection in MT-2 cells(IC50=8.8 ±0.4 nM); inhibition of peptide against cell-cell fusion between H9/HIV-1 IIIB cells and MT-2 cells(IC50=14.8 ± 2.8 nM);##HIV-1 Bal:inhibition of virus infection in MT-2 cells(IC50=6.7 ± 0.5 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00506,DRAVPe00506.cif,Linear,Free,Free,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3584.06,C160H252N40O51S,ACFGHPRV,EK,5.19,6,7,-1,5,6,-171.43,-8813,30 hour,>20 hour,>10 hour,55.71,12490,462.59,27795416,J Virol. 2016 Dec 16;91(1):e01445-16.,"Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. ",Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.,10.1128/JVI.01445-16,,Anti-HIV
DRAVPe00507,WEEWDKKIEEYTKKIEELIKKSQNQQSM,28,WQ-SM(628-655),Synthetic construct,P04578,,HIV,Retroviridae,ELISA,[Ref.27795416]HIV-1 IIIB:inhibition of virus infection in MT-2 cells(IC50=60.4 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00507,DRAVPe00507.cif,Linear,Free,Free,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3570.03,C159H250N40O51S,ACFGHPRV,EK,5.19,6,7,-1,5,6,-171.79,-8896,2.8 hour,3 min,2 min,55.71,12490,462.59,27795416,J Virol. 2016 Dec 16;91(1):e01445-16.,"Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. ",Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.,10.1128/JVI.01445-16,,Anti-HIV
DRAVPe00508,WEEWDKKIEEYTKKIEELIKKSQNQQSW,28,WQ-SW(628-655),Synthetic construct,P04578,,HIV,Retroviridae,ELISA,[Ref.27795416]HIV-1 IIIB:inhibition of virus infection in MT-2 cells(IC50=47.7 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00508,DRAVPe00508.cif,Linear,Free,Free,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3625.05,C165H251N41O51,ACFGHMPRV,EK,5.19,6,7,-1,5,7,-181.79,-8898,2.8 hour,3 min,2 min,55.71,17990,666.3,27795416,J Virol. 2016 Dec 16;91(1):e01445-16.,"Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. ",Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.,10.1128/JVI.01445-16,,Anti-HIV
DRAVPe00509,WEEWDKKIEEYTKKIEELIKKSQNQQSY,28,WQ-SY(628-655),Synthetic construct,P04578,,HIV,Retroviridae,ELISA,[Ref.27795416]HIV-1 IIIB:inhibition of virus infection in MT-2 cells(IC50=54.8 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00509,DRAVPe00509.cif,Linear,Free,Free,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3602.01,C163H250N40O52,ACFGHMPRV,EK,5.19,6,7,-1,6,6,-183.21,-9145,2.8 hour,3 min,2 min,55.71,13980,517.78,27795416,J Virol. 2016 Dec 16;91(1):e01445-16.,"Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. ",Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.,10.1128/JVI.01445-16,,Anti-HIV
DRAVPe00510,WEEWDKKIEEYTKKIEELIKKSQNQQSDLD,30,WQ-SDLD(628-657),Synthetic construct,P04578,,HIV,Retroviridae,ELISA,[Ref.27795416]HIV-1 IIIB:inhibition of virus infection in MT-2 cells(IC50=44.1 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00510,DRAVPe00510.cif,Linear,Free,Free,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3782.18,C168H262N42O57,ACFGHMPRV,EK,4.65,6,9,-3,5,7,-177.33,-10383,2.8 hour,3 min,2 min,65.0,12490,430.69,27795416,J Virol. 2016 Dec 16;91(1):e01445-16.,"Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. ",Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.,10.1128/JVI.01445-16,,Anti-HIV
DRAVPe00511,WEEWDKKIEEYTKKIEELIKKSQNQQLDL,29,WQ-LDL(628-656),Synthetic construct,P04578,,HIV,Retroviridae,ELISA,[Ref.27795416]HIV-1 IIIB:inhibition of virus infection in MT-2 cells(IC50=3.7 ±1.1 nM); inhibition of peptide against cell-cell fusion between H9/HIV-1 IIIB cells and MT-2 cells(IC50=6.4 ±2.7 nM);##HIV-1 Bal:inhibition of virus infection in MT-2 cells(IC50=3.6± 0.2 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00511,DRAVPe00511.cif,Linear,Free,Free,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3693.17,C167H263N41O53,ACFGHMPRV,EK,4.86,6,8,-2,4,8,-155.52,-8679,2.8 hour,3 min,2 min,80.69,12490,446.07,27795416,J Virol. 2016 Dec 16;91(1):e01445-16.,"Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. ",Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.,10.1128/JVI.01445-16,,Anti-HIV
DRAVPe00512,WEEWDKKIEEYTKKIEELIKKSQNQQIDI,29,WQ-IDI(628-656),Synthetic construct,P04578,,HIV,Retroviridae,ELISA,[Ref.27795416]HIV-1 IIIB:inhibition of virus infection in MT-2 cells(IC50=3.7 ±0.3 nM); inhibition of peptide against cell-cell fusion between H9/HIV-1 IIIB cells and MT-2 cells(IC50=6.4 ± 1.8 nM);##HIV-1 Bal:inhibition of virus infection in MT-2 cells(IC50=3.2 ± 0.2 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00512,DRAVPe00512.cif,Linear,Free,Free,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3693.17,C167H263N41O53,ACFGHMPRV,EK,4.86,6,8,-2,4,8,-150.69,-8679,2.8 hour,3 min,2 min,80.69,12490,446.07,27795416,J Virol. 2016 Dec 16;91(1):e01445-16.,"Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. ",Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.,10.1128/JVI.01445-16,,Anti-HIV
DRAVPe00513,WEEWDKKIEEYTKKIEELIKKSQNQQLDI,29,WQ-LDI(628-656),Synthetic construct,P04578,,HIV,Retroviridae,ELISA,[Ref.27795416]HIV-1 IIIB:inhibition of virus infection in MT-2 cells(IC50=3.6±0.2nM); inhibition of peptide against cell-cell fusion between H9/HIV-1 IIIB cells and MT-2 cells(IC50=7.2 ± 1.0 nM);##HIV-1 Bal:inhibition of virus infection in MT-2 cells(IC50=3.1 ± 0.1 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00513,DRAVPe00513.cif,Linear,Free,Free,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3693.17,C167H263N41O53,ACFGHMPRV,EK,4.86,6,8,-2,4,8,-153.1,-8679,2.8 hour,3 min,2 min,80.69,12490,446.07,27795416,J Virol. 2016 Dec 16;91(1):e01445-16.,"Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. ",Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.,10.1128/JVI.01445-16,,Anti-HIV
DRAVPe00514,WEEWDKKIEEYTKKIEELIKKSQNQQIDL,29,WQ-IDL(628-656),Synthetic construct,P04578,,HIV,Retroviridae,ELISA,[Ref.27795416]HIV-1 IIIB:inhibition of virus infection in MT-2 cells(IC50=1.6 ±0.1 nM); inhibition of peptide against cell-cell fusion between H9/HIV-1 IIIB cells and MT-2 cells(IC50=5.6± 1.2 nM);##HIV-1 Bal:inhibition of virus infection in MT-2 cells(IC50=2.5 ± 0.1 nM);##HIV-1 clinical isolates(8 clinical isolates):inhibition of virus infection in MT-2 cells(IC50=2.0-90.7 nM);##HIV-1 pseudoviruses(7 pseudoviruses):inhibition of pseudoviruses infection in MT-2 cells(IC50=0.8-37.4 nM);##HIV-1 T20-resistant strains(5 strains):inhibition of virus infection in MT-2 cells(IC50=1.6-22.0 nM);##HIV-1 T2635-resistant strain(6 strains):inhibition of virus infection in MT-2 cells(IC50=8.5-61.4 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00514,DRAVPe00514.cif,Linear,Free,Free,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3693.17,C167H263N41O53,ACFGHMPRV,EK,4.86,6,8,-2,4,8,-153.1,-8679,2.8 hour,3 min,2 min,80.69,12490,446.07,27795416,J Virol. 2016 Dec 16;91(1):e01445-16.,"Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. ",Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.,10.1128/JVI.01445-16,,Anti-HIV
DRAVPe00515,MTWEEWDKKIEEYTKKIEELIKKSQNQQIDL,31,MT-WQ-IDL(626-656),Synthetic construct,P04578,,HIV,Retroviridae,ELISA,[Ref.27795416]HIV-1 IIIB:inhibition of virus infection in MT-2 cells(IC50=0.6±0.1 nM); inhibition of peptide against cell-cell fusion between H9/HIV-1 IIIB cells and MT-2 cells(IC50=1.2± 0.2 nM);##HIV-1 Bal:inhibition of virus infection in MT-2 cells(IC50=0.6 ±0.1 nM);##HIV-1 clinical isolates(8 clinical isolates):inhibition of virus infection in MT-2 cells(IC50=0.5-15.1 nM);##HIV-1 pseudoviruses(7 pseudoviruses):inhibition of pseudoviruses infection in MT-2 cells(IC50=0.1-9.0 nM);##HIV-1 T20-resistant strains(5 strains):inhibition of virus infection in MT-2 cells(IC50=0.1-4.4 nM);##HIV-1 T2635-resistant strain(6 strains):inhibition of virus infection in MT-2 cells(IC50=1.1-11.3 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00515,DRAVPe00515.cif,Linear,Free,Free,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3925.47,C176H279N43O56S,ACFGHPRV,EK,4.86,6,8,-2,5,8,-139.35,-8701,30 hour,>20 hour,>10 hour,75.48,12490,416.33,27795416,J Virol. 2016 Dec 16;91(1):e01445-16.,"Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. ",Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.,10.1128/JVI.01445-16,,Anti-HIV
DRAVPe00516,EEQKTQLKNKIEIDWTKMELEQDWSKIYKEI,31,MT-WQ-IDL-scrambled,Synthetic construct,P04578,,HIV,Retroviridae,ELISA,[Ref.27795416]HIV-1 IIIB:inhibition of peptide against cell-cell fusion between H9/HIV-1 IIIB cells and MT-2 cells(IC50>500 nM);##HIV-1 Bal:inhibition of virus infection in MT-2 cells(IC50>500 nM);##,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00516,DRAVPe00516.cif,Linear,Free,Free,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3925.47,C176H279N43O56S,ACFGHPRV,EK,4.86,6,8,-2,5,8,-139.35,-8701,1 hour,30 min,>10 hour,75.48,12490,416.33,27795416,J Virol. 2016 Dec 16;91(1):e01445-16.,"Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. ",Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.,10.1128/JVI.01445-16,,Anti-HIV
DRAVPe00517,TTLLDLTYEMLSLQQVVKALNESYIDLKEL,30,M0,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,ELISA,[Ref.27795416]MERS-CoV:inhibition of MERS-CoV S-medicated cell-cell fusion in MT-2 cells(IC50=4.5 μM);inhibition of pseudovirus infection in MT-2 cells(IC50=17.8 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00517,DRAVPe00517.cif,Linear,Free,Free,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3485.05,C157H259N35O51S,CFGHPRW,L,4.18,2,5,-3,8,12,16.33,-2496,7.2 hour,>20 hour,>10 hour,139.67,2980,102.76,27795416,J Virol. 2016 Dec 16;91(1):e01445-16.,"Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. ",Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.,10.1128/JVI.01445-16,,Anti-MERS-CoV
DRAVPe00518,EANTTLLDLTYEMLSLQQVVKALNESYIDLKEL,33,M1,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,ELISA,[Ref.27795416]MERS-CoV:inhibition of MERS-CoV S-medicated cell-cell fusion in MT-2 cells(IC50=0.9 μM);inhibition of pseudovirus infection in MT-2 cells(IC50=2.3 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00518,DRAVPe00518.cif,Linear,Free,Free,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3799.35,C169H277N39O57S,CFGHPRW,L,4.08,2,6,-4,9,13,-0.91,-3660,1 hour,30 min,>10 hour,130.0,2980,93.13,27795416,J Virol. 2016 Dec 16;91(1):e01445-16.,"Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. ",Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.,10.1128/JVI.01445-16,,Anti-MERS-CoV
DRAVPe00519,WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL,34,C34,Synthetic construct,No entry found,,HIV,Retroviridae,MAGI assay,[Ref.19073606]HIV-1 NL4-3:inhibition of virus replication in HeLa cells(EC50=7.3± 2.5 nM);##HIV-1(NL4-3V38A):inhibition of virus replication in HeLa cells(EC50=15± 2.3 nM);##HIV-1(NL4-3N43D):inhibition of virus replication in HeLa cells(EC50=23 ± 5.0 nM);##HIV-1(NL4-3N43D/S138A):inhibition of virus replication in HeLa cells(EC50=19 ±4.7 nM).##[Ref.27795416]HIV-1 IIIB:inhibition of virus infection in MT-2 cells(IC50=7.2±0.2 nM); inhibition of peptide against cell-cell fusion between H9/HIV-1 IIIB cells and MT-2 cells(IC50=18.8± 1.6 nM);##HIV-1 Bal:inhibition of virus infection in MT-2 cells(IC50=7.6±0.2 nM);##,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00519,DRAVPe00519.cif,Linear,Free,Free,,L,membrane,"The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion.",4248.6,C184H280N50O64S,ACFGPV,E,4.21,3,8,-5,9,9,-127.06,-10170,2.8 hour,3 min,2 min,80.29,12490,378.48,19073606##27795416,J Biol Chem. 2009 Feb 20;284(8):4914-20.##J Virol. 2016 Dec 16;91(1):e01445-16.,"Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.##Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. ",Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.##Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.,10.1074/jbc.M807169200##10.1128/JVI.01445-16,DRAVPa0875,Anti-HIV
DRAVPe00520,YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF,36,T-20(Enfuvirtide),Synthetic construct,No entry found,,HIV,Retroviridae,"MAGI/cMAGI infectivity assay,neutralization assay",[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=2.4 ± 0.6 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50=23± 8.2 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50=49 ± 10 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50=84 ± 16 nM).##[Ref.27795416]HIV-1 IIIB:inhibition of virus infection in MT-2 cells(IC50=71.8±2.2 nM); inhibition of peptide against cell-cell fusion between H9/HIV-1 IIIB cells and MT-2 cells(IC50=91.0± 1.2 nM);##HIV-1 Bal:inhibition of virus infection in MT-2 cells(IC50=70.5 ±0.9 nM);##HIV-1 clinical isolates(8 clinical isolates):inhibition of virus infection in MT-2 cells(IC50=20.4-157.3 nM);##HIV-1 pseudoviruses(7 pseudoviruses):inhibition of pseudoviruses infection in MT-2 cells(IC50=7.1-91.0 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00520,DRAVPe00520.cif,Linear,Free,Free,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.",4450.88,C202H298N50O64,CGMPRV,EL,4.3,3,7,-4,9,13,-87.5,-7259,2.8 hour,10 min,2 min,89.44,17990,514.0,19073606##27795416,J Biol Chem. 2009 Feb 20;284(8):4914-20.##J Virol. 2016 Dec 16;91(1):e01445-16.,"Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.##Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. ",Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.##Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.,10.1074/jbc.M807169200##10.1128/JVI.01445-16,DRAVPa0326,Anti-HIV
DRAVPe00521,LQQLLFIHFRIGRRRRRRRR,20,peptide 4,Synthetic construct,No entry found,,HIV,Retroviridae,Integrase assay,[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.13 ± 0.02 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.06 ± 0.01 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00521,DRAVPe00521.cif,Linear,Acetylation,Amidation,,L,Integrase,The peptide acts antiviral activity by inhibiting the activity of integrase.,2734.31,C120H209N51O23,ACDEKMNPSTVWY,R,12.9,10,0,10,1,7,-125.5,-11852,5.5 hour,3 min,2 min,97.5,0,0.0,20708407,Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.,"Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H.",Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.,10.1016/j.bmc.2010.07.050,,Anti-HIV
DRAVPe00522,EAIIRILQQLLFIHFRIGRRRRRRRR,26,peptide 5,Synthetic construct,No entry found,,HIV,Retroviridae,Integrase assay,[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.09 ± 0.01 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.04 ± 0.01 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00522,DRAVPe00522.cif,Linear,Acetylation,Amidation,,L,Integrase,The peptide acts antiviral activity by inhibiting the activity of integrase.,3430.17,C152H266N60O31,CDKMNPSTVWY,R,12.6,11,1,10,1,11,-68.46,-12368,1 hour,30 min,>10 hour,123.85,0,0.0,20708407,Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.,"Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H.",Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.,10.1016/j.bmc.2010.07.050,,Anti-HIV
DRAVPe00523,ILQQLLFIHFRIGRRRRRRRR,21,peptide 6,Synthetic construct,No entry found,,HIV,Retroviridae,Integrase assay,[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.10 ± 0.01 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.07 ± 0.01 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00523,DRAVPe00523.cif,Linear,Acetylation,Amidation,,L,Integrase,The peptide acts antiviral activity by inhibiting the activity of integrase.,2847.47,C126H220N52O24,ACDEKMNPSTVWY,R,12.9,10,0,10,1,8,-98.1,-11360,20 hour,30 min,>10 hour,111.43,0,0.0,20708407,Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.,"Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H.",Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.,10.1016/j.bmc.2010.07.050,,Anti-HIV
DRAVPe00524,RILQQLLFIHFRIGRRRRRRRR,22,peptide 7,Synthetic construct,No entry found,,HIV,Retroviridae,Integrase assay,[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.13 ± 0.02 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.11 ± 0.01 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00524,DRAVPe00524.cif,Linear,Acetylation,Amidation,,L,Integrase,The peptide acts antiviral activity by inhibiting the activity of integrase.,3003.65,C132H232N56O25,ACDEKMNPSTVWY,R,12.95,11,0,11,1,8,-114.09,-12852,1 hour,2 min,2 min,106.36,0,0.0,20708407,Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.,"Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H.",Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.,10.1016/j.bmc.2010.07.050,,Anti-HIV
DRAVPe00525,IRILQQLLFIHFRIGRRRRRRRR,23,peptide 8,Synthetic construct,No entry found,,HIV,Retroviridae,Integrase assay,[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.26 ±0.04 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.11 ± 0.01 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00525,DRAVPe00525.cif,Linear,Acetylation,Amidation,,L,Integrase,The peptide acts antiviral activity by inhibiting the activity of integrase.,3116.81,C138H243N57O26,ACDEKMNPSTVWY,R,12.95,11,0,11,1,9,-89.57,-12360,20 hour,30 min,>10 hour,118.7,0,0.0,20708407,Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.,"Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H.",Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.,10.1016/j.bmc.2010.07.050,,Anti-HIV
DRAVPe00526,IIRILQQLLFIHFRIGRRRRRRRR,24,peptide 9,Synthetic construct,No entry found,,HIV,Retroviridae,Integrase assay,[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.11 ± 0.01 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.07 ± 0.01 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00526,DRAVPe00526.cif,Linear,Acetylation,Amidation,,L,Integrase,The peptide acts antiviral activity by inhibiting the activity of integrase.,3229.97,C144H254N58O27,ACDEKMNPSTVWY,R,12.95,11,0,11,1,10,-67.08,-11868,20 hour,30 min,>10 hour,130.0,0,0.0,20708407,Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.,"Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H.",Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.,10.1016/j.bmc.2010.07.050,,Anti-HIV
DRAVPe00527,AIIRILQQLLFIHFRIGRRRRRRRR,25,peptide 10,Synthetic construct,No entry found,,HIV,Retroviridae,Integrase assay,[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.08 ± 0.01 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.05 ± 0.01 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00527,DRAVPe00527.cif,Linear,Acetylation,Amidation,,L,Integrase,The peptide acts antiviral activity by inhibiting the activity of integrase.,3301.05,C147H259N59O28,CDEKMNPSTVWY,R,12.95,11,0,11,1,11,-57.2,-11687,4.4 hour,>20 hour,>10 hour,128.8,0,0.0,20708407,Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.,"Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H.",Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.,10.1016/j.bmc.2010.07.050,,Anti-HIV
DRAVPe00528,EAIIRILQQLLFIEFRIKRRRRRRRR,26,peptide 11,Synthetic construct,No entry found,,HIV,Retroviridae,Integrase assay,[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.05± 0.01 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.01 ± 0.001 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00528,DRAVPe00528.cif,Linear,Acetylation,Amidation,,L,Integrase,The peptide acts antiviral activity by inhibiting the activity of integrase.,3493.26,C155H275N59O33,CDGHMNPSTVWY,R,12.37,11,2,9,0,11,-83.08,-13232,1 hour,30 min,>10 hour,123.85,0,0.0,3422.14,C151H266N58O33,CDHKMNPSTVWY,R,12.369999999999999,,Anti-HIV
DRAVPe00529,EEIIRKLQQLLFIHFRIGRRRRRRRR,26,peptide 12,Synthetic construct,No entry found,,HIV,Retroviridae,Integrase assay,[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.12 ± 0.01 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.047 ± 0.01 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00529,DRAVPe00529.cif,Linear,Acetylation,Amidation,,L,Integrase,The peptide acts antiviral activity by inhibiting the activity of integrase.,3503.22,C154H269N61O33,ACDMNPSTVWY,R,12.37,12,2,10,1,9,-121.15,-14277,1 hour,30 min,>10 hour,105.0,0,0.0,20708407,Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.,"Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H.",Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.,10.1016/j.bmc.2010.07.050,,Anti-HIV
DRAVPe00530,EAIIRILQELLFKHFRIGRRRRRRRR,26,peptide 13,Synthetic construct,No entry found,,HIV,Retroviridae,Integrase assay,[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.14 ± 0.02 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.065 ± 0.01 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00530,DRAVPe00530.cif,Linear,Acetylation,Amidation,,L,Integrase,The peptide acts antiviral activity by inhibiting the activity of integrase.,3446.17,C152H266N60O32,CDMNPSTVWY,R,12.37,12,2,10,1,10,-100.77,-13542,1 hour,30 min,>10 hour,108.85,0,0.0,20708407,Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.,"Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H.",Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.,10.1016/j.bmc.2010.07.050,,Anti-HIV
DRAVPe00531,EAIERILKQLLFIHFRIGRRRRRRRR,26,peptide 14,Synthetic construct,No entry found,,HIV,Retroviridae,Integrase assay,[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.23± 0.03 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.15 ± 0.002 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00531,DRAVPe00531.cif,Linear,Acetylation,Amidation,,L,Integrase,The peptide acts antiviral activity by inhibiting the activity of integrase.,3446.17,C152H266N60O32,CDMNPSTVWY,R,12.37,12,2,10,1,10,-100.77,-13542,1 hour,30 min,>10 hour,108.85,0,0.0,20708407,Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.,"Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H.",Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.,10.1016/j.bmc.2010.07.050,,Anti-HIV
DRAVPe00532,EAEIRIKQQLLFIHFRIGRRRRRRRR,26,peptide 15,Synthetic construct,No entry found,,HIV,Retroviridae,Integrase assay,[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.04 ± 0.01 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.031± 0.01 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00532,DRAVPe00532.cif,Linear,Acetylation,Amidation,,L,Integrase,The peptide acts antiviral activity by inhibiting the activity of integrase.,3461.14,C151H263N61O33,CDMNPSTVWY,R,12.37,12,2,10,1,9,-128.85,-14588,1 hour,30 min,>10 hour,93.85,0,0.0,20708407,Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.,"Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H.",Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.,10.1016/j.bmc.2010.07.050,,Anti-HIV
DRAVPe00533,EAIIRILQQLEFIHKRIGRRRRRRRR,26,peptide 16,Synthetic construct,No entry found,,HIV,Retroviridae,Integrase assay,[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.71 ± 0.21 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.06 ± 0.004µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00533,DRAVPe00533.cif,Linear,Acetylation,Amidation,,L,Integrase,The peptide acts antiviral activity by inhibiting the activity of integrase.,3427.12,C148H265N61O33,CDMNPSTVWY,R,12.37,12,2,10,1,9,-122.31,-14394,1 hour,30 min,>10 hour,108.85,0,0.0,20708407,Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.,"Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H.",Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.,10.1016/j.bmc.2010.07.050,,Anti-HIV
DRAVPe00534,EEIIRKLQQLLFIEFRIKRRRRRRRR,26,peptide 17,Synthetic construct,No entry found,,HIV,Retroviridae,Integrase assay,[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.18 ± 0.06 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.08 ± 0.02 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00534,DRAVPe00534.cif,Linear,Acetylation,Amidation,,L,Integrase,The peptide acts antiviral activity by inhibiting the activity of integrase.,3566.32,C157H278N60O35,ACDGHMNPSTVWY,R,12.18,12,3,9,0,9,-135.77,-15141,1 hour,30 min,>10 hour,105.0,0,0.0,20708407,Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.,"Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H.",Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.,10.1016/j.bmc.2010.07.050,,Anti-HIV
DRAVPe00535,AQQLLFIHFRIGRRRRRRRR,20,peptide 18,Synthetic construct,No entry found,,HIV,Retroviridae,Integrase assay,[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.12 ± 0.004 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.08 ± 0.01 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00535,DRAVPe00535.cif,Linear,Acetylation,Amidation,,L,Integrase,The peptide acts antiviral activity by inhibiting the activity of integrase.,2692.23,C117H203N51O23,CDEKMNPSTVWY,R,12.9,10,0,10,1,7,-135.5,-12163,4.4 hour,>20 hour,>10 hour,83.0,0,0.0,20708407,Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.,"Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H.",Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.,10.1016/j.bmc.2010.07.050,,Anti-HIV
DRAVPe00536,LAQLLFIHFRIGRRRRRRRR,20,peptide 19,Synthetic construct,No entry found,,HIV,Retroviridae,Integrase assay,[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.13 ± 0.02 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.06 ± 0.01 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00536,DRAVPe00536.cif,Linear,Acetylation,Amidation,,L,Integrase,The peptide acts antiviral activity by inhibiting the activity of integrase.,2677.26,C118H206N50O22,CDEKMNPSTVWY,R,12.9,10,0,10,1,8,-99.0,-11117,5.5 hour,3 min,2 min,102.5,0,0.0,20708407,Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.,"Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H.",Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.,10.1016/j.bmc.2010.07.050,,Anti-HIV
DRAVPe00537,LQALLFIHFRIGRRRRRRRR,20,peptide 20,Synthetic construct,No entry found,,HIV,Retroviridae,Integrase assay,[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.10 ± 0.004 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.06 ± 0.01 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00537,DRAVPe00537.cif,Linear,Acetylation,Amidation,,L,Integrase,The peptide acts antiviral activity by inhibiting the activity of integrase.,2677.26,C118H206N50O22,CDEKMNPSTVWY,R,12.9,10,0,10,1,8,-99.0,-11117,5.5 hour,3 min,2 min,102.5,0,0.0,20708407,Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.,"Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H.",Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.,10.1016/j.bmc.2010.07.050,,Anti-HIV
DRAVPe00538,LQQALFIHFRIGRRRRRRRR,20,peptide 21,Synthetic construct,No entry found,,HIV,Retroviridae,Integrase assay,[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.12 ± 0.02 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.07 ± 0.01 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00538,DRAVPe00538.cif,Linear,Acetylation,Amidation,,L,Integrase,The peptide acts antiviral activity by inhibiting the activity of integrase.,2692.23,C117H203N51O23,CDEKMNPSTVWY,R,12.9,10,0,10,1,7,-135.5,-12163,5.5 hour,3 min,2 min,83.0,0,0.0,20708407,Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.,"Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H.",Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.,10.1016/j.bmc.2010.07.050,,Anti-HIV
DRAVPe00539,LQQLAFIHFRIGRRRRRRRR,20,peptide 22,Synthetic construct,No entry found,,HIV,Retroviridae,Integrase assay,[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.13 ± 0.003 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.06 ± 0.01 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00539,DRAVPe00539.cif,Linear,Acetylation,Amidation,,L,Integrase,The peptide acts antiviral activity by inhibiting the activity of integrase.,2692.23,C117H203N51O23,CDEKMNPSTVWY,R,12.9,10,0,10,1,7,-135.5,-12163,5.5 hour,3 min,2 min,83.0,0,0.0,20708407,Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.,"Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H.",Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.,10.1016/j.bmc.2010.07.050,,Anti-HIV
DRAVPe00540,LQQLLAIHFRIGRRRRRRRR,20,peptide 23,Synthetic construct,No entry found,,HIV,Retroviridae,Integrase assay,[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.34 ± 0.06 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.18 ± 0.03 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00540,DRAVPe00540.cif,Linear,Acetylation,Amidation,,L,Integrase,The peptide acts antiviral activity by inhibiting the activity of integrase.,2658.21,C114H205N51O23,CDEKMNPSTVWY,R,12.9,10,0,10,1,7,-130.5,-11969,5.5 hour,3 min,2 min,102.5,0,0.0,20708407,Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.,"Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H.",Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.,10.1016/j.bmc.2010.07.050,,Anti-HIV
DRAVPe00541,LQQLLFAHFRIGRRRRRRRR,20,peptide 24,Synthetic construct,No entry found,,HIV,Retroviridae,Integrase assay,[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.33 ± 0.02 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.22± 0.01 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00541,DRAVPe00541.cif,Linear,Acetylation,Amidation,,L,Integrase,The peptide acts antiviral activity by inhibiting the activity of integrase.,2692.23,C117H203N51O23,CDEKMNPSTVWY,R,12.9,10,0,10,1,7,-139.0,-12163,5.5 hour,3 min,2 min,83.0,0,0.0,20708407,Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.,"Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H.",Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.,10.1016/j.bmc.2010.07.050,,Anti-HIV
DRAVPe00542,LQQLLFIAFRIGRRRRRRRR,20,peptide 25,Synthetic construct,No entry found,,HIV,Retroviridae,Integrase assay,[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.13 ± 0.01 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.06 ± 0.01 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00542,DRAVPe00542.cif,Linear,Acetylation,Amidation,,L,Integrase,The peptide acts antiviral activity by inhibiting the activity of integrase.,2668.25,C117H207N49O23,CDEHKMNPSTVWY,R,12.9,9,0,9,1,8,-100.5,-11205,5.5 hour,3 min,2 min,102.5,0,0.0,20708407,Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.,"Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H.",Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.,10.1016/j.bmc.2010.07.050,,Anti-HIV
DRAVPe00543,LQQLLFIHARIGRRRRRRRR,20,peptide 26,Synthetic construct,No entry found,,HIV,Retroviridae,Integrase assay,[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.25 ± 0.02 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.12± 0.01 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00543,DRAVPe00543.cif,Linear,Acetylation,Amidation,,L,Integrase,The peptide acts antiviral activity by inhibiting the activity of integrase.,2658.21,C114H205N51O23,CDEKMNPSTVWY,R,12.9,10,0,10,1,7,-130.5,-11969,5.5 hour,3 min,2 min,102.5,0,0.0,20708407,Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.,"Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H.",Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.,10.1016/j.bmc.2010.07.050,,Anti-HIV
DRAVPe00544,LQQLLFIHFAIGRRRRRRRR,20,peptide 27,Synthetic construct,No entry found,,HIV,Retroviridae,Integrase assay,[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.11 ± 0.01 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.05 ± 0.01 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00544,DRAVPe00544.cif,Linear,Acetylation,Amidation,,L,Integrase,The peptide acts antiviral activity by inhibiting the activity of integrase.,2649.2,C117H202N48O23,CDEKMNPSTVWY,R,12.85,9,0,9,1,8,-94.0,-10179,5.5 hour,3 min,2 min,102.5,0,0.0,20708407,Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.,"Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H.",Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.,10.1016/j.bmc.2010.07.050,,Anti-HIV
DRAVPe00545,LQQLLFIHFRAGRRRRRRRR,20,peptide 28,Synthetic construct,No entry found,,HIV,Retroviridae,Integrase assay,[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.20 ± 0.03 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.16 ± 0.02µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00545,DRAVPe00545.cif,Linear,Acetylation,Amidation,,L,Integrase,The peptide acts antiviral activity by inhibiting the activity of integrase.,2692.23,C117H203N51O23,CDEKMNPSTVWY,R,12.9,10,0,10,1,7,-139.0,-12163,5.5 hour,3 min,2 min,83.0,0,0.0,20708407,Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.,"Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H.",Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.,10.1016/j.bmc.2010.07.050,,Anti-HIV
DRAVPe00546,LQQLLFIHFRIARRRRRRRR,20,peptide 29,Synthetic construct,No entry found,,HIV,Retroviridae,Integrase assay,[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.09 ± 0.01 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.09 ± 0.01 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00546,DRAVPe00546.cif,Linear,Acetylation,Amidation,,L,Integrase,The peptide acts antiviral activity by inhibiting the activity of integrase.,2748.33,C121H211N51O23,CDEGKMNPSTVWY,R,12.9,10,0,10,0,8,-114.5,-11765,5.5 hour,3 min,2 min,102.5,0,0.0,20708407,Bioorg Med Chem. 2010 Sep 15;18(18):6771-5.,"Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H.",Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.,10.1016/j.bmc.2010.07.050,,Anti-HIV
DRAVPe00547,RQLLSGIVQQQNNLLRAIEAQQHLLQK,27,C8- N27,Synthetic construct,No entry found,,HIV,Retroviridae,cell-cell fusion inhibition assay,[Ref.20605950]HIV-1:inhibition of peptide against cell-cell fusion between Jurkat E6-1 and HXBc2 cells(IC50=1075±90 nM);inhibition of peptide against virus-cell fusion on CD4-expressing cells(IC50=293±27 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00547,DRAVPe00547.cif,Linear,C8(octanoic acid),Free,,L,membrane,"N peptide may target an exposed C-helix region of gp41 and can interact with their coiled coil formation within a gp41 dimer,which can inhibit HIV-1 entry.",3140.64,C136H235N45O40,CDFMPTWY,Q,10.84,4,1,3,4,11,-47.04,-5436,1 hour,2 min,2 min,133.7,0,0.0,20605950,FASEB J. 2010 Nov;24(11):4196-202. ,"Wexler-Cohen Y, Ashkenazi A, Viard M, Blumenthal R, Shai Y.",Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain. ,10.1096/fj.09-151704,,Anti-HIV
DRAVPe00548,RQLLSGIVQQQNNLLRAIEAQQHLLQK,27,C12- N27,Synthetic construct,No entry found,,HIV,Retroviridae,cell-cell fusion inhibition assay,[Ref.20605950]HIV-1:inhibition of peptide against cell-cell fusion between Jurkat E6-1 and HXBc2 cells(IC50=473±74 nM);inhibition of peptide against virus-cell fusion on CD4-expressing cells(IC50=182±15 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00548,DRAVPe00548.cif,Linear,C12(dodecanoic acid),Free,,L,membrane,"N peptide may target an exposed C-helix region of gp41 and can interact with their coiled coil formation within a gp41 dimer,which can inhibit HIV-1 entry.",3140.64,C136H235N45O40,CDFMPTWY,Q,10.84,4,1,3,4,11,-47.04,-5436,1 hour,2 min,2 min,133.7,0,0.0,20605950,FASEB J. 2010 Nov;24(11):4196-202. ,"Wexler-Cohen Y, Ashkenazi A, Viard M, Blumenthal R, Shai Y.",Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain. ,10.1096/fj.09-151704,,Anti-HIV
DRAVPe00549,RQLLSGIVQQQNNLLRAIEAQQHLLQK,27,C16-N27,Synthetic construct,No entry found,,HIV,Retroviridae,cell-cell fusion inhibition assay,[Ref.20605950]HIV-1:inhibition of peptide against cell-cell fusion between Jurkat E6-1 and HXBc2 cells(IC50=148±4 nM);inhibition of peptide against virus-cell fusion on CD4-expressing cells(IC50=10±1 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00549,DRAVPe00549.cif,Linear,C16(hexadecanoic acid),Free,,L,membrane,"N peptide may target an exposed C-helix region of gp41 and can interact with their coiled coil formation within a gp41 dimer,which can inhibit HIV-1 entry.",3140.64,C136H235N45O40,CDFMPTWY,Q,10.84,4,1,3,4,11,-47.04,-5436,1 hour,2 min,2 min,133.7,0,0.0,20605950,FASEB J. 2010 Nov;24(11):4196-202. ,"Wexler-Cohen Y, Ashkenazi A, Viard M, Blumenthal R, Shai Y.",Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain. ,10.1096/fj.09-151704,,Anti-HIV
DRAVPe00550,RQLLSGIVQQQNNLLRAIEAQQHLL,25,C16- N25,Synthetic construct,No entry found,,HIV,Retroviridae,cell-cell fusion inhibition assay,[Ref.20605950]HIV-1:inhibition of peptide against cell-cell fusion between Jurkat E6-1 and HXBc2 cells(IC50=484±60 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00550,DRAVPe00550.cif,Linear,C16(hexadecanoic acid),Free,,L,membrane,"N peptide may target an exposed C-helix region of gp41 and can interact with their coiled coil formation within a gp41 dimer,which can inhibit HIV-1 entry.",2884.33,C125H215N41O37,CDFKMPTWY,LQ,9.61,3,1,2,4,11,-21.2,-4327,1 hour,2 min,2 min,144.4,0,0.0,20605950,FASEB J. 2010 Nov;24(11):4196-202. ,"Wexler-Cohen Y, Ashkenazi A, Viard M, Blumenthal R, Shai Y.",Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain. ,10.1096/fj.09-151704,,Anti-HIV
DRAVPe00551,RQLLSGIVQQQNNLLRAIEAQQH,23,C16- N23,Synthetic construct,No entry found,,HIV,Retroviridae,cell-cell fusion inhibition assay,[Ref.20605950]HIV-1:inhibition of peptide against cell-cell fusion between Jurkat E6-1 and HXBc2 cells(IC50=1931±187 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00551,DRAVPe00551.cif,Linear,C16(hexadecanoic acid),Free,,L,membrane,"N peptide may target an exposed C-helix region of gp41 and can interact with their coiled coil formation within a gp41 dimer,which can inhibit HIV-1 entry.",2658.02,C113H193N39O35,CDFKMPTWY,Q,9.61,3,1,2,4,9,-56.09,-5311,1 hour,2 min,2 min,123.04,0,0.0,20605950,FASEB J. 2010 Nov;24(11):4196-202. ,"Wexler-Cohen Y, Ashkenazi A, Viard M, Blumenthal R, Shai Y.",Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain. ,10.1096/fj.09-151704,,Anti-HIV
DRAVPe00552,XDLTXEMLSLQQVVKALNESY,21,P21S1,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay,[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50>50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00552,DRAVPe00552.cif,Cyclic,Acetylation,Amidation,①The 'X' (position: 1 and 5) in sequence indicates S5 stapling amino acid. Note: S5 is (S)-pentenyl alanine. ②X (1) and X (5) are cross-linked by hydrocarbon stapling.,L,membrane,The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion.,2404.15,C95H153N23O31S,CFGHIPRW,L,4.14,1,3,-2,5,7,-5.71,-2320,,,,106.67,1490,74.5,29442512,J Med Chem. 2018 Mar 8;61(5):2018-2026.,"Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K.",Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. ,10.1021/acs.jmedchem.7b01732,,Anti-MERS-CoV
DRAVPe00553,LXLTYXMLSLQQVVKALNESY,21,P21S2,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay,[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=3.90 ± 1.1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00553,DRAVPe00553.cif,Cyclic,Acetylation,Amidation,①The 'X' (position: 2 and 6) in sequence indicates S5 stapling amino acid. Note: S5 is (S)-pentenyl alanine. ②X (2) and X (6) are cross-linked by hydrocarbon stapling.,L,membrane,The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion.,2436.28,C101H161N23O28S,CDFGHIPRW,L,6.0,1,1,0,6,8,39.52,-289,5.5 hour,3 min,2 min,125.24,2980,149.0,29442512,J Med Chem. 2018 Mar 8;61(5):2018-2026.,"Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K.",Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. ,10.1021/acs.jmedchem.7b01732,,Anti-MERS-CoV
DRAVPe00554,LDLXYEMXSLQQVVKALNESY,21,P21S3,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay,[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50>50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00554,DRAVPe00554.cif,Cyclic,Acetylation,Amidation,①The 'X' (position: 4 and 8) in sequence indicates S5 stapling amino acid. Note: S5 is (S)-pentenyl alanine. ②X (4) and X (8) are cross-linked by hydrocarbon stapling.,L,membrane,The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion.,2466.22,C100H155N23O31S,CFGHIPRTW,L,4.14,1,3,-2,5,7,-8.57,-2077,5.5 hour,3 min,2 min,106.67,2980,149.0,29442512,J Med Chem. 2018 Mar 8;61(5):2018-2026.,"Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K.",Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. ,10.1021/acs.jmedchem.7b01732,,Anti-MERS-CoV
DRAVPe00555,LDLTXEMLXLQQVVKALNESY,21,P21S4,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay,[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=7.14 ± 0.7 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00555,DRAVPe00555.cif,Cyclic,Acetylation,Amidation,①The 'X' (position: 5 and 9) in sequence indicates S5 stapling amino acid. Note: S5 is (S)-pentenyl alanine. ②X (5) and X (9) are cross-linked by hydrocarbon stapling.,L,membrane,The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion.,2430.23,C98H159N23O30S,CFGHIPRW,L,4.14,1,3,-2,4,8,16.19,-1488,5.5 hour,3 min,2 min,125.24,1490,74.5,29442512,J Med Chem. 2018 Mar 8;61(5):2018-2026.,"Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K.",Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. ,10.1021/acs.jmedchem.7b01732,,Anti-MERS-CoV
DRAVPe00556,LDLTYEMXSLQXVVKALNESY,21,P21S5,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay,[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=10.7±2.6 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00556,DRAVPe00556.cif,Cyclic,Acetylation,Amidation,①The 'X' (position: 8 and 12) in sequence indicates S5 stapling amino acid. Note: S5 is (S)-pentenyl alanine. ②X (8) and X (12) are cross-linked by hydrocarbon stapling.,L,membrane,The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion.,2439.19,C99H154N22O31S,CFGHIPRW,L,4.14,1,3,-2,6,7,4.76,-1780,5.5 hour,3 min,2 min,106.67,2980,149.0,29442512,J Med Chem. 2018 Mar 8;61(5):2018-2026.,"Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K.",Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. ,10.1021/acs.jmedchem.7b01732,,Anti-MERS-CoV
DRAVPe00557,LDLTYEMLXLQQXVKALNESY,21,P21S6,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay,[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50>50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00557,DRAVPe00557.cif,Cyclic,Acetylation,Amidation,①The 'X' (position: 9 and 13) in sequence indicates S5 stapling amino acid. Note: S5 is (S)-pentenyl alanine. ②X (9) and X (13) are cross-linked by hydrocarbon stapling.,L,membrane,The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion.,2494.27,C102H159N23O31S,CFGHIPRW,L,4.14,1,3,-2,5,7,-10.0,-1906,5.5 hour,3 min,2 min,111.43,2980,149.0,29442512,J Med Chem. 2018 Mar 8;61(5):2018-2026.,"Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K.",Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. ,10.1021/acs.jmedchem.7b01732,,Anti-MERS-CoV
DRAVPe00558,LDLTYEMLSLXQVVXALNESY,21,P21S7,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay,[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50>50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00558,DRAVPe00558.cif,Cyclic,Acetylation,Amidation,①The 'X' (position: 11 and 15) in sequence indicates S5 stapling amino acid. Note: S5 is (S)-pentenyl alanine. ②X (11) and X (15) are cross-linked by hydrocarbon stapling.,L,membrane,The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion.,2424.18,C99H153N21O31S,CFGHIKPRW,L,3.57,0,3,-3,6,8,41.43,-733,5.5 hour,3 min,2 min,125.24,2980,149.0,29442512,J Med Chem. 2018 Mar 8;61(5):2018-2026.,"Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K.",Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. ,10.1021/acs.jmedchem.7b01732,,Anti-MERS-CoV
DRAVPe00559,LDLTYEMLSLQXVVKXLNESY,21,P21S8,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay,[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=0.26±0.05 μM);##WT MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells(EC50=3.03 ± 0.29 μM);##Q1020H-MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells(EC50=4.06± 0.34 μM);##Q1020R-MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells(EC50=1.98± 0.28 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.29442512]Calu-3 cell:CC50>100 μM,DRAVPe00559,DRAVPe00559.cif,Cyclic,Acetylation,Amidation,①The 'X' (position: 12 and 16) in sequence indicates S5 stapling amino acid. Note: S5 is (S)-pentenyl alanine. ②X (12) and X (16) are cross-linked by hydrocarbon stapling.,L,membrane,The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion.,2481.27,C102H160N22O31S,ACFGHIPRW,L,4.14,1,3,-2,6,7,14.29,-1469,5.5 hour,3 min,2 min,120.48,2980,149.0,29442512,J Med Chem. 2018 Mar 8;61(5):2018-2026.,"Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K.",Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. ,10.1021/acs.jmedchem.7b01732,,Anti-MERS-CoV
DRAVPe00560,LDLTYEMLSLQQVVXALNXSY,21,P21S9,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay,[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=14.1 ± 2.3 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00560,DRAVPe00560.cif,Cyclic,Acetylation,Amidation,①The 'X' (position: 15 and 19) in sequence indicates S5 stapling amino acid. Note: S5 is (S)-pentenyl alanine. ②X (15) and X (19) are cross-linked by hydrocarbon stapling.,L,membrane,The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion.,2423.19,C99H154N22O30S,CFGHIKPRW,L,3.67,0,2,-2,6,8,41.43,-606,5.5 hour,3 min,2 min,125.24,2980,149.0,29442512,J Med Chem. 2018 Mar 8;61(5):2018-2026.,"Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K.",Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. ,10.1021/acs.jmedchem.7b01732,,Anti-MERS-CoV
DRAVPe00561,LDLTYEMLSLQQVVKXLNEXY,21,P21S10,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay,[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=0.33 ± 0.04 μM);##WT MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells(EC50=0.97± 0.08 μM);##Q1020H-MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells(EC50=1.82± 0.28 μM);##Q1020R-MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells(EC50=0.89± 0.07 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.29442512]Calu-3 cell:CC50>100 μM,DRAVPe00561,DRAVPe00561.cif,Cyclic,Acetylation,Amidation,①The 'X' (position: 16 and 20) in sequence indicates S5 stapling amino acid. Note: S5 is (S)-pentenyl alanine. ②X (16) and X (20) are cross-linked by hydrocarbon stapling.,L,membrane,The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion.,2522.33,C104H163N23O31S,ACFGHIPRW,L,4.14,1,3,-2,5,7,1.43,-1683,5.5 hour,3 min,2 min,120.48,2980,149.0,29442512,J Med Chem. 2018 Mar 8;61(5):2018-2026.,"Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K.",Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. ,10.1021/acs.jmedchem.7b01732,,Anti-MERS-CoV
DRAVPe00562,LXLTYXMLSLQQVVKALNESY,21,P21L2,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay,[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=10.9 ±1.1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00562,DRAVPe00562.cif,Linear,Acetylation,Amidation,The 'X' at position 2 and 6 are S5((S)-pentenyl alanine),L,membrane,The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion.,2436.28,C101H161N23O28S,CDFGHIPRW,L,6.0,1,1,0,6,8,39.52,-289,5.5 hour,3 min,2 min,125.24,2980,149.0,29442512,J Med Chem. 2018 Mar 8;61(5):2018-2026.,"Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K.",Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. ,10.1021/acs.jmedchem.7b01732,,Anti-MERS-CoV
DRAVPe00563,LDLTXEMLXLQQVVKALNESY,21,P21L4,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay,[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=8.21 ±0.9 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00563,DRAVPe00563.cif,Linear,Acetylation,Amidation,The 'X' at position 5 and 9 are S5((S)-pentenyl alanine),L,membrane,The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion.,2430.23,C98H159N23O30S,CFGHIPRW,L,4.14,1,3,-2,4,8,16.19,-1488,5.5 hour,3 min,2 min,125.24,1490,74.5,29442512,J Med Chem. 2018 Mar 8;61(5):2018-2026.,"Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K.",Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. ,10.1021/acs.jmedchem.7b01732,,Anti-MERS-CoV
DRAVPe00564,LDLTYEMXSLQXVVKALNESY,21,P21L5,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay,[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=4.49 ± 0.6 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00564,DRAVPe00564.cif,Linear,Acetylation,Amidation,The 'X' at position 8 and 12 are S5((S)-pentenyl alanine),L,membrane,The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion.,2439.19,C99H154N22O31S,CFGHIPRW,L,4.14,1,3,-2,6,7,4.76,-1780,5.5 hour,3 min,2 min,106.67,2980,149.0,29442512,J Med Chem. 2018 Mar 8;61(5):2018-2026.,"Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K.",Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. ,10.1021/acs.jmedchem.7b01732,,Anti-MERS-CoV
DRAVPe00565,LDLTYEMLSLQXVVKXLNESY,21,P21L8,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay,[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=20.6± 3.3 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00565,DRAVPe00565.cif,Linear,Acetylation,Amidation,The 'X' at position 12 and 16 are S5((S)-pentenyl alanine),L,membrane,The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion.,2481.27,C102H160N22O31S,ACFGHIPRW,L,4.14,1,3,-2,6,7,14.29,-1469,5.5 hour,3 min,2 min,120.48,2980,149.0,29442512,J Med Chem. 2018 Mar 8;61(5):2018-2026.,"Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K.",Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. ,10.1021/acs.jmedchem.7b01732,,Anti-MERS-CoV
DRAVPe00566,LDLTYEMLSLQQVVXALNXSY,21,P21L9,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay,[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=10.9 ± 1.0 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00566,DRAVPe00566.cif,Linear,Acetylation,Amidation,The 'X' at position 15 and 19 are S5((S)-pentenyl alanine),L,membrane,The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion.,2423.19,C99H154N22O30S,CFGHIKPRW,L,3.67,0,2,-2,6,8,41.43,-606,5.5 hour,3 min,2 min,125.24,2980,149.0,29442512,J Med Chem. 2018 Mar 8;61(5):2018-2026.,"Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K.",Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. ,10.1021/acs.jmedchem.7b01732,,Anti-MERS-CoV
DRAVPe00567,LDLTYEMLSLQQVVKXLNEXY,21,P21L10,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay,[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=3.55 ± 0.2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00567,DRAVPe00567.cif,Linear,Acetylation,Amidation,The 'X' at position 16 and 20 are S5((S)-pentenyl alanine),L,membrane,The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion.,2522.33,C104H163N23O31S,ACFGHIPRW,L,4.14,1,3,-2,5,7,1.43,-1683,5.5 hour,3 min,2 min,120.48,2980,149.0,29442512,J Med Chem. 2018 Mar 8;61(5):2018-2026.,"Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K.",Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. ,10.1021/acs.jmedchem.7b01732,,Anti-MERS-CoV
DRAVPe00568,LDLTYEMLSLQXVVKXLNESY,21,P21R8,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay,[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=16.3 ± 1.1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00568,DRAVPe00568.cif,Cyclic,Acetylation,Amidation,①The 'X' at position 12 and 16 are R5 amino acids. ②X (12) and X (16) are cross-linked by hydrocarbon stapling.,L,membrane,The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion.,2481.27,C102H160N22O31S,ACFGHIPRW,L,4.14,1,3,-2,6,7,14.29,-1469,5.5 hour,3 min,2 min,120.48,2980,149.0,29442512,J Med Chem. 2018 Mar 8;61(5):2018-2026.,"Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K.",Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. ,10.1021/acs.jmedchem.7b01732,,Anti-MERS-CoV
DRAVPe00569,LDLTYEZLSLQXVVKXLNESY,21,P21S8Z,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay,[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=0.63 ± 0.05 μM);##WT MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells(EC50=2.80 ± 0.74 μM);##Q1020H-MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells(EC50=4.15± 0.25 μM);##Q1020R-MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells(EC50=2.49±0.18 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.29442512]Calu-3 cell:CC50>100 μM,DRAVPe00569,DRAVPe00569.cif,Cyclic,Acetylation,Amidation,①The 'X' (position: 12 and 16) in sequence indicates S5 stapling amino acid. Note: S5 is (S)-pentenyl alanine. ②X (12) and X (16) are cross-linked by hydrocarbon stapling. The 'Z' at position 7 indicates R8 ((R)-octenyl alanine),L,membrane,The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion.,2478.83,C97H149N21O29,ACFGHIMPRW,L,4.14,1,3,-2,6,7,5.24,-1704,5.5 hour,3 min,2 min,120.48,2980,149.0,29442512,J Med Chem. 2018 Mar 8;61(5):2018-2026.,"Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K.",Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. ,10.1021/acs.jmedchem.7b01732,,Anti-MERS-CoV
DRAVPe00570,LDLTYEMLSLQXVVKXLNESF,21,P21S8F,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay,[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=2.16± 1.1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00570,DRAVPe00570.cif,Cyclic,Acetylation,Amidation,①The 'X' (position: 12 and 16) in sequence indicates S5 stapling amino acid. Note: S5 is (S)-pentenyl alanine. ②X (12) and X (16) are cross-linked by hydrocarbon stapling.,L,membrane,The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion.,2465.27,C102H160N22O30S,ACGHIPRW,L,4.14,1,3,-2,5,8,33.81,-1157,5.5 hour,3 min,2 min,120.48,1490,74.5,29442512,J Med Chem. 2018 Mar 8;61(5):2018-2026.,"Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K.",Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. ,10.1021/acs.jmedchem.7b01732,,Anti-MERS-CoV
DRAVPe00571,LDLTYEZLSLQXVVKXLNESF,21,P21S8ZF,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay,[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=3.89 ± 0.8 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00571,DRAVPe00571.cif,Cyclic,Acetylation,Amidation,"①The 'X' (position: 12 and 16) in sequence indicates S5 stapling amino acid. Note: S5 is (S)-pentenyl alanine. ②X (12) and X (16) are cross-linked by hydrocarbon stapling.,The 'Z' at position 7 indicates R8 ((R)-octenyl alanine)",L,membrane,The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion.,2462.83,C97H149N21O28,ACGHIMPRW,L,4.14,1,3,-2,5,8,24.76,-1392,5.5 hour,3 min,2 min,120.48,1490,74.5,29442512,J Med Chem. 2018 Mar 8;61(5):2018-2026.,"Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K.",Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. ,10.1021/acs.jmedchem.7b01732,,Anti-MERS-CoV
DRAVPe00572,LDLTYEMLSLQQVVKALNESY,21,P21,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay,[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50>50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00572,DRAVPe00572.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion.,2457.82,C110H177N25O36S,CFGHIPRW,L,4.14,1,3,-2,6,8,6.19,-1842,5.5 hour,3 min,2 min,125.24,2980,149.0,29442512,J Med Chem. 2018 Mar 8;61(5):2018-2026.,"Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K.",Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. ,10.1021/acs.jmedchem.7b01732,,Anti-MERS-CoV
DRAVPe00573,SLTQINTTLLDLEYEMKKLEEVVKKLEESYIDLKEL,36,HR2P-M2,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay,[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=0.75 ± 0.09 μM);##WT MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells(EC50=1.07±0.21 μM);##Q1020H-MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells(EC50=1.25± 0.18 μM);##Q1020R-MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells(EC50=0.64± 0.16 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.29442512]Calu-3 cell:CC50>100 μM,DRAVPe00573,DRAVPe00573.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion.,4299.98,C193H321N43O64S,ACFGHPRW,L,4.48,5,9,-4,8,12,-40.56,-6020,1.9 hour,>20 hour,>10 hour,124.44,2980,85.14,29442512,J Med Chem. 2018 Mar 8;61(5):2018-2026.,"Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K.",Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. ,10.1021/acs.jmedchem.7b01732,,Anti-MERS-CoV
DRAVPe00574,FNATYLNLTGEIDDLEFRSEKLHNTTVELAILIDNI,36,FP3(FCoV Sgp (1338-1373)),Synthetic construct(derived from S protein of FCoV),P10033,,FCoV,Coronaviridae,plaque reduction assay,[Ref.24312629]feline coronavirus(FCoV):inhibition of virus replication in Fcwf-4 cells(IC50=14.21 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.24312629]Fcwf-4 cell:CC50>200 μM.,DRAVPe00574,DRAVPe00574.cif,Linear,Free,Free,,L,membrane,The peptide can interfere the fusion of the viral envelope with host membrane and thus inhibits viral replication.,4136.62,C185H292N46O61,CMPQW,L,4.19,3,7,-4,11,15,-3.33,-5515,1.1 hour,3 min,2 min,121.94,1490,42.57,24312629, PLoS One. 2013 Dec 3;8(12):e82081.,"Liu IJ, Tsai WT, Hsieh LE, Chueh LL.",Peptides corresponding to the predicted heptad repeat 2 domain of the feline coronavirus spike protein are potent inhibitors of viral infection.,10.1371/journal.pone.0082081,,Anti-FCoV
DRAVPe00575,FNATYLNLTGEIDDLEFRSEKLHNTTVELAILIDNINNTLVNL,43,FP4(FCoV Sgp (1338-1380)),Synthetic construct(derived from S protein of FCoV),P10033,,FCoV,Coronaviridae,plaque reduction assay,[Ref.24312629]feline coronavirus(FCoV):inhibition of virus replication in Fcwf-4 cells(IC50=1.8 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.24312629]Fcwf-4 cell:CC50>200 μM.,DRAVPe00575,DRAVPe00575.cif,Linear,Free,Free,,L,membrane,The peptide can interfere the fusion of the viral envelope with host membrane and thus inhibits viral replication.,4905.49,C218H348N56O72,CMPQW,L,4.19,3,7,-4,15,18,-1.4,-6376,1.1 hour,3 min,2 min,126.98,1490,35.48,24312629, PLoS One. 2013 Dec 3;8(12):e82081.,"Liu IJ, Tsai WT, Hsieh LE, Chueh LL.",Peptides corresponding to the predicted heptad repeat 2 domain of the feline coronavirus spike protein are potent inhibitors of viral infection.,10.1371/journal.pone.0082081,,Anti-FCoV
DRAVPe00576,FNATYLNLTGEIDDLEFRSEKLHNTTVELAILIDNINNTLVNLEWLNRIE,50,FP5(FCoV Sgp (1338-1387)),Synthetic construct(derived from S protein of FCoV),P10033,,FCoV,Coronaviridae,plaque reduction assay,[Ref.24312629]feline coronavirus(FCoV):inhibition of virus replication in Fcwf-4 cells(IC50=1.33 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.24312629]Fcwf-4 cell:CC50>200 μM.,DRAVPe00576,DRAVPe00576.cif,Linear,Free,Free,,L,membrane,The peptide can interfere the fusion of the viral envelope with host membrane and thus inhibits viral replication.,5846.55,C261H412N68O84,CMPQ,LN,4.25,4,9,-5,16,21,-16.4,-8677,1.1 hour,3 min,2 min,124.8,6990,142.65,24312629, PLoS One. 2013 Dec 3;8(12):e82081.,"Liu IJ, Tsai WT, Hsieh LE, Chueh LL.",Peptides corresponding to the predicted heptad repeat 2 domain of the feline coronavirus spike protein are potent inhibitors of viral infection.,10.1371/journal.pone.0082081,,Anti-FCoV
DRAVPe00577,WEEWDKKIEEYTKKIEELIKKSEEQQKKNEKELK,34,SC34EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=0.9±0.1 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=0.7±0.2 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00577,DRAVPe00577.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,4365.95,C196H315N49O63,ACFGHMPRV,EK,5.43,10,11,-1,4,7,-210.29,-12689,2.8 hour,3 min,2 min,57.35,12490,378.48,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00578,WEEWDKKIEEYTKKIEELIKKSEEQQKKNEKEL,33,SC33EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=1.1±0.1 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=0.7±0.4 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00578,DRAVPe00578.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,4237.77,C190H303N47O62,ACFGHMPRV,E,5.08,9,11,-2,4,7,-204.85,-12134,2.8 hour,3 min,2 min,59.09,12490,390.31,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00579,WEEWDKKIEEYTKKIEELIKKSEEQQKKNEKE,32,SC32EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=1.1±0.2 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=0.8±0.2 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00579,DRAVPe00579.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,4124.61,C184H292N46O61,ACFGHMPRV,E,5.08,9,11,-2,4,6,-223.13,-12626,2.8 hour,3 min,2 min,48.75,12490,402.9,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00580,WEEWDKKIEEYTKKIEELIKKSEEQQKKNEK,31,SC31EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=1.3±0.2 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=0.9±0.3 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00580,DRAVPe00580.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3995.5,C179H285N45O58,ACFGHMPRV,EK,5.38,9,10,-1,4,6,-219.03,-11945,2.8 hour,3 min,2 min,50.32,12490,416.33,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00581,WEEWDKKIEEYTKKIEELIKKSEEQQKKNE,30,SC30EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=1±0 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=0.9±0.1 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00581,DRAVPe00581.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3867.32,C173H273N43O57,ACFGHMPRV,E,5.03,8,10,-2,4,6,-213.33,-11390,2.8 hour,3 min,2 min,52.0,12490,430.69,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00582,WEEWDKKIEEYTKKIEELIKKSEEQQKKN,29,SC29EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=1.2±0.2 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=1±0.2 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00582,DRAVPe00582.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3738.21,C168H266N42O54,ACFGHMPRV,EK,5.33,8,9,-1,4,6,-208.62,-10709,2.8 hour,3 min,2 min,53.79,12490,446.07,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00583,WEEWDKKIEEYTKKIEELIKKSEEQQKK,28,SC28EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=18±3 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=13±1.5 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00583,DRAVPe00583.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3624.11,C164H260N40O52,ACFGHMNPRV,EK,5.33,8,9,-1,3,6,-203.57,-10045,2.8 hour,3 min,2 min,55.71,12490,462.59,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00584,WEEWDKKIEEYTKKIEELIKKSEEQQK,27,SC27EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=29±2.1 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=21.4±2.5 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00584,DRAVPe00584.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3495.93,C158H248N38O51,ACFGHMNPRV,E,4.97,7,9,-2,3,6,-196.67,-9490,2.8 hour,3 min,2 min,57.78,12490,480.38,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00585,WEEWDKKIEEYTKKIEELIKKSEEQQ,26,SC26EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=44.9±5.2 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=36.2±4.2 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00585,DRAVPe00585.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3367.76,C152H236N36O50,ACFGHMNPRV,E,4.73,6,9,-3,3,6,-189.23,-8935,2.8 hour,3 min,2 min,60.0,12490,499.6,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00586,WEEWDKKIEEYTKKIEELIKKSEEQ,25,SC25EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=79.8±9.3 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=41.5±3.1 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00586,DRAVPe00586.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3239.63,C147H228N34O48,ACFGHMNPRV,E,4.73,6,9,-3,3,6,-182.8,-8381,2.8 hour,3 min,2 min,62.4,12490,520.42,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00587,WEEWDKKIEEYTKKIEELIKKSEE,24,SC24EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=107.6±8 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=75.7±11.2 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00587,DRAVPe00587.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3111.5,C142H220N32O46,ACFGHMNPQRV,E,4.73,6,9,-3,3,6,-175.83,-7827,2.8 hour,3 min,2 min,65.0,12490,543.04,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00588,WEEWDKKIEEYTKKIEELIKKSE,23,SC23EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=105.1±15.3 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=94.2±12.3 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00588,DRAVPe00588.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,2982.38,C137H213N31O43,ACFGHMNPQRV,E,4.9,6,8,-2,3,6,-168.26,-7146,2.8 hour,3 min,2 min,67.83,12490,567.73,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00589,WEEWDKKIEEYTKKIEELIKKS,22,SC22EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=66.9±15.9 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=98.6±7.2 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00589,DRAVPe00589.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,2853.26,C132H206N30O40,ACFGHMNPQRV,EK,5.19,6,7,-1,3,6,-160.0,-6465,2.8 hour,3 min,2 min,70.91,12490,594.76,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00590,WEEWDKKIEEYTKKIEELIKK,21,SC21EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=113.2±8 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=105.4±12.8 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00590,DRAVPe00590.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,2766.19,C129H201N29O38,ACFGHMNPQRSV,EK,5.19,6,7,-1,2,6,-163.81,-6125,2.8 hour,3 min,2 min,74.29,12490,624.5,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00591,WEEWDKKIEEYTKKIEELIK,20,SC20EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=126.6±10.7 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=202.4±5.4 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00591,DRAVPe00591.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,2638.01,C123H189N27O37,ACFGHMNPQRSV,E,4.82,5,7,-2,2,6,-152.5,-5570,2.8 hour,3 min,2 min,78.0,12490,657.37,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00592,WEEWDKKIEEYTKKIEELI,19,SC19EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=70.7±9 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=217.2±16.5 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00592,DRAVPe00592.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,2509.84,C117H177N25O36,ACFGHMNPQRSV,E,4.55,4,7,-3,2,6,-140.0,-5015,2.8 hour,3 min,2 min,82.11,12490,693.89,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00593,WEEWDKKIEEYTKKIEEL,18,SC18EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50>2000 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50>2000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00593,DRAVPe00593.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,2396.68,C111H166N24O35,ACFGHMNPQRSV,E,4.55,4,7,-3,2,5,-172.78,-5507,2.8 hour,3 min,2 min,65.0,12490,734.71,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00594,MTWEEWDKKIEEYTKKIEELIKKSEEQQKKNEKELK,36,MT-SC34EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=1±0.2 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=0.7±0.2 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00594,DRAVPe00594.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,4598.25,C205H331N51O66S,ACFGHPRV,EK,5.42,10,11,-1,5,7,-195.28,-12711,30 hour,>20 hour,>10 hour,54.17,12490,356.86,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00595,MTWEEWDKKIEEYTKKIEELIKKSEEQQKKNEKEL,35,MT-SC33EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=1.2±0.1 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=0.8±0.2 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00595,DRAVPe00595.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,4470.07,C199H319N49O65S,ACFGHPRV,E,5.08,9,11,-2,5,7,-189.71,-12156,30 hour,>20 hour,>10 hour,55.71,12490,367.35,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00596,MTWEEWDKKIEEYTKKIEELIKKSEEQQKKNEKE,34,MT-SC32EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=1.3±0.1 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=1.1±0.3 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00596,DRAVPe00596.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,4356.91,C193H308N48O64S,ACFGHPRV,E,5.08,9,11,-2,5,6,-206.47,-12648,30 hour,>20 hour,>10 hour,45.88,12490,378.48,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00597,MTWEEWDKKIEEYTKKIEELIKKSEEQQKKNEK,33,MT-SC31EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=1.3±0.1 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=0.9±0.4 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00597,DRAVPe00597.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,4227.8,C188H301N47O61S,ACFGHPRV,EK,5.37,9,10,-1,5,6,-202.12,-11967,30 hour,>20 hour,>10 hour,47.27,12490,390.31,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00598,MTWEEWDKKIEEYTKKIEELIKKSEEQQKKNE,32,MT-SC30EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=0.8±0.1 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=0.8±0.2 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00598,DRAVPe00598.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,4099.62,C182H289N45O60S,ACFGHPRV,E,5.03,8,10,-2,5,6,-196.25,-11412,30 hour,>20 hour,>10 hour,48.75,12490,402.9,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00599,MTWEEWDKKIEEYTKKIEELIKKSEEQQKKN,31,MT-SC29EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=0.9±0.2 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=1.1±0.2 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00599,DRAVPe00599.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3970.51,C177H282N44O57S,ACFGHPRV,EK,5.32,8,9,-1,5,6,-191.29,-10731,30 hour,>20 hour,>10 hour,50.32,12490,416.33,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00600,MTWEEWDKKIEEYTKKIEELIKKSEEQQKK,30,MT-SC28EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=1.3±0.2 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=1.2±0.6 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00600,DRAVPe00600.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3856.4,C173H276N42O55S,ACFGHNPRV,EK,5.32,8,9,-1,4,6,-186.0,-10067,30 hour,>20 hour,>10 hour,52.0,12490,430.69,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00601,MTWEEWDKKIEEYTKKIEELIKKSEEQQK,29,MT-SC27EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=1.1±0.2 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=1.4±0.6 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00601,DRAVPe00601.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3728.23,C167H264N40O54S,ACFGHNPRV,E,4.97,7,9,-2,4,6,-178.97,-9512,30 hour,>20 hour,>10 hour,53.79,12490,446.07,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00602,MTWEEWDKKIEEYTKKIEELIKKSEEQQ,28,MT-SC26EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=1.6±0.2 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=1.1±0.2 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00602,DRAVPe00602.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3600.05,C161H252N38O53S,ACFGHNPRV,E,4.73,6,9,-3,4,6,-171.43,-8957,30 hour,>20 hour,>10 hour,55.71,12490,462.59,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00603,MTWEEWDKKIEEYTKKIEELIKKSEEQ,27,MT-SC25EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=1.9±0.2 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=2±0.9 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00603,DRAVPe00603.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3471.92,C156H244N36O51S,ACFGHNPRV,E,4.73,6,9,-3,4,6,-164.81,-8403,30 hour,>20 hour,>10 hour,57.78,12490,480.38,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00604,MTWEEWDKKIEEYTKKIEELIKKSEE,26,MT-SC24EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=2.8±0.2 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=2.3±0.5 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00604,DRAVPe00604.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3343.79,C151H236N34O49S,ACFGHNPQRV,E,4.73,6,9,-3,4,6,-157.69,-7849,30 hour,>20 hour,>10 hour,60.0,12490,499.6,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00605,MTWEEWDKKIEEYTKKIEELIKKSE,25,MT-SC23EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=2.1±0.2 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=1.9±0.7 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00605,DRAVPe00605.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3214.68,C146H229N33O46S,ACFGHNPQRV,E,4.9,6,8,-2,4,6,-150.0,-7168,30 hour,>20 hour,>10 hour,62.4,12490,520.42,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00606,MTWEEWDKKIEEYTKKIEELIKKS,24,MT-SC22EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=2.4±0.3 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=2.2±0.9 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00606,DRAVPe00606.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3085.56,C141H222N32O43S,ACFGHNPQRV,EK,5.19,6,7,-1,4,6,-141.67,-6487,30 hour,>20 hour,>10 hour,65.0,12490,543.04,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00607,MTWEEWDKKIEEYTKKIEELIKK,23,MT-SC21EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=3.8±0.4 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=3.1±1.2 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00607,DRAVPe00607.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,2998.48,C138H217N31O41S,ACFGHNPQRSV,EK,5.19,6,7,-1,3,6,-144.35,-6147,30 hour,>20 hour,>10 hour,67.83,12490,567.73,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00608,MTWEEWDKKIEEYTKKIEELIK,22,MT-SC20EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=3.7±0.5 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=3.3±1.4 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00608,DRAVPe00608.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,2870.31,C132H205N29O40S,ACFGHNPQRSV,E,4.82,5,7,-2,3,6,-133.18,-5592,30 hour,>20 hour,>10 hour,70.91,12490,594.76,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00609,MTWEEWDKKIEEYTKKIEELI,21,MT-SC19EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=5±0.9 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=4.9±1.5 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00609,DRAVPe00609.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,2742.14,C126H193N27O39S,ACFGHNPQRSV,E,4.55,4,7,-3,3,6,-120.95,-5037,30 hour,>20 hour,>10 hour,74.29,12490,624.5,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00610,MTWEEWDKKIEEYTKKIEEL,20,MT-SC18EK,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50>2000 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50>2000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00610,DRAVPe00610.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,2628.98,C120H182N26O38S,ACFGHNPQRSV,E,4.55,4,7,-3,3,5,-149.5,-5529,30 hour,>20 hour,>10 hour,58.5,12490,657.37,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00611,MTWEEWDKKIEEYTKKIEELIKKSQNQQEKN,31,MT-WQ-EKN,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=1.1±0.1 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=0.8±0.1 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00611,DRAVPe00611.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3955.45,C175H277N45O57S,ACFGHPRV,EK,5.26,7,8,-1,6,6,-190.0,-10713,30 hour,>20 hour,>10 hour,50.32,12490,416.33,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00612,WEEWDKKIEEYTKKIEELIKKSQNQQEKN,29,WQ-EKN,Synthetic construct,Q5DP94,,HIV,Retroviridae,"dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay",[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=1.4±0.2 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=0.8±0.1 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00612,DRAVPe00612.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation.,3723.15,C166H261N43O54,ACFGHMPRV,EK,5.26,7,8,-1,5,6,-207.24,-10691,2.8 hour,3 min,2 min,53.79,12490,446.07,31277353,Viruses. 2019 Jul 3;11(7):609. ,"Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.",Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.,10.3390/v11070609,,Anti-HIV
DRAVPe00613,YTSLIREILVESRIQQEKNERELRDIDKWASLWNWF,36,"T20v1(T20 [H6R; S7E; L8,26I; I9L; E10V; Q13,21R; N14I; L24R; E25D])",Synthetic construct(derived from T20),P04578,,HIV,Retroviridae,neutralization assay,[Ref.31228294]HIV-1 N43:inhibition of virus infection in U87 cells(IC50=0.06 µg/ml);##HIV-1 JRCSF:inhibition of virus infection in U87 cells(IC50=0.10 µg/ml);##HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells(IC50=0.06 µg/ml);##HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells(IC50=0.17 µg/ml);##HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells(IC50=0.12 µg/ml);##HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells(IC50=0.06 µg/ml);##HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells(IC50=0.29 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00613,DRAVPe00613.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",4566.16,C207H319N57O60,CGHMP,E,5.15,6,7,-1,7,14,-81.67,-10436,2.8 hour,10 min,2 min,97.5,17990,514.0,31228294,Protein Sci. 2019 Aug;28(8):1501-1512.,"Chen G, Cook JD, Ye W, Lee JE, Sidhu SS.",Optimization of peptidic HIV-1 fusion inhibitor T20 by phage display.,10.1002/pro.3669,,Anti-HIV
DRAVPe00614,YTSLIHSIIEESRNRQEKNEQALLELDKWASLWNWF,36,"T20v2(T20 [L8I; Q13,15R; E22A])",Synthetic construct(derived from T20),P04578,,HIV,Retroviridae,neutralization assay,[Ref.31228294]HIV-1 N43:inhibition of virus infection in U87 cells(IC50=0.06 µg/ml);##HIV-1 JRCSF:inhibition of virus infection in U87 cells(IC50=0.06 µg/ml);##HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells(IC50=0.03 µg/ml);##HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells(IC50=0.17 µg/ml);##HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells(IC50=0.09 µg/ml);##HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells(IC50=0.03 µg/ml);##HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells(IC50=1.05 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00614,DRAVPe00614.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",4448.96,C202H304N54O60,CGMPV,EL,5.06,5,6,-1,9,14,-76.39,-8273,2.8 hour,10 min,2 min,92.22,17990,514.0,31228294,Protein Sci. 2019 Aug;28(8):1501-1512.,"Chen G, Cook JD, Ye W, Lee JE, Sidhu SS.",Optimization of peptidic HIV-1 fusion inhibitor T20 by phage display.,10.1002/pro.3669,,Anti-HIV
DRAVPe00615,YTSLLRSIIEEGRNQQEKNEQALLELDKWASLWNWF,36,"T20v3(T20 [I5L, H6R, L8I; S12G; Q13R; E22A])",Synthetic construct(derived from T20),P04578,,HIV,Retroviridae,neutralization assay,[Ref.31228294]HIV-1 N43:inhibition of virus infection in U87 cells(IC50=0.13 µg/ml);##HIV-1 JRCSF:inhibition of virus infection in U87 cells(IC50=0.08 µg/ml);##HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells(IC50=0.03 µg/ml);##HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells(IC50=0.19 µg/ml);##HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells(IC50=0.08 µg/ml);##HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells(IC50=0.03 µg/ml);##HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells(IC50=1.34 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00615,DRAVPe00615.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",4409.92,C200H303N53O60,CHMPV,L,4.72,4,6,-2,9,14,-78.06,-7927,2.8 hour,10 min,2 min,92.22,17990,514.0,31228294,Protein Sci. 2019 Aug;28(8):1501-1512.,"Chen G, Cook JD, Ye W, Lee JE, Sidhu SS.",Optimization of peptidic HIV-1 fusion inhibitor T20 by phage display.,10.1002/pro.3669,,Anti-HIV
DRAVPe00616,YTSLIRSIIEESRNQQEKNEQKLLEVDKWASLWNWF,36,"T20v4(T20 [H6R, L8I, Q13R, E22K, L26V])",Synthetic construct(derived from T20),P04578,,HIV,Retroviridae,neutralization assay,[Ref.31228294]HIV-1 N43:inhibition of virus infection in U87 cells(IC50=0.15 µg/ml);##HIV-1 JRCSF:inhibition of virus infection in U87 cells(IC50=0.12 µg/ml);##HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells(IC50=0.04 µg/ml);##HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells(IC50=0.22 µg/ml);##HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells(IC50=0.50 µg/ml);##HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells(IC50=0.03 µg/ml);##HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells(IC50=1.80 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00616,DRAVPe00616.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",4483.02,C203H310N54O61,CGHMP,E,5.11,5,6,-1,9,13,-91.94,-9185,2.8 hour,10 min,2 min,86.67,17990,514.0,31228294,Protein Sci. 2019 Aug;28(8):1501-1512.,"Chen G, Cook JD, Ye W, Lee JE, Sidhu SS.",Optimization of peptidic HIV-1 fusion inhibitor T20 by phage display.,10.1002/pro.3669,,Anti-HIV
DRAVPe00617,YTSLLRSLIEESRNLQEKNEQALLEVDKWASLWNWF,36,"T20v5(T20 [I5L, H6R, Q13R, Q15L, E22A, L26V])",Synthetic construct(derived from T20),P04578,,HIV,Retroviridae,neutralization assay,[Ref.31228294]HIV-1 N43:inhibition of virus infection in U87 cells(IC50=0.17 µg/ml);##HIV-1 JRCSF:inhibition of virus infection in U87 cells(IC50=0.15 µg/ml);##HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells(IC50=0.14 µg/ml);##HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells(IC50=0.50 µg/ml);##HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells(IC50=0.29 µg/ml);##HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells(IC50=0.13 µg/ml);##HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells(IC50=5.69 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00617,DRAVPe00617.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",4410.95,C201H306N52O60,CGHMP,L,4.72,4,6,-2,9,15,-59.72,-7403,2.8 hour,10 min,2 min,100.28,17990,514.0,31228294,Protein Sci. 2019 Aug;28(8):1501-1512.,"Chen G, Cook JD, Ye W, Lee JE, Sidhu SS.",Optimization of peptidic HIV-1 fusion inhibitor T20 by phage display.,10.1002/pro.3669,,Anti-HIV
DRAVPe00618,YTSLLWSIIEEGRNLQEKNEQKLLELDKWASLWNWF,36,"T20v6(T20 [I5L, H6W, L8I, S12G, Q13R, Q15L, E22K])",Synthetic construct(derived from T20),P04578,,HIV,Retroviridae,neutralization assay,[Ref.31228294]HIV-1 N43:inhibition of virus infection in U87 cells(IC50=0.16 µg/ml);##HIV-1 JRCSF:inhibition of virus infection in U87 cells(IC50=0.14 µg/ml);##HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells(IC50=0.21 µg/ml);##HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells(IC50=0.62 µg/ml);##HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells(IC50=0.59 µg/ml);##HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells(IC50=0.10 µg/ml);##HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells(IC50=5.68 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00618,DRAVPe00618.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",4482.07,C209H311N51O59,CHMPV,L,4.72,4,6,-2,9,15,-63.61,-5892,2.8 hour,10 min,2 min,100.28,23490,671.14,31228294,Protein Sci. 2019 Aug;28(8):1501-1512.,"Chen G, Cook JD, Ye W, Lee JE, Sidhu SS.",Optimization of peptidic HIV-1 fusion inhibitor T20 by phage display.,10.1002/pro.3669,,Anti-HIV
DRAVPe00619,YTSLIWKVLNDAREQQENNQETLVEIDKWASLWNWF,36,"T20v7(T20 [H6W; S7K; L8,24V; I9L; E10N; E11D; S12A; Q13R; N14E; K18N; E20Q; Q21E; L26I])",Synthetic construct(derived from T20),P04578,,HIV,Retroviridae,neutralization assay,[Ref.31228294]HIV-1 N43:inhibition of virus infection in U87 cells(IC50=0.37 µg/ml);##HIV-1 JRCSF:inhibition of virus infection in U87 cells(IC50=0.16 µg/ml);##HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells(IC50=0.45 µg/ml);##HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells(IC50=1.12 µg/ml);##HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells(IC50=0.23 µg/ml);##HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells(IC50=0.07 µg/ml);##HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells(IC50=5.10 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00619,DRAVPe00619.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",4468.95,C205H300N52O61,CGHMP,ELNW,4.36,3,6,-3,9,15,-74.17,-7244,2.8 hour,10 min,2 min,86.67,23490,671.14,31228294,Protein Sci. 2019 Aug;28(8):1501-1512.,"Chen G, Cook JD, Ye W, Lee JE, Sidhu SS.",Optimization of peptidic HIV-1 fusion inhibitor T20 by phage display.,10.1002/pro.3669,,Anti-HIV
DRAVPe00620,YTSLIREIMNKSWGQQRRNEGTLAEIDKWASLWNWF,36,"T20v8(T20 [H6R; S7E; L8,26I; I9M; E10N; E11K; Q13W; N14G; E17R; K18R; Q21G; E22T; L24A])",Synthetic construct(derived from T20),P04578,,HIV,Retroviridae,neutralization assay,[Ref.31228294]HIV-1 N43:inhibition of virus infection in U87 cells(IC50=0.40 µg/ml);##HIV-1 JRCSF:inhibition of virus infection in U87 cells(IC50=0.24 µg/ml);##HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells(IC50=0.31 µg/ml);##HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells(IC50=0.53 µg/ml);##HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells(IC50=1.11 µg/ml);##HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells(IC50=0.24 µg/ml);##HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells(IC50=10.2 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00620,DRAVPe00620.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",4428.99,C201H300N56O56S,CHPV,W,8.5,5,4,1,11,13,-80.83,-8182,2.8 hour,10 min,2 min,70.56,23490,671.14,31228294,Protein Sci. 2019 Aug;28(8):1501-1512.,"Chen G, Cook JD, Ye W, Lee JE, Sidhu SS.",Optimization of peptidic HIV-1 fusion inhibitor T20 by phage display.,10.1002/pro.3669,,Anti-HIV
DRAVPe00621,YTSLIRELISNARTQQTDNEESLRNVDKWASLWNWF,36,"T20v9(T20 [H6R; S7E; E10,22S; E11,25N; S12A; Q13R; N14T; E17T; K18D; Q21E; L24R; L26V])",Synthetic construct(derived from T20),P04578,,HIV,Retroviridae,neutralization assay,[Ref.31228294]HIV-1 N43:inhibition of virus infection in U87 cells(IC50=1.20 µg/ml);##HIV-1 JRCSF:inhibition of virus infection in U87 cells(IC50=0.34 µg/ml);##HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells(IC50=0.41 µg/ml);##HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells(IC50=0.82 µg/ml);##HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells(IC50=1.09 µg/ml);##HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells(IC50=0.35 µg/ml);##HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells(IC50=16.8 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00621,DRAVPe00621.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",4385.82,C195H295N55O61,CGHMP,LNS,4.94,4,5,-1,12,13,-84.44,-10012,2.8 hour,10 min,2 min,78.61,17990,514.0,31228294,Protein Sci. 2019 Aug;28(8):1501-1512.,"Chen G, Cook JD, Ye W, Lee JE, Sidhu SS.",Optimization of peptidic HIV-1 fusion inhibitor T20 by phage display.,10.1002/pro.3669,,Anti-HIV
DRAVPe00622,YTSLIWSIIIDGREQQRDNEGVLADLDKWASLWNWF,36,T20v10(T20 [H6W; L8I; E10I;E11D;S12G;Q13R;N14E;E17R;K18D;Q21G;E22V;L24D;E25D]),Synthetic construct(derived from T20),P04578,,HIV,Retroviridae,neutralization assay,[Ref.31228294]HIV-1 N43:inhibition of virus infection in U87 cells(IC50=23.3 µg/ml);##HIV-1 JRCSF:inhibition of virus infection in U87 cells(IC50=0.50 µg/ml);##HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells(IC50=3.35 µg/ml);##HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells(IC50=12.0 µg/ml);##HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells(IC50=0.45 µg/ml);##HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells(IC50=0.11 µg/ml);##HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells(IC50=24.4 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00622,DRAVPe00622.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",4339.83,C200H293N51O58,CHMP,DILW,4.23,3,6,-3,9,16,-35.83,-5996,2.8 hour,10 min,2 min,100.28,23490,671.14,31228294,Protein Sci. 2019 Aug;28(8):1501-1512.,"Chen G, Cook JD, Ye W, Lee JE, Sidhu SS.",Optimization of peptidic HIV-1 fusion inhibitor T20 by phage display.,10.1002/pro.3669,,Anti-HIV
DRAVPe00623,EKINQSLAFIRKSDELLHNV,20,peptide 4(RSV fusion protein(497-515)),Synthetic construct(derived from RSV fusion protein),P03420,,RSV,Paramyxoviridae,rHRSV-mCherry inhibition assay,[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50>50 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00623,DRAVPe00623.cif,Linear,Acetylation,Free,,L,membrane,The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry.,2354.69,C104H172N30O32,CGMPTWY,L,6.86,4,3,1,4,8,-44.5,-4521,1 hour,30 min,>10 hour,117.0,0,0.0,,,,,,,Anti-RSV
DRAVPe00624,EKINQSLXFIRXSDXLLHXV,20,peptide 4a(derived from RSV fusion protein(497-515)),Synthetic construct(derived from RSV fusion protein),No entry found,,RSV,Paramyxoviridae,rHRSV-mCherry inhibition assay,[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=1.82±0.42 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00624,DRAVPe00624.cif,Cyclic,Acetylation,Free,"The 'X' at position 8,12,15,19 indicates S-pentenylalanine, X(8) and X(12), X(15) and X(19) are cross-linked by hydrocarbon stapling.",L,membrane,The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry.,2357.54,C86H134N24O21,ACGMPTWY,X,6.85,3,2,1,3,7,1.0,-2802,1 hour,30 min,>10 hour,112.0,0,0.0,28137809,Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.,"Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O.",A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.,10.1128/AAC.02241-16,,Anti-RSV
DRAVPe00625,EKIXQSLXFIXKSDXLLHNV,20,peptide 4bb(derived from RSV fusion protein(497-515)),Synthetic construct(derived from RSV fusion protein),No entry found,,RSV,Paramyxoviridae,rHRSV-mCherry inhibition assay,[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=0.74±0.27 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00625,DRAVPe00625.cif,Cyclic,Acetylation,Free,"The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling.",L,membrane,The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry.,2329.53,C86H134N22O21,ACGMPRTWY,X,6.85,3,2,1,3,7,4.0,-1865,1 hour,30 min,>10 hour,112.0,0,0.0,28137809,Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.,"Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O.",A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.,10.1128/AAC.02241-16,,Anti-RSV
DRAVPe00626,EXINXSLXFIRXSDELLHNV,20,peptide 4ca(derived from RSV fusion protein(497-515)),Synthetic construct(derived from RSV fusion protein),No entry found,,RSV,Paramyxoviridae,rHRSV-mCherry inhibition assay,[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=0.59±0.13 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00626,DRAVPe00626.cif,Cyclic,Acetylation,Free,"The 'X' at position 2 indicates R-pentenylalanine; The 'X' at position 5,8,12 indicates S-pentenylalanine, X(2) and X(5), X(8) and X(12) are cross-linked by hydrocarbon stapling.",L,membrane,The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry.,2344.46,C84H127N23O23,ACGKMPQTWY,X,4.65,2,3,-1,4,7,3.0,-3038,1 hour,30 min,>10 hour,112.0,0,0.0,28137809,Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.,"Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O.",A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.,10.1128/AAC.02241-16,,Anti-RSV
DRAVPe00627,XKINQSLXFIRXSDELLHXV,20,peptide 4ef(derived from RSV fusion protein(497-515)),Synthetic construct(derived from RSV fusion protein),No entry found,,RSV,Paramyxoviridae,rHRSV-mCherry inhibition assay,[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=3.07±1.45 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00627,DRAVPe00627.cif,Cyclic,Acetylation,Free,"The 'X' at position 1,8 indicates R-octenyl-alanine; The 'X' at position 12,19 indicates S-pentenylalanine, X(1) and X(8), X(12) and X(19) are cross-linked by hydrocarbon stapling.",L,membrane,The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry.,2357.54,C86H134N24O21,ACGMPTWY,X,6.75,3,2,1,3,7,1.0,-2802,,,,112.0,0,0.0,28137809,Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.,"Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O.",A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.,10.1128/AAC.02241-16,,Anti-RSV
DRAVPe00628,EKIXQSLXFIRXSDELLHXV,20,peptide 4bf(derived from RSV fusion protein(497-515)),Synthetic construct(derived from RSV fusion protein),No entry found,,RSV,Paramyxoviridae,rHRSV-mCherry inhibition assay,[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=2.49±0.09 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00628,DRAVPe00628.cif,Cyclic,Acetylation,Free,"The 'X' at position 12 indicates R-octenyl-alanine; The 'X' at position 4,8,19 indicates S-pentenylalanine, X(4) and X(8), X(12) and X(19) are cross-linked by hydrocarbon stapling.",L,membrane,The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry.,2372.55,C87H135N23O22,ACGMNPTWY,X,5.45,3,3,0,2,7,1.0,-2819,1 hour,30 min,>10 hour,112.0,0,0.0,28137809,Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.,"Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O.",A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.,10.1128/AAC.02241-16,,Anti-RSV
DRAVPe00629,EKIAQSLXFIRXSDXLLHXV,20,peptide 4a[N500A],Synthetic construct,No entry found,,RSV,Paramyxoviridae,rHRSV-mCherry inhibition assay,[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=20.41±2.4 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00629,DRAVPe00629.cif,Cyclic,Acetylation,Free,"The 'X' at position 8,12,15,19 indicates S-pentenylalanine, X(8) and X(12), X(15) and X(19) are cross-linked by hydrocarbon stapling.",L,membrane,The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry.,2314.52,C85H133N23O20,CGMNPTWY,X,6.85,3,2,1,2,8,27.5,-1957,1 hour,30 min,>10 hour,117.0,0,0.0,28137809,Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.,"Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O.",A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.,10.1128/AAC.02241-16,,Anti-RSV
DRAVPe00630,EKINQSLXFIAXSDXLLHXV,20,peptide 4a[R507A],Synthetic construct,No entry found,,RSV,Paramyxoviridae,rHRSV-mCherry inhibition assay,[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=175±0.00 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00630,DRAVPe00630.cif,Cyclic,Acetylation,Free,"The 'X' at position 8,12,15,19 indicates S-pentenylalanine, X(8) and X(12), X(15) and X(19) are cross-linked by hydrocarbon stapling.",L,membrane,The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry.,2272.43,C83H127N21O21,CGMPRTWY,X,5.32,2,2,0,3,8,32.5,-1129,1 hour,30 min,>10 hour,117.0,0,0.0,28137809,Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.,"Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O.",A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.,10.1128/AAC.02241-16,,Anti-RSV
DRAVPe00631,AKIXQSLXFIXKSDXLLHNV,20,peptide 4bb[E497A],Synthetic construct,No entry found,,RSV,Paramyxoviridae,rHRSV-mCherry inhibition assay,[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=1.16±0.08 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00631,DRAVPe00631.cif,Cyclic,Acetylation,Free,"The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling.",L,membrane,The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry.,2271.49,C84H132N22O19,CEGMPRTWY,X,8.64,3,1,2,3,8,30.5,-1003,4.4 hour,>20 hour,>10 hour,117.0,0,0.0,28137809,Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.,"Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O.",A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.,10.1128/AAC.02241-16,,Anti-RSV
DRAVPe00632,EAIXQSLXFIXKSDXLLHNV,20,peptide 4bb[K498A],Synthetic construct,No entry found,,RSV,Paramyxoviridae,rHRSV-mCherry inhibition assay,[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=0.60±0.02 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00632,DRAVPe00632.cif,Cyclic,Acetylation,Free,"The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling.",L,membrane,The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry.,2272.43,C83H127N21O21,CGMPRTWY,X,5.32,2,2,0,3,8,32.5,-1129,1 hour,30 min,>10 hour,117.0,0,0.0,28137809,Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.,"Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O.",A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.,10.1128/AAC.02241-16,,Anti-RSV
DRAVPe00633,EKAXQSLXFIXKSDXLLHNV,20,peptide 4bb[I499A],Synthetic construct,No entry found,,RSV,Paramyxoviridae,rHRSV-mCherry inhibition assay,[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=1.30±0.89 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00633,DRAVPe00633.cif,Cyclic,Acetylation,Free,"The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling.",L,membrane,The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry.,2287.45,C83H128N22O21,CGMPRTWY,X,6.85,3,2,1,3,7,-9.5,-2176,1 hour,30 min,>10 hour,97.5,0,0.0,28137809,Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.,"Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O.",A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.,10.1128/AAC.02241-16,,Anti-RSV
DRAVPe00634,EKIXASLXFIXKSDXLLHNV,20,peptide 4bb[Q501A],Synthetic construct,No entry found,,RSV,Paramyxoviridae,rHRSV-mCherry inhibition assay,[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=0.28±0.43 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00634,DRAVPe00634.cif,Cyclic,Acetylation,Free,"The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling.",L,membrane,The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry.,2272.48,C84H131N21O20,CGMPQRTWY,X,6.85,3,2,1,3,8,30.5,-1130,1 hour,30 min,>10 hour,117.0,0,0.0,28137809,Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.,"Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O.",A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.,10.1128/AAC.02241-16,,Anti-RSV
DRAVPe00635,EKIXQALXFIXKSDXLLHNV,20,peptide 4bb[S502A],Synthetic construct,No entry found,,RSV,Paramyxoviridae,rHRSV-mCherry inhibition assay,[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=0.66±0.26 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00635,DRAVPe00635.cif,Cyclic,Acetylation,Free,"The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling.",L,membrane,The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry.,2313.53,C86H134N22O20,CGMPRTWY,X,6.85,3,2,1,2,8,17.0,-1344,1 hour,30 min,>10 hour,117.0,0,0.0,28137809,Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.,"Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O.",A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.,10.1128/AAC.02241-16,,Anti-RSV
DRAVPe00636,EKIXQSAXFIXKSDXLLHNV,20,peptide 4bb[L503A],Synthetic construct,No entry found,,RSV,Paramyxoviridae,rHRSV-mCherry inhibition assay,[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=0.95±0.53 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00636,DRAVPe00636.cif,Cyclic,Acetylation,Free,"The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling.",L,membrane,The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry.,2287.45,C83H128N22O21,CGMPRTWY,X,6.85,3,2,1,3,7,-6.0,-2176,1 hour,30 min,>10 hour,97.5,0,0.0,28137809,Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.,"Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O.",A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.,10.1128/AAC.02241-16,,Anti-RSV
DRAVPe00637,EKIXQSLXAIXKSDXLLHNV,20,peptide 4bb[F505A],Synthetic construct,No entry found,,RSV,Paramyxoviridae,rHRSV-mCherry inhibition assay,[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=1.39±0.10 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00637,DRAVPe00637.cif,Cyclic,Acetylation,Free,"The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling.",L,membrane,The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry.,2253.43,C80H130N22O21,CFGMPRTWY,X,6.85,3,2,1,3,7,-1.0,-1982,1 hour,30 min,>10 hour,117.0,0,0.0,28137809,Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.,"Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O.",A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.,10.1128/AAC.02241-16,,Anti-RSV
DRAVPe00638,EKIXQSLXFAXKSDXLLHNV,20,peptide 4bb[I506A],Synthetic construct,No entry found,,RSV,Paramyxoviridae,rHRSV-mCherry inhibition assay,[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=10.44±2.97 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00638,DRAVPe00638.cif,Cyclic,Acetylation,Free,"The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling.",L,membrane,The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry.,2287.45,C83H128N22O21,CGMPRTWY,X,6.85,3,2,1,3,7,-9.5,-2176,1 hour,30 min,>10 hour,97.5,0,0.0,28137809,Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.,"Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O.",A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.,10.1128/AAC.02241-16,,Anti-RSV
DRAVPe00639,EKIXQSLXFIXASDXLLHNV,20,peptide 4bb[K508A],Synthetic construct,No entry found,,RSV,Paramyxoviridae,rHRSV-mCherry inhibition assay,[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=10.93±13.90 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00639,DRAVPe00639.cif,Cyclic,Acetylation,Free,"The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling.",L,membrane,The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry.,2272.43,C83H127N21O21,CGMPRTWY,X,5.32,2,2,0,3,8,32.5,-1129,1 hour,30 min,>10 hour,117.0,0,0.0,28137809,Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.,"Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O.",A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.,10.1128/AAC.02241-16,,Anti-RSV
DRAVPe00640,EKIXQSLXFIXKADXLLHNV,20,peptide 4bb[S509A],Synthetic construct,No entry found,,RSV,Paramyxoviridae,rHRSV-mCherry inhibition assay,[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=82.04±1.56 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00640,DRAVPe00640.cif,Cyclic,Acetylation,Free,"The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling.",L,membrane,The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry.,2313.53,C86H134N22O20,CGMPRTWY,X,6.85,3,2,1,2,8,17.0,-1344,1 hour,30 min,>10 hour,117.0,0,0.0,28137809,Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.,"Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O.",A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.,10.1128/AAC.02241-16,,Anti-RSV
DRAVPe00641,EKIXQSLXFIXKSAXLLHNV,20,peptide 4bb[D510A],Synthetic construct,No entry found,,RSV,Paramyxoviridae,rHRSV-mCherry inhibition assay,[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=1.10±0.08 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00641,DRAVPe00641.cif,Cyclic,Acetylation,Free,"The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling.",L,membrane,The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry.,2285.52,C85H134N22O19,CDGMPRTWY,X,8.69,3,1,2,3,8,30.5,-812,1 hour,30 min,>10 hour,117.0,0,0.0,28137809,Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.,"Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O.",A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.,10.1128/AAC.02241-16,,Anti-RSV
DRAVPe00642,EKIXQSLXFIXKSDXALHNV,20,peptide 4bb[L512A],Synthetic construct,No entry found,,RSV,Paramyxoviridae,rHRSV-mCherry inhibition assay,[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=0.88±0.06 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00642,DRAVPe00642.cif,Cyclic,Acetylation,Free,"The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling.",L,membrane,The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry.,2287.45,C83H128N22O21,CGMPRTWY,X,6.85,3,2,1,3,7,-6.0,-2176,1 hour,30 min,>10 hour,97.5,0,0.0,28137809,Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.,"Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O.",A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.,10.1128/AAC.02241-16,,Anti-RSV
DRAVPe00643,EKIXQSLXFIXKSDXLLANV,20,peptide 4bb[H514A],Synthetic construct,No entry found,,RSV,Paramyxoviridae,rHRSV-mCherry inhibition assay,[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=0.52±0.07 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00643,DRAVPe00643.cif,Cyclic,Acetylation,Free,"The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling.",L,membrane,The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry.,2263.47,C83H132N20O21,CGHMPRTWY,X,6.17,2,2,0,3,8,29.0,-1218,1 hour,30 min,>10 hour,117.0,0,0.0,28137809,Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.,"Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O.",A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.,10.1128/AAC.02241-16,,Anti-RSV
DRAVPe00644,EKIXQSLXFIXKSDXLLHAV,20,peptide 4bb[N515A],Synthetic construct,No entry found,,RSV,Paramyxoviridae,rHRSV-mCherry inhibition assay,[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=2.71±2.93 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00644,DRAVPe00644.cif,Cyclic,Acetylation,Free,"The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling.",L,membrane,The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry.,2286.5,C85H133N21O20,CGMNPRTWY,X,6.85,3,2,1,2,8,30.5,-1020,1 hour,30 min,>10 hour,117.0,0,0.0,28137809,Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.,"Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O.",A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.,10.1128/AAC.02241-16,,Anti-RSV
DRAVPe00645,EKIXQSLXFIXKSDXLLHNA,20,peptide 4bb[V516A],Synthetic construct,No entry found,,RSV,Paramyxoviridae,rHRSV-mCherry inhibition assay,[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=0.60±0.03 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00645,DRAVPe00645.cif,Cyclic,Acetylation,Free,"The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling.",L,membrane,The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry.,2301.47,C84H130N22O21,CGMPRTVWY,X,6.85,3,2,1,3,7,-8.0,-2088,1 hour,30 min,>10 hour,102.5,0,0.0,28137809,Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.,"Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O.",A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.,10.1128/AAC.02241-16,,Anti-RSV
DRAVPe00646,EXINXSLXFIRXSDALLHNV,20,peptide 4ca[E511A],Synthetic construct,No entry found,,RSV,Paramyxoviridae,rHRSV-mCherry inhibition assay,[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=1.00±0.03 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00646,DRAVPe00646.cif,Cyclic,Acetylation,Free,"The 'X' at position 2 indicates R-pentenylalanine; The 'X' at position 5,8,12 indicates S-pentenylalanine, X(2) and X(5), X(8) and X(12) are cross-linked by hydrocarbon stapling.",L,membrane,The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry.,2286.42,C82H125N23O21,CGKMPQTWY,X,5.32,2,2,0,4,8,29.5,-2176,1 hour,30 min,>10 hour,117.0,0,0.0,28137809,Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16.,"Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O.",A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.,10.1128/AAC.02241-16,,Anti-RSV
DRAVPe00647,YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF,36,ENF (T-20),Synthetic construct,P04578,,"HIV,SIV",Retroviridae,"MAGI/cMAGI infectivity assay,neutralization assay","[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.006 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.050 μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.526 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=54.958 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=47.822 μg/ml).##[Ref.31228294]HIV-1 N43:inhibition of virus infection in U87 cells(IC50=0.37 µg/ml);##HIV-1 JRCSF:inhibition of virus infection in U87 cells(IC50=0.09 µg/ml);##HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells(IC50=0.03 µg/ml);##HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells(IC50=0.30 µg/ml);##HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells(IC50=0.03 µg/ml);##HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells(IC50=0.02 µg/ml);##HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells(IC50=3.58 µg/ml).##[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=24633±2467 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=10825±1354 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=4503±384 pM);##HIV-1(3 A, 13 B, 7 C, 1 G, 1 A/C, 5 A/E, 6 B/C pseudovirus subtypes):inhibition of pseudovirus infection in TZM-bl cells(IC50=34858 pM);##T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells(IC50=9.12 nM);##T-20 resistant HIV-1 NL4-3(WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T):inhibition of virus infection in TZM-bl cells(IC50=90.18-2250 nM);##HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells(IC50=263.68-829.01 nM);##SIV(239,PBJ):inhibition of virus infection in TZM-bl cells(IC50=490.8-648.49 nM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30089693]TZM-bl cell:CC50=157.87 ± 8.79 μM;##MT-4 cell:CC50=171.73± 23.13 μM;##HEK293T cell:CC50=216.23± 33.08 μM;##PBMC:CC50=81.23± 4.59 μM.,DRAVPe00647,DRAVPe00647.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.",4450.88,C202H298N50O64,CGMPRV,EL,4.3,3,7,-4,9,13,-87.5,-7259,2.8 hour,10 min,2 min,89.44,17990,514.0,17640899##31228294##30089693,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. ##Protein Sci. 2019 Aug;28(8):1501-1512.##J Virol. 2018 Sep 26;92(20):e01088-18.,"Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.##Chen G, Cook JD, Ye W, Lee JE, Sidhu SS.##Chong H, Zhu Y, Yu D, He Y.","Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.##Optimization of peptidic HIV-1 fusion inhibitor T20 by phage display.##Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1073/pnas.0701478104##10.1002/pro.3669##10.1128/JVI.01088-18,,"Anti-HIV,Anti-SIV"
DRAVPe00648,YTSLIHSLIEESQNQQEKNEQELLEX,26,LP-53,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=2949±400 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=9968±2224 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=21352±1876 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00648,DRAVPe00648.cif,Linear,Acetylation,Amidation,The 'X' at position 26 is Lys-C16(palmitic acid),L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3114.56,C128H202N34O48,ACDFGMPRVW,E,4.2,2,6,-4,7,6,-112.69,-6990,2.8 hour,10 min,2 min,90.0,1490,59.6,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00649,YTSLIEELIKKSEEQQKKNEEELKX,25,LP-54,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=149±48 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=301±26 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=1796±340 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00649,DRAVPe00649.cif,Linear,Acetylation,Amidation,The 'X' at position 25 is Lys-C16(palmitic acid),L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3048.62,C128H212N32O45,ACDFGHMPRVW,E,4.86,5,7,-2,5,5,-150.8,-7805,2.8 hour,10 min,2 min,78.0,1490,62.08,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00650,WEQKIEELLKKAEEQQKKNEEELKKX,26,LP-55,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay","[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=14±2 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=8±1 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=12±1 pM);##T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells(IC50<0.01 nM);##T-20 resistant HIV-1 NL4-3(WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T):inhibition of virus infection in TZM-bl cells(IC50=0.11-189.34 nM);##HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells(IC50=10.67-137.77 nM);##SIV(239,PBJ):inhibition of virus infection in TZM-bl cells(IC50=0.19-10.61 nM);##HIV-1(3 A, 13 B, 7 C, 1 G, 1 A/C, 5 A/E, 6 B/C pseudovirus subtypes):inhibition of pseudovirus infection in TZM-bl cells(IC50=34 pM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00650,DRAVPe00650.cif,Linear,Acetylation,Amidation,The 'X' at position 25 is Lys-C16(palmitic acid),L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3267.91,C139H229N37O45,CDFGHMPRSTVY,E,5.3,7,8,-1,1,6,-201.92,-9277,2.8 hour,3 min,2 min,63.85,5500,220.0,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00651,WEQKIEELLKKAEEQQKKNEEELKXX,26,LP-56,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=12±2 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=9±1 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=11±2 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00651,DRAVPe00651.cif,Linear,Acetylation,Amidation,"The 'X' at position 26 is Lys-C16(palmitic acid),The 'X' at position 25 is Lys-AEEA(8-amino-3,6-dioxaoctanoic acid)",L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3251.07,C133H215N35O43,CDFGHMPRSTVY,E,4.94,6,8,-2,1,6,-186.92,-8722,2.8 hour,3 min,2 min,63.85,5500,220.0,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00652,WEQKIEELLKKAEEQQKKNEEEX,23,LP-57,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=213±21 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=178±38 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=1917±440 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00652,DRAVPe00652.cif,Linear,Acetylation,Amidation,The 'X' at position 23 is Lys-C16(palmitic acid),L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",2898.41,C121H194N32O42,CDFGHMPRSTVY,E,4.69,5,8,-3,1,5,-210.87,-8659,2.8 hour,3 min,2 min,55.22,5500,250.0,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00653,WEQKIEELLKKAEEQQKKNEX,21,LP-58,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=143000±19911 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=110900±3715 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=107033±9473 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00653,DRAVPe00653.cif,Linear,Acetylation,Amidation,The 'X' at position 21 is Lys-C16(palmitic acid),L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",2640.18,C111H180N30O36,CDFGHMPRSTVY,E,5.16,5,6,-1,1,5,-197.62,-7297,2.8 hour,3 min,2 min,60.48,5500,275.0,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00654,WEQKIEELLKKAEEQQKX,18,LP-59,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50>900000 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=240800±23649 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=210477±25537 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00654,DRAVPe00654.cif,Linear,Acetylation,Amidation,The 'X' at position 18 is Lys-C16(palmitic acid),L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",2268.78,C96H155N25O30,CDFGHMNPRSTVY,E,5.07,4,5,-1,0,5,-170.0,-5397,2.8 hour,3 min,2 min,70.56,5500,323.53,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00655,SLIEELIKKSEEQQKKNEEELKKLEX,26,LP-60,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=55±6 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=48±6 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=62±27 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00655,DRAVPe00655.cif,Linear,Acetylation,Amidation,The 'X' at position 26 is Lys-C16(palmitic acid),L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3154.79,C132H226N34O46,ACDFGHMPRTVWY,E,4.94,6,8,-2,3,6,-151.15,-8278,1.9 hour,>20 hour,>10 hour,90.0,0,0.0,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00656,IEELIKKSEEQQKKNEEELKKLEX,24,LP-61,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay","[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=85±9 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=43±9 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=126±63 pM);##HIV-1(3 A, 13 B, 7 C, 1 G, 1 A/C, 5 A/E, 6 B/C pseudovirus subtypes):inhibition of pseudovirus infection in TZM-bl cells(IC50=144 pM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30089693]TZM-bl cell:CC50=193.63±13.92 μM;##MT-4 cell:CC50=164.47±37.69 μM;##HEK293T cell:CC50=140.43± 10.7μM;##PBMC:CC50=46.43± 2.6 μM.,DRAVPe00656,DRAVPe00656.cif,Linear,Acetylation,Amidation,The 'X' at position 24 is Lys-C16(palmitic acid),L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",2954.55,C123H210N32O43,ACDFGHMPRTVWY,E,4.94,6,8,-2,2,5,-176.25,-8430,20 hour,30 min,>10 hour,81.25,0,0.0,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00657,EQKIEELLKKAEEQQKKNEEELKKLEX,27,LP-62,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=15±1 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=5±1 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=12±1 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00657,DRAVPe00657.cif,Linear,Acetylation,Amidation,The 'X' at position 27 is Lys-C16(palmitic acid),L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3323.98,C139H237N37O48,CDFGHMPRSTVWY,E,5.0,7,9,-2,1,6,-190.0,-9699,1 hour,30 min,>10 hour,75.93,0,0.0,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00658,QKIEELLKKAEEQQKKNEEELKKLEX,26,LP-63,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=17±5 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=6±2 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=13±2 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00658,DRAVPe00658.cif,Linear,Acetylation,Amidation,The 'X' at position 26 is Lys-C16(palmitic acid),L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3194.86,C134H230N36O45,CDFGHMPRSTVWY,E,5.3,7,8,-1,1,6,-183.85,-9018,0.8 hour,10 min,>10 hour,78.85,0,0.0,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00659,KIEELLKKAEEQQKKNEEELKKLEX,25,LP-64,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay","[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=128±27 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=36±1 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=25±2 pM);##T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells(IC50=0.04 nM);##T-20 resistant HIV-1 NL4-3(WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T):inhibition of virus infection in TZM-bl cells(IC50=0.08-140.75 nM);##HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells(IC50=0.23-0.75 nM);##SIV(239,PBJ):inhibition of virus infection in TZM-bl cells(IC50=0.10-0.11 nM);##HIV-1(3 A, 13 B, 7 C, 1 G, 1 A/C, 5 A/E, 6 B/C pseudovirus subtypes):inhibition of pseudovirus infection in TZM-bl cells(IC50=58 pM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00659,DRAVPe00659.cif,Linear,Acetylation,Amidation,The 'X' at position 25 is Lys-C16(palmitic acid),L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3066.73,C129H222N34O43,CDFGHMPRSTVWY,E,5.3,7,8,-1,1,6,-177.2,-8464,1.3 hour,3 min,2 min,82.0,0,0.0,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00660,IEELLKKAEEQQKKNEEELKKLEX,24,LP-65,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay","[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=14±3 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=8±3 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=7±2 pM);##T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells(IC50<0.01 nM);##T-20 resistant HIV-1 NL4-3(WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T):inhibition of virus infection in TZM-bl cells(IC50=0.15-88.63 nM);##HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells(IC50=0.23-0.75 nM);##SIV(239,PBJ):inhibition of virus infection in TZM-bl cells(IC50=0.07-0.04 nM);##HIV-1(3 A, 13 B, 7 C, 1 G, 1 A/C, 5 A/E, 6 B/C pseudovirus subtypes):inhibition of pseudovirus infection in TZM-bl cells(IC50=35 pM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30089693]TZM-bl cell:CC50=256.23 ±14.58 μM;##MT-4 cell:CC50=213.4±59.59 μM;##HEK293T cell:CC50=208.43± 22.9μM;##PBMC:CC50=49.95± 2.97 μM.,DRAVPe00660,DRAVPe00660.cif,Linear,Acetylation,Amidation,The 'X' at position 24 is Lys-C16(palmitic acid),L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",2938.56,C123H210N32O42,CDFGHMPRSTVWY,E,4.94,6,8,-2,1,6,-168.33,-7909,20 hour,30 min,>10 hour,85.42,0,0.0,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00661,EELLKKAEEQQKKNEEELKKLEX,23,LP-66,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=1008±248 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=434±71 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=1109±193 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00661,DRAVPe00661.cif,Linear,Acetylation,Amidation,The 'X' at position 23 is Lys-C16(palmitic acid),L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",2825.4,C117H199N31O41,CDFGHIMPRSTVWY,E,4.94,6,8,-2,1,5,-195.22,-8401,1 hour,30 min,>10 hour,72.17,0,0.0,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00662,LLEQAEEQQKKNEEELKKLEX,21,LP-67,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=3417±419 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=627±154 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=1527±565 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00662,DRAVPe00662.cif,Linear,Acetylation,Amidation,The 'X' at position 21 is Lys-C16(palmitic acid),L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",2568.06,C105H176N28O38,CDFGHIMPRSTVWY,E,4.6,4,7,-3,1,5,-176.67,-7164,5.5 hour,3 min,2 min,79.05,0,0.0,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00663,AEEQQKKNEEELKKLEX,17,LP-68,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50>250000 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50>250000 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50>250000 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00663,DRAVPe00663.cif,Linear,Acetylation,Amidation,The 'X' at position 17 is Lys-C16(palmitic acid),L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",2084.5,C83H139N23O31,CDFGHIMPRSTVWY,E,4.77,4,6,-2,1,3,-221.76,-6913,4.4 hour,>20 hour,>10 hour,51.76,0,0.0,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00664,IEELLKKAEEQQKKNEEELKX,21,LP-69,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay","[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=239±16 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=125±27 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=157±29 pM);##T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells(IC50=0.31 nM);##T-20 resistant HIV-1 NL4-3(WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T):inhibition of virus infection in TZM-bl cells(IC50=2.01-1815.67 nM);##HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells(IC50=9.83-152.28 nM);##SIV(239,PBJ):inhibition of virus infection in TZM-bl cells(IC50=0.56-11.91 nM);##HIV-1(3 A, 13 B, 7 C, 1 G, 1 A/C, 5 A/E, 6 B/C pseudovirus subtypes):inhibition of pseudovirus infection in TZM-bl cells(IC50=1391 pM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00664,DRAVPe00664.cif,Linear,Acetylation,Amidation,The 'X' at position 21 is Lys-C16(palmitic acid),L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",2568.11,C106H180N28O37,CDFGHMPRSTVWY,E,4.86,5,7,-2,1,5,-175.24,-7165,20 hour,30 min,>10 hour,79.05,0,0.0,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00665,INNYTSLIEELIKKSEEQQKKNEEELKKLEX,31,LP-70,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=25±3 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=21±4 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=30±10 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00665,DRAVPe00665.cif,Linear,Acetylation,Amidation,The 'X' at position 31 is Lys-C16(palmitic acid),L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3760.44,C159H265N41O55,ACDFGHMPRVW,E,4.94,6,8,-2,7,7,-141.29,-9385,20 hour,30 min,>10 hour,88.06,1490,49.67,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00666,IEEYTKKIEEILKKSEEQQKKNEEELKKLEX,31,LP-71,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=27±2 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=25±3 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=55±5 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00666,DRAVPe00666.cif,Linear,Acetylation,Amidation,The 'X' at position 31 is Lys-C16(palmitic acid),L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3846.57,C164H275N41O56,ACDFGHMPRVW,E,5.06,8,10,-2,4,6,-176.13,-10681,20 hour,30 min,>10 hour,75.48,1490,49.67,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00667,VRYLEANIEELLKKAEEQQKKNEEELKKLEX,31,LP-72,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=23±3 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=28±1 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=24±9 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00667,DRAVPe00667.cif,Linear,Acetylation,Amidation,The 'X' at position 31 is Lys-C16(palmitic acid),L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3784.51,C161H269N43O53,CDFGHMPSTW,E,5.0,7,9,-2,3,9,-140.0,-9683,100 hour,>20 hour,>10 hour,91.29,1490,49.67,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00668,VEELEKKIEELLKKAEEQQKKNEEELKKLEX,31,LP-73,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=33±6 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=19±3 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=42±2 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00668,DRAVPe00668.cif,Linear,Acetylation,Amidation,The 'X' at position 31 is Lys-C16(palmitic acid),L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3794.54,C161H275N41O55,CDFGHMPRSTWY,E,4.88,8,11,-3,1,8,-163.55,-10166,100 hour,>20 hour,>10 hour,88.06,0,0.0,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00669,WEEWEKKIEEYTKKIEEILKKSEEQQKKNEEELKKLEX,38,LP-74,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=110±10 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=59±11 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=59±32 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00669,DRAVPe00669.cif,Linear,Acetylation,Amidation,The 'X' at position 38 is Lys-C16(palmitic acid),L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",4862.7,C213H340N52O69,ACDFGHMPRV,E,4.98,10,13,-3,4,8,-196.58,-13368,2.8 hour,3 min,2 min,61.58,12490,337.57,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00670,EMTWEEWEKKIEEYTKKIEEILKKSEEQQKKNEEELKKLEX,41,LP-75,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=100±22 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=65±8 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=86±26 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00670,DRAVPe00670.cif,Linear,Acetylation,Amidation,The 'X' at position 41 is Lys-C16(palmitic acid),L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",5224.11,C227H363N55O75S,ACDFGHPRV,E,4.85,10,14,-4,5,8,-187.8,-14071,1 hour,30 min,>10 hour,57.07,12490,312.25,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00671,WQEWEQKITALLEQAQIQQEKNEYELQKLDKX,32,LP-46,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=88±4 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=50±8 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=44±7 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00671,DRAVPe00671.cif,Linear,Acetylation,Amidation,The 'X' at position 31 is Lys-C16(palmitic acid).,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",4000.66,C174H269N45O55,CFGHMPRSV,Q,4.55,4,7,-3,3,10,-137.81,-8211,2.8 hour,3 min,2 min,79.38,12490,402.9,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00672,WEQKITALLEQAQIQQEKNEYELQKLDKX,29,LP-48,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=83±9 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=47±6 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=37±4 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00672,DRAVPe00672.cif,Linear,Acetylation,Amidation,The 'X' at position 28 is Lys-C16(palmitic acid).,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3557.2,C153H244N40O49,CFGHMPRSV,Q,4.72,4,6,-2,3,9,-124.83,-7209,2.8 hour,3 min,2 min,87.59,6990,249.64,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00673,WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLX,35,C34-C16,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=247±28 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=65±25 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=109±13 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00673,DRAVPe00673.cif,Linear,Acetylation,Amidation,The 'X' at position 35 is Lys-C16(palmitic acid).,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",4359.93,C184H278N50O63S,ACFGPV,E,4.21,3,8,-5,9,9,-123.43,-10170,2.8 hour,3 min,2 min,78.0,12490,367.35,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00674,WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLGSGX,38,C34-Chol,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=316±62 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=24±2 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=37±5 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00674,DRAVPe00674.cif,Linear,Acetylation,Amidation,The 'X' at position 38 is Cys-Chol(cholesterol),L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",4561.12,C191H289N53O67S,ACFPV,E,4.21,3,8,-5,12,9,-117.89,-10322,2.8 hour,3 min,2 min,71.84,12490,337.57,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00675,YTSLIHSLIEESQNQQEKNEQELLELDK,28,P-40,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50>2000 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50>2000 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50>2000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00675,DRAVPe00675.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3359.65,C144H232N38O54,ACFGMPRVW,E,4.3,3,7,-4,7,7,-117.5,-7925,2.8 hour,10 min,2 min,97.5,1490,55.19,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,DRAVPa0419,Anti-HIV
DRAVPe00676,YTSLIEELIKKSEEQQKKNEEELKKLEK,28,P-50,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=35.6±1.3 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=191.1±57.2 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=21.8±3 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00676,DRAVPe00676.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3435.92,C151H256N38O52,ACDFGHMPRVW,E,5.3,7,8,-1,5,6,-161.43,-9104,2.8 hour,10 min,2 min,83.57,1490,55.19,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00677,LEANIEELLKKAEEQQKKNEEELKKLEK,28,P-51,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=10.2±0.7 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=24.9±2.9 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=45.4±10.7 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00677,DRAVPe00677.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3382.86,C147H253N39O51,CDFGHMPRSTVWY,E,5.0,7,9,-2,2,8,-163.21,-9136,5.5 hour,3 min,2 min,90.71,0,0.0,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00678,WEQKIEELLKKAEEQQKKNEEELKKLEK,28,P-52,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay","[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=0.9±0.1 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=1.9±0.6 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=1.9±0.4 nM);##HIV-1(3 A, 13 B, 7 C, 1 G, 1 A/C, 5 A/E, 6 B/C pseudovirus subtypes):inhibition of pseudovirus infection in TZM-bl cells(IC50=20541 pM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30089693]TZM-bl cell:CC50=916.6 ±42.46 μM;##MT-4 cell:CC50=770.63±131.46 μM;##HEK293T cell:CC50=649.07± 37.03μM;##PBMC:CC50=91.19± 20.46 μM.,DRAVPe00678,DRAVPe00678.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3527.03,C156H261N41O51,CDFGHMPRSTVY,E,5.36,8,9,-1,1,7,-200.36,-10021,2.8 hour,3 min,2 min,73.21,5500,203.7,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00679,YTSLIEELIKKSEEQQKKNEEELKK,25,P-54,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50>750 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50>750 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50>750 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00679,DRAVPe00679.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3065.47,C134H226N34O47,ACDFGHMPRVW,E,5.24,6,7,-1,5,5,-166.4,-8360,2.8 hour,10 min,2 min,78.0,1490,62.08,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00680,WEQKIEELLKKAEEQQKKNEEELKK,25,P-55,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=14.2±1.8 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=16.9±2 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=32.3±9.9 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00680,DRAVPe00680.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3156.58,C139H231N37O46,CDFGHMPRSTVY,E,5.3,7,8,-1,1,6,-210.0,-9277,2.8 hour,3 min,2 min,66.4,5500,229.17,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00681,WEQKIEELLKKAEEQQKKNEEEK,23,P-57,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50>750 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50>750 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50>750 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00681,DRAVPe00681.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",2915.25,C127H208N34O44,CDFGHMPRSTVY,E,4.94,6,8,-2,1,5,-227.83,-9214,2.8 hour,3 min,2 min,55.22,5500,250.0,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00682,WEQKIEELLKKAEEQQKKNEK,21,P-58,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50>750 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50>750 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50>750 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00682,DRAVPe00682.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",2657.02,C117H194N32O38,CDFGHMPRSTVY,EK,6.38,6,6,0,1,5,-216.19,-7852,2.8 hour,3 min,2 min,60.48,5500,275.0,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00683,WEQKIEELLKKAEEQQKK,18,P-59,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50>750 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50>750 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50>750 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00683,DRAVPe00683.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",2285.63,C102H169N27O32,CDFGHMNPRSTVY,EK,6.34,5,5,0,0,5,-191.67,-5952,2.8 hour,3 min,2 min,70.56,5500,323.53,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00684,SLIEELIKKSEEQQKKNEEELKKLEK,26,P-60,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50>750 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=591.4±65.2 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50>750 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00684,DRAVPe00684.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3171.64,C138H240N36O48,ACDFGHMPRTVWY,E,5.29,7,8,-1,3,6,-166.15,-8833,1.9 hour,>20 hour,>10 hour,90.0,0,0.0,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00685,EQKIEELLKKAEEQQKKNEEELKKLEK,27,P-62,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=25.3±2.6 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=44.2±2.6 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=22.1±3.9 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00685,DRAVPe00685.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3340.82,C145H251N39O50,CDFGHMPRSTVWY,E,5.36,8,9,-1,1,6,-204.44,-10254,1 hour,30 min,>10 hour,75.93,0,0.0,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00686,QKIEELLKKAEEQQKKNEEELKKLEK,26,P-63,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=16.1±2.5 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=24±2.2 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=24.4±2.8 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00686,DRAVPe00686.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3211.7,C140H244N38O47,CDFGHMPRSTVWY,EK,6.44,8,8,0,1,6,-198.85,-9573,0.8 hour,10 min,>10 hour,78.85,0,0.0,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00687,KIEELLKKAEEQQKKNEEELKKLEK,25,P-64,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=7.6±1.3 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=9.3±0.6 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=10.4±2.8 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00687,DRAVPe00687.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3083.57,C135H236N36O45,CDFGHMPRSTVWY,EK,6.44,8,8,0,1,6,-192.8,-9019,1.3 hour,3 min,2 min,82.0,0,0.0,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00688,IEELLKKAEEQQKKNEEELKKLEK,24,P-65,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=17.9±2.2 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=25.7±1.3 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=25.8±1.9 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00688,DRAVPe00688.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",2955.4,C129H224N34O44,CDFGHMPRSTVWY,E,5.3,7,8,-1,1,6,-184.58,-8464,20 hour,30 min,>10 hour,85.42,0,0.0,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00689,IEELLKKAEEQQKKNEEELKK,21,P-69,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50>7508 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50>750 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50>750 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00689,DRAVPe00689.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",2584.95,C112H194N30O39,CDFGHMPRSTVWY,E,5.24,6,7,-1,1,5,-193.81,-7720,20 hour,30 min,>10 hour,79.05,0,0.0,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00690,INNYTSLIEELIKKSEEQQKKNEEELKKLEK,31,P-70,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=8.5±0.5 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=36.5±6.4 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=49.7±5.7 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00690,DRAVPe00690.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3777.28,C165H279N43O57,ACDFGHMPRVW,E,5.3,7,8,-1,7,7,-153.87,-9940,20 hour,30 min,>10 hour,88.06,1490,49.67,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00691,IEEYTKKIEEILKKSEEQQKKNEEELKKLEK,31,P-71,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=2.1±0.2 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=9.1±3.2 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=38.7±7.6 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00691,DRAVPe00691.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3863.42,C170H289N43O58,ACDFGHMPRVW,E,5.41,9,10,-1,4,6,-188.71,-11236,20 hour,30 min,>10 hour,75.48,1490,49.67,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00692,VRYLEANIEELLKKAEEQQKKNEEELKKLEK,31,P-72,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=4.1±0.9 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=16.2±3.4 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=15.9±1.2 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00692,DRAVPe00692.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3801.35,C167H283N45O55,CDFGHMPSTW,E,5.36,8,9,-1,3,9,-152.58,-10238,100 hour,>20 hour,>10 hour,91.29,1490,49.67,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00693,VEELEKKIEELLKKAEEQQKKNEEELKKLEK,31,P-73,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=2±0.2 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=5.6±0.7 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=8.2±1.3 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00693,DRAVPe00693.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3811.39,C167H289N43O57,CDFGHMPRSTWY,E,5.11,9,11,-2,1,8,-176.13,-10721,100 hour,>20 hour,>10 hour,88.06,0,0.0,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00694,WEEWEKKIEEYTKKIEEILKKSEEQQKKNEEELKKLEK,38,P-74,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=0.4±0.1 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=0.8±0.1 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=1.4±0.4 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00694,DRAVPe00694.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",4879.54,C219H354N54O71,ACDFGHMPRV,E,5.19,11,13,-2,4,8,-206.84,-13923,2.8 hour,3 min,2 min,61.58,12490,337.57,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00695,EMTWEEWEKKIEEYTKKIEEILKKSEEQQKKNEEELKKLEK,41,P-75,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=0.4±0.1 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=0.9±0.2 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=0.6±0.1 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00695,DRAVPe00695.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",5240.95,C233H377N57O77S,ACDFGHPRV,E,5.02,11,14,-3,5,8,-197.32,-14626,1 hour,30 min,>10 hour,57.07,12490,312.25,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00696,ILPWKWPWWPWRR,13,Indolicidin (Cathelicidin-4),Bos taurus (Bovine),P33046##A3KN14,1G8C##1G89,"HSV,HIV","Herpesviridae, Retroviridae",HIV-1 integrase inhibition assay,[Ref.15081088]Herpes simplex virus type 1 (HSV-1):inhibition of HSV-1 infection in Vero cells(EC50=28.68 μM);##Herpes simplex virus type 2 (HSV-2):inhibition of HSV-2 infection in Vero cells(EC50=5.00 μM).##[Ref.15482931]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=60 µM);inhibition of strand transfer catalyzed by integrase(IC50=57 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.15081088]Vero cells:CC50>100 μM.,DRAVPe00696,DRAVPe00696.cif,Linear,Free,Amidtion,,L,HIV Integrase,The HIV-1 integrase plays a crucial role in the HIV-1 virus replication cycle. The peptide can inhibit the activity of integrase and thus inhibit virus replication.,1907.3,C100H131N25O14,ACDEFGHMNQSTVY,W,12.01,3,0,3,0,7,-106.92,-1390,20 hour,30 min,>10 hour,60.0,27500,2291.67,15081088##15482931, Int J Antimicrob Agents. 2004 Apr;23(4):382-9.##Bioorg Med Chem Lett. 2004 Nov 15;14(22):5595-8.,"Albiol Matanic VC, Castilla V.##Krajewski K, Marchand C, Long YQ, Pommier Y, Roller PP. ",Antiviral activity of antimicrobial cationic peptides against Junin virus and herpes simplex virus.##Synthesis and HIV-1 integrase inhibitory activity of dimeric and tetrameric analogs of indolicidin.,10.1016/j.ijantimicag.2003.07.022##10.1016/j.bmcl.2004.08.061,,"Anti-HSV,Anti-HIV"
DRAVPe00697,ILPWKWPWWPWPP,13,Indolicidin [R12P][R13P],Synthetic construct(derived from Indolicidin),No entry found,,HIV,Retroviridae,HIV-1 integrase inhibition assay,[Ref.15482931]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=16 µM);inhibition of strand transfer catalyzed by integrase(IC50=13 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00697,DRAVPe00697.cif,Linear,Free,Amidtion,,L,HIV Integrase,The HIV-1 integrase plays a crucial role in the HIV-1 virus replication cycle. The peptide can inhibit the activity of integrase and thus inhibit virus replication.,1789.16,C98H121N19O14,ACDEFGHMNQRSTVY,PW,8.75,1,0,1,0,7,-62.31,1594,20 hour,30 min,>10 hour,60.0,27500,2291.67,15482931,Bioorg Med Chem Lett. 2004 Nov 15;14(22):5595-8.,"Krajewski K, Marchand C, Long YQ, Pommier Y, Roller PP. ",Synthesis and HIV-1 integrase inhibitory activity of dimeric and tetrameric analogs of indolicidin.,10.1016/j.bmcl.2004.08.061,,Anti-HIV
DRAVPe00698,LPWKWPWWPWPP,12,Indolicidin (2-13)[R12P][R13P],Synthetic construct(derived from Indolicidin),No entry found,,HIV,Retroviridae,HIV-1 integrase inhibition assay,[Ref.15482931]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=185 µM);inhibition of strand transfer catalyzed by integrase(IC50=215 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00698,DRAVPe00698.cif,Linear,Free,Amidtion,,L,HIV Integrase,The HIV-1 integrase plays a crucial role in the HIV-1 virus replication cycle. The peptide can inhibit the activity of integrase and thus inhibit virus replication.,1676.0,C92H110N18O13,ACDEFGHIMNQRSTVY,PW,8.75,1,0,1,0,6,-105.0,1102,5.5 hour,3 min,2 min,32.5,27500,2500.0,15482931,Bioorg Med Chem Lett. 2004 Nov 15;14(22):5595-8.,"Krajewski K, Marchand C, Long YQ, Pommier Y, Roller PP. ",Synthesis and HIV-1 integrase inhibitory activity of dimeric and tetrameric analogs of indolicidin.,10.1016/j.bmcl.2004.08.061,,Anti-HIV
DRAVPe00699,ILPWKWPWWPWP,12,Indolicidin (1-12)[R12P],Synthetic construct(derived from Indolicidin),No entry found,,HIV,Retroviridae,HIV-1 integrase inhibition assay,[Ref.15482931]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=180 µM);inhibition of strand transfer catalyzed by integrase(IC50=80 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00699,DRAVPe00699.cif,Linear,Free,Amidtion,,L,HIV Integrase,The HIV-1 integrase plays a crucial role in the HIV-1 virus replication cycle. The peptide can inhibit the activity of integrase and thus inhibit virus replication.,1692.04,C93H114N18O13,ACDEFGHMNQRSTVY,W,8.75,1,0,1,0,7,-54.17,1594,20 hour,30 min,>10 hour,65.0,27500,2500.0,15482931,Bioorg Med Chem Lett. 2004 Nov 15;14(22):5595-8.,"Krajewski K, Marchand C, Long YQ, Pommier Y, Roller PP. ",Synthesis and HIV-1 integrase inhibitory activity of dimeric and tetrameric analogs of indolicidin.,10.1016/j.bmcl.2004.08.061,,Anti-HIV
DRAVPe00700,ILPWGWPWWPWPP,13,Indolicidin [K5G;R12P;R13P],Synthetic construct(derived from Indolicidin),No entry found,,HIV,Retroviridae,HIV-1 integrase inhibition assay,[Ref.15482931]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50>333 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00700,DRAVPe00700.cif,Linear,Free,Amidtion,,L,HIV Integrase,The HIV-1 integrase plays a crucial role in the HIV-1 virus replication cycle. The peptide can inhibit the activity of integrase and thus inhibit virus replication.,1718.04,C94H112N18O14,ACDEFHKMNQRSTVY,PW,5.52,0,0,0,1,7,-35.38,2243,20 hour,30 min,>10 hour,60.0,27500,2291.67,15482931,Bioorg Med Chem Lett. 2004 Nov 15;14(22):5595-8.,"Krajewski K, Marchand C, Long YQ, Pommier Y, Roller PP. ",Synthesis and HIV-1 integrase inhibitory activity of dimeric and tetrameric analogs of indolicidin.,10.1016/j.bmcl.2004.08.061,,Anti-HIV
DRAVPe00701,ILPWGWPWWPWRR,13,Indolicidin [K5G],Synthetic construct(derived from Indolicidin),No entry found,,HIV,Retroviridae,HIV-1 integrase inhibition assay,[Ref.15482931]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=49 µM);inhibition of strand transfer catalyzed by integrase(IC50=19 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00701,DRAVPe00701.cif,Linear,Free,Amidtion,,L,HIV Integrase,The HIV-1 integrase plays a crucial role in the HIV-1 virus replication cycle. The peptide can inhibit the activity of integrase and thus inhibit virus replication.,1836.18,C96H122N24O14,ACDEFHKMNQSTVY,W,12.0,2,0,2,1,7,-80.0,-741,20 hour,30 min,>10 hour,60.0,27500,2291.67,15482931,Bioorg Med Chem Lett. 2004 Nov 15;14(22):5595-8.,"Krajewski K, Marchand C, Long YQ, Pommier Y, Roller PP. ",Synthesis and HIV-1 integrase inhibitory activity of dimeric and tetrameric analogs of indolicidin.,10.1016/j.bmcl.2004.08.061,,Anti-HIV
DRAVPe00702,ILAWKWAWWAWPP,13,"Indolicidin [P3,7,10A,R12,13P]",Synthetic construct(derived from Indolicidin),No entry found,,HIV,Retroviridae,HIV-1 integrase inhibition assay,[Ref.15482931]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=54 µM);inhibition of strand transfer catalyzed by integrase(IC50=41 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00702,DRAVPe00702.cif,Linear,Free,Amidtion,,L,HIV Integrase,The HIV-1 integrase plays a crucial role in the HIV-1 virus replication cycle. The peptide can inhibit the activity of integrase and thus inhibit virus replication.,1711.04,C92H115N19O14,CDEFGHMNQRSTVY,W,8.75,1,0,1,0,10,16.15,2137,20 hour,30 min,>10 hour,83.08,27500,2291.67,15482931,Bioorg Med Chem Lett. 2004 Nov 15;14(22):5595-8.,"Krajewski K, Marchand C, Long YQ, Pommier Y, Roller PP. ",Synthesis and HIV-1 integrase inhibitory activity of dimeric and tetrameric analogs of indolicidin.,10.1016/j.bmcl.2004.08.061,,Anti-HIV
DRAVPe00703,LLEYSI,6,peptide 1 from hydrolysate of oyster,Crassostrea gigas(hydrolysate of oyster),No entry found,,HIV,Retroviridae,HIV-1 protease inhibition assay,[Ref.9918775]HIV-1:inhibition of HIV-1 protease(IC50=20 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00703,DRAVPe00703.cif,Linear,Free,Free,,L,HIV-1 protease,"The HIV-1 protease is a virally encoded protease that serves to cleave the gag and gag-pol polyprotein precursor into mature, functional proteins. This specific proteolysis occurs late in the viral life cycle and is essential for the maturation of the infectious virus. The peptide inhibits HIV-1 protease and thus acts antiviral activity.",736.86,C35H56N6O11,ACDFGHKMNPQRTVW,L,4.0,0,1,-1,2,3,108.33,441,5.5 hour,3 min,2 min,195.0,1490,298.0,9918775,Biochem Biophys Res Commun. 1998 Dec 30;253(3):604-8.,"Lee TG, Maruyama S. ",Isolation of HIV-1 protease-inhibiting peptides from thermolysin hydrolysate of oyster proteins.,10.1006/bbrc.1998.9824,,Anti-HIV
DRAVPe00704,LLEYSL,6,peptide 2 from hydrolysate of oyster,Crassostrea gigas(hydrolysate of oyster),No entry found,,HIV,Retroviridae,HIV-1 protease inhibition assay,[Ref.9918775]HIV-1:inhibition of HIV-1 protease(IC50=15 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00704,DRAVPe00704.cif,Linear,Free,Free,,L,HIV-1 protease,"The HIV-1 protease is a virally encoded protease that serves to cleave the gag and gag-pol polyprotein precursor into mature, functional proteins. This specific proteolysis occurs late in the viral life cycle and is essential for the maturation of the infectious virus. The peptide inhibits HIV-1 protease and thus acts antiviral activity.",736.86,C35H56N6O11,ACDFGHIKMNPQRTVW,L,4.0,0,1,-1,2,3,96.67,441,5.5 hour,3 min,2 min,195.0,1490,298.0,9918775,Biochem Biophys Res Commun. 1998 Dec 30;253(3):604-8.,"Lee TG, Maruyama S. ",Isolation of HIV-1 protease-inhibiting peptides from thermolysin hydrolysate of oyster proteins.,10.1006/bbrc.1998.9824,,Anti-HIV
DRAVPe00705,LLEYS,5,peptide derived from hydrolysate of oyster,Synthetic construct,No entry found,,HIV,Retroviridae,HIV-1 protease inhibition assay,[Ref.9918775]HIV-1:inhibition of HIV-1 protease(IC50=120 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00705,DRAVPe00705.cif,Linear,Free,Free,,L,HIV-1 protease,"The HIV-1 protease is a virally encoded protease that serves to cleave the gag and gag-pol polyprotein precursor into mature, functional proteins. This specific proteolysis occurs late in the viral life cycle and is essential for the maturation of the infectious virus. The peptide inhibits HIV-1 protease and thus acts antiviral activity.",623.7,C29H45N5O10,ACDFGHIKMNPQRTVW,L,4.0,0,1,-1,2,2,40.0,-51,5.5 hour,3 min,2 min,156.0,1490,372.5,9918775,Biochem Biophys Res Commun. 1998 Dec 30;253(3):604-8.,"Lee TG, Maruyama S. ",Isolation of HIV-1 protease-inhibiting peptides from thermolysin hydrolysate of oyster proteins.,10.1006/bbrc.1998.9824,,Anti-HIV
DRAVPe00706,LEYSI,5,peptide derived from hydrolysate of oyster,Synthetic construct,No entry found,,HIV,Retroviridae,HIV-1 protease inhibition assay,[Ref.9918775]HIV-1:inhibition of HIV-1 protease(IC50=550 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00706,DRAVPe00706.cif,Linear,Free,Free,,L,HIV-1 protease,"The HIV-1 protease is a virally encoded protease that serves to cleave the gag and gag-pol polyprotein precursor into mature, functional proteins. This specific proteolysis occurs late in the viral life cycle and is essential for the maturation of the infectious virus. The peptide inhibits HIV-1 protease and thus acts antiviral activity.",623.7,C29H45N5O10,ACDFGHKMNPQRTVW,EILSY,4.0,0,1,-1,2,2,54.0,-51,5.5 hour,3 min,2 min,156.0,1490,372.5,9918775,Biochem Biophys Res Commun. 1998 Dec 30;253(3):604-8.,"Lee TG, Maruyama S. ",Isolation of HIV-1 protease-inhibiting peptides from thermolysin hydrolysate of oyster proteins.,10.1006/bbrc.1998.9824,,Anti-HIV
DRAVPe00707,LLEY,4,peptide derived from hydrolysate of oyster,Synthetic construct,No entry found,,HIV,Retroviridae,HIV-1 protease inhibition assay,[Ref.9918775]HIV-1:inhibition of HIV-1 protease(IC50=5100 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00707,DRAVPe00707.cif,Linear,Free,Free,,L,HIV-1 protease,"The HIV-1 protease is a virally encoded protease that serves to cleave the gag and gag-pol polyprotein precursor into mature, functional proteins. This specific proteolysis occurs late in the viral life cycle and is essential for the maturation of the infectious virus. The peptide inhibits HIV-1 protease and thus acts antiviral activity.",536.63,C26H40N4O8,ACDFGHIKMNPQRSTVW,L,4.0,0,1,-1,1,2,70.0,289,5.5 hour,3 min,2 min,195.0,1490,496.67,9918775,Biochem Biophys Res Commun. 1998 Dec 30;253(3):604-8.,"Lee TG, Maruyama S. ",Isolation of HIV-1 protease-inhibiting peptides from thermolysin hydrolysate of oyster proteins.,10.1006/bbrc.1998.9824,,Anti-HIV
DRAVPe00708,LEYS,4,peptide derived from hydrolysate of oyster,Synthetic construct,No entry found,,HIV,Retroviridae,HIV-1 protease inhibition assay,[Ref.9918775]HIV-1:inhibition of HIV-1 protease(IC50=4800 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00708,DRAVPe00708.cif,Linear,Free,Free,,L,HIV-1 protease,"The HIV-1 protease is a virally encoded protease that serves to cleave the gag and gag-pol polyprotein precursor into mature, functional proteins. This specific proteolysis occurs late in the viral life cycle and is essential for the maturation of the infectious virus. The peptide inhibits HIV-1 protease and thus acts antiviral activity.",510.54,C23H34N4O9,ACDFGHIKMNPQRTVW,ELSY,4.0,0,1,-1,2,1,-45.0,-543,5.5 hour,3 min,2 min,97.5,1490,496.67,9918775,Biochem Biophys Res Commun. 1998 Dec 30;253(3):604-8.,"Lee TG, Maruyama S. ",Isolation of HIV-1 protease-inhibiting peptides from thermolysin hydrolysate of oyster proteins.,10.1006/bbrc.1998.9824,,Anti-HIV
DRAVPe00709,FVFLM,5,FM5,Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin),No entry found,,HIV,Retroviridae,,[Ref.22406118]HIV-1 IIIB:inhibition of virus replication(IC50>100 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00709,DRAVPe00709.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,655.85,C34H49N5O6S,ACDEGHIKNPQRSTWY,F,5.52,0,0,0,0,4,310.0,1727,1.1 hour,3 min,2 min,136.0,0,0.0,22406118,Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. ,"Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K.",Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity.,10.1016/j.bmcl.2012.02.037,,Anti-HIV
DRAVPe00710,PFVFLM,6,PM6,Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin),No entry found,,HIV,Retroviridae,,[Ref.22406118]HIV-1 IIIB:inhibition of virus replication(IC50>100 μM);inhibition of cell-cell fusion between H9/HIV-1IIIB cells and MT-2 cells(IC50>200 μM),No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00710,DRAVPe00710.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,752.97,C39H56N6O7S,ACDEGHIKNQRSTWY,F,5.96,0,0,0,0,4,231.67,1727,>20 hour,>20 hour,?,113.33,0,0.0,22406118,Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. ,"Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K.",Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity.,10.1016/j.bmcl.2012.02.037,,Anti-HIV
DRAVPe00711,KPFVFLM,7,KM7,Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin),No entry found,,HIV,Retroviridae,,[Ref.22406118]HIV-1 IIIB:inhibition of virus replication(IC50>100 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00711,DRAVPe00711.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,881.14,C45H68N8O8S,ACDEGHINQRSTWY,F,8.75,1,0,1,0,4,142.86,1172,1.3 hour,3 min,2 min,97.14,0,0.0,22406118,Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. ,"Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K.",Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity.,10.1016/j.bmcl.2012.02.037,,Anti-HIV
DRAVPe00712,NKPFVFLM,8,NM8,Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin),No entry found,,HIV,Retroviridae,,[Ref.22406118]HIV-1 IIIB:inhibition of virus replication(IC50>100 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00712,DRAVPe00712.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,995.25,C49H74N10O10S,ACDEGHIQRSTWY,F,8.75,1,0,1,1,4,81.25,508,1.4 hour,3 min,>10 hour,85.0,0,0.0,22406118,Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. ,"Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K.",Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity.,10.1016/j.bmcl.2012.02.037,,Anti-HIV
DRAVPe00713,PFVYLI,6,PI6,Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin),No entry found,,HIV,Retroviridae,,[Ref.22406118]HIV-1 IIIB:inhibition of virus replication(IC50>100 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00713,DRAVPe00713.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,750.94,C40H58N6O8,ACDEGHKMNQRSTW,FILPVY,5.95,0,0,0,1,4,206.67,1672,>20 hour,>20 hour,?,178.33,1490,298.0,22406118,Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. ,"Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K.",Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity.,10.1016/j.bmcl.2012.02.037,,Anti-HIV
DRAVPe00714,PFVFLE,6,PE6,Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin),No entry found,,HIV,Retroviridae,,[Ref.22406118]HIV-1 IIIB:inhibition of virus replication(IC50>100 μM);inhibition of cell-cell fusion between H9/HIV-1IIIB cells and MT-2 cells(IC50>200 μM),No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00714,DRAVPe00714.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,750.89,C39H54N6O9,ACDGHIKMNQRSTWY,F,4.0,0,1,-1,0,4,141.67,811,>20 hour,>20 hour,?,113.33,0,0.0,22406118,Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. ,"Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K.",Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity.,10.1016/j.bmcl.2012.02.037,,Anti-HIV
DRAVPe00715,EFVFLM,6,EM6,Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin),No entry found,,HIV,Retroviridae,,[Ref.22406118]HIV-1 IIIB:inhibition of virus replication(IC50>100 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00715,DRAVPe00715.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,784.97,C39H56N6O9S,ACDGHIKNPQRSTWY,F,4.0,0,1,-1,0,4,200.0,1046,1 hour,30 min,>10 hour,113.33,0,0.0,22406118,Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. ,"Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K.",Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity.,10.1016/j.bmcl.2012.02.037,,Anti-HIV
DRAVPe00716,PEVFLM,6,PEM6,Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin),No entry found,,HIV,Retroviridae,,[Ref.22406118]HIV-1 IIIB:inhibition of virus replication(IC50>100 μM);inhibition of cell-cell fusion between H9/HIV-1IIIB cells and MT-2 cells(IC50>200 μM),No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00716,DRAVPe00716.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,734.91,C35H54N6O9S,ACDGHIKNQRSTWY,EFLMPV,4.0,0,1,-1,0,3,126.67,748,>20 hour,>20 hour,?,113.33,0,0.0,22406118,Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. ,"Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K.",Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity.,10.1016/j.bmcl.2012.02.037,,Anti-HIV
DRAVPe00717,PFVFLR,6,PR6,Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin),No entry found,,HIV,Retroviridae,,[Ref.22406118]HIV-1 IIIB:inhibition of virus replication(IC50>100 μM);inhibition of cell-cell fusion between H9/HIV-1IIIB cells and MT-2 cells(IC50>200 μM),No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00717,DRAVPe00717.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,777.96,C40H59N9O7,ACDEGHIKMNQSTWY,F,10.18,1,0,1,0,4,125.0,0,>20 hour,>20 hour,?,113.33,0,0.0,22406118,Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. ,"Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K.",Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity.,10.1016/j.bmcl.2012.02.037,,Anti-HIV
DRAVPe00718,CPFVFLM,7,CPM,Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin),No entry found,,HIV,Retroviridae,,[Ref.22406118]HIV-1 IIIB:inhibition of virus replication(IC50=8.96 ± 2.23 μM);inhibition of cell-cell fusion between H9/HIV-1IIIB cells and MT-2 cells between H9/HIV-1IIIB cells and MT-2 cells(IC50=67.20 ± 4.05 μM);##HIV-1:inhibition of pseudovirus infection(IC50=5.95 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22406118]MT-2 cells:CC50>200 μM.,DRAVPe00718,DRAVPe00718.cif,Cyclic,Cyclization (N termini to C termini),Cyclization (N termini to C termini),,L,Not found,The cyclic peptide inhibited HIV-1 infection by blocking virus fusion with and entry into the target cells.,856.11,C42H61N7O8S2,ADEGHIKNQRSTWY,F,5.52,0,0,0,1,4,234.29,1855,1.2 hour,>20 hour,>10 hour,97.14,0,0.0,22406118,Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. ,"Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K.",Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity.,10.1016/j.bmcl.2012.02.037,,Anti-HIV
DRAVPe00719,CPFVFLE,7,CPE,Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin),No entry found,,HIV,Retroviridae,,[Ref.22406118]HIV-1 IIIB:inhibition of virus replication(IC50=55.84 ± 3.31μM);inhibition of cell-cell fusion between H9/HIV-1IIIB cells and MT-2 cells(IC50=115.58 ± 6.28 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22406118]MT-2 cells:CC50>200 μM.,DRAVPe00719,DRAVPe00719.cif,Cyclic,Cyclization (N termini to C termini),Cyclization (N termini to C termini),,L,Not found,The cyclic peptide inhibited HIV-1 infection by blocking virus fusion with and entry into the target cells.,854.03,C42H59N7O10S,ADGHIKMNQRSTWY,F,4.0,0,1,-1,1,4,157.14,939,1.2 hour,>20 hour,>10 hour,97.14,0,0.0,22406118,Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. ,"Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K.",Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity.,10.1016/j.bmcl.2012.02.037,,Anti-HIV
DRAVPe00720,CPFVFLR,7,CPR,Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin),No entry found,,HIV,Retroviridae,,[Ref.22406118]HIV-1 IIIB:inhibition of virus replication(IC50=74.07± 22.84 μM);inhibition of cell-cell fusion between H9/HIV-1IIIB cells and MT-2 cells(IC50=73.98 ± 7.44 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22406118]MT-2 cells:CC50>200 μM.,DRAVPe00720,DRAVPe00720.cif,Cyclic,Cyclization (N termini to C termini),Cyclization (N termini to C termini),,L,Not found,The cyclic peptide inhibited HIV-1 infection by blocking virus fusion with and entry into the target cells.,881.1,C43H64N10O8S,ADEGHIKMNQSTWY,F,8.25,1,0,1,1,4,142.86,128,1.2 hour,>20 hour,>10 hour,97.14,0,0.0,22406118,Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. ,"Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K.",Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity.,10.1016/j.bmcl.2012.02.037,,Anti-HIV
DRAVPe00721,CPEVFLM,7,CPEM,Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin),No entry found,,HIV,Retroviridae,,[Ref.22406118]HIV-1 IIIB:inhibition of virus replication(IC50>100 μM);inhibition of cell-cell fusion between H9/HIV-1IIIB cells and MT-2 cells(IC50>200 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22406118]MT-2 cells:CC50>200 μM.,DRAVPe00721,DRAVPe00721.cif,Cyclic,Cyclization (N termini to C termini),Cyclization (N termini to C termini),,L,Not found,The cyclic peptide inhibited HIV-1 infection by blocking virus fusion with and entry into the target cells.,838.05,C38H59N7O10S2,ADGHIKNQRSTWY,CEFLMPV,4.0,0,1,-1,1,3,144.29,876,1.2 hour,>20 hour,>10 hour,97.14,0,0.0,22406118,Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. ,"Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K.",Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity.,10.1016/j.bmcl.2012.02.037,,Anti-HIV
DRAVPe00722,IWNHGNITLGEWYNQTKDLQQKFYEIIMDIEQNNV,35,T1562(FIV envelope protein (724-758)),Synthetic construct(derived from FIV envelope protein),P16090,,FIV,Retroviridae,"plaque-forming assay,RT infectivity assay","[Ref.12186891]Feline immunodeficiency virus (FIV):inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells(EC50=0.318 μM,EC90=1.236 μM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00722,DRAVPe00722.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4296.78,C194H288N50O59S,ACPRS,IN,4.5,3,5,-2,11,11,-78.86,-6406,20 hour,30 min,>10 hour,86.29,13980,411.18,12186891,J Virol. 2002 Sep;76(18):9079-86.,"Medinas RJ, Lambert DM, Tompkins WA.",C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. ,10.1128/jvi.76.18.9079-9086.2002,,Anti-FIV
DRAVPe00723,WNHGNITLGEWYNQTKDLQQKFYEIIMDIEQNNVQ,35,T1568(FIV envelope protein (725-759)),Synthetic construct(derived from FIV envelope protein),P16090,,FIV,Retroviridae,"plaque-forming assay,RT infectivity assay","[Ref.12186891]Feline immunodeficiency virus (FIV):inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells(EC50=0.259 μM,EC90=0.971 μM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00723,DRAVPe00723.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4311.75,C193H285N51O60S,ACPRS,NQ,4.5,3,5,-2,11,10,-101.71,-7452,2.8 hour,3 min,2 min,75.14,13980,411.18,12186891,J Virol. 2002 Sep;76(18):9079-86.,"Medinas RJ, Lambert DM, Tompkins WA.",C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. ,10.1128/jvi.76.18.9079-9086.2002,,Anti-FIV
DRAVPe00724,GNITLGEWYNQTKDLQQKFYEIIMDIEQNNVQG,33,T1967(FIV envelope protein (728-760)),Synthetic construct(derived from FIV envelope protein),P16090,,"FIV,HIV",Retroviridae,"plaque-forming assay,RT infectivity assay","[Ref.12186891]Feline immunodeficiency virus (FIV):inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells(EC50=2.454 μM,EC90>2.518 μM);##HIV-1:inhibition of cell-cell fusion between CEM4/IIIb cells and MOLT4 cells(EC50=2.053 μM,EC90>2.518 μM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00724,DRAVPe00724.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3931.35,C174H265N45O57S,ACHPRS,Q,4.18,2,5,-3,11,9,-86.06,-6461,30 hour,>20 hour,>10 hour,79.7,8480,265.0,12186891,J Virol. 2002 Sep;76(18):9079-86.,"Medinas RJ, Lambert DM, Tompkins WA.",C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. ,10.1128/jvi.76.18.9079-9086.2002,,"Anti-FIV,Anti-HIV"
DRAVPe00725,NITLGEWYNQTKDLQQKFYEIIMDIEQNNVQGK,33,T1968(FIV envelope protein (729-761)),Synthetic construct(derived from FIV envelope protein),P16090,,"FIV,HIV",Retroviridae,"plaque-forming assay,RT infectivity assay","[Ref.12186891]Feline immunodeficiency virus (FIV):inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells(EC50=0.586 μM,EC90=2.067 μM);##HIV-1:inhibition of cell-cell fusion between CEM4/IIIb cells and MOLT4 cells(EC50>2.473 μM,EC90>2.473 μM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00725,DRAVPe00725.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4002.47,C178H274N46O57S,ACHPRS,Q,4.51,3,5,-2,10,9,-96.67,-7110,1.4 hour,3 min,>10 hour,79.7,8480,265.0,12186891,J Virol. 2002 Sep;76(18):9079-86.,"Medinas RJ, Lambert DM, Tompkins WA.",C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. ,10.1128/jvi.76.18.9079-9086.2002,,"Anti-FIV,Anti-HIV"
DRAVPe00726,ITLGEWYNQTKDLQQKFYEIIMDIEQNNVQGKKGI,35,T1569(FIV envelope protein (730-764)),Synthetic construct(derived from FIV envelope protein),P16090,,"FIV,HIV",Retroviridae,"plaque-forming assay,RT infectivity assay","[Ref.12186891]Feline immunodeficiency virus (FIV):inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells(EC50=0.026 μM,EC90=0.117 μM);inhibition of virus infection in FCD4-E cells(EC50=0.055 μM,EC90=0.106 μM);##HIV-1:inhibition of cell-cell fusion between CEM4/IIIb cells and MOLT4 cells(EC50>2.356 μM,EC90>2.356 μM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00726,DRAVPe00726.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4186.75,C188H294N48O58S,ACHPRS,IQ,4.94,4,5,-1,10,10,-80.57,-6415,20 hour,30 min,>10 hour,86.29,8480,249.41,12186891,J Virol. 2002 Sep;76(18):9079-86.,"Medinas RJ, Lambert DM, Tompkins WA.",C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. ,10.1128/jvi.76.18.9079-9086.2002,,"Anti-FIV,Anti-HIV"
DRAVPe00727,TLGEWYNQTKDLQQKFYEIIMDIEQNNVQGKKG,33,T1969(FIV envelope protein (731-763)),Synthetic construct(derived from FIV envelope protein),P16090,,FIV,Retroviridae,"plaque-forming assay,RT infectivity assay","[Ref.12186891]Feline immunodeficiency virus (FIV):inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells(EC50=0.435 μM,EC90=1.413 μM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00727,DRAVPe00727.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3960.43,C176H272N46O56S,ACHPRS,Q,4.93,4,5,-1,10,8,-112.73,-7399,7.2 hour,>20 hour,>10 hour,67.88,8480,265.0,12186891,J Virol. 2002 Sep;76(18):9079-86.,"Medinas RJ, Lambert DM, Tompkins WA.",C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. ,10.1128/jvi.76.18.9079-9086.2002,,Anti-FIV
DRAVPe00728,LGEWYNQTKDLQQKFYEIIMDIEQNNVQGKKGIQQ,35,T1577(FIV envelope protein (732-766)),Synthetic construct(derived from FIV envelope protein),P16090,,"FIV,HIV",Retroviridae,"plaque-forming assay,RT infectivity assay","[Ref.12186891]Feline immunodeficiency virus (FIV):inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells(EC50=0.050 μM,EC90=0.162 μM);inhibition of virus infection in FCD4-E cells(EC50=0.098 μM,EC90=0.177 μM);##HIV-1:inhibition of cell-cell fusion between CEM4/IIIb cells and MOLT4 cells(EC50=1.933 μM,EC90>2.342 μM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00728,DRAVPe00728.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4228.75,C188H292N50O59S,ACHPRS,Q,4.94,4,5,-1,9,9,-111.43,-7758,5.5 hour,3 min,2 min,75.14,8480,249.41,12186891,J Virol. 2002 Sep;76(18):9079-86.,"Medinas RJ, Lambert DM, Tompkins WA.",C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. ,10.1128/jvi.76.18.9079-9086.2002,,"Anti-FIV,Anti-HIV"
DRAVPe00729,GEWYNQTKDLQQKFYEIIMDIEQNNVQGKKGIQQL,35,T1971(FIV envelope protein (733-767)),Synthetic construct(derived from FIV envelope protein),P16090,,"FIV,HIV",Retroviridae,"plaque-forming assay,RT infectivity assay","[Ref.12186891]Feline immunodeficiency virus (FIV):inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells(EC50=0.012 μM,EC90=0.033 μM);##HIV-1:inhibition of cell-cell fusion between CEM4/IIIb cells and MOLT4 cells(EC50>2.342 μM,EC90>2.342 μM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12186891]No cytotoxic effects against HeLa cells at the concentration of 23 μM.,DRAVPe00729,DRAVPe00729.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4228.75,C188H292N50O59S,ACHPRS,Q,4.94,4,5,-1,9,9,-111.43,-7758,30 hour,>20 hour,>10 hour,75.14,8480,249.41,12186891,J Virol. 2002 Sep;76(18):9079-86.,"Medinas RJ, Lambert DM, Tompkins WA.",C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. ,10.1128/jvi.76.18.9079-9086.2002,,"Anti-FIV,Anti-HIV"
DRAVPe00730,EWYNQTKDLQQKFYEIIMDIEQNNVQGKKGIQQLQ,35,T1972(FIV envelope protein (734-768)),Synthetic construct(derived from FIV envelope protein),P16090,,"FIV,HIV",Retroviridae,"plaque-forming assay,RT infectivity assay","[Ref.12186891]Feline immunodeficiency virus (FIV):inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells(EC50=0.012 μM,EC90=0.054 μM);##HIV-1:inhibition of cell-cell fusion between CEM4/IIIb cells and MOLT4 cells(EC50>2.304 μM,EC90>2.304 μM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12186891]No cytotoxic effects against HeLa cells at the concentration of 23 μM.,DRAVPe00730,DRAVPe00730.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4299.82,C191H297N51O60S,ACHPRS,Q,4.94,4,5,-1,8,9,-120.29,-8406,1 hour,30 min,>10 hour,75.14,8480,249.41,12186891,J Virol. 2002 Sep;76(18):9079-86.,"Medinas RJ, Lambert DM, Tompkins WA.",C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. ,10.1128/jvi.76.18.9079-9086.2002,,"Anti-FIV,Anti-HIV"
DRAVPe00731,WYNQTKDLQQKFYEIIMDIEQNNVQGKKGIQQLQK,35,T1578(FIV envelope protein (735-769)),Synthetic construct(derived from FIV envelope protein),P16090,,FIV,Retroviridae,"plaque-forming assay,RT infectivity assay","[Ref.12186891]Feline immunodeficiency virus (FIV):inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells(EC50=0.020 μM,EC90=0.090 μM);inhibition of virus infection in FCD4-E cells(EC50=0.053 μM,EC90=0.157 μM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00731,DRAVPe00731.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4298.88,C192H302N52O58S,ACHPRS,Q,8.3,5,4,1,8,9,-121.43,-8280,2.8 hour,3 min,2 min,75.14,8480,249.41,12186891,J Virol. 2002 Sep;76(18):9079-86.,"Medinas RJ, Lambert DM, Tompkins WA.",C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. ,10.1128/jvi.76.18.9079-9086.2002,,Anti-FIV
DRAVPe00732,YNQTKDLQQKFYEIIMDIEQNNVQGKKGIQQLQKW,35,T1588(FIV envelope protein (736-770)),Synthetic construct(derived from FIV envelope protein),P16090,,FIV,Retroviridae,"plaque-forming assay,RT infectivity assay","[Ref.12186891]Feline immunodeficiency virus (FIV):inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells(EC50=0.030 μM,EC90=0.125 μM);inhibition of virus infection in FCD4-E cells(EC50=0.168 μM,EC90=0.4236 μM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00732,DRAVPe00732.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4298.88,C192H302N52O58S,ACHPRS,Q,8.3,5,4,1,8,9,-121.43,-8280,2.8 hour,10 min,2 min,75.14,8480,249.41,12186891,J Virol. 2002 Sep;76(18):9079-86.,"Medinas RJ, Lambert DM, Tompkins WA.",C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. ,10.1128/jvi.76.18.9079-9086.2002,,Anti-FIV
DRAVPe00733,NQTKDLQQKFYEIIMDIEQNNVQGKKGIQQLQKWE,35,T1988(FIV envelope protein (737-771)),Synthetic construct(derived from FIV envelope protein),P16090,,"FIV,HIV",Retroviridae,"plaque-forming assay,RT infectivity assay","[Ref.12186891]Feline immunodeficiency virus (FIV):inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells(EC50=1.990 μM,EC90>2.322 μM);##HIV-1:inhibition of cell-cell fusion between CEM4/IIIb cells and MOLT4 cells(EC50>2.322 μM,EC90>2.322 μM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00733,DRAVPe00733.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4264.82,C188H300N52O59S,ACHPRS,Q,6.28,5,5,0,7,9,-127.71,-8947,1.4 hour,3 min,>10 hour,75.14,6990,205.59,12186891,J Virol. 2002 Sep;76(18):9079-86.,"Medinas RJ, Lambert DM, Tompkins WA.",C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. ,10.1128/jvi.76.18.9079-9086.2002,,"Anti-FIV,Anti-HIV"
DRAVPe00734,QTKDLQQKFYEIIMDIEQNNVQGKKGIQQLQKWED,35,T1989(FIV envelope protein (738-772)),Synthetic construct(derived from FIV envelope protein),P16090,,FIV,Retroviridae,"plaque-forming assay,RT infectivity assay","[Ref.12186891]Feline immunodeficiency virus (FIV):inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells(EC50>2.321 μM,EC90>2.321 μM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00734,DRAVPe00734.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4265.81,C188H299N51O60S,ACHPRS,Q,5.0,5,6,-1,6,9,-127.71,-9155,0.8 hour,10 min,>10 hour,75.14,6990,205.59,12186891,J Virol. 2002 Sep;76(18):9079-86.,"Medinas RJ, Lambert DM, Tompkins WA.",C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. ,10.1128/jvi.76.18.9079-9086.2002,,Anti-FIV
DRAVPe00735,TKDLQQKFYEIIMDIEQNNVQGKKGIQQLQKWEDW,35,T1589(FIV envelope protein (739-773)),Synthetic construct(derived from FIV envelope protein),P16090,,"FIV,HIV",Retroviridae,"plaque-forming assay,RT infectivity assay","[Ref.12186891]Feline immunodeficiency virus (FIV):inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells(EC50=1.145 μM,EC90>2.290 μM);##HIV-1:inhibition of cell-cell fusion between CEM4/IIIb cells and MOLT4 cells(EC50>2.321 μM,EC90>2.321 μM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00735,DRAVPe00735.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4323.89,C194H301N51O59S,ACHPRS,Q,4.99,5,6,-1,6,10,-120.29,-8368,7.2 hour,>20 hour,>10 hour,75.14,12490,367.35,12186891,J Virol. 2002 Sep;76(18):9079-86.,"Medinas RJ, Lambert DM, Tompkins WA.",C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. ,10.1128/jvi.76.18.9079-9086.2002,,"Anti-FIV,Anti-HIV"
DRAVPe00736,FYEIIMDIEQNNVQGKKGIQQLQKWEDWVGWIGNI,35,T1566(FIV envelope protein (746-780)),Synthetic construct(derived from FIV envelope protein),P16090,,FIV,Retroviridae,"plaque-forming assay,RT infectivity assay","[Ref.12186891]Feline immunodeficiency virus (FIV):inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells(EC50>2.346 μM,EC90>2.346 μM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00736,DRAVPe00736.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4221.8,C194H291N49O55S,ACHPRST,I,4.51,3,5,-2,8,13,-54.0,-4368,1.1 hour,3 min,2 min,94.57,17990,529.12,12186891,J Virol. 2002 Sep;76(18):9079-86.,"Medinas RJ, Lambert DM, Tompkins WA.",C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. ,10.1128/jvi.76.18.9079-9086.2002,,Anti-FIV
DRAVPe00737,XTWXEWDREINNYTSLIHSLIEESQNQQEKNEQELLE,37,T649v,Synthetic construct,P04582,,HIV,Retroviridae,luciferase assay,[Ref.20660316]HIV-1 HxB2:inhibition of virus infection in Cf2Th-CD4-CXCR4 cells(IC50=2.9±0.4 nM);##HIV-1 YU2:inhibition of virus infection in Cf2Th-CD4-CCR5 cells(IC50>3000 nM);##HIV-1 V38A/N42T:inhibition of virus infection in Cf2Th-CD4-CXCR4 cells(IC50=15.8±1.9 nM);##HIV-1 V38E/N42S:inhibition of virus infection in Cf2Th-CD4-CXCR4 cells(IC50=44.4±6.5 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00737,DRAVPe00737.cif,Cyclic,Free,Free,The 'X' at position 1 indicates Norleucine.,L,Not found,The peptide disrupts assembly of the six-helix bundle viral fusion apparatus by mimicking the heptad repeat 2 (HR2) oligomerization domain of the gp41 envelope glycoprotein.,4570.29,C188H281N51O66,ACFGMPV,E,4.14,3,9,-6,10,9,-133.24,-11343,,,,73.78,12490,346.94,20660316,Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14093-8.,"Bird GH, Madani N, Perry AF, Princiotto AM, Supko JG, He X, Gavathiotis E, Sodroski JG, Walensky LD. ",Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic.,10.1073/pnas.1002713107,,Anti-HIV
DRAVPe00738,XTWXEWDXEINNYTSLIHSLIEESQNQQEKNEQELLE,37,SAH-gp41(626-662)A,Synthetic construct,P04582,,HIV,Retroviridae,luciferase assay,[Ref.20660316]HIV-1 HxB2:inhibition of virus infection in Cf2Th-CD4-CXCR4 cells(IC50=2.1±0.3 nM);##HIV-1 YU2:inhibition of virus infection in Cf2Th-CD4-CCR5 cells(IC50=339±162 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00738,DRAVPe00738.cif,Cyclic,Free,Free,"The 'X' at position 1 indicates Norleucine,the 'X' at position 4,8 indicates S-2-(4'-pentenyl) alanine. X(4) and X (5) are cross-linked by hydrocarbon stapling.",L,Not found,The peptide disrupts assembly of the six-helix bundle viral fusion apparatus by mimicking the heptad repeat 2 (HR2) oligomerization domain of the gp41 envelope glycoprotein.,4525.44,C182H267N47O64,ACFGMPRV,E,3.93,2,9,-7,10,9,-121.08,-9851,,,,73.78,12490,346.94,20660316,Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14093-8.,"Bird GH, Madani N, Perry AF, Princiotto AM, Supko JG, He X, Gavathiotis E, Sodroski JG, Walensky LD. ",Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic.,10.1073/pnas.1002713107,,Anti-HIV
DRAVPe00739,XTWMEWDREINNYTSLIHSLIEESQNQXEKNXQELLE,37,SAH-gp41(626-662) B,Synthetic construct,P04582,,HIV,Retroviridae,luciferase assay,[Ref.20660316]HIV-1 HxB2:inhibition of virus infection in Cf2Th-CD4-CXCR4 cells(IC50=4.5±1.4 nM);##HIV-1 YU2:inhibition of virus infection in Cf2Th-CD4-CCR5 cells(IC50=1958±259 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00739,DRAVPe00739.cif,Cyclic,Free,Free,"The 'X' at position 1 indicates Norleucine,the 'X' at position 28,32 indicates S-2-(4'-pentenyl) alanine. X(28) and X (32) are cross-linked by hydrocarbon stapling.",L,Not found,The peptide disrupts assembly of the six-helix bundle viral fusion apparatus by mimicking the heptad repeat 2 (HR2) oligomerization domain of the gp41 envelope glycoprotein.,4555.57,C183H273N49O61S,ACFGPV,E,4.21,3,8,-5,10,9,-109.19,-9873,,,,73.78,12490,346.94,20660316,Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14093-8.,"Bird GH, Madani N, Perry AF, Princiotto AM, Supko JG, He X, Gavathiotis E, Sodroski JG, Walensky LD. ",Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic.,10.1073/pnas.1002713107,,Anti-HIV
DRAVPe00740,XTWXEWDXEINNYTSLIHSLIEESQNQXEKNXQELLE,37,"SAH-gp41(626-662) A,B",Synthetic construct,P04582,,HIV,Retroviridae,luciferase assay,[Ref.20660316]HIV-1 HxB2:inhibition of virus infection in Cf2Th-CD4-CXCR4 cells(IC50=2.5±0.2 nM);##HIV-1 YU2:inhibition of virus infection in Cf2Th-CD4-CCR5 cells(IC50=87±30 nM);##HIV-1 V38A/N42T:inhibition of virus infection in Cf2Th-CD4-CXCR4 cells(IC50=10.7±2.2 nM);##HIV-1 V38E/N42S:inhibition of virus infection in Cf2Th-CD4-CXCR4 cells(IC50=16.1±3.9 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00740,DRAVPe00740.cif,Cyclic,Free,Free,"The 'X' at position 1 indicates Norleucine,the 'X' at position 4,8.28,32 indicates S-2-(4'-pentenyl) alanine. X(4) and X (5),  X(28) and X (32) are cross-linked by hydrocarbon stapling.",L,Not found,The peptide disrupts assembly of the six-helix bundle viral fusion apparatus by mimicking the heptad repeat 2 (HR2) oligomerization domain of the gp41 envelope glycoprotein.,4490.85,C172H248N44O57,ACFGMPRV,E,3.99,2,8,-6,10,9,-102.16,-8616,,,,73.78,12490,346.94,20660316,Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14093-8.,"Bird GH, Madani N, Perry AF, Princiotto AM, Supko JG, He X, Gavathiotis E, Sodroski JG, Walensky LD. ",Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic.,10.1073/pnas.1002713107,,Anti-HIV
DRAVPe00741,AEEASKKAEEASKKAEEASKKAEEASKKAEEASKKXX,37,AAS,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,MERS-CoV S Protein-Mediated Cell–Cell Fusion Assay,[Ref.30192544]MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells(EC50=4.47±1.7 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30192544]Huh-7 cell:CC50=2.38±0.9 μM.,DRAVPe00741,DRAVPe00741.cif,Linear,Acetylation,Amidation,"The 'X' at 36 indicates β-alanine,the 'X' at 37 indicates Lys-C16(palmitic acid).",L,membrane,The peptide can interact with both MERS-CoV and IAV NHR trimeric coiled coils to prevent virus–cell membrane fusion.,3959.75,C155H263N45O59,CDFGHILMNPQRTVWY,AEK,6.53,10,10,0,5,10,-162.16,-12250,4.4 hour,>20 hour,>10 hour,27.03,0,0.0,30192544, J Med Chem. 2018 Oct 11;61(19):8734-8745.,"Wang C, Zhao L, Xia S, Zhang T, Cao R, Liang G, Li Y, Meng G, Wang W, Shi W, Zhong W, Jiang S, Liu K. ",De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. ,10.1021/acs.jmedchem.8b00890,,Anti-MERS-CoV
DRAVPe00742,VEEVSKKVEEVSKKVEEVSKKVEEVSKKVEEVSKKXX,37,VVS,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,MERS-CoV S Protein-Mediated Cell–Cell Fusion Assay,[Ref.30192544]MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells(EC50>10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30192544]Huh-7 cell:CC50=74.5±6.8 μM.,DRAVPe00742,DRAVPe00742.cif,Linear,Acetylation,Amidation,"The 'X' at 36 indicates β-alanine,the 'X' at 37 indicates Lys-C16(palmitic acid).",L,membrane,The peptide can interact with both MERS-CoV and IAV NHR trimeric coiled coils to prevent virus–cell membrane fusion.,4240.29,C175H303N45O59,ACDFGHILMNPQRTWY,EKV,6.46,10,10,0,5,10,-97.3,-10020,100 hour,>20 hour,>10 hour,78.38,0,0.0,30192544, J Med Chem. 2018 Oct 11;61(19):8734-8745.,"Wang C, Zhao L, Xia S, Zhang T, Cao R, Liang G, Li Y, Meng G, Wang W, Shi W, Zhong W, Jiang S, Liu K. ",De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. ,10.1021/acs.jmedchem.8b00890,,Anti-MERS-CoV
DRAVPe00743,FEEFSKKFEEFSKKFEEFSKKFEEFSKKFEEFSKKXX,37,FFS,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,MERS-CoV S Protein-Mediated Cell–Cell Fusion Assay,[Ref.30192544]MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells(EC50=3.11±0.9 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30192544]Huh-7 cell:CC50>100 μM.,DRAVPe00743,DRAVPe00743.cif,Linear,Acetylation,Amidation,"The 'X' at 36 indicates β-alanine,the 'X' at 37 indicates Lys-C16(palmitic acid).",L,membrane,The peptide can interact with both MERS-CoV and IAV NHR trimeric coiled coils to prevent virus–cell membrane fusion.,4720.73,C215H303N45O59,ACDGHILMNPQRTVWY,EFK,6.49,10,10,0,5,10,-135.14,-11080,1.1 hour,3 min,2 min,0.0,0,0.0,30192544, J Med Chem. 2018 Oct 11;61(19):8734-8745.,"Wang C, Zhao L, Xia S, Zhang T, Cao R, Liang G, Li Y, Meng G, Wang W, Shi W, Zhong W, Jiang S, Liu K. ",De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. ,10.1021/acs.jmedchem.8b00890,,Anti-MERS-CoV
DRAVPe00744,YEEYSKKYEEYSKKYEEYSKKYEEYSKKYEEYSKKXX,37,YYS,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,MERS-CoV S Protein-Mediated Cell–Cell Fusion Assay,[Ref.30192544]MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells(EC50=6.26±2.1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30192544]Huh-7 cell:CC50=19.8±1.6 μM.,DRAVPe00744,DRAVPe00744.cif,Linear,Acetylation,Amidation,"The 'X' at 36 indicates β-alanine,the 'X' at 37 indicates Lys-C16(palmitic acid).",L,membrane,The peptide can interact with both MERS-CoV and IAV NHR trimeric coiled coils to prevent virus–cell membrane fusion.,4880.72,C215H303N45O69,ACDFGHILMNPQRTVW,EKY,6.48,10,10,0,15,0,-245.95,-14200,2.8 hour,10 min,2 min,0.0,14900,413.89,30192544, J Med Chem. 2018 Oct 11;61(19):8734-8745.,"Wang C, Zhao L, Xia S, Zhang T, Cao R, Liang G, Li Y, Meng G, Wang W, Shi W, Zhong W, Jiang S, Liu K. ",De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. ,10.1021/acs.jmedchem.8b00890,,Anti-MERS-CoV
DRAVPe00745,LEELSKKLEELSKKLEELSKKLEELSKKLEELSKKXX,37,LLS,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,MERS-CoV S Protein-Mediated Cell–Cell Fusion Assay,[Ref.30192544]MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells(EC50=0.24±0.08 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30192544]Huh-7 cell:CC50=4.04±0.4 μM.,DRAVPe00745,DRAVPe00745.cif,Linear,Acetylation,Amidation,"The 'X' at 36 indicates β-alanine,the 'X' at 37 indicates Lys-C16(palmitic acid).",L,membrane,The peptide can interact with both MERS-CoV and IAV NHR trimeric coiled coils to prevent virus–cell membrane fusion.,4380.56,C185H323N45O59,ACDFGHIMNPQRTVWY,EKL,6.49,10,10,0,5,10,-108.11,-9140,5.5 hour,3 min,2 min,105.41,0,0.0,30192544, J Med Chem. 2018 Oct 11;61(19):8734-8745.,"Wang C, Zhao L, Xia S, Zhang T, Cao R, Liang G, Li Y, Meng G, Wang W, Shi W, Zhong W, Jiang S, Liu K. ",De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. ,10.1021/acs.jmedchem.8b00890,,Anti-MERS-CoV
DRAVPe00746,IEEISKKIEEISKKIEEISKKIEEISKKIEEISKKXX,37,IIS,Synthetic construct,No entry found,,"MERS-CoV,H3N2,H1N1","Coronaviridae, Orthomyxoviridae",MERS-CoV S Protein-Mediated Cell–Cell Fusion Assay,[Ref.30192544]MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells(EC50=0.10±0.02 μM);##A/Puerto Rico/8/34 (H1N1):inhibition of virus infection in MDCK cells(EC50=1.96±0.28 μM);##A/Hong Kong/8/68 (H3N2):inhibition of virus infection in MDCK cells(EC50=6.38±1.06 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30192544]Huh-7 cell:CC50=88.8±28 μM;##MDCK cell:CC50>100 μM.,DRAVPe00746,DRAVPe00746.cif,Linear,Acetylation,Amidation,"The 'X' at 36 indicates β-alanine,the 'X' at 37 indicates Lys-C16(palmitic acid).",L,membrane,The peptide can interact with both MERS-CoV and IAV NHR trimeric coiled coils to prevent virus–cell membrane fusion.,4380.56,C185H323N45O59,ACDFGHLMNPQRTVWY,EIK,6.49,10,10,0,5,10,-89.19,-9140,20 hour,30 min,>10 hour,105.41,0,0.0,30192544, J Med Chem. 2018 Oct 11;61(19):8734-8745.,"Wang C, Zhao L, Xia S, Zhang T, Cao R, Liang G, Li Y, Meng G, Wang W, Shi W, Zhong W, Jiang S, Liu K. ",De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. ,10.1021/acs.jmedchem.8b00890,,"Anti-MERS-CoV,Anti-H3N2,Anti-H1N1"
DRAVPe00747,IEEIYKKIEEIYKKIEEIYKKIEEIYKKIEEIYKKXX,37,IIY,Synthetic construct,No entry found,,"MERS-CoV,H3N2,H1N1","Coronaviridae, Orthomyxoviridae",MERS-CoV S Protein-Mediated Cell–Cell Fusion Assay,[Ref.30192544]MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells(EC50=0.52±0.4 μM);##A/Puerto Rico/8/34 (H1N1):inhibition of virus infection in MDCK cells(EC50=3.15±1.79 μM);##A/Hong Kong/8/68 (H3N2):inhibition of virus infection in MDCK cells(EC50=12.9±5.55 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30192544]Huh-7 cell:CC50>100 μM;##MDCK cell:CC50>100 μM.,DRAVPe00747,DRAVPe00747.cif,Linear,Acetylation,Amidation,"The 'X' at 36 indicates β-alanine,the 'X' at 37 indicates Lys-C16(palmitic acid).",L,membrane,The peptide can interact with both MERS-CoV and IAV NHR trimeric coiled coils to prevent virus–cell membrane fusion.,4761.05,C215H343N45O59,ACDFGHLMNPQRSTVW,EIK,6.48,10,10,0,5,10,-95.95,-7510,20 hour,30 min,>10 hour,105.41,7450,206.94,30192544, J Med Chem. 2018 Oct 11;61(19):8734-8745.,"Wang C, Zhao L, Xia S, Zhang T, Cao R, Liang G, Li Y, Meng G, Wang W, Shi W, Zhong W, Jiang S, Liu K. ",De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. ,10.1021/acs.jmedchem.8b00890,,"Anti-MERS-CoV,Anti-H3N2,Anti-H1N1"
DRAVPe00748,IEEIWKKIEEIWKKIEEIWKKIEEIWKKIEEIWKKXX,37,IIW,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,MERS-CoV S Protein-Mediated Cell–Cell Fusion Assay,[Ref.30192544]MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells(EC50=10.6±2.4 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30192544]Huh-7 cell:CC50>100 μM.,DRAVPe00748,DRAVPe00748.cif,Linear,Acetylation,Amidation,"The 'X' at 36 indicates β-alanine,the 'X' at 37 indicates Lys-C16(palmitic acid).",L,membrane,The peptide can interact with both MERS-CoV and IAV NHR trimeric coiled coils to prevent virus–cell membrane fusion.,4876.23,C225H348N50O54,ACDFGHLMNPQRSTVY,EIK,6.49,10,10,0,0,15,-90.54,-6275,20 hour,30 min,>10 hour,105.41,27500,763.89,30192544, J Med Chem. 2018 Oct 11;61(19):8734-8745.,"Wang C, Zhao L, Xia S, Zhang T, Cao R, Liang G, Li Y, Meng G, Wang W, Shi W, Zhong W, Jiang S, Liu K. ",De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. ,10.1021/acs.jmedchem.8b00890,,Anti-MERS-CoV
DRAVPe00749,IEEIHKKIEEIHKKIEEIHKKIEEIHKKIEEIHKKXX,37,IIH,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,MERS-CoV S Protein-Mediated Cell–Cell Fusion Assay,[Ref.30192544]MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells(EC50=1.68±0.47 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30192544]Huh-7 cell:CC50>100 μM.,DRAVPe00749,DRAVPe00749.cif,Linear,Acetylation,Amidation,"The 'X' at 36 indicates β-alanine,the 'X' at 37 indicates Lys-C16(palmitic acid).",L,membrane,The peptide can interact with both MERS-CoV and IAV NHR trimeric coiled coils to prevent virus–cell membrane fusion.,4630.87,C200H333N55O54,ACDFGLMNPQRSTVWY,EIK,7.16,15,10,5,0,10,-121.62,-9770,20 hour,30 min,>10 hour,105.41,0,0.0,30192544, J Med Chem. 2018 Oct 11;61(19):8734-8745.,"Wang C, Zhao L, Xia S, Zhang T, Cao R, Liang G, Li Y, Meng G, Wang W, Shi W, Zhong W, Jiang S, Liu K. ",De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. ,10.1021/acs.jmedchem.8b00890,,Anti-MERS-CoV
DRAVPe00750,IEEIQKKIEEIQKKIEEIQKKIEEIQKKIEEIQKKXX,37,IIQ,Synthetic construct,No entry found,,"MERS-CoV,H3N2,H1N1,HIV,EboV","Coronaviridae, Orthomyxoviridae, Filoviridae",MERS-CoV S Protein-Mediated Cell–Cell Fusion Assay,[Ref.30192544]MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells(EC50=0.11±0.02 μM);inhibition of pseudovirus infection in Huh-7 cells(IC50=0.13±0.1 μM);##A/Puerto Rico/8/34 (H1N1):inhibition of virus infection in MDCK cells(EC50=1.73±0.81 μM);##A/Hong Kong/8/68 (H3N2):inhibition of virus infection in MDCK cells(EC50=0.70±0.09 μM);##HIV-1 inhibition of cell-cell fusion in TZM-bl cells(EC50=3.63 ±0.54 μM);##Ebola virus (EboV):inhibition of pseudovirus infection in TZM-bl cells(EC50=1.02 ± 0.54 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30192544]Huh-7 cell:CC50>100 μM;##MDCK cell:CC50>100 μM;##TZM-bl cell:CC50>100 μM.,DRAVPe00750,DRAVPe00750.cif,Linear,Acetylation,Amidation,"The 'X' at 36 indicates β-alanine,the 'X' at 37 indicates Lys-C16(palmitic acid).",L,membrane,The peptide can interact with both MERS-CoV and IAV NHR trimeric coiled coils to prevent virus–cell membrane fusion.,4585.82,C195H338N50O59,ACDFGHLMNPRSTVWY,EIK,6.49,10,10,0,0,10,-125.68,-10210,20 hour,30 min,>10 hour,105.41,0,0.0,30192544, J Med Chem. 2018 Oct 11;61(19):8734-8745.,"Wang C, Zhao L, Xia S, Zhang T, Cao R, Liang G, Li Y, Meng G, Wang W, Shi W, Zhong W, Jiang S, Liu K. ",De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. ,10.1021/acs.jmedchem.8b00890,,"Anti-MERS-CoV,Anti-H3N2,Anti-H1N1,Anti-HIV,Anti-EBOV"
DRAVPe00751,IEEIKKKIEEIKKKIEEIKKKIEEIKKKIEEIKKKXX,37,IIK,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,MERS-CoV S Protein-Mediated Cell–Cell Fusion Assay,[Ref.30192544]MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells(EC50=0.45±0.13 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30192544]Huh-7 cell:CC50=4.54±0.6 μM.,DRAVPe00751,DRAVPe00751.cif,Linear,Acetylation,Amidation,"The 'X' at 36 indicates β-alanine,the 'X' at 37 indicates Lys-C16(palmitic acid).",L,membrane,The peptide can interact with both MERS-CoV and IAV NHR trimeric coiled coils to prevent virus–cell membrane fusion.,4586.04,C200H358N50O54,ACDFGHLMNPQRSTVWY,K,9.56,15,10,5,0,10,-131.08,-10215,20 hour,30 min,>10 hour,105.41,0,0.0,30192544, J Med Chem. 2018 Oct 11;61(19):8734-8745.,"Wang C, Zhao L, Xia S, Zhang T, Cao R, Liang G, Li Y, Meng G, Wang W, Shi W, Zhong W, Jiang S, Liu K. ",De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. ,10.1021/acs.jmedchem.8b00890,,Anti-MERS-CoV
DRAVPe00752,IEEIEKKIEEIEKKIEEIEKKIEEIEKKIEEIEKKXX,37,IIE,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,MERS-CoV S Protein-Mediated Cell–Cell Fusion Assay,[Ref.30192544]MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells(EC50=2.93±0.95 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30192544]Huh-7 cell:CC50>100 μM.,DRAVPe00752,DRAVPe00752.cif,Linear,Acetylation,Amidation,"The 'X' at 36 indicates β-alanine,the 'X' at 37 indicates Lys-C16(palmitic acid).",L,membrane,The peptide can interact with both MERS-CoV and IAV NHR trimeric coiled coils to prevent virus–cell membrane fusion.,4590.74,C195H333N45O64,ACDFGHLMNPQRSTVWY,E,4.76,10,15,-5,0,10,-125.68,-10845,20 hour,30 min,>10 hour,105.41,0,0.0,30192544, J Med Chem. 2018 Oct 11;61(19):8734-8745.,"Wang C, Zhao L, Xia S, Zhang T, Cao R, Liang G, Li Y, Meng G, Wang W, Shi W, Zhong W, Jiang S, Liu K. ",De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. ,10.1021/acs.jmedchem.8b00890,,Anti-MERS-CoV
DRAVPe00753,LWGEIWNTVKGLI,13,Eval418,Synthetic construct,No entry found,,HSV,Herpesviridae,Antiviral assays,[Ref.29290802]HSV-1:inhibition of viral inactivation in Vero cells(IC50=2.48 μg/ml);inhibition of viral attachment in Vero cells(IC50=3.70 μg/ml);inhibition of viral entry in Vero cells(IC50=31.71 μg/ml).,[Ref.29290802]the cell viability of erythrocytes was also more than 95% at concentrations of Eval418 of 10 μg/mL or less.,[Ref.29290802]Vero cell:CC50=68.50μg/mL; the cell viability of the peptide-treated Vero cells was greater than 95% after treatment with Eval418 at 10 μg/mL.,DRAVPe00753,DRAVPe00753.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,1528.81,C74H113N17O18,ACDFHMPQRSY,GILW,6.0,1,1,0,4,7,50.77,869,5.5 hour,3 min,2 min,142.31,11000,916.67,29290802,Theranostics. 2018 Jan 1;8(1):199-211. ,"Zeng Z, Zhang R, Hong W, Cheng Y, Wang H, Lang Y, Ji Z, Wu Y, Li W, Xie Y, Cao Z.",Histidine-rich Modification of a Scorpion-derived Peptide Improves Bioavailability and Inhibitory Activity against HSV-1.,10.7150/thno.21425,,Anti-HSV
DRAVPe00754,LWGHIWNFVHGLI,13,Eval418-FH2,Synthetic construct(derived from Eval418),No entry found,,HSV,Herpesviridae,Antiviral assays,[Ref.29290802]HSV-1:inhibition of viral inactivation in Vero cells(IC50=1.50 μg/ml);inhibition of viral attachment in Vero cells(IC50=1.43 μg/ml);inhibition of viral entry in Vero cells(IC50=8.63 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.29290802]Vero cell:CC50=27.60 μg/mL.,DRAVPe00754,DRAVPe00754.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,1591.88,C80H110N20O15,ACDEKMPQRSTY,GHILW,6.92,2,0,2,3,8,85.38,1728,5.5 hour,3 min,2 min,142.31,11000,916.67,29290802,Theranostics. 2018 Jan 1;8(1):199-211. ,"Zeng Z, Zhang R, Hong W, Cheng Y, Wang H, Lang Y, Ji Z, Wu Y, Li W, Xie Y, Cao Z.",Histidine-rich Modification of a Scorpion-derived Peptide Improves Bioavailability and Inhibitory Activity against HSV-1.,10.7150/thno.21425,,Anti-HSV
DRAVPe00755,LWHHIWNFVHGLI,13,Eval418-FH3,Synthetic construct(derived from Eval418),No entry found,,HSV,Herpesviridae,Antiviral assays,[Ref.29290802]HSV-1:inhibition of viral inactivation in Vero cells(IC50=1.01 μg/ml);inhibition of viral attachment in Vero cells(IC50=0.86 μg/ml);inhibition of viral entry in Vero cells(IC50=4.23 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.29290802]Vero cell:CC50=26.83 μg/mL.,DRAVPe00755,DRAVPe00755.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,1671.97,C84H114N22O15,ACDEKMPQRSTY,H,7.02,3,0,3,2,8,63.85,1168,5.5 hour,3 min,2 min,142.31,11000,916.67,29290802,Theranostics. 2018 Jan 1;8(1):199-211. ,"Zeng Z, Zhang R, Hong W, Cheng Y, Wang H, Lang Y, Ji Z, Wu Y, Li W, Xie Y, Cao Z.",Histidine-rich Modification of a Scorpion-derived Peptide Improves Bioavailability and Inhibitory Activity against HSV-1.,10.7150/thno.21425,,Anti-HSV
DRAVPe00756,LWHHIWNTVHHLI,13,Eval418-FH4,Synthetic construct(derived from Eval418),No entry found,,HSV,Herpesviridae,Antiviral assays,[Ref.29290802]HSV-1:inhibition of viral inactivation in Vero cells(IC50=0.87 μg/ml);inhibition of viral attachment in Vero cells(IC50=0.63 μg/ml);inhibition of viral entry in Vero cells(IC50=4.37 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.29290802]Vero cell:CC50=27.58 μg/mL.,DRAVPe00756,DRAVPe00756.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,1705.99,C83H116N24O16,ACDEFGKMPQRSY,H,7.1,4,0,4,2,7,15.38,53,5.5 hour,3 min,2 min,142.31,11000,916.67,29290802,Theranostics. 2018 Jan 1;8(1):199-211. ,"Zeng Z, Zhang R, Hong W, Cheng Y, Wang H, Lang Y, Ji Z, Wu Y, Li W, Xie Y, Cao Z.",Histidine-rich Modification of a Scorpion-derived Peptide Improves Bioavailability and Inhibitory Activity against HSV-1.,10.7150/thno.21425,,Anti-HSV
DRAVPe00757,LWHHIWHTVHHLI,13,Eval418-FH5,Synthetic construct(derived from Eval418),No entry found,,HSV,Herpesviridae,Antiviral assays,[Ref.29290802]HSV-1:inhibition of viral inactivation in Vero cells(IC50=0.86 μg/ml);inhibition of viral attachment in Vero cells(IC50=0.67 μg/ml);inhibition of viral entry in Vero cells(IC50=2.88 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.29290802]Vero cell:CC50=106.68 μg/mL.,DRAVPe00757,DRAVPe00757.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,1729.02,C85H117N25O15,ACDEFGKMNPQRSY,H,7.16,5,0,5,1,7,17.69,251,5.5 hour,3 min,2 min,142.31,11000,916.67,29290802,Theranostics. 2018 Jan 1;8(1):199-211. ,"Zeng Z, Zhang R, Hong W, Cheng Y, Wang H, Lang Y, Ji Z, Wu Y, Li W, Xie Y, Cao Z.",Histidine-rich Modification of a Scorpion-derived Peptide Improves Bioavailability and Inhibitory Activity against HSV-1.,10.7150/thno.21425,,Anti-HSV
DRAVPe01816,LWGEIWNTVKGLI,13,Eval418,Synthetic construct,No entry found,,HSV-1,Herpesviridae,Plaque reduction assay,[Ref.29290802]Herpes simplex virus type 1(HSV-1): inhibition of viral inactivation in Vero cells(IC50=2.48 µg/mL); inhibition of viral attachment in Vero cells(IC50=3.70 µg/mL); inhibition of viral entry in Vero cells(IC50=31.71 µg/mL).,[Ref.29290802]The hemolysis rate of human erythrocytes was less than 50% when the concentration of Eval418 was as high as 200 μg/mL.,[Ref.29290802]Vero cells: CC50 = 68.50 µg/mL.,,DRAVPe01816.cif,Linear,Free,Amidation,,L,Not found,No mechanism information found in the reference(s).,1528.81,C74H113N17O18,ACDFHMPQRSY,GILW,6.0,1,1,0,4,7,50.77,869,5.5 hour,3 min,2 min,142.31,11000,916.67,29290802,Theranostics. 2018 Jan 1;8(1):199-211. ,"Zeng Z, Zhang R, Hong W, Cheng Y, Wang H, Lang Y, Ji Z, Wu Y, Li W, Xie Y, Cao Z.",Histidine-rich Modification of a Scorpion-derived Peptide Improves Bioavailability and Inhibitory Activity against HSV-1.,10.7150/thno.21425,,Anti-HSV-1
DRAVPe01817,LWGHIWNFVHGLI,13,Eval418-FH2,Synthetic construct,No entry found,,HSV-1,Herpesviridae,Plaque reduction assay,[Ref.29290802]Herpes simplex virus type 1(HSV-1): inhibition of viral inactivation in Vero cells(IC50=1.50 µg/mL); inhibition of viral attachment in Vero cells(IC50=1.43 µg/mL); inhibition of viral entry in Vero cells(IC50=8.63 µg/mL).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.29290802]Vero cells: CC50 = 27.60 µg/mL.,,DRAVPe01817.cif,Linear,Free,Amidation,,L,Not found,No mechanism information found in the reference(s).,1591.88,C80H110N20O15,ACDEKMPQRSTY,GHILW,6.92,2,0,2,3,8,85.38,1728,5.5 hour,3 min,2 min,142.31,11000,916.67,29290802,Theranostics. 2018 Jan 1;8(1):199-211. ,"Zeng Z, Zhang R, Hong W, Cheng Y, Wang H, Lang Y, Ji Z, Wu Y, Li W, Xie Y, Cao Z.",Histidine-rich Modification of a Scorpion-derived Peptide Improves Bioavailability and Inhibitory Activity against HSV-1.,10.7150/thno.21425,,Anti-HSV-1
DRAVPe01818,LWHHIWNFVHGLI,13,Eval418-FH3,Synthetic construct,No entry found,,HSV-1,Herpesviridae,Plaque reduction assay,[Ref.29290802]Herpes simplex virus type 1(HSV-1): inhibition of viral inactivation in Vero cells(IC50=1.01 µg/mL); inhibition of viral attachment in Vero cells(IC50=0.86 µg/mL); inhibition of viral entry in Vero cells(IC50=4.23 µg/mL).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.29290802]Vero cells: CC50 = 26.83 µg/mL.,,DRAVPe01818.cif,Linear,Free,Amidation,,L,Not found,No mechanism information found in the reference(s).,1671.97,C84H114N22O15,ACDEKMPQRSTY,H,7.02,3,0,3,2,8,63.85,1168,5.5 hour,3 min,2 min,142.31,11000,916.67,29290802,Theranostics. 2018 Jan 1;8(1):199-211.,"Zeng Z, Zhang R, Hong W, Cheng Y, Wang H, Lang Y, Ji Z, Wu Y, Li W, Xie Y, Cao Z.",Histidine-rich Modification of a Scorpion-derived Peptide Improves Bioavailability and Inhibitory Activity against HSV-1.,10.7150/thno.21425,,Anti-HSV-1
DRAVPe01819,LWHHIWNTVHHLI,13,Eval418-FH4,Synthetic construct,No entry found,,HSV-1,Herpesviridae,Plaque reduction assay,[Ref.29290802]Herpes simplex virus type 1(HSV-1): inhibition of viral inactivation in Vero cells(IC50=0.87 µg/mL); inhibition of viral attachment in Vero cells(IC50=0.63 µg/mL); inhibition of viral entry in Vero cells(IC50=4.37 µg/mL).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.29290802]Vero cells: CC50 = 27.58 µg/mL.,,DRAVPe01819.cif,Linear,Free,Amidation,,L,Not found,No mechanism information found in the reference(s).,1705.99,C83H116N24O16,ACDEFGKMPQRSY,H,7.1,4,0,4,2,7,15.38,53,5.5 hour,3 min,2 min,142.31,11000,916.67,29290802,Theranostics. 2018 Jan 1;8(1):199-211.,"Zeng Z, Zhang R, Hong W, Cheng Y, Wang H, Lang Y, Ji Z, Wu Y, Li W, Xie Y, Cao Z.",Histidine-rich Modification of a Scorpion-derived Peptide Improves Bioavailability and Inhibitory Activity against HSV-1.,10.7150/thno.21425,,Anti-HSV-1
DRAVPe01820,LWHHIWHTVHHLI,13,Eval418-FH5,Synthetic construct,No entry found,,HSV-1,Herpesviridae,Plaque reduction assay,[Ref.29290802]Herpes simplex virus type 1(HSV-1): inhibition of viral inactivation in Vero cells(IC50=0.86 µg/mL); inhibition of viral attachment in Vero cells(IC50=0.67 µg/mL); inhibition of viral entry in Vero cells(IC50=2.88 µg/mL).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.29290802]Vero cells: CC50 = 106.68 µg/mL.,,DRAVPe01820.cif,Linear,Free,Amidation,,L,Not found,No mechanism information found in the reference(s).,1729.02,C85H117N25O15,ACDEFGKMNPQRSY,H,7.16,5,0,5,1,7,17.69,251,5.5 hour,3 min,2 min,142.31,11000,916.67,29290802,Theranostics. 2018 Jan 1;8(1):199-211.,"Zeng Z, Zhang R, Hong W, Cheng Y, Wang H, Lang Y, Ji Z, Wu Y, Li W, Xie Y, Cao Z.",Histidine-rich Modification of a Scorpion-derived Peptide Improves Bioavailability and Inhibitory Activity against HSV-1.,10.7150/thno.21425,,Anti-HSV-1
DRAVPe00758,WQCLTLTHRGFVLLTITVLR,20,IN-1,Synthetic construct,No entry found,,HIV,Retroviridae,MAGI assay,[Ref.18201721]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=38 µM);inhibition of strand transfer catalyzed by integrase(IC50=12 µM).##[Ref.19850483]HIV-1:inhibition of integrase catalytic activity(77% inhibition at 62.5μM);inhibition of virus replication in TZM-bl cells(70% inhibition at 62.5μM);inhibition of intergration(63% inhibition at 62.5μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18201721]No cytotixic against HeLa cells and H9 T-lymphocyte cultured cells up to ~62.5 μM.,DRAVPe00758,DRAVPe00758.cif,Linear,Free,Free,,L,Integrase,The peptide can inhibit integrase and thus inhibit virus replication.,2370.88,C110H180N30O26S,ADEKMNPSY,L,10.35,3,0,3,6,10,87.0,-519,2.8 hour,3 min,2 min,146.0,5500,289.47,18201721##19850483,J Mol Biol. 2008 Feb 29;376(4):971-82. ##Bioorg Med Chem. 2009 Nov 15;17(22):7635-42.,"Armon-Omer A, Levin A, Hayouka Z, Butz K, Hoppe-Seyler F, Loya S, Hizi A, Friedler A, Loyter A. ##Maes M, Levin A, Hayouka Z, Shalev DE, Loyter A, Friedler A. ",Correlation between shiftide activity and HIV-1 integrase inhibition by a peptide selected from a combinatorial library.##Peptide inhibitors of HIV-1 integrase: from mechanistic studies to improved lead compounds.,10.1016/j.jmb.2007.11.095##10.1016/j.bmc.2009.09.053,,Anti-HIV
DRAVPe00759,WQCLTLTHRG,10,IN(1-10),Synthetic construct,No entry found,,HIV,Retroviridae,MAGI assay,[Ref.19850483]HIV-1:inhibition of integrase catalytic activity(73% inhibition at 62.5μM);inhibition of virus replication in TZM-bl cells(68% inhibition at 62.5μM);inhibition of intergration(64% inhibition at 62.5μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00759,DRAVPe00759.cif,Linear,Free,Free,,L,Integrase,The peptide can inhibit integrase and thus inhibit virus replication.,1214.41,C53H83N17O14S,ADEFIKMNPSVY,LT,8.26,2,0,2,4,3,-38.0,-1587,2.8 hour,3 min,2 min,78.0,5500,611.11,19850483,Bioorg Med Chem. 2009 Nov 15;17(22):7635-42.,"Maes M, Levin A, Hayouka Z, Shalev DE, Loyter A, Friedler A. ",Peptide inhibitors of HIV-1 integrase: from mechanistic studies to improved lead compounds.,10.1016/j.bmc.2009.09.053,,Anti-HIV
DRAVPe00760,WFVLLTITVLR,11,IN(11-20),Synthetic construct,No entry found,,HIV,Retroviridae,MAGI assay,[Ref.19850483]HIV-1:inhibition of integrase catalytic activity(24% inhibition at 62.5μM);inhibition of virus replication in TZM-bl cells(29% inhibition at 62.5μM);inhibition of intergration(23% inhibition at 62.5μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00760,DRAVPe00760.cif,Linear,Free,Free,,L,Integrase,The peptide can inhibit integrase and thus inhibit virus replication.,1360.71,C68H109N15O14,ACDEGHKMNPQSY,L,9.75,1,0,1,2,8,184.55,1301,2.8 hour,3 min,2 min,194.55,5500,550.0,19850483,Bioorg Med Chem. 2009 Nov 15;17(22):7635-42.,"Maes M, Levin A, Hayouka Z, Shalev DE, Loyter A, Friedler A. ",Peptide inhibitors of HIV-1 integrase: from mechanistic studies to improved lead compounds.,10.1016/j.bmc.2009.09.053,,Anti-HIV
DRAVPe00761,WQSLTLTHRG,10,IN(1-10)[C3S],Synthetic construct,No entry found,,HIV,Retroviridae,MAGI assay,[Ref.19850483]HIV-1:inhibition of integrase catalytic activity(62% inhibition at 62.5μM);inhibition of virus replication in TZM-bl cells(60% inhibition at 62.5μM);inhibition of intergration(51% inhibition at 62.5μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00761,DRAVPe00761.cif,Linear,Free,Free,,L,Integrase,The peptide can inhibit integrase and thus inhibit virus replication.,1198.35,C53H83N17O15,ACDEFIKMNPVY,LT,9.76,2,0,2,4,3,-71.0,-2055,2.8 hour,3 min,2 min,78.0,5500,611.11,19850483,Bioorg Med Chem. 2009 Nov 15;17(22):7635-42.,"Maes M, Levin A, Hayouka Z, Shalev DE, Loyter A, Friedler A. ",Peptide inhibitors of HIV-1 integrase: from mechanistic studies to improved lead compounds.,10.1016/j.bmc.2009.09.053,,Anti-HIV
DRAVPe00762,VSGHGQHGVHG,11,Alloferon (3-13),Synthetic construct(derived from Alloferon-1),P83412,,"Herpesvirus,Coxsackie virus","Herpesviridae, Picornaviridae",antiviral assay,[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=500 µM);##HHV-1 clinical strain:inhibition of virus replication in Hep-2 cells(IC50=117 µM);##Coxsackie virus B2(clinical strain):inhibition of virus replication in Hep-2 cells(IC50=38 µM);##Coxsackie virus 971 PT B2:inhibition of virus replication in HEp-2 cells(IC50=250	µM);inhibition of virus replication in LLC-MK2 cells(IC50=93 µM).,No hemolysis information or data found in the reference(s) presented in this entry,"[Ref.22883213]No cytotoxic against Vero, Hep-2 and LLC-MK2 cells up to 165 µM.",DRAVPe00762,DRAVPe00762.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1071.12,C44H66N18O14,ACDEFIKLMNPRTWY,G,7.0,3,0,3,5,2,-64.55,-1108,100 hour,>20 hour,>10 hour,52.73,0,0.0,22883213,Chem Biol Drug Des. 2013 Feb;81(2):302-9. ,"Kuczer M, Majewska A, Zahorska R. ",New alloferon analogues: synthesis and antiviral properties.,10.1111/cbdd.12020,,"Anti-Herpesvirus,Anti-Coxsackie virus"
DRAVPe00763,SGHGQHGVHG,10,Alloferon (4-13),Synthetic construct(derived from Alloferon-1),P83412,,"Herpesvirus,Coxsackie virus","Herpesviridae, Picornaviridae",antiviral assay,[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=186 µM);inhibition of virus replication in Hep-2 cells(IC50=310 µM);##HHV-1 clinical strain:inhibition of virus replication in Vero cells(IC50=173 µM);inhibition of virus replication in Hep-2 cells(IC50=450 µM);##Coxsackie virus B2(clinical strain):inhibition of virus replication in Hep-2 cells(IC50=170 µM);inhibition of virus replication in LLC-MK2 cells(IC50=170 µM);##Coxsackie virus 971 PT B2:inhibition of virus replication in HEp-2 cells(IC50=210 µM);inhibition of virus replication in LLC-MK2 cells(IC50=180 µM).,No hemolysis information or data found in the reference(s) presented in this entry,"[Ref.22883213]No cytotoxic against Vero, Hep-2 and LLC-MK2 cells up to 420 µM.",DRAVPe00763,DRAVPe00763.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,971.99,C39H57N17O13,ACDEFIKLMNPRTWY,G,6.78,3,0,3,5,1,-113.0,-1512,1.9 hour,>20 hour,>10 hour,29.0,0,0.0,22883213,Chem Biol Drug Des. 2013 Feb;81(2):302-9. ,"Kuczer M, Majewska A, Zahorska R. ",New alloferon analogues: synthesis and antiviral properties.,10.1111/cbdd.12020,,"Anti-Herpesvirus,Anti-Coxsackie virus"
DRAVPe00764,GHGQHGVHG,9,Alloferon (5-13),Synthetic construct(derived from Alloferon-1),P83412,,"Herpesvirus,Coxsackie virus","Herpesviridae, Picornaviridae",antiviral assay,[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Hep-2 cells(IC50=360 µM);##HHV-1 clinical strain:inhibition of virus replication in Hep-2 cells(IC50=290 µM);##Coxsackie virus B2(clinical strain):inhibition of virus replication in Hep-2 cells(IC50=170 µM);##Coxsackie virus 971 PT B2:inhibition of virus replication in LLC-MK2 cells(IC50=230 µM).,No hemolysis information or data found in the reference(s) presented in this entry,"[Ref.22883213]No cytotoxic against Vero, Hep-2 and LLC-MK2 cells up to 448 µM.",DRAVPe00764,DRAVPe00764.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,884.91,C36H52N16O11,ACDEFIKLMNPRSTWY,G,7.02,3,0,3,4,1,-116.67,-1172,30 hour,>20 hour,>10 hour,32.22,0,0.0,22883213,Chem Biol Drug Des. 2013 Feb;81(2):302-9.,"Kuczer M, Majewska A, Zahorska R. ",New alloferon analogues: synthesis and antiviral properties.,10.1111/cbdd.12020,,"Anti-Herpesvirus,Anti-Coxsackie virus"
DRAVPe00765,HGQHGVHG,8,Alloferon (6-13),Synthetic construct(derived from Alloferon-1),P83412,,"Herpesvirus,Coxsackie virus","Herpesviridae, Picornaviridae",antiviral assay,[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=179 µM);##HHV-1 clinical strain:inhibition of virus replication in Vero cells(IC50=117 µM);##Coxsackie virus B2(clinical strain):inhibition of virus replication in Hep-2 cells(IC50=78 µM);inhibition of virus replication in LLC-MK2 cells(IC50=170 µM);##Coxsackie virus 971 PT B2:inhibition of virus replication in HEp-2 cells(IC50=190 µM);inhibition of virus replication in LLC-MK2 cells(IC50=410 µM).,No hemolysis information or data found in the reference(s) presented in this entry,"[Ref.22883213]No cytotoxic against Vero, Hep-2 and LLC-MK2 cells up to 468 µM.",DRAVPe00765,DRAVPe00765.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,827.86,C34H49N15O10,ACDEFIKLMNPRSTWY,GH,7.02,3,0,3,3,1,-126.25,-1266,3.5 hour,10 min,>10 hour,36.25,0,0.0,22883213,Chem Biol Drug Des. 2013 Feb;81(2):302-9.,"Kuczer M, Majewska A, Zahorska R. ",New alloferon analogues: synthesis and antiviral properties.,10.1111/cbdd.12020,,"Anti-Herpesvirus,Anti-Coxsackie virus"
DRAVPe00766,GQHGVHG,7,Alloferon (7-13),Synthetic construct(derived from Alloferon-1),P83412,,"Herpesvirus,Coxsackie virus","Herpesviridae, Picornaviridae",antiviral assay,[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=215 µM);inhibition of virus replication in HEp-2 cells(IC50=840 µM);##HHV-1 clinical strain:inhibition of virus replication in Vero cells(IC50=168 µM);inhibition of virus replication in Vero cells(IC50=280 µM);##Coxsackie virus B2(clinical strain):inhibition of virus replication in Hep-2 cells(IC50=170 µM);inhibition of virus replication in LLC-MK2 cells(IC50=190 µM);##Coxsackie virus 971 PT B2:inhibition of virus replication in HEp-2 cells(IC50=870 µM);inhibition of virus replication in LLC-MK2 cells(IC50=170 µM).,No hemolysis information or data found in the reference(s) presented in this entry,"[Ref.22883213]No cytotoxic against Vero, Hep-2 and LLC-MK2 cells up to 775 µM.",DRAVPe00766,DRAVPe00766.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,690.72,C28H42N12O9,ACDEFIKLMNPRSTWY,G,6.92,2,0,2,3,1,-98.57,-800,30 hour,>20 hour,>10 hour,41.43,0,0.0,22883213,Chem Biol Drug Des. 2013 Feb;81(2):302-9.,"Kuczer M, Majewska A, Zahorska R. ",New alloferon analogues: synthesis and antiviral properties.,10.1111/cbdd.12020,,"Anti-Herpesvirus,Anti-Coxsackie virus"
DRAVPe00767,QHGVHG,6,Alloferon (8-13),Synthetic construct(derived from Alloferon-1),P83412,,"Herpesvirus,Coxsackie virus","Herpesviridae, Picornaviridae",antiviral assay,[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=1300 µM);##HHV-1 clinical strain:inhibition of virus replication in Vero cells(IC50=950 µM);inhibition of virus replication in Hep-2 cells(IC50=280 µM);##Coxsackie virus B2(clinical strain):inhibition of virus replication in Hep-2 cells(IC50=170 µM);##Coxsackie virus 971 PT B2:inhibition of virus replication in HEp-2 cells(IC50=500 µM);inhibition of virus replication in LLC-MK2 cells(IC50=210 µM).,No hemolysis information or data found in the reference(s) presented in this entry,"[Ref.22883213]No cytotoxic against Vero, Hep-2 and LLC-MK2 cells up to 380 µM.",DRAVPe00767,DRAVPe00767.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,633.66,C26H39N11O8,ACDEFIKLMNPRSTWY,GH,6.92,2,0,2,2,1,-108.33,-894,0.8 hour,10 min,>10 hour,48.33,0,0.0,22883213,Chem Biol Drug Des. 2013 Feb;81(2):302-9.,"Kuczer M, Majewska A, Zahorska R. ",New alloferon analogues: synthesis and antiviral properties.,10.1111/cbdd.12020,,"Anti-Herpesvirus,Anti-Coxsackie virus"
DRAVPe00768,HGVHG,5,Alloferon (9-13),Synthetic construct(derived from Alloferon-1),P83412,,"Herpesvirus,Coxsackie virus","Herpesviridae, Picornaviridae",antiviral assay,[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=300 µM);##HHV-1 clinical strain:inhibition of virus replication in Vero cells(IC50=400 µM);##Coxsackie virus B2(clinical strain):inhibition of virus replication in Hep-2 cells(IC50=350 µM);inhibition of virus replication in LLC-MK2 cells(IC50=290 µM);##Coxsackie virus 971 PT B2:inhibition of virus replication in HEp-2 cells(IC50=350 µM);inhibition of virus replication in LLC-MK2 cells(IC50=180 µM).,No hemolysis information or data found in the reference(s) presented in this entry,"[Ref.22883213]No cytotoxic against Vero, Hep-2 and LLC-MK2 cells up to 826 µM.",DRAVPe00768,DRAVPe00768.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,505.53,C21H31N9O6,ACDEFIKLMNPQRSTWY,GH,6.92,2,0,2,2,1,-60.0,-340,3.5 hour,10 min,>10 hour,58.0,0,0.0,22883213,Chem Biol Drug Des. 2013 Feb;81(2):302-9.,"Kuczer M, Majewska A, Zahorska R. ",New alloferon analogues: synthesis and antiviral properties.,10.1111/cbdd.12020,,"Anti-Herpesvirus,Anti-Coxsackie virus"
DRAVPe00769,GVHG,4,Alloferon (10-13),Synthetic construct(derived from Alloferon-1),P83412,,"Herpesvirus,Coxsackie virus","Herpesviridae, Picornaviridae",antiviral assay,[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=500 µM);##HHV-1 clinical strain:inhibition of virus replication in Vero cells(IC50=1500 µM);##Coxsackie virus 971 PT B2:inhibition of virus replication in HEp-2 cells(IC50=1040 µM);inhibition of virus replication in LLC-MK2 cells(IC50=540 µM).,No hemolysis information or data found in the reference(s) presented in this entry,"[Ref.22883213]No cytotoxic against Vero, Hep-2 and LLC-MK2 cells up to 1174 µM.",DRAVPe00769,DRAVPe00769.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,368.39,C15H24N6O5,ACDEFIKLMNPQRSTWY,G,6.74,1,0,1,2,1,5.0,126,30 hour,>20 hour,>10 hour,72.5,0,0.0,22883213,Chem Biol Drug Des. 2013 Feb;81(2):302-9.,"Kuczer M, Majewska A, Zahorska R. ",New alloferon analogues: synthesis and antiviral properties.,10.1111/cbdd.12020,,"Anti-Herpesvirus,Anti-Coxsackie virus"
DRAVPe00770,HGVSGHGQHGV,11,Alloferon (1-11),Synthetic construct(derived from Alloferon-1),P83412,,Herpesvirus,Herpesviridae,antiviral assay,[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=178 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22883213]No cytotoxic against Vero cells up to 260 µM.,DRAVPe00770,DRAVPe00770.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1071.12,C44H66N18O14,ACDEFIKLMNPRTWY,G,7.02,3,0,3,5,2,-64.55,-1108,3.5 hour,10 min,>10 hour,52.73,0,0.0,22883213,Chem Biol Drug Des. 2013 Feb;81(2):302-9.,"Kuczer M, Majewska A, Zahorska R. ",New alloferon analogues: synthesis and antiviral properties.,10.1111/cbdd.12020,,Anti-Herpesvirus
DRAVPe00771,HGVSGHGQHG,10,Alloferon (1-10),Synthetic construct(derived from Alloferon-1),P83412,,Herpesvirus,Herpesviridae,antiviral assay,[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=520 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22883213]No cytotoxic against Vero cells up to 350 µM.,DRAVPe00771,DRAVPe00771.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,971.99,C39H57N17O13,ACDEFIKLMNPRTWY,G,7.02,3,0,3,5,1,-113.0,-1512,3.5 hour,10 min,>10 hour,29.0,0,0.0,22883213,Chem Biol Drug Des. 2013 Feb;81(2):302-9.,"Kuczer M, Majewska A, Zahorska R. ",New alloferon analogues: synthesis and antiviral properties.,10.1111/cbdd.12020,,Anti-Herpesvirus
DRAVPe00772,HGVSGHGQ,8,Alloferon (1-8),Synthetic construct(derived from Alloferon-1),P83412,,Herpesvirus,Herpesviridae,antiviral assay,[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=310 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22883213]No cytotoxic against Vero cells up to 447 µM.,DRAVPe00772,DRAVPe00772.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,777.79,C31H47N13O11,ACDEFIKLMNPRTWY,G,6.92,2,0,2,4,1,-96.25,-1140,3.5 hour,10 min,>10 hour,36.25,0,0.0,22883213,Chem Biol Drug Des. 2013 Feb;81(2):302-9.,"Kuczer M, Majewska A, Zahorska R. ",New alloferon analogues: synthesis and antiviral properties.,10.1111/cbdd.12020,,Anti-Herpesvirus
DRAVPe00773,HGVSGHG,7,Alloferon (1-7),Synthetic construct(derived from Alloferon-1),P83412,,Herpesvirus,Herpesviridae,antiviral assay,[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=550 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22883213]No cytotoxic against Vero cells up to 504 µM.,DRAVPe00773,DRAVPe00773.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,649.66,C26H39N11O9,ACDEFIKLMNPQRTWY,G,6.92,2,0,2,4,1,-60.0,-586,3.5 hour,10 min,>10 hour,41.43,0,0.0,22883213,Chem Biol Drug Des. 2013 Feb;81(2):302-9.,"Kuczer M, Majewska A, Zahorska R. ",New alloferon analogues: synthesis and antiviral properties.,10.1111/cbdd.12020,,Anti-Herpesvirus
DRAVPe00774,FGVSGHGQHGVHG,13,Alloferon [H1F],Synthetic construct(derived from Alloferon-1),P83412,,Herpesvirus,Herpesviridae,antiviral assay,[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=160 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22883213]No cytotoxic against Vero cells up to 290 µM.,DRAVPe00774,DRAVPe00774.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1275.35,C55H78N20O16,ACDEIKLMNPRTWY,G,7.02,3,0,3,6,3,-36.15,-716,1.1 hour,3 min,2 min,44.62,0,0.0,22883213,Chem Biol Drug Des. 2013 Feb;81(2):302-9.,"Kuczer M, Majewska A, Zahorska R. ",New alloferon analogues: synthesis and antiviral properties.,10.1111/cbdd.12020,,Anti-Herpesvirus
DRAVPe00775,YGVSGHGQHGVHG,13,Alloferon [H1Y],Synthetic construct(derived from Alloferon-1),P83412,,Herpesvirus,Herpesviridae,antiviral assay,[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=190 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22883213]No cytotoxic against Vero cells up to 315 µM.,DRAVPe00775,DRAVPe00775.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1291.35,C55H78N20O17,ACDEFIKLMNPRTW,G,7.02,3,0,3,7,2,-67.69,-1028,2.8 hour,10 min,2 min,44.62,1490,124.17,22883213,Chem Biol Drug Des. 2013 Feb;81(2):302-9.,"Kuczer M, Majewska A, Zahorska R. ",New alloferon analogues: synthesis and antiviral properties.,10.1111/cbdd.12020,,Anti-Herpesvirus
DRAVPe00776,WGVSGHGQHGVHG,13,Alloferon [H1W],Synthetic construct(derived from Alloferon-1),P83412,,Herpesvirus,Herpesviridae,antiviral assay,[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=190 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22883213]No cytotoxic against Vero cells up to 282 µM.,DRAVPe00776,DRAVPe00776.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1314.39,C57H79N21O16,ACDEFIKLMNPRTY,G,7.02,3,0,3,6,3,-64.62,-781,2.8 hour,3 min,2 min,44.62,5500,458.33,22883213,Chem Biol Drug Des. 2013 Feb;81(2):302-9.,"Kuczer M, Majewska A, Zahorska R. ",New alloferon analogues: synthesis and antiviral properties.,10.1111/cbdd.12020,,Anti-Herpesvirus
DRAVPe00777,XGVSGHGQHGVHG,13,Alloferon [H1Phg],Synthetic construct(derived from Alloferon-1),P83412,,Herpesvirus,Herpesviridae,antiviral assay,[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=190 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22883213]No cytotoxic against Vero cells up to 350 µM.,DRAVPe00777,DRAVPe00777.cif,Linear,Free,Free,The 'X' at position 1 indicates Phenylglycine.,L,Not found,No machanism information found in the reference(s) presented in this entry,1239.5,C46H67N19O14,ACDEFIKLMNPRTWY,G,7.02,3,0,3,6,2,-57.69,-1014,,,,44.62,0,0.0,22883213,Chem Biol Drug Des. 2013 Feb;81(2):302-9.,"Kuczer M, Majewska A, Zahorska R. ",New alloferon analogues: synthesis and antiviral properties.,10.1111/cbdd.12020,,Anti-Herpesvirus
DRAVPe00778,XGVSGHGQHGVHG,13,Alloferon [H1Phe(p-Cl)],Synthetic construct(derived from Alloferon-1),P83412,,Herpesvirus,Herpesviridae,antiviral assay,[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=110 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22883213]No cytotoxic against Vero cells up to 255 µM.,DRAVPe00778,DRAVPe00778.cif,Linear,Free,Free,The 'X' at position 1 indicates 4-Chloro-phenylalanine.,L,Not found,No machanism information found in the reference(s) presented in this entry,1239.5,C46H67N19O14,ACDEFIKLMNPRTWY,G,7.02,3,0,3,6,2,-57.69,-1014,,,,44.62,0,0.0,22883213,Chem Biol Drug Des. 2013 Feb;81(2):302-9.,"Kuczer M, Majewska A, Zahorska R. ",New alloferon analogues: synthesis and antiviral properties.,10.1111/cbdd.12020,,Anti-Herpesvirus
DRAVPe00779,XGVSGHGQHGVHG,13,Alloferon [H1Phe(p-OME)],Synthetic construct(derived from Alloferon-1),P83412,,Herpesvirus,Herpesviridae,antiviral assay,[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=220 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22883213]No cytotoxic against Vero cells up to 312 µM.,DRAVPe00779,DRAVPe00779.cif,Linear,Free,Free,The 'X' at position 1 indicates 4-Methoxy-phenylalanine.,L,Not found,No machanism information found in the reference(s) presented in this entry,1239.5,C46H67N19O14,ACDEFIKLMNPRTWY,G,7.02,3,0,3,6,2,-57.69,-1014,,,,44.62,0,0.0,22883213,Chem Biol Drug Des. 2013 Feb;81(2):302-9.,"Kuczer M, Majewska A, Zahorska R. ",New alloferon analogues: synthesis and antiviral properties.,10.1111/cbdd.12020,,Anti-Herpesvirus
DRAVPe00780,EMTWEEWEKKIEEYTKKIEEILXX,24,LP-11,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=931±68 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=201±41 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=253±40 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00780,DRAVPe00780.cif,Linear,Acetylation,Amidation,"The 'X' at position 24 is Lys-C16(palmitic acid),The 'X' at position 23 is Lys-PEG8.",L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3107.94,C132H198N28O40S,ACDFGHNPQRSV,E,4.47,4,8,-4,3,6,-120.42,-5527,1 hour,30 min,>10 hour,65.0,12490,543.04,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00781,EMTWEEWEKKVEELEKKIEELLXX,24,LP-19,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=296±45 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=95±18 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=92±11 pM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00781,DRAVPe00781.cif,Linear,Acetylation,Amidation,"The 'X' at position 24 is Lys-C16(palmitic acid),The 'X' at position 23 is Lys-PEG8.",L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3071.91,C129H198N28O40S,ACDFGHNPQRSY,E,4.38,4,9,-5,1,7,-115.0,-5533,1 hour,30 min,>10 hour,77.08,11000,478.26,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00782,YTSLIHSLIEESQNQQEKNEQELLELDX,28,LP-40,Synthetic construct,P03377,,HIV,Retroviridae,"cell-fusion assay,single-cycle infection assay",[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=361±60 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=392±73 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=384±33 pM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30089693]TZM-bl cell:CC50=800.8 ± 62.29 μM;##MT-4 cell:CC50=366.3± 119.08 μM;##HEK293T cell:CC50=408± 40.1μM;##PBMC:CC50=212.6± 25.71 μM.,DRAVPe00782,DRAVPe00782.cif,Linear,Acetylation,Amidation,The 'X' at position 28 is Lys-C16(palmitic acid),L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3342.8,C138H218N36O52,ACFGMPRVW,E,4.06,2,7,-5,7,7,-103.57,-7370,2.8 hour,10 min,2 min,97.5,1490,55.19,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,Anti-HIV
DRAVPe00783,YTSLIEELIKKSEEQQKKNEEELKKLEX,28,LP-50,Synthetic construct,P03377,,"HIV,SIV",Retroviridae,"cell-fusion assay,single-cycle infection assay","[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=21±3 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=7±1 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=23±2 pM);##T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells(IC50<0.01 nM);##T-20 resistant HIV-1 NL4-3(WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T):inhibition of virus infection in TZM-bl cells(IC50=0.06-136.12 nM);##HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells(IC50=0.09-5.81 nM);##SIV(239,PBJ):inhibition of virus infection in TZM-bl cells(IC50=0.06 nM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30089693]TZM-bl cell:CC50=106.4 ± 2.72 μM;##MT-4 cell:CC50=138.37± 6.55 μM;##HEK293T cell:CC50=166.77± 35.33μM;##PBMC:CC50=40.01± 4.63 μM.,DRAVPe00783,DRAVPe00783.cif,Linear,Acetylation,Amidation,The 'X' at position 28 is Lys-C16(palmitic acid),L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3419.07,C145H242N36O50,ACDFGHMPRVW,E,4.94,6,8,-2,5,6,-147.5,-8549,2.8 hour,10 min,2 min,83.57,1490,55.19,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,"Anti-HIV,Anti-SIV"
DRAVPe00784,LEANIEELLKKAEEQQKKNEEELKKLEX,28,LP-51,Synthetic construct,P03377,,"HIV,SIV",Retroviridae,"cell-fusion assay,single-cycle infection assay","[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=21±10 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=6±1 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=27±5 pM);##T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells(IC50<0.01 nM);##T-20 resistant HIV-1 NL4-3(WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T):inhibition of virus infection in TZM-bl cells(IC50=0.02-12.07 nM);##HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells(IC50=0.09-0.84 nM);##SIV(239,PBJ):inhibition of virus infection in TZM-bl cells(IC50=0.03-0.06 nM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30089693]TZM-bl cell:CC50=434.03±90.38 μM;##MT-4 cell:CC50=135.07±32.3 μM;##HEK293T cell:CC50=130.07± 15.27μM;##PBMC:CC50=46.83±4.65 μM.,DRAVPe00784,DRAVPe00784.cif,Linear,Acetylation,Amidation,The 'X' at position 28 is Lys-C16(palmitic acid),L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3366.01,C141H239N37O49,CDFGHMPRSTVWY,E,4.76,6,9,-3,2,8,-149.29,-8581,5.5 hour,3 min,2 min,90.71,0,0.0,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,"Anti-HIV,Anti-SIV"
DRAVPe00785,WEQKIEELLKKAEEQQKKNEEELKKLEX,28,LP-52,Synthetic construct,P03377,,"HIV,SIV",Retroviridae,"cell-fusion assay,single-cycle infection assay","[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=13±1 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=4±0 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=5±1 pM);##HIV-1(3 A, 13 B, 7 C, 1 G, 1 A/C, 5 A/E, 6 B/C pseudovirus subtypes):inhibition of pseudovirus infection in TZM-bl cells(IC50=17 pM);##T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells(IC50<0.01 nM);##T-20 resistant HIV-1 NL4-3(WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T):inhibition of virus infection in TZM-bl cells(IC50=0.01-1.86 nM);##HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells(IC50=0.06-0.34 nM);##SIV(239,PBJ):inhibition of virus infection in TZM-bl cells(IC50=0.01-0.04 nM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30089693]TZM-bl cell:CC50=112.9 ± 2.21 μM;##MT-4 cell:CC50=94.06± 4.97 μM;##HEK293T cell:CC50=88.86± 6.68μM;##PBMC:CC50=114.8± 12.68 μM.,DRAVPe00785,DRAVPe00785.cif,Linear,Acetylation,Amidation,The 'X' at position 28 is Lys-C16(palmitic acid),L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",3510.19,C150H247N39O49,CDFGHMPRSTVY,E,5.0,7,9,-2,1,7,-186.43,-9466,2.8 hour,3 min,2 min,73.21,5500,203.7,30089693,J Virol. 2018 Sep 26;92(20):e01088-18.,"Chong H, Zhu Y, Yu D, He Y.","Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",10.1128/JVI.01088-18,,"Anti-HIV,Anti-SIV"
DRAVPe00786,WEQKIEELLKKAEEQQKKNEEELKKLEX,28,LP-80,Synthetic construct,P03377,,"HIV,SIV",Retroviridae,"cell-fusion assay,single-cycle infection assay","[Ref.30867304]HIV-1 NL4-3(X4):inhibition of virus replication in TZM-bl cells(IC50=2.66±0.76 pM);##HIV-1 JR-CSF(R5):inhibition of virus replication in TZM-bl cells(IC50=7.12±0.28 pM);##HIV-1 89.6(R5X4):inhibition of virus replication in TZM-bl cells(IC50=13.00±4.55 pM);##HIV-1 pseudovirus:inhibition of pseudovirus infection in TZM-bl cells(IC50=5 pM);##T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells(IC50=0.003±0.001 nM);##T-20 resistant HIV-1 NL4-3(WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T):inhibition of virus infection in TZM-bl cells(IC50=0.007-4.006 nM);##HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells(IC50=0.288-0.299 nM);##SIV(239,PBJ):inhibition of virus infection in TZM-bl cells(IC50=0.034-0.155 nM);##HIV-1(1A,2B,1C,1G,1A/C,1A/E,1B/C subtype):inhibition of cell-cell fusion between HEK293T cells and TZM-bl cells(IC50=13.4 pM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00786,DRAVPe00786.cif,Linear,Acetylation,Amidation,The 'X' at position 28 is Lys-C18(stearic acid),L,membrane,"The peptide had extremely potent activity to block HIV envelope-mediated cell-cell fusion,showing a greatly increased potency relative to its inhibition on virus infection. Besides, it efficiently bounds to both the cellular and viral membranes to exert their antiviral activities.",3510.19,C150H247N39O49,CDFGHMPRSTVY,E,5.0,7,9,-2,1,7,-186.43,-9466,2.8 hour,3 min,2 min,73.21,5500,203.7,30867304,J Virol. 2019 May 15;93(11):e02312-18.,"Zhu Y, Chong H, Yu D, Guo Y, Zhou Y, He Y.",Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity. ,10.1128/JVI.02312-18,,"Anti-HIV,Anti-SIV"
DRAVPe00787,WEQKIEELLKKAEEQQKKNEEELKKLEKX,29,LP-83,Synthetic construct,P03377,,"HIV,SIV",Retroviridae,"cell-fusion assay,single-cycle infection assay","[Ref.30867304]HIV-1 NL4-3(X4):inhibition of virus replication in TZM-bl cells(IC50=0.49±0.03 pM);##HIV-1 JR-CSF(R5):inhibition of virus replication in TZM-bl cells(IC50=4.54±1.42 pM);##HIV-1 89.6(R5X4):inhibition of virus replication in TZM-bl cells(IC50=4.75±0.83 pM);##HIV-1 pseudovirus:inhibition of pseudovirus infection in TZM-bl cells(IC50=2.91 pM);##T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells(IC50=0.002±0 nM);##T-20 resistant HIV-1 NL4-3(WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T):inhibition of virus infection in TZM-bl cells(IC50=0.002-0.041 nM);##HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells(IC50=0.02-0.032 nM);##SIV(239,PBJ):inhibition of virus infection in TZM-bl cells(IC50=0.004-0.006 nM);##HIV-1(1A,2B,1C,1G,1A/C,1A/E,1B/C subtype):inhibition of cell-cell fusion between HEK293T cells and TZM-bl cells(IC50=8.55 pM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30867304]Human PBMC:CC50=40.27 µM;##Human embryonic kidney HEK293T cells:CC50=25.31 µM;##TZM-bl cells:CC50=12.34 μM;##MT-4 cells:CC50=19.65 μM;##C8166 cells:CC50=19.19 μM;##U937 cells:CC50=9.97 μ,DRAVPe00787,DRAVPe00787.cif,Linear,Acetylation,Amidation,The 'X' at position 29 is Cys-Chol(cholesterol),L,membrane,"The peptide had extremely potent activity to block HIV envelope-mediated cell-cell fusion,showing a greatly increased potency relative to its inhibition on virus infection. Besides, it efficiently bounds to both the cellular and viral membranes to exert their antiviral activities.",3638.36,C156H259N41O50,CDFGHMPRSTVY,E,5.36,8,9,-1,1,7,-193.45,-10021,2.8 hour,3 min,2 min,70.69,5500,196.43,30867304,J Virol. 2019 May 15;93(11):e02312-18.,"Zhu Y, Chong H, Yu D, Guo Y, Zhou Y, He Y.",Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity. ,10.1128/JVI.02312-18,,"Anti-HIV,Anti-SIV"
DRAVPe00788,LEANIEELLKKAEEQQKKNEEELKKLEKX,29,LP-86,Synthetic construct,P03377,,"HIV,SIV",Retroviridae,"cell-fusion assay,single-cycle infection assay","[Ref.30867304]HIV-1 NL4-3(X4):inhibition of virus replication in TZM-bl cells(IC50=0.43±0.03 pM);##HIV-1 JR-CSF(R5):inhibition of virus replication in TZM-bl cells(IC50=4.78±0.69 pM);##HIV-1 89.6(R5X4):inhibition of virus replication in TZM-bl cells(IC50=7.24±1.36 pM);##HIV-1 pseudovirus:inhibition of pseudovirus infection in TZM-bl cells(IC50=4.91 pM);##T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells(IC50=0.003±0 nM);##T-20 resistant HIV-1 NL4-3(WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T):inhibition of virus infection in TZM-bl cells(IC50=0.003-0.17 nM);##HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells(IC50=0.014-0.026 nM);##SIV(239,PBJ):inhibition of virus infection in TZM-bl cells(IC50=0.005-0.006 nM);##HIV-1(1A,2B,1C,1G,1A/C,1A/E,1B/C subtype):inhibition of cell-cell fusion between HEK293T cells and TZM-bl cells(IC50=12.27 pM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00788,DRAVPe00788.cif,Linear,Acetylation,Amidation,The 'X' at position 29 is Cys-Chol(cholesterol),L,membrane,"The peptide had extremely potent activity to block HIV envelope-mediated cell-cell fusion,showing a greatly increased potency relative to its inhibition on virus infection. Besides, it efficiently bounds to both the cellular and viral membranes to exert their antiviral activities.",3494.19,C147H251N39O50,CDFGHMPRSTVWY,E,5.0,7,9,-2,2,8,-157.59,-9136,5.5 hour,3 min,2 min,87.59,0,0.0,30867304,J Virol. 2019 May 15;93(11):e02312-18.,"Zhu Y, Chong H, Yu D, Guo Y, Zhou Y, He Y.",Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity. ,10.1128/JVI.02312-18,,"Anti-HIV,Anti-SIV"
DRAVPe00789,WEQKIEELLKKAEEQQKKNEEELKX,25,LP-93,Synthetic construct,P03377,,"HIV,SIV",Retroviridae,"cell-fusion assay,single-cycle infection assay","[Ref.30867304]HIV-1 NL4-3(X4):inhibition of virus replication in TZM-bl cells(IC50=6.27±1.26 pM);##HIV-1 JR-CSF(R5):inhibition of virus replication in TZM-bl cells(IC50=6.55±1.97 pM);##HIV-1 89.6(R5X4):inhibition of virus replication in TZM-bl cells(IC50=7.57±0.62pM);##HIV-1 pseudovirus:inhibition of pseudovirus infection in TZM-bl cells(IC50=9.89 pM);##T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells(IC50=0.006±0.001 nM);##T-20 resistant HIV-1 NL4-3(WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T):inhibition of virus infection in TZM-bl cells(IC50=0.012-2.17 nM);##HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells(IC50=1.244-3.514 nM);##SIV(239,PBJ):inhibition of virus infection in TZM-bl cells(IC50=0.013-0.773 nM);##HIV-1(1A,2B,1C,1G,1A/C,1A/E,1B/C subtype):inhibition of cell-cell fusion between HEK293T cells and TZM-bl cells(IC50=14.51pM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00789,DRAVPe00789.cif,Linear,Acetylation,Amidation,The 'X' at position 25 is Lys-Chol(cholesterol),L,membrane,"The peptide had extremely potent activity to block HIV envelope-mediated cell-cell fusion,showing a greatly increased potency relative to its inhibition on virus infection. Besides, it efficiently bounds to both the cellular and viral membranes to exert their antiviral activities.",3139.74,C133H217N35O44,CDFGHMPRSTVY,E,4.94,6,8,-2,1,6,-194.4,-8722,2.8 hour,3 min,2 min,66.4,5500,229.17,30867304,J Virol. 2019 May 15;93(11):e02312-18.,"Zhu Y, Chong H, Yu D, Guo Y, Zhou Y, He Y.",Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity.,10.1128/JVI.02312-18,,"Anti-HIV,Anti-SIV"
DRAVPe00790,IEELLKKAEEQQKKNEEELKKLEX,24,LP-94,Synthetic construct,P03377,,"HIV,SIV",Retroviridae,"cell-fusion assay,single-cycle infection assay","[Ref.30867304]HIV-1 NL4-3(X4):inhibition of virus replication in TZM-bl cells(IC50=1.75±0.23 pM);##HIV-1 JR-CSF(R5):inhibition of virus replication in TZM-bl cells(IC50=5.90±1.80 pM);##HIV-1 89.6(R5X4):inhibition of virus replication in TZM-bl cells(IC50=15.69±1.97 pM);##HIV-1 pseudovirus:inhibition of pseudovirus infection in TZM-bl cells(IC50=6.54 pM);##T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells(IC50=0.004±0.002 nM);##T-20 resistant HIV-1 NL4-3(WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T):inhibition of virus infection in TZM-bl cells(IC50=0.004-2.295 nM);##HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells(IC50=0.019-0.027 nM);##SIV(239,PBJ):inhibition of virus infection in TZM-bl cells(IC50=0.011-0.018 nM);##HIV-1(1A,2B,1C,1G,1A/C,1A/E,1B/C subtype):inhibition of cell-cell fusion between HEK293T cells and TZM-bl cells(IC50=27.36 pM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00790,DRAVPe00790.cif,Linear,Acetylation,Amidation,The 'X' at position 24 is Lys-Chol(cholesterol),L,membrane,"The peptide had extremely potent activity to block HIV envelope-mediated cell-cell fusion,showing a greatly increased potency relative to its inhibition on virus infection. Besides, it efficiently bounds to both the cellular and viral membranes to exert their antiviral activities.",2938.56,C123H210N32O42,CDFGHMPRSTVWY,E,4.94,6,8,-2,1,6,-168.33,-7909,20 hour,30 min,>10 hour,85.42,0,0.0,30867304,J Virol. 2019 May 15;93(11):e02312-18.,"Zhu Y, Chong H, Yu D, Guo Y, Zhou Y, He Y.",Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity.,10.1128/JVI.02312-18,,"Anti-HIV,Anti-SIV"
DRAVPe00791,IEELLKKAEEQQKKNEEELKX,21,LP-95,Synthetic construct,P03377,,"HIV,SIV",Retroviridae,"cell-fusion assay,single-cycle infection assay","[Ref.30867304]HIV-1 NL4-3(X4):inhibition of virus replication in TZM-bl cells(IC50=199.92±32.69 pM);##HIV-1 JR-CSF(R5):inhibition of virus replication in TZM-bl cells(IC50=24.36±0.15 pM);##HIV-1 89.6(R5X4):inhibition of virus replication in TZM-bl cells(IC50=4781.17±699.33 pM);##HIV-1 pseudovirus:inhibition of pseudovirus infection in TZM-bl cells(IC50=148.88 pM);##T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells(IC50=0.067±0.026 nM);##T-20 resistant HIV-1 NL4-3(WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T):inhibition of virus infection in TZM-bl cells(IC50=0.39-408.556 nM);##HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells(IC50=2.857-13.512 nM);##SIV(239,PBJ):inhibition of virus infection in TZM-bl cells(IC50=0.556-0.862 nM);##HIV-1(1A,2B,1C,1G,1A/C,1A/E,1B/C subtype):inhibition of cell-cell fusion between HEK293T cells and TZM-bl cells(IC50=29.84 pM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00791,DRAVPe00791.cif,Linear,Acetylation,Amidation,The 'X' at position 21 is Lys-Chol(cholesterol),L,membrane,"The peptide had extremely potent activity to block HIV envelope-mediated cell-cell fusion,showing a greatly increased potency relative to its inhibition on virus infection. Besides, it efficiently bounds to both the cellular and viral membranes to exert their antiviral activities.",2568.11,C106H180N28O37,CDFGHMPRSTVWY,E,4.86,5,7,-2,1,5,-175.24,-7165,20 hour,30 min,>10 hour,79.05,0,0.0,30867304,J Virol. 2019 May 15;93(11):e02312-18.,"Zhu Y, Chong H, Yu D, Guo Y, Zhou Y, He Y.",Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity.,10.1128/JVI.02312-18,,"Anti-HIV,Anti-SIV"
DRAVPe00792,TTWEAWDRAIAEYAARIEALIRAAQEQQEKNEAALREL,38,T2635,Synthetic construct,No entry found,,HIV,Retroviridae,MAGI/cMAGI infectivity assay,[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.007 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.018μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.025 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.015 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.021 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00792,DRAVPe00792.cif,Linear,Acetylation,Amidation,,L,membrane,"The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.",4415.89,C193H305N57O62,CFGHMPSV,A,4.64,5,8,-3,4,18,-67.11,-9788,7.2 hour,>20 hour,>10 hour,87.89,12490,337.57,17640899,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. ,"Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.","Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.",10.1073/pnas.0701478104,DRAVPa1315,Anti-HIV
DRAVPe00793,EWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLW,41,C41,Synthetic construct,No entry found,,HIV,Retroviridae,cell-cell fusion inhibition assay,[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=1.5 ± 0.1 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00793,DRAVPe00793.cif,Linear,Free,Free,,L,envelope glycoprotein(gp41),The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion.,5060.48,C223H337N59O76,CFGMPV,E,4.22,4,10,-6,10,13,-117.8,-11455,1 hour,30 min,>10 hour,88.05,17990,449.75,22770564,Bioconjug Chem. 2012 Aug 15;23(8):1648-60. ,"Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA.",Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation.,10.1021/bc3002248,,Anti-HIV
DRAVPe00794,XEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLW,42,X- C41(C41 N teminus-PEG conjugation),Synthetic construct,No entry found,,HIV,Retroviridae,cell-cell fusion inhibition assay,[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=7.2 ± 0.7 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00794,DRAVPe00794.cif,Linear,Free,Free,The 'X' at position 1 indicates PEG750-Cys.,L,envelope glycoprotein(gp41),The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion.,5171.81,C223H335N59O75,CFGMPV,E,4.22,4,10,-6,10,13,-115.0,-11455,,,,85.95,17990,438.78,22770564,Bioconjug Chem. 2012 Aug 15;23(8):1648-60. ,"Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA.",Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation.,10.1021/bc3002248,,Anti-HIV
DRAVPe00795,XEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLW,42,X- C41(C41 N teminus-PEG conjugation),Synthetic construct,No entry found,,HIV,Retroviridae,cell-cell fusion inhibition assay,[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=11.2± 1.9 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00795,DRAVPe00795.cif,Linear,Free,Free,The 'X' at position 1 indicates PEG2000-Cys.,L,envelope glycoprotein(gp41),The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion.,5171.81,C223H335N59O75,CFGMPV,E,4.22,4,10,-6,10,13,-115.0,-11455,,,,85.95,17990,438.78,22770564,Bioconjug Chem. 2012 Aug 15;23(8):1648-60. ,"Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA.",Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation.,10.1021/bc3002248,,Anti-HIV
DRAVPe00796,EWDXEINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLW,41,C41 [R4X](R4C),Synthetic construct,No entry found,,HIV,Retroviridae,cell-cell fusion inhibition assay,[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=5.1± 1.1 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00796,DRAVPe00796.cif,Linear,Free,Free,The 'X' at position 4 indicates PEG750-Cys.,L,envelope glycoprotein(gp41),The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion.,5015.62,C217H323N55O74,CFGMPRV,E,4.04,3,10,-7,10,13,-106.83,-9963,1 hour,30 min,>10 hour,88.05,17990,449.75,22770564,Bioconjug Chem. 2012 Aug 15;23(8):1648-60.,"Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA.",Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation.,10.1021/bc3002248,,Anti-HIV
DRAVPe00797,EWDXEINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLW,41,C41 [R4X](R4C),Synthetic construct,No entry found,,HIV,Retroviridae,cell-cell fusion inhibition assay,[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=8.7± 1.3 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00797,DRAVPe00797.cif,Linear,Free,Free,The 'X' at position 4 indicates PEG2000-Cys.,L,envelope glycoprotein(gp41),The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion.,5015.62,C217H323N55O74,CFGMPRV,E,4.04,3,10,-7,10,13,-106.83,-9963,1 hour,30 min,>10 hour,88.05,17990,449.75,22770564,Bioconjug Chem. 2012 Aug 15;23(8):1648-60.,"Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA.",Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation.,10.1021/bc3002248,,Anti-HIV
DRAVPe00798,EWDREINNYTXLIHSLIEESQNQQEKNEQELLELDKWASLW,41,C41 [S11X](S11C),Synthetic construct,No entry found,,HIV,Retroviridae,cell-cell fusion inhibition assay,[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=4.4± 0.8 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00798,DRAVPe00798.cif,Linear,Free,Free,The 'X' at position 11 indicates PEG750-Cys.,L,envelope glycoprotein(gp41),The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion.,5084.73,C220H330N58O73,CFGMPV,E,4.22,4,10,-6,9,13,-115.85,-11115,1 hour,30 min,>10 hour,88.05,17990,449.75,22770564,Bioconjug Chem. 2012 Aug 15;23(8):1648-60.,"Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA.",Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation.,10.1021/bc3002248,,Anti-HIV
DRAVPe00799,EWDREINNYTXLIHSLIEESQNQQEKNEQELLELDKWASLW,41,C41 [S11X](S11C),Synthetic construct,No entry found,,HIV,Retroviridae,cell-cell fusion inhibition assay,[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=4.9± 0.5 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00799,DRAVPe00799.cif,Linear,Free,Free,The 'X' at position 11 indicates PEG2000-Cys.,L,envelope glycoprotein(gp41),The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion.,5084.73,C220H330N58O73,CFGMPV,E,4.22,4,10,-6,9,13,-115.85,-11115,1 hour,30 min,>10 hour,88.05,17990,449.75,22770564,Bioconjug Chem. 2012 Aug 15;23(8):1648-60.,"Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA.",Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation.,10.1021/bc3002248,,Anti-HIV
DRAVPe00800,EWDREINNYTSLIHXLIEESQNQQEKNEQELLELDKWASLW,41,C41 [S15X](S15C),Synthetic construct,No entry found,,HIV,Retroviridae,cell-cell fusion inhibition assay,[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=4.1± 1.0 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00800,DRAVPe00800.cif,Linear,Free,Free,The 'X' at position 15 indicates PEG750-Cys.,L,envelope glycoprotein(gp41),The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion.,5084.73,C220H330N58O73,CFGMPV,E,4.22,4,10,-6,9,13,-115.85,-11115,1 hour,30 min,>10 hour,88.05,17990,449.75,22770564,Bioconjug Chem. 2012 Aug 15;23(8):1648-60.,"Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA.",Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation.,10.1021/bc3002248,,Anti-HIV
DRAVPe00801,EWDREINNYTSLIHXLIEESQNQQEKNEQELLELDKWASLW,41,C41 [S15X](S15C),Synthetic construct,No entry found,,HIV,Retroviridae,cell-cell fusion inhibition assay,[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=5.0± 0.5 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00801,DRAVPe00801.cif,Linear,Free,Free,The 'X' at position 15 indicates PEG2000-Cys.,L,envelope glycoprotein(gp41),The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion.,5084.73,C220H330N58O73,CFGMPV,E,4.22,4,10,-6,9,13,-115.85,-11115,1 hour,30 min,>10 hour,88.05,17990,449.75,22770564,Bioconjug Chem. 2012 Aug 15;23(8):1648-60.,"Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA.",Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation.,10.1021/bc3002248,,Anti-HIV
DRAVPe00802,EWDREINNYTSLIHSLIXESQNQQEKNEQELLELDKWASLW,41,C41 [E18X](E18C),Synthetic construct,No entry found,,HIV,Retroviridae,cell-cell fusion inhibition assay,[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=4.5± 1.0 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00802,DRAVPe00802.cif,Linear,Free,Free,The 'X' at position 18 indicates PEG750-Cys.,L,envelope glycoprotein(gp41),The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion.,5042.69,C218H328N58O72,CFGMPV,E,4.29,4,9,-5,10,13,-109.27,-10774,1 hour,30 min,>10 hour,88.05,17990,449.75,22770564,Bioconjug Chem. 2012 Aug 15;23(8):1648-60.,"Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA.",Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation.,10.1021/bc3002248,,Anti-HIV
DRAVPe00803,EWDREINNYTSLIHSLIXESQNQQEKNEQELLELDKWASLW,41,C41 [E18X](E18C),Synthetic construct,No entry found,,HIV,Retroviridae,cell-cell fusion inhibition assay,[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=4.9± 0.6 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00803,DRAVPe00803.cif,Linear,Free,Free,The 'X' at position 18 indicates PEG2000-Cys.,L,envelope glycoprotein(gp41),The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion.,5042.69,C218H328N58O72,CFGMPV,E,4.29,4,9,-5,10,13,-109.27,-10774,1 hour,30 min,>10 hour,88.05,17990,449.75,22770564,Bioconjug Chem. 2012 Aug 15;23(8):1648-60.,"Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA.",Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation.,10.1021/bc3002248,,Anti-HIV
DRAVPe00804,EWDREINNYTSLIHSLIEESQXQQEKNEQELLELDKWASLW,41,C41 [N22X](N22C),Synthetic construct,No entry found,,HIV,Retroviridae,cell-cell fusion inhibition assay,[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=4.2± 0.9 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00804,DRAVPe00804.cif,Linear,Free,Free,The 'X' at position 22 indicates PEG750-Cys.,L,envelope glycoprotein(gp41),The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion.,5057.7,C219H329N57O73,CFGMPV,E,4.22,4,10,-6,9,13,-109.27,-10791,1 hour,30 min,>10 hour,88.05,17990,449.75,22770564,Bioconjug Chem. 2012 Aug 15;23(8):1648-60.,"Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA.",Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation.,10.1021/bc3002248,,Anti-HIV
DRAVPe00805,EWDREINNYTSLIHSLIEESQXQQEKNEQELLELDKWASLW,41,C41 [N22X](N22C),Synthetic construct,No entry found,,HIV,Retroviridae,cell-cell fusion inhibition assay,[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=5.1± 0.5 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00805,DRAVPe00805.cif,Linear,Free,Free,The 'X' at position 22 indicates PEG2000-Cys.,L,envelope glycoprotein(gp41),The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion.,5057.7,C219H329N57O73,CFGMPV,E,4.22,4,10,-6,9,13,-109.27,-10791,1 hour,30 min,>10 hour,88.05,17990,449.75,22770564,Bioconjug Chem. 2012 Aug 15;23(8):1648-60.,"Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA.",Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation.,10.1021/bc3002248,,Anti-HIV
DRAVPe00806,EWDREINNYTSLIHSLIEESQNQQEKNEXELLELDKWASLW,41,C41 [Q29X](Q29C),Synthetic construct,No entry found,,HIV,Retroviridae,cell-cell fusion inhibition assay,[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=5.2± 0.8 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00806,DRAVPe00806.cif,Linear,Free,Free,The 'X' at position 29 indicates PEG750-Cys.,L,envelope glycoprotein(gp41),The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion.,5043.68,C218H327N57O73,CFGMPV,E,4.22,4,10,-6,10,13,-109.27,-10901,1 hour,30 min,>10 hour,88.05,17990,449.75,22770564,Bioconjug Chem. 2012 Aug 15;23(8):1648-60.,"Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA.",Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation.,10.1021/bc3002248,,Anti-HIV
DRAVPe00807,EWDREINNYTSLIHSLIEESQNQQEKNEXELLELDKWASLW,41,C41 [Q29X](Q29C),Synthetic construct,No entry found,,HIV,Retroviridae,cell-cell fusion inhibition assay,[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=5.5± 0.5 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00807,DRAVPe00807.cif,Linear,Free,Free,The 'X' at position 29 indicates PEG2000-Cys.,L,envelope glycoprotein(gp41),The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion.,5043.68,C218H327N57O73,CFGMPV,E,4.22,4,10,-6,10,13,-109.27,-10901,1 hour,30 min,>10 hour,88.05,17990,449.75,22770564,Bioconjug Chem. 2012 Aug 15;23(8):1648-60.,"Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA.",Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation.,10.1021/bc3002248,,Anti-HIV
DRAVPe00808,EWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWX,42,C41 -X(C41 C teminus-PEG conjugation),Synthetic construct,No entry found,,HIV,Retroviridae,cell-cell fusion inhibition assay,[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=10.9± 2.2 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00808,DRAVPe00808.cif,Linear,Free,Free,The 'X' at position 42 indicates PEG750-Cys.,L,envelope glycoprotein(gp41),The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion.,5171.81,C223H335N59O75,CFGMPV,E,4.22,4,10,-6,10,13,-115.0,-11455,1 hour,30 min,>10 hour,85.95,17990,438.78,22770564,Bioconjug Chem. 2012 Aug 15;23(8):1648-60.,"Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA.",Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation.,10.1021/bc3002248,,Anti-HIV
DRAVPe00809,EWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWX,42,C41 -X(C41 C teminus-PEG conjugation),Synthetic construct,No entry found,,HIV,Retroviridae,cell-cell fusion inhibition assay,[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=43.3± 14.8 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00809,DRAVPe00809.cif,Linear,Free,Free,The 'X' at position 42 indicates PEG2000-Cys.,L,envelope glycoprotein(gp41),The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion.,5171.81,C223H335N59O75,CFGMPV,E,4.22,4,10,-6,10,13,-115.0,-11455,1 hour,30 min,>10 hour,85.95,17990,438.78,22770564,Bioconjug Chem. 2012 Aug 15;23(8):1648-60.,"Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA.",Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation.,10.1021/bc3002248,,Anti-HIV
DRAVPe00810,EWDREINNYTSLIHSLIEEXQNQQEKNEQELLELDKWASLW,41,C41 [S20X](S20C),Synthetic construct,No entry found,,HIV,Retroviridae,cell-cell fusion inhibition assay,[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50>400 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00810,DRAVPe00810.cif,Linear,Free,Free,The 'X' at position 20 indicates PEG750-Cys.,L,envelope glycoprotein(gp41),The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion.,5084.73,C220H330N58O73,CFGMPV,E,4.22,4,10,-6,9,13,-115.85,-11115,1 hour,30 min,>10 hour,88.05,17990,449.75,22770564,Bioconjug Chem. 2012 Aug 15;23(8):1648-60.,"Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA.",Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation.,10.1021/bc3002248,,Anti-HIV
DRAVPe00811,EWDREINNYTSLIHSLIEEXQNQQEKNEQELLELDKWASLW,41,C41 [S20X](S20C),Synthetic construct,No entry found,,HIV,Retroviridae,cell-cell fusion inhibition assay,[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50>400 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00811,DRAVPe00811.cif,Linear,Free,Free,The 'X' at position 20 indicates PEG2000-Cys.,L,envelope glycoprotein(gp41),The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion.,5084.73,C220H330N58O73,CFGMPV,E,4.22,4,10,-6,9,13,-115.85,-11115,1 hour,30 min,>10 hour,88.05,17990,449.75,22770564,Bioconjug Chem. 2012 Aug 15;23(8):1648-60.,"Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA.",Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation.,10.1021/bc3002248,,Anti-HIV
DRAVPe00812,RMKQIEDKIEEIESKQKKIENEIARIKKLLQLTVWGIKQLQARIL,45,IQN17,Synthetic construct,No entry found,,HIV,Retroviridae,HIV luciferase assay,[Ref.11572974]HIV-1:inhibition of cell-cell fusion between 293T cells and  HOS-CD4/fusion cells(IC50=0.19±0.03 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00812,DRAVPe00812.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV-1 entry by inhibiting the fusion between virus and cell membrane.,5431.51,C243H423N69O68S,CFHPY,IK,9.78,11,7,4,4,17,-62.89,-10181,1 hour,2 min,2 min,123.56,5500,125.0,11572974,Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92.,"Eckert DM, Kim PS. ",Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.,10.1073/pnas.201392898,DRAVPa0204,Anti-HIV
DRAVPe00813,RMKQIEDKIEEIESKQKKIENEIARIKKLLQLTVWDIKQLQARIL,45,IQN17[G572D],Synthetic construct,No entry found,,HIV,Retroviridae,HIV luciferase assay,[Ref.11572974]HIV-1:inhibition of cell-cell fusion between 293T cells and  HOS-CD4/fusion cells(IC50=15±5 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00813,DRAVPe00813.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV-1 entry by inhibiting the fusion between virus and cell membrane.,5489.55,C245H425N69O70S,CFGHPY,IK,9.52,11,8,3,3,17,-69.78,-11147,1 hour,2 min,2 min,123.56,5500,125.0,11572974,Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92.,"Eckert DM, Kim PS. ",Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.,10.1073/pnas.201392898,,Anti-HIV
DRAVPe00814,RMKQIEDKIEEIESKQKKIENEIARIKKLIEAQQHLLQLTVWGIKQLQARIL,52,IQN23,Synthetic construct,No entry found,,HIV,Retroviridae,HIV luciferase assay,[Ref.11572974]HIV-1:inhibition of cell-cell fusion between 293T cells and  HOS-CD4/fusion cells(IC50=0.015±0.007 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00814,DRAVPe00814.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV-1 entry by inhibiting the fusion between virus and cell membrane.,6251.43,C279H480N80O79S,CFPY,IK,9.52,12,8,4,4,20,-61.35,-11271,1 hour,2 min,2 min,123.85,5500,107.84,11572974,Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92.,"Eckert DM, Kim PS. ",Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.,10.1073/pnas.201392898,DRAVPa0205,Anti-HIV
DRAVPe00815,RMKQIEDKIEEIESKQKKIENEIARIKKLISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL,66,IQN36,Synthetic construct,No entry found,,HIV,Retroviridae,HIV luciferase assay,[Ref.11572974]HIV-1:inhibition of cell-cell fusion between 293T cells and  HOS-CD4/fusion cells(IC50=0.088±0.035 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00815,DRAVPe00815.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV-1 entry by inhibiting the fusion between virus and cell membrane.,7787.19,C345H594N102O99S,CFPY,IQ,9.77,13,8,5,8,26,-49.24,-13446,1 hour,2 min,2 min,127.12,5500,84.62,11572974,Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92.,"Eckert DM, Kim PS. ",Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.,10.1073/pnas.201392898,DRAVPa0206,Anti-HIV
DRAVPe00816,IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL,41,IZN17,Synthetic construct,No entry found,,HIV,Retroviridae,HIV luciferase assay,[Ref.11572974]HIV-1:inhibition of cell-cell fusion between 293T cells and  HOS-CD4/fusion cells(IC50=0.022±0.011 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00816,DRAVPe00816.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV-1 entry by inhibiting the fusion between virus and cell membrane.,4813.88,C222H388N58O59,CDFHMNPSY,K,9.7,10,6,4,2,19,-24.88,-5195,20 hour,30 min,>10 hour,140.49,5500,137.5,11572974,Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92.,"Eckert DM, Kim PS. ",Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.,10.1073/pnas.201392898,DRAVPa0190,Anti-HIV
DRAVPe00817,IKKEIEAIKKEQEAIKKKIEAIEKEIEAQQHLLQLTVWGIKQLQARIL,48,IZN23,Synthetic construct,No entry found,,HIV,Retroviridae,HIV luciferase assay,[Ref.11572974]HIV-1:inhibition of cell-cell fusion between 293T cells and  HOS-CD4/fusion cells(IC50=0.030±0.01 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00817,DRAVPe00817.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV-1 entry by inhibiting the fusion between virus and cell membrane.,5649.75,C257H441N69O72,CDFMNPSY,IK,9.11,11,8,3,2,21,-43.96,-7458,20 hour,30 min,>10 hour,130.21,5500,117.02,11572974,Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92.,"Eckert DM, Kim PS. ",Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.,10.1073/pnas.201392898,DRAVPa0191,Anti-HIV
DRAVPe00818,IKKEIEAIKKEQEAIKKKIEAIEKEISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL,62,IZN36,Synthetic construct,No entry found,,HIV,Retroviridae,HIV luciferase assay,[Ref.11572974]HIV-1:inhibition of cell-cell fusion between 293T cells and  HOS-CD4/fusion cells(IC50=0.026±0.007 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00818,DRAVPe00818.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV-1 entry by inhibiting the fusion between virus and cell membrane.,7185.51,C323H555N91O92,CDFMPY,I,9.46,12,8,4,6,27,-35.0,-9633,20 hour,30 min,>10 hour,132.26,5500,90.16,11572974,Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92.,"Eckert DM, Kim PS. ",Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.,10.1073/pnas.201392898,DRAVPa0197,Anti-HIV
DRAVPe00819,RMKQIEDKIEEIESKIKKIENEIARIKKLLQLTVWGIKQLQARIL,45,IIN17,Synthetic construct,No entry found,,HIV,Retroviridae,HIV luciferase assay,[Ref.11572974]HIV-1:inhibition of cell-cell fusion between 293T cells and  HOS-CD4/fusion cells(IC50=0.14±0.05 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00819,DRAVPe00819.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV-1 entry by inhibiting the fusion between virus and cell membrane.,5416.54,C244H426N68O67S,CFHPY,I,9.78,11,7,4,4,18,-45.11,-9135,1 hour,2 min,2 min,132.22,5500,125.0,11572974,Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92.,"Eckert DM, Kim PS. ",Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.,10.1073/pnas.201392898,,Anti-HIV
DRAVPe00820,KIEEIESKQKKIENEIARIKKLLQLTVWGIKQLQARIL,38,IQ22N17,Synthetic construct,No entry found,,HIV,Retroviridae,HIV luciferase assay,[Ref.11572974]HIV-1:inhibition of cell-cell fusion between 293T cells and  HOS-CD4/fusion cells(IC50=1.4±0.3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00820,DRAVPe00820.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV-1 entry by inhibiting the fusion between virus and cell membrane.,4530.46,C206H359N57O56,CDFHMPY,IK,9.87,9,5,4,4,16,-41.58,-6754,1.3 hour,3 min,2 min,136.05,5500,148.65,11572974,Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92.,"Eckert DM, Kim PS. ",Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.,10.1073/pnas.201392898,,Anti-HIV
DRAVPe00821,KIEEIESKIKKIENEIARIKKLLQLTVWGIKQLQARIL,38,II22N17,Synthetic construct,No entry found,,HIV,Retroviridae,HIV luciferase assay,[Ref.11572974]HIV-1:inhibition of cell-cell fusion between 293T cells and  HOS-CD4/fusion cells(IC50=0.16±0.01 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00821,DRAVPe00821.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV-1 entry by inhibiting the fusion between virus and cell membrane.,4515.49,C207H362N56O55,CDFHMPY,I,9.87,9,5,4,4,17,-20.53,-5708,1.3 hour,3 min,2 min,146.32,5500,148.65,11572974,Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92.,"Eckert DM, Kim PS. ",Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.,10.1073/pnas.201392898,,Anti-HIV
DRAVPe00822,KQKKIENEIARIKKLLQLTVWGIKQLQARIL,31,IQ15N17,Synthetic construct,No entry found,,HIV,Retroviridae,HIV luciferase assay,[Ref.11572974]HIV-1:inhibition of cell-cell fusion between 293T cells and  HOS-CD4/fusion cells(IC50=5.5±1..5 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00822,DRAVPe00822.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV-1 entry by inhibiting the fusion between virus and cell membrane.,3701.55,C170H299N49O42,CDFHMPSY,K,10.66,8,2,6,3,14,-30.97,-4800,1.3 hour,3 min,2 min,141.61,5500,183.33,11572974,Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92.,"Eckert DM, Kim PS. ",Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.,10.1073/pnas.201392898,,Anti-HIV
DRAVPe00823,KIKKIENEIARIKKLLQLTVWGIKQLQARIL,31,II15N17,Synthetic construct,No entry found,,HIV,Retroviridae,HIV luciferase assay,[Ref.11572974]HIV-1:inhibition of cell-cell fusion between 293T cells and  HOS-CD4/fusion cells(IC50=2.1±0.8 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,DRAVPe00823,DRAVPe00823.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide inhibits HIV-1 entry by inhibiting the fusion between virus and cell membrane.,3686.58,C171H302N48O41,CDFHMPSY,IK,10.66,8,2,6,3,15,-5.16,-3754,1.3 hour,3 min,2 min,154.19,5500,183.33,11572974,Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92.,"Eckert DM, Kim PS. ",Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.,10.1073/pnas.201392898,,Anti-HIV
DRAVPe00824,ALWKTMLKKLGTMALHAGKAALGAAADTI,29,Dermaseptin-S1 (1-29),Synthetic construct(derived from Dermaseptin-S1),P24302,,HSV,Herpesviridae,antiviral assay,[Ref.20718719]HSV-1:inhibition of virus infection in Vero cells(IC50=1.7 µM).,[Ref.20718719]human red cells:HC50>100 µM.,[Ref.20718719]Vero cells:CC50=20 µM;293TT(embryonic human culture cells):CC50=40 µM.,DRAVPe00824,DRAVPe00824.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,2953.6,C133H226N36O35S2,CEFNPQRSVY,A,10.0,5,1,4,6,15,52.41,1056,4.4 hour,>20 hour,>10 hour,108.28,5500,196.43,20718719,APMIS. 2010 Sep 1;118(9):674-80.,"Savoia D, Donalisio M, Civra A, Salvadori S, Guerrini R.",In vitro activity of dermaseptin S1 derivatives against genital pathogens. ,10.1111/j.1600-0463.2010.02637.x,,Anti-HSV
DRAVPe00825,ALWTTMLKKLGKMALHAGKAALGAAADTI,29,"Dermaseptin-S1 (1-29)[K4T,T12K]",Synthetic construct(derived from Dermaseptin-S1),P24302,,HSV,Herpesviridae,antiviral assay,[Ref.20718719]HSV-1:inhibition of virus infection in Vero cells(IC50=1.3 µM).,[Ref.20718719]human red cells:HC50>100 µM.,[Ref.20718719]Vero cells:CC50=20 µM;293TT(embryonic human culture cells):CC50=40 µM.,DRAVPe00825,DRAVPe00825.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,2953.6,C133H226N36O35S2,CEFNPQRSVY,A,10.0,5,1,4,6,15,52.41,1056,4.4 hour,>20 hour,>10 hour,108.28,5500,196.43,20718719,APMIS. 2010 Sep 1;118(9):674-80.,"Savoia D, Donalisio M, Civra A, Salvadori S, Guerrini R.",In vitro activity of dermaseptin S1 derivatives against genital pathogens. ,10.1111/j.1600-0463.2010.02637.x,,Anti-HSV
DRAVPe00826,ALWKTMLKKLGTMALHAGK,19,Dermaseptin-S1 (1-19),Synthetic construct(derived from Dermaseptin-S1),P24302,,HSV,Herpesviridae,antiviral assay,[Ref.20718719]HSV-1:inhibition of virus infection in Vero cells(IC50=9 µM).,[Ref.20718719]human red cells:HC50>100 µM.,[Ref.20718719]Vero cells:CC50=80 µM;293TT(embryonic human culture cells):CC50=80 µM.,DRAVPe00826,DRAVPe00826.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,2098.64,C96H164N26O22S2,CDEFINPQRSVY,KL,10.48,5,0,5,4,8,13.16,202,4.4 hour,>20 hour,>10 hour,97.89,5500,305.56,20718719,APMIS. 2010 Sep 1;118(9):674-80.,"Savoia D, Donalisio M, Civra A, Salvadori S, Guerrini R.",In vitro activity of dermaseptin S1 derivatives against genital pathogens. ,10.1111/j.1600-0463.2010.02637.x,,Anti-HSV
DRAVPe00827,ALXKTMLKKLGTMAL,15,Dermaseptin-S1 (1-15)[W31NAL],Synthetic construct(derived from Dermaseptin-S1),P24302,,HSV,Herpesviridae,antiviral assay,[Ref.20718719]HSV-1:inhibition of virus infection in Vero cells(IC50=2.7 µM).,[Ref.20718719]human red cells:HC50=75 µM.,[Ref.20718719]Vero cells:CC50=50 µM;293TT(embryonic human culture cells):CC50>100 µM.,DRAVPe00827,DRAVPe00827.cif,Linear,Free,Amidation,The 'X' at position 3 indicates Nal (3-[1-naphthyl]alanine).,L,Not found,No machanism information found in the reference(s) presented in this entry,1630.31,C68H125N17O16S2,CDEFHINPQRSVWY,L,10.3,3,0,3,3,6,60.67,715,4.4 hour,>20 hour,>10 hour,117.33,0,0.0,20718719,APMIS. 2010 Sep 1;118(9):674-80.,"Savoia D, Donalisio M, Civra A, Salvadori S, Guerrini R.",In vitro activity of dermaseptin S1 derivatives against genital pathogens.,10.1111/j.1600-0463.2010.02637.x,,Anti-HSV
DRAVPe00828,ALHKTMLKKLGTMAL,15,Dermaseptin-S1 (1-15)[W3H],Synthetic construct(derived from Dermaseptin-S1),P24302,,HSV,Herpesviridae,antiviral assay,[Ref.20718719]HSV-1:inhibition of virus infection in Vero cells(IC50=5 µM).,[Ref.20718719]human red cells:HC50=100 µM.,[Ref.20718719]Vero cells:CC50>100 µM;293TT(embryonic human culture cells):CC50>100 µM.,DRAVPe00828,DRAVPe00828.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,1656.12,C74H134N20O18S2,CDEFINPQRSVWY,L,10.3,4,0,4,3,6,39.33,249,4.4 hour,>20 hour,>10 hour,117.33,0,0.0,20718719,APMIS. 2010 Sep 1;118(9):674-80.,"Savoia D, Donalisio M, Civra A, Salvadori S, Guerrini R.",In vitro activity of dermaseptin S1 derivatives against genital pathogens.,10.1111/j.1600-0463.2010.02637.x,,Anti-HSV
DRAVPe00829,KALXKTMLKKLGTMAL,16,K-Dermaseptin-S1 (1-15)[W31NAL],Synthetic construct(derived from Dermaseptin-S1),P24302,,HSV,Herpesviridae,antiviral assay,[Ref.20718719]HSV-1:inhibition of virus infection in Vero cells(IC50=5 µM).,[Ref.20718719]human red cells:HC50=80 µM.,[Ref.20718719]Vero cells:CC50=50 µM;293TT(embryonic human culture cells):CC50>100 µM.,DRAVPe00829,DRAVPe00829.cif,Linear,Free,Amidation,The 'X' at position 4 indicates Nal (3-[1-naphthyl]alanine).,L,Not found,No machanism information found in the reference(s) presented in this entry,1758.48,C74H137N19O17S2,CDEFHINPQRSVWY,KL,10.48,4,0,4,3,6,32.5,160,1.3 hour,3 min,2 min,110.0,0,0.0,20718719,APMIS. 2010 Sep 1;118(9):674-80.,"Savoia D, Donalisio M, Civra A, Salvadori S, Guerrini R.",In vitro activity of dermaseptin S1 derivatives against genital pathogens.,10.1111/j.1600-0463.2010.02637.x,,Anti-HSV
DRAVPe00830,ALWKTMLKKLGTMA,14,Dermaseptin-S1 (1-14),Synthetic construct(derived from Dermaseptin-S1),P24302,,HSV,Herpesviridae,antiviral assay,[Ref.20718719]HSV-1:inhibition of virus infection in Vero cells(IC50=10.5 µM).,[Ref.20718719]human red cells:HC50>100 µM.,[Ref.20718719]Vero cells:CC50=85 µM;293TT(embryonic human culture cells):CC50>100 µM.,DRAVPe00830,DRAVPe00830.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,1592.03,C73H126N18O17S2,CDEFHINPQRSVY,KL,10.3,3,0,3,3,6,31.43,456,4.4 hour,>20 hour,>10 hour,97.86,5500,423.08,20718719,APMIS. 2010 Sep 1;118(9):674-80.,"Savoia D, Donalisio M, Civra A, Salvadori S, Guerrini R.",In vitro activity of dermaseptin S1 derivatives against genital pathogens.,10.1111/j.1600-0463.2010.02637.x,,Anti-HSV
DRAVPe00831,ALWKTMLKKLGTM,13,Dermaseptin-S1 (1-13),Synthetic construct(derived from Dermaseptin-S1),P24302,,HSV,Herpesviridae,antiviral assay,[Ref.20718719]HSV-1:inhibition of virus infection in Vero cells(IC50=10 µM).,[Ref.20718719]human red cells:HC50>100 µM.,[Ref.20718719]Vero cells:CC50=100 µM;293TT(embryonic human culture cells):CC50>100 µM.,DRAVPe00831,DRAVPe00831.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,1520.96,C70H121N17O16S2,CDEFHINPQRSVY,KL,10.3,3,0,3,3,5,20.0,275,4.4 hour,>20 hour,>10 hour,97.69,5500,458.33,20718719,APMIS. 2010 Sep 1;118(9):674-80.,"Savoia D, Donalisio M, Civra A, Salvadori S, Guerrini R.",In vitro activity of dermaseptin S1 derivatives against genital pathogens.,10.1111/j.1600-0463.2010.02637.x,,Anti-HSV
DRAVPe00832,ALWKTMLKKLGT,12,Dermaseptin-S1 (1-12),Synthetic construct(derived from Dermaseptin-S1),P24302,,HSV,Herpesviridae,antiviral assay,[Ref.20718719]HSV-1:inhibition of virus infection in Vero cells(IC50=100 µM).,[Ref.20718719]human red cells:HC50>100 µM.,[Ref.20718719]Vero cells:CC50>100 µM;293TT(embryonic human culture cells):CC50>100 µM.,DRAVPe00832,DRAVPe00832.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,1389.76,C65H112N16O15S,CDEFHINPQRSVY,KL,10.3,3,0,3,3,5,5.83,40,4.4 hour,>20 hour,>10 hour,105.83,5500,500.0,20718719,APMIS. 2010 Sep 1;118(9):674-80.,"Savoia D, Donalisio M, Civra A, Salvadori S, Guerrini R.",In vitro activity of dermaseptin S1 derivatives against genital pathogens.,10.1111/j.1600-0463.2010.02637.x,,Anti-HSV
DRAVPe00833,EMTWEEWEKKIEEYTKKIEEILKKSQNQQIDL,32,HP23-E6-IDL,Synthetic construct,No entry  found,,HIV,Retroviridae,HIV-1-Mediated Cell-Cell Fusion Assay,"[Ref.30901967]HIV-1IIIB(X4 virus):inhibition of virus infection in MT-2 cells(IC50=338 pM);inhibition of cell-cell fusion between H9/IIIB cells and MT-2 cells(IC50=1.14 nM);##HIV-1Bal(R5 virus):inhibition of virus infection in MT-2 cells(IC50=813 pM);##HIV-1 NL4-3 D36G(6 T-20 resistant strains, WT,V38A,V38A/N42D,V38E/N42S,V38A/N42T,N42T/N43K):inhibition of virus infection in MT-2 cells(IC50=748-1543 pM);##HIV-1 LAI (7 T2635-Resistant Strains,WT,A6V,Q66R,K90E,K154Q,Q79E/N126K,K90E/N126K):inhibition of virus infection in MT-2 cells(IC50=349-1423 pM);##HIV-1 NL4-3 (5 HP23-Resistant Strains,WT,E49K,E49K/N126K,D36G/E49K/N126K,L34S/D36G/E49K/E136G):inhibition of virus infection in MT-2 cells(IC50=699-4937 pM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30901967]No cytotoxicity against MT-2 or M7 cells at the concentrations as high as 8 μM.,DRAVPe00833,DRAVPe00833.cif,Linear,Free,Free,,L,membrane,It was a fusion inhibitor and inhibits cell-cell fusion,4068.61,C182H288N44O59S,ACFGHPRV,E,4.73,6,9,-3,5,8,-145.94,-9191,1 hour,30 min,>10 hour,73.13,12490,402.9,30901967,Molecules. 2019 Mar 21;24(6):1134.,"Su S, Rasquinha G, Du L, Wang Q, Xu W, Li W, Lu L, Jiang S. ",A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life.,10.3390/molecules24061134,,Anti-HIV
DRAVPe00834,EMTWEEWEKKIEEYIKKIEEILKKSQNQQIDL,32,YIK(625-656),Synthetic construct,No entry  found,,HIV,Retroviridae,HIV-1-Mediated Cell-Cell Fusion Assay,"[Ref.30901967]HIV-1IIIB(X4 virus):inhibition of virus infection in MT-2 cells(IC50=275pM);inhibition of cell-cell fusion between H9/IIIB cells and MT-2 cells(IC50=1.12 nM);##HIV-1Bal(R5 virus):inhibition of virus infection in MT-2 cells(IC50=640 pM);##HIV-1 NL4-3 D36G(6 T-20 resistant strains, WT,V38A,V38A/N42D,V38E/N42S,V38A/N42T,N42T/N43K):inhibition of virus infection in MT-2 cells(IC50=627-1423 pM);##HIV-1 LAI (7 T2635-Resistant Strains,WT,A6V,Q66R,K90E,K154Q,Q79E/N126K,K90E/N126K):inhibition of virus infection in MT-2 cells(IC50=460-1490 pM);##HIV-1 NL4-3 (5 HP23-Resistant Strains,WT,E49K,E49K/N126K,D36G/E49K/N126K,L34S/D36G/E49K/E136G):inhibition of virus infection in MT-2 cells(IC50=856-5286 pM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30901967]No cytotoxicity against MT-2 or M7 cells at the concentrations as high as 8 μM.,DRAVPe00834,DRAVPe00834.cif,Linear,Free,Free,,L,membrane,It was a fusion inhibitor and inhibits cell-cell fusion,4080.66,C184H292N44O58S,ACFGHPRV,E,4.73,6,9,-3,4,9,-129.69,-8442,1 hour,30 min,>10 hour,85.31,12490,402.9,30901967,Molecules. 2019 Mar 21;24(6):1134.,"Su S, Rasquinha G, Du L, Wang Q, Xu W, Li W, Lu L, Jiang S. ",A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life.,10.3390/molecules24061134,,Anti-HIV
DRAVPe00835,EMTWEEWEKKIEEYIKKIEEILKKSQNQQIDLGSGX,36,YIK-C16(625-656),Synthetic construct,No entry  found,,HIV,Retroviridae,HIV-1-Mediated Cell-Cell Fusion Assay,"[Ref.30901967]HIV-1IIIB(X4 virus):inhibition of virus infection in MT-2 cells(IC50=76 pM);inhibition of cell-cell fusion between H9/IIIB cells and MT-2 cells(IC50=0.55 nM);##HIV-1Bal(R5 virus):inhibition of virus infection in MT-2 cells(IC50=61 pM);##HIV-1 NL4-3 D36G(6 T-20 resistant strains, WT,V38A,V38A/N42D,V38E/N42S,V38A/N42T,N42T/N43K):inhibition of virus infection in MT-2 cells(IC50=40-179 pM);##HIV-1 LAI (7 T2635-Resistant Strains,WT,A6V,Q66R,K90E,K154Q,Q79E/N126K,K90E/N126K):inhibition of virus infection in MT-2 cells(IC50=65-106 pM);##HIV-1 NL4-3 (5 HP23-Resistant Strains,WT,E49K,E49K/N126K,D36G/E49K/N126K,L34S/D36G/E49K/E136G):inhibition of virus infection in MT-2 cells(IC50=65-188 pM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30901967]No cytotoxicity against MT-2 or M7 cells at the concentrations as high as 8 μM.,DRAVPe00835,DRAVPe00835.cif,Linear,Free,Free,The 'X' at position 36 indicates PEG4-Lys-C16(Palmitic Acid).,L,membrane,It was a fusion inhibitor and inhibits cell-cell fusion,4393.18,C191H301N47O61S,ACFHPRV,E,4.73,6,9,-3,7,9,-119.72,-8594,1 hour,30 min,>10 hour,75.83,12490,356.86,30901967,Molecules. 2019 Mar 21;24(6):1134.,"Su S, Rasquinha G, Du L, Wang Q, Xu W, Li W, Lu L, Jiang S. ",A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life.,10.3390/molecules24061134,,Anti-HIV
DRAVPe00836,GGLKKLGKKLEGAGKRVFNAAEKALPVVAGAKAL,34,Cecropin A,Aedes aegypti (Yellowfever mosquito),P01508,2MMM,"Tacaribe virus,JV,Pichinde virus",Arenaviridae,,"[Ref.15081088]Junin virus(JV):inhibtion of JV infection in Vero cells(EC50=3.4 μM,EC90=28.57 μM);##Tacaribe virus:inhibition of tacaribe virus infection in Vero cells(IC50=1.96 μM,EC90=33.39 μM);##Pichinde virus:inhibition of Pichinde virus infection in Vero cells(IC50=6.56 μM,EC90=39 μM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.15081088]Vero cells:CC50>100 μM.,DRAVPe00836,DRAVPe00836.cif,Linear,Free,Amidtion,,L,glycoprotein G1,"Cecropin A caused an altered intracellular distribution and membrane expression of the viral glycoprotein G1, as it was shown by membrane and cytoplasmic IF assays,which indicate that the inhibition of G1 transport and/or insertion into the cell membrane might prevent the formation of infectious particles leading to the reduction of cell-associated infectivity.",3391.11,C154H269N45O40,CDHIMQSTWY,AK,10.39,8,2,6,7,16,2.06,-1602,30 hour,>20 hour,>10 hour,103.53,0,0.0,15081088, Int J Antimicrob Agents. 2004 Apr;23(4):382-9.,"Albiol Matanic VC, Castilla V. ",Antiviral activity of antimicrobial cationic peptides against Junin virus and herpes simplex virus. ,10.1016/j.ijantimicag.2003.07.022,,"Anti-Tacaribe virus,Anti-JV,Anti-Pichinde virus"
DRAVPe00837,GIGAVLKVLTTGLPALISWIKRKRQQ,26,Melittin,Apis mellifera (Honeybee),P01501,2MLT,"JV,HSV, Influenza A virus, EV-71, RSV,VSV, HIV","Arenaviridae, Herpesviridae, Orthomyxoviridae, Picornaviridae, Pneumoviridae, Rhabdoviridae, Retroviridae",,[Ref.15081088]Junin virus(JV):inhibtion of JV infection in Vero cells(EC50=0.86 μM);##Herpes simplex virus type 1 (HSV-1):inhibition of HSV-1 infection in Vero cells(EC50=1.35 μM);##Herpes simplex virus type 2 (HSV-2):inhibition of HSV-2 infection in Vero cells(EC50=2.05 μM).##[Ref.31422545] GFP-fused influenza A (PR8):exerts antiviral activity in MDCK cells(EC50=1.15 ± 0.09 μg/mL);##Enterovirus A71 (EV-A71):exerts antiviral activity in HeLa cells(EC50=0.76 ± 0.03 μg/mL);##GFP-fused coxsakievirus (H3):exerts antiviral activity in HeLa cells(EC50=0.99 ± 0.09 μg/mL);## GFP-fused RSV:exerts antiviral activity in HEp2 cells(EC50=0.99 ± 0.09 μg/mL);##  GFP-fused VSV:exerts antiviral activity in Vero cells(EC50=1.18 ± 0.09 μg/mL);##  HIV-1 (NLHX):exerts antiviral activity in Vaginal epithelial cells (VK2)(EC50=2.4 μM);##  HIV-2 (NLYU2):exerts antiviral activity in Vaginal epithelial cells (VK2)(EC50=3.6 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.15081088]Vero cells:CC50=8.51 μM.,DRAVPe00837,DRAVPe00837.cif,Linear,Free,Amidtion,,L,Not found,"Melittin suppresses cell fusion mediated by HSV-1 syncytial mutants probably by interfering with the activity of the Na, K ATPase, cellular enzyme involved in the membrane fusion process.",2847.49,C131H228N38O32,CDEFHMNY,L,12.02,5,0,5,6,12,27.31,-1482,30 hour,>20 hour,>10 hour,135.0,5500,220.0,15081088##31422545, Int J Antimicrob Agents. 2004 Apr;23(4):382-9.##Eur J Clin Microbiol Infect Dis. 2020 Jan;39(1):5-17.,"Albiol Matanic VC, Castilla V. ##Memariani H, Memariani M, Moravvej H, Shahidi-Dadras M. ",Antiviral activity of antimicrobial cationic peptides against Junin virus and herpes simplex virus. ##Melittin: a venom-derived peptide with promising anti-viral properties.,10.1016/j.ijantimicag.2003.07.022##10.1007/s10096-019-03674-0,,"Anti-JV,Anti-HSV, Anti-Anti-Influenza A virus, EV-71, Anti-RSV,Anti-VSV, Anti-HIV"
DRAVPe00838,GIGKFLHSAGKFGKAFVGEIMKS,23,Magainin-1,Xenopus laevis (African clawed frog),P11006,,HSV,Herpesviridae,,[Ref.15081088]Herpes simplex virus type 1 (HSV-1):inhibition of HSV-1 infection in Vero cells(EC50=36.59 μM);##Herpes simplex virus type 2 (HSV-2):inhibition of HSV-2 infection in Vero cells(EC50=33.20 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.15081088]Vero cells:CC50>100 μM.,DRAVPe00838,DRAVPe00838.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2409.87,C112H177N29O28S,CDNPQRTWY,G,10.0,5,1,4,7,9,21.74,-206,30 hour,>20 hour,>10 hour,72.17,0,0.0,15081088, Int J Antimicrob Agents. 2004 Apr;23(4):382-9.,"Albiol Matanic VC, Castilla V. ",Antiviral activity of antimicrobial cationic peptides against Junin virus and herpes simplex virus. ,10.1016/j.ijantimicag.2003.07.022,,Anti-HSV
DRAVPe00839,GIGKFLHSAKKFGKAFVGEIMNS,23,Magainin II,Xenopus ruwenzoriensis (Uganda clawed frog),C0HKN6,2MAG##2LSA,"CCV,HSV",Herpesviridae,,[Ref.15193922]Channel Catfish virus(CCV): inhibition of CCV infection in catfish ovary(CCO) cells(reduce viral infectivity by 50% at 48 μM).##[Ref.15081088]Herpes simplex virus type 1 (HSV-1):inhibition of HSV-1 infection in Vero cells(EC50=22.16 μM);##Herpes simplex virus type 2 (HSV-2):inhibition of HSV-2 infection in Vero cells(EC50=19.80 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.15081088]Vero cells:CC50>100 μM.,DRAVPe00839,DRAVPe00839.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2466.93,C114H180N30O29S,CDPQRTWY,GK,10.0,5,1,4,7,9,8.26,-964,30 hour,>20 hour,>10 hour,72.17,0,0.0,15193922##15081088,Virology. 2004 Jun 1;323(2):268-75.## Int J Antimicrob Agents. 2004 Apr;23(4):382-9.,"Chinchar VG, Bryan L, Silphadaung U, Noga E, Wade D, Rollins-Smith L.##Albiol Matanic VC, Castilla V. ",Inactivation of viruses infecting ectothermic animals by amphibian and piscine antimicrobial peptides.##Antiviral activity of antimicrobial cationic peptides against Junin virus and herpes simplex virus. ,10.1016/j.virol.2004.02.029##10.1016/j.ijantimicag.2003.07.022,,"Anti-CCV,Anti-HSV"
DRAVPe00840,PACQDFLGAMIHLKAKTNISIR,22,3(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(28% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00840,DRAVPe00840.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2427.91,C107H179N31O29S2,EVWY,AI,9.37,4,1,3,5,9,19.09,-1997,>20 hour,>20 hour,?,102.27,0,0.0,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00841,LKAKTNISIREGPTLGNWAR,20,4(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(24% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00841,DRAVPe00841.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2225.58,C98H165N31O28,CDFHMQVY,AGIKLNRT,11.0,4,1,3,7,7,-63.0,-4206,5.5 hour,3 min,2 min,88.0,5500,289.47,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00842,EGPTLGNWAREIWATLFKKA,20,5(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(100% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00842,DRAVPe00842.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2288.63,C107H162N28O28,CDHMQSVY,A,8.69,3,2,1,5,9,-40.5,-2171,1 hour,30 min,>10 hour,73.5,11000,578.95,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00843,EIWATLFKKATRQCRRGRIW,20,6(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(100% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00843,DRAVPe00843.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2520.0,C114H183N37O26S,DHMNPSVY,R,11.56,6,1,5,4,8,-73.5,-6003,1 hour,30 min,>10 hour,68.5,11000,578.95,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00844,TRQCRRGRIWKRWNETITGP,20,7(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(94% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00844,DRAVPe00844.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2514.9,C108H176N40O28S,ADFHLMSVY,R,11.83,6,1,5,7,4,-158.5,-8919,7.2 hour,>20 hour,>10 hour,39.0,11000,578.95,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00845,SGCANNTCYNAnti-VSVIVPDYQC,20,9(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(24% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00845,DRAVPe00845.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2150.38,C89H136N24O32S3,EFHKLMRW,CNV,3.8,0,1,-1,12,5,10.0,-2020,1.9 hour,>20 hour,>10 hour,68.0,3105,163.42,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00846,YLDRVDTWLQGKINISLCLT,20,11(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(9% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00846,DRAVPe00846.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2351.75,C106H171N27O31S,AEFHMP,L,5.95,2,2,0,7,8,18.5,-2066,2.8 hour,10 min,2 min,131.5,6990,367.89,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00847,GKINISLCLTGGKMLYNKVT,20,12(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(10% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00847,DRAVPe00847.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2153.63,C95H165N25O27S2,ADEFHPQRW,GKL,9.63,3,0,3,10,6,28.0,-352,30 hour,>20 hour,>10 hour,112.0,1490,78.42,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00848,GGKMLYNKVTKQLSYCTDPL,20,13(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(5% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00848,DRAVPe00848.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2259.66,C100H163N25O30S2,AEFHIRW,KL,9.05,3,1,2,9,4,-47.0,-2206,30 hour,>20 hour,>10 hour,73.0,2980,156.84,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00849,KQLSYCTDPLQIPLINYTFG,20,14(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(15% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00849,DRAVPe00849.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2314.68,C107H164N24O31S,AEHMRVW,L,5.83,1,1,0,8,6,-3.0,-1101,1.3 hour,3 min,2 min,97.5,2980,156.84,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00850,PNQTCMWNTSQIQDPEIPKC,20,16(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(5% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00850,DRAVPe00850.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2333.63,C98H153N27O33S3,AFGHLRVY,PQ,4.37,1,2,-1,7,3,-102.0,-4244,>20 hour,>20 hour,?,39.0,5625,296.05,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00851,QIQDPEIPKCGWWNQMAYYN,20,17(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(2% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00851,DRAVPe00851.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2484.79,C113H158N28O32S2,FHLRSTV,Q,4.37,1,2,-1,6,5,-106.0,-3038,0.8 hour,10 min,>10 hour,44.0,13980,735.79,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00852,FHCQRTQSQPGSWFRAISSWKQ,22,20(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(4% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00852,DRAVPe00852.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2665.97,C119H173N37O32S,DELMNVY,QS,10.86,4,0,4,7,6,-106.36,-5881,1.1 hour,3 min,2 min,22.27,11000,523.81,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00853,GSWFRAISSWKQRNRWEWRPDF,22,21(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(6% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00853,DRAVPe00853.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2896.23,C135H187N41O32,CHLMTVY,RW,11.54,5,2,3,5,8,-145.45,-8019,30 hour,>20 hour,>10 hour,22.27,22000,1047.62,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00854,KQRNRWEWRPDFKSKKVKISLPC,23,22(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(6% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00854,DRAVPe00854.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2930.47,C133H213N41O32S,AGHMTY,K,10.56,8,2,6,4,6,-155.65,-8422,1.3 hour,3 min,2 min,46.52,11000,500.0,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00855,KSKKVKISLPCNSTKNLTFA,20,23(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(10% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00855,DRAVPe00855.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2207.66,C98H171N27O28S,DEGHMQRWY,K,10.2,5,0,5,8,6,-42.5,-3150,1.3 hour,3 min,2 min,78.0,0,0.0,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00856,CNSTKNLTFAMRSSGDYGEV,20,24(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(25% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00856,DRAVPe00856.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2180.39,C90H142N26O33S2,HIPQW,S,6.06,2,2,0,11,4,-56.5,-4550,1.2 hour,>20 hour,>10 hour,39.0,1490,78.42,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00857,MRSSGDYGEVTGAWIEFGCH,20,25(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(27% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00857,DRAVPe00857.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2202.4,C95H136N26O31S2,KLNPQ,G,4.65,2,3,-1,9,5,-33.0,-2796,30 hour,>20 hour,>10 hour,39.0,6990,367.89,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00858,TGAWIEFGCHRNKSNLHTEA,20,26(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(5% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00858,DRAVPe00858.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2271.49,C98H147N31O30S,DMPQVY,AEGHNT,6.62,4,2,2,8,6,-77.5,-4330,7.2 hour,>20 hour,>10 hour,49.0,5500,289.47,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00859,RNKSNLHTEARFRIRCRAnti-WNV,20,27(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(2% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00859,DRAVPe00859.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2556.94,C109H178N42O28S,DGMPQY,R,11.83,7,1,6,6,6,-132.0,-9523,1 hour,2 min,2 min,58.5,5500,289.47,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00860,RFRIRCRAnti-WNVGSDTSLIDTC,20,28(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(40% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00860,DRAVPe00860.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2398.74,C101H164N34O30S2,AEHKMPQY,R,9.02,4,2,2,8,6,-40.0,-6809,1 hour,2 min,2 min,73.0,5625,296.05,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00861,GSDTSLIDTCGNTPNVSGAN,20,29(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(12% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00861,DRAVPe00861.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,1923.0,C75H123N23O34S,EFHKMQRWY,GNST,3.56,0,2,-2,13,4,-40.0,-3548,30 hour,>20 hour,>10 hour,58.5,0,0.0,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00862,PVDCTMYSNKMYNCSLQNGF,20,31(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(8% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00862,DRAVPe00862.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2315.63,C98H147N25O32S4,AEHIRW,N,6.17,1,1,0,11,3,-43.5,-2924,>20 hour,>20 hour,?,34.0,3105,163.42,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00863,MYNCSLQNGFTMKVDDLIVH,20,32(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(33% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00863,DRAVPe00863.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2328.7,C101H158N26O31S3,AEPRW,DLMNV,5.19,2,2,0,7,6,9.0,-1984,30 hour,>20 hour,>10 hour,87.5,1490,78.42,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00864,TMKVDDLIVHFNMTKAVEMV,20,33(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(25% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00864,DRAVPe00864.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2321.79,C102H169N25O30S3,CGPQRSWY,V,5.35,3,3,0,3,8,45.0,-1395,7.2 hour,>20 hour,>10 hour,102.0,0,0.0,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00865,FNMTKAVEMVNIAGNWSCTS,20,34(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(15% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00865,DRAVPe00865.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2203.53,C94H147N25O30S3,DHLPQRY,N,5.99,1,1,0,9,7,17.0,-1537,1.1 hour,3 min,2 min,58.5,5500,289.47,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00866,NIAGNWSCTSDLPSSWGYMN,20,35(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(22% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00866,DRAVPe00866.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2203.39,C95H135N25O32S2,EFHKQRV,S,3.8,0,1,-1,12,5,-44.5,-2313,1.4 hour,3 min,>10 hour,44.0,12490,657.37,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00867,CTSDLPSSWGYMNCNCTNSSSS,22,36(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(5% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00867,DRAVPe00867.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2344.5,C92H138N26O38S4,AEFHIKQRV,S,3.8,0,1,-1,17,2,-54.55,-4334,1.2 hour,>20 hour,>10 hour,17.73,7115,338.81,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00868,CNCTNSSSSYSGTKMACPSNRG,22,37(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(60% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00868,DRAVPe00868.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2255.45,C85H139N29O35S4,DEFHILQVW,S,8.68,2,0,2,17,1,-80.0,-5619,1.2 hour,>20 hour,>10 hour,4.55,1615,76.9,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00869,SGTKMACPSNRGILRNWYNP,20,38(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(52% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00869,DRAVPe00869.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2265.59,C97H153N31O28S2,DEFHQV,N,10.05,3,0,3,10,4,-87.0,-4533,1.9 hour,>20 hour,>10 hour,44.0,6990,367.89,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00870,RGILRNWYNPFAGLRQSLEQ,20,39(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(60% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00870,DRAVPe00870.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2418.74,C109H168N34O29,CDHKMTV,LR,10.74,3,1,2,6,7,-79.5,-5079,1 hour,2 min,2 min,83.0,6990,367.89,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00871,VAGLRQSLEQYQVVKQPDYL,20,40(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(48% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00871,DRAVPe00871.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2334.66,C105H168N28O32,CFHIMNTW,Q,6.04,2,2,0,4,7,-45.0,-3221,100 hour,>20 hour,>10 hour,107.0,2980,156.84,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00872,YQVVKQPDYLLVPEEVMEYK,20,41(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(38% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00872,DRAVPe00872.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2470.86,C115H176N24O34S,ACFGHINRSTW,V,4.41,2,4,-2,3,6,-48.0,-2340,2.8 hour,10 min,2 min,97.0,4470,235.26,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00873,PDYLLVPEEVMEYKPRRKRAAI,22,42(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(54% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00873,DRAVPe00873.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2674.16,C121H197N33O33S,CFGHNQSTW,EPR,8.83,5,4,1,2,7,-75.91,-5648,>20 hour,>20 hour,?,88.64,2980,141.9,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00874,YKPRRKRAAIHVMLALATVLSI,22,43(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(52% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00874,DRAVPe00874.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2508.11,C114H199N35O26S,CDEFGNQW,A,11.73,6,0,6,3,11,40.91,-2436,2.8 hour,10 min,2 min,133.18,1490,70.95,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00875,HVMLALATVLSIAGAGTGATAI,22,44(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(58% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00875,DRAVPe00875.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2038.43,C90H156N24O27S,CDEFKNPQRWY,A,6.74,1,0,1,7,13,155.45,3294,3.5 hour,10 min,>10 hour,142.27,0,0.0,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00876,AGAGTGATAIGMVTQYHQVL,20,45(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(60% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00876,DRAVPe00876.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,1946.21,C84H136N24O27S,CDEFKNPRSW,AG,6.78,1,0,1,8,8,53.0,768,4.4 hour,>20 hour,>10 hour,88.0,1490,78.42,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00877,GMVTQYHQVLATHQEAIEKV,20,46(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(43% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00877,DRAVPe00877.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2282.6,C100H160N28O31S,CDFNPRSW,QV,6.0,3,2,1,4,7,-22.5,-2152,30 hour,>20 hour,>10 hour,92.5,1490,78.42,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00878,ATHQEAIEKVTGALKINNLR,20,47(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(44% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00878,DRAVPe00878.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2206.53,C95H164N30O30,CDFMPSWY,A,8.64,4,2,2,5,8,-43.0,-3817,4.4 hour,>20 hour,>10 hour,107.5,0,0.0,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00879,TGALKINNLRLVTLEHQVLV,20,48(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(73% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00879,DRAVPe00879.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2231.67,C100H175N29O28,CDFMPSWY,L,8.44,3,1,2,5,10,52.5,-1151,7.2 hour,>20 hour,>10 hour,165.5,0,0.0,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00880,LVTLEHQVLVIGLKVEAMEK,20,49(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(45% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00880,DRAVPe00880.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2249.74,C102H177N25O29S,CDFNPRSWY,LV,5.5,3,3,0,2,10,70.5,156,5.5 hour,3 min,2 min,160.5,0,0.0,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00881,IGLKVEAMEKFLYTAFAMQE,20,50(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(74% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00881,DRAVPe00881.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2319.76,C107H167N23O30S2,CDHNPRSW,AE,4.79,2,3,-1,3,9,34.5,-395,20 hour,30 min,>10 hour,88.0,1490,78.42,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00882,FLYTAFAMQELGCNQNQFFC,20,51(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(18% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00882,DRAVPe00882.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2375.72,C108H151N25O30S3,DHIKPRSVW,F,4.0,0,1,-1,7,8,29.5,-819,1.1 hour,3 min,2 min,49.0,1615,85.0,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00883,LGCNQNQFFCKIPLELWTRY,20,52(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(21% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00883,DRAVPe00883.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2473.89,C114H169N29O29S2,ADHMSV,L,8.05,2,1,1,7,7,-21.5,-2288,5.5 hour,3 min,2 min,78.0,7115,374.47,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00884,NMTINQTIWNHGNITLGEWY,20,54(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(4% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00884,DRAVPe00884.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2405.67,C108H157N29O32S,ACDFKPRSV,N,5.24,1,1,0,10,6,-55.0,-2285,1.4 hour,3 min,>10 hour,78.0,12490,657.37,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00885,HGNITLGEWYNQTKDLQQKF,20,55(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(35% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00885,DRAVPe00885.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2420.67,C109H162N30O33,ACMPRSV,Q,6.75,3,2,1,7,5,-125.0,-4452,3.5 hour,10 min,>10 hour,58.5,6990,367.89,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00886,NQTKDLQQKFYEIIMDIEQN,20,56(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(68% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00886,DRAVPe00886.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2498.79,C109H172N28O37S,ACGHPRSVW,Q,4.32,2,4,-2,4,5,-114.0,-5530,1.4 hour,3 min,>10 hour,78.0,1490,78.42,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00887,YEIIMDIEQNNVQGKTGIQQ,20,57(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(37% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00887,DRAVPe00887.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2321.59,C99H161N27O35S,ACFHLPRSW,IQ,4.14,1,3,-2,6,5,-70.5,-3809,2.8 hour,10 min,2 min,92.5,1490,78.42,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00888,NVQGKTGIQQLQKWEDWVRW,20,58(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(96% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00888,DRAVPe00888.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2499.81,C114H171N33O31,ACFHMPSY,Q,8.59,3,2,1,4,7,-121.5,-4613,1.4 hour,3 min,>10 hour,68.0,16500,868.42,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00889,LQKWEDWVRWIGNIPQYLKG,20,59(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(98% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00889,DRAVPe00889.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2529.93,C121H177N31O29,ACFHMST,W,8.5,3,2,1,4,8,-77.0,-2682,5.5 hour,3 min,2 min,92.5,17990,946.84,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00890,IGNIPQYLKGLLGGILGIGL,20,60(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(60% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00890,DRAVPe00890.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2009.46,C95H161N23O24,ACDEFHMRSTVW,G,8.59,1,0,1,8,9,104.0,3205,20 hour,30 min,>10 hour,175.5,1490,78.42,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00891,LLGGILGIGLGVLLLILCLP,20,61(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(88% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00891,DRAVPe00891.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,1960.58,C95H170N20O21S,ADEFHKMNQRSTWY,L,5.52,0,0,0,6,13,254.0,6906,5.5 hour,3 min,2 min,248.5,0,0.0,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00892,GVLLLILCLPTLVDCIRNCI,20,62(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(32% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00892,DRAVPe00892.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2184.79,C98H174N24O25S3,AEFHKMQSWY,L,5.82,1,1,0,6,11,190.0,2429,30 hour,>20 hour,>10 hour,204.5,125,6.58,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00893,TLVDCIRNCIHKILGYTVIA,20,63(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(9% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00893,DRAVPe00893.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2245.73,C100H169N27O27S2,EFMPQSW,I,7.76,3,1,2,7,9,95.5,-286,7.2 hour,>20 hour,>10 hour,151.0,1615,85.0,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00894,HKILGYTVIAMPEVEGEEIQ,20,64(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(8% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00894,DRAVPe00894.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2256.6,C101H162N24O32S,CDFNRSW,E,4.48,2,4,-2,4,7,2.0,-1190,3.5 hour,10 min,>10 hour,112.0,1490,78.42,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00895,MPEVEGEEIQPQMELRRNGR,20,65(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(7% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00895,DRAVPe00895.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2398.69,C98H164N32O34S2,ACDFHKSTWY,E,4.65,3,5,-2,3,3,-146.0,-7607,30 hour,>20 hour,>10 hour,53.5,0,0.0,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00896,PQMELRRNGRQCGMSEKEEE,20,66(derived from FIV envelope glycoprotein ),Synthetic construct(derived from FIV envelope glycoprotein (gE)),P16090,,FIV,Retroviridae,Syncitia assay,[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(6% inhibition at 16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00896,DRAVPe00896.cif,Linear,Free,Free,,L,Syncytium formation,The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus.,2407.68,C94H159N33O35S3,ADFHITVWY,E,5.07,4,5,-1,5,1,-192.5,-9270,>20 hour,>20 hour,?,19.5,0,0.0,8661378,Virology. 1996 Jun 15;220(2):274-84. ,"Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C.",Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides.,10.1006/viro.1996.0315,,Anti-FIV
DRAVPe00897,IINFYDPLVFPSDEFDASISQVNEKINQSLAFIRK,35,T-104,Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein),P69353,,RSV,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2cell from viral cytopathic effect(CPE)(EC50=91 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00897,DRAVPe00897.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4059.59,C187H285N45O56,CGHMTW,I,4.44,3,5,-2,8,15,-4.86,-5248,20 hour,30 min,>10 hour,100.29,1490,43.82,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa1211,Anti-RSV
DRAVPe00898,INFYDPLVFPSDEFDASISQVNEKINQSLAFIRKS,35,T-105,Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein),P69353,,RSV,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=93 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00898,DRAVPe00898.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4033.51,C184H279N45O57,CGHMTW,S,4.44,3,5,-2,9,14,-20.0,-6080,20 hour,30 min,>10 hour,89.14,1490,43.82,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa1212,Anti-RSV
DRAVPe00899,NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSD,35,T-106,Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein),P69353,,RSV,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50>100 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00899,DRAVPe00899.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4035.44,C182H273N45O59,CGHMTW,S,4.23,3,6,-3,9,13,-42.86,-7444,1.4 hour,3 min,>10 hour,78.0,1490,43.82,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,,Anti-RSV
DRAVPe00900,FYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDE,35,T-107,Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein),P69353,,RSV,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=20 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00900,DRAVPe00900.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4050.45,C183H274N44O60,CGHMTW,S,4.14,3,7,-4,8,13,-42.86,-7461,1.1 hour,3 min,2 min,78.0,1490,43.82,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa0681,Anti-RSV
DRAVPe00901,YDPLVFPSDEFDASISQVNEKINQSLAFIRKSDEL,35,T-108,Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein),P69353,,RSV,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=6 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00901,DRAVPe00901.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4016.43,C180H276N44O60,CGHMTW,S,4.14,3,7,-4,8,13,-40.0,-7267,2.8 hour,10 min,2 min,89.14,1490,43.82,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa1214,Anti-RSV
DRAVPe00902,DPLVFPSDEFDASISQVNEKINQSLAFIRKSDELL,35,T-109,Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein),P69353,,RSV,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=8 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00902,DRAVPe00902.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3966.41,C177H278N44O59,CGHMTWY,S,4.14,3,7,-4,7,14,-25.43,-6761,1.1 hour,3 min,>10 hour,100.29,0,0.0,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa0712,Anti-RSV
DRAVPe00903,PLVFPSDEFDASISQVNEKINQSLAFIRKSDELLH,35,T-110,Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein),P69353,,RSV,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=30 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00903,DRAVPe00903.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3988.47,C179H280N46O57,CGMTWY,S,4.58,4,6,-2,7,14,-24.57,-6355,>20 hour,>20 hour,?,100.29,0,0.0,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa1216,Anti-RSV
DRAVPe00904,LVFPSDEFDASISQVNEKINQSLAFIRKSDELLHN,35,T-111,Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein),P69353,,RSV,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=9 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00904,DRAVPe00904.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4005.45,C178H279N47O58,CGMTWY,S,4.58,4,6,-2,8,14,-30.0,-7019,5.5 hour,3 min,2 min,100.29,0,0.0,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa1217,Anti-RSV
DRAVPe00905,VFPSDEFDASISQVNEKINQSLAFIRKSDELLHNV,35,T-112,Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein),P69353,,RSV,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=19 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00905,DRAVPe00905.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3991.43,C177H277N47O58,CGMTWY,S,4.58,4,6,-2,8,14,-28.86,-7107,100 hour,>20 hour,>10 hour,97.43,0,0.0,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa1218,Anti-RSV
DRAVPe00906,FPSDEFDASISQVNEKINQSLAFIRKSDELLHNVN,35,T-113,Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein),P69353,,RSV,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=8 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00906,DRAVPe00906.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4006.4,C176H274N48O59,CGMTWY,S,4.58,4,6,-2,9,13,-50.86,-8175,1.1 hour,3 min,2 min,89.14,0,0.0,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa1219,Anti-RSV
DRAVPe00907,PSDEFDASISQVNEKINQSLAFIRKSDELLHNVNA,35,T-114,Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein),P69353,,RSV,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=6 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00907,DRAVPe00907.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3930.3,C170H270N48O59,CGMTWY,S,4.58,4,6,-2,9,13,-53.71,-8292,>20 hour,>20 hour,?,92.0,0,0.0,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa1220,Anti-RSV
DRAVPe00908,SDEFDASISQVNEKINQSLAFIRKSDELLHNVNAG,35,T-115,Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein),P69353,,RSV,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=6 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00908,DRAVPe00908.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3890.24,C167H266N48O59,CMPTWY,S,4.58,4,6,-2,10,13,-50.29,-8198,1.9 hour,>20 hour,>10 hour,92.0,0,0.0,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa1221,Anti-RSV
DRAVPe00909,DEFDASISQVNEKINQSLAFIRKSDELLHNVNAGK,35,T-116,Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein),P69353,,RSV,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=12 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00909,DRAVPe00909.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3931.33,C170H273N49O58,CMPTWY,NS,4.95,5,6,-1,9,13,-59.14,-8413,1.1 hour,3 min,>10 hour,92.0,0,0.0,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa1222,Anti-RSV
DRAVPe00910,EFDASISQVNEKINQSLAFIRKSDELLHNVNAGKS,35,T-117,Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein),P69353,,RSV,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=13 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00910,DRAVPe00910.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3903.32,C169H273N49O57,CMPTWY,S,5.56,5,5,0,10,13,-51.43,-7881,1 hour,30 min,>10 hour,92.0,0,0.0,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa1223,Anti-RSV
DRAVPe00911,FDASISQVNEKINQSLAFIRKSDELLHNVNAGKST,35,T-118,Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein),P69353,,"RSV,HPIV,MeV",Paramyxoviridae,"Cytopathic effect(CPE) assay,antifusion assay,plaque reduction assay",[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=6 μg/ml);inhibition of cell-cell fusion in HEp2 cell(EC50=0.051 μg/ml);##measles virus(MV):inhibition of cell-cell fusion in HEp2 cell(EC50>25 μg/ml);##Human parainfluenza virus type 3(HPIV3):inhibition of cell-cell fusion in HEp2 cell(EC50>25 μg/ml);##HIV-1 LAI:inhibition of cell-cell fusion in HEp2 cell(EC50>50 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00911,DRAVPe00911.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3875.31,C168H273N49O56,CMPWY,S,6.76,5,4,1,11,13,-43.43,-7457,1.1 hour,3 min,2 min,92.0,0,0.0,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa1144,"Anti-RSV,Anti-HPIV,Anti-MeV"
DRAVPe00912,DASISQVNEKINQSLAFIRKSDELLHNVNAGKSTT,35,T-119,Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein),P69353,,RSV,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=8 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00912,DRAVPe00912.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3829.24,C163H271N49O57,CMPWY,S,6.76,5,4,1,12,12,-53.43,-8012,1.1 hour,3 min,>10 hour,92.0,0,0.0,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa1225,Anti-RSV
DRAVPe00913,YTPNDITLNNSVALDPIDISIELNKAKSDLEESKE,35,T-189,Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein),P69353,,HPIV-3,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Human parainfluenza virus type 3(HPIV3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50>100 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00913,DRAVPe00913.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3890.27,C168H274N42O63,CFGHMQRW,DEILNS,4.07,3,8,-5,11,11,-62.29,-7719,2.8 hour,10 min,2 min,103.14,1490,43.82,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,,Anti-HPIV-3
DRAVPe00914,TPNDITLNNSVALDPIDISIELNKAKSDLEESKEW,35,T-190,Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein),P69353,,HPIV-3,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50>100 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00914,DRAVPe00914.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3913.3,C170H275N43O62,CFGHMQRY,DEILNS,4.07,3,8,-5,10,12,-61.14,-7472,7.2 hour,>20 hour,>10 hour,103.14,5500,161.76,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,,Anti-HPIV-3
DRAVPe00915,PNDITLNNSVALDPIDISIELNKAKSDLEESKEWI,35,T-191,Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein),P69353,,HPIV-3,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50>100 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00915,DRAVPe00915.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3925.36,C172H279N43O61,CFGHMQRY,I,4.07,3,8,-5,9,13,-46.29,-6723,>20 hour,>20 hour,?,114.29,5500,161.76,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,,Anti-HPIV-3
DRAVPe00916,NDITLNNSVALDPIDISIELNKAKSDLEESKEWIR,35,T-192,Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein),P69353,,HPIV-3,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50>100 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00916,DRAVPe00916.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3984.43,C173H284N46O61,CFGHMQY,I,4.29,4,8,-4,9,13,-54.57,-8215,1.4 hour,3 min,>10 hour,114.29,5500,161.76,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,,Anti-HPIV-3
DRAVPe00917,DITLNNSVALDPIDISIELNKAKSDLEESKEWIRR,35,T-193,Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein),P69353,,HPIV-3,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50>100 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00917,DRAVPe00917.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4026.51,C175H290N48O60,CFGHMQY,I,4.51,5,8,-3,8,13,-57.43,-9043,1.1 hour,3 min,>10 hour,114.29,5500,161.76,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,,Anti-HPIV-3
DRAVPe00918,ITLNNSVALDPIDISIELNKAKSDLEESKEWIRRS,35,T-194,Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein),P69353,,HPIV-3,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=62 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00918,DRAVPe00918.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3998.5,C174H290N48O59,CFGHMQY,IS,4.72,5,7,-2,9,13,-49.71,-8511,20 hour,30 min,>10 hour,114.29,5500,161.76,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa0742,Anti-HPIV-3
DRAVPe00919,TLNNSVALDPIDISIELNKAKSDLEESKEWIRRSN,35,T-195,Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein),P69353,,HPIV-3,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=72 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00919,DRAVPe00919.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3999.45,C172H285N49O60,CFGHMQY,S,4.71,5,7,-2,10,12,-72.57,-9667,7.2 hour,>20 hour,>10 hour,103.14,5500,161.76,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa0358,Anti-HPIV-3
DRAVPe00920,LNNSVALDPIDISIELNKAKSDLEESKEWIRRSNQ,35,T-196,Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein),P69353,,HPIV-3,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=1 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00920,DRAVPe00920.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4026.47,C173H286N50O60,CFGHMTY,S,4.72,5,7,-2,9,12,-80.57,-9964,5.5 hour,3 min,2 min,103.14,5500,161.76,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa0359,Anti-HPIV-3
DRAVPe00921,NNSVALDPIDISIELNKAKSDLEESKEWIRRSNQK,35,T-197,Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein),P69353,,HPIV-3,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=6 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00921,DRAVPe00921.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4041.49,C173H287N51O60,CFGHMTY,S,5.1,6,7,-1,9,11,-102.57,-11011,1.4 hour,3 min,>10 hour,92.0,5500,161.76,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa0360,Anti-HPIV-3
DRAVPe00922,NSVALDPIDISIELNKAKSDLEESKEWIRRSNQKL,35,T-198,Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein),P69353,,HPIV-3,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=0.2 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00922,DRAVPe00922.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4040.54,C175H292N50O59,CFGHMTY,S,5.1,6,7,-1,8,12,-81.71,-9855,1.4 hour,3 min,>10 hour,103.14,5500,161.76,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa0361,Anti-HPIV-3
DRAVPe00923,SVALDPIDISIELNKAKSDLEESKEWIRRSNQKLD,35,T-199,Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein),P69353,,HPIV-3,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=2 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00923,DRAVPe00923.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4041.53,C175H291N49O60,CFGHMTY,S,4.77,6,8,-2,7,12,-81.71,-10063,1.9 hour,>20 hour,>10 hour,103.14,5500,161.76,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa0362,Anti-HPIV-3
DRAVPe00924,VALDPIDISIELNKAKSDLEESKEWIRRSNQKLDS,35,T-200,Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein),P69353,,HPIV-3,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=1 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00924,DRAVPe00924.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4041.53,C175H291N49O60,CFGHMTY,S,4.77,6,8,-2,7,12,-81.71,-10063,100 hour,>20 hour,>10 hour,103.14,5500,161.76,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa0363,Anti-HPIV-3
DRAVPe00925,ALDPIDISIELNKAKSDLEESKEWIRRSNQKLDSI,35,T-201,Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein),P69353,,HPIV-3,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=0.1 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00925,DRAVPe00925.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4055.55,C176H293N49O60,CFGHMTVY,IS,4.77,6,8,-2,7,12,-80.86,-9975,4.4 hour,>20 hour,>10 hour,106.0,5500,161.76,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa0364,Anti-HPIV-3
DRAVPe00926,LDPIDISIELNKAKSDLEESKEWIRRSNQKLDSIG,35,T-202,Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein),P69353,,HPIV-3,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=0.03 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00926,DRAVPe00926.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4041.53,C175H291N49O60,CFHMTVY,IS,4.77,6,8,-2,8,11,-87.14,-10062,5.5 hour,3 min,2 min,103.14,5500,161.76,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa0365,Anti-HPIV-3
DRAVPe00927,DPIDISIELNKAKSDLEESKEWIRRSNQKLDSIGN,35,T-203,Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein),P69353,,HPIV-3,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=0.2 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00927,DRAVPe00927.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4042.47,C173H286N50O61,CFHMTVY,IS,4.77,6,8,-2,9,10,-108.0,-11218,1.1 hour,3 min,>10 hour,92.0,5500,161.76,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa0366,Anti-HPIV-3
DRAVPe00928,PIDISIELNKAKSDLEESKEWIRRSNQKLDSIGNW,35,T-204,Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein),P69353,,HPIV-3,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=0.07 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00928,DRAVPe00928.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4113.6,C180H291N51O59,CFHMTVY,IS,5.1,6,7,-1,9,11,-100.57,-10113,>20 hour,>20 hour,?,92.0,11000,323.53,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa0367,Anti-HPIV-3
DRAVPe00929,IDISIELNKAKSDLEESKEWIRRSNQKLDSIGNWH,35,T-205,Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein),P69353,,"HPIV-3,MeV,RSV,HIV","Paramyxoviridae, Retroviridae",Luminescence fusion assay,[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=0.11 μg/ml);inhibition of cell-cell fusion in HEp2 cell(EC50=0.038 μg/ml);##measles virus(MV):inhibition of cell-cell fusion in HEp2 cell(EC50=1.19 μg/ml);##Respiratory syncytial virus(RSV):inhibition of cell-cell fusion in HEp2 cell(EC50=1.76 μg/ml);##HIV-1 LAI:inhibition of cell-cell fusion in HEp2 cell(EC50>50 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00929,DRAVPe00929.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4153.62,C181H291N53O59,CFMPTVY,IS,5.64,7,7,0,9,11,-105.14,-10579,20 hour,30 min,>10 hour,92.0,11000,323.53,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa0368,"Anti-HPIV-3,Anti-MeV,Anti-RSV,Anti-HIV"
DRAVPe00930,IDISIELNKAKSDLEESKEWIRRSNQKLDSIGNWH,35,HPIV3 F HRC derived peptide(454-488),Synthetic construct(derived from HPIV3 fusion (F) protein),P06828,,"HeV,HPIV-3",Paramyxoviridae,Luminescence fusion assay,[Ref.16973588]Hendra virus(HeV):inhibition of virus infection in HeLa cells(IC50=50 nM);inhibition of fusion in HeLa cells(IC50=5000 nM);##human parainfluenza virus 3 (HPIV3):inhibition of virus infection in HeLa cells(IC50=500 nM);inhibition of fusion in HeLa cells(IC50=1500 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00930,DRAVPe00930.cif,Linear,Free,Free,,L,membrane,"The HeV receptor-binding protein (G) is required in order for the fusion protein (F) to mediate fusion.  HeV F, once triggered by the receptor-bound G, undergoes multistep conformational changes leading to a six-helix bundle (6HB) structure that accomplishes fusion of the viral and cellular membranes. Peptides derived from the HRN and HRC regions of F are proposed to inhibit fusion by preventing F, after the initial triggering step, from forming the 10HB structure that is required for fusion.",4153.62,C181H291N53O59,CFMPTVY,IS,5.64,7,7,0,9,11,-105.14,-10579,20 hour,30 min,>10 hour,92.0,11000,323.53,16973588,J Virol. 2006 Oct;80(19):9837-49.,"Porotto M, Doctor L, Carta P, Fornabaio M, Greengard O, Kellogg GE, Moscona A.",Inhibition of hendra virus fusion.,10.1128/JVI.00736-06,,"Anti-HeV,Anti-HPIV-3"
DRAVPe00931,DISIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQ,35,T-206,Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein),P69353,,HPIV-3,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=2 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00931,DRAVPe00931.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4168.59,C180H288N54O60,CFMPTVY,S,5.64,7,7,0,9,10,-128.0,-11625,1.1 hour,3 min,>10 hour,80.86,11000,323.53,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa0369,Anti-HPIV-3
DRAVPe00932,ISIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQS,35,T-207,Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein),P69353,,HPIV-3,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=2 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00932,DRAVPe00932.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4140.58,C179H288N54O59,CFMPTVY,S,6.78,7,6,1,10,10,-120.29,-11093,20 hour,30 min,>10 hour,80.86,11000,323.53,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa0370,Anti-HPIV-3
DRAVPe00933,SIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSS,35,T-208,Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein),P69353,,HPIV-3,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=1 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00933,DRAVPe00933.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4114.5,C176H282N54O60,CFMPTVY,S,6.5,7,6,1,11,9,-135.43,-11925,1.9 hour,>20 hour,>10 hour,69.71,11000,323.53,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa0371,Anti-HPIV-3
DRAVPe00934,IELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSST,35,T-209,Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein),P69353,,HPIV-3,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=2 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00934,DRAVPe00934.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4128.53,C177H284N54O60,CFMPVY,S,6.78,7,6,1,11,9,-135.14,-11842,20 hour,30 min,>10 hour,69.71,11000,323.53,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa0372,Anti-HPIV-3
DRAVPe00935,ELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSSTT,35,T-210,Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein),P69353,,HPIV-3,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=2.4 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00935,DRAVPe00935.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,4116.47,C175H280N54O61,CFMPVY,S,6.87,7,6,1,12,8,-150.0,-12591,1 hour,30 min,>10 hour,58.57,11000,323.53,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa0373,Anti-HPIV-3
DRAVPe00936,PDAVYLHRIDLGPPISLERLDVGTNLGNAIAKLED,35,T-252,Synthetic construct(derived from measles virus(MV) fusion (F) protein),P69353,,MeV,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50>100 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00936,DRAVPe00936.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3786.3,C168H274N46O53,CFMQW,L,4.52,4,6,-2,8,14,-8.0,-4733,>20 hour,>20 hour,?,125.43,1490,43.82,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,DRAVPa0399,Anti-MeV
DRAVPe00937,DAVYLHRIDLGPPISLERLDVGTNLQNAIAKLEDA,35,T-253,Synthetic construct(derived from measles virus(MV) fusion (F) protein),P69353,,MeV,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50>100 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00937,DRAVPe00937.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3831.34,C169H277N47O54,CFMW,L,4.52,4,6,-2,7,15,-7.14,-5200,1.1 hour,3 min,>10 hour,128.29,1490,43.82,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,,Anti-MeV
DRAVPe00938,AVYLHRIDLGPPISLERLDVGTNLQNAIAKLEDAK,35,T-254,Synthetic construct(derived from measles virus(MV) fusion (F) protein),P69353,,MeV,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50>100 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00938,DRAVPe00938.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3844.43,C171H284N48O52,CFMW,L,5.52,5,5,0,7,15,-8.29,-4883,4.4 hour,>20 hour,>10 hour,128.29,1490,43.82,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,,Anti-MeV
DRAVPe00939,VYLHRIDLGPPISLERLDVGTNLQNAIAKLEDAKE,35,T-255,Synthetic construct(derived from measles virus(MV) fusion (F) protein),P69353,,MeV,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=85.3 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00939,DRAVPe00939.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3902.46,C173H286N48O54,CFMW,L,4.95,5,6,-1,7,14,-23.43,-5745,100 hour,>20 hour,>10 hour,125.43,1490,43.82,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,,Anti-MeV
DRAVPe00940,YLHRIDLGPPISLERLDVGTNLGNAIAKLEDAKEL,35,T-256,Synthetic construct(derived from measles virus(MV) fusion (F) protein),P69353,,MeV,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=90.7 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00940,DRAVPe00940.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3845.41,C171H283N47O53,CFMQW,L,4.95,5,6,-1,8,14,-15.71,-5009,2.8 hour,10 min,2 min,128.29,1490,43.82,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,,Anti-MeV
DRAVPe00941,LHRIDLGPPISLERLDVGTNLGNAIAKLEDAKELL,35,T-257,Synthetic construct(derived from measles virus(MV) fusion (F) protein),P69353,,"MeV,RSV,HPIV-3,HIV","Paramyxoviridae, Retroviridae","Cytopathic effect(CPE) assay,antifusion assay,plaque reduction assay",[Ref.8700906]measles virus(MeV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=1.5 μg/ml);inhibition of cell-cell fusion in HEp2 cell(EC50=0.068 μg/ml);##Human parainfluenza virus type 3(HPIV-3):inhibition of cell-cell fusion in HEp2 cell(EC50>25 μg/ml);##Respiratory syncytial virus(RSV):inhibition of cell-cell fusion in HEp2 cell(EC50>25 μg/ml);##HIV-1 LAI:inhibition of cell-cell fusion in HEp2 cell(EC50>50 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00941,DRAVPe00941.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3795.39,C168H285N47O52,CFMQWY,L,4.95,5,6,-1,7,15,-1.14,-4503,5.5 hour,3 min,2 min,139.43,0,0.0,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,,"Anti-MeV,Anti-RSV,Anti-HPIV-3,Anti-HIV"
DRAVPe00942,HRIDLGPPISLERLDVGTNLGNAIAKLEDAKELLE,35,T-258,Synthetic construct(derived from measles virus(MV) fusion (F) protein),P69353,,MeV,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=2.2 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00942,DRAVPe00942.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3811.35,C167H281N47O54,CFMQWY,L,4.7,5,7,-2,7,14,-22.0,-5676,3.5 hour,10 min,>10 hour,128.29,0,0.0,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,,Anti-MeV
DRAVPe00943,RIDLGPPISLERLDVGTNLGNAIAKLEDAKELLES,35,T-259,Synthetic construct(derived from measles virus(MV) fusion (F) protein),P69353,,MeV,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=1.7 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00943,DRAVPe00943.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3761.29,C164H279N45O55,CFHMQWY,L,4.44,4,7,-3,8,14,-15.14,-5550,1 hour,2 min,2 min,128.29,0,0.0,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,,Anti-MeV
DRAVPe00944,IDLGPPISLERLDVGTNLGNAIAKLEDAKELLESS,35,T-260,Synthetic construct(derived from measles virus(MV) fusion (F) protein),P69353,,MeV,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=4.9 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00944,DRAVPe00944.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3692.18,C161H272N42O56,CFHMQWY,L,4.2,3,7,-4,9,14,-4.57,-4398,20 hour,30 min,>10 hour,128.29,0,0.0,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,,Anti-MeV
DRAVPe00945,DLGPPISLERLDVGTNLGNAIAKLEDAKELLESSD,35,T-261,Synthetic construct(derived from measles virus(MV) fusion (F) protein),P69353,,MeV,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=5.7 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00945,DRAVPe00945.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3694.11,C159H266N42O58,CFHMQWY,L,4.07,3,8,-5,9,13,-27.43,-5762,1.1 hour,3 min,>10 hour,117.14,0,0.0,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,,Anti-MeV
DRAVPe00946,LGPPISLERLDVGTNLGNAIAKLEDAKELLESSDQ,35,T-262,Synthetic construct(derived from measles virus(MV) fusion (F) protein),P69353,,MeV,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=6.5 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00946,DRAVPe00946.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3707.15,C160H269N43O57,CFHMWY,L,4.2,3,7,-4,9,13,-27.43,-5444,5.5 hour,3 min,2 min,117.14,0,0.0,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,,Anti-MeV
DRAVPe00947,GPPISLERLDVGTNLGNAIAKLEDAKELLESSDQI,35,T-263,Synthetic construct(derived from measles virus(MV) fusion (F) protein),P69353,,MeV,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=10.1 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00947,DRAVPe00947.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3707.15,C160H269N43O57,CFHMWY,L,4.2,3,7,-4,9,13,-25.43,-5444,30 hour,>20 hour,>10 hour,117.14,0,0.0,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,,Anti-MeV
DRAVPe00948,PPISLERLDVGTNLGNAIAKLEDAKELLESSDQIL,35,T-264,Synthetic construct(derived from measles virus(MV) fusion (F) protein),P69353,,MeV,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=1.1 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00948,DRAVPe00948.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3763.26,C164H277N43O57,CFHMWY,L,4.2,3,7,-4,8,14,-13.43,-5046,>20 hour,>20 hour,?,128.29,0,0.0,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,,Anti-MeV
DRAVPe00949,PISLERLDVGTNLGNAIAKLEDAKELLESSDQILR,35,T-265,Synthetic construct(derived from measles virus(MV) fusion (F) protein),P69353,,MeV,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=3.1 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00949,DRAVPe00949.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3822.33,C165H282N46O57,CFHMWY,L,4.44,4,7,-3,8,14,-21.71,-6538,>20 hour,>20 hour,?,128.29,0,0.0,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,,Anti-MeV
DRAVPe00950,ISLERLDVGTNLGNAIAKLEDAKELLESSDQILRS,35,T-266,Synthetic construct(derived from measles virus(MV) fusion (F) protein),P69353,,MeV,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=13.0 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00950,DRAVPe00950.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3812.29,C163H280N46O58,CFHMPWY,L,4.44,4,7,-3,9,14,-19.43,-6878,20 hour,30 min,>10 hour,128.29,0,0.0,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,,Anti-MeV
DRAVPe00951,SLERLDVGTNLGNAIAKLEDAKELLESSDQILRSM,35,T-267,Synthetic construct(derived from measles virus(MV) fusion (F) protein),P69353,,MeV,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=12.3 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00951,DRAVPe00951.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3830.32,C162H278N46O58S,CFHPWY,L,4.44,4,7,-3,9,13,-26.86,-7135,1.9 hour,>20 hour,>10 hour,117.14,0,0.0,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,,Anti-MeV
DRAVPe00952,LERLDVGTNLGNAIAKLEDAKELLESSDQILRSMK,35,T-268,Synthetic construct(derived from measles virus(MV) fusion (F) protein),P69353,,MeV,Paramyxoviridae,Cytopathic effect(CPE) assay,[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=7.3 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM).,DRAVPe00952,DRAVPe00952.cif,Linear,Acetylation,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3871.42,C165H285N47O57S,CFHPWY,L,4.72,5,7,-2,8,13,-35.71,-7350,5.5 hour,3 min,2 min,117.14,0,0.0,8700906,Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.,"Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.",Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. ,10.1073/pnas.93.5.2186,,Anti-MeV
DRAVPe00953,DDSVVCAAMSYSYA,14,P1(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(22% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00953,DRAVPe00953.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1481.61,C62H92N14O24S2,EFGHIKLNPQRTW,AS,3.56,0,2,-2,6,5,44.29,-1078,1.1 hour,3 min,>10 hour,62.86,2980,229.23,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00954,DDSVVCAAMSYSFA,14,P2(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(29% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00954,DRAVPe00954.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1465.61,C62H92N14O23S2,EGHIKLNPQRTW,AS,3.56,0,2,-2,5,6,73.57,-766,1.1 hour,3 min,>10 hour,62.86,1490,114.62,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00955,DDSVVCAAMSYSHA,14,P3(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(26% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00955,DRAVPe00955.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1455.58,C59H90N16O23S2,EFGIKLNPQRTW,AS,4.2,1,2,-1,5,5,30.71,-1530,1.1 hour,3 min,>10 hour,62.86,1490,114.62,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00956,DDSVVSAAMSYSYA,14,P4(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( 7±9% inhibition at 1 µM; 47±1% inhibition at 3 µM; 89±6% inhibition at 10 µM; IC50=3.5 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00956,DRAVPe00956.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1465.55,C62H92N14O25S,CEFGHIKLNPQRTW,S,3.56,0,2,-2,6,5,20.71,-1546,1.1 hour,3 min,>10 hour,62.86,2980,229.23,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00957,DDSVVSAAMSYSFA,14,P5(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(14% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00957,DRAVPe00957.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1449.55,C62H92N14O24S,CEGHIKLNPQRTW,S,3.56,0,2,-2,5,6,50.0,-1234,1.1 hour,3 min,>10 hour,62.86,1490,114.62,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00958,DDSVVAAMSYSYA,13,P7(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(9% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00958,DRAVPe00958.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1378.47,C59H87N13O23S,CEFGHIKLNPQRTW,AS,3.56,0,2,-2,5,5,28.46,-1206,1.1 hour,3 min,>10 hour,67.69,2980,248.33,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00959,DDSVVAAMSYSFA,13,P8(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(2% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00959,DRAVPe00959.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1362.47,C59H87N13O22S,CEGHIKLNPQRTW,AS,3.56,0,2,-2,4,6,60.0,-894,1.1 hour,3 min,>10 hour,67.69,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00960,DDSVVAAMSYSHA,13,P9(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(22% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00960,DRAVPe00960.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1352.44,C56H85N15O22S,CEFGIKLNPQRTW,AS,4.2,1,2,-1,4,5,13.85,-1658,1.1 hour,3 min,>10 hour,67.69,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00961,ADLEVVAATYVLVA,14,P10(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( 6±11% inhibition at 1 µM;27±5% inhibition at 3 µM;  75±1% inhibition at 10 µM; IC50=6.3µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00961,DRAVPe00961.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1433.66,C66H108N14O21,CFGHIKMNPQRSW,AV,3.67,0,2,-2,2,10,161.43,1500,4.4 hour,>20 hour,>10 hour,167.14,1490,114.62,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00962,ADLEVVAATFVLVA,14,P11(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(-2±7% inhibition at 1 µM; 29±5% inhibition at 3 µM;  83±5% inhibition at 10 µM; IC50=5.72 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00962,DRAVPe00962.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1417.67,C66H108N14O20,CGHIKMNPQRSWY,AV,3.67,0,2,-2,1,11,190.71,1812,4.4 hour,>20 hour,>10 hour,167.14,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00963,ADLEVVAATHVLVA,14,P12(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( 11±16% inhibition at 1 µM; 77±3% inhibition at 3 µM;  95±1% inhibition at 10 µM; IC50=2.2 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00963,DRAVPe00963.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1407.63,C63H106N16O20,CFGIKMNPQRSWY,AV,4.35,1,2,-1,1,10,147.86,1048,4.4 hour,>20 hour,>10 hour,167.14,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00964,ADLEVVAATYV,11,P13(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(15% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00964,DRAVPe00964.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1150.29,C52H83N11O18,CFGHIKMNPQRSW,AV,3.67,0,2,-2,2,7,116.36,423,4.4 hour,>20 hour,>10 hour,141.82,1490,149.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00965,KKKKVVAATYVLVA,14,P15(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(30% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00965,DRAVPe00965.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1517.92,C72H128N18O17,CDEFGHIMNPQRSW,KV,10.18,4,0,4,2,8,60.0,160,1.3 hour,3 min,2 min,132.14,1490,114.62,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00966,DDDEVVAATYVLVA,14,P17(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(1% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00966,DRAVPe00966.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1479.6,C65H102N14O25,CFGHIKMNPQRSW,V,3.37,0,4,-4,2,8,71.43,-917,1.1 hour,3 min,>10 hour,132.14,1490,114.62,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00967,ADLEVVAATYVDDD,14,P19(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(9% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00967,DRAVPe00967.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1495.56,C64H98N14O27,CFGHIKMNPQRSW,D,3.28,0,5,-5,2,7,16.43,-2193,4.4 hour,>20 hour,>10 hour,111.43,1490,114.62,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00968,ADLEVVAATYVDVA,14,P20(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( 18±21% inhibition at 1 µM; 75±1% inhibition at 3 µM;  96±1% inhibition at 10 µM; IC50=2.1 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00968,DRAVPe00968.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1435.59,C64H102N14O23,CFGHIKMNPQRSW,AV,3.49,0,3,-3,2,9,109.29,136,4.4 hour,>20 hour,>10 hour,139.29,1490,114.62,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00969,ADLEVVAATYVLDA,14,P21(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(22% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00969,DRAVPe00969.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1449.62,C65H104N14O23,CFGHIKMNPQRSW,A,3.49,0,3,-3,2,9,106.43,224,4.4 hour,>20 hour,>10 hour,146.43,1490,114.62,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00970,ADLEVVAATYVLVD,14,P22(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(38% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00970,DRAVPe00970.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1477.67,C67H108N14O23,CFGHIKMNPQRSW,V,3.49,0,3,-3,2,9,123.57,447,4.4 hour,>20 hour,>10 hour,160.0,1490,114.62,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00971,ADLEVVAATYVDDA,14,P23(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(20% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00971,DRAVPe00971.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1451.55,C63H98N14O25,CFGHIKMNPQRSW,A,3.37,0,4,-4,2,8,54.29,-1140,4.4 hour,>20 hour,>10 hour,118.57,1490,114.62,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00972,ADLEVVAATYVLDD,14,P24(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( 5±4% inhibition at 1 µM; 26±4% inhibition at 3 µM;  65±3% inhibition at 10 µM; IC50=7.4 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00972,DRAVPe00972.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1493.63,C66H104N14O25,CFGHIKMNPQRSW,ADV,3.37,0,4,-4,2,8,68.57,-829,4.4 hour,>20 hour,>10 hour,139.29,1490,114.62,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00973,ADLEVVAATYVDVD,14,P25(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(19% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00973,DRAVPe00973.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1479.6,C65H102N14O25,CFGHIKMNPQRSW,V,3.37,0,4,-4,2,8,71.43,-917,4.4 hour,>20 hour,>10 hour,132.14,1490,114.62,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00974,KKKKVVAATYVKKA,14,P27(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(13% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00974,DRAVPe00974.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1561.98,C73H132N20O17,CDEFGHILMNPQRSW,K,10.4,6,0,6,2,6,-52.86,-1846,1.3 hour,3 min,2 min,83.57,1490,114.62,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00975,KKKKVVAATYFFFA,14,P30(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(5% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00975,DRAVPe00975.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1648.02,C83H126N18O17,CDEGHILMNPQRSW,K,10.18,4,0,4,2,8,32.86,-246,1.3 hour,3 min,2 min,62.86,1490,114.62,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00976,KKKKVVAATYFLVA,14,P31(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(4% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00976,DRAVPe00976.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1565.96,C76H128N18O17,CDEGHIMNPQRSW,K,10.18,4,0,4,2,8,50.0,54,1.3 hour,3 min,2 min,111.43,1490,114.62,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00977,KKKKVVAATYVLVF,14,P33(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(12% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00977,DRAVPe00977.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1594.02,C78H132N18O17,CDEGHIMNPQRSW,KV,10.18,4,0,4,2,8,67.14,277,1.3 hour,3 min,2 min,125.0,1490,114.62,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00978,KKKKVVAATYVLFA,14,P34(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(12% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00978,DRAVPe00978.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1565.96,C76H128N18O17,CDEGHIMNPQRSW,K,10.18,4,0,4,2,8,50.0,54,1.3 hour,3 min,2 min,111.43,1490,114.62,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00979,KKKKVVAATYKKVA,14,P37(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(4% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00979,DRAVPe00979.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1561.98,C73H132N20O17,CDEFGHILMNPQRSW,K,10.4,6,0,6,2,6,-52.86,-1846,1.3 hour,3 min,2 min,83.57,1490,114.62,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00980,AKLKVVAATYVLKK,14,P38(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(5% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00980,DRAVPe00980.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1531.95,C73H130N18O17,CDEFGHIMNPQRSW,K,10.18,4,0,4,2,8,57.14,248,4.4 hour,>20 hour,>10 hour,139.29,1490,114.62,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00981,KKKKVVAATYKKKK,14,P42(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(8% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00981,DRAVPe00981.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1648.11,C77H142N22O17,CDEFGHILMNPQRSW,K,10.54,8,0,8,2,4,-151.43,-3541,1.3 hour,3 min,2 min,55.71,1490,114.62,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00982,ADLEVVAATYVKKK,14,P44(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(2% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00982,DRAVPe00982.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1534.82,C70H119N17O21,CFGHIMNPQRSW,AKV,8.47,3,2,1,2,7,7.86,-1242,4.4 hour,>20 hour,>10 hour,111.43,1490,114.62,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00983,ADLEVVAATYKKKK,14,P45(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(7% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00983,DRAVPe00983.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1563.86,C71H122N18O21,CFGHIMNPQRSW,K,9.41,4,2,2,2,6,-50.0,-2201,4.4 hour,>20 hour,>10 hour,90.71,1490,114.62,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00984,ADLEVVAATYAAAA,14,P47(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(8% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00984,DRAVPe00984.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1335.48,C59H94N14O21,CFGHIKMNPQRSW,A,3.67,0,2,-2,2,10,112.86,743,4.4 hour,>20 hour,>10 hour,119.29,1490,114.62,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00985,KDLKVVAATYVKKK,14,P48(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(21% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00985,DRAVPe00985.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1590.97,C74H131N19O19,CEFGHIMNPQRSW,K,10.0,5,1,4,2,6,-35.71,-1852,1.3 hour,3 min,2 min,104.29,1490,114.62,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00986,KKKKAVAATYVLV,13,P49(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(59% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00986,DRAVPe00986.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1418.79,C67H119N17O16,CDEFGHIMNPQRSW,K,10.18,4,0,4,2,7,32.31,-244,1.3 hour,3 min,2 min,120.0,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00987,KKKKVAAATYVLV,13,P50(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( 7±1% inhibition at 1 µM; 51±10% inhibition at 3 µM;  74±1% inhibition at 10 µM; IC50=3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00987,DRAVPe00987.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1418.79,C67H119N17O16,CDEFGHIMNPQRSW,K,10.18,4,0,4,2,7,32.31,-244,1.3 hour,3 min,2 min,120.0,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00988,KKKKVVAAAYVLV,13,P51(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(19% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00988,DRAVPe00988.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1416.81,C68H121N17O15,CDEFGHIMNPQRSTW,KV,10.18,4,0,4,1,8,70.0,417,1.3 hour,3 min,2 min,142.31,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00989,KKKKVVAATAVLV,13,P52(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(13% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00989,DRAVPe00989.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1354.74,C63H119N17O15,CDEFGHIMNPQRSWY,KV,10.48,4,0,4,1,8,74.62,174,1.3 hour,3 min,2 min,142.31,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00990,KKKKVVAATYVAV,13,P54(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(21% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00990,DRAVPe00990.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1404.76,C66H117N17O16,CDEFGHILMNPQRSW,KV,10.18,4,0,4,2,7,35.38,-332,1.3 hour,3 min,2 min,112.31,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00991,KKKKVVAATYVLA,13,P55(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(19% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00991,DRAVPe00991.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1418.79,C67H119N17O16,CDEFGHIMNPQRSW,K,10.18,4,0,4,2,7,32.31,-244,1.3 hour,3 min,2 min,120.0,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00992,KKKKVLAATYVLV,13,P57(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(12% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00992,DRAVPe00992.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1460.87,C70H125N17O16,CDEFGHIMNPQRSW,K,10.18,4,0,4,2,7,47.69,67,1.3 hour,3 min,2 min,142.31,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00993,KKKKVVLATYVLV,13,P58(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( 21±8% inhibition at 1 µM; 30±5% inhibition at 3 µM;  61±15% inhibition at 10 µM; IC50=7.5 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00993,DRAVPe00993.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1488.92,C72H129N17O16,CDEFGHIMNPQRSW,KV,10.18,4,0,4,2,7,66.15,290,1.3 hour,3 min,2 min,156.92,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00994,KKKKVVAALYVLV,13,P60(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(7% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00994,DRAVPe00994.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1458.89,C71H127N17O15,CDEFGHIMNPQRSTW,KV,10.18,4,0,4,1,8,85.38,728,1.3 hour,3 min,2 min,164.62,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00995,KKKKVVAATYLLV,13,P61(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(26% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00995,DRAVPe00995.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1460.87,C70H125N17O16,CDEFGHIMNPQRSW,K,10.18,4,0,4,2,7,47.69,67,1.3 hour,3 min,2 min,142.31,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00996,KKKKVVAATYVLL,13,P62(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(25% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00996,DRAVPe00996.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1460.87,C70H125N17O16,CDEFGHIMNPQRSW,K,10.18,4,0,4,2,7,47.69,67,1.3 hour,3 min,2 min,142.31,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00997,KKKKFVAATYVLV,13,P63(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( 32±7% inhibition at 1 µM; 35±8% inhibition at 3 µM;  61±6% inhibition at 10 µM; IC50=7 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00997,DRAVPe00997.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1494.88,C73H123N17O16,CDEGHIMNPQRSW,K,10.18,4,0,4,2,7,40.0,-127,1.3 hour,3 min,2 min,112.31,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00998,KKKKVFAATYVLV,13,P64(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(26% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00998,DRAVPe00998.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1494.88,C73H123N17O16,CDEGHIMNPQRSW,K,10.18,4,0,4,2,7,40.0,-127,1.3 hour,3 min,2 min,112.31,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe00999,KKKKVVFATYVLV,13,P65(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(34% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe00999,DRAVPe00999.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1522.94,C75H127N17O16,CDEGHIMNPQRSW,KV,10.18,4,0,4,2,7,58.46,96,1.3 hour,3 min,2 min,126.92,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01000,KKKKVVAFTYVLV,13,P66(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(23% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01000,DRAVPe01000.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1522.94,C75H127N17O16,CDEGHIMNPQRSW,KV,10.18,4,0,4,2,7,58.46,96,1.3 hour,3 min,2 min,126.92,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01001,KKKKVVAAFYVLV,13,P67(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(3% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01001,DRAVPe01001.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1492.91,C74H125N17O15,CDEGHIMNPQRSTW,KV,10.18,4,0,4,1,8,77.69,534,1.3 hour,3 min,2 min,134.62,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01002,KKKKVVAATFVLV,13,P68(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(28% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01002,DRAVPe01002.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1430.84,C69H123N17O15,CDEGHIMNPQRSWY,KV,10.48,4,0,4,1,8,82.31,291,1.3 hour,3 min,2 min,134.62,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01003,KKKKVVAATYFLV,13,P69(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(14% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01003,DRAVPe01003.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1494.88,C73H123N17O16,CDEGHIMNPQRSW,K,10.18,4,0,4,2,7,40.0,-127,1.3 hour,3 min,2 min,112.31,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01004,KKKKVVAATYVFV,13,P70(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(15% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01004,DRAVPe01004.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1480.86,C72H121N17O16,CDEGHILMNPQRSW,KV,10.18,4,0,4,2,7,43.08,-215,1.3 hour,3 min,2 min,104.62,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01005,KKKKVVAATYVLF,13,P71(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(1% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01005,DRAVPe01005.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1494.88,C73H123N17O16,CDEGHIMNPQRSW,K,10.18,4,0,4,2,7,40.0,-127,1.3 hour,3 min,2 min,112.31,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01006,KKKKEVAATYVLV,13,P72(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(2% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01006,DRAVPe01006.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1476.82,C69H121N17O18,CDFGHIMNPQRSW,K,9.83,4,1,3,2,6,-8.46,-1106,1.3 hour,3 min,2 min,112.31,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01007,KKKKVVAETYVLV,13,P75(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(19% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01007,DRAVPe01007.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1504.88,C71H125N17O18,CDFGHIMNPQRSW,KV,9.83,4,1,3,2,6,10.0,-883,1.3 hour,3 min,2 min,126.92,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01008,KKKKVVAAEYVLV,13,P76(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(5% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01008,DRAVPe01008.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1474.85,C70H123N17O17,CDFGHIMNPQRSTW,KV,9.83,4,1,3,1,7,29.23,-445,1.3 hour,3 min,2 min,134.62,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01009,KKKKVVAATEVLV,13,P77(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(4% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01009,DRAVPe01009.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1412.78,C65H121N17O17,CDFGHIMNPQRSWY,KV,10.0,4,1,3,1,7,33.85,-688,1.3 hour,3 min,2 min,134.62,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01010,KKKKVKAATYVLV,13,P82(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(25% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01010,DRAVPe01010.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1475.88,C70H126N18O16,CDEFGHIMNPQRSW,K,10.3,5,0,5,2,6,-11.54,-980,1.3 hour,3 min,2 min,112.31,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01011,KKKKVVKATYVLV,13,P83(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( 26±12% inhibition at 1 µM; 37±10% inhibition at 3 µM;  63±2% inhibition at 10 µM; IC50=6.5 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01011,DRAVPe01011.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1503.94,C72H130N18O16,CDEFGHIMNPQRSW,K,10.3,5,0,5,2,6,6.92,-757,1.3 hour,3 min,2 min,126.92,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01012,KKKKVVAKTYVLV,13,P84(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(12% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01012,DRAVPe01012.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1503.94,C72H130N18O16,CDEFGHIMNPQRSW,K,10.3,5,0,5,2,6,6.92,-757,1.3 hour,3 min,2 min,126.92,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01013,KKKKTVAATYVLV,13,P89(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(27% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01013,DRAVPe01013.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1448.81,C68H121N17O17,CDEFGHIMNPQRSW,K,10.18,4,0,4,3,6,13.08,-682,1.3 hour,3 min,2 min,112.31,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01014,KKKKVTAATYVLV,13,P90(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( 15±12% inhibition at 1 µM; 44±3% inhibition at 3 µM;  77±6% inhibition at 10 µM; IC50=4.3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01014,DRAVPe01014.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1448.81,C68H121N17O17,CDEFGHIMNPQRSW,K,10.18,4,0,4,3,6,13.08,-682,1.3 hour,3 min,2 min,112.31,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01015,KKKKVVTATYVLV,13,P91(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(1% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01015,DRAVPe01015.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1476.87,C70H125N17O17,CDEFGHIMNPQRSW,KV,10.18,4,0,4,3,6,31.54,-459,1.3 hour,3 min,2 min,126.92,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01016,KKKKVVATTYVLV,13,P92(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(16% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01016,DRAVPe01016.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1476.87,C70H125N17O17,CDEFGHIMNPQRSW,KV,10.18,4,0,4,3,6,31.54,-459,1.3 hour,3 min,2 min,126.92,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01017,KKKKVVAATTVLV,13,P93(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(2223% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01017,DRAVPe01017.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1384.77,C64H121N17O16,CDEFGHIMNPQRSWY,KV,10.48,4,0,4,2,7,55.38,-264,1.3 hour,3 min,2 min,134.62,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01018,KKKKVVAATYVLT,13,P96(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(8% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01018,DRAVPe01018.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1448.81,C68H121N17O17,CDEFGHIMNPQRSW,K,10.18,4,0,4,3,6,13.08,-682,1.3 hour,3 min,2 min,112.31,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01019,KKKKVVGATYVLV,13,P99(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(14% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01019,DRAVPe01019.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1432.81,C68H121N17O16,CDEFHIMNPQRSW,KV,10.18,4,0,4,3,6,33.85,-108,1.3 hour,3 min,2 min,126.92,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01020,KKKKVVAGTYVLV,13,P100(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(30% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01020,DRAVPe01020.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1432.81,C68H121N17O16,CDEFHIMNPQRSW,KV,10.18,4,0,4,3,6,33.85,-108,1.3 hour,3 min,2 min,126.92,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01021,KKKKVVAAGYVLV,13,P101(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(2% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01021,DRAVPe01021.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1402.79,C67H119N17O15,CDEFHIMNPQRSTW,KV,10.18,4,0,4,2,7,53.08,330,1.3 hour,3 min,2 min,134.62,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01022,KKKKVVAATGVLV,13,P102(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(26% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01022,DRAVPe01022.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1340.72,C62H117N17O15,CDEFHIMNPQRSWY,KV,10.48,4,0,4,2,7,57.69,87,1.3 hour,3 min,2 min,134.62,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01023,KKKKVVAATYVGV,13,P104(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(14% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01023,DRAVPe01023.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1390.73,C65H115N17O16,CDEFHILMNPQRSW,KV,10.18,4,0,4,3,6,18.46,-419,1.3 hour,3 min,2 min,104.62,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01024,KKKKVVAATYVLG,13,P105(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(13% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01024,DRAVPe01024.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1404.76,C66H117N17O16,CDEFHIMNPQRSW,K,10.18,4,0,4,3,6,15.38,-331,1.3 hour,3 min,2 min,112.31,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01025,KKKKVVAATYVLV,13,P106(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(17% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01025,DRAVPe01025.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1446.84,C69H123N17O16,CDEFGHIMNPQRSW,KV,10.18,4,0,4,2,7,50.77,-21,1.3 hour,3 min,2 min,134.62,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01026,KKKKPVAATYVLV,13,P107(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(24% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01026,DRAVPe01026.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1444.82,C69H121N17O16,CDEFGHIMNQRSW,K,10.18,4,0,4,2,6,6.15,-425,1.3 hour,3 min,2 min,112.31,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01027,KKKKVPAATYVLV,13,P108(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(3% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01027,DRAVPe01027.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1444.82,C69H121N17O16,CDEFGHIMNQRSW,K,10.18,4,0,4,2,6,6.15,-425,1.3 hour,3 min,2 min,112.31,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01028,KKKKVVAATYVPV,13,P113(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(10% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01028,DRAVPe01028.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1430.8,C68H119N17O16,CDEFGHILMNQRSW,KV,10.18,4,0,4,2,6,9.23,-513,1.3 hour,3 min,2 min,104.62,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01029,KKKKVVLATLVLV,13,P116(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(5% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01029,DRAVPe01029.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1438.9,C69H131N17O15,CDEFGHIMNPQRSWY,KV,10.48,4,0,4,1,8,105.38,796,1.3 hour,3 min,2 min,186.92,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01030,KKKKLVLPFLFFV,13,P119(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(6% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01030,DRAVPe01030.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1607.1,C84H135N17O14,ACDEGHIMNQRSTWY,K,10.48,4,0,4,0,8,84.62,958,1.3 hour,3 min,2 min,134.62,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01031,KKKKLLAPFLFFV,13,P120(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(4% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01031,DRAVPe01031.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1579.05,C82H131N17O14,CDEGHIMNQRSTWY,K,10.48,4,0,4,0,8,66.15,735,1.3 hour,3 min,2 min,120.0,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01032,KKKKLLLAFLFFV,13,P121(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(4% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01032,DRAVPe01032.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1595.09,C83H135N17O14,CDEGHIMNPQRSTWY,KL,10.48,4,0,4,0,9,107.69,1227,1.3 hour,3 min,2 min,150.0,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01033,KKKKLLLPTLFFV,13,P122(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(2% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01033,DRAVPe01033.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1575.06,C80H135N17O15,ACDEGHIMNQRSWY,KL,10.48,4,0,4,1,7,54.62,491,1.3 hour,3 min,2 min,142.31,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01034,KKKKLVLATYVLV,13,P126(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(2% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01034,DRAVPe01034.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1502.95,C73H131N17O16,CDEFGHIMNPQRSW,K,10.18,4,0,4,2,7,63.08,378,1.3 hour,3 min,2 min,164.62,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01035,KKKKLVAAFYVLV,13,P128(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(18% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01035,DRAVPe01035.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1506.94,C75H127N17O15,CDEGHIMNPQRSTW,K,10.18,4,0,4,1,8,74.62,622,1.3 hour,3 min,2 min,142.31,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01036,KKKKLVAATYVFV,13,P129(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(8% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01036,DRAVPe01036.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1494.88,C73H123N17O16,CDEGHIMNPQRSW,K,10.18,4,0,4,2,7,40.0,-127,1.3 hour,3 min,2 min,112.31,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01037,KKKKLVAATYVLF,13,P130(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(14% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01037,DRAVPe01037.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1508.91,C74H125N17O16,CDEGHIMNPQRSW,K,10.18,4,0,4,2,7,36.92,-39,1.3 hour,3 min,2 min,120.0,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01038,KKKKVLAPTYVLV,13,P132(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(1% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01038,DRAVPe01038.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1486.9,C72H127N17O16,CDEFGHIMNQRSW,K,10.18,4,0,4,2,6,21.54,-114,1.3 hour,3 min,2 min,134.62,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01039,KKKKVVLAFYVLV,13,P138(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(10% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01039,DRAVPe01039.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1534.99,C77H131N17O15,CDEGHIMNPQRSTW,KV,10.18,4,0,4,1,8,93.08,845,1.3 hour,3 min,2 min,156.92,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01040,KKKKVVAPFYVLV,13,P140(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(2% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01040,DRAVPe01040.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1518.95,C76H127N17O15,CDEGHIMNQRSTW,KV,10.18,4,0,4,1,7,51.54,353,1.3 hour,3 min,2 min,126.92,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01041,KKKKVVAPTLVLV,13,P141(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(3% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01041,DRAVPe01041.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1422.86,C68H127N17O15,CDEFGHIMNQRSWY,KV,10.48,4,0,4,1,7,63.85,304,1.3 hour,3 min,2 min,156.92,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01042,KKKKVVAPTYFLV,13,P142(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(15% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01042,DRAVPe01042.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1520.92,C75H125N17O16,CDEGHIMNQRSW,K,10.18,4,0,4,2,6,13.85,-308,1.3 hour,3 min,2 min,104.62,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01043,KKKKVVAPTYVLF,13,P144(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(15% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01043,DRAVPe01043.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1520.92,C75H125N17O16,CDEGHIMNQRSW,K,10.18,4,0,4,2,6,13.85,-308,1.3 hour,3 min,2 min,104.62,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01044,KKKKVVAAFLVLV,13,P145(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(20% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01044,DRAVPe01044.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1442.9,C71H127N17O14,CDEGHIMNPQRSTWY,KV,10.48,4,0,4,0,9,116.92,1040,1.3 hour,3 min,2 min,164.62,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01045,KKKKVVAAFYFLV,13,P146(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(7% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01045,DRAVPe01045.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1540.96,C78H125N17O15,CDEGHIMNPQRSTW,K,10.18,4,0,4,1,8,66.92,428,1.3 hour,3 min,2 min,112.31,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01046,KKKKVVAAFYVLF,13,P148(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(8% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01046,DRAVPe01046.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1540.96,C78H125N17O15,CDEGHIMNPQRSTW,K,10.18,4,0,4,1,8,66.92,428,1.3 hour,3 min,2 min,112.31,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01047,KKKKVVAATLVLF,13,P151(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(9% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01047,DRAVPe01047.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1444.87,C70H125N17O15,CDEGHIMNPQRSWY,K,10.48,4,0,4,1,8,79.23,379,1.3 hour,3 min,2 min,142.31,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01048,KKKKVLLPFLFFF,13,P154(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(2% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01048,DRAVPe01048.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1655.15,C88H135N17O14,ACDEGHIMNQRSTWY,FK,10.48,4,0,4,0,8,73.85,852,1.3 hour,3 min,2 min,112.31,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01049,KKKKLVLPFLFFF,13,P155(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(12% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01049,DRAVPe01049.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1655.15,C88H135N17O14,ACDEGHIMNQRSTWY,FK,10.48,4,0,4,0,8,73.85,852,1.3 hour,3 min,2 min,112.31,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01050,KKKKLLAPFLFFF,13,P156(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(14% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01050,DRAVPe01050.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1627.09,C86H131N17O14,CDEGHIMNQRSTVWY,FK,10.48,4,0,4,0,8,55.38,629,1.3 hour,3 min,2 min,97.69,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01051,KKKKLLLAFLFFF,13,P157(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(16% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01051,DRAVPe01051.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1643.13,C87H135N17O14,CDEGHIMNPQRSTVWY,FKL,10.48,4,0,4,0,9,96.92,1121,1.3 hour,3 min,2 min,127.69,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01052,KKKKLLLPFYFFF,13,P159(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(24% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01052,DRAVPe01052.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1719.19,C92H135N17O15,ACDEGHIMNQRSTVW,FK,10.18,4,0,4,1,7,31.54,434,1.3 hour,3 min,2 min,90.0,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01053,KKKKLLLPFLFLF,13,P161(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(4% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01053,DRAVPe01053.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1635.16,C86H139N17O14,ACDEGHIMNQRSTVWY,L,10.48,4,0,4,0,8,78.46,1134,1.3 hour,3 min,2 min,150.0,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01054,KKKKLLLPFLFFF,13,P162(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(19% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01054,DRAVPe01054.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1669.17,C89H137N17O14,ACDEGHIMNQRSTVWY,FKL,10.48,4,0,4,0,8,70.77,940,1.3 hour,3 min,2 min,120.0,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01055,KKKKVVLPFLFFF,13,P163(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( -2±1% inhibition at 1 µM; 29±4% inhibition at 3 µM;  69±9% inhibition at 10 µM; IC50=7 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01055,DRAVPe01055.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1641.12,C87H133N17O14,ACDEGHIMNQRSTWY,FK,10.48,4,0,4,0,8,76.92,764,1.3 hour,3 min,2 min,104.62,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01056,KKKKLVAPFLFFF,13,P164(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(15% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01056,DRAVPe01056.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1613.06,C85H129N17O14,CDEGHIMNQRSTWY,FK,10.48,4,0,4,0,8,58.46,541,1.3 hour,3 min,2 min,90.0,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01057,KKKKLLAAFLFFF,13,P165(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( 29±5% inhibition at 1 µM; 28±9% inhibition at 3 µM;  61±17% inhibition at 10 µM; IC50=7.6 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01057,DRAVPe01057.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1601.05,C84H129N17O14,CDEGHIMNPQRSTVWY,FK,10.48,4,0,4,0,9,81.54,810,1.3 hour,3 min,2 min,105.38,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01058,KKKKLLLATLFFF,13,P166(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(16% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01058,DRAVPe01058.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1597.06,C82H133N17O15,CDEGHIMNPQRSVWY,KL,10.48,4,0,4,1,8,70.0,566,1.3 hour,3 min,2 min,127.69,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01059,KKKKLLLPTYFFF,13,P167(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(3% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01059,DRAVPe01059.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1673.12,C87H133N17O16,ACDEGHIMNQRSVW,K,10.18,4,0,4,2,6,4.62,-121,1.3 hour,3 min,2 min,90.0,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01060,KKKKLLLPFLVLF,13,P169(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(4% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01060,DRAVPe01060.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1587.11,C82H139N17O14,ACDEGHIMNQRSTWY,L,10.48,4,0,4,0,8,89.23,1240,1.3 hour,3 min,2 min,172.31,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01061,KKKKVLAPFLFFF,13,P170(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(8% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01061,DRAVPe01061.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1613.06,C85H129N17O14,CDEGHIMNQRSTWY,FK,10.48,4,0,4,0,8,58.46,541,1.3 hour,3 min,2 min,90.0,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01062,KKKKVLLPFYFFF,13,P172(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(27% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01062,DRAVPe01062.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1705.16,C91H133N17O15,ACDEGHIMNQRSTW,FK,10.18,4,0,4,1,7,34.62,346,1.3 hour,3 min,2 min,82.31,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01063,KKKKLVLAFLFFF,13,P175(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(18% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01063,DRAVPe01063.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1629.11,C86H133N17O14,CDEGHIMNPQRSTWY,FK,10.48,4,0,4,0,9,100.0,1033,1.3 hour,3 min,2 min,120.0,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01064,KKKKLVLPTLFFF,13,P176(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(29% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01064,DRAVPe01064.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1609.07,C83H133N17O15,ACDEGHIMNQRSWY,K,10.48,4,0,4,1,7,46.92,297,1.3 hour,3 min,2 min,112.31,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01065,KKKKLVLPFYFFF,13,P177(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(14% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01065,DRAVPe01065.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1705.16,C91H133N17O15,ACDEGHIMNQRSTW,FK,10.18,4,0,4,1,7,34.62,346,1.3 hour,3 min,2 min,82.31,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01066,KKKKLVLPFLLFF,13,P178(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(18% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01066,DRAVPe01066.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1621.13,C85H137N17O14,ACDEGHIMNQRSTWY,KL,10.48,4,0,4,0,8,81.54,1046,1.3 hour,3 min,2 min,142.31,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01067,KKKKLVLPFLFVF,13,P179(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( 14±6% inhibition at 1 µM; 34±11% inhibition at 3 µM;  55±11% inhibition at 10 µM; IC50=8.3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01067,DRAVPe01067.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1607.1,C84H135N17O14,ACDEGHIMNQRSTWY,K,10.48,4,0,4,0,8,84.62,958,1.3 hour,3 min,2 min,134.62,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01068,KKKKLLAPFLVFF,13,P180(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(9% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01068,DRAVPe01068.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1579.05,C82H131N17O14,CDEGHIMNQRSTWY,K,10.48,4,0,4,0,8,66.15,735,1.3 hour,3 min,2 min,120.0,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01069,KKKKLLLAFYFFF,13,P181(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(3% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01069,DRAVPe01069.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1693.15,C90H133N17O15,CDEGHIMNPQRSTVW,FK,10.18,4,0,4,1,8,57.69,615,1.3 hour,3 min,2 min,97.69,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01070,KKKKLLLAFLFLF,13,P182(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(8% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01070,DRAVPe01070.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1609.12,C84H137N17O14,CDEGHIMNPQRSTVWY,L,10.48,4,0,4,0,9,104.62,1315,1.3 hour,3 min,2 min,157.69,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01071,KKKKLLLPTLVFF,13,P183(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(3% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01071,DRAVPe01071.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1575.06,C80H135N17O15,ACDEGHIMNQRSWY,KL,10.48,4,0,4,1,7,54.62,491,1.3 hour,3 min,2 min,142.31,0,0.0,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01072,KKKKLLLPFYFLF,13,P185(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(22% inhibition at 3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01072,DRAVPe01072.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1685.17,C89H137N17O15,ACDEGHIMNQRSTVW,KL,10.18,4,0,4,1,7,39.23,628,1.3 hour,3 min,2 min,120.0,1490,124.17,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01073,AKDLEVVTSTYVLVEA,16,P189(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( 5±7% inhibition at 1 µM; 74±6% inhibition at 3 µM;  96±3% inhibition at 10 µM; IC50=2.3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01073,DRAVPe01073.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1736.98,C78H129N17O27,CFGHIMNPQRW,V,4.14,1,3,-2,4,8,63.13,-695,4.4 hour,>20 hour,>10 hour,133.75,1490,99.33,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01074,AKDLEVVCSTYVLVEA,16,P190(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( 24 ±15% inhibition at 1 µM; 86 ±3% inhibition at 3 µM;  99 ±2% inhibition at 10 µM; IC50=1.8 µM),No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01074,DRAVPe01074.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1739.01,C77H127N17O26S,FGHIMNPQRW,V,4.14,1,3,-2,4,8,83.13,-310,4.4 hour,>20 hour,>10 hour,133.75,1490,99.33,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01075,AECVVSCSMSYTKA,14,P197(derived from HCV polyprotein),Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein),P26662,,HCV,Flaviviridae,NS3-6K inhibition assay(determined by Fluorescent probe),[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( 7±7% inhibition at 1 µM; 29±6% inhibition at 3 µM;  66±3% inhibition at 10 µM; IC50=7 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01075,DRAVPe01075.cif,Linear,Free,Free,,L,NS3 protease,"HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication",1478.71,C60H99N15O22S3,DFGHILNPQRW,S,6.03,1,1,0,7,4,50.71,-866,4.4 hour,>20 hour,>10 hour,55.71,1615,124.23,14694985,Antivir Chem Chemother. 2003 Sep;14(5):225-33.,"Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.",Peptide inhibitors of hepatitis C virus NS3 protease. ,10.1177/095632020301400501,,Anti-HCV
DRAVPe01076,SWLRDIWDWICEVLSDFK,18,C5A(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,"HCV,DENV,MeV,RSV,HIV","Flaviviridae, Paramyxoviridae, Retroviridae",RT-QPCR assay,"[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=0.79 μM);##HCV (JFH-1) genotype 2a:inhibition of infection in Huh-7.5.1 cells(IC50=0.6 μM);##HCV (H77 envelope) genotype 1a:inhibition of infection in Huh-7.5.1 cells(IC50=3.9 μM);##HCV (Con1 envelope) genotype 1b:inhibition of infection in Huh-7.5.1 cells(IC50=1.6 μM);##HCV (J6CF envelope) genotype 2a:inhibition of infection in Huh-7.5.1 cells(IC50=1.1 μM);##Dengue virus:inhibition of infection in Huh-7.5.1 cells(IC50=2.0 μM);##West Nile virus:inhibition of infection in Huh-7.5.1 cells(IC50=4.5 μM);##Measles virus:inhibition of infection in Huh-7.5.1 cells(IC50=2.7 μM);##Respiratory syncytial virus:inhibition of infection in Huh-7.5.1 cells(IC50=4.5 μM);##Human immunodeficiency virus:inhibition of infection in Huh-7.5.1 cells(IC50=1.3 μM);##IC50>18 μM against Adenovirus,Borna disease virus,Coronavirus 229E,Coxsackie virus,Hepatitis B virus,Influenza virus,Lymphocytic choriomeningitis virus,Rhinovirus,Rotavirus WISC2,Vaccinia virus,Vesicular stomatitis virus.",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01076,DRAVPe01076.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",2311.64,C109H155N25O29S,AGHMNPQTY,DW,4.23,2,4,-2,3,9,-3.33,-2527,1.9 hour,>20 hour,>10 hour,102.78,16500,970.59,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,"Anti-HCV,Anti-DENV,Anti-MeV,Anti-RSV,Anti-HIV"
DRAVPe01077,swlrdiwdwicevlsdfk,18,2(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=0.32 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01077,DRAVPe01077.cif,Linear,Free,Free,,D,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",2311.64,H-34O-17,ACDEFGHIKLMNPQRSTVWY,ACDEFGHIKLMNPQRSTVWY,4.23,0,0,0,0,0,0.0,0,,,,0.0,0,0.0,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01078,SWLRDIWDWICEVLSD,16,3(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=0.98 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01078,DRAVPe01078.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",2036.29,C94H134N22O27S,AFGHKMNPQTY,DW,3.84,1,4,-3,3,8,3.13,-2270,1.9 hour,>20 hour,>10 hour,115.63,16500,1100.0,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01079,SWLRDIWDWICEVL,14,4(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=11.3 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01079,DRAVPe01079.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",1834.12,C87H124N20O22S,AFGHKMNPQTY,W,4.03,1,3,-2,2,8,34.29,-1058,1.9 hour,>20 hour,>10 hour,132.14,16500,1269.23,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,DRAVPa1474,Anti-HCV
DRAVPe01080,SWLRDIWDWICEV,13,5(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50>27 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01080,DRAVPe01080.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",1720.96,C81H113N19O21S,AFGHKMNPQTY,W,4.03,1,3,-2,2,7,7.69,-1550,1.9 hour,>20 hour,>10 hour,112.31,16500,1375.0,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01081,SWLRDIWDWICE,12,6(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50>27 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01081,DRAVPe01081.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",1621.83,C76H104N18O20S,AFGHKMNPQTVY,W,4.03,1,3,-2,2,6,-26.67,-1954,1.9 hour,>20 hour,>10 hour,97.5,16500,1500.0,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01082,SWLRDIWDWI,10,7(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50>27 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01082,DRAVPe01082.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",1389.58,C68H92N16O16,ACEFGHKMNPQTVY,W,4.21,1,2,-1,1,6,-22.0,-1401,1.9 hour,>20 hour,>10 hour,117.0,16500,1833.33,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01083,SWLRDIWD,8,8(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50>27 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01083,DRAVPe01083.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",1090.2,C51H71N13O14,ACEFGHKMNPQTVY,DW,4.21,1,2,-1,1,4,-72.5,-2126,1.9 hour,>20 hour,>10 hour,97.5,11000,1571.43,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01084,LRDIWDWICEVLSDFK,16,9(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50>27 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01084,DRAVPe01084.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",2038.35,C95H140N22O26S,AGHMNPQTY,D,4.23,2,4,-2,2,8,6.88,-2420,5.5 hour,3 min,2 min,115.63,11000,733.33,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01085,DIWDWICEVLSDFK,14,10(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50>27 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01085,DRAVPe01085.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",1769.0,C83H117N17O24S,AGHMNPQRTY,D,3.84,1,4,-3,2,7,12.86,-1420,1.1 hour,3 min,>10 hour,104.29,11000,846.15,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01086,WDWICEVLSDFK,12,11(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50>27 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01086,DRAVPe01086.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",1540.75,C73H101N15O20S,AGHMNPQRTY,DW,4.03,1,3,-2,2,6,6.67,-1040,2.8 hour,3 min,2 min,89.17,11000,1000.0,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01087,WICEVLSDFK,10,12(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50>27 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01087,DRAVPe01087.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",1239.45,C58H86N12O16S,AGHMNPQRTY,CDEFIKLSVW,4.37,1,2,-1,2,5,52.0,-401,2.8 hour,3 min,2 min,107.0,5500,611.11,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01088,CEVLSDFK,8,13(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50>27 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01088,DRAVPe01088.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",940.08,C41H65N9O14S,AGHIMNPQRTWY,CDEFKLSV,4.37,1,2,-1,2,3,20.0,-1126,1.2 hour,>20 hour,>10 hour,85.0,0,0.0,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01089,SGSWLRDIWDWICEVLSDFK,20,14(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=1.7 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01089,DRAVPe01089.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",2455.77,C114H163N27O32S,AHMNPQTY,DSW,4.23,2,4,-2,5,9,-9.0,-2773,1.9 hour,>20 hour,>10 hour,92.5,16500,868.42,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01090,GSWLRDIWDWICEVLSDFK,19,15(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=0.51 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01090,DRAVPe01090.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",2368.69,C111H158N26O30S,AHMNPQTY,DW,4.23,2,4,-2,4,9,-5.26,-2433,30 hour,>20 hour,>10 hour,97.37,16500,916.67,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01091,SWLRDIWDWICEVLSDFKT,19,16(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=1.7 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01091,DRAVPe01091.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",2412.74,C113H162N26O31S,AGHMNPQY,DW,4.23,2,4,-2,4,9,-6.84,-2784,1.9 hour,>20 hour,>10 hour,97.37,16500,916.67,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01092,SWLRDIWDWICEVLSDFKTW,20,17(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=0.51 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01092,DRAVPe01092.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",2598.96,C124H172N28O32S,AGHMNPQY,W,4.23,2,4,-2,4,10,-11.0,-2551,1.9 hour,>20 hour,>10 hour,92.5,22000,1157.89,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01093,SWRLIDWDWICEVLSDFK,18,18(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=4.0 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01093,DRAVPe01093.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",2311.64,C109H155N25O29S,AGHMNPQTY,DW,4.23,2,4,-2,3,9,-3.33,-2527,1.9 hour,>20 hour,>10 hour,102.78,16500,970.59,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01094,SWRLDIWDWICESVLDFK,18,19(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50>30 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01094,DRAVPe01094.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",2311.64,C109H155N25O29S,AGHMNPQTY,DW,4.23,2,4,-2,3,9,-3.33,-2527,1.9 hour,>20 hour,>10 hour,102.78,16500,970.59,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01095,DWLKAFYDKVAEKLKEAF,18,21(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50>28 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01095,DRAVPe01095.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",2201.55,C106H157N23O28,CGHIMNPQRST,K,6.21,4,4,0,1,9,-50.0,-2580,1.1 hour,3 min,>10 hour,76.11,6990,411.18,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,DRAVPa1305,Anti-HCV
DRAVPe01096,VLDLIYSLHKQINRGLKKIVL,21,22(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50>36 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01096,DRAVPe01096.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",2464.04,C115H199N31O28,ACEFMPTW,L,10.0,5,1,4,4,10,40.48,-1229,100 hour,>20 hour,>10 hour,176.19,1490,74.5,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01097,KFDSLVECIWDWIDRLWS,18,23(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=0.85 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01097,DRAVPe01097.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",2311.64,C109H155N25O29S,AGHMNPQTY,DW,4.23,2,4,-2,3,9,-3.33,-2527,1.3 hour,3 min,2 min,102.78,16500,970.59,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01098,KWLCRIWSWISDVLDDFE,18,25(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=0.50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01098,DRAVPe01098.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",2311.64,C109H155N25O29S,AGHMNPQTY,DW,4.23,2,4,-2,3,9,-3.33,-2527,1.3 hour,3 min,2 min,102.78,16500,970.59,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01099,SIWRDWVDLICEFLSDWK,18,26(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=0.40 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01099,DRAVPe01099.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",2311.64,C109H155N25O29S,AGHMNPQTY,DW,4.23,2,4,-2,3,9,-3.33,-2527,1.9 hour,>20 hour,>10 hour,102.78,16500,970.59,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01100,SWLRDVWDWICTVLTDFK,18,27(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=3.9 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01100,DRAVPe01100.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",2283.63,C108H155N25O28S,AEGHMNPQY,DW,4.43,2,3,-1,4,9,11.11,-2108,1.9 hour,>20 hour,>10 hour,97.22,16500,970.59,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01101,SWLRDVWDWVCTILTDFK,18,28(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=2.1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01101,DRAVPe01101.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",2283.63,C108H155N25O28S,AEGHMNPQY,DW,4.43,2,3,-1,4,9,11.11,-2108,1.9 hour,>20 hour,>10 hour,97.22,16500,970.59,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01102,DWLRIIWDWVCSVVSDFK,18,29(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=0.55 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01102,DRAVPe01102.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",2267.63,C108H155N25O27S,AEGHMNPQTY,DVW,4.43,2,3,-1,3,10,41.67,-1530,1.1 hour,3 min,>10 hour,113.33,16500,970.59,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01103,SWLWEVWDWVLHVLSDFK,18,30(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=7.0 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01103,DRAVPe01103.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",2345.68,C117H157N25O27,ACGIMNPQRTY,W,4.53,2,3,-1,2,11,22.22,-208,1.9 hour,>20 hour,>10 hour,113.33,22000,1294.12,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01104,TWLRAIWDWVCTALTDFK,18,31(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=7.1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01104,DRAVPe01104.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",2225.59,C106H153N25O26S,EGHMNPQSY,TW,5.62,2,2,0,4,10,27.78,-1195,7.2 hour,>20 hour,>10 hour,92.22,16500,970.59,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01105,SWLRDVWDWVCTVLSDFK,18,32(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=3.5 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01105,DRAVPe01105.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",2255.58,C106H151N25O28S,AEGHIMNPQY,DVW,4.43,2,3,-1,4,9,8.89,-2279,1.9 hour,>20 hour,>10 hour,91.67,16500,970.59,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01106,SWLRDIWDWISEVLSDFK,18,33[11S](derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=13.5 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01106,DRAVPe01106.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",2295.58,C109H155N25O30,ACGHMNPQTY,DSW,4.23,2,4,-2,3,9,-21.67,-2995,1.9 hour,>20 hour,>10 hour,102.78,16500,970.59,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01107,SWLRDIWDWIREVLSDFK,18,34[11R](derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=12.5 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01107,DRAVPe01107.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",2364.69,C112H162N28O29,ACGHMNPQTY,DW,4.68,3,4,-1,2,9,-42.22,-4147,1.9 hour,>20 hour,>10 hour,102.78,16500,970.59,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01108,SWLRDIWDWIEEVLSDFK,18,35[11E](derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=13.0 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01108,DRAVPe01108.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",2337.62,C111H157N25O31,ACGHMNPQTY,DW,4.1,2,5,-3,2,9,-36.67,-3336,1.9 hour,>20 hour,>10 hour,102.78,16500,970.59,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01109,SWLDDIWDWICEVLSDFE,18,36(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=4.7 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01109,DRAVPe01109.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",2271.48,C106H143N21O33S,AGHKMNPQRTY,D,3.25,0,6,-6,3,9,4.44,-2033,1.9 hour,>20 hour,>10 hour,102.78,16500,970.59,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01110,SWLRDIWDWICKVLSDFK,18,38(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=6.8 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01110,DRAVPe01110.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",2310.7,C110H160N26O27S,AEGHMNPQTY,DW,5.76,3,3,0,3,9,-5.56,-2401,1.9 hour,>20 hour,>10 hour,102.78,16500,970.59,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01111,SWLDRIWRWICKVLSRFE,18,39(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=1.7 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01111,DRAVPe01111.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",2393.84,C113H169N31O25S,AGHMNPQTY,RW,9.49,4,2,2,3,9,-14.44,-3767,1.9 hour,>20 hour,>10 hour,102.78,16500,970.59,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01112,SWLRDIWRWICKVLSRFK,18,40(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=0.84 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01112,DRAVPe01112.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",2392.9,C114H174N32O23S,AEGHMNPQTY,RW,10.92,5,1,4,3,9,-16.67,-3641,1.9 hour,>20 hour,>10 hour,102.78,16500,970.59,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01113,SWLRRIWRWICKVLSRFK,18,41(derived from HCV C5A),Synthetic construct(derived from HCV non-structural protein 5A),P26664,,HCV,Flaviviridae,RT-QPCR assay,[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=0.89 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01113,DRAVPe01113.cif,Linear,Free,Free,,L,membrane,"The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation.",2434.0,C116H181N35O21S,ADEGHMNPQTY,R,12.01,6,0,6,3,9,-22.22,-4261,1.9 hour,>20 hour,>10 hour,102.78,16500,970.59,18287023,Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93.,"Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV.",A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.,10.1073/pnas.0712380105,,Anti-HCV
DRAVPe01114,RTQRRGRTGRGKPGIYR,17,HCVA(1484-1500),Synthetic construct(derived from HCV NS3 helicase protein),P26664,,"HCV,WNV,JEV",Flaviviridae,Helicase assay,[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50=27.1±2.4 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50=37.1±3.9 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50=49.8±4.3 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01114,DRAVPe01114.cif,Linear,Free,Free,,L,NTPase/helicase,"The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism.",2015.31,C83H147N37O22,ACDEFHLMNSVW,R,12.3,7,0,7,7,1,-210.59,-9721,1 hour,2 min,2 min,22.94,1490,93.13,18479669,Biochem Pharmacol. 2008 Jul 1;76(1):28-38. ,"Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A.",Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI).,10.1016/j.bcp.2008.03.018,,"Anti-HCV,Anti-WNV,Anti-JEV"
DRAVPe01115,STQRRGRTGRGRRGIYR,17,HCVB(1484-1500),Synthetic construct(derived from HCV NS3 helicase protein),P26663,,"HCV,WNV,JEV",Flaviviridae,Helicase assay,[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50=24.3±1.8 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50=33.6±3.5 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50=47.2±4.7 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01115,DRAVPe01115.cif,Linear,Free,Free,,L,NTPase/helicase,"The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism.",2033.29,C81H145N39O23,ACDEFHKLMNPVW,R,12.4,7,0,7,8,1,-209.41,-10998,1.9 hour,>20 hour,>10 hour,22.94,1490,93.13,18479669,Biochem Pharmacol. 2008 Jul 1;76(1):28-38. ,"Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A.",Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI).,10.1016/j.bcp.2008.03.018,,"Anti-HCV,Anti-WNV,Anti-JEV"
DRAVPe01116,RRGRTGRGRRGIYR,14,HCV(1487-1500),Synthetic construct(derived from HCV NS3 helicase protein),P26663,,"HCV,WNV,JEV",Flaviviridae,Helicase assay,[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50=0.2±0.01 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50=2.7±0.3 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50=21.1±2.2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01116,DRAVPe01116.cif,Linear,Free,Free,,L,NTPase/helicase,"The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism.",1716.98,C69H125N35O17,ACDEFHKLMNPQSVW,R,12.4,7,0,7,6,1,-218.57,-9847,1 hour,2 min,2 min,27.86,1490,114.62,18479669,Biochem Pharmacol. 2008 Jul 1;76(1):28-38. ,"Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A.",Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI).,10.1016/j.bcp.2008.03.018,,"Anti-HCV,Anti-WNV,Anti-JEV"
DRAVPe01117,RTGRGRRGIYR,11,HCV(1490-1500),Synthetic construct(derived from HCV NS3 helicase protein),P26663,,"HCV,WNV,JEV",Flaviviridae,Helicase assay,[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50=34.6±3.2 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50=106±6.1 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50=322±9.7 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01117,DRAVPe01117.cif,Linear,Free,Free,,L,NTPase/helicase,"The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism.",1347.55,C55H98N26O14,ACDEFHKLMNPQSVW,R,12.18,5,0,5,5,1,-192.73,-6957,1 hour,2 min,2 min,35.45,1490,149.0,18479669,Biochem Pharmacol. 2008 Jul 1;76(1):28-38. ,"Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A.",Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI).,10.1016/j.bcp.2008.03.018,,"Anti-HCV,Anti-WNV,Anti-JEV"
DRAVPe01118,RGRRGIYR,8,HCV(1493-1500),Synthetic construct(derived from HCV NS3 helicase protein),P26663,,"HCV,WNV,JEV",Flaviviridae,Helicase assay,[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50=313±11.3 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50=397±10.6 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50>500 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01118,DRAVPe01118.cif,Linear,Free,Free,,L,NTPase/helicase,"The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism.",1033.2,C43H76N20O10,ACDEFHKLMNPQSTVW,R,12.0,4,0,4,3,1,-195.0,-5302,1 hour,2 min,2 min,48.75,1490,212.86,18479669,Biochem Pharmacol. 2008 Jul 1;76(1):28-38. ,"Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A.",Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI).,10.1016/j.bcp.2008.03.018,,"Anti-HCV,Anti-WNV,Anti-JEV"
DRAVPe01119,RGIYR,5,HCV(1496-1500),Synthetic construct(derived from HCV NS3 helicase protein),P26663,,"HCV,WNV,JEV",Flaviviridae,Helicase assay,[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50>500 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50>500 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50>500 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01119,DRAVPe01119.cif,Linear,Free,Free,,L,NTPase/helicase,"The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism.",663.78,C29H49N11O7,ACDEFHKLMNPQSTVW,R,10.84,2,0,2,2,1,-124.0,-2412,1 hour,2 min,2 min,78.0,1490,372.5,18479669,Biochem Pharmacol. 2008 Jul 1;76(1):28-38. ,"Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A.",Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI).,10.1016/j.bcp.2008.03.018,,"Anti-HCV,Anti-WNV,Anti-JEV"
DRAVPe01120,SQVGD,5,WNV(1968-1972),Synthetic construct(derived from WNV NS3 helicase protein),P06935,,"HCV,WNV,JEV",Flaviviridae,Helicase assay,[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50>500 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50>500 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50>500 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01120,DRAVPe01120.cif,Linear,Free,Free,,L,NTPase/helicase,"The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism.",504.5,C19H32N6O10,ACEFHIKLMNPRTWY,DGQSV,3.8,0,1,-1,2,1,-80.0,-1268,1.9 hour,>20 hour,>10 hour,58.0,0,0.0,18479669,Biochem Pharmacol. 2008 Jul 1;76(1):28-38. ,"Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A.",Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI).,10.1016/j.bcp.2008.03.018,,"Anti-HCV,Anti-WNV,Anti-JEV"
DRAVPe01121,RNPSQVGD,8,WNV(1965-1972),Synthetic construct(derived from WNV NS3 helicase protein),P06935,,"HCV,WNV,JEV",Flaviviridae,Helicase assay,[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50>500 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50=383±12.3 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50=437±13.4 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01121,DRAVPe01121.cif,Linear,Free,Free,,L,NTPase/helicase,"The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism.",871.91,C34H57N13O14,ACEFHIKLMTWY,DGNPQRSV,5.84,1,1,0,3,1,-170.0,-3424,1 hour,2 min,2 min,36.25,0,0.0,18479669,Biochem Pharmacol. 2008 Jul 1;76(1):28-38. ,"Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A.",Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI).,10.1016/j.bcp.2008.03.018,,"Anti-HCV,Anti-WNV,Anti-JEV"
DRAVPe01122,RIGRNPSQVGD,11,WNV(1962-1972),Synthetic construct(derived from WNV NS3 helicase protein),P06935,,"HCV,WNV,JEV",Flaviviridae,Helicase assay,[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50=417±17.6 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50=285±8.1 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50=334±12.1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01122,DRAVPe01122.cif,Linear,Free,Free,,L,NTPase/helicase,"The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism.",1198.3,C48H83N19O17,ACEFHKLMTWY,GR,9.6,2,1,1,4,2,-127.27,-4330,1 hour,2 min,2 min,61.82,0,0.0,18479669,Biochem Pharmacol. 2008 Jul 1;76(1):28-38. ,"Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A.",Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI).,10.1016/j.bcp.2008.03.018,,"Anti-HCV,Anti-WNV,Anti-JEV"
DRAVPe01123,RRGRIGRNPSQVGD,14,WNV(1959-1972),Synthetic construct(derived from WNV NS3 helicase protein),P06935,,"HCV,WNV,JEV",Flaviviridae,Helicase assay,[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50=169±6.8 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50=156±6.9 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50=191±7.3 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01123,DRAVPe01123.cif,Linear,Free,Free,,L,NTPase/helicase,"The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism.",1567.73,C62H110N28O20,ACEFHKLMTWY,R,12.0,4,1,3,5,2,-167.14,-7220,1 hour,2 min,2 min,48.57,0,0.0,18479669,Biochem Pharmacol. 2008 Jul 1;76(1):28-38. ,"Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A.",Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI).,10.1016/j.bcp.2008.03.018,,"Anti-HCV,Anti-WNV,Anti-JEV"
DRAVPe01124,AAQRRGRIGRNPSQVGD,17,WNV(1956-1972),Synthetic construct(derived from WNV NS3 helicase protein),P06935,,"HCV,WNV,JEV",Flaviviridae,Helicase assay,[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50=358±13.2 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50>500 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50>500 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01124,DRAVPe01124.cif,Linear,Free,Free,,L,NTPase/helicase,"The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism.",1838.02,C73H128N32O24,CEFHKLMTWY,R,12.0,4,1,3,5,4,-137.06,-7412,4.4 hour,>20 hour,>10 hour,51.76,0,0.0,18479669,Biochem Pharmacol. 2008 Jul 1;76(1):28-38. ,"Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A.",Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI).,10.1016/j.bcp.2008.03.018,,"Anti-HCV,Anti-WNV,Anti-JEV"
DRAVPe01125,NQVGD,5,JEV(1971-1975),Synthetic construct(derived from JEV NS3 helicase protein),P27395,,"HCV,WNV,JEV",Flaviviridae,Helicase assay,[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50>500 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50>500 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50>500 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01125,DRAVPe01125.cif,Linear,Free,Free,,L,NTPase/helicase,"The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism.",531.52,C20H33N7O10,ACEFHIKLMPRSTWY,DGNQV,3.8,0,1,-1,2,1,-134.0,-1592,1.4 hour,3 min,>10 hour,58.0,0,0.0,18479669,Biochem Pharmacol. 2008 Jul 1;76(1):28-38. ,"Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A.",Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI).,10.1016/j.bcp.2008.03.018,,"Anti-HCV,Anti-WNV,Anti-JEV"
DRAVPe01126,RNPNQVGD,8,JEV(1968-1975),Synthetic construct(derived from JEV NS3 helicase protein),P27395,,"HCV,WNV,JEV",Flaviviridae,Helicase assay,[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50>500 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50>500 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50>500 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01126,DRAVPe01126.cif,Linear,Free,Free,,L,NTPase/helicase,"The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism.",898.93,C35H58N14O14,ACEFHIKLMSTWY,N,5.84,1,1,0,3,1,-203.75,-3748,1 hour,2 min,2 min,36.25,0,0.0,18479669,Biochem Pharmacol. 2008 Jul 1;76(1):28-38. ,"Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A.",Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI).,10.1016/j.bcp.2008.03.018,,"Anti-HCV,Anti-WNV,Anti-JEV"
DRAVPe01127,RVGRNPNQVGD,11,JEV(1965-1975),Synthetic construct(derived from JEV NS3 helicase protein),P27395,,"HCV,WNV,JEV",Flaviviridae,Helicase assay,[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50=374±12.8 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50=448±14.3 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50>500 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01127,DRAVPe01127.cif,Linear,Free,Free,,L,NTPase/helicase,"The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism.",1211.3,C48H82N20O17,ACEFHIKLMSTWY,GNRV,9.6,2,1,1,4,2,-154.55,-4742,1 hour,2 min,2 min,52.73,0,0.0,18479669,Biochem Pharmacol. 2008 Jul 1;76(1):28-38. ,"Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A.",Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI).,10.1016/j.bcp.2008.03.018,,"Anti-HCV,Anti-WNV,Anti-JEV"
DRAVPe01128,RRGRVGRNPNQVGD,14,JEV(1962-1975),Synthetic construct(derived from JEV NS3 helicase protein),P27395,,"HCV,WNV,JEV",Flaviviridae,Helicase assay,[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50=196±9.4 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50=215±7.2 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50=253±6.5 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01128,DRAVPe01128.cif,Linear,Free,Free,,L,NTPase/helicase,"The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism.",1580.73,C62H109N29O20,ACEFHIKLMSTWY,R,12.0,4,1,3,5,2,-188.57,-7632,1 hour,2 min,2 min,41.43,0,0.0,18479669,Biochem Pharmacol. 2008 Jul 1;76(1):28-38. ,"Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A.",Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI).,10.1016/j.bcp.2008.03.018,,"Anti-HCV,Anti-WNV,Anti-JEV"
DRAVPe01129,AAQRRGRVGRNPNQVGD,17,JEV(1959-1975),Synthetic construct(derived from JEV NS3 helicase protein),P27395,,"HCV,WNV,JEV",Flaviviridae,Helicase assay,[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50=442±17.7 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50>500 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50>500 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01129,DRAVPe01129.cif,Linear,Free,Free,,L,NTPase/helicase,"The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism.",1851.02,C73H127N33O24,CEFHIKLMSTWY,R,12.0,4,1,3,5,4,-154.71,-7824,4.4 hour,>20 hour,>10 hour,45.88,0,0.0,18479669,Biochem Pharmacol. 2008 Jul 1;76(1):28-38. ,"Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A.",Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI).,10.1016/j.bcp.2008.03.018,,"Anti-HCV,Anti-WNV,Anti-JEV"
DRAVPe01130,TTPKFTVAWDWVPKR,15,gB64(gB346-360),Synthetic construct(derived from HSV-1 B glycoprotein (gB)),P06437,,HSV,Herpesviridae,beta-galactosidase activity(Comprehensive antiviral assay),[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50=85 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01130,DRAVPe01130.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1832.14,C88H130N22O21,CEGHILMNQSY,T,9.99,3,1,2,3,6,-66.0,-2492,7.2 hour,>20 hour,>10 hour,45.33,11000,785.71,19104014,Antimicrob Agents Chemother. 2009 Mar;53(3):987-96.,"Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR.",Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection.,10.1128/AAC.00793-08,,Anti-HSV
DRAVPe01131,KTTSSIEFARLQFTY,15,gB94(496-510),Synthetic construct(derived from HSV-1 B glycoprotein (gB)),P06437,,HSV,Herpesviridae,"beta-galactosidase activity(Comprehensive antiviral assay,Virus inactivation assay,cell protection assay,entry assay,attachment assay)",[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50=6.5±1.3 µM);inhibition of virus entry in Vero cells(EC50>200 µM);inhibition of virus infection in Vero cells(EC50=165.0±71.9 µM);ability of inactive virus(EC50=125±11.4 µM);inhibition of virus attachment on Vero cells(EC50>200 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.19104014]Not cytotoxic for Vero cells up to 200 µM.,DRAVPe01131,DRAVPe01131.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1792.02,C82H126N20O25,CDGHMNPVW,T,8.59,2,1,1,6,5,-31.33,-2986,1.3 hour,3 min,2 min,58.67,1490,106.43,19104014,Antimicrob Agents Chemother. 2009 Mar;53(3):987-96.,"Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR.",Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection.,10.1128/AAC.00793-08,,Anti-HSV
DRAVPe01132,GHRRYFTFGGGYVYF,15,gB122(636-650),Synthetic construct(derived from HSV-1 B glycoprotein (gB)),P06437,,HSV,Herpesviridae,"beta-galactosidase activity(Comprehensive antiviral assay,Virus inactivation assay,cell protection assay,entry assay,attachment assay)",[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50=15.0±2.2 µM);inhibition of virus entry in Vero cells(EC50=17.6±2.6 µM);inhibition of virus infection in Vero cells(EC50=71.5±17.4 µM);ability of inactive virus(EC50=118±11.6 µM);inhibition of virus attachment on Vero cells(EC50>200 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.19104014]Not cytotoxic for Vero cells up to 200 µM.,DRAVPe01132,DRAVPe01132.cif,Linear,Free,Free,,L,Not found,"It is also possible that gB122 could either prematurely trigger or inhibit a conformational change in the gB-1 molecule required for entry,and may be acting by blocking a protein-protein interaction.",1827.03,C89H115N23O20,ACDEIKLMNPQSW,G,9.7,3,0,3,8,4,-38.67,-2075,30 hour,>20 hour,>10 hour,19.33,4470,319.29,19104014,Antimicrob Agents Chemother. 2009 Mar;53(3):987-96.,"Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR.",Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection.,10.1128/AAC.00793-08,,Anti-HSV
DRAVPe01133,Anti-HeVVPLEVYTRHEIK,15,gB131(681-695),Synthetic construct(derived from HSV-1 B glycoprotein (gB)),P06437,,HSV,Herpesviridae,"beta-galactosidase activity(Comprehensive antiviral assay,Virus inactivation assay,cell protection assay,entry assay,attachment assay)",[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50=18.7±2.70 µM);inhibition of virus entry in Vero cells(EC50=12.2±6.56 µM);inhibition of virus infection in Vero cells(EC50>200 µM);ability of inactive virus(EC50>200 µM);inhibition of virus attachment on Vero cells(EC50>200 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.19104014]Not cytotoxic for Vero cells up to 200 µM.,DRAVPe01133,DRAVPe01133.cif,Linear,Free,Free,,L,Not found,The gB131 peptide could be interfering with a conformational change involving interactions between residues in this region or by blocking a binding interaction.,1849.12,C84H133N23O24,ACDFGMNQSW,EV,6.02,4,3,1,2,5,-53.33,-3097,3.5 hour,10 min,>10 hour,110.0,1490,106.43,19104014,Antimicrob Agents Chemother. 2009 Mar;53(3):987-96.,"Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR.",Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection.,10.1128/AAC.00793-08,,Anti-HSV
DRAVPe01134,HRRYFTFGGGYVYF,14,gB122(637-650),Synthetic construct(derived from HSV-1 B glycoprotein (gB)),P06437,,HSV,Herpesviridae,beta-galactosidase activity(Comprehensive antiviral assay),[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50=31.2 ± 5.1 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01134,DRAVPe01134.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1769.98,C87H112N22O19,ACDEIKLMNPQSW,FGY,9.7,3,0,3,7,4,-38.57,-2169,3.5 hour,10 min,>10 hour,20.71,4470,343.85,19104014,Antimicrob Agents Chemother. 2009 Mar;53(3):987-96.,"Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR.",Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection.,10.1128/AAC.00793-08,,Anti-HSV
DRAVPe01135,GHRAYFTFGGGYVYF,15,gB122R4A,Synthetic construct(derived from HSV-1 B glycoprotein (gB)),P06437,,HSV,Herpesviridae,beta-galactosidase activity(Comprehensive antiviral assay),[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50=26.4 ± 13.5 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01135,DRAVPe01135.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1741.93,C86H108N20O20,CDEIKLMNPQSW,G,8.5,2,0,2,8,5,3.33,-402,30 hour,>20 hour,>10 hour,26.0,4470,319.29,19104014,Antimicrob Agents Chemother. 2009 Mar;53(3):987-96.,"Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR.",Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection.,10.1128/AAC.00793-08,,Anti-HSV
DRAVPe01136,GHRRAFTFGGGYVYF,15,gB122Y5A,Synthetic construct(derived from HSV-1 B glycoprotein (gB)),P06437,,HSV,Herpesviridae,beta-galactosidase activity(Comprehensive antiviral assay),[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50=119.2 ± 26.6 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01136,DRAVPe01136.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1734.94,C83H111N23O19,CDEIKLMNPQSW,G,9.99,3,0,3,7,5,-18.0,-1880,30 hour,>20 hour,>10 hour,26.0,2980,212.86,19104014,Antimicrob Agents Chemother. 2009 Mar;53(3):987-96.,"Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR.",Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection.,10.1128/AAC.00793-08,,Anti-HSV
DRAVPe01137,GHRRYATFGGGYVYF,15,gB122F6A,Synthetic construct(derived from HSV-1 B glycoprotein (gB)),P06437,,HSV,Herpesviridae,beta-galactosidase activity(Comprehensive antiviral assay),[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50=67.6 ± 8.1 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01137,DRAVPe01137.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1750.94,C83H111N23O20,CDEIKLMNPQSW,G,9.7,3,0,3,8,4,-45.33,-2192,30 hour,>20 hour,>10 hour,26.0,4470,319.29,19104014,Antimicrob Agents Chemother. 2009 Mar;53(3):987-96.,"Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR.",Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection.,10.1128/AAC.00793-08,,Anti-HSV
DRAVPe01138,GHRRYFTAGGGYVYF,15,gB122F8A,Synthetic construct(derived from HSV-1 B glycoprotein (gB)),P06437,,HSV,Herpesviridae,beta-galactosidase activity(Comprehensive antiviral assay),[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50=37.5 ± 4.2 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01138,DRAVPe01138.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1750.94,C83H111N23O20,CDEIKLMNPQSW,G,9.7,3,0,3,8,4,-45.33,-2192,30 hour,>20 hour,>10 hour,26.0,4470,319.29,19104014,Antimicrob Agents Chemother. 2009 Mar;53(3):987-96.,"Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR.",Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection.,10.1128/AAC.00793-08,,Anti-HSV
DRAVPe01139,GHRRYFTFGAGYVYF,15,gB122G10L,Synthetic construct(derived from HSV-1 B glycoprotein (gB)),P06437,,HSV,Herpesviridae,beta-galactosidase activity(Comprehensive antiviral assay),[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50=25.1 ± 4.9 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01139,DRAVPe01139.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1841.06,C90H117N23O20,CDEIKLMNPQSW,FGY,9.7,3,0,3,7,5,-24.0,-1988,30 hour,>20 hour,>10 hour,26.0,4470,319.29,19104014,Antimicrob Agents Chemother. 2009 Mar;53(3):987-96.,"Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR.",Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection.,10.1128/AAC.00793-08,,Anti-HSV
DRAVPe01140,GHRRYFTFGGGYVAF,15,gB122Y14A,Synthetic construct(derived from HSV-1 B glycoprotein (gB)),P06437,,HSV,Herpesviridae,beta-galactosidase activity(Comprehensive antiviral assay),[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50=58.0 ± 5.2 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01140,DRAVPe01140.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1734.94,C83H111N23O19,CDEIKLMNPQSW,G,9.99,3,0,3,7,5,-18.0,-1880,30 hour,>20 hour,>10 hour,26.0,2980,212.86,19104014,Antimicrob Agents Chemother. 2009 Mar;53(3):987-96.,"Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR.",Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection.,10.1128/AAC.00793-08,,Anti-HSV
DRAVPe01141,GHRRYFTFGGGYVYA,15,gB122F15A,Synthetic construct(derived from HSV-1 B glycoprotein (gB)),P06437,,HSV,Herpesviridae,beta-galactosidase activity(Comprehensive antiviral assay),[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50=48.6 ± 6.2 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01141,DRAVPe01141.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1750.94,C83H111N23O20,CDEIKLMNPQSW,G,9.7,3,0,3,8,4,-45.33,-2192,30 hour,>20 hour,>10 hour,26.0,4470,319.29,19104014,Antimicrob Agents Chemother. 2009 Mar;53(3):987-96.,"Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR.",Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection.,10.1128/AAC.00793-08,,Anti-HSV
DRAVPe01142,RYFTFGGGYVYF,12,gB122Δ1-3,Synthetic construct(derived from HSV-1 B glycoprotein (gB)),P06437,,HSV,Herpesviridae,beta-galactosidase activity(Comprehensive antiviral assay),[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50=34.9 ± 1.8 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01142,DRAVPe01142.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1476.65,C75H93N15O17,ACDEHIKLMNPQSW,FGY,8.5,1,0,1,7,4,19.17,-211,1 hour,2 min,2 min,24.17,4470,406.36,19104014,Antimicrob Agents Chemother. 2009 Mar;53(3):987-96.,"Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR.",Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection.,10.1128/AAC.00793-08,,Anti-HSV
DRAVPe01143,TFGGGYVYF,9,gB122Δ1-6,Synthetic construct(derived from HSV-1 B glycoprotein (gB)),P06437,,HSV,Herpesviridae,beta-galactosidase activity(Comprehensive antiviral assay),[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50>100 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01143,DRAVPe01143.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1010.11,C51H63N9O13,ACDEHIKLMNPQRSW,G,5.18,0,0,0,6,3,58.89,997,7.2 hour,>20 hour,>10 hour,32.22,2980,372.5,19104014,Antimicrob Agents Chemother. 2009 Mar;53(3):987-96.,"Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR.",Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection.,10.1128/AAC.00793-08,,Anti-HSV
DRAVPe01144,GHRRYFTFGGGY,12,gB122Δ13-15,Synthetic construct(derived from HSV-1 B glycoprotein (gB)),P06437,,HSV,Herpesviridae,beta-galactosidase activity(Comprehensive antiviral assay),[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50=91.4± 9.8 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01144,DRAVPe01144.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1417.55,C66H88N20O16,ACDEIKLMNPQSVW,G,9.99,3,0,3,7,2,-95.83,-2763,30 hour,>20 hour,>10 hour,0.0,2980,270.91,19104014,Antimicrob Agents Chemother. 2009 Mar;53(3):987-96.,"Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR.",Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection.,10.1128/AAC.00793-08,,Anti-HSV
DRAVPe01145,GHRRYFTFG,9,gB122Δ10-15,Synthetic construct(derived from HSV-1 B glycoprotein (gB)),P06437,,HSV,Herpesviridae,beta-galactosidase activity(Comprehensive antiviral assay),[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50>100 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01145,DRAVPe01145.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1140.27,C53H73N17O12,ACDEIKLMNPQSVW,FGR,10.84,3,0,3,4,2,-104.44,-2937,30 hour,>20 hour,>10 hour,0.0,1490,186.25,19104014,Antimicrob Agents Chemother. 2009 Mar;53(3):987-96.,"Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR.",Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection.,10.1128/AAC.00793-08,,Anti-HSV
DRAVPe01146,MDVNPTLLFLKVPAQNAISTTFPYT,25,FluA-PB1(1-25),Synthetic construct(derived from INFV A polymerase (PB1)),Q6DNS6,,Influenza A,Orthomyxoviridae,ELISA,[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=1.80 ±0.49 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01146,DRAVPe01146.cif,Linear,Free,Free,,L,PA subunit,"Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication.",2782.25,C129H201N29O37S,CEGHRW,T,5.59,1,1,0,8,10,31.2,-722,30 hour,>20 hour,>10 hour,93.6,1490,62.08,19841738,PLoS One. 2009 Oct 20;4(10):e7517.,"Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M.",Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. ,10.1371/journal.pone.0007517,,Anti-Influenza A
DRAVPe01147,VNPTLLFLKVPAQNAISTTFPYT,23,FluA-PB1(3-25),Synthetic construct(derived from INFV A polymerase (PB1)),Q6DNS6,,Influenza A,Orthomyxoviridae,ELISA,[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=661.77 ±22.08 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01147,DRAVPe01147.cif,Linear,Free,Free,,L,PA subunit,"Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication.",2535.97,C120H187N27O33,CDEGHMRW,T,8.56,1,0,1,8,10,40.87,-85,100 hour,>20 hour,>10 hour,101.74,1490,67.73,19841738,PLoS One. 2009 Oct 20;4(10):e7517.,"Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M.",Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. ,10.1371/journal.pone.0007517,,Anti-Influenza A
DRAVPe01148,PTLLFLKVPAQNAISTTFPYT,21,FluA-PB1(5-25),Synthetic construct(derived from INFV A polymerase (PB1)),Q6DNS6,,Influenza A,Orthomyxoviridae,ELISA,[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=483.20 ±51.98 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01148,DRAVPe01148.cif,Linear,Free,Free,,L,PA subunit,"Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication.",2322.73,C111H172N24O30,CDEGHMRW,T,9.01,1,0,1,7,9,41.43,175,>20 hour,>20 hour,?,97.62,1490,74.5,19841738,PLoS One. 2009 Oct 20;4(10):e7517.,"Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M.",Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. ,10.1371/journal.pone.0007517,,Anti-Influenza A
DRAVPe01149,LLFLKVPAQNAISTTFPYT,19,FluA-PB1(7-25),Synthetic construct(derived from INFV A polymerase (PB1)),Q6DNS6,,Influenza A,Orthomyxoviridae,ELISA,[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01149,DRAVPe01149.cif,Linear,Free,Free,,L,PA subunit,"Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication.",2124.51,C102H158N22O27,CDEGHMRW,LT,8.59,1,0,1,6,9,57.89,432,5.5 hour,3 min,2 min,107.89,1490,82.78,19841738,PLoS One. 2009 Oct 20;4(10):e7517.,"Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M.",Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. ,10.1371/journal.pone.0007517,,Anti-Influenza A
DRAVPe01150,FLKVPAQNAISTTFPYT,17,FluA-PB1(9-25),Synthetic construct(derived from INFV A polymerase (PB1)),Q6DNS6,,Influenza A,Orthomyxoviridae,ELISA,[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01150,DRAVPe01150.cif,Linear,Free,Free,,L,PA subunit,"Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication.",1898.19,C90H136N20O25,CDEGHMRW,T,8.59,1,0,1,6,7,20.0,-552,1.1 hour,3 min,2 min,74.71,1490,93.13,19841738,PLoS One. 2009 Oct 20;4(10):e7517.,"Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M.",Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. ,10.1371/journal.pone.0007517,,Anti-Influenza A
DRAVPe01151,KVPAQNAISTTFPYT,15,FluA-PB1(11-25),Synthetic construct(derived from INFV A polymerase (PB1)),Q6DNS6,,Influenza A,Orthomyxoviridae,ELISA,[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01151,DRAVPe01151.cif,Linear,Free,Free,,L,PA subunit,"Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication.",1637.85,C75H116N18O23,CDEGHLMRW,T,8.59,1,0,1,6,5,-21.33,-1342,1.3 hour,3 min,2 min,58.67,1490,106.43,19841738,PLoS One. 2009 Oct 20;4(10):e7517.,"Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M.",Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. ,10.1371/journal.pone.0007517,,Anti-Influenza A
DRAVPe01152,MDVNPTLLFLKVPAQNAIST,20,FluA-PB1(1-20),Synthetic construct(derived from INFV A polymerase (PB1)),Q6DNS6,,Influenza A,Orthomyxoviridae,ELISA,[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=33.80 ±5.53 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01152,DRAVPe01152.cif,Linear,Free,Free,,L,PA subunit,"Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication.",2172.57,C98H162N24O29S,CEGHRWY,L,5.59,1,1,0,5,9,46.5,-492,30 hour,>20 hour,>10 hour,117.0,0,0.0,19841738,PLoS One. 2009 Oct 20;4(10):e7517.,"Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M.",Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. ,10.1371/journal.pone.0007517,,Anti-Influenza A
DRAVPe01153,MDVNPTLLFLKVPAQNAI,18,FluA-PB1(1-18),Synthetic construct(derived from INFV A polymerase (PB1)),Q6DNS6,,Influenza A,Orthomyxoviridae,ELISA,[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=29.45 ±5.16 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01153,DRAVPe01153.cif,Linear,Free,Free,,L,PA subunit,"Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication.",1984.38,C91H150N22O25S,CEGHRSWY,L,5.59,1,1,0,3,9,60.0,105,30 hour,>20 hour,>10 hour,130.0,0,0.0,19841738,PLoS One. 2009 Oct 20;4(10):e7517.,"Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M.",Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. ,10.1371/journal.pone.0007517,,Anti-Influenza A
DRAVPe01154,MDVNPTLLFLKVPAQN,16,FluA-PB1(1-16),Synthetic construct(derived from INFV A polymerase (PB1)),Q6DNS6,,Influenza A,Orthomyxoviridae,ELISA,[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=45.86 ±4.22 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01154,DRAVPe01154.cif,Linear,Free,Free,,L,PA subunit,"Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication.",1800.15,C82H134N20O23S,CEGHIRSWY,L,5.59,1,1,0,3,7,28.13,-568,30 hour,>20 hour,>10 hour,115.63,0,0.0,19841738,PLoS One. 2009 Oct 20;4(10):e7517.,"Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M.",Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. ,10.1371/journal.pone.0007517,,Anti-Influenza A
DRAVPe01155,MDVNPTLLFLKVPA,14,FluA-PB1(1-14),Synthetic construct(derived from INFV A polymerase (PB1)),Q6DNS6,,Influenza A,Orthomyxoviridae,ELISA,[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=34.53±2.19 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01155,DRAVPe01155.cif,Linear,Free,Free,,L,PA subunit,"Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication.",1557.91,C73H120N16O19S,CEGHIQRSWY,L,5.59,1,1,0,2,7,82.14,650,30 hour,>20 hour,>10 hour,132.14,0,0.0,19841738,PLoS One. 2009 Oct 20;4(10):e7517.,"Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M.",Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. ,10.1371/journal.pone.0007517,,Anti-Influenza A
DRAVPe01156,MDVNPTLLFLKVP,13,FluA-PB1(1-13),Synthetic construct(derived from INFV A polymerase (PB1)),Q6DNS6,,Influenza A,Orthomyxoviridae,ELISA,[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=138.17 ±7.88 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01156,DRAVPe01156.cif,Linear,Free,Free,,L,PA subunit,"Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication.",1486.83,C70H115N15O18S,ACEGHIQRSWY,L,5.59,1,1,0,2,6,74.62,469,30 hour,>20 hour,>10 hour,134.62,0,0.0,19841738,PLoS One. 2009 Oct 20;4(10):e7517.,"Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M.",Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. ,10.1371/journal.pone.0007517,,Anti-Influenza A
DRAVPe01157,MDVNPTLLFLKV,12,FluA-PB1(1-12),Synthetic construct(derived from INFV A polymerase (PB1)),Q6DNS6,,Influenza A,Orthomyxoviridae,ELISA,[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=643.93 ±180.75 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01157,DRAVPe01157.cif,Linear,Free,Free,,L,PA subunit,"Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication.",1389.72,C65H108N14O17S,ACEGHIQRSWY,L,5.59,1,1,0,2,6,94.17,469,30 hour,>20 hour,>10 hour,145.83,0,0.0,19841738,PLoS One. 2009 Oct 20;4(10):e7517.,"Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M.",Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. ,10.1371/journal.pone.0007517,,Anti-Influenza A
DRAVPe01158,MDVNPTLLFLK,11,FluA-PB1(1-11),Synthetic construct(derived from INFV A polymerase (PB1)),Q6DNS6,,Influenza A,Orthomyxoviridae,ELISA,[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=899.53 ±54.31 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01158,DRAVPe01158.cif,Linear,Free,Free,,L,PA subunit,"Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication.",1290.58,C60H99N13O16S,ACEGHIQRSWY,L,5.59,1,1,0,2,5,64.55,65,30 hour,>20 hour,>10 hour,132.73,0,0.0,19841738,PLoS One. 2009 Oct 20;4(10):e7517.,"Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M.",Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. ,10.1371/journal.pone.0007517,,Anti-Influenza A
DRAVPe01159,MDVNPTLLFL,10,FluA-PB1(1-10),Synthetic construct(derived from INFV A polymerase (PB1)),Q6DNS6,,Influenza A,Orthomyxoviridae,ELISA,[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01159,DRAVPe01159.cif,Linear,Free,Free,,L,PA subunit,"Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication.",1162.41,C54H87N11O15S,ACEGHIKQRSWY,L,3.8,0,1,-1,2,5,110.0,620,30 hour,>20 hour,>10 hour,146.0,0,0.0,19841738,PLoS One. 2009 Oct 20;4(10):e7517.,"Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M.",Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. ,10.1371/journal.pone.0007517,,Anti-Influenza A
DRAVPe01160,MDVNPTLLF,9,FluA-PB1(1-9),Synthetic construct(derived from INFV A polymerase (PB1)),Q6DNS6,,Influenza A,Orthomyxoviridae,ELISA,[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01160,DRAVPe01160.cif,Linear,Free,Free,,L,PA subunit,"Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication.",1049.25,C48H76N10O14S,ACEGHIKQRSWY,L,3.8,0,1,-1,2,4,80.0,128,30 hour,>20 hour,>10 hour,118.89,0,0.0,19841738,PLoS One. 2009 Oct 20;4(10):e7517.,"Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M.",Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. ,10.1371/journal.pone.0007517,,Anti-Influenza A
DRAVPe01161,MDVNPTLL,8,FluA-PB1(1-8),Synthetic construct(derived from INFV A polymerase (PB1)),Q6DNS6,,Influenza A,Orthomyxoviridae,ELISA,[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01161,DRAVPe01161.cif,Linear,Free,Free,,L,PA subunit,"Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication.",902.07,C39H67N9O13S,ACEFGHIKQRSWY,L,3.8,0,1,-1,2,3,55.0,-170,30 hour,>20 hour,>10 hour,133.75,0,0.0,19841738,PLoS One. 2009 Oct 20;4(10):e7517.,"Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M.",Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. ,10.1371/journal.pone.0007517,,Anti-Influenza A
DRAVPe01162,MDVNPTL,7,FluA-PB1(1-7),Synthetic construct(derived from INFV A polymerase (PB1)),Q6DNS6,,Influenza A,Orthomyxoviridae,ELISA,[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01162,DRAVPe01162.cif,Linear,Free,Free,,L,PA subunit,"Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication.",788.91,C33H56N8O12S,ACEFGHIKQRSWY,DLMNPTV,3.8,0,1,-1,2,2,8.57,-662,30 hour,>20 hour,>10 hour,97.14,0,0.0,19841738,PLoS One. 2009 Oct 20;4(10):e7517.,"Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M.",Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. ,10.1371/journal.pone.0007517,,Anti-Influenza A
DRAVPe01163,MDVNPT,6,FluA-PB1(1-6),Synthetic construct(derived from INFV A polymerase (PB1)),Q6DNS6,,Influenza A,Orthomyxoviridae,ELISA,[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01163,DRAVPe01163.cif,Linear,Free,Free,,L,PA subunit,"Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication.",675.75,C27H45N7O11S,ACEFGHIKLQRSWY,DMNPTV,3.8,0,1,-1,2,1,-53.33,-1154,30 hour,>20 hour,>10 hour,48.33,0,0.0,19841738,PLoS One. 2009 Oct 20;4(10):e7517.,"Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M.",Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. ,10.1371/journal.pone.0007517,,Anti-Influenza A
DRAVPe01164,MDVNPTLLFLKVPAQ,15,FluA-PB1(1-15),Synthetic construct(derived from INFV A polymerase (PB1)),Q6DNS6,,Influenza A,Orthomyxoviridae,ELISA,[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=43.32 ±5.31nM);##Influenza B(FluB):inhibition of PA-binding activity and virus replication(IC50>3000nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01164,DRAVPe01164.cif,Linear,Free,Free,,L,PA subunit,"Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication.",1686.04,C78H128N18O21S,CEGHIRSWY,L,5.59,1,1,0,2,7,53.33,96,30 hour,>20 hour,>10 hour,123.33,0,0.0,19841738,PLoS One. 2009 Oct 20;4(10):e7517.,"Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M.",Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. ,10.1371/journal.pone.0007517,,Anti-Influenza A
DRAVPe01165,MNINPYPLFIDVPIQ,15,PB1-1-15 B,Synthetic construct(derived from INFV A polymerase (PB1)),Q6DNS6,,Influenza A,Orthomyxoviridae,ELISA,[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM);##Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=45.0 ±12.5 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01165,DRAVPe01165.cif,Linear,Free,Free,,L,PA subunit,"Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication.",1774.11,C84H128N18O22S,ACEGHKRSTW,IP,3.8,0,1,-1,3,6,40.67,137,30 hour,>20 hour,>10 hour,123.33,1490,106.43,19841738,PLoS One. 2009 Oct 20;4(10):e7517.,"Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M.",Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. ,10.1371/journal.pone.0007517,,Anti-Influenza A
DRAVPe01166,MNINPTLLFLKVPIQ,15,"PB1-1-15 A D2N,V3I,L14I",Synthetic construct(derived from INFV A polymerase (PB1)),Q6DNS6,,Influenza A,Orthomyxoviridae,ELISA,[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=6.69 ±1.73 nM);##Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01166,DRAVPe01166.cif,Linear,Free,Free,,L,PA subunit,"Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication.",1741.16,C82H137N19O20S,ACDEGHRSWY,L,8.5,1,0,1,3,7,73.33,703,30 hour,>20 hour,>10 hour,149.33,0,0.0,19841738,PLoS One. 2009 Oct 20;4(10):e7517.,"Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M.",Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. ,10.1371/journal.pone.0007517,,Anti-Influenza A
DRAVPe01167,MDVNPTLLFIDVPAQ,15,"PB1-1-15 A L10I,K11D",Synthetic construct(derived from INFV A polymerase (PB1)),Q6DNS6,,Influenza A,Orthomyxoviridae,ELISA,[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM);##Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01167,DRAVPe01167.cif,Linear,Free,Free,,L,PA subunit,"Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication.",1672.96,C76H121N17O23S,CEGHKRSWY,DLPV,3.56,0,2,-2,2,7,60.67,-221,30 hour,>20 hour,>10 hour,123.33,0,0.0,19841738,PLoS One. 2009 Oct 20;4(10):e7517.,"Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M.",Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. ,10.1371/journal.pone.0007517,,Anti-Influenza A
DRAVPe01168,MNINPTLLFLKVPAQ,15,"PB1-1-15 A D2N,V3I",Synthetic construct(derived from INFV A polymerase (PB1)),Q6DNS6,,Influenza A,Orthomyxoviridae,ELISA,[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=12.96 ±3.98 nM);##Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01168,DRAVPe01168.cif,Linear,Free,Free,,L,PA subunit,"Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication.",1699.08,C79H131N19O20S,CDEGHRSWY,L,8.5,1,0,1,3,7,55.33,392,30 hour,>20 hour,>10 hour,130.0,0,0.0,19841738,PLoS One. 2009 Oct 20;4(10):e7517.,"Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M.",Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. ,10.1371/journal.pone.0007517,,Anti-Influenza A
DRAVPe01169,MDVNPYFLFLKVPAQ,15,"PB1-1-15 A T6Y,L7F",Synthetic construct(derived from INFV A polymerase (PB1)),Q6DNS6,,Influenza A,Orthomyxoviridae,ELISA,[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=7.51 ±0.71 nM);##Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=345.0 ±81.5 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01169,DRAVPe01169.cif,Linear,Free,Free,,L,PA subunit,"Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication.",1782.13,C86H128N18O21S,CEGHIRSTW,FLPV,5.59,1,1,0,2,7,42.67,145,30 hour,>20 hour,>10 hour,97.33,1490,106.43,19841738,PLoS One. 2009 Oct 20;4(10):e7517.,"Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M.",Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. ,10.1371/journal.pone.0007517,,Anti-Influenza A
DRAVPe01170,MDVNPTFLFLKVPAQ,15,PB1-1-15 A L7F,Synthetic construct(derived from INFV A polymerase (PB1)),Q6DNS6,,Influenza A,Orthomyxoviridae,ELISA,[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM);##Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01170,DRAVPe01170.cif,Linear,Free,Free,,L,PA subunit,"Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication.",1720.06,C81H126N18O21S,CEGHIRSWY,FLPV,5.59,1,1,0,2,7,46.67,-98,30 hour,>20 hour,>10 hour,97.33,0,0.0,19841738,PLoS One. 2009 Oct 20;4(10):e7517.,"Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M.",Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. ,10.1371/journal.pone.0007517,,Anti-Influenza A
DRAVPe01171,MDVNPYLLFLKVPAQ,15,PB1-1-15 A T6Y,Synthetic construct(derived from INFV A polymerase (PB1)),Q6DNS6,,Influenza A,Orthomyxoviridae,ELISA,[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=21.64 ±1.48 nM);##Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=107.1 ±31.3 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01171,DRAVPe01171.cif,Linear,Free,Free,,L,PA subunit,"Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication.",1748.11,C83H130N18O21S,CEGHIRSTW,L,5.59,1,1,0,2,7,49.33,339,30 hour,>20 hour,>10 hour,123.33,1490,106.43,19841738,PLoS One. 2009 Oct 20;4(10):e7517.,"Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M.",Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. ,10.1371/journal.pone.0007517,,Anti-Influenza A
DRAVPe01172,MDVNPFLLFLKVPAQ,15,PB1-1-15 A T6F,Synthetic construct(derived from INFV A polymerase (PB1)),Q6DNS6,,Influenza A,Orthomyxoviridae,ELISA,[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=2.84 ±0.48 nM);##Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=750.4 ±249.6 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01172,DRAVPe01172.cif,Linear,Free,Free,,L,PA subunit,"Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication.",1732.11,C83H130N18O20S,CEGHIRSTWY,L,5.59,1,1,0,1,8,76.67,651,30 hour,>20 hour,>10 hour,123.33,0,0.0,19841738,PLoS One. 2009 Oct 20;4(10):e7517.,"Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M.",Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. ,10.1371/journal.pone.0007517,,Anti-Influenza A
DRAVPe01173,MDVNPWLLFLKVPAQ,15,PB1-1-15 A T6W,Synthetic construct(derived from INFV A polymerase (PB1)),Q6DNS6,,Influenza A,Orthomyxoviridae,ELISA,[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=3.40 ±0.51 nM);##Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=628.3 ±389.1 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01173,DRAVPe01173.cif,Linear,Free,Free,,L,PA subunit,"Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication.",1771.15,C85H131N19O20S,CEGHIRSTY,L,5.59,1,1,0,1,8,52.0,586,30 hour,>20 hour,>10 hour,123.33,5500,392.86,19841738,PLoS One. 2009 Oct 20;4(10):e7517.,"Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M.",Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. ,10.1371/journal.pone.0007517,,Anti-Influenza A
DRAVPe01174,MDVNPHLLFLKVPAQ,15,PB1-1-15 A T6H,Synthetic construct(derived from INFV A polymerase (PB1)),Q6DNS6,,Influenza A,Orthomyxoviridae,ELISA,[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=292.16 ±34.04 nM);##Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01174,DRAVPe01174.cif,Linear,Free,Free,,L,PA subunit,"Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication.",1722.08,C80H128N20O20S,CEGIRSTWY,L,6.5,2,1,1,1,7,36.67,-113,30 hour,>20 hour,>10 hour,123.33,0,0.0,19841738,PLoS One. 2009 Oct 20;4(10):e7517.,"Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M.",Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. ,10.1371/journal.pone.0007517,,Anti-Influenza A
DRAVPe01175,MDVNPCLLFLKVPAQ,15,PB1-1-15 A T6C,Synthetic construct(derived from INFV A polymerase (PB1)),Q6DNS6,,Influenza A,Orthomyxoviridae,ELISA,[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=43.58 ±5.67 nM);##Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01175,DRAVPe01175.cif,Linear,Free,Free,,L,PA subunit,"Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication.",1688.08,C77H126N18O20S2,EGHIRSTWY,L,5.59,1,1,0,2,7,74.67,481,30 hour,>20 hour,>10 hour,123.33,0,0.0,19841738,PLoS One. 2009 Oct 20;4(10):e7517.,"Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M.",Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. ,10.1371/journal.pone.0007517,,Anti-Influenza A
DRAVPe01176,GWWYKGRARPVSAVA,15,18-c01,Synthetic construct,No entry found,,"H3N2,H1N1",Orthomyxoviridae,Plaque assay,[Ref.19558186]H1N1(A/PR/8/34):inhibition of virus infection in  Madin-Darby canine kidney(MDCK) cells(IC50=3.2 μM);##H3N2(A/Aichi/2/68):inhibition of virus infection in Madin-Darby canine kidney(MDCK) cells(IC50>10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01176,DRAVPe01176.cif,Linear,Alkylated(C18),Amidation,,L,sialylgalactose,The peptide has affinity for glycoconjugates on the cell surface. And its binding to the cell resulted in the significant inhibition of influenza virus infections.,1703.97,C80H118N24O18,CDEFHILMNQT,A,11.0,3,0,3,4,7,-36.0,-1888,30 hour,>20 hour,>10 hour,58.67,12490,892.14,19558186,J Med Chem. 2009 Jul 23;52(14):4247-56.,"Matsubara T, Sumi M, Kubota H, Taki T, Okahata Y, Sato T.",Inhibition of influenza virus infections by sialylgalactose-binding peptides selected from a phage library. ,10.1021/jm801570y,,"Anti-H3N2,Anti-H1N1"
DRAVPe01177,RAVWRHSVATPSHSV,15,C18-c03,Synthetic construct,No entry found,,"H3N2,H1N1",Orthomyxoviridae,Plaque assay,[Ref.19558186]H1N1(A/PR/8/34):inhibition of virus infection in  Madin-Darby canine kidney(MDCK) cells(IC50=6.5 μM);##H3N2(A/Aichi/2/68):inhibition of virus infection in Madin-Darby canine kidney(MDCK) cells(IC50=68 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01177,DRAVPe01177.cif,Linear,Alkylated(C18),Amidation,,L,sialylgalactose,The peptide has affinity for glycoconjugates on the cell surface. And its binding to the cell resulted in the significant inhibition of influenza virus infections.,1689.9,C74H116N26O20,CDEFGIKLMNQY,SV,12.0,4,0,4,4,6,-32.0,-3386,1 hour,2 min,2 min,71.33,5500,392.86,19558186,J Med Chem. 2009 Jul 23;52(14):4247-56.,"Matsubara T, Sumi M, Kubota H, Taki T, Okahata Y, Sato T.",Inhibition of influenza virus infections by sialylgalactose-binding peptides selected from a phage library. ,10.1021/jm801570y,,"Anti-H3N2,Anti-H1N1"
DRAVPe01178,GAWYKGRARPVSAVA,15,C18-c01W2A,Synthetic construct,No entry found,,H1N1,Orthomyxoviridae,Plaque assay,[Ref.19558186]H1N1(A/PR/8/34):inhibition of virus infection in  Madin-Darby canine kidney(MDCK) cells(IC50=53 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01178,DRAVPe01178.cif,Linear,Alkylated(C18),Amidation,,L,sialylgalactose,The peptide has affinity for glycoconjugates on the cell surface. And its binding to the cell resulted in the significant inhibition of influenza virus infections.,1588.83,C72H113N23O18,CDEFHILMNQT,A,11.0,3,0,3,4,7,-18.0,-1940,30 hour,>20 hour,>10 hour,65.33,6990,499.29,19558186,J Med Chem. 2009 Jul 23;52(14):4247-56.,"Matsubara T, Sumi M, Kubota H, Taki T, Okahata Y, Sato T.",Inhibition of influenza virus infections by sialylgalactose-binding peptides selected from a phage library. ,10.1021/jm801570y,,Anti-H1N1
DRAVPe01179,GWWYKGRARAVSAVA,15,C18-c01P10A,Synthetic construct,No entry found,,H1N1,Orthomyxoviridae,Plaque assay,[Ref.19558186]H1N1(A/PR/8/34):inhibition of virus infection in  Madin-Darby canine kidney(MDCK) cells(IC50=89 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01179,DRAVPe01179.cif,Linear,Alkylated(C18),Amidation,,L,sialylgalactose,The peptide has affinity for glycoconjugates on the cell surface. And its binding to the cell resulted in the significant inhibition of influenza virus infections.,1677.93,C78H116N24O18,CDEFHILMNPQT,A,11.0,3,0,3,4,8,-13.33,-1707,30 hour,>20 hour,>10 hour,65.33,12490,892.14,19558186,J Med Chem. 2009 Jul 23;52(14):4247-56.,"Matsubara T, Sumi M, Kubota H, Taki T, Okahata Y, Sato T.",Inhibition of influenza virus infections by sialylgalactose-binding peptides selected from a phage library. ,10.1021/jm801570y,,Anti-H1N1
DRAVPe01180,AVASVPRARGKYWWG,15,C18-c01r,Synthetic construct,No entry found,,"H3N2,H1N1",Orthomyxoviridae,Plaque assay,[Ref.19558186]H1N1(A/PR/8/34):inhibition of virus infection in  Madin-Darby canine kidney(MDCK) cells(IC50=44 μM);##H3N2(A/Aichi/2/68):inhibition of virus infection in Madin-Darby canine kidney(MDCK) cells(IC50=17 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01180,DRAVPe01180.cif,Linear,Alkylated(C18),Amidation,,L,sialylgalactose,The peptide has affinity for glycoconjugates on the cell surface. And its binding to the cell resulted in the significant inhibition of influenza virus infections.,1703.97,C80H118N24O18,CDEFHILMNQT,A,11.0,3,0,3,4,7,-36.0,-1888,4.4 hour,>20 hour,>10 hour,58.67,12490,892.14,19558186,J Med Chem. 2009 Jul 23;52(14):4247-56.,"Matsubara T, Sumi M, Kubota H, Taki T, Okahata Y, Sato T.",Inhibition of influenza virus infections by sialylgalactose-binding peptides selected from a phage library. ,10.1021/jm801570y,,"Anti-H3N2,Anti-H1N1"
DRAVPe01181,DFRRLPGAFWQLRQP,15,C18-p1b,Synthetic construct,No entry found,,"H3N2,H1N1",Orthomyxoviridae,Plaque assay,[Ref.19558186]H1N1(A/PR/8/34):inhibition of virus infection in  Madin-Darby canine kidney(MDCK) cells(IC50=52 μM);##H3N2(A/Aichi/2/68):inhibition of virus infection in Madin-Darby canine kidney(MDCK) cells(IC50=19 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01181,DRAVPe01181.cif,Linear,Alkylated(C18),Amidation,,L,sialylgalactose,The peptide has affinity for glycoconjugates on the cell surface. And its binding to the cell resulted in the significant inhibition of influenza virus infections.,1887.18,C88H131N27O20,CEHIKMNSTVY,R,11.7,3,1,2,1,6,-90.0,-4368,1.1 hour,3 min,>10 hour,58.67,5500,392.86,19558186,J Med Chem. 2009 Jul 23;52(14):4247-56.,"Matsubara T, Sumi M, Kubota H, Taki T, Okahata Y, Sato T.",Inhibition of influenza virus infections by sialylgalactose-binding peptides selected from a phage library. ,10.1021/jm801570y,,"Anti-H3N2,Anti-H1N1"
DRAVPe01182,AETVESCLAKPHTEN,15,C18-cp3c,Synthetic construct,No entry found,,"H3N2,H1N1",Orthomyxoviridae,Plaque assay,[Ref.19558186]H1N1(A/PR/8/34):inhibition of virus infection in  Madin-Darby canine kidney(MDCK) cells(IC50=66 μM);##H3N2(A/Aichi/2/68):inhibition of virus infection in Madin-Darby canine kidney(MDCK) cells(IC50>100 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01182,DRAVPe01182.cif,Linear,Alkylated(C18),Amidation,,L,sialylgalactose,The peptide has affinity for glycoconjugates on the cell surface. And its binding to the cell resulted in the significant inhibition of influenza virus infections.,1628.77,C67H109N19O26S,DFGIMQRWY,E,4.75,2,3,-1,5,4,-72.0,-3196,4.4 hour,>20 hour,>10 hour,58.67,0,0.0,19558186,J Med Chem. 2009 Jul 23;52(14):4247-56.,"Matsubara T, Sumi M, Kubota H, Taki T, Okahata Y, Sato T.",Inhibition of influenza virus infections by sialylgalactose-binding peptides selected from a phage library. ,10.1021/jm801570y,,"Anti-H3N2,Anti-H1N1"
DRAVPe01183,GWWYKGRARPVSAVA,15,c01,Synthetic construct,No entry found,,H1N1,Orthomyxoviridae,Plaque assay,[Ref.19558186]H1N1(A/PR/8/34):inhibition of virus infection in  Madin-Darby canine kidney(MDCK) cells(IC50>500 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01183,DRAVPe01183.cif,Linear,Free,Amidation,,L,sialylgalactose,The peptide has affinity for glycoconjugates on the cell surface. And its binding to the cell resulted in the significant inhibition of influenza virus infections.,1703.97,C80H118N24O18,CDEFHILMNQT,A,11.0,3,0,3,4,7,-36.0,-1888,30 hour,>20 hour,>10 hour,58.67,12490,892.14,19558186,J Med Chem. 2009 Jul 23;52(14):4247-56.,"Matsubara T, Sumi M, Kubota H, Taki T, Okahata Y, Sato T.",Inhibition of influenza virus infections by sialylgalactose-binding peptides selected from a phage library. ,10.1021/jm801570y,,Anti-H1N1
DRAVPe01184,RAVWRHSVATPSHSV,15,c03,Synthetic construct,No entry found,,H1N1,Orthomyxoviridae,Plaque assay,[Ref.19558186]H1N1(A/PR/8/34):inhibition of virus infection in  Madin-Darby canine kidney(MDCK) cells(IC50>500 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01184,DRAVPe01184.cif,Linear,Free,Amidation,,L,sialylgalactose,The peptide has affinity for glycoconjugates on the cell surface. And its binding to the cell resulted in the significant inhibition of influenza virus infections.,1689.9,C74H116N26O20,CDEFGIKLMNQY,SV,12.0,4,0,4,4,6,-32.0,-3386,1 hour,2 min,2 min,71.33,5500,392.86,19558186,J Med Chem. 2009 Jul 23;52(14):4247-56.,"Matsubara T, Sumi M, Kubota H, Taki T, Okahata Y, Sato T.",Inhibition of influenza virus infections by sialylgalactose-binding peptides selected from a phage library. ,10.1021/jm801570y,,Anti-H1N1
DRAVPe01185,RRKKAAVALLPAVLLALLAP,20,EB,Synthetic construct(derived from FGF-4 signal sequence),P08620,,Influenza virus,Orthomyxoviridae,Hemagglutinin assay,"[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(95 ± 2% inhibition at 10 μM,EC50=3.2 ± 0.0 μM).",[Ref.21220525]Did not lyse red blood cells up to 30 μM.,[Ref.21220525]A549 cells:CD50=83.5 ± 22.0 μM;##MDCK cells:CD50=85.5 ± 1.3 μM.,DRAVPe01185,DRAVPe01185.cif,Linear,Free,Free,,L,Not found,The peptide inhibits influenza virus replication by preventing attachment to cells.,2084.67,C98H178N28O21,CDEFGHIMNQSTWY,AL,12.02,4,0,4,0,14,110.0,752,1 hour,2 min,2 min,176.0,0,0.0,21220525, Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3.,"Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. ",Identification of the minimal active sequence of an anti-influenza virus peptide. ,10.1128/AAC.01428-10,DRAVPa1689,Anti-Influenza virus
DRAVPe01186,RRKKAAVALLPAVLLALLA,19,A2,Synthetic construct(derived from FGF-4 signal sequence),P08620,,Influenza virus,Orthomyxoviridae,Hemagglutinin assay,[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(94 ± 2% inhibition at 10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01186,DRAVPe01186.cif,Linear,Free,Free,,L,Not found,The peptide inhibits influenza virus replication by preventing attachment to cells.,1987.55,C93H171N27O20,CDEFGHIMNQSTWY,AL,12.02,4,0,4,0,14,124.21,752,1 hour,2 min,2 min,185.26,0,0.0,21220525, Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3.,"Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. ",Identification of the minimal active sequence of an anti-influenza virus peptide. ,10.1128/AAC.01428-10,DRAVPa1690,Anti-Influenza virus
DRAVPe01187,RRKKAAVALLPAVLLALL,18,A3,Synthetic construct(derived from FGF-4 signal sequence),P08620,,Influenza virus,Orthomyxoviridae,Hemagglutinin assay,[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(95 ± 2% inhibition at 10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01187,DRAVPe01187.cif,Linear,Free,Free,,L,Not found,The peptide inhibits influenza virus replication by preventing attachment to cells.,1916.47,C90H166N26O19,CDEFGHIMNQSTWY,L,12.02,4,0,4,0,13,121.11,571,1 hour,2 min,2 min,190.0,0,0.0,21220525, Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3.,"Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. ",Identification of the minimal active sequence of an anti-influenza virus peptide. ,10.1128/AAC.01428-10,DRAVPa1691,Anti-Influenza virus
DRAVPe01188,RRKKAAVALLPAVLLAL,17,A4,Synthetic construct(derived from FGF-4 signal sequence),P08620,,Influenza virus,Orthomyxoviridae,Hemagglutinin assay,[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(89 ± 3% inhibition at 10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01188,DRAVPe01188.cif,Linear,Free,Free,,L,Not found,The peptide inhibits influenza virus replication by preventing attachment to cells.,1803.31,C84H155N25O18,CDEFGHIMNQSTWY,AL,12.02,4,0,4,0,12,105.88,79,1 hour,2 min,2 min,178.24,0,0.0,21220525, Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3.,"Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. ",Identification of the minimal active sequence of an anti-influenza virus peptide. ,10.1128/AAC.01428-10,DRAVPa1692,Anti-Influenza virus
DRAVPe01189,RRKKAAVALLPAVLLA,16,A5,Synthetic construct(derived from FGF-4 signal sequence),P08620,,Influenza virus,Orthomyxoviridae,Hemagglutinin assay,[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(96 ±32% inhibition at 10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01189,DRAVPe01189.cif,Linear,Free,Free,,L,Not found,The peptide inhibits influenza virus replication by preventing attachment to cells.,1690.15,C78H144N24O17,CDEFGHIMNQSTWY,A,12.02,4,0,4,0,11,88.75,-413,1 hour,2 min,2 min,165.0,0,0.0,21220525, Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3.,"Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. ",Identification of the minimal active sequence of an anti-influenza virus peptide. ,10.1128/AAC.01428-10,DRAVPa1693,Anti-Influenza virus
DRAVPe01190,RRKKAAVALLP,11,A10,Synthetic construct(derived from FGF-4 signal sequence),P08620,,Influenza virus,Orthomyxoviridae,Hemagglutinin assay,[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(4 ±8% inhibition at 10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01190,DRAVPe01190.cif,Linear,Free,Free,,L,Not found,The peptide inhibits influenza virus replication by preventing attachment to cells.,1222.54,C55H103N19O12,CDEFGHIMNQSTWY,A,12.02,4,0,4,0,6,-10.91,-2163,1 hour,2 min,2 min,124.55,0,0.0,21220525, Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3.,"Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. ",Identification of the minimal active sequence of an anti-influenza virus peptide. ,10.1128/AAC.01428-10,DRAVPa1698,Anti-Influenza virus
DRAVPe01191,RRKKAVALLPAVLLALLAP,19,B6,Synthetic construct(derived from FGF-4 signal sequence),P08620,,Influenza virus,Orthomyxoviridae,Hemagglutinin assay,[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(94 ± 6% inhibition at 10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01191,DRAVPe01191.cif,Linear,Free,Free,,L,Not found,The peptide inhibits influenza virus replication by preventing attachment to cells.,2013.59,C95H173N27O20,CDEFGHIMNQSTWY,L,12.02,4,0,4,0,13,106.32,571,1 hour,2 min,2 min,180.0,0,0.0,21220525, Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3.,"Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. ",Identification of the minimal active sequence of an anti-influenza virus peptide. ,10.1128/AAC.01428-10,DRAVPa1706,Anti-Influenza virus
DRAVPe01192,RRKKVALLPAVLLALLAP,18,B7,Synthetic construct(derived from FGF-4 signal sequence),P08620,,Influenza virus,Orthomyxoviridae,Hemagglutinin assay,[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(94 ± 4% inhibition at 10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01192,DRAVPe01192.cif,Linear,Free,Free,,L,Not found,The peptide inhibits influenza virus replication by preventing attachment to cells.,1942.51,C92H168N26O19,CDEFGHIMNQSTWY,L,12.02,4,0,4,0,12,102.22,390,1 hour,2 min,2 min,184.44,0,0.0,21220525, Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3.,"Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. ",Identification of the minimal active sequence of an anti-influenza virus peptide. ,10.1128/AAC.01428-10,DRAVPa1707,Anti-Influenza virus
DRAVPe01193,RRKKALLPAVLLALLAP,17,B8,Synthetic construct(derived from FGF-4 signal sequence),P08620,,Influenza virus,Orthomyxoviridae,Hemagglutinin assay,[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(94 ± 3% inhibition at 10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01193,DRAVPe01193.cif,Linear,Free,Free,,L,Not found,The peptide inhibits influenza virus replication by preventing attachment to cells.,1843.38,C87H159N25O18,CDEFGHIMNQSTWY,L,12.02,4,0,4,0,11,83.53,-14,1 hour,2 min,2 min,178.24,0,0.0,21220525, Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3.,"Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. ",Identification of the minimal active sequence of an anti-influenza virus peptide. ,10.1128/AAC.01428-10,DRAVPa1708,Anti-Influenza virus
DRAVPe01194,RRKKLLPAVLLALLAP,16,B9,Synthetic construct(derived from FGF-4 signal sequence),P08620,,Influenza virus,Orthomyxoviridae,Hemagglutinin assay,[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(94 ± 4% inhibition at 10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01194,DRAVPe01194.cif,Linear,Free,Free,,L,Not found,The peptide inhibits influenza virus replication by preventing attachment to cells.,1772.3,C84H154N24O17,CDEFGHIMNQSTWY,L,12.02,4,0,4,0,10,77.5,-195,1 hour,2 min,2 min,183.13,0,0.0,21220525, Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3.,"Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. ",Identification of the minimal active sequence of an anti-influenza virus peptide. ,10.1128/AAC.01428-10,DRAVPa1709,Anti-Influenza virus
DRAVPe01195,RRKKLPAVLLALLAP,15,B10,Synthetic construct(derived from FGF-4 signal sequence),P08620,,Influenza virus,Orthomyxoviridae,Hemagglutinin assay,[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(94 ± 4% inhibition at 10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01195,DRAVPe01195.cif,Linear,Free,Free,,L,Not found,The peptide inhibits influenza virus replication by preventing attachment to cells.,1659.14,C78H143N23O16,CDEFGHIMNQSTWY,L,12.02,4,0,4,0,9,57.33,-687,1 hour,2 min,2 min,169.33,0,0.0,21220525, Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3.,"Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. ",Identification of the minimal active sequence of an anti-influenza virus peptide. ,10.1128/AAC.01428-10,DRAVPa1710,Anti-Influenza virus
DRAVPe01196,RRKKPAVLLALLAP,14,B11,Synthetic construct(derived from FGF-4 signal sequence),P08620,,Influenza virus,Orthomyxoviridae,Hemagglutinin assay,[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(96 ± 0% inhibition at 10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01196,DRAVPe01196.cif,Linear,Free,Free,,L,Not found,The peptide inhibits influenza virus replication by preventing attachment to cells.,1545.98,C72H132N22O15,CDEFGHIMNQSTWY,L,12.02,4,0,4,0,8,34.29,-1179,1 hour,2 min,2 min,153.57,0,0.0,21220525, Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3.,"Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. ",Identification of the minimal active sequence of an anti-influenza virus peptide. ,10.1128/AAC.01428-10,DRAVPa1006,Anti-Influenza virus
DRAVPe01197,RRKKAVLLALLAP,13,B12,Synthetic construct(derived from FGF-4 signal sequence),P08620,,Influenza virus,Orthomyxoviridae,Hemagglutinin assay,[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(97 ± 2% inhibition at 10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01197,DRAVPe01197.cif,Linear,Free,Free,,L,Not found,The peptide inhibits influenza virus replication by preventing attachment to cells.,1448.86,C67H125N21O14,CDEFGHIMNQSTWY,L,12.02,4,0,4,0,8,49.23,-1179,1 hour,2 min,2 min,165.38,0,0.0,21220525, Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3.,"Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. ",Identification of the minimal active sequence of an anti-influenza virus peptide. ,10.1128/AAC.01428-10,,Anti-Influenza virus
DRAVPe01198,RRKKVLLALLAP,12,C1,Synthetic construct(derived from FGF-4 signal sequence),P08620,,Influenza virus,Orthomyxoviridae,Hemagglutinin assay,[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(40 ±19 % inhibition at 10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01198,DRAVPe01198.cif,Linear,Free,Free,,L,Not found,The peptide inhibits influenza virus replication by preventing attachment to cells.,1377.78,C64H120N20O13,CDEFGHIMNQSTWY,L,12.02,4,0,4,0,7,38.33,-1360,1 hour,2 min,2 min,170.83,0,0.0,21220525, Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3.,"Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. ",Identification of the minimal active sequence of an anti-influenza virus peptide. ,10.1128/AAC.01428-10,DRAVPa1711,Anti-Influenza virus
DRAVPe01199,RRKKAAVALLAVLLALLA,18,EBNP(EB without prolines),Synthetic construct(derived from FGF-4 signal sequence),P08620,,Influenza virus,Orthomyxoviridae,Hemagglutinin assay,[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(EC50=3.0 ± 0.0 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01199,DRAVPe01199.cif,Linear,Free,Free,,L,Not found,The peptide inhibits influenza virus replication by preventing attachment to cells.,1890.43,C88H164N26O19,CDEFGHIMNPQSTWY,AL,12.02,4,0,4,0,14,140.0,752,1 hour,2 min,2 min,195.56,0,0.0,21220525, Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3.,"Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. ",Identification of the minimal active sequence of an anti-influenza virus peptide. ,10.1128/AAC.01428-10,DRAVPa1721,Anti-Influenza virus
DRAVPe01200,RRKKVALLAVLLALLA,16,B7NP(B7 without prolines),Synthetic construct(derived from FGF-4 signal sequence),P08620,,Influenza virus,Orthomyxoviridae,Hemagglutinin assay,[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(EC50=0.3 ± 0.1 μM).,[Ref.21220525]>50% hemolysis agaisnt human red blood cells at 30 μM.,[Ref.21220525]A549 cells:CD50=126.3± 23.0 μM;##MDCK cells:CD50=105.3 ± 8.0 μM.,DRAVPe01200,DRAVPe01200.cif,Linear,Free,Free,,L,Not found,The peptide inhibits influenza virus replication by preventing attachment to cells.,1748.28,C82H154N24O17,CDEFGHIMNPQSTWY,L,12.02,4,0,4,0,12,135.0,390,1 hour,2 min,2 min,207.5,0,0.0,21220525, Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3.,"Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. ",Identification of the minimal active sequence of an anti-influenza virus peptide. ,10.1128/AAC.01428-10,DRAVPa1720,Anti-Influenza virus
DRAVPe01201,RRKKALLAVLLALLA,15,B8NP,Synthetic construct(derived from FGF-4 signal sequence),P08620,,Influenza virus,Orthomyxoviridae,Hemagglutinin assay,[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(EC50=0.4 ± 0.2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01201,DRAVPe01201.cif,Linear,Free,Free,,L,Not found,The peptide inhibits influenza virus replication by preventing attachment to cells.,1649.14,C77H145N23O16,CDEFGHIMNPQSTWY,L,12.02,4,0,4,0,11,116.0,-14,1 hour,2 min,2 min,202.0,0,0.0,21220525, Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3.,"Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. ",Identification of the minimal active sequence of an anti-influenza virus peptide. ,10.1128/AAC.01428-10,,Anti-Influenza virus
DRAVPe01202,RRKKLLAVLLALLA,14,B9NP,Synthetic construct(derived from FGF-4 signal sequence),P08620,,Influenza virus,Orthomyxoviridae,Hemagglutinin assay,[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(EC50=3.1 ± 0.1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01202,DRAVPe01202.cif,Linear,Free,Free,,L,Not found,The peptide inhibits influenza virus replication by preventing attachment to cells.,1578.06,C74H140N22O15,CDEFGHIMNPQSTWY,L,12.02,4,0,4,0,10,111.43,-195,1 hour,2 min,2 min,209.29,0,0.0,21220525, Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3.,"Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. ",Identification of the minimal active sequence of an anti-influenza virus peptide. ,10.1128/AAC.01428-10,DRAVPa1722,Anti-Influenza virus
DRAVPe01203,RRKKLAVLLALLA,13,B10NP,Synthetic construct(derived from FGF-4 signal sequence),P08620,,Influenza virus,Orthomyxoviridae,Hemagglutinin assay,[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(EC50=3.5 ± 2.6 μM).,[Ref.21220525]Did not lyse human red blood cells up to 30 μM.,[Ref.21220525]A549 cells:CD50=120.0 ± 28.0 μM;##MDCK cells:CD50=90.0 ± 16.3 μM.,DRAVPe01203,DRAVPe01203.cif,Linear,Free,Free,,L,Not found,The peptide inhibits influenza virus replication by preventing attachment to cells.,1464.9,C68H129N21O14,CDEFGHIMNPQSTWY,L,12.02,4,0,4,0,9,90.77,-687,1 hour,2 min,2 min,195.38,0,0.0,21220525, Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3.,"Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. ",Identification of the minimal active sequence of an anti-influenza virus peptide. ,10.1128/AAC.01428-10,DRAVPa1723,Anti-Influenza virus
DRAVPe01204,LFRLIKSLIKRLVSAFK,17,Mucroporin-M1,Synthetic construct(derived from Mucroporin),B9UIY3,,"SARS-CoV,H5N1,MeV","Coronaviridae, Orthomyxoviridae, Paramyxoviridae",Plaque formation assay,[Ref.21620914]measles virus (MeV):inhibition of MeV infection in Vero cells(EC50=7.15 μg/ml (3.52 μM));##SARS-CoV(pseudoviruse):inhibition of SARS-CoV infection in MDCK cells(EC50=14.46 μg/ml (7.12 μM));##H5N1(pseudovirus):inhibition of H5N1 infection in MDCK cells(EC50=2.10 μg/ml (1.03 μM)).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.21620914]Vero cells:CC50=70.46μg/ ml(34.70μM);##HeLa-ACE2 cells:CC50=61.58 μg/ml (30.31 μM);##MDCK cells:CC50=83.35 μg/ml (41.03 μM).,DRAVPe01204,DRAVPe01204.cif,Linear,Free,Amidation,,L,membrane,"Mucroporin-M1 may bind to the virus envelope by surface charge interactions and inhibits MeV, SARS-CoV and influenza H5N1 by direct virucidal action.",2032.59,C98H170N26O20,CDEGHMNPQTWY,L,12.02,5,0,5,2,10,79.41,-1196,5.5 hour,3 min,2 min,160.59,0,0.0,21620914,Peptides. 2011 Jul;32(7):1518-25.,"Li Q, Zhao Z, Zhou D, Chen Y, Hong W, Cao L, Yang J, Zhang Y, Shi W, Cao Z, Wu Y, Yan H, Li W. ","Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses. ",10.1016/j.peptides.2011.05.015,,"Anti-SARS-CoV,Anti-H5N1,Anti-MeV"
DRAVPe01205,KAKAKAKAKAKAKAKAKAKAK,21,RJ1,Synthetic construct,No entry found,,HSV,Herpesviridae,"Plaque reduction assay,ELISA",[Ref.15498607]herpes simplex virus 2(HSV-2):inhibition of HSV-2 infection in MRC-5 cells(IC50=53.2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.15498607]human fibroblasts(MRC-5 cells):CC50>455 μM.,DRAVPe01205,DRAVPe01205.cif,Linear,Free,Free,,L,Not found,"The peptide was able to inhibit the entry of HSV-1 into the host cell, probably by blocking heparan sulfate(HS) at the cell surface.",2138.72,C96H184N32O22,CDEFGHILMNPQRSTVWY,K,11.0,11,0,11,0,10,-118.57,-4295,1.3 hour,3 min,2 min,47.62,0,0.0,15498607,Antiviral Res. 2004 Nov;64(2):119-26.,"Jenssen H, Andersen JH, Mantzilas D, Gutteberg TJ. ","A wide range of medium-sized, highly cationic, alpha-helical peptides show antiviral activity against herpes simplex virus.",10.1016/j.antiviral.2004.08.003,,Anti-HSV
DRAVPe01206,KAAKKAAKAAKKAAKWAKKAA,21,RJ3,Synthetic construct,No entry found,,HSV,Herpesviridae,"Plaque reduction assay,ELISA",[Ref.15498607]herpes simplex virus 1(HSV-1):inhibition of HSV-1 infection in MRC-5 cells(IC50=117.0 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.15498607]human fibroblasts(MRC-5 cells):CC50>467 μM.,DRAVPe01206,DRAVPe01206.cif,Linear,Free,Free,,L,Not found,"The peptide was able to inhibit the entry of HSV-1 into the host cell, probably by blocking heparan sulfate(HS) at the cell surface.",2139.66,C98H175N31O22,CDEFGHILMNPQRSTVY,A,10.9,9,0,9,0,12,-77.14,-2771,1.3 hour,3 min,2 min,52.38,5500,275.0,15498607,Antiviral Res. 2004 Nov;64(2):119-26.,"Jenssen H, Andersen JH, Mantzilas D, Gutteberg TJ. ","A wide range of medium-sized, highly cationic, alpha-helical peptides show antiviral activity against herpes simplex virus.",10.1016/j.antiviral.2004.08.003,,Anti-HSV
DRAVPe01207,AKKAAKKAKKAAKKAKKAAKK,21,RJ5,Synthetic construct,No entry found,,HSV,Herpesviridae,"Plaque reduction assay,ELISA",[Ref.15498607]herpes simplex virus 1(HSV-1):inhibition of HSV-1 infection in MRC-5 cells(IC50=41.0 μM);##herpes simplex virus 2(HSV-2):inhibition of HSV-2 infection in MRC-5 cells(IC50=14.3 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.15498607]human fibroblasts(MRC-5 cells):CC50>468 μM.,DRAVPe01207,DRAVPe01207.cif,Linear,Free,Free,,L,Not found,"The peptide was able to inhibit the entry of HSV-1 into the host cell, probably by blocking heparan sulfate(HS) at the cell surface.",2195.81,C99H191N33O22,CDEFGHILMNPQRSTVWY,K,11.04,12,0,12,0,9,-145.71,-5031,4.4 hour,>20 hour,>10 hour,42.86,0,0.0,15498607,Antiviral Res. 2004 Nov;64(2):119-26.,"Jenssen H, Andersen JH, Mantzilas D, Gutteberg TJ. ","A wide range of medium-sized, highly cationic, alpha-helical peptides show antiviral activity against herpes simplex virus.",10.1016/j.antiviral.2004.08.003,,Anti-HSV
DRAVPe01208,AKKAAKKAKKAAKKAKKWAKK,21,RJ6,Synthetic construct,No entry found,,HSV,Herpesviridae,"Plaque reduction assay,ELISA",[Ref.15498607]herpes simplex virus 1(HSV-1):inhibition of HSV-1 infection in MRC-5 cells(IC50=47.3 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.15498607]human fibroblasts(MRC-5 cells):CC50>433 μM.,DRAVPe01208,DRAVPe01208.cif,Linear,Free,Free,,L,Not found,"The peptide was able to inhibit the entry of HSV-1 into the host cell, probably by blocking heparan sulfate(HS) at the cell surface.",2310.95,C107H196N34O22,CDEFGHILMNPQRSTVY,K,11.04,12,0,12,0,9,-158.57,-4979,4.4 hour,>20 hour,>10 hour,38.1,5500,275.0,15498607,Antiviral Res. 2004 Nov;64(2):119-26.,"Jenssen H, Andersen JH, Mantzilas D, Gutteberg TJ. ","A wide range of medium-sized, highly cationic, alpha-helical peptides show antiviral activity against herpes simplex virus.",10.1016/j.antiviral.2004.08.003,,Anti-HSV
DRAVPe01209,AKKAWKKAKKAAKKAKKWAKK,21,RJ7,Synthetic construct,No entry found,,HSV,Herpesviridae,"Plaque reduction assay,ELISA",[Ref.15498607]herpes simplex virus 1(HSV-1):inhibition of HSV-1 infection in MRC-5 cells(IC50=40.8 μM);##herpes simplex virus 2(HSV-2):inhibition of HSV-2 infection in MRC-5 cells(IC50=44.9 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.15498607]human fibroblasts(MRC-5 cells):CC50>412 μM.,DRAVPe01209,DRAVPe01209.cif,Linear,Free,Free,,L,Not found,"The peptide was able to inhibit the entry of HSV-1 into the host cell, probably by blocking heparan sulfate(HS) at the cell surface.",2426.08,C115H201N35O22,CDEFGHILMNPQRSTVY,K,11.04,12,0,12,0,9,-171.43,-4927,4.4 hour,>20 hour,>10 hour,33.33,11000,550.0,15498607,Antiviral Res. 2004 Nov;64(2):119-26.,"Jenssen H, Andersen JH, Mantzilas D, Gutteberg TJ. ","A wide range of medium-sized, highly cationic, alpha-helical peptides show antiviral activity against herpes simplex virus.",10.1016/j.antiviral.2004.08.003,,Anti-HSV
DRAVPe01210,ARRAWRRARRAARRARRAARR,21,RJ8,Synthetic construct,No entry found,,HSV,Herpesviridae,"Plaque reduction assay,ELISA",[Ref.15498607]herpes simplex virus 1(HSV-1):inhibition of HSV-1 infection in MRC-5 cells(IC50=18.2 μM);##herpes simplex virus 2(HSV-2):inhibition of HSV-2 infection in MRC-5 cells(IC50=22.2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.15498607]human fibroblasts(MRC-5 cells):CC50>395 μM.,DRAVPe01210,DRAVPe01210.cif,Linear,Free,Free,,L,Not found,"The peptide was able to inhibit the entry of HSV-1 into the host cell, probably by blocking heparan sulfate(HS) at the cell surface.",2647.11,C107H196N58O22,CDEFGHIKLMNPQSTVY,R,13.04,12,0,12,0,9,-192.86,-16223,4.4 hour,>20 hour,>10 hour,38.1,5500,275.0,15498607,Antiviral Res. 2004 Nov;64(2):119-26.,"Jenssen H, Andersen JH, Mantzilas D, Gutteberg TJ. ","A wide range of medium-sized, highly cationic, alpha-helical peptides show antiviral activity against herpes simplex virus.",10.1016/j.antiviral.2004.08.003,,Anti-HSV
DRAVPe01211,ARRAKRRARRAARRARRKARR,21,RJ9,Synthetic construct,No entry found,,HSV,Herpesviridae,"Plaque reduction assay,ELISA",[Ref.15498607]herpes simplex virus 1(HSV-1):inhibition of HSV-1 infection in MRC-5 cells(IC50=13.0 μM);##herpes simplex virus 2(HSV-2):inhibition of HSV-2 infection in MRC-5 cells(IC50=46.0 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.15498607]human fibroblasts(MRC-5 cells):CC50>433 μM.,DRAVPe01211,DRAVPe01211.cif,Linear,Free,Free,,L,Not found,"The peptide was able to inhibit the entry of HSV-1 into the host cell, probably by blocking heparan sulfate(HS) at the cell surface.",2646.17,C105H205N59O22,CDEFGHILMNPQSTVWY,R,13.04,14,0,14,0,7,-234.29,-17747,4.4 hour,>20 hour,>10 hour,33.33,0,0.0,15498607,Antiviral Res. 2004 Nov;64(2):119-26.,"Jenssen H, Andersen JH, Mantzilas D, Gutteberg TJ. ","A wide range of medium-sized, highly cationic, alpha-helical peptides show antiviral activity against herpes simplex virus.",10.1016/j.antiviral.2004.08.003,,Anti-HSV
DRAVPe01212,ARRAKRRARRAKRRARRKKRR,21,RJ10,Synthetic construct,No entry found,,HSV,Herpesviridae,"Plaque reduction assay,ELISA",[Ref.15498607]herpes simplex virus 1(HSV-1):inhibition of HSV-1 infection in MRC-5 cells(IC50=24.6 μM);##herpes simplex virus 2(HSV-2):inhibition of HSV-2 infection in MRC-5 cells(IC50=54.7 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.15498607]human fibroblasts(MRC-5 cells):CC50>422 μM.,DRAVPe01212,DRAVPe01212.cif,Linear,Free,Free,,L,Not found,"The peptide was able to inhibit the entry of HSV-1 into the host cell, probably by blocking heparan sulfate(HS) at the cell surface.",2760.36,C111H219N61O22,CDEFGHILMNPQSTVWY,R,13.04,16,0,16,0,5,-288.57,-19219,4.4 hour,>20 hour,>10 hour,23.81,0,0.0,15498607,Antiviral Res. 2004 Nov;64(2):119-26.,"Jenssen H, Andersen JH, Mantzilas D, Gutteberg TJ. ","A wide range of medium-sized, highly cationic, alpha-helical peptides show antiviral activity against herpes simplex virus.",10.1016/j.antiviral.2004.08.003,,Anti-HSV
DRAVPe01213,QLQKWEDWVRWIGNIPQYLKG,21,Peptide 59(FIV ectodomain 767-786),Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus),P16090,,FIV,Retroviridae,enzyme-linked immunosorbent assay(ELISA),[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50=0.03 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50=0.01 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12610147]No detectable cytotoxicity on MBM cell viability and proliferation.,DRAVPe01213,DRAVPe01213.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2658.06,C126H185N33O31,ACFHMST,QW,8.5,3,2,1,4,8,-90.0,-3236,0.8 hour,10 min,>10 hour,88.1,17990,899.5,12610147,J Virol. 2003 Mar;77(6):3724-33.,"Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M.",Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein.,10.1128/jvi.77.6.3724-3733.2003,,Anti-FIV
DRAVPe01214,QKWEDWVRWIGN,12,C12a(FIV ectodomain 768-779),Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus),P16090,,FIV,Retroviridae,enzyme-linked immunosorbent assay(ELISA),[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50=0.25 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50=0.18 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01214,DRAVPe01214.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1616.8,C76H105N21O19,ACFHLMPSTY,W,6.07,2,2,0,2,5,-140.0,-3129,0.8 hour,10 min,>10 hour,56.67,16500,1500.0,12610147,J Virol. 2003 Mar;77(6):3724-33.,"Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M.",Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein.,10.1128/jvi.77.6.3724-3733.2003,,Anti-FIV
DRAVPe01215,WEDWVRWIGNIP,12,C12b(FIV ectodomain 770-781),Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus),P16090,,FIV,Retroviridae,enzyme-linked immunosorbent assay(ELISA),[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50=0.04 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50=0.09 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01215,DRAVPe01215.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1570.77,C76H103N19O18,ACFHKLMQSTY,W,4.37,1,2,-1,2,6,-54.17,-1528,2.8 hour,3 min,2 min,89.17,16500,1500.0,12610147,J Virol. 2003 Mar;77(6):3724-33.,"Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M.",Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein.,10.1128/jvi.77.6.3724-3733.2003,,Anti-FIV
DRAVPe01216,QLQKWEDWVRWI,12,C12c(FIV ectodomain 766-777),Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus),P16090,,FIV,Retroviridae,enzyme-linked immunosorbent assay(ELISA),[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50=0.03 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50=0.04 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01216,DRAVPe01216.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1686.93,C81H115N21O19,ACFGHMNPSTY,W,6.07,2,2,0,0,6,-105.0,-2621,0.8 hour,10 min,>10 hour,89.17,16500,1500.0,12610147,J Virol. 2003 Mar;77(6):3724-33.,"Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M.",Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein.,10.1128/jvi.77.6.3724-3733.2003,,Anti-FIV
DRAVPe01217,WEDWVRWI,8,C8(FIV ectodomain 770-777),Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus),P16090,,FIV,Retroviridae,enzyme-linked immunosorbent assay(ELISA),[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50=0.07 ± 0.02 µg/ml);##FIV-GL8(Feline immunodeficiency virus GL8):inhibition of virus replication in MBM cells(IC50=0.46 ± 0.20 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50=0.05 ± 0.01 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12610147]No detectable cytotoxicity on MBM cell viability and proliferation.,DRAVPe01217,DRAVPe01217.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1189.34,C59H76N14O13,ACFGHKLMNPQSTY,W,4.37,1,2,-1,0,5,-68.75,-1450,2.8 hour,3 min,2 min,85.0,16500,2357.14,12610147,J Virol. 2003 Mar;77(6):3724-33.,"Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M.",Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein.,10.1128/jvi.77.6.3724-3733.2003,,Anti-FIV
DRAVPe01218,DWVRWI,6,C6a(FIV ectodomain 772-777),Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus),P16090,,FIV,Retroviridae,enzyme-linked immunosorbent assay(ELISA),[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50=0.15 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50=0.07 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01218,DRAVPe01218.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,874.01,C43H59N11O9,ACEFGHKLMNPQSTY,W,5.84,1,1,0,0,4,-18.33,-1002,1.1 hour,3 min,>10 hour,113.33,11000,2200.0,12610147,J Virol. 2003 Mar;77(6):3724-33.,"Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M.",Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein.,10.1128/jvi.77.6.3724-3733.2003,,Anti-FIV
DRAVPe01219,WEDWVR,6,C6b(FIV ectodomain 770-775),Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus),P16090,,FIV,Retroviridae,enzyme-linked immunosorbent assay(ELISA),[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50>50 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50>50 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01219,DRAVPe01219.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,889.97,C42H55N11O11,ACFGHIKLMNPQSTY,W,4.37,1,2,-1,0,3,-151.67,-2175,2.8 hour,3 min,2 min,48.33,11000,2200.0,12610147,J Virol. 2003 Mar;77(6):3724-33.,"Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M.",Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein.,10.1128/jvi.77.6.3724-3733.2003,,Anti-FIV
DRAVPe01220,WVRWI,5,C5(FIV ectodomain 773-777),Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus),P16090,,FIV,Retroviridae,enzyme-linked immunosorbent assay(ELISA),[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50=0.20 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50=0.11 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01220,DRAVPe01220.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,758.92,C39H54N10O6,ACDEFGHKLMNPQSTY,W,9.75,1,0,1,0,4,48.0,-130,2.8 hour,3 min,2 min,136.0,11000,2750.0,12610147,J Virol. 2003 Mar;77(6):3724-33.,"Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M.",Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein.,10.1128/jvi.77.6.3724-3733.2003,,Anti-FIV
DRAVPe01221,WVRW,4,C4a(FIV ectodomain 773-776),Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus),P16090,,FIV,Retroviridae,enzyme-linked immunosorbent assay(ELISA),[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50=36 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50=24 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01221,DRAVPe01221.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,645.76,C33H43N9O5,ACDEFGHIKLMNPQSTY,W,9.75,1,0,1,0,3,-52.5,-622,2.8 hour,3 min,2 min,72.5,11000,3666.67,12610147,J Virol. 2003 Mar;77(6):3724-33.,"Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M.",Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein.,10.1128/jvi.77.6.3724-3733.2003,,Anti-FIV
DRAVPe01222,VRWI,4,C4b(FIV ectodomain 774-777),Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus),P16090,,FIV,Retroviridae,enzyme-linked immunosorbent assay(ELISA),[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50=7.80 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50=4.06 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01222,DRAVPe01222.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,572.71,C28H44N8O5,ACDEFGHKLMNPQSTY,IRVW,9.72,1,0,1,0,3,82.5,-363,100 hour,>20 hour,>10 hour,170.0,5500,1833.33,12610147,J Virol. 2003 Mar;77(6):3724-33.,"Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M.",Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein.,10.1128/jvi.77.6.3724-3733.2003,,Anti-FIV
DRAVPe01223,AEDWVRWI,8,C8W->A770,Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus),P16090,,FIV,Retroviridae,enzyme-linked immunosorbent assay(ELISA),[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50=4.30 ± 0.70 µg/ml);##FIV-GL8(Feline immunodeficiency virus GL8):inhibition of virus replication in MBM cells(IC50>50 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50=2.10± 0.10 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12610147]No detectable cytotoxicity on MBM cell viability and proliferation.,DRAVPe01223,DRAVPe01223.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1074.2,C51H71N13O13,CFGHKLMNPQSTY,W,4.37,1,2,-1,0,5,-35.0,-1502,4.4 hour,>20 hour,>10 hour,97.5,11000,1571.43,12610147,J Virol. 2003 Mar;77(6):3724-33.,"Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M.",Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein.,10.1128/jvi.77.6.3724-3733.2003,,Anti-FIV
DRAVPe01224,WADWVRWI,8,C8E->A771,Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus),P16090,,FIV,Retroviridae,enzyme-linked immunosorbent assay(ELISA),[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50=0.16 ± 0.03 µg/ml);##FIV-GL8(Feline immunodeficiency virus GL8):inhibition of virus replication in MBM cells(IC50=0.22 ± 0.05 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50=0.12 ± 0.01 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12610148]No detectable cytotoxicity on MBM cell viability and proliferation.,DRAVPe01224,DRAVPe01224.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1131.3,C57H74N14O11,CEFGHKLMNPQSTY,W,5.84,1,1,0,0,6,-2.5,-588,2.8 hour,3 min,2 min,97.5,16500,2357.14,12610147,J Virol. 2003 Mar;77(6):3724-33.,"Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M.",Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein.,10.1128/jvi.77.6.3724-3733.2003,,Anti-FIV
DRAVPe01225,WEAWVRWI,8,C8D->A772,Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus),P16090,,FIV,Retroviridae,enzyme-linked immunosorbent assay(ELISA),[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50=0.10± 0.02 µg/ml);##FIV-GL8(Feline immunodeficiency virus GL8):inhibition of virus replication in MBM cells(IC50=0.40 ± 0.22 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50=0.03 ± 0.06 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12610149]No detectable cytotoxicity on MBM cell viability and proliferation.,DRAVPe01225,DRAVPe01225.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1145.33,C58H76N14O11,CDFGHKLMNPQSTY,W,6.0,1,1,0,0,6,-2.5,-397,2.8 hour,3 min,2 min,97.5,16500,2357.14,12610147,J Virol. 2003 Mar;77(6):3724-33.,"Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M.",Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein.,10.1128/jvi.77.6.3724-3733.2003,,Anti-FIV
DRAVPe01226,WEDAVRWI,8,C8W->A773,Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus),P16090,,FIV,Retroviridae,enzyme-linked immunosorbent assay(ELISA),[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50>50 µg/ml);##FIV-GL8(Feline immunodeficiency virus GL8):inhibition of virus replication in MBM cells(IC50>50 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50>50 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12610150]No detectable cytotoxicity on MBM cell viability and proliferation.,DRAVPe01226,DRAVPe01226.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1074.2,C51H71N13O13,CFGHKLMNPQSTY,W,4.37,1,2,-1,0,5,-35.0,-1502,2.8 hour,3 min,2 min,97.5,11000,1571.43,12610147,J Virol. 2003 Mar;77(6):3724-33.,"Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M.",Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein.,10.1128/jvi.77.6.3724-3733.2003,,Anti-FIV
DRAVPe01227,WEDWARWI,8,C8V->A774,Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus),P16090,,FIV,Retroviridae,enzyme-linked immunosorbent assay(ELISA),[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50=0.07 ± 0.03 µg/ml);##FIV-GL8(Feline immunodeficiency virus GL8):inhibition of virus replication in MBM cells(IC50=0.54 ± 0.02 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50=0.15 ± 0.12 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12610151]No detectable cytotoxicity on MBM cell viability and proliferation.,DRAVPe01227,DRAVPe01227.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1161.28,C57H72N14O13,CFGHKLMNPQSTVY,W,4.37,1,2,-1,0,5,-98.75,-1673,2.8 hour,3 min,2 min,61.25,16500,2357.14,12610147,J Virol. 2003 Mar;77(6):3724-33.,"Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M.",Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein.,10.1128/jvi.77.6.3724-3733.2003,,Anti-FIV
DRAVPe01228,WEDWVAWI,8,C8G->A775,Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus),P16090,,FIV,Retroviridae,enzyme-linked immunosorbent assay(ELISA),[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50=0.09 ± 0.03 µg/ml);##FIV-GL8(Feline immunodeficiency virus GL8):inhibition of virus replication in MBM cells(IC50=0.38 ± 0.04 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50=0.25 ± 0.06 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12610152]No detectable cytotoxicity on MBM cell viability and proliferation.,DRAVPe01228,DRAVPe01228.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1104.23,C56H69N11O13,CFGHKLMNPQRSTY,W,3.67,0,2,-2,0,6,10.0,223,2.8 hour,3 min,2 min,97.5,16500,2357.14,12610147,J Virol. 2003 Mar;77(6):3724-33.,"Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M.",Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein.,10.1128/jvi.77.6.3724-3733.2003,,Anti-FIV
DRAVPe01229,WEDWVRAI,8,C8W->A776,Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus),P16090,,FIV,Retroviridae,enzyme-linked immunosorbent assay(ELISA),[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50>50 µg/ml);##FIV-GL8(Feline immunodeficiency virus GL8):inhibition of virus replication in MBM cells(IC50>50);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50>50 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12610153]No detectable cytotoxicity on MBM cell viability and proliferation.,DRAVPe01229,DRAVPe01229.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1074.2,C51H71N13O13,CFGHKLMNPQSTY,W,4.37,1,2,-1,0,5,-35.0,-1502,2.8 hour,3 min,2 min,97.5,11000,1571.43,12610147,J Virol. 2003 Mar;77(6):3724-33.,"Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M.",Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein.,10.1128/jvi.77.6.3724-3733.2003,,Anti-FIV
DRAVPe01230,WEDWVRWA,8,C8I->A777,Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus),P16090,,FIV,Retroviridae,enzyme-linked immunosorbent assay(ELISA),[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50=0.15 ± 0.01 µg/ml);##FIV-GL8(Feline immunodeficiency virus GL8):inhibition of virus replication in MBM cells(IC50=0.64± 0.08 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50=0.13 ± 0.04 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12610154]No detectable cytotoxicity on MBM cell viability and proliferation.,DRAVPe01230,DRAVPe01230.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1147.26,C56H70N14O13,CFGHIKLMNPQSTY,W,4.37,1,2,-1,0,5,-102.5,-1761,2.8 hour,3 min,2 min,48.75,16500,2357.14,12610147,J Virol. 2003 Mar;77(6):3724-33.,"Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M.",Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein.,10.1128/jvi.77.6.3724-3733.2003,,Anti-FIV
DRAVPe01231,TDVILMCFSIDSPDSLENI,19,77-95(wild type),Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=7.6 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01231,DRAVPe01231.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2112.39,C91H146N20O33S2,AGHKQRWY,DIS,3.37,0,4,-4,6,7,54.21,-1713,7.2 hour,>20 hour,>10 hour,117.89,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01232,CSIELSDIPLSVDFNTMID,19,77-95(scrambled),Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50>50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01232,DRAVPe01232.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2112.39,C91H146N20O33S2,AGHKQRWY,DIS,3.37,0,4,-4,6,7,54.21,-1713,1.2 hour,>20 hour,>10 hour,117.89,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01233,ADVILMCFSIDSPDSLENI,19,77-95[77A],Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=2.56 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01233,DRAVPe01233.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2082.37,C90H144N20O32S2,GHKQRTWY,DIS,3.37,0,4,-4,5,8,67.37,-1275,4.4 hour,>20 hour,>10 hour,123.16,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01234,TAVILMCFSIDSPDSLENI,19,77-95[78A],Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=1.37 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01234,DRAVPe01234.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2068.38,C90H146N20O31S2,GHKQRWY,IS,3.49,0,3,-3,6,8,82.11,-660,7.2 hour,>20 hour,>10 hour,123.16,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01235,TDAILMCFSIDSPDSLENI,19,77-95[79A],Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=6.60 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01235,DRAVPe01235.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2084.34,C89H142N20O33S2,GHKQRVWY,DIS,3.37,0,4,-4,6,7,41.58,-1936,7.2 hour,>20 hour,>10 hour,107.89,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01236,TDVALMCFSIDSPDSLENI,19,77-95[80A],Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=11.6 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01236,DRAVPe01236.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2070.31,C88H140N20O33S2,GHKQRWY,DS,3.37,0,4,-4,6,7,40.0,-2024,7.2 hour,>20 hour,>10 hour,102.63,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01237,TDVIAMCFSIDSPDSLENI,19,77-95[81A],Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=5.42 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01237,DRAVPe01237.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2070.31,C88H140N20O33S2,GHKQRWY,DIS,3.37,0,4,-4,6,7,43.68,-2024,7.2 hour,>20 hour,>10 hour,102.63,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01238,TDVILACFSIDSPDSLENI,19,77-95[82A],Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=1.43 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01238,DRAVPe01238.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2052.28,C89H142N20O33S,GHKMQRWY,DIS,3.37,0,4,-4,6,8,53.68,-1767,7.2 hour,>20 hour,>10 hour,123.16,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01239,TDVILMAFSIDSPDSLENI,19,77-95[83A],Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50>50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01239,DRAVPe01239.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2080.33,C91H146N20O33S,CGHKQRWY,DIS,3.37,0,4,-4,5,8,50.53,-1660,7.2 hour,>20 hour,>10 hour,123.16,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01240,TDVILMCASIDSPDSLENI,19,77-95[84A],Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=6.29 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01240,DRAVPe01240.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2036.3,C85H142N20O33S2,FGHKQRWY,DIS,3.37,0,4,-4,6,7,48.95,-1830,7.2 hour,>20 hour,>10 hour,123.16,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01241,TDVILMCFAIDSPDSLENI,19,77-95[85A],Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=6.82 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01241,DRAVPe01241.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2096.39,C91H146N20O32S2,GHKQRWY,DI,3.37,0,4,-4,5,8,67.89,-1192,7.2 hour,>20 hour,>10 hour,123.16,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01242,TDVILMCFSADSPDSLENI,19,77-95[86A],Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=3.52 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01242,DRAVPe01242.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2070.31,C88H140N20O33S2,GHKQRWY,DS,3.37,0,4,-4,6,7,40.0,-2024,7.2 hour,>20 hour,>10 hour,102.63,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01243,TDVILMCFSIASPDSLENI,19,77-95[87A],Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=4.36 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01243,DRAVPe01243.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2068.38,C90H146N20O31S2,GHKQRWY,IS,3.49,0,3,-3,6,8,82.11,-660,7.2 hour,>20 hour,>10 hour,123.16,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01244,TDVILMCFSIDAPDSLENI,19,77-95[88A],Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=2.26 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01244,DRAVPe01244.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2096.39,C91H146N20O32S2,GHKQRWY,DI,3.37,0,4,-4,5,8,67.89,-1192,7.2 hour,>20 hour,>10 hour,123.16,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01245,TDVILMCFSIDSADSLENI,19,77-95[89A],Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=15.32 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01245,DRAVPe01245.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2086.36,C89H144N20O33S2,GHKPQRWY,DIS,3.37,0,4,-4,6,8,72.11,-1532,7.2 hour,>20 hour,>10 hour,123.16,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01246,TDVILMCFSIDSPASLENI,19,77-95[90A],Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=2.61 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01246,DRAVPe01246.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2068.38,C90H146N20O31S2,GHKQRWY,IS,3.49,0,3,-3,6,8,82.11,-660,7.2 hour,>20 hour,>10 hour,123.16,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01247,TDVILMCFSIDSPDALENI,19,77-95[91A],Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=1.19 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01247,DRAVPe01247.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2096.39,C91H146N20O32S2,GHKQRWY,DI,3.37,0,4,-4,5,8,67.89,-1192,7.2 hour,>20 hour,>10 hour,123.16,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01248,TDVILMCFSIDSPDSAENI,19,77-95[92A],Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=2.27 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01248,DRAVPe01248.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2070.31,C88H140N20O33S2,GHKQRWY,DIS,3.37,0,4,-4,6,7,43.68,-2024,7.2 hour,>20 hour,>10 hour,102.63,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01249,TDVILMCFSIDSPDSLANI,19,77-95[93A],Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=9.83 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01249,DRAVPe01249.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2054.36,C89H144N20O31S2,EGHKQRWY,DIS,3.42,0,3,-3,6,8,82.11,-851,7.2 hour,>20 hour,>10 hour,123.16,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01250,TDVILMCFSIDSPDSLEAI,19,77-95[94A],Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=18.47 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01250,DRAVPe01250.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2069.37,C90H145N19O32S2,GHKNQRWY,DIS,3.37,0,4,-4,5,8,82.11,-868,7.2 hour,>20 hour,>10 hour,123.16,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01251,TDVILMCFSIDSPDSLENA,19,77-95[95A],Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=4.89 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01251,DRAVPe01251.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2070.31,C88H140N20O33S2,GHKQRWY,DS,3.37,0,4,-4,6,7,40.0,-2024,7.2 hour,>20 hour,>10 hour,102.63,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01252,TDVILMCFSI,10,77-86,Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50>50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01252,DRAVPe01252.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1141.41,C51H84N10O15S2,AEGHKNPQRWY,I,3.8,0,1,-1,3,5,192.0,1072,7.2 hour,>20 hour,>10 hour,146.0,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01253,TDVILMCFSIDSP,13,77–89,Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50>50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01253,DRAVPe01253.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1440.69,C63H101N13O21S2,AEGHKNQRWY,DIS,3.56,0,2,-2,4,5,102.31,-140,7.2 hour,>20 hour,>10 hour,112.31,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01254,TDVILMCFSIDSPDSL,16,77-92,Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=10.86 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01254,DRAVPe01254.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1756.02,C76H122N16O27S2,AEGHKNQRWY,DS,3.42,0,3,-3,5,6,80.0,-860,7.2 hour,>20 hour,>10 hour,115.63,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01255,DVILMCFSIDSPDSLENI,18,78-95,Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=1.23 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01255,DRAVPe01255.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2011.29,C87H139N19O31S2,AGHKQRTWY,DIS,3.37,0,4,-4,5,7,61.11,-1456,1.1 hour,3 min,>10 hour,124.44,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01256,VILMCFSIDSPDSLENI,17,79-95,Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=16.95 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01256,DRAVPe01256.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1896.2,C83H134N18O28S2,AGHKQRTWY,IS,3.49,0,3,-3,5,7,85.29,-584,100 hour,>20 hour,>10 hour,131.76,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01257,ILMCFSIDSPDSLENI,16,80-95,Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=7.17 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01257,DRAVPe01257.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1797.07,C78H125N17O27S2,AGHKQRTVWY,IS,3.49,0,3,-3,5,6,64.38,-988,20 hour,30 min,>10 hour,121.88,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01258,CFSIDSPDSLENI,13,83-95,Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50>50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01258,DRAVPe01258.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1439.56,C61H94N14O24S,AGHKMQRTVWY,S,3.49,0,3,-3,5,4,0.77,-2207,1.2 hour,>20 hour,>10 hour,90.0,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01259,ILMCFSIDSPDSLEN,15,80-94,Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=1.75 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01259,DRAVPe01259.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1683.91,C72H114N16O26S2,AGHKQRTVWY,S,3.49,0,3,-3,5,5,38.67,-1480,20 hour,30 min,>10 hour,104.0,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01260,ILMCFSIDSPDSLE,14,80-93,Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=3.50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01260,DRAVPe01260.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1569.8,C68H108N14O24S2,AGHKNQRTVWY,S,3.49,0,3,-3,4,5,66.43,-816,20 hour,30 min,>10 hour,111.43,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01261,ILMCFSIDSPDSL,13,80-92,Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=12.40 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01261,DRAVPe01261.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1440.69,C63H101N13O21S2,AEGHKNQRTVWY,S,3.56,0,2,-2,4,5,98.46,-135,20 hour,30 min,>10 hour,120.0,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01262,ILMCFSIDSPDS,12,80-91,Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=6.36 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01262,DRAVPe01262.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1327.53,C57H90N12O20S2,AEGHKNQRTVWY,S,3.56,0,2,-2,4,4,75.0,-627,20 hour,30 min,>10 hour,97.5,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01263,ILMCFSIDSPD,11,80-90,Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=4.61 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01263,DRAVPe01263.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1240.45,C54H85N11O18S2,AEGHKNQRTVWY,DIS,3.56,0,2,-2,3,4,89.09,-287,20 hour,30 min,>10 hour,106.36,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01264,ILMCFSIDSP,10,80-89,Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=35.77 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01264,DRAVPe01264.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1125.36,C50H80N10O15S2,AEGHKNQRTVWY,IS,3.8,0,1,-1,3,4,133.0,585,20 hour,30 min,>10 hour,117.0,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01265,ILMCFSIDS,9,80-88,Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50>50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01265,DRAVPe01265.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1028.25,C45H73N9O14S2,AEGHKNPQRTVWY,IS,3.8,0,1,-1,3,4,165.56,585,20 hour,30 min,>10 hour,130.0,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01266,ILMCFSID,8,80-87,Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50>50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01266,DRAVPe01266.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,941.17,C42H68N8O12S2,AEGHKNPQRTVWY,I,3.8,0,1,-1,2,4,196.25,925,20 hour,30 min,>10 hour,146.25,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01267,ILMCFSI,7,80-86,Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50>50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01267,DRAVPe01267.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,826.08,C38H63N7O9S2,ADEGHKNPQRTVWY,I,5.52,0,0,0,2,4,274.29,1797,20 hour,30 min,>10 hour,167.14,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01268,ILMCFS,6,80-85,Synthetic construct(derived from RhoA protein),P08134,,RSV,Paramyxoviridae,viral antigen reduction assay,[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50>50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01268,DRAVPe01268.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,712.92,C32H52N6O8S2,ADEGHKNPQRTVWY,CFILMS,5.52,0,0,0,2,3,245.0,1305,20 hour,30 min,>10 hour,130.0,0,0.0,14576104,Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7.,"Budge PJ, Lebowitz J, Graham BS. ",Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.,10.1128/AAC.47.11.3470-3477.2003,,Anti-RSV
DRAVPe01269,NGIGVTQNVLYENQKQIANQFNKAISQIQESLTTTSTA,38,HR1-1(HR1 region 889–926),Synthetic construct(derived from SARS-CoV spike protein),P59594,,SARS-CoV,Coronaviridae,luciferase assay,[Ref.15184046]HIV-luc/SARS pseudotyped virus:inhibition of virus infection in  293T cells(EC50=0.14 μM);##SARS-CoV(wild-type):inhibition of virus infection in 293T cells(EC50=3.68 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01269,DRAVPe01269.cif,Linear,Free,Free,,L,membrane,"soluble synthesized HR1, HR2 or homologues can bind the exposed HR1 or HR2 region and block the formation of the six-helix bundle, thus inhibiting virus fusion with the target cell.",4153.57,C178H291N51O63,CDHMPRW,Q,6.14,2,2,0,16,12,-50.26,-6646,1.4 hour,3 min,>10 hour,84.74,1490,40.27,15184046,Biochem Biophys Res Commun. 2004 Jul 2;319(3):746-52.,"Yuan K, Yi L, Chen J, Qu X, Qing T, Rao X, Jiang P, Hu J, Xiong Z, Nie Y, Shi X, Wang W, Ling C, Yin X, Fan K, Lai L, Ding M, Deng H.",Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein.,10.1016/j.bbrc.2004.05.046,,Anti-SARS-CoV
DRAVPe01270,IQKEIDRLNEVAKNLNESLIDLQELGK,27,HR2-18(HR2 region 1161–1187),Synthetic construct(derived from SARS-CoV spike protein),P59594,,SARS-CoV,Coronaviridae,luciferase assay,[Ref.15184046]HIV-luc/SARS pseudotyped virus:inhibition of virus infection in  293T cells(EC50=1.19 μM);##SARS-CoV(wild-type):inhibition of virus infection in 293T cells(EC50=5.22 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01270,DRAVPe01270.cif,Linear,Free,Free,,L,membrane,"soluble synthesized HR1, HR2 or homologues can bind the exposed HR1 or HR2 region and block the formation of the six-helix bundle, thus inhibiting virus fusion with the target cell.",3123.55,C135H232N38O46,CFHMPTWY,L,4.66,4,6,-2,5,10,-64.44,-6450,20 hour,30 min,>10 hour,130.0,0,0.0,15184046,Biochem Biophys Res Commun. 2004 Jul 2;319(3):746-52.,"Yuan K, Yi L, Chen J, Qu X, Qing T, Rao X, Jiang P, Hu J, Xiong Z, Nie Y, Shi X, Wang W, Ling C, Yin X, Fan K, Lai L, Ding M, Deng H.",Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein.,10.1016/j.bbrc.2004.05.046,,Anti-SARS-CoV
DRAVPe01271,HRILMRIRQMMT,12,p9,Synthetic construct,No entry found,,PRRSV,Arteriviridae,MTT assay,[Ref.22743126]Porcine reproductive and respiratory syndrome virus(PRRSV):inhibition of PRRSV replication in MARC-145 cells(IC50=56.47 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22743126]MARC-145 cells:CC50=473.00 μM.,DRAVPe01271,DRAVPe01271.cif,Linear,Free,Free,,L,PRRSV polymerase,"PRRSV polymerase is an RNA-dependent RNA polymerase and is an enzyme specific to viruses, RNA-dependent RNA polymerase is one of the most important proteins for intracellular replication of viruses.The peptide could exert antiviral activity by inhibiting polymerase.",1586.01,C66H120N24O15S3,ACDEFGKNPSVWY,MR,12.3,4,0,4,1,3,-20.0,-3572,3.5 hour,10 min,>10 hour,97.5,0,0.0,22743126,Virology. 2012 Oct 10;432(1):73-80.,"Liu K, Feng X, Ma Z, Luo C, Zhou B, Cao R, Huang L, Miao D, Pang R, He D, Lian X, Chen P. ",Antiviral activity of phage display selected peptides against Porcine reproductive and respiratory syndrome virus in vitro.,10.1016/j.virol.2012.05.010,,Anti-PRRSV
DRAVPe01272,ARILMRIRQMMT,12,1-P9,Synthetic construct,No entry found,,PRRSV,Arteriviridae,MTT assay,[Ref.22743126]Porcine reproductive and respiratory syndrome virus(PRRSV):inhibition of PRRSV replication in MARC-145 cells(IC50=56.12263 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22743126]MARC-145 cells:CC50>500 μM.,DRAVPe01272,DRAVPe01272.cif,Linear,Free,Free,,L,PRRSV polymerase,"PRRSV polymerase is an RNA-dependent RNA polymerase and is an enzyme specific to viruses, RNA-dependent RNA polymerase is one of the most important proteins for intracellular replication of viruses.The peptide could exert antiviral activity by inhibiting polymerase.",1519.95,C63H118N22O15S3,CDEFGHKNPSVWY,MR,12.3,3,0,3,1,4,21.67,-2925,4.4 hour,>20 hour,>10 hour,105.83,0,0.0,22743126,Virology. 2012 Oct 10;432(1):73-80.,"Liu K, Feng X, Ma Z, Luo C, Zhou B, Cao R, Huang L, Miao D, Pang R, He D, Lian X, Chen P. ",Antiviral activity of phage display selected peptides against Porcine reproductive and respiratory syndrome virus in vitro.,10.1016/j.virol.2012.05.010,,Anti-PRRSV
DRAVPe01273,HRALMRIRQMMT,12,3-P9,Synthetic construct,No entry found,,PRRSV,Arteriviridae,MTT assay,[Ref.22743126]Porcine reproductive and respiratory syndrome virus(PRRSV):inhibition of PRRSV replication in MARC-145 cells(IC50=34.18095 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22743126]MARC-145 cells:CC50>500 μM.,DRAVPe01273,DRAVPe01273.cif,Linear,Free,Free,,L,PRRSV polymerase,"PRRSV polymerase is an RNA-dependent RNA polymerase and is an enzyme specific to viruses, RNA-dependent RNA polymerase is one of the most important proteins for intracellular replication of viruses.The peptide could exert antiviral activity by inhibiting polymerase.",1543.93,C63H114N24O15S3,CDEFGKNPSVWY,MR,12.3,4,0,4,1,3,-42.5,-3883,3.5 hour,10 min,>10 hour,73.33,0,0.0,22743126,Virology. 2012 Oct 10;432(1):73-80.,"Liu K, Feng X, Ma Z, Luo C, Zhou B, Cao R, Huang L, Miao D, Pang R, He D, Lian X, Chen P. ",Antiviral activity of phage display selected peptides against Porcine reproductive and respiratory syndrome virus in vitro.,10.1016/j.virol.2012.05.010,,Anti-PRRSV
DRAVPe01274,HRIAMRIRQMMT,12,4-P9,Synthetic construct,No entry found,,PRRSV,Arteriviridae,MTT assay,[Ref.22743126]Porcine reproductive and respiratory syndrome virus(PRRSV):inhibition of PRRSV replication in MARC-145 cells(IC50=54.5872 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22743126]MARC-145 cells:CC50>500 μM.,DRAVPe01274,DRAVPe01274.cif,Linear,Free,Free,,L,PRRSV polymerase,"PRRSV polymerase is an RNA-dependent RNA polymerase and is an enzyme specific to viruses, RNA-dependent RNA polymerase is one of the most important proteins for intracellular replication of viruses.The peptide could exert antiviral activity by inhibiting polymerase.",1543.93,C63H114N24O15S3,CDEFGKLNPSVWY,MR,12.3,4,0,4,1,3,-36.67,-3883,3.5 hour,10 min,>10 hour,73.33,0,0.0,22743126,Virology. 2012 Oct 10;432(1):73-80.,"Liu K, Feng X, Ma Z, Luo C, Zhou B, Cao R, Huang L, Miao D, Pang R, He D, Lian X, Chen P. ",Antiviral activity of phage display selected peptides against Porcine reproductive and respiratory syndrome virus in vitro.,10.1016/j.virol.2012.05.010,,Anti-PRRSV
DRAVPe01275,HRILARIRQMMT,12,5-P9,Synthetic construct,No entry found,,PRRSV,Arteriviridae,MTT assay,[Ref.22743126]Porcine reproductive and respiratory syndrome virus(PRRSV):inhibition of PRRSV replication in MARC-145 cells(IC50=435.4996 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22743126]MARC-145 cells:CC50>500 μM.,DRAVPe01275,DRAVPe01275.cif,Linear,Free,Free,,L,PRRSV polymerase,"PRRSV polymerase is an RNA-dependent RNA polymerase and is an enzyme specific to viruses, RNA-dependent RNA polymerase is one of the most important proteins for intracellular replication of viruses.The peptide could exert antiviral activity by inhibiting polymerase.",1525.9,C64H116N24O15S2,CDEFGKNPSVWY,R,12.3,4,0,4,1,4,-20.83,-3626,3.5 hour,10 min,>10 hour,105.83,0,0.0,22743126,Virology. 2012 Oct 10;432(1):73-80.,"Liu K, Feng X, Ma Z, Luo C, Zhou B, Cao R, Huang L, Miao D, Pang R, He D, Lian X, Chen P. ",Antiviral activity of phage display selected peptides against Porcine reproductive and respiratory syndrome virus in vitro.,10.1016/j.virol.2012.05.010,,Anti-PRRSV
DRAVPe01276,HRILMRARQMMT,12,7-P9,Synthetic construct,No entry found,,PRRSV,Arteriviridae,MTT assay,[Ref.22743126]Porcine reproductive and respiratory syndrome virus(PRRSV):inhibition of PRRSV replication in MARC-145 cells(IC50=150.1405 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22743126]MARC-145 cells:CC50>500 μM.,DRAVPe01276,DRAVPe01276.cif,Linear,Free,Free,,L,PRRSV polymerase,"PRRSV polymerase is an RNA-dependent RNA polymerase and is an enzyme specific to viruses, RNA-dependent RNA polymerase is one of the most important proteins for intracellular replication of viruses.The peptide could exert antiviral activity by inhibiting polymerase.",1543.93,C63H114N24O15S3,CDEFGKNPSVWY,MR,12.3,4,0,4,1,3,-42.5,-3883,3.5 hour,10 min,>10 hour,73.33,0,0.0,22743126,Virology. 2012 Oct 10;432(1):73-80.,"Liu K, Feng X, Ma Z, Luo C, Zhou B, Cao R, Huang L, Miao D, Pang R, He D, Lian X, Chen P. ",Antiviral activity of phage display selected peptides against Porcine reproductive and respiratory syndrome virus in vitro.,10.1016/j.virol.2012.05.010,,Anti-PRRSV
DRAVPe01277,HRILMRIAQMMT,12,8-P9,Synthetic construct,No entry found,,PRRSV,Arteriviridae,MTT assay,[Ref.22743126]Porcine reproductive and respiratory syndrome virus(PRRSV):inhibition of PRRSV replication in MARC-145 cells(IC50=60.60846 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01277,DRAVPe01277.cif,Linear,Free,Free,,L,PRRSV polymerase,"PRRSV polymerase is an RNA-dependent RNA polymerase and is an enzyme specific to viruses, RNA-dependent RNA polymerase is one of the most important proteins for intracellular replication of viruses.The peptide could exert antiviral activity by inhibiting polymerase.",1500.9,C63H113N21O15S3,CDEFGKNPSVWY,M,12.0,3,0,3,1,4,32.5,-1899,3.5 hour,10 min,>10 hour,105.83,0,0.0,22743126,Virology. 2012 Oct 10;432(1):73-80.,"Liu K, Feng X, Ma Z, Luo C, Zhou B, Cao R, Huang L, Miao D, Pang R, He D, Lian X, Chen P. ",Antiviral activity of phage display selected peptides against Porcine reproductive and respiratory syndrome virus in vitro.,10.1016/j.virol.2012.05.010,,Anti-PRRSV
DRAVPe01278,HRILMRIRAMMT,12,9-P9,Synthetic construct,No entry found,,PRRSV,Arteriviridae,MTT assay,[Ref.22743126]Porcine reproductive and respiratory syndrome virus(PRRSV):inhibition of PRRSV replication in MARC-145 cells(IC50=34.13563 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22743126]MARC-145 cells:CC50>500 μM.,DRAVPe01278,DRAVPe01278.cif,Linear,Free,Free,,L,PRRSV polymerase,"PRRSV polymerase is an RNA-dependent RNA polymerase and is an enzyme specific to viruses, RNA-dependent RNA polymerase is one of the most important proteins for intracellular replication of viruses.The peptide could exert antiviral activity by inhibiting polymerase.",1528.96,C64H117N23O14S3,CDEFGKNPQSVWY,MR,12.3,4,0,4,1,4,24.17,-2837,3.5 hour,10 min,>10 hour,105.83,0,0.0,22743126,Virology. 2012 Oct 10;432(1):73-80.,"Liu K, Feng X, Ma Z, Luo C, Zhou B, Cao R, Huang L, Miao D, Pang R, He D, Lian X, Chen P. ",Antiviral activity of phage display selected peptides against Porcine reproductive and respiratory syndrome virus in vitro.,10.1016/j.virol.2012.05.010,,Anti-PRRSV
DRAVPe01279,HRILMRIRQAMT,12,10-P9,Synthetic construct,No entry found,,PRRSV,Arteriviridae,MTT assay,[Ref.22743126]Porcine reproductive and respiratory syndrome virus(PRRSV):inhibition of PRRSV replication in MARC-145 cells(IC50=57.98146 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22743126]MARC-145 cells:CC50>500 μM.,DRAVPe01279,DRAVPe01279.cif,Linear,Free,Free,,L,PRRSV polymerase,"PRRSV polymerase is an RNA-dependent RNA polymerase and is an enzyme specific to viruses, RNA-dependent RNA polymerase is one of the most important proteins for intracellular replication of viruses.The peptide could exert antiviral activity by inhibiting polymerase.",1525.9,C64H116N24O15S2,CDEFGKNPSVWY,R,12.3,4,0,4,1,4,-20.83,-3626,3.5 hour,10 min,>10 hour,105.83,0,0.0,22743126,Virology. 2012 Oct 10;432(1):73-80.,"Liu K, Feng X, Ma Z, Luo C, Zhou B, Cao R, Huang L, Miao D, Pang R, He D, Lian X, Chen P. ",Antiviral activity of phage display selected peptides against Porcine reproductive and respiratory syndrome virus in vitro.,10.1016/j.virol.2012.05.010,,Anti-PRRSV
DRAVPe01280,HRILMRIRQMAT,12,11-P9,Synthetic construct,No entry found,,PRRSV,Arteriviridae,MTT assay,[Ref.22743126]Porcine reproductive and respiratory syndrome virus(PRRSV):inhibition of PRRSV replication in MARC-145 cells(IC50=120.5239 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22743126]MARC-145 cells:CC50>500 μM.,DRAVPe01280,DRAVPe01280.cif,Linear,Free,Free,,L,PRRSV polymerase,"PRRSV polymerase is an RNA-dependent RNA polymerase and is an enzyme specific to viruses, RNA-dependent RNA polymerase is one of the most important proteins for intracellular replication of viruses.The peptide could exert antiviral activity by inhibiting polymerase.",1525.9,C64H116N24O15S2,CDEFGKNPSVWY,R,12.3,4,0,4,1,4,-20.83,-3626,3.5 hour,10 min,>10 hour,105.83,0,0.0,22743126,Virology. 2012 Oct 10;432(1):73-80.,"Liu K, Feng X, Ma Z, Luo C, Zhou B, Cao R, Huang L, Miao D, Pang R, He D, Lian X, Chen P. ",Antiviral activity of phage display selected peptides against Porcine reproductive and respiratory syndrome virus in vitro.,10.1016/j.virol.2012.05.010,,Anti-PRRSV
DRAVPe01281,HRILMRIRQMMA,12,12-P9,Synthetic construct,No entry found,,PRRSV,Arteriviridae,MTT assay,[Ref.22743126]Porcine reproductive and respiratory syndrome virus(PRRSV):inhibition of PRRSV replication in MARC-145 cells(IC50=89.41235 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22743126]MARC-145 cells:CC50=186.2536 μM.,DRAVPe01281,DRAVPe01281.cif,Linear,Free,Free,,L,PRRSV polymerase,"PRRSV polymerase is an RNA-dependent RNA polymerase and is an enzyme specific to viruses, RNA-dependent RNA polymerase is one of the most important proteins for intracellular replication of viruses.The peptide could exert antiviral activity by inhibiting polymerase.",1555.98,C65H118N24O14S3,CDEFGKNPSTVWY,MR,12.3,4,0,4,0,4,0.83,-3134,3.5 hour,10 min,>10 hour,105.83,0,0.0,22743126,Virology. 2012 Oct 10;432(1):73-80.,"Liu K, Feng X, Ma Z, Luo C, Zhou B, Cao R, Huang L, Miao D, Pang R, He D, Lian X, Chen P. ",Antiviral activity of phage display selected peptides against Porcine reproductive and respiratory syndrome virus in vitro.,10.1016/j.virol.2012.05.010,,Anti-PRRSV
DRAVPe01282,LMRIRQMMT,9,a-p9,Synthetic construct,No entry found,,PRRSV,Arteriviridae,MTT assay,[Ref.22743126]Porcine reproductive and respiratory syndrome virus(PRRSV):inhibition of PRRSV replication in MARC-145 cells(IC50=263.8101 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22743126]MARC-145 cells:CC50>500 μM.,DRAVPe01282,DRAVPe01282.cif,Linear,Free,Free,,L,PRRSV polymerase,"PRRSV polymerase is an RNA-dependent RNA polymerase and is an enzyme specific to viruses, RNA-dependent RNA polymerase is one of the most important proteins for intracellular replication of viruses.The peptide could exert antiviral activity by inhibiting polymerase.",1179.52,C48H90N16O12S3,ACDEFGHKNPSVWY,M,12.0,2,0,2,1,2,8.89,-2106,5.5 hour,3 min,2 min,86.67,0,0.0,22743126,Virology. 2012 Oct 10;432(1):73-80.,"Liu K, Feng X, Ma Z, Luo C, Zhou B, Cao R, Huang L, Miao D, Pang R, He D, Lian X, Chen P. ",Antiviral activity of phage display selected peptides against Porcine reproductive and respiratory syndrome virus in vitro.,10.1016/j.virol.2012.05.010,,Anti-PRRSV
DRAVPe01283,HRILMRIR,8,b-p9,Synthetic construct,No entry found,,PRRSV,Arteriviridae,MTT assay,[Ref.22743126]Porcine reproductive and respiratory syndrome virus(PRRSV):inhibition of PRRSV replication in MARC-145 cells(IC50=43.50202 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22743126]MARC-145 cells:CC50>500 μM.,DRAVPe01283,DRAVPe01283.cif,Linear,Free,Free,,L,PRRSV polymerase,"PRRSV polymerase is an RNA-dependent RNA polymerase and is an enzyme specific to viruses, RNA-dependent RNA polymerase is one of the most important proteins for intracellular replication of viruses.The peptide could exert antiviral activity by inhibiting polymerase.",1094.39,C47H87N19O9S,ACDEFGKNPQSTVWY,R,12.3,4,0,4,0,3,-25.0,-3231,3.5 hour,10 min,>10 hour,146.25,0,0.0,22743126,Virology. 2012 Oct 10;432(1):73-80.,"Liu K, Feng X, Ma Z, Luo C, Zhou B, Cao R, Huang L, Miao D, Pang R, He D, Lian X, Chen P. ",Antiviral activity of phage display selected peptides against Porcine reproductive and respiratory syndrome virus in vitro.,10.1016/j.virol.2012.05.010,,Anti-PRRSV
DRAVPe01284,LMRIR,5,c-p9,Synthetic construct,No entry found,,PRRSV,Arteriviridae,MTT assay,[Ref.22743126]Porcine reproductive and respiratory syndrome virus(PRRSV):inhibition of PRRSV replication in MARC-145 cells(IC50=716.4193 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22743126]MARC-145 cells:CC50>500 μM.,DRAVPe01284,DRAVPe01284.cif,Linear,Free,Free,,L,PRRSV polymerase,"PRRSV polymerase is an RNA-dependent RNA polymerase and is an enzyme specific to viruses, RNA-dependent RNA polymerase is one of the most important proteins for intracellular replication of viruses.The peptide could exert antiviral activity by inhibiting polymerase.",687.9,C29H57N11O6S,ACDEFGHKNPQSTVWY,R,12.0,2,0,2,0,2,24.0,-1765,5.5 hour,3 min,2 min,156.0,0,0.0,22743126,Virology. 2012 Oct 10;432(1):73-80.,"Liu K, Feng X, Ma Z, Luo C, Zhou B, Cao R, Huang L, Miao D, Pang R, He D, Lian X, Chen P. ",Antiviral activity of phage display selected peptides against Porcine reproductive and respiratory syndrome virus in vitro.,10.1016/j.virol.2012.05.010,,Anti-PRRSV
DRAVPe01285,hrilmrirqmmt,12,D-P9,Synthetic construct,No entry found,,PRRSV,Arteriviridae,MTT assay,[Ref.22743126]Porcine reproductive and respiratory syndrome virus(PRRSV):inhibition of PRRSV replication in MARC-145 cells(IC50=16.12312 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01285,DRAVPe01285.cif,Linear,Free,Free,,D,PRRSV polymerase,"PRRSV polymerase is an RNA-dependent RNA polymerase and is an enzyme specific to viruses, RNA-dependent RNA polymerase is one of the most important proteins for intracellular replication of viruses.The peptide could exert antiviral activity by inhibiting polymerase.",1586.01,H-22O-11,ACDEFGHIKLMNPQRSTVWY,ACDEFGHIKLMNPQRSTVWY,12.3,0,0,0,0,0,0.0,0,,,,0.0,0,0.0,22743126,Virology. 2012 Oct 10;432(1):73-80.,"Liu K, Feng X, Ma Z, Luo C, Zhou B, Cao R, Huang L, Miao D, Pang R, He D, Lian X, Chen P. ",Antiviral activity of phage display selected peptides against Porcine reproductive and respiratory syndrome virus in vitro.,10.1016/j.virol.2012.05.010,,Anti-PRRSV
DRAVPe01286,AWDFGSIGGVFTSVGKLVHQVFGTAYGVL,29,DV1(419-447),Synthetic construct(derived from DENV1 E protein stem),P27909,,DENV,Flaviviridae,Plaque assay,[Ref.20881042]Dengue 1 virus(DENV1):inhibition of infection in BHK-21 cells(IC90=1.5 μM);##Dengue 2 virus(DENV2):inhibition of infection in BHK-21 cells(IC90=2 μM);##Dengue 3 virus(DENV3):inhibition of infection in BHK-21 cells(IC90>6 μM);##Dengue 4 virus(DENV4):inhibition of infection in BHK-21 cells(IC90>6 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01286,DRAVPe01286.cif,Linear,Free,Free,,L,Not found,The peptide shows antiviral activity by inhibiting virus entry.,3013.45,C143H210N34O38,CEMNPR,G,6.79,2,1,1,11,14,80.69,1894,4.4 hour,>20 hour,>10 hour,97.24,6990,249.64,20881042,J Virol. 2010 Dec;84(24):12549-54.,"Schmidt AG, Yang PL, Harrison SC.",Peptide inhibitors of flavivirus entry derived from the E protein stem.,10.1128/JVI.01440-10,,Anti-DENV
DRAVPe01287,AWDFGSLGGVFTSIGKALHQVFGAIYGAA,29,DV2(419-447),Synthetic construct(derived from DENV2 E protein stem),P29984,,DENV,Flaviviridae,Plaque assay,[Ref.20881042]Dengue 1 virus(DENV1):inhibition of infection in BHK-21 cells(IC90<0.1 μM);##Dengue 2 virus(DENV2):inhibition of infection in BHK-21 cells(IC90=0.3 μM);##Dengue 3 virus(DENV3):inhibition of infection in BHK-21 cells(IC90=2 μM);##Dengue 4 virus(DENV4):inhibition of infection in BHK-21 cells(IC90=0.7 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01287,DRAVPe01287.cif,Linear,Free,Free,,L,Not found,The peptide shows antiviral activity by inhibiting virus entry.,2941.34,C139H202N34O37,CEMNPR,G,6.79,2,1,1,10,15,73.79,1974,4.4 hour,>20 hour,>10 hour,91.03,6990,249.64,20881042,J Virol. 2010 Dec;84(24):12549-54.,"Schmidt AG, Yang PL, Harrison SC.",Peptide inhibitors of flavivirus entry derived from the E protein stem.,10.1128/JVI.01440-10,,Anti-DENV
DRAVPe01288,AWDFGSVGGVLNSLGKMVHQIFGSAYTAL,29,DV3(419-447),Synthetic construct(derived from DENV3 E protein stem),Q99D35,,DENV,Flaviviridae,Plaque assay,[Ref.20881042]Dengue 1 virus(DENV1):inhibition of infection in BHK-21 cells(IC90<0.1 μM);##Dengue 2 virus(DENV2):inhibition of infection in BHK-21 cells(IC90=2 μM);##Dengue 3 virus(DENV3):inhibition of infection in BHK-21 cells(IC90=4 μM);##Dengue 4 virus(DENV4):inhibition of infection in BHK-21 cells(IC90=1.5 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01288,DRAVPe01288.cif,Linear,Free,Free,,L,Not found,The peptide shows antiviral activity by inhibiting virus entry.,3026.46,C139H209N35O39S,CEPR,G,6.79,2,1,1,11,13,56.9,855,4.4 hour,>20 hour,>10 hour,94.14,6990,249.64,20881042,J Virol. 2010 Dec;84(24):12549-54.,"Schmidt AG, Yang PL, Harrison SC.",Peptide inhibitors of flavivirus entry derived from the E protein stem.,10.1128/JVI.01440-10,,Anti-DENV
DRAVPe01289,AWDFGSVGGLFTSLGKAVHQVFGSVYTTM,29,DV4(419-447),Synthetic construct(derived from DENV4 E protein stem),P27909,,DENV,Flaviviridae,Plaque assay,[Ref.20881042]Dengue 1 virus(DENV1):inhibition of infection in BHK-21 cells(IC90=5 μM);##Dengue 2 virus(DENV2):inhibition of infection in BHK-21 cells(IC90=6 μM);##Dengue 3 virus(DENV3):inhibition of infection in BHK-21 cells(IC90>6 μM);##Dengue 4 virus(DENV4):inhibition of infection in BHK-21 cells(IC90=6 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01289,DRAVPe01289.cif,Linear,Free,Free,,L,Not found,The peptide shows antiviral activity by inhibiting virus entry.,3063.48,C142H208N34O40S,CEINPR,G,6.79,2,1,1,12,12,53.45,542,4.4 hour,>20 hour,>10 hour,73.79,6990,249.64,20881042,J Virol. 2010 Dec;84(24):12549-54.,"Schmidt AG, Yang PL, Harrison SC.",Peptide inhibitors of flavivirus entry derived from the E protein stem.,10.1128/JVI.01440-10,,Anti-DENV
DRAVPe01290,YENQKQIANQFNKAISQIQESLTTTSTA,28,HR1-a(899-926),Synthetic construct(derived from SARS-CoV spike protein),P59594,,SARS-CoV,Coronaviridae,Luciferase assay,[Ref.18442051]HIV‐luc/SARS Pseudotyped Virus:inhibition of viral-entry in Vero E3 cells(EC50=1.16 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01290,DRAVPe01290.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,3157.44,C135H218N38O49,CDGHMPRVW,Q,6.14,2,2,0,11,8,-85.0,-6487,2.8 hour,10 min,2 min,66.43,1490,55.19,18442051,J Cell Biochem. 2008 Aug 15;104(6):2335-47.,"Chu LH, Chan SH, Tsai SN, Wang Y, Cheng CH, Wong KB, Waye MM, Ngai SM.",Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors. ,10.1002/jcb.21790,,Anti-SARS-CoV
DRAVPe01291,DVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYI,48,GST-removed HR2(1145-1192),Synthetic construct(derived from SARS-CoV spike protein),P59594,,SARS-CoV,Coronaviridae,Luciferase assay,[Ref.18442051]HIV‐luc/SARS Pseudotyped Virus:inhibition of viral-entry in Vero E3 cells(EC50=2.15 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01291,DRAVPe01291.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,5390.0,C235H384N62O82,CFHMPTW,IL,4.11,4,10,-6,13,18,-31.67,-8788,1.1 hour,3 min,>10 hour,125.83,2980,63.4,18442051,J Cell Biochem. 2008 Aug 15;104(6):2335-47.,"Chu LH, Chan SH, Tsai SN, Wang Y, Cheng CH, Wong KB, Waye MM, Ngai SM.",Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors. ,10.1002/jcb.21790,,Anti-SARS-CoV
DRAVPe01736,DVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYI,48,SARS-Cov-S (1145-1192),Synthetic construct,P59594,,SARS-CoV PsV,Coronaviridae,HIV‐luc/SARS Pseudotyped Virus Entry Inhibition Assay,[Ref.18442051]SARS-CoV PsV: inhibition of HIV-luc/SARS PsV infection in Vero-E6 cells (EC50=2.15μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01736.cif,Linear,Free,Free,,L,not found,No machanism information found in the reference(s) presented in this entry,5390.0,C235H384N62O82,CFHMPTW,IL,4.11,4,10,-6,13,18,-31.67,-8788,1.1 hour,3 min,>10 hour,125.83,2980,63.4,18442051,J Cell Biochem. 2008 Aug 15;104(6):2335-47.,"Chu LH, Chan SH, Tsai SN, Wang Y, Cheng CH, Wong KB, Waye MM, Ngai SM.",Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors.,10.1002/jcb.21790,,Anti-SARS-CoV
DRAVPe01735,YENQKQIANQFNKAISQIQESLTTTSTA,28,SARS-Cov-S (899-926),Synthetic construct,P59594,,SARS-CoV PsV,Coronaviridae,HIV‐luc/SARS Pseudotyped Virus Entry Inhibition Assay,[Ref.18442051]SARS-CoV PsV: inhibition of HIV-luc/SARS PsV infection in Vero-E6 cells (EC50=1.16μM),No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01735.cif,Linear,Free,Free,,L,not found,No machanism information found in the reference(s) presented in this entry,3157.44,C135H218N38O49,CDGHMPRVW,Q,6.14,2,2,0,11,8,-85.0,-6487,2.8 hour,10 min,2 min,66.43,1490,55.19,18442051,J Cell Biochem. 2008 Aug 15;104(6):2335-47.,"Chu LH, Chan SH, Tsai SN, Wang Y, Cheng CH, Wong KB, Waye MM, Ngai SM.",Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors.,10.1002/jcb.21790,,Anti-SARS-CoV
DRAVPe01292,ELDSPKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE,64,sHR2-1(derived from SARS-CoV spike protein heptad repeat),Synthetic construct(derived from SARS-CoV spike protein heptad repeat),P59594,,SARS-CoV,Coronaviridae,Indirect immunofluorescence assay,[Ref.15150417]SARS-CoV:inhibition of virus infection in Vero cells(EC50=43 ± 6.4 μM);##murine coronavirus:inhibition of virus infection in Vero cells(EC50>50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01292,DRAVPe01292.cif,Linear,Free,Free,,L,membrane,"The peptide exhibits antiviral activity by competitive binding to the HR1 region of the SARS-CoV spike protein, thus blocking the formation of the six-helix bundle and consequently membrane fusion.",7244.99,C316H507N83O111,CMW,ELD,4.34,8,15,-7,17,20,-73.75,-14963,1 hour,30 min,>10 hour,100.47,2980,47.3,15150417,Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60.,"Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ.",Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.,10.1073/pnas.0400576101,,Anti-SARS-CoV
DRAVPe01293,PKEELDKYFKNHTSPDVDLGLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE,62,sHR2-2(derived from SARS-CoV spike protein heptad repeat),Synthetic construct(derived from SARS-CoV spike protein heptad repeat),P59594,,SARS-CoV,Coronaviridae,Indirect immunofluorescence assay,[Ref.15150417]SARS-CoV:inhibition of virus infection in Vero cells(EC50=24 ± 2.8 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01293,DRAVPe01293.cif,Linear,Free,Free,,L,membrane,"The peptide exhibits antiviral activity by competitive binding to the HR2 region of the SARS-CoV spike protein, thus blocking the formation of the six-helix bundle and consequently membrane fusion.",6970.76,C306H493N81O104,CMW,LE,4.49,8,13,-5,17,20,-64.19,-12976,>20 hour,>20 hour,?,103.71,2980,48.85,15150417,Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60.,"Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ.",Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.,10.1073/pnas.0400576101,,Anti-SARS-CoV
DRAVPe01294,LDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE,56,sHR2-3(derived from SARS-CoV spike protein heptad repeat),Synthetic construct(derived from SARS-CoV spike protein heptad repeat),P59594,,SARS-CoV,Coronaviridae,Indirect immunofluorescence assay,[Ref.15150417]SARS-CoV:inhibition of virus infection in Vero cells(EC50>50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01294,DRAVPe01294.cif,Linear,Free,Free,,L,membrane,"The peptide exhibits antiviral activity by competitive binding to the HR3 region of the SARS-CoV spike protein, thus blocking the formation of the six-helix bundle and consequently membrane fusion.",6317.03,C277H446N74O94,CMW,LDN,4.5,7,11,-4,16,19,-54.82,-11645,5.5 hour,3 min,2 min,107.86,2980,54.18,15150417,Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60.,"Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ.",Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.,10.1073/pnas.0400576101,,Anti-SARS-CoV
DRAVPe01295,FKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE,52,sHR2-4(derived from SARS-CoV spike protein heptad repeat),Synthetic construct(derived from SARS-CoV spike protein heptad repeat),P59594,,SARS-CoV,Coronaviridae,Indirect immunofluorescence assay,[Ref.15150417]SARS-CoV:inhibition of virus infection in Vero cells(EC50>50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01295,DRAVPe01295.cif,Linear,Free,Free,,L,membrane,"The peptide exhibits antiviral activity by competitive binding to the HR4 region of the SARS-CoV spike protein, thus blocking the formation of the six-helix bundle and consequently membrane fusion.",5797.43,C252H409N69O87,CMW,LNDEI,4.45,6,10,-4,15,18,-49.62,-10696,1.1 hour,3 min,2 min,108.65,1490,29.22,15150417,Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60.,"Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ.",Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.,10.1073/pnas.0400576101,,Anti-SARS-CoV
DRAVPe01296,TSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE,48,sHR2-5(derived from SARS-CoV spike protein heptad repeat),Synthetic construct(derived from SARS-CoV spike protein heptad repeat),P59594,,SARS-CoV,Coronaviridae,Indirect immunofluorescence assay,[Ref.15150417]SARS-CoV:inhibition of virus infection in Vero cells(EC50>50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01296,DRAVPe01296.cif,Linear,Free,Free,,L,membrane,"The peptide exhibits antiviral activity by competitive binding to the HR5 region of the SARS-CoV spike protein, thus blocking the formation of the six-helix bundle and consequently membrane fusion.",5270.83,C227H375N61O82,CFHMW,L,4.11,4,10,-6,14,17,-37.5,-9309,7.2 hour,>20 hour,>10 hour,117.71,1490,31.7,15150417,Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60.,"Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ.",Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.,10.1073/pnas.0400576101,,Anti-SARS-CoV
DRAVPe01297,VDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE,44,sHR2-6(derived from SARS-CoV spike protein heptad repeat),Synthetic construct(derived from SARS-CoV spike protein heptad repeat),P59594,,SARS-CoV,Coronaviridae,Indirect immunofluorescence assay,[Ref.15150417]SARS-CoV:inhibition of virus infection in Vero cells(EC50>50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01297,DRAVPe01297.cif,Linear,Free,Free,,L,membrane,"The peptide exhibits antiviral activity by competitive binding to the HR6 region of the SARS-CoV spike protein, thus blocking the formation of the six-helix bundle and consequently membrane fusion.",4870.45,C211H351N57O74,CFHMPTW,L,4.21,4,9,-5,12,17,-25.91,-7840,100 hour,>20 hour,>10 hour,128.41,1490,34.65,15150417,Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60.,"Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ.",Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.,10.1073/pnas.0400576101,,Anti-SARS-CoV
DRAVPe01298,DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE,40,sHR2-7(derived from SARS-CoV spike protein heptad repeat),Synthetic construct(derived from SARS-CoV spike protein heptad repeat),P59594,,SARS-CoV,Coronaviridae,Indirect immunofluorescence assay,[Ref.15150417]SARS-CoV:inhibition of virus infection in Vero cells(EC50>50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01298,DRAVPe01298.cif,Linear,Free,Free,,L,membrane,"The peptide exhibits antiviral activity by competitive binding to the HR7 region of the SARS-CoV spike protein, thus blocking the formation of the six-helix bundle and consequently membrane fusion.",4486.01,C194H323N53O68,CFHMPTW,EILN,4.33,4,8,-4,11,15,-38.75,-7958,1.1 hour,3 min,>10 hour,124.25,1490,38.21,15150417,Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60.,"Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ.",Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.,10.1073/pnas.0400576101,,Anti-SARS-CoV
DRAVPe01299,ELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK,68,sHR2-8(derived from SARS-CoV spike protein heptad repeat),Synthetic construct(derived from SARS-CoV spike protein heptad repeat),P59594,,SARS-CoV,Coronaviridae,Indirect immunofluorescence assay,[Ref.15150417]SARS-CoV:inhibition of virus infection in Vero cells(EC50=17 ± 3.0 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01299,DRAVPe01299.cif,Linear,Free,Free,,L,membrane,"The peptide exhibits antiviral activity by competitive binding to the HR8 region of the SARS-CoV spike protein, thus blocking the formation of the six-helix bundle and consequently membrane fusion.",7827.69,C346H549N89O117,CMW,ELDK,4.46,9,15,-6,18,22,-69.12,-15296,1 hour,30 min,>10 hour,100.29,4470,66.72,15150417,Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60.,"Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ.",Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.,10.1073/pnas.0400576101,,Anti-SARS-CoV
DRAVPe01300,ELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL,60,sHR2-9(derived from SARS-CoV spike protein heptad repeat),Synthetic construct(derived from SARS-CoV spike protein heptad repeat),P59594,,SARS-CoV,Coronaviridae,Indirect immunofluorescence assay,[Ref.15150417]SARS-CoV:inhibition of virus infection in Vero cells(EC50=34 ± 4.0 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01300,DRAVPe01300.cif,Linear,Free,Free,,L,membrane,"The peptide exhibits antiviral activity by competitive binding to the HR9 region of the SARS-CoV spike protein, thus blocking the formation of the six-helix bundle and consequently membrane fusion.",6817.53,C298H478N78O104,CMW,LDE,4.27,7,14,-7,15,21,-56.17,-13509,1 hour,30 min,>10 hour,107.17,1490,25.25,15150417,Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60.,"Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ.",Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.,10.1073/pnas.0400576101,,Anti-SARS-CoV
DRAVPe01301,ELDSPKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLID,56,sHR2-10(derived from SARS-CoV spike protein heptad repeat),Synthetic construct(derived from SARS-CoV spike protein heptad repeat),P59594,,SARS-CoV,Coronaviridae,Indirect immunofluorescence assay,[Ref.15150417]SARS-CoV:inhibition of virus infection in Vero cells(EC50>50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01301,DRAVPe01301.cif,Linear,Free,Free,,L,membrane,"The peptide exhibits antiviral activity by competitive binding to the HR10 region of the SARS-CoV spike protein, thus blocking the formation of the six-helix bundle and consequently membrane fusion.",6283.91,C272H439N73O97,CMW,DELN,4.32,7,13,-6,15,18,-69.11,-13556,1 hour,30 min,>10 hour,100.89,1490,27.09,15150417,Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60.,"Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ.",Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.,10.1073/pnas.0400576101,,Anti-SARS-CoV
DRAVPe01302,DLSLDFEKLNVTLLDLTYEMNRIQDAIKKLNESYINLKE,39,mHR2(derived from SARS-CoV spike protein heptad repeat),Synthetic construct(derived from SARS-CoV spike protein heptad repeat),P11224,,SARS-CoV,Coronaviridae,Indirect immunofluorescence assay,[Ref.15150417]SARS-CoV:inhibition of virus infection in Vero cells(EC50>50 μM);##murine coronavirus:inhibition of virus infection in Vero cells(EC50=0.9 ± 0.1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01302,DRAVPe01302.cif,Linear,Free,Free,,L,membrane,"The peptide exhibits antiviral activity by competitive binding to the HR11 region of the SARS-CoV spike protein, thus blocking the formation of the six-helix bundle and consequently membrane fusion.",4644.31,C207H337N51O67S,CGHPW,L,4.51,5,8,-3,10,14,-42.56,-7826,1.1 hour,3 min,>10 hour,120.0,2980,78.42,15150417,Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60.,"Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ.",Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.,10.1073/pnas.0400576101,,Anti-SARS-CoV
DRAVPe01744,DLSLDFEKLNVTLLDLTYEMNRIQDAIKKLNESYINLKE,39,MHV-S (1216-1254),Synthetic construct,P11224,,"SARS-CoV, MHV",Coronaviridae,Infection inhibition assay,[Ref.15150417]SARS-CoV: inhibition of SARS-CoV infection in Vero 118 cells (EC50>50µM);##MHV(mouse hepatitis virus): inhibition of MHV infection in Vero 118 cells (EC50=0.9±0.1µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01744.cif,Linear,Free,Free,,L,membrane,Inhibits virus infection by interfering with six-helix bundle formation(fusion inhibitor).,4644.31,C207H337N51O67S,CGHPW,L,4.51,5,8,-3,10,14,-42.56,-7826,1.1 hour,3 min,>10 hour,120.0,2980,78.42,15150417,Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60.,"Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ.",Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.,10.1073/pnas.0400576101,,"Anti-SARS-CoV, Anti-MHV"
DRAVPe01742,ELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL,60,SARS-CoV-S (1134-1185),Synthetic construct,P59594,,"SARS-CoV, MHV",Coronaviridae,Infection inhibition assay,[Ref.15150417]SARS-CoV: inhibition of SARS-CoV infection in Vero 118 cells (EC50=34±4.0µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01742.cif,Linear,Free,Free,,L,membrane,Inhibits virus infection by interfering with six-helix bundle formation(fusion inhibitor).,6817.53,C298H478N78O104,CMW,LDE,4.27,7,14,-7,15,21,-56.17,-13509,1 hour,30 min,>10 hour,107.17,1490,25.25,15150417,Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60.,"Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ.",Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.,10.1073/pnas.0400576101,,"Anti-SARS-CoV, Anti-MHV"
DRAVPe01743,NQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLIT,46,SARS-CoV-S (935-980),Synthetic construct,P59594,,"SARS-CoV, MHV",Coronaviridae,Infection inhibition assay,[Ref.15150417]SARS-CoV: inhibition of SARS-CoV infection in Vero 118 cells (EC50>50µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01743.cif,Linear,Free,Free,,L,membrane,Inhibits virus infection by interfering with six-helix bundle formation(fusion inhibitor).,5040.71,C218H369N63O73,CHMPWY,L,4.86,4,5,-1,13,20,-0.43,-7678,1.4 hour,3 min,>10 hour,127.17,0,0.0,15150417,Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60.,"Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ.",Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.,10.1073/pnas.0400576101,,"Anti-SARS-CoV, Anti-MHV"
DRAVPe01741,ELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK,68,SARS-CoV-S (1134-1193),Synthetic construct,P59594,,"SARS-CoV, MHV",Coronaviridae,Infection inhibition assay,[Ref.15150417]SARS-CoV: inhibition of SARS-CoV infection in Vero 118 cells (EC50=17±3.0µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01741.cif,Linear,Free,Free,,L,membrane,Inhibits virus infection by interfering with six-helix bundle formation(fusion inhibitor).,7827.69,C346H549N89O117,CMW,ELDK,4.46,9,15,-6,18,22,-69.12,-15296,1 hour,30 min,>10 hour,100.29,4470,66.72,15150417,Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60.,"Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ.",Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.,10.1073/pnas.0400576101,,"Anti-SARS-CoV, Anti-MHV"
DRAVPe01740,DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE,40,SARS-CoV-S (1150-1189),Synthetic construct,P59594,,"SARS-CoV, MHV",Coronaviridae,Infection inhibition assay,[Ref.15150417]SARS-CoV: inhibition of SARS-CoV infection in Vero 118 cells (EC50>50µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01740.cif,Linear,Free,Free,,L,membrane,Inhibits virus infection by interfering with six-helix bundle formation(fusion inhibitor).,4486.01,C194H323N53O68,CFHMPTW,EILN,4.33,4,8,-4,11,15,-38.75,-7958,1.1 hour,3 min,>10 hour,124.25,1490,38.21,15150417,Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60.,"Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ.",Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.,10.1073/pnas.0400576101,,"Anti-SARS-CoV, Anti-MHV"
DRAVPe01739,LDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE,56,SARS-CoV-S (1134-1189),Synthetic construct,P59594,,"SARS-CoV, MHV",Coronaviridae,Infection inhibition assay,[Ref.15150417]SARS-CoV: inhibition of SARS-CoV infection in Vero 118 cells (EC50>50µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01739.cif,Linear,Free,Free,,L,membrane,Inhibits virus infection by interfering with six-helix bundle formation(fusion inhibitor).,6317.03,C277H446N74O94,CMW,LDN,4.5,7,11,-4,16,19,-54.82,-11645,5.5 hour,3 min,2 min,107.86,2980,54.18,15150417,Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60.,"Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ.",Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.,10.1073/pnas.0400576101,,"Anti-SARS-CoV, Anti-MHV"
DRAVPe01738,ELDSPKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE,64,SARS-CoV (1126-1189)[F5P],Synthetic construct,P59594,,"SARS-CoV, MHV",Coronaviridae,Infection inhibition assay,[Ref.15150417]SARS-CoV: inhibition of SARS-CoV infection in Vero 118 cells (EC50=43±6.4µM);##MHV(mouse hepatitis virus): inhibition of MHV infection in Vero 118 cells (EC50>50µM),No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01738.cif,Linear,Free,Free,,L,membrane,Inhibits virus infection by interfering with six-helix bundle formation(fusion inhibitor).,7244.99,C316H507N83O111,CMW,ELD,4.34,8,15,-7,17,20,-73.75,-14963,1 hour,30 min,>10 hour,100.47,2980,47.3,15150417,Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60.,"Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ.",Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.,10.1073/pnas.0400576101,,"Anti-SARS-CoV, Anti-MHV"
DRAVPe01737,PKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE,60,SARS-CoV (1130-1189)[F1P],Synthetic construct,P59594,,"SARS-CoV, MHV",Coronaviridae,Infection inhibition assay,[Ref.15150417]SARS-CoV: inhibition of SARS-CoV infection in Vero 118 cells (EC50=24±2.8µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,,DRAVPe01737.cif,Linear,Free,Free,,L,membrane,Inhibits virus infection by interfering with six-helix bundle formation(fusion inhibitor).,6800.55,C298H479N79O102,CMW,ELDKN,4.49,8,13,-5,16,19,-72.0,-13562,>20 hour,>20 hour,?,100.67,2980,50.51,15150417,Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60.,"Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ.",Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.,10.1073/pnas.0400576101,,"Anti-SARS-CoV, Anti-MHV"
DRAVPe01303,ATCYCRTGRCATRESLSGVCEISGRLYRLCCR,32,"Human defensin-5 (HD-5; Defensin, alpha 5; Human, mammals, animals)",Homo sapiens (Human),Q01523##A0JDY6##Q3KNV2,1ZMP,"SARS-CoV-2,HSV,HIV","Coronaviridae, Herpesviridae, Retroviridae",Plaque assay,"[Ref.34206990]SARS-CoV-2:inhibition of infection in HEK293T-hACE2 cells(60% inhibition at 12.5 μg/mL (3.45 μM));##SARS-CoV-2 variant P.1:inhibition of infection in HeLa-hACE2 cells(72% inbibition at 50 μg/mL);##SARS-CoV-2 variant B.1.1.7:inhibition of infection in HeLa-hACE2 cells(32% inbibition at 50 μg/mL).##[Ref.23269800]Herpes simplex virus2(HSV-2):Potential for CaSki cell protection from HSV-2 infection(47.8% ±3.9% cell protection rates at 25 μg/ml,69.4% ± 5.4% cell protection at 50 μg/ml);neutralization activity against HSV-2 during the preinfection stage(IC50=35 μg/ml);##HIV-1:inhibition of virus infection in JLTRG cells(IC50=7.51 μg/ ml).",[Ref.26206286] It has 0% hemolysis at 100μM against human red blood cells.,[Ref.34206990]No cytotoxicity on HEK293T cells up to 50 μg/mL.##[Ref.23269800]No cytotoxicity against CaSki cells up to 100μg/ ml.,DRAVPe01303,DRAVPe01303.cif,Cyclic,Free,Free,"Disulfide bonds between Cys3 and Cys31,Cys5 and Cys20,Cys10 and Cys30.",L,Not found,The peptide exhibits antiviral activity by inhibiting virus entry.,3588.19,C144H244N50O45S6,DFHKMNPQW,CR,8.96,6,2,4,17,7,-11.25,-8349,4.4 hour,>20 hour,>10 hour,64.06,3355,108.23,34206990##26206286##23269800,Viruses. 2021 Jun 26;13(7):1246.##Peptides. 2015 Sep;71:128-40.##J Virol. 2013 Mar;87(5):2835-45. ,"Xu C, Wang A, Marin M, Honnen W, Ramasamy S, Porter E, Subbian S, Pinter A, Melikyan GB, Lu W, Chang TL.##Basil Mathew Ramakrishnan Nagaraj##Wang A, Chen F, Wang Y, Shen M, Xu Y, Hu J, Wang S, Geng F, Wang C, Ran X, Su Y, Cheng T, Wang J. ",Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry.##Antimicrobial activity of human  -defensin 5 and its linear analogs: N-terminal fatty acylation results in enhanced antimicrobial activity of the linear analogs.##Enhancement of antiviral activity of human alpha-defensin 5 against herpes simplex virus 2 by arginine mutagenesis at adaptive evolution sites.,10.3390/v13071246##10.1016/j.peptides.2015.07.009##10.1128/JVI.02209-12,,"Anti-SARS-CoV-2,Anti-HSV,Anti-HIV"
DRAVPe01304,ATCYCRTGRCATRESLSGVCRISGRLYRLCCR,32,HD5[E21R],Synthetic construct(derived from human alpha defensin(HD5)),Q01523,,"HSV,HIV","Herpesviridae, Retroviridae",Plaque assay,"[Ref.23269800]Herpes simplex virus2(HSV-2):Potential for CaSki cell protection from HSV-2 infection(61.5% ± 7.1% cell protection rates at 25 μg/ml,90.2% ± 4.9% cell protection at 50 μg/ml);neutralization activity against HSV-2 during the preinfection stage(IC50=25 μg/ml);##HIV-1:inhibition of virus infection in JLTRG cells(IC50=3.53 μg/ ml).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.23269800]No cytotoxicity against CaSki cells up to 100μg/ ml.,DRAVPe01304,DRAVPe01304.cif,Cyclic,Free,Free,"Disulfide bonds between Cys3 and Cys31,Cys5 and Cys20,Cys10 and Cys30.",L,capsid protein gD,"The interaction between peptide and viral capsid proteins may cause aggregation of virions to prevent viruses from normal binding to target cells. Another possibility is that the binding of HD5 derivatives to the virion envelope blocks the epitopes of interaction between viruses and cell receptors, which are necessary for viral adsorption or entry into host cells.",3615.26,C145H249N53O43S6,DFHKMNPQW,R,9.49,7,1,6,17,7,-14.38,-9160,4.4 hour,>20 hour,>10 hour,64.06,3355,108.23,23269800,J Virol. 2013 Mar;87(5):2835-45. ,"Wang A, Chen F, Wang Y, Shen M, Xu Y, Hu J, Wang S, Geng F, Wang C, Ran X, Su Y, Cheng T, Wang J. ",Enhancement of antiviral activity of human alpha-defensin 5 against herpes simplex virus 2 by arginine mutagenesis at adaptive evolution sites.,10.1128/JVI.02209-12,,"Anti-HSV,Anti-HIV"
DRAVPe01305,ATCYCRTGRCATRESLSGVCEIRGRLYRLCCR,32,HD5[S23R],Synthetic construct(derived from human alpha defensin(HD5)),Q01523,,HSV,Herpesviridae,Plaque assay,[Ref.23269800]Herpes simplex virus2(HSV-2):neutralization activity against HSV-2 during the preinfection stage(IC50=36 μg/ml);,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.23269800]No cytotoxicity against CaSki cells up to 100μg/ ml.,DRAVPe01305,DRAVPe01305.cif,Cyclic,Free,Free,"Disulfide bonds between Cys3 and Cys31,Cys5 and Cys20,Cys10 and Cys30.",L,capsid protein gD,"The interaction between peptide and viral capsid proteins may cause aggregation of virions to prevent viruses from normal binding to target cells. Another possibility is that the binding of HD5 derivatives to the virion envelope blocks the epitopes of interaction between viruses and cell receptors, which are necessary for viral adsorption or entry into host cells.",3657.3,C147H251N53O44S6,DFHKMNPQW,R,9.22,7,2,5,16,7,-22.81,-9501,4.4 hour,>20 hour,>10 hour,64.06,3355,108.23,23269800,J Virol. 2013 Mar;87(5):2835-45. ,"Wang A, Chen F, Wang Y, Shen M, Xu Y, Hu J, Wang S, Geng F, Wang C, Ran X, Su Y, Cheng T, Wang J. ",Enhancement of antiviral activity of human alpha-defensin 5 against herpes simplex virus 2 by arginine mutagenesis at adaptive evolution sites.,10.1128/JVI.02209-12,,Anti-HSV
DRAVPe01306,ATCYCRRGRCATRESLSGVCEISGRLYRLCCR,32,HD5[T7R],Synthetic construct(derived from human alpha defensin(HD5)),Q01523,,HSV,Herpesviridae,Plaque assay,[Ref.23269800]Herpes simplex virus2(HSV-2):neutralization activity against HSV-2 during the preinfection stage(IC50=40 μg/ml);,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.23269800]No cytotoxicity against CaSki cells up to 100μg/ ml.,DRAVPe01306,DRAVPe01306.cif,Cyclic,Free,Free,"Disulfide bonds between Cys3 and Cys31,Cys5 and Cys20,Cys10 and Cys30.",L,capsid protein gD,"The interaction between peptide and viral capsid proteins may cause aggregation of virions to prevent viruses from normal binding to target cells. Another possibility is that the binding of HD5 derivatives to the virion envelope blocks the epitopes of interaction between viruses and cell receptors, which are necessary for viral adsorption or entry into host cells.",3643.27,C146H249N53O44S6,DFHKMNPQW,R,9.22,7,2,5,16,7,-23.13,-9584,4.4 hour,>20 hour,>10 hour,64.06,3355,108.23,23269800,J Virol. 2013 Mar;87(5):2835-45. ,"Wang A, Chen F, Wang Y, Shen M, Xu Y, Hu J, Wang S, Geng F, Wang C, Ran X, Su Y, Cheng T, Wang J. ",Enhancement of antiviral activity of human alpha-defensin 5 against herpes simplex virus 2 by arginine mutagenesis at adaptive evolution sites.,10.1128/JVI.02209-12,,Anti-HSV
DRAVPe01307,ATCYCRTGRCATRESRSGVCEISGRLYRLCCR,32,HD5[L16R],Synthetic construct(derived from human alpha defensin(HD5)),Q01523,,HSV,Herpesviridae,Plaque assay,[Ref.23269800]Herpes simplex virus2(HSV-2):Potential for CaSki cell protection from HSV-2 infection(51.2% ± 7.2% cell protection at 100 μg/ml);neutralization activity against HSV-2 during the preinfection stage(IC50=67 μg/ml);,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.23269800]No cytotoxicity against CaSki cells up to 100μg/ ml.,DRAVPe01307,DRAVPe01307.cif,Cyclic,Free,Free,"Disulfide bonds between Cys3 and Cys31,Cys5 and Cys20,Cys10 and Cys30.",L,capsid protein gD,"The interaction between peptide and viral capsid proteins may cause aggregation of virions to prevent viruses from normal binding to target cells. Another possibility is that the binding of HD5 derivatives to the virion envelope blocks the epitopes of interaction between viruses and cell receptors, which are necessary for viral adsorption or entry into host cells.",3631.22,C144H245N53O45S6,DFHKMNPQW,R,9.22,7,2,5,17,6,-37.19,-10333,4.4 hour,>20 hour,>10 hour,51.88,3355,108.23,23269800,J Virol. 2013 Mar;87(5):2835-46. ,"Wang A, Chen F, Wang Y, Shen M, Xu Y, Hu J, Wang S, Geng F, Wang C, Ran X, Su Y, Cheng T, Wang J. ",Enhancement of antiviral activity of human alpha-defensin 5 against herpes simplex virus 2 by arginine mutagenesis at adaptive evolution sites.,10.1128/JVI.02209-12,,Anti-HSV
DRAVPe01308,PPVYTKDVDISSQISSMNQSLQQSKDYIKEAQKILDTVNPSL,42,HeV F HRC derived peptide(447-488),Synthetic construct(derived from HeV fusion (F) protein),O89342,,"HeV,HPIV3",Paramyxoviridae,Luminescence fusion assay,[Ref.16973588]Henda virus(HeV):inhibition of virus infection in HeLa cells(IC50=75 nM);inhibition of fusion in HeLa cells(IC50=40 nM);##human parainfluenza virus 3 (HPIV3):inhibition of virus infection in HeLa cells(IC50>10000 nM);inhibition of fusion in HeLa cells(IC50>10000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01308,DRAVPe01308.cif,Linear,Free,Free,,L,membrane,"The HeV receptor-binding protein (G) is required in order for the fusion protein (F) to mediate fusion.  HeV F, once triggered by the receptor-bound G, undergoes multistep conformational changes leading to a six-helix bundle (6HB) structure that accomplishes fusion of the viral and cellular membranes. Peptides derived from the HRN and HRC regions of F are proposed to inhibit fusion by preventing F, after the initial triggering step, from forming the 6HB structure that is required for fusion. ",4710.29,C205H335N53O71S,CFGHRW,S,4.78,4,5,-1,13,11,-62.62,-8337,>20 hour,>20 hour,?,88.1,2980,72.68,16973588,J Virol. 2006 Oct;80(19):9837-49.,"Porotto M, Doctor L, Carta P, Fornabaio M, Greengard O, Kellogg GE, Moscona A.",Inhibition of hendra virus fusion.,10.1128/JVI.00736-06,,"Anti-HeV,Anti-HPIV3"
DRAVPe01309,VYTDKVDISSQISSMNQSLQQSKDYIKEAQKILDTV,36,HeV F HRC derived peptide(449-484),Synthetic construct(derived from HeV fusion (F) protein),O89342,,"HeV,HPIV3",Paramyxoviridae,Luminescence fusion assay,[Ref.16973588]Henda virus(HeV):inhibition of virus infection in HeLa cells(IC50=75 nM);inhibition of fusion in HeLa cells(IC50=40 nM);##human parainfluenza virus 3 (HPIV3):inhibition of virus infection in HeLa cells(IC50>10000 nM);inhibition of fusion in HeLa cells(IC50>10000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01309,DRAVPe01309.cif,Linear,Free,Free,,L,membrane,"The HeV receptor-binding protein (G) is required in order for the fusion protein (F) to mediate fusion.  HeV F, once triggered by the receptor-bound G, undergoes multistep conformational changes leading to a six-helix bundle (6HB) structure that accomplishes fusion of the viral and cellular membranes. Peptides derived from the HRN and HRC regions of F are proposed to inhibit fusion by preventing F, after the initial triggering step, from forming the 7HB structure that is required for fusion.",4104.6,C177H292N46O63S,CFGHPRW,S,4.78,4,5,-1,11,10,-58.33,-7825,100 hour,>20 hour,>10 hour,91.94,2980,85.14,16973588,J Virol. 2006 Oct;80(19):9837-49.,"Porotto M, Doctor L, Carta P, Fornabaio M, Greengard O, Kellogg GE, Moscona A.",Inhibition of hendra virus fusion.,10.1128/JVI.00736-06,,"Anti-HeV,Anti-HPIV3"
DRAVPe01310,DITLNNSVALDPIDISIELNKAKSDLEESKEWIRRSNQKLDSIGN,45,HPIV3 F HRC derived peptide(442-486),Synthetic construct(derived from HPIV3 fusion (F) protein),P06828,,"HeV,HPIV3",Paramyxoviridae,Luminescence fusion assay,[Ref.16973588]Henda virus(HeV):inhibition of virus infection in HeLa cells(IC50=20 nM);inhibition of fusion in HeLa cells(IC50=7.5 nM);##human parainfluenza virus 3 (HPIV3):inhibition of virus infection in HeLa cells(IC50=500 nM);inhibition of fusion in HeLa cells(IC50=500 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01310,DRAVPe01310.cif,Linear,Free,Free,,L,membrane,"The HeV receptor-binding protein (G) is required in order for the fusion protein (F) to mediate fusion.  HeV F, once triggered by the receptor-bound G, undergoes multistep conformational changes leading to a six-helix bundle (6HB) structure that accomplishes fusion of the viral and cellular membranes. Peptides derived from the HRN and HRC regions of F are proposed to inhibit fusion by preventing F, after the initial triggering step, from forming the 8HB structure that is required for fusion.",5083.64,C218H362N62O77,CFHMY,IS,4.56,6,9,-3,13,15,-70.44,-11954,1.1 hour,3 min,>10 hour,106.22,5500,125.0,16973588,J Virol. 2006 Oct;80(19):9837-49.,"Porotto M, Doctor L, Carta P, Fornabaio M, Greengard O, Kellogg GE, Moscona A.",Inhibition of hendra virus fusion.,10.1128/JVI.00736-06,,"Anti-HeV,Anti-HPIV3"
DRAVPe01311,VALDPIDISIELNKAKSDLEESKEWIRRSNQKLDSI,36,HPIV3 F HRC derived peptide(449-484),Synthetic construct(derived from HPIV3 fusion (F) protein),P06828,,"HeV,HPIV3",Paramyxoviridae,Luminescence fusion assay,[Ref.16973588]Henda virus(HeV):inhibition of virus infection in HeLa cells(IC50=20 nM);inhibition of fusion in HeLa cells(IC50=7.5 nM);##human parainfluenza virus 3 (HPIV3):inhibition of virus infection in HeLa cells(IC50=500 nM);inhibition of fusion in HeLa cells(IC50=500 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01311,DRAVPe01311.cif,Linear,Free,Free,,L,membrane,"The HeV receptor-binding protein (G) is required in order for the fusion protein (F) to mediate fusion.  HeV F, once triggered by the receptor-bound G, undergoes multistep conformational changes leading to a six-helix bundle (6HB) structure that accomplishes fusion of the viral and cellular membranes. Peptides derived from the HRN and HRC regions of F are proposed to inhibit fusion by preventing F, after the initial triggering step, from forming the 9HB structure that is required for fusion.",4154.69,C181H302N50O61,CFGHMTY,IS,4.77,6,8,-2,7,13,-66.94,-9571,100 hour,>20 hour,>10 hour,111.11,5500,157.14,16973588,J Virol. 2006 Oct;80(19):9837-49.,"Porotto M, Doctor L, Carta P, Fornabaio M, Greengard O, Kellogg GE, Moscona A.",Inhibition of hendra virus fusion.,10.1128/JVI.00736-06,,"Anti-HeV,Anti-HPIV3"
DRAVPe01312,VANDPIDISIELNKAKSDLEESKEWIRRSNQKLDSI,36,HPIV3 F HRC derived peptide(449-484)[L451N],Synthetic construct(derived from HPIV3 fusion (F) protein),P06828,,"HeV,HPIV3",Paramyxoviridae,Luminescence fusion assay,[Ref.16973588]Henda virus(HeV):inhibition of virus infection in HeLa cells(IC50=100 nM);inhibition of fusion in HeLa cells(IC50=3000 nM);##human parainfluenza virus 3 (HPIV3):inhibition of virus infection in HeLa cells(IC50=1100 nM);inhibition of fusion in HeLa cells(IC50=750 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01312,DRAVPe01312.cif,Linear,Free,Free,,L,membrane,"The HeV receptor-binding protein (G) is required in order for the fusion protein (F) to mediate fusion.  HeV F, once triggered by the receptor-bound G, undergoes multistep conformational changes leading to a six-helix bundle (6HB) structure that accomplishes fusion of the viral and cellular membranes. Peptides derived from the HRN and HRC regions of F are proposed to inhibit fusion by preventing F, after the initial triggering step, from forming the 11HB structure that is required for fusion.",4155.63,C179H297N51O62,CFGHMTY,IS,4.77,6,8,-2,8,12,-87.22,-10727,100 hour,>20 hour,>10 hour,100.28,5500,157.14,16973588,J Virol. 2006 Oct;80(19):9837-49.,"Porotto M, Doctor L, Carta P, Fornabaio M, Greengard O, Kellogg GE, Moscona A.",Inhibition of hendra virus fusion.,10.1128/JVI.00736-06,,"Anti-HeV,Anti-HPIV3"
DRAVPe01313,VALDPIDISIELNKAKSDLEESKEWIRRSNQKLDSD,36,HPIV3 F HRC derived peptide(449-484)[I484D],Synthetic construct(derived from HPIV3 fusion (F) protein),P06828,,"HeV,HPIV3",Paramyxoviridae,Luminescence fusion assay,[Ref.16973588]Henda virus(HeV):inhibition of virus infection in HeLa cells(IC50=100 nM);inhibition of fusion in HeLa cells(IC50=8000 nM);##human parainfluenza virus 3 (HPIV3):inhibition of virus infection in HeLa cells(IC50=500 nM);inhibition of fusion in HeLa cells(IC50=350 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01313,DRAVPe01313.cif,Linear,Free,Free,,L,membrane,"The HeV receptor-binding protein (G) is required in order for the fusion protein (F) to mediate fusion.  HeV F, once triggered by the receptor-bound G, undergoes multistep conformational changes leading to a six-helix bundle (6HB) structure that accomplishes fusion of the viral and cellular membranes. Peptides derived from the HRN and HRC regions of F are proposed to inhibit fusion by preventing F, after the initial triggering step, from forming the 12HB structure that is required for fusion.",4156.62,C179H296N50O63,CFGHMTY,DS,4.56,6,9,-3,7,12,-89.17,-10935,100 hour,>20 hour,>10 hour,100.28,5500,157.14,16973588,J Virol. 2006 Oct;80(19):9837-49.,"Porotto M, Doctor L, Carta P, Fornabaio M, Greengard O, Kellogg GE, Moscona A.",Inhibition of hendra virus fusion.,10.1128/JVI.00736-06,,"Anti-HeV,Anti-HPIV3"
DRAVPe01314,VANDPIDISIELNKAKSDLEESKEWIRRSNQKLDSD,36,"HPIV3 F HRC derived peptide(449-484)[L451N,I484D]",Synthetic construct(derived from HPIV3 fusion (F) protein),P06828,,"HeV,HPIV3",Paramyxoviridae,Luminescence fusion assay,[Ref.16973588]Henda virus(HeV):inhibition of virus infection in HeLa cells(IC50>10000 nM);inhibition of fusion in HeLa cells(IC50>1000 nM);##human parainfluenza virus 3 (HPIV3):inhibition of virus infection in HeLa cells(IC50=1100 nM);inhibition of fusion in HeLa cells(IC50=750 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01314,DRAVPe01314.cif,Linear,Free,Free,,L,membrane,"The HeV receptor-binding protein (G) is required in order for the fusion protein (F) to mediate fusion.  HeV F, once triggered by the receptor-bound G, undergoes multistep conformational changes leading to a six-helix bundle (6HB) structure that accomplishes fusion of the viral and cellular membranes. Peptides derived from the HRN and HRC regions of F are proposed to inhibit fusion by preventing F, after the initial triggering step, from forming the 13HB structure that is required for fusion.",4157.56,C177H291N51O64,CFGHMTY,DS,4.56,6,9,-3,8,11,-109.44,-12091,100 hour,>20 hour,>10 hour,89.44,5500,157.14,16973588,J Virol. 2006 Oct;80(19):9837-49.,"Porotto M, Doctor L, Carta P, Fornabaio M, Greengard O, Kellogg GE, Moscona A.",Inhibition of hendra virus fusion.,10.1128/JVI.00736-06,,"Anti-HeV,Anti-HPIV3"
DRAVPe01315,VALDPIDISIELNKAKSDLEESKEWIRR,28,HPIV3 F HRC derived peptide(449-476),Synthetic construct(derived from HPIV3 fusion (F) protein),P06828,,"HeV,HPIV3",Paramyxoviridae,Luminescence fusion assay,[Ref.16973588]Henda virus(HeV):inhibition of virus infection in HeLa cells(IC50>10000 nM);inhibition of fusion in HeLa cells(IC50>1000 nM);##human parainfluenza virus 3 (HPIV3):inhibition of virus infection in HeLa cells(IC50>10000 nM);inhibition of fusion in HeLa cells(IC50>10000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01315,DRAVPe01315.cif,Linear,Free,Free,,L,membrane,"The HeV receptor-binding protein (G) is required in order for the fusion protein (F) to mediate fusion.  HeV F, once triggered by the receptor-bound G, undergoes multistep conformational changes leading to a six-helix bundle (6HB) structure that accomplishes fusion of the viral and cellular membranes. Peptides derived from the HRN and HRC regions of F are proposed to inhibit fusion by preventing F, after the initial triggering step, from forming the 14HB structure that is required for fusion.",3268.71,C144H239N39O47,CFGHMQTY,EI,4.72,5,7,-2,4,11,-58.57,-7230,100 hour,>20 hour,>10 hour,115.0,5500,203.7,16973588,J Virol. 2006 Oct;80(19):9837-49.,"Porotto M, Doctor L, Carta P, Fornabaio M, Greengard O, Kellogg GE, Moscona A.",Inhibition of hendra virus fusion.,10.1128/JVI.00736-06,,"Anti-HeV,Anti-HPIV3"
DRAVPe01316,SIELNKAKSDLEESKEWIRRSNQKLDSI,28,HPIV3 F HRC derived peptide(457-484),Synthetic construct(derived from HPIV3 fusion (F) protein),P06828,,"HeV,HPIV3",Paramyxoviridae,Luminescence fusion assay,[Ref.16973588]Henda virus(HeV):inhibition of virus infection in HeLa cells(IC50>10000 nM);inhibition of fusion in HeLa cells(IC50>1000 nM);##human parainfluenza virus 3 (HPIV3):inhibition of virus infection in HeLa cells(IC50>10000 nM);inhibition of fusion in HeLa cells(IC50>10000 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01316,DRAVPe01316.cif,Linear,Free,Free,,L,membrane,"The HeV receptor-binding protein (G) is required in order for the fusion protein (F) to mediate fusion.  HeV F, once triggered by the receptor-bound G, undergoes multistep conformational changes leading to a six-helix bundle (6HB) structure that accomplishes fusion of the viral and cellular membranes. Peptides derived from the HRN and HRC regions of F are proposed to inhibit fusion by preventing F, after the initial triggering step, from forming the 15HB structure that is required for fusion.",3317.7,C142H238N42O49,CFGHMPTVY,S,6.06,6,6,0,7,8,-122.5,-9888,1.9 hour,>20 hour,>10 hour,87.14,5500,203.7,16973588,J Virol. 2006 Oct;80(19):9837-49.,"Porotto M, Doctor L, Carta P, Fornabaio M, Greengard O, Kellogg GE, Moscona A.",Inhibition of hendra virus fusion.,10.1128/JVI.00736-06,,"Anti-HeV,Anti-HPIV3"
DRAVPe01317,MANAGLQLLGFILAFLGW,18,CL58,Synthetic construct(derived from human claudin-1),O95832,,HCV,Flaviviridae,Pseudoviral particle infection assay,[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50=2.1 ± 0.5 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22378192]Huh7.5.1 cells:CC50~200 Μm.,DRAVPe01317,DRAVPe01317.cif,Linear,Free,Free,,L,membrane protein,The peptide inhibits virus entry in a postbinding step.,1935.36,C94H143N21O21S,CDEHKPRSTVY,L,5.28,0,0,0,4,12,151.67,3623,30 hour,>20 hour,>10 hour,146.67,5500,323.53,22378192,Hepatology. 2012 Aug;56(2):507-15. ,"Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. ",A human claudin-1-derived peptide inhibits hepatitis C virus entry.,10.1002/hep.25685,,Anti-HCV
DRAVPe01318,GLQLLGFILAFLGWIGAI,18,CL58.1,Synthetic construct(derived from human claudin-1),O95832,,HCV,Flaviviridae,Pseudoviral particle infection assay,[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50>25 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01318,DRAVPe01318.cif,Linear,Free,Free,,L,membrane protein,The peptide inhibits virus entry in a postbinding step.,1902.35,C96H148N20O20,CDEHKMNPRSTVY,L,5.52,0,0,0,4,13,198.33,4949,30 hour,>20 hour,>10 hour,184.44,5500,323.53,22378192,Hepatology. 2012 Aug;56(2):507-16. ,"Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. ",A human claudin-1-derived peptide inhibits hepatitis C virus entry.,10.1002/hep.25685,,Anti-HCV
DRAVPe01319,LLGFILAFLGWIGAIVST,18,CL58.2,Synthetic construct(derived from human claudin-1),O95832,,HCV,Flaviviridae,Pseudoviral particle infection assay,[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50=4.3 ± 0.3 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01319,DRAVPe01319.cif,Linear,Free,Free,,L,membrane protein,The peptide inhibits virus entry in a postbinding step.,1891.33,C95H147N19O21,CDEHKMNPQRY,L,5.52,0,0,0,5,13,213.89,4724,5.5 hour,3 min,2 min,178.89,5500,323.53,22378192,Hepatology. 2012 Aug;56(2):507-17. ,"Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. ",A human claudin-1-derived peptide inhibits hepatitis C virus entry.,10.1002/hep.25685,,Anti-HCV
DRAVPe01320,FILAFLGWIGAIVSTALP,18,CL58.3,Synthetic construct(derived from human claudin-1),O95832,,HCV,Flaviviridae,Pseudoviral particle infection assay,[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50=8.9± 1.0 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01320,DRAVPe01320.cif,Linear,Free,Free,,L,membrane protein,The peptide inhibits virus entry in a postbinding step.,1889.31,C95H145N19O21,CDEHKMNQRY,AIL,5.52,0,0,0,4,13,196.11,4319,1.1 hour,3 min,2 min,162.78,5500,323.53,22378192,Hepatology. 2012 Aug;56(2):507-18. ,"Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. ",A human claudin-1-derived peptide inhibits hepatitis C virus entry.,10.1002/hep.25685,,Anti-HCV
DRAVPe01321,AFLGWIGAIVSTALPQWR,18,CL58.4,Synthetic construct(derived from human claudin-1),O95832,,HCV,Flaviviridae,Pseudoviral particle infection assay,[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50=12.5± 1.5 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01321,DRAVPe01321.cif,Linear,Free,Free,,L,membrane protein,The peptide inhibits virus entry in a postbinding step.,1986.35,C96H144N24O22,CDEHKMNY,A,9.79,1,0,1,4,11,85.0,1224,4.4 hour,>20 hour,>10 hour,119.44,11000,647.06,22378192,Hepatology. 2012 Aug;56(2):507-19. ,"Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. ",A human claudin-1-derived peptide inhibits hepatitis C virus entry.,10.1002/hep.25685,,Anti-HCV
DRAVPe01322,GWIGAIVSTALPQWRIYS,18,CL58.5,Synthetic construct(derived from human claudin-1),O95832,,HCV,Flaviviridae,Pseudoviral particle infection assay,[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50=21.5± 1.9 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01322,DRAVPe01322.cif,Linear,Free,Free,,L,membrane protein,The peptide inhibits virus entry in a postbinding step.,2018.35,C96H144N24O24,CDEFHKMN,I,8.75,1,0,1,6,9,51.67,391,30 hour,>20 hour,>10 hour,113.89,12490,734.71,22378192,Hepatology. 2012 Aug;56(2):507-20. ,"Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. ",A human claudin-1-derived peptide inhibits hepatitis C virus entry.,10.1002/hep.25685,,Anti-HCV
DRAVPe01323,GAIVSTALPQWRIYSYAG,18,CL58.6,Synthetic construct(derived from human claudin-1),O95832,,HCV,Flaviviridae,Pseudoviral particle infection assay,[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50=23.8 ± 2.1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01323,DRAVPe01323.cif,Linear,Free,Free,,L,membrane protein,The peptide inhibits virus entry in a postbinding step.,1953.23,C91H137N23O25,CDEFHKMN,A,8.59,1,0,1,7,8,34.44,-167,30 hour,>20 hour,>10 hour,97.78,8480,498.82,22378192,Hepatology. 2012 Aug;56(2):507-21. ,"Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. ",A human claudin-1-derived peptide inhibits hepatitis C virus entry.,10.1002/hep.25685,,Anti-HCV
DRAVPe01324,VSTALPQWRIYSYAGDNI,18,CL58.7,Synthetic construct(derived from human claudin-1),O95832,,HCV,Flaviviridae,Pseudoviral particle infection assay,[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50>25 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01324,DRAVPe01324.cif,Linear,Free,Free,,L,membrane protein,The peptide inhibits virus entry in a postbinding step.,2054.29,C94H140N24O28,CEFHKM,AISY,5.81,1,1,0,7,7,-12.22,-1978,100 hour,>20 hour,>10 hour,92.22,8480,498.82,22378192,Hepatology. 2012 Aug;56(2):507-22. ,"Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. ",A human claudin-1-derived peptide inhibits hepatitis C virus entry.,10.1002/hep.25685,,Anti-HCV
DRAVPe01325,ALPQWRIYSYAGDNIVTA,18,CL58.8,Synthetic construct(derived from human claudin-1),O95832,,HCV,Flaviviridae,Pseudoviral particle infection assay,[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50>25 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01325,DRAVPe01325.cif,Linear,Free,Free,,L,membrane protein,The peptide inhibits virus entry in a postbinding step.,2038.29,C94H140N24O27,CEFHKM,A,5.88,1,1,0,6,8,2.22,-1457,4.4 hour,>20 hour,>10 hour,97.78,8480,498.82,22378192,Hepatology. 2012 Aug;56(2):507-23. ,"Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. ",A human claudin-1-derived peptide inhibits hepatitis C virus entry.,10.1002/hep.25685,,Anti-HCV
DRAVPe01326,MANAGLQLLGFILA,14,CL58-4,Synthetic construct(derived from human claudin-1),O95832,,HCV,Flaviviridae,Pseudoviral particle infection assay,[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50>25 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01326,DRAVPe01326.cif,Linear,Free,Free,,L,membrane protein,The peptide inhibits virus entry in a postbinding step.,1431.76,C66H110N16O17S,CDEHKPRSTVWY,L,5.28,0,0,0,3,9,157.14,2506,30 hour,>20 hour,>10 hour,160.71,0,0.0,22378192,Hepatology. 2012 Aug;56(2):507-24. ,"Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. ",A human claudin-1-derived peptide inhibits hepatitis C virus entry.,10.1002/hep.25685,,Anti-HCV
DRAVPe01327,MANAGLQLLGFILAFL,16,CL58-2,Synthetic construct(derived from human claudin-1),O95832,,HCV,Flaviviridae,Pseudoviral particle infection assay,[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50=7.6± 0.9 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01327,DRAVPe01327.cif,Linear,Free,Free,,L,membrane protein,The peptide inhibits virus entry in a postbinding step.,1692.09,C81H130N18O19S,CDEHKPRSTVWY,L,5.28,0,0,0,3,11,178.75,3296,30 hour,>20 hour,>10 hour,165.0,0,0.0,22378192,Hepatology. 2012 Aug;56(2):507-25. ,"Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. ",A human claudin-1-derived peptide inhibits hepatitis C virus entry.,10.1002/hep.25685,,Anti-HCV
DRAVPe01328,MANAGLQLLGFILAFLGWIG,20,CL58+2,Synthetic construct(derived from human claudin-1),O95832,,HCV,Flaviviridae,Pseudoviral particle infection assay,[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50=17.8 ± 1.1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01328,DRAVPe01328.cif,Linear,Free,Free,,L,membrane protein,The peptide inhibits virus entry in a postbinding step.,2105.57,C102H157N23O23S,CDEHKPRSTVY,L,5.28,0,0,0,5,13,157.0,4209,30 hour,>20 hour,>10 hour,151.5,5500,289.47,22378192,Hepatology. 2012 Aug;56(2):507-26. ,"Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. ",A human claudin-1-derived peptide inhibits hepatitis C virus entry.,10.1002/hep.25685,,Anti-HCV
DRAVPe01329,MANAGLQLLGFILAFLGWIGAI,22,CL58+4,Synthetic construct(derived from human claudin-1),O95832,,HCV,Flaviviridae,Pseudoviral particle infection assay,[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50=4.0 ± 0.3 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01329,DRAVPe01329.cif,Linear,Free,Free,,L,membrane protein,The peptide inhibits virus entry in a postbinding step.,2289.81,C111H173N25O25S,CDEHKPRSTVY,L,5.28,0,0,0,5,15,171.36,4882,30 hour,>20 hour,>10 hour,160.0,5500,261.9,22378192,Hepatology. 2012 Aug;56(2):507-27. ,"Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. ",A human claudin-1-derived peptide inhibits hepatitis C virus entry.,10.1002/hep.25685,,Anti-HCV
DRAVPe01330,MANAGLQLLGFILAFLGWIGAIVS,24,CL58+6,Synthetic construct(derived from human claudin-1),O95832,,HCV,Flaviviridae,Pseudoviral particle infection assay,[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50=5.1 ± 0.6 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01330,DRAVPe01330.cif,Linear,Free,Free,,L,membrane protein,The peptide inhibits virus entry in a postbinding step.,2476.02,C119H187N27O28S,CDEHKPRTY,L,5.28,0,0,0,6,16,171.25,4946,30 hour,>20 hour,>10 hour,158.75,5500,239.13,22378192,Hepatology. 2012 Aug;56(2):507-28. ,"Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. ",A human claudin-1-derived peptide inhibits hepatitis C virus entry.,10.1002/hep.25685,,Anti-HCV
DRAVPe01331,managlqllgfilaflgw,18,CL58.d,,No entry found,,HCV,Flaviviridae,Pseudoviral particle infection assay,[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50=1.8 ± 0.4 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01331,DRAVPe01331.cif,Linear,Free,Free,,D,membrane protein,The peptide inhibits virus entry in a postbinding step.,1935.36,H-34O-17,ACDEFGHIKLMNPQRSTVWY,ACDEFGHIKLMNPQRSTVWY,5.28,0,0,0,0,0,0.0,0,,,,0.0,0,0.0,22378192,Hepatology. 2012 Aug;56(2):507-29. ,"Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. ",A human claudin-1-derived peptide inhibits hepatitis C virus entry.,10.1002/hep.25685,,Anti-HCV
DRAVPe01332,AGALMFAWLLLGLQGIFN,18,CL58.S,Synthetic construct(derived from human claudin-1),O95832,,HCV,Flaviviridae,Pseudoviral particle infection assay,[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50>25 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01332,DRAVPe01332.cif,Linear,Free,Free,,L,membrane protein,The peptide inhibits virus entry in a postbinding step.,1935.36,C94H143N21O21S,CDEHKPRSTVY,L,5.57,0,0,0,4,12,151.67,3623,4.4 hour,>20 hour,>10 hour,146.67,5500,323.53,22378192,Hepatology. 2012 Aug;56(2):507-29. ,"Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. ",A human claudin-1-derived peptide inhibits hepatitis C virus entry.,10.1002/hep.25685,,Anti-HCV
DRAVPe01333,MASAGMQILGVVLTLLGW,18,CL-6,Synthetic construct(derived from human claudin-1),P56747,,HCV,Flaviviridae,Pseudoviral particle infection assay,[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50>25 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01333,DRAVPe01333.cif,Linear,Free,Free,,L,membrane protein,The peptide inhibits virus entry in a postbinding step.,1860.3,C85H142N20O22S2,CDEFHKNPRY,L,5.28,0,0,0,5,10,157.78,3464,30 hour,>20 hour,>10 hour,151.67,5500,323.53,22378192,Hepatology. 2012 Aug;56(2):507-30. ,"Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. ",A human claudin-1-derived peptide inhibits hepatitis C virus entry.,10.1002/hep.25685,,Anti-HCV
DRAVPe01334,MANSGLQLLGFSMALLGW,18,CL-7,Synthetic construct(derived from human claudin-1),Q3B794,,HCV,Flaviviridae,Pseudoviral particle infection assay,[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50>25 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01334,DRAVPe01334.cif,Linear,Free,Free,,L,membrane protein,The peptide inhibits virus entry in a postbinding step.,1909.29,C87H137N21O23S2,CDEHIKPRTVY,L,5.28,0,0,0,6,9,102.78,2207,30 hour,>20 hour,>10 hour,119.44,5500,323.53,22378192,Hepatology. 2012 Aug;56(2):507-31. ,"Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. ",A human claudin-1-derived peptide inhibits hepatitis C virus entry.,10.1002/hep.25685,,Anti-HCV
DRAVPe01335,MASTGLELLGMTLAVLGW,18,CL-9,Synthetic construct(derived from human claudin-1),O95484,,HCV,Flaviviridae,Pseudoviral particle infection assay,[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50>25 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01335,DRAVPe01335.cif,Linear,Free,Free,,L,membrane protein,The peptide inhibits virus entry in a postbinding step.,1863.26,C84H139N19O24S2,CDFHIKNPQRY,L,4.0,0,1,-1,6,9,126.67,2676,30 hour,>20 hour,>10 hour,135.56,5500,323.53,22378192,Hepatology. 2012 Aug;56(2):507-32. ,"Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. ",A human claudin-1-derived peptide inhibits hepatitis C virus entry.,10.1002/hep.25685,,Anti-HCV
DRAVPe01336,EELRVRLASHLRKLRKRLLRDADDLQKRLAVYEEQAQQIRLQAEAFQARLKSWFEPLVEDM,61,hEP-1,Synthetic construct(derived from human apolipoprotein E),P02649,,HCV,Flaviviridae,RT PCR,[Ref.22334503]hepatitis C virus(HCVpp):inhibition of infection in Huh7.5.1 cells(IC50=0.67 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22334503]Huh7.5.1 cell:CC50>100 μg/ ml(〜14μM).,DRAVPe01336,DRAVPe01336.cif,Linear,Free,Free,,L,,"hEP peptide blocks the binding of virus to cells, suggesting a role of apoE at the very early stage of HCV entry. ",7405.56,C327H539N101O93S,CGNT,L,9.4,14,11,3,3,25,-74.1,-18940,1 hour,30 min,>10 hour,102.46,6990,116.5,22334503,Hepatology. 2012 Aug;56(2):484-91.,"Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T.",Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding.,10.1002/hep.25665,,Anti-HCV
DRAVPe01337,CEELRVRLASHLRKLRKRLLRDADDLQKRLAVY,33,hEP-2,Synthetic construct(derived from human apolipoprotein E),P02649,,HCV,Flaviviridae,RT PCR,[Ref.22334503]hepatitis C virus(HCVpp):inhibition of infection in Huh7.5.1 cells(IC50=0.5 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01337,DRAVPe01337.cif,Linear,Free,Free,,L,Not found,"hEP peptide blocks the binding of virus to cells, suggesting a role of apoE at the very early stage of HCV entry. ",4034.79,C175H306N60O47S,FGIMNPTW,L,10.4,11,5,6,3,13,-69.09,-12046,1.2 hour,>20 hour,>10 hour,121.21,1490,46.56,22334503,Hepatology. 2012 Aug;56(2):484-91.,"Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T.",Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding.,10.1002/hep.25665,,Anti-HCV
DRAVPe01338,EELRVRLASHLRKLRKRLLRDADDLQKRLAVY,32,hEP-2/deltaCys,Synthetic construct(derived from human apolipoprotein E),P02649,,HCV,Flaviviridae,RT PCR,[Ref.22334503]hepatitis C virus(HCVpp):inhibition of infection in Huh7.5.1 cells(IC50>10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01338,DRAVPe01338.cif,Linear,Free,Free,,L,Not found,"hEP peptide blocks the binding of virus to cells, suggesting a role of apoE at the very early stage of HCV entry. ",3931.65,C172H301N59O46,CFGIMNPTW,L,10.87,11,5,6,2,13,-79.06,-12174,1 hour,30 min,>10 hour,125.0,1490,48.06,22334503,Hepatology. 2012 Aug;56(2):484-91.,"Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T.",Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding.,10.1002/hep.25665,,Anti-HCV
DRAVPe01339,CEEIRARLSTHLRKMRKRLMRDADDLQKRLAVY,33,mEP-2,Synthetic construct(derived from human apolipoprotein E),P02649,,HCV,Flaviviridae,RT PCR,[Ref.22334503]hepatitis C virus(HCVpp):inhibition of infection in Huh7.5.1 cells(IC50>10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01339,DRAVPe01339.cif,Linear,Free,Free,,L,Not found,"hEP peptide blocks the binding of virus to cells, suggesting a role of apoE at the very early stage of HCV entry. ",4072.83,C172H300N60O48S3,FGNPW,R,10.4,11,5,6,4,10,-93.33,-13221,1.2 hour,>20 hour,>10 hour,88.79,1490,46.56,22334503,Hepatology. 2012 Aug;56(2):484-91.,"Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T.",Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding.,10.1002/hep.25665,,Anti-HCV
DRAVPe01340,CEEQAQQIRLQAEAFQARLKSWFEPLVEDM,30,hEP-3,Synthetic construct(derived from human apolipoprotein E),P02649,,HCV,Flaviviridae,RT PCR,[Ref.22334503]hepatitis C virus(HCVpp):inhibition of infection in Huh7.5.1 cells(IC50>10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01340,DRAVPe01340.cif,Linear,Free,Free,,L,Not found,"hEP peptide blocks the binding of virus to cells, suggesting a role of apoE at the very early stage of HCV entry. ",3595.06,C158H245N43O49S2,GHNTY,EQ,4.42,3,6,-3,2,12,-58.0,-6638,1.2 hour,>20 hour,>10 hour,75.0,5500,189.66,22334503,Hepatology. 2012 Aug;56(2):484-91.,"Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T.",Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding.,10.1002/hep.25665,,Anti-HCV
DRAVPe01341,CVRLASHLRKLRKRLLRDADDL,22,hEP-4,Synthetic construct(derived from human apolipoprotein E),P02649,,HCV,Flaviviridae,RT PCR,[Ref.22334503]hepatitis C virus(HCVpp):inhibition of infection in Huh7.5.1 cells(IC50>10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01341,DRAVPe01341.cif,Linear,Free,Free,,L,Not found,"hEP peptide blocks the binding of virus to cells, suggesting a role of apoE at the very early stage of HCV entry. ",2648.17,C113H203N41O30S,EFGIMNPQTWY,L,10.79,8,3,5,2,9,-53.18,-8146,1.2 hour,>20 hour,>10 hour,128.64,0,0.0,22334503,Hepatology. 2012 Aug;56(2):484-91.,"Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T.",Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding.,10.1002/hep.25665,,Anti-HCV
DRAVPe01342,CIRLQAEAFQARLKSWFEPLV,21,hEP-5,Synthetic construct(derived from human apolipoprotein E),P02649,,HCV,Flaviviridae,RT PCR,[Ref.22334503]hepatitis C virus(HCVpp):inhibition of infection in Huh7.5.1 cells(IC50>10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01342,DRAVPe01342.cif,Linear,Free,Free,,L,Not found,"hEP peptide blocks the binding of virus to cells, suggesting a role of apoE at the very early stage of HCV entry. ",2505.96,C116H181N31O29S,DGHMNTY,AL,8.22,3,2,1,2,11,16.19,-2477,1.2 hour,>20 hour,>10 hour,102.38,5500,275.0,22334503,Hepatology. 2012 Aug;56(2):484-91.,"Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T.",Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding.,10.1002/hep.25665,,Anti-HCV
DRAVPe01343,VRLASHLRKLRKRLLRDADDLIRLQAEAFQARLKSWFEPLV,41,hEP-6,Synthetic construct(derived from human apolipoprotein E),P02649,,HCV,Flaviviridae,RT PCR,[Ref.22334503]hepatitis C virus(HCVpp):inhibition of infection in Huh7.5.1 cells(IC50>10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01343,DRAVPe01343.cif,Linear,Free,Free,,L,Not found,"hEP peptide blocks the binding of virus to cells, suggesting a role of apoE at the very early stage of HCV entry. ",4929.84,C223H372N70O56,CGMNTY,L,11.29,11,5,6,2,20,-32.44,-10879,100 hour,>20 hour,>10 hour,121.46,5500,137.5,22334503,Hepatology. 2012 Aug;56(2):484-91.,"Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T.",Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding.,10.1002/hep.25665,,Anti-HCV
DRAVPe01344,LRVRLASHLRKLRKRLLRDADDLQKRLAVY,30,hEP-7,Synthetic construct(derived from human apolipoprotein E),P02649,,HCV,Flaviviridae,RT PCR,[Ref.22334503]hepatitis C virus(HCVpp):inhibition of infection in Huh7.5.1 cells(IC50>10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01344,DRAVPe01344.cif,Linear,Free,Free,,L,Not found,"hEP peptide blocks the binding of virus to cells, suggesting a role of apoE at the very early stage of HCV entry. ",3673.42,C162H287N57O40,CEFGIMNPTW,L,11.63,11,3,8,2,13,-61.0,-10812,5.5 hour,3 min,2 min,133.33,1490,51.38,22334503,Hepatology. 2012 Aug;56(2):484-91.,"Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T.",Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding.,10.1002/hep.25665,,Anti-HCV
DRAVPe01345,EELRVRLASHLRKLRKRLLRDADDL,25,hEP-8,Synthetic construct(derived from human apolipoprotein E),P02649,,HCV,Flaviviridae,RT PCR,[Ref.22334503]hepatitis C virus(HCVpp):inhibition of infection in Huh7.5.1 cells(IC50>10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01345,DRAVPe01345.cif,Linear,Free,Free,,L,Not found,"hEP peptide blocks the binding of virus to cells, suggesting a role of apoE at the very early stage of HCV entry. ",3072.61,C132H235N47O37,CFGIMNPQTWY,L,10.74,9,5,4,1,10,-87.6,-10636,1 hour,30 min,>10 hour,128.8,0,0.0,22334503,Hepatology. 2012 Aug;56(2):484-91.,"Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T.",Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding.,10.1002/hep.25665,,Anti-HCV
DRAVPe01346,VRLASHLRKLRKRLLRDADDLQKRLAVY,28,hEP-9,Synthetic construct(derived from human apolipoprotein E),P02649,,HCV,Flaviviridae,RT PCR,[Ref.22334503]hepatitis C virus(HCVpp):inhibition of infection in Huh7.5.1 cells(IC50>10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01346,DRAVPe01346.cif,Linear,Free,Free,,L,Not found,"hEP peptide blocks the binding of virus to cells, suggesting a role of apoE at the very early stage of HCV entry. ",3404.07,C150H264N52O38,CEFGIMNPTW,L,11.38,10,3,7,2,12,-62.86,-9812,100 hour,>20 hour,>10 hour,128.93,1490,55.19,22334503,Hepatology. 2012 Aug;56(2):484-91.,"Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T.",Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding.,10.1002/hep.25665,,Anti-HCV
DRAVPe01347,CVRLASHLRKLRKRLLRDADDLQKRLAVY,29,hEP-10,Synthetic construct(derived from human apolipoprotein E),P02649,,HCV,Flaviviridae,RT PCR,[Ref.22334503]hepatitis C virus(HCVpp):inhibition of infection in Huh7.5.1 cells(IC50=0.8 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01347,DRAVPe01347.cif,Linear,Free,Free,,L,Not found,"hEP peptide blocks the binding of virus to cells, suggesting a role of apoE at the very early stage of HCV entry. ",3507.21,C153H269N53O39S,EFGIMNPTW,L,10.91,10,3,7,3,12,-52.07,-9684,1.2 hour,>20 hour,>10 hour,124.48,1490,53.21,22334503,Hepatology. 2012 Aug;56(2):484-91.,"Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T.",Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding.,10.1002/hep.25665,,Anti-HCV
DRAVPe01348,CLRVRLASHLRKLRKRLLRDADDL,24,hEP-11,Synthetic construct(derived from human apolipoprotein E),P02649,,HCV,Flaviviridae,RT PCR,[Ref.22334503]hepatitis C virus(HCVpp):inhibition of infection in Huh7.5.1 cells(IC50=4 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01348,DRAVPe01348.cif,Linear,Free,Free,,L,Not found,"hEP peptide blocks the binding of virus to cells, suggesting a role of apoE at the very early stage of HCV entry. ",2917.52,C125H226N46O32S,EFGIMNPQTWY,L,11.35,9,3,6,2,10,-51.67,-9146,1.2 hour,>20 hour,>10 hour,134.17,0,0.0,22334503,Hepatology. 2012 Aug;56(2):484-91.,"Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T.",Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding.,10.1002/hep.25665,,Anti-HCV
DRAVPe01349,CLRKLRKRLLRC,12,hEP-12,Synthetic construct(derived from human apolipoprotein E),P28995,,HCV,Flaviviridae,RT PCR,[Ref.22334503]hepatitis C virus(HCVpp):inhibition of infection in Huh7.5.1 cells(IC50>10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01349,DRAVPe01349.cif,Linear,Free,Free,,L,Not found,"hEP peptide blocks the binding of virus to cells, suggesting a role of apoE at the very early stage of HCV entry. ",1558.03,C66H128N26O13S2,ADEFGHIMNPQSTVWY,LR,11.56,6,0,6,2,4,-46.67,-4854,1.2 hour,>20 hour,>10 hour,130.0,125,11.36,22334503,Hepatology. 2012 Aug;56(2):484-91.,"Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T.",Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding.,10.1002/hep.25665,,Anti-HCV
DRAVPe01350,ECRSTSYAGAVVNDL,15,H2-(1-15),Synthetic construct(derived from HSV ribonucleotide reductase subunit 2),P10224,,HSV,Herpesviridae,Ribonucleotide reductase assay,[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=42 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01350,DRAVPe01350.cif,Linear,Free,Free,,L,ribonucleotide reductase,The peptide inhibits the activity of ribonucleotide rductase.,1584.72,C65H105N19O25S,FHIKMPQW,ASV,4.37,1,2,-1,7,5,-4.67,-2776,1 hour,30 min,>10 hour,78.0,1490,106.43,3040743,J Biol Chem. 1987 Sep 15;262(26):12413-6.,"Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P.",Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase.,Not available,,Anti-HSV
DRAVPe01351,STSYAGAVVNDL,12,H2-(4-15),Synthetic construct(derived from HSV ribonucleotide reductase subunit 2),P10224,,HSV,Herpesviridae,Ribonucleotide reductase assay,[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=29 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01351,DRAVPe01351.cif,Linear,Free,Free,,L,ribonucleotide reductase,The peptide inhibits the activity of ribonucleotide rductase.,1196.28,C51H81N13O20,CEFHIKMPQRW,ASV,3.8,0,1,-1,6,5,40.0,-731,1.9 hour,>20 hour,>10 hour,97.5,1490,135.45,3040743,J Biol Chem. 1987 Sep 15;262(26):12413-6.,"Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P.",Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase.,Not available,,Anti-HSV
DRAVPe01352,YAGAVVNDL,9,H2-(7-15),Synthetic construct(derived from HSV ribonucleotide reductase subunit 2),P10224,,HSV,Herpesviridae,Ribonucleotide reductase assay,[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=36-60 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01352,DRAVPe01352.cif,Linear,Free,Free,,L,ribonucleotide reductase,The peptide inhibits the activity of ribonucleotide rductase.,921.02,C41H64N10O14,CEFHIKMPQRSTW,AV,3.8,0,1,-1,3,5,78.89,206,2.8 hour,10 min,2 min,130.0,1490,186.25,3040743,J Biol Chem. 1987 Sep 15;262(26):12413-6.,"Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P.",Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase.,Not available,,Anti-HSV
DRAVPe01353,AGAVVNDL,8,H2-(8-15),Synthetic construct(derived from HSV ribonucleotide reductase subunit 2),P10224,,HSV,Herpesviridae,Ribonucleotide reductase assay,[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=283 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01353,DRAVPe01353.cif,Linear,Free,Free,,L,ribonucleotide reductase,The peptide inhibits the activity of ribonucleotide rductase.,757.84,C32H55N9O12,CEFHIKMPQRSTWY,AV,3.8,0,1,-1,2,5,105.0,220,4.4 hour,>20 hour,>10 hour,146.25,0,0.0,3040743,J Biol Chem. 1987 Sep 15;262(26):12413-6.,"Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P.",Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase.,Not available,,Anti-HSV
DRAVPe01354,GAVVNDL,7,H2-(9-15),Synthetic construct(derived from HSV ribonucleotide reductase subunit 2),P10224,,HSV,Herpesviridae,Ribonucleotide reductase assay,[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=225 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01354,DRAVPe01354.cif,Linear,Free,Free,,L,ribonucleotide reductase,The peptide inhibits the activity of ribonucleotide rductase.,686.76,C29H50N8O11,CEFHIKMPQRSTWY,V,3.8,0,1,-1,2,4,94.29,39,30 hour,>20 hour,>10 hour,152.86,0,0.0,3040743,J Biol Chem. 1987 Sep 15;262(26):12413-6.,"Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P.",Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase.,Not available,,Anti-HSV
DRAVPe01355,AVVNDL,6,H2-(10-15),Synthetic construct(derived from HSV ribonucleotide reductase subunit 2),P10224,,HSV,Herpesviridae,Ribonucleotide reductase assay,[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=190 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01355,DRAVPe01355.cif,Linear,Free,Free,,L,ribonucleotide reductase,The peptide inhibits the activity of ribonucleotide rductase.,629.71,C27H47N7O10,CEFGHIKMPQRSTWY,V,3.8,0,1,-1,1,4,116.67,-55,4.4 hour,>20 hour,>10 hour,178.33,0,0.0,3040743,J Biol Chem. 1987 Sep 15;262(26):12413-6.,"Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P.",Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase.,Not available,,Anti-HSV
DRAVPe01356,VVNDL,5,H2-(11-15),Synthetic construct(derived from HSV ribonucleotide reductase subunit 2),P10224,,HSV,Herpesviridae,Ribonucleotide reductase assay,[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=760 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01356,DRAVPe01356.cif,Linear,Free,Free,,L,ribonucleotide reductase,The peptide inhibits the activity of ribonucleotide rductase.,558.63,C24H42N6O9,ACEFGHIKMPQRSTWY,V,3.8,0,1,-1,1,3,104.0,-236,100 hour,>20 hour,>10 hour,194.0,0,0.0,3040743,J Biol Chem. 1987 Sep 15;262(26):12413-6.,"Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P.",Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase.,Not available,,Anti-HSV
DRAVPe01357,YAGAVVNDL,9,Ac-H2-(7-15),Synthetic construct,No entry found,,HSV,Herpesviridae,Ribonucleotide reductase assay,[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=20 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01357,DRAVPe01357.cif,Linear,Acetylation,Free,,L,ribonucleotide reductase,The peptide inhibits the activity of ribonucleotide rductase.,921.02,C41H64N10O14,CEFHIKMPQRSTW,AV,3.8,0,1,-1,3,5,78.89,206,2.8 hour,10 min,2 min,130.0,1490,186.25,3040743,J Biol Chem. 1987 Sep 15;262(26):12413-6.,"Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P.",Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase.,Not available,,Anti-HSV
DRAVPe01358,YAGAVVNDL,9,H2-(7-15) amide,Synthetic construct,No entry found,,HSV,Herpesviridae,Ribonucleotide reductase assay,[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=190 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01358,DRAVPe01358.cif,Linear,Free,Amidation,,L,ribonucleotide reductase,The peptide inhibits the activity of ribonucleotide rductase.,921.02,C41H64N10O14,CEFHIKMPQRSTW,AV,3.8,0,1,-1,3,5,78.89,206,2.8 hour,10 min,2 min,130.0,1490,186.25,3040743,J Biol Chem. 1987 Sep 15;262(26):12413-6.,"Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P.",Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase.,Not available,,Anti-HSV
DRAVPe01359,YAGAVVNDL,9,Ac-H2-(7-15) amide,Synthetic construct,No entry found,,HSV,Herpesviridae,Ribonucleotide reductase assay,[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=76 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01359,DRAVPe01359.cif,Linear,Acetylation,Amidation,,L,ribonucleotide reductase,The peptide inhibits the activity of ribonucleotide rductase.,921.02,C41H64N10O14,CEFHIKMPQRSTW,AV,3.8,0,1,-1,3,5,78.89,206,2.8 hour,10 min,2 min,130.0,1490,186.25,3040743,J Biol Chem. 1987 Sep 15;262(26):12413-6.,"Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P.",Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase.,Not available,,Anti-HSV
DRAVPe01360,VVNDL,5,Ac-H2-(11-15),Synthetic construct,No entry found,,HSV,Herpesviridae,Ribonucleotide reductase assay,[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=400 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01360,DRAVPe01360.cif,Linear,Acetylation,Free,,L,ribonucleotide reductase,The peptide inhibits the activity of ribonucleotide rductase.,558.63,C24H42N6O9,ACEFGHIKMPQRSTWY,V,3.8,0,1,-1,1,3,104.0,-236,100 hour,>20 hour,>10 hour,194.0,0,0.0,3040743,J Biol Chem. 1987 Sep 15;262(26):12413-6.,"Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P.",Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase.,Not available,,Anti-HSV
DRAVPe01361,YAVVNDL,7,[Tyr9]H2-(9-15),Synthetic construct,No entry found,,HSV,Herpesviridae,Ribonucleotide reductase assay,[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=340 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01361,DRAVPe01361.cif,Linear,Free,Free,,L,ribonucleotide reductase,The peptide inhibits the activity of ribonucleotide rductase.,792.89,C36H56N8O12,CEFGHIKMPQRSTW,V,3.8,0,1,-1,2,4,81.43,-69,2.8 hour,10 min,2 min,152.86,1490,248.33,3040743,J Biol Chem. 1987 Sep 15;262(26):12413-6.,"Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P.",Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase.,Not available,,Anti-HSV
DRAVPe01362,YAVVNDL,7,Ac-[Tyr9]H2-(9-15),Synthetic construct,No entry found,,HSV,Herpesviridae,Ribonucleotide reductase assay,[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=330 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01362,DRAVPe01362.cif,Linear,Acetylation,Free,,L,ribonucleotide reductase,The peptide inhibits the activity of ribonucleotide rductase.,792.89,C36H56N8O12,CEFGHIKMPQRSTW,V,3.8,0,1,-1,2,4,81.43,-69,2.8 hour,10 min,2 min,152.86,1490,248.33,3040743,J Biol Chem. 1987 Sep 15;262(26):12413-6.,"Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P.",Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase.,Not available,,Anti-HSV
DRAVPe01363,YGAVVNDL,8,[Tyr8]H2-(8-15),Synthetic construct,No entry found,,HSV,Herpesviridae,Ribonucleotide reductase assay,[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=330 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01363,DRAVPe01363.cif,Linear,Free,Free,,L,ribonucleotide reductase,The peptide inhibits the activity of ribonucleotide rductase.,849.94,C38H59N9O13,CEFHIKMPQRSTW,V,3.8,0,1,-1,3,4,66.25,25,2.8 hour,10 min,2 min,133.75,1490,212.86,3040743,J Biol Chem. 1987 Sep 15;262(26):12413-6.,"Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P.",Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase.,Not available,,Anti-HSV
DRAVPe01364,YGAVVNDL,8,Ac-[Tyr8]H2-(8-15),Synthetic construct,No entry found,,HSV,Herpesviridae,Ribonucleotide reductase assay,[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=150 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01364,DRAVPe01364.cif,Linear,Acetylation,Free,,L,ribonucleotide reductase,The peptide inhibits the activity of ribonucleotide rductase.,849.94,C38H59N9O13,CEFHIKMPQRSTW,V,3.8,0,1,-1,3,4,66.25,25,2.8 hour,10 min,2 min,133.75,1490,212.86,3040743,J Biol Chem. 1987 Sep 15;262(26):12413-6.,"Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P.",Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase.,Not available,,Anti-HSV
DRAVPe01365,AAGAVVNDL,9,[Ala7]H2-(7-15),Synthetic construct,No entry found,,HSV,Herpesviridae,Ribonucleotide reductase assay,[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=280 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01365,DRAVPe01365.cif,Linear,Free,Free,,L,ribonucleotide reductase,The peptide inhibits the activity of ribonucleotide rductase.,828.92,C35H60N10O13,CEFHIKMPQRSTWY,A,3.8,0,1,-1,2,6,113.33,401,4.4 hour,>20 hour,>10 hour,141.11,0,0.0,3040743,J Biol Chem. 1987 Sep 15;262(26):12413-6.,"Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P.",Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase.,Not available,,Anti-HSV
DRAVPe01366,yAGAVVNDL,9,[D-Tyr7]H2-(7-15),Synthetic construct,No entry found,,HSV,Herpesviridae,Ribonucleotide reductase assay,[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=200 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01366,DRAVPe01366.cif,Linear,Free,Free,,Mixed(D-Tyr1),ribonucleotide reductase,The peptide inhibits the activity of ribonucleotide rductase.,921.02,C32H53N9O11,CEFHIKMPQRSTWY,AV,3.8,0,1,-1,2,5,93.33,220,,,,130.0,0,0.0,3040743,J Biol Chem. 1987 Sep 15;262(26):12413-6.,"Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P.",Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase.,Not available,,Anti-HSV
DRAVPe01367,yAGAVVNDL,9,Ac-[D-Tyr7]H2-(7-15),Synthetic construct,No entry found,,HSV,Herpesviridae,Ribonucleotide reductase assay,[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=165 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01367,DRAVPe01367.cif,Linear,Acetylation,Free,,Mixed(D-Tyr1),ribonucleotide reductase,The peptide inhibits the activity of ribonucleotide rductase.,921.02,C32H53N9O11,CEFHIKMPQRSTWY,AV,3.8,0,1,-1,2,5,93.33,220,,,,130.0,0,0.0,3040743,J Biol Chem. 1987 Sep 15;262(26):12413-6.,"Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P.",Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase.,Not available,,Anti-HSV
DRAVPe01368,XAGAVVNDL,9,[Tyr7(OMe)]H2-(7-15),Synthetic construct,No entry found,,HSV,Herpesviridae,Ribonucleotide reductase assay,[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=88 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01368,DRAVPe01368.cif,Linear,Free,Free,The 'X' at position 1 is methoxy Tyrosine.,L,ribonucleotide reductase,The peptide inhibits the activity of ribonucleotide rductase.,869.17,C32H53N9O11,CEFHIKMPQRSTWY,AV,3.8,0,1,-1,2,5,93.33,220,,,,130.0,0,0.0,3040743,J Biol Chem. 1987 Sep 15;262(26):12413-6.,"Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P.",Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase.,Not available,,Anti-HSV
DRAVPe01369,XAGAVVNDL,9,Ac[Tyr7(OMe)]H2-(7-15),Synthetic construct,No entry found,,HSV,Herpesviridae,Ribonucleotide reductase assay,[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=40 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01369,DRAVPe01369.cif,Linear,Acetylation,Free,The 'X' at position 1 is methoxy Tyrosine.,L,ribonucleotide reductase,The peptide inhibits the activity of ribonucleotide rductase.,869.17,C32H53N9O11,CEFHIKMPQRSTWY,AV,3.8,0,1,-1,2,5,93.33,220,,,,130.0,0,0.0,3040743,J Biol Chem. 1987 Sep 15;262(26):12413-6.,"Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P.",Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase.,Not available,,Anti-HSV
DRAVPe01370,XAGAVVNDL,9,[desamino-Tyr7]H2-(7-15),Synthetic construct,No entry found,,HSV,Herpesviridae,Ribonucleotide reductase assay,[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=33 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01370,DRAVPe01370.cif,Linear,Free,Free,The 'X' at position 1 is 3-(4-hydroxyphenyl)propionic acid.,L,ribonucleotide reductase,The peptide inhibits the activity of ribonucleotide rductase.,869.17,C32H53N9O11,CEFHIKMPQRSTWY,AV,3.8,0,1,-1,2,5,93.33,220,,,,130.0,0,0.0,3040743,J Biol Chem. 1987 Sep 15;262(26):12413-6.,"Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P.",Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase.,Not available,,Anti-HSV
DRAVPe01371,YaGAVVNDL,9,[D-Ala8]H2-(7-15),Synthetic construct,No entry found,,HSV,Herpesviridae,Ribonucleotide reductase assay,[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=200 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01371,DRAVPe01371.cif,Linear,Free,Free,,Mixed(D-Ala2),ribonucleotide reductase,The peptide inhibits the activity of ribonucleotide rductase.,921.02,C38H57N9O12,CEFHIKMPQRSTW,V,3.8,0,1,-1,3,4,58.89,25,2.8 hour,10 min,2 min,118.89,1490,186.25,3040743,J Biol Chem. 1987 Sep 15;262(26):12413-6.,"Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P.",Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase.,Not available,,Anti-HSV
DRAVPe01372,YaGAVVNDL,9,Ac-[D-Ala8]H2-(7-15),Synthetic construct,No entry found,,HSV,Herpesviridae,Ribonucleotide reductase assay,[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=230 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01372,DRAVPe01372.cif,Linear,Acetylation,Free,,Mixed(D-Ala2),ribonucleotide reductase,The peptide inhibits the activity of ribonucleotide rductase.,921.02,C38H57N9O12,CEFHIKMPQRSTW,V,3.8,0,1,-1,3,4,58.89,25,2.8 hour,10 min,2 min,118.89,1490,186.25,3040743,J Biol Chem. 1987 Sep 15;262(26):12413-6.,"Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P.",Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase.,Not available,,Anti-HSV
DRAVPe01373,YXGAVVNDL,9,[β-Ala8]H2-(7-15),Synthetic construct,No entry found,,HSV,Herpesviridae,Ribonucleotide reductase assay,[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=100 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01373,DRAVPe01373.cif,Linear,Free,Free,The 'X' at position 2 is 3-aminoproprionic acid.,L,ribonucleotide reductase,The peptide inhibits the activity of ribonucleotide rductase.,961.27,C38H57N9O12,CEFHIKMPQRSTW,V,3.8,0,1,-1,3,4,58.89,25,2.8 hour,10 min,2 min,118.89,1490,186.25,3040743,J Biol Chem. 1987 Sep 15;262(26):12413-6.,"Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P.",Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase.,Not available,,Anti-HSV
DRAVPe01374,YAGAVANDL,9,[Ala12]H2-(7-15),Synthetic construct,No entry found,,HSV,Herpesviridae,Ribonucleotide reductase assay,[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=760 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01374,DRAVPe01374.cif,Linear,Free,Free,,L,ribonucleotide reductase,The peptide inhibits the activity of ribonucleotide rductase.,892.96,C39H60N10O14,CEFHIKMPQRSTW,A,3.8,0,1,-1,3,5,52.22,-17,2.8 hour,10 min,2 min,108.89,1490,186.25,3040743,J Biol Chem. 1987 Sep 15;262(26):12413-6.,"Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P.",Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase.,Not available,,Anti-HSV
DRAVPe01375,YTMLVVDDL,9,EBV H2-(7-15),Synthetic construct(derived from EBV ribonucleotide reductase subunit 2),No entry found,,HSV,Herpesviridae,Ribonucleotide reductase assay,[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=110 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01375,DRAVPe01375.cif,Linear,Free,Free,,L,ribonucleotide reductase,The peptide inhibits the activity of ribonucleotide rductase.,1068.25,C48H77N9O16S,ACEFGHIKNPQRSW,DLV,3.56,0,2,-2,2,4,98.89,12,2.8 hour,10 min,2 min,151.11,1490,186.25,3040743,J Biol Chem. 1987 Sep 15;262(26):12413-6.,"Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P.",Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase.,Not available,,Anti-HSV
DRAVPe01376,YAGTVINDL,9,VZV H2-(7-15),Synthetic construct(derived from VZV ribonucleotide reductase subunit 2),No entry found,,HSV,Herpesviridae,Ribonucleotide reductase assay,[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=15 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01376,DRAVPe01376.cif,Linear,Free,Free,,L,ribonucleotide reductase,The peptide inhibits the activity of ribonucleotide rductase.,965.07,C43H68N10O15,CEFHKMPQRSW,ADGILNTVY,3.8,0,1,-1,4,4,54.44,-144,2.8 hour,10 min,2 min,130.0,1490,186.25,3040743,J Biol Chem. 1987 Sep 15;262(26):12413-6.,"Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P.",Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase.,Not available,,Anti-HSV
DRAVPe01377,FKLRAKIKVRLRAKIKL,17,D4E1,Synthetic construct,No entry found,,FIV,Retroviridae,reverse transcriptase (RT) assay,[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=0.46 μM);##Feline immunodeficiency virus(FIV-Black):inhibition of reverse transcriptase activity in CrFK cells(IC50=0.43 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12208971]CrFK cell:TC50=5.90 μM.,DRAVPe01377,DRAVPe01377.cif,Linear,Free,Free,,L,Not found,The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions.,2081.71,C98H181N31O18,CDEGHMNPQSTWY,K,12.32,8,0,8,0,9,-11.76,-3727,1.1 hour,3 min,2 min,143.53,0,0.0,12208971,J Virol. 2002 Oct;76(19):9952-61.,"Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA.",Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. ,10.1128/jvi.76.19.9952-9961.2002,,Anti-FIV
DRAVPe01378,FAVAVKAVAVKAVAVKAVKKAVKKVKKAVKKAVKKKK,37,DC1,Synthetic construct,No entry found,,FIV,Retroviridae,reverse transcriptase (RT) assay,[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=0.75 μM);##Feline immunodeficiency virus(FIV-Black):inhibition of reverse transcriptase activity in CrFK cells(IC50=0.78 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12208971]CrFK cell:TC50=9.20 μM.,DRAVPe01378,DRAVPe01378.cif,Linear,Free,Free,,L,Not found,The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions.,3889.05,C184H340N52O38,CDEGHILMNPQRSTWY,K,11.15,15,0,15,0,22,22.97,-1773,1.1 hour,3 min,2 min,113.24,0,0.0,12208971,J Virol. 2002 Oct;76(19):9952-61.,"Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA.",Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. ,10.1128/jvi.76.19.9952-9961.2002,,Anti-FIV
DRAVPe01379,FLAAARIAKRVAKKARKLAKRAARKRK,27,D1D6,Synthetic construct,No entry found,,FIV,Retroviridae,reverse transcriptase (RT) assay,[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=0.94 μM);##Feline immunodeficiency virus(FIV-Black):inhibition of reverse transcriptase activity in CrFK cells(IC50=1.47 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12208971]CrFK cell:TC50=8.93 μM.,DRAVPe01379,DRAVPe01379.cif,Linear,Free,Free,,L,Not found,The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions.,3077.86,C137H254N52O28,CDEGHMNPQSTWY,A,12.71,13,0,13,0,14,-70.37,-9030,1.1 hour,3 min,2 min,87.41,0,0.0,12208971,J Virol. 2002 Oct;76(19):9952-61.,"Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA.",Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. ,10.1128/jvi.76.19.9952-9961.2002,,Anti-FIV
DRAVPe01380,FRFKIKFRLKFRFKARFKFRAKFRA,25,D4C3,Synthetic construct,No entry found,,FIV,Retroviridae,reverse transcriptase (RT) assay,[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=1.32 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12208971]CrFK cell:TC50=3.81 μM.,DRAVPe01380,DRAVPe01380.cif,Linear,Free,Free,,L,Not found,The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions.,3341.15,C165H255N49O26,CDEGHMNPQSTVWY,F,12.71,12,0,12,0,13,-57.2,-8371,1.1 hour,3 min,2 min,43.2,0,0.0,12208971,J Virol. 2002 Oct;76(19):9952-61.,"Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA.",Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. ,10.1128/jvi.76.19.9952-9961.2002,,Anti-FIV
DRAVPe01381,FAVGLRAIKRALKKLRRGVRKVAKDL,26,D5F,Synthetic construct,No entry found,,FIV,Retroviridae,reverse transcriptase (RT) assay,[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=5.47 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12208971]CrFK cell:TC50=8.73 μM.,DRAVPe01381,DRAVPe01381.cif,Linear,Free,Free,,L,Not found,The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions.,2963.7,C134H244N46O29,CEHMNPQSTWY,KR,12.19,10,1,9,2,13,-15.38,-6225,1.1 hour,3 min,2 min,123.85,0,0.0,12208971,J Virol. 2002 Oct;76(19):9952-61.,"Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA.",Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. ,10.1128/jvi.76.19.9952-9961.2002,,Anti-FIV
DRAVPe01382,KRKRAVKRVGRRLKKLARKIARLGVAKLAGLRAVKLF,37,D5C1,Synthetic construct,No entry found,,FIV,Retroviridae,reverse transcriptase (RT) assay,[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=3.38 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12208971]CrFK cell:TC50=5.26 μM.,DRAVPe01382,DRAVPe01382.cif,Linear,Free,Free,,L,Not found,The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions.,4226.36,C191H355N69O38,CDEHMNPQSTWY,KR,12.85,16,0,16,3,18,-28.92,-9650,1.3 hour,3 min,2 min,121.35,0,0.0,12208971,J Virol. 2002 Oct;76(19):9952-61.,"Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA.",Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. ,10.1128/jvi.76.19.9952-9961.2002,,Anti-FIV
DRAVPe01383,GAKKGAKKGKKGAKKGAKGAGAKGAGAFKKKK,32,D2B15,Synthetic construct,No entry found,,FIV,Retroviridae,reverse transcriptase (RT) assay,[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=4.07 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12208971]CrFK cell:TC50=6.19 μM.,DRAVPe01383,DRAVPe01383.cif,Linear,Free,Free,,L,Not found,The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions.,3041.73,C135H246N46O33,CDEHILMNPQRSTVWY,K,11.11,14,0,14,9,9,-128.13,-5178,30 hour,>20 hour,>10 hour,25.0,0,0.0,12208971,J Virol. 2002 Oct;76(19):9952-61.,"Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA.",Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. ,10.1128/jvi.76.19.9952-9961.2002,,Anti-FIV
DRAVPe01384,FAKKFAKKFKKFAKKFAKFAFAF,23,D2A21,Synthetic construct,No entry found,,FIV,Retroviridae,reverse transcriptase (RT) assay,[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=3.05 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12208971]CrFK cell:TC50=3.43 μM.,DRAVPe01384,DRAVPe01384.cif,Linear,Free,Free,,L,Not found,The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions.,2775.47,C144H212N32O24,CDEGHILMNPQRSTVWY,K,10.9,9,0,9,0,14,-8.26,-1525,1.1 hour,3 min,2 min,26.09,0,0.0,12208971,J Virol. 2002 Oct;76(19):9952-61.,"Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA.",Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. ,10.1128/jvi.76.19.9952-9961.2002,,Anti-FIV
DRAVPe01385,KKKKFVKKVAKKVKKVAKKVAKVAVAV,27,D2A3,Synthetic construct,No entry found,,FIV,Retroviridae,reverse transcriptase (RT) assay,[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=3.00 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12208971]CrFK cell:TC50=3.24 μM.,DRAVPe01385,DRAVPe01385.cif,Linear,Free,Free,,L,Not found,The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions.,2979.91,C142H264N40O28,CDEGHILMNPQRSTWY,K,11.08,13,0,13,0,14,-19.63,-2780,1.3 hour,3 min,2 min,104.44,0,0.0,12208971,J Virol. 2002 Oct;76(19):9952-61.,"Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA.",Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. ,10.1128/jvi.76.19.9952-9961.2002,,Anti-FIV
DRAVPe01386,FLFAFRIFKRVFKKFRKLFKRAF,23,D1A22,Synthetic construct,No entry found,,FIV,Retroviridae,reverse transcriptase (RT) assay,[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=10.51 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12208971]CrFK cell:TC50=10.79 μM.,DRAVPe01386,DRAVPe01386.cif,Linear,Free,Free,,L,Not found,The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions.,3041.82,C155H234N40O24,CDEGHMNPQSTWY,F,12.49,9,0,9,0,14,20.87,-4117,1.1 hour,3 min,2 min,72.17,0,0.0,12208971,J Virol. 2002 Oct;76(19):9952-61.,"Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA.",Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. ,10.1128/jvi.76.19.9952-9961.2002,,Anti-FIV
DRAVPe01387,KRKRAVKRVGRRLKKKLARKIARLGVAF,28,D5C,Synthetic construct,No entry found,,FIV,Retroviridae,reverse transcriptase (RT) assay,[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=7.82 μM);##Feline immunodeficiency virus(FIV-Black):inhibition of reverse transcriptase activity in CrFK cells(IC50=6.84 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12208971]CrFK cell:TC50=7.48 μM.,DRAVPe01387,DRAVPe01387.cif,Linear,Free,Free,,L,Not found,The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions.,3304.18,C148H276N56O29,CDEHMNPQSTWY,KR,12.78,14,0,14,2,12,-75.36,-9939,1.3 hour,3 min,2 min,101.07,0,0.0,12208971,J Virol. 2002 Oct;76(19):9952-61.,"Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA.",Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. ,10.1128/jvi.76.19.9952-9961.2002,,Anti-FIV
DRAVPe01388,KRKRFAKKFLRFLRKVIRFLKRFIRRF,27,D3A15,Synthetic construct,No entry found,,FIV,Retroviridae,reverse transcriptase (RT) assay,[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=3.69 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12208971]CrFK cell:TC50=3.28 μM.,DRAVPe01388,DRAVPe01388.cif,Linear,Free,Free,,L,Not found,The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions.,3655.63,C176H293N57O28,CDEGHMNPQSTWY,R,12.85,14,0,14,0,13,-60.0,-10433,1.3 hour,3 min,2 min,86.67,0,0.0,12208971,J Virol. 2002 Oct;76(19):9952-61.,"Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA.",Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. ,10.1128/jvi.76.19.9952-9961.2002,,Anti-FIV
DRAVPe01389,FALALKALKKALKKLKKALKKAL,23,DP1,Synthetic construct,No entry found,,FIV,Retroviridae,reverse transcriptase (RT) assay,[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=7.07 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12208971]CrFK cell:TC50=5.17 μM.,DRAVPe01389,DRAVPe01389.cif,Linear,Free,Free,,L,Not found,The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions.,2537.35,C123H226N32O24,CDEGHIMNPQRSTVWY,K,10.9,9,0,9,0,14,22.17,-167,1.1 hour,3 min,2 min,144.78,0,0.0,12208971,J Virol. 2002 Oct;76(19):9952-61.,"Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA.",Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. ,10.1128/jvi.76.19.9952-9961.2002,,Anti-FIV
DRAVPe01390,FAIAIKAIKKAIKKIKKAIKKAI,23,D1D2,Synthetic construct,No entry found,,FIV,Retroviridae,reverse transcriptase (RT) assay,[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=8.71 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12208971]CrFK cell:TC50=5.87 μM.,DRAVPe01390,DRAVPe01390.cif,Linear,Free,Free,,L,Not found,The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions.,2537.35,C123H226N32O24,CDEGHLMNPQRSTVWY,K,10.9,9,0,9,0,14,43.48,-167,1.1 hour,3 min,2 min,144.78,0,0.0,12208971,J Virol. 2002 Oct;76(19):9952-61.,"Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA.",Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. ,10.1128/jvi.76.19.9952-9961.2002,,Anti-FIV
DRAVPe01391,FKVKAKVKAKVKAKVKAKKKK,21,D4B,Synthetic construct,No entry found,,FIV,Retroviridae,reverse transcriptase (RT) assay,[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=2.85 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12208971]CrFK cell:TC50=0.92 μM.,DRAVPe01391,DRAVPe01391.cif,Linear,Free,Free,,L,Not found,The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions.,2384.13,C113H211N33O22,CDEGHILMNPQRSTWY,K,11.04,12,0,12,0,9,-95.24,-4022,1.1 hour,3 min,2 min,74.29,0,0.0,12208971,J Virol. 2002 Oct;76(19):9952-61.,"Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA.",Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. ,10.1128/jvi.76.19.9952-9961.2002,,Anti-FIV
DRAVPe01392,AVKRVGRRLKKLARKIARLGVAF,23,D5D,Synthetic construct,No entry found,,FIV,Retroviridae,reverse transcriptase (RT) assay,[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=3.37 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01392,DRAVPe01392.cif,Linear,Free,Free,,L,Not found,The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions.,2607.28,C118H216N42O24,CDEHMNPQSTWY,R,12.61,9,0,9,2,12,-1.74,-5290,4.4 hour,>20 hour,>10 hour,123.04,0,0.0,12208971,J Virol. 2002 Oct;76(19):9952-61.,"Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA.",Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. ,10.1128/jvi.76.19.9952-9961.2002,,Anti-FIV
DRAVPe01393,LPRRLHLEPAFLPYSVKAHECC,22,UL54(1221-1242),Synthetic construct(derived from human cytomegalovirus(HCMV) UL54 protein),P08546,,HCMV,Herpesviridae,ELISA,[Ref.12857903]human cytomegalovirus(HCMV):inhibition of phyical interaction between UL54 and UL44(IC50=11 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01393,DRAVPe01393.cif,Linear,Free,Free,,L,DNA polymerase,"Peptide derived from C-terminus of UL54 can block the physical interaction between UL54 and UL44,thus inhibits the activity of DNA polymerase.",2580.06,C117H183N33O29S2,DGIMNQTW,L,8.06,5,2,3,4,8,-10.91,-2899,5.5 hour,3 min,2 min,93.18,1615,76.9,12857903,J Virol. 2003 Aug;77(15):8336-44.,"Loregian A, Rigatti R, Murphy M, Schievano E, Palu G, Marsden HS.",Inhibition of human cytomegalovirus DNA polymerase by C-terminal peptides from the UL54 subunit.,10.1128/jvi.77.15.8336-8344.2003,,Anti-HCMV
DRAVPe01394,PGGETARKDKFLHMVLPRRL,20,UL54(1206-1225),Synthetic construct(derived from human cytomegalovirus(HCMV) UL54 protein),P08546,,HCMV,Herpesviridae,ELISA,[Ref.12857903]human cytomegalovirus(HCMV):inhibition of phyical interaction between UL54 and UL44(IC50>500 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01394,DRAVPe01394.cif,Linear,Free,Free,,L,DNA polymerase,"Peptide derived from C-terminus of UL54 can block the physical interaction between UL54 and UL44,thus inhibits the activity of DNA polymerase.",2321.77,C103H173N33O26S,CINQSWY,LR,10.91,6,2,4,3,6,-70.5,-5080,>20 hour,>20 hour,?,78.0,0,0.0,12857903,J Virol. 2003 Aug;77(15):8336-44.,"Loregian A, Rigatti R, Murphy M, Schievano E, Palu G, Marsden HS.",Inhibition of human cytomegalovirus DNA polymerase by C-terminal peptides from the UL54 subunit.,10.1128/jvi.77.15.8336-8344.2003,,Anti-HCMV
DRAVPe01395,EQVLKAVTNVLSPVFPGGET,20,UL54(1191-1210),Synthetic construct(derived from human cytomegalovirus(HCMV) UL54 protein),P08546,,HCMV,Herpesviridae,ELISA,[Ref.12857903]human cytomegalovirus(HCMV):inhibition of phyical interaction between UL54 and UL44(IC50=280 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01395,DRAVPe01395.cif,Linear,Free,Free,,L,DNA polymerase,"Peptide derived from C-terminus of UL54 can block the physical interaction between UL54 and UL44,thus inhibits the activity of DNA polymerase.",2085.39,C94H153N23O30,CDHIMRWY,V,4.53,1,2,-1,6,8,24.5,-722,1 hour,30 min,>10 hour,102.0,0,0.0,12857903,J Virol. 2003 Aug;77(15):8336-44.,"Loregian A, Rigatti R, Murphy M, Schievano E, Palu G, Marsden HS.",Inhibition of human cytomegalovirus DNA polymerase by C-terminal peptides from the UL54 subunit.,10.1128/jvi.77.15.8336-8344.2003,,Anti-HCMV
DRAVPe01396,YVREHGVPIHADKYFEQVLK,20,UL54(1176-1195),Synthetic construct(derived from human cytomegalovirus(HCMV) UL54 protein),P08546,,HCMV,Herpesviridae,ELISA,[Ref.12857903]human cytomegalovirus(HCMV):inhibition of phyical interaction between UL54 and UL44(IC50>500 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01396,DRAVPe01396.cif,Linear,Free,Free,,L,DNA polymerase,"Peptide derived from C-terminus of UL54 can block the physical interaction between UL54 and UL44,thus inhibits the activity of DNA polymerase.",2428.78,C113H170N30O30,CMNSTW,V,6.92,5,3,2,3,7,-59.0,-3581,2.8 hour,10 min,2 min,87.5,2980,156.84,12857903,J Virol. 2003 Aug;77(15):8336-44.,"Loregian A, Rigatti R, Murphy M, Schievano E, Palu G, Marsden HS.",Inhibition of human cytomegalovirus DNA polymerase by C-terminal peptides from the UL54 subunit.,10.1128/jvi.77.15.8336-8344.2003,,Anti-HCMV
DRAVPe01397,PPSAVCNYEVAEDPSYVREH,20,UL54(1161-1180),Synthetic construct(derived from human cytomegalovirus(HCMV) UL54 protein),P08546,,HCMV,Herpesviridae,ELISA,[Ref.12857903]human cytomegalovirus(HCMV):inhibition of phyical interaction between UL54 and UL44(IC50>500 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01397,DRAVPe01397.cif,Linear,Free,Free,,L,DNA polymerase,"Peptide derived from C-terminus of UL54 can block the physical interaction between UL54 and UL44,thus inhibits the activity of DNA polymerase.",2262.44,C98H144N26O34S,FGIKLMQTW,EPV,4.4,2,4,-2,6,5,-77.5,-4543,>20 hour,>20 hour,?,53.5,2980,156.84,12857903,J Virol. 2003 Aug;77(15):8336-44.,"Loregian A, Rigatti R, Murphy M, Schievano E, Palu G, Marsden HS.",Inhibition of human cytomegalovirus DNA polymerase by C-terminal peptides from the UL54 subunit.,10.1128/jvi.77.15.8336-8344.2003,,Anti-HCMV
DRAVPe01398,RRLHLEPAFLPYSVKAHECC,20,UL54(1223-1242),Synthetic construct(derived from human cytomegalovirus(HCMV) UL54 protein),P08546,,HCMV,Herpesviridae,ELISA,[Ref.12857903]human cytomegalovirus(HCMV):inhibition of phyical interaction between UL54 and UL44(IC50=20 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01398,DRAVPe01398.cif,Linear,Free,Free,,L,DNA polymerase,"Peptide derived from C-terminus of UL54 can block the physical interaction between UL54 and UL44,thus inhibits the activity of DNA polymerase.",2369.79,C106H165N31O27S2,DGIMNQTW,L,8.06,5,2,3,4,7,-23.0,-3391,1 hour,2 min,2 min,83.0,1615,85.0,12857903,J Virol. 2003 Aug;77(15):8336-44.,"Loregian A, Rigatti R, Murphy M, Schievano E, Palu G, Marsden HS.",Inhibition of human cytomegalovirus DNA polymerase by C-terminal peptides from the UL54 subunit.,10.1128/jvi.77.15.8336-8344.2003,,Anti-HCMV
DRAVPe01399,LPRRLHLEPAFLPYSVKAHEC,21,UL54(1221-1241),Synthetic construct(derived from human cytomegalovirus(HCMV) UL54 protein),P08546,,HCMV,Herpesviridae,ELISA,[Ref.12857903]human cytomegalovirus(HCMV):inhibition of phyical interaction between UL54 and UL44(IC50=75 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01399,DRAVPe01399.cif,Linear,Free,Free,,L,DNA polymerase,"Peptide derived from C-terminus of UL54 can block the physical interaction between UL54 and UL44,thus inhibits the activity of DNA polymerase.",2476.93,C114H178N32O28S,DGIMNQTW,L,8.22,5,2,3,3,8,-23.33,-3027,5.5 hour,3 min,2 min,97.62,1490,74.5,12857903,J Virol. 2003 Aug;77(15):8336-44.,"Loregian A, Rigatti R, Murphy M, Schievano E, Palu G, Marsden HS.",Inhibition of human cytomegalovirus DNA polymerase by C-terminal peptides from the UL54 subunit.,10.1128/jvi.77.15.8336-8344.2003,,Anti-HCMV
DRAVPe01400,LPRRLHLEPAFLPYSVKAHE,20,UL54(1221-1240),Synthetic construct(derived from human cytomegalovirus(HCMV) UL54 protein),P08546,,HCMV,Herpesviridae,ELISA,[Ref.12857903]human cytomegalovirus(HCMV):inhibition of phyical interaction between UL54 and UL44(IC50>500 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01400,DRAVPe01400.cif,Linear,Free,Free,,L,DNA polymerase,"Peptide derived from C-terminus of UL54 can block the physical interaction between UL54 and UL44,thus inhibits the activity of DNA polymerase.",2373.79,C111H173N31O27,CDGIMNQTW,L,8.6,5,2,3,2,8,-37.0,-3155,5.5 hour,3 min,2 min,102.5,1490,78.42,12857903,J Virol. 2003 Aug;77(15):8336-44.,"Loregian A, Rigatti R, Murphy M, Schievano E, Palu G, Marsden HS.",Inhibition of human cytomegalovirus DNA polymerase by C-terminal peptides from the UL54 subunit.,10.1128/jvi.77.15.8336-8344.2003,,Anti-HCMV
DRAVPe01401,ACFPWGNTWCGGK,13,NTW (S-S),Synthetic construct,No entry found,,HCV,Flaviviridae,Surface plasmon resonance,[Ref.12951030]Hepatitis C virus(HCV):inhibition of polymerase activity(IC50=13.0 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01401,DRAVPe01401.cif,Cyclic,Free,Free,Disulfide bond between Cys2 and Cys10,L,RNA-dependent RNA polymerase,"The peptide inhibits the de novo synthesis catalyzed by the enzyme, which suggests that it likely inhibited the formation of a preinitiation complex between the enzyme and the 3′OH end of the linear poly (C) substrate.",1426.63,C65H87N17O16S2,DEHILMQRSVY,G,8.1,1,0,1,7,4,-23.85,7,4.4 hour,>20 hour,>10 hour,7.69,11125,927.08,12951030,Virology. 2003 Aug 15;313(1):158-69.,"Amin A, Zaccardi J, Mullen S, Olland S, Orlowski M, Feld B, Labonte P, Mak P.",Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase.,10.1016/s0042-6822(03)00313-1,,Anti-HCV
DRAVPe01402,ACFPWGNTWCGGK,13,NTW (L),Synthetic construct,No entry found,,HCV,Flaviviridae,Surface plasmon resonance,[Ref.12951030]Hepatitis C virus(HCV):inhibition of polymerase activity(IC50>150 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01402,DRAVPe01402.cif,Linear,Free,Free,,L,RNA-dependent RNA polymerase,"The peptide inhibits the de novo synthesis catalyzed by the enzyme, which suggests that it likely inhibited the formation of a preinitiation complex between the enzyme and the 3′OH end of the linear poly (C) substrate.",1426.63,C65H87N17O16S2,DEHILMQRSVY,G,8.1,1,0,1,7,4,-23.85,7,4.4 hour,>20 hour,>10 hour,7.69,11125,927.08,12951030,Virology. 2003 Aug 15;313(1):158-69.,"Amin A, Zaccardi J, Mullen S, Olland S, Orlowski M, Feld B, Labonte P, Mak P.",Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase.,10.1016/s0042-6822(03)00313-1,,Anti-HCV
DRAVPe01403,ACFPWGKEYCGGK,13,KEY (S-S),Synthetic construct,No entry found,,HCV,Flaviviridae,Surface plasmon resonance,[Ref.12951030]Hepatitis C virus(HCV):inhibition of polymerase activity(IC50=22.0 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01403,DRAVPe01403.cif,Cyclic,Free,Free,Disulfide bond between Cys2 and Cys10,L,RNA-dependent RNA polymerase,"The peptide inhibits the de novo synthesis catalyzed by the enzyme, which suggests that it likely inhibited the formation of a preinitiation complex between the enzyme and the 3′OH end of the linear poly (C) substrate.",1445.67,C66H92N16O17S2,DHILMNQRSTV,G,8.07,2,1,1,6,3,-51.54,-555,4.4 hour,>20 hour,>10 hour,7.69,7115,592.92,12951030,Virology. 2003 Aug 15;313(1):158-69.,"Amin A, Zaccardi J, Mullen S, Olland S, Orlowski M, Feld B, Labonte P, Mak P.",Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase.,10.1016/s0042-6822(03)00313-1,,Anti-HCV
DRAVPe01404,ACFPWGKEYCGGK,13,KEY (L),Synthetic construct,No entry found,,HCV,Flaviviridae,Surface plasmon resonance,[Ref.12951030]Hepatitis C virus(HCV):inhibition of polymerase activity(IC50>150 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01404,DRAVPe01404.cif,Linear,Free,Free,,L,RNA-dependent RNA polymerase,"The peptide inhibits the de novo synthesis catalyzed by the enzyme, which suggests that it likely inhibited the formation of a preinitiation complex between the enzyme and the 3′OH end of the linear poly (C) substrate.",1445.67,C66H92N16O17S2,DHILMNQRSTV,G,8.07,2,1,1,6,3,-51.54,-555,4.4 hour,>20 hour,>10 hour,7.69,7115,592.92,12951030,Virology. 2003 Aug 15;313(1):158-69.,"Amin A, Zaccardi J, Mullen S, Olland S, Orlowski M, Feld B, Labonte P, Mak P.",Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase.,10.1016/s0042-6822(03)00313-1,,Anti-HCV
DRAVPe01405,ACFPWGNQWCGGK,13,NQW (S-S),Synthetic construct,No entry found,,HCV,Flaviviridae,Surface plasmon resonance,[Ref.12951030]Hepatitis C virus(HCV):inhibition of polymerase activity(IC50=6.0 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01405,DRAVPe01405.cif,Cyclic,Free,Free,Disulfide bond between Cys2 and Cys10,L,RNA-dependent RNA polymerase,"The peptide inhibits the de novo synthesis catalyzed by the enzyme, which suggests that it likely inhibited the formation of a preinitiation complex between the enzyme and the 3′OH end of the linear poly (C) substrate.",1453.66,C66H88N18O16S2,DEHILMRSTVY,G,8.1,1,0,1,6,4,-45.38,-290,4.4 hour,>20 hour,>10 hour,7.69,11125,927.08,12951030,Virology. 2003 Aug 15;313(1):158-69.,"Amin A, Zaccardi J, Mullen S, Olland S, Orlowski M, Feld B, Labonte P, Mak P.",Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase.,10.1016/s0042-6822(03)00313-1,,Anti-HCV
DRAVPe01406,ACFPWGNQWCGGK,13,NQW (L),Synthetic construct,No entry found,,HCV,Flaviviridae,Surface plasmon resonance,[Ref.12951030]Hepatitis C virus(HCV):inhibition of polymerase activity(IC50=37.0 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01406,DRAVPe01406.cif,Linear,Free,Free,,L,RNA-dependent RNA polymerase,"The peptide inhibits the de novo synthesis catalyzed by the enzyme, which suggests that it likely inhibited the formation of a preinitiation complex between the enzyme and the 3′OH end of the linear poly (C) substrate.",1453.66,C66H88N18O16S2,DEHILMRSTVY,G,8.1,1,0,1,6,4,-45.38,-290,4.4 hour,>20 hour,>10 hour,7.69,11125,927.08,12951030,Virology. 2003 Aug 15;313(1):158-69.,"Amin A, Zaccardi J, Mullen S, Olland S, Orlowski M, Feld B, Labonte P, Mak P.",Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase.,10.1016/s0042-6822(03)00313-1,,Anti-HCV
DRAVPe01407,CFPWGC,6,FPWG (S-S),Synthetic construct,No entry found,,HCV,Flaviviridae,Surface plasmon resonance,[Ref.12951030]Hepatitis C virus(HCV):inhibition of polymerase activity(IC50=50.0 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01407,DRAVPe01407.cif,Cyclic,Cyclization of a n-terminal Cys residue (forming a disulfide bond),Cyclization of a C-terminal Cys residue (forming a disulfide bond),Disulfide bond between Cys1 and Cys6,L,RNA-dependent RNA polymerase,"The peptide inhibits the de novo synthesis catalyzed by the enzyme, which suggests that it likely inhibited the formation of a preinitiation complex between the enzyme and the 3′OH end of the linear poly (C) substrate.",711.85,C33H41N7O7S2,ADEHIKLMNQRSTVY,C,5.51,0,0,0,3,2,81.67,881,1.2 hour,>20 hour,>10 hour,0.0,5625,1125.0,12951030,Virology. 2003 Aug 15;313(1):158-69.,"Amin A, Zaccardi J, Mullen S, Olland S, Orlowski M, Feld B, Labonte P, Mak P.",Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase.,10.1016/s0042-6822(03)00313-1,,Anti-HCV
DRAVPe01408,CFPWGC,6,FPWG (L),Synthetic construct,No entry found,,HCV,Flaviviridae,Surface plasmon resonance,[Ref.12951030]Hepatitis C virus(HCV):inhibition of polymerase activity(IC50>150 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01408,DRAVPe01408.cif,Linear,Free,Free,,L,RNA-dependent RNA polymerase,"The peptide inhibits the de novo synthesis catalyzed by the enzyme, which suggests that it likely inhibited the formation of a preinitiation complex between the enzyme and the 3′OH end of the linear poly (C) substrate.",711.85,C33H41N7O7S2,ADEHIKLMNQRSTVY,C,5.51,0,0,0,3,2,81.67,881,1.2 hour,>20 hour,>10 hour,0.0,5625,1125.0,12951030,Virology. 2003 Aug 15;313(1):158-69.,"Amin A, Zaccardi J, Mullen S, Olland S, Orlowski M, Feld B, Labonte P, Mak P.",Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase.,10.1016/s0042-6822(03)00313-1,,Anti-HCV
DRAVPe01409,ACAPWGNTWCGGK,13,NTW (S-S)[F1A],Synthetic construct,No entry found,,HCV,Flaviviridae,Surface plasmon resonance,[Ref.12951030]Hepatitis C virus(HCV):inhibition of polymerase activity(IC50>200 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01409,DRAVPe01409.cif,Cyclic,Free,Free,Disulfide bond between Cys2 and Cys10,L,RNA-dependent RNA polymerase,"The peptide inhibits the de novo synthesis catalyzed by the enzyme, which suggests that it likely inhibited the formation of a preinitiation complex between the enzyme and the 3′OH end of the linear poly (C) substrate.",1350.53,C59H83N17O16S2,DEFHILMQRSVY,G,8.1,1,0,1,7,4,-31.54,-110,4.4 hour,>20 hour,>10 hour,15.38,11125,927.08,12951030,Virology. 2003 Aug 15;313(1):158-69.,"Amin A, Zaccardi J, Mullen S, Olland S, Orlowski M, Feld B, Labonte P, Mak P.",Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase.,10.1016/s0042-6822(03)00313-1,,Anti-HCV
DRAVPe01410,ACFAWGNTWCGGK,13,NTW (S-S)[P2A],Synthetic construct,No entry found,,HCV,Flaviviridae,Surface plasmon resonance,[Ref.12951030]Hepatitis C virus(HCV):inhibition of polymerase activity(IC50=39 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01410,DRAVPe01410.cif,Cyclic,Free,Free,Disulfide bond between Cys2 and Cys10,L,RNA-dependent RNA polymerase,"The peptide inhibits the de novo synthesis catalyzed by the enzyme, which suggests that it likely inhibited the formation of a preinitiation complex between the enzyme and the 3′OH end of the linear poly (C) substrate.",1400.59,C63H85N17O16S2,DEHILMPQRSVY,G,8.1,1,0,1,7,5,2.31,188,4.4 hour,>20 hour,>10 hour,15.38,11125,927.08,12951030,Virology. 2003 Aug 15;313(1):158-69.,"Amin A, Zaccardi J, Mullen S, Olland S, Orlowski M, Feld B, Labonte P, Mak P.",Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase.,10.1016/s0042-6822(03)00313-1,,Anti-HCV
DRAVPe01411,ACFPAGNTWCGGK,13,NTW (S-S)[W3A],Synthetic construct,No entry found,,HCV,Flaviviridae,Surface plasmon resonance,[Ref.12951030]Hepatitis C virus(HCV):inhibition of polymerase activity(IC50=43 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01411,DRAVPe01411.cif,Cyclic,Free,Free,Disulfide bond between Cys2 and Cys10,L,RNA-dependent RNA polymerase,"The peptide inhibits the de novo synthesis catalyzed by the enzyme, which suggests that it likely inhibited the formation of a preinitiation complex between the enzyme and the 3′OH end of the linear poly (C) substrate.",1311.5,C57H82N16O16S2,DEHILMQRSVY,G,8.1,1,0,1,7,4,-3.08,-45,4.4 hour,>20 hour,>10 hour,15.38,5625,468.75,12951030,Virology. 2003 Aug 15;313(1):158-69.,"Amin A, Zaccardi J, Mullen S, Olland S, Orlowski M, Feld B, Labonte P, Mak P.",Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase.,10.1016/s0042-6822(03)00313-1,,Anti-HCV
DRAVPe01412,ACFPWANTWCGGK,13,NTW (S-S)[G4A],Synthetic construct,No entry found,,HCV,Flaviviridae,Surface plasmon resonance,[Ref.12951030]Hepatitis C virus(HCV):inhibition of polymerase activity(IC50=7.4 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01412,DRAVPe01412.cif,Cyclic,Free,Free,Disulfide bond between Cys2 and Cys10,L,RNA-dependent RNA polymerase,"The peptide inhibits the de novo synthesis catalyzed by the enzyme, which suggests that it likely inhibited the formation of a preinitiation complex between the enzyme and the 3′OH end of the linear poly (C) substrate.",1440.66,C66H89N17O16S2,DEHILMQRSVY,ACGW,8.1,1,0,1,6,5,-6.92,94,4.4 hour,>20 hour,>10 hour,15.38,11125,927.08,12951030,Virology. 2003 Aug 15;313(1):158-69.,"Amin A, Zaccardi J, Mullen S, Olland S, Orlowski M, Feld B, Labonte P, Mak P.",Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase.,10.1016/s0042-6822(03)00313-1,,Anti-HCV
DRAVPe01413,ACFPWGATWCGGK,13,NTW (S-S)[N5A],Synthetic construct,No entry found,,HCV,Flaviviridae,Surface plasmon resonance,[Ref.12951030]Hepatitis C virus(HCV):inhibition of polymerase activity(IC50=40 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01413,DRAVPe01413.cif,Cyclic,Free,Free,Disulfide bond between Cys2 and Cys10,L,RNA-dependent RNA polymerase,"The peptide inhibits the de novo synthesis catalyzed by the enzyme, which suggests that it likely inhibited the formation of a preinitiation complex between the enzyme and the 3′OH end of the linear poly (C) substrate.",1383.61,C64H86N16O15S2,DEHILMNQRSVY,G,8.1,1,0,1,6,5,16.92,852,4.4 hour,>20 hour,>10 hour,15.38,11125,927.08,12951030,Virology. 2003 Aug 15;313(1):158-69.,"Amin A, Zaccardi J, Mullen S, Olland S, Orlowski M, Feld B, Labonte P, Mak P.",Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase.,10.1016/s0042-6822(03)00313-1,,Anti-HCV
DRAVPe01414,ACFPWGNAWCGGK,13,NTW (S-S)[T6A],Synthetic construct,No entry found,,HCV,Flaviviridae,Surface plasmon resonance,[Ref.12951030]Hepatitis C virus(HCV):inhibition of polymerase activity(IC50=11 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01414,DRAVPe01414.cif,Cyclic,Free,Free,Disulfide bond between Cys2 and Cys10,L,RNA-dependent RNA polymerase,"The peptide inhibits the de novo synthesis catalyzed by the enzyme, which suggests that it likely inhibited the formation of a preinitiation complex between the enzyme and the 3′OH end of the linear poly (C) substrate.",1396.6,C64H85N17O15S2,DEHILMQRSTVY,G,8.1,1,0,1,6,5,-4.62,445,4.4 hour,>20 hour,>10 hour,15.38,11125,927.08,12951030,Virology. 2003 Aug 15;313(1):158-69.,"Amin A, Zaccardi J, Mullen S, Olland S, Orlowski M, Feld B, Labonte P, Mak P.",Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase.,10.1016/s0042-6822(03)00313-1,,Anti-HCV
DRAVPe01415,ACFPWGNTACGGK,13,NTW (S-S)[W7A],Synthetic construct,No entry found,,HCV,Flaviviridae,Surface plasmon resonance,[Ref.12951030]Hepatitis C virus(HCV):inhibition of polymerase activity(IC50=80 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01415,DRAVPe01415.cif,Cyclic,Free,Free,Disulfide bond between Cys2 and Cys10,L,RNA-dependent RNA polymerase,"The peptide inhibits the de novo synthesis catalyzed by the enzyme, which suggests that it likely inhibited the formation of a preinitiation complex between the enzyme and the 3′OH end of the linear poly (C) substrate.",1311.5,C57H82N16O16S2,DEHILMQRSVY,G,8.1,1,0,1,7,4,-3.08,-45,4.4 hour,>20 hour,>10 hour,15.38,5625,468.75,12951030,Virology. 2003 Aug 15;313(1):158-69.,"Amin A, Zaccardi J, Mullen S, Olland S, Orlowski M, Feld B, Labonte P, Mak P.",Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase.,10.1016/s0042-6822(03)00313-1,,Anti-HCV
DRAVPe01416,MWKTPTLKYFGGFNFSQI,18,SARSWW-I(770-788),Synthetic construct(derived from SARS-CoV spike protein),P11224,,SARS-CoV,Coronaviridae,Plaque formation assay,[Ref.16616792]SARS-CoV:inhibition of plaque information on Vero E6 cells(58% inhibition at ~30 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.16616792]No cytotoxicity against Vero E6 cells up to 30 μM.,DRAVPe01416,DRAVPe01416.cif,Linear,Free,Free,,L,membrane,No machanism information found in the reference(s) presented in this entry,2165.54,C105H149N23O25S,ACDEHRV,F,9.7,2,0,2,7,6,-16.67,-662,30 hour,>20 hour,>10 hour,43.33,6990,411.18,16616792,Virus Res. 2006 Sep;120(1-2):146-55.,"Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF. ",Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein,10.1016/j.virusres.2006.03.001,,Anti-SARS-CoV
DRAVPe01417,ATAGWTFGAGAALQIPFAMQMAY,23,SARSWW-II(864-886),Synthetic construct(derived from SARS-CoV spike protein),P11224,,SARS-CoV,Coronaviridae,Plaque formation assay,[Ref.16616792]SARS-CoV:inhibition of plaque information on Vero E6 cells(39% inhibition at ~30 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.16616792]No cytotoxicity against Vero E6 cells up to 30 μM.,DRAVPe01417,DRAVPe01417.cif,Linear,Free,Free,,L,membrane,No machanism information found in the reference(s) presented in this entry,2374.76,C110H160N26O29S2,CDEHKNRSV,A,5.57,0,0,0,6,12,73.48,2196,4.4 hour,>20 hour,>10 hour,64.35,6990,317.73,16616792,Virus Res. 2006 Sep;120(1-2):146-55.,"Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF. ",Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein,10.1016/j.virusres.2006.03.001,,Anti-SARS-CoV
DRAVPe01418,GYHLMSFPQAAPHGVVFLHVTW,22,SARSWW-III(1028-1049),Synthetic construct(derived from SARS-CoV spike protein),P11224,,SARS-CoV,Coronaviridae,Plaque formation assay,"[Ref.16616792]SARS-CoV:inhibition of plaque information on Vero E6 cells(90% inhibition at ~30 μM,IC50=2 μM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.16616792]No cytotoxicity against Vero E6 cells up to 30 μM.,DRAVPe01418,DRAVPe01418.cif,Linear,Free,Free,,L,membrane,No machanism information found in the reference(s) presented in this entry,2494.9,C120H168N30O27S,CDEIKNR,HV,7.02,3,0,3,5,10,47.73,1247,30 hour,>20 hour,>10 hour,84.09,6990,332.86,16616792,Virus Res. 2006 Sep;120(1-2):146-55.,"Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF. ",Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein,10.1016/j.virusres.2006.03.001,,Anti-SARS-CoV
DRAVPe01419,GVFVFNGTSWFITQRNFFS,19,SARSWW-IV(1075-1093),Synthetic construct(derived from SARS-CoV spike protein),P11224,,SARS-CoV,Coronaviridae,Plaque formation assay,"[Ref.16616792]SARS-CoV:inhibition of plaque information on Vero E6 cells(83% inhibition at ~30 μM,IC50=2 μM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.16616792]No cytotoxicity against Vero E6 cells up to 30 μM.,DRAVPe01419,DRAVPe01419.cif,Linear,Free,Free,,L,membrane,No machanism information found in the reference(s) presented in this entry,2254.53,C109H148N26O27,ACDEHKLMPY,F,9.75,1,0,1,8,9,37.89,-1357,30 hour,>20 hour,>10 hour,51.05,5500,305.56,16616792,Virus Res. 2006 Sep;120(1-2):146-55.,"Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF. ",Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein,10.1016/j.virusres.2006.03.001,,Anti-SARS-CoV
DRAVPe01420,AACEVAKNLNESLIDLQELGKYEQYIKW,28,SARSWW-Vb(1169-1194),Synthetic construct(derived from SARS-CoV spike protein),P11224,,SARS-CoV,Coronaviridae,Plaque formation assay,[Ref.16616792]SARS-CoV:inhibition of plaque information on Vero E6 cells(42% inhibition at ~30 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.16616792]No cytotoxicity against Vero E6 cells up to 30 μM.,DRAVPe01420,DRAVPe01420.cif,Linear,Free,Free,,L,membrane,No machanism information found in the reference(s) presented in this entry,3269.72,C147H230N36O46S,FHMPRT,EL,4.59,3,5,-2,7,11,-41.43,-3711,4.4 hour,>20 hour,>10 hour,104.64,8480,314.07,16616792,Virus Res. 2006 Sep;120(1-2):146-55.,"Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF. ",Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein,10.1016/j.virusres.2006.03.001,,Anti-SARS-CoV
DRAVPe01421,GYFVQDDGEWKFTGSSYYY,19,MHVWW-IV(1144-1162),Synthetic construct(derived from MHV spike protein),P11224,,SARS-CoV,Coronaviridae,Plaque formation assay,[Ref.16616792]SARS-CoV:inhibition of plaque information on Vero E6 cells(IC50=4 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.16616792]No cytotoxicity against Vero E6 cells up to 30 μM.,DRAVPe01421,DRAVPe01421.cif,Linear,Free,Free,,L,membrane,No machanism information found in the reference(s) presented in this entry,2312.43,C110H138N22O34,ACHILMNPR,Y,4.03,1,3,-2,10,4,-93.16,-3012,30 hour,>20 hour,>10 hour,15.26,11460,636.67,16616792,Virus Res. 2006 Sep;120(1-2):146-55.,"Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF. ",Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein,10.1016/j.virusres.2006.03.001,,Anti-SARS-CoV
DRAVPe01422,AAHLIDALYAEFLGGRVLTTPVVHRALFYASAVLRQPFLAGVPSA,45,gH493-537(derived from HSV-1 H glycoprotein),Synthetic construct(derived from HSV-1 H glycoprotein (gH)),Q9DHD5,,HSV,Herpesviridae,Plaque assay,[Ref.18572274]Herpes simplex virus type 1(HSV-1):inhibition of viral-entry in Vero cells(50-60% inhibition at 250μM-500μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18572274]No cytotoxicity against Vero cells up to 500 μM.,DRAVPe01422,DRAVPe01422.cif,Linear,Free,Free,,L,mambrane,The peptide inhibits virus entry and thus protects cells from infection.,4780.6,C224H349N59O57,CKMNW,A,8.64,5,2,3,9,25,77.11,24,4.4 hour,>20 hour,>10 hour,121.56,2980,67.73,18572274,Peptides. 2008 Sep;29(9):1461-71.,"Galdiero S, Falanga A, Vitiello M, D'Isanto M, Cantisani M, Kampanaraki A, Benedetti E, Browne H, Galdiero M.",Peptides containing membrane-interacting motifs inhibit herpes simplex virus type 1 infectivity.,10.1016/j.peptides.2008.04.022,,Anti-HSV
DRAVPe01423,AAHLIDALYAEFLGGRVLTT,20,gH493-512(derived from HSV-1 H glycoprotein),Synthetic construct(derived from HSV-1 H glycoprotein (gH)),Q9DHD5,,HSV,Herpesviridae,Plaque assay,[Ref.18572274]Herpes simplex virus type 1(HSV-1):inhibition of viral-entry in Vero cells(60% inhibition at 250μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18572274]No cytotoxicity against Vero cells up to 500 μM.,DRAVPe01423,DRAVPe01423.cif,Linear,Free,Free,,L,mambrane,The peptide inhibits virus entry and thus protects cells from infection.,2131.46,C98H155N25O28,CKMNPQSW,AL,5.32,2,2,0,5,11,78.5,35,4.4 hour,>20 hour,>10 hour,132.0,1490,78.42,18572274,Peptides. 2008 Sep;29(9):1461-71.,"Galdiero S, Falanga A, Vitiello M, D'Isanto M, Cantisani M, Kampanaraki A, Benedetti E, Browne H, Galdiero M.",Peptides containing membrane-interacting motifs inhibit herpes simplex virus type 1 infectivity.,10.1016/j.peptides.2008.04.022,,Anti-HSV
DRAVPe01424,GLASTLTRWAHYNALIRAF,19,gH626-644(derived from HSV-1 H glycoprotein),Synthetic construct(derived from HSV-1 H glycoprotein (gH)),Q9DHD5,,HSV,Herpesviridae,Plaque assay,[Ref.18572274]Herpes simplex virus type 1(HSV-1):inhibition of viral-entry in Vero cells(50-60% inhibition at 250μM-500μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18572274]No cytotoxicity against Vero cells up to 500 μM.,DRAVPe01424,DRAVPe01424.cif,Linear,Free,Free,,L,mambrane,The peptide inhibits virus entry and thus protects cells from infection.,2161.49,C100H153N29O25,CDEKMPQV,A,10.84,3,0,3,6,10,28.42,-1665,30 hour,>20 hour,>10 hour,103.16,6990,388.33,18572274,Peptides. 2008 Sep;29(9):1461-71.,"Galdiero S, Falanga A, Vitiello M, D'Isanto M, Cantisani M, Kampanaraki A, Benedetti E, Browne H, Galdiero M.",Peptides containing membrane-interacting motifs inhibit herpes simplex virus type 1 infectivity.,10.1016/j.peptides.2008.04.022,,Anti-HSV
DRAVPe01425,CCFLNITNSHVSILQERPPLENRVLTGWGL,30,Pcr-400,Synthetic construct(derived from HTLV-1 envelope glycoprotein (gp21)),P14075,,HTLV,Retroviridae,Luciferase assay,[Ref.19114713]:Human T cell leukemia virus type 1(HTLV-1):inhibition of mambrane fusion in 293T cells(IC50=0.18 ± 0.01 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01425,DRAVPe01425.cif,Linear,Acetylation,Amidation,,L,mambrane,The peptide is an effective inhibitor of HTLV-1 envelope-catalyzed membrane fusion and thus inhibits virus entry.,3410.96,C151H241N43O43S2,ADKMY,L,6.74,3,2,1,11,11,10.33,-3325,1.2 hour,>20 hour,>10 hour,110.33,5625,193.97,19114713,J Biol Chem. 2009 Mar 6;284(10):6575-84. ,"Lamb D, Mirsaliotis A, Kelly SM, Brighty DW.",Basic residues are critical to the activity of peptide inhibitors of human T cell leukemia virus type 1 entry.,10.1074/jbc.M806725200,,Anti-HTLV
DRAVPe01426,LNITNSHVSILQERPPLENRVL,22,Pcr-Δ8,Synthetic construct(derived from HTLV-1 envelope glycoprotein (gp21)),P14075,,HTLV,Retroviridae,Luciferase assay,[Ref.19114713]:Human T cell leukemia virus type 1(HTLV-1):inhibition of mambrane fusion in 293T cells(IC50=5.8 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01426,DRAVPe01426.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide is an effective inhibitor of HTLV-1 envelope-catalyzed membrane fusion and thus inhibits virus entry.,2542.92,C111H188N34O34,ACDFGKMWY,L,6.76,3,2,1,6,8,-27.73,-4535,5.5 hour,3 min,2 min,132.73,0,0.0,19114713,J Biol Chem. 2009 Mar 6;284(10):6575-84. ,"Lamb D, Mirsaliotis A, Kelly SM, Brighty DW.",Basic residues are critical to the activity of peptide inhibitors of human T cell leukemia virus type 1 entry.,10.1074/jbc.M806725200,,Anti-HTLV
DRAVPe01427,CFLNITNSHVSILQERPPLENRV,23,Pcr-Δ7,Synthetic construct(derived from HTLV-1 envelope glycoprotein (gp21)),P14075,,HTLV,Retroviridae,Luciferase assay,[Ref.19114713]:Human T cell leukemia virus type 1(HTLV-1):inhibition of mambrane fusion in 293T cells(IC50=0.19± 0.01 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01427,DRAVPe01427.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide is an effective inhibitor of HTLV-1 envelope-catalyzed membrane fusion and thus inhibits virus entry.,2680.08,C117H191N35O35S,ADGKMWY,LN,6.75,3,2,1,7,8,-20.0,-4601,1.2 hour,>20 hour,>10 hour,110.0,0,0.0,19114713,J Biol Chem. 2009 Mar 6;284(10):6575-84. ,"Lamb D, Mirsaliotis A, Kelly SM, Brighty DW.",Basic residues are critical to the activity of peptide inhibitors of human T cell leukemia virus type 1 entry.,10.1074/jbc.M806725200,,Anti-HTLV
DRAVPe01428,CFLNITNSHVSILQEAPPLENRV,23,Pcr-R416A,Synthetic construct(derived from HTLV-1 envelope glycoprotein (gp21)),P14075,,HTLV,Retroviridae,Luciferase assay,[Ref.19114713]:Human T cell leukemia virus type 1(HTLV-1):inhibition of mambrane fusion in 293T cells(IC50=1.55 ± 0.08 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01428,DRAVPe01428.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide is an effective inhibitor of HTLV-1 envelope-catalyzed membrane fusion and thus inhibits virus entry.,2594.97,C114H184N32O35S,DGKMWY,LN,5.4,2,2,0,7,9,7.39,-2928,1.2 hour,>20 hour,>10 hour,114.35,0,0.0,19114713,J Biol Chem. 2009 Mar 6;284(10):6575-84. ,"Lamb D, Mirsaliotis A, Kelly SM, Brighty DW.",Basic residues are critical to the activity of peptide inhibitors of human T cell leukemia virus type 1 entry.,10.1074/jbc.M806725200,,Anti-HTLV
DRAVPe01429,CFLNITNSHVSILQEAPPLENAV,23,Pcr-R422A,Synthetic construct(derived from HTLV-1 envelope glycoprotein (gp21)),P14075,,HTLV,Retroviridae,Luciferase assay,[Ref.19114713]:Human T cell leukemia virus type 1(HTLV-1):inhibition of mambrane fusion in 293T cells(IC50=8.5 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01429,DRAVPe01429.cif,Linear,Acetylation,Amidation,,L,membrane,The peptide is an effective inhibitor of HTLV-1 envelope-catalyzed membrane fusion and thus inhibits virus entry.,2509.86,C111H177N29O35S,DGKMRWY,LN,4.51,1,2,-1,7,10,34.78,-1255,1.2 hour,>20 hour,>10 hour,118.7,0,0.0,19114713,J Biol Chem. 2009 Mar 6;284(10):6575-84. ,"Lamb D, Mirsaliotis A, Kelly SM, Brighty DW.",Basic residues are critical to the activity of peptide inhibitors of human T cell leukemia virus type 1 entry.,10.1074/jbc.M806725200,,Anti-HTLV
DRAVPe01430,KQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTCWAICKRIPNKKPGKK,49,G149-197(derived from RSV attachment glycoprotein),Synthetic construct(derived from RSV attachment glycoprotein),P03423,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=80 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01430,DRAVPe01430.cif,Cyclic,Acetylation,Amidation,The peptide formed two disulfide bonds.,L,Not found,No machanism information found in the reference(s) presented in this entry,5687.62,C253H395N75O67S4,LMY,K,9.88,11,2,9,16,11,-107.35,-11980,1.3 hour,3 min,2 min,37.76,5750,119.79,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01431,FHFEVFNFVPCSICSNNPTCWAICKRIPNKKPGKK,35,G163-197(derived from RSV attachment glycoprotein),Synthetic construct(derived from RSV attachment glycoprotein),P03423,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=80 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01431,DRAVPe01431.cif,Cyclic,Acetylation,Amidation,The peptide formed two disulfide bonds.,L,Not found,No machanism information found in the reference(s) presented in this entry,4054.82,C185H282N50O45S4,DLMQY,K,9.44,7,1,6,12,11,-28.0,-4511,1.1 hour,3 min,2 min,52.86,5750,169.12,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01432,VPCSICSNNPTCWAICKRIPNKKPGKK,27,G171-197(derived from RSV attachment glycoprotein),Synthetic construct(derived from RSV attachment glycoprotein),P03423,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50>165 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01432,DRAVPe01432.cif,Cyclic,Acetylation,Amidation,The peptide formed two disulfide bonds.,L,Not found,No machanism information found in the reference(s) presented in this entry,2986.62,C129H217N39O34S4,DEFHLMQY,K,9.7,6,0,6,11,6,-55.56,-4296,100 hour,>20 hour,>10 hour,57.78,5750,221.15,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01433,CSICSNNPTCWAICKRIPNKKPGKK,25,G173-197(derived from RSV attachment glycoprotein),Synthetic construct(derived from RSV attachment glycoprotein),P03423,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50>177 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01433,DRAVPe01433.cif,Cyclic,Acetylation,Amidation,The peptide formed two disulfide bonds.,L,Not found,No machanism information found in the reference(s) presented in this entry,2790.37,C119H201N37O32S4,DEFHLMQVY,K,9.7,6,0,6,11,5,-70.4,-4700,1.2 hour,>20 hour,>10 hour,50.8,5750,239.58,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01434,KQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTCWAICKRI,41,G149-189(derived from RSV attachment glycoprotein),Synthetic construct(derived from RSV attachment glycoprotein),P03423,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=12 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01434,DRAVPe01434.cif,Cyclic,Acetylation,Amidation,The peptide formed two disulfide bonds.,L,Not found,No machanism information found in the reference(s) presented in this entry,4809.54,C213H324N62O58S4,GLMY,N,9.21,7,2,5,14,11,-72.93,-9190,1.3 hour,3 min,2 min,45.12,5750,143.75,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01435,KPPSKPNNDFHFEVFNFVPCSICSNNPTCWAICKRI,36,G154-189(derived from RSV attachment glycoprotein),Synthetic construct(derived from RSV attachment glycoprotein),P03423,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=12 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01435,DRAVPe01435.cif,Cyclic,Acetylation,Amidation,The peptide formed two disulfide bonds.,L,Not found,No machanism information found in the reference(s) presented in this entry,4154.81,C187H278N50O50S4,GLMQY,NP,8.52,5,2,3,13,11,-30.56,-5371,1.3 hour,3 min,2 min,51.39,5750,164.29,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01436,KPNNDFHFEVFNFVPCSICSNNPTCWAICKRI,32,G158-189(derived from RSV attachment glycoprotein),Synthetic construct(derived from RSV attachment glycoprotein),P03423,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=25 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01436,DRAVPe01436.cif,Cyclic,Acetylation,Amidation,The peptide formed two disulfide bonds.,L,Not found,No machanism information found in the reference(s) presented in this entry,3745.32,C168H247N45O45S4,GLMQY,N,7.89,4,2,2,12,11,-9.69,-4476,1.3 hour,3 min,2 min,57.81,5750,185.48,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01437,KQRQNKPPSKPNNDFHFEVFN,21,G149-169(derived from RSV attachment glycoprotein),Synthetic construct(derived from RSV attachment glycoprotein),P03423,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50>190 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01437,DRAVPe01437.cif,Cyclic,Acetylation,Amidation,The peptide formed two disulfide bonds.,L,Not found,No machanism information found in the reference(s) presented in this entry,2571.84,C115H171N35O33,ACGILMTWY,N,9.7,5,2,3,5,4,-192.38,-7982,1.3 hour,3 min,2 min,13.81,0,0.0,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01438,KQRQNKPPSKPNNDFHF,17,G149-165(derived from RSV attachment glycoprotein),Synthetic construct(derived from RSV attachment glycoprotein),P03423,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50>240 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01438,DRAVPe01438.cif,Cyclic,Acetylation,Amidation,The peptide formed two disulfide bonds.,L,Not found,No machanism information found in the reference(s) presented in this entry,2082.31,C92H140N30O26,ACEGILMTVWY,KNP,10.29,5,1,4,4,2,-237.65,-7339,1.3 hour,3 min,2 min,0.0,0,0.0,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01439,KPPSKPNNDFHFEVFNFVP,19,G154-172(derived from RSV attachment glycoprotein),Synthetic construct(derived from RSV attachment glycoprotein),P03423,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=220 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01439,DRAVPe01439.cif,Cyclic,Acetylation,Amidation,The peptide formed two disulfide bonds.,L,Not found,No machanism information found in the reference(s) presented in this entry,2260.54,C108H150N26O28,ACGILMQRTWY,FP,6.75,3,2,1,4,6,-84.74,-3461,1.3 hour,3 min,2 min,30.53,0,0.0,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01440,KPPSKPNNDFHFEVFNFV,18,G154-171(derived from RSV attachment glycoprotein),Synthetic construct(derived from RSV attachment glycoprotein),P03423,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=14 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01440,DRAVPe01440.cif,Cyclic,Acetylation,Amidation,The peptide formed two disulfide bonds.,L,Not found,No machanism information found in the reference(s) presented in this entry,2163.42,C103H143N25O27,ACGILMQRTWY,F,6.75,3,2,1,4,6,-80.56,-3461,1.3 hour,3 min,2 min,32.22,0,0.0,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01441,KPPSKPNNDFHFEVFNF,17,G154-170(derived from RSV attachment glycoprotein),Synthetic construct(derived from RSV attachment glycoprotein),P03423,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=7 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01441,DRAVPe01441.cif,Cyclic,Acetylation,Amidation,The peptide formed two disulfide bonds.,L,Not found,No machanism information found in the reference(s) presented in this entry,2064.29,C98H134N24O26,ACGILMQRTWY,F,6.75,3,2,1,4,5,-110.0,-3865,1.3 hour,3 min,2 min,17.06,0,0.0,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01442,KPPSKPNNDFHFEVFN,16,G154-169(derived from RSV attachment glycoprotein),Synthetic construct(derived from RSV attachment glycoprotein),P03423,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50>510 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01442,DRAVPe01442.cif,Cyclic,Acetylation,Amidation,The peptide formed two disulfide bonds.,L,Not found,No machanism information found in the reference(s) presented in this entry,1917.11,C89H125N23O25,ACGILMQRTWY,FNP,6.75,3,2,1,4,4,-134.38,-4163,1.3 hour,3 min,2 min,18.13,0,0.0,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01443,KQRQNKPPSKPNNDFHFEVFNFVPBSIBG,29,G149-177,Synthetic construct,No entry found,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=4 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01443,DRAVPe01443.cif,Linear,Acetylation,Amidation,"The 'B' at position 25,28 are S-acetamidomethyl cysteine.",L,Not found,No machanism information found in the reference(s) presented in this entry,3401.86,C145H211N41O38,ACLMTWY,FNP,9.7,5,2,3,7,7,-109.31,-7034,1.3 hour,3 min,2 min,33.45,0,0.0,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01444,KPPSKPNNDFHFEVFNFVPBSIBG,24,G154-177,Synthetic construct,No entry found,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=5 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01444,DRAVPe01444.cif,Linear,Acetylation,Amidation,"The 'B' at position 20,23 are S-acetamidomethyl cysteine.",L,Not found,No machanism information found in the reference(s) presented in this entry,2747.13,C119H165N29O30,ACLMQRTWY,FP,6.75,3,2,1,6,7,-53.33,-3215,1.3 hour,3 min,2 min,40.42,0,0.0,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01445,KPNNDFHFEVFNFVPBSIBG,20,G158-177,Synthetic construct,No entry found,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01445,DRAVPe01445.cif,Linear,Acetylation,Amidation,"The 'B' at position 16,19 are S-acetamidomethyl cysteine.",L,Not found,No machanism information found in the reference(s) presented in this entry,2337.65,C100H134N24O25,ACLMQRTWY,F,5.32,2,2,0,5,7,-24.5,-2320,1.3 hour,3 min,2 min,48.5,0,0.0,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01446,DFHFEVFNFVPBSIBG,16,G162-177,Synthetic construct,No entry found,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=60 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01446,DRAVPe01446.cif,Linear,Acetylation,Amidation,"The 'B' at position 12,15 are S-acetamidomethyl cysteine.",L,Not found,No machanism information found in the reference(s) presented in this entry,1884.15,C81H103N17O19,ACKLMQRTWY,F,4.35,1,2,-1,3,7,47.5,-437,1.1 hour,3 min,>10 hour,60.63,0,0.0,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01447,EVFNFVPBSIBG,12,G166-177,Synthetic construct,No entry found,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=80 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01447,DRAVPe01447.cif,Linear,Acetylation,Amidation,"The 'B' at position 8,11 are S-acetamidomethyl cysteine.",L,Not found,No machanism information found in the reference(s) presented in this entry,1337.57,C53H73N11O13,ACDHKLMQRTWY,FV,4.0,0,1,-1,3,5,72.5,305,1 hour,30 min,>10 hour,80.83,0,0.0,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01448,FVPBSIBG,8,G170-177,Synthetic construct,No entry found,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50》500 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01448,DRAVPe01448.cif,Linear,Acetylation,Amidation,"The 'B' at position 4,7 are S-acetamidomethyl cysteine.",L,Not found,No machanism information found in the reference(s) presented in this entry,848.04,C30H42N6O6,ACDEHKLMNQRTWY,FGIPSV,5.52,0,0,0,2,3,108.75,948,1.1 hour,3 min,2 min,85.0,0,0.0,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01449,KQRQNKPPSKPNNDFHFEVFNFVPB,25,G149-173,Synthetic construct,No entry found,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=80 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01449,DRAVPe01449.cif,Linear,Acetylation,Amidation,The 'B' at position 25 is S-acetamidomethyl cysteine.,L,Not found,No machanism information found in the reference(s) presented in this entry,3029.92,C134H194N38O35,ACGILMTWY,FNP,9.7,5,2,3,5,6,-140.0,-7280,1.3 hour,3 min,2 min,23.2,0,0.0,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01450,KPPSKPNNDFHFEVFNFVPBSIAG,24,G154-177[B176A],Synthetic construct,No entry found,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=6 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01450,DRAVPe01450.cif,Linear,Acetylation,Amidation,The 'B' at position 20 is S-acetamidomethyl cysteine.,L,Not found,No machanism information found in the reference(s) presented in this entry,2703.56,C122H172N30O32,CLMQRTWY,FP,6.75,3,2,1,6,8,-45.83,-3034,1.3 hour,3 min,2 min,44.58,0,0.0,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01451,KPPSKPNNDFHFEVFNFVPBSABG,24,G154-177[I175A],Synthetic construct,No entry found,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=22 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01451,DRAVPe01451.cif,Linear,Acetylation,Amidation,"The 'B' at position 20,23 are S-acetamidomethyl cysteine.",L,Not found,No machanism information found in the reference(s) presented in this entry,2705.05,C116H159N29O30,CILMQRTWY,FP,6.75,3,2,1,6,7,-64.58,-3526,1.3 hour,3 min,2 min,28.33,0,0.0,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01452,KPPSKPNNDFHFEVFNFVPBAIBG,24,G154-177[S174A],Synthetic construct,No entry found,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=11 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01452,DRAVPe01452.cif,Linear,Acetylation,Amidation,"The 'B' at position 20,23 are S-acetamidomethyl cysteine.",L,Not found,No machanism information found in the reference(s) presented in this entry,2731.13,C119H165N29O29,CLMQRTWY,FP,6.75,3,2,1,5,8,-42.5,-2694,1.3 hour,3 min,2 min,44.58,0,0.0,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01453,KPPSKPNNDFHFEVFNFVPASIBG,24,G154-177[B173A],Synthetic construct,No entry found,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=11 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01453,DRAVPe01453.cif,Linear,Acetylation,Amidation,The 'B' at position 23 is S-acetamidomethyl cysteine.,L,Not found,No machanism information found in the reference(s) presented in this entry,2703.56,C122H172N30O32,CLMQRTWY,FP,6.75,3,2,1,6,8,-45.83,-3034,1.3 hour,3 min,2 min,44.58,0,0.0,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01454,KPPSKPNNDFHFEVFNFVABSIBG,24,G154-177[P172A],Synthetic construct,No entry found,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=11 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01454,DRAVPe01454.cif,Linear,Acetylation,Amidation,"The 'B' at position 20,23 are S-acetamidomethyl cysteine.",L,Not found,No machanism information found in the reference(s) presented in this entry,2721.09,C117H163N29O30,CLMQRTWY,F,6.75,3,2,1,6,8,-39.17,-3034,1.3 hour,3 min,2 min,44.58,0,0.0,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01455,KPPSKPNNDFHFEVFNFAPBSIBG,24,G154-177[V171A],Synthetic construct,No entry found,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=11 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01455,DRAVPe01455.cif,Linear,Acetylation,Amidation,"The 'B' at position 20,23 are S-acetamidomethyl cysteine.",L,Not found,No machanism information found in the reference(s) presented in this entry,2719.08,C117H161N29O30,CLMQRTWY,FP,6.75,3,2,1,6,7,-63.33,-3438,1.3 hour,3 min,2 min,32.5,0,0.0,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01456,KPPSKPNNDFHFEVFNAVPBSIBG,24,G154-177[F170A],Synthetic construct,No entry found,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=22 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01456,DRAVPe01456.cif,Linear,Acetylation,Amidation,"The 'B' at position 20,23 are S-acetamidomethyl cysteine.",L,Not found,No machanism information found in the reference(s) presented in this entry,2671.03,C113H161N29O30,CLMQRTWY,P,6.75,3,2,1,6,7,-57.5,-3332,1.3 hour,3 min,2 min,44.58,0,0.0,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01457,KPPSKPNNDFHFEVFAFVPBSIBG,24,G154-177[N169A],Synthetic construct,No entry found,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=11 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01457,DRAVPe01457.cif,Linear,Acetylation,Amidation,"The 'B' at position 20,23 are S-acetamidomethyl cysteine.",L,Not found,No machanism information found in the reference(s) presented in this entry,2704.11,C118H164N28O29,CLMQRTWY,FP,6.75,3,2,1,5,8,-31.25,-2370,1.3 hour,3 min,2 min,44.58,0,0.0,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01458,KPPSKPNNDFHFEVANFVPBSIBG,24,G154-177[F168A],Synthetic construct,No entry found,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=90 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01458,DRAVPe01458.cif,Linear,Acetylation,Amidation,"The 'B' at position 20,23 are S-acetamidomethyl cysteine.",L,Not found,No machanism information found in the reference(s) presented in this entry,2671.03,C113H161N29O30,CLMQRTWY,P,6.75,3,2,1,6,7,-57.5,-3332,1.3 hour,3 min,2 min,44.58,0,0.0,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01459,KPPSKPNNDFHFEAFNFVPBSIBG,24,G154-177[V167A],Synthetic construct,No entry found,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=11 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01459,DRAVPe01459.cif,Linear,Acetylation,Amidation,"The 'B' at position 20,23 are S-acetamidomethyl cysteine.",L,Not found,No machanism information found in the reference(s) presented in this entry,2719.08,C117H161N29O30,CLMQRTWY,FP,6.75,3,2,1,6,7,-63.33,-3438,1.3 hour,3 min,2 min,32.5,0,0.0,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01460,KPPSKPNNDFHFAVFNFVPBSIBG,24,G154-177[E166A],Synthetic construct,No entry found,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=0.75 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01460,DRAVPe01460.cif,Linear,Acetylation,Amidation,"The 'B' at position 20,23 are S-acetamidomethyl cysteine.",L,Not found,No machanism information found in the reference(s) presented in this entry,2689.1,C117H163N29O28,CELMQRTWY,FP,8.6,3,1,2,6,8,-31.25,-2353,1.3 hour,3 min,2 min,44.58,0,0.0,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01461,KPPSKPNNDFHAEVFNFVPBSIBG,24,G154-177[F165A],Synthetic construct,No entry found,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=5 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01461,DRAVPe01461.cif,Linear,Acetylation,Amidation,"The 'B' at position 20,23 are S-acetamidomethyl cysteine.",L,Not found,No machanism information found in the reference(s) presented in this entry,2671.03,C113H161N29O30,CLMQRTWY,P,6.75,3,2,1,6,7,-57.5,-3332,1.3 hour,3 min,2 min,44.58,0,0.0,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01462,KQRQNKPPSKPNNDFHFEVANAVPBSIBG,29,G149-177[F168/170A],Synthetic construct,No entry found,,RSV,Paramyxoviridae,NMR,[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50>165 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01462,DRAVPe01462.cif,Linear,Acetylation,Amidation,"The 'B' at position 25,28 are S-acetamidomethyl cysteine.",L,Not found,No machanism information found in the reference(s) presented in this entry,3249.66,C133H203N41O38,CLMTWY,NP,9.7,5,2,3,7,7,-116.21,-7268,1.3 hour,3 min,2 min,40.34,0,0.0,11487583,J Biol Chem. 2001 Oct 19;276(42):38988-94.,"Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. ",Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.,10.1074/jbc.M106288200,,Anti-RSV
DRAVPe01463,DTRACDVIALLCHLNT,16,P1,Synthetic construct,No entry found,,"WNV,DENV",Flaviviridae,RT-QPCR,"[Ref.17151121]west nile virus(WNV):inhibition of virus infection in Vero cells(P1 significantly inhibited WNV infectivity at a concentration of 1 mM,IC50=67.0 ± 0.1 μM);##Dengue virus serotype 2:inhibition of virus infection in Vero cells(99.3±0.7% inhibition at 200 μM)",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.17151121]No cytotoxicity against Vero cells up to 500μM.,DRAVPe01463,DRAVPe01463.cif,Linear,Free,Free,,L,E proteins,No machanism information found in the reference(s) presented in this entry,1758.04,C73H124N22O24S2,EFGKMPQSWY,L,5.21,2,2,0,5,7,56.88,-1890,1.1 hour,3 min,>10 hour,128.13,125,8.33,17151121,J Virol. 2007 Feb;81(4):2047-55. ,"Bai F, Town T, Pradhan D, Cox J, Ashish, Ledizet M, Anderson JF, Flavell RA, Krueger JK, Koski RA, Fikrig E.",Antiviral peptides targeting the west nile virus envelope protein.,10.1128/JVI.01840-06,,"Anti-WNV,Anti-DENV"
DRAVPe01464,CDVIALLCHLNT,12,P8,Synthetic construct,No entry found,,WNV,Flaviviridae,RT-QPCR,[Ref.17151121]west nile virus(WNV):inhibition of virus infection in Vero cells(P10 significantly inhibited WNV infectivity).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01464,DRAVPe01464.cif,Linear,Free,Free,,L,E proteins,No machanism information found in the reference(s) presented in this entry,1314.58,C56H95N15O17S2,EFGKMPQRSWY,L,5.08,1,1,0,4,6,133.33,550,1.2 hour,>20 hour,>10 hour,162.5,125,11.36,17151121,J Virol. 2007 Feb;81(4):2047-55. ,"Bai F, Town T, Pradhan D, Cox J, Ashish, Ledizet M, Anderson JF, Flavell RA, Krueger JK, Koski RA, Fikrig E.",Antiviral peptides targeting the west nile virus envelope protein.,10.1128/JVI.01840-06,,Anti-WNV
DRAVPe01465,CDVIALLACHLNT,13,P9,Synthetic construct,No entry found,,WNV,Flaviviridae,RT-QPCR,"[Ref.17151121]west nile virus(WNV):inhibition of virus infection in Vero cells(96.3±2.8% inhibition at 100 μM,IC50=2.60 ± 0.01 μM);inhibition of virus entry in Vero cells(65.2±14.5% inhibition at 100 μM);inhibition of virus attachment to Vero cells(96.3±2.7% inhibition at 1mM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.17151121]No cytotoxicity against Vero cells up to 500μM.,DRAVPe01465,DRAVPe01465.cif,Linear,Free,Free,,L,E proteins,P9 blocked cirus attachment,1385.66,C59H100N16O18S2,EFGKMPQRSWY,L,5.08,1,1,0,4,7,136.92,731,1.2 hour,>20 hour,>10 hour,157.69,125,10.42,17151121,J Virol. 2007 Feb;81(4):2047-55. ,"Bai F, Town T, Pradhan D, Cox J, Ashish, Ledizet M, Anderson JF, Flavell RA, Krueger JK, Koski RA, Fikrig E.",Antiviral peptides targeting the west nile virus envelope protein.,10.1128/JVI.01840-06,,Anti-WNV
DRAVPe01466,CDVIALLCHLNTPSF,15,P10,Synthetic construct,No entry found,,WNV,Flaviviridae,RT-QPCR,[Ref.17151121]west nile virus(WNV):inhibition of virus infection in Vero cells(P10 significantly inhibited WNV infectivity).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01466,DRAVPe01466.cif,Linear,Free,Free,,L,E proteins,No machanism information found in the reference(s) presented in this entry,1645.95,C73H116N18O21S2,EGKMQRWY,L,5.08,1,1,0,5,7,109.33,508,1.2 hour,>20 hour,>10 hour,130.0,125,8.93,17151121,J Virol. 2007 Feb;81(4):2047-55. ,"Bai F, Town T, Pradhan D, Cox J, Ashish, Ledizet M, Anderson JF, Flavell RA, Krueger JK, Koski RA, Fikrig E.",Antiviral peptides targeting the west nile virus envelope protein.,10.1128/JVI.01840-06,,Anti-WNV
DRAVPe01467,CDVIALLCHLNTPSFNTTHYRESWY,25,P11,Synthetic construct,No entry found,,WNV,Flaviviridae,RT-QPCR,[Ref.17151121]west nile virus(WNV):inhibition of virus infection in Vero cells(P10 significantly inhibited WNV infectivity).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01467,DRAVPe01467.cif,Linear,Free,Free,,L,E proteins,No machanism information found in the reference(s) presented in this entry,2984.35,C134H195N35O39S2,GKMQ,LT,5.99,3,2,1,11,8,-16.0,-3444,1.2 hour,>20 hour,>10 hour,78.0,8605,358.54,17151121,J Virol. 2007 Feb;81(4):2047-55. ,"Bai F, Town T, Pradhan D, Cox J, Ashish, Ledizet M, Anderson JF, Flavell RA, Krueger JK, Koski RA, Fikrig E.",Antiviral peptides targeting the west nile virus envelope protein.,10.1128/JVI.01840-06,,Anti-WNV
DRAVPe01468,SSCNMGWDTPAAnti-CCVWFPYWV,20,A4,Synthetic construct,No entry found,,HCMV,Herpesviridae,GFP assay,[Ref.19740994]human cytomegalovirus(HCMV):inhibition of virus replication in HeLa cells(70% inhibition).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01468,DRAVPe01468.cif,Linear,Free,Free,,L,pUL84(nonconventional nuclear localization signal of the essential viral replication factor),The peptide specifically bind to UL84 protein and  utilized to inhibit HCMV replication.,2352.7,C108H142N24O28S4,EHIKLQR,CW,3.8,0,1,-1,9,7,27.5,212,1.9 hour,>20 hour,>10 hour,34.0,18115,953.42,19740994,J Virol. 2009 Nov;83(22):11902-13. ,"Kaiser N, Lischka P, Wagenknecht N, Stamminger T.",Inhibition of human cytomegalovirus replication via peptide aptamers directed against the nonconventional nuclear localization signal of the essential viral replication factor pUL84.,10.1128/JVI.01378-09,,Anti-HCMV
DRAVPe01469,MAVGLVLCDWWLGEYLLEA,19,A8,Synthetic construct,No entry found,,HCMV,Herpesviridae,GFP assay,[Ref.19740994]human cytomegalovirus(HCMV):inhibition of virus replication in HeLa cells(70% inhibition).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01469,DRAVPe01469.cif,Linear,Free,Free,,L,pUL84(nonconventional nuclear localization signal of the essential viral replication factor),The peptide specifically bind to UL84 protein and  utilized to inhibit HCMV replication.,2181.59,C103H153N21O27S2,FHIKNPQRST,L,3.57,0,3,-3,4,11,110.53,2399,30 hour,>20 hour,>10 hour,143.68,12490,693.89,19740994,J Virol. 2009 Nov;83(22):11902-13. ,"Kaiser N, Lischka P, Wagenknecht N, Stamminger T.",Inhibition of human cytomegalovirus replication via peptide aptamers directed against the nonconventional nuclear localization signal of the essential viral replication factor pUL84.,10.1128/JVI.01378-09,,Anti-HCMV
DRAVPe01470,PVLQPALSLSCGPEPLLLSC,20,A56,Synthetic construct,No entry found,,HCMV,Herpesviridae,GFP assay,[Ref.19740994]human cytomegalovirus(HCMV):inhibition of virus replication in HeLa cells(40% inhibition).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01470,DRAVPe01470.cif,Linear,Free,Free,,L,pUL84(nonconventional nuclear localization signal of the essential viral replication factor),The peptide specifically bind to UL84 protein and  utilized to inhibit HCMV replication.,2037.46,C91H153N21O27S2,DFHIKMNRTWY,L,4.0,0,1,-1,6,8,88.0,1632,>20 hour,>20 hour,?,136.5,125,6.58,19740994,J Virol. 2009 Nov;83(22):11902-13. ,"Kaiser N, Lischka P, Wagenknecht N, Stamminger T.",Inhibition of human cytomegalovirus replication via peptide aptamers directed against the nonconventional nuclear localization signal of the essential viral replication factor pUL84.,10.1128/JVI.01378-09,,Anti-HCMV
DRAVPe01471,IEVTFVNRRGDGAELWYLSA,20,A110,Synthetic construct,No entry found,,HCMV,Herpesviridae,GFP assay,[Ref.19740994]human cytomegalovirus(HCMV):inhibition of virus replication in HeLa cells(35% inhibition).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01471,DRAVPe01471.cif,Linear,Free,Free,,L,pUL84(nonconventional nuclear localization signal of the essential viral replication factor),The peptide specifically bind to UL84 protein and  utilized to inhibit HCMV replication.,2296.57,C104H158N28O31,CHKMPQ,AEGLRV,4.68,2,3,-1,6,9,-3.0,-3128,20 hour,30 min,>10 hour,97.5,6990,367.89,19740994,J Virol. 2009 Nov;83(22):11902-13. ,"Kaiser N, Lischka P, Wagenknecht N, Stamminger T.",Inhibition of human cytomegalovirus replication via peptide aptamers directed against the nonconventional nuclear localization signal of the essential viral replication factor pUL84.,10.1128/JVI.01378-09,,Anti-HCMV
DRAVPe01472,SFAIKWEYVLLLFLL,15,Peptide 75(710-725)[Δ1],Synthetic construct(derived from HCV envelope protein),P26663,,HCV,Flaviviridae,Luciferase assay,[Ref.20156485]hepatitis C virus(HCVpp):inhibition of virus infection in Huh-7 human hepatoma cells(91% inhibition at 50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01472,DRAVPe01472.cif,Linear,Free,Free,,L,envelope protein,The peptide inhibits a post-binding step in HCV entry.,1855.29,C96H143N17O20,CDGHMNPQRT,L,5.72,1,1,0,2,11,164.67,2776,1.9 hour,>20 hour,>10 hour,182.0,6990,499.29,20156485,Antiviral Res. 2010 May;86(2):172-9.,"Liu R, Tewari M, Kong R, Zhang R, Ingravallo P, Ralston R.",A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. ,10.1016/j.antiviral.2010.02.316,,Anti-HCV
DRAVPe01473,FAIKWEYVLLLFLL,14,Peptide 75(710-725)[Δ1-2],Synthetic construct(derived from HCV envelope protein),P26663,,HCV,Flaviviridae,Luciferase assay,[Ref.20156485]hepatitis C virus(HCVpp):inhibition of virus infection in Huh-7 human hepatoma cells(95% inhibition at 50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01473,DRAVPe01473.cif,Linear,Free,Free,,L,envelope protein,The peptide inhibits a post-binding step in HCV entry.,1768.22,C93H138N16O18,CDGHMNPQRST,L,6.0,1,1,0,1,11,182.14,3116,1.1 hour,3 min,2 min,195.0,6990,537.69,20156485,Antiviral Res. 2010 May;86(2):172-9.,"Liu R, Tewari M, Kong R, Zhang R, Ingravallo P, Ralston R.",A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. ,10.1016/j.antiviral.2010.02.316,,Anti-HCV
DRAVPe01474,AIKWEYVLLLFLL,13,Peptide 75(710-725)[Δ1-3],Synthetic construct(derived from HCV envelope protein),P26663,,HCV,Flaviviridae,Luciferase assay,[Ref.20156485]hepatitis C virus(HCVpp):inhibition of virus infection in Huh-7 human hepatoma cells(92% inhibition at 50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01474,DRAVPe01474.cif,Linear,Free,Free,,L,envelope protein,The peptide inhibits a post-binding step in HCV entry.,1621.04,C84H129N15O17,CDGHMNPQRST,L,6.05,1,1,0,1,10,174.62,2818,4.4 hour,>20 hour,>10 hour,210.0,6990,582.5,20156485,Antiviral Res. 2010 May;86(2):172-9.,"Liu R, Tewari M, Kong R, Zhang R, Ingravallo P, Ralston R.",A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. ,10.1016/j.antiviral.2010.02.316,,Anti-HCV
DRAVPe01475,IKWEYVLLLFLL,12,Peptide 75(710-725)[Δ1-4],Synthetic construct(derived from HCV envelope protein),P26663,,HCV,Flaviviridae,Luciferase assay,[Ref.20156485]hepatitis C virus(HCVpp):inhibition of virus infection in Huh-7 human hepatoma cells(88% inhibition at 50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01475,DRAVPe01475.cif,Linear,Free,Free,,L,envelope protein,The peptide inhibits a post-binding step in HCV entry.,1549.96,C81H124N14O16,ACDGHMNPQRST,L,6.0,1,1,0,1,9,174.17,2637,20 hour,30 min,>10 hour,219.17,6990,635.45,20156485,Antiviral Res. 2010 May;86(2):172-9.,"Liu R, Tewari M, Kong R, Zhang R, Ingravallo P, Ralston R.",A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. ,10.1016/j.antiviral.2010.02.316,,Anti-HCV
DRAVPe01476,KWEYVLLLFLL,11,Peptide 75(710-725)[Δ1-5],Synthetic construct(derived from HCV envelope protein),P26663,,HCV,Flaviviridae,Luciferase assay,[Ref.20156485]hepatitis C virus(HCVpp):inhibition of virus infection in Huh-7 human hepatoma cells(78% inhibition at 50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01476,DRAVPe01476.cif,Linear,Free,Free,,L,envelope protein,The peptide inhibits a post-binding step in HCV entry.,1436.8,C75H113N13O15,ACDGHIMNPQRST,L,6.0,1,1,0,1,8,149.09,2145,1.3 hour,3 min,2 min,203.64,6990,699.0,20156485,Antiviral Res. 2010 May;86(2):172-9.,"Liu R, Tewari M, Kong R, Zhang R, Ingravallo P, Ralston R.",A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. ,10.1016/j.antiviral.2010.02.316,,Anti-HCV
DRAVPe01477,WEYVLLLFLL,10,Peptide 75(710-725)[Δ1-6],Synthetic construct(derived from HCV envelope protein),P26663,,HCV,Flaviviridae,Luciferase assay,[Ref.20156485]hepatitis C virus(HCVpp):inhibition of virus infection in Huh-7 human hepatoma cells(82% inhibition at 50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01477,DRAVPe01477.cif,Linear,Free,Free,,L,envelope protein,The peptide inhibits a post-binding step in HCV entry.,1308.63,C69H101N11O14,ACDGHIKMNPQRST,L,4.0,0,1,-1,1,8,203.0,2700,2.8 hour,3 min,2 min,224.0,6990,776.67,20156485,Antiviral Res. 2010 May;86(2):172-9.,"Liu R, Tewari M, Kong R, Zhang R, Ingravallo P, Ralston R.",A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. ,10.1016/j.antiviral.2010.02.316,,Anti-HCV
DRAVPe01478,VSFAIKWEYVLLLFL,15,Peptide 75(710-725)[Δ16],Synthetic construct(derived from HCV envelope protein),P26663,,HCV,Flaviviridae,Luciferase assay,[Ref.20156485]hepatitis C virus(HCVpp):inhibition of virus infection in Huh-7 human hepatoma cells(63% inhibition at 50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01478,DRAVPe01478.cif,Linear,Free,Free,,L,envelope protein,The peptide inhibits a post-binding step in HCV entry.,1841.27,C95H141N17O20,CDGHMNPQRT,L,5.97,1,1,0,2,11,167.33,2688,100 hour,>20 hour,>10 hour,175.33,6990,499.29,20156485,Antiviral Res. 2010 May;86(2):172-9.,"Liu R, Tewari M, Kong R, Zhang R, Ingravallo P, Ralston R.",A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. ,10.1016/j.antiviral.2010.02.316,,Anti-HCV
DRAVPe01479,VSFAIKWEYVLLLF,14,Peptide 75(710-725)[Δ15-16],Synthetic construct(derived from HCV envelope protein),P26663,,HCV,Flaviviridae,Luciferase assay,[Ref.20156485]hepatitis C virus(HCVpp):inhibition of virus infection in Huh-7 human hepatoma cells(49% inhibition at 50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01479,DRAVPe01479.cif,Linear,Free,Free,,L,envelope protein,The peptide inhibits a post-binding step in HCV entry.,1728.11,C89H130N16O19,CDGHMNPQRT,L,5.97,1,1,0,2,10,152.14,2196,100 hour,>20 hour,>10 hour,160.0,6990,537.69,20156485,Antiviral Res. 2010 May;86(2):172-9.,"Liu R, Tewari M, Kong R, Zhang R, Ingravallo P, Ralston R.",A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. ,10.1016/j.antiviral.2010.02.316,,Anti-HCV
DRAVPe01480,VSFAIKWEYVLLL,13,Peptide 75(710-725)[Δ14-16],Synthetic construct(derived from HCV envelope protein),P26663,,HCV,Flaviviridae,Luciferase assay,[Ref.20156485]hepatitis C virus(HCVpp):inhibition of virus infection in Huh-7 human hepatoma cells(49% inhibition at 50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01480,DRAVPe01480.cif,Linear,Free,Free,,L,envelope protein,The peptide inhibits a post-binding step in HCV entry.,1580.93,C80H121N15O18,CDGHMNPQRT,L,5.97,1,1,0,2,9,142.31,1898,100 hour,>20 hour,>10 hour,172.31,6990,582.5,20156485,Antiviral Res. 2010 May;86(2):172-9.,"Liu R, Tewari M, Kong R, Zhang R, Ingravallo P, Ralston R.",A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. ,10.1016/j.antiviral.2010.02.316,,Anti-HCV
DRAVPe01481,VSFAIKWEYVLL,12,Peptide 75(710-725)[Δ13-16],Synthetic construct(derived from HCV envelope protein),P26663,,HCV,Flaviviridae,Luciferase assay,[Ref.20156485]hepatitis C virus(HCVpp):inhibition of virus infection in Huh-7 human hepatoma cells(44% inhibition at 50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01481,DRAVPe01481.cif,Linear,Free,Free,,L,envelope protein,The peptide inhibits a post-binding step in HCV entry.,1467.77,C74H110N14O17,CDGHMNPQRT,LV,5.97,1,1,0,2,8,122.5,1406,100 hour,>20 hour,>10 hour,154.17,6990,635.45,20156485,Antiviral Res. 2010 May;86(2):172-9.,"Liu R, Tewari M, Kong R, Zhang R, Ingravallo P, Ralston R.",A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. ,10.1016/j.antiviral.2010.02.316,,Anti-HCV
DRAVPe01482,VSFAIKWEYVL,11,Peptide 75(710-725)[Δ12-16],Synthetic construct(derived from HCV envelope protein),P26663,,HCV,Flaviviridae,Luciferase assay,[Ref.20156485]hepatitis C virus(HCVpp):inhibition of virus infection in Huh-7 human hepatoma cells(17% inhibition at 50 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01482,DRAVPe01482.cif,Linear,Free,Free,,L,envelope protein,The peptide inhibits a post-binding step in HCV entry.,1354.61,C68H99N13O16,CDGHMNPQRT,V,5.97,1,1,0,2,7,99.09,914,100 hour,>20 hour,>10 hour,132.73,6990,699.0,20156485,Antiviral Res. 2010 May;86(2):172-9.,"Liu R, Tewari M, Kong R, Zhang R, Ingravallo P, Ralston R.",A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. ,10.1016/j.antiviral.2010.02.316,,Anti-HCV
DRAVPe01483,VSFAIKWEYVLLLFLL,16,Peptide 75(710-725),Synthetic construct(derived from HCV envelope protein),P26663,,HCV,Flaviviridae,Luciferase assay,"[Ref.20156485]hepatitis C virus(HCVpp):inhibition of virus infection in Huh-7 human hepatoma cells(EC50=0.3 ± 0.4 μM,EC90=14 ± 12 μM);inhibition of virus infection in primary human hepatocytes(EC50=0.3μM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20156485]No cytotoxicity against Huh-7 cells.,DRAVPe01483,DRAVPe01483.cif,Linear,Free,Free,,L,envelope protein,The peptide inhibits a post-binding step in HCV entry.,1954.43,C101H152N18O21,CDGHMNPQRT,L,5.97,1,1,0,2,12,180.63,3180,100 hour,>20 hour,>10 hour,188.75,6990,466.0,20156485,Antiviral Res. 2010 May;86(2):172-9.,"Liu R, Tewari M, Kong R, Zhang R, Ingravallo P, Ralston R.",A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. ,10.1016/j.antiviral.2010.02.316,,Anti-HCV
DRAVPe01484,RWMVWRHWFHRLRLPYNPGKNKQNQQWP,28,DN57opt,Synthetic construct,No entry found,,DENV,Flaviviridae,Focus reduction assay,"[Ref.20582308]dengue 2 virus(DENV-2):inhibition of virus infection in LLC-MK2 cells(IC50=8±1 μM,97% inhibition at 20μM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20582308]the peptide was found to be mildly toxic to LLC-MK2 cells at 40 µM.,DRAVPe01484,DRAVPe01484.cif,Linear,Free,Free,,L,E glycoprotein,"The peptide blocks virus:cell binding, interfere with a step during viral entry, alter the surface structure of dengue viral particles, and that they interact directly with dengue virus envelope protein.",3760.35,C176H252N56O36S,ACDEIST,RW,12.01,8,0,8,5,8,-167.14,-8731,1 hour,2 min,2 min,38.21,23490,870.0,20582308,PLoS Negl Trop Dis. 2010 Jun 22;4(6):e721. ,"Costin JM, Jenwitheesuk E, Lok SM, Hunsperger E, Conrads KA, Fontaine KA, Rees CR, Rossmann MG, Isern S, Samudrala R, Michael SF.",Structural optimization and de novo design of dengue virus entry inhibitory peptides.,10.1371/journal.pntd.0000721,,Anti-DENV
DRAVPe01485,RQMRAWGQDYQHGGMGYSC,19,DN81opt,Synthetic construct,No entry found,,DENV,Flaviviridae,Focus reduction assay,"[Ref.20582308]dengue 2 virus(DENV-2):inhibition of virus infection in LLC-MK2 cells(IC50=36±6  μM,57% inhibition at 50μM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01485,DRAVPe01485.cif,Linear,Free,Free,,L,E glycoprotein,"The peptide blocks virus:cell binding, interfere with a step during viral entry, alter the surface structure of dengue viral particles, and that they interact directly with dengue virus envelope protein.",2231.47,C93H135N31O28S3,EFIKLNPTV,G,8.21,3,1,2,8,2,-126.32,-4964,1 hour,2 min,2 min,5.26,8480,471.11,20582308,PLoS Negl Trop Dis. 2010 Jun 22;4(6):e721. ,"Costin JM, Jenwitheesuk E, Lok SM, Hunsperger E, Conrads KA, Fontaine KA, Rees CR, Rossmann MG, Isern S, Samudrala R, Michael SF.",Structural optimization and de novo design of dengue virus entry inhibitory peptides.,10.1371/journal.pntd.0000721,,Anti-DENV
DRAVPe01486,FWFTLIKTQAKQPARYRRFC,20,1OAN1,Synthetic construct,No entry found,,DENV,Flaviviridae,Focus reduction assay,"[Ref.20582308]dengue 2 virus(DENV-2):inhibition of virus infection in LLC-MK2 cells(IC50=7±4  μM,99% inhibition at 50 μM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.20582308]the peptide showed no toxic to LLC-MK2 cells at 50 µM.,DRAVPe01486,DRAVPe01486.cif,Linear,Free,Free,,L,E glycoprotein,"The peptide blocks virus:cell binding, interfere with a step during viral entry, alter the surface structure of dengue viral particles, and that they interact directly with dengue virus envelope protein.",2561.05,C121H182N34O26S,DEGHMNSV,FR,11.01,5,0,5,4,8,-53.5,-4621,1.1 hour,3 min,2 min,49.0,6990,367.89,20582308,PLoS Negl Trop Dis. 2010 Jun 22;4(6):e721. ,"Costin JM, Jenwitheesuk E, Lok SM, Hunsperger E, Conrads KA, Fontaine KA, Rees CR, Rossmann MG, Isern S, Samudrala R, Michael SF.",Structural optimization and de novo design of dengue virus entry inhibitory peptides.,10.1371/journal.pntd.0000721,,Anti-DENV
DRAVPe01487,LLDCWVRLGRYLLRRLKT,18,GBVA1(1-18),Synthetic construct(derived from GBVA non-structutal protein 5A),Q69422,,HCV,Flaviviridae,qRT-PCR assay,"[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=10 μM,88% inhibition at 20 μM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01487,DRAVPe01487.cif,Linear,Free,Free,,L,Not found,The peptide inhibits virus entry.,2274.8,C104H176N32O23S,AEFHIMNPQS,L,10.85,5,1,4,4,8,4.44,-3855,5.5 hour,3 min,2 min,146.11,6990,411.18,23175359,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01488,LLDCWVRLGRYLLRRLKTPFTRL,23,GBVA2(1-23),Synthetic construct(derived from GBVA non-structutal protein 5A),Q69422,,HCV,Flaviviridae,qRT-PCR assay,"[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=15 μM,50% inhibition at 20 μM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01488,DRAVPe01488.cif,Linear,Free,Free,,L,Not found,The peptide inhibits virus entry.,2889.55,C134H222N40O29S,AEHIMNQS,L,11.44,6,1,5,5,10,2.61,-4814,5.5 hour,3 min,2 min,131.3,6990,317.73,23175359,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01489,LLDCWVRLGRYLLRRLKTPFT,21,GBVA3(1-21),Synthetic construct(derived from GBVA non-structutal protein 5A),Q69422,,HCV,Flaviviridae,qRT-PCR assay,"[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50>20 μM,0% inhibition at 20 μM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01489,DRAVPe01489.cif,Linear,Free,Free,,L,Not found,The peptide inhibits virus entry.,2620.2,C122H199N35O27S,AEHIMNQS,L,10.85,5,1,4,5,9,6.19,-3814,5.5 hour,3 min,2 min,125.24,6990,349.5,23175359,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01490,LLDCWVRLGRYLLRRLKTP,19,GBVA4(1-19),Synthetic construct(derived from GBVA non-structutal protein 5A),Q69422,,HCV,Flaviviridae,qRT-PCR assay,"[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=3 μM,99% inhibition at 20 μM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01490,DRAVPe01490.cif,Linear,Free,Free,,L,Not found,The peptide inhibits virus entry.,2371.92,C109H183N33O24S,AEFHIMNQS,L,10.85,5,1,4,4,8,-4.21,-3855,5.5 hour,3 min,2 min,138.42,6990,388.33,23175359,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01491,LLDCWVRLGRYLLRRLK,17,GBVA5(1-17),Synthetic construct(derived from GBVA non-structutal protein 5A),Q69422,,HCV,Flaviviridae,qRT-PCR assay,"[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=5 μM,99% inhibition at 20 μM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01491,DRAVPe01491.cif,Linear,Free,Free,,L,Not found,The peptide inhibits virus entry.,2173.7,C100H169N31O21S,AEFHIMNPQST,L,10.85,5,1,4,3,8,8.82,-3598,5.5 hour,3 min,2 min,154.71,6990,436.88,23175359,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01492,LDCWVRLGRYLLRRLKTPFTRL,22,GBVA6(2-23),Synthetic construct(derived from GBVA non-structutal protein 5A),Q69422,,HCV,Flaviviridae,qRT-PCR assay,"[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50>20 μM,0 inhibition at 20 μM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01492,DRAVPe01492.cif,Linear,Free,Free,,L,Not found,The peptide inhibits virus entry.,2776.39,C128H211N39O28S,AEHIMNQS,L,11.44,6,1,5,5,9,-14.55,-5306,5.5 hour,3 min,2 min,119.55,6990,332.86,23175359,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01493,CWVRLGRYLLRRLKTPFTRL,20,GBVA7(4-23),Synthetic construct(derived from GBVA non-structutal protein 5A),Q69422,,HCV,Flaviviridae,qRT-PCR assay,"[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=12 μM,89% inhibition at 20 μM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01493,DRAVPe01493.cif,Linear,Free,Free,,L,Not found,The peptide inhibits virus entry.,2548.14,C118H195N37O24S,ADEHIMNQS,LR,11.83,6,0,6,5,8,-17.5,-4926,1.2 hour,>20 hour,>10 hour,112.0,6990,367.89,23175359,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01494,LDCWVRLGRYLLRRLKTP,18,GBVA8(2-19),Synthetic construct(derived from GBVA non-structutal protein 5A),Q69422,,HCV,Flaviviridae,qRT-PCR assay,"[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=4 μM,99% inhibition at 20 μM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01494,DRAVPe01494.cif,Linear,Free,Free,,L,Not found,The peptide inhibits virus entry.,2258.76,C103H172N32O23S,AEFHIMNQS,L,10.85,5,1,4,4,7,-25.56,-4347,5.5 hour,3 min,2 min,124.44,6990,411.18,23175359,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01495,DCWVRLGRYLLRRLKTPF,18,GBVA9(3-20),Synthetic construct(derived from GBVA non-structutal protein 5A),Q69422,,HCV,Flaviviridae,qRT-PCR assay,"[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=12 μM,90% inhibition at 20 μM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01495,DRAVPe01495.cif,Linear,Free,Free,,L,Not found,The peptide inhibits virus entry.,2292.78,C106H170N32O23S,AEHIMNQS,LR,10.85,5,1,4,4,7,-31.11,-4541,1.1 hour,3 min,>10 hour,102.78,6990,411.18,23175359,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01496,CWVRLGRYLLRRLKTPFT,18,GBVA10(4-21),Synthetic construct(derived from GBVA non-structutal protein 5A),Q69422,,HCV,Flaviviridae,qRT-PCR assay,"[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=2 μM,100% inhibition at 20 μM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01496,DRAVPe01496.cif,Linear,Free,Free,,L,Not found,The peptide inhibits virus entry.,2278.79,C106H172N32O22S,ADEHIMNQS,LR,11.56,5,0,5,5,7,-15.56,-3926,1.2 hour,>20 hour,>10 hour,102.78,6990,411.18,23175359,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01497,WVRLGRYLLRRLKTPFTR,18,GBVA11(5-22),Synthetic construct(derived from GBVA non-structutal protein 5A),Q69422,,HCV,Flaviviridae,qRT-PCR assay,"[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=12 μM,58% inhibition at 20 μM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01497,DRAVPe01497.cif,Linear,Free,Free,,L,Not found,The peptide inhibits virus entry.,2331.84,C109H179N35O22,ACDEHIMNQS,R,12.18,6,0,6,4,7,-54.44,-5546,2.8 hour,3 min,2 min,102.78,6990,411.18,23175359,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01498,VRLGRYLLRRLKTPFTRL,18,GBVA12(6-23),Synthetic construct(derived from GBVA non-structutal protein 5A),Q69422,,HCV,Flaviviridae,qRT-PCR assay,"[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50>20 μM,0 inhibition at 20 μM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01498,DRAVPe01498.cif,Linear,Free,Free,,L,Not found,The peptide inhibits virus entry.,2258.79,C104H180N34O22,ACDEHIMNQSW,LR,12.18,6,0,6,4,7,-28.33,-5287,100 hour,>20 hour,>10 hour,124.44,1490,87.65,23175359,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01499,CWVRLGRYKLRRLKTPFT,18,GBVA10-1(L9K),Synthetic construct(derived from GBVA non-structutal protein 5A),No entry found,,HCV,Flaviviridae,qRT-PCR assay,[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50>20 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01499,DRAVPe01499.cif,Linear,Free,Free,,L,Not found,The peptide inhibits virus entry.,2293.81,C106H173N33O22S,ADEHIMNQS,R,11.57,6,0,6,5,6,-58.33,-4973,1.2 hour,>20 hour,>10 hour,81.11,6990,411.18,23175360,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01500,CWVRLGRYSLRRLKTPFT,18,GBVA10-2(L9S),Synthetic construct(derived from GBVA non-structutal protein 5A),No entry found,,HCV,Flaviviridae,qRT-PCR assay,[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=18 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01500,DRAVPe01500.cif,Linear,Free,Free,,L,Not found,The peptide inhibits virus entry.,2252.71,C103H166N32O23S,ADEHIMNQ,R,11.56,5,0,5,6,6,-41.11,-4758,1.2 hour,>20 hour,>10 hour,81.11,6990,411.18,23175359,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01501,CWVRLGRYALRRLKTPFT,18,GBVA10-3(L9A),Synthetic construct(derived from GBVA non-structutal protein 5A),No entry found,,HCV,Flaviviridae,qRT-PCR assay,[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01501,DRAVPe01501.cif,Linear,Free,Free,,L,Not found,The peptide inhibits virus entry.,2236.71,C103H166N32O22S,DEHIMNQS,R,11.56,5,0,5,5,7,-26.67,-4237,1.2 hour,>20 hour,>10 hour,86.67,6990,411.18,23175359,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01502,CWVRLGRYVLRRLKTPFT,18,GBVA10-4(L9V),Synthetic construct(derived from GBVA non-structutal protein 5A),No entry found,,HCV,Flaviviridae,qRT-PCR assay,[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=16 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01502,DRAVPe01502.cif,Linear,Free,Free,,L,Not found,The peptide inhibits virus entry.,2264.77,C105H170N32O22S,ADEHIMNQS,R,11.56,5,0,5,5,7,-13.33,-4014,1.2 hour,>20 hour,>10 hour,97.22,6990,411.18,23175359,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01503,CWVRLARYLLRRLKTPFT,18,GBVA10-5(G6A),Synthetic construct(derived from GBVA non-structutal protein 5A),No entry found,,HCV,Flaviviridae,qRT-PCR assay,[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=2.5 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01503,DRAVPe01503.cif,Linear,Free,Free,,L,Not found,The peptide inhibits virus entry.,2292.82,C107H174N32O22S,DEGHIMNQS,LR,11.56,5,0,5,4,8,-3.33,-3839,1.2 hour,>20 hour,>10 hour,108.33,6990,411.18,23175359,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01504,CWVRLVRYLLRRLKTPFT,18,GBVA10-6(G6V),Synthetic construct(derived from GBVA non-structutal protein 5A),No entry found,,HCV,Flaviviridae,qRT-PCR assay,[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=1.25 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01504,DRAVPe01504.cif,Linear,Free,Free,,L,Not found,The peptide inhibits virus entry.,2320.87,C109H178N32O22S,ADEGHIMNQS,LR,11.56,5,0,5,4,8,10.0,-3616,1.2 hour,>20 hour,>10 hour,118.89,6990,411.18,23175359,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01505,CWVRLLRYLLRRLKTPFT,18,GBVA10-7(G6L),Synthetic construct(derived from GBVA non-structutal protein 5A),No entry found,,HCV,Flaviviridae,qRT-PCR assay,[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=1.25 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01505,DRAVPe01505.cif,Linear,Free,Free,,L,Not found,The peptide inhibits virus entry.,2334.9,C110H180N32O22S,ADEGHIMNQS,L,11.56,5,0,5,4,8,7.78,-3528,1.2 hour,>20 hour,>10 hour,124.44,6990,411.18,23175359,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01506,CWVRLLRYLLRRLKTLFT,18,GBVA10-8(G6L/P16L),Synthetic construct(derived from GBVA non-structutal protein 5A),No entry found,,HCV,Flaviviridae,qRT-PCR assay,[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=1.25 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01506,DRAVPe01506.cif,Linear,Free,Free,,L,Not found,The peptide inhibits virus entry.,2350.94,C111H184N32O22S,ADEGHIMNPQS,L,11.56,5,0,5,4,9,37.78,-3036,1.2 hour,>20 hour,>10 hour,146.11,6990,411.18,23175359,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01507,CWVRLGRYLLRRLKTLFT,18,GBVA10-9(P16L),Synthetic construct(derived from GBVA non-structutal protein 5A),No entry found,,HCV,Flaviviridae,qRT-PCR assay,[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=0.16 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.23175359]HepG2 cell:LC50=90 μM(4h of treatment);##HeLa cell:LC50=40 μM(4h of treatment);##Huh7.5.1 cell:LC50=90 μM(4h of treatment);LC50=50 μM(24h of treatment).,DRAVPe01507,DRAVPe01507.cif,Linear,Free,Free,,L,Not found,GBVA10-9 can inhibit virus entry at a postattachment step.,2294.84,C107H176N32O22S,ADEHIMNPQS,L,11.56,5,0,5,5,8,14.44,-3434,1.2 hour,>20 hour,>10 hour,124.44,6990,411.18,23175359,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01508,CWVRLGRYILRRLKTPFT,18,GBVA10-10(L9I),Synthetic construct(derived from GBVA non-structutal protein 5A),No entry found,,HCV,Flaviviridae,qRT-PCR assay,[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01508,DRAVPe01508.cif,Linear,Free,Free,,L,Not found,The peptide inhibits virus entry.,2278.79,C106H172N32O22S,ADEHMNQS,R,11.56,5,0,5,5,7,-11.67,-3926,1.2 hour,>20 hour,>10 hour,102.78,6990,411.18,23175359,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01509,CWVRLGRYILRRIKTPFT,18,GBVA10-11(L9I/L13I),Synthetic construct(derived from GBVA non-structutal protein 5A),No entry found,,HCV,Flaviviridae,qRT-PCR assay,[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=0.63 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01509,DRAVPe01509.cif,Linear,Free,Free,,L,Not found,The peptide inhibits virus entry.,2278.79,C106H172N32O22S,ADEHMNQS,R,11.56,5,0,5,5,7,-7.78,-3926,1.2 hour,>20 hour,>10 hour,102.78,6990,411.18,23175359,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01510,CWVRIGRYILRRIKTPFT,18,GBVA10-12(L5I/L9I/L13I),Synthetic construct(derived from GBVA non-structutal protein 5A),No entry found,,HCV,Flaviviridae,qRT-PCR assay,[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50>20 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01510,DRAVPe01510.cif,Linear,Free,Free,,L,Not found,The peptide inhibits virus entry.,2278.79,C106H172N32O22S,ADEHMNQS,R,11.56,5,0,5,5,7,-3.89,-3926,1.2 hour,>20 hour,>10 hour,102.78,6990,411.18,23175359,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01511,KWVRLGRKLLRRLKKPFK,18,GBVA10-13(C1K/Y8K/T15K/T18K),Synthetic construct(derived from GBVA non-structutal protein 5A),No entry found,,HCV,Flaviviridae,qRT-PCR assay,[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50>20 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01511,DRAVPe01511.cif,Linear,Free,Free,,L,Not found,The peptide inhibits virus entry.,2322.96,C110H192N36O19,ACDEHIMNQSTY,K,12.49,9,0,9,1,7,-101.11,-5746,1.3 hour,3 min,2 min,102.78,5500,323.53,23175361,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01512,KWVRLGRKLLRRLKKPFT,18,GBVA10-14(C1K/Y8K/T15K),Synthetic construct(derived from GBVA non-structutal protein 5A),No entry found,,HCV,Flaviviridae,qRT-PCR assay,[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50>20 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01512,DRAVPe01512.cif,Linear,Free,Free,,L,Not found,The peptide inhibits virus entry.,2295.9,C108H187N35O20,ACDEHIMNQSY,KLR,12.48,8,0,8,2,7,-83.33,-5448,1.3 hour,3 min,2 min,102.78,5500,323.53,23175359,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01513,CWVRLGRKLLRRLKKPFT,18,GBVA10-15(Y8K/T15K),Synthetic construct(derived from GBVA non-structutal protein 5A),No entry found,,HCV,Flaviviridae,qRT-PCR assay,[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50>20 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01513,DRAVPe01513.cif,Linear,Free,Free,,L,Not found,The peptide inhibits virus entry.,2270.86,C105H180N34O20S,ADEHIMNQSY,LR,12.01,7,0,7,3,7,-47.78,-4765,1.2 hour,>20 hour,>10 hour,102.78,5500,323.53,23175359,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01514,CWVRLGRKLLRRLKTPFT,19,GBVA10-16(Y8K),Synthetic construct(derived from GBVA non-structutal protein 5A),No entry found,,HCV,Flaviviridae,qRT-PCR assay,[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50>20 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01514,DRAVPe01514.cif,Linear,Free,Free,,L,Not found,The peptide inhibits virus entry.,2243.79,C103H175N33O21S,ADEHIMNQSY,LR,12.01,6,0,6,4,7,-30.0,-4467,1.2 hour,>20 hour,>10 hour,102.78,5500,323.53,23175359,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01515,EWVRLGRELLRRLKEPFT,18,GBVA10-17(C1E/Y8E/T15E),Synthetic construct(derived from GBVA non-structutal protein 5A),No entry found,,HCV,Flaviviridae,qRT-PCR assay,[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50>20 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01515,DRAVPe01515.cif,Linear,Free,Free,,L,Not found,The peptide inhibits virus entry.,2298.72,C105H172N32O26,ACDHIMNQSY,LR,10.67,5,3,2,2,7,-76.67,-5826,1 hour,30 min,>10 hour,102.78,5500,323.53,23175359,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01516,EWVRLGRELLRRLKEPFE,19,GBVA10-18(C1E/Y8E/T15E/T18E),Synthetic construct(derived from GBVA non-structutal protein 5A),No entry found,,HCV,Flaviviridae,qRT-PCR assay,[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50>20 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01516,DRAVPe01516.cif,Linear,Free,Free,,L,Not found,The peptide inhibits virus entry.,2326.73,C106H172N32O27,ACDHIMNQSTY,ELR,8.84,5,4,1,1,7,-92.22,-6250,1 hour,30 min,>10 hour,102.78,5500,323.53,23175359,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01517,CWVRLGRELLRRLKEPFT,18,GBVA10-19(Y8E/T15E),Synthetic construct(derived from GBVA non-structutal protein 5A),No entry found,,HCV,Flaviviridae,qRT-PCR assay,[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50>20 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01517,DRAVPe01517.cif,Linear,Free,Free,,L,Not found,The peptide inhibits virus entry.,2272.74,C103H170N32O24S,ADHIMNQSY,LR,10.69,5,2,3,3,7,-43.33,-5017,1.2 hour,>20 hour,>10 hour,102.78,5500,323.53,23175359,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01518,CWVRLGRELLRRLKTPFT,18,GBVA10-20(Y8E),Synthetic construct(derived from GBVA non-structutal protein 5A),No entry found,,HCV,Flaviviridae,qRT-PCR assay,[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50>20 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01518,DRAVPe01518.cif,Linear,Free,Free,,L,Not found,The peptide inhibits virus entry.,2244.73,C102H170N32O23S,ADHIMNQSY,LR,11.54,5,1,4,4,7,-27.78,-4593,1.2 hour,>20 hour,>10 hour,102.78,5500,323.53,23175359,J Virol. 2013 Feb;87(3):1649-57.,"Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W.",Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.,10.1128/JVI.02201-12,,Anti-HCV
DRAVPe01519,IPESSELTLQELLGEERR,18,E6ap18,Synthetic construct(derived from E6-associated protein (E6AP)),No entry found,,HPV,Papillomaviridae,CD spectroscopy,[Ref.15182185]Human papillomavirus(HPV):inhibition of E6-E6ap interaction(IC50=10.5±1.4 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01519,DRAVPe01519.cif,Linear,Acetylation,Amidation,,L,E6 protein,No machanism information found in the reference(s) presented in this entry,2099.33,C89H151N25O33,ACDFHKMNVWY,E,4.33,2,5,-3,4,5,-81.11,-5326,20 hour,30 min,>10 hour,108.33,0,0.0,15182185,Biochemistry. 2004 Jun 15;43(23):7421-31. ,"Liu Y, Liu Z, Androphy E, Chen J, Baleja JD.",Design and characterization of helical peptides that inhibit the E6 protein of papillomavirus.,10.1021/bi049552a,,Anti-HPV
DRAVPe01520,YKFACPECPKRFMRSDHLTLHILLHENKK,29,E6apc1,Synthetic construct(derived from E6-associated protein (E6AP)),No entry found,,HPV,Papillomaviridae,CD spectroscopy,[Ref.15182185]Human papillomavirus(HPV):inhibition of E6-E6ap interaction(IC50>1000 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01520,DRAVPe01520.cif,Linear,Acetylation,Amidation,,L,E6 protein,No machanism information found in the reference(s) presented in this entry,3556.23,C160H252N46O40S3,GQVW,KL,9.24,9,3,6,6,8,-69.66,-6383,2.8 hour,10 min,2 min,70.69,1615,57.68,15182185,Biochemistry. 2004 Jun 15;43(23):7421-31. ,"Liu Y, Liu Z, Androphy E, Chen J, Baleja JD.",Design and characterization of helical peptides that inhibit the E6 protein of papillomavirus.,10.1021/bi049552a,,Anti-HPV
DRAVPe01521,YKFACPECPKRFMRSDHLSKHITLHELLGEERR,33,E6apc2,Synthetic construct(derived from E6-associated protein (E6AP)),No entry found,,HPV,Papillomaviridae,CD spectroscopy,[Ref.15182185]Human papillomavirus(HPV):inhibition of E6-E6ap interaction(IC50=19.3±2.9μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01521,DRAVPe01521.cif,Linear,Acetylation,Amidation,,L,E6 protein,No machanism information found in the reference(s) presented in this entry,4028.68,C177H280N54O48S3,NQVW,ELR,8.82,10,5,5,7,8,-90.91,-9756,2.8 hour,10 min,2 min,62.12,1615,50.47,15182185,Biochemistry. 2004 Jun 15;43(23):7421-31. ,"Liu Y, Liu Z, Androphy E, Chen J, Baleja JD.",Design and characterization of helical peptides that inhibit the E6 protein of papillomavirus.,10.1021/bi049552a,,Anti-HPV
DRAVPe01522,ALQELLGQWLKDGGPSSGRPPPS,23,E6apn1,Synthetic construct(derived from E6-associated protein (E6AP)),No entry found,,HPV,Papillomaviridae,CD spectroscopy,[Ref.15182185]Human papillomavirus(HPV):inhibition of E6-E6ap interaction(IC50=36.8±3.2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01522,DRAVPe01522.cif,Linear,Acetylation,Amidation,,L,E6 protein,No machanism information found in the reference(s) presented in this entry,2390.68,C106H168N30O33,CFHIMNTVY,GLP,6.11,2,2,0,7,6,-72.61,-2970,4.4 hour,>20 hour,>10 hour,72.17,5500,250.0,15182185,Biochemistry. 2004 Jun 15;43(23):7421-31. ,"Liu Y, Liu Z, Androphy E, Chen J, Baleja JD.",Design and characterization of helical peptides that inhibit the E6 protein of papillomavirus.,10.1021/bi049552a,,Anti-HPV
DRAVPe01523,ALQELLGEYIQWLKDGGPSSGRPPPS,26,E6apn2,Synthetic construct(derived from E6-associated protein (E6AP)),No entry found,,HPV,Papillomaviridae,CD spectroscopy,[Ref.15182185]Human papillomavirus(HPV):inhibition of E6-E6ap interaction(IC50=26.2±4.8 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01523,DRAVPe01523.cif,Linear,Acetylation,Amidation,,L,E6 protein,No machanism information found in the reference(s) presented in this entry,2796.13,C126H195N33O39,CFHMNTV,GLP,4.68,2,3,-1,8,7,-65.38,-3173,4.4 hour,>20 hour,>10 hour,78.85,6990,279.6,15182185,Biochemistry. 2004 Jun 15;43(23):7421-31. ,"Liu Y, Liu Z, Androphy E, Chen J, Baleja JD.",Design and characterization of helical peptides that inhibit the E6 protein of papillomavirus.,10.1021/bi049552a,,Anti-HPV
DRAVPe01524,YLQELLGE,8,E6apm,Synthetic construct(derived from E6-associated protein (E6AP)),No entry found,,HPV,Papillomaviridae,CD spectroscopy,[Ref.15182185]Human papillomavirus(HPV):inhibition of E6-E6ap interaction(IC50=74.3±1.9 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01524,DRAVPe01524.cif,Linear,Acetylation,Amidation,,L,E6 protein,No machanism information found in the reference(s) presented in this entry,964.08,C44H69N9O15,ACDFHIKMNPRSTVW,L,3.79,0,2,-2,2,3,-10.0,-360,2.8 hour,10 min,2 min,146.25,1490,212.86,15182185,Biochemistry. 2004 Jun 15;43(23):7421-31. ,"Liu Y, Liu Z, Androphy E, Chen J, Baleja JD.",Design and characterization of helical peptides that inhibit the E6 protein of papillomavirus.,10.1021/bi049552a,,Anti-HPV
DRAVPe01525,LLPIVGNLLKSLL,13,Temporin B,Rana temporaria(European common frog),P79874,6GIL,HSV,Herpesviridae,,[Ref.29483113]Herpes simplex virus 1 (HSV-1):viral titer inhibition on Vero cells(IC50=2.507 μg/ml);inhibition of HSV-1 replication in HeLa S3 cells(IC50=93 μg/ml);inhibition of HSV-1 replication in HEK-293 cells(IC50=84 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.29483113]Vero cells:CC50=90.4μg/ml;##no toxicity was observed at concentrations as high as 50 μg/ml against HeLa S3 and HEK-293 cells.,DRAVPe01525,DRAVPe01525.cif,Linear,Free,Amidation,,L,envelope,"Temporin B could disrupt the envelope of virus,and partially affected different stages of the HSV-1 life cycle, including the attachment and the entry of the virus into the host cell, as well as the subsequent postinfection phase.",1392.79,C67H121N15O16,ACDEFHMQRTWY,L,8.75,1,0,1,3,8,163.85,2383,5.5 hour,3 min,2 min,232.31,0,0.0,29483113,Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02367-17.,"Marcocci ME, Amatore D, Villa S, Casciaro B, Aimola P, Franci G, Grieco P, Galdiero M, Palamara AT, Mangoni ML, Nencioni L. ",The Amphibian Antimicrobial Peptide Temporin B Inhibits In Vitro Herpes Simplex Virus 1 Infection.,10.1128/AAC.02367-17,,Anti-HSV
DRAVPe01526,VTCYCRRTRCGFRERLSGACGYRGRIYRLCCR,32,RatNP-1,Rattus norvegicus,Q62716,,HSV,Herpesviridae,,[Ref.12543649]HSV-2:inhibition of HSV-2 infection in Vero cells(98.7%±0.7% inhibition at 25 μg/ ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.12543649]No cytotoxic effect on CaSki cells was observed at the concentration of 25 or 100 μg/ml.,DRAVPe01526,DRAVPe01526.cif,Cyclic,Free,Free,"Disulfide bonds between Cys3 and Cys31,Cys5 and Cys20,Cys10 and Cys30.",L,membrane,NP-1 inactivates HSV and prevents viral entry and cell-to-cell spread. NP-1 blocks fusion events important in HSV acquisition and transmission.,3835.54,C158H261N59O41S6,DHKMNPQW,R,9.99,9,1,8,16,6,-49.38,-11502,100 hour,>20 hour,>10 hour,48.75,4845,156.29,12543649,Antimicrob Agents Chemother. 2003 Feb;47(2):494-500.,"Sinha S, Cheshenko N, Lehrer RI, Herold BC.","NP-1, a rabbit alpha-defensin, prevents the entry and intercellular spread of herpes simplex virus type 2. ",10.1128/AAC.47.2.494-500.2003,,Anti-HSV
DRAVPe01527,FLSGIVGMLGKLF,13,"Temporin-SHa (temporin SHa; Temporin-1Sa, Temp-1Sa; XXA; UCLL1c; natural AMPs; frog, amphibians, animals)","Pelophylax saharica, North Africa",B3KYH4,,HSV,Herpesviridae,,[Ref.30669255]HSV-1:inhibition of HSV-1 replication in human keratinocytes(52% inhibition at 10 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30669255]Significant cytotoxicity was observed on Keratinocyte at the concentration of 20 μM with a cell viability of 77%,DRAVPe01527,DRAVPe01527.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,1381.74,C67H108N14O15S,ACDEHNPQRTWY,GL,8.75,1,0,1,4,7,166.92,2590,1.1 hour,3 min,2 min,142.31,0,0.0,30669255,Viruses. 2019 Jan 18;11(1):77.,"Roy M, Lebeau L, Chessa C, Damour A, Ladram A, Oury B, Boutolleau D, Bodet C, Lévêque N. ",Comparison of Anti-Viral Activity of Frog Skin Anti-Microbial Peptides Temporin-Sha and [K³]SHa to LL-37 and Temporin-Tb against Herpes Simplex Virus Type 1.,10.3390/v11010077,,Anti-HSV
DRAVPe01528,FLKGIVGMLGKLF,13,Temporin-Sha[K3],Synthetic construct(derived from Temporin-SHa),No entry found,,HSV,Herpesviridae,,"[Ref.30669255]HSV-1:inhibition of HSV-1 replication in human keratinocytes(48% inhibition at 2.5 µM,57% inhibition at 5 µM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30669255]Significant cytotoxicity was observed on Keratinocyte at the concentration of 10 μM with a cell viability of 74%.,DRAVPe01528,DRAVPe01528.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,1422.84,C70H115N15O14S,ACDEHNPQRSTWY,GL,10.0,2,0,2,3,7,143.08,2375,1.1 hour,3 min,2 min,142.31,0,0.0,30669255,Viruses. 2019 Jan 18;11(1):77.,"Roy M, Lebeau L, Chessa C, Damour A, Ladram A, Oury B, Boutolleau D, Bodet C, Lévêque N. ",Comparison of Anti-Viral Activity of Frog Skin Anti-Microbial Peptides Temporin-Sha and [K³]SHa to LL-37 and Temporin-Tb against Herpes Simplex Virus Type 1.,10.3390/v11010077,,Anti-HSV
DRAVPe01529,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,37,LL-37 (human cathelicidin LL-37),"neutrophils, monocytes; mast cells; lymphocytes, Mesenchymal Stem Cells; islets; skin, sweat; airway surface liquid, saliva; Homo sapiens; Also Pan troglodytes",P49913,2K6O,"HSV, EBOV","Herpesviridae, Filoviridae",Plaque assay,"[Ref.30669255]HSV-1:inhibition of HSV-1 replication in human keratinocytes(75% inhibition at 1.25 µM,94% inhibition at 2.5 µM).##[Ref.32252021]Ebola Virus(EBOV):inhibition of viral infection in Hela cells(IC50=4.03 µM);inhibition of viral infection in primary macrophages(IC50>20 µM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30669255]Significant cytotoxicity was observed on Keratinocyte at the concentration of 5 μM with a cell viability of 80%.,DRAVPe01529,DRAVPe01529.cif,Cyclic,Cyclization (N termini to C termini),Cyclization (N termini to C termini),,L,Not found,"Act as CatB inhibitors to block the endosomal processing of EBOV GP, thus preventing virus entry.",4493.32,C205H340N60O53,ACHMWY,K,10.61,11,5,6,6,13,-72.43,-11100,5.5 hour,3 min,2 min,89.46,0,0.0,30669255##32252021,Viruses. 2019 Jan 18;11(1):77.##iScience. 2020 Apr 24;23(4):100999.,"Roy M, Lebeau L, Chessa C, Damour A, Ladram A, Oury B, Boutolleau D, Bodet C, Lévêque N. ##Yu Y, Cooper CL, Wang G, Morwitzer MJ, Kota K, Tran JP, Bradfute SB, Liu Y, Shao J, Zhang AK, Luo LG, Reid SP, Hinrichs SH, Su K.",Comparison of Anti-Viral Activity of Frog Skin Anti-Microbial Peptides Temporin-Sha and [K³]SHa to LL-37 and Temporin-Tb against Herpes Simplex Virus Type 1.##Engineered Human Cathelicidin Antimicrobial Peptides Inhibit Ebola Virus Infection.,10.3390/v11010077##10.1016/j.isci.2020.100999,,"Anti-HSV, Anti-EBOV"
DRAVPe01530,LLGDLLRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,37,"LL-37[F5,6L]",Synthetic construct(derived from human cathelicidin LL-37),No entry found,,HIV,Retroviridae,,[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50=1.6 μM).(EC50:50% effective concentration for inhibition of virus replication),No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18591279]CEM-SS cells:TC50=18.4 μM.(TC50:the concentration that reduced cell viability by 50%),DRAVPe01530,DRAVPe01530.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,4425.29,C199H344N60O53,ACHMWY,KL,10.61,11,5,6,6,13,-67.03,-10712,5.5 hour,3 min,2 min,110.54,0,0.0,18591279,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. ,"Wang G, Watson KM, Buckheit RW Jr. ",Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,10.1128/AAC.00452-08,,Anti-HIV
DRAVPe01531,LLGDLLRKSKEKIGKEFKRIVQR,23,LL-23,Synthetic construct(derived from human cathelicidin LL-37),No entry found,,HIV,Retroviridae,,[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50>35.4 μM).(EC50:50% effective concentration for inhibition of virus replication),No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18591279]CEM-SS cells:TC50>35.4 μM.(TC50:the concentration that reduced cell viability by 50%),DRAVPe01531,DRAVPe01531.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2755.35,C124H220N38O32,ACHMNPTWY,K,10.55,8,3,5,3,8,-75.65,-6537,5.5 hour,3 min,2 min,114.35,0,0.0,18591279,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. ,"Wang G, Watson KM, Buckheit RW Jr. ",Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,10.1128/AAC.00452-08,,Anti-HIV
DRAVPe01532,KRIVQRIKDFLRNLVPRTES,20,KR-20,Synthetic construct(derived from human cathelicidin LL-37),No entry found,,HIV,Retroviridae,,[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50>40.5 μM).(EC50:50% effective concentration for inhibition of virus replication),No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18591279]CEM-SS cells:TC50>40.5 μM.(TC50:the concentration that reduced cell viability by 50%),DRAVPe01532,DRAVPe01532.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2468.93,C109H190N36O29,ACGHMWY,R,11.55,6,2,4,3,7,-75.5,-7372,1.3 hour,3 min,2 min,107.0,0,0.0,18591279,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. ,"Wang G, Watson KM, Buckheit RW Jr. ",Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,10.1128/AAC.00452-08,,Anti-HIV
DRAVPe01533,SKEKIGKEFKRIVQRIKDFLR,21,SK-21,Synthetic construct(derived from human cathelicidin LL-37),No entry found,,HIV,Retroviridae,,[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50=10.8 μM).(EC50:50% effective concentration for inhibition of virus replication),No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18591279]CEM-SS cells:TC50=22.5 μM.(TC50:the concentration that reduced cell viability by 50%),DRAVPe01533,DRAVPe01533.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2619.15,C119H204N36O30,ACHMNPTWY,K,10.55,8,3,5,2,7,-100.48,-7317,1.9 hour,>20 hour,>10 hour,88.1,0,0.0,18591279,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. ,"Wang G, Watson KM, Buckheit RW Jr. ",Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,10.1128/AAC.00452-08,,Anti-HIV
DRAVPe01534,FKRIVQRIKDFLR,13,FK-13,Synthetic construct(derived from human cathelicidin LL-37),No entry found,,HIV,Retroviridae,,[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50=3.4 μM).(EC50:50% effective concentration for inhibition of virus replication),No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18591279]CEM-SS cells:TC50=10.4 μM.(TC50:the concentration that reduced cell viability by 50%),DRAVPe01534,DRAVPe01534.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1719.11,C80H135N25O17,ACEGHMNPSTWY,R,11.72,5,1,4,0,6,-43.85,-4536,1.1 hour,3 min,2 min,112.31,0,0.0,18591279,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. ,"Wang G, Watson KM, Buckheit RW Jr. ",Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,10.1128/AAC.00452-08,,Anti-HIV
DRAVPe01535,RLFDKIRQVIRKF,13,Retro-FK-13,Synthetic construct(derived from human cathelicidin LL-37),No entry found,,HIV,Retroviridae,,[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50>58.1 μM).(EC50:50% effective concentration for inhibition of virus replication),No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18591279]CEM-SS cells:TC50=33.7 μM.(TC50:the concentration that reduced cell viability by 50%),DRAVPe01535,DRAVPe01535.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1719.11,C80H135N25O17,ACEGHMNPSTWY,R,11.72,5,1,4,0,6,-43.85,-4536,1 hour,2 min,2 min,112.31,0,0.0,18591279,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. ,"Wang G, Watson KM, Buckheit RW Jr. ",Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,10.1128/AAC.00452-08,,Anti-HIV
DRAVPe01536,KRIVQRIKDFLR,12,KR-12,Synthetic construct(derived from human cathelicidin LL-37),No entry found,,HIV,Retroviridae,,[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50>63.5 μM).(EC50:50% effective concentration for inhibition of virus replication),No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18591279]CEM-SS cells:TC50>63.5 μM.(TC50:the concentration that reduced cell viability by 50%),DRAVPe01536,DRAVPe01536.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1571.93,C71H126N24O16,ACEGHMNPSTWY,R,11.72,5,1,4,0,5,-70.83,-4834,1.3 hour,3 min,2 min,121.67,0,0.0,18591279,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. ,"Wang G, Watson KM, Buckheit RW Jr. ",Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,10.1128/AAC.00452-08,,Anti-HIV
DRAVPe01537,SKVNGQSGRMEFFWTILK,18,HA-pep25,Synthetic construct(derived from influenza viral HA),No entry found,,Influenza A virus,Orthomyxoviridae,Infection assay,[Ref.27623031]Influenza A Virus(A/PuertoRico/8/1934):inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(IC50=34.0 ± 11.5μM);##AInfluenza A Virus(/Vietnam/1203/2004):inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(IC50=12.0 ± 2.1μM);##influenza A virus(A/Goose/Qinghai/59/2005):inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(IC50=34.8 ± 1.5μM);##influenza A virus(A/Duck/Anhui/SC702/2013):inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(IC50=51.0 ± 0.6μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01537.cif,Linear,Free,Free,,L,HA receptor binding domain (RBD),Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry.,2128.48,C97H150N26O26S,ACDHPY,FGKS,9.99,3,1,2,6,6,-37.78,-2798,1.9 hour,>20 hour,>10 hour,59.44,5500,323.53,27623031,ACS Infect Dis. 2016 Mar 11;2(3):187-93,"Chen Q, Guo Y",Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor,10.1021/acsinfecdis.5b00139,,Anti-Influenza A virus
DRAVPe01538,GFKRIVQRiKDFLRNLV,17,GF-17d1,Synthetic construct(derived from human cathelicidin LL-37),No entry found,,HIV,Retroviridae,,[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50>47.5 μM).(EC50:50% effective concentration for inhibition of virus replication),No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18591279]CEM-SS cells:TC50=22.7 μM.(TC50:the concentration that reduced cell viability by 50%),DRAVPe01538,DRAVPe01538.cif,Linear,Free,Free,,Mixed(D-Ile9),Not found,No machanism information found in the reference(s) presented in this entry,2102.56,C91H151N29O20,ACEHMPSTWY,R,11.72,5,1,4,2,7,-35.88,-4702,30 hour,>20 hour,>10 hour,102.94,0,0.0,18591279,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. ,"Wang G, Watson KM, Buckheit RW Jr. ",Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,10.1128/AAC.00452-08,,Anti-HIV
DRAVPe01539,GFKRIVQRiKDFlRNLV,17,GF-17d2,Synthetic construct(derived from human cathelicidin LL-37),No entry found,,HIV,Retroviridae,,[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50>47.5μM).(EC50:50% effective concentration for inhibition of virus replication),No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18591279]CEM-SS cells:TC50>47.5 μM.(TC50:the concentration that reduced cell viability by 50%),DRAVPe01539,DRAVPe01539.cif,Linear,Free,Free,,"Mixed(D-Ile9,D-Leu13)",Not found,No machanism information found in the reference(s) presented in this entry,2102.56,C85H138N28O18,ACEHMPSTWY,R,11.72,5,1,4,2,6,-58.24,-5194,30 hour,>20 hour,>10 hour,80.0,0,0.0,18591279,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. ,"Wang G, Watson KM, Buckheit RW Jr. ",Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,10.1128/AAC.00452-08,,Anti-HIV
DRAVPe01540,GIKEFKRIVQRIKDFLRNLV,20,GI-20,Synthetic construct(derived from human cathelicidin LL-37),No entry found,,HIV,Retroviridae,,[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50=1.08 μM).(EC50:50% effective concentration for inhibition of virus replication),No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18591279]CEM-SS cells:TC50=22.7 μM.(TC50:the concentration that reduced cell viability by 50%),DRAVPe01540,DRAVPe01540.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2473.01,C114H194N34O27,ACHMPSTWY,IKR,11.0,6,2,4,2,9,-22.5,-4954,30 hour,>20 hour,>10 hour,126.5,0,0.0,18591279,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. ,"Wang G, Watson KM, Buckheit RW Jr. ",Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,10.1128/AAC.00452-08,,Anti-HIV
DRAVPe01541,GIKEXKRIVQRIKDFLRNLV,20,GI-20X17,Synthetic construct(derived from human cathelicidin LL-37),No entry found,,HIV,Retroviridae,,[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50>40.6 μM).(EC50:50% effective concentration for inhibition of virus replication),No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18591279]CEM-SS cells:TC50=7.3 μM.(TC50:the concentration that reduced cell viability by 50%),DRAVPe01541,DRAVPe01541.cif,Linear,Free,Free,The 'X' at position 5 is phenylglycine,L,Not found,No machanism information found in the reference(s) presented in this entry,2437.16,C105H183N33O25,ACHMPSTWY,IKR,11.0,6,2,4,2,8,-36.5,-5252,30 hour,>20 hour,>10 hour,126.5,0,0.0,18591279,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. ,"Wang G, Watson KM, Buckheit RW Jr. ",Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,10.1128/AAC.00452-08,,Anti-HIV
DRAVPe01542,GIKEWKRIVQRIKDFLRNLV,20,GI-20W17,Synthetic construct(derived from human cathelicidin LL-37),No entry found,,HIV,Retroviridae,,[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50=7.4 μM).(EC50:50% effective concentration for inhibition of virus replication),No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18591279]CEM-SS cells:TC50=23.6 μM.(TC50:the concentration that reduced cell viability by 50%),DRAVPe01542,DRAVPe01542.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2512.04,C116H195N35O27,ACHMPSTY,IKR,11.0,6,2,4,2,9,-41.0,-5019,30 hour,>20 hour,>10 hour,126.5,5500,289.47,18591279,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. ,"Wang G, Watson KM, Buckheit RW Jr. ",Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,10.1128/AAC.00452-08,,Anti-HIV
DRAVPe01543,GIKQFKRIVQRIKDFLRNLV,20,GI-20Q16,Synthetic construct(derived from human cathelicidin LL-37),No entry found,,HIV,Retroviridae,,[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50=0.91 μM).(EC50:50% effective concentration for inhibition of virus replication),No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18591279]CEM-SS cells:TC50=13.7 μM.(TC50:the concentration that reduced cell viability by 50%),DRAVPe01543,DRAVPe01543.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2472.02,C114H195N35O26,ACEHMPSTWY,IKR,11.73,6,1,5,2,9,-22.5,-4827,30 hour,>20 hour,>10 hour,126.5,0,0.0,18591279,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. ,"Wang G, Watson KM, Buckheit RW Jr. ",Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,10.1128/AAC.00452-08,,Anti-HIV
DRAVPe01544,GIKEFKREFQRIKDFLRNLV,20,GI-20EF,Synthetic construct(derived from human cathelicidin LL-37),No entry found,,HIV,Retroviridae,,[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50=1.6 μM).(EC50:50% effective concentration for inhibition of virus replication),No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18591279]CEM-SS cells:TC50=9.9 μM.(TC50:the concentration that reduced cell viability by 50%),DRAVPe01544,DRAVPe01544.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2537.01,C117H190N34O29,ACHMPSTWY,FKR,10.27,6,3,3,2,8,-69.5,-6233,30 hour,>20 hour,>10 hour,92.5,0,0.0,18591279,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. ,"Wang G, Watson KM, Buckheit RW Jr. ",Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,10.1128/AAC.00452-08,,Anti-HIV
DRAVPe01545,GRFKRFRKKFKKLFKKIS,18,BMAP-18,Synthetic construct(derived from BMAP-27),No entry found,,HIV,Retroviridae,,[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50=0.35 μM).(EC50:50% effective concentration for inhibition of virus replication),No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18591279]CEM-SS cells:TC50=8.45 μM.(TC50:the concentration that reduced cell viability by 50%),DRAVPe01545,DRAVPe01545.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2342.95,C113H188N34O20,ACDEHMNPQTVWY,K,12.32,10,0,10,2,6,-125.0,-6431,30 hour,>20 hour,>10 hour,43.33,0,0.0,18591279,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. ,"Wang G, Watson KM, Buckheit RW Jr. ",Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,10.1128/AAC.00452-08,,Anti-HIV
DRAVPe01546,GRFKRFRKPFKKLFKKIS,18,BMAP-18P9,Synthetic construct(derived from BMAP-27),No entry found,,HIV,Retroviridae,,[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50=3.20 μM).(EC50:50% effective concentration for inhibition of virus replication),No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18591279]CEM-SS cells:TC50=18.9 μM.(TC50:the concentration that reduced cell viability by 50%),DRAVPe01546,DRAVPe01546.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2311.89,C112H183N33O20,ACDEHMNQTVWY,K,12.32,9,0,9,2,6,-112.22,-5876,30 hour,>20 hour,>10 hour,43.33,0,0.0,18591279,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. ,"Wang G, Watson KM, Buckheit RW Jr. ",Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,10.1128/AAC.00452-08,,Anti-HIV
DRAVPe01547,GRFKRXRKKXKKLFKKIS,18,BMAP-18X6X10,Synthetic construct(derived from BMAP-27),No entry found,,HIV,Retroviridae,,[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50=0.68 μM).(EC50:50% effective concentration for inhibition of virus replication),No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18591279]CEM-SS cells:TC50=10.2 μM.(TC50:the concentration that reduced cell viability by 50%),DRAVPe01547,DRAVPe01547.cif,Linear,Free,Free,The 'X' at position 6 and 10 are phenylglycine,L,Not found,No machanism information found in the reference(s) presented in this entry,2271.26,C95H166N32O16,ACDEHMNPQTVWY,K,12.32,10,0,10,2,4,-156.11,-7027,30 hour,>20 hour,>10 hour,43.33,0,0.0,18591279,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. ,"Wang G, Watson KM, Buckheit RW Jr. ",Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,10.1128/AAC.00452-08,,Anti-HIV
DRAVPe01548,GRFKRIRKKLKKLFKKIS,18,BMAP-18I6L10,Synthetic construct(derived from BMAP-27),No entry found,,HIV,Retroviridae,,[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50>44.0 μM).(EC50:50% effective concentration for inhibition of virus replication),No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18591279]CEM-SS cells:TC50=2.79 μM.(TC50:the concentration that reduced cell viability by 50%),DRAVPe01548,DRAVPe01548.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2274.92,C107H192N34O20,ACDEHMNPQTVWY,K,12.32,10,0,10,2,6,-110.0,-6043,30 hour,>20 hour,>10 hour,86.67,0,0.0,18591279,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. ,"Wang G, Watson KM, Buckheit RW Jr. ",Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,10.1128/AAC.00452-08,,Anti-HIV
DRAVPe01549,GRFKRFRKKFKKLFK,15,BMAP-15,Synthetic construct(derived from BMAP-27),No entry found,,HIV,Retroviridae,,[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50>49.6 μM).(EC50:50% effective concentration for inhibition of virus replication),No hemolysis information or data found in the reference(s) presented in this entry,[Ref.18591279]CEM-SS cells:TC50>49.6 μM.(TC50:the concentration that reduced cell viability by 50%),DRAVPe01549,DRAVPe01549.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,2014.54,C98H160N30O16,ACDEHIMNPQSTVWY,K,12.32,9,0,9,1,5,-148.67,-6028,30 hour,>20 hour,>10 hour,26.0,0,0.0,18591279,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. ,"Wang G, Watson KM, Buckheit RW Jr. ",Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,10.1128/AAC.00452-08,,Anti-HIV
DRAVPe01550,GGLRSLGRKILRAWKKYGPIIVPIIRIG,28,"BMAP-28 (BMAP28, bovine myeloid antimicrobial peptide 28; natural AMPs; cathelicidin-5, cattle, ruminant, mammals, animals; BBMm;ZZP; UCLL1; Derivatives: mBMAP-28",Cow Bos taurus,P54229,2NDC,"HSV,PRCV","Herpesviridae, Coronaviridae",,[Ref.15019203]Herpes simplex virus type 1(HSV-1):72% protection from HSV-1 and 72% inhibited of viral replication in Vero cells at 5 μM;##porcine respiratory corona virus(PRCV):did not prove active against PRCV at 0.5–50 μM in Swine Testicular (ST) cells.,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.15019203]17% cytotoxic against Vero76 cells at 5 μM;95% cytotoxic against Vero76 cells at 50 μM.,DRAVPe01550,DRAVPe01550.cif,Linear,Free,Amidation,,L,Not found,No machanism information found in the reference(s) presented in this entry,3131.89,C147H252N44O31,CDEFHMNQT,I,12.02,7,0,7,7,12,23.21,-2271,30 hour,>20 hour,>10 hour,139.29,6990,258.89,15019203,Peptides. 2003 Nov;24(11):1723-31.,"Benincasa M, Skerlavaj B, Gennaro R, Pellegrini A, Zanetti M. ",In vitro and in vivo antimicrobial activity of two alpha-helical cathelicidin peptides and of their synthetic analogs.,10.1016/j.peptides.2003.07.025,,"Anti-HSV,Anti-PRCV"
DRAVPe01551,FFPVIGRILNGIL,13,Temporin G,"European common frog, Rana temporaria",P79875,,"influenza virus,Sendai virus","Orthomyxoviridae, Paramyxoviridae",,[Ref.33538061]influenza virus:inhibition of replication in A549 cells(IC50=13 μM);##Sendai virus:inhibit the replication of Sendai virus in A549 cells.,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.33538061]A549 cells:CC50=73 μM;,DRAVPe01551,DRAVPe01551.cif,Linear,Free,Amidation,,L,Not found,"Temporin G block the conformational rearrangements of HA2 subunit, which are essential for the viral envelope fusion with intracellular endocytic vesicles, thereby neutralizing the virus entry into the host cell. ",1458.81,C72H115N17O15,ACDEHKMQSTWY,I,9.75,1,0,1,3,8,157.69,1492,1.1 hour,3 min,2 min,172.31,0,0.0,33538061,FASEB J. 2021 Feb;35(2):e21358. ,"De Angelis M, Casciaro B, Genovese A, Brancaccio D, Marcocci ME, Novellino E, Carotenuto A, Palamara AT, Mangoni ML, Nencioni L. ","Temporin G, an amphibian antimicrobial peptide against influenza and parainfluenza respiratory viruses: Insights into biological activity and mechanism of action. ",10.1096/fj.202001885RR,,"Anti-Influenza virus,Anti-Sendai virus"
DRAVPe01552,MKTFSVAVAVAIVLAFICTQESSALPVTGVEELVELVSSDDPVADHQELPVELGERLFNIRKKRASPKCTPYCYPTRDGVFCGVRCDF,88,EC-hepcidin1,Epinephelus coioides,No entry found,,SGIV,Iridoviridae,,[Ref.21145974]Singapore grouper iridovirus (SGIV):strongly inhibit the replication of SGIV.(EC-hepcidin1 is more active than EC-hepcidin2),No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01552,DRAVPe01552.cif,Cyclic,Free,Free,There are two pairs of disulfide bonds.,L,Not found,No machanism information found in the reference(s) presented in this entry,9665.17,C429H682N112O129S6,W,V,4.99,10,12,-2,23,34,17.73,-10622,30 hour,>20 hour,>10 hour,91.82,3230,37.13,21145974,Fish Shellfish Immunol. 2011 Feb;30(2):559-68. ,"Zhou JG, Wei JG, Xu D, Cui HC, Yan Y, Ou-Yang ZL, Huang XH, Huang YH, Qin QW.","Molecular cloning and characterization of two novel hepcidins from orange-spotted grouper, Epinephelus coioides. ",10.1016/j.fsi.2010.11.021,,Anti-SGIV
DRAVPe01553,MKTFSVAVAVAVVLAFICTQESSALPVTGIEELVEPVSSDNNDNHQGLPVELRERLVNIRKKRAPTDCIPYCYPTGDGFHCGVTCRF,87,EC-hepcidin2,Epinephelus coioides,No entry found,,SGIV,Iridoviridae,,[Ref.21145974]Singapore grouper iridovirus (SGIV):strongly inhibit the replication of SGIV.(EC-hepcidin1 is more active than EC-hepcidin2),No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01553,DRAVPe01553.cif,Cyclic,Free,Free,There are two pairs of disulfide bonds.,L,Not found,No machanism information found in the reference(s) presented in this entry,9525.93,C418H665N115O127S6,W,V,5.55,10,10,0,27,31,5.06,-11678,30 hour,>20 hour,>10 hour,88.39,3230,37.56,21145974,Fish Shellfish Immunol. 2011 Feb;30(2):559-68. ,"Zhou JG, Wei JG, Xu D, Cui HC, Yan Y, Ou-Yang ZL, Huang XH, Huang YH, Qin QW.","Molecular cloning and characterization of two novel hepcidins from orange-spotted grouper, Epinephelus coioides. ",10.1016/j.fsi.2010.11.021,,Anti-SGIV
DRAVPe01554,ALWKTMLKKLGTMALHAGKAALGAAADTISQGTQ,34,Dermaseptin-1,Phyllomedusa sauvagei (Sauvage's leaf frog),P24302##P80277,,"CCV,FV3","Herpesviridae, Iridoviridae",,[Ref.15193922]Channel Catfish virus(CCV): inhibition of CCV infection in catfish ovary(CCO) cells(reduce viral infectivity by 50% at 3 μM);##Frog Virus 3(FV3): inhibition of FV3 infection in fathead minnow(FHM) cells(reduce viral infectivity by 50% at 12 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.11601906]No cytotoxicity against catfish ovary(CCO) cells at 0.1-11.4 μM.,DRAVPe01554,DRAVPe01554.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,3455.09,C152H257N43O44S2,CEFNPRVY,A,10.0,5,1,4,9,15,18.53,-555,4.4 hour,>20 hour,>10 hour,92.35,5500,166.67,15193922,Virology. 2004 Jun 1;323(2):268-75.,"Chinchar VG, Bryan L, Silphadaung U, Noga E, Wade D, Rollins-Smith L.",Inactivation of viruses infecting ectothermic animals by amphibian and piscine antimicrobial peptides.,10.1016/j.virol.2004.02.029,,"Anti-CCV,Anti-FV3"
DRAVPe01555,ALWMTLLKKVLKAAAKAALNAVLVGANA,28,"Dermaseptin-4 (DS IV; Dermaseptin-S4, DS4; Frogs, amphibians, animals)",Phyllomedusa sauvagei (Sauvage's leaf frog),P80280,,"HSV,HIV","Herpesviridae, Retroviridae",Chemiluminescence Reporter Gene Assay,[Ref.23161023]HSV-2 acyclovir-sensitive strain(911411):inhibition the cytopathic effect(CPE) of HSV-2 in Vero cells(EC50=2.10 μM);##HSV-2 acyclovir-resistant strain(ROI2):inhibition of cytopathic effet(CPE) of HSV-2 in Vero cells(EC50=6 μM). ##[Ref.15780876]human immunodeficiency virus type 1 (HIV-1):Inhibition of viral infection in Vero P4-CCR5 cells(IC50=2 µM).,[Ref:11850249]IC50=20 μM against human erythrocytes,[Ref.23161023]Vero cells:CC50=7.50 μM.##[Ref.15780876]P4-CCR5 cells:CC50=4.5 μM.,DRAVPe01555,DRAVPe01555.cif,Linear,Free,Free,,L,viral membrane,"exerts a selective activity on viral particles and disturbs their organization by breaking the viral membrane, leading to the exposure of HIV-1 core and its dissociation. ",2850.55,C132H229N35O32S,CDEFHIPQRSY,A,10.48,4,0,4,4,19,103.21,2550,4.4 hour,>20 hour,>10 hour,146.79,5500,203.7,11850249##23161023##15780876,Antimicrob Agents Chemother. 2002 Mar;46(3):689-694.##J Med Virol. 2013 Feb;85(2):272-81.##Virology. 2005 Apr 10;334(2):264-75. ,"Navon-Venezia S, Feder R, Gaidukov L, Carmeli Y, Mor A.##Bergaoui I, Zairi A, Tangy F, Aouni M, Selmi B, Hani K. ##Lorin C, Saidi H, Belaid A, Zairi A, Baleux F, Hocini H, Bélec L, Hani K, Tangy F.",Antibacterial properties of dermaseptin S4 derivatives with in vivo activity.## In vitro antiviral activity of dermaseptin S(4) and derivatives from amphibian skin against herpes simplex virus type 2.##The antimicrobial peptide dermaseptin S4 inhibits HIV-1 infectivity in vitro. ,10.1128/AAC.46.3.689-694.2002##10.1002/jmv.23450##10.1016/j.virol.2005.02.002,,"Anti-HSV,Anti-HIV"
DRAVPe01556,GFCRCLCRRGVCRCICTR,18,RTD-1(Rhesus theta-defensin 1),Macaca mulatta (Rhesus macaque),P82271##P82270##Q9TU01,1HVZ,HIV,Retroviridae,,[Ref.15210812]HIV-1 A:inhibition of infection in JC53-BL cells(IC50=3.63 ± 0.85 µg/ml);##HIV-1 B:inhibition of infection in JC53-BL cells(IC50=0.94 ± 0.59 µg/ml);##HIV-1 C:inhibition of infection in JC53-BL cells(IC50=3.98 ± 0.70 µg/ml);##HIV-1 CRF01_AE:inhibition of infection in JC53-BL cells(IC50=2.55 ± 1.92 µg/ml);##HIV-1 D:inhibition of infection in JC53-BL cells(IC50=0.94 ± 0.42 µg/ml);##HIV-1 G:inhibition of infection in JC53-BL cells(IC50=1.15 ± 0.59 µg/ml);##HIV-1 BF:inhibition of infection in JC53-BL cells(IC50=2.38 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01556,DRAVPe01556.cif,Cyclization (N termini to C termini),Cyclization (N termini to C termini),Cyclization (N termini to C termini),"Disulfide bonds between Cys3 and Cys16,Cys5 and Cys14,Cys7 and Cys12.",L,"gp120,CD4","The peptide binds to gp120 and CD4, thereby inhibiting HIV entry.",2105.62,C82H145N33O20S6,ADEHKMNPQSWY,C,9.3,5,0,5,9,4,35.0,-5075,30 hour,>20 hour,>10 hour,59.44,375,22.06,15210812,J Immunol. 2004 Jul 1;173(1):515-20.,"Wang W, Owen SM, Rudolph DL, Cole AM, Hong T, Waring AJ, Lal RB, Lehrer RI.",Activity of alpha- and theta-defensins against primary isolates of HIV-1. ,10.4049/jimmunol.173.1.515,,Anti-HIV
DRAVPe01557,GVCRCLCRRGVCRCLCRR,18,"RTD-2 (RTD 2, rhesus theta-defensin 2)",Macaca mulatta (Rhesus macaque),P82271,,HIV,Retroviridae,,[Ref.15210812]HIV-1 A:inhibition of infection in JC53-BL cells(IC50=5.20 ± 1.58 µg/ml);##HIV-1 B:inhibition of infection in JC53-BL cells(IC50=1.78± 0.57 µg/ml);##HIV-1 C:inhibition of infection in JC53-BL cells(IC50=6.74 ± 1.27 µg/ml);##HIV-1 CRF01_AE:inhibition of infection in JC53-BL cells(IC50=3.66 ± 0.69 µg/ml);##HIV-1 D:inhibition of infection in JC53-BL cells(IC50=3.02 ± 0.10 µg/ml);##HIV-1 G:inhibition of infection in JC53-BL cells(IC50=3.08 ± 1.35 µg/ml);##HIV-1 BF:inhibition of infection in JC53-BL cells(IC50=5.16 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01557,DRAVPe01557.cif,Cyclic,Cyclization (N termini to C termini),Cyclization (N termini to C termini),"Disulfide bonds between Cys3 and Cys16,Cys5 and Cys14,Cys7 and Cys12.",L,"gp120,CD4","The peptide binds to gp120 and CD4, thereby inhibiting HIV entry.",2112.66,C80H150N36O19S6,ADEFHIKMNPQSTWY,CR,9.69,6,0,6,8,4,17.78,-6204,30 hour,>20 hour,>10 hour,75.56,375,22.06,15210812,J Immunol. 2004 Jul 1;173(1):515-20.,"Wang W, Owen SM, Rudolph DL, Cole AM, Hong T, Waring AJ, Lal RB, Lehrer RI.",Activity of alpha- and theta-defensins against primary isolates of HIV-1. ,10.4049/jimmunol.173.1.515,,Anti-HIV
DRAVPe01558,GFCRCICTRGFCRCICTR,18,RTD-3 (rhesus theta defensin 3),Macaca mulatta (Rhesus macaque),"P82270,Q9TU01",,HIV,Retroviridae,,[Ref.15210812]HIV-1 A:inhibition of infection in JC53-BL cells(IC50=3.26 ± 0.58 µg/ml);##HIV-1 B:inhibition of infection in JC53-BL cells(IC50=1.74± 0.40 µg/ml);##HIV-1 C:inhibition of infection in JC53-BL cells(IC50=4.31 ± 0.90 µg/ml);##HIV-1 CRF01_AE:inhibition of infection in JC53-BL cells(IC50=2.09 ± 0.60 µg/ml);##HIV-1 D:inhibition of infection in JC53-BL cells(IC50=2.31 ± 0.21 µg/ml);##HIV-1 G:inhibition of infection in JC53-BL cells(IC50=3.04 ± 0.64 µg/ml);##HIV-1 BF:inhibition of infection in JC53-BL cells(IC50=0.89 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01558,DRAVPe01558.cif,Cyclic,Cyclization (N termini to C termini),Cyclization (N termini to C termini),"Disulfide bonds between Cys3 and Cys16,Cys5 and Cys14,Cys7 and Cys12.",L,"gp120,CD4","The peptide binds to gp120 and CD4, thereby inhibiting HIV entry.",2098.58,C84H140N30O21S6,ADEHKLMNPQSVWY,C,9.01,4,0,4,10,4,52.22,-3946,30 hour,>20 hour,>10 hour,43.33,375,22.06,15210812,J Immunol. 2004 Jul 1;173(1):515-20.,"Wang W, Owen SM, Rudolph DL, Cole AM, Hong T, Waring AJ, Lal RB, Lehrer RI.",Activity of alpha- and theta-defensins against primary isolates of HIV-1. ,10.4049/jimmunol.173.1.515,,Anti-HIV
DRAVPe01559,GICRCICGRGICRCICGR,18,Retrocyclin-1 (RC1),Synthetic construct,No entry found,,HIV,Retroviridae,,[Ref.15210812]HIV-1 A:inhibition of infection in JC53-BL cells(IC50=5.51 ± 1.13 µg/ml);##HIV-1 B:inhibition of infection in JC53-BL cells(IC50=4.15± 0.99 µg/ml);##HIV-1 CRF01_AE:inhibition of infection in JC53-BL cells(IC50=5.33± 0.80 µg/ml);##HIV-1 D:inhibition of infection in JC53-BL cells(IC50=4.57 ± 0.53 µg/ml);##HIV-1 G:inhibition of infection in JC53-BL cells(IC50=5.86 ± 0.95 µg/ml);##HIV-1 BF:inhibition of infection in JC53-BL cells(IC50=7.24 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01559,DRAVPe01559.cif,Cyclic,Free,Free,"Disulfide bonds between Cys3 and Cys16,Cys5 and Cys14,Cys7 and Cys12.",L,"gp120,CD4","The peptide binds to gp120 and CD4, thereby inhibiting HIV entry.",1942.44,C74H136N30O19S6,ADEFHKLMNPQSTVWY,C,9.01,4,0,4,10,4,74.44,-2856,30 hour,>20 hour,>10 hour,86.67,375,22.06,15210812,J Immunol. 2004 Jul 1;173(1):515-20.,"Wang W, Owen SM, Rudolph DL, Cole AM, Hong T, Waring AJ, Lal RB, Lehrer RI.",Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1,10.4049/jimmunol.173.1.515,DRAVPa0039,Anti-HIV
DRAVPe01560,GICRCICGRRICRCICGR,18,Retrocyclin-2 (RC2; HTD-2),Synthetic construct,No entry found,2LZI,HIV,Retroviridae,,[Ref.15210812]HIV-1 A:inhibition of infection in JC53-BL cells(IC50=2.30 ± 1.41 µg/ml);##HIV-1 B:inhibition of infection in JC53-BL cells(IC50=1.05± 0.28 µg/ml);##HIV-1 C:inhibition of infection in JC53-BL cells(IC50=3.32 ± 0.76 µg/ml);##HIV-1 CRF01_AE:inhibition of infection in JC53-BL cells(IC50=1.14 ± 0.29 µg/ml);##HIV-1 D:inhibition of infection in JC53-BL cells(IC50=3.17 ± 1.53 µg/ml);##HIV-1 G:inhibition of infection in JC53-BL cells(IC50=3.06 ± 0.43 µg/ml);##HIV-1 BF:inhibition of infection in JC53-BL cells(IC50=0.18 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01560,DRAVPe01560.cif,Cyclic,Free,Free,"Disulfide bonds between Cys3 and Cys16,Cys5 and Cys14,Cys7 and Cys12.",L,"gp120,CD4","The peptide binds to gp120 and CD4, thereby inhibiting HIV entry.",2041.58,C78H145N33O19S6,ADEFHKLMNPQSTVWY,C,9.3,5,0,5,9,4,51.67,-4442,30 hour,>20 hour,>10 hour,86.67,375,22.06,15210812,J Immunol. 2004 Jul 1;173(1):515-20.,"Wang W, Owen SM, Rudolph DL, Cole AM, Hong T, Waring AJ, Lal RB, Lehrer RI.",Activity of alpha- and theta-defensins against primary isolates of HIV-1.,10.4049/jimmunol.173.1.515,DRAVPa0166,Anti-HIV
DRAVPe01561,GICRCICGKGICRCICGR,18,RC-101,Synthetic construct,No entry found,,HIV,Retroviridae,,[Ref.15588337]HIV-1 92US714:inhibition of virus replication in JC53-BL cells(IC50=2.3 µg/ml);##HIV-1 93US151:inhibition of virus replication in JC53-BL cells(IC50=0.5 µg/ml);##HIV-1 92HT593:inhibition of virus replication in JC53-BL cells(IC50=0.8 µg/ml);##HIV-1 92US727:inhibition of virus replication in JC53-BL cells(IC50=1.7 µg/ml);##HIV-1 5148-1382:inhibition of virus replication in JC53-BL cells(IC50=4.1 µg/ml);##HIV-1 5157-1326:inhibition of virus replication in JC53-BL cells(IC50=3.6 µg/ml);##HIV-1 5157-35097:inhibition of virus replication in JC53-BL cells(IC50=4.0 µg/ml);##HIV-1 193317:inhibition of virus replication in JC53-BL cells(IC50=2.7 µg/ml);##HIV-1 196554:inhibition of virus replication in JC53-BL cells(IC50=0.5 µg/ml);##HIV-1 196531:inhibition of virus replication in JC53-BL cells(IC50=2.7 µg/ml);##HIV-1 92UG037:inhibition of virus replication in JC53-BL cells(IC50=0.9 µg/ml);##HIV-1 192431:inhibition of virus replication in JC53-BL cells(IC50=0.5 µg/ml);##HIV-1 193358:inhibition of virus replication in JC53-BL cells(IC50=2.8 µg/ml);##HIV-1 98CN009:inhibition of virus replication in JC53-BL cells(IC50=8.5 µg/ml);##HIV-1 98TZ017:inhibition of virus replication in JC53-BL cells(IC50=4.9 µg/ml);##HIV-1 93UG053:inhibition of virus replication in JC53-BL cells(IC50=1.5 µg/ml);##HIV-1 92UG005:inhibition of virus replication in JC53-BL cells(IC50=1.0 µg/ml);##HIV-1 HM14:inhibition of virus replication in JC53-BL cells(IC50=0.8 µg/ml);##HIV-1 93TH060:inhibition of virus replication in JC53-BL cells(IC50=2.2 µg/ml);##HIV-1 HM16:inhibition of virus replication in JC53-BL cells(IC50=0.6µg/ml);##HIV-1 92BR023:inhibition of virus replication in JC53-BL cells(IC50=3.0 µg/ml);##HIV-1 92RW009:inhibition of virus replication in JC53-BL cells(IC50=2.7 µg/ml);##HIV-1 92RW024:inhibition of virus replication in JC53-BL cells(IC50=2.9 µg/ml);##HIV-1 93UG059:inhibition of virus replication in JC53-BL cells(IC50=).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01561,DRAVPe01561.cif,Cyclic,Free,Free,"Disulfide bonds between Cys3 and Cys16,Cys5 and Cys14,Cys7 and Cys12.",L,"gp120,CD4","The peptide binds to gp120 and CD4, thereby inhibiting HIV entry.",1914.43,C74H136N28O19S6,ADEFHLMNPQSTVWY,C,8.98,4,0,4,10,4,77.78,-1919,30 hour,>20 hour,>10 hour,86.67,375,22.06,15588337,AIDS Res Hum Retroviruses. 2004 Nov;20(11):1157-65.,"Owen SM, Rudolph DL, Wang W, Cole AM, Waring AJ, Lal RB, Lehrer RI. ","RC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates.",10.1089/aid.2004.20.1157,DRAVPa0040,Anti-HIV
DRAVPe01562,GICRCICGRYICRCICGR,18,RC-115,Synthetic construct,No entry found,,HIV,Retroviridae,,[Ref.15588337]HIV-1 92US714:inhibition of virus replication in JC53-BL cells(IC50>10 µg/ml);##HIV-1 93US151:inhibition of virus replication in JC53-BL cells(IC50=2.1 µg/ml);##HIV-1 92HT593:inhibition of virus replication in JC53-BL cells(IC50=4.2 µg/ml);##HIV-1 92US727:inhibition of virus replication in JC53-BL cells(IC50=5.4 µg/ml);##HIV-1 5148-1382:inhibition of virus replication in JC53-BL cells(IC50=4.1 µg/ml);##HIV-1 5157-1326:inhibition of virus replication in JC53-BL cells(IC50=4.2 µg/ml);##HIV-1 5157-35097:inhibition of virus replication in JC53-BL cells(IC50=4.53 µg/ml);##HIV-1 193317:inhibition of virus replication in JC53-BL cells(IC50=7.1 µg/ml);##HIV-1 196554:inhibition of virus replication in JC53-BL cells(IC50=4.5 µg/ml);##HIV-1 196531:inhibition of virus replication in JC53-BL cells(IC50=2.7 µg/ml);##HIV-1 92UG037:inhibition of virus replication in JC53-BL cells(IC50=1.9 µg/ml);##HIV-1 192431:inhibition of virus replication in JC53-BL cells(IC50=5.4 µg/ml);##HIV-1 193358:inhibition of virus replication in JC53-BL cells(IC50=>10 µg/ml);##HIV-1 98CN009:inhibition of virus replication in JC53-BL cells(IC50>10 µg/ml);##HIV-1 98TZ017:inhibition of virus replication in JC53-BL cells(IC50=7.1 µg/ml);##HIV-1 93UG053:inhibition of virus replication in JC53-BL cells(IC50=3.9 µg/ml);##HIV-1 92UG005:inhibition of virus replication in JC53-BL cells(IC50=4.1 µg/ml);##HIV-1 94UG114:inhibition of virus replication in JC53-BL cells(IC50=3.5 µg/ml);##HIV-1 HM14:inhibition of virus replication in JC53-BL cells(IC50=3.4 µg/ml);##HIV-1 93TH060:inhibition of virus replication in JC53-BL cells(IC50=5.0 µg/ml);##HIV-1 HM16:inhibition of virus replication in JC53-BL cells(IC50=3.3µg/ml);##HIV-1 RU132:inhibition of virus replication in JC53-BL cells(IC50=3.0µg/ml);##HIV-1 RU570:inhibition of virus replication in JC53-BL cells(IC50= 5.8µg/ml);##HIV-1 92BR023:inhibition of virus replication in JC53-BL cells(IC50=2.4 µg/ml);##HIV-1 92RW009:inhibition of virus replication in JC53-BL cells(IC50=4.7 µg/ml);##HIV-1 92RW024:inhibition of virus replication in JC53-BL cells(IC50=4.5 µg/ml);##HIV-1 93UG059:inhibition of virus replication in JC53-BL cells(IC50=4.6 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01562,DRAVPe01562.cif,Cyclic,Free,Free,"Disulfide bonds between Cys3 and Cys16,Cys5 and Cys14,Cys7 and Cys12.",L,"gp120,CD4","The peptide binds to gp120 and CD4, thereby inhibiting HIV entry.",2048.57,C81H142N30O20S6,ADEFHKLMNPQSTVW,C,8.98,4,0,4,10,4,69.44,-2964,30 hour,>20 hour,>10 hour,86.67,1865,109.71,15588337,AIDS Res Hum Retroviruses. 2004 Nov;20(11):1157-65.,"Owen SM, Rudolph DL, Wang W, Cole AM, Waring AJ, Lal RB, Lehrer RI. ","RC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates.",10.1089/aid.2004.20.1157,DRAVPa0164,Anti-HIV
DRAVPe01563,RYICRCICGRGICRCICG,18,RC-116,Synthetic construct,No entry found,,HIV,Retroviridae,,[Ref.15588337]HIV-1 92US714:inhibition of virus replication in JC53-BL cells(IC50=9.5 µg/ml);##HIV-1 93US151:inhibition of virus replication in JC53-BL cells(IC50=1.3 µg/ml);##HIV-1 92HT593:inhibition of virus replication in JC53-BL cells(IC50=3.7 µg/ml);##HIV-1 92US727:inhibition of virus replication in JC53-BL cells(IC50=4.6µg/ml);##HIV-1 5148-1382:inhibition of virus replication in JC53-BL cells(IC50=5.2 µg/ml);##HIV-1 5157-1326:inhibition of virus replication in JC53-BL cells(IC50=4.8 µg/ml);##HIV-1 5157-35097:inhibition of virus replication in JC53-BL cells(IC50=5.2 µg/ml);##HIV-1 193317:inhibition of virus replication in JC53-BL cells(IC50=7.1 µg/ml);##HIV-1 196554:inhibition of virus replication in JC53-BL cells(IC50=2.4 µg/ml);##HIV-1 196531:inhibition of virus replication in JC53-BL cells(IC50=7.8 µg/ml);##HIV-1 92UG037:inhibition of virus replication in JC53-BL cells(IC50=3.1 µg/ml);##HIV-1 192431:inhibition of virus replication in JC53-BL cells(IC50=2.4 µg/ml);##HIV-1 193358:inhibition of virus replication in JC53-BL cells(IC50=7.8 µg/ml);##HIV-1 98CN009:inhibition of virus replication in JC53-BL cells(IC50>10 µg/ml);##HIV-1 98TZ017:inhibition of virus replication in JC53-BL cells(IC50>10 µg/ml);##HIV-1 93UG053:inhibition of virus replication in JC53-BL cells(IC50=6.6 µg/ml);##HIV-1 92UG005:inhibition of virus replication in JC53-BL cells(IC50=5.2 µg/ml);##HIV-1 94UG114:inhibition of virus replication in JC53-BL cells(IC50=4.2 µg/ml);##HIV-1 HM14:inhibition of virus replication in JC53-BL cells(IC50=3.3 µg/ml);##HIV-1 93TH060:inhibition of virus replication in JC53-BL cells(IC50=6.5 µg/ml);##HIV-1 HM16:inhibition of virus replication in JC53-BL cells(IC50=2.9 µg/ml);##HIV-1 RU132:inhibition of virus replication in JC53-BL cells(IC50=4.9 µg/ml);##HIV-1 RU570:inhibition of virus replication in JC53-BL cells(IC50=9.6 µg/ml);##HIV-1 92BR023:inhibition of virus replication in JC53-BL cells(IC50=2.9 µg/ml);##HIV-1 92RW009:inhibition of virus replication in JC53-BL cells(IC50=7.8 µg/ml);##HIV-1 92RW024:inhibition of virus replication in JC53-BL cells(IC50=6.6 µg/ml);##HIV-1 93UG059:inhibition of virus replication in JC53-BL cells(IC50=5.7 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information found in the reference(s) presented,DRAVPe01563,DRAVPe01563.cif,Cyclic,Free,Free,"Disulfide bonds between Cys4 and Cys17,Cys6 and Cys15,Cys8 and Cys13.",L,"gp120,CD4","The peptide binds to gp120 and CD4, thereby inhibiting HIV entry.",2048.57,C81H142N30O20S6,ADEFHKLMNPQSTVW,C,8.98,4,0,4,10,4,69.44,-2964,1 hour,2 min,2 min,86.67,1865,109.71,15588337,AIDS Res Hum Retroviruses. 2004 Nov;20(11):1157-65.,"Owen SM, Rudolph DL, Wang W, Cole AM, Waring AJ, Lal RB, Lehrer RI. ","RC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates.",10.1089/aid.2004.20.1157,DRAVPa0165,Anti-HIV
DRAVPe01564,RPRLSHKGPMPF,12,Apelin-12,Synthetic construct,Q9TUI9##K7GLR4,,HIV,Retroviridae,Reverse transcriptase assay,[Ref.10802050]HIV:Inhibition of HIV infection in NP-2/CD4/APJ cells(IC50=63.0 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01564.cif,Linear,Free,Free,,L,APJ receptor,"APJ receptor could help HIV virus enter the target cells. The peptide can bind with APJ receptor and block virus entry, thus inhibiting virus infection.",1422.71,C64H103N21O14S,ACDEINQTVWY,P,12.01,4,0,4,2,2,-113.33,-3226,1 hour,2 min,2 min,32.5,0,0.0,10802050,FEBS Lett. 2000 May 4;473(1):15-8.,"Zou MX, Liu HY, Haraguchi Y, Soda Y, Tatemoto K, Hoshino H.",Apelin peptides block the entry of human immunodeficiency virus (HIV).,10.1016/s0014-5793(00)01487-3,,Anti-HIV
DRAVPe01565,QRPRLSHKGPMPF,13,Apelin-13,Bos taurus (Bovine),Q9TUI9##A0A484GMR2##A0A5N3XG03##A0A2Y9M6A9##A0A5G2R3Z5##A0A2Y9SZ03##A0A2U4A1K6,,HIV,Retroviridae,Reverse transcriptase assay,[Ref.10802050]HIV:Inhibition of HIV infection in NP-2/CD4/APJ cells(IC50=26.0 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01565.cif,Linear,Free,Free,,L,APJ receptor,"APJ receptor could help HIV virus enter the target cells. The peptide can bind with APJ receptor and block virus entry, thus inhibiting virus infection.",1550.84,C69H111N23O16S,ACDEINTVWY,P,12.01,4,0,4,2,2,-131.54,-3780,0.8 hour,10 min,>10 hour,30.0,0,0.0,10802050,FEBS Lett. 2000 May 4;473(1):15-8.,"Zou MX, Liu HY, Haraguchi Y, Soda Y, Tatemoto K, Hoshino H.",Apelin peptides block the entry of human immunodeficiency virus (HIV).,10.1016/s0014-5793(00)01487-3,,Anti-HIV
DRAVPe01566,KFRRQRPRLSHKGPMPF,17,Apelin-17,Synthetic construct,Q9TUI9##K7GLR4,,HIV,Retroviridae,Reverse transcriptase assay,[Ref.10802050]HIV:Inhibition of HIV infection in NP-2/CD4/APJ cells(IC50=4.8 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01566.cif,Linear,Free,Free,,L,APJ receptor,"APJ receptor could help HIV virus enter the target cells. The peptide can bind with APJ receptor and block virus entry, thus inhibiting virus infection.",2138.57,C96H156N34O20S,ACDEINTVWY,R,12.48,7,0,7,2,3,-160.0,-7021,1.3 hour,3 min,2 min,22.94,0,0.0,10802050,FEBS Lett. 2000 May 4;473(1):15-8.,"Zou MX, Liu HY, Haraguchi Y, Soda Y, Tatemoto K, Hoshino H.",Apelin peptides block the entry of human immunodeficiency virus (HIV).,10.1016/s0014-5793(00)01487-3,,Anti-HIV
DRAVPe01567,LVQPRGPRSGPGPWQGGRRKFRRQRPRLSHKGPMPF,36,Apelin-36,Bos taurus (Bovine),Q9TUI9##A0A484GMR2##A0A5N3XG03##A0A2Y9M6A9##A0A5G2R3Z5##A0A2Y9SZ03##A0A2U4A1K6,,HIV,Retroviridae,Reverse transcriptase assay,[Ref.10802050]HIV:Inhibition of HIV infection in NP-2/CD4/APJ cells(IC50=0.3 μg/ml).##[Ref.11090199]HIV-1:inhibition of HIV-1 infection in CD4 APJ cells(IC50=7 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01567.cif,Linear,Free,Free,,L,APJ receptor,"APJ receptor could help HIV virus enter the target cells. The peptide can bind with APJ receptor and block virus entry, thus inhibiting virus infection.",4178.89,C185H298N68O42S,ACDEINTY,R,12.85,11,0,11,8,6,-150.83,-12838,5.5 hour,3 min,2 min,29.72,5500,157.14,10802050##11090199,FEBS Lett. 2000 May 4;473(1):15-8.##J Virol. 2000 Dec;74(24):11972-6.,"Zou MX, Liu HY, Haraguchi Y, Soda Y, Tatemoto K, Hoshino H.##Cayabyab M, Hinuma S, Farzan M, Choe H, Fukusumi S, Kitada C, Nishizawa N, Hosoya M, Nishimura O, Messele T, Pollakis G, Goudsmit J, Fujino M, Sodroski J.","Apelin peptides block the entry of human immunodeficiency virus (HIV).##Apelin, the natural ligand of the orphan seven-transmembrane receptor APJ, inhibits human immunodeficiency virus type 1 entry. ",10.1016/s0014-5793(00)01487-3##10.1128/jvi.74.24.11972-11976.2000,,Anti-HIV
DRAVPe01568,RRQRPRLSHKGPMPF,15,Apelin-15,Synthetic construct,Q9TUI9,,HIV,Retroviridae,Reverse transcriptase assay,[Ref.11090199]HIV-1:inhibition of HIV-1 infection in CD4 APJ cells(IC50=12μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01568.cif,Linear,Free,Free,,L,APJ receptor,"APJ receptor could help HIV virus enter the target cells. The peptide can bind with APJ receptor and block virus entry, thus inhibiting virus infection.",1863.22,C81H135N31O18S,ACDEINTVWY,R,12.48,6,0,6,2,2,-174.0,-6764,1 hour,2 min,2 min,26.0,0,0.0,11090199,J Virol. 2000 Dec;74(24):11972-6.,"Cayabyab M, Hinuma S, Farzan M, Choe H, Fukusumi S, Kitada C, Nishizawa N, Hosoya M, Nishimura O, Messele T, Pollakis G, Goudsmit J, Fujino M, Sodroski J.","Apelin, the natural ligand of the orphan seven-transmembrane receptor APJ, inhibits human immunodeficiency virus type 1 entry. ",10.1128/jvi.74.24.11972-11976.2000,,Anti-HIV
DRAVPe01569,RRKFRRQRPRLSHKGPMPF,19,Apelin-19,Synthetic construct,Q9TUI9,,HIV,Retroviridae,Reverse transcriptase assay,[Ref.11090199]HIV-1:inhibition of HIV-1 infection in CD4 APJ cells(IC50=4.7 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01569.cif,Linear,Free,Free,,L,APJ receptor,"APJ receptor could help HIV virus enter the target cells. The peptide can bind with APJ receptor and block virus entry, thus inhibiting virus infection.",2450.95,C108H180N42O22S,ACDEINTVWY,R,12.7,9,0,9,2,3,-190.53,-10005,1 hour,2 min,2 min,20.53,0,0.0,11090199,J Virol. 2000 Dec;74(24):11972-6.,"Cayabyab M, Hinuma S, Farzan M, Choe H, Fukusumi S, Kitada C, Nishizawa N, Hosoya M, Nishimura O, Messele T, Pollakis G, Goudsmit J, Fujino M, Sodroski J.","Apelin, the natural ligand of the orphan seven-transmembrane receptor APJ, inhibits human immunodeficiency virus type 1 entry. ",10.1128/jvi.74.24.11972-11976.2000,,Anti-HIV
DRAVPe01570,RRQRPRLSHKGPM,13,Apelin-15-(63-75)-peptide,Synthetic construct,Q9TUI9,,HIV,Retroviridae,Reverse transcriptase assay,[Ref.11090199]HIV-1:inhibition of HIV-1 infection in CD4 APJ cells(IC50=3.3 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01570.cif,Linear,Free,Free,,L,APJ receptor,"APJ receptor could help HIV virus enter the target cells. The peptide can bind with APJ receptor and block virus entry, thus inhibiting virus infection.",1618.93,C67H119N29O16S,ACDEFINTVWY,R,12.48,6,0,6,2,1,-210.0,-7062,1 hour,2 min,2 min,30.0,0,0.0,11090199,J Virol. 2000 Dec;74(24):11972-6.,"Cayabyab M, Hinuma S, Farzan M, Choe H, Fukusumi S, Kitada C, Nishizawa N, Hosoya M, Nishimura O, Messele T, Pollakis G, Goudsmit J, Fujino M, Sodroski J.","Apelin, the natural ligand of the orphan seven-transmembrane receptor APJ, inhibits human immunodeficiency virus type 1 entry. ",10.1128/jvi.74.24.11972-11976.2000,,Anti-HIV
DRAVPe01571,RRQRPRLSHKGPX,13,[Met(O)75]apelin-15-(63-75)-peptide,Synthetic construct,Q9TUI9,,HIV,Retroviridae,Reverse transcriptase assay,[Ref.11090199]HIV-1:inhibition of HIV-1 infection in CD4 APJ cells(IC50=45 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01571.cif,Linear,Free,Free,The 'X'  at position 13 indicates oxidized methionine.,L,APJ receptor,"APJ receptor could help HIV virus enter the target cells. The peptide can bind with APJ receptor and block virus entry, thus inhibiting virus infection.",1599.06,C62H108N28O14,ACDEFIMNTVWY,R,12.48,6,0,6,2,1,-224.62,-7297,1 hour,2 min,2 min,30.0,0,0.0,11090199,J Virol. 2000 Dec;74(24):11972-6.,"Cayabyab M, Hinuma S, Farzan M, Choe H, Fukusumi S, Kitada C, Nishizawa N, Hosoya M, Nishimura O, Messele T, Pollakis G, Goudsmit J, Fujino M, Sodroski J.","Apelin, the natural ligand of the orphan seven-transmembrane receptor APJ, inhibits human immunodeficiency virus type 1 entry. ",10.1128/jvi.74.24.11972-11976.2000,,Anti-HIV
DRAVPe01572,RRQRPRLSHKGP,12,Apelin-15-(63-74)-peptide,Synthetic construct,Q9TUI9,,HIV,Retroviridae,Reverse transcriptase assay,[Ref.11090199]HIV-1:inhibition of HIV-1 infection in CD4 APJ cells(IC50=37 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01572.cif,Linear,Free,Free,,L,APJ receptor,"APJ receptor could help HIV virus enter the target cells. The peptide can bind with APJ receptor and block virus entry, thus inhibiting virus infection.",1487.73,C62H110N28O15,ACDEFIMNTVWY,R,12.48,6,0,6,2,1,-243.33,-7297,1 hour,2 min,2 min,32.5,0,0.0,11090199,J Virol. 2000 Dec;74(24):11972-6.,"Cayabyab M, Hinuma S, Farzan M, Choe H, Fukusumi S, Kitada C, Nishizawa N, Hosoya M, Nishimura O, Messele T, Pollakis G, Goudsmit J, Fujino M, Sodroski J.","Apelin, the natural ligand of the orphan seven-transmembrane receptor APJ, inhibits human immunodeficiency virus type 1 entry. ",10.1128/jvi.74.24.11972-11976.2000,,Anti-HIV
DRAVPe01573,GRKKRRQRRR,10,TAT(48-57),Synthetic construct,P04610,,HIV,Retroviridae,infection inhibition assay,[Ref.22319541]HIV-1 IIIB:inhibition of virus infection in P4-R5 MAGI cells(EC50=0.094 mg/mL).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22319541]No cytotoxicity against P4-R5 MAGI cells up to 100 μM.,,DRAVPe01573.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1396.67,C55H109N31O12,ACDEFHILMNPSTVWY,R,12.7,8,0,8,1,0,-387.0,-10522,30 hour,>20 hour,>10 hour,0.0,0,0.0,22319541,Int J Pept. 2012;2012:349427.,"Keogan S, Passic S, Krebs FC.",Infection by CXCR4-Tropic Human Immunodeficiency Virus Type 1 Is Inhibited by the Cationic Cell-Penetrating Peptide Derived from HIV-1 Tat.,10.1155/2012/349427,DRAVPa1019,Anti-HIV
DRAVPe01574,RRKKRRQRRR,10,TAT(48-57)[G1R],Synthetic construct,P04610,,HIV,Retroviridae,infection inhibition assay,[Ref.22319541]HIV-1 IIIB:inhibition of virus infection in P4-R5 MAGI cells(EC50=0.065 mg/mL).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01574.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1495.81,C59H118N34O12,ACDEFGHILMNPSTVWY,R,12.78,9,0,9,0,0,-428.0,-12108,1 hour,2 min,2 min,0.0,0,0.0,22319541,Int J Pept. 2012;2012:349427.,"Keogan S, Passic S, Krebs FC.",Infection by CXCR4-Tropic Human Immunodeficiency Virus Type 1 Is Inhibited by the Cationic Cell-Penetrating Peptide Derived from HIV-1 Tat.,10.1155/2012/349427,,Anti-HIV
DRAVPe01575,GRKKRRRRRR,10,TAT(48-57)[Q7R],Synthetic construct,P04610,,HIV,Retroviridae,infection inhibition assay,[Ref.22319541]HIV-1 IIIB:inhibition of virus infection in P4-R5 MAGI cells(EC50=0.071 mg/mL).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01575.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1424.73,C56H113N33O11,ACDEFHILMNPQSTVWY,R,12.78,9,0,9,1,0,-397.0,-11460,30 hour,>20 hour,>10 hour,0.0,0,0.0,22319541,Int J Pept. 2012;2012:349427.,"Keogan S, Passic S, Krebs FC.",Infection by CXCR4-Tropic Human Immunodeficiency Virus Type 1 Is Inhibited by the Cationic Cell-Penetrating Peptide Derived from HIV-1 Tat.,10.1155/2012/349427,,Anti-HIV
DRAVPe01576,RRKKRRRRRR,10,"TAT(48-57)[G1R,Q7R]",Synthetic construct,P04610,,HIV,Retroviridae,infection inhibition assay,[Ref.22319541]HIV-1 IIIB:inhibition of virus infection in P4-R5 MAGI cells(EC50=0.025 mg/mL).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01576.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1523.86,C60H122N36O11,ACDEFGHILMNPQSTVWY,R,12.85,10,0,10,0,0,-438.0,-13046,1 hour,2 min,2 min,0.0,0,0.0,22319541,Int J Pept. 2012;2012:349427.,"Keogan S, Passic S, Krebs FC.",Infection by CXCR4-Tropic Human Immunodeficiency Virus Type 1 Is Inhibited by the Cationic Cell-Penetrating Peptide Derived from HIV-1 Tat.,10.1155/2012/349427,,Anti-HIV
DRAVPe01577,RRRRRRRRRR,10,R-10,Synthetic construct,No entry found,,HIV,Retroviridae,infection inhibition assay,[Ref.22319541]HIV-1 IIIB:inhibition of virus infection in P4-R5 MAGI cells(EC50=0.014 mg/mL).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01577.cif,Linear,Free,Free,,L,Not found,No machanism information found in the reference(s) presented in this entry,1579.89,C60H122N40O11,ACDEFGHIKLMNPQSTVWY,R,12.95,10,0,10,0,0,-450.0,-14920,1 hour,2 min,2 min,0.0,0,0.0,22319541,Int J Pept. 2012;2012:349427.,"Keogan S, Passic S, Krebs FC.",Infection by CXCR4-Tropic Human Immunodeficiency Virus Type 1 Is Inhibited by the Cationic Cell-Penetrating Peptide Derived from HIV-1 Tat.,10.1155/2012/349427,,Anti-HIV
DRAVPe01578,KGEAMHGQVDCSPGIWQLDC,20,#4330 derived from HIV-1 integrase,Synthetic construct,P04587,,HIV,Retroviridae,Assay for the enzymatic activities of RT,[Ref.17257575]HIV-1:inhibition of reverse transcriptase(RNA-dependent DNA polymerase) activity(IC50=4 μM);inhibition of reverse transcriptase(DNA-dependent DNA polymerase) activity(IC50=6.8 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01578.cif,Linear,Free,Free,,L,Reverse Transcriptase,The peptide could bind the reverse transcriptase and inhibits its DNA-polymerase activity and thus inhibits virus replication.,2174.45,C91H140N26O30S3,FNRTY,G,4.54,2,3,-1,6,5,-39.5,-2319,1.3 hour,3 min,2 min,58.5,5625,296.05,17257575,Arch Biochem Biophys. 2007 Feb 15;458(2):202-12.,"Oz Gleenberg I, Herschhorn A, Goldgur Y, Hizi A.",Inhibition of human immunodeficiency virus type-1 reverse transcriptase by a novel peptide derived from the viral integrase.,10.1016/j.abb.2006.12.007,,Anti-HIV
DRAVPe01579,ASCDKCQLKGEAMHG,15,#5649 derived from HIV-1 integrase,Synthetic construct,P04587,,HIV,Retroviridae,Assay for the enzymatic activities of RT,[Ref.17257575]HIV-1: inhibition of reverse transcriptase(RNA-dependent DNA polymerase) activity(91.5 ± 2.5% residual DNA polymerase activity at 30 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01579.cif,Linear,Free,Free,,L,Reverse Transcriptase,The peptide could bind the reverse transcriptase and inhibits its DNA-polymerase activity and thus inhibits virus replication.,1577.81,C62H104N20O22S3,FINPRTVWY,ACGK,6.77,3,2,1,5,3,-58.67,-2490,4.4 hour,>20 hour,>10 hour,39.33,125,8.93,17257575,Arch Biochem Biophys. 2007 Feb 15;458(2):202-12.,"Oz Gleenberg I, Herschhorn A, Goldgur Y, Hizi A.",Inhibition of human immunodeficiency virus type-1 reverse transcriptase by a novel peptide derived from the viral integrase.,10.1016/j.abb.2006.12.007,,Anti-HIV
DRAVPe01580,KCQLKGEAMHGQVDC,15,#5650 derived from HIV-1 integrase,Synthetic construct,P04587,,HIV,Retroviridae,Assay for the enzymatic activities of RT,[Ref.17257575]HIV-1: inhibition of reverse transcriptase(RNA-dependent DNA polymerase) activity(63± 3% residual DNA polymerase activity at 30 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01580.cif,Linear,Free,Free,,L,Reverse Transcriptase,The peptide could bind the reverse transcriptase and inhibits its DNA-polymerase activity and thus inhibits virus replication.,1646.91,C66H111N21O22S3,FINPRSTWY,CGKQ,6.73,3,2,1,4,3,-60.67,-2481,1.3 hour,3 min,2 min,52.0,125,8.93,17257575,Arch Biochem Biophys. 2007 Feb 15;458(2):202-12.,"Oz Gleenberg I, Herschhorn A, Goldgur Y, Hizi A.",Inhibition of human immunodeficiency virus type-1 reverse transcriptase by a novel peptide derived from the viral integrase.,10.1016/j.abb.2006.12.007,,Anti-HIV
DRAVPe01581,KGEAMHGQVDCSPGI,15,#5651 derived from HIV-1 integrase,Synthetic construct,P04587,,HIV,Retroviridae,Assay for the enzymatic activities of RT,[Ref.17257575]HIV-1: inhibition of reverse transcriptase(RNA-dependent DNA polymerase) activity(99 ± 6% residual DNA polymerase activity at 30 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01581.cif,Linear,Free,Free,,L,Reverse Transcriptase,The peptide could bind the reverse transcriptase and inhibits its DNA-polymerase activity and thus inhibits virus replication.,1528.72,C62H101N19O22S2,FLNRTWY,G,5.32,2,2,0,5,3,-42.0,-1746,1.3 hour,3 min,2 min,52.0,0,0.0,17257575,Arch Biochem Biophys. 2007 Feb 15;458(2):202-12.,"Oz Gleenberg I, Herschhorn A, Goldgur Y, Hizi A.",Inhibition of human immunodeficiency virus type-1 reverse transcriptase by a novel peptide derived from the viral integrase.,10.1016/j.abb.2006.12.007,,Anti-HIV
DRAVPe01582,MHGQVDCSPGIWQLD,15,#5652 derived from HIV-1 integrase,Synthetic construct,P04587,,HIV,Retroviridae,Assay for the enzymatic activities of RT,[Ref.17257575]HIV-1: inhibition of reverse transcriptase(RNA-dependent DNA polymerase) activity(79 ± 3% residual DNA polymerase activity at 30 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01582.cif,Linear,Free,Free,,L,Reverse Transcriptase,The peptide could bind the reverse transcriptase and inhibits its DNA-polymerase activity and thus inhibits virus replication.,1685.89,C72H108N20O23S2,AEFKNRTY,DGQ,4.2,1,2,-1,4,4,-29.33,-1486,30 hour,>20 hour,>10 hour,71.33,5500,392.86,17257575,Arch Biochem Biophys. 2007 Feb 15;458(2):202-12.,"Oz Gleenberg I, Herschhorn A, Goldgur Y, Hizi A.",Inhibition of human immunodeficiency virus type-1 reverse transcriptase by a novel peptide derived from the viral integrase.,10.1016/j.abb.2006.12.007,,Anti-HIV
DRAVPe01583,VDCSPGIWQLDCTHL,15,#5653 derived from HIV-1 integrase,Synthetic construct,P04587,,HIV,Retroviridae,Assay for the enzymatic activities of RT,[Ref.17257575]HIV-1: inhibition of reverse transcriptase(RNA-dependent DNA polymerase) activity(58 ± 3% residual DNA polymerase activity at 30 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01583.cif,Linear,Free,Free,,L,Reverse Transcriptase,The peptide could bind the reverse transcriptase and inhibits its DNA-polymerase activity and thus inhibits virus replication.,1686.92,C73H111N19O23S2,AEFKMNRY,CDL,4.2,1,2,-1,5,5,21.33,-898,100 hour,>20 hour,>10 hour,97.33,5625,401.79,17257575,Arch Biochem Biophys. 2007 Feb 15;458(2):202-12.,"Oz Gleenberg I, Herschhorn A, Goldgur Y, Hizi A.",Inhibition of human immunodeficiency virus type-1 reverse transcriptase by a novel peptide derived from the viral integrase.,10.1016/j.abb.2006.12.007,,Anti-HIV
DRAVPe01584,PGIWQLDCTHLEGKI,15,#5654 derived from HIV-1 integrase,Synthetic construct,P04587,,HIV,Retroviridae,Assay for the enzymatic activities of RT,[Ref.17257575]HIV-1: inhibition of reverse transcriptase(RNA-dependent DNA polymerase) activity(62.5 ± 0.5% residual DNA polymerase activity at 30 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01584.cif,Linear,Free,Free,,L,Reverse Transcriptase,The peptide could bind the reverse transcriptase and inhibits its DNA-polymerase activity and thus inhibits virus replication.,1709.98,C77H120N20O22S,AFMNRSVY,GIL,5.33,2,2,0,4,5,-16.67,-868,>20 hour,>20 hour,?,104.0,5500,392.86,17257575,Arch Biochem Biophys. 2007 Feb 15;458(2):202-12.,"Oz Gleenberg I, Herschhorn A, Goldgur Y, Hizi A.",Inhibition of human immunodeficiency virus type-1 reverse transcriptase by a novel peptide derived from the viral integrase.,10.1016/j.abb.2006.12.007,,Anti-HIV
DRAVPe01585,SWLRDLWDWICEVLSDFK,18,NS5A-derived peptide C5A [I6L],Synthetic construct,V5RF15,,"HCV,HIV","Flaviviridae, Retroviridae","Pseudotyped HIV (HIVpp) and antiviral assay,HCV production and infection assay",[Ref.21801309]HCV: inhibition of HCVcc infection in Huh7.5.1 cells(IC50=1.40±0.13 μM);##HIV-1:inhibition of pseudotyped HIV infection in TZM-BL cells(IC50>5.00 μM).,[Ref.21801309]Human erythrocytes:MHC=13.84 μM.,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01585.cif,Linear,Free,Free,,L,membrane,"The peptide inhibits HCV and HIV infection in vitro, which can disrupt the integrity of the viral membrane and capsid core while preserving the integrity of host membranes.",2311.64,C109H155N25O29S,AGHMNPQTY,DLW,4.23,2,4,-2,3,9,-7.22,-2527,1.9 hour,>20 hour,>10 hour,102.78,16500,970.59,21801309,Chem Biol Drug Des. 2011 Nov;78(5):835-43.,"Li GR, He LY, Liu XY, Liu AP, Huang YB, Qiu C, Zhang XY, Xu JQ, Yang W, Chen YX.",Rational design of peptides with anti-HCV/HIV activities and enhanced specificity.,10.1111/j.1747-0285.2011.01201.x,,"Anti-HCV,Anti-HIV"
DRAVPe01586,SWLRDIWDWLCEVLSDFK,18,NS5A-derived peptide C5A [I10L],Synthetic construct,V5RF15,,"HCV,HIV","Flaviviridae, Retroviridae","Pseudotyped HIV (HIVpp) and antiviral assay,HCV production and infection assay",[Ref.21801309]HCV: inhibition of HCVcc infection in Huh7.5.1 cells(IC50=1.20±0.09 μM);##HIV-1:inhibition of pseudotyped HIV infection in TZM-BL cells(IC50=1.84±0.16 μM).,[Ref.21801309]Human erythrocytes:MHC=6.92 μM.,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01586.cif,Linear,Free,Free,,L,membrane,"The peptide inhibits HCV and HIV infection in vitro, which can disrupt the integrity of the viral membrane and capsid core while preserving the integrity of host membranes.",2311.64,C109H155N25O29S,AGHMNPQTY,DLW,4.23,2,4,-2,3,9,-7.22,-2527,1.9 hour,>20 hour,>10 hour,102.78,16500,970.59,21801309,Chem Biol Drug Des. 2011 Nov;78(5):835-43.,"Li GR, He LY, Liu XY, Liu AP, Huang YB, Qiu C, Zhang XY, Xu JQ, Yang W, Chen YX.",Rational design of peptides with anti-HCV/HIV activities and enhanced specificity.,10.1111/j.1747-0285.2011.01201.x,,"Anti-HCV,Anti-HIV"
DRAVPe01587,SWLRDIWDWICELLSDFK,18,NS5A-derived peptide C5A [V13L],Synthetic construct,V5RF15,,"HCV,HIV","Flaviviridae, Retroviridae","Pseudotyped HIV (HIVpp) and antiviral assay,HCV production and infection assay",[Ref.21801309]HCV: inhibition of HCVcc infection in Huh7.5.1 cells(IC50=1.20±0.11 μM);##HIV-1:inhibition of pseudotyped HIV infection in TZM-BL cells(IC50=2.76±0.19 μM).,[Ref.21801309]Human erythrocytes:MHC=3.44 μM.,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01587.cif,Linear,Free,Free,,L,membrane,"The peptide inhibits HCV and HIV infection in vitro, which can disrupt the integrity of the viral membrane and capsid core while preserving the integrity of host membranes.",2325.67,C110H157N25O29S,AGHMNPQTVY,DLW,4.23,2,4,-2,3,9,-5.56,-2439,1.9 hour,>20 hour,>10 hour,108.33,16500,970.59,21801309,Chem Biol Drug Des. 2011 Nov;78(5):835-43.,"Li GR, He LY, Liu XY, Liu AP, Huang YB, Qiu C, Zhang XY, Xu JQ, Yang W, Chen YX.",Rational design of peptides with anti-HCV/HIV activities and enhanced specificity.,10.1111/j.1747-0285.2011.01201.x,,"Anti-HCV,Anti-HIV"
DRAVPe01588,SWLRDLWDWLCEVLSDFK,18,"NS5A-derived peptide C5A [I6L,I10L]",Synthetic construct,V5RF15,,"HCV,HIV","Flaviviridae, Retroviridae","Pseudotyped HIV (HIVpp) and antiviral assay,HCV production and infection assay",[Ref.21801309]HCV: inhibition of HCVcc infection in Huh7.5.1 cells(IC50=1.40±0.15 μM);##HIV-1:inhibition of pseudotyped HIV infection in TZM-BL cells(IC50>5.00 μM).,[Ref.21801309]Human erythrocytes:MHC=6.92 μM.,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01588.cif,Linear,Free,Free,,L,membrane,"The peptide inhibits HCV and HIV infection in vitro, which can disrupt the integrity of the viral membrane and capsid core while preserving the integrity of host membranes.",2311.64,C109H155N25O29S,AGHIMNPQTY,L,4.23,2,4,-2,3,9,-11.11,-2527,1.9 hour,>20 hour,>10 hour,102.78,16500,970.59,21801309,Chem Biol Drug Des. 2011 Nov;78(5):835-43.,"Li GR, He LY, Liu XY, Liu AP, Huang YB, Qiu C, Zhang XY, Xu JQ, Yang W, Chen YX.",Rational design of peptides with anti-HCV/HIV activities and enhanced specificity.,10.1111/j.1747-0285.2011.01201.x,,"Anti-HCV,Anti-HIV"
DRAVPe01589,SWLRDLWDWICELLSDFK,18,"NS5A-derived peptide C5A [I6L,V13L]",Synthetic construct,V5RF15,,"HCV,HIV","Flaviviridae, Retroviridae","Pseudotyped HIV (HIVpp) and antiviral assay,HCV production and infection assay",[Ref.21801309]HCV: inhibition of HCVcc infection in Huh7.5.1 cells(IC50=0.78±0.07 μM);##HIV-1:inhibition of pseudotyped HIV infection in TZM-BL cells(IC50=3.31±0.31 μM).,[Ref.21801309]Human erythrocytes:MHC=53.75 μM.,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01589.cif,Linear,Free,Free,,L,membrane,"The peptide inhibits HCV and HIV infection in vitro, which can disrupt the integrity of the viral membrane and capsid core while preserving the integrity of host membranes.",2325.67,C110H157N25O29S,AGHMNPQTVY,L,4.23,2,4,-2,3,9,-9.44,-2439,1.9 hour,>20 hour,>10 hour,108.33,16500,970.59,21801309,Chem Biol Drug Des. 2011 Nov;78(5):835-43.,"Li GR, He LY, Liu XY, Liu AP, Huang YB, Qiu C, Zhang XY, Xu JQ, Yang W, Chen YX.",Rational design of peptides with anti-HCV/HIV activities and enhanced specificity.,10.1111/j.1747-0285.2011.01201.x,,"Anti-HCV,Anti-HIV"
DRAVPe01590,SWLRDIWDWLCELLSDFK,18,"NS5A-derived peptide C5A [I10L,V13L]",Synthetic construct,V5RF15,,"HCV,HIV","Flaviviridae, Retroviridae","Pseudotyped HIV (HIVpp) and antiviral assay,HCV production and infection assay",[Ref.21801309]HCV: inhibition of HCVcc infection in Huh7.5.1 cells(IC50=0.82±0.10 μM);##HIV-1:inhibition of pseudotyped HIV infection in TZM-BL cells(IC50=2.58±0.22 μM).,[Ref.21801309]Human erythrocytes:MHC=3.44 μM.,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01590.cif,Linear,Free,Free,,L,membrane,"The peptide inhibits HCV and HIV infection in vitro, which can disrupt the integrity of the viral membrane and capsid core while preserving the integrity of host membranes.",2325.67,C110H157N25O29S,AGHMNPQTVY,L,4.23,2,4,-2,3,9,-9.44,-2439,1.9 hour,>20 hour,>10 hour,108.33,16500,970.59,21801309,Chem Biol Drug Des. 2011 Nov;78(5):835-43.,"Li GR, He LY, Liu XY, Liu AP, Huang YB, Qiu C, Zhang XY, Xu JQ, Yang W, Chen YX.",Rational design of peptides with anti-HCV/HIV activities and enhanced specificity.,10.1111/j.1747-0285.2011.01201.x,,"Anti-HCV,Anti-HIV"
DRAVPe01591,SWLRDLWDWLCELLSDFK,18,"NS5A-derived peptide C5A [I6L,I10L,V13L]",Synthetic construct,V5RF15,,"HCV,HIV","Flaviviridae, Retroviridae","Pseudotyped HIV (HIVpp) and antiviral assay,HCV production and infection assay",[Ref.21801309]HCV: inhibition of HCVcc infection in Huh7.5.1 cells(IC50=1.20±0.14 μM);##HIV-1:inhibition of pseudotyped HIV infection in TZM-BL cells(IC50=0.59±0.03 μM).,[Ref.21801309]Human erythrocytes:MHC=107.50 μM.,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01591.cif,Linear,Free,Free,,L,membrane,"The peptide inhibits HCV and HIV infection in vitro, which can disrupt the integrity of the viral membrane and capsid core while preserving the integrity of host membranes.",2325.67,C110H157N25O29S,AGHIMNPQTVY,L,4.23,2,4,-2,3,9,-13.33,-2439,1.9 hour,>20 hour,>10 hour,108.33,16500,970.59,21801309,Chem Biol Drug Des. 2011 Nov;78(5):835-43.,"Li GR, He LY, Liu XY, Liu AP, Huang YB, Qiu C, Zhang XY, Xu JQ, Yang W, Chen YX.",Rational design of peptides with anti-HCV/HIV activities and enhanced specificity.,10.1111/j.1747-0285.2011.01201.x,,"Anti-HCV,Anti-HIV"
DRAVPe01592,SWLRDIWDWVCEVLSDFK,18,NS5A-derived peptide C5A [I10V],Synthetic construct,V5RF15,,"HCV,HIV","Flaviviridae, Retroviridae","Pseudotyped HIV (HIVpp) and antiviral assay,HCV production and infection assay",[Ref.21801309]HCV: inhibition of HCVcc infection in Huh7.5.1 cells(IC50=1.40±0.117 μM);##HIV-1:inhibition of pseudotyped HIV infection in TZM-BL cells(IC50=1.86±0.25 μM).,[Ref.21801309]Human erythrocytes:MHC=13.93 μM.,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01592.cif,Linear,Free,Free,,L,membrane,"The peptide inhibits HCV and HIV infection in vitro, which can disrupt the integrity of the viral membrane and capsid core while preserving the integrity of host membranes.",2297.61,C108H153N25O29S,AGHMNPQTY,DW,4.23,2,4,-2,3,9,-5.0,-2615,1.9 hour,>20 hour,>10 hour,97.22,16500,970.59,21801309,Chem Biol Drug Des. 2011 Nov;78(5):835-43.,"Li GR, He LY, Liu XY, Liu AP, Huang YB, Qiu C, Zhang XY, Xu JQ, Yang W, Chen YX.",Rational design of peptides with anti-HCV/HIV activities and enhanced specificity.,10.1111/j.1747-0285.2011.01201.x,,"Anti-HCV,Anti-HIV"
DRAVPe01593,SWLRDIWDWACEVLSDFK,18,NS5A-derived peptide C5A [I10A],Synthetic construct,V5RF15,,"HCV,HIV","Flaviviridae, Retroviridae","Pseudotyped HIV (HIVpp) and antiviral assay,HCV production and infection assay",[Ref.21801309]HCV: inhibition of HCVcc infection in Huh7.5.1 cells(IC50=4.00±0.36 μM);##HIV-1:inhibition of pseudotyped HIV infection in TZM-BL cells(IC50=2.21±0.28 μM).,[Ref.21801309]Human erythrocytes:MHC=14.10 μM.,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01593.cif,Linear,Free,Free,,L,membrane,"The peptide inhibits HCV and HIV infection in vitro, which can disrupt the integrity of the viral membrane and capsid core while preserving the integrity of host membranes.",2269.56,C106H149N25O29S,GHMNPQTY,DW,4.23,2,4,-2,3,9,-18.33,-2838,1.9 hour,>20 hour,>10 hour,86.67,16500,970.59,21801309,Chem Biol Drug Des. 2011 Nov;78(5):835-43.,"Li GR, He LY, Liu XY, Liu AP, Huang YB, Qiu C, Zhang XY, Xu JQ, Yang W, Chen YX.",Rational design of peptides with anti-HCV/HIV activities and enhanced specificity.,10.1111/j.1747-0285.2011.01201.x,,"Anti-HCV,Anti-HIV"
DRAVPe01594,SWLRDIWDWGCEVLSDFK,18,NS5A-derived peptide C5A [I10G],Synthetic construct,V5RF15,,"HCV,HIV","Flaviviridae, Retroviridae","Pseudotyped HIV (HIVpp) and antiviral assay,HCV production and infection assay",[Ref.21801309]HCV: inhibition of HCVcc infection in Huh7.5.1 cells(IC50>5.00 μM);##HIV-1:inhibition of pseudotyped HIV infection in TZM-BL cells(IC50=3.50±0.36 μM).,[Ref.21801309]Human erythrocytes:MHC=28.38 μM.,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01594.cif,Linear,Free,Free,,L,membrane,"The peptide inhibits HCV and HIV infection in vitro, which can disrupt the integrity of the viral membrane and capsid core while preserving the integrity of host membranes.",2255.53,C105H147N25O29S,AHMNPQTY,DW,4.23,2,4,-2,4,8,-30.56,-2925,1.9 hour,>20 hour,>10 hour,81.11,16500,970.59,21801309,Chem Biol Drug Des. 2011 Nov;78(5):835-43.,"Li GR, He LY, Liu XY, Liu AP, Huang YB, Qiu C, Zhang XY, Xu JQ, Yang W, Chen YX.",Rational design of peptides with anti-HCV/HIV activities and enhanced specificity.,10.1111/j.1747-0285.2011.01201.x,,"Anti-HCV,Anti-HIV"
DRAVPe01595,SWLRDIWDWSCEVLSDFK,18,NS5A-derived peptide C5A [I10S],Synthetic construct,V5RF15,,"HCV,HIV","Flaviviridae, Retroviridae","Pseudotyped HIV (HIVpp) and antiviral assay,HCV production and infection assay",[Ref.21801309]HCV: inhibition of HCVcc infection in Huh7.5.1 cells(IC50>5.00 μM);##HIV-1:inhibition of pseudotyped HIV infection in TZM-BL cells(IC50>5.00 μM).,[Ref.21801309]Human erythrocytes:MHC=28.00 μM.,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01595.cif,Linear,Free,Free,,L,membrane,"The peptide inhibits HCV and HIV infection in vitro, which can disrupt the integrity of the viral membrane and capsid core while preserving the integrity of host membranes.",2285.56,C106H149N25O30S,AGHMNPQTY,DSW,4.23,2,4,-2,4,8,-32.78,-3359,1.9 hour,>20 hour,>10 hour,81.11,16500,970.59,21801309,Chem Biol Drug Des. 2011 Nov;78(5):835-43.,"Li GR, He LY, Liu XY, Liu AP, Huang YB, Qiu C, Zhang XY, Xu JQ, Yang W, Chen YX.",Rational design of peptides with anti-HCV/HIV activities and enhanced specificity.,10.1111/j.1747-0285.2011.01201.x,,"Anti-HCV,Anti-HIV"
DRAVPe01596,SWLRDIWDWECEVLSDFK,18,NS5A-derived peptide C5A [I10E],Synthetic construct,V5RF15,,"HCV,HIV","Flaviviridae, Retroviridae","Pseudotyped HIV (HIVpp) and antiviral assay,HCV production and infection assay",[Ref.21801309]HCV: inhibition of HCVcc infection in Huh7.5.1 cells(IC50>5.00 μM);##HIV-1:inhibition of pseudotyped HIV infection in TZM-BL cells(IC50>5.00 μM).,[Ref.21801309]Human erythrocytes:MHC=214.91 μM.,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01596.cif,Linear,Free,Free,,L,membrane,"The peptide inhibits HCV and HIV infection in vitro, which can disrupt the integrity of the viral membrane and capsid core while preserving the integrity of host membranes.",2327.6,C108H151N25O31S,AGHMNPQTY,DW,4.1,2,5,-3,3,8,-47.78,-3700,1.9 hour,>20 hour,>10 hour,81.11,16500,970.59,21801309,Chem Biol Drug Des. 2011 Nov;78(5):835-43.,"Li GR, He LY, Liu XY, Liu AP, Huang YB, Qiu C, Zhang XY, Xu JQ, Yang W, Chen YX.",Rational design of peptides with anti-HCV/HIV activities and enhanced specificity.,10.1111/j.1747-0285.2011.01201.x,,"Anti-HCV,Anti-HIV"
DRAVPe01597,SWLRDIWDWKCEVLSDFK,18,NS5A-derived peptide C5A [I10K],Synthetic construct,V5RF15,,"HCV,HIV","Flaviviridae, Retroviridae","Pseudotyped HIV (HIVpp) and antiviral assay,HCV production and infection assay",[Ref.21801309]HCV: inhibition of HCVcc infection in Huh7.5.1 cells(IC50>5.00 μM);##HIV-1:inhibition of pseudotyped HIV infection in TZM-BL cells(IC50>5.00 μM).,[Ref.21801309]Human erythrocytes:MHC=214.81 μM.,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01597.cif,Linear,Free,Free,,L,membrane,"The peptide inhibits HCV and HIV infection in vitro, which can disrupt the integrity of the viral membrane and capsid core while preserving the integrity of host membranes.",2326.65,C109H156N26O29S,AGHMNPQTY,DW,4.68,3,4,-1,3,8,-50.0,-3574,1.9 hour,>20 hour,>10 hour,81.11,16500,970.59,21801309,Chem Biol Drug Des. 2011 Nov;78(5):835-43.,"Li GR, He LY, Liu XY, Liu AP, Huang YB, Qiu C, Zhang XY, Xu JQ, Yang W, Chen YX.",Rational design of peptides with anti-HCV/HIV activities and enhanced specificity.,10.1111/j.1747-0285.2011.01201.x,,"Anti-HCV,Anti-HIV"
DRAVPe01598,TRQARRNRRRRWRERQR,17,Rev (34-50),Synthetic construct,P05866,1ULL,HIV,Retroviridae,MAGI assay,[Ref.20580677]HIV-1 IIIB:inhibition of virus replication in PM1-CCR5 cells(EC50=1.7±0.25 μM);##HIV-1 Bal:inhibition of virus replication in PM1-CCR5 cells(EC50>10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01598.cif,Linear,Free,Free,,L,Not found,Peptide derived from the RNA-binding domain of HIV-1 Rev can act as dual-target inhibitors that inhibit HIV-1 entry and viral production in the early and late phases of replication. ,2437.77,C97H173N51O24,CDFGHIKLMPSVY,R,12.6,10,1,9,2,2,-345.88,-17216,7.2 hour,>20 hour,>10 hour,5.88,5500,343.75,20580677,Int J Biochem Cell Biol. 2010 Sep;42(9):1482-8.,"Shimane K, Kodama EN, Nakase I, Futaki S, Sakurai Y, Sakagami Y, Li X, Hattori T, Sarafianos SG, Matsuoka M.","Rev-derived peptides inhibit HIV-1 replication by antagonism of Rev and a co-receptor, CXCR4.",10.1016/j.biocel.2010.05.005,,Anti-HIV
DRAVPe01599,TRQARRNRRRRWRERQRAAAAC,22,Rev (34-50) -A4C,Synthetic construct,P05866,,HIV,Retroviridae,MAGI assay,[Ref.20580677]HIV-1 IIIB:inhibition of virus replication in PM1-CCR5 cells(EC50=0.35±0.07 μM);##HIV-1 Bal:inhibition of virus replication in PM1-CCR5 cells(EC50>10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01599.cif,Linear,Free,Free,,L,Not found,Peptide derived from the RNA-binding domain of HIV-1 Rev can act as dual-target inhibitors that inhibit HIV-1 entry and viral production in the early and late phases of replication. ,2825.22,C112H198N56O29S,DFGHIKLMPSVY,R,12.37,10,1,9,3,6,-223.18,-16364,7.2 hour,>20 hour,>10 hour,22.73,5500,261.9,20580677,Int J Biochem Cell Biol. 2010 Sep;42(9):1482-8.,"Shimane K, Kodama EN, Nakase I, Futaki S, Sakurai Y, Sakagami Y, Li X, Hattori T, Sarafianos SG, Matsuoka M.","Rev-derived peptides inhibit HIV-1 replication by antagonism of Rev and a co-receptor, CXCR4.",10.1016/j.biocel.2010.05.005,,Anti-HIV
DRAVPe01600,TRQARRNRRRRWRERQRAAAACYGRKKRRQRRR,33,Rev (34-50) -A4C-RTD,Synthetic construct,P05866##P04612,,HIV,Retroviridae,MAGI assay,[Ref.20580677]HIV-1 IIIB:inhibition of virus replication in PM1-CCR5 cells(EC50=0.37±0.09 μM);##HIV-1 Bal:inhibition of virus replication in PM1-CCR5 cells(EC50>10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01600.cif,Linear,Free,Free,,L,Not found,Peptide derived from the RNA-binding domain of HIV-1 Rev can act as dual-target inhibitors that inhibit HIV-1 entry and viral production in the early and late phases of replication. ,4367.05,C176H314N88O42S,DFHILMPSV,R,12.48,18,1,17,5,6,-270.0,-26900,7.2 hour,>20 hour,>10 hour,15.15,6990,218.44,20580677,Int J Biochem Cell Biol. 2010 Sep;42(9):1482-8.,"Shimane K, Kodama EN, Nakase I, Futaki S, Sakurai Y, Sakagami Y, Li X, Hattori T, Sarafianos SG, Matsuoka M.","Rev-derived peptides inhibit HIV-1 replication by antagonism of Rev and a co-receptor, CXCR4.",10.1016/j.biocel.2010.05.005,,Anti-HIV
DRAVPe01601,MPKTRRRPRRSQRKRPPTPWP,21,Rex (1-21),Synthetic construct,P0C207,,HIV,Retroviridae,MAGI assay,[Ref.20580677]HIV-1 IIIB:inhibition of virus replication in PM1-CCR5 cells(EC50>10 μM);##HIV-1 Bal:inhibition of virus replication in PM1-CCR5 cells(EC50>10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01601.cif,Linear,Free,Free,,L,Not found,Peptide derived from the RNA-binding domain of HIV-1 Rev can act as dual-target inhibitors that inhibit HIV-1 entry and viral production in the early and late phases of replication. ,2685.2,C116H198N46O26S,ACDEFGHILNVY,R,12.78,9,0,9,3,1,-255.24,-12494,30 hour,>20 hour,>10 hour,0.0,5500,275.0,20580677,Int J Biochem Cell Biol. 2010 Sep;42(9):1482-8.,"Shimane K, Kodama EN, Nakase I, Futaki S, Sakurai Y, Sakagami Y, Li X, Hattori T, Sarafianos SG, Matsuoka M.","Rev-derived peptides inhibit HIV-1 replication by antagonism of Rev and a co-receptor, CXCR4.",10.1016/j.biocel.2010.05.005,,Anti-HIV
DRAVPe01602,MPKTRRRPRRSQRKRPPTPWPYGRKKRRQRRR,32,Rex (1-21) -RTD,Synthetic construct,P0C207##P04612,,HIV,Retroviridae,MAGI assay,[Ref.20580677]HIV-1 IIIB:inhibition of virus replication in PM1-CCR5 cells(EC50=2.5±0.76 μM);##HIV-1 Bal:inhibition of virus replication in PM1-CCR5 cells(EC50>10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01602.cif,Linear,Free,Free,,L,Not found,Peptide derived from the RNA-binding domain of HIV-1 Rev can act as dual-target inhibitors that inhibit HIV-1 entry and viral production in the early and late phases of replication. ,4227.03,C180H314N78O39S,ACDEFHILNV,R,12.74,17,0,17,5,1,-292.5,-23030,30 hour,>20 hour,>10 hour,0.0,6990,225.48,20580677,Int J Biochem Cell Biol. 2010 Sep;42(9):1482-8.,"Shimane K, Kodama EN, Nakase I, Futaki S, Sakurai Y, Sakagami Y, Li X, Hattori T, Sarafianos SG, Matsuoka M.","Rev-derived peptides inhibit HIV-1 replication by antagonism of Rev and a co-receptor, CXCR4.",10.1016/j.biocel.2010.05.005,,Anti-HIV
DRAVPe01603,RPRGRRGSRPSGAERRRRRAAAA,23,RSG-P2G4,Synthetic construct,,,HIV,Retroviridae,MAGI assay,[Ref.20580677]HIV-1 IIIB:inhibition of virus replication in PM1-CCR5 cells(EC50=2.2±0.51 μM);##HIV-1 Bal:inhibition of virus replication in PM1-CCR5 cells(EC50>10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01603.cif,Linear,Free,Free,,L,Not found,Peptide derived from the RNA-binding domain of HIV-1 Rev can act as dual-target inhibitors that inhibit HIV-1 entry and viral production in the early and late phases of replication. ,2603.95,C102H187N53O28,CDFHIKLMNQTVWY,R,12.6,10,1,9,5,5,-197.83,-15094,1 hour,2 min,2 min,21.74,0,0.0,20580677,Int J Biochem Cell Biol. 2010 Sep;42(9):1482-8.,"Shimane K, Kodama EN, Nakase I, Futaki S, Sakurai Y, Sakagami Y, Li X, Hattori T, Sarafianos SG, Matsuoka M.","Rev-derived peptides inhibit HIV-1 replication by antagonism of Rev and a co-receptor, CXCR4.",10.1016/j.biocel.2010.05.005,,Anti-HIV
DRAVPe01604,RSQKEGLHYTCSSHFPYSQYQFWK,24,CCR5 ECL2 (168-191),Synthetic construct,P51681,,HIV,Retroviridae,HIV neutralization assay,[Ref.22403408]HIV-1 YU2:inhibition of virus infection in TZM-bl cells(IC50=136 ± 49 μM);##HIV-1 BaL26:inhibition of virus infection in TZM-bl cells(IC50=138± 36 μM);##HIV-1 HxB2:inhibition of virus infection in TZM-bl cells(IC50=89±31 μM);##HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=103±37 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01604.cif,Linear,Free,Free,,L,gp120,The peptide binds gp120 and inhibits virus entry.,3008.32,C138H191N37O38S,ADIMNV,S,9.05,5,1,4,10,4,-131.25,-5993,1 hour,2 min,2 min,16.25,9970,433.48,22403408,J Biol Chem. 2012 Apr 27;287(18):15076-86.,"Dogo-Isonagie C, Lam S, Gustchina E, Acharya P, Yang Y, Shahzad-ul-Hussan S, Clore GM, Kwong PD, Bewley CA.",Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1.,10.1074/jbc.M111.332361,,Anti-HIV
DRAVPe01605,CSSHFPYSQYQFWK,14,CCR5 ECL2 (178-191),Synthetic construct,P51681,,HIV,Retroviridae,HIV neutralization assay,[Ref.22403408]HIV-1 YU2:inhibition of virus infection in TZM-bl cells(IC50=28 ±7 μM);##HIV-1 BaL26:inhibition of virus infection in TZM-bl cells(IC50=65± 3 μM);##HIV-1 HxB2:inhibition of virus infection in TZM-bl cells(IC50=54±2 μM);##HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=53±2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01605.cif,Linear,Free,Free,,L,gp120,The peptide binds gp120 and inhibits virus entry.,1808.0,C86H110N20O22S,ADEGILMNRTV,S,8.18,2,0,2,6,3,-96.43,-2220,1.2 hour,>20 hour,>10 hour,0.0,8480,652.31,22403408,J Biol Chem. 2012 Apr 27;287(18):15076-86.,"Dogo-Isonagie C, Lam S, Gustchina E, Acharya P, Yang Y, Shahzad-ul-Hussan S, Clore GM, Kwong PD, Bewley CA.",Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1.,10.1074/jbc.M111.332361,,Anti-HIV
DRAVPe01606,QKEGLHYTCSSHFPYSQYQF,20,CCR5 ECL2 (170-189),Synthetic construct,P51681,,HIV,Retroviridae,HIV neutralization assay,[Ref.22403408]HIV-1 YU2:inhibition of virus infection in TZM-bl cells(IC50=237 ± 31 μM);##HIV-1 BaL26:inhibition of virus infection in TZM-bl cells(IC50=612± 21 μM);##HIV-1 HxB2:inhibition of virus infection in TZM-bl cells(IC50=374±28 μM);##HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=600±24 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01606.cif,Linear,Free,Free,,L,gp120,The peptide binds gp120 and inhibits virus entry.,2450.67,C112H152N28O33S,ADIMNRVW,QSY,6.91,3,1,2,9,3,-107.0,-3839,0.8 hour,10 min,>10 hour,19.5,4470,235.26,22403408,J Biol Chem. 2012 Apr 27;287(18):15076-86.,"Dogo-Isonagie C, Lam S, Gustchina E, Acharya P, Yang Y, Shahzad-ul-Hussan S, Clore GM, Kwong PD, Bewley CA.",Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1.,10.1074/jbc.M111.332361,,Anti-HIV
DRAVPe01607,RRWYRWW,7,Octa 1,Synthetic construct,No entry found,,HSV,Herpesviridae,plaque reduction assay,[Ref.17681018]HSV-1:inhibition of virus infection in NP-2/CD4/CCR5 cells(IC50>20 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01607.cif,Linear,Free,Free,,L,Not found,"The anti-HSV1 activity of apoEdp involves inhibition of virus particle attachment to cells, with this likely being related to the derivation of this peptide from the apoE HSPG/LDLR binding region.",1208.39,C60H77N19O9,ACDEFGHIKLMNPQSTV,RW,11.71,3,0,3,1,3,-250.0,-3791,1 hour,2 min,2 min,0.0,17990,2998.33,17681018,FEBS J. 2007 Sep;274(17):4511-25.,"Kelly BA, Neil SJ, McKnight A, Santos JM, Sinnis P, Jack ER, Middleton DA, Dobson CB.",Apolipoprotein E-derived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity.,10.1111/j.1742-4658.2007.05981.x,,Anti-HSV
DRAVPe01608,RRWYRWWRRRWYRWWR,16,MU89 (Octa 1 dp),Synthetic construct,No entry found,,HSV,Herpesviridae,plaque reduction assay,[Ref.17681018]HSV-1:inhibition of virus infection in NP-2/CD4/CCR5 cells(IC50=8.3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01608.cif,Linear,Free,Free,,L,Not found,"The anti-HSV1 activity of apoEdp involves inhibition of virus particle attachment to cells, with this likely being related to the derivation of this peptide from the apoE HSPG/LDLR binding region.",2711.15,C132H176N46O19,ACDEFGHIKLMNPQSTV,R,12.22,8,0,8,2,6,-275.0,-10566,1 hour,2 min,2 min,0.0,35980,2398.67,17681018,FEBS J. 2007 Sep;274(17):4511-25.,"Kelly BA, Neil SJ, McKnight A, Santos JM, Sinnis P, Jack ER, Middleton DA, Dobson CB.",Apolipoprotein E-derived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity.,10.1111/j.1742-4658.2007.05981.x,,Anti-HSV
DRAVPe01609,RWWRWWR,7,Hepta 1,Synthetic construct,No entry found,,HSV,Herpesviridae,plaque reduction assay,[Ref.17681018]HSV-1:inhibition of virus infection in NP-2/CD4/CCR5 cells(IC50>20 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01609.cif,Linear,Free,Free,,L,Not found,"The anti-HSV1 activity of apoEdp involves inhibition of virus particle attachment to cells, with this likely being related to the derivation of this peptide from the apoE HSPG/LDLR binding region.",1231.43,C62H78N20O8,ACDEFGHIKLMNPQSTVY,W,12.3,3,0,3,0,4,-244.29,-3544,1 hour,2 min,2 min,0.0,22000,3666.67,17681018,FEBS J. 2007 Sep;274(17):4511-25.,"Kelly BA, Neil SJ, McKnight A, Santos JM, Sinnis P, Jack ER, Middleton DA, Dobson CB.",Apolipoprotein E-derived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity.,10.1111/j.1742-4658.2007.05981.x,,Anti-HSV
DRAVPe01610,RWWRWWRRWWRWWR,14,MU92 (Hepta 1 dp),Synthetic construct,No entry found,,HSV,Herpesviridae,plaque reduction assay,[Ref.17681018]HSV-1:inhibition of virus infection in NP-2/CD4/CCR5 cells(IC50=3.3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01610.cif,Linear,Free,Free,,L,Not found,"The anti-HSV1 activity of apoEdp involves inhibition of virus particle attachment to cells, with this likely being related to the derivation of this peptide from the apoE HSPG/LDLR binding region.",2444.85,C124H154N40O15,ACDEFGHIKLMNPQSTVY,W,12.7,6,0,6,0,8,-244.29,-7088,1 hour,2 min,2 min,0.0,44000,3384.62,17681018,FEBS J. 2007 Sep;274(17):4511-25.,"Kelly BA, Neil SJ, McKnight A, Santos JM, Sinnis P, Jack ER, Middleton DA, Dobson CB.",Apolipoprotein E-derived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity.,10.1111/j.1742-4658.2007.05981.x,,Anti-HSV
DRAVPe01611,YRWWRWARRW,10,Deca 1,Synthetic construct,No entry found,,HSV,Herpesviridae,plaque reduction assay,[Ref.17681018]HSV-1:inhibition of virus infection in NP-2/CD4/CCR5 cells(IC50>20 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01611.cif,Linear,Free,Free,,L,Not found,"The anti-HSV1 activity of apoEdp involves inhibition of virus particle attachment to cells, with this likely being related to the derivation of this peptide from the apoE HSPG/LDLR binding region.",1621.87,C80H104N26O12,CDEFGHIKLMNPQSTV,RW,12.0,4,0,4,1,5,-211.0,-4869,2.8 hour,10 min,2 min,10.0,23490,2610.0,17681018,FEBS J. 2007 Sep;274(17):4511-25.,"Kelly BA, Neil SJ, McKnight A, Santos JM, Sinnis P, Jack ER, Middleton DA, Dobson CB.",Apolipoprotein E-derived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity.,10.1111/j.1742-4658.2007.05981.x,,Anti-HSV
DRAVPe01612,YRWWRWARRWYRWWRWARRW,20,MU94 (Deca 1 dp),Synthetic construct,No entry found,,HSV,Herpesviridae,plaque reduction assay,[Ref.17681018]HSV-1:inhibition of virus infection in NP-2/CD4/CCR5 cells(IC50=5 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01612.cif,Linear,Free,Free,,L,Not found,"The anti-HSV1 activity of apoEdp involves inhibition of virus particle attachment to cells, with this likely being related to the derivation of this peptide from the apoE HSPG/LDLR binding region.",3225.73,C160H206N52O23,CDEFGHIKLMNPQSTV,RW,12.22,8,0,8,2,10,-211.0,-9738,2.8 hour,10 min,2 min,10.0,46980,2472.63,17681018,FEBS J. 2007 Sep;274(17):4511-25.,"Kelly BA, Neil SJ, McKnight A, Santos JM, Sinnis P, Jack ER, Middleton DA, Dobson CB.",Apolipoprotein E-derived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity.,10.1111/j.1742-4658.2007.05981.x,,Anti-HSV
DRAVPe01613,APKAMRLLRRLLRRLLR,17,N-[RLLR]3,Synthetic construct,No entry found,,HSV,Herpesviridae,plaque reduction assay,[Ref.17681018]HSV-1:inhibition of virus infection in NP-2/CD4/CCR5 cells(IC50=7.3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01613.cif,Linear,Free,Free,,L,Not found,"The anti-HSV1 activity of apoEdp involves inhibition of virus particle attachment to cells, with this likely being related to the derivation of this peptide from the apoE HSPG/LDLR binding region.",2132.74,C94H178N36O18S,CDEFGHINQSTVWY,LR,12.7,7,0,7,0,8,-24.71,-5958,4.4 hour,>20 hour,>10 hour,149.41,0,0.0,17681018,FEBS J. 2007 Sep;274(17):4511-25.,"Kelly BA, Neil SJ, McKnight A, Santos JM, Sinnis P, Jack ER, Middleton DA, Dobson CB.",Apolipoprotein E-derived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity.,10.1111/j.1742-4658.2007.05981.x,,Anti-HSV
DRAVPe01614,RLLRRLLRRLLRRLLRRLLR,20,RLLR5,Synthetic construct,No entry found,,HSV,Herpesviridae,plaque reduction assay,[Ref.17681018]HSV-1:inhibition of virus infection in NP-2/CD4/CCR5 cells(IC50<3.3 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01614.cif,Linear,Free,Free,,L,Not found,"The anti-HSV1 activity of apoEdp involves inhibition of virus particle attachment to cells, with this likely being related to the derivation of this peptide from the apoE HSPG/LDLR binding region.",2711.48,C120H232N50O21,ACDEFGHIKMNPQSTVWY,LR,12.95,10,0,10,0,10,-35.0,-10000,1 hour,2 min,2 min,195.0,0,0.0,17681018,FEBS J. 2007 Sep;274(17):4511-25.,"Kelly BA, Neil SJ, McKnight A, Santos JM, Sinnis P, Jack ER, Middleton DA, Dobson CB.",Apolipoprotein E-derived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity.,10.1111/j.1742-4658.2007.05981.x,,Anti-HSV
DRAVPe01615,RRRRRRRWWWRRRRRRRR,18,MU103,Synthetic construct,No entry found,,HSV,Herpesviridae,plaque reduction assay,[Ref.17681018]HSV-1:inhibition of virus infection in NP-2/CD4/CCR5 cells(IC50>20 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01615.cif,Linear,Free,Free,,L,Not found,"The anti-HSV1 activity of apoEdp involves inhibition of virus particle attachment to cells, with this likely being related to the derivation of this peptide from the apoE HSPG/LDLR binding region.",2919.47,C123H212N66O19,ACDEFGHIKLMNPQSTVY,R,13.15,15,0,15,0,3,-390.0,-21681,1 hour,2 min,2 min,0.0,16500,970.59,17681018,FEBS J. 2007 Sep;274(17):4511-25.,"Kelly BA, Neil SJ, McKnight A, Santos JM, Sinnis P, Jack ER, Middleton DA, Dobson CB.",Apolipoprotein E-derived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity.,10.1111/j.1742-4658.2007.05981.x,,Anti-HSV
DRAVPe01616,RRRRRRRRRRRRRRRWWW,18,MU104,Synthetic construct,No entry found,,HSV,Herpesviridae,plaque reduction assay,[Ref.17681018]HSV-1:inhibition of virus infection in NP-2/CD4/CCR5 cells(IC50=9.25 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01616.cif,Linear,Free,Free,,L,Not found,"The anti-HSV1 activity of apoEdp involves inhibition of virus particle attachment to cells, with this likely being related to the derivation of this peptide from the apoE HSPG/LDLR binding region.",2919.47,C123H212N66O19,ACDEFGHIKLMNPQSTVY,R,13.15,15,0,15,0,3,-390.0,-21681,1 hour,2 min,2 min,0.0,16500,970.59,17681018,FEBS J. 2007 Sep;274(17):4511-25.,"Kelly BA, Neil SJ, McKnight A, Santos JM, Sinnis P, Jack ER, Middleton DA, Dobson CB.",Apolipoprotein E-derived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity.,10.1111/j.1742-4658.2007.05981.x,,Anti-HSV
DRAVPe01617,WRKWRKRWWWRKWRKRWW,18,ApoEdpL-W,Synthetic construct,No entry found,,"HSV,HIV,VSV","Herpesviridae, Retroviridae, Rhabdoviridae",plaque reduction assay,[Ref.17681018]HSV-1:inhibition of virus infection in NP-2/CD4/CCR5 cells(IC50=3.1 µM);##HIV-1:inhibition of virus replication(>80% inhibition at 10 µM).,[Ref.17681018]15% hemolysis against human red blood cells at 35 μM.,[Ref.17681018]No significant cytotoxicity against Vero cells up to 40 μM.,,DRAVPe01617.cif,Linear,Free,Free,,L,Not found,"The anti-HSV1 activity of apoEdp involves inhibition of virus particle attachment to cells, with this likely being related to the derivation of this peptide from the apoE HSPG/LDLR binding region.",2957.54,C148H202N48O19,ACDEFGHILMNPQSTVY,W,12.7,10,0,10,0,8,-276.67,-9308,2.8 hour,3 min,2 min,0.0,44000,2588.24,17681018,FEBS J. 2007 Sep;274(17):4511-25.,"Kelly BA, Neil SJ, McKnight A, Santos JM, Sinnis P, Jack ER, Middleton DA, Dobson CB.",Apolipoprotein E-derived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity.,10.1111/j.1742-4658.2007.05981.x,,"Anti-HSV,Anti-HIV,Anti-VSV"
DRAVPe01618,HCKFWW,6,,Synthetic construct,No entry found,,HIV,Retroviridae,integrase assay,[Ref.8524782]HIV-1:inhibition of integrase-mediated 3'-processing and integration(IC50=2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01618.cif,Linear,Free,Amidation,,L,integrase,"The peptide may inhibit integrase-mediated 3'-processing and integration, which is useful for inhibiting virus replication.",906.07,C46H55N11O7S,ADEGILMNPQRSTVY,W,8.23,2,0,2,1,3,-60.0,-129,3.5 hour,10 min,>10 hour,0.0,11000,2200.0,8524782,Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60.,"Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH.",Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.,10.1073/pnas.92.25.11456,,Anti-HIV
DRAVPe01619,HCKFWI,6,,Synthetic construct,No entry found,,HIV,Retroviridae,integrase assay,[Ref.8524782]HIV-1:inhibition of integrase-mediated 3'-processing and integration(IC50=4 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01619.cif,Linear,Free,Amidation,,L,integrase,"The peptide may inhibit integrase-mediated 3'-processing and integration, which is useful for inhibiting virus replication.",833.02,C41H56N10O7S,ADEGLMNPQRSTVY,CFHIKW,8.23,2,0,2,1,3,30.0,130,3.5 hour,10 min,>10 hour,65.0,5500,1100.0,8524782,Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60.,"Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH.",Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.,10.1073/pnas.92.25.11456,,Anti-HIV
DRAVPe01620,HCKFWF,6,,Synthetic construct,No entry found,,HIV,Retroviridae,integrase assay,[Ref.8524782]HIV-1:inhibition of integrase-mediated 3'-processing and integration(IC50=7 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01620.cif,Linear,Free,Amidation,,L,integrase,"The peptide may inhibit integrase-mediated 3'-processing and integration, which is useful for inhibiting virus replication.",867.04,C44H54N10O7S,ADEGILMNPQRSTVY,F,8.23,2,0,2,1,3,1.67,-64,3.5 hour,10 min,>10 hour,0.0,5500,1100.0,8524782,Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60.,"Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH.",Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.,10.1073/pnas.92.25.11456,,Anti-HIV
DRAVPe01621,HCKFAW,6,,Synthetic construct,No entry found,,HIV,Retroviridae,integrase assay,[Ref.8524782]HIV-1:inhibition of integrase-mediated 3'-processing and integration(IC50=150 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01621.cif,Linear,Free,Amidation,,L,integrase,"The peptide may inhibit integrase-mediated 3'-processing and integration, which is useful for inhibiting virus replication.",790.94,C38H50N10O7S,DEGILMNPQRSTVY,ACFHKW,8.23,2,0,2,1,3,-15.0,-181,3.5 hour,10 min,>10 hour,16.67,5500,1100.0,8524782,Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60.,"Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH.",Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.,10.1073/pnas.92.25.11456,,Anti-HIV
DRAVPe01622,HCKFWA,6,,Synthetic construct,No entry found,,HIV,Retroviridae,integrase assay,[Ref.8524782]HIV-1:inhibition of integrase-mediated 3'-processing and integration(IC50=210 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01622.cif,Linear,Free,Amidation,,L,integrase,"The peptide may inhibit integrase-mediated 3'-processing and integration, which is useful for inhibiting virus replication.",790.94,C38H50N10O7S,DEGILMNPQRSTVY,ACFHKW,8.23,2,0,2,1,3,-15.0,-181,3.5 hour,10 min,>10 hour,16.67,5500,1100.0,8524782,Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60.,"Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH.",Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.,10.1073/pnas.92.25.11456,,Anti-HIV
DRAVPe01623,HCKAWW,6,,Synthetic construct,No entry found,,HIV,Retroviridae,integrase assay,[Ref.8524782]HIV-1:inhibition of integrase-mediated 3'-processing and integration(IC50=8 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01623.cif,Linear,Free,Amidation,,L,integrase,"The peptide may inhibit integrase-mediated 3'-processing and integration, which is useful for inhibiting virus replication.",829.97,C40H51N11O7S,DEFGILMNPQRSTVY,W,8.23,2,0,2,1,3,-76.67,-246,3.5 hour,10 min,>10 hour,16.67,11000,2200.0,8524782,Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60.,"Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH.",Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.,10.1073/pnas.92.25.11456,,Anti-HIV
DRAVPe01624,ACKFWW,6,,Synthetic construct,No entry found,,HIV,Retroviridae,integrase assay,[Ref.8524782]HIV-1:inhibition of integrase-mediated 3'-processing and integration(IC50=51 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01624.cif,Linear,Free,Amidation,,L,integrase,"The peptide may inhibit integrase-mediated 3'-processing and integration, which is useful for inhibiting virus replication.",840.01,C43H53N9O7S,DEGHILMNPQRSTVY,W,8.27,1,0,1,1,4,23.33,518,4.4 hour,>20 hour,>10 hour,16.67,11000,2200.0,8524782,Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60.,"Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH.",Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.,10.1073/pnas.92.25.11456,,Anti-HIV
DRAVPe01812,GWINEKKMQQKIDEKIGKNIIGGMAKAVIHKMAKNEFQCVANVDTLGNCKKHCAKTTGEKGYCHGTKCKCGIELSY,76,Smp76,Scorpio maurus palmatu,No entry found,,DENV,Flaviviridae,Plaque assay,[Ref.32435168]Dengue Virus(DENV):inhibition of viral infection in Vero/SLAM cells(IC50= 0.01 μg/ml).,[Ref.32435168]human red blood cells:HC50>10 μg/ml.,[Ref.32435168]Huh7it-1 cells:CC50>10 μg/ml.,,DRAVPe01812.cif,Cyclic,Free,Free,"Disulfide bonds between Cys39 and Cys63, Cys49 and Cys68, Cys53 and Cys70.",L,Not found,No mechanism information found in the reference(s).,8402.89,C362H595N105O106S9,PR,K,9.22,17,7,10,27,19,-56.84,-11300,30 hour,>20 hour,>10 hour,64.21,8855,118.07,32435168,Int J Pept Res Ther. 2020;26(2):811-821. ,"El-Bitar AMH, Sarhan M, Abdel-Rahman MA, Quintero-Hernandez V, Aoki-Utsubo C, Moustafa MA, Possani LD, Hotta H.","Smp76, a Scorpine-Like Peptide Isolated from the Venom of the Scorpion Scorpio maurus palmatus, with a Potent Antiviral Activity Against Hepatitis C Virus and Dengue Virus.",10.1007/s10989-019-09888-2,,Anti-DENV
DRAVPe01813,GFGCPFNQGQCHKHCQSIRRRGGYCDGFLKTRCVCYR,37,BmKDfsin4,Mesobuthus martensii,No entry found,,HBV,Hepadnaviridae,ELISA,"[Ref.27128943]hepatitic B Virus (HBV): Pharmacological profiles of BmKDfsin4 against HBeAg, HBsAg and HBV DNA on HepG2.2.15 cells(HBeAg: IC50= 3.95 μM; HBsAg: IC50= 2.28 μM; HBV DNA: IC50= 1.26 μM).",[Ref.27128943]Human erythrocytes: 50% hemolysis concentration was 66.85 μM.,[Ref.27128943]HepG2.2.15 cells: CC50= 167.82 μM;##HepG2 cells: CC50= 154.24 μM;##L-02 cells: CC50= 103.77 μM.,,DRAVPe01813.cif,Cyclic,Free,Free,"Disulfide bonds between Cys4 and Cys25, Cys11 and Cys33, Cys15 and Cys35.",L,Not found,"BmKDfsin4 had been shown to exhibit powerful inhibitory activity against HBV replication by reducing the production of HBeAg, HBsAg, and HBV DNAin cell culture medium and the production of intracellular HBsAg, HBV core protein, HBx protein, and HBV RT.",4282.95,C181H278N62O48S6,AEMW,CG,9.38,9,1,8,17,6,-71.35,-9711,30 hour,>20 hour,>10 hour,28.92,3355,93.19,27128943,Toxins (Basel). 2016 Apr 27;8(5):124.,"Zeng Z, Zhang Q, Hong W, Xie Y, Liu Y, Li W, Wu Y, Cao Z. ",A Scorpion Defensin BmKDfsin4 Inhibits Hepatitis B Virus Replication in Vitro.,10.3390/toxins8050124,,Anti-HBV
DRAVPe01814,ILGKIWEGIKSIF,13,Hp1036,Heterometrus petersii,P0DME6,,HSV-1,Herpesviridae,Plaque forming assay,[Ref.24315793]Herpes simplex virus type 1(HSV-1):inhibition of viral inactivation in Vero cells(EC50=0.43 ± 0.09 μM);inhibition of viral attachment in Vero cells(EC50=2.87 ± 0.16 μM);inhibition of viral entry in Vero cells(EC50=4.29 ± 0.35 μM);inhibition of postentry in Vero cells(EC50=7.86 ± 0.80 μM).,[Ref.24315793]Human erythrocytes: HC50 = 34.91 ± 0.47 μM.,[Ref.24315793]Vero cells: CC50 = 46.71 ± 3.80 μM.,,DRAVPe01814.cif,Linear,Free,Amidation,,L,Not found, inhibit HSV-1 when it attaches to the cell surface and when it has already bound to the cells but not entered yet and also exhibited potent inhibitory effects against viral particles proliferation in postentry stage.,1503.85,C74H118N16O17,ACDHMNPQRTVY,I,8.59,2,1,1,3,7,83.08,1048,20 hour,30 min,>10 hour,150.0,5500,458.33,24315793,Antiviral Res. 2014 Feb;102:1-10.,"Hong W, Li T, Song Y, Zhang R, Zeng Z, Han S, Zhang X, Wu Y, Li W, Cao Z.", Inhibitory activity and mechanism of two scorpion venom peptides against herpes simplex virus type 1. ,10.1016/j.antiviral.2013.11.013,,Anti-HSV-1
DRAVPe01815,ILSYLWNGIKSIF,13,Hp1239,Heterometrus petersii,P0DME8,,HSV-1,Herpesviridae,Plaque forming assay,[Ref.24315793]Herpes simplex virus type 1(HSV-1):inhibition of viral inactivation in Vero cells(EC50=0.41 ± 0.06 μM);inhibition of viral attachment in Vero cells(EC50=5.73 ± 0.61 μM);inhibition of viral entry in Vero cells(EC50=4.32 ± 0.47 μM);inhibition of postentry in Vero cells(EC50=8.41 ± 0.73 μM).,[Ref.24315793]Human erythrocytes: HC50 = 33.32 ± 0.96 μM.,[Ref.24315793]Vero cells: CC50 = 26.15 ± 1.91 μM.,,DRAVPe01815.cif,Linear,Free,Amidation,,L,Not found, inhibit HSV-1 when it attaches to the cell surface and when it has already bound to the cells but not entered yet and also exhibited potent inhibitory effects against viral particles proliferation in postentry stage.,1553.86,C77H116N16O18,ACDEHMPQRTV,I,8.59,1,0,1,5,7,94.62,1172,20 hour,30 min,>10 hour,150.0,6990,582.5,24315793,Antiviral Res. 2014 Feb;102:1-10.,"Hong W, Li T, Song Y, Zhang R, Zeng Z, Han S, Zhang X, Wu Y, Li W, Cao Z.", Inhibitory activity and mechanism of two scorpion venom peptides against herpes simplex virus type 1. ,10.1016/j.antiviral.2013.11.013,,Anti-HSV-1
DRAVPe01821,LLMVNEATRFQTVSGFV,17,BPIP,Synthetic construct,No entry found,,SARS-CoV-2,Coronaviridae,MBP-tagged (SARS-CoV-2) assay,[Ref.35896605]SARS-CoV-2: inhibition of Mpro (IC50= 0.52 nM).,[Ref.35896605]BRIP is not hemolytic at 500 nM and slightly hemolytic at 50 µM.,No cytotoxicity information or data found in the reference(s) presented in this entry,,DRAVPe01821.cif,Linear,Free,Free,,L,Mpro,"The peptide inhibits Mpro, a protein crucial for viral replication.",1912.23,C86H138N22O25S,CDHIKPWY,V,6.0,1,1,0,5,8,70.0,-943,5.5 hour,3 min,2 min,102.94,0,0.0,35896605,Sci Rep. 2022 Jul 27;12(1):12802,"Kashyap P, Bhardwaj VK, Chauhan M, Chauhan V, Kumar A, Purohit R, Kumar A, Kumar S",A ricin-based peptide BRIP from Hordeum vulgare inhibits Mpro of SARS-CoV-2,10.1038/s41598-022-15977-y,,Anti-SARS-CoV-2
DRAVPe01822,KFFRKKSVKK,10,BF-30,Bungarus fasciatus,No entry found,,Influenza A virus,Orthomyxoviridae,Cytopathic effect (CPE) reduction assay,[Ref.30447229]Influenza A virus H1N1:inhibition of viral replication in MDCK cells(EC50=5.20±0.9 μM);##influenza A virus H3N2: inhibition of viral replication in MDCK cells(EC50=7.36 ± 1.2 μM);##influenza A virus(oseltamivir-resistant strain): inhibition of viral replication in MDCK cells(EC50=18.91 ± 7.0 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30447229]MDCK cells:CC50=67.7μM.,,DRAVPe01822.cif,Linear,Free,Free,,L,Not found,BF-30 could inhibit the replication of various influenza subtypes by fusing virion membranes and reducing infectivity. ,1295.64,C62H106N18O12,ACDEGHILMNPQTWY,K,11.39,6,0,6,1,3,-150.0,-3607,1.3 hour,3 min,2 min,29.0,0,0.0,30447229,Peptides. 2019 Feb;112:14-22. ,"Xu J, Chen S, Jin J, Ma L, Guo M, Zhou C, Dou J.",Inhibition of peptide BF-30 on influenza A virus infection in vitro/vivo by causing virion membrane fusion.,10.1016/j.peptides.2018.10.004,,Anti-Anti-Influenza A virus
DRAVPe01823,FLGAILKIGHALAKTVLPMVTNAFKPKQ,28,Figainin 2,Boana raniceps (Hypsiboas raniceps),A0A2L2DDD0,,"CHIKV,DENV,YFV",,immunofluorescence assay,[Ref.32443921]chikungunya virus (CHIKV):inhibition of viral infection in Huh7 cells(EC50=17 μM);##Dengue Serotype 4 Virus(DENV4):inhibition of viral infection in Huh7 cells(EC50=20.8 μM);##Yellow Fever viral (YFV):inhibition of viral infection in Huh7 cells(EC50=21.8 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.32443921]No cytotoxicity against noninfected Huh7 cells at concentrations as high as 25 µM.,,DRAVPe01823.cif,Linear,Free,Free,,L,Not found,No mechanism information found in the reference(s).,3007.72,C142H236N36O33S,CDERSWY,AKL,10.48,5,0,5,5,14,57.5,1085,1.1 hour,3 min,2 min,118.57,0,0.0,32443921,Biomolecules. 2020 May 20;10(5):790. ,"Santana CJC, Magalhães ACM, Prías-Márquez CA, Falico DA, Dos Santos Júnior ACM, Lima BD, Ricart CAO, de Pilger DRB, Bonotto RM, Moraes CB, Freitas-Júnior LH, Álvares ADCM, Freitas SM, Luz IS, Pires OR Jr, Fontes W, Castro MS.","Biological Properties of a Novel Multifunctional Host Defense Peptide from the Skin Secretion of the Chaco Tree Frog, Boana raniceps.",10.3390/biom10050790,,"Anti-CHIKV,Anti-DENV,Anti-YFV"
DRAVPe01824,QMRRKVELFTYMRFD,15,SP40 ,Synthetic construct,No entry found,,EV-A71,Picornaviridae,cell protection assay,[Ref.34314773]Enterovirus A71 (EV-A71):inhibition of viral replication into RD cells(IC50=18 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.34314773]RD cells: CC50=228.7 μM.,,DRAVPe01824.cif,Linear,Acetylation,Amidation,Free,L,Not found,SP40 peptide could associate with the cellular receptors at the surface of cells and prevented the attachment of EV-A71 to the cellular receptors,2020.4,C90H142N26O23S2,ACGHINPSW,R,9.98,4,2,2,2,4,-83.33,-5447,0.8 hour,10 min,>10 hour,45.33,1490,106.43,34314773,Virus Res. 2021 Oct 2;303:198456. ,"Zarif F, Anasir MI, Koh JX, Chew MF, Poh CL.",Stability and antiviral activity of SP40 peptide in human serum.,10.1016/j.virusres.2021.198456.,,Anti-EV-A71
DRAVPe01825,MRRKVELFTYMRFD,14,TP1,Synthetic construct,No entry found,,EV-A71,Picornaviridae,cell protection assay,[Ref.34314773]Enterovirus A71 (EV-A71):inhibition of viral replication into RD cells(IC50=6.6 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.34314773]RD cells: CC50=683.6 μM.,,DRAVPe01825.cif,Linear,Acetylation,Amidation,Free,L,Not found,The peptide could associate with the cellular receptors at the surface of cells and prevented the attachment of EV-A71 to the cellular receptors.,1892.27,C85H134N24O21S2,ACGHINPQSW,R,9.98,4,2,2,2,4,-64.29,-4893,30 hour,>20 hour,>10 hour,48.57,1490,114.62,34314773,Virus Res. 2021 Oct 2;303:198456. ,"Zarif F, Anasir MI, Koh JX, Chew MF, Poh CL.",Stability and antiviral activity of SP41 peptide in human serum.,10.1016/j.virusres.2021.198456.,,Anti-EV-A71
DRAVPe01826,RRKVELFTYMRFD,13,TP2,Synthetic construct,No entry found,,EV-A71,Picornaviridae,cell protection assay,[Ref.34314773]Enterovirus A71 (EV-A71):inhibition of viral replication into RD cells(IC50=6 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.34314773]RD cells: CC50=345 μM.,,DRAVPe01826.cif,Linear,Acetylation,Amidation,Free,L,Not found,The peptide could associate with the cellular receptors at the surface of cells and prevented the attachment of EV-A71 to the cellular receptors.,1761.07,C80H125N23O20S,ACGHINPQSW,R,9.98,4,2,2,2,4,-83.85,-5128,1 hour,2 min,2 min,52.31,1490,124.17,34314773,Virus Res. 2021 Oct 2;303:198456.,"Zarif F, Anasir MI, Koh JX, Chew MF, Poh CL.",Stability and antiviral activity of SP42 peptide in human serum.,10.1016/j.virusres.2021.198456.,,Anti-EV-A71
DRAVPe01827,RKVELFTYMRFD,12,TP3,Synthetic construct,No entry found,,EV-A71,Picornaviridae,cell protection assay,[Ref.34314773]Enterovirus A71 (EV-A71):inhibition of viral replication into RD cells(IC50=5.7 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.34314773]RD cells: CC50=1123 μM.,,DRAVPe01827.cif,Linear,Acetylation,Amidation,Free,L,Not found,The peptide could associate with the cellular receptors at the surface of cells and prevented the attachment of EV-A71 to the cellular receptors.,1604.89,C74H113N19O19S,ACGHINPQSW,FR,8.59,3,2,1,2,4,-53.33,-3636,1 hour,2 min,2 min,56.67,1490,135.45,34314773,Virus Res. 2021 Oct 2;303:198456.,"Zarif F, Anasir MI, Koh JX, Chew MF, Poh CL.",Stability and antiviral activity of SP43 peptide in human serum.,10.1016/j.virusres.2021.198456.,,Anti-EV-A71
DRAVPe01828,QMRRKVELFTYMRF,14,TP10,Synthetic construct,No entry found,,EV-A71,Picornaviridae,cell protection assay,[Ref.34314773]Enterovirus A71 (EV-A71):inhibition of viral replication into RD cells(IC50=6.7 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.34314773]RD cells: CC50=231 μM.,,DRAVPe01828.cif,Linear,Acetylation,Amidation,Free,L,Not found,The peptide could associate with the cellular receptors at the surface of cells and prevented the attachment of EV-A71 to the cellular receptors.,1905.31,C86H137N25O20S2,ACDGHINPSW,R,10.9,4,1,3,2,4,-64.29,-4575,0.8 hour,10 min,>10 hour,48.57,1490,114.62,34314773,Virus Res. 2021 Oct 2;303:198456.,"Zarif F, Anasir MI, Koh JX, Chew MF, Poh CL.",Stability and antiviral activity of SP44 peptide in human serum.,10.1016/j.virusres.2021.198456.,,Anti-EV-A71
DRAVPe01829,AKVTMTCSAS,10,KP,Synthetic construct,P01680,,HSV-1,Herpesviridae,Plaque reduction assay,[Ref.30654366]HSV-1:inhibition of viral replication in Vero cells (96% inhibition at 50 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30654366]<10% cytotoxicity against Vero cells at the concentration of 100μg/ mL.,,DRAVPe01829.cif,Linear,Free,Free,,L,Not found,No mechanism information found in the reference(s).,998.18,C39H71N11O15S2,DEFGHILNPQRWY,AST,8.27,1,0,1,5,3,53.0,-620,4.4 hour,>20 hour,>10 hour,49.0,0,0.0,30654366,Intervirology. 2018;61(4):166-173.,"Sala A, Ardizzoni A, Ciociola T, Magliani W, Conti S, Blasi E, Cermelli C",Antiviral Activity of Synthetic Peptides Derived from Physiological Proteins. ,10.1159/000494354,,Anti-HSV-1
DRAVPe01830,KKVTMTCSAS,10,K10S,Synthetic construct,P01680,,"HSV-1, CoxV B5, AdV, VSV","Herpesviridae, Picornaviridae, Adenoviridae, Rhabdoviridae",Plaque reduction assay,"[Ref.30654366]HSV-1:inhibition of viral replication in Vero cells (45% inhibition at 10 µg/ml, 76% inhibition at 50 µg/ml, 89% inhibition at 100 µg/ml);##Coxsackie virus B5:inhibition of viral replication in Vero cells (75% inhibition at 50 µg/ml, 94% inhibition at 100 µg/ml);##Vesicular Stomatitis Virus (VSV):inhibition of viral replication in Vero cells (78% inhibition at 50 µg/ml, 96% inhibition at 100 µg/ml);##Adenovirus:inhibition of viral replication in Vero cells (75% inhibition at 50 µg/ml, 91% inhibition at 100 µg/ml).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30654366]20% cytotoxicity against Vero cells at the concentration of 100μg/ mL.,,DRAVPe01830.cif,Linear,Free,Free,,L,Not found,No mechanism information found in the reference(s).,1055.27,C42H78N12O15S2,DEFGHILNPQRWY,KST,9.31,2,0,2,5,2,-4.0,-1356,1.3 hour,3 min,2 min,39.0,0,0.0,30654366,Intervirology. 2018;61(4):166-173.,"Sala A, Ardizzoni A, Ciociola T, Magliani W, Conti S, Blasi E, Cermelli C",Antiviral Activity of Synthetic Peptides Derived from Physiological Proteins. ,10.1159/000494354,,"Anti-HSV-1, Anti-CoxV B5, Anti-AdV, Anti-VSV"
DRAVPe01831,NQVSATCSVK,10,L5A,Synthetic construct,P0DOX5,,VSV,Rhabdoviridae,Plaque reduction assay,"[Ref.30654366]Vesicular Stomatitis Virus (VSV):inhibition of viral replication in Vero cells (45% inhibition at 50 µg/ml, 50% inhibition at 100 µg/ml).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30654366]20% cytotoxicity against Vero cells at the concentration of 100μg/ mL.,,DRAVPe01831.cif,Linear,Free,Free,,L,Not found,No mechanism information found in the reference(s).,1036.17,C41H73N13O16S,DEFGHILMPRWY,SV,8.22,1,0,1,5,3,-5.0,-1593,1.4 hour,3 min,>10 hour,68.0,0,0.0,30654366,Intervirology. 2018;61(4):166-173.,"Sala A, Ardizzoni A, Ciociola T, Magliani W, Conti S, Blasi E, Cermelli C",Antiviral Activity of Synthetic Peptides Derived from Physiological Proteins. ,10.1159/000494354,,Anti-VSV
DRAVPe01832,KKLVAASQAALGL,13,K13L,Synthetic construct,P02768-2,,CoxV B5,Picornaviridae,Plaque reduction assay,"[Ref.30654366]Coxsackie virus B5:inhibition of viral replication in Vero cells (60% inhibition at 10 µg/ml, 80% inhibition at 50 µg/ml, 87% inhibition at 100 µg/ml).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30654366]30% cytotoxicity against Vero cells at the concentration of 100μg/ mL.,,DRAVPe01832.cif,Linear,Free,Free,,L,Not found,No mechanism information found in the reference(s).,1269.55,C57H104N16O16,CDEFHIMNPRTWY,A,10.0,2,0,2,2,8,79.23,694,1.3 hour,3 min,2 min,143.08,0,0.0,30654366,Intervirology. 2018;61(4):166-173.,"Sala A, Ardizzoni A, Ciociola T, Magliani W, Conti S, Blasi E, Cermelli C",Antiviral Activity of Synthetic Peptides Derived from Physiological Proteins. ,10.1159/000494354,,Anti-CoxV B5
DRAVPe01833,DSGEGDFLAEGGGVR,15,D15R,Synthetic construct,P02671,,CoxV B5,Picornaviridae,Plaque reduction assay,"[Ref.30654366]Coxsackie virus B5:inhibition of viral replication in Vero cells (82% inhibition at 10 µg/ml, 85% inhibition at 50 µg/ml, 93% inhibition at 100 µg/ml).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30654366]<10% cytotoxicity against Vero cells at the concentration of 100μg/ mL.,,DRAVPe01833.cif,Linear,Free,Free,,L,Not found,No mechanism information found in the reference(s).,1465.5,C60H92N18O25,CHIKMNPQTWY,G,3.92,1,4,-3,6,4,-58.0,-3093,1.1 hour,3 min,>10 hour,52.0,0,0.0,30654366,Intervirology. 2018;61(4):166-173.,"Sala A, Ardizzoni A, Ciociola T, Magliani W, Conti S, Blasi E, Cermelli C",Antiviral Activity of Synthetic Peptides Derived from Physiological Proteins. ,10.1159/000494354,,Anti-CoxV B5
DRAVPe01834,GLEEELQFSLGSKINVK,17,G17K,Synthetic construct,P0C0L5,,CoxV B5,Picornaviridae,Plaque reduction assay,"[Ref.30654366]Coxsackie virus B5:inhibition of viral replication in Vero cells (60% inhibition at 10 µg/ml, 75% inhibition at 50 µg/ml, 88% inhibition at 100 µg/ml).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30654366]<10% cytotoxicity against Vero cells at the concentration of 100μg/ mL.,,DRAVPe01834.cif,Linear,Free,Free,,L,Not found,No mechanism information found in the reference(s).,1891.15,C84H139N21O28,ACDHMPRTWY,EL,4.79,2,3,-1,5,6,-28.24,-2193,30 hour,>20 hour,>10 hour,108.82,0,0.0,30654366,Intervirology. 2018;61(4):166-173.,"Sala A, Ardizzoni A, Ciociola T, Magliani W, Conti S, Blasi E, Cermelli C",Antiviral Activity of Synthetic Peptides Derived from Physiological Proteins. ,10.1159/000494354,,Anti-CoxV B5
DRAVPe01835,SEETKENEGFTVTAEGK,17,S17K,Synthetic construct,P01024,,AdV,Adenoviridae,Plaque reduction assay,"[Ref.30654366]Adenovirus:inhibition of viral replication in Vero cells (60% inhibition at 10 µg/ml, 65% inhibition at 50 µg/ml, 80% inhibition at 100 µg/ml).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30654366]<10% cytotoxicity against Vero cells at the concentration of 100μg/ mL.,,DRAVPe01835.cif,Linear,Free,Free,,L,Not found,No mechanism information found in the reference(s).,1855.93,C77H122N20O33,CDHILMPQRWY,E,4.32,2,5,-3,7,3,-139.41,-5219,1.9 hour,>20 hour,>10 hour,22.94,0,0.0,30654366,Intervirology. 2018;61(4):166-173.,"Sala A, Ardizzoni A, Ciociola T, Magliani W, Conti S, Blasi E, Cermelli C",Antiviral Activity of Synthetic Peptides Derived from Physiological Proteins. ,10.1159/000494354,,Anti-AdV
DRAVPe01836,LCLRNWDQGHRP,12,L12P,Synthetic construct,A0M8Q8,,"HSV-1, CoxV B5","Herpesviridae, Picornaviridae",Plaque reduction assay,"[Ref.30654366]HSV-1:inhibition of viral replication in Vero cells (78% inhibition at 10 µg/ml, 84% inhibition at 50 µg/ml);##Coxsackie virus B5:inhibition of viral replication in Vero cells (60% inhibition at 10 µg/ml, 42% inhibition at 50 µg/ml).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30654366]<10% cytotoxicity against Vero cells at the concentration of 100μg/ mL.,,DRAVPe01836.cif,Linear,Free,Free,,L,Not found,No mechanism information found in the reference(s).,1494.69,C64H99N23O17S,AEFIKMSTVY,LR,8.26,3,1,2,3,3,-129.17,-4101,5.5 hour,3 min,2 min,65.0,5500,500.0,30654366,Intervirology. 2018;61(4):166-173.,"Sala A, Ardizzoni A, Ciociola T, Magliani W, Conti S, Blasi E, Cermelli C",Antiviral Activity of Synthetic Peptides Derived from Physiological Proteins. ,10.1159/000494354,,"Anti-HSV-1, Anti-CoxV B5"
DRAVPe01837,GKRKSGCA,8,Entry 1,Synthetic construct,No entry found,,DENV,Flaviviridae,Fluorimetric assay,[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 114.2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Cyclic,No specific N-terminal,No specific C-terminal,The N-terminal and C-terminal cyclized by a amide bond.,L,NS2B-NS3 protease,"The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus.",805.95,C31H59N13O10S,DEFHILMNPQTVWY,GK,10.06,3,0,3,4,1,-120.0,-2445,30 hour,>20 hour,>10 hour,12.5,0,0.0,28539222,Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590.,"Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y.",Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.,10.1016/j.bmcl.2017.05.027,,Anti-DENV
DRAVPe01838,GKRKSGAA,8,Entry 6,Synthetic construct,No entry found,,DENV,Flaviviridae,Fluorimetric assay,[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 57.4 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Cyclic,No specific N-terminal,No specific C-terminal,The N-terminal and C-terminal cyclized by a amide bond.,L,NS2B-NS3 protease,"The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus.",773.89,C31H59N13O10,CDEFHILMNPQTVWY,AGK,11.17,3,0,3,3,2,-128.75,-2392,30 hour,>20 hour,>10 hour,25.0,0,0.0,28539222,Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590.,"Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y.",Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.,10.1016/j.bmcl.2017.05.027,,Anti-DENV
DRAVPe01839,GKRKSXCA,8,Entry 7,Synthetic construct,No entry found,,DENV,Flaviviridae,Fluorimetric assay,[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 22.1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Cyclic,No specific N-terminal,No specific C-terminal,The 'X' at position 6 indicates phenylglycine(Phg). The N-terminal and C-terminal cyclized by a amide bond.,L,NS2B-NS3 protease,"The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus.",860.23,C29H54N12O8S,DEFHILMNPQTVWY,K,10.06,3,0,3,3,1,-115.0,-2539,30 hour,>20 hour,>10 hour,12.5,0,0.0,28539222,Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590.,"Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y.",Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.,10.1016/j.bmcl.2017.05.027,,Anti-DENV
DRAVPe01840,GKRKSFCA,8,Entry 8,Synthetic construct,No entry found,,DENV,Flaviviridae,Fluorimetric assay,[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 39.3 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Cyclic,No specific N-terminal,No specific C-terminal,The N-terminal and C-terminal cyclized by a amide bond.,L,NS2B-NS3 protease,"The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus.",896.08,C38H65N13O10S,DEHILMNPQTVWY,K,10.06,3,0,3,3,2,-80.0,-2241,30 hour,>20 hour,>10 hour,12.5,0,0.0,28539222,Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590.,"Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y.",Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.,10.1016/j.bmcl.2017.05.027,,Anti-DENV
DRAVPe01841,GKRKSXCA,8,Entry 9,Synthetic construct,No entry found,,DENV,Flaviviridae,Fluorimetric assay,[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 9.2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Cyclic,No specific N-terminal,No specific C-terminal,The 'X' at position 6 indicates homophenylalanine(hPhe). The N-terminal and C-terminal cyclized by a amide bond.,L,NS2B-NS3 protease,"The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus.",860.23,C29H54N12O8S,DEFHILMNPQTVWY,K,10.06,3,0,3,3,1,-115.0,-2539,30 hour,>20 hour,>10 hour,12.5,0,0.0,28539222,Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590.,"Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y.",Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.,10.1016/j.bmcl.2017.05.027,,Anti-DENV
DRAVPe01842,GKRKSxCA,8,Entry 10,Synthetic construct,No entry found,,DENV,Flaviviridae,Fluorimetric assay,[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 38.7 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Cyclic,No specific N-terminal,No specific C-terminal,The 'x' at position 6 indicates D-homophenylalanine(D-hPhe). The N-terminal and C-terminal cyclized by a amide bond.,Mixed(D-hPhe6),NS2B-NS3 protease,"The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus.",860.23,C29H54N12O8S,DEFHILMNPQTVWY,K,10.06,3,0,3,3,1,-115.0,-2539,30 hour,>20 hour,>10 hour,12.5,0,0.0,28539222,Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590.,"Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y.",Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.,10.1016/j.bmcl.2017.05.027,,Anti-DENV
DRAVPe01843,GKRKSXAA,8,Entry 11,Synthetic construct,No entry found,,DENV,Flaviviridae,Fluorimetric assay,[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 18.4 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Cyclic,No specific N-terminal,No specific C-terminal,The 'X' at position 6 indicates homophenylalanine(hPhe). The N-terminal and C-terminal cyclized by a amide bond.,L,NS2B-NS3 protease,"The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus.",828.17,C29H54N12O8,CDEFHILMNPQTVWY,AK,11.17,3,0,3,2,2,-123.75,-2486,30 hour,>20 hour,>10 hour,25.0,0,0.0,28539222,Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590.,"Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y.",Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.,10.1016/j.bmcl.2017.05.027,,Anti-DENV
DRAVPe01844,GKRKSXAX,8,Entry 12,Synthetic construct,No entry found,,DENV,Flaviviridae,Fluorimetric assay,[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 22.2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Cyclic,No specific N-terminal,No specific C-terminal,"The 'X' at position 6 indicates homophenylalanine(hPhe), position 8 indicates homophenylalanine(Phg). The N-terminal and C-terminal cyclized by a amide bond.",L,NS2B-NS3 protease,"The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus.",868.42,C26H47N11O6,CDEFHILMNPQTVWY,KX,11.17,3,0,3,2,1,-146.25,-2667,30 hour,>20 hour,>10 hour,12.5,0,0.0,28539222,Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590.,"Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y.",Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.,10.1016/j.bmcl.2017.05.027,,Anti-DENV
DRAVPe01845,GKRKSXAx,8,Entry 13,Synthetic construct,No entry found,,DENV,Flaviviridae,Fluorimetric assay,[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 15.1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Cyclic,No specific N-terminal,No specific C-terminal,"The 'X' at position 6 indicates homophenylalanine(hPhe), position 8 indicates D-homophenylalanine(D-Phg). The N-terminal and C-terminal cyclized by a amide bond.",Mixed(D-Phg8),NS2B-NS3 protease,"The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus.",868.42,C26H47N11O6,CDEFHILMNPQTVWY,K,11.17,3,0,3,2,1,-146.25,-2667,30 hour,>20 hour,>10 hour,12.5,0,0.0,28539222,Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590.,"Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y.",Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.,10.1016/j.bmcl.2017.05.027,,Anti-DENV
DRAVPe01846,GKRKSXAF,8,Entry 14,Synthetic construct,No entry found,,DENV,Flaviviridae,Fluorimetric assay,[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 19.8 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Cyclic,No specific N-terminal,No specific C-terminal,The 'X' at position 6 indicates homophenylalanine(hPhe). The N-terminal and C-terminal cyclized by a amide bond.,L,NS2B-NS3 protease,"The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus.",904.27,C35H58N12O8,CDEHILMNPQTVWY,K,11.17,3,0,3,2,2,-111.25,-2369,30 hour,>20 hour,>10 hour,12.5,0,0.0,28539222,Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590.,"Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y.",Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.,10.1016/j.bmcl.2017.05.027,,Anti-DENV
DRAVPe01847,GKRKSXAf,8,Entry 15,Synthetic construct,No entry found,,DENV,Flaviviridae,Fluorimetric assay,[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 7.6 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Cyclic,No specific N-terminal,No specific C-terminal,The 'X' at position 6 indicates homophenylalanine(hPhe). The N-terminal and C-terminal cyclized by a amide bond.,Mixed(D-Phe8),NS2B-NS3 protease,"The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus.",904.27,C26H47N11O6,CDEFHILMNPQTVWY,K,11.17,3,0,3,2,1,-146.25,-2667,30 hour,>20 hour,>10 hour,12.5,0,0.0,28539222,Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590.,"Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y.",Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.,10.1016/j.bmcl.2017.05.027,,Anti-DENV
DRAVPe01848,GKRKSXAX,8,Entry 16,Synthetic construct,No entry found,,DENV,Flaviviridae,Fluorimetric assay,[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 25.6 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Cyclic,No specific N-terminal,No specific C-terminal,The 'X' at position 6 and 8 indicates homophenylalanine(hPhe). The N-terminal and C-terminal cyclized by a amide bond.,L,NS2B-NS3 protease,"The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus.",868.42,C26H47N11O6,CDEFHILMNPQTVWY,KX,11.17,3,0,3,2,1,-146.25,-2667,30 hour,>20 hour,>10 hour,12.5,0,0.0,28539222,Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590.,"Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y.",Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.,10.1016/j.bmcl.2017.05.027,,Anti-DENV
DRAVPe01849,GKRKSXAx,8,Entry 17,Synthetic construct,No entry found,,DENV,Flaviviridae,Fluorimetric assay,[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 16.2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Cyclic,No specific N-terminal,No specific C-terminal,The 'X' at position 6 and 8 indicates homophenylalanine(hPhe/D-hPhe). The N-terminal and C-terminal cyclized by a amide bond.,Mixed(D-hPhe8),NS2B-NS3 protease,"The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus.",868.42,C26H47N11O6,CDEFHILMNPQTVWY,K,11.17,3,0,3,2,1,-146.25,-2667,30 hour,>20 hour,>10 hour,12.5,0,0.0,28539222,Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590.,"Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y.",Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.,10.1016/j.bmcl.2017.05.027,,Anti-DENV
DRAVPe01850,GKRKSXSf,8,Entry 18,Synthetic construct,No entry found,,DENV,Flaviviridae,Fluorimetric assay,[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 5.0 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Cyclic,No specific N-terminal,No specific C-terminal,The 'X' at position 6 indicates homophenylalanine(hPhe). The N-terminal and C-terminal cyclized by a amide bond.,Mixed(D-Phe8),NS2B-NS3 protease,"The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus.",920.27,C26H47N11O7,ACDEFHILMNPQTVWY,KS,11.17,3,0,3,3,0,-178.75,-3188,30 hour,>20 hour,>10 hour,0.0,0,0.0,28539222,Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590.,"Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y.",Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.,10.1016/j.bmcl.2017.05.027,,Anti-DENV
DRAVPe01851,AKRKSXSf,8,Entry 19,Synthetic construct,No entry found,,DENV,Flaviviridae,Fluorimetric assay,[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 28.5 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Cyclic,No specific N-terminal,No specific C-terminal,The 'X' at position 6 indicates homophenylalanine(hPhe). The N-terminal and C-terminal cyclized by a amide bond.,Mixed(D-Phe8),NS2B-NS3 protease,"The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus.",934.29,C27H49N11O7,CDEFGHILMNPQTVWY,KS,11.17,3,0,3,2,1,-151.25,-3101,4.4 hour,>20 hour,>10 hour,12.5,0,0.0,28539222,Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590.,"Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y.",Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.,10.1016/j.bmcl.2017.05.027,,Anti-DENV
DRAVPe01852,aKRKSXSf,8,Entry 20,Synthetic construct,No entry found,,DENV,Flaviviridae,Fluorimetric assay,[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 3.3 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Cyclic,No specific N-terminal,No specific C-terminal,The 'X' at position 6 indicates homophenylalanine(hPhe). The N-terminal and C-terminal cyclized by a amide bond.,"Mixed(D-Ala1, Phe8)",NS2B-NS3 protease,"The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus.",934.29,C24H42N10O5,ACDEFGHILMNPQTVWY,KS,11.17,3,0,3,2,0,-173.75,-3282,,,,0.0,0,0.0,28539222,Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590.,"Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y.",Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.,10.1016/j.bmcl.2017.05.027,,Anti-DENV
DRAVPe01853,PKRKSXSf,8,Entry 21,Synthetic construct,No entry found,,DENV,Flaviviridae,Fluorimetric assay,[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 52.0 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Cyclic,No specific N-terminal,No specific C-terminal,The 'X' at position 6 indicates homophenylalanine(hPhe). The N-terminal and C-terminal cyclized by a amide bond.,Mixed(D-Phe8),NS2B-NS3 protease,"The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus.",960.33,C29H51N11O7,ACDEFGHILMNQTVWY,KS,11.17,3,0,3,2,0,-193.75,-3282,>20 hour,>20 hour,?,0.0,0,0.0,28539222,Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590.,"Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y.",Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.,10.1016/j.bmcl.2017.05.027,,Anti-DENV
DRAVPe01854,pKRKSXSf,8,Entry 22,Synthetic construct,No entry found,,DENV,Flaviviridae,Fluorimetric assay,[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 0.95 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Cyclic,No specific N-terminal,No specific C-terminal,The 'X' at position 6 indicates homophenylalanine(hPhe). The N-terminal and C-terminal cyclized by a amide bond.,"Mixed(D-Pro1, Phe8)",NS2B-NS3 protease,"The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus.",960.33,C24H42N10O5,ACDEFGHILMNPQTVWY,KS,11.17,3,0,3,2,0,-173.75,-3282,,,,0.0,0,0.0,28539222,Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590.,"Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y.",Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.,10.1016/j.bmcl.2017.05.027,,Anti-DENV
DRAVPe01855,pKRKSXSf,8,Entry 23,Synthetic construct,No entry found,,DENV,Flaviviridae,Fluorimetric assay,[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 2.6 μM); inhibition of virus-induced cytopathic effects (CPE) in BHK-21 cells(EC50=306.2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.28539222]BHK-21 cells: CC50>400 μM.,,,Cyclic,No specific N-terminal,No specific C-terminal,The 'X' at position 6 indicates L-2-naphthylalanine(l-2Nal). The N-terminal and C-terminal cyclized by a amide bond.,"Mixed(D-Pro1, Phe8)",NS2B-NS3 protease,"The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus.",960.33,C24H42N10O5,ACDEFGHILMNPQTVWY,KS,11.17,3,0,3,2,0,-173.75,-3282,,,,0.0,0,0.0,28539222,Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590.,"Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y.",Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.,10.1016/j.bmcl.2017.05.027,,Anti-DENV
DRAVPe01856,pKRKSXSf,8,Entry 24,Synthetic construct,No entry found,,DENV,Flaviviridae,Fluorimetric assay,[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 3.8 μM); inhibition of virus-induced cytopathic effects (CPE) in BHK-21 cells(EC50=293.0 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.28539222]BHK-21 cells: CC50>400 μM.,,,Cyclic,No specific N-terminal,No specific C-terminal,The 'X' at position 6 indicates biphenylalanine (L-bPhe). The N-terminal and C-terminal cyclized by a amide bond.,"Mixed(D-Pro1, Phe8)",NS2B-NS3 protease,"The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus.",960.33,C24H42N10O5,ACDEFGHILMNPQTVWY,KS,11.17,3,0,3,2,0,-173.75,-3282,,,,0.0,0,0.0,28539222,Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590.,"Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y.",Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.,10.1016/j.bmcl.2017.05.027,,Anti-DENV
DRAVPe01857,pRRKSXSf,8,Entry 25,Synthetic construct,No entry found,,DENV,Flaviviridae,Fluorimetric assay,[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 3.8 μM); inhibition of virus-induced cytopathic effects (CPE) in BHK-21 cells(EC50=108.1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.28539222]BHK-21 cells: CC50>400 μM.,,,Cyclic,No specific N-terminal,No specific C-terminal,The 'X' at position 6 indicates biphenylalanine (L-bPhe). The N-terminal and C-terminal cyclized by a amide bond.,"Mixed(D-Pro1, Phe8)",NS2B-NS3 protease,"The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus.",988.34,C24H42N12O5,ACDEFGHILMNPQTVWY,RS,12.01,3,0,3,2,0,-181.25,-4219,,,,0.0,0,0.0,28539222,Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590.,"Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y.",Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.,10.1016/j.bmcl.2017.05.027,,Anti-DENV
DRAVPe01858,rRRKSXSf,8,Entry 26,Synthetic construct,No entry found,,DENV,Flaviviridae,Fluorimetric assay,[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 3.7 μM); inhibition of virus-induced cytopathic effects (CPE) in BHK-21 cells(EC50=87.5 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.28539222]BHK-21 cells: CC50>400 μM.,,,Cyclic,No specific N-terminal,No specific C-terminal,The 'X' at position 6 indicates biphenylalanine (L-bPhe). The N-terminal and C-terminal cyclized by a amide bond.,"Mixed(D-Arg1, Phe8)",NS2B-NS3 protease,"The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus.",1047.42,C24H42N12O5,ACDEFGHILMNPQTVWY,RS,12.3,3,0,3,2,0,-181.25,-4219,,,,0.0,0,0.0,28539222,Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590.,"Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y.",Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.,10.1016/j.bmcl.2017.05.027,,Anti-DENV
DRAVPe01859,rRRKSXSr,8,Entry 27,Synthetic construct,No entry found,,DENV,Flaviviridae,Fluorimetric assay,[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 2.3 μM); inhibition of virus-induced cytopathic effects (CPE) in BHK-21 cells(EC50=141.1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.28539222]BHK-21 cells: CC50>400 μM.,,,Cyclic,No specific N-terminal,No specific C-terminal,The 'X' at position 6 indicates biphenylalanine (L-bPhe). The N-terminal and C-terminal cyclized by a amide bond.,"Mixed(D-Arg1, 8)",NS2B-NS3 protease,"The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus.",1056.43,C24H42N12O5,ACDEFGHILMNPQTVWY,RS,12.48,3,0,3,2,0,-181.25,-4219,,,,0.0,0,0.0,28539222,Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590.,"Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y.",Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.,10.1016/j.bmcl.2017.05.027,,Anti-DENV
DRAVPe01860,rRRKSXXf,8,Entry 28,Synthetic construct,No entry found,,DENV,Flaviviridae,Fluorimetric assay,[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 1.6 μM); inhibition of virus-induced cytopathic effects (CPE) in BHK-21 cells(EC50=23.2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.28539222]BHK-21 cells: CC50=233 μM.,,,Cyclic,No specific N-terminal,No specific C-terminal,"The 'X' at position 6 indicates homophenylalanine(hPhe), position 7 indicates L-1-naphthylalanine(L-1Nal). The N-terminal and C-terminal cyclized by a amide bond.","Mixed(D-Arg1, Phe8)",NS2B-NS3 protease,"The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus.",1071.67,C21H35N11O2,ACDEFGHILMNPQTVWY,RX,12.3,3,0,3,1,0,-171.25,-3879,,,,0.0,0,0.0,28539222,Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590.,"Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y.",Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.,10.1016/j.bmcl.2017.05.027,,Anti-DENV
DRAVPe01861,rRRKAXXf,8,Entry 29,Synthetic construct,No entry found,,DENV,Flaviviridae,Fluorimetric assay,[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 1.7 μM); inhibition of virus-induced cytopathic effects (CPE) in BHK-21 cells(EC50=11.8 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.28539222]BHK-21 cells: CC50=134.1 μM.,,,Cyclic,No specific N-terminal,No specific C-terminal,"The 'X' at position 6 indicates homophenylalanine(hPhe), position 7 indicates L-1-naphthylalanine(L-1Nal). The N-terminal and C-terminal cyclized by a amide bond.","Mixed(D-Arg1, Phe8)",NS2B-NS3 protease,"The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus.",1055.67,C21H35N11O,CDEFGHILMNPQSTVWY,RX,12.3,3,0,3,0,1,-138.75,-3358,,,,12.5,0,0.0,28539222,Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590.,"Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y.",Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.,10.1016/j.bmcl.2017.05.027,,Anti-DENV
DRAVPe01862,rRRKSXXf,8,Entry 30,Synthetic construct,No entry found,,DENV,Flaviviridae,Fluorimetric assay,[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 1.5 μM); inhibition of virus-induced cytopathic effects (CPE) in BHK-21 cells(EC50=48.5 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.28539222]BHK-21 cells: CC50=210 μM.,,,Cyclic,No specific N-terminal,No specific C-terminal,"The 'X' at position 6 indicates homophenylalanine(hPhe), position 7 indicates L-2-naphthylalanine(L-2Nal). The N-terminal and C-terminal cyclized by a amide bond.","Mixed(D-Arg1, Phe8)",NS2B-NS3 protease,"The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus.",1071.67,C21H35N11O2,ACDEFGHILMNPQTVWY,RX,12.3,3,0,3,1,0,-171.25,-3879,,,,0.0,0,0.0,28539222,Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590.,"Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y.",Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.,10.1016/j.bmcl.2017.05.027,,Anti-DENV
DRAVPe01863,rRRKfXFx,8,Entry 31,Synthetic construct,No entry found,,DENV,Flaviviridae,Fluorimetric assay,[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 1.7 μM); inhibition of virus-induced cytopathic effects (CPE) in BHK-21 cells(EC50=4.6 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.28539222]BHK-21 cells: CC50=86 μM.,,,Cyclic,No specific N-terminal,No specific C-terminal,"The 'X' at position 6 indicates homophenylalanine(hPhe), position 8 indicates D-2-naphthylalanine(D-2Nal). The N-terminal and C-terminal cyclized by a amide bond.","Mixed(D-Arg1, Phe5, 2Nal8)",NS2B-NS3 protease,"The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus.",1131.77,C27H39N11O,ACDEGHILMNPQSTVWY,R,12.3,3,0,3,0,1,-126.25,-3241,,,,0.0,0,0.0,28539222,Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590.,"Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y.",Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.,10.1016/j.bmcl.2017.05.027,,Anti-DENV
DRAVPe01864,rRRKxXFx,8,Entry 32,Synthetic construct,No entry found,,DENV,Flaviviridae,Fluorimetric assay,[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 1.1 μM); inhibition of virus-induced cytopathic effects (CPE) in BHK-21 cells(EC50=2.0 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.28539222]BHK-21 cells: CC50=24 μM.,,,Cyclic,No specific N-terminal,No specific C-terminal,"The 'X' at position 6 indicates homophenylalanine(hPhe), position 5 and 8 indicates D-2-naphthylalanine(D-2Nal). The N-terminal and C-terminal cyclized by a amide bond.","Mixed(D-Arg1, 2Nal5, 8)",NS2B-NS3 protease,"The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus.",1095.92,C27H39N11O,ACDEGHILMNPQSTVWY,R,12.3,3,0,3,0,1,-126.25,-3241,,,,0.0,0,0.0,28539222,Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590.,"Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y.",Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.,10.1016/j.bmcl.2017.05.027,,Anti-DENV
DRAVPe01865,CGGGGGSLTEINTELLDLEYEMKKLEEVVKKLEESYIDLKEL,42,PIH,Synthetic construct,No entry found,,MERS-CoV,Coronaviridae,,[Ref.31099550]MERS-CoV:inhibition of cell-cell fusion between 293T cells and Huh-7 cells(IC50=1.171 μM).,No hemolysis information or data found in the reference(s) presented in this entry,"[Ref.31099550]PIH displayed no significant cytotoxicity to 293T, Huh-7, and L02 cells even at a high concentration of 100 μM.",,,Linear,Free,Free,,L,membrane,"Inhibits MERS-Cov S protein-mediated cell fusion, which is the major pathway of MERS-CoV-induced host infections.",4717.37,C207H340N48O72S2,AFHPQRW,E,4.32,5,11,-6,13,12,-40.24,-5973,1.2 hour,>20 hour,>10 hour,106.67,2980,72.68,31099550,ACS Appl Mater Interfaces. 2019 Jun 5;11(22):19799-19807.,"Huang X, Li M, Xu Y, Zhang J, Meng X, An X, Sun L, Guo L, Shan X, Ge J, Chen J, Luo Y, Wu H, Zhang Y, Jiang Q, Ning X. ",Novel Gold Nanorod-Based HR1 Peptide Inhibitor for Middle East Respiratory Syndrome Coronavirus.,10.1021/acsami.9b04240,,Anti-MERS-CoV
DRAVPe01866,PWLKPGDLDL,10,DET2,Synthetic construct,No entry found,,DENV,Flaviviridae,Plaque formation assay,"[Ref.23630436]dengue virus 2(DENV2):inhibition of viral replication in LLC-MK2 cells(41.5±20.0% inhibition at 200 µM, IC50>500 µM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.23630436]Monkey kidney epithelial cells LLC-MK2: 8% Cell death at 500 µM.,,,Linear,Free,Free,,L,E protein,"The peptide caused structural abnormalities and alteration of the arrangement of the viral E protein, which interferes with virus binding and entry. ",1153.34,C55H84N12O15,ACEFHIMNQRSTVY,L,4.21,1,2,-1,1,4,-40.0,-496,>20 hour,>20 hour,?,117.0,5500,611.11,23630436,Int J Med Sci. 2013 Apr 16;10(6):719-29. ,"Alhoot MA, Rathinam AK, Wang SM, Manikam R, Sekaran SD.",Inhibition of dengue virus entry into target cells using synthetic antiviral peptides.,10.7150/ijms.5037,,Anti-DENV
DRAVPe01867,AGVKDGKLDF,10,DET4,Synthetic construct,No entry found,,DENV,Flaviviridae,Plaque formation assay,"[Ref.23630436]dengue virus 2(DENV2):inhibition of viral replication in LLC-MK2 cells(84.6±5.6%  inhibition at 500 µM, IC50=35 µM).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.23630436]Monkey kidney epithelial cells LLC-MK2: 5% Cell death at 500 µM.,,,Linear,Free,Free,,L,E protein,"The peptide caused structural abnormalities and alteration of the arrangement of the viral E protein, which interferes with virus binding and entry. ",1049.19,C47H76N12O15,CEHIMNPQRSTWY,DGK,6.0,2,2,0,2,4,-30.0,-1291,4.4 hour,>20 hour,>10 hour,78.0,0,0.0,23630436,Int J Med Sci. 2013 Apr 16;10(6):719-29. ,"Alhoot MA, Rathinam AK, Wang SM, Manikam R, Sekaran SD.",Inhibition of dengue virus entry into target cells using synthetic antiviral peptides.,10.7150/ijms.5037,,Anti-DENV
DRAVPe01868,WLVFFVIFYFFR,12,FP1 (Tkip),Synthetic construct,No entry found,,Influenza virus,Orthomyxoviridae,Plaque reduction assay,[Ref.22258859]influenza A virus A/WSN/33 H1N1:inhibition of viral replication in MDCK cells(IC50=0.09360 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,HA,the mechanism whereby FluPep mediates its antiviral effects is likely to involve inhibiting the binding of HA to sialic acid receptors or through interference with the fusion process by blocking protease cleavage.,1684.06,C93H118N16O14,ACDEGHKMNPQST,F,8.75,1,0,1,1,10,200.0,2009,2.8 hour,3 min,2 min,113.33,6990,635.45,22258859,J Gen Virol. 2012 May;93(Pt 5):980-986.,"Nicol MQ, Ligertwood Y, Bacon MN, Dutia BM, Nash AA. ",A novel family of peptides with potent activity against influenza A viruses. ,10.1099/vir.0.038679-0,,Anti-Influenza virus
DRAVPe01869,WLVFFVIAYFAR,12,FP2,Synthetic construct,No entry found,,Influenza virus,Orthomyxoviridae,Plaque reduction assay,[Ref.22258859]influenza A virus A/WSN/33 H1N1:inhibition of viral replication in MDCK cells(IC50=0.00087 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,HA,the mechanism whereby FluPep mediates its antiviral effects is likely to involve inhibiting the binding of HA to sialic acid receptors or through interference with the fusion process by blocking protease cleavage.,1531.86,C81H110N16O14,CDEGHKMNPQST,F,8.75,1,0,1,1,10,183.33,1775,2.8 hour,3 min,2 min,130.0,6990,635.45,22258859,J Gen Virol. 2012 May;93(Pt 5):980-986.,"Nicol MQ, Ligertwood Y, Bacon MN, Dutia BM, Nash AA. ",A novel family of peptides with potent activity against influenza A viruses. ,10.1099/vir.0.038679-0,,Anti-Influenza virus
DRAVPe01870,WLVFFVIFYFFRRRKK,16,FP3,Synthetic construct,No entry found,,Influenza virus,Orthomyxoviridae,Plaque reduction assay,[Ref.22258859]influenza A virus A/WSN/33 H1N1:inhibition of viral replication in MDCK cells(IC50=0.00003 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,HA,the mechanism whereby FluPep mediates its antiviral effects is likely to involve inhibiting the binding of HA to sialic acid receptors or through interference with the fusion process by blocking protease cleavage.,2252.78,C117H166N28O18,ACDEGHMNPQST,F,11.73,5,0,5,1,10,45.0,-2085,2.8 hour,3 min,2 min,85.0,6990,466.0,22258859,J Gen Virol. 2012 May;93(Pt 5):980-986.,"Nicol MQ, Ligertwood Y, Bacon MN, Dutia BM, Nash AA. ",A novel family of peptides with potent activity against influenza A viruses. ,10.1099/vir.0.038679-0,,Anti-Influenza virus
DRAVPe01871,RRKKWLVFFVIFYFFR,16,FP4,Synthetic construct,No entry found,,Influenza virus,Orthomyxoviridae,Plaque reduction assay,[Ref.22258859]influenza A virus A/WSN/33 H1N1:inhibition of viral replication in MDCK cells(IC50=0.00004 µM);##influenza A virus PR8/Eng09 (H1N1):inhibition of viral replication in MDCK cells(IC50=0.0778 µM);##influenza A virus PR8/Vic (H3N2):inhibition of viral replication in MDCK cells(IC50=0.0535 µM);##influenza A virus PR8/Viet (H5N1):inhibition of viral replication in MDCK cells(IC50=0.1325 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,HA,the mechanism whereby FluPep mediates its antiviral effects is likely to involve inhibiting the binding of HA to sialic acid receptors or through interference with the fusion process by blocking protease cleavage.,2252.78,C117H166N28O18,ACDEGHMNPQST,F,11.73,5,0,5,1,10,45.0,-2085,1 hour,2 min,2 min,85.0,6990,466.0,22258859,J Gen Virol. 2012 May;93(Pt 5):980-986.,"Nicol MQ, Ligertwood Y, Bacon MN, Dutia BM, Nash AA. ",A novel family of peptides with potent activity against influenza A viruses. ,10.1099/vir.0.038679-0,,Anti-Influenza virus
DRAVPe01872,RRKKIFYFFR,10,FP7,Synthetic construct,No entry found,,Influenza virus,Orthomyxoviridae,Plaque reduction assay,[Ref.22258859]influenza A virus A/WSN/33 H1N1:inhibition of viral replication in MDCK cells(IC50=0.15483 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,HA,the mechanism whereby FluPep mediates its antiviral effects is likely to involve inhibiting the binding of HA to sialic acid receptors or through interference with the fusion process by blocking protease cleavage.,1460.79,C72H109N21O12,ACDEGHLMNPQSTVW,FR,11.73,5,0,5,1,4,-97.0,-4214,1 hour,2 min,2 min,39.0,1490,165.56,22258859,J Gen Virol. 2012 May;93(Pt 5):980-986.,"Nicol MQ, Ligertwood Y, Bacon MN, Dutia BM, Nash AA. ",A novel family of peptides with potent activity against influenza A viruses. ,10.1099/vir.0.038679-0,,Anti-Influenza virus
DRAVPe01873,WLVFFVRRKK,10,FP8,Synthetic construct,No entry found,,Influenza virus,Orthomyxoviridae,Plaque reduction assay,[Ref.22258859]influenza A virus A/WSN/33 H1N1:inhibition of viral replication in MDCK cells(IC50=0.63806 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,HA,the mechanism whereby FluPep mediates its antiviral effects is likely to involve inhibiting the binding of HA to sialic acid receptors or through interference with the fusion process by blocking protease cleavage.,1378.73,C69H107N19O11,ACDEGHIMNPQSTY,FKRV,12.02,4,0,4,0,6,1.0,-1965,2.8 hour,3 min,2 min,97.0,5500,611.11,22258859,J Gen Virol. 2012 May;93(Pt 5):980-986.,"Nicol MQ, Ligertwood Y, Bacon MN, Dutia BM, Nash AA. ",A novel family of peptides with potent activity against influenza A viruses. ,10.1099/vir.0.038679-0,,Anti-Influenza virus
DRAVPe01874,FFVIFYRRKK,10,FP9,Synthetic construct,No entry found,,Influenza virus,Orthomyxoviridae,Plaque reduction assay,[Ref.22258859]influenza A virus A/WSN/33 H1N1:inhibition of viral replication in MDCK cells(IC50=1.48175 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,HA,the mechanism whereby FluPep mediates its antiviral effects is likely to involve inhibiting the binding of HA to sialic acid receptors or through interference with the fusion process by blocking protease cleavage.,1403.74,C71H106N18O12,ACDEGHLMNPQSTW,F,11.1,4,0,4,1,5,-10.0,-2318,1.1 hour,3 min,2 min,68.0,1490,165.56,22258859,J Gen Virol. 2012 May;93(Pt 5):980-986.,"Nicol MQ, Ligertwood Y, Bacon MN, Dutia BM, Nash AA. ",A novel family of peptides with potent activity against influenza A viruses. ,10.1099/vir.0.038679-0,,Anti-Influenza virus
DRAVPe01875,GYRARPKFKAGKR,13,HPV-31 L1 Cta,Synthetic construct,No entry found,,HPV,Papillomaviridae,luminescence assay,[Ref.15170645]human papillomavirus(HPV):inhibition of HPV virus-like particle cell entry(86±3% inhibition at 10 μg/ml); inhibition of pseudovirions infection(91±4% inhibition at 10 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,Not found,No mechanism information found in the reference(s).,1534.83,C69H115N25O15,CDEHILMNQSTVW,KR,11.74,6,0,6,3,3,-173.08,-5307,30 hour,>20 hour,>10 hour,15.38,1490,124.17,15170645,J Med Virol. 2004 Jul;73(3):474-80.,"Bousarghin L, Touzé A, Yvonnet B, Coursaget P.",Positively charged synthetic peptides from structural proteins of papillomaviruses abrogate human papillomavirus infectivity.,10.1002/jmv.20114,,Anti-HPV
DRAVPe01876,TTTPAKRKKTKK,12,HPV-31 L1 Ctb,Synthetic construct,No entry found,,HPV,Papillomaviridae,luminescence assay,[Ref.15170645]human papillomavirus(HPV):inhibition of HPV virus-like particle cell entry(12±10% inhibition at 10 μg/ml); inhibition of pseudovirions infection(15±8% inhibition at 10 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,Not found,No mechanism information found in the reference(s).,1387.69,C60H114N20O17,CDEFGHILMNQSVWY,K,11.39,6,0,6,4,1,-221.67,-5114,7.2 hour,>20 hour,>10 hour,8.33,0,0.0,15170645,J Med Virol. 2004 Jul;73(3):474-80.,"Bousarghin L, Touzé A, Yvonnet B, Coursaget P.",Positively charged synthetic peptides from structural proteins of papillomaviruses abrogate human papillomavirus infectivity.,10.1002/jmv.20114,,Anti-HPV
DRAVPe01877,MLRKRRKRL,9,HPV-16 L2 Ct,Synthetic construct,No entry found,,HPV,Papillomaviridae,luminescence assay,[Ref.15170645]human papillomavirus(HPV):inhibition of HPV virus-like particle cell entry(78±6% inhibition at 10 μg/ml); inhibition of pseudovirions infection(96±20% inhibition at 10 μg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,Not found,No mechanism information found in the reference(s).,1256.62,C53H105N23O10S,ACDEFGHINPQSTVWY,R,12.48,6,0,6,0,2,-181.11,-5859,30 hour,>20 hour,>10 hour,86.67,0,0.0,15170645,J Med Virol. 2004 Jul;73(3):474-80.,"Bousarghin L, Touzé A, Yvonnet B, Coursaget P.",Positively charged synthetic peptides from structural proteins of papillomaviruses abrogate human papillomavirus infectivity.,10.1002/jmv.20114,,Anti-HPV
DRAVPe01878,GCKKYRRFRWKFKGKFWFWG,20,Pep19-2.5,Synthetic construct,No entry found,,"HIV, HSV-1, HCV, HBV","Retroviridae,Herpesviridae, Flaviviridae, Hepadnaviridae",luciferase infection assay,[Ref.22457281]HIV-1 BaL:inhibition of viral entry in 293T cells(IC50=8 µg/ml);##HIV-1 NL4-3:inhibition of viral entry in 293T cells(IC50=16 µg/ml);##HSV-1:inhibition of viral entry in Vero cells(IC50=0.42 µg/ml);##Hepatitis C virus (HCV):inhibition of viral entry in 293T cells(IC50=40 µg/ml);##Hepatitis B virus (HBV):inhibition of viral entry in 293T cells(IC50=1 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,"[Ref.22457281]No significant cytotoxicity to Vero, TZM-bl and Jurkat cells even at a high concentration of 20 μg/mL.",,,Linear,Free,Free,,L,membrane,"SALPs block entry of a variety of human pathogenic enveloped viruses, such as HIV-1, HBV, HCV, and HSV 1 and 2 by blocking heparan sulfate on the host cell plasma membrane, which serves as a the docking molecule for these pathogens.",2712.26,C135H187N37O22S,ADEHILMNPQSTV,K,11.17,8,0,8,5,7,-122.5,-4964,30 hour,>20 hour,>10 hour,0.0,17990,946.84,22457281,J Infect Dis. 2012 Jun;205(11):1654-64.,"Krepstakies M, Lucifora J, Nagel CH, Zeisel MB, Holstermann B, Hohenberg H, Kowalski I, Gutsmann T, Baumert TF, Brandenburg K, Hauber J, Protzer U.",A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses.,10.1093/infdis/jis273,,"Anti-HIV, Anti-HSV-1, Anti-HCV, Anti-HBV"
DRAVPe01879,GKKYRRFRWKFKFGKWFWFG,20,Pep19-4,Synthetic construct,No entry found,,"HIV, HSV-1, HCV","Retroviridae,Herpesviridae, Flaviviridae",luciferase infection assay,[Ref.22457281]HIV-1 BaL:inhibition of viral entry in 293T cells(IC50=22 µg/ml);##HIV-1 NL4-3:inhibition of viral entry in 293T cells(IC50=10 µg/ml);##HSV-1:inhibition of viral entry in Vero cells(IC50=1.8 µg/ml);##Hepatitis C virus (HCV):inhibition of viral entry in 293T cells(IC50=37 µg/ml).,No hemolysis information or data found in the reference(s) presented in this entry,"[Ref.22457281]No significant cytotoxicity to Vero, TZM-bl and Jurkat cells even at a high concentration of 20 μg/mL.",,,Linear,Free,Free,,L,membrane,"SALPs block entry of a variety of human pathogenic enveloped viruses, such as HIV-1, HBV, HCV, and HSV 1 and 2 by blocking heparan sulfate on the host cell plasma membrane, which serves as a the docking molecule for these pathogens.",2756.3,C141H191N37O22,ACDEHILMNPQSTV,FK,11.76,8,0,8,4,8,-121.0,-4794,30 hour,>20 hour,>10 hour,0.0,17990,946.84,22457281,J Infect Dis. 2012 Jun;205(11):1654-64.,"Krepstakies M, Lucifora J, Nagel CH, Zeisel MB, Holstermann B, Hohenberg H, Kowalski I, Gutsmann T, Baumert TF, Brandenburg K, Hauber J, Protzer U.",A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses.,10.1093/infdis/jis273,,"Anti-HIV, Anti-HSV-1, Anti-HCV"
DRAVPe01880,ATSSANSKA,9,Loop3,Synthetic construct,No entry found,,JEV,Flaviviridae,Plaque assay,[Ref.22465300]Japanese encephalitis virus(JEV):inhibition of viral replication in BHK-21 cells(IC50=10 ± 1.4 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22465300]Did not stimulate significant cytotoxicity in BHK-21 cells even at 200 μM.,,,Linear,Free,Free,,L,Envelope protein,prevent JEV infection by interfering in virus attachment to the cells.,835.87,C32H57N11O15,CDEFGHILMPQRVWY,AS,8.8,1,0,1,5,3,-56.67,-1953,4.4 hour,>20 hour,>10 hour,33.33,0,0.0,22465300,Antiviral Res. 2012 May;94(2):179-83.,"Li C, Zhang LY, Sun MX, Li PP, Huang L, Wei JC, Yao YL, Isahg H, Chen PY, Mao X.",Inhibition of Japanese encephalitis virus entry into the cells by the envelope glycoprotein domain III (EDIII) and the loop3 peptide derived from EDIII.,10.1016/j.antiviral.2012.03.002,,Anti-JEV
DRAVPe01881,SISNALNKLEESNRNLDKVNVKLT,24,C24,Synthetic construct,No entry found,,NDV,Paramyxoviridae,Plaque reduction assay,[Ref.12127571]Newcastle disease virus (NDV):inhibition of syncytium formation between NDV-infected cells(IC50=3.27 μM),No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,F protein,"By binding to the opposite HR region in the F protein, peptides would inhibit fusion from the initial steps (lipid- and contents-mixing), blocking the conformational changes in the fusion protein required for triggering fusion.",2700.04,C114H199N35O40,CFGHMPQWY,N,8.22,4,3,1,9,8,-72.5,-6539,1.9 hour,>20 hour,>10 hour,109.58,0,0.0,12127571,Int J Biochem Cell Biol. 2002 Oct;34(10):1207-20.,"San Román K, Villar E, Muñoz-Barroso I.",Mode of action of two inhibitory peptides from heptad repeat domains of the fusion protein of Newcastle disease virus.,10.1016/s1357-2725(02)00045-6,,Anti-NDV
DRAVPe01882,KQNAANILRLKESIAATNEAVAnti-HeV,24,N24,Synthetic construct,No entry found,,NDV,Paramyxoviridae,Plaque reduction assay,[Ref.12127571]Newcastle disease virus (NDV):inhibition of syncytium formation between NDV-infected cells(IC50=22.5 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,F protein,"By binding to the opposite HR region in the F protein, peptides would inhibit fusion from the initial steps (lipid- and contents-mixing), blocking the conformational changes in the fusion protein required for triggering fusion.",2619.96,C112H191N35O37,CDFGMPWY,A,6.76,4,3,1,5,11,-31.25,-4573,1.3 hour,3 min,2 min,110.0,0,0.0,12127571,Int J Biochem Cell Biol. 2002 Oct;34(10):1207-20.,"San Román K, Villar E, Muñoz-Barroso I.",Mode of action of two inhibitory peptides from heptad repeat domains of the fusion protein of Newcastle disease virus.,10.1016/s1357-2725(02)00045-6,,Anti-NDV
DRAVPe01883,GRRRRSVQWCAVSQPEATKCFQWQRNMRKVRGPPVSCIKRDSPIQCIQA,49,HLFcin 1-49,Synthetic construct,No entry found,,HPV,Papillomaviridae,Western blotting,[Ref.17481742]human papillomavirus(HPV):inhibition of pseudovirus infection in C33A cells(IC50=0.32±0.18μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Cyclic,Free,Free,"Disulfide bonds between Cys10 and Cys46, Cys20 and Cys37.",L,Not found,No mechanism information found in the reference(s).,5743.71,C244H403N85O66S5,HLY,R,11.24,11,2,9,12,13,-85.1,-15425,30 hour,>20 hour,>10 hour,53.67,11250,234.38,17481742,Antiviral Res. 2007 Sep;75(3):258-65.,"Mistry N, Drobni P, Näslund J, Sunkari VG, Jenssen H, Evander M.",The anti-papillomavirus activity of human and bovine lactoferricin.,10.1016/j.antiviral.2007.03.012,,Anti-HPV
DRAVPe01884,FKCRRWQWRMKKLGAPSITCVRRAFA,26,BLfcinB 17-42,Synthetic construct,No entry found,,HPV,Papillomaviridae,Western blotting,[Ref.17481742]human papillomavirus(HPV):inhibition of pseudovirus infection in C33A cells(IC50=0.25±0.24 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Cyclic,Free,Free,Disulfide bonds between Cys3 and Cys20.,L,Not found,No mechanism information found in the reference(s).,3196.9,C144H231N47O30S3,DEHNY,R,11.84,8,0,8,5,10,-48.46,-6698,1.1 hour,3 min,2 min,52.69,11125,445.0,17481742,Antiviral Res. 2007 Sep;75(3):258-65.,"Mistry N, Drobni P, Näslund J, Sunkari VG, Jenssen H, Evander M.",The anti-papillomavirus activity of human and bovine lactoferricin.,10.1016/j.antiviral.2007.03.012,,Anti-HPV
DRAVPe01885,AGDDQGLDKCVPNSKEK,17,,Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutinin assay,[Ref.22595270]Influenza A virus (A/Roma-ISS/2/08 H1N1):inhibition of viral  replication in MDCK cells(EC50=3.7±0.35 pM);##Influenza A virus (A/Parma/24/09 H1N1):inhibition of viral  replication in MDCK cells(EC50=3.4±0.14 pM);##Influenza A virus (A/Parma/05/06 H3N2):inhibition of viral  replication in MDCK cells(EC50=7.3±0.65 pM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22595270]MDCK cells:CC50>25 μM.,,,Linear,Free,Free,,L,HA,The peptide may bind with HA  and precent the attachment to target cells.,1803.96,C73H122N22O29S,FHIMRTWY,DK,4.68,3,4,-1,5,3,-138.82,-5127,4.4 hour,>20 hour,>10 hour,45.88,0,0.0,22595270,Pathog Glob Health. 2012 Mar;106(1):12-9.,"Ammendolia MG, Agamennone M, Pietrantoni A, Lannutti F, Siciliano RA, De Giulio B, Amici C, Superti F.",Bovine lactoferrin-derived peptides as novel broad-spectrum inhibitors of influenza virus.,10.1179/2047773212Y.0000000004,,Anti-Anti-Influenza A virus
DRAVPe01886,NGESSADWAKN,11,,Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutinin assay,[Ref.22595270]Influenza A virus (A/Roma-ISS/2/08 H1N1):inhibition of viral  replication in MDCK cells(EC50=225±5.8 fM);##Influenza A virus (A/Parma/24/09 H1N1):inhibition of viral  replication in MDCK cells(EC50=50±1.37 fM);##Influenza A virus (A/Parma/05/06 H3N2):inhibition of viral  replication in MDCK cells(EC50=22.5±1.16 pM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22595270]MDCK cells:CC50>25 μM.,,,Linear,Free,Free,,L,HA,The peptide may bind with HA  and precent the attachment to target cells.,1178.18,C48H71N15O20,CFHILMPQRTVY,ANS,4.37,1,2,-1,5,3,-156.36,-3427,1.4 hour,3 min,>10 hour,18.18,5500,550.0,22595270,Pathog Glob Health. 2012 Mar;106(1):12-9.,"Ammendolia MG, Agamennone M, Pietrantoni A, Lannutti F, Siciliano RA, De Giulio B, Amici C, Superti F.",Bovine lactoferrin-derived peptides as novel broad-spectrum inhibitors of influenza virus.,10.1179/2047773212Y.0000000004,,Anti-Anti-Influenza A virus
DRAVPe01887,SKHSSLDCVLRP,12,,Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutinin assay,[Ref.22595270]Influenza A virus (A/Roma-ISS/2/08 H1N1):inhibition of viral  replication in MDCK cells(EC50=4±0.37 pM);##Influenza A virus (A/Parma/24/09 H1N1):inhibition of viral  replication in MDCK cells(EC50=3.1±0.12 pM);##Influenza A virus (A/Parma/05/06 H3N2):inhibition of viral  replication in MDCK cells(EC50=5.8±0.7 pM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.22595270]MDCK cells:CC50>25 μM.,,,Linear,Free,Free,,L,HA,The peptide may bind with HA  and precent the attachment to target cells.,1341.55,C56H96N18O18S,AEFGIMNQTWY,S,7.97,3,1,2,4,3,-40.0,-2889,1.9 hour,>20 hour,>10 hour,89.17,0,0.0,22595270,Pathog Glob Health. 2012 Mar;106(1):12-9.,"Ammendolia MG, Agamennone M, Pietrantoni A, Lannutti F, Siciliano RA, De Giulio B, Amici C, Superti F.",Bovine lactoferrin-derived peptides as novel broad-spectrum inhibitors of influenza virus.,10.1179/2047773212Y.0000000004,,Anti-Anti-Influenza A virus
DRAVPe01888,AVSKVLHLEGEVNKISALLSTNKAVVSLSNGAnti-VSVLTSKVLDLDNYIDKQLLPIVNK,56,HR1-30a,Synthetic construct,No entry found,,RSV,Paramyxoviridae,Cell fusion assay,[Ref.12615056]respiratory syncytial virus(RSV):inhibition of cell fusion in Hep2 cells( IC50=1.68 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,F protein,Peptide derived from hRSV F protein give strong virus–cell fusion inhibition effect. ,5989.0,C268H458N70O83,CFMRW,LV,8.35,7,5,2,17,25,33.75,-3793,4.4 hour,>20 hour,>10 hour,142.5,1490,27.09,12615056,Biochem Biophys Res Commun. 2003 Mar 14;302(3):469-75. ,"Wang E, Sun X, Qian Y, Zhao L, Tien P, Gao GF.",Both heptad repeats of human respiratory syncytial virus fusion protein are potent inhibitors of viral fusion.,10.1016/s0006-291x(03)00197-9,,Anti-RSV
DRAVPe01889,NFYDPLVFPSDEFDASISQVNEKINQSLASIRKSDELLHNVNAGK,45,HR2-30a,Synthetic construct,No entry found,,RSV,Paramyxoviridae,Cell fusion assay,[Ref.12615056]respiratory syncytial virus(RSV):inhibition of cell fusion in Hep2 cells( IC50=2.93 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,F protein,Peptide derived from hRSV F protein give strong virus–cell fusion inhibition effect. ,5051.56,C223H346N60O74,CMTW,S,4.65,5,7,-2,13,16,-51.11,-9449,1.4 hour,3 min,>10 hour,86.67,1490,33.86,12615056,Biochem Biophys Res Commun. 2003 Mar 14;302(3):469-75. ,"Wang E, Sun X, Qian Y, Zhao L, Tien P, Gao GF.",Both heptad repeats of human respiratory syncytial virus fusion protein are potent inhibitors of viral fusion.,10.1016/s0006-291x(03)00197-9,,Anti-RSV
DRAVPe01890,NKGCATCSIGAACLVDGPIPDFEIAGAtGLfGLWG,35,Subtilosin-A,Bacillus subtilis,O07623,1PXQ,HSV-2,Herpesviridae,Plaque formation assay,"[Ref.25087911]herpes simplex virus type 2(HSV-2): inhibition of viral replication in Vero cells(90% inhibition at 25 μg/mL,EC50= 18.2μg/mL).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.25087911]Vero cells: CC50=316.8 μg/mL.,,,Cyclic,No specific N-terminal,No specific C-terminal,"The N-terminal and C-terminal cyclized by a amide bond. Thioether bridges between Cys4 and Phe31,Cys7 and Thr28,Cys13 and Phe22.","Mixed(D-Thr28,D-Phe31)",Not found,Subtilosin displays antiviral and virucidal actions against HSV-2. The target of subtilosin inhibitory effect would be late stages of the viral replicative cycle such as viral glycoprotein intracellular transport.,3425.94,C139H214N36O41S3,HMQRY,G,4.03,1,3,-2,13,14,63.14,1593,1.4 hour,3 min,>10 hour,89.43,5625,165.44,25087911,J Appl Microbiol. 2014 Nov;117(5):1253-9.,"Quintana VM, Torres NI, Wachsman MB, Sinko PJ, Castilla V, Chikindas M.",Antiherpes simplex virus type 2 activity of the antimicrobial peptide subtilosin.,10.1111/jam.12618,,Anti-HSV-2
DRAVPe01891,RRKKAAVALLPAVLLALLAP,20,EB,Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutinin assay,[Ref.17005658]Influenza A virus(A/Hong Kong/483/97 ([HK/483] strain H5N1)): inhibition of viral replication by preventing attachment to cRBCs(IC50=8 μM); inhibition of influenza virus-induced cell death and replication in vitro(IC50=4.5 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.17005658]No cytotoxicity against MDCK cells up to 50μM,,,Linear,Free,Free,,L,HA,"The binding of EB to HA could lead to a conformation change in HA, decreasing the affinity for sialic acids on the cell surface. ",2084.67,C98H178N28O21,CDEFGHIMNQSTWY,AL,12.02,4,0,4,0,14,110.0,752,1 hour,2 min,2 min,176.0,0,0.0,17005658,J Virol. 2006 Dec;80(24):11960-7.,"Jones JC, Turpin EA, Bultmann H, Brandt CR, Schultz-Cherry S.",Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells.,10.1128/JVI.01678-06,,Anti-Anti-Influenza A virus
DRAVPe01892,EF,2,EF,Synthetic construct,No entry found,,DENV,Flaviviridae,Foci-forming reduction assay,[Ref.24612829]dengue virus 2(DENV2):inhibition of viral entry in Vero cells(IC50=96.50 µM); inhibition of viral replication in Vero cells(83.47% inhibition at 200 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.24612829]No cytotoxicity against Vero cells up to 500 µM.,,,Linear,Free,Free,,L,E protein,No mechanism information found in the reference(s).,294.31,C14H18N2O5,ACDGHIKLMNPQRSTVWY,EF,4.0,0,1,-1,0,1,-35.0,-383,1 hour,30 min,>10 hour,0.0,0,0.0,24612829,Chem Biol Drug Des. 2014 Aug;84(2):148-57.,"Panya A, Bangphoomi K, Choowongkomon K, Yenchitsomanus PT. ",Peptide inhibitors against dengue virus infection.,10.1111/cbdd.12309,,Anti-DENV
DRAVPe01893,KEN,3,KEN,Synthetic construct,No entry found,,DENV,Flaviviridae,Foci-forming reduction assay,[Ref.24612829]dengue virus 2(DENV2):inhibition of viral entry in Vero cells(IC50=331.9 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.24612829]No cytotoxicity against Vero cells up to 500 µM.,,,Linear,Free,Free,,L,E protein,No mechanism information found in the reference(s).,389.41,C15H27N5O7,ACDFGHILMPQRSTVWY,EKN,6.0,1,1,0,1,0,-363.33,-1900,1.3 hour,3 min,2 min,0.0,0,0.0,24612829,Chem Biol Drug Des. 2014 Aug;84(2):148-57.,"Panya A, Bangphoomi K, Choowongkomon K, Yenchitsomanus PT. ",Peptide inhibitors against dengue virus infection.,10.1111/cbdd.12309,,Anti-DENV
DRAVPe01894,SVALVPHVGMGLETRTETWMSSEGAWKHVQRIETWILRHPG,41,MLH40,Synthetic construct,No entry found,,DENV,Flaviviridae,cell-based flavivirus immunodetection assay,[Ref.25891143]dengue virus 1(DENV1):inhibition of viral infection in Vero cells(IC50=30.35 ± 1.25 μM);##dengue virus 2(DENV2):inhibition of viral infection in Vero cells(IC50=31.41 ± 1.09 μM);##dengue virus 3(DENV3):inhibition of viral infection in Vero cells(IC50=27.95 ± 1.41 μM);##dengue virus 4(DENV4):inhibition of viral infection in Vero cells(IC50=24.45 ± 1.20 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,Not found,No mechanism information found in the reference(s).,4684.37,C209H325N61O58S2,CDFNY,EGTV,6.79,7,4,3,11,14,-30.73,-5772,1.9 hour,>20 hour,>10 hour,80.73,16500,412.5,25891143,Chem Biol Drug Des. 2015 Nov;86(5):1093-104.,"Panya A, Sawasdee N, Junking M, Srisawat C, Choowongkomon K, Yenchitsomanus PT. ",A peptide inhibitor derived from the conserved ectodomain region of DENV membrane (M) protein with activity against dengue virus infection. ,10.1111/cbdd.12576,,Anti-DENV
DRAVPe01895,GLLYFAIFFVAAWHIRGR,18,H2-2,Synthetic construct,No entry found,,HCV,Flaviviridae,,[Ref.26251517]Hepatitis C Virus(HCV):inhibition of viral infection in Huh7.5.1 cells(EC50=1.60 ± 0.11 μM); inhibition of post-infection in Huh7.5.1 cells(EC50=2.19 ± 0.16 μM).,[Ref.26251517]<10% hemolysis even at 400 μM against human erythrocytes.,[Ref.26251517]Huh7.5.1 cells: CC50=83.64 ± 6.95 μM;##Bel7402 cells:CC50~200 μM;##HeLa cells:CC50~200 μM.,,,Linear,Free,Amidation,,L,Not found,No mechanism information found in the reference(s).,2137.56,C107H153N27O20,CDEKMNPQST,AF,10.84,3,0,3,3,12,107.78,766,30 hour,>20 hour,>10 hour,119.44,6990,411.18,26251517,J Biol Chem. 2015 Sep 18;290(38):23254-63.,"Hong W, Lang Y, Li T, Zeng Z, Song Y, Wu Y, Li W, Cao Z. ",A p7 Ion Channel-derived Peptide Inhibits Hepatitis C Virus Infection in Vitro. ,10.1074/jbc.M115.662452,,Anti-HCV
DRAVPe01896,HGLLYFAIFFVAAWHIRGR,19,H2-3,Synthetic construct,No entry found,,HCV,Flaviviridae,,[Ref.26251517]Hepatitis C Virus(HCV):inhibition of viral infection in Huh7.5.1 cells(EC50=0.54 ± 0.08 μM); inhibition of post-infection in Huh7.5.1 cells(EC50=1.09 ± 0.11 μM);H2-3 peptide inactivated HCV(EC50=82.11 nM).,[Ref.26251517]<10% hemolysis even at 400 μM against human erythrocytes.,[Ref.26251517]Huh7.5.1 cells: CC50=115.99 ± 16.68 μM;##Bel7402 cells:CC50~200 μM;##HeLa cells:CC50~200 μM.,,,Linear,Free,Amidation,,L,Not found,No mechanism information found in the reference(s).,2274.7,C113H160N30O21,CDEKMNPQST,AF,10.84,4,0,4,3,12,85.26,300,3.5 hour,10 min,>10 hour,113.16,6990,388.33,26251517,J Biol Chem. 2015 Sep 18;290(38):23254-63.,"Hong W, Lang Y, Li T, Zeng Z, Song Y, Wu Y, Li W, Cao Z. ",A p7 Ion Channel-derived Peptide Inhibits Hepatitis C Virus Infection in Vitro. ,10.1074/jbc.M115.662452,,Anti-HCV
DRAVPe01897,WPFCLLLMAL,10,H3,Synthetic construct,No entry found,,HCV,Flaviviridae,,[Ref.26251517]Hepatitis C Virus(HCV):inhibition of viral infection in Huh7.5.1 cells(EC50=0.52 ± 0.07 μM); inhibition of post-infection in Huh7.5.1 cells(EC50=1.54 ± 0.73 μM).,[Ref.26251517]<10% hemolysis even at 400 μM against human erythrocytes.,[Ref.26251517]Huh7.5.1 cells: CC50=47.22 ± 5.29 μM;##Bel7402 cells:CC50~200 μM;##HeLa cells:CC50~200 μM.,,,Linear,Free,Amidation,,L,Not found,No mechanism information found in the reference(s).,1206.57,C60H91N11O11S2,DEGHIKNQRSTVY,L,5.52,0,0,0,1,7,217.0,3043,2.8 hour,3 min,2 min,166.0,5500,611.11,26251517,J Biol Chem. 2015 Sep 18;290(38):23254-63.,"Hong W, Lang Y, Li T, Zeng Z, Song Y, Wu Y, Li W, Cao Z. ",A p7 Ion Channel-derived Peptide Inhibits Hepatitis C Virus Infection in Vitro. ,10.1074/jbc.M115.662452,,Anti-HCV
DRAVPe01898,LYGNEGCGWAGWLLSPRG,18,SL173,Synthetic construct,No entry found,,HCV,Flaviviridae,ELISA,[Ref.19264632]hepatitis C virus(J6/JFH1):inhibition of viral infection in Huh-7.5 cells(80% inhibition at 20 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,Not found,No mechanism information found in the reference(s).,1936.17,C88H126N24O24S,DFHIKMQTV,G,5.99,1,1,0,9,6,-18.33,-470,5.5 hour,3 min,2 min,70.56,12490,734.71,19264632,J Gen Virol. 2009 Jun;90(Pt 6):1319-1328.,"Kota S, Coito C, Mousseau G, Lavergne JP, Strosberg AD. ",Peptide inhibitors of hepatitis C virus core oligomerization and virus production.,10.1099/vir.0.008565-0,,Anti-HCV
DRAVPe01899,GWAGWLLSPRGSRPSWGP,18,SL174,Synthetic construct,No entry found,,HCV,Flaviviridae,ELISA,[Ref.19264632]hepatitis C virus(J6/JFH1):inhibition of viral infection in Huh-7.5 cells(15% inhibition at 20 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,Not found,No mechanism information found in the reference(s).,1967.22,C92H131N27O22,CDEFHIKMNQTVY,G,12.0,2,0,2,7,6,-61.67,-1764,30 hour,>20 hour,>10 hour,48.89,16500,970.59,19264632,J Gen Virol. 2009 Jun;90(Pt 6):1319-1328.,"Kota S, Coito C, Mousseau G, Lavergne JP, Strosberg AD. ",Peptide inhibitors of hepatitis C virus core oligomerization and virus production.,10.1099/vir.0.008565-0,,Anti-HCV
DRAVPe01900,GWAGWLLSPRGSRPS,15,SL175,Synthetic construct,No entry found,,HCV,Flaviviridae,ELISA,[Ref.19264632]hepatitis C virus(J6/JFH1):inhibition of viral infection in Huh-7.5 cells(50% inhibition at 20 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,Not found,No mechanism information found in the reference(s).,1626.84,C74H111N23O19,CDEFHIKMNQTVY,GS,12.0,2,0,2,6,5,-54.67,-2091,30 hour,>20 hour,>10 hour,58.67,11000,785.71,19264632,J Gen Virol. 2009 Jun;90(Pt 6):1319-1328.,"Kota S, Coito C, Mousseau G, Lavergne JP, Strosberg AD. ",Peptide inhibitors of hepatitis C virus core oligomerization and virus production.,10.1099/vir.0.008565-0,,Anti-HCV
DRAVPe01901,MDVNP,5,PB1 (1–5),Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=185 ± 2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",574.65,C23H38N6O9S,ACEFGHIKLQRSTWY,DMNPV,3.8,0,1,-1,1,1,-50.0,-897,30 hour,>20 hour,>10 hour,58.0,0,0.0,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments. ,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01902,MDVNPTLLFL KVPAQNAIST TFPYT,27,PB1 (1–25),Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=122 ± 3 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",2782.25,C129H197N29O35S,CEGHRW,T,5.59,1,1,0,8,10,28.89,-722,30 hour,>20 hour,>10 hour,86.67,1490,57.31,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments. ,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01903,TLLFLKVPAQ NAISTTFPYT,21,PB1 (6–25),Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=129 ± 2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",2225.61,C106H163N23O28,CDEGHMRW,T,8.26,1,0,1,7,9,49.05,175,7.2 hour,>20 hour,>10 hour,97.62,1490,74.5,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01904,AQNAISTTFPYT,12,PB1 (14–25),Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=380 ± 2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",1313.43,C59H88N14O20,CDEGHKLMRVW,T,5.57,0,0,0,6,4,-15.83,-1191,4.4 hour,>20 hour,>10 hour,49.17,1490,135.45,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01905,Anti-MeVVQQTRMD KLTQGRQTYD,21,PB1 (111–130),Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=58 ± 2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",2427.73,C100H165N31O34S2,ACFHINPSW,Q,5.88,3,3,0,5,3,-120.0,-7101,30 hour,>20 hour,>10 hour,46.19,1490,74.5,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01906,LPVGGNEKKA KLANVVRKMM,21,PB1 (271–290),Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=33 ± 1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",2183.7,C95H169N29O24S2,CDFHIQSTWY,K,10.46,5,1,4,4,7,-25.71,-2505,5.5 hour,3 min,2 min,88.1,0,0.0,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01907,FNESTR,6,PB1 (381–386),Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=664 ± 3 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",752.78,C31H48N10O12,ACDGHIKLMPQVWY,EFNRST,6.0,1,1,0,3,1,-170.0,-3136,1.1 hour,3 min,2 min,0.0,0,0.0,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01908,FNESTRKKIE,10,PB1 (381–390),Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=400 ± 8 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",1251.41,C54H90N16O18,ACDGHLMPQVWY,EK,8.59,3,2,1,3,2,-170.0,-4435,1.1 hour,3 min,2 min,39.0,0,0.0,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01909,FNESTRKKIE KIRPLLVEGT,21,PB1 (381–400),Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=23 ± 1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",2358.77,C105H178N30O30,ACDHMQWY,EK,9.7,5,3,2,5,6,-72.86,-5446,1.1 hour,3 min,2 min,88.1,0,0.0,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01910,KIRPLLVEGT,10,PB1 (391–400),Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=71 ± 3μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",1125.38,C51H92N14O14,ACDFHMNQSWY,L,8.75,2,1,1,2,4,17.0,-1011,1.3 hour,3 min,2 min,146.0,0,0.0,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01911,MFNMLSTVLG,10,PB1 (411–420),Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=369 ± 3 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",1112.37,C49H81N11O14S2,ACDEHIKPQRWY,LM,5.28,0,0,0,4,4,130.0,989,30 hour,>20 hour,>10 hour,107.0,0,0.0,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01912,IGVTVI,6,PB1 (525–530),Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=833 ± 6 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",600.76,C28H52N6O8,ACDEFHKLMNPQRSWY,IV,5.52,0,0,0,2,4,271.67,1629,20 hour,30 min,>10 hour,226.67,0,0.0,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01913,IGVTVIKNNMI,11,PB1 (525–535),Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=416 ± 3μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",1201.49,C53H96N14O15S,ACDEFHLPQRSWY,I,8.75,1,0,1,4,5,107.27,473,20 hour,30 min,>10 hour,159.09,0,0.0,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01914,TLLFLKVP,8,PB1 (6–13),Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=102 ± 3 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",930.2,C47H79N9O10,ACDEGHIMNQRSWY,L,8.41,1,0,1,1,5,152.5,1366,7.2 hour,>20 hour,>10 hour,182.5,0,0.0,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01915,TLLFLKVP,8,PB1 (6–13)-NH2,Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=35 ± 3 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Amidation,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",930.2,C47H79N9O10,ACDEGHIMNQRSWY,L,8.41,1,0,1,1,5,152.5,1366,7.2 hour,>20 hour,>10 hour,182.5,0,0.0,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01916,TLLFLKVP,8,Ac-PB1 (6–13),Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=33 ± 2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Acetylation,Free,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",930.2,C47H79N9O10,ACDEGHIMNQRSWY,L,8.41,1,0,1,1,5,152.5,1366,7.2 hour,>20 hour,>10 hour,182.5,0,0.0,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01917,TLLFLKVP,8,Ac-PB1 (6–13)-NH2,Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=12 ± 2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Acetylation,Amidation,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",930.2,C47H79N9O10,ACDEGHIMNQRSWY,L,8.41,1,0,1,1,5,152.5,1366,7.2 hour,>20 hour,>10 hour,182.5,0,0.0,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01918,TLLFLKVPA,9,PB1 (6–14),Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=34 ± 2 μM);##Influenza A virus(A/Puerto Rico/8/34 (H1N1)):antiviral activity of the peptide in MDCK cells(ED50=8.9 ± 1.0 μM);##Influenza A virus(A/Aichi/2/68 (H3N2)):antiviral activity of the peptide in MDCK cells(ED50=10.7 ± 0.9 μM);##Influenza A virus(A/Mallard/Pennsylvania/10218/84 (H5N2)):antiviral activity of the peptide in MDCK cells(ED50=8.5 ± 1.1 μM);##Influenza A virus(A/Vladivostok/02/09 of H1N1):antiviral activity of the peptide in MDCK cells(ED50=1.7 ± 0.8 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",1001.28,C50H84N10O11,CDEGHIMNQRSWY,L,8.41,1,0,1,1,6,155.56,1547,7.2 hour,>20 hour,>10 hour,173.33,0,0.0,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01919,TLLFLKVPA,9,PB1 (6–14)-NH2,Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=6 ± 1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Amidation,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",1001.28,C50H84N10O11,CDEGHIMNQRSWY,L,8.41,1,0,1,1,6,155.56,1547,7.2 hour,>20 hour,>10 hour,173.33,0,0.0,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01920,TLLFLKVPA,9,Ac-PB1 (6–14),Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=82 ± 3 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Acetylation,Free,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",1001.28,C50H84N10O11,CDEGHIMNQRSWY,L,8.41,1,0,1,1,6,155.56,1547,7.2 hour,>20 hour,>10 hour,173.33,0,0.0,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01921,TLLFLKVPA,9,Ac-PB1 (6–14)-NH2,Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=4 ± 1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Acetylation,Amidation,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",1001.28,C50H84N10O11,CDEGHIMNQRSWY,L,8.41,1,0,1,1,6,155.56,1547,7.2 hour,>20 hour,>10 hour,173.33,0,0.0,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01922,GDPPY,5,PB1 (26–30),Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=115 ± 3 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",547.57,C25H33N5O9,ACEFHIKLMNQRSTVW,P,3.8,0,1,-1,2,0,-168.0,-792,30 hour,>20 hour,>10 hour,0.0,1490,372.5,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01923,GDPPY,5,PB1 (26–30)-NH2,Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=100 ± 5 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Amidation,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",547.57,C25H33N5O9,ACEFHIKLMNQRSTVW,P,3.8,0,1,-1,2,0,-168.0,-792,30 hour,>20 hour,>10 hour,0.0,1490,372.5,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01924,GDPPY,5,Ac-PB1 (26–30),Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=95 ± 3 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Acetylation,Free,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",547.57,C25H33N5O9,ACEFHIKLMNQRSTVW,P,3.8,0,1,-1,2,0,-168.0,-792,30 hour,>20 hour,>10 hour,0.0,1490,372.5,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01925,GDPPY,5,Ac-PB1 (26–30)-NH2,Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=254 ± 3 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Acetylation,Amidation,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",547.57,C25H33N5O9,ACEFHIKLMNQRSTVW,P,3.8,0,1,-1,2,0,-168.0,-792,30 hour,>20 hour,>10 hour,0.0,1490,372.5,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01926,LLVEGT,6,PB1 (395–400),Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=91 ± 2 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",630.74,C28H50N6O10,ACDFHIKMNPQRSWY,L,4.0,0,1,-1,2,3,120.0,544,5.5 hour,3 min,2 min,178.33,0,0.0,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01927,LLVEGT,6,PB1 (395–400)-NH2,Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=794 ± 4 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Amidation,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",630.74,C28H50N6O10,ACDFHIKMNPQRSWY,L,4.0,0,1,-1,2,3,120.0,544,5.5 hour,3 min,2 min,178.33,0,0.0,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01928,LLVEGT,6,Ac-PB1 (395–400),Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=297 ± 3 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Acetylation,Free,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",630.74,C28H50N6O10,ACDFHIKMNPQRSWY,L,4.0,0,1,-1,2,3,120.0,544,5.5 hour,3 min,2 min,178.33,0,0.0,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01929,LLVEGT,6,Ac-PB1 (395–400)-NH2,Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=744 ± 4 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Acetylation,Amidation,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",630.74,C28H50N6O10,ACDFHIKMNPQRSWY,L,4.0,0,1,-1,2,3,120.0,544,5.5 hour,3 min,2 min,178.33,0,0.0,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01930,KNNMINNDLG,10,PB1 (531–540),Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=51 ± 3 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",1132.26,C45H77N15O17S,ACEFHPQRSTVWY,N,5.84,1,1,0,5,2,-116.0,-2770,1.3 hour,3 min,2 min,78.0,0,0.0,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01931,KNNMINNDLG,10,PB1 (531–540)-NH2,Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=44 ± 1 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Amidation,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",1132.26,C45H77N15O17S,ACEFHPQRSTVWY,N,5.84,1,1,0,5,2,-116.0,-2770,1.3 hour,3 min,2 min,78.0,0,0.0,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01932,KNNMINNDLG,10,Ac-PB1 (531–540),Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=71 ± 3 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Acetylation,Free,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",1132.26,C45H77N15O17S,ACEFHPQRSTVWY,N,5.84,1,1,0,5,2,-116.0,-2770,1.3 hour,3 min,2 min,78.0,0,0.0,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01933,KNNMINNDLG,10,Ac-PB1 (531–540)-NH2,Synthetic construct,No entry found,,Influenza A virus,Orthomyxoviridae,Hemagglutination assay,[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=109 ± 4 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Acetylation,Amidation,,L,Not found,"The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide  could interfere with these processes thus inhibiting virus replication.",1132.26,C45H77N15O17S,ACEFHPQRSTVWY,N,5.84,1,1,0,5,2,-116.0,-2770,1.3 hour,3 min,2 min,78.0,0,0.0,25446335,Antiviral Res. 2015 Jan;113:4-10.,"Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI.",Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.,10.1016/j.antiviral.2014.10.015,,Anti-Anti-Influenza A virus
DRAVPe01934,LNLFKKTINGLISDSLVIR,19,AVP-p,Synthetic construct,No entry found,,PICV,Arenaviridae,Plaque reduction assay,[Ref.24850726]Pichinde virus (PICV):inhibition of viral infection in Vero cells(IC50=7.05 ± 2.19 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.24850726]No significant loss of viability was observed in Vero cells or human foreskin fibroblasts (HFF) up to 100 μM.,,,Linear,Free,Free,Noen,L,Not found,that untimely deployment of fusion machinery by the peptide could render virions less able to engage in on-pathway receptor binding or endosomal fusion. ,2144.59,C98H170N26O27,ACEHMPQWY,L,9.99,3,1,2,6,9,53.68,-1499,5.5 hour,3 min,2 min,158.95,0,0.0,24850726,J Virol. 2014 Aug;88(15):8556-64.,"Spence JS, Melnik LI, Badani H, Wimley WC, Garry RF. ",Inhibition of arenavirus infection by a glycoprotein-derived peptide with a novel mechanism. ,10.1128/JVI.01133-14,,Anti-PICV
DRAVPe01935,GRKKRRQRRRC,11,TAT-Cd0,Synthetic construct,No entry found,,HSV-1,Herpesviridae,Antiviral assay,[Ref.21029018]Herpes simplex virus type 1(HSV-1):inhibition of viral infection in human corneal epithelial (HCE) cells(EC50=0.20 μM); exert antiviral activity by entry block(EC50=0.1 μM);exert antiviral activity by postentry(EC50~30.0 μM);exert antiviral activity by cell protection(EC50=0.4 μM);exert antiviral activity by virus inactivation(EC50=9.5 μM);exert antiviral activity by inhibitng attachment(EC50=3.0 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.21029018]human corneal epithelial (HCE) cells:CC50~100 μM.,,,Linear,Free,Amidation,,L,Not found,No mechanism information found in the reference(s).,1499.81,C58H114N32O13S,ADEFHILMNPSTVWY,R,12.3,8,0,8,2,0,-329.09,-10394,30 hour,>20 hour,>10 hour,0.0,0,0.0,21029018,J Ocul Pharmacol Ther. 2010 Dec;26(6):541-7. ,"Larsen IV, Brandt CR.",A cationic TAT peptide inhibits Herpes simplex virus type 1 infection of human corneal epithelial cells.,10.1089/jop.2010.0076,DRAVPa1018,Anti-HSV-1
DRAVPe01936,GREERRQRRRC,11,"E50,51TAT-Cd0",Synthetic construct,No entry found,,HSV-1,Herpesviridae,Antiviral assay,[Ref.21029018]Herpes simplex virus type 1(HSV-1):inhibition of viral infection in human corneal epithelial (HCE) cells(EC50~30.0 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Amidation,,L,Not found,No mechanism information found in the reference(s).,1501.69,C56H104N30O17S,ADFHIKLMNPSTVWY,R,11.7,6,2,4,2,0,-321.82,-10646,30 hour,>20 hour,>10 hour,0.0,0,0.0,21029018,J Ocul Pharmacol Ther. 2010 Dec;26(6):541-7. ,"Larsen IV, Brandt CR.",A cationic TAT peptide inhibits Herpes simplex virus type 1 infection of human corneal epithelial cells.,10.1089/jop.2010.0076,,Anti-HSV-1
DRAVPe01937,NDSRGIDAEEELETKAELVITKLKTPLMRGKVVVGAAGA,39,MDVgHH2L,Synthetic construct,No entry found,,"NDV,MDV","Paramyxoviridae, Herpesviridae",Plaque formation assay,[Ref.24412629]Newcastle disease virus(NDV):inhibition of viral infection in chicken embryo fibroblasts(IC50=43.4 ± 2.0 μmol/L);##Marek's disease virus(MDV):inhibition of viral infection in chicken embryo fibroblasts(IC50=34.0 ± 2.00 μmol/L).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,membrane,"peptides from the hydrophobic fusogenic domains of gB and gH can block virus entry, disrupt cellular membranes by interacting with the cellular factors, or play a role in the glycoprotein conformational changes ",4110.74,C177H306N50O59S,CFHQWY,AE,5.15,6,7,-1,9,15,-17.44,-6044,1.4 hour,3 min,>10 hour,102.56,0,0.0,24412629,J Virol Methods. 2014 Apr;199:11-6.,"Chi XJ, Wang XJ, Wang CY, Cui XJ, Wang XJ.",In vitro and in vivo broad antiviral activity of peptides homologous to fusion glycoproteins of Newcastle disease virus and Marek's disease virus. ,10.1016/j.jviromet.2013.12.022,,"Anti-NDV,Anti-MDV"
DRAVPe01938,NADIIKSLIRKTIINASKNTASLSILQHLYVLRS,34,MDVgBH3,Synthetic construct,No entry found,,"NDV,MDV","Paramyxoviridae, Herpesviridae",Plaque formation assay,[Ref.24412629]Newcastle disease virus(NDV):inhibition of viral infection in chicken embryo fibroblasts(IC50=52.9 ± 0.9 μmol/L);##Marek's disease virus(MDV):inhibition of viral infection in chicken embryo fibroblasts(IC50=37.5 ± 1.2 μmol/L).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,membrane,"peptides from the hydrophobic fusogenic domains of gB and gH can block virus entry, disrupt cellular membranes by interacting with the cellular factors, or play a role in the glycoprotein conformational changes ",3795.48,C169H293N49O49,CEFGMPW,I,10.45,6,1,5,11,15,22.06,-4402,1.4 hour,3 min,>10 hour,143.53,1490,45.15,24412629,J Virol Methods. 2014 Apr;199:11-6.,"Chi XJ, Wang XJ, Wang CY, Cui XJ, Wang XJ.",In vitro and in vivo broad antiviral activity of peptides homologous to fusion glycoproteins of Newcastle disease virus and Marek's disease virus. ,10.1016/j.jviromet.2013.12.022,,"Anti-NDV,Anti-MDV"
DRAVPe01939,LGNVNNSISNALDKLEESNSKLDKVNVKLTGTSAL,35,NDVHR2,Synthetic construct,No entry found,,"NDV,MDV","Paramyxoviridae, Herpesviridae",Plaque formation assay,[Ref.24412629]Newcastle disease virus(NDV):inhibition of viral infection in chicken embryo fibroblasts(IC50=18.9 ± 2.8 μmol/L);##Marek's disease virus(MDV):inhibition of viral infection in chicken embryo fibroblasts(IC50=65.3 ±0.9 μmol/L).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,membrane,"peptides from the hydrophobic fusogenic domains of gB and gH can block virus entry, disrupt cellular membranes by interacting with the cellular factors, or play a role in the glycoprotein conformational changes ",3687.12,C156H269N45O57,CFHMPQRWY,LN,6.21,4,4,0,15,12,-38.0,-6318,5.5 hour,3 min,2 min,108.57,0,0.0,24412629,J Virol Methods. 2014 Apr;199:11-6.,"Chi XJ, Wang XJ, Wang CY, Cui XJ, Wang XJ.",In vitro and in vivo broad antiviral activity of peptides homologous to fusion glycoproteins of Newcastle disease virus and Marek's disease virus. ,10.1016/j.jviromet.2013.12.022,,"Anti-NDV,Anti-MDV"
DRAVPe01940,TIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVRELKDFV,43,HRA1,Synthetic construct,No entry found,,MPV,Paramyxoviridae,RT-PCR assay ,[Ref.17967906]Human Metapneumovirus(hMPV):inhibition of viral infection in LLC-MK2 cells(IC50=177 nM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.17967906]No cytotoxicity against LLC-MK2 cells at the highest concentrations tested (9 μM).,,,Linear,Free,Free,,L,F protein,"In hMPV, the F proteins assemble as trimers inside which three HRA (as well as three HRB) are creating a coiled coil. Then, the two pairs of coiled-coils (HRA and HRB) interact, creating a six-helix bundle structure that brings the viral and the cellular membranes close together, causing membrane merge and fusion pore dilatation. Peptide designed based in the HRA and HRB domains of the F protein can inhibit the  process.",4656.4,C204H353N59O64,CHMPQWY,V,9.52,7,5,2,12,19,4.65,-6990,7.2 hour,>20 hour,>10 hour,115.58,0,0.0,17967906,Antimicrob Agents Chemother. 2008 Jan;52(1):279-87. ,"Deffrasnes C, Hamelin ME, Prince GA, Boivin G.",Identification and evaluation of a highly effective fusion inhibitor for human metapneumovirus.,10.1128/AAC.00793-07,,Anti-MPV
DRAVPe01941,AKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVRELKDFVSKN,48,HRA2,Synthetic construct,No entry found,,MPV,Paramyxoviridae,RT-PCR assay ,[Ref.17967906]Human Metapneumovirus(hMPV):inhibition of viral infection in LLC-MK2 cells(IC50=2.1 nM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.17967906]No cytotoxicity against LLC-MK2 cells at the highest concentrations tested (9 μM).,,,Linear,Free,Free,,L,F protein,"In hMPV, the F proteins assemble as trimers inside which three HRA (as well as three HRB) are creating a coiled coil. Then, the two pairs of coiled-coils (HRA and HRB) interact, creating a six-helix bundle structure that brings the viral and the cellular membranes close together, causing membrane merge and fusion pore dilatation. Peptide designed based in the HRA and HRB domains of the F protein can inhibit the  process.",5185.01,C226H393N67O71,CHMPQWY,AKV,9.99,9,5,4,14,20,-17.29,-8923,4.4 hour,>20 hour,>10 hour,105.63,0,0.0,17967906,Antimicrob Agents Chemother. 2008 Jan;52(1):279-87. ,"Deffrasnes C, Hamelin ME, Prince GA, Boivin G.",Identification and evaluation of a highly effective fusion inhibitor for human metapneumovirus.,10.1128/AAC.00793-07,,Anti-MPV
DRAVPe01942,LESEVTAIKNALKKTNEAVSTLGNGVRVLATAVRE,35,HRA3,Synthetic construct,No entry found,,MPV,Paramyxoviridae,RT-PCR assay ,[Ref.17967906]Human Metapneumovirus(hMPV):inhibition of viral infection in LLC-MK2 cells(IC50=3240 nM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.17967906]No cytotoxicity against LLC-MK2 cells at the highest concentrations tested (9 μM).,,,Linear,Free,Free,,L,F protein,"In hMPV, the F proteins assemble as trimers inside which three HRA (as well as three HRB) are creating a coiled coil. Then, the two pairs of coiled-coils (HRA and HRB) interact, creating a six-helix bundle structure that brings the viral and the cellular membranes close together, causing membrane merge and fusion pore dilatation. Peptide designed based in the HRA and HRB domains of the F protein can inhibit the  process.",3683.22,C158H277N47O53,CDFHMPQWY,AV,8.5,5,4,1,11,15,-2.0,-5500,5.5 hour,3 min,2 min,111.43,0,0.0,17967906,Antimicrob Agents Chemother. 2008 Jan;52(1):279-87. ,"Deffrasnes C, Hamelin ME, Prince GA, Boivin G.",Identification and evaluation of a highly effective fusion inhibitor for human metapneumovirus.,10.1128/AAC.00793-07,,Anti-MPV
DRAVPe01943,FNVALDQVFESIENSQALVDQSNRILSSAEKGNTG,35,HRB5,Synthetic construct,No entry found,,MPV,Paramyxoviridae,RT-PCR assay ,[Ref.17967906]Human Metapneumovirus(hMPV):inhibition of viral infection in LLC-MK2 cells(IC50=1520 nM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.17967906]No cytotoxicity against LLC-MK2 cells at the highest concentrations tested (9 μM).,,,Linear,Free,Free,,L,F protein,"In hMPV, the F proteins assemble as trimers inside which three HRA (as well as three HRB) are creating a coiled coil. Then, the two pairs of coiled-coils (HRA and HRB) interact, creating a six-helix bundle structure that brings the viral and the cellular membranes close together, causing membrane merge and fusion pore dilatation. Peptide designed based in the HRA and HRB domains of the F protein can inhibit the  process.",3782.09,C161H258N46O59,CHMPWY,S,4.18,2,5,-3,12,13,-34.0,-7110,1.1 hour,3 min,2 min,89.14,0,0.0,17967906,Antimicrob Agents Chemother. 2008 Jan;52(1):279-87. ,"Deffrasnes C, Hamelin ME, Prince GA, Boivin G.",Identification and evaluation of a highly effective fusion inhibitor for human metapneumovirus.,10.1128/AAC.00793-07,,Anti-MPV
DRAVPe01944,PEDQFNVALDQVFESIENSQALVDQSNRILSSAEKGNTG,39,HRB6,Synthetic construct,No entry found,,MPV,Paramyxoviridae,RT-PCR assay ,[Ref.17967906]Human Metapneumovirus(hMPV):inhibition of viral infection in LLC-MK2 cells(IC50=3310 nM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.17967906]No cytotoxicity against LLC-MK2 cells at the highest concentrations tested (9 μM).,,,Linear,Free,Free,,L,F protein,"In hMPV, the F proteins assemble as trimers inside which three HRA (as well as three HRB) are creating a coiled coil. Then, the two pairs of coiled-coils (HRA and HRB) interact, creating a six-helix bundle structure that brings the viral and the cellular membranes close together, causing membrane merge and fusion pore dilatation. Peptide designed based in the HRA and HRB domains of the F protein can inhibit the  process.",4251.54,C180H285N51O68,CHMWY,S,3.95,2,7,-5,12,13,-61.54,-9217,>20 hour,>20 hour,?,80.0,0,0.0,17967906,Antimicrob Agents Chemother. 2008 Jan;52(1):279-87. ,"Deffrasnes C, Hamelin ME, Prince GA, Boivin G.",Identification and evaluation of a highly effective fusion inhibitor for human metapneumovirus.,10.1128/AAC.00793-07,,Anti-MPV
DRAVPe01945,SWLVNRDWFHDLNLPWTGSSAGTWQ,25,TP1,Synthetic construct,No entry found,,TMUV,Flaviviridae,"Plaque assay, Western blotting",[Ref.32456819]Tembusu virus (TMUV):inhibition of viral infection in BHK-21 cells(IC50=14.19 mg/L).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.32456819]No cytotoxicity against BHK-21 cells up to 150mg / L.,,,Linear,Free,Free,,L,Not found,TP1 functions through a mechanism that involves release of the viral genome and interference with cellular TMUV binding,2974.24,C138H189N37O38,CEIKMY,W,5.19,2,2,0,9,10,-59.2,-3639,1.9 hour,>20 hour,>10 hour,62.4,22000,916.67,32456819,Vet Microbiol. 2020 Jun;245:108708.,"Zhao D, Zhang L, Han K, Liu Q, Yang J, Huang X, Liu Y, Li Y, Zhao P. ",Peptide inhibitors of tembusu virus infection derived from the envelope protein. ,10.1016/j.vetmic.2020.108708,,Anti-TMUV
DRAVPe01946,MVALGDTAWDFGSVGGVLTSIGKGIHQVFGSAFKSL,36,TP2,Synthetic construct,No entry found,,TMUV,Flaviviridae,"Plaque assay, Western blotting",[Ref.32456819]Tembusu virus (TMUV):inhibition of viral infection in BHK-21 cells(IC50=7.64 mg/L).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.32456819]No cytotoxicity against BHK-21 cells up to 150mg / L.,,,Linear,Free,Free,,L,Not found,TP2 might be an interference factor between TMUV and the cell. ,3654.2,C167H258N42O48S,CENPRY,G,6.5,3,2,1,13,16,64.17,891,30 hour,>20 hour,>10 hour,94.72,5500,157.14,32456819,Vet Microbiol. 2020 Jun;245:108708.,"Zhao D, Zhang L, Han K, Liu Q, Yang J, Huang X, Liu Y, Li Y, Zhao P. ",Peptide inhibitors of tembusu virus infection derived from the envelope protein. ,10.1016/j.vetmic.2020.108708,,Anti-TMUV
DRAVPe01947,RRRQRRKKRGYGFVNLLFLVVE,22,TAT-Kα2,Synthetic construct,No entry found,,"VSV,NDV,RSV,Influenza virus, HSV","Herpesviridae,Paramyxoviridae,Orthomyxoviridae",Plaque assay,[Ref.28687749]Vesicular stomatitis virus(VSV):inhibition of viral infection in 293T cells(IC50=2.9 μM);##Respiratory Syncytial Virus(RSV):inhibition of viral infection in Hep2 cells(IC50=3.4 μM);##Newcastle disease virus(NDV):inhibition of viral infection(IC50=0.8 μM);##Parainfluenza virus:inhibition of viral infection(IC50=2.4 μM);##Influenza virus (H1N1) A/Puerto Rico/8/34:inhibition of viral infection(IC50=0.5 μM);##Influenza virus (H5N2) A/bird/Korea/W81/2005:inhibition of viral infection(IC50=0.8 μM);##Influenza virus (H7N3) A/Aquatic bird/Korea/W44/2005:inhibition of viral infection(IC50=1.2 μM);##Influenza virus (H9N2) A/Chicken/Korea/116/2004:inhibition of viral infection(IC50=0.7 μM);##Porcine epidemic diarrhea virus:inhibition of viral infection(IC50=3.5 μM);##Herpes simplex virus:inhibition of viral infection(IC50=5.7 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.28687749]No cytotoxicity against MDCK cells up to 100 μM.,,,Linear,Free,Free,,L,Envolope,display virucidal activity by disrupting viral envelopes.,2791.35,C126H212N44O28,ACDHIMPSTW,R,12.01,8,1,7,4,8,-80.91,-8503,1 hour,2 min,2 min,92.73,1490,70.95,28687749,Sci Rep. 2017 Jul 7;7(1):4875.,"Moon HJ, Nikapitiya C, Lee HC, Park ME, Kim JH, Kim TH, Yoon JE, Cho WK, Ma JY, Kim CJ, Jung JU, Lee JS.",Inhibition of highly pathogenic avian influenza (HPAI) virus by a peptide derived from vFLIP through its direct destabilization of viruses,10.1038/s41598-017-04777-4,,"Anti-VSV,NDV,Anti-RSV,Anti-Influenza virus, Anti-HSV"
DRAVPe01948,MGRFKRFRKKFKKLFKKLS,19,Bomidin,Synthetic construct,P54228,,"DENV, HSV,SARS-CoV-2","Flaviviridae,Herpesviridae,Coronaviridae","Plaque-formation assay,fluorescent focus assay, ELISA",[Ref.35663971]Dengue virus 2(DENV2):inhibition of viral infection in Huh7 cells(50% inhibition at 10 μM);##HSV:inhibition of viral infection in Huh7 cells(50% inhibition at 10 μM);##SARS-CoV-2:inhibition of viral infection in Huh7 cells(80% inhibition at 10 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.35663971]Vero E6 cells:CC50=169.6 ± 1.1 µM.,,,Linear,Free,Free,,L,membrane,bomidin readily disrupted viral membranes (with components similar to those in the endoplasmic reticulum) and bacterial membranes but did not alter the overall structures of the cell membranes,2474.14,C118H197N35O21S,ACDEHINPQTVWY,K,12.32,10,0,10,2,6,-112.11,-6196,30 hour,>20 hour,>10 hour,41.05,0,0.0,35663971,Front Immunol. 2022 May 19;13:851642.,"Liu R, Liu Z, Peng H, Lv Y, Feng Y, Kang J, Lu N, Ma R, Hou S, Sun W, Ying Q, Wang F, Gao Q, Zhao P, Zhu C, Wang Y, Wu X. ",Bomidin: An Optimized Antimicrobial Peptide With Broad Antiviral Activity Against Enveloped Viruses.,10.3389/fimmu.2022.851642,,"Anti-DENV, Anti-HSV,Anti-SARS-CoV-2"
DRAVPe01949,DHVTPDIAYNPRTYM,15,Pep-RTYM,Acacia catechu,No entry found,,DENV,Flaviviridae,Focus-Forming Unit (FFU) Assay,[Ref.33172110]Dengue virus 2(DENV2):inhibition of viral infection in Vero cells(IC50=7.9 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.33172110]No cytotoxicity against Vero cells up to 1000 μM.,,,Linear,Free,Free,,L,Not found,the biding of peptide to virus particles might disrupt the ability of the virus to bind to the host cell receptor or possibly block the internalization of the virus into the host cells.,1792.98,C79H117N21O25S,CEFGKLQSW,DPTY,5.21,2,2,0,5,3,-86.67,-3596,1.1 hour,3 min,>10 hour,52.0,2980,212.86,33172110,Viruses. 2020 Nov 6;12(11):1267.,"Panya A, Sawasdee N, Songprakhon P, Tragoolpua Y, Rotarayanont S, Choowongkomon K, Yenchitsomanus PT. ",Synthetic Bioactive Peptide Derived from the Asian Medicinal Plant Acacia catechu Binds to Dengue Virus and Inhibits Cell Entry.,10.3390/v12111267,,Anti-DENV
DRAVPe01950,DHVTPDIAYNPWAYF,15,Pep-WAYF,Acacia catechu,No entry found,,DENV,Flaviviridae,Focus-Forming Unit (FFU) Assay,[Ref.33172110]Dengue virus 2(DENV2):inhibition of viral infection in Vero cells(IC50=15.67 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.33172110]No cytotoxicity against Vero cells up to 1000 μM.,,,Linear,Free,Free,,L,Not found,the biding of peptide to virus particles might disrupt the ability of the virus to bind to the host cell receptor or possibly block the internalization of the virus into the host cells.,1808.97,C87H113N19O24,CEGKLMQRS,ADPY,4.2,1,2,-1,4,6,-40.0,-1370,1.1 hour,3 min,>10 hour,58.67,8480,605.71,33172110,Viruses. 2020 Nov 6;12(11):1267.,"Panya A, Sawasdee N, Songprakhon P, Tragoolpua Y, Rotarayanont S, Choowongkomon K, Yenchitsomanus PT. ",Synthetic Bioactive Peptide Derived from the Asian Medicinal Plant Acacia catechu Binds to Dengue Virus and Inhibits Cell Entry.,10.3390/v12111267,,Anti-DENV
DRAVPe01951,DHVTPDIAYNP,11,Pep-CORE,Acacia catechu,No entry found,,DENV,Flaviviridae,Focus-Forming Unit (FFU) Assay,[Ref.33172110]Dengue virus 2(DENV2):inhibition of viral infection in Vero cells(IC50=20.89 μM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.33172110]No cytotoxicity against Vero cells up to 1000 μM.,,,Linear,Free,Free,,L,Not found,the biding of peptide to virus particles might disrupt the ability of the virus to bind to the host cell receptor or possibly block the internalization of the virus into the host cells.,1241.32,C55H80N14O19,CEFGKLMQRSW,DP,4.2,1,2,-1,3,3,-76.36,-2068,1.1 hour,3 min,>10 hour,70.91,1490,149.0,33172110,Viruses. 2020 Nov 6;12(11):1267.,"Panya A, Sawasdee N, Songprakhon P, Tragoolpua Y, Rotarayanont S, Choowongkomon K, Yenchitsomanus PT. ",Synthetic Bioactive Peptide Derived from the Asian Medicinal Plant Acacia catechu Binds to Dengue Virus and Inhibits Cell Entry.,10.3390/v12111267,,Anti-DENV
DRAVPe01952,KKR,3,Cmpd 2,Synthetic construct,No entry found,,ZIKV,Flaviviridae,Protease assay,[Ref.35123179]Zika virus(ZIKV):inhibition the activity of Zika virus NS2B-NS3 protease(IC50=41.0 ± 3.9 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Phenylacetyl,Free,,L,NS2B-NS3 viral serine protease,The peptide inhibits the NS2B-NS3 protease and thus inhibits virus replication.,430.55,C18H38N8O4,ACDEFGHILMNPQSTVWY,K,11.17,3,0,3,0,0,-410.0,-2602,1.3 hour,3 min,2 min,0.0,0,0.0,35123179,Bioorg Med Chem. 2022 Mar 1;57:116631.,"Colarusso S, Ferrigno F, Ponzi S, Pavone F, Conte I, Abate L, Beghetto E, Missineo A, Amaudrut J, Bresciani A, Paonessa G, Tomei L, Montalbetti C, Bianchi E, Toniatti C, Ontoria JM. ",SAR evolution towards potent C-terminal carboxamide peptide inhibitors of Zika virus NS2B-NS3 protease. ,10.1016/j.bmc.2022.116631,,Anti-ZIKV
DRAVPe01953,KKR,3,Cmpd 11,Synthetic construct,No entry found,,ZIKV,Flaviviridae,Protease assay,[Ref.35123179]Zika virus(ZIKV):inhibition the activity of Zika virus NS2B-NS3 protease(IC50=3.6 ± 0.9 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Phenylacetyl,Amidation,,L,NS2B-NS3 viral serine protease,The peptide inhibits the NS2B-NS3 protease and thus inhibits virus replication.,430.55,C18H38N8O4,ACDEFGHILMNPQSTVWY,K,11.17,3,0,3,0,0,-410.0,-2602,1.3 hour,3 min,2 min,0.0,0,0.0,35123179,Bioorg Med Chem. 2022 Mar 1;57:116631.,"Colarusso S, Ferrigno F, Ponzi S, Pavone F, Conte I, Abate L, Beghetto E, Missineo A, Amaudrut J, Bresciani A, Paonessa G, Tomei L, Montalbetti C, Bianchi E, Toniatti C, Ontoria JM. ",SAR evolution towards potent C-terminal carboxamide peptide inhibitors of Zika virus NS2B-NS3 protease. ,10.1016/j.bmc.2022.116631,,Anti-ZIKV
DRAVPe01954,GKR,3,Cmpd 12,Synthetic construct,No entry found,,ZIKV,Flaviviridae,Protease assay,[Ref.35123179]Zika virus(ZIKV):inhibition the activity of Zika virus NS2B-NS3 protease(40% inhibition at 100 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Phenylacetyl,Free,,L,NS2B-NS3 viral serine protease,The peptide inhibits the NS2B-NS3 protease and thus inhibits virus replication.,359.43,C14H29N7O4,ACDEFHILMNPQSTVWY,GKR,11.0,2,0,2,1,0,-293.33,-1953,30 hour,>20 hour,>10 hour,0.0,0,0.0,35123179,Bioorg Med Chem. 2022 Mar 1;57:116631.,"Colarusso S, Ferrigno F, Ponzi S, Pavone F, Conte I, Abate L, Beghetto E, Missineo A, Amaudrut J, Bresciani A, Paonessa G, Tomei L, Montalbetti C, Bianchi E, Toniatti C, Ontoria JM. ",SAR evolution towards potent C-terminal carboxamide peptide inhibitors of Zika virus NS2B-NS3 protease. ,10.1016/j.bmc.2022.116631,,Anti-ZIKV
DRAVPe01955,GKR,3,Cmpd 13,Synthetic construct,No entry found,,ZIKV,Flaviviridae,Protease assay,[Ref.35123179]Zika virus(ZIKV):inhibition the activity of Zika virus NS2B-NS3 protease(40% inhibition at 100 μM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Phenylacetyl,Amidation,,L,NS2B-NS3 viral serine protease,The peptide inhibits the NS2B-NS3 protease and thus inhibits virus replication.,359.43,C14H29N7O4,ACDEFHILMNPQSTVWY,GKR,11.0,2,0,2,1,0,-293.33,-1953,30 hour,>20 hour,>10 hour,0.0,0,0.0,35123179,Bioorg Med Chem. 2022 Mar 1;57:116631.,"Colarusso S, Ferrigno F, Ponzi S, Pavone F, Conte I, Abate L, Beghetto E, Missineo A, Amaudrut J, Bresciani A, Paonessa G, Tomei L, Montalbetti C, Bianchi E, Toniatti C, Ontoria JM. ",SAR evolution towards potent C-terminal carboxamide peptide inhibitors of Zika virus NS2B-NS3 protease. ,10.1016/j.bmc.2022.116631,,Anti-ZIKV
DRAVPe01956,ALWMTLLKKVLKAAAKAALNAVLVGANA,28,Dermaseptin-4,Phyllomedusa sauvagii,P80280,,HIV,Retroviridae,Chemiluminescence Reporter Gene Assay,[Ref.15780876]human immunodeficiency virus type 1 (HIV-1):Inhibition of viral infection in Vero P4-CCR5 cells(IC50=2 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.15780876]P4-CCR5 cells:CC50=5.6 μM.,,,Linear,Free,Amidation,,L,viral membrane,"exerts a selective activity on viral particles and disturbs their organization by breaking the viral membrane, leading to the exposure of HIV-1 core and its dissociation. ",2850.55,C132H229N35O32S,CDEFHIPQRSY,A,10.48,4,0,4,4,19,103.21,2550,4.4 hour,>20 hour,>10 hour,146.79,5500,203.7,15780876,Virology. 2005 Apr 10;334(2):264-75. ,"Lorin C, Saidi H, Belaid A, Zairi A, Baleux F, Hocini H, Bélec L, Hani K, Tangy F.",The antimicrobial peptide dermaseptin S4 inhibits HIV-1 infectivity in vitro. ,10.1016/j.virol.2005.02.002,,Anti-HIV
DRAVPe01957,ALWKTLLKKVLKAAAK,16,Dermaseptin S4 (1-16)[M4K],Synthetic construct,P80280,,HIV,Retroviridae,Chemiluminescence Reporter Gene Assay,[Ref.15780876]human immunodeficiency virus type 1 (HIV-1):Inhibition of viral infection in Vero P4-CCR5 cells(IC50=28 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.15780876]P4-CCR5 cells:CC50>100 μM.,,,Linear,Free,Amidation,,L,viral membrane,"exerts a selective activity on viral particles and disturbs their organization by breaking the viral membrane, leading to the exposure of HIV-1 core and its dissociation. ",1782.29,C86H152N22O18,CDEFGHIMNPQRSY,K,10.6,5,0,5,1,10,34.38,297,4.4 hour,>20 hour,>10 hour,140.63,5500,366.67,15780876,Virology. 2005 Apr 10;334(2):264-75. ,"Lorin C, Saidi H, Belaid A, Zairi A, Baleux F, Hocini H, Bélec L, Hani K, Tangy F.",The antimicrobial peptide dermaseptin S4 inhibits HIV-1 infectivity in vitro. ,10.1016/j.virol.2005.02.002,,Anti-HIV
DRAVPe01958,GIGDPVTCLKSGAICAnti-HPVFCPRRYKQIGTCGLPGTKCCKKP,41,"Beta-defensin 2(BD-2, hBD-2, SAP1)",Homo sapiens,O15263,1FD4,HIV,Retroviridae,ELISA,"[Ref.16254366]HIV-1 BaL:inhibition of viral infection in TZM-bl cells(80% Inhibition at 100 µg/ml, 68% Inhibition at 50 µg/ml, 55% Inhibition at 25 µg/ml, 45% Inhibition at 12.5 µg/ml, 32% Inhibition at 6.2 µg/ml, 28% Inhibition at 3.1 µg/ml, 18% Inhibition at 1.6 µg/ml, 20% Inhibition at 0.8 µg/ml,);##HIV-1 IIIB:inhibition of viral infection in TZM-bl cells(95% Inhibition at 100 µg/ml, 87% Inhibition at 50 µg/ml, 75% Inhibition at 25 µg/ml, 62% Inhibition at 12.5 µg/ml, 55% Inhibition at 6.2 µg/ml, 35% Inhibition at 3.1 µg/ml, 28% Inhibition at 1.6 µg/ml, 25% Inhibition at 0.8 µg/ml,).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Cyclic,Free,Free,"Disulfide bonds between Cys8 and Cys37, Cys15 and Cys30, Cys20 and Cys38.",L,Not found,No mechanism information found in the reference(s).,4334.24,C188H311N55O50S6,EMNW,CG,9.3,8,1,7,17,9,-10.24,-3697,30 hour,>20 hour,>10 hour,64.15,1865,46.63,16254366,J Virol. 2005 Nov;79(22):14318-29. ,"Sun L, Finnegan CM, Kish-Catalone T, Blumenthal R, Garzino-Demo P, La Terra Maggiore GM, Berrone S, Kleinman C, Wu Z, Abdelwahab S, Lu W, Garzino-Demo A.",Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection. ,10.1128/JVI.79.22.14318-14329.2005,,Anti-HIV
DRAVPe01959,NEYHGFVDKANNENKRKKQQGRDDFVVKPNNFANRRRKDDYNENYYDDVDAADVV,55,Cicadin,Cicada flammata,P83282,,HIV,Retroviridae,ELISA,"[Ref.11814612]HIV-1:inhibition the activity of reverse transcriptase(11.35±1.8% Inhibition at 0.1 µM, 85.8±2.3% Inhibition at 1 µM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,Not found,No mechanism information found in the reference(s).,6596.04,C283H427N89O95,CILMSTW,DN,5.7,12,12,0,15,13,-175.27,-24057,1.4 hour,3 min,>10 hour,38.91,5960,110.37,11814612,Peptides. 2002 Jan;23(1):7-11. ,"Wang H, Ng TB.","Isolation of cicadin, a novel and potent antifungal peptide from dried juvenile cicadas.",10.1016/s0196-9781(01)00573-3,,Anti-HIV
DRAVPe01961,QSHLSLCRWCCNCCRSNKGC,20,Hepcidin TH2-3,Oreochromis mossambicus,I3KHK3,,FMDV,Picornaviridae,Plaque forming assay,"[Ref.30012343]Foot-and-Mouth Disease virus(FMDV):Inhibition of viral replication in BHK-21 cells(IC50=25.1±1.5 µg/ml, IC90=78.5±7.6 µg/ml).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30012343]Baby Hamster Kidney cells BHK-21:CC50=120.2±2.5 µg/ml.,,,Cyclic,Free,Cyclization(Cys7 and Cys20),"Disulfide bonds between Cys7 and Cys20, Cys10 and Cys13, Cys11 and Cys14.",L,Not found,No mechanism information found in the reference(s).,2301.7,C89H145N33O27S6,ADEFIMPTVY,C,8.7,4,0,4,12,3,-38.5,-4828,0.8 hour,10 min,>10 hour,39.0,5875,309.21,30012343,Peptides. 2018 Aug;106:91-95.,"Huang HN, Pan CY, Chen JY. ",Grouper (Epinephelus coioides) antimicrobial peptide epinecidin-1 exhibits antiviral activity against foot-and-mouth disease virus in vitro.,10.1016/j.peptides.2018.07.003,,Anti-FMDV
DRAVPe01962,FIHHIIGGLFSVGKHIHSLIHGH,23,"Tilapia piscidin 3, TP3",Oreochromis niloticus,L0CMD2,,FMDV,Picornaviridae,Plaque forming assay,"[Ref.30012343]Foot-and-Mouth Disease virus(FMDV):Inhibition of viral replication in BHK-21 cells(IC50=2.5±0.2 µg/ml, IC90=25.0±3.2 µg/ml).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30012343]Baby Hamster Kidney cells BHK-21:CC50=39.0±1.2 µg/ml.,,,Linear,Free,Amidation,,L,Not found,No mechanism information found in the reference(s).,2557.0,C121H182N36O26,ACDEMNPQRTWY,H,8.79,7,0,7,6,10,59.13,789,1.1 hour,3 min,2 min,131.3,0,0.0,30012343,Peptides. 2018 Aug;106:91-95.,"Huang HN, Pan CY, Chen JY. ",Grouper (Epinephelus coioides) antimicrobial peptide epinecidin-1 exhibits antiviral activity against foot-and-mouth disease virus in vitro.,10.1016/j.peptides.2018.07.003,,Anti-FMDV
DRAVPe01963,FIHHIIGGLFSAGKAIHRLIRRRRR,25,"Tilapia piscidin 4, TP4",Oreochromis niloticus,L0CKG3,,FMDV,Picornaviridae,Plaque forming assay,"[Ref.30012343]Foot-and-Mouth Disease virus(FMDV):Inhibition of viral replication in BHK-21 cells(IC50=1.5±0.1 µg/ml, IC90=7.5±1.3 µg/ml).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30012343]Baby Hamster Kidney cells BHK-21:CC50=9.7±1.5 µg/ml.,,,Linear,Free,Amidation,,L,Not found,No mechanism information found in the reference(s).,2981.6,C135H226N50O27,CDEMNPQTVWY,R,12.7,10,0,10,4,11,-12.8,-6561,1.1 hour,3 min,2 min,117.2,0,0.0,30012343,Peptides. 2018 Aug;106:91-95.,"Huang HN, Pan CY, Chen JY. ",Grouper (Epinephelus coioides) antimicrobial peptide epinecidin-1 exhibits antiviral activity against foot-and-mouth disease virus in vitro.,10.1016/j.peptides.2018.07.003,,Anti-FMDV
DRAVPe01964,GFIFHIIKGLFHAGKMIHGLV,21,Epinecidin-1 (22-42),Synthetic construct,Q6JWQ9,,FMDV,Picornaviridae,Plaque forming assay,"[Ref.30012343]Foot-and-Mouth Disease virus(FMDV):Inhibition of viral replication in BHK-21 cells(IC50=0.6±0.1 µg/ml, IC90=12.5±1.1 µg/ml).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30012343]Baby Hamster Kidney cells BHK-21:CC50=19.5±3.1 µg/ml.,,,Linear,Free,Amidation,,L,Not found,No mechanism information found in the reference(s).,2335.88,C114H175N29O22S,CDENPQRSTWY,GI,10.0,5,0,5,4,11,109.05,2534,30 hour,>20 hour,>10 hour,130.0,0,0.0,30012343,Peptides. 2018 Aug;106:91-95.,"Huang HN, Pan CY, Chen JY. ",Grouper (Epinephelus coioides) antimicrobial peptide epinecidin-1 exhibits antiviral activity against foot-and-mouth disease virus in vitro.,10.1016/j.peptides.2018.07.003,,Anti-FMDV
DRAVPe01965,GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE,33,Pardaxin P-4,Pardachirus marmoratus,P81861,1XC0,FMDV,Picornaviridae,Plaque forming assay,"[Ref.30012343]Foot-and-Mouth Disease virus(FMDV):Inhibition of viral replication in BHK-21 cells(IC50=2.4±0.1 µg/ml, IC90=12.1±1.1 µg/ml).",No hemolysis information or data found in the reference(s) presented in this entry,[Ref.30012343]Baby Hamster Kidney cells BHK-21:CC50=19.5±3.2 µg/ml.,,,Linear,Free,Free,,L,Not found,No mechanism information found in the reference(s).,3323.88,C154H248N36O45,CDHMNRWY,S,8.59,2,1,1,12,15,74.55,1171,30 hour,>20 hour,>10 hour,112.42,0,0.0,30012343,Peptides. 2018 Aug;106:91-95.,"Huang HN, Pan CY, Chen JY. ",Grouper (Epinephelus coioides) antimicrobial peptide epinecidin-1 exhibits antiviral activity against foot-and-mouth disease virus in vitro.,10.1016/j.peptides.2018.07.003,,Anti-FMDV
DRAVPe01966,AKKAAKKAKKAAKKIEKAAKK,21,RJ5-I15E16,Synthetic construct,No entry found,,HSV,Herpesviridae,Not found,[Ref.16923027]Herpes simplex virus 1(HSV-1):inhibition of viral entry into Vero cells(IC50=112 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.16923027]No cytotoxicity against Human fibroblasts MRC-5 cells up to 448 µM.,,,Linear,Free,Free,,L,Not found,No mechanism information found in the reference(s).,2238.84,C101H192N32O24,CDFGHLMNPQRSTVWY,K,10.65,11,1,10,0,9,-130.95,-4846,4.4 hour,>20 hour,>10 hour,56.67,0,0.0,16923027,Chem Biol Drug Des. 2006 Jul;68(1):58-66.,"Jenssen H, Gutteberg TJ, Rekdal Ø, Lejon T.","Prediction of activity, synthesis and biological testing of anti-HSV active peptides. ",10.1111/j.1747-0285.2006.00412.x,,Anti-HSV
DRAVPe01967,AKKAKKKAKKAAKKIKKKAKK,21,RJ9-I15,Synthetic construct,No entry found,,HSV,Herpesviridae,Not found,[Ref.16923027]Herpes simplex virus 1(HSV-1):inhibition of viral entry into Vero cells(IC50=11 µM); inhibition of viral infection in MRC-5 cells(IC50=119 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.16923027]No cytotoxicity against Human fibroblasts MRC-5 cells up to 448 µM.,,,Linear,Free,Free,,L,Not found,No mechanism information found in the reference(s).,2352.08,C108H211N35O22,CDEFGHLMNPQRSTVWY,K,11.11,14,0,14,0,7,-187.14,-6192,4.4 hour,>20 hour,>10 hour,47.14,0,0.0,16923027,Chem Biol Drug Des. 2006 Jul;68(1):58-66.,"Jenssen H, Gutteberg TJ, Rekdal Ø, Lejon T.","Prediction of activity, synthesis and biological testing of anti-HSV active peptides. ",10.1111/j.1747-0285.2006.00412.x,,Anti-HSV
DRAVPe01968,ARRARRRARRAARRARRGARR,21,RJ8-R5G18,Synthetic construct,No entry found,,HSV,Herpesviridae,Not found,[Ref.16923027]Herpes simplex virus 1(HSV-1):inhibition of viral entry into Vero cells(IC50=1.9 µM); inhibition of viral infection in MRC-5 cells(IC50=4.8 µM);##Herpes simplex virus 2(HSV-2):inhibition of viral infection in MRC-5 cells(IC50=96 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.16923027]No cytotoxicity against Human fibroblasts MRC-5 cells up to 448 µM.,,,Linear,Free,Free,,L,Not found,No mechanism information found in the reference(s).,2603.06,C101H196N60O22,CDEFHIKLMNPQSTVWY,R,13.08,13,0,13,1,7,-220.48,-18035,4.4 hour,>20 hour,>10 hour,33.33,0,0.0,16923027,Chem Biol Drug Des. 2006 Jul;68(1):58-66.,"Jenssen H, Gutteberg TJ, Rekdal Ø, Lejon T.","Prediction of activity, synthesis and biological testing of anti-HSV active peptides. ",10.1111/j.1747-0285.2006.00412.x,,Anti-HSV
DRAVPe01969,ARRARRRARRAARRARRWARR,21,RJ8-R5W18,Synthetic construct,No entry found,,HSV,Herpesviridae,Not found,[Ref.16923027]Herpes simplex virus 1(HSV-1):inhibition of viral entry into Vero cells(IC50=9.2 µM); inhibition of viral infection in MRC-5 cells(IC50=2.8 µM);##Herpes simplex virus 2(HSV-2):inhibition of viral infection in MRC-5 cells(IC50=162 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.16923027]No cytotoxicity against Human fibroblasts MRC-5 cells up to 448 µM.,,,Linear,Free,Free,,L,Not found,No mechanism information found in the reference(s).,2732.22,C110H203N61O22,CDEFGHIKLMNPQSTVY,R,13.08,13,0,13,0,8,-222.86,-17896,4.4 hour,>20 hour,>10 hour,33.33,5500,275.0,16923027,Chem Biol Drug Des. 2006 Jul;68(1):58-66.,"Jenssen H, Gutteberg TJ, Rekdal Ø, Lejon T.","Prediction of activity, synthesis and biological testing of anti-HSV active peptides. ",10.1111/j.1747-0285.2006.00412.x,,Anti-HSV
DRAVPe01970,KAAKKAAKWAKKAAKWAKKAA,21,"RJ2-W9,16",Synthetic construct,No entry found,,HSV,Herpesviridae,Not found,[Ref.16923027]Herpes simplex virus 1(HSV-1):inhibition of viral entry into Vero cells(IC50=111 µM); inhibition of viral infection in MRC-5 cells(IC50=32 µM);##Herpes simplex virus 2(HSV-2):inhibition of viral infection in MRC-5 cells(IC50=48 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.16923027]No cytotoxicity against Human fibroblasts MRC-5 cells up to 448 µM.,,,Linear,Free,Free,,L,Not found,No mechanism information found in the reference(s).,2254.8,C106H180N32O22,CDEFGHILMNPQRSTVY,A,10.9,9,0,9,0,12,-90.0,-2719,1.3 hour,3 min,2 min,47.62,11000,550.0,16923027,Chem Biol Drug Des. 2006 Jul;68(1):58-66.,"Jenssen H, Gutteberg TJ, Rekdal Ø, Lejon T.","Prediction of activity, synthesis and biological testing of anti-HSV active peptides. ",10.1111/j.1747-0285.2006.00412.x,,Anti-HSV
DRAVPe01971,KYAKKAAKYAKKAAKYAKKAA,21,"RJ2-Y2,9,16",Synthetic construct,No entry found,,HSV,Herpesviridae,Not found,[Ref.16923027]Herpes simplex virus 1(HSV-1):inhibition of viral entry into Vero cells(IC50=146 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.16923027]No cytotoxicity against Human fibroblasts MRC-5 cells up to 448 µM.,,,Linear,Free,Free,,L,Not found,No mechanism information found in the reference(s).,2300.82,C108H182N30O25,CDEFGHILMNPQRSTVW,AK,10.3,9,0,9,3,9,-108.57,-3408,1.3 hour,3 min,2 min,42.86,4470,223.5,16923027,Chem Biol Drug Des. 2006 Jul;68(1):58-66.,"Jenssen H, Gutteberg TJ, Rekdal Ø, Lejon T.","Prediction of activity, synthesis and biological testing of anti-HSV active peptides. ",10.1111/j.1747-0285.2006.00412.x,,Anti-HSV
DRAVPe01972,AAKAWKKAKAWKKAKWWKKAA,21,"RJ2-A1,4,8; K3,6,7,9,13; W5,11,17",Synthetic construct,No entry found,,HSV,Herpesviridae,Not found,[Ref.16923027]Herpes simplex virus 1(HSV-1):inhibition of viral entry into Vero cells(IC50=238 µM).,No hemolysis information or data found in the reference(s) presented in this entry,[Ref.16923027]No cytotoxicity against Human fibroblasts MRC-5 cells up to 448 µM.,,,Linear,Free,Free,,L,Not found,No mechanism information found in the reference(s).,2485.07,C122H190N34O22,CDEFGHILMNPQRSTVY,K,10.9,9,0,9,0,12,-115.71,-2615,4.4 hour,>20 hour,>10 hour,38.1,22000,1100.0,16923027,Chem Biol Drug Des. 2006 Jul;68(1):58-66.,"Jenssen H, Gutteberg TJ, Rekdal Ø, Lejon T.","Prediction of activity, synthesis and biological testing of anti-HSV active peptides. ",10.1111/j.1747-0285.2006.00412.x,,Anti-HSV
DRAVPe01973,WNHTTWMEWDREINNYTSLIHSLIEESQNQQEKNEQ,36,"CHR-1, Env GP (623-658)",Synthetic construct,P04578,,HIV,Retroviridae,ELISA,[Ref.17276993]human immunodeficiency virus (HIV):inhibition of cell-cell fusion in MT-2 cells(IC50=17.27 ± 0.31 nM; IC90=26.41 ± 0.55 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,cell membrane,"The peptide can interact with the viral NHR to form stable heterologous 6-HBs, resulting in inhibition of fusion between the viral and target cell membranes.",4532.84,C196H288N56O67S,ACFGPV,E,4.53,4,7,-3,12,8,-156.39,-11884,2.8 hour,3 min,2 min,54.17,17990,514.0,17276993,J Biol Chem. 2007 Mar 30;282(13):9612-9620.,"Liu S, Jing W, Cheung B, Lu H, Sun J, Yan X, Niu J, Farmar J, Wu S, Jiang S. ",HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides,10.1074/jbc.M609148200,,Anti-HIV
DRAVPe01974,WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLEL,36,"C36, Env GP (628-663)",Synthetic construct,P04578,,HIV,Retroviridae,ELISA,[Ref.17276993]human immunodeficiency virus (HIV):inhibition of cell-cell fusion in MT-2 cells(IC50=4.67 ± 0.07 nM; IC90=7.04 ± 0.12 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,cell membrane,"The peptide can interact with the viral NHR to form stable heterologous 6-HBs, resulting in inhibition of fusion between the viral and target cell membranes.",4490.88,C195H298N52O68S,ACFGPV,E,4.14,3,9,-6,9,10,-119.17,-10359,2.8 hour,3 min,2 min,86.67,12490,356.86,17276993,J Biol Chem. 2007 Mar 30;282(13):9612-9620.,"Liu S, Jing W, Cheung B, Lu H, Sun J, Yan X, Niu J, Farmar J, Wu S, Jiang S. ",HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides,10.1074/jbc.M609148200,DRAVPa0917,Anti-HIV
DRAVPe01975,REINNYTSLIHSLIEESQNQQEKNEQELLELDKWAS,36,"CHR-3, Env GP (633-668)",Synthetic construct,P04578,,HIV,Retroviridae,ELISA,"[Ref.17276993]human immunodeficiency virus (HIV):inhibition of cell-cell fusion in MT-2 cells(IC50=1,470.00 ± 20.0 nM; IC90=2,380.00 ± 35.00 nM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,Not found,CHR-3 interacts with N46 to form unstable 6-HB,4330.69,C186H294N52O67,CFGMPV,E,4.42,4,8,-4,10,10,-120.28,-10860,1 hour,2 min,2 min,89.44,6990,199.71,17276993,J Biol Chem. 2007 Mar 30;282(13):9612-9620.,"Liu S, Jing W, Cheung B, Lu H, Sun J, Yan X, Niu J, Farmar J, Wu S, Jiang S. ",HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides,10.1074/jbc.M609148200,,Anti-HIV
DRAVPe01976,HSLIEESQNQQEKNEQELLELDKWASLWNWFNITNW,36,"CHR-5, Env GP (643-678)",Synthetic construct,P04578,,HIV,Retroviridae,ELISA,"[Ref.17276993]human immunodeficiency virus (HIV):inhibition of cell-cell fusion in MT-2 cells(IC50=2,185.00 ± 15.00 nM; IC90=2,858.00 ± 6.00 nM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,Not found,CHR-5 can bind to LUVs of POPC,4501.89,C203H295N53O64,CGMPRVY,E,4.3,3,7,-4,9,13,-114.17,-8492,3.5 hour,10 min,>10 hour,78.61,22000,628.57,17276993,J Biol Chem. 2007 Mar 30;282(13):9612-9620.,"Liu S, Jing W, Cheung B, Lu H, Sun J, Yan X, Niu J, Farmar J, Wu S, Jiang S. ",HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides,10.1074/jbc.M609148200,,Anti-HIV
DRAVPe01977,STSQKAnti-SIVAYTM,12,"SARS-CoV S (668–679), SP-10",Synthetic construct,P59594,,SARS-CoV,Coronaviridae,ELISA,[Ref.16337697]SARS-CoV:Inhibition of pseudovirus infection in Vero cells(IC50=1.88 ± 0.52 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,ACE2,block the binding of S protein to ACE2.,1315.5,C56H94N14O20S,CDEFGHLNPRW,S,8.31,1,0,1,6,3,-0.83,-1345,1.9 hour,>20 hour,>10 hour,65.0,1490,135.45,16337697,Antiviral Res. 2006 Feb;69(2):70-6.,"Ho TY, Wu SL, Chen JC, Wei YC, Cheng SE, Chang YH, Liu HJ, Hsiang CY.",Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction.,10.1016/j.antiviral.2005.10.005,,Anti-SARS-CoV
DRAVPe01978,GFLYVYKGYQPI,12,"SARS-CoV S (192-203), SP-4",Synthetic construct,P59594,,SARS-CoV,Coronaviridae,ELISA,[Ref.16337697]SARS-CoV:Inhibition of pseudovirus infection in Vero cells(IC50=4.30 ± 2.18 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,ACE2,block the binding of S protein to ACE2.,1447.7,C73H102N14O17,ACDEHMNRSTW,Y,8.43,1,0,1,5,4,13.33,723,30 hour,>20 hour,>10 hour,89.17,4470,406.36,16337697,Antiviral Res. 2006 Feb;69(2):70-6.,"Ho TY, Wu SL, Chen JC, Wei YC, Cheng SE, Chang YH, Liu HJ, Hsiang CY.",Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction.,10.1016/j.antiviral.2005.10.005,,Anti-SARS-CoV
DRAVPe01979,FYTTTGIGYQPY,12,"SARS-CoV S (483-494), SP-8",Synthetic construct,P59594,,SARS-CoV,Coronaviridae,ELISA,[Ref.16337697]SARS-CoV:Inhibition of pseudovirus infection in Vero cells(IC50=6.99 ± 0.71 nM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,ACE2,block the binding of S protein to ACE2.,1410.55,C68H91N13O20,ACDEHKLMNRSVW,TY,5.52,0,0,0,8,2,-38.33,-389,1.1 hour,3 min,2 min,32.5,4470,406.36,16337697,Antiviral Res. 2006 Feb;69(2):70-6.,"Ho TY, Wu SL, Chen JC, Wei YC, Cheng SE, Chang YH, Liu HJ, Hsiang CY.",Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction.,10.1016/j.antiviral.2005.10.005,,Anti-SARS-CoV
DRAVPe01980,IHAEIKNSLKIDNLDVNRCIEAL,23,LEDGF/p75 (355-377),Synthetic construct,O75475,,HIV,Retroviridae,IN enzymatic assay,[Ref.18331842]Human immunodeficiency virus (HIV): Inhibition of integrase activity (3' end processing)(IC50=165±28 µM); inhibition of integrase activity(strand transfer)(IC50=153±28 µM).,No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Free,,L,Integrase,The LEDGF/p75 peptide modestly inhibited IN catalysis and was dependent on IN–DNA assembly. The peptide was also effective at disrupting LEDGF/p75–IN complex formation.,2622.03,C113H193N33O36S,FGMPQTWY,I,5.48,4,4,0,5,10,-4.78,-4168,20 hour,30 min,>10 hour,140.0,0,0.0,18331842,FEBS Lett. 2008 Apr 30;582(10):1425-30. ,"Al-Mawsawi LQ, Christ F, Dayam R, Debyser Z, Neamati N.",Inhibitory profile of a LEDGF/p75 peptide against HIV-1 integrase: insight into integrase-DNA complex formation and catalysis.,10.1016/j.febslet.2008.02.076,,Anti-HIV
DRAVPe01981,IEEQAKTFLDKFQAnti-HeVEEIYWQS,23,"Peptide1(ACE2 (21-43)[N13Q,A16V,D18E,L19I,F20Y,Y21W])",Synthetic construct,Q9BYF1,,SARS-CoV-2,Coronaviridae,luciferase assay,"[Ref.34328726]SARS-CoV-2:Inhibition of virus entry in HEK293T/ACE2 cells (via inhibition of SRBD:ACE2 interaction)(IC50=11 ± 1 nM, 100% inhibition at 25 µM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Amidation,,L,Spike protein,antagonizes the SARS-CoV-2 S-RBD:ACE2 interaction and inhibits the virus entry.,2898.18,C133H193N31O42,CGMNPR,E,4.41,3,6,-3,3,8,-94.78,-5236,20 hour,30 min,>10 hour,67.83,6990,317.73,34328726,J Med Chem. 2022 Feb 24;65(4):2836-2847. ,"Sadremomtaz A, Al-Dahmani ZM, Ruiz-Moreno AJ, Monti A, Wang C, Azad T, Bell JC, Doti N, Velasco-Velázquez MA, de Jong D, de Jonge J, Smit J, Dömling A, van Goor H, Groves MR.",Synthetic Peptides That Antagonize the Angiotensin-Converting Enzyme-2 (ACE-2) Interaction with SARS-CoV-2 Receptor Binding Spike Protein,10.1021/acs.jmedchem.1c00477,,Anti-SARS-CoV-2
DRAVPe01982,QDKHEEDYQMYNKGDKED,18,Peptide2,Synthetic construct,No entry found,,SARS-CoV-2,Coronaviridae,luciferase assay,"[Ref.34328726]SARS-CoV-2:Inhibition of virus entry in HEK293T/ACE2 cells (via inhibition of SRBD:ACE2 interaction)(IC50=18 ± 2 nM, 95% inhibition at 0.39 µM, 100% inhibition at 25 µM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Amidation,,L,Spike protein,antagonizes the SARS-CoV-2 S-RBD:ACE2 interaction and inhibits the virus entry.,2272.34,C94H138N26O38S,ACFILPRSTVW,D,4.38,4,7,-3,4,0,-283.33,-9133,0.8 hour,10 min,>10 hour,0.0,2980,175.29,34328726,J Med Chem. 2022 Feb 24;65(4):2836-2847. ,"Sadremomtaz A, Al-Dahmani ZM, Ruiz-Moreno AJ, Monti A, Wang C, Azad T, Bell JC, Doti N, Velasco-Velázquez MA, de Jong D, de Jonge J, Smit J, Dömling A, van Goor H, Groves MR.",Synthetic Peptides That Antagonize the Angiotensin-Converting Enzyme-2 (ACE-2) Interaction with SARS-CoV-2 Receptor Binding Spike Protein,10.1021/acs.jmedchem.1c00477,,Anti-SARS-CoV-2
DRAVPe01983,DKFNHEAEDLFYQSSLASWNYNT,23,Peptide3,Synthetic construct,Q9BYF1,,SARS-CoV-2,Coronaviridae,luciferase assay,"[Ref.34328726]SARS-CoV-2:Inhibition of virus entry in HEK293T/ACE2 cells (via inhibition of SRBD:ACE2 interaction)(IC50=6 ± 4 nM, 100% inhibition at 25 µM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Amidation,,L,Spike protein,antagonizes the SARS-CoV-2 S-RBD:ACE2 interaction and inhibits the virus entry.,2779.92,C125H171N31O42,CGIMPRV,NS,4.31,2,4,-2,9,7,-108.26,-5803,1.1 hour,3 min,>10 hour,42.61,8480,385.45,34328726,J Med Chem. 2022 Feb 24;65(4):2836-2847. ,"Sadremomtaz A, Al-Dahmani ZM, Ruiz-Moreno AJ, Monti A, Wang C, Azad T, Bell JC, Doti N, Velasco-Velázquez MA, de Jong D, de Jonge J, Smit J, Dömling A, van Goor H, Groves MR.",Synthetic Peptides That Antagonize the Angiotensin-Converting Enzyme-2 (ACE-2) Interaction with SARS-CoV-2 Receptor Binding Spike Protein,10.1021/acs.jmedchem.1c00477,,Anti-SARS-CoV-2
DRAVPe01984,IDENARSYIDKFQHDAEEMWYQ,22,Peptide4,Synthetic construct,No entry found,,SARS-CoV-2,Coronaviridae,luciferase assay,"[Ref.34328726]SARS-CoV-2:Inhibition of virus entry in HEK293T/ACE2 cells (via inhibition of SRBD:ACE2 interaction)(IC50=32 ± 2 nM, 95% inhibition at 0.39 µM, 100% inhibition at 25 µM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Amidation,,L,Spike protein,antagonizes the SARS-CoV-2 S-RBD:ACE2 interaction and inhibits the virus entry.,2788.98,C123H174N32O41S,CGLPTV,DE,4.29,3,6,-3,4,6,-136.82,-7200,20 hour,30 min,>10 hour,44.55,8480,403.81,34328726,J Med Chem. 2022 Feb 24;65(4):2836-2847. ,"Sadremomtaz A, Al-Dahmani ZM, Ruiz-Moreno AJ, Monti A, Wang C, Azad T, Bell JC, Doti N, Velasco-Velázquez MA, de Jong D, de Jonge J, Smit J, Dömling A, van Goor H, Groves MR.",Synthetic Peptides That Antagonize the Angiotensin-Converting Enzyme-2 (ACE-2) Interaction with SARS-CoV-2 Receptor Binding Spike Protein,10.1021/acs.jmedchem.1c00477,,Anti-SARS-CoV-2
DRAVPe01985,IYALLENAEDYNLVN,15,Peptide5,Synthetic construct,No entry found,,SARS-CoV-2,Coronaviridae,luciferase assay,"[Ref.34328726]SARS-CoV-2:Inhibition of virus entry in HEK293T/ACE2 cells (via inhibition of SRBD:ACE2 interaction)(IC50=9 ± 4 nM, 100% inhibition at 25 µM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Amidation,,L,Spike protein,antagonizes the SARS-CoV-2 S-RBD:ACE2 interaction and inhibits the virus entry.,1753.93,C79H120N18O27,CFGHKMPQRSTW,LN,3.57,0,3,-3,5,7,0.67,-1520,20 hour,30 min,>10 hour,136.67,2980,212.86,34328726,J Med Chem. 2022 Feb 24;65(4):2836-2847. ,"Sadremomtaz A, Al-Dahmani ZM, Ruiz-Moreno AJ, Monti A, Wang C, Azad T, Bell JC, Doti N, Velasco-Velázquez MA, de Jong D, de Jonge J, Smit J, Dömling A, van Goor H, Groves MR.",Synthetic Peptides That Antagonize the Angiotensin-Converting Enzyme-2 (ACE-2) Interaction with SARS-CoV-2 Receptor Binding Spike Protein,10.1021/acs.jmedchem.1c00477,,Anti-SARS-CoV-2
DRAVPe01986,SRDKHEEHEKENDRGQ,16,Peptide6,Synthetic construct,No entry found,,SARS-CoV-2,Coronaviridae,luciferase assay,"[Ref.34328726]SARS-CoV-2:Inhibition of virus entry in HEK293T/ACE2 cells (via inhibition of SRBD:ACE2 interaction)(IC50=10 ± 5 nM, 100% inhibition at 25 µM).",No hemolysis information or data found in the reference(s) presented in this entry,No cytotoxicity information or data found in the reference(s) presented in this entry,,,Linear,Free,Amidation,,L,Spike protein,antagonizes the SARS-CoV-2 S-RBD:ACE2 interaction and inhibits the virus entry.,1994.02,C78H124N30O32,ACFILMPTVWY,E,5.43,6,6,0,3,0,-327.5,-10958,1.9 hour,>20 hour,>10 hour,0.0,0,0.0,34328726,J Med Chem. 2022 Feb 24;65(4):2836-2847. ,"Sadremomtaz A, Al-Dahmani ZM, Ruiz-Moreno AJ, Monti A, Wang C, Azad T, Bell JC, Doti N, Velasco-Velázquez MA, de Jong D, de Jonge J, Smit J, Dömling A, van Goor H, Groves MR.",Synthetic Peptides That Antagonize the Angiotensin-Converting Enzyme-2 (ACE-2) Interaction with SARS-CoV-2 Receptor Binding Spike Protein,10.1021/acs.jmedchem.1c00477,,Anti-SARS-CoV-2
